<SEC-DOCUMENT>0001558370-24-003784.txt : 20240322
<SEC-HEADER>0001558370-24-003784.hdr.sgml : 20240322
<ACCEPTANCE-DATETIME>20240322164050
ACCESSION NUMBER:		0001558370-24-003784
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240322
DATE AS OF CHANGE:		20240322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioXcel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001720893
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				821386754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38410
		FILM NUMBER:		24775850

	BUSINESS ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-643-8060

	MAIL ADDRESS:	
		STREET 1:		555 LONG WHARF DRIVE
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>btai-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.5.0.8 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/22/2024 8:30:26 PM -->
<!-- iXBRL Library version: 1.0.8703.18788 -->
<!-- iXBRL Service Job ID: 6d192126-29d8-4ef7-a9a8-4ab9bb2a8c05 -->
<html xmlns:btai="http://www.bioxceltherapeutics.com/20231231" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" xs:nil="true" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_eEl5TI-KZ0u2kjJRlD2BZw"/><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" xs:nil="true" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_xLbLaHMg2E6Pe0qsTwBCpw"/><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" xs:nil="true" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" name="us-gaap:PreferredStockValue" id="Hidden_XzcQek6kG0WjzoawbI-6aQ"/><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" xs:nil="true" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" name="us-gaap:PreferredStockValue" id="Hidden_3ul1BO7V2EW5KZOaIYDk9A"/><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityCentralIndexKey" id="Tc_BOF4tdKyO0uDQDNLs_0REg_2_1">0001720893</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentFiscalYearFocus" id="Tc_HMREsrWRUEih8oPX7ygMhw_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentFiscalPeriodFocus" id="Tc_4Tn2MUuckEuCacWAje5ueQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:AmendmentFlag" id="Tc_PhAM4NFw1EKSkpK3apW7lA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" name="us-gaap:CommonStockSharesIssued" id="Hidden_5tpEl_7wWkyfmmgg0VxDAA">28147000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_PcWL0v_iXEK7OCLk66t6LA">29930000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_UzDBOVFgC0-CcCS6Fm3vVA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_eRKTMJzlkkWDdufIKYHGfw">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z8wGFoFQHkGh9pMeSDi2Ig" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="Hidden_lFagk5bTnEemlWdu4CgnkQ">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_YDje09iS6UufW2YFrYa5Ng">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENmMDZVWL0Sj71YGtPStYQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_ENbZ6Viv9kSPsLzsnlVWSQ">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="btai-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_xk0Q89gawUCTwiTOaOpAWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_PntQCMUJZkeGnizT8u1Fug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xHeZV4Ol5U-qHZKumtzK4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_x7P2HSC51kqvtDIeyiG1VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e3G2VXdksEeqw2aI3K5qYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eqYihjzZTUmciy86aDfMcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAiZHn3hQE6KSYUOLwW1Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yGTb9URg5keSwgCiIyKD1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_spu6vwv6wkeAKS8ZgaBZyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PRtGyQfymEacLjG_UJArXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_GlNf8HOiWUu7zXkTvkFBsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ZWLEjeNqVUifL0AxwuMoJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_kttjLkP_lUGbpgLUyc0SDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_EzEfX9_flUy4assVwEUnZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:StockPlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_u28NxTusVku5UX5Tspxcdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_QZPms-_JDE62jRgrcbtUIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_SZqxVW5oU0abbZ9IElW9dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Y1r3H-NssUGDKP2nkYl0gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_Y3C2KLUibEGjwn_Zo1eoew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v-MW3gW6_0OhWwhL83cZBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OTZS4zpsIUmXN4c6tbKJVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bVD8ivCGrESTiF07tgD9xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pKAAtUPo1Ey3Co1MIzsM-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WnuQlcoII0qSBZBbrHkrEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_h6CnSCl4dECh1YLUxQk6ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_p2sWFHswF0-DPdbaZVQ8aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p3_hhWFiREeo8nnIsabskA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5JKcWlgs30ac0qBkTIeQIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_UWn9MaHj40m9ggi57C5_7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IX6hI-H8FE6Sxk8kEK1KPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_VRCkfH11u0yQPf850NGkwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_us-gaap_GranteeStatusAxis_srt_ExecutiveOfficerMember_7KyW7kaoLEujFskhyoTCJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0uPjNo82rUCxuxmCApfRtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_LFEwrHLb3k630YwocgejDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENmMDZVWL0Sj71YGtPStYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_8_2023_To_8_8_2023_3YScg74_R0ConxpN-Oxzqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DPrRJZyMuUC3HpIpzHgSwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_qZV9TJRkVkSO1q1Z2RQAKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_dxjhG7eFUUSaXMpZC0s-aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lfv86wIfO0uGyrJUEO6W4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Q0FkyLMLpE6C08_6RQv7GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-GBUxd3EAE6_mzgWpsJOzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_hB0HP0jhXkSZURCC-uucwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ALKhxrCkjkOwdbr4SCwncA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_Vc2MKw-dukuwAowcKM-VEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GDQlj4QAs0O-w3hPNOGBnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_j_3iRADS3U-7NdeM4T4eaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_W29nsD5d7kyN70aN7TzDxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1XLHPADP90S8ZwGclsNpbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aNHYV9yCoUm00_-U0XfV2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_C6w_xNcT_EqUj9i8wEs-yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_CBA1W1BLL0GwUTYi-6y_ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vn8IA3nckU24niIfjblXlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Pe0_O6hXxUaHjPzlWLuThQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_7EMAZ25l10i2MUh_SEohkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_yu4AYaDZ_Ue7i6ZZWzIm3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_W2i9WK1SZUeMOgcqPDEO-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AXJr0CJxhEq-UxVe_rzlPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_owHhLehS_EmtWcsJidsnPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FwZJLNhx_0moyuSOcfdYXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V-ADkks9QE-9-kuUtA7EMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_huSrkOX7SUmY8-_tuWQFpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_RWFw3r1oWUC3XL39vHaqqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_8_2022_To_7_8_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_V64yF2oxIU6GdMLQcz2BkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-08</xbrli:startDate><xbrli:endDate>2022-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2023Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SiWlKh8skUWL3uCUhIDNLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">btai:ShareBasedPaymentArrangementGrantDate2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2022Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9upi1ce5e0qUxLvJvKR5mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">btai:ShareBasedPaymentArrangementGrantDate2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_a1Cs0RhSBUWu9ebIk9a4Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uLG7LMwfw0CKpBUSpaBN1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CZOqcLp0PUKVcyA1bGHQyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_n9fLqTrqZkCK8GBCnlZSGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_NC_OkAZruUWuB05QvPr4mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_A6wlGoCQXEKa2GVlvoBZ6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mA8YOGT8Mk-UH8QN9ncEhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_zrIRZIK4QUyE2BqXAHd39w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGhzkv0Pn0-_E2xmVYozig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_EiQqzjUCAki7PrEDtNqD5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_nhdn74qyc0WhUslR4qua3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_UWym6eYkO0i2Db4epU9hOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember__t5_rrWTAkSvW4vx2R3MKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputProbabilityOfExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_l5-tles4rk6AJ38rbZ5qDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputEstimatedPremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2iBcLPYPak63zB2SGjujoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZjevHEcIPEOgTS172gTu_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wGIdAt1pk0uCvgXve4GiLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tz8ZkPV9rEagiQzVm1c8XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_7PDK9HAQOUe7s0Ry8BL5WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7hC-g0hRVUyUylsJ4F6ZoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnJ5CJh_wUO7oAOB1qWnWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VGlEMLwpK0G_B3i2obOKVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Wce1URlIPE-m9fYpV9zeJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BBwsCn9q10ez32Xp3IZYGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_If0SwRWVoEKPCeiBpygDpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_S6sTUJ5nc0O-S3nh1hH-8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__Ry2HIqDsUKb1qJ9uR4b3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z8wGFoFQHkGh9pMeSDi2Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_PfOMnn2r6Em4dZ9LbC_GWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_73tBnm99SkWJuAHEaVzHcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_lqY8_zjpaE6CKAXuo279Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_wzC_0CZ3tUyxRyd-2zvgHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_N1udVxFwqUa9M9O90JMIFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_v1M2BA7xuUyhRRqLClhhMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_h7P1Xd1OZUajABk9uxWk4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_gIbrrmF-LU2BVh3G5muq_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jfJvbh6zN0ezSU9wjtHC3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cC-JtWvLskOqp8xXQ1r_1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_LxCPLzm9okOLdFn3Z8l8lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_GpdoISruzku_097J5reooA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Z17gbjnh30i21j6FjyTHjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_r3W4hkyAb0-K4kHx7gA8ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jlMfMWAUtUG3OTUw8vN1rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LO90L5PoDEivpd5VLIVaEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_o3kSuLNg7k-AKoYTLeldyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YNOnCMIhzk-zL6WUrMzXvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_9h1xuVneFkulBXYqApNPsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember_uCqLAxkpTUCf_97fB1ROog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_Hr72ObP9Ykyp9_0xmJWLlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_T5Zf7K9_uEKO9VCroUlqcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:MatthewWileyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_8dg2ROr62EmFMKrYPCbbVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_YXURVutUlkePgjsTcxszAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:MatthewWileyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_8OBjMItu10CBEHoI7-kTZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2024_SyzKieY9dk2q39Ecc0mTCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_bpv_lNdtNUaJOmv6QXYrHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_qQIgqhjIAU-25A9Enh5x8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_CyJ8S634XkOrnMXvZQo-Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_os9ZcTj60EKmwN-8QTANZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_fZkIV0wemUSj8D-mDkwN0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_qDjBignJyUitVErr7JersQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cSh0m3wu4kefKlStrPWJ1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_UZzwa5c1w0eu9CL07OEeQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_V8-C-RxYK0aXAjUC8xvmzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterFundingOfTrancheBLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cxmDc-hxWEiaxO1wwjZa8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eky2EVddxU2Zk8lYvRBFDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QEq2Y_AI2EClDFuZWnDU8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KN9Fx05BHkKau-z8hNvRxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-12</xbrli:startDate><xbrli:endDate>2024-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1kRdDymbCUqa9XieGI09Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_4_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qN1X0eAfCkKStJDFYn04Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fDwcE2NcAkalD934EMLcKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ORjQlGmsX0GTKU-h12WP4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_Ku-HMoUhaECwUSnCUZw31A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-05</xbrli:startDate><xbrli:endDate>2023-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_NXCCj7glw0uPyaR6Y2-w9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-13</xbrli:startDate><xbrli:endDate>2023-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-20</xbrli:startDate><xbrli:endDate>2020-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_anIgAQjD802S5HzYHrjq2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_wzQDKTToGUu0fupDsFLSUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i38r8XQuQEOi9Le4Y7r8lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5UeYbgXGDEaW_6Z1qh8tGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember__S0J6TAmqEaBUKJsiY7Iag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_mAbI1B8ghUiyZZyzM0aMpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_dIkd-uFGvk-VmaG81kxPvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_oxNFZAw51EWZ3rfLAxMbLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-19</xbrli:startDate><xbrli:endDate>2022-04-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_TCiII9VhN0SRNqnqQ9rjQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3yVQCurUjku_rn_lePc8vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-30</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_LbKlmh1ElU2MfLJqOKFfxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_KcpdD2ZAMkKgL8-kiMrvzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720893</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg"><xbrli:measure>btai:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_laXuDs1PtUqwsUSCfciCQA"><xbrli:measure>btai:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9fe13889_550e_46bc_848b_70afb40c6982"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentType" id="Narr_9AF_nI_kpEmTFIV3GDpKmg"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><a id="_a847c753_2275_4a3e_abe3_1baf8bd99860"></a><a id="Tc_TOc21g8DvkGZVKY2yqMcaQ_1_0"></a><a id="Tc_EbjZkPLsC0Gm8Ma1WrCmgw_2_1"></a><a id="Tc_GA5VFDCl30yOJY4i3gZEeA_3_0"></a><a id="Tc_0cdHgwSgRkeyPXAiHvIFmQ_4_0"></a><a id="Tc_mAqlfveTE0mEU2NUh4jaLQ_5_1"></a><a id="Tc_6KqRac5W-kykJEA5t05dFg_6_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Mark one)</b></p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentAnnualReport" id="Tc_XzYZCzNrVECtMEFKpSJM1w_2_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Annual Report Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentPeriodEndDate" id="Narr_9OukaXrcu0u0Ps_2SPbKNA"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:CurrentFiscalYearEndDate" id="Narr_8y4GVhwqwUqLmUcOZuPJ4w"><b style="font-size:7pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, 2023</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">or</b></p></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentTransitionReport" id="Tc_eF03MWIreEWAyjIi2guLAw_5_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Transition Report Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from              to             .</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:7pt;font-weight:bold;">Commission file number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityFileNumber" id="Narr_VvertoLWQUyDJRtP43_iYA"><b style="font-size:7pt;font-weight:bold;">001-38410</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityRegistrantName" id="Narr_WPHkWBYVU0ebAuUNRGcwqQ"><b style="font-weight:bold;">BioXcel Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">(Exact name of Registrant as specified in its charter)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityIncorporationStateCountryCode" id="Narr_hKfX9qhyr0qvcrhiBfcpbg"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(State or other jurisdiction of</span><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">incorporation or organization)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityTaxIdentificationNumber" id="Narr_Z8owcyIXSEyFVugQyJeZTw"><b style="font-size:7pt;font-weight:bold;">82-1386754</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(I.R.S. Employer</span><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">Identification No.)</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityAddressAddressLine1" id="Narr_S8apThuCr0COIWpHBl8fpg"><b style="font-size:7pt;font-weight:bold;">555 Long Wharf Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityAddressCityOrTown" id="Narr_8H5nHoSTO0WEfIduOAEoRw"><b style="font-size:7pt;font-weight:bold;">New Haven</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityAddressStateOrProvince" id="Narr_OV6hfyUWvUmzyG5kIZhi2g"><b style="font-size:7pt;font-weight:bold;">CT</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(Address of principal executive offices)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityAddressPostalZipCode" id="Narr_1NxXmi-I2UWlqQUmQmk_kg"><b style="font-size:7pt;font-weight:bold;">06511</b></ix:nonNumeric><span style="font-size:7pt;"><br/></span><span style="font-size:7pt;">(Zip Code)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:7pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:CityAreaCode" id="Narr_y4Hv24AVPk6qfFhu32Zb8Q"><b style="font-size:7pt;font-weight:bold;">475</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:LocalPhoneNumber" id="Narr_CwU2jlhVjUWva0qPb541Ng"><b style="font-size:7pt;font-weight:bold;">238-6837</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_266d601b_6b44_470f_8a2c_8f44a0c673ed"></a><a id="Tc_JI0pcHTwtkqGdNuJEVljlQ_1_0"></a><a id="Tc_0Eubkp7AakSxOuJYvVoH7g_1_1"></a><a id="Tc_VkIyda7VM0iIiiokkHKAzQ_1_2"></a><a id="Tc_Tg5CSDOJ6kWBi0UYr5qYtA_2_0"></a><a id="Tc_mFEtlpiw4Uu71AN286BRjQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of each class</span></p></td><td style="vertical-align:top;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of exchange on which registered</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:Security12bTitle" id="Narr_MvInt1AU7ESBEjPEAfTJaA"><b style="font-size:7pt;font-weight:bold;">Common Stock</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, par value $0.001 per share</b></p></td><td style="vertical-align:top;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:TradingSymbol" id="Tc_69bD9rcA8UaaqgZaA3qzXA_2_1"><b style="font-size:7pt;font-weight:bold;">BTAI</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;white-space:pre-wrap;">  </b><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:SecurityExchangeName" id="Narr_7ya4PzZ5gEu5BOMgseq77g"><b style="font-size:7pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:&#160;<b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">  </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_NrAO8lkudEyJU2pFNFBiFA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">  </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityVoluntaryFilers" id="Narr_WnIM-cjaI0egUynFRbgfYA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityCurrentReportingStatus" id="Narr_fWjLgQao-UCfEmLC5NCc6A"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityInteractiveDataCurrent" id="Narr_fFV1iEc_xEKOad_ZacOf1Q"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 0pt 10pt;">Large&#160;accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:18pt;margin:0pt;">Accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityFilerCategory" id="Narr_l3wJMGfwtECT5zAnSA2x3w"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p></td><td style="vertical-align:top;width:27.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;">Smaller&#160;reporting&#160;company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntitySmallBusiness" id="Narr_jxsg_BGdREeJu6d2cayLBg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 10pt;"><span style="font-size:7pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityEmergingGrowthCompany" id="Narr_uEUQQda_b0uGk1yw4XLsgg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;text-indent:18pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:IcfrAuditorAttestationFlag" id="Narr_60MFf6XUhU2g2EU42pu_KQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_PoE8soLhIkGejdIr_uQI9A"><span style="font-size:7pt;">&#61551;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#61551;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:EntityShellCompany" id="Narr_IFB5_FMcE0uLcn_fe3Hc4Q"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt;">As of June 30, 2023, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2023_8OBjMItu10CBEHoI7-kTZQ" decimals="0" name="dei:EntityPublicFloat" id="Narr_RAiKlHS22kyLMA6a-t1_kw">134,938,946</ix:nonFraction> (based upon the closing sale price of the registrant&#8217;s common stock reported on the Nasdaq Capital Market on that date). This calculation excludes shares held by the registrant&#8217;s current directors and executive officers and stockholders that the registrant has concluded are affiliates of the registrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_18_2024_SyzKieY9dk2q39Ecc0mTCg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_ydwpwXlsLUCZop-aQKNLcw">30,576,671</ix:nonFraction> shares of our common stock outstanding at March 18, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:36pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt;">Portions of the registrant&#8217;s definitive proxy statement for its 2024 annual meeting of stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><a id="_9319cf8f_7f3b_4b46_a005_5009eabebd33"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#FORWARDLOOKINGSTATEMENTS_331203"><span style="font-style:normal;font-weight:normal;">Forward Looking Statements</span></a></p></td><td style="vertical-align:bottom;width:10.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SummaryRiskFactors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_674733"><span style="font-style:normal;font-weight:normal;">Part&#160;I.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1Business_810543"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1Business_810543"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_143189"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1ARiskFactors_143189"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_512583"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_512583"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Item 1C</span></a>.</p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2Properties_105398"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item2Properties_105398"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3LegalProceedings_216198"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item3LegalProceedings_216198"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_460898"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_460898"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PartII_326423"><span style="font-style:normal;font-weight:normal;">Part&#160;II.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6Reserved_721061"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item6Reserved_721061"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">120</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">136</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">136</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">137</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9AControlsandProcedures_710755"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9AControlsandProcedures_710755"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">137</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9BOtherInformation_895714"><span style="font-style:normal;font-weight:normal;">Item&#160;9B</span></a>.</p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9BOtherInformation_895714"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">137</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">139</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTIII_44466"><span style="font-style:normal;font-weight:normal;">Part&#160;III.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">140</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_58666"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_58666"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">140</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">141</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">141</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">141</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PARTIV_900935"><span style="font-style:normal;font-weight:normal;">Part&#160;IV.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item15ExhibitsFinancialStatementSchedule"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">141</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item16Form10KSummary_689937"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#Item16Form10KSummary_689937"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">146</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SIGNATURES_328256"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">147</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d5a037e6_ede0_4abf_ab94_ba79c0f79219"></a><a id="FORWARDLOOKINGSTATEMENTS_331203"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements contained in this Annual Report on Form 10-K, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sales strategy for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategy relating to, anticipated benefits from, and cost savings from our Reprioritization (as defined herein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital and continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our TRANQUILITY program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of our total addressable markets and related underlying estimates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans relating to clinical trials and marketing applications for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to research, develop and commercialize our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to seek to enter into collaborations for the development and commercialization of certain product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of any future collaboration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and results of discussions we have with regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance, clinical utility, number of prescribers and formulary wins of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and manufacturing capabilities and strategy, including the potential benefits from any advertising campaigns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our participation in, and any potential benefits from, events, conferences, presentations and conventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and need for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential investments in, or other strategic options for, our subsidiary, OnkosXcel Therapeutics, LLC (&#8220;OnkosXcel&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with covenants under our financing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments related to legal proceedings and investigations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our relationship with BioXcel LLC.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those listed under Part&#160;I, Item&#160;1A. &#8220;Risk Factors,&#8221; Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report on Form 10-K. These and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) could cause actual results to differ materially from those indicated by the forward-looking statements made in this filing. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">As used in this Annual Report on Form 10-K, unless otherwise specified or the context otherwise requires, the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;BTI&#8221; refer to BioXcel Therapeutics, Inc., and &#8220;BioXcel, LLC&#8221; refers to the Company&#8217;s former parent company and significant stockholder, BioXcel LLC, and its predecessor, BioXcel Corporation.  All brand names or trademarks appearing in this Annual Report on Form 10-K are the property of their respective owners, including IGALMI</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, which is a trademark of BioXcel Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may use our website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors &amp; Media section of its website at <i style="font-style:italic;">www.bioxceltherapeutics.com</i>. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the &#8220;Email Alerts&#8221; option under the News / Events menu of the Investors &amp; Media section of our website at <i style="font-style:italic;">www.bioxceltherapeutics.com</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SummaryRiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our strategic reprioritization and related reduction in force may not achieve our intended outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement (as defined herein) would trigger an event of default thereunder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under our financing facilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience in drug discovery and drug development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease and may also subject us to additional risks and uncertainties, including regulatory, stockholder or other actions, loss of investor confidence and negative impacts on the trading price of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the near term, we are dependent on the success of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and four of our product candidates, BXCL501, BXCL502, BXCL701 and BXCL702. If we are unable to complete the clinical development of or obtain marketing approval for our product candidates or successfully commercialize </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or our product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;), and comparable foreign authorities are lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, difficult to design, difficult to conduct and involve an uncertain outcome.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on enrollment of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The discovery and development of product candidates based on EvolverAI, BioXcel LLC&#8217;s proprietary pharmaceutical discovery and development engine, as well as our own AI platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Although the FDA has approved IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and for any product candidates for which we obtain approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Although we obtained FDA approval for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, our products and product candidates may not be accepted by physicians or the medical community in general, and there may be insufficient insurance coverage and reimbursement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are found in violation of federal, state or foreign health care &#8220;fraud and abuse&#8221; laws, we may be required to pay significant fines and penalties, which may adversely affect our business, financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We continue to depend on BioXcel LLC to provide us with certain services for our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BioXcel LLC has significant influence over the direction of our business, and the concentrated ownership of our common stock will prevent you and other stockholders from influencing significant decisions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on third parties for the manufacture of our clinical supplies of our product candidates, and our commercial supplies of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, and we intend to rely on third parties to produce commercial supplies of any other approved product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data breaches or cyber-attacks could disrupt our business, operations and information technology systems, and financial results, or result in the loss or exposure of confidential or sensitive Company information.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business. Such proceedings,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claims and investigations could be costly and time-consuming to defend and could result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face risks associated with the increased scrutiny relating to environmental, social and governance matters.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TRADEMARKS, TRADE NAMES AND SERVICE MARKS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This Annual Report includes our trademarks, trade names and service marks, including, without limitation, &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>&#8221; and our logo, which are our property and are protected under applicable intellectual property laws. Solely for convenience, trademarks, trade names and service marks may appear in this Annual Report without the &#174;, TM and SM symbols, but such references are not intended to indicate, in any way, that we or the applicable owner forgo or will not assert, to the fullest extent permitted under applicable law, our rights or the rights of any applicable licensors to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDUSTRY AND OTHER DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless otherwise indicated, information contained in this Annual Report concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. While we believe the information from these third-party publications, research, surveys and studies included in this Annual Report is reliable, we do not guarantee the accuracy or completeness of such information, and we have not independently verified this information. Management&#8217;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in this Annual Report under &#8220;Forward Looking Statements,&#8221; &#8220;Risk Factor Summary&#8221; and Part I, Item 1A &#8220;Risk Factors.&#8221; These and other factors could cause our future performance and market expectations to differ materially from our assumptions and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5ac40da6_e0f1_4e7b_8e07_54489b683dbe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="PARTI_674733"></a><a id="_7b7ab54c_8f2a_4db7_ba0a_ef13fcd326f0"></a><a id="Item1Business_810543"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;1. Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.38;text-indent:15.75pt;margin:0pt 6.95pt 0pt 2pt;">BioXcel Therapeutics, Inc. (&#8220;BTI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and, through the Company&#8217;s wholly owned subsidiary, OnkosXcel Therapeutics LLC (&#8220;OnkosXcel&#8221;), immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On April 6, 2022, we announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (dexmedetomidine (or &#8220;Dex&#8221;)) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> was commercially available in doses of 120 and 180 microgram (&#8220;mcg&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;">Our most advanced neuroscience candidate is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">,</sup> BXCL501 is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease in the at-home setting and in care facilities. As described further below, we have<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>deprioritized the development of BXCL501 for certain other proposed indications, including development of BXCL501 as a potential adjunctive treatment for major depressive disorder (&#8220;MDD&#8221;), as well as our BXCL701 program, except as noted under &#8220;Immuno-Oncology&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator being developed by OnkosXcel as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Neuroscience</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Neuroscience Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our goal is to become the leading AI-enabled neuroscience therapeutics company. We continue to evaluate all strategic options for our neuroscience assets, which could include licensing, partnering, and co-commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Novel Drug Re-Innovation Approach</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We aim to deploy and implement, throughout the drug development process, an AI ecosystem designed to rapidly identify medications related to our key focus areas of neuroscience and immuno-oncology. Our in-house, uniquely integrated AI-to-drug-development capability is complemented by the services and technology of BioXcel LLC, our former parent company. It includes a labeled properties graph (also referred to as a &#8220;knowledge graph&#8221;) that visually relates collected big data in the form of entities and their properties that include neuropsychiatric symptoms, brain circuits, drug targets, and existing drugs. We believe that understanding the relation between entities relevant to drug development may lead to novel potential uses for existing drugs. Predictive algorithms or queries of the knowledge graph may uncover not only single drugs but potentially identify new combinations of drugs that we believe may be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">more effective in treating disorders than single agents. New combinations of drugs may lower tolerable doses of drugs and provide the basis for stronger intellectual property positions. Our AI team works closely with our Business Development team to prioritize in a data-driven manner the most valuable external opportunities. These opportunities may be found in new potential uses for launched drugs, in drugs that are part of pharmaceutical company pipelines no longer being pursued, or within academic efforts to develop new drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Traditional drug development is marred by low success rates, long drug development cycles, and exorbitant development costs that are increasing year over year. In addition, many serious diseases remain unaddressed due to limitations of the current drug discovery paradigm.  The pharmacological universe spans more than 27,000 active pharmaceutical agents, of which only approximately 4,000 are approved and marketed. Marketed drugs may not be exclusively effective in the indication for which they are approved but relevant to other indications, including rare diseases, and thus represent an untapped potential for addressing unmet medical needs and recouping research and development costs. Many of the remaining agents are active clinical candidates that are shelved or have failed for reasons other than toxicity, which offers the opportunity to re-innovate for other indications or patient segments. Such agents potentially represent an unrealized investment of billions of research and development dollars by the private and public sectors, while failing to remediate immeasurable patient suffering and sacrifice during clinical development. Also, these compounds may have known pharmaco-dynamic and pharmaco-kinetic properties, potentially allowing for a more data-driven selection of appropriate doses for development programs. Finally, with respect to neuropsychiatric indications, we prioritize those compounds with structural design features that we believe may contribute to high blood-brain barrier permeability, and therefore could increase the likelihood of compound penetration into the brain. Lack of brain penetration is a common cause for failure of many drugs developed for neuropsychiatric indications. In addition, we are prioritizing compounds with available human safety data, acceptable pharmacokinetic results, and data that support a high probability of achieving reasonable brain concentrations after dosing. The compounds in our pipeline have been identified using this proprietary platform.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This drug re-innovation model has been exemplified by the successful development and commercialization of drugs such as Tecfidera<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Biogen, Inc.), Thalomid<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Celgene Corporation), and Viagra<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Pfizer, Inc.). All of these drugs were identified by insights in biology and disease pathophysiology. The successful business models of biotech companies like Axsome Therapeutics, Inc. and Karuna Therapeutics, Inc. are based on the re-innovation and combination of existing clinical candidates or marketed drugs to provide novel solutions for patients. Unfortunately, such discoveries have been severely limited in scope due to the lack of a genuinely integrated approach to mining big data and advanced analytics. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our AI-based discovery and development process is the foundation of our drug re-innovation model for identifying the next wave of potential medicines. Our therapeutic area experts have over 200 years of combined experience across the drug discovery and development value chain. We believe that our method of finding potential product candidates gives us a higher probability of success because it combines AI expertise and intuition of human experience in drug development. We believe the combination of AI and drug discovery and development expertise facilitates the generation of therapeutic candidates and gives us a significant competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:268.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our approach is illustrated below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k001.jpg" alt="Graphic" style="display:inline-block;height:267.83pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:476.11pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We continue to integrate and evolve our neuroscience and immuno-oncology AI machine learning and drug discovery and development platform. Our platform led to the identification of Dex, the rapid development of BXCL501, and its approval by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, as well as the advancement of BXCL501 for other potential indications. We are continuing to leverage our platform to identify and develop new neuroscience and immuno-oncology programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:232.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Neuroscience Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a summary of the status of our neuroscience clinical development programs as of the date of this Annual Report on Form 10-K: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k002.jpg" alt="Graphic" style="display:inline-block;height:231.8pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a selective adrenergic agent with a sublingual or buccal route of administration, BXCL501 is designed to be easy to administer and has shown a rapid onset of action in multiple clinical trials, including clinical trials studying patients with schizophrenia, bipolar disorders, and dementia. We believe the results from these studies suggest that BXCL501 has the potential to generate a calming effect without producing excessive sedation. We believe that BXCL501 is highly differentiated from antipsychotics currently used as a standard of care for the treatment of agitation that often produce unwanted side effects such as excessive sedation and extra-pyramidal motor effects. Managing patient agitation in neuropsychiatric and neurodegenerative disorders represents a significant challenge for physicians and caregivers. We believe that BXCL501 has the potential to address these challenges while providing an efficient treatment regimen for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agitation Overview and Market Opportunity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Agitation in patients with neuropsychiatric diseases is a serious medical condition. Agitation is characterized by feelings of unease, excessive talking, and/or unintentional and purposeless motions, such as wringing of the hands or pacing. People experiencing agitation may also express excitement, hostility, poor impulse control, tension, uncooperativeness, and occasional disruptive behavior, which may lead to aggression and violence. In many cases, people develop agitation when treatment for their underlying disorder is not working well. Stressful situations or traumatic events can also trigger agitation. Agitation can occur suddenly or slowly and vary in length, lasting for a few minutes or for an extended period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">With the agitation issues associated with schizophrenia and bipolar disease coupled with a fast-growing elderly population that is potentially likely to experience agitation associated with Alzheimer&#8217;s disease, the difficulties and expenses of acute treatment of agitation are expected to grow significantly. We estimate that in the United States, there are approximately 1.9 million patients diagnosed with Alzheimer&#8217;s disease-related dementia (&#8220;AAD&#8221;) and that those patients experience agitation at a rate of about six episodes per month, on average.  In addition, we estimate that there are approximately 1.6 million Americans diagnosed with schizophrenia or bipolar disorders and that those patients experience agitation at a rate of about three episodes per month, on average. We, therefore, believe there is significant potential market opportunity for BXCL501 if approved for use in these patient populations in the at-home setting. The </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">foregoing estimates of the incidence of each patient population and the number of agitation episodes experienced and potential market opportunity are based on management&#8217;s estimates and third-party data, which may be materially different from actual agitation episodes and actual treatable patients. For additional information regarding risks associated with these estimates, see Part I, Item 1A, Risk Factors </span><i style="font-style:italic;">&#8220;&#8212; Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatments for Agitation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Antipsychotics, the current standard of care for acute treatment of agitation in schizophrenia and bipolar disorder, are also used off-label to treat agitation in dementia and other conditions. Side effects of these medications include movement disorders, including akathisia and extrapyramidal symptoms. One of the serious limitations of these drugs is that they can sedate the patient and do not permit verbal interaction with the hospital staff to continue. Intramuscular (&#8220;IM&#8221;)-delivered antipsychotics, such as haloperidol and olanzapine, are used extensively in this setting but are invasive and often require patient restraint. This type of treatment can dehumanize patients and cause trauma that could have long-term impact on them. Furthermore, these treatments include a black box warning for use in elderly patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While sublingual tablet formulations utilizing antipsychotics have been developed, these formulations have long half-lives (21-24 hours) and significant side effects when given acutely or chronically. Oral agents such as benzodiazepines are also used but have a slow onset of action and are consequently ineffective in the acute treatment of agitation. Side effects of these agents include sedation, amnesia, confusion, and paradoxical responses. They can intensify cognitive slowing and worsen memory and motor impairment, contributing to an increased risk of falls and fractures. In addition, long-term use of benzodiazepines has been found to be habit-forming and can cause addiction or relapse to abuse substances. Nonadherence with oral agents can also be problematic as patients may attempt to spit out these medications. We believe that, based on the current method of administration of oral medicine for agitation, an orally dissolving, mucoadhesive film could offer compliance advantages by making it less likely that patients will avoid treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The sublingual or buccal route of administration is an accepted alternative to oral administration of drug delivery to the central nervous system when rapid onset or more controlled delivery is required. Currently, there are six products approved for film administration, including our product, IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>. For example, BioDelivery Sciences International, Inc., a commercial-stage specialty pharmaceutical company, has developed a buccal film formulation of buprenorphine for chronic pain management and buprenorphine and naloxone for opioid dependence. We developed BXCL501 as a differentiated sublingual film dosage form of Dex, which we believe may offer benefits such as ease of use and quick absorption for rapid therapeutic effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mechanism of Action: &#945;2a Adrenergic Receptor and NE Role in Acute Agitation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">BXCL501 is a sublingual formulation of Dex that is designed to be easily administered and have a rapid onset of action. Dex is approved in the U.S. for the sedation of initially intubated and mechanically ventilated patients during treatment in the intensive care unit (&#8220;ICU&#8221;). It is also used in the intensive care setting for sedation of non-intubated patients prior to and/or during surgical and other invasive procedures. Dex, launched in the U.S. as Precedex<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#8482;</sup> in 1999, is a selective &#945;2a adrenergic receptor agonist that has a strong safety record and has been studied in over 130 clinical trials to date. It has also been sold in the European Union (&#8220;EU&#8221;) and other countries under the trade name Dexdor<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> as a sedative for intensive care patients. Dex was approved by the European Commission for sedation of adult ICU patients requiring a sedation level no deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale 0 to -3). It has been used to prevent or treat hyperactive delirium resulting from anesthesia in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the ICU. Given these uses of the IV formulation of Dex, we believe Dex formulated in a sublingual film and at much lower doses allows for ease of administration in settings where rapid acute treatment of agitation is needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">IGALMI</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-style:italic;font-weight:bold;"> Commercial Progress</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We continue to support IGALMI&#8482; in the hospital setting through limited and focused commercial activity.&#160; On August 14, 2023, the Company announced it had implemented a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer deemed core to the Company&#8217;s business, and a shift to focus on the development of BXCL501 for use in the at-home and care facilities in the treatment of acute agitation in schizophrenia and bipolar disorders, and in the treatment of acute agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease (collectively, the &#8220;Reprioritization&#8221;). Following the Reprioritization, a small Corporate Account Director (&#8220;CAD&#8221;) team supports current customers and targeted Integrated Delivery Networks (&#8220;IDNs&#8221;) with educational support and contracting opportunities, while our trade operation supports customers with drug supply.&#160; The goal of this approach is to help maintain current business and potentially broaden IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> utilization through volume contracting. Over time, we believe the revised commercial effort is expected to allow the Company to continue to make inroads into the institutional market in a more cost-efficient manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Commercial efforts for the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> launch were impacted significantly in the six months ended December 31, 2023 due to the reduction in force, which included the elimination of sales, marketing, and commercial operations staff. The realigned CAD team generated $376,000 in net revenue for the three-month period ended December 31, 2023 through legacy sales and volume-based contracts, up from $341,000 for the three-month period ended September 30, 2023. Net revenues from IGALMI&#8482; product sales for the years ended December 31, 2023 and 2022 were $1.4 million and $375,000 respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On October 30, 2023, we announced that the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) assigned a new J-Code for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (J1105). J-Codes are permanent codes used by healthcare providers, commercial insurance plans, and government payers to help standardize the reimbursement process. A J-Code can help simplify claims submission as compared to use of a miscellaneous or unlisted code, which in turn can streamline the billing and reimbursement process. The J-Code for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> has been published online in the CMS HCPCS Application Summaries and Coding Recommendations, Third Quarter, 2023 HCPCS Coding Cycle. We believe this J-Code, which became effective on January 1, 2024, will facilitate access to IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> for patients with agitation associated with bipolar disorder or schizophrenia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved outside the U.S., we would consider launching the product through collaborations with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our continued commercialization efforts for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> are designed to build the foundation to launch additional potential follow-on indications, if any, paving the way for our expanding neuroscience business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">BXCL501 Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, BXCL501 remains an investigational, proprietary, orally dissolving film formulation of Dex, a selective alpha-2 receptor agonist, targeting symptoms from stress-related behaviors such as agitation. BXCL501 is our most advanced neuroscience clinical program, being evaluated for the at-home acute treatment of agitation related to bipolar disorders or schizophrenia and for the acute treatment of agitation (non-daily) in patients with dementia due to probable Alzheimer&#8217;s disease in care facilities and at-home settings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As a selective adrenergic agent with a sublingual or buccal route of administration, BXCL501 is designed to be easily administered and, compared to medications that may take days or weeks, has shown a relatively rapid onset of action in multiple clinical trials, including those studying patients with bipolar disorders, schizophrenia, and Alzheimer&#8217;s disease. We believe results from these studies suggest that BXCL501 has the potential to reduce agitation without producing excessive sedation. We also believe BXCL501 is highly differentiated from antipsychotics, which are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">currently used as first-line standard-of-care treatments despite often producing unwanted side effects such as excessive sedation or extra pyramidal motor effects. Managing patient agitation in neuropsychiatric and neurodegenerative disorders represents a significant challenge for physicians and caregivers. We believe BXCL501 has the potential to address these challenges while providing an efficient treatment regimen for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We also believe that BXCL501, if approved for the respective indications, has the potential to become the standard of care for the acute treatment of agitation arising from diseases such as schizophrenia and bipolar disorder and Alzheimer&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, given the differentiated design of BXCL501 and its potential mechanism of action, we believe BXCL501 has the potential to address several diseases or conditions for which agitation is a symptom of the condition or underlying disease, including opioid withdrawal and post-traumatic stress disorder (&#8220;PTSD&#8221;), which are being evaluated in clinical trials run by third-parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">BXCL501 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">TRANQUILITY Program: Acute Agitation Associated with Dementia due to Probable Alzheimer&#8217;s Disease (AAD)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On June 29, 2023, we announced positive topline results from TRANQUILITY II, a randomized, double-blind, placebo-controlled, parallel group trial that evaluated the safety and efficacy of BXCL501 for the acute treatment of Alzheimer&#8217;s-related agitation in adults 65 years and older with mild to moderate dementia in assisted living facilities (&#8220;ALFs&#8221;) and residential care settings who required minimal assistance with activities of daily living. The trial dosed 149 patients. Randomized patients self-administered 40 mcg or 60 mcg of BXCL501 or placebo for agitation episodes that occurred over a 12-week period. The primary endpoint was the change from pre-dose in PEC total score at 2 hours post-dose for the first treated episode of agitation. The key secondary efficacy endpoints were PEC change from pre-dose at 1-hour post-dose of study treatment for the first treated episode of agitation, and PEC change from pre-dose at 30 minutes post-dose of study treatment for the first treated episode of agitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The Phase 3 trial met its primary efficacy endpoint with the 60 mcg dose; a statistically significant and clinically meaningful 7.5 point reduction from baseline in Positive and Negative Syndrome Scale-Excitatory Component (&#8220;PEC&#8221;) total score was observed at 2 hours versus 5.4 with placebo (p=0.0112). The 60 mcg dose also met the first key secondary endpoint of reducing agitation symptoms at 1 hour during the first episode of agitation (p=0.0185) but did not meet the other key secondary endpoint of change from baseline in PEC score at 30 minutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Efficacy for this dose was supported by several secondary measures, including CGI-Improvement and Agitation-Calmness Evaluation Scale. Most patients (76%) responded to the first 60 mcg dose and were determined to be &#8220;Very Much&#8221; or &#8220;Much Improved&#8221; (CGI-I of 1 or 2, respectively) compared to 50% with placebo. The primary endpoint was not met for the 40 mcg dose, with a 5.7 point reduction from baseline in PEC score.    </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;">On June 29, 2023, we also announced that we had learned that an investigator in this study, who enrolled approximately 40% of the patients, engaged in misconduct. Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Our TRANQUILITY III trial was designed to evaluate the safety and efficacy of BXCL501 in patients residing predominantly in nursing homes with moderate to severe dementia due to Alzheimer&#8217;s disease who require moderate or greater assistance with activities of daily living. We halted additional enrollment in this Phase 3 after initial enrolled patients were observed to have more frequent episodes of agitation than originally anticipated, suggesting that agitation may present chronically in this population. Due to the chronic nature of agitation episodes observed in this population thus far, we believe that continued evaluation of BXCL501 in this population would require a different development program targeting more frequent or chronic use. We have chosen to focus our development efforts on the urgent need for episodic treatment in the care facility and at-home setting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0.3pt 0pt 0pt 0pt;">In a Type B/Breakthrough Therapy designation meeting with the FDA on October 11, 2023, we reviewed our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">TRANQUILITY clinical trial program and discussed the data package required to support submission of an sNDA for the potential approval of BXCL501 for the acute treatment of agitation in patients with mild to moderate dementia due to probable Alzheimer&#8217;s disease in the ALF and at-home settings. Specifically, we sought feedback from the FDA as to whether our data package consisting of TRANQUILITY I and II, along with the clinical pharmacology and toxicology programs previously discussed with the FDA, would be sufficient to support an sNDA submission for the potential use of BXCL501 to treat agitation in patients with mild to moderate dementia due to probable Alzheimer&#8217;s disease in either the at-home or ALF setting, or, if not, what additional data would be required. Based on the FDA&#8217;s feedback in this meeting, we understand that the FDA will require additional efficacy data, including repeat efficacy data, and that it requested long-term safety data. We therefore requested another meeting with the FDA to further discuss the additional data that would be required to support an sNDA submission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0.3pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">On February 20, 2024, we held a Type B/Breakthrough Therapy designation meeting with the FDA. The original purpose of this meeting was to obtain feedback on the design of a proposed at-home study that did not include caregiver-collected efficacy endpoints, based on our belief that obtaining caregiver assessments of efficacy would be challenging. We believe there are no validated caregiver endpoints for assessing efficacy in Alzheimer&#8217;s disease patients in the at-home setting. As a result, we focused on requesting feedback from the FDA regarding our proposal for an at-home clinical study with safety as the primary objective, and to better understand what additional data would be required to submit an sNDA to support labeling for BXCL501 to include the acute treatment of agitation associated with dementia in probable Alzheimer&#8217;s disease or, in the alternative, in this population in the care setting only.  In its preliminary responses, the FDA reiterated its prior comments that we generate additional efficacy data, including repeat-dose efficacy data, to support an sNDA submission, as the FDA indicated that our proposed efficacy database, which currently includes the 70 patients who have been treated with 60 mcg of BXCL501 in TRANQUILITY I and TRANQUILITY II, would not contain substantial evidence of effectiveness absent additional data. The FDA advised that we generate the necessary efficacy data in care facilities prior to conducting any trials in the at-home setting. In addition, the FDA indicated the need to generate long-term safety data to support an sNDA submission, including from probable Alzheimer&#8217;s disease patients exposed to BXCL501, for up to one year. We have received the final meeting minutes from the FDA, which we believe are consistent with the FDA&#8217;s preliminary responses and the subsequent meeting discussion. Based on the FDA&#8217;s feedback, we are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia using the Positive and Negative Syndrome Scale-Excitatory Component (&#8220;PEC&#8221;) as the primary efficacy measure, as used in the prior TRANQUILITY II study. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. Also, although we announced in November 2023 that we were planning to conduct a Phase 3 trial in the at-home setting, with safety as the primary objective (TRANQUILITY At Home), given the priority to expand the database to generate additional efficacy and safety data in care facilities, we are re-evaluating the timing for initiating TRANQUILITY At Home.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">SERENITY Program: Agitation Associated with Bipolar Disorders I and II and Schizophrenia (at-home use)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We initiated the SERENITY III clinical study of BXCL501 in patients with agitation associated with bipolar disorders or schizophrenia in SERENITY III, which consists of two parts. The first part was comparable to our pivotal SERENITY I and II studies. Using similar inclusion and exclusion criterion under a well-controlled in-patient setting, acutely agitated patients with schizophrenia or bipolar disorders were randomized to self-administer either 60 mcg of BXCL501 or placebo in a double-blind placebo-controlled trial. The primary endpoint of Part I was efficacy, as measured by the change in PEC score change from baseline at two hours post-dose. The secondary objectives of Part I were safety and tolerability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On May 25, 2023, we reported topline results from Part I of the study. Although the trial did not meet its primary efficacy endpoint, we believe the efficacy results, observed with the 60 mcg dose, representing half of the lowest approved dose of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> for in-patient use (120 mcg), were promising. Specifically, greater than 50% of individuals were responders, defined as those patients who achieved a 40% or greater reduction in PEC score. Furthermore, this population responder rate was consistent and dose-proportionate to the same response rates observed in the larger SERENITY I and II trials. Although the primary efficacy endpoint as a group mean change in PEC score from baseline at 2 hours was not statistically significant at the primary endpoint at 2 hours (p=0.077), BXCL501 statistically separated from placebo at 4 hours (p=0.049). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Part II of the SERENITY III study was designed to evaluate the same dose tested in Part I, 60 mcg (with an optional additional 60 mcg dose), but in the at-home setting and focusing on safety only. However, because the trial did not meet its primary efficacy endpoint using this 60 mcg dose in Part I, we paused continuation of Part II of the study pending feedback from the FDA. We held a Type C meeting on November 8, 2023 with the FDA to discuss changes to Part II of our SERENITY III study. We proposed the evaluation of an 80 mcg dose based on previous clinical experience with this dose during our Phase 1b trial in schizophrenia patients with agitation, and pharmacokinetic and pharmacodynamic modeling suggesting that use of an 80 mcg dose of BXCL501 could provide an optimal balance between safety and efficacy for at-home use. Based on feedback from the FDA during the meeting, we made the decision to evaluate a 120 mcg dose in the at-home setting. The 120 mcg dose has already demonstrated efficacy based on the approved conditions of use for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="white-space:pre-wrap;"> (when administered under the supervision of a healthcare provider, for a single agitation episode), so we sought further feedback from the FDA regarding the proposed design of this study amendment in a request for a follow-up meeting with the FDA, which was held on March 6, 2024.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Based on the FDA&#8217;s feedback in advance of and during the March 6, 2024 meeting, we plan to move forward to evaluate at-home use of the 120 mcg dose of BXCL501, with safety as the primary objective and efficacy measures as exploratory endpoints to support continued efficacy in the at-home setting as recommended by the FDA in the November 8, 2023 meeting, for the acute treatment of agitation in bipolar disorders or schizophrenia. We also plan to conduct a clinical study designed to enroll approximately 30 patients to evaluate the correlation between patient-reported or informant-reported efficacy with trained rater-reported efficacy using PEC measurements, which the FDA had previously recommended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is already approved at the 120 mcg dose based on efficacy data that we previously generated in treating a single episode of agitation. Consistent with the data generated to date, the label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> currently includes a limitation on use (&#8220;LOU&#8221;), noting the lack of efficacy or safety data beyond 24 hours following the first dose. During our March 6, 2024 Type C meeting with the FDA, we discussed, among other things, whether evaluating the at-home use of BXCL501 120 mcg, with safety as the primary objective and efficacy measures as exploratory endpoints, if successful, could support the submission of an sNDA seeking expansion of the current label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> 120 mcg to allow at-home use and labeling without the current LOU. Based on FDA feedback, we believe that our ability to seek labeling without the current LOU will depend, in part, on the number of agitation episodes we observe during our planned study period. We plan to provide further guidance regarding our plans for the SERENITY program following receipt of the final meeting minutes from the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Adjunctive treatment in&#160;Major Depressive Disorder (&#8220;MDD&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We were previously evaluating BXCL501 as an adjunctive treatment for MDD. The initial clinical study in this program was a double-blind, placebo-controlled, multiple ascending dose (&#8220;MAD&#8221;) trial to evaluate the safety and tolerability of daily doses of BXCL501 in healthy volunteers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">On May 16, 2023, we reported positive topline results from a MAD study. It enrolled 125 healthy adult volunteers across seven different cohorts in a 2:1 randomization to BXCL501 or placebo film. Healthy volunteers were dosed for 7 consecutive days. Both safety and pharmacokinetics were assessed.  The study included 7 cohorts. Four distinct cohorts received 30 mcg, 60 mcg, 80 mcg, or 120 mcg doses of BXCL501 or placebo once daily. Two additional dosing cohorts received twice-daily (BID) BXCL501 at either 30 mcg in the morning and 60 mcg in the evening, or 40 mcg in the morning and 80 mcg in the evening. The final escalation cohort evaluated BXCL501 at 60 mcg in the morning and 80 mcg in the evening in combination with 30 mg of duloxetine BID. BXCL501 was generally well tolerated across all dosing cohorts. Based upon pre-specified stopping criteria, a maximum tolerated dose was not reached. All adverse events were reported as mild or moderate. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">As part of the Reprioritization announced on August 14, 2023, we have paused our plan to develop a Phase 2 human proof-of-concept trial design to investigate BXCL501 as a potential adjunctive treatment and its potential accelerant effect in combination with first-line selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Pediatric Study</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In June 2021, we initiated a global clinical trial designed to evaluate the safety and efficacy of BXCL501 in the acute treatment of agitation associated with pediatric schizophrenia and bipolar disorders, in part to fulfill pediatric study requirements agreed to with the FDA in connection with the approval of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>. The trial protocol has been reviewed by the FDA, as well as by the European Medicines Agency, to fulfill potential commitments to study the effects of BXCL501 in pediatric patients ages 13 to 17 with schizophrenia and ages 10 to 17 with bipolar disorders. Enrollment of patients with schizophrenia, schizoaffective disorder, bipolar I, and bipolar II disorder is ongoing in this multisite, double-blind, placebo-controlled parallel group trial. Approximately 54% of the 150 total subjects have been enrolled in the U.S. and 81 of such subjects have completed the clinical trial. In July 2023, we stopped activities in the European region as enrollment and site recruitment was unproductive. Similar to our registration trials in schizophrenia and bipolar disorder (SERENITY I and II), the primary endpoint is the change from baseline PEC total score at two hours. The U.S. portion of this program remains active following the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Neuroscience Opportunities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">BXCL501 Pipeline Opportunities for Franchise Expansion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Given the differentiated design of BXCL501 and its selective mechanism of action, we believe BXCL501 has the potential for broad applicability across several indications where agitation is a symptom of a condition or underlying disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Government-Supported Investigator-Initiated Trial Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company has been awarded key opportunities for the development of BXCL501 in post-traumatic stress disorder (&#8220;PTSD&#8221;), alcohol use disorder (&#8220;AUD&#8221;), and opioid use disorder (&#8220;OUD&#8221;). These are being funded through Cooperative Agreements with the U.S. Department of Defense Congressionally Directed Medical Research Program and National Institute on Drug Abuse (&#8220;NIDA&#8221;).  Clinical and regulatory responsibilities are led by clinical researchers and regulatory staff at the Veterans Affairs Connecticut Healthcare System, Yale University Medical School, RTI International, Columbia University New York State Psychiatric Institute, and NIDA. The Company has retained all rights to commercialization of BXCL501 in all potential indications evaluated in clinical trials supported by the U.S. government.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><b style="font-weight:bold;background:#ffffff;">Opioid Use Disorder Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 22.3pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.5pt;margin:0pt;"><span style="background:#ffffff;">As previously announced, NIDA awarded a grant to Columbia University to fund clinical testing of BXCL501 as a potential treatment for opioid withdrawal in patients diagnosed with OUD. The original 160-patient, three-site, four-arm</span><span style="background:#ffffff;">&#160;</span><span style="color:#212121;">study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 mcg and 240 mcg BID), lofexidine (as a positive control), and placebo. The study&#8217;s goal is to evaluate the safety and efficacy of BXCL501 relative to lofexidine and placebo in subjects with OUD.</span><span style="color:#212121;">&#160; A </span><span style="color:#212121;">majority of OUD patients participating in the study are anticipated to be exposed to</span><span style="background:#ffffff;"> fentanyl adulterated or associated with xylazine</span><span style="color:#212121;">. To date, a</span><span style="background:#ffffff;">ll three initial sites have recruited, enrolled, and dosed patients diagnosed with OUD who are physically dependent on opioids, including prescription opioids. The Company is supplying the drug product for the conduct of this study, which is sponsored by Columbia University</span><span style="color:#212121;">. We expect that the results from current study will be used to select a recommended dose of BXCL501 to compare to placebo in a later outpatient Phase 3 study sponsored by </span><span style="background:#ffffff;">NIDA. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On November 6, 2023, we announced that NIDA has requested Columbia University, the trial coordinator, to add a fourth site to target trial completion in 2024.</span> <span style="background:#ffffff;">The patient screening and enrollment process for the fourth site commenced in March 2024. Pending favorable results, after completion of the trial, we plan to seek FDA feedback on potential registrational paths.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;background:#ffffff;">Alcohol Use Disorder with Comorbid Post-traumatic Stress Disorder Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2020, the Veterans Affairs Connecticut Healthcare System and Yale University Medical School were awarded a grant by the U.S. Department of Defense&#8217;s Congressionally Directed Medical Research Program with the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">overall objective to evaluate BXCL501 in patients who suffer from AUD with comorbid PTSD. The Company provided BXCL501 for the inpatient Alcohol Interaction Study, which has been completed. We understand Yale is currently seeking approval from its IRB and allowance from the FDA to proceed with a trial evaluating the effects of up to 80 mcg BID of BXCL501 per day for 28 days on alcohol consumption, PTSD symptoms, cognitive function, memory, sleep, and mood in patients diagnosed with mild, moderate, or severe AUD and who meet Criterion A for comorbid PTSD. The new outpatient study has received funding approval from the Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (funded through a Cooperative Agreement between the U.S. Department of Defense Congressionally Directed Medical Research Program and RTI International). We believe the results from this study will be used to inform a Phase 3 study intended to commence with support by the alliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Algorithms for Wearable Technologies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The Company completed a healthy volunteer study designed to train an algorithm to detect a state of hyper-arousal, which often precedes agitated behaviors. In hyper-aroused healthy volunteers, robust signals were measured using wearable technology (phones and watches). As part of the Reprioritization announced on August 14, 2023, we deprioritized our plan to develop wearable technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">BXCL502 Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We identified a second neuropsychiatric drug candidate, BXCL502 &#8722; Latrepirdine (Dimebon) &#8722; through our AI-based platform. We plan to evaluate BXCL502 initially as a monotherapy and possibly in combination with BXCL501 for the chronic treatment of agitation in patients with dementia and acute stress disorder. The active pharmaceutical ingredient (&#8220;API&#8221;) underlying BXCL502 is designed to affect serotonergic signaling in the brain. Our preclinical data suggests BXCL502 has the potential to treat stress-related neuropsychiatric symptoms in dementia and other stress-related disorders. In previously published third-party clinical trial data, daily administration of the API of BXCL502 demonstrated improvement in behaviors using a well-established, clinically validated symptom scale. Formulation and further clinical development planning are currently under way with BXCL502 and are expected to continue in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Product Candidates Leveraging the AI Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are targeting neuropsychiatric disorders with high unmet medical needs. Our focus is on treating stress-related symptoms, such as agitation, that are responsible for increased levels of healthcare burden. We are also using AI approaches and machine learning to identify new candidates for rare neurological diseases and to re-innovate late-stage drug candidates, such as BXCL503, targeting apathy in dementia, and BXCL504, targeting aggression in dementia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We utilize proprietary algorithms to identify associated mechanisms with existing pharmacology to test whether these agents can improve the disease profile in the animal model either through disease modification or symptomatic manner. The agents identified must be those we believe can enter the clinic with the potential for an efficient development path (similar to BXCL501). We are also developing an AI-based research and development platform to help identify potential product candidates and indications across a range of treatment areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Competition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The neuroscience and rare disease segments of the industry are highly competitive. While we believe that our technology, development experience, and scientific knowledge provide competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many of our competitors may have significantly greater financial resources, and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals, and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, if any, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective, more convenient, less expensive, or have fewer or less severe side effects than any medicines we may develop. Our competitors also may obtain FDA or other regulatory approval for their medicines more rapidly than us, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic medicines. There are many generic medicines currently on the market for certain indications that we are pursuing, and additional generics are expected to become available over the coming years. We expect that any of our therapeutic product candidates that are approved will be priced at a significant premium over competitive generic medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any of our other product candidates that are approved, if any, will compete with the drugs discussed below, in addition to any other drugs currently in development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Drugs used for the acute treatment of agitation related to schizophrenia and bipolar disorder are antipsychotics frequently administered via IM injection that typically requires patient restraint. These include IM aripiprazole, olanzapine, ziprasidone, and haloperidol. Oral products include the sublingually administered atypical antipsychotic asenapine, as well as benzodiazepines, lorazepam, and midazolam. The typical antipsychotic Adasuve<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (loxapine) from Alexza is delivered via inhalation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Manufacturing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We do not have manufacturing facilities. We currently rely on strategic manufacturing partners, in particular ARx, LLC (&#8220;ARx&#8221;), and expect to continue to rely on third parties for the manufacture of our product candidates for clinical research and our products for commercialization efforts. ARx has agreed to exclusively manufacture and supply all of our worldwide supply of film formulation of dexmedetomidine to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and for ongoing clinical trials of BXCL501, subject to certain alternative supply provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BXCL501 drug product is manufactured using commercially available components and packaging materials. The equipment employed for manufacture and analysis is consistent with standard pharmaceutical production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Commercialization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to retain worldwide commercialization rights for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and other approved product candidates, if any, but could consider collaboration opportunities to maximize returns or facilitate commercialization efforts in foreign jurisdictions. For additional information regarding our commercialization efforts for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, see above under &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> Commercial Progress.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As product candidates advance through our pipeline, our commercialization plans may change. Clinical data, the size of the development programs, the size of the target market, the required commercial infrastructure, and manufacturing needs may all influence global commercialization strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Neuroscience Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our policy is to protect and enhance the proprietary technologies, inventions, and improvements that are commercially important to our business by filing patent applications in the U.S. and other jurisdictions related to our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">proprietary technology, inventions, improvements, and product candidates. We also rely on trademarks, trade secrets, and know-how relating to our proprietary technologies and product candidates, continuing innovation, and in-licensing technology and products. This reliance is expected to develop, maintain, and strengthen our proprietary position for novel therapeutics and novel formulations of existing therapeutics across multiple therapeutic areas. We also plan to rely on data exclusivity, market exclusivity, and patent term extensions when available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">We have multiple patent families filed to protect our Neuroscience program, including BXCL501.  As of March 15, 2024, our neuroscience patent portfolio included two Patent Cooperation Treaty (&#8220;PCT&#8221;) applications not yet in national phase, 19 U.S. utility applications, seven U.S. provisional applications, one allowed US application, ten issued U.S. utility patents, 112 pending non-U.S. utility applications, 18 allowed or granted non-U.S. patents (including three in Japan), one pending U.S. design patent application, and 34 allowed or registered design patents (including two in Japan). Eight U.S. utility patents, directed to our proprietary sublingual film formulation of Dex and methods of treating agitation, are now listed in the&#160;FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the &#8220;Orange Book&#8221;) for IGALMI&#8482; with expiration dates between 2039 and 2043. In the formulation family, we also have a granted patent in China, two granted patents in Eurasia, and pending applications in the U.S., China, and other major markets. We expect that patents issued in this family will expire no earlier than 2039. We have also filed applications in additional patent families that are relevant to BXCL501. We have applications pending in the U.S., Europe and Japan directed to methods of treating insomnia using sublingual Dex. We expect that patents issued from these applications, if any, will expire no earlier than 2035. We also have applications filed in 16 regions/countries, including the U.S., Europe, Japan, and China, directed to methods of treating agitation. We expect that patents issued from these applications, if any, will expire between 2039 and 2043. We also have one PCT application directed to treating mania and another to treating depression. If patents are issued from those cases, we expect them to expire no earlier than 2041 and 2042, respectively.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In March 2024, the Company announced that the European Patent Office granted the Company&#8217;s European Patent No. 3,562,486 (the &#8220;&#8217;486 patent&#8221;), which covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia. The &#8216;486 patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg. The &#8216;486 patent will expire no earlier than December 29, 2037.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In February 2024, the Company announced that the United States Patent and Trademark Office (&#8220;USPTO&#8221;) had allowed U.S. Patent Application No. 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer&#8217;s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form. The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers. The patent, when issued, is expected to have an expiration date of December 29, 2037, subject to patent term adjustment (&#8220;PTA&#8221;), patent term extension (&#8220;PTE&#8221;) and terminal disclaimers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In February 2024, the Company also announced the USPTO issued U.S. Patent No. 11,890,272 (the &#8220;'272 Patent&#8221;) on February 6, 2024. The '272 Patent claims a method of treating agitation associated with schizophrenia or bipolar disorder through oromucosal administration of about 120 mcg to about 180 mcg of dexmedetomidine where the patient has a QT interval of less than 470 msec. The '272 Patent has an expiration date of July 17, 2040, subject to PTA, PTE and terminal disclaimers. The '272 Patent has been accepted for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the &#8220;Orange Book&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;background:#ffffff;margin:0pt;">In February 2024, the Company also received notice that the USPTO had allowed U.S. Patent Application No. 18/216,890 with claims pertaining to a method of treating agitation using an oromucosal formulation of dexmedetomidine or a pharmaceutically acceptable salt thereof through the administration of an initial dose of 60 mcg, 80 mcg, 90 mcg, 120 mcg or 180 mcg of dexmedetomidine and, after at least two hours, administering an oromucosal formulation of dexmedetomidine or a pharmaceutically acceptable salt thereof in a second dose of 40 mcg, 60 mcg, 80 mcg or 90 mcg of dexmedetomidine, where the patient has a QT interval of less than 470 msec. The patent, when issued, is expected to have an expiration date of July 17, 2040, subject to PTA, PTE and terminal disclaimers. The Company expects that this patent, when issued, will be submitted for listing in the Orange Book with the eight currently listed U.S. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-bottom:10pt;background:#ffffff;margin:0pt;">patents for IGALMI&#8482; (dexmedetomidine) sublingual film. Collectively, these nine patents will in general extend patent protection for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> until January 12, 2043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. Depending upon the timing, duration, and specifics of FDA approval of our product candidates, a U.S. patent that we own or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (a.k.a., the &#8220;Hatch-Waxman Act&#8221;). The act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the drug approval regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of a new drug application (&#8220;NDA&#8221;), plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the application for extension must be made prior to patent expiration. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">The term of a patent can also be extended by Patent Term Adjustment (&#8220;PTA&#8221;) established in 35 U.S.C. 154(b). The intention of the PTA is to accommodate for delays caused by the USPTO during the prosecution of a US utility or plant patent application. Under PTA, the USPTO delay is divided into three types: type A (delays after 14 months from the filing date of the application until the USPTO issues a first Office Action and delays after four months from the filing of certain actions by the applicant until the USPTO responds to such actions); type B (delays after three years from the earliest effective filing date until a patent is granted); and type C (delays due to interferences, secrecy orders, and successful appeals). The total amount of PTA is calculated by adding the types A, B, and C delays, and then subtracting any delay that is overlapped among three types or that is attributable to the applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The term of a patent can also be shortened by a terminal disclaimer. A terminal disclaimer is a statement filed by a patent owner in which the owner disclaims or dedicates to the public the terminal part of the term of a patent. Often, the terminal disclaimer is filed in cases where at least one claim of a pending application would have been obvious in light of at least one claim in an earlier-filed patent, (or non-statutory obviousness-type double patenting rejection).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The patent positions of companies such as ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of method of use patents or reformulation patents has emerged in the U.S. patent laws and their interpretation outside of the U.S. are also uncertain. Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our technology or product candidates and enforce the patent rights that we license, and also could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions, and improvements. With respect to both licensed and company owned intellectual property, we cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use, or the manufacture of those products. In addition, if a pending patent application is granted, it is possible that only a subset of the claims that are currently contained in the pending patent application will be issued. Further, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and the issued patents that we in-license and those that may issue in the future may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies outside the scope of the rights granted under any issued </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">patents that we own or exclusively in license. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. For additional information regarding intellectual property regulations and risks, see below under &#8220;Immuno-Oncology Intellectual Property&#8221; and Part I, Item 1A, &#8220;Risk Factors - Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Immuno-Oncology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, we announced the formation of a wholly owned subsidiary, OnkosXcel to develop potentially transformative medicines in oncology. OnkosXcel uses proprietary AI capabilities to drive the capital-efficient development of innovative anti-cancer therapeutics. On March 14, 2023, we announced that OnkosXcel had confidentially submitted a draft registration statement on Form S-1 with the SEC relating to the proposed initial public offering of its common stock following its conversion into a corporation. The Company is continuing to evaluate strategic options for OnkosXcel. With the Company&#8217;s Reprioritization announcement on August 14, 2023, further work on the immuno-oncology programs described below have generally been paused, except as noted below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our approach to drug discovery leverages the application and methodology of our proprietary AI-based research and development platform, complemented by EvolverAI, utilized in the successful development of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> with the aim of efficiently identifying and developing immuno-oncology product candidates. We believe that BXCL701 reflects the potential of this discovery approach in immuno-oncology. BXCL701 is an investigational, oral innate immune activator which demonstrated a 25% composite response rate in a Phase 2a clinical trial to treat patients with small cell neuroendocrine (&#8220;SCNC&#8221;)-phenotype metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;). On February 12, 2024, the Company announced that the FDA has designated as a Fast Track development program the investigation of BXCL701 in combination with a checkpoint inhibitor for the treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability. We intend to finalize a potential registrational trial design in mCRPC patients with SCNC phenotype following planned meetings with the FDA in the first half of 2024. However, the start of any such trial is paused following our Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">mCRPC is often characterized as a &#8220;cold&#8221; tumor, which is a tumor with an immunosuppressive tumor microenvironment (&#8220;TME&#8221;) and poor immune cell infiltration. Currently approved checkpoint inhibitors (&#8220;CPIs&#8221;) that target programmed cell death 1 (&#8220;PD-1&#8221;) or cytotoxic T-lymphocyte-associated protein 4 (&#8220;CTLA-4") have failed to demonstrate meaningful single-agent activity against such difficult-to-treat tumor types, including mCRPC. BXCL701 is designed to promote an immune-induced inflammatory response in the TME primarily via inhibition of dipeptidyl peptidases (&#8220;DPP&#8221;) 8 and 9, which we believe can provide enhanced CPIs therapeutic utility. We believe BXCL701 can potentially provide significant benefits for the approximately 20% of the estimated 299,010 men who will be diagnosed with prostate cancer in the U.S. in 2024 and are expected to progress to the more aggressive mCRPC form of the disease, including approximately 20%, or 11,960, of those patients who develop the SCNC phenotype, for which there are currently limited treatment options. Immune checkpoints represent a myriad of inhibitory pathways that act to regulate the duration and intensity of an antigen-induced immune response and factor prominently in mediating immune tolerance. They function as critical gatekeepers that prevent the indiscriminate attack of normal host cells by components of the immune system. Certain cancers co-opt these pathways and overexpress immune checkpoint molecules to camouflage themselves to avoid detection and destruction. CPIs, designed to harness the intrinsic power resident in the immune system, work by disabling the suppressive function of immune checkpoints, allowing the immune system to bypass such cancers&#8217; shield of immune tolerance. CPIs are expected to generate sales of more than $50 billion worldwide by 2025, up from sales of approximately $29 billion in 2020. While CPIs have proven to be a significant advancement in cancer therapy, those currently approved by the FDA do not produce meaningful results in a majority of patients, as the clinical benefit is generally viewed to be limited to between 13% and 30% of cancer patients, and the duration of response is relatively short.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We believe the limited efficacy of approved CPIs results primarily from their intervention at later stages of the immune response. As a result, other targets and pathways can be exploited by the tumor to create a TME that can evade the enhanced immunological response enabled by approved CPIs. While numerous agents designed to target the earlier stages of an immune response are in development for use in combination with CPIs, their activity is restricted to a single </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">component of the immune response. In contrast, we have developed BXCL701 to simultaneously address multiple components of the immune response, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cancer antigen presentation by dendritic cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of dendritic cell trafficking to tumor draining lymph nodes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priming and activation of T cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: acceleration of tumor-induced priming of T cells and the formation of potent cytotoxic T lymphocytes (&#8220;CTLs&#8221;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Infiltration of immune cells into the tumor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of release of chemokines that attract effector T cells but block regulatory T cells, and also induce NK cell and neutrophil migration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Killing of tumor cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: induction of formation of CTLs and NK cells expressing tumor-killing perforins and granzymes, as well as the formation of memory T cells that can selectively kill returning tumor cells.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accordingly, we believe BXCL701 may have utility in stimulating increased activation, proliferation, and infiltration of tumor cells by immune effector cells, enabling its potential application in combination with currently approved CPIs, across a range of solid tumors and hematological malignancies, to potentially:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Convert immunological cold tumors into ones sensitive to CPIs;</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Enhance hot tumors&#8217; response rate and depth of response to CPIs; and</i></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Restore CPI sensitivity to tumors that were previously responsive.</i></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Central to our drug discovery initiatives are proprietary, AI-driven platform technologies we employ to identify novel therapeutic uses for approved therapeutics and candidates in clinical evaluation. The first and most advanced of our AI-driven discovery programs is our innate immune modulation program, which supported the pursuit of BXCL701 as a development candidate. We believe the application of this program provides us actionable insights into the inflammasome, a component of the innate immune system responsible for activation of the inflammatory response. We are working to develop our second AI-driven product candidate, BXCL702, by leveraging our innate immunity modulation program via re-innovation or in-licensing and we intend to nominate a candidate by 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Immuno-Oncology Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Below is a summary of the status of our immuno-oncology clinical development programs as of the date of this Annual Report on Form 10-K. We believe our product candidates, if successfully developed and approved, have the potential to become compelling treatment options for their respective indications. With our Strategic Reprioritization announcement on August 14, 2023, further work on our immuno-oncology program has been paused, other than as noted below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:215.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k003.jpg" alt="Graphic" style="display:inline-block;height:215.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">An Overview of the Immune System</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The immune system is a host defense system comprised of multiple structures and processes within an organism that protects against disease. As with other mammalian species, the human immune system is comprised of the innate immune system and the adaptive immune system. The innate immune system involves an immediate, non-specific response to infected or diseased cells. Triggering its activation are pathogen-associated and damage-associated molecular patterns recognized by pattern-recognition receptors, which reside on the surface of various types of leukocytes, or white blood cells, making up the innate immune system including phagocytes, eosinophils, and natural killer cells. The innate immune response also participates in promoting activity of the adaptive immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The adaptive immune system is made up of special types of leukocytes known as T and B lymphocytes, or T cells and B cells, respectively. T cells participate primarily in the cell-mediated immune response while B cells are involved in the humoral immune response. T lymphocytes can be further segregated into distinct cell types, with the primary types being CD8, or cytotoxic, T cells and CD4 T cells. CTLs directly eliminate cells that are infected with viruses or other pathogens or are otherwise damaged or dysfunctional. Anti-cancer activity is primarily CD8 T cell mediated. CD4 T cells, which have limited cytotoxic activity, mediate the activity of other cells to eliminate pathogens. Activation of a resting CD4 T cell causes it to release cytokines that influence the activity of an array of cell types. Cytokines released by activated Type 1 CD4 T cells enhance the microbicidal activity of macrophages and the activity of CD8 T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A critical capability of the immune system is its ability to distinguish between healthy, functioning host cells and either non-self-infectious agents or damaged or dysfunctional host cells. The ability to differentiate between these entities is the central feature of immune tolerance. A significant limitation of currently approved therapeutics against endogenous diseases such as cancer is the inability to overcome host immune tolerance and elicit a strong, target-specific immune response while avoiding off-target complications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immune Tolerance and the Role of Immune Checkpoints</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The immune system&#8217;s ability to distinguish between a normal, healthy cell and an infected, damaged, dysfunctional, or cancer cell is accomplished through an immunological selection process that occurs in the thymus during early development. Antigen specific immune cells, such as T cells, B cells and NK cells, which recognize molecular markers originating from normal, healthy tissues are eliminated in the thymic medulla to avoid possible autoimmune consequences through a negative selection process. This results in the suppression of immune effector cell activation and proliferation. Immune checkpoints represent a myriad of inhibitory pathways that act to regulate the duration and intensity of antigen-induced immune responses and factor prominently in mediating immune tolerance. A number of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">checkpoint molecules have been identified and studied in cancer therapy in the past decades. Two of the more well-characterized immune checkpoint molecules are CTLA-4 and PD-1, and its related ligand, PD-L1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As key regulators of the immune system, immune checkpoints are critical gatekeepers that prevent the indiscriminate attack of normal host cells by components of the immune system. Their suppressive function usually depends on ligand-induced signaling, with protein structures on the surface of immune effector cells binding to complementary molecular structures on partnered cells. This signaling not only dampens the generation of co-stimulatory cytokines instrumental in triggering and sustaining a robust immune response, such as interleukin 2 and interferon gamma, but also results in an upregulation of regulatory T cells, which acts to further suppress immune effector cell activity. These factors bias the immune response towards anergy and senescence rather than activation and proliferation. Certain tumors co-opt these pathways and overexpress immune checkpoint molecules on their cell surface to camouflage themselves to evade detection and destruction by the immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immunotherapy and the Emergence of Checkpoint Inhibitors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cancer immunotherapy, designed to harness the intrinsic power resident in the immune system by modulating immune cell function, has proven to be a major advancement in cancer treatment. Immune CPIs have emerged as one of the most promising classes of cancer immunotherapy. CPIs work by disabling the inhibitory function of immune checkpoint proteins. Disabling immune checkpoints allows the immune system to bypass the shield of immune tolerance the checkpoints provide, allowing the tumor-directed immune effector cells to engage the tumor. Seven CPIs targeting PD1/PD-L1 and CTLA-4 have been approved by the FDA to treat more than a dozen different types of cancer. CPIs directed towards other validated checkpoints, including lymphocyte activation gene 3 and T cell immunoreceptor with immunoglobulin and ITIM domain have recently been approved or are advancing through clinical development. These CPIs are largely involved in modulating the activity of the adaptive immune system. Immune checkpoint molecules, such as CD47, which regulate responses mediated by the innate immune system, are also under evaluation as potential therapeutic targets for checkpoint inhibition. CPIs across a spectrum of cancer types are expected to generate sales of more than $50 billion worldwide by 2025, up from sales of $29 billion in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Limitations of Current Approaches</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">While CPIs have proven to be a significant advancement in cancer therapy, those currently approved by the FDA do not produce meaningful results in a majority of patients: clinical benefit is generally viewed to be limited to between 13% and 30% of cancer patients and the duration of response to treatment is often short. CPIs require the infiltration of anti-tumor CD8 T cells for therapeutic activity, and patients whose tumors are characterized by a TME that lacks activated TILs, typically fail to respond to therapy. Moreover, the expression of positive costimulatory signals is critical to the amplification and diversification of a TIL-based response following initial activation, without which treatment durability is limited. We are focused on advancing therapeutic candidates designed to overcome these challenges and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:258.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">enhance the sensitivity of immunologically inaccessible, or cold, tumors to an efficacious immune response. The chart below shows the single agent objective response rate (&#8220;ORR&#8221;) of CPIs by different cancer types and clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k004.jpg" alt="Graphic" style="display:inline-block;height:258.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Leveraging the insights enabled by the application and methodology of our proprietary AI-based platform complemented by EvolverAI, which was used to identify novel therapeutic uses for our approved therapeutics and product candidates in clinical evaluation, and our industry expertise, we are pursuing two proprietary discovery programs to advance our goal of developing anti-cancer therapeutics. The first program, which encompasses BXCL701 across a range of indications, is based on the application of innate immune modulation technology. This program has been constructed to embrace key distinguishing characteristics of the innate immune system and we believe it is supported by our development efforts. This approach has driven the development of BXCL701, which we are currently evaluating in a Phase 1b/2a clinical proof-of-concept trial as a potential treatment for mCRPC with either SCNC or adenocarcinoma phenotype. Fundamental to the innate immune modulation program is BXCL701&#8217;s potential to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Convert cold tumors into ones sensitive to CPIs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enhance hot tumors&#8217; response rate and depth of response to CPIs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restore CPI sensitivity to tumors which had previously been responsive.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 Innate Immune Activator</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BXCL701 is an oral small molecule inhibitor of a class of enzymes called DPPs, specifically DPP8/9 and DPP4. Inhibition of DPP8/9 initiates activation of the inflammasome and ultimately activation of the innate immune system. Key characteristics of BXCL701 include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Orally bioavailable, potentially sole inhibitor of both DPP8/9 and DPP4, key regulators of the inflammasome directed innate immune response, currently in clinical development for cancer.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Novel proposed mechanism of action may complement CPIs activity, enabling therapeutic access to immunologically cold tumors as well as other difficult-to-treat cancers, including relapsed or refractory tumor types.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 clinical proof-of-concept achieved in treating mCRPC patients with either adenocarcinoma or SCNC phenotype.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The initial focus on mCRPC with SCNC phenotype is designed to provide for a more efficient clinical development pathway than current industry standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for mCRPC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prostate cancer is the most common malignancy and the second-leading cause of cancer-related deaths in men in the U.S. According to the American Cancer Society, approximately 299,010 men will be diagnosed with, and 35,250 men will die of, prostate cancer in 2024. The majority of these cases are classified as adenocarcinomas and involve low risk, localized or regional disease for which the five-year survival rate ranges from 60% to 99%. However, an estimated 20% of these newly diagnosed cases will progress to the more aggressive metastatic disease. The five-year survival rate for men with metastatic prostate cancer drops significantly, to approximately 30%. Approximately 20% of patients with mCRPC will develop the SCNC phenotype, which is characterized by poor prognosis and low survival rate with a five-year life expectancy of 14%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Prostate function requires the presence of various androgens, such as testosterone. Early cancerous prostate cells typically also require androgens to proliferate. Accordingly, aggressive forms of prostate cancer can initially be treated using androgen deprivation therapy (&#8220;ADT&#8221;). While ADT offers temporary therapeutic benefit, in almost all patients the treatment eventually loses efficacy, referred to as &#8220;castration resistance.&#8221; Cases of castration-resistant prostate cancer (&#8220;CRPC&#8221;) are generally treated with a second-generation androgen receptor (&#8220;AR&#8221;) inhibitor, such as XTANDI</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (enzalutamide), or an androgen synthesis inhibitor, such as ZYTIGA</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (abiraterone), which targets the enzyme CYP17 to block the production of testosterone. These therapeutics have widely become the standard of care, though only ZYTIGA has been approved to treat mCRPC, as well as metastatic high-risk castration-sensitive prostate cancer. XTANDI has been approved to treat CRPC and metastatic castration-sensitive prostate cancer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Virtually all patients who initially respond to ZYTIGA and XTANDI are expected to progress to even more aggressive forms of prostate cancer requiring further treatment. Patients whose disease has progressed after treatment with these second-generation targeted endocrine therapies are administered a docetaxel containing drug regimen that provides a survival benefit of only 10 months. The poly-ADP ribose polymerase (&#8220;PARP&#8221;) inhibitors LYNPARZA</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (olaparib) and RUBRACA</span><sup style="font-family:'Symbol';font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup><span style="font-size:10pt;"> (rucaparib) are approved for the treatment of mCRPC in patients whose disease has progressed after receiving XTANDI or ZYTIGA, but their approval is limited to instances of mCRPC linked to a BRCA gene mutation. As such, an unmet medical need remains for patients with mCRPC who are not eligible for PARP inhibitor treatment after treatment with the targeted endocrine therapy and docetaxel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, a number of men, both newly diagnosed patients and men whose disease has progressed after second-generation targeted endocrine therapy, will develop an aggressive tumor that typically expresses very little AR and accordingly does not respond to therapeutics targeting the AR signaling pathway. Prostate cancer with this phenotype is referred to as SCNC, for which there is currently no effective treatment. The incidence of SCNC is increasing with the widespread use of AR inhibitor therapy. Treatment protocols for patients with SCNC typically involve cytotoxic chemotherapies despite their short duration of response and considerable toxicities. These patients represent an additional unmet medical need among men with prostate cancer. We believe BXCL701 may prove efficacious in addressing the unmet needs of both adenocarcinoma and SCNC prostate cancer phenotypes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">mCRPC is often characterized as a cold tumor, or a tumor with an immunosuppressive TME and poor immune cell infiltration. Currently approved CPIs, which target PD-1 and CTLA-4, have not demonstrated significant single-agent therapeutic activity. For instance, a Phase 2 investigator sponsored trial (&#8220;IST&#8221;) to assess the efficacy of the PD-L1 inhibitor avelumab, marketed by EMD Serono and Pfizer as BAVENCIO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><sup style="font-family:'Symbol';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#226;</sup>, to treat mCRPC with SCNC phenotype, as well as aggressive variant prostate cancer with adenocarcinoma histology, generated an ORR of 6.7% (representing 1 of 15 patients who was known to be microsatellite instability-high, an established marker of response to CPIs).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the limited efficacy of CPIs results primarily from their intervention at later stages of the immune response. As a result, other targets and pathways can be exploited by the tumor to create a TME that can evade the enhanced immunological response enabled by approved CPIs. BXCL701 is designed to act on multiple components of immune system functioning, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Cancer antigen presentation by dendritic cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of dendritic cell trafficking to tumor draining lymph nodes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Priming and activation of T cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: acceleration of tumor-induced priming of T cells and the formation of potent CTLs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Infiltration of immune cells into the tumor</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: stimulation of release of chemokines that attract effector T cells but block regulatory T cells and also induce NK cell and neutrophil migration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Killing of tumor cells</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: induction of formation of CTLs and NK cells expressing tumor-killing perforins and granzymes as well as the formation of memory T cells that can selectively kill returning tumor cells.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe BXCL701 may have utility in stimulating increased activation, proliferation, and infiltration of tumor cells by immune effector cells, enabling its potential use in combination with currently approved CPIs to treat cold tumors, such as mCRPC. We elected to pursue mCRPC as an indication for BXCL701 due to its enrichment for DPP mutations, which are especially prevalent in tumors with SCNC phenotype.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BXCL701 is being evaluated in a Phase 1b/2a clinical proof-of-concept trial that we are sponsoring to investigate its potential efficacy when used in combination with pembrolizumab. Enrollment in this trial is complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We received initial comments from the FDA on our proposed clinical development plan, and we plan to meet with the FDA in an End-of-Phase 2 meeting in the first half of 2024 to discuss the development path forward. However, the start of any such additional trial is paused following the Company&#8217;s Reprioritization. The Phase 1b portion of our Phase 1b/2 clinical trial was a dose escalation safety lead-in which employed a standard 3 x 3 trial design to determine the recommended Phase 2 dose (&#8220;RP2D&#8221;). During each 21-day treatment cycle, 200 mg of pembrolizumab were administered intravenously on day one, with BXCL701 taken twice daily on days one through 14, for a minimum of two cycles. The results of this Phase 1b trial, which were presented at The Society for Immunotherapy of Cancer&#8217;s 35<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Anniversary Annual Meeting, allowed us to identify 0.3 mg, taken twice daily, as the RP2D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k005.jpg" alt="Graphic" style="display:inline-block;height:273.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Phase 2a portion of the trial was segregated into two 28-patient trial cohorts, one cohort consisting of mCRPC patients with SCNC phenotype and a second cohort consisting of mCRPC patients with adenocarcinoma phenotype. Initially, we focused on mCRPC with SCNC phenotype as the primary patient population for BXCL701, since DPP9 is amplified in approximately 17% of treatment-emergent mCRPC with SCNC phenotype, compared to 5% or less in the broader prostate cancer population. However, we also observed responses in mCRPC patients with adenocarcinoma phenotype who were microsatellite stable in the Phase 1b portion of the trial. On this basis, we widened our Phase 2a trial to include relapsed mCRPC patients with either SCNC or adenocarcinoma phenotype. Both cohorts employed a Simon two-stage trial design of 15 trial participants followed by 13 additional patients. The primary endpoint of the Phase 2a portion of this trial was a composite response rate, determined as either a RECIST 1.1 response (defined as a reduction in RECIST score of 30% or more), and/or a reduction in prostate specific antigen (&#8220;PSA&#8221;) level of 50% or more, and/or a conversion in circulating tumor cells (&#8220;CTCs&#8221;) from 5 or more CTCs/7.5 milliliter (&#8220;ml&#8221;) to less than 5 CTCs/7.5 ml. Secondary endpoints included duration of response, progression-free survival, overall survival, changes in circulating cytokines, and certain disease-specific biomarkers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe the results observed in the Phase 2a trial of BXCL701 administered in combination with pembrolizumab support further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We were particularly encouraged by the results observed in the cohort consisting of mCRPC patients with SCNC phenotype. Updated Phase 2a results for the SCNC cohort were presented at the 30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Prostate Cancer Foundation Scientific Retreat (PCF 2023). BXCL701 in combination with pembrolizumab demonstrated a 25% (seven out of 28 evaluable patients) composite response rate in mCRPC patients with SCNC phenotype, for whom there is no standard of care. As of a data cutoff of September 6, 2023, five of these responders were RECIST 1.1 responders (four confirmed responses and one unconfirmed response) with decreases in tumor size ranging from -45% to -67% and a median duration of response of 7.6 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:264.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k006.jpg" alt="Graphic" style="display:inline-block;height:264.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">AEs consistent with cytokine activation, including fever, nausea, chills, fatigue, headache, and dizziness were observed during the trial and were generally mild to moderate. SAEs experienced by six trial participants - one patient hospitalized with Grade 1 orthostatic hypotension, one patient hospitalized with Grade 3 hypotension and acute kidney injury (&#8220;AKI&#8221;), which resolved, one patient with Grade 3 hypothyroidism which resolved, one patient with Grade 3 colitis, one patient with Grade 3 generalized oedema, and one patient hospitalized with Grade 4/5 tumor lysis syndrome/AKI, which resulted in fatality after the patient voluntarily discontinued dialysis - were reported as related or possibly related to BXCL701 or pembrolizumab, though there was no evidence that BXCL701 potentiated immune-related AEs associated with CPIs. The table below summarizes treatment-related AEs observed in the SCNC cohort as of December 19, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:260.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:260.15pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On October 10, 2023, we reported positive overall survival (OS) results from the Phase 2a portion of the trial in SCNC patients. BXCL701 in combination with pembrolizumab demonstrated a compelling median OS and 12-month survival rate. As of a data cutoff of September 6, 2023, evaluable patients with SCNC (n = 28) showed a median OS of 13.6 months (95% CI 10.9&#8211;NR), and a 12-month survival rate of 56.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On February 12, 2024 the Company announced that the FDA designated as a Fast Track development program the investigation of BXCL701 in combination with a checkpoint inhibitor for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Phase 2a trial has also been completed for the adenocarcinoma cohort. Updated results for this trial cohort were also presented at PCF 2023. BXCL701 in combination with pembrolizumab demonstrated a 21% (six out of 29 evaluable patients) composite response rate in mCRPC patients with adenocarcinoma phenotype, for whom there are limited treatment options. As of a cutoff date of September 6, 2023, five of these composite responders were RECIST 1.1 responders (four confirmed responses and one unconfirmed response) with decreases in tumor size ranging from -30% to -99% and a median duration of response to 19 months.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:269.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k008.jpg" alt="Graphic" style="display:inline-block;height:269.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of the cutoff date of December 19, 2022, the majority of AEs experienced by patients in the adenocarcinoma cohort were low grade. AEs consistent with cytokine activation were observed, including fever, myalgia, nausea, chills, fatigue, dyspnea, headache and dizziness. SAEs experienced by five patients (12%) were reported as possibly related to BXCL701 or pembrolizumab: two reports of hypotension; one report of dizziness; one report of peripheral edema; one report of pyrexia; one report of Myasthenia Gravis; and one report of Cytokine Release Syndrome. Two patients (5%) discontinued therapy due to AEs. There was no evidence that BXCL701 potentiated immune-related AEs related to CPIs. The table below summarizes treatment-related AEs observed in the adenocarcinoma cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:283.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="btai-20231231x10k009.jpg" alt="Graphic" style="display:inline-block;height:283.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 8, 2023, we reported positive OS results from the Phase 2a portion of the trial in patients with adenocarcinoma. As of a data cutoff of September 6, 2023, among evaluable patients with adenocarcinoma (n = 29) BXCL701 in combination with pembrolizumab demonstrated a median OS of 15.5 months (95% CI 9.6&#8211;NR), and a 12-month survival rate of 59.3%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for Small Cell Lung Cancer (&#8220;SCLC&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimates that in 2024, about 35,187 cases of SCLC will be diagnosed in the U.S. Approximately 60-70% of these patients present with extensive disease, and first-line therapy for a majority of these patients involves the combination of a CPI with platinum-based chemotherapy or etoposide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are encouraged by the therapeutic potential of BXCL701 for SCLC given the activity it has demonstrated in the ongoing SCNC clinical trial. We are preparing the protocol for a Phase 1b/2 trial design to be a dose-escalation safety lead-in to establish a RP2D. However, the start of any such trial is paused following the Reprioritization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BXCL701 as a Potential Treatment for Other Cancers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to its potential use in combination with CPIs to treat mCRPC, an immunologically cold tumor, we are developing BXCL701 as a therapeutic for pancreatic cancer, and other solid tumors with greater, or &#8220;non-cold,&#8221; immunological activity that are nonetheless regarded as difficult-to-treat, and hematological malignancies. We believe the synergistic potential of BXCL701 and CPIs, when administered in combination, could increase cancer cell susceptibility to an enhanced immune response, potentially increasing the clinical benefit of CPIs, whose single-agent efficacy in treating these tumor types is generally viewed to be limited to between 13% and 30% of cancer patients and the duration of response to treatment is often short. As such, we envision the potential therapeutic benefit of BXCL701 increasing the sensitivity of cold tumors to CPI therapy, enabling the potential treatment of a range of cancers including pancreatic cancer, breast cancer, colorectal cancer, and ovarian cancer, as well as enhancing the depth of response to CPIs in other cancers. In addition, based on the preclinical observation that BXCL701 showed direct cytotoxic activity </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">against certain leukemic cells, we have initiated clinical development targeting relapsed or refractory acute myeloid leukemia (&#8220;AML&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pancreatic Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimates that in 2024, approximately 66,440 cases of pancreatic cancer will be diagnosed in the U.S. We are supporting a Phase 2 IST sponsored by Georgetown Lombardi Comprehensive Cancer Center (&#8220;Georgetown Lombardi&#8221;), designed to evaluate the use of BXCL701 along with pembrolizumab to treat pancreatic cancer. Few therapeutic options are available for patients with this disease, which has a five-year survival rate of less than 10%, among the lowest of all cancers. Pancreatic cancer has among the highest levels of overexpression and amplification of DPPs. Preclinical models demonstrated synergy between DPP inhibition with BXCL701 and anti-PD-1 antibody in the pancreatic cancer tumor microenvironment. Based on these preclinical observations, Georgetown Lombardi has initiated a Phase 2 IST to assess the safety of BXCL701 when administered in combination with pembrolizumab (safety lead-in), as well as to estimate the 18-week progression-free survival rate (primary objective of the efficacy phase) in previously treated metastatic pancreatic ductal adenocarcinoma. This trial started in the third quarter of 2023. On February 6, 2024, we announced the completion of patient enrollment in the safety lead-in portion of the trial. As part of the trial&#8217;s safety lead-in, the first six patients have been enrolled and will be observed for a six-week safety window period. The trial is then expected to enroll approximately 39 patients in its efficacy phase in a Simon 2-stage single-arm, open-label design (19 patients in stage 1 and 20 patients in stage 2). Patients will be monitored radiographically and by tumor markers for response assessment. Tumor biopsies and blood samples will also be collected over the course of treatment to better understand the potential mechanism of action for the combination. The human proof of concept portion of the trial is expected to start in the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Relapsed or Refractory AML</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The American Cancer Society estimates that in 2024, about 20,800 new cases of AML will be diagnosed in the U.S. We are supporting a Phase 1b IST sponsored by the Dana-Farber Cancer Institute (&#8220;Dana-Farber&#8221;) designed to evaluate the use of BXCL701, along with the current standard of care to treat relapsed or refractory AML. We believe that pyroptosis triggered by BXCL701 may provide potent single agent cytotoxicity directed towards AML. We also believe that DPP9 copy number may provide an actionable biomarker, as high copy number has been observed to correlate with BXCL701 toxicity in human AML cell lines. DPP8/9 inhibition has been shown to be cytotoxic to THP-1 cells, monocytic cancer cells cultured from a patient with AML, but not other cell lines, suggesting a specific vulnerability of AML to these inhibitors which we believe can be exploited for therapeutic benefit. Based on these preclinical observations, Dana-Farber has initiated a Phase 1b trial to assess the safety of BXCL701 and to determine the maximum tolerated dose or the RP2D of BXCL701 as a single agent. This trial started in the first quarter of 2023. Subject to successful completion of this Phase 1b trial, we anticipate that Dana-Farber will conduct further studies to determine BXCL701's objective response rate in AML in combination with the standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Potential Anti-cancer Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We collaborated with the University of Texas MD Anderson Cancer Center in a Phase 2a IST to evaluate the potential efficacy of BXCL701 administered in combination with pembrolizumab in patients with advanced solid cancer. The design of this open label trial included two cohorts and incorporated a two-stage configuration, which allowed for an expansion of patient enrollment to a total of 17 patients in each cohort if a RECIST 1.1 complete response or partial response was observed in at least one of the initial nine patients. The first cohort enrolled patients who previously had not received CPI therapy, with a second cohort consisting of patients that were either refractory to CPI therapy or had relapsed while on CPI therapy, meaning that no further response to CPI treatment is anticipated among patients in the second cohort. Trial participants received 200 mg of pembrolizumab on day 1 of a 21-day cycle, with 0.2 mg of BXCL701 administered twice-daily (&#8220;BID&#8221;) on days 1 through 7 during the first cycle, the dose increasing to 0.3 mg BID on Days 8 through 14 during the first and the subsequent cycles. Evaluable trial participants were required to receive a minimum of two treatment cycles. A preliminary assessment of BXCL701 dosed in combination with a CPI, as of completion of the first stage, noted responses in one patient in each of the CPI na&#239;ve and CPI refractory/relapsed cohorts, including a partial response in CPI-na&#239;ve, microsatellite stable endometrial carcinoma, PD-L1 negative (CPS &lt;1) and a partial response in CPI-refractory uveal melanoma. These preliminary results were presented at the 2021 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">American Society of Clinical Oncology annual meeting (ASCO 2021). Patient enrollment in this trial was completed in the third quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe BXCL701 may have potential application in breast cancer, as its use in combination with monoclonal antibody therapy generated encouraging in vivo data in a preclinical disease model where enhanced antibody-dependent cellular cytotoxicity was observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA has granted BXCL701 orphan drug designation for the treatment of AML, stage IIb to IV melanoma, pancreatic cancer, and soft tissue sarcoma. As we consider BXCL701&#8217;s therapeutic potential for additional indications that represent unmet medical needs, we intend to apply for additional orphan drug designations for BXCL701.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Biomarker Development Initiatives Intended to Complement BXCL701 Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are also actively engaged in the identification and development of predictive biomarkers that we believe could be used in conjunction with BXCL701 to predict the likelihood of patient response to therapy across the range of targeted indications. Based on preliminary data from AML patients, we believe DPP9 copy number could correlate to BXCL701 response rate, with a greater likelihood of BXCL701 cytotoxicity in patients with increased DPP9 copy number. We are pursuing its use in our biomarker discovery activities as a potential companion diagnostic. At the Society for Immunotherapy of Cancer&#8217;s 38<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Annual Meeting (SITC 2023), we presented data from the Phase 2a trial in SCNC patients, which indicated DPP9 overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Manufacturing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely on third party contract manufacturing organizations to support development and manufacture of product candidates for our clinical trials, and, if any of our current or future product candidates receives marketing approval, we expect to rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Currently, the Patheon pharma services division of Thermo Fisher Scientific Inc. and another third-party contract manufacturer supply the drug substance and clinical trial supplies for BXCL701, and we expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of BXCL701.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BXCL701 drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard organic synthesis or pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed. We have selected a larger third-party drug product manufacturer and will be executing technology transfer of drug product manufacture to a larger manufacturer. We also plan to maintain the current drug substance and product manufacturer as part of our supply chain strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Competition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries have made substantial investments in recent years into the rapid development of novel immunotherapies for the treatment of a range of pathologies, including infectious diseases and cancers, making this a highly competitive market. We believe BXCL701 is the only innate immune system activator in clinical development specifically addressing the cold tumor problem in immuno-oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We face substantial competition from multiple sources, including large and specialty pharmaceutical, biopharmaceutical and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions. Our competitors compete with us on the level of the technologies employed, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i) obtain support for their research, development, and commercialization of products or (ii) combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of immunotherapy and, furthermore, within the treatment of infectious diseases and cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the current standard of care treatments for patients with infectious diseases or cancers, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from these studies and trials have fueled increasing levels of interest in the field of immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Large pharmaceutical companies that have commercialized or are developing immunotherapies to treat cancer include AstraZeneca AB, Bristol-Myers Squibb Company, Merck &amp; Co., Inc., Novartis AG, Pfizer Inc., and F. Hoffmann-La Roche Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We face significant competition from pharmaceutical and biotechnology companies that target specific tumor-associated antigens using immune cells or other cytotoxic modalities. These generally include immune cell redirecting therapeutics such as T cell engagers, adoptive cellular therapies such as CAR-Ts, antibody drug conjugates, targeted radiopharmaceuticals, targeted immunotoxin, and targeted cancer vaccines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Clinical stage companies that compete with us directly on the level of the development of product candidates targeting the innate immune system include Amgen Inc., Mirati Therapeutics, Inc., Bristol- Myers Squibb Company, Ryvu Therapeutics, Merck &amp; Co., Inc., Replimune Group Inc., Nektar Therapeutics, Novartis AG, Xbiotech Inc., Stingthera, Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd and Aravive, Inc. Clinical stage companies that compete with us directly on the level of the development of product candidates targeting the mCRPC include Astellas Pharma Inc., Pfizer Inc., Bayer AG, Janssen, Sanofi S.A., Clovis Oncology, Inc., AstraZeneca AB, Merck &amp; Co., Inc., GSK plc, Tempest Therapeutics, Inc., Zenith Epigenetics Ltd. and Gossamer Bio, Inc. Clinical stage companies that compete with us directly on the level of the development of product candidates utilizing the therapeutic potential of synthetic lethality include Repare Therapeutics Inc., IDEAYA Biosciences, Inc. and Tango Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offerings. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immuno-Oncology Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;margin:0pt;">Intellectual property is of vital importance in our field and in biotechnology generally. We seek to protect and enhance proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, enforcing, and defending patent and other intellectual property rights, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and review, data exclusivity, market exclusivity, and patent term extensions where available. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">As of February 29, 2024, we have multiple patent families filed to protect our immuno-oncology program, including our core patent family directed to methods of using BXCL701 with immune checkpoint inhibitors, which is granted in the U.S., Japan, Australia, Canada, Russia, China, South Africa, Mexico, New Zealand, and United Arab Emirates, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">with at least one pending application in the U.S., China, Mexico, the Republic of Korea, New Zealand, Russia, Australia, Brazil, Hong Kong, and Europe. Patents issued from this family, if any, are expected to expire no earlier than 2036. We have one additional patent issued in the U.S. directed to a method of selecting patients based on a biomarker, with an expected expiration date no earlier than 2039.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additional applications are directed to administering BXCL701 in combinations with various other molecules, biomarkers, and dosing regimens. We also have four provisional applications directed to novel formulations of BXCL701, various dosing regimens, methods of use, and combination therapies. We expect that patents issued from these applications, if any, will expire from 2039 to 2044.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect to file additional patent applications in support of current and new immuno-oncology clinical candidates as well as new platform and core technologies. For additional information regarding intellectual property regulations and risks, see above under &#8220;&#8212;Neuroscience&#8212;Neuroscience Intellectual Property&#8221; and Part I, Item 1A, &#8220;Risk Factors - Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Relationship with BioXcel LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel LLC currently holds an ownership interest of approximately 29% in the Company and our pipeline compounds were identified by applying our growing internal AI capabilities, along with BioXcel LLC&#8217;s EvolverAI, a proprietary pharmaceutical discovery and development engine, for drug re-innovation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into the Amended and Restated Asset Contribution Agreement (the &#8220;Contribution Agreement&#8221;), pursuant to which BioXcel LLC, agreed to contribute BioXcel LLC&#8217;s rights, title and interest in BXCL501, BXCL701, BXCL502 and BXCL702, and all of the assets and liabilities associated in consideration for (i) 9,480,000 shares of our common stock, (ii) $1 million upon completion of an initial public offering, (iii) $500,000 upon the later of the 12-month anniversary of an initial public offering and the first dosing of a patient in the bridging bioavailability/bioequivalence study for the BXCL501 program, (iv) $500,000 upon the later of the 12 month anniversary of an initial public offering and the first dosing of a patient in the Phase 2 proof of concept open-label monotherapy or combination trial with Keytruda for the BXCL701 program and (v) a one-time payment of $5 million within 60 days after the achievement of $50 million in cumulative net sales of any product or combination of products resulting from the development and commercialization of any one of the contributed product candidates or a product derived therefrom. As of December 31, 2023, all of the foregoing have been paid except for (v).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which services provided by BioXcel LLC through its subsidiaries in India and the U.S. will continue indefinitely, as agreed upon by the parties. These services include certain intellectual property prosecution and management and research and development activities. The Company has an option, exercisable until December 31, 2024, to enter into a collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing EvolverAI, its proprietary pharmaceutical discovery and development engine. To maintain the ability to exercise the foregoing option, pursuant to an amendment to the Services Agreement effective as of April 19, 2022, the Company has agreed to pay BioXcel LLC $18,000 per month from March 13, 2023 to December 31, 2024. The parties are obligated to negotiate the collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10 million in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement were $1.3 million and $1.4 million for the years ended December 31, 2023 and 2022, respectively.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Regulation and Product Approval</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of drug products. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the U.S. We, along with any third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable U.S. federal, state, and local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">U.S. Drug Development Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and its implementing regulations. The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies, and formulation studies in accordance with FDA&#8217;s Good Laboratory Practice requirements and other applicable regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board (&#8220;IRB&#8221;) or ethics committee at each clinical site before each clinical trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCPs&#8221;) to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of an NDA after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements to assure that the facilities, methods, and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and potential inspection of selected clinical investigation sites to assess compliance with GCPs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA to permit commercial marketing of the product for specified indications for use in the U.S.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Prior to beginning the first clinical trial with a product candidate in the U.S., a sponsor must submit an IND to the FDA. An IND is a request for allowance from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Submission of an IND may or may not result in FDA allowance to begin a clinical trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include among other things, the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and its investigators for actual or suspected serious and adverse events, along with any findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs and findings from animal or in vitro testing suggesting a significant risk to humans, as well as any clinically important increased incidence of a suspected serious adverse reaction compared to that listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether a study can move forward at designated check points, based on access to data from the study, and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other for other grounds, such as no demonstration of efficacy. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule, and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product labeling.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be conducted after initial marketing approval and may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, during the development of a drug, sponsors are given opportunities to periodically meet with or seek feedback from the FDA. These interactions may be requested, for example, prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. These interactions can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach alignment on the next phase of development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">U.S. Review and Approval Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, including results from preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the filing date to complete a standard review of an NDA for a drug that is a new molecular entity, and of ten months from the date of NDA receipt to complete a standard review of an NDA for a drug that is not a new molecular entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that review, evaluate and provide a recommendation as to whether the NDA should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing and sale of the product with specific prescribing information for specific indications. A CRL usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, including additional clinical trials, or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA or, address all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If regulatory approval of a product is granted, such approval will be granted for specific indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-market studies and additional surveillance programs to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Pediatric Research Equity Act (&#8220;PREA&#8221;), requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Expedited Development and Review Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The FDA offers expedited development and review programs for qualifying product candidates. For example, the Fast Track program is intended to expedite or facilitate the process for reviewing product candidates that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the NDA may be eligible for priority review. An NDA for a  Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The Breakthrough Therapy designation includes the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other FDA review programs intended to expedite the FDA review and approval process, such as priority review. An NDA is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new-molecular-entity NDAs, priority review designation means the FDA&#8217;s goal is to take action on the application within six months of the 60-day filing date, or with respect to non-new-molecular-entity NDAs, within six months of the NDA receipt date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, depending on the design of the applicable clinical studies, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the FDA will generally require the sponsor to perform adequate and well-controlled confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit, and may require that such confirmatory studies be underway prior to granting accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the relevant product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fast Track designation, Breakthrough Therapy designation, priority review, and accelerated approval do not change the standards for approval, but such designations may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions to qualify for such program or may decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Orphan Drug Designation and Exclusivity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. and when there is no reasonable expectation that the cost of developing and making available the drug in the U.S. will be recovered from sales in the U.S. for that drug. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research costs and a waiver of the NDA user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Post-approval Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse events, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters, or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds on clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal health care programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases, and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA closely regulates the marketing, labeling, advertising, and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Hatch-Waxman Act</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA's prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject's bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant's drug or a method of using the drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification (a &#8220;paragraph IV certification&#8221;). If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification to the FDA, the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant's favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor's decision to initiate patent litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Hatch-Waxman Act establishes periods of non-patent regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA, including a 505(b)(2) NDA, may obtain five years of non-patent data exclusivity upon approval of a new drug containing new chemical entities that have not been previously approved by the FDA. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The Hatch-Waxman Act also provides three years of non-patent exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug's approval. As a general matter, the three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FDA Approval and Regulation of Medical Devices and Companion Diagnostics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If safe and effective use of a therapeutic depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, if the FDA determines that a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the U.S., the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, medical devices, including companion diagnostic tests, require marketing clearance or approval from the FDA prior to commercial distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The two primary types of FDA marketing authorization applicable to a medical device are premarket notification (&#8220;510(k) clearance&#8221;) and premarket approval (&#8220;PMA&#8221;). To obtain 510(k) clearance, a manufacturer must submit to the FDA a premarket notification submission demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a legally marketed predicate device. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class III (i.e., high-risk) device. The device sponsor must then fulfill more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance with the &#8220;de novo&#8221; process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or depending on the modification, approval of a PMA application or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), de novo classification or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until it receives 510(k) clearance, approval of a PMA application, or issuance of a de novo classification. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the QSR which imposes elaborate testing, control, documentation and other quality assurance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Approval of a PMA is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA may be delayed for several </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained, or problems are identified following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which currently cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In January 2024, the FDA announced that it intends to initiate the process to reclassify most in vitro diagnostic tests (&#8220;IVDs&#8221;) that are currently Class III into Class II, including companion diagnostics.  If such reclassification efforts occur, any companion diagnostics that are the subject of the down-classification may no longer require premarket approval, but rather may become subject to the generally less burdensome 510(k) clearance process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">International Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the U.S., we are and will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, marketing authorization, post-marketing requirements, and any commercial sales and distribution of our products. We must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of any products in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Non-Clinical Studies and Clinical Trials</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Similar to the U.S., the various phases of non-clinical and clinical research in the EU are subject to significant regulatory controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice (&#8220;GLP&#8221;) as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on GCP as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.  If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (&#8220;CTR&#8221;) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While the EU Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;) to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB, respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the EU Clinical Trials Directive, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the EU Clinical Trials Directive remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the development of a medicinal product, the EMA and national regulators provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;). A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical trials, and pharmacovigilance plans and risk-management programs. Advice is not legally binding to any future MA application (&#8220;MAA&#8221;) of the product concerned. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Marketing Authorization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In order to market our product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal products candidates can only be placed on the market after obtaining a MA. To obtain regulatory approval of a product candidate in the EU, we must submit a MAA. The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Centralized MA&#8221;: are issued by the European Commission through the centralized procedure based on the opinion of the EMA&#8217;s CHMP and are valid throughout the EU. The centralized procedure is compulsory for certain types of medicinal products such as (i) medicinal products derived from biotechnology processes, such as genetic engineering, (ii) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV or AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicinal products, and (iv) advanced therapy medicinal products (&#8220;ATMPs&#8221;) such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure is optional for product candidates containing a new active substance not yet authorized in the EU, or for product candidates that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;National MA&#8221;: are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized MAs. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure, an identical </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the centralized procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. At the end of the review period, the CHMP provides an opinion to the European Commission. If this opinion is favorable, the European Commission may then adopt a decision to grant an MA. In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the Breakthrough Therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme, facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the national competent authority decides on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Data and Marketing Exclusivity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The EU also provides opportunities for market exclusivity. Upon receiving an MA, reference product generally receives eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall 10-year market exclusivity period can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Orphan Medicinal Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the U.S. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention, or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The application for orphan drug designation must be submitted before the MAA. Orphan designation entitles a party to incentives such as fee reductions or fee waivers, protocol assistance, and access to the Centralized MA process. Upon grant of a MA, orphan medicinal products are entitled to 10 years of market exclusivity for the approved therapeutic indication. During the 10-year market exclusivity period, the competent authorities cannot accept a MAA, or grant a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">MA, or accept an application to extend a MA, for the same indication, in respect of a similar medicinal product. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, a MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective, or otherwise clinically superior; (2) the applicant consents to a second orphan medicinal product application; or (3) the applicant cannot supply enough orphan medicinal product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil, or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The aforementioned EU rules are generally applicable in the European Economic Area (&#8220;EEA&#8221;), which consists of the 27 EU member states plus Iceland, Liechtenstein, Norway, Switzerland and Turkey, as well as cooperating countries Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia, and Serbia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since the end of the Brexit transition period on January 1, 2021, Great Britain (England, Scotland and Wales) has not been directly subject to EU laws, however under the terms of the Ireland/Northern Ireland Protocol, EU laws generally apply to Northern Ireland. The EU laws that have been transposed into UK law through secondary legislation remain applicable in Great Britain, however new legislation such as the EU CTR is not applicable in Great Britain (&#8220;GB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Trade and Cooperation Agreement (&#8220;TCA&#8221;) became effective on January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;) inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Other Foreign Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For other countries outside of Europe, such as countries in Eastern Europe, Latin America, or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Regulation of Companion Diagnostics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the EU, in vitro diagnostic medical devices were regulated by Directive 98/79/EC, which regulated the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufacturers and devices, as well as the vigilance procedure. In vitro diagnostic medical devices had to comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The regulation of companion diagnostics is subject to further requirements since in-vitro medical diagnostic devices Regulation (No 2017/746) (&#8220;IVDR&#8221;) became applicable on May 26, 2022. The IVDR applies since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;"> The IVDR introduced a new classification system for companion diagnostics, which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure process for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure process, or an MAA for the medicinal product has been submitted through the centralized procedure process. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The aforementioned EU rules are generally applicable in the EEA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of drug products for which we obtain regulatory approval. In the U.S. and other countries, sales of products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers, and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, new products are facing increasingly high barriers to entry. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The marketability of products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is secured for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To raise sufficient financial resources to commercialize our approved products and continue to advance our product candidates, we will need to address pricing pressures and potential third-party reimbursement coverage for our approved products and product candidates. In the U.S. and elsewhere, sales of pharmaceutical products depend in significant part on the availability of reimbursement to the consumer from third-party payors, such as government payors, like Medicare and Medicaid, and private insurance plans. Third-party payors are increasingly challenging the prices charged for medical products and services. It is and will continue to be time consuming and expensive for us or our strategic collaborators to go through the process of seeking reimbursement from Medicare and private payors. Our products may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Healthcare Reform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">We participate in the Medicaid Drug Rebate Program and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future.  The U.S. government and other governments have shown significant interest in pursuing health care reform, which has resulted in changes to these programs and impacts </span>IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and our product candidates that may be approved. For example, in March 2010, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) was enacted and substantially changed the way health care is financed in the U.S. by both government and private insurers. Among other cost containment measures, the ACA established:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a Medicare Part D coverage gap discount program, in which pharmaceutical manufacturers who wish to have their drugs covered under Part D must offer discounts to eligible beneficiaries during their coverage gap period, or the &#8220;donut hole&#8221;; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been judicial, executive and congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. In addition, we expect that federal, state, and local governments in the U.S. will continue to consider legislation to limit the growth of health care costs, including the cost of prescription drugs. Future legislation could limit payments for pharmaceuticals such as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and the product candidates that we are developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which will remain in effect through 2032, absent additional congressional action. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, in March 2021, Congress enacted the American Rescue Plan Act of 2021, which, among other things, eliminated the statutory Medicaid drug rebate cap, effective January 1, 2024. The rebate was previously capped at a drugs average manufacturer price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law.  This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges.  While the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, individual U.S. states have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Future legislation could limit payments for pharmaceuticals such as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and the product candidates that we are developing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Other Health Care Laws and Compliance Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For approved products, we may be subject to various federal, state, and foreign laws targeting fraud and abuse in the health care industry. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, and transparency laws and regulations with respect to drug pricing and payments and other transfers of value made to physicians and other health care professionals, as well as similar foreign laws in jurisdictions outside the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal health care program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for health care items or services reimbursed by any source, not only the Medicare and Medicaid programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The &#8220;qui tam&#8221; provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payer and not merely a federal health care program. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus significant civil penalties for each separate false claim.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Also, the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created several federal crimes, including health care fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Physician Payment Sunshine Act (the &#8220;Sunshine Act&#8221;), which was enacted as part of the ACA, requires applicable manufacturers of drugs, devices, biologicals, or medical supplies covered under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, to report annually to the Secretary of the Department of Health and Human Services payments or other transfers of value made by that entity, or by a third-party as directed by that entity, to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain non-physician providers including physician assistants and nurse practitioners, and teaching hospitals, or to third parties on behalf of such providers, as well as ownership and investment interests held by physicians and their immediate family members during the course of the preceding calendar year. Failure to comply with the reporting requirements can result in significant civil monetary penalties for any payment or other transfer of value that is not reported. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Moreover, analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers, many of which differ from each other in significant ways, thus further complicating compliance efforts; and restrict marketing practices or require disclosure of marketing expenditures and pricing information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Violations of any of these laws or any other governmental laws and regulations that may apply include, without limitation, significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded health care programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Data Privacy &amp; Security</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;), the California Privacy Rights Act (&#8220;CPRA&#8221;), and the EU General Data Protection Regulation (&#8220;GDPR&#8221;), govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation.  Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, our use of AI and machine learning may be subject to laws and evolving regulations regarding the use of AI or machine learning, controlling for data bias, and anti-discrimination.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Employees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August 2023, our Board of Directors approved the Reprioritization. Following a comprehensive review of the business, we determined to focus on high-potential agitation-market opportunities using our innovative, AI-based clinical drug development platforms. We intend to reduce more than 50% of our cash burn, as compared to our cash burn levels during the second quarter of 2023, to approximately $80 million on a go-forward annualized basis. As part of the Reprioritization, our Board of Directors approved a reduction of approximately 60% of our workforce, from approximately 190 to 80 employees. These actions also included a shift in commercial strategy for IGALMI&#8482; in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer deemed core to our business, and a shift in focus to develop BXCL501 for use in the at-home setting in the treatment of agitation in schizophrenia, bipolar disorders, and in patients with mild to moderate dementia due to probable Alzheimer&#8217;s disease. We recorded restructuring costs of $4.2 million in the year ended December 31, 2023, including severance and benefit costs of $4.1 million and contract termination costs of $0.1 million, substantially all of which were paid in 2023. As of December 31, 2023, we had 74 full-time employees. We also leverage certain experts in drug development and AI that are employed by BioXcel LLC to provide flexibility for our business needs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Culture</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that the success of our human capital management investments is evidenced by our low employee turnover, a number which is regularly reviewed by our Board of Directors as part of their oversight of our human capital strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Engagement, Talent Development &amp; Benefits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries, bonuses, opportunities for equity ownership and other comparable benefits for our industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee and Visitor Safety Protocols</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We follow health and safety guidelines to protect the well-being of our employees and visitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Diversity &amp; Inclusion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our entire workforce. We believe that our business benefits from the different perspectives a diverse workforce brings, and we pride ourselves on having a strong, inclusive and positive culture based on our shared mission and values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company was incorporated as a Delaware corporation on March&#160;29, 2017. Our principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511 and our telephone number is (475) 238-6837.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our website address is www.bioxceltherapeutics.com. The contents of, or information accessible through, our website are not part of this Annual Report on Form 10-K. We make our filings with the SEC, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may use our website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors &amp; Media sections of our website at www.bioxceltherapeutics.com. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the &#8220;Email Alerts&#8221; option under the News / Events menu of the Investors &amp; Media section of our website at www.bioxceltherapeutics.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The reference to our website address does not constitute incorporation by reference of the information contained on or available through our website, and you should not consider such information to be a part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_87b4e232_c53b_4fae_9eb3_c8b18e4b2eb9"></a><a id="Item1ARiskFactors_143189"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks described below, as well as general economic and business risks and the other information in this Annual Report on Form&#160;10-K. The occurrence of any of the events or circumstances described below or other adverse events could have a material adverse effect on our business, results of operations and financial condition and could cause the trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited operating history and have not generated substantial product revenues to date, which may make it difficult to evaluate the success of our business and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We were incorporated in March 2017 and our operations to date have been largely focused on staffing our Company, raising capital, advancing the development of our product candidates, including conducting clinical and preclinical studies and establishing our commercial organization. We have only one product approved for commercial sale, and have limited experience in obtaining marketing approvals, manufacturing products on a commercial scale, and conducting sales and marketing activities necessary for successful commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We are transitioning from a company with primarily a research and development focus to a company also capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since our inception, we have incurred significant operating losses. Our net loss was $179.1 million and $165.8 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had a stockholders&#8217; deficit of approximately $56.5 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We have only one product candidate approved for marketing in the U.S., none in any other jurisdiction, and may never receive approval beyond the one product approved to date. It could be several years, if ever, before we have a commercialized product that generates significant revenues through sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or our product candidates, if approved. As a result, we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain it. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses may increase in the long term as we:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span> evaluate the development of our product candidates;</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">conduct preclinical studies and clinical trials for our current product candidates and any future product candidates that we may pursue;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>continue to develop, maintain, expand and protect our intellectual property portfolio;</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">&#8226;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">&#8226; </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">develop an appropriate sales, marketing, and distribution infrastructure to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any other product candidates for which we may obtain marketing approval;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>potentially hire additional clinical, commercial, regulatory, scientific and finance personnel; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>incur additional legal, accounting and other expenses in operating as a public company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To become and remain profitable, we must develop and commercialize more products or product candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing, and selling IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any current and future product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient revenue to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we have obtained U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, because of the numerous risks and uncertainties associated with product development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will obtain marketing approval to commercialize any additional product candidates. If we are required by the FDA, or other regulatory authorities such as the European Medicines Agency (&#8220;EMA&#8221;) to perform studies and trials in addition to those currently expected, or if there are any delays in the development, or in the completion of any planned or future preclinical studies or clinical trials of our current or future product candidates, our expenses could increase and profitability could be further delayed. For example, developments with respect to our TRANQUILITY program evaluating BXCL501 in patients with dementia due to probable Alzheimer&#8217;s disease may increase the likelihood that we experience such costs or delays, as discussed in the risk factor below entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our failure to become and remain profitable would decrease the value of our Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our Company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our strategic reprioritization and related reduction in force may not achieve our intended outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In August 2023, we announced a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). We have taken actions to reduce certain operational and workforce expenses that are no longer deemed core to our ongoing operations in order to extend our cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions include a shift in commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization on at-home treatment setting opportunities for BXCL501. As part of this strategy, we reduced our workforce by approximately 60%. As of December 31, 2023, the Reprioritization was substantially completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The reduction in force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction in force. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we may be unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. The workforce reduction could also harm our reputation, making our ability to recruit skilled personnel difficult.  If we are unable to realize the anticipated benefits from the reduction in force, or if we experience significant adverse consequences from the reduction in force, our business, financial condition, and results of operations may be materially adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In addition, we may not realize the benefits of or there may be unanticipated costs associated with our Reprioritization. As a result of the Reprioritization, including our strategic refocus, we may not generate material revenues from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the near term because our commercial force will be significantly reduced. If we are unable to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in a different setting or unable to develop, receive marketing approval for and successfully commercialize BXCL501, BXCL701 and any of our other product candidates on our own or with any future </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">collaborator, or experience delays because of any of these factors or otherwise, our business could be materially and substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">In addition, because we have limited financial and managerial resources, under our Reprioritization, we intend to focus on specific product candidates, indications and development programs. We may also conduct several clinical trials for our product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. As a result, we may forgo or delay pursuit of opportunities with other product candidates or other indications that could have had greater commercial potential or likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. If we are not successful in increasing our efficiency as a result of this Reprioritization, our efforts to develop and commercialize our product candidates may be delayed or halted and our business could be materially adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Furthermore, we may undertake further similar cost-saving initiatives, which may include additional restructuring or workforce reductions. These types of cost-reduction activities can be complex and result in unintended consequences and costs, including decreased employee morale, loss of institutional knowledge and expertise and adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives. In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement (as defined herein) would trigger an event of default thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We will require additional future funding to support current and anticipated future expenses. We currently anticipate continuing to develop and conduct clinical trials with respect to our current and any future product candidates; seek to identify and develop additional product candidates; acquire or in-license other product candidates or technologies; seek regulatory approvals for our product candidates that successfully complete clinical trials, if any; establish sales, marketing, distribution and other commercial infrastructure to support the commercialization of products for which we may obtain marketing approval; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; hire and retain limited additional personnel, such as clinical, quality control and scientific personnel; add operational, financial and management information systems and personnel, including personnel to support our product development and help us comply with our obligations as a public company; and add equipment and physical infrastructure to support our research and development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may be required to expend significant funds to continue to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the U.S. and advance the development of BXCL501, BXCL701, BXCL502 and our other product candidates. In addition, while we may seek one or more collaborators for future development of our current product candidates or any future product candidates that we may develop for one or more indications, we may not be able to enter into a collaboration for any of our product candidates for such indications on suitable terms, on a timely basis or at all. In any event, our existing cash will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of our product candidates or our other preclinical programs. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We may also seek third-party investments in or other strategic options for our subsidiary, OnkosXcel. Further financing may not be available to us on acceptable terms, or at all. In addition, we are reliant on the financial institutions with which we hold our cash and cash equivalents. If such institutions were to close, we may not be able to recover all of our cash or cash equivalents held at such institutions. Moreover, market volatility resulting from COVID-19, credit crises, adverse macroeconomic conditions, such as high interest or inflation rates, or other factors, as well as Company-specific factors such as the progress of our development pipeline, adverse clinical events or results, regulatory investigations, or ongoing or potential legal proceedings, could also adversely impact our ability to access capital as and when needed. Our failure </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Management believes that, after giving effect to the Reprioritization, the Company&#8217;s cash and cash equivalents of $65.2 million as of December 31, 2023 will allow the Company to fund its operations and meet its liquidity requirements into mid-2024. However, the expected cost benefit of the Reprioritization cannot be assured, and there can be no assurance that we will be able to extend our cash runway by meeting the conditions for additional funding under the terms of our Credit Agreement (defined below) or otherwise. In addition, the failure to raise additional financing in accordance with the minimum capital raising requirements of our Credit Agreement would trigger an event of default thereunder. The Fourth Amendment to our Credit Agreement includes covenants that we will receive, (i) after March 20, 2024, which is the effective date of the Fourth Amendment, and on or before April 15, 2024, at least $25.0 million in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after March 20, 2024 (so long as such partnering transactions would not require us or any of our subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), and (ii) after March 20, 2024 and on or before November 30, 2024, at least $50.0 million (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion from partnering transactions entered into after March 20, 2024. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) would constitute an immediate event of default under the Credit Agreement without any cure or grace period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, our estimate as to how long we expect our existing cash to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, timing, costs, and results of clinical trials of our product candidates, including any delays that have occurred or may occur due to the recent developments with the TRANQUILITY program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and for any of our product candidates that receive marketing approval, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue received from commercial sales of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory policies or laws that may affect our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in physician acceptance or medical society recommendations that may affect commercial efforts;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of acquiring potential new product candidates or technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our operations continue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of legal proceedings and investigations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any adverse market conditions or other macroeconomic factors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As we continue our research and development activities, we will require additional resources to continue as a going concern. We can provide no assurance that we will successfully obtain additional resources to improve our financial condition. If we are unable to obtain necessary additional capital, we could be compelled to pursue alternative options, including, without limitation, implementing further workforce reductions, reducing or ceasing product development programs and advancement of our clinical trials and product candidates, selling our assets or seeking other strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have significant indebtedness and other contractual obligations that could impair our liquidity, restrict our ability to do business and thereby harm our business, results of operations and financial condition. We may not have sufficient cash flow from operations to satisfy our obligations under the Credit Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we had aggregate principal indebtedness of $102.7 million outstanding under our Credit Agreement and Guaranty (as amended, the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restrictive covenants in the Credit Agreement place limits on our ability to conduct our business. The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. In addition, certain events, including receipt of a warning letter from the FDA, may constitute an event of default. We must also comply with certain covenants under the Credit Agreement, including a financial covenant that requires we maintain a minimum cash liquidity amount of $15 million (or higher upon certain events, including as described in the Fourth Amendment to the Credit Agreement described in Note 19, Subsequent Events in the audited financial statements included elsewhere in this Annual Report on Form 10-K) and a minimum revenue requirement measured on a quarterly basis based on the revenue attributable to BXCL501 for the six consecutive month period ending on the last day of the relevant quarter, subject to cure payments of not less than $1.0 million if we fail to meet the minimum revenue requirement. The minimum revenue requirement applies beginning with the preceding six-month period ending on December 31, 2024, and ranges from approximately $4.5 million for the fourth quarter of 2024 to approximately $47.9 million for the first quarter of 2027. If we fail to meet the minimum revenue requirements for the preceding six-month periods ending on December 31, 2024, March 31, 2025, June 30, 2025 and September 30, 2025, we could be required to make revenue cure payments for the revenue shortfalls of up to $4.5 million, $6.2 million, $8.5 million, and $8.5 million, respectively, plus aggregate prepayment fees of $1.9 million. Under the Credit Agreement, these cure payments would be due on April 21, 2025, June 6, 2025, September 5, 2025 and December 8, 2025, respectively. We are only permitted to make cure payments for revenue shortfalls up to three times during the term of the Credit Agreement, after which we would default on the Credit Agreement if we are unable to satisfy the minimum revenue requirement for any subsequent fiscal quarter. In addition, certain events, including certain regulatory events and any &#8220;going concern&#8221; or similar qualification in a report of the Company&#8217;s independent registered public accountants relating to the Company&#8217;s annual financial statements, constitute an event of default under the Credit Agreement. The report of our independent registered public accounting firm included in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph. In March 2024 we entered into a Fourth Amendment to the Credit Agreement, pursuant to which the Lenders waived compliance with this covenant with respect to the report contained in this Annual Report on Form 10-K. The Fourth Amendment to the Credit Agreement also includes other covenants relating to minimum cash liquidity covenants and minimum capital raising requirements, as described further in Note 19, Subsequent Events in the audited financial statements included elsewhere in this Annual </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Report on Form 10-K, and failure to comply with such obligations, or other obligations required under the Credit Agreement, could trigger an event of default. Certain change of control events can also trigger an event of default under the Credit Agreement, including control by any entity or group of entities, other than BioXcel LLC and its affiliates, that acquires 35% or more of our voting capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to make scheduled payments or payments to maintain compliance with covenants or to restructure or refinance these and other outstanding debt obligations depends on our financial and operating performance, including growth in revenue from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and BXCL501, which will be affected by prevailing economic, industry and competitive conditions and by financial, business and other factors beyond our control. A failure to pay our debt, fixed costs and other obligations or a breach of our contractual obligations or other event of default could result in a variety of adverse consequences, including the acceleration of our obligations or the exercise of remedies by our creditors and lessors. In such a situation, it is unlikely that we would be able to cure our breach, fulfill our obligations, make required payments or otherwise cover our fixed costs, which would have a material adverse effect on our business, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, historically we have relied on debt and equity financings as our primary sources of liquidity. If our future cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay expenditures, sell assets, seek additional capital or seek to restructure or refinance our indebtedness. Any refinancing or restructuring of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants. These alternative measures may not be successful and may not permit us to meet our scheduled or any accelerated debt service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and might be required to sell material assets or pursue other strategic alternatives to attempt to meet our debt service obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2023, we had $65.2 million in cash and cash equivalents. Based on our existing cash, cash equivalents and lack of current availability under our funding facilities, we do not believe we have sufficient cash on hand to support current operations and service our debt obligations for at least one year from the date of issuance of the audited consolidated financial statements appearing in this Annual Report on Form 10-K. This condition raises substantial doubt about our ability to continue as a going concern for at least one year from the date that our financial statements for the year ended December 31, 2023 are issued. In order to mitigate the current and potential future liquidity issues, we have undertaken the Reprioritization and may, among other things, seek to raise capital through the issuance of common stock, or by restructuring, refinancing, and/or amending the terms of the Credit Agreement (including with respect to regulatory related events of default that do not contain a cure period) or pursue other strategic alternatives.  However, such transactions may not be successful and we may not be able to raise additional equity and/or financing necessary to meet our obligations. Moreover, our Credit Agreement contains covenants that we may be unable to comply with and which could result in the acceleration of our debt service obligations, further reducing our capital resources and ability to fund our operations. As such, there can be no assurance that we will be able to continue as a going concern and we may be forced to delay, reduce or discontinue our product development programs or commercialization efforts in order to preserve cash. For additional cost-saving and other strategic initiatives we may be compelled to pursue, see the risk factor entitled, </span><i style="font-style:italic;">&#8220;We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Discovery and Development of Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in drug discovery and drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prior to the acquisition of our product and product candidates, we were not involved in and had no control over their preclinical and clinical development. In addition, we are relying upon the parties we acquired our product candidates from to have conducted research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, accurately reported the results of all clinical trials conducted prior to our acquisition of the applicable product candidate, and correctly collected and interpreted the data from these studies and trials. To the extent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">any of these activities did not occur, our expected development time and costs could increase, which could adversely affect our prospects for marketing approval of, and receiving any future revenue from, these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Following our discovery of principal investigator misconduct at one of the clinical sites in our TRANQUILITY II Phase 3 clinical trial, we initiated an investigation into the issues associated with the trial.  This principal investigator had previously been subject to a December 2022 FDA inspection of her clinical site in connection with the TRANQUILITY II clinical trial.  At the conclusion of this inspection, the FDA issued an FDA Form-483 identifying three inspectional observations. These observations related to the principal investigator&#8217;s failure to adhere to the informed consent form approved by the Institutional Review Board for a limited number of subjects whose records the FDA reviewed, maintain adequate case histories for certain patients whose records the FDA reviewed, and adhere to the investigational plan in certain instances. For example, the FDA cited the principal investigator&#8217;s delay in informing the sponsor&#8217;s medical monitor or pharmacovigilance safety vendor of an SAE, for one of the subjects, which report was made to our vendor outside of the 24 hour time period prescribed by the clinical trial protocol. The principal investigator for this clinical site responded to the FDA observations within the time period requested. The FDA inspection remains open, however, as the FDA has not issued an Establishment Inspection Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In May 2023, it came to our attention that this same principal investigator in the TRANQUILITY II clinical trial may have fabricated email correspondence around the time of the FDA inspection, purporting to demonstrate that the investigator timely submitted to our pharmacovigilance safety vendor a report of an SAE from a different subject than the one cited in the FDA Form-483, and purporting to show that the vendor had confirmed receipt. Upon receipt of this information, we promptly initiated an investigation and received confirmation that the principal investigator fabricated the email correspondence related to the timing of the reporting of this SAE to our pharmacovigilance vendor to make it appear as though this SAE had been timely reported as required by the clinical trial protocol. This principal investigator has not participated in any other clinical trial sponsored or conducted by us. Both we and the principal investigator&#8217;s employer have reported this incident to the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">However, the FDA may not accept or agree with our conclusions or analyses or may interpret or weigh their importance differently. Further, if we or the FDA determine that there are issues with data integrity and/or compliance with good clinical practice (&#8220;GCP&#8221;) requirements at the trial site, we may be unable to use some or all of the subject data generated at this clinical site to support a marketing application. Any issues identified at this trial site may also be identified at other trial sites.  If all of data from this clinical trial site were discarded, the TRANQUILITY II trial would no longer be adequately powered for statistical significance or would not be considered adequately well-controlled by the FDA, and in either case, we would need to conduct a new comparable clinical trial before we are able to seek any approval of BXCL501 for use in patients with acute agitation (non-daily) due to dementia in probable Alzheimer&#8217;s disease. If a substantial portion of the data were discarded, similar outcomes may also occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we are continuing to seek feedback from the FDA with respect to our TRANQUILITY program. For example, on February 20, 2024, we held a Type B/Breakthrough Therapy designation meeting with the FDA. The original purpose of this meeting was to obtain feedback on the design of a proposed at-home study that did not include caregiver-collected efficacy endpoints, based on our belief that obtaining caregiver assessments of efficacy would be challenging. We believe there are no validated caregiver endpoints for assessing efficacy in Alzheimer&#8217;s disease patients in the at-home setting. As a result, we focused on requesting feedback from the FDA regarding our proposal for an at-home clinical study with safety as the primary objective, and to better understand what additional data would be required to submit an sNDA to support labeling for BXCL501 to include the acute treatment of agitation associated with dementia in probable Alzheimer&#8217;s disease or, in the alternative, in this population in the care setting only. In its preliminary responses, the FDA reiterated its prior comments that we generate additional efficacy data, including repeat-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">dose efficacy data, to support an sNDA submission, as the FDA indicated that our proposed efficacy database, which currently includes the 70 patients who have been treated with 60 mcg of BXCL501 in TRANQUILITY I and TRANQUILITY II, would not contain substantial evidence of effectiveness absent additional data.  The FDA advised that we generate the necessary efficacy data in care facilities prior to conducting any trials in the at-home setting. In addition, the FDA indicated the need to generate long-term safety data to support an sNDA submission, including from probable Alzheimer&#8217;s disease patients exposed to BXCL501, for up to one year. We have received the final meeting minutes from the FDA, which we believe are consistent with the FDA&#8217;s preliminary responses and the subsequent meeting discussion. Based on the FDA&#8217;s feedback, we are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia using the PEC as the primary efficacy measure, as used in the prior TRANQUILITY II study. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. Also, although we announced in November 2023 that we were planning to conduct a Phase 3 trial in the at-home setting, with safety as the primary objective (TRANQUILITY At Home), given the priority to expand the database to generate additional efficacy and safety data in care facilities, we are re-evaluating the timing for initiating TRANQUILITY At Home. Conducting any new clinical trial can take significant time, funding and resources, and there are no assurances we could raise the capital or have the liquidity and resources to conduct further clinical trials in our TRANQUILITY program. Any new clinical trials conducted in our target patient populations may have different safety or efficacy results from the topline data the Company previously announced for the TRANQUILITY II clinical trial. Further, any government investigation, disqualification, or debarment of, or proceeding or action against the principal investigator, or any government investigation, proceeding or action against us, could further delay development and approval of BXCL501 for this indication, and otherwise have a material adverse effect on us, our financial condition (including triggering a potential event of default under our Credit Agreement), results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have limited clinical data supporting potential safety or efficacy of BXCL501 for use in the at-home setting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In August 2023, we announced our intention to pursue a strategic reprioritization of our commercialization and development efforts (the &#8220;Reprioritization&#8221;), including among other things, a shift in focus to primarily develop BXCL501 for use in expanded settings, including the at-home setting and care facilities, for the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease and the acute treatment of agitation in schizophrenia and bipolar patients in the at-home setting. Although we have conducted several clinical trials that evaluated BXCL501 in the institutional setting, we have limited data supporting BXCL501&#8217;s potential use in the at-home setting. In particular, we have not conducted a clinical trial evaluating the at-home use of BXCL501 in the acute treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we will seek additional feedback from the FDA regarding the potential of its ongoing or completed clinical trials to support submission of one or more sNDAs and to support a label for use in the home, it is possible that the FDA may not consider our available data adequate to support such submissions. For example, on October 11, 2023, we received feedback from the FDA that TRANQUILITY I and TRANQUILITY II alone are not sufficient to support an sNDA submission for the use of BXCL501 to treat acute agitation (non-daily) in patients with dementia due to probable Alzheimer&#8217;s disease in either the at-home setting or care facilities, and the FDA indicated that we should, among other things, conduct a further clinical trial to evaluate safety and collect efficacy data of BXCL501 before we are able to submit an sNDA seeking approval of BXCL501 for use in such populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a description of recent developments relating to our TRANQUILITY program, please see the prior risk factor, &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease.</i>&#8221; We cannot provide assurance that we will be able to seek or obtain approval of BXCL501 for treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease in the at-home setting based on this updated development plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although we continue to seek feedback from the FDA with respect to our TRANQUILITY program, the FDA may not agree that any trial designs we propose are sufficient to establish both the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer&#8217;s disease in either a care setting or an at-home setting. For example, to assess safety, the FDA has indicated that we need to expose more patients to BXCL501 for a longer period of time and that an efficacy trial of a shorter duration, combined with the patients in its previous </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">trials, would not support submissions of an sNDA. Further, to assess efficacy in the home setting, the FDA may determine that we cannot rely on our previous studies of BXCL501 for this proposed indication since those studies were conducted in assisted living facilities and they are not comparable to the at-home setting. The FDA may also require us to seek approval for BXCL501 for use in care facilities prior to seeking any approval for at-home use in the targeted AD patient population. In particular, we are planning to generate additional Phase 3 safety and efficacy data in a variety of relevant care-facility settings, but even if our planned clinical efforts are successful and even if we are able to obtain approval of BXCL501 for use in patients with dementia due to probable Alzheimer's disease, we cannot provide assurance that we will be able to seek or obtain approval of BXCL501 for the treatment of agitation in patients with dementia due to probable Alzheimer&#8217;s disease in the at-home setting based on this data and we will be required to generate additional data to evaluate the at-home use of BXCL501 in our targeted Alzheimer's dementia population before we are able to seek approval for such at-home use in this population, if ever. In addition, the FDA may determine that we cannot rely on the data from our prior TRANQUILITY II Phase 3 trial to support an sNDA as a result of potential data integrity issues at the trial site, as the FDA may not agree with our belief that data reliability and integrity remain intact. See Part II, Item 1A, &#8220;Risk Factors&#8212;Risks Related to the Discovery and Development of Product Candidates&#8212;<i style="font-style:italic;">Developments relating to its TRANQUILITY II Phase 3 trial may impact the timing of its development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>&#8221; for additional information. If the FDA does not accept the data from our prior TRANQUILITY II Phase 3 trial, we could be required to conduct additional clinical trials beyond those we currently contemplate, which would increase our costs and delay potential submission of an sNDA for BXCL501 which in turn would adversely affect our financial position and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accordingly, if the FDA reaches these conclusions or otherwise finds that our proposed clinical studies would not adequately evaluate the safety and efficacy of BXCL501 for the acute treatment of agitation associated with dementia due to probable Alzheimer&#8217;s disease in an at-home setting and/or care setting, we may need to evaluate more patients for a longer period of time to demonstrate the safety and efficacy of BXCL501.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">With respect to our SERENITY program, we also held a Type C Meeting with the FDA on March 6, 2024 to obtain further feedback on our proposed changes to the design of SERENITY III Part 2, including with respect to the trial endpoints, and to discuss the content and format of a potential sNDA submission to expand the label of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> 120 micrograms to the acute treatment of agitation associated with schizophrenia and bipolar disorders in the outpatient setting. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is already approved at the 120 mcg dose based on efficacy data that we previously generated in treating a single episode of agitation. Consistent with the data generated to date, the label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> currently includes a limitation on use (&#8220;LOU&#8221;), noting the lack of efficacy or safety data beyond 24 hours following the first dose. During our March 6, 2024 Type C meeting with the FDA, we discussed, among other things, whether evaluating the at-home use of BXCL501 120 mcg, with safety as the primary objective and efficacy measures as exploratory endpoints, if successful, could support the submission of an sNDA seeking expansion of the current label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> 120 mcg to allow at-home use and labeling without the current LOU. Based on current FDA feedback, we plan to amend the SERENITY III protocol to evaluate the safety and efficacy of the 120 mg dose in the at-home setting. We believe that our ability to seek labeling without the current LOU will depend, in part, on the number of agitation episodes we observe during our planned study period. Even if our amended SERENITY III trial is successful in demonstrating safety in the at-home setting, and even if the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> 120 mcg label is expanded to allow outpatient use, there is no guarantee that we will observe and/or treat a sufficient number of agitation episodes during the study period to support removal of the current LOU. We plan to provide further guidance regarding our plans for the SERENITY program following receipt of the final meeting minutes from the FDA. Even if the protocol for SERENITY III Part 2 is amended as described above, and even if the study produces favorable data, such data may not be sufficient for approval without additional clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any modifications to our proposed trial designs by the FDA would delay our initiation of such proposed trials, increase the costs of any trial that we do conduct and delay our submission of an sNDAs for BXCL501. Requirements to conduct additional clinical trials evaluating BXCL501 in support of our planned sNDAs seeking approvals for BXCL501 for our targeted patient populations in at-home settings would increase our costs, and could have a material adverse effect on our prospects and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">In the near term, we are dependent on the success of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and the development of four of our product candidates, BXCL501, BXCL502, BXCL701 and BXCL702. If we are unable to complete the clinical development of or obtain marketing approval for our product candidates or successfully commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and our other product candidates, either alone or with a collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently have only one product that has received regulatory approval and may never be able to develop additional marketable product candidates. We are continuing to invest a significant portion of our efforts and financial resources in the commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and development of our four product candidates, BXCL501, BXCL502, BXCL701 and BXCL702, as well as other product candidates. In connection with the Reprioritization, we have significantly reduced the resources devoted to commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and it is possible that will have adverse consequences on the revenue that we are able to generate from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the near term. As part of the Company&#8217;s Reprioritization, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> commercial team shifted focus to a hospital/Integrated Delivery Network (&#8220;IDN&#8221;) contracting strategy with a Corporate Account Director (CAD) team. The goal of the realigned CAD team is to work with large IDNs and drive sales utilizing a top-down approach. Over time, the revised commercial effort is expected to allow the Company to continue to make inroads into the institutional market in a more cost-efficient manner. However, we have limited experience in drug development and commercialization, and our prospects are substantially dependent on our ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize product candidates in one or more additional disease indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The success of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and of BXCL501, BXCL701, BXCL502 and our other product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of an investigational new drug application (&#8220;IND&#8221;) by the FDA or acceptance of comparable applications by foreign regulatory authorities allowing us to conduct clinical trials of our product candidates in the U.S. or in foreign jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation, progress, timing, costs and results of clinical trials of our product candidates and potential product candidates, including any delays caused by the developments relating to the TRANQUILITY program, and any additional trials we may need to conduct prior to seeking approvals for BXCL501 in at-home and/or care facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of safety and efficacy of our product candidates to the satisfaction of the FDA, or any comparable foreign regulatory authority, and sufficient for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and performance of our current and future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature of any required post-marketing clinical trials or other commitments to applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of supply arrangements with third-party raw materials suppliers and manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the U.S. and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protection of our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community and third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with other therapies.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of these factors are beyond our control, including the results of clinical trials, the time required for the FDA, or any comparable foreign regulatory authorities, to review any regulatory submissions we may make, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or develop, receive marketing approval for and successfully commercialize BXCL501, BXCL701 and our other product candidates, on our own or with any future collaborator, or experience delays because of any of these factors or otherwise, our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials, that we announce or publish from time to time, may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions based on such preliminary data are subject to change, and have in the past changed, following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our Company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the biopharmaceutical industry to suffer significant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">setbacks in advanced clinical trials due to nonclinical findings made while clinical studies are underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Our future clinical trial results may not be successful, and notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. The historical failure rate for product candidates in our industry is high. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. We obtained regulatory approval for our first product candidate for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, which is in the early stages of commercialization. It is possible that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our current product candidates, or any that may be developed in the future, could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA, or comparable foreign regulatory authorities, that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA, or comparable foreign regulatory authorities, for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may disagree that our changes to branded reference drugs meet the criteria for the 505(b)(2) regulatory pathway or comparable foreign regulatory pathways;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, or comparable foreign regulatory authorities, may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have limited experience in completing clinical trials of product candidates. Consequently, we may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, even if we were to obtain approval, regulatory authorities may approve our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate or may restrict its distribution. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have only submitted one NDA to the FDA and have not submitted any similar marketing applications to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates currently in development, or any than may be developed in the future, will be successful in clinical trials or receive regulatory approval. Further, our product candidates currently in development, or any that may be developed in the future, may not </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">receive regulatory approval even if we believe they are successful in clinical trials. If we do not receive regulatory approvals for additional product candidates, we may not be able to continue our operations. For any regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients that we are targeting for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or our other product candidates are not as significant as we estimate, we may not generate significant revenues from sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or such other product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to seek regulatory approval to commercialize our product candidates in the U.S., the European Union (&#8220;EU&#8221;) and in additional foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application (&#8220;CTA&#8221;), to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors could choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those are governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Clinical trials are expensive, time-consuming, difficult to design, difficult to conduct, and involve an uncertain outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Before obtaining marketing approval from the FDA, or other comparable foreign regulatory authorities, for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates, in accordance with applicable law and regulations. Failure can occur at any time during the clinical trial process. Although we are planning for certain clinical trials relating to BXCL501, BXCL701, BXCL502 and our other product candidates, there can be no assurance that the FDA, or other comparable foreign regulatory authorities, will accept our proposed trial designs as sufficient to establish the safety and/or efficacy of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may experience delays in our clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, or comparable foreign regulatory authorities, disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory allowances or authorizations to commence a trial or consensus with regulatory authorities on trial designs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board approval at each site, or independent ethics committee approval at any sites outside the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dependence on the needs and timing of third-party collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes to clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of SAEs in trials of the same class of agents conducted by other companies or institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a facility manufacturing our product candidates or any of their components being ordered by the FDA, or comparable foreign regulatory authorities, to temporarily or permanently shut down due to violations of current good manufacturing practice (&#8220;cGMP&#8221;) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our manufacturing process that may be necessary or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCPs or other regulatory requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">third-party contractors not performing data collection or analysis in a timely or accurate manner;  third-party contractors not complying with training and trial protocol; or third-party contractors becoming debarred or suspended or otherwise penalized by the FDA, such as in the case of the recent events relating to the TRANQUILITY II clinical trial, or other government or regulatory authorities, for violations of regulatory </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">requirements, in which case, we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, which increases the risk that such CROs or trial sites may fail to perform in accordance with regulatory requirements, clinical trial protocols or with the agreements governing their services to us. For example, investigator misconduct affecting our TRANQUILITY II trial, which evaluated BXCL501 in patients with probable Alzheimer&#8217;s disease, may have a material adverse impact on our development program for BXCL501 in these patients, as described more fully in the risk factor above entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, conducting clinical trials in foreign countries, as we may do for our current and future product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol due to differences in health care services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. For example, current geopolitical conflicts in Eastern Europe and the Middle East may adversely impact our ability to conduct trials in those regions and elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on enrollment of patients in our clinical trials to continue development of our product candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. Patient enrollment is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the size of the patient population required for analysis of the trial&#8217;s primary endpoints, our ability to recruit clinical trial investigators with the appropriate competencies and experience, our ability to obtain and maintain patient consents, the risk that patients enrolled in clinical trials will drop out of the trials before completion, and competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Many pharmaceutical companies are conducting clinical trials in patients with the disease indications that our product candidates are designed to target. As a result, we must compete with them for clinical sites, physicians and the limited number of patients who fulfill the stringent requirements for participation in clinical trials. Also, due to the confidential nature of clinical trials, we do not know how many of the eligible patients may be enrolled in competing studies and who are consequently not available to us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients. The delay or inability to meet planned patient enrollment may result in increased costs and delay or termination of our trials, which could have a harmful effect on our ability to develop products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The clinical evaluation of BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates in patients, in many cases, is ongoing and it is possible that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. For example, in our Phase 2 clinical trial of BXCL701 for the treatment of emergent neuroendocrine prostate cancer, one patient experienced acidosis with a fatal outcome. Although the clinical investigator could not determine that the fatality was related to treatment with BXCL701, it is possible that BXCL701 could be tied to unacceptable side effects in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we observe drug-related AEs or other unacceptable safety concerns in clinical trials, we, the FDA, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA, or comparable foreign regulatory authorities, could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. For example, the FDA placed Point Therapeutics, Inc.&#8217;s IND for BXCL701 on clinical hold following an increase in observed mortality in patients receiving BXCL701 in a Phase 3 trial in patients with non-small cell lung cancer. Though we believe that this result was caused by, among other things, an imbalance in the disease severity of patients enrolled in the active arm of the clinical trial, there is no guarantee that excess mortality will not be observed in future clinical studies. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles observed in our clinical trials and upon commercialization of any of our product candidates that may receive regulatory approval. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, if we or others later identify undesirable side effects caused by IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or any other product candidate that receives marketing approval, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such a product is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing or distribution of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or create a medication guide outlining the risks of such side effects for distribution to patients, or similar risk management measures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product or product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The discovery and development of product candidates based on EvolverAI, BioXcel LLC&#8217;s proprietary pharmaceutical discovery and development engine, and our artificial intelligence (&#8220;AI&#8221;) platform is novel and unproven, and we do not know whether we will be able to develop any products of commercial value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are leveraging our own AI platform and BioXcel LLC&#8217;s EvolverAI, a proprietary pharmaceutical discovery and development engine, to create a pipeline of neuroscience and immuno-oncology product candidates for patients whose diseases have not been adequately addressed to date by other approaches and to design and conduct efficient clinical trials with a higher likelihood of success. While we believe that applying our AI platform and BioXcel LLC&#8217;s EvolverAI to create medicines for defined patient populations may potentially enable drug research and clinical development that is more efficient than conventional drug research and development, our approach is novel. Although we obtained FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, because our approach is novel, the cost and time needed to develop our product candidates is difficult to predict, and our efforts may not result in the discovery and development of commercially viable medicines. We may also be incorrect about the effects of our product and product candidates on the diseases of our defined patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore, our estimates of our defined patient populations available for study and treatment may be lower than expected, which could adversely affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully commercialize. Our approach may not result in time savings, higher success rates or reduced costs as we expect it to, and if not, we may not attract collaborators or develop new drugs as quickly or cost effectively as expected and therefore we may not be able to commercialize our approach as originally expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may fail to help us discover and develop additional potential product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any drug discovery that we are conducting using the Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may not be successful in identifying compounds that have commercial value or therapeutic utility. The Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may initially show promise in identifying potential product candidates, yet fail to yield viable additional product candidates for clinical development or potential commercialization for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new product candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compounds found through the Company&#8217;s AI platform and BioXcel LLC&#8217;s EvolverAI may not demonstrate efficacy, safety or tolerability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential product candidate may not be capable of being produced at an acceptable cost.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our future success depends on our ability to continue to develop and implement our proprietary AI algorithms and models, and to maintain the confidentiality of this technology. Changes to existing regulations, their interpretation or implementation, or new regulations could impede our use of this technology or require that we disclose our proprietary </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">technology to our competitors, which could impair our competitive position and result in an adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We obtained Fast Track designation for certain of our product candidates, and we may seek Fast Track designation for other indications or for our other product candidates, but we might not receive such designations, and even if we do, such designations may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review if the relevant criteria are met. An NDA for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We obtained Fast Track designation for BXCL501 for the acute treatment of mild-to-moderate agitation associated with schizophrenia, bipolar disorder, and dementia, and we further obtained Fast Track designation for BXCL701, in combination with a checkpoint inhibitor, for the treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability, and we may seek additional Fast Track designation for BXCL501 or BXCL701 or for one or more of our other product candidates, but we might not receive such designations from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We obtained Breakthrough Therapy Designation for BXCL501 for the acute treatment of agitation associated with dementia, and we may seek additional Breakthrough Therapy designations for our product candidates if the clinical data support such a designation for one or more product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as Breakthrough Therapies by the FDA also receive the benefits associated with Fast Track designation, including the potential for rolling review of an NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the period for FDA review or approval will not be shortened.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA does not conclude that our product candidates satisfy the requirements for the 505(b)(2) regulatory approval pathway, or if the requirements for approval of any of our product candidates under Section 505(b)(2) are not as we expect, the approval pathway for our product candidates will likely take significantly longer, cost significantly more and encounter significantly greater complications and risks than anticipated, and in any case may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We intend to seek FDA approval through the 505(b)(2) regulatory pathway for certain of our product candidates. The Hatch-Waxman Act added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;). Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant. If the FDA does not allow us to pursue the 505(b)(2) regulatory pathway for our product candidates as anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates would likely substantially increase. Moreover, the inability to pursue the 505(b)(2) regulatory pathway could result in new competitive products reaching the market faster than our product candidates, which could materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the 505(b)(2) regulatory pathway for a product candidate, we cannot assure you that we will receive the requisite or timely approvals for commercialization of such product candidate. In addition, we expect that our competitors will file citizens&#8217; petitions with the FDA in an attempt to persuade the FDA that our product candidates, or the clinical studies that support their approval, contain deficiencies. Such actions by our competitors could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are required by the FDA, or similar regulatory authorities, to obtain approval (or clearance, or certification) of a companion diagnostic device in connection with approval of one of our product candidates, and we do not obtain, or face delays in obtaining approval (or clearance, or certification) of a companion diagnostic device, we will not be able to commercialize the product candidate, and our ability to generate revenue will be materially impaired</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. For example, we may decide to collaborate with patient diagnostic companies during our clinical trial enrollment process for BXCL701 to help identify patients with tumor gene alterations that we believe may be most likely to respond to treatment with BXCL701. The process of obtaining or creating such diagnostic is time consuming and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable foreign regulatory authorities, and, to date, the FDA has generally required premarket approval of companion diagnostics for cancer therapies. Generally, when a companion diagnostic is essential to the safe and effective use of a therapeutic product, the FDA requires that the companion diagnostic be approved before or concurrent with approval of the therapeutic product and before a product can be commercialized. The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect. In January 2024, the FDA announced that it intends to initiate the process to reclassify most in vitro diagnostic tests (&#8220;IVDs&#8221;) that are currently Class III into Class II, including companion diagnostic IVDs.  If such reclassification efforts occur, any companion diagnostics that are the subject of the down-classification may no longer require premarket approval, but rather may be marketed pursuant to the generally less burdensome 510(k) clearance process.  However, there is no assurance that any companion diagnostic required for our pharmaceutical development programs will benefit from the reclassification, or that the reclassification, even if it does occur, will result in a shorter timeline to development or marketing of the companion diagnostic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the FDA, or a comparable foreign regulatory authority, requires approval (or certification or clearance) of a companion diagnostic for any of our product candidates, whether before or after the product candidate obtains marketing approval, we and/or third-party collaborators may encounter difficulties in developing and obtaining approval (or clearance, or certification) for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval (or clearance, or certification) of a companion diagnostic could delay or prevent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">approval or continued marketing of our related product candidates. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidates, if approved, on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Approval, clearance or certification of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU. On May 25, 2017, the new In Vitro Medical Devices Regulation No. 2017/746 (&#8220;IVDR&#8221;) entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member states laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. The IVDR became effective in May 2022. However, on October 14, 2021, the European Commission proposed a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. The European Parliament and Council adopted the proposed regulation on December 15, 2021. The IVDR has applied since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The regulation of companion diagnostics in the EU is subject to further requirements since the IVDR became applicable as it introduced a new classification system for companion diagnostics. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization (&#8220;MA&#8221;) application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">These modifications may make it more difficult and costly for us to obtain regulatory clearances, approvals or certifications for our companion diagnostics or to manufacture, market or distribute our products after clearance, approval or certification is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Although the FDA has approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, we will still face extensive and ongoing regulatory requirements and obligations for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and for any product candidates for which we obtain approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any regulatory approvals that we may receive for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or any of our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA-approved label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> includes certain warnings and precautions regarding hypotension, orthostatic hypotension, bradycardia, somnolence, and QT interval prolongation. The FDA may also require a REMS to approve a product candidate, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> are and will remain subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, and on-going compliance with cGMPs, and GCPs for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory authority discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, discovery of previously unknown AEs or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product manufacturing, distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, the policies of the FDA and other regulatory authorities may change, and additional government regulations may be enacted that could impose extensive and ongoing regulatory requirements and obligations on any product candidate for which we obtain marketing approval. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The FDA and other regulatory authorities strictly regulate marketing, labeling, advertising and promotion of prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA or any other regulatory authority may grant is limited to those specific diseases and indications for which a product is deemed to be safe and effective. For example, the FDA-approved label for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is currently limited to the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults to be self-administrated by patients under the supervision of a health care provider. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While physicians in the U.S. may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote the products is narrowly limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. For example, other formulations of Dex, the active ingredient in IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, have been approved for uses beyond those authorized in IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> approved labeling, such as for use in sedation of surgical patients, and we are continuing to develop BXCL501 for potential use in patients with dementia, MDD, Alzheimer&#8217;s disease and other indications. We do not market or promote IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> for these uses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on off-label use. If we are found to have promoted our products for any off-label uses, the U.S. federal government (and other foreign governments) could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, or other regulatory authorities, could also require that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result of some of these aforementioned issues. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA, following its relocation to Amsterdam and corresponding staff changes, may also slow the time necessary for new drug or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations, any resurgence of the virus or emergence of new variants may lead to further inspectional delays. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may choose to conduct one or more of our clinical trials or a portion of our clinical trials for our product candidates outside the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the clinical trial was not otherwise subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study was conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an on-site inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and could result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to extensive regulations outside the U.S. and may not obtain marketing approvals for products in Europe and other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to regulations in the U.S., should we or our collaborators pursue marketing approvals for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and for BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates internationally, we and our collaborators will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we, or our collaborators, obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect to pursue marketing approvals for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and may pursue marketing approvals for BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates in Europe and other jurisdictions outside the U.S. with collaborative partners. The time and process required to obtain regulatory approvals and reimbursement in Europe and other jurisdictions may be different from those in the U.S. Also, regulatory approval in one jurisdiction does not ensure approvals in any other jurisdiction; however, negative regulatory decisions in any jurisdiction may have a negative impact on the regulatory process in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following a national referendum and enactment of legislation by the government of the United Kingdom (&#8220;UK&#8221;), the UK formally withdrew from the EU on January 31, 2020 and ratified a trade and cooperation agreement governing its future relationship (commonly referred to as &#8220;Brexit&#8221;). The agreement, which was applied provisionally from January 1, 2021 and entered into force on May 1, 2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and requires complex additional bilateral negotiations between the UK and the EU as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since January 1, 2021, the UK operates under a distinct regulatory regime to the EU. EU pharmaceutical laws only apply in respect of the UK to Northern Ireland (as set out in the Protocol on Ireland/Northern Ireland). EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. While the UK has indicated a general intention that new laws regarding the development, manufacture and commercialization of medicinal products in the UK will align closely with EU law, there are limited detailed proposals for future regulation of medicinal products. The trade and cooperation agreement includes specific provisions concerning medicinal products, which include the mutual recognition of cGMP, inspections of manufacturing facilities for medicinal products and cGMP documents issued (such mutual recognition can be rejected by either party in certain circumstances) but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. For example, it is not clear to what extent the UK will adopt legislation aligned with, or similar to, the EU CTR which became applicable on January 31, 2022 and which significantly reforms the assessment and supervision processes for clinical trials throughout the EU. On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) launched an eight-week consultation on reframing the UK legislation for clinical trials which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The MHRA responded to the consultation on March 21, 2023 and confirmed that it would bring forward changes to the legislation. The final legal texts introduced by the UK Government will ultimately determine the extent to which the UK clinical trials framework aligns with or diverges from the EU CTR. A decision by the UK not to closely align its regulations with the new approach that will be adopted in the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Therefore, there remains political and economic uncertainty regarding to what extent the regulation of medicinal products will differ between the UK and the EU in the future. Any divergences will increase the cost and complexity of running our business, including with respect to the conduct of clinical trials. Brexit also materially impacted the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">regulatory regime with respect to the approval of our product candidates. Great Britain is no longer covered by the EU&#8217;s procedures for the grant of MAs (Northern Ireland is covered by the centralized authorization procedure and can be covered under the decentralized or mutual recognition procedures). As of January 1, 2021, all existing centralized MAs were automatically converted into UK MAs effective in Great Britain and issued with a UK MA number on January 1, 2021 (unless MA holders opted out of this scheme). A separate MA is now required to market drugs in Great Britain. It is currently unclear whether the regulator in the UK, the MHRA, is sufficiently prepared to handle the increased volume of MA applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in Great Britain and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in Great Britain for our product candidates, which could significantly and materially harm our business. Any of these factors could have a significant adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are found in violation of federal, state or foreign health care &#8220;fraud and abuse&#8221; laws, we may be required to pay significant fines and penalties, including, without limitation, debarment, suspension or exclusion from participation in federal, state or similar health care programs, which may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the U.S., we are subject to various federal and state health care &#8220;fraud and abuse&#8221; laws, including anti- kickback laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect us, and our ability to successfully commercialize our products in the U.S. We may have to comply with similar laws and regulations outside the U.S. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">false claims laws prohibit anyone from knowingly and willfully presenting or causing to be presented for payment to third-party payers, including government payers, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically unnecessary items or services. Cases have been brought under false claims laws alleging that off-label promotion of pharmaceutical products or the provision of kickbacks has resulted in the submission of false claims to governmental health care programs. In addition, the government may assert that a claim, including items or services resulting from a violation of the federal Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the false claims laws. Further, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) prohibits persons or entities from knowingly and willfully executing a scheme to defraud any health care benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti- Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows, or should know, it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician sunshine requirements under the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;), which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to health care providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures and pricing information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to health care providers.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state or foreign health care programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to market our products and adversely impact our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may be unable to maintain sufficient clinical trial liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our inability to retain sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability claims could prevent or inhibit our ability to conduct clinical trials for product candidates we develop. We may be unable to obtain appropriate levels of such insurance. Even if we do secure clinical trial liability insurance for our programs, we may not be able to achieve sufficient levels of such insurance. Any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that exceeds the limits of our insurance coverage. We have supplemented our clinical trial coverage with product liability coverage in connection with the commercial launch of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and expect that we would similarly supplement our coverage for any of our other product candidates that may receive regulatory approval, but we may be unable to obtain such increased coverage on acceptable terms or at all. If we are found liable in a clinical trial lawsuit or a product liability lawsuit in the future, we will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Commercialization of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If our products do not gain market acceptance or if we fail to accurately forecast demand or manage our inventories, our business will suffer because we might not be able to fund future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A number of factors may affect the market acceptance of our products or any other products or product candidates we develop or acquire, including, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price of our products relative to other products for the same or similar treatments;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perception by patients, physicians and other members of the health care community of the effectiveness, utility and safety of our products for their indicated applications and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to fund our sales and marketing efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts, including our strategic refocus to hospital/IDNs as part of the Reprioritization.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products, which would cause our business to suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We plan to continue to commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> TM</sup> sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder, to be self-administered by patients under the supervision of a healthcare provider, which is our only approved product to date. However, in connection with the Reprioritization, we significantly reduced the resources devoted to commercialization of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> TM</sup> and it is possible that will have adverse consequences on the revenue that we are able to generate from IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> TM</sup>. Revenues for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> TM</sup> for the year ended December 31, 2023 were $1.4 million. If our commercial products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for an sNDA for other BXCL501 indications, including in the at-home setting for the acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease, or for other product candidates that it may develop. Our results of operations could be materially harmed if we are unable to successfully commercialize IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> TM</sup> for any currently or additionally approved indications or any future product candidates that we may have approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our results of operations could be materially harmed if we are unable to accurately forecast customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and manage our inventory. To ensure adequate inventory supply, we must forecast inventory needs and place orders with our suppliers based on our estimates of future demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>. Our ability to accurately forecast demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or for products of our competitors, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters, and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, our third-party contract manufacturer may not be able to deliver products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers or our third-party manufacturers may not be able to allocate sufficient capacity in order to meet our increased requirements, which could have an adverse effect on our ability to meet customer demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We seek to maintain sufficient levels of inventory to protect ourselves from supply interruptions. As a result, we are subject to the risk that a portion of our inventory will become obsolete or expire, which could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our estimated number of episodes of agitation and our corresponding estimated total addressable market are subject to inherent challenges and uncertainties. If we have overestimated the number of episodes or the size of our total addressable market for our current and potential future products or product candidates, or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:14pt 0pt 0pt 0pt;">We have based our potential market opportunity on a number of internal and third-party estimates and resources, including, without limitation, management&#8217;s estimates and research, as well as industry and general publications and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">research, surveys and studies conducted by third parties, which may be incorrect.&#160;<span style="white-space:pre-wrap;"> Our estimated potential market opportunity is based on estimates of episodes of agitation across our indications, and these estimated episodes of agitation are also based on internal and third-party estimates and market resources using data self-reported by patients. The conditions supporting our assumptions or estimates and the market data supporting these assumptions and estimates may change at any time or otherwise be inaccurate, thereby reducing the predictive accuracy of these underlying factors.  Our total addressable market will ultimately depend upon, among other things, the number of actual treatable episodes, the diagnosis criteria included in the final label for each of our product candidates, if approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients and treatable episodes in the United States and other major markets and elsewhere may turn out to be materially lower than expected, the number of treatable episodes may be significantly fewer than total episodes experienced, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would harm our results of operations and our business. For example, our estimates of the monthly average episodes for patients diagnosed with bipolar disorder and patients diagnosed with schizophrenia and, therefore, our estimated total addressable market are based on third-party market surveys which differ from an observational study in the EU of inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar disorder conducted which found that only 40% of enrolled patients reported agitation episodes in the six-month study period. If third-party or internally generated data prove to be inaccurate or we make errors in our assumptions based on that data, our total addressable market may be meaningfully smaller than we have estimated, our future growth opportunities and sales growth may be impaired, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We obtained Orphan Drug Designation for BXCL701 for the treatment of pancreatic cancer, melanoma, acute myeloid leukemia and soft tissue sarcoma and we may seek Orphan Drug Designation for other indications or product candidates, and we may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity, and may not receive Orphan Drug Designation for other indications or for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Regulatory authorities in some jurisdictions, including the U.S. and EU, may designate drugs intended for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, orphan drug designation is granted by the European Commission based on a scientific opinion of the EMA&#8217;s Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application for orphan designation must be submitted before the application for MA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the U.S. provides that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same disease or condition for seven years. In limited circumstances, the applicable exclusivity period is 10 years in the EU. The EU exclusivity period can be reduced to six years if, at the end of the fifth year, it is established that a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In January 2021, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of soft tissue sarcoma. In September 2019, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of acute myeloid leukemia. Prior to 2019, the FDA granted Orphan Drug Designation to BXCL701 for the treatment of pancreatic cancer and melanoma. We may seek Orphan Drug Designations for BXCL701 in other diseases or conditions or for other product candidates. There can be no assurances that we will be able to obtain such designations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan- designated indication due to the uncertainties associated with developing pharmaceutical products, and it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same disease or condition before we do. If that were to happen, our applications for that disease or condition may not be approved until the competing company&#8217;s period of exclusivity expires. In addition, exclusive marketing rights in the U.S. and abroad may be limited if we seek approval for an indication broader than the orphan-designated disease or condition or may be lost if the FDA or foreign regulatory authorities later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same disease or condition. Even after an orphan drug is approved, the FDA or foreign regulatory authorities can subsequently approve the same drug with the same active ingredient for the same condition if the FDA or foreign regulatory authorities conclude that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process and does not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or any product candidate for which we may obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have limited experience in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, BXCL501, BXCL502, BXCL701, BXCL702 or any other product candidate. Typically, pharmaceutical companies would employ groups of sales representatives and associated sales and marketing staff numbering in the hundreds to thousands of individuals to call on the large number of physicians and hospitals. Following our Reprioritization, we may need to rebuild a commercial sales and marketing team if we seek to modify our commercial strategy for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or initiate commercial sales for any product candidate in the future, which will likely require significant cost. We may seek to collaborate with a third-party to market our drugs or may seek to market and sell our drugs by ourselves. If we seek to collaborate with a third-party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to us. We may also need to hire additional personnel skilled in marketing and sales for our direct marketing and selling efforts. We cannot be sure that we will be able to acquire, or establish third-party relationships to provide, any or all of these marketing and sales capabilities. The maintenance and expansion of our direct sales force or establishment of a contract sales force, or a combination thereof, as applicable, to market our products is expensive and time-consuming and could delay any product launch. In addition, reputational harm from the Reprioritization may adversely impact our efforts to hire personnel skilled in marketing and sales. Further, we can give no assurances that we will be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts will be sufficient to grow our revenues or that our sales efforts will ever lead to profits. A direct sales force has in the past subjected and may in the future subject us to higher fixed costs than those of companies that market competing products through independent third parties, due to the costs that we bear associated with employee benefits, training, and managing sales personnel. As a result, we could be at a competitive disadvantage. Additionally, these fixed costs may slow our ability to reduce costs if needed, which could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We operate in a highly competitive and rapidly changing industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biopharmaceutical product development is highly competitive and subject to rapid and significant technological advancements. Our success is highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated, well-established pharmaceutical companies who already possess a large share of the market, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in the U.S., the EU and other jurisdictions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industry could result in even more resources being concentrated among a small number of our competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Competition may further increase as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Established biopharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The availability of our competitors&#8217; products could limit the demand and the price we are able to charge for products and product candidates, if any, that we commercialize. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Although we obtained FDA approval for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, our products and product candidates may not be accepted by physicians or the medical community in general, and there may be insufficient insurance coverage and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, or BXCL501, BXCL502, BXCL701, BXCL702 and our other product candidates or any other product candidate successfully developed by us, independently or with partners, if approved, will be accepted by physicians, hospitals and other health care facilities. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> competes, and BXCL501, BXCL502, BXCL701, BXCL702 and any future product candidates we develop will compete, with a number of products manufactured and marketed by major pharmaceutical and biotechnology companies. The degree of market acceptance of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any drugs we develop depends on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our demonstration of the clinical efficacy and safety of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market approval and commercial launch of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indication(s) for which our products and product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product label and package insert requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advantages and disadvantages of our products and product candidates compared to existing therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued interest in and growth of the market for anti-cancer or anti-agitation drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strength of sales, marketing, and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product pricing in absolute terms and relative to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future changes in health care laws, regulations, and medical policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of coverage and reimbursement in select jurisdictions, and future changes to coverage and reimbursement policies of government and third-party payors.</span></td></tr></table><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or any product candidate for which we obtain regulatory approval. In the U.S. and other countries, sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any other products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government health administrative authorities, such as Medicaid and Medicare, managed care providers, private health insurers and other organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Third-party payors are increasingly challenging the prices charged for medical products and services. It will be time consuming and expensive for us to go through the process of seeking coverage and reimbursement from Medicare and private payors. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any other products for which we receive regulatory approval may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our proposed products on a profitable basis. Further federal, state and foreign government proposals and health care reforms are likely which could limit the prices that can be charged for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and the product candidates that we develop and may further limit our commercial opportunities. Our results of operations could be materially adversely affected by proposed health care reforms, by the Inflation Reduction Act and other drug pricing legislation in the U.S., by the possible effect of such current or future legislation on amounts that private insurers will pay and by other health care reforms that may be enacted or adopted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Health care reform measures could hinder or prevent our product candidates&#8217; commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The U.S. government and other governments have shown significant interest in pursuing health care reform. Any government-adopted reform measures could adversely impact the pricing of health care products and services in the U.S. or internationally and the amount of reimbursement available from governmental agencies or other third-party payors for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and the product candidates that we develop. The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability to set prices for our products, which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">New laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to health care availability, methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging due to several reasons, including policies advanced by the current executive administration in the U.S., new health care legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For example, in the U.S., the ACA, which was enacted in 2010, has substantially changed the way health care is financed by both government health plans and private insurers, and significantly impacts the pharmaceutical industry. For example, the ACA imposed a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to government programs. In addition, as part of the ACA&#8217;s provisions closing a funding gap that existed in the Medicare Part D prescription drug program, manufacturers are required to provide a discount on branded prescription drugs for drugs provided to certain beneficiaries who fall within the &#8220;donut hole.&#8221; Similarly, the ACA increased the level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1% of the average manufacturer price and required collection of rebates for drugs paid by Medicaid managed care organizations. The ACA also included changes to the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) including expansion of the list of eligible covered entities that may purchase drugs under the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These changes include the Budget Control Act of 2011, which resulted in aggregate reductions of Medicare payments to providers, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute, will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">remain in effect through 2032, unless additional Congressional action is taken. Furthermore, the American Taxpayer Relief Act of 2012, further reduced Medicare payments to several types of providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, beginning January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law.  This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010.  Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations.  HHS has issued and will continue to issue guidance implementing the IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The cost of prescription pharmaceuticals in the U.S. will likely continue to be the subject of considerable discussion. Members of Congress and the Biden Administration have indicated they will continue to pursue further legislative or administrative measures to control prescription drug costs. There have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Individual states in the U.S. continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">It is likely that federal and state legislatures within the U.S. and foreign governments will continue to consider changes to existing health care legislation. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect the demand for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and any other drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain adequate coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EU, similar developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the U.S. and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. While the regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We participate in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;) and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. As a condition of having federal funds being made available for covered outpatient drugs under Medicaid and Medicare Part B, a manufacturer must enroll in the MDRP. Under this program, we must pay a rebate to state Medicaid programs for each unit of our covered outpatient drug dispensed to a Medicaid beneficiary and paid for by a state Medicaid program. Medicaid drug rebates are based on pricing data that we must report on a monthly and quarterly basis to CMS. For the MDRP, this data includes the average manufacturer price (&#8220;AMP&#8221;) for each drug and, in the case of an innovator product, like IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, the best price. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after the data originally was due. Further, under the IRA, AMP figures we report will also be used to calculate a rebate on Medicare Part D utilization, triggered by price increases that outpace inflation. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered outpatient drugs under Medicaid or, if applicable, Medicare Part B. Failure to make necessary disclosures and/or to identify overpayments additionally could result in allegations against us under the Federal False Claims Act and other laws and regulations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Federal law requires that a manufacturer that participates in the MDRP also participate in the 340B program in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B, and we participate in the 340B program. The 340B program is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;) and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs used in an outpatient setting. These 340B program covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B program discounted pricing on drugs used in an inpatient setting.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, we also must participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we must report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Individual states continue to consider and have enacted legislation to limit the growth of health care costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by manufacturers, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time-consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we may be required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit required price data on a timely basis, or if we are found to have charged 340B program covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, pursuant to which we participate in the MDRP, no federal payments would be available under Medicaid or Medicare for our covered outpatient drugs. We cannot assure you that price data submissions we make will not be found to be incomplete or incorrect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Relationship with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">BioXcel LLC has significant influence over the direction of our business, and the concentrated ownership of our common stock will prevent you and other stockholders from influencing significant decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023, BioXcel LLC owned approximately 29% of the economic interest and voting power of our outstanding common stock and BioXcel LLC is controlled by BioXcel Holdings, Inc. Our Chief Executive Officer and member of our board of directors, Vimal Mehta, Ph.D., is the Chief Executive Officer, President, Treasurer and Secretary and a member of the board of managers of BioXcel LLC and Chief Executive Officer, President, Treasurer </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">and Secretary and the sole member of the board of directors of BioXcel Holdings, Inc. See &#8220;<i style="font-style:italic;">The management of and beneficial ownership in BioXcel LLC by our executive officers and our directors may create, or may create the appearance of, conflicts of interest.</i>&#8221; below. Even though BioXcel LLC controls less than a majority of the voting power of our outstanding common stock, it may influence the outcome of such corporate actions so long as it owns a significant portion of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Approval of commercial terms between us and BioXcel LLC does not preclude the possibility of stockholder litigation, including but not limited to derivative litigation nominally against BioXcel LLC and against its directors and officers and also against us and our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The commercial terms of the Separation and Shared Services Agreement (as amended and/or restated and in effect as of the date hereof, the &#8220;Services Agreement&#8221;), and the Amended and Restated Asset Contribution Agreement (as amended and/or restated and in effect as of the date hereof, the &#8220;Contribution Agreement&#8221;), that we entered into with BioXcel LLC have not been negotiated by persons consisting solely of disinterested directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No assurance can be given that any equity or debt holder of BioXcel LLC or the Company will not claim in a lawsuit that such terms in fact are not in the best interests of BioXcel LLC or the Company and its applicable equity holders, that the directors and officers of BioXcel LLC or the Company breached their fiduciary duties in connection with such agreements and that any disclosures by the Company to its stockholders regarding these agreements and the relationship between BioXcel LLC and us did not satisfy applicable requirements. In any such instance, we and our directors and officers may also be named as defendants and we would have to defend ourselves and our directors and officers. While we would seek indemnification from BioXcel LLC under the terms of these agreements against any damages or other costs, which could be substantial, no such indemnification has yet been agreed to or may be agreed to and be in effect. Further, any such litigation would be time-consuming and would divert focus and resources from the development of our product candidates and our business, including but not limited to possibly delaying our clinical trials due to our management having to spend time and attention on such litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We continue to depend on BioXcel LLC to provide us with certain services for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We rely, in part, on BioXcel LLC and access to its EvolverAI, to complement our in-house, uniquely integrated AI-to-drug-development capability. EvolverAI is a research and development engine created and owned by BioXcel LLC, to identify, research and develop potential product candidates in neuroscience and immuno-oncology. We negotiated the Services Agreement with BioXcel LLC pursuant to which BioXcel LLC agreed to perform certain intellectual property prosecution and management and research and development activities for us utilizing its EvolverAI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Under the Services Agreement, we have an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI.  We agreed to pay BioXcel LLC $18,000 per month from March 13, 2023, to December 31, 2024 in exchange for this option. We agreed to negotiate any such collaborative services agreement in good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10 million in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30 million in the aggregate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, at the time of our initial public offering (&#8220;IPO&#8221;), BioXcel LLC granted us (i) a first right to negotiate exclusive rights to any additional product candidates in the fields of neuroscience and immuno-oncology that BioXcel LLC may identify on its own and not in connection with BioXcel LLC&#8217;s provision of services to us under the Services Agreement and (ii) an exclusivity agreement in the neuroscience and immuno-oncology fields whereby BioXcel LLC agreed not develop drugs, or engage in preclinical discovery for the purpose of developing drugs, in the neuroscience and immuno-oncology fields for or on behalf of a third party, utilizing EvolverAI or otherwise. This first right to negotiate and exclusivity period expired on March 12, 2023, and there is no assurance that we will extend the terms of the agreement. We are continuing to assess our ongoing business needs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On September 19, 2023, the Company, Krishnan Nandabalan, Ph.D., InveniAI LLC (&#8220;Inveni&#8221;) and Invea Therapeutics, Inc. (&#8220;Invea&#8221;) and the other parties thereto entered into a non-compete agreement pursuant to which Dr. Nandabalan, Inveni and Invea agreed not to compete with the Company and its controlled affiliates in the fields of neuroscience and immuno-oncology for a period of five years from September 19, 2023 and not to solicit employees of the Company or its controlled affiliates for a period of two years from September 19, 2023. Inveni and Invea are subsidiaries of BioXcel LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our rights under the Services Agreement were to become limited or if we are otherwise precluded from conducting research and development using EvolverAI, or if BioXcel LLC, Inveni or Invea do not fulfill their obligations under the agreements, such development could materially adversely affect our future operating results, financial condition, and prospects. Furthermore, certain individuals conducting services on our behalf are not our employees, and we cannot control whether they devote sufficient time, skill and resources to our ongoing development programs. We also cannot ensure that BioXcel LLC retains sufficient resources or personnel or otherwise to conduct its operations. BioXcel LLC may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting research and development activities, which could impede their ability to devote appropriate time to our research and development programs. BioXcel LLC is not currently restricted from using EvolverAI to perform drug discovery services for our direct competitors, and if we do not extend the exclusivity period in the neuroscience and immuno-oncology fields, this could harm our competitive position and adversely affect our future operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The management of and beneficial ownership in BioXcel LLC may create, or may create the appearance of, conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our Chief Executive Officer and member of our board of directors, Vimal Mehta, Ph.D., is the Chief Executive Officer, President, Treasurer and Secretary and a member of the board of managers of BioXcel LLC and Chief Executive Officer, President, Treasurer and Secretary and the sole member of the board of directors of BioXcel Holdings, Inc.  Additionally, as of December 31, 2023, Dr. Mehta, through his beneficial ownership of BioXcel LLC, beneficially owned approximately 31% of the Company. The management and ownership of BioXcel LLC by Dr. Mehta may create the appearance of conflicts of interest when Dr. Mehta is faced with decisions that could have different implications for BioXcel LLC than the decisions have for us, including decisions that relate to our Services Agreement and Contribution Agreement, as well as potential agreements relating to future product candidates and AI-related services or collaborations. Any perceived conflicts of interest resulting from investors questioning the independence of our management or the integrity of corporate governance procedures may materially affect our stock price and expose us to litigation risk.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any disputes that arise between us and BioXcel LLC with respect to our past and ongoing relationships could harm our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Disputes may arise between BioXcel LLC and us in a number of areas relating to our past and ongoing relationships, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with contractual provisions applicable to BioXcel LLC and us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labor, tax, employee benefit, indemnification and other matters arising from the separation of BTI from BioXcel LLC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution and supply obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee retention and recruiting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business combinations involving us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales or distributions by BioXcel LLC of all or any portion of its ownership interest in us;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature, quality and pricing of services BioXcel LLC has agreed to provide us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business opportunities that may be attractive to both BioXcel LLC and us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We entered into the Services Agreement with BioXcel LLC related to the separation of our business operations from those of BioXcel LLC that contains certain limitations on BioXcel LLC&#8217;s ability to control various aspects of our business and operations, notwithstanding BioXcel LLC&#8217;s substantial ownership position. This agreement may be amended upon agreement between us and BioXcel LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">BioXcel LLC may experience challenges with the acquisition, development, enhancement, or deployment of technology necessary for EvolverAI. We may face similar challenges with other AI platforms that we utilize, including our own in-house proprietary platform.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel LLC operates in businesses that require sophisticated computer systems and software for data collection, data processing, cloud-based platforms, analytics, statistical projections and forecasting, mobile computing, social media analytics and other applications and technologies. BioXcel LLC seeks to address its technology risks by increasing its reliance on the use of innovations by cross-industry technology leaders and adapt these for their pharmaceutical, biotechnology, biopharmaceutical, diagnostic, medical device and contract research and manufacturing clients. Some of the technologies supporting the industries they serve are changing rapidly and we must continue to adapt to these changes in a timely and effective manner at an acceptable cost. They also must continue to deliver data to their clients in forms that are easy to use while simultaneously providing clear answers to complex questions. We also utilize our own in-house AI platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no guarantee that we or BioXcel LLC will be able to develop, acquire or integrate new technologies, that these new technologies will meet our and BioXcel LLC&#8217;s needs or achieve our expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors. Significant technological change could render BioXcel LLC&#8217;s EvolverAI or other AI platforms that we utilize obsolete. BioXcel LLC&#8217;s and our continued success will depend on the ability to adapt to changing technologies, manage and process ever-increasing amounts of data and information and improve the performance, features and reliability of these services in response to changing client and industry demands. If EvolverAI or other AI and machine learning models that we use are incorrectly designed, do not operate properly, the data we use to train them is incomplete, inadequate or biased in some way, or if we do not have sufficient rights to use the data on which our AI and machine learning models rely, the performance of our products, services and businesses, as well as our reputation, could suffer or we could incur liability through the violation of laws, third-party privacy rights or contracts to which we are a party. BioXcel LLC or we may experience difficulties that could delay or prevent the successful design, development, testing, and introduction of advanced versions of EvolverAI, limiting our ability to identify new product candidates. New services, or enhancements to existing EvolverAI services, may not adequately meet our requirements. Any of these failures could have a material adverse effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are substantially dependent on third parties for the manufacture of our clinical supplies of our product candidates and our commercial supplies of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and we intend to rely on third parties to produce commercial supplies of any other approved product candidate. Therefore, our development of our products could be stopped or delayed, and our commercialization of any future product could be stopped, delayed or made less profitable if third-party manufacturers fail to obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug product in sufficient quantities or at acceptable prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We entered into a commercial supply agreement with ARx, LLC (&#8220;ARx&#8221;) pursuant to which ARx has agreed to exclusively manufacture and supply us with all of our worldwide demand of film formulation of Dex to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and for ongoing clinical trials of our product candidate BXCL501, subject to certain alternative supply provisions. If ARx is unable or ceases to produce our supply of Dex in sufficient quantities as and when needed or if the ARx agreement becomes too costly, our business would be harmed because there can be no assurance that we will be able to identify or enter into agreements with alternative suppliers on a timely basis on acceptable terms, if at all. An interruption in our ability to sell our products to customers could occur if we encounter </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">delays or difficulties in securing Dex, or if the quantity or quality supplied does not meet our specifications, or if we cannot then obtain an acceptable substitute. If any of these events occur, our business and operating results could be harmed. Our specified minimum annual payment could adversely affect our cash flows in the future, such as in times when we have sufficient inventory and would otherwise be able to use our cash for other purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The manufacture of biotechnology and pharmaceutical products is complex and requires significant expertise, capital investment, process controls and know-how. Common difficulties in biotechnology and pharmaceutical manufacturing may include: sourcing and producing raw materials, transferring technology from chemistry and development activities to production activities, validating initial production designs, scaling manufacturing techniques, improving costs and yields, establishing and maintaining quality controls and stability requirements, eliminating contaminations and operator errors, and maintaining compliance with regulatory requirements. We do not currently have nor do we plan to acquire the infrastructure or capability internally to produce an adequate supply of compounds to meet future requirements for clinical trials and commercialization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing facilities are subject to inspection before the FDA or foreign regulatory authorities will issue an approval to market a new drug product, and ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., and any other manufacturers that we may use must adhere to the cGMP or similar foreign regulations prescribed by the FDA or foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As such, these third-party manufacturers will be required to comply with cGMPs, and other applicable laws and regulations. We have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities of these third parties for the manufacture of our other product candidates or any products that we may successfully develop, or if it withdraws any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture for us, we may need to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers for clinical or commercial supply on acceptable terms, or at all. Any of these factors would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We, ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., and/or our other third-party manufacturers may be adversely affected by developments outside of our control, and these developments may delay or prevent further manufacturing of our products. Adverse developments may include labor disputes, resource constraints, shipment delays, inventory shortages, lot failures, unexpected sources of contamination, lawsuits related to our manufacturing techniques, equipment used during manufacturing, or composition of matter, unstable political environments, acts of terrorism, war, natural disasters, and other natural and man-made disasters. If we, ARx, the Patheon pharma services division of Thermo Fisher Scientific Inc., or our other third-party manufacturers were to encounter any of the above difficulties, or otherwise fail to comply with contractual obligations, our ability to provide any product for clinical trial or commercial purposes would be jeopardized. This may increase the costs associated with completing our clinical trials and commercial production. Further, production disruptions may cause us to terminate ongoing clinical trials and/or commence new clinical trials at additional expense. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications or pass safety inspections. Moreover, as a result of the COVID-19 pandemic, third-party manufacturers have been and may in the future be affected, which could disrupt their activities and, as a result, we could face difficulty sourcing key components necessary to produce supply of our commercial product and product candidates, which may negatively affect our preclinical and clinical development activities. If production difficulties cannot be solved with acceptable costs, expenses, and timeframes, we may be forced to abandon our clinical development and commercialization plans, which could have a material adverse effect on our business, prospects, financial condition, and the value of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We, or third-party manufacturers on whom we rely, including ARx, may be unable to successfully scale-up manufacturing of our product and product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing any approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, we, or our manufacturers, including ARx, and the Patheon pharma services division of Thermo Fisher Scientific Inc., will need to manufacture them in large quantities. We, or our manufacturers, may be unable to successfully increase the manufacturing capacity for any of our approved products or product candidates in a timely or cost-effective manner, or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">at all. In addition, quality issues may arise during scale-up activities. If we, or any of our manufacturers, are unable to successfully scale up the manufacture of our approved products or product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our approved products, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our approved products or product candidates successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our failure to find third-party collaborators to assist or share in the costs of product development could materially harm our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our strategy for the development and commercialization of our proprietary products and product candidates may include the formation of collaborative arrangements with third parties. Collaborators have significant discretion in determining the efforts and resources they apply and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical and biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">funding research, preclinical development, clinical trials and manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully commercializing IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or product candidates.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are not able to establish collaboration agreements, we may be required to undertake product development and commercialization at our own expense. Such an undertaking may limit the number of product candidates that we will be able to develop, significantly increase our capital requirements and place additional strain on our internal resources. Our failure to enter into collaborations could materially harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, our dependence on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These agreements may not be on terms that prove favorable to us and may require us to relinquish certain rights in our product candidates. To the extent we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization of product candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to develop or commercialize successfully any product candidate to which they have obtained rights from us could materially harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have relied upon and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCPs, which are regulations and guidelines enforced by the FDA, the competent authorities of the European Economic Area (&#8220;EEA&#8221;) countries and comparable foreign regulatory authorities for all of our products in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If regulatory authorities determine that we or any of our CROs failed to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP and similar foreign regulations. Any failure, whether by us or our CROs, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, if any of our relationships with our third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. For example, investigator misconduct during our TRANQUILITY II trial evaluating BXCL501 in patients with probable Alzheimer&#8217;s disease could require us to conduct additional clinical trials before we are able to seek or obtain approval for BXCL501 for use in this patient population, as described more fully in the risk factor above entitled: &#8220;<i style="font-style:italic;">Developments relating to our TRANQUILITY II Phase 3 trial may impact the timing of our development plans for, and prospects for seeking or obtaining regulatory approval of, BXCL501 for the acute treatment of agitation (non-daily) associated with dementia in patients with probable Alzheimer&#8217;s disease</i>.&#8221; As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our GCP preclinical studies or our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Pandemics, epidemics or outbreaks of an infectious disease, such as COVID-19, may materially and adversely impact our business, including our preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a result of outbreaks from variants of COVID-19, or other pandemics, epidemics or outbreaks of infectious disease, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in initiating, operating and completing our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other interruptions or delays to our sourced discovery and clinical activities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions from COVID-19 or other pandemics, epidemics or outbreaks of infectious disease, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Unfavorable global political or economic events and conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our results of operations could be adversely affected by general conditions in the world, and their impact on the global economy and in the global financial markets. The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. A severe or prolonged economic downturn or recession and a continued increase in inflation rates or interest rates could result in a variety of risks to our business, and our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Increased inflation rates and related increases in interest rates can adversely affect us by increasing our costs, including labor and employee benefit costs. In addition, events such as pandemics, epidemics, or outbreaks of an infectious disease may materially and adversely impact our business if we or any of the third parties with whom we engage were to experience shutdowns or other business disruptions. Furthermore, geopolitical conflicts and war, such as the current military conflict between Russia and Ukraine and the war between Israel and Hamas, could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions have and may in the future be initiated by nations including the U.S., the EU or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our future success may depend on our ability to attract and retain qualified personnel, including consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are dependent on the principal members of our management and scientific teams. Our success and the execution of our operating strategy, to the extent we continue operations, depend largely on the continued service of our employees. In addition to our employees, we have access to certain of BioXcel LLC&#8217;s employees and resources through the various agreements we have with BioXcel LLC. We have expanded our management team to include an operational ramp-up of additional technical staff required to achieve our business objectives. We will need to retain such employees, and may need to continue to expand our managerial, commercial, operational, technical, and scientific, financial, and other resources to manage our operations and clinical trials, continue our research and development activities, and any approved product candidates. Our management and scientific personnel, systems and facilities currently in place may not be adequate to support our future growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may utilize the services of third-party vendors to perform tasks including preclinical and clinical trial management, statistics and analysis, regulatory affairs, medical advisory, market research, formulation development, chemistry, manufacturing and control activities, other drug development functions, legal, auditing, financial advisory, and investor relations. Because we rely on numerous consultants to outsource many key functions of our business, we will need to be able to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for our product candidate or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to recruit and retain qualified personnel, we may be unable to successfully implement the tasks necessary to further develop and commercialize our product candidate and, accordingly, may not achieve our research, development and commercialization goals.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our success depends largely upon the continued services of our key executive officers, including Vimal Mehta, our Chief Executive Officer, President and a member of our Board, as well as the other principal members of our management, scientific, clinical teams and commercial readiness teams. We do not maintain &#8220;key person&#8221; insurance for any of these executive officers or any of our other key employees. We also rely on our leadership team in the areas of research and development, marketing, services and selling, general and administrative functions. From time to time, there may be changes in our executive management and leadership teams resulting from the hiring or departure of executives or other key employees, which could disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To continue to execute our business strategy, we also must attract and retain highly skilled personnel. We might not be successful in maintaining our unique culture and continuing to attract and retain qualified personnel. We have, from time to time, had difficulty hiring and retaining highly skilled personnel with appropriate qualifications, including as a result of the Reprioritization and related consequences for our reputation. We may experience such difficulties in the future, and any further restructuring or related reduction in force could exacerbate such difficulties. The pool of qualified personnel with experience working within the biopharmaceutical and biotechnology market is limited overall. In addition, many of the companies with which we compete for experienced personnel have greater resources than we have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, prior workforce reductions and any future similar cost-saving initiatives may make it difficult for us to maintain valuable aspects of our culture, retain institutional knowledge and expertise, to prevent a negative effect on employee morale or attrition beyond our planned reduction in headcount, and to attract competent personnel who are willing to embrace our culture in the future. Our executive officers and other employees are at-will employees, which means they may terminate their employment relationship with us at any time, and their knowledge of our business and industry would be extremely difficult to replace. We may not be able to retain the services of any members of our senior management or other key employees. If we do not succeed in retaining and motivating existing employees or attracting well-qualified employees in the future, our business, financial condition and results of operations could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, in making employment decisions, particularly in the biotechnology and high-technology industries, job candidates often consider the value of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the price of our stock might, therefore, adversely affect our ability to attract or retain highly skilled personnel. Furthermore, the requirement to expense the fair value of stock options and other equity instruments might discourage us from granting the size or type of stock option or equity awards that job candidates require to join our Company. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may acquire other companies or technologies, which could divert our management&#8217;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may in the future seek to acquire or invest in businesses, applications and services or technologies that we believe could complement or expand our services, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we do not have any experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to integrate or benefit from acquired technologies or services in a profitable manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated costs or liabilities associated with the acquisition;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty integrating the accounting systems, operations and personnel of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty converting the customers of the acquired business onto our platform and contract terms, including disparities in the revenue, licensing, support or professional services model of the acquired company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s attention from other business concerns;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse effects to our existing business relationships with business partners and customers as a result of the acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential loss of key employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of resources that are needed in other parts of our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use of substantial portions of our available cash to consummate the acquisition.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial position may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with any regulations applicable to us, to provide accurate information to regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state health care fraud and abuse laws and regulations, or to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our operations, and those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes, floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical epidemics, and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems and those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental loss, negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man- made disasters. Several of our employees conduct business outside of our headquarters and leased or owned facilities. These locations may be subject to additional security and other risk factors due to the limited control of our employees. If such an event as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">described above were to occur in the future, it may cause interruptions in our operations, delay research and development programs, clinical trials, regulatory activities, manufacturing and quality assurance activities, sales and marketing activities, hiring, training of employees and persons within associated third parties, and other business activities. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Likewise, we will rely on third parties, including ARx, to manufacture IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and our product candidates and to conduct clinical trials, and similar events as those described in the prior paragraph relating to their business systems, equipment and facilities could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidate could be delayed or altogether terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data breaches or cyber-attacks could disrupt our business operations and information technology systems or those of third parties on which we rely, adversely impact our financial results, or result in the loss or exposure of confidential or sensitive product candidate, clinical trial, employee, or Company information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including our mobile and web-based applications, our e-commerce platform and our enterprise software. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, clinical trial data, and personal information (collectively, &#8220;Confidential Information&#8221;) of customers and our employees and contractors. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our information technology systems and those of third parties on which we rely have been and may in the future be attacked or breached by individuals or organizations intending to obtain our Confidential Information; harm or disrupt our business operations; or otherwise misappropriate information or Company funds. A security compromise of our information technology systems or business operations, or those of third parties on which we rely, could occur through a variety of methods such as from cyber-attacks and cyber-intrusions over the Internet, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, malware, computer viruses, email spoofing, attachments to e-mails, persons inside or outside our organization or persons with access to systems inside our organization. The risk of such intrusions, threats to data and information technology systems and breaches has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While we maintain some of our own critical information technology systems, we also depend on third parties to provide important information technology services relating to several key business functions. Our measures to prevent, detect and mitigate these threats, including password protection, firewalls, backup servers, threat monitoring and periodic penetration testing, may not be successful in preventing a data breach or limiting the effects of a breach. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the security measures employed by third-party service providers may prove to be ineffective at preventing breaches of their systems. Any attack that results in disruptions to our operations, or the unauthorized release or loss of Confidential Information, could have a material adverse effect on our business reputation, increase our costs and expose us to material legal claims and liability (such as class actions) and result in regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future customers, and/or significant incident response, system restoration or remediation and future compliance costs. If the unauthorized release or loss of Confidential Information were to occur, our operations and financial results and our share price could be adversely affected. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Additionally, our use of AI and machine learning may be subject to laws and evolving regulations regarding the use of AI or machine learning, controlling for data bias, and anti-discrimination, and we may not always be able to anticipate how to respond to these laws or regulations. Further, there is an increase in litigation in a number of jurisdictions, including the United States, relating to the use of AI, particularly generative AI. New laws regulating AI are at an advanced stage of the legislative process in the EU, and it is possible that new laws and regulations will be adopted in the United States and in other non-U.S. jurisdictions, or that existing laws and regulations may be interpreted in ways that would affect the operation of our learning platforms, online testing business and data analytics and the way in which we use AI and machine learning technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In Europe, on December 8, 2023, the European Union legislators reached a political agreement on the EU Artificial Intelligence Act (&#8220;EU AI Act&#8221;) which establishes a comprehensive, risk-based governance framework for artificial intelligence in the EU market. The EU AI Act is expected to enter into force in 2024, and the majority of the substantive requirements will apply two years later. The EU AI Act will apply to companies that develop, use and/ or provide artificial intelligence in the EU and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose artificial intelligence and foundation models, and proposes fines for breach of up to 7% of worldwide annual turnover.  In addition, on September 28, 2022, the European Commission proposed two Directives seeking to establish a harmonized civil liability regime for AI in the EU. Once fully applicable, this regulatory framework is expected to have a material impact on the way AI is regulated in the EU, and together with developing guidance and/ or decisions in this area, may affect our use of AI and our ability to provide, improve or commercialize our services, require additional compliance measures and changes to our operations and processes, result in increased compliance costs and potential increases in civil claims against us, and could adversely affect our business, operations and financial condition. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission, and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. If we are determined to act as a covered entity or business associate under HIPAA and be directly regulated under HIPAA, any person acting on our behalf may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;), requires covered businesses that process the personal information of California residents to, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">among other things: provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information, and enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. If we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In Europe, the General Data Protection Regulation (&#8220;GDPR&#8221;) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, since January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR (i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover). On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increased scrutiny of and evolving expectations for environmental, social and governance (&#8220;ESG&#8221;) initiatives may impose additional costs or otherwise adversely impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There has been an increased focus from investors, capital providers, shareholder advocacy groups, other market participants, customers, and other stakeholder groups regarding companies&#8217; ESG initiatives. While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or goals, among others) or commitments to improve the ESG profile of our Company and/or offerings, such initiatives or achievements of such commitments may be costly and may not have the desired effect. Additionally, some investors may use third-party or proprietary ESG ratings to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our ESG practices are inadequate. The criteria by which companies&#8217; ESG practices are assessed are evolving, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">elect not to or are unable to satisfy new criteria or do not meet the criteria, some investors may conclude that our policies with respect to ESG are inadequate and choose not to invest in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If our ESG practices do not meet evolving investor or other stakeholder expectations and our standards, reputation, ability to attract or retain employees and desirability as an investment or business partner could be negatively impacted. Similarly, our failure or perceived failure to adequately pursue or fulfill any ESG goals and objectives or to satisfy various reporting standards, if any, could expose us to additional regulatory, social or other scrutiny, the imposition of unexpected costs, or damage to our reputation, which in turn could have a material adverse effect on our business and could cause the market value of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our failure to successfully acquire, develop and market additional product candidates or approved drug products could impair our ability to grow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of our growth strategy, we may evaluate, acquire, license, develop and/or market third-party products or product candidates and technologies. Our internal research capabilities are limited and we may be dependent upon pharmaceutical and biotechnology companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify, select and acquire promising pharmaceutical product candidates and products. The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, future acquisitions may entail numerous operational and financial risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of our business and diversion of our management&#8217;s and technical personnel&#8217;s time and attention to develop acquired products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher than expected acquisition and integration costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key employees of any acquired businesses.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any products that we develop or approved products that we acquire will be manufactured profitably or achieve market acceptance. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our net operating losses and tax credits to offset future taxable income and income tax liabilities may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, the Company had federal net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $351.3 million and state NOLs of approximately $360.1 million. If not utilized, the federal and state NOLs, which are subject to expiration, will begin to expire in 2037. Federal NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely but may only be used to offset 80% of our taxable income in future taxable years beginning after December 31, 2020. As of December 31, 2023, we also had approximately $14.3 million of federal orphan drug credits and research and development credits and $1.2 million of state research and development credits, which will begin to expire in 2037 if not utilized. The utilization of such NOLs and tax credits and realization of tax benefits in future years depends upon our having taxable income and income tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-ownership change NOLs and tax credits to offset future taxable income or income tax liabilities. For these purposes, an ownership change generally occurs where the aggregate change in stock ownership, of one or more stockholders or groups of stockholders owning at least 5% of a corporation's stock, exceeds 50 percentage points over a rolling three-year period. We may have experienced ownership changes in the past, and future changes in our stock ownership, many of which are outside of our control, could result in ownership changes in the future. Our state NOLs or tax credits may also be impaired under state law. Accordingly, even if we attain profitability, we may not be able to utilize a material portion of our NOLs or tax credits. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success will depend in part on obtaining, maintaining enforcing and defending our patents, trademarks, trade secrets and other intellectual property rights and proprietary technology for our current and future approved products and product candidates, the processes used to manufacture them and the methods for using them, as well as successfully defending these patents against third-party challenges. We are the owner of record of certain patents and patent applications pending in the U.S. and in certain foreign jurisdictions. Patents issued from non-provisional applications, which are typically filed from provisional patent applications or from PCT applications that enter the national phase. Neither provisional patent applications nor PCT applications issue directly as patents. We own PCT patent applications relating to our platform technologies covering methods of use and applications of the platform technologies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We cannot be certain that any future patents will issue with claims that cover our product candidates. Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents, trademarks, trade secrets and other intellectual property rights and proprietary technology that cover these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions that have been the subject of much litigation in recent years and for which important legal principles remain unresolved. Therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the U.S. or in foreign jurisdictions outside of the U.S. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict which of our patent applications will issue, the breadth of claims that may be enforced in the patents that may be issued from the applications we currently, or may in the future, own or license from third parties, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Further, if any patents we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third-party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition, reexamination, review, reissue, post grant review or invalidity proceedings before U.S. or non-U.S. patent offices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to independently develop, make and commercialize compounds that are similar to, or are alternatives or duplicates of any of our product candidates, but that are not covered by the claims of our patents or are not infringing, misappropriating, or otherwise violating our other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to make the inventions covered by our issued patents or pending patent applications that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our pending patent applications or those that we may own in the future may not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of our issued patents or patent applications when issued may not cover our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any patents that we obtain may not provide us with any competitive advantages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop, manufacture and commercialize competitive products or product candidates for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to seek patent protection for some of our proprietary technology or product candidates to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any granted patents may be held invalid or unenforceable as a result of legal challenges by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. In addition, the USPTO and various foreign governmental patent agencies require compliance with various procedural, document submission, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be required to enter into intellectual property license agreements that are important to our business. These license agreements may impose various diligence, payment, and other obligations on us. For example, we may enter into exclusive license agreements with universities, research institutions, or peer industry third parties pursuant to which we may be required to use commercially reasonable efforts to engage in various development and commercialization activities with respect to licensed products and may need to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations under our agreements with any of these licensors, we may be subject to termination of the license agreement in whole or in part; increased financial obligations to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop or commercialize products covered by the license agreement will be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, disputes may arise regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a third-party expresses interest in an area under a license that we are not pursuing, under the terms of certain of our license agreements, we may be required to sublicense rights in that area to a third-party, and that sublicense could harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected approved products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We or our licensors may be subject to claims that third parties have an interest in our patents, trade secrets, or other intellectual property that we regard as our own or our licensor&#8217;s, based on claims that the relevant agreements with employees or consultants obligating them to assign their intellectual property rights to us or our licensor are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. We may also be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">patent applications, or other intellectual property rights, including as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets, or other intellectual property, and it may be necessary or we may desire to obtain a license to a third party&#8217;s intellectual property rights to settle any such claim; however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If we or our licensors fail in defending any such claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. A court could prohibit us from using technologies, features or other intellectual property rights that are essential to our products or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our products or product candidates could have a material adverse effect on our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our products or technologies. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our products or services, which could materially and adversely affect our business, financial condition and results of operations. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our product candidates have been or will be submitted to the FDA for approval under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not obtained a right of reference. The 505(b)(2) application would enable us to reference published literature and/or the FDA&#8217;s previous findings of safety and effectiveness for a branded reference drug with the same active ingredient. For NDAs submitted under Section 505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act, such NDAs may be required to include paragraph IV certifications, that certify that any patents listed in the FDA&#8217;s Orange Book, with respect to any product referenced in the 505(b)(2) application, are invalid, unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the Hatch-Waxman Act, the holder of patents that the 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the paragraph IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2) applicant within 45 days of the patent owner&#8217;s receipt of notice triggers a one-time, automatic, 30-month stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA, unless patent litigation is resolved in the favor of the paragraph IV certification filer, or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2) application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the branded reference drug product has expired. The FDA may also require us to perform one or more additional clinical studies or measurements to support the change from the branded reference drug, which could be time consuming and could substantially delay our achievement of regulatory approvals </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">for such product candidates. The FDA may also reject our future 505(b)(2) submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which would require us to provide extensive data to establish safety and effectiveness of the drug product for the proposed use and could cause delay and be considerably more expensive and time consuming. These factors, among others, may limit our ability to successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our intellectual property related to IGALMI</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-style:italic;font-weight:bold;"> BXCL501, BXCL502, BXCL701, BXCL702 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property rights, the commercial value of our products or product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. We regularly monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek enforce our rights against potential infringement, misappropriation or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we choose to commence a proceeding or litigation to prevent another party from infringing our patents, that party could counterclaim  that our patents are invalid or should not be enforced against them. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is a risk that the examiner or court will decide that our patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the related inventions. There is also the risk that, even if the validity of our patents is upheld, the examiner or court may construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that such other party&#8217;s activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court has recently modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge to any patents we obtain or license. Any proceedings or litigation to enforce our intellectual property rights or defend ourselves against claims of infringement of third-party intellectual property rights could be costly and divert the attention of managerial and scientific personnel, regardless of whether such litigation is ultimately resolved in our favor. We may not have sufficient resources to bring these actions to a successful conclusion. If a defendant were to prevail on its legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we could lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.  Moreover, if we are unable to successfully defend against claims that we have infringed the intellectual property rights of others, we may be prevented from using certain intellectual property and may be liable for damages, which in turn could materially adversely affect our business, financial condition or results of operations. Even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings. Further, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, the monetary cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Further, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, and/or third party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our commercial success will depend in part on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products, or the manufacture or use of our product candidates. In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the United States or abroad. Such mechanisms include interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. If third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. The costs of these lawsuits could affect our results of operations and divert the attention of managerial and scientific personnel. Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that we are infringing the third-party&#8217;s patents and would order us to stop the activities covered by the patents. In that event, we may not have a viable way around the patent and may need to halt commercialization of the relevant product candidate. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&#8217;s patents. We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">found to be willfully infringing a third party&#8217;s patents or other intellectual property rights. In addition, we may be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims brought by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">some patent applications in the U.S. may be maintained in secrecy until the patents are issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications in the U.S. are typically not published until 18 months after the priority date; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publications in the scientific literature often lag behind actual discoveries.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed U.S. patent applications on inventions similar to ours that claim priority to any applications filed prior to the priority dates of our applications, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar inventions prior to our own inventions, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for IGALMI</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-style:italic;font-weight:bold;">, or our product candidates, our business may be materially harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following the approval by the FDA for our NDA to market IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, we became eligible to seek and sought patent term restoration under the Hatch-Waxman Act for one of the U.S. patents covering our approved product or the use thereof. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Despite seeking patent term extension for our product candidates, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to enforce our intellectual property rights throughout the world. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Finally, a Unitary Patent and Unified Patent Court (&#8220;UPC&#8221;) system was implemented in Europe on June 1, 2023. This new regime may present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, by default automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our trademarks could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our products or technologies, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Further, there can be no assurance that competitors will not infringe on our trademarks or that we will have adequate resources to enforce our trademarks. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We rely on our trademarks, trade names and brand names, such as &#8220;IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>&#8221; and our logo, to distinguish our company and our products from our competitors and the products of our competitors, and have registered or applied to register many of these trademarks in the United States and certain countries outside the United States, however, we have not yet registered all of our trademarks in all of our current and potential markets. There can be no assurance that our trademark applications will be approved for registration. During trademark registration proceedings, we may receive </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties may also oppose our trademark applications and may seek to cancel trademark registrations or otherwise challenge our use of the trademarks. Opposition or cancellation proceedings may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the United States, where trademark rights are acquired based on use and not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Our trademarks or trade names may be infringed, circumvented, declared generic or determined to be violating or infringing on other marks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how and/or other proprietary information to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. In addition, despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property rights by employees, consultants and other third parties who have access to such intellectual property or other proprietary rights is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. There can be no assurances that such employees, consultants, advisors or third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant or other third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee, consultant or other third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products or services that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">able to obtain adequate remedies for any breach. While we use commonly accepted security measures, trade secret violations are often a matter of state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our intellectual property rights or confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, any license agreements we enter into in the future may require us to notify, and in some cases license back to the licensor, certain additional proprietary information or intellectual property that we developed using the rights licensed to us under these agreements. Any such licenses back to the licensor could allow our licensors to use that proprietary information or intellectual property in a manner that could harm our business. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Further, it is possible that others will independently develop the same or similar technology, products or services or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology or products similar to ours, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have misappropriated the intellectual property rights, including know-how or trade secrets of a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be subject to claims that our employees or consultants have wrongfully used for our benefit or disclosed to us confidential information of third parties. As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or engagement. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how, or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or our employees, consultants or independent contractors have, inadvertently or otherwise misappropriated the intellectual property, including know-how, trade secrets or other proprietary information of their former employers or clients. To the extent that our employees, consultants or contractors use intellectual property rights or proprietary information owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely impact our business. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our intellectual property may not be sufficient to protect our products from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may be subject to competition despite the existence of intellectual property we license or own. We can give no assurances that our intellectual property claims will be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing competitive products. The existence of competitive products that avoid our intellectual property could materially adversely affect our operating results and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Furthermore, limitations, or perceived limitations, in our intellectual property may limit the interest of third parties to partner, collaborate or otherwise transact with us, if third parties perceive a higher than acceptable risk to commercialization of our products or future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our drug re-innovation approach involves the filing of patent applications covering new methods of use and/or new formulations of previously known, studied and/or marketed drugs. Although the protection afforded by our patent and patent applications may be significant with respect to BXCL501, BXCL502, BXCL701 and BXCL702, when looking at our patents&#8217; ability to block competition, the protection offered by our patents may be, to some extent, more limited than the protection provided by patents claiming the composition of matter of entirely new chemical structures previously unknown. If a competitor were able to successfully design around any method of use and formulation patents we may have in the future, our business and competitive advantage could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may elect to sue a third party, or otherwise make a claim, alleging infringement or other violation of patents, trademarks, trade dress, copyrights, trade secrets, domain names or other intellectual property rights that we either own or license from BioXcel LLC. If we do not prevail in enforcing our intellectual property rights in this type of litigation, we may be subject to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">paying monetary damages related to the legal expenses of the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facing additional competition that may have a significant adverse effect on our product pricing, market share, business operations, financial condition, and the commercial viability of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restructuring our company or delaying or terminating select business opportunities, including, but not limited to, research and development, clinical trial, and commercialization activities, due to a potential deterioration of our financial condition or market competitiveness.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A third-party may also challenge the validity, enforceability or scope of the intellectual property rights that we license or own; and the result of these challenges may narrow the scope or claims of or invalidate patents that are integral to our product candidates in the future. There can be no assurance that we will be able to successfully defend patents we own in an action against third parties due to the unpredictability of litigation and the high costs associated with intellectual property litigation, amongst other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Intellectual property rights and enforcement may be less extensive in jurisdictions outside of the U.S.; thus, we may not be able to protect our intellectual property and third parties may be able to market competitive products that may use some or all of our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Changes to patent law, including the Leahy-Smith America Invents Act of 2011 and the Patent Reform Act of 2009 and other future article of legislation, may substantially change the regulations and procedures surrounding patent applications, issuance of patents, and prosecution of patents. We can give no assurances that our patents and those of our licensor, BioXcel LLC, can be defended or will protect us against future intellectual property challenges, particularly as they pertain to changes in patent law and future patent law interpretations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, enforcing and maintaining our intellectual property protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by the USPTO, courts and foreign government patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Owning our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The price of our common stock may fluctuate substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">You should consider an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a significant loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this &#8220;Risk Factors&#8221; section, are:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sale of our common stock by our stockholders, executives, and directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">volatility and limitations in trading volumes of our shares of common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">speculative trading in and short sales of our stock, as well as trading phenomena such as the &#8220;short squeeze&#8221; and &#8220;short and distort&#8221; schemes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain financings to conduct and complete research and development activities including, but not limited to, our clinical trials, and other business activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible delays in the expected recognition of revenue due to lengthy and sometimes unpredictable sales timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and success of introductions of new applications and services by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">network outages or security breaches;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract new customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customer renewal rates and the timing and terms of customer renewals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to secure resources and the necessary personnel to conduct clinical trials on our desired schedule;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement, enrollment or results of our clinical trials for our product candidates or any future clinical trials we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays or adverse developments or perceived adverse developments with respect to the FDA&#8217;s review of our preclinical and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our submission for studies or product approvals or adverse regulatory decisions, including failure to receive regulatory approval for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated safety concerns related to the use of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failures to meet external expectations or management guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements and events surrounding financing efforts, including debt and equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to enter into new markets or develop new products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reputational issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from existing technologies and products or new technologies and products that may emerge;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general economic, political and market conditions in or any of the regions in which we conduct our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in industry conditions or perceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in valuations of similar companies or groups of companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analyst research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departures and additions of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which may be out of our control.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Because certain of our stockholders control a significant number of shares of our common stock, they may have significant influence over actions requiring stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, our directors, executive officers and BioXcel LLC, and their respective affiliates, beneficially owned approximately 35% of our outstanding shares of common stock. As a result, these stockholders, acting together, would have significant control over the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. In addition, these stockholders, acting together, would have significant control over the management and affairs of our Company. Accordingly, this concentration of ownership might harm the market price of our common stock by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delaying, deferring or preventing a change in corporate control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impeding a merger, consolidation, takeover or other business combination involving us; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase, if any, of our share price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">If we were deemed to be an investment company under the Investment Company Act of 1940, as amended (the &#8220;1940 Act&#8221;), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under Sections 3(a)(1)(A) and (C) of the 1940 Act, a company generally will be deemed to be an &#8220;investment company&#8221; for purposes of the 1940 Act if (1) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">items) on an unconsolidated basis. We do not believe that we are an &#8220;investment company,&#8221; as such term is defined in the 1940 Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding Sections 3(a)(1)(A) and (C) of the 1940 Act, we are a research and development company and comply with the safe harbor requirements of Rule 3a-8 of the 1940 Act. We intend to conduct our operations so that we will not be deemed an investment company. However, if we were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on our capital structure and our ability to transact with affiliates, could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a &#8220;smaller reporting company&#8221; and are able to avail ourselves of reduced disclosure requirements applicable to smaller reporting companies, which could make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company, and we will remain a smaller reporting company until we determine that either (1) our annual revenues are at least $100 million and our voting and non-voting common stock held by non-affiliates is at least $250 million measured on the last business day of our most recent second fiscal quarter, or (2) our voting and non-voting common stock held by non-affiliates is at least $700 million measured on the last business day of our most recent second fiscal quarter. Smaller reporting companies are able to provide simplified executive compensation disclosure, and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors. In addition, as a non-accelerated filer, we are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have elected to take advantage of certain of the reduced reporting obligations. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are and may in the future be subject to legal proceedings, claims and investigations in or outside the ordinary course of business. Such proceedings, claims and investigations could be costly and time-consuming to defend and could result in unfavorable outcomes, which may have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are, and may in the future become, subject to various legal proceedings, claims and investigations that arise in or outside the ordinary course of business. For example, on July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned Martin v. BioXcel Therapeutics, et al., 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. The amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. Defendants filed a motion to dismiss on February 6, 2024, which has not been decided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Panancherry et al v. Mehta et al, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation, 3:23-cv-1554 (D. Conn.). The above-captioned consolidated action is currently stayed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Smith v. Mehta et al, 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Derivative Litigation, 1:24-cv-00041 (D. Del.). The Company expects to seek a stay in the above-captioned consolidated action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company is also cooperating with an investigation by the SEC. The above-captioned proceedings, as well as any investigation or proceeding that may be instituted by the SEC may result in substantial costs or liabilities, as well as a diversion of management&#8217;s attention and resources, which could harm our business, result in a decline in the market price of our common stock and impact our financing efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The potential costs and liabilities associated with legal proceedings, claims and investigations involving us or members of our leadership team is uncertain, and the results of such legal proceedings, claims and investigations cannot be predicted with certainty. Lawsuits and other administrative or legal proceedings that may arise can involve substantial costs, including the costs associated with investigation, litigation and possible settlement, judgment, penalty or fine. In addition, lawsuits and other legal proceedings may be time consuming to defend or prosecute and may require a commitment of management and personnel resources that will be diverted from our normal business operations. Also, our insurance coverage may be insufficient, our assets may be insufficient to cover any amounts that exceed our insurance coverage, and we may have to pay damage awards or otherwise may enter into settlement arrangements in connection with such claims. Moreover, we may be unable to continue to maintain our existing insurance at a reasonable cost, if at all, or to secure additional coverage, which may result in costs associated with lawsuits and other legal proceedings being uninsured. Any such payments or settlement arrangements in current or future litigation could have a material adverse effect on our business, operating results or financial condition. Even if the plaintiffs&#8217; claims are not successful, current or future litigation could result in substantial costs and significantly and adversely impact our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results and financial condition, and negatively affect the price of our common stock. In addition, such lawsuits may make it more difficult to finance our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Biotechnology and pharmaceutical companies with publicly traded stock or who obtain funding through the stock market often experience significant stock price volatility, based on events beyond their control, including outcomes of clinical trials, actions of regulators and product approvals. Such further litigation, may result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business and result in a decline in the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our certificate of incorporation, our bylaws, and Delaware law may have anti-takeover effects that could discourage, delay, or prevent a change in control, which may cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our amended and restated certificate of incorporation, our amended and restated bylaws and Delaware law could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. We are authorized to issue up to 10 million shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights and sinking fund provisions. No preferred stock is currently outstanding. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Provisions of our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law also could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, the certificate of incorporation and bylaws and Delaware law, as applicable, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide the board of directors with the ability to alter the bylaws without stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">place limitations on the removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management is required to devote substantial time to compliance matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As a publicly traded company we have incurred and will continue to incur significant legal, accounting and other expenses. The obligations of being a public company in the U.S. require significant expenditures and place significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and the listing requirements of the stock exchange on which our securities are listed. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations will make some activities more time-consuming and costly, particularly as we are no longer an &#8220;emerging growth company.&#8221; In addition, we expect these and similar rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain such insurance. Our continued compliance with applicable requirements and to keep pace with new regulations requires management and other personnel to devote a substantial amount of their time, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</p><p style="font-family:'MS Mincho';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.</p><p style="font-family:'MS Mincho';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock, the lack of research coverage may adversely affect the market price of our common stock. Furthermore, if one or more of the analysts who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, which has occurred in the past, our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could lose visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume to decline and may also impair our ability to expand our business with existing customers and attract new customers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales and issuances of our common stock could result in additional dilution of the&#160;percentage ownership of our stockholders and could cause our share price to fall.</p><p style="font-family:'MS Mincho';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We expect that significant additional capital will be needed in the future to continue our planned operations, including increased marketing, hiring new personnel, commercializing our products, and continuing activities as an operating public company. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'MS Mincho';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to comply with the rules&#160;under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Section 404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting. If we fail to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future, or, if we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. We have discovered material weaknesses in the past. If future material weaknesses or significant deficiencies are discovered or if we otherwise fail to achieve and maintain the adequacy of our internal control, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Comprehensive tax reform bills could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">In 2017, the U.S. government enacted comprehensive federal income tax legislation that includes significant changes to the taxation of business entities. These changes include, among others, a permanent reduction to the corporate income tax rate. Notwithstanding the reduction in the corporate income tax rate, the overall impact of this tax reform is uncertain, and our business and financial condition could be adversely affected. Future changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of any foreign earnings, and the deductibility of expenses under future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></p><a id="_5ecc33d4_e988_49a9_a741_d0ed89cd7db4"></a><a id="Item1BUnresolvedStaffComments_512583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1B.&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8ce15dae_55c4_4803_b4cb_027b135063d8"></a><a id="Item1C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item 1C. Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cybersecurity Risk Management and Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We designed and assessed our program based on the National Institute of Standards and Technology Cybersecurity Framework. This does not imply that we meet any particular technical standards, specifications, or requirements, only that we used the National Institute of Standards and Technology Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our cybersecurity risk management program includes:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a management team responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our response to cybersecurity incidents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>cybersecurity awareness training of our employees, incident response personnel, and senior management; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a third-party risk management process for service providers, suppliers, and vendors.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled &#8220;Risk Factors&#8212; Business interruptions could adversely affect future operations, revenues, and financial conditions, and may increase our costs and expenses.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cybersecurity Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from the internal Security Incident Management Team or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Security Incident Management Team, which includes our Chief Financial Officer, the Executive Director of Information Technology, Chief Legal Officer and the Quality Assurance Director, has approximately 30 combined years of risk management experience and is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our Security Incident Management Team&#8217;s experience includes prior work experience in cybersecurity; financial management and controls, data quality assurance and liability and risk management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_68ab8a5c_2db5_4d59_aea8_6f7ca453558e"></a><a id="Item2Properties_105398"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.&#160;Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our corporate headquarters are located at 555 Long Wharf Drive in New Haven, Connecticut. The Company occupies 18,285 square feet of space. The leases for this space expire in February 2026 and we have a renewal option for one additional five-year term. We believe that our existing facilities are suitable and adequate to meet our current needs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_64127a11_51c7_4d90_b66e_a89a4d0b4077"></a><a id="Item3LegalProceedings_216198"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, we may be subject to litigation and claims arising in the ordinary course of business. For information about our legal proceedings, see Note 18 to our audited financial statements included elsewhere in this Annual Report on Form 10-K which is information is incorporation herein by reference.</p><p style="font-family:'MS Mincho';font-size:10pt;text-align:justify;text-indent:18pt;margin:10pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">In addition, on February 12, 2024, we became aware that the SEC has initiated an investigation involving the Company and is seeking the production of certain documents. We are fully cooperating with the SEC&#8217;s investigation. We cannot predict or determine whether any proceeding may be instituted by the SEC in connection with its investigation or the outcome of any proceeding that may be instituted, or the effects any such proceeding could have on the Company&#8217;s business or financing efforts.</span></p><a id="_0d7215f6_efa0_41b3_9311_b68d8446a4c9"></a><a id="Item4MineSafetyDisclosures_460898"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="PartII_326423"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part&#160;II</p><a id="_27d01559_8a5d_4a07_9391_0a7ef92be3c7"></a><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our common stock is traded on The Nasdaq Capital Market<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> under the symbol &#8220;BTAI.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 21, 2024, there were 12 stockholders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors that our board of directors deems relevant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by Item&#160;5 of Form&#160;10-K regarding equity compensation plans is incorporated herein by reference to Item&#160;11. of Part&#160;III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Unregistered Sales of Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There were no unregistered sales of equity securities by the Company during the three months ended December 31, 2023 except as reported in the Company&#8217;s Current Report on Form 8-K filed on December 6, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="Item6Reserved_721061"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 6. Reserved</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1869a723_4809_4404_b20e_2fd75ff01065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_eaba35f7_86df_41d5_957f_7b160ed9aa79"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled &#8220;Risk Factors&#8221; included elsewhere in this Annual Report on Form 10-K. All dollar amounts in the below Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations are presented in U.S. dollars, and all dollar and share amounts are presented in thousands, unless otherwise noted or the context otherwise provides.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) to develop transformative medicines in neuroscience and, through the Company&#8217;s wholly owned subsidiary, OnkosXcel Therapeutics LLC (&#8220;OnkosXcel&#8221;), immuno-oncology. We are focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. We employ various AI platforms to reduce therapeutic development costs and potentially accelerate development timelines. Our approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. We believe this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our most advanced neuroscience candidate is BXCL501. In indications other than those approved by the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) as IGALMI&#8482;, BXCL501 is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine (or &#8220;Dex&#8221;) in development for the treatment of agitation associated with psychiatric and neurological disorders. Our most advanced immuno-oncology asset, BXCL701, is an investigational oral innate immune activator being developed by OnkosXcel Therapeutics as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">On April 6, 2022, we announced that the FDA approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> was commercially available in doses of 120 and 180 microgram (&#8220;mcg).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">We are continuing to develop BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer&#8217;s disease in the at-home setting and in care facilities. As described further below, we have recently deprioritized the development of BXCL501 for certain indications, including development of BXCL501 as a potential adjunctive treatment for major depressive disorder (&#8220;MDD&#8221;), as well as our BXCL701 program except as noted in Part, Item 1, &#8220;Business&#8221; under the heading &#8220;Immuno-Oncology.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For our TRANQUILITY program, we have conducted clinical studies evaluating BXCL501 for the acute treatment of agitation associated with mild to moderate dementia in patients with probable Alzheimer&#8217;s disease, who reside in assisted living facilities (&#8220;ALFs&#8221;) and residential care settings and who required minimal assistance with activities of daily living. On June 29, 2023, we announced positive topline data from our TRANQUILITY II trial, as well as information regarding certain investigator misconduct and noncompliance at a clinical trial site. Since that time, we have taken steps to further investigate and evaluate the conduct of the TRANQUILITY II trial at this clinical site. Based on these steps to date, we believe that there have been no further instances of misconduct or fraud or other findings that adversely impact the data integrity or reliability of the eligibility, safety, and efficacy data obtained at the clinical trial site in question.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We had previously been conducting the TRANQUILITY III clinical trial, which was designed to evaluate the potential for BXCL501 to treat acute agitation in patients with moderate to severe dementia associated with probable Alzheimer&#8217;s disease living in nursing homes and who require moderate to full assistance with activities of daily living. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We paused enrollment in TRANQUILITY III due to the much higher-than-expected background frequency of episodes of agitation experienced by the first several patients enrolled in the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We held Type B/Breakthrough Therapy Designation meetings with the FDA on October 11, 2023 and on February 20, 2024 to obtain additional feedback on our plans for further development of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer&#8217;s disease. We are currently planning to generate additional Phase 3 efficacy and safety data, in a variety of relevant care-facility settings and across severity of dementia using the Positive and Negative Syndrome Scale-Excitatory Component (&#8220;PEC&#8221;) as the primary efficacy measure. In addition, we plan to discuss the details of the requirement for long-term safety data at a future meeting with the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In our SERENITY program, we are evaluating BXCL501 for use in the at-home setting for agitation associated with bipolar disorders or schizophrenia. We completed Part 1 of the SERENITY III trial and announced topline results on May 25, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We reviewed our SERENITY III program with the FDA in Type C meetings on November 8, 2023 and March 6, 2024. Based on the feedback received from the FDA to date, we plan to move forward to evaluate at-home use of the 120 mcg dose of BXCL501, with safety as the primary objective and efficacy measures as exploratory endpoints to support continued efficacy in the at-home setting as recommended by the FDA in the November 8, 2023 meeting, for the acute treatment of agitation in bipolar disorders or schizophrenia. We also plan to conduct a clinical study designed to enroll approximately 30 patients to evaluate the correlation between patient-reported or informant-reported efficacy with trained rater-reported efficacy using PEC measurements, which the FDA had previously recommended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Strategic Reprioritization  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On August 8, 2023, our Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). We determined to take actions to reduce certain operational and workforce expenses no longer deemed core to ongoing operations to extend its cash runway and drive innovation and growth in high-potential clinical development and value-creating opportunities. These actions included a shift in commercial strategy for IGALMI&#8482; in the institutional setting as described, a reduction of in-hospital commercialization expenses, a de-prioritization of programs no longer determined to be core to ongoing operations, and a prioritization on at-home treatment setting opportunities for BXCL501, all as described in Part I, Item 1, &#8220;Business&#8221;. As part of this strategy, our Board of Directors approved a reduction of approximately 60% of our workforce. Annualized operating expenses are expected to be reduced by approximately $80,000. As of December 31, 2023, the Reprioritization was substantially completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a result of the Reprioritization, the Company recorded restructuring costs of $4,163 in the year ended December 31, 2023. These costs consisted of severance and benefit costs of $4,063 and contract termination costs of $100. The Company paid $3,998 of severance and benefit costs and $100 of contract termination costs during the year ended December 31, 2023. Any remaining costs are expected to be paid during the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IGALMI</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-weight:bold;"> Revised Commercialization Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As part of the Company&#8217;s Reprioritization, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> commercial team shifted focus to a hospital/Integrated Delivery Network (&#8220;IDN&#8221;) contracting strategy with a Corporate Account Director (&#8220;CAD&#8221;) team. The goal of the realigned CAD team is to work with large IDNs and drive sales utilizing a top-down approach. Over time, the revised commercial effort is expected to allow the Company to continue to make inroads into the institutional market in a more cost-efficient manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;">Commercial efforts for the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> launch were impacted significantly in the six months ended December 31, 2023, due to the reduction in force, which included the elimination of sales, marketing, and commercial operations staff. The realigned CAD team generated $376 in net revenue for the three-month period ended December 31, 2023 through legacy sales and volume-based contracts, up from $341 for the three-month period ended September 30, 2023. Net revenues from IGALMI&#8482; product sales for the years ended December 31, 2023 and 2022 were $1,380 and $375, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On October 30, 2023, we announced that the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) assigned a new J-Code for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (J1105). J-Codes are permanent codes used by healthcare providers, commercial insurance plans, and government payers to help standardize the reimbursement process. A J-Code can help simplify claims submission as compared to use of a miscellaneous or unlisted code, which in turn can streamline the billing and reimbursement process. The J-Code for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> has been published online in the CMS HCPCS Application Summaries and Coding Recommendations, Third Quarter, 2023 HCPCS Coding Cycle. We believe this J-Code will facilitate access to IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> for patients with agitation associated with bipolar disorder or schizophrenia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">December 2023 Refinancing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">On December 5, 2023 (the &#8220;Second Amendment Effective Date&#8221;), we entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among us, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent (as amended, the &#8220;Credit Agreement&#8221;). Among other things, the Second Amendment deferred the effectiveness of the Credit Agreement&#8217;s Revenue Covenant (as defined below) to the fourth quarter of 2024 and reduced the required minimum revenue levels under the Revenue Covenant; modified the interest rate of loans under the Credit Agreement; provided for warrants to be issued to the Lenders to purchase 70 shares of our common stock; and lowered the strike price of warrants previously issued to the Lenders under the Credit Agreement to $3.6452 per share. Also on the Second Amendment Effective Date, we terminated the Revenue Interest Financing Agreement (as amended, the &#8220;RIFA&#8221;) by and among the Company, the purchasers party thereto (the &#8220;Purchasers&#8221;) and OFA, as administrative agent. The $30,000 in financing previously provided to us under the RIFA was converted to an outstanding loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;) pursuant to the Second Amendment. All commitments for potential future funding under the RIFA were terminated. For additional information, see below under &#8220;Liquidity and Capital Resources&#8212;Sources of Liquidity&#8212;Financing Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">March 2024 Waiver</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>On March 20, 2024 (the &#8220;Effective Date&#8221;), we entered into a Fourth Amendment (the &#8220;Fourth Amendment&#8221;) to the Credit Agreement pursuant to which the Lenders waived the covenant that we not receive a report and opinion from our independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to our financial statements for the year ended December 31, 2023. Accordingly, while our independent registered public accounting firm&#8217;s report contained in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. The Fourth Amendment also includes a number of other changes to the Credit Agreement, as described below under &#8220;&#8212; Liquidity and Capital Resources&#8212;Sources of Liquidity&#8212;Financing Agreements.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:231pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Our Clinical Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the status of our major clinical development programs as of the date of this Annual Report on Form 10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="btai-20231231x10k010.jpg" alt="Graphic" style="display:inline-block;height:231pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For additional information regarding our pipeline candidates, see Part I, Item 1, &#8220;Business&#8221; in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Product Revenue, Net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Revenue relates to sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and reflect limited market access since commercial launch in July 2022. The revenues are net of rebates, chargebacks, discounts, and other adjustments. During the fourth quarter of 2022, we began contracting directly with intermediaries such as GPOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><b style="font-style:normal;font-weight:bold;">Operating Costs and Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cost of Goods Sold</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold primarily relates to the costs of producing, packaging, and delivering our product to customers as well as costs related to excess or obsolete inventory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our research and development expenses reflect costs associated with the identification of our preclinical and clinical product candidates. Expenditures primarily consist of salary, benefits and non-cash stock-based compensation for our research and development personnel, costs incurred under agreements with contract research organizations and sites that conduct our non-clinical studies and clinical trials, costs of outside consultants engaged in research and development activities, travel expenses, the cost of acquiring, developing and manufacturing preclinical and clinical trial materials and lab supplies, and depreciation and other expenses. Payments to BioXcel LLC are also included in research and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">development expenses. Costs associated with third parties that provide non-clinical services such as toxicology, pharmacology, research and discovery, biomarker studies and similar services are included in the professional fees category of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expense research and development costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our research and development costs by program for the&#160;years ended December&#160;31, 2023 and 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">BXCL501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,661</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,044</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">BXCL701</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,631</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other research and development programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,142</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,687</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total direct external costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57,853</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64,362</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Internal personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,675</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,831</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Sub-total direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80,528</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87,193</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indirect costs and overhead</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,798</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,046</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total research and development expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84,326</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,239</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Selling, General and Administrative</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses primarily consist of salaries, benefits and non-cash stock-based compensation for our sales, executive and administrative personnel. Selling, general and administrative expenses also include legal expenses to pursue patent protection of our intellectual property and other corporate matters, professional fees for audit and tax services and insurance charges. We may also incur increased costs to comply with corporate governance, internal controls, investor relations and disclosures and similar requirements applicable to public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">With our Reprioritization substantially completed as of December 31, 2023, we expect that our selling, general and administrative expenses will decline due to the restructured commercialization plan of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and reduced personnel costs. However, we may also experience increased selling, general and administrative expenses due to higher fees for outside consultants, attorneys, and accountants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Restructuring Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">On August 8, 2023, our Board of Directors approved the Reprioritization. We took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend our cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for IGALMI&#8482; in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of this strategy, the Company&#8217;s Board of Directors approved a reduction of approximately 60% of the Company&#8217;s workforce. The Company notified impacted employees on August 14, 2023. Annual operating expenses are expected to be reduced by approximately $80,000. Management believes that, after giving effect to the Reprioritization, the Company&#8217;s cash and cash equivalents of $65.2 million as of December 31, 2023 will allow the Company to fund its operations and meet its liquidity requirements into mid-2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a result of the Reprioritization, the Company recorded restructuring costs of $4,163 for the year ended December 31, 2023. These costs consisted of severance and benefit payments of $4,063 and contract termination costs of $100, which were paid in cash. The Company paid $3,998 of severance and benefit costs and $100 of contract termination </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">costs during the year ended December 31, 2023. As of December 31, 2023, the Reprioritization was substantially completed and any remaining costs are expected to be paid during the first quarter of 2024.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Other Expense (Income)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Other (income) expense primarily consists of interest costs associated with the Credit Agreement the Company entered into in April 2022, changes in fair value of derivative financial instruments, and interest income earned on cash and cash equivalents that were comprised primarily of money market funds. Interest expense may increase in the future as our loans provided under the Credit Agreement are subject to floating interest rates following our December 2023 amendment to the Credit Agreement and, if we meet required milestones, we may draw down additional funds under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A description of recently issued accounting pronouncements is set forth in Note&#160;3, Summary of Significant Accounting Policies to the consolidated financial statements included in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2023 and 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Product Revenue, Net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Commercial sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> launched in July 2022. Product revenue, net for the years ended December 31, 2023 and 2022 was $1,380 and $375, respectively, comprised of sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>. As part of the Company&#8217;s Reprioritization, the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> commercial team shifted focus to a hospital/contracting strategy with a CAD team. The goal of the realigned CAD team is to work with large Integrated Delivery Networks and drive sales utilizing a top-down approach. The realigned CAD team generated $376 in net revenue for the three-month period ended December 31, 2023 through legacy sales and volume-based contracts. Commercial efforts for the IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> launch were impacted significantly in the six months ended December 31, 2023, due to the reduction in force, which included the elimination of sales, marketing, and commercial operations staff. However, the revised commercial effort is expected to allow the Company to continue to make inroads into the institutional market in a more cost-efficient manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Cost of Goods Sold</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold for the years ended December 31, 2023 and 2022, were $1,260 and $20, respectively, which primarily related to the costs to produce, package and deliver IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> to customers, as well as costs related to excess or obsolete inventory. We entered into a commercial supply agreement with ARx, LLC (&#8220;ARx&#8221;) pursuant to which ARx has agreed to exclusively manufacture and supply us with all of our worldwide demand of film formulation of Dex to be used for the commercial supply of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM </sup>and for ongoing clinical trials of our product candidate BXCL501, subject to certain alternative supply provisions. The increase in Cost of goods sold for the year ended December 31, 2023 is primarily the result of increased sales and the increase in the reserve for excess and obsolete inventory.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses for the&#160;years ended December&#160;31, 2023 and 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,351</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,272</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,921)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,324</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,558</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,766</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,590</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,342</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 248</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trials expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,094</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,536)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chemical, manufacturing and controls cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,144</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,457)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Travel and other costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84,326</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,239</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,913)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The decrease of $6,913 for the year ended December 31, 2023, compared to the year ended December 31, 2022 is primarily attributable to the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in clinical trials expense as a result of reduced costs associated with the wind down of the SERENITY III study to evaluate BXCL501 for at home use for the acute treatment of agitation related to schizophrenia and bipolar disorders, as well as the TRANQUILITY II study of BXCL501 for the potential treatment of agitation in patients with Alzheimer&#8217;s disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in personnel and related costs during the fourth quarter of 2023 as a result of the Company&#8217;s Reprioritization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in Chemical, manufacturing and controls (&#8220;CMC&#8221;) costs due to lower CMC costs related to decreased clinical trial activities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An increase in non-cash stock-based compensation due to higher award forfeitures in 2022.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>&#8217;s approval by the FDA, we capitalize costs related to commercial production of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> as inventory and expense those CMC costs related to clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Selling, General and Administrative Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses for the years ended December 31, 2023 and 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">% Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel and related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27,171</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,690</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-cash stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,290</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (489)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,310</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,313</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,997</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 56</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,485</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,006</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (521)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,370</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (627)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Travel and other costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,414</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,811</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 32</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 83,413</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 68,761</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,652</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The increase of $14,652 for the year ended December 31, 2023, relative to the year ended December 31, 2022 is primarily attributable to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Increased professional fees, primarily related to higher legal costs for the investigation of our TRANQUILITY II study, the write-off of previously deferred costs related to the initial public offering of OnkosXcel, and higher corporate operating support levels partially offset by reductions in consulting and recruiting fees.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An increase in personnel costs due to our efforts to expand our functional teams, particularly in sales, to support commercialization of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the U.S., prior to the Reprioritization.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An increase in travel and other costs as a result of the commercial launch of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased non-cash stock-based compensation costs due to increased award forfeitures in 2023 resulting from the Reprioritization and decreased insurance costs as a result of completed clinical activities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Decreased commercial and marketing costs due to higher spend levels in 2022 resulting from the commercial launch of IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Restructuring Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Restructuring costs were $4,163 for the year ended December 31, 2023. See &#8220;Components of Our Results of Operations - Restructuring Costs&#8221; above for a discussion of the Company&#8217;s Reprioritization and restructuring activities. There were no restructuring costs for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Other (Income) Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense increased to $13,314 for the year ended December 31, 2023 compared to $8,213 for the year ended December 31, 2022, due to higher average debt balances during the year due to borrowings under the Credit Agreement and, prior to its termination, the RIFA that the Company put in place in April 2022. The expense was partially offset by interest income earned on cash and cash equivalents that were held primarily in short-term money market funds. Interest income increased to $5,649 for the year ended December 31, 2023 compared to $2,528 for the year ended December 31, 2022, due to higher average cash balances during the year. Other (income) expense, net is primarily associated with changes in fair value of derivative financial instruments for the period, which relate to instruments associated with the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inflation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented. For a discussion of inflationary risks to our future revenues under the Inflation Reduction Act, see &#8220;<i style="font-style:italic;">Health care reform measures could hinder or prevent our product candidates</i>&#8217; commercial success.&#8221; in Part I, Item 1A., &#8220;Risk Factors&#8221; elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, we had cash and cash equivalents of $65,221, working capital of $44,876 and stockholders&#8217; deficit of $56,508. Net cash used in operating activities was $155,006 and $135,341 for the years ended December 31, 2023 and 2022, respectively. We incurred losses of approximately $179,053 and $165,757 for the years ended December 31, 2023 and 2022, respectively. We will need to generate significant product revenues to achieve profitability. Our history of significant losses, negative cash flows from operations, potential near-term increased covenant-driven amortization payments or full repayment obligations under our Credit Agreement, the regulatory event of default triggers under the Credit Agreement, other funding requirement covenants under the Credit Agreement, limited liquidity resources currently on hand, and dependence on our ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>raise funding through debt financing and/or restructuring of its existing Credit Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>reduce overhead and headcount to focus on core priorities, and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span>&#9679;<span style="display:inline-block;width:29.96pt;"></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To date, we have continued research and development activities while managing our cash position. However, we require additional funding to continue as a going concern. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly when there is market uncertainty or an economic downturn or if other events make investment in our securities less appealing. If we are unable to secure adequate additional funding as and when needed on acceptable or commercially reasonable terms, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates. In addition, there are various macro-economic trends affecting the financing markets whose impact on our liquidity and future funding requirements are uncertain as of the filing date of this Annual Report on Form 10-K. We will need substantial additional funding, and if we are unable to raise capital when needed, we could be compelled to pursue alternative options, including, without limitation, implementing further workforce reductions, reducing or ceasing product development programs and advancement of our clinical trials and product candidates, selling our assets or seeking other strategic alternatives. See &#8220;Risks Related to Financial Position and Need for Additional Capital<i style="font-style:italic;"> &#8212; We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts or otherwise seek strategic alternatives.</i>&#8221; in Part I. Item 1A., &#8220;Risk Factors&#8221; elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Sources of Liquidity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have primarily focused our efforts on raising capital and building the products in our pipeline, and, although we generate revenue from sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, we do not expect to generate positive cash flows from operations in the near term. Since our inception, our operations have been financed primarily from proceeds from the sale of equity securities, including our initial public offering, private placements of our common stock, registered offerings of our common stock, an Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), and borrowings under our Credit Agreement (as described below). We have not yet established an ongoing source of revenue sufficient to cover our operating costs and will need to do so in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On April 19, 2022, we entered into two financing agreements: the Credit Agreement and the RIFA. Pursuant to the Credit Agreement, the Lenders originally agreed to provide us up to $135,000 in senior secured term loans to us. On April 28, 2022, we borrowed the first $70,000 tranche of loans under the Credit Agreement. Pursuant to the RIFA, the Purchasers agreed to provide us with up to $120,000 in financing for our near-term commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, development and commercialization of BXCL501 and other general corporate purposes. On July 8, 2022, we drew down the first tranche of $30,000 under the RIFA. In connection with the Credit Agreement, we granted to the Lenders (i) warrants to purchase up to 278 shares of our common stock (the &#8220;Original Warrants&#8221;), (ii) rights to purchase up to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">$5,000 of our common stock and (iii) warrants to purchase up to 175 individual ownership units (i.e., not in thousands) in OnkosXcel (the &#8220;OnkosXcel Warrants&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 13, 2023, we, the Lenders and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for, among other things, a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel, pursuant to which we are permitted to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from the $25,000 at any time outstanding. The First Amendment waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of our obligation to notify OFA of such default, including our investment in an amount in excess of what was previously permitted under the OnkosXcel investment covenant. In connection with the First Amendment, we paid to the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, we entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;) with the Lenders and OFA, as administrative agent. The Second Amendment terminated the RIFA and converted the financing previously provided to us thereunder to term loans under the Credit Agreement. In addition, the Second Amendment replaced the Credit Agreement&#8217;s existing &#8220;Tranche B&#8221; and &#8220;Tranche C&#8221; term loan opportunities with three new tranches aggregating up to $100,000 in potential funding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $20,000 &#8220;Tranche B&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2024: (i) us raising an aggregate of at least $40,000 after the date of the First Amendment from (a) equity proceeds or (b) a bona fide contract with a governmental authority to use BXCL501 for opioid withdrawal, (ii) initiation of a new clinical trial in the TRANQUILITY program based on our meeting with the FDA held on October 11, 2023, and (iii) the total pro forma indebtedness outstanding under the Credit Agreement as a percentage of our trailing 30-day market capitalization being less than 30%;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $30,000 &#8220;Tranche C&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2025: (i) either (a) receipt of approval from the FDA of an sNDA in respect of the use of BXCL501 for the acute treatment of agitation associated with dementia or (b) the receipt of approval from the FDA of an sNDA in respect of the use of BXCL501 for (x) the acute treatment of agitation associated with schizophrenia in adults and (y) the acute treatment of agitation associated with bipolar I or II disorder in adults, in each case, in the community/at home setting without the requirement for administration under the supervision of a healthcare provider, and (ii) the total pro forma indebtedness outstanding under the Credit Agreement as a percentage of our trailing 30-day market capitalization being less than 30%; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A $50,000 &#8220;Tranche D&#8221; term loan available upon satisfaction of the following conditions on or before December 31, 2025: (i) the conditions precedent to the borrowing of Tranche C (as described in the preceding bullet point) have been satisfied, and (ii) our total net revenue attributable to sales of BXCL501 (for the avoidance of doubt, including any revenues attributable to use of BXCL501 for opioid withdrawal) for the trailing twelve consecutive month period exceeding a specified amount.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Second Amendment also modified the interest rate of the loans provided under the Credit Agreement to be a floating rate per annum equal to the secured overnight financing rate (&#8220;SOFR&#8221;) (subject to a SOFR floor of 2.5% and a cap of 5.5%) plus 7.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following the Second Amendment, we must also comply with certain covenants under the Credit Agreement, including a financial covenant that requires we maintain a minimum cash liquidity amount of $15,000 (or higher upon certain events) and a modified minimum revenue requirement measured on a quarterly basis based on the revenue attributable to BXCL501 for the six consecutive month period ending on the last day of the relevant quarter (the &#8220;Revenue Covenant&#8221;), subject to cure payments of not less than $1,000 if we fail to meet the minimum revenue requirement. The Revenue Covenant applies beginning with the six-month period ending on December 31, 2024. If we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">fail to meet the minimum Revenue Covenant for the preceding six-month periods ending on December 31, 2024, March 31, 2025, June 30, 2025 and September 30, 2025, we could be required to make revenue cure payments of up to $4,500, $6,200, $8,500, and $8,500, respectively, plus aggregate prepayment fees of $1,900. Under the Credit Agreement, these cure payments would be due on April 21, 2025, June 6, 2025, September 5, 2025 and December 8, 2025, respectively. We are only permitted to make cure payments for revenue shortfalls up to three times during the term of the Credit Agreement, after which we would default on the Credit Agreement if we are unable to satisfy the minimum revenue requirement for any subsequent fiscal quarter. As of December 31, 2023, we had aggregate principal indebtedness of $102,680 outstanding under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, we amended and restated the Original Warrants granted to the Lenders on April 19, 2022 to purchase up to 278 shares of the Company&#8217;s common stock at an exercise price of $20.04 per share. Pursuant to the amendment and restatement of the Original Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Original Warrants&#8221;), the exercise price of the Original Warrants has been reduced to $3.6452 per share, which represents the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Second Amendment Effective Date. In addition, the Company granted new warrants to the Lenders to purchase up to 70 shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $3.6452 per share (the &#8220;2023 Warrants&#8221;). The Original Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the &#8220;Effective Date, we entered into the Fourth Amendment to the Credit Agreement (&#8220;the Fourth Amendment&#8221;), pursuant to which the Lenders waived the covenant that we not receive a report and opinion from our independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to our financial statements for the year ended December 31, 2023. Accordingly, while our independent registered public accounting firm&#8217;s report contained in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fourth Amendment includes covenants that we will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require us or any of our subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, in the case of clause (i) of the preceding sentence, until May 15, 2024 (for the avoidance of doubt, failure to perform clause (ii) would constitute an immediate event of default under the Credit Agreement without any cure or grace period). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Fourth Amendment provides that if we have not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that we are required to maintain at all times will increase to $25,000 from $15,000, unless and until we have received, after the Effective Date and on or before November 30, 2024, at least $50,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, on the Effective Date, we granted new warrants to the Lenders to purchase up to 100 shares of our common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $3.0723 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">price of our common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of our common stock, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). We entered into a registration rights agreement with the Lenders (as amended and restated in connection with the Second Amendment, the &#8220;Amended and Restated Registration Rights Agreement&#8221;) and filed registration statements on Form S-3 to register the shares issuable upon exercise of the Original Warrants, 2023 Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of our common stock issuable under the Original Warrants, the 2023 Warrants and the Lenders&#8217; Equity Investment Right is 5,852.<span style="font-size:12pt;"> </span>On the Effective Date, we further amended and restated the Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of entering into the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted the OnkosXcel Warrants to the Lenders to purchase 175 individual limited liability company units. The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">See Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> and Note 19, <i style="font-style:italic;">Subsequent Events</i> in the notes to consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information relating to the Credit Agreement and RIFA, including applicable interest rates, payment obligations and certain restrictive and financial covenants thereunder. As of December 31, 2023, we were in compliance with all restrictive and financial covenants under the Credit Agreement, other than the &#8220;going concern&#8221; covenant described above as to which the Lenders have waived compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In May 2021, we entered into the Sale Agreement with Jefferies pursuant to which we could offer and sell shares of our common stock, having an aggregate offering price of up to $100,000, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. On November 1, 2023, we entered into an amendment to the Sale Agreement with Jefferies to increase the size of the &#8220;at the market offering&#8221; program; pursuant to the Sale Agreement, as amended, we can offer and sell shares of our common stock having an aggregate offering price of up to $150,000 (excluding any shares of common stock already sold in the &#8220;at the market offering&#8221; program prior to the date of the amendment), from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. During the year ended December 31, 2023, we sold 1,408 shares under the Sale Agreement for net proceeds of $26,221. We did not sell any shares, and no proceeds were received under the Sale Agreement during the year ended December 31, 2022. From January 1, 2024 through March 19, 2024, we sold 647 shares under the Sale Agreement for gross proceeds of $1,743 and received proceeds of $1,691, net of issuance costs of $52.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cash Flows</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (155,006)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (135,341)</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (20)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (139)</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,522</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,237</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities for the&#160;year ended December&#160;31, 2023 was $155,006 and was primarily attributable to our net loss of $179,053 and a $3,219 decrease in accounts payable, accrued expenses, due to related parties, and other current liabilities, partially offset by a $2,888 decrease in prepaid expenses, other current assets and other assets, $18,614 in non-cash stock-based compensation, and a $4,369 increase in accrued and payable in kind interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities was $135,341 for the&#160;year ended December&#160;31, 2022, and was primarily attributable to our $165,757 net loss, a $1,985 increase in inventory of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> and a $3,905 increase in prepaid expenses, other current assets and other assets, partially offset by $17,337 in non-cash stock-based compensation, a $4,611 increase in accrued and payment in kind interest, and $13,030 increase in accounts payable, accrued expenses, due to related parties and other current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;">Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in investing activities for the year ended December 31, 2023, was $20 and was primarily attributable to leasehold improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash used in investing activities was $139 for the year ended December 31, 2022, and was primarily attributable to the purchase of equipment and leasehold improvements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 22.5pt;"><span style="font-style:italic;">Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2023, was $26,522 and was primarily attributable to net proceeds of $26,221 from the sale of common stock under the Sale Agreement with Jefferies and net proceeds of $508 from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2022, was $96,237 and was primarily attributable to $98,600 of proceeds received from the OFA Facilities, net of $2,646 of debt issuance costs and proceeds of $283 from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Operating Capital and Capital Expenditure Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We expect to continue to incur significant and increasing operating losses at least for the next several years as we commercialize IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-weight:normal;"> and as we expand our clinical trials of and seek marketing approval focused on BXCL501 while pursuing development of additional product candidates for BXCL502, BXCL701 and BXCL702. We expect to continue to incur net losses in the near term. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our planned clinical trials and our expenditures on other research and development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. We anticipate that our expenses will increase substantially as we:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our clinical development of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct additional research and development with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify, acquire, license, develop and commercialize product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">integrate acquired technologies into a comprehensive regulatory and product development strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire scientific, clinical, quality control and administrative personnel and utilize professional services, including consultants, lawyers, and accountants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development and commercial efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fully develop a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any product candidates for which we may obtain regulatory approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to operate as a public company.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that our existing cash and cash equivalents as of December 31, 2023 will not be sufficient to enable us to fund operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of the consolidated financial statements included in this Annual Report on Form 10-K, including funding our ongoing research and development and commercialization efforts. In particular, after giving effect to the Reprioritization, we believe that our cash and cash equivalents of $65.2 million as of December 31, 2023 will allow us to fund our operations and meet our liquidity requirements into mid-2024, assuming we are able to comply with the covenants under our Credit Agreement. We expect that we will need to obtain substantial additional funding to fund our ongoing operations. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted, and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends, which could adversely impact our ability to conduct our business. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves. To date, we have continued research and development activities while managing our cash position. However, we can provide no assurance that will be successful in obtaining additional necessary resources and, if we are unable to fund our operations, including our clinical trials, we may need to focus on advancing fewer of our product candidates or otherwise consider strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total $10,000 for the three-year period and the minimum commitment for 2024 is $5,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February 2022, we signed a distribution agreement with a third party to distribute product related to BXCL501 in the U.S. The distributor will be paid defined fees for its services under the agreement, which can be terminated by either party for cause. The distribution agreement can also be terminated by us without cause, subject to payment of agreed termination fees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;). The HQ Lease expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed. The Company has approximately $837 of payments remaining under the HQ Lease. For additional details, see Note 13, <i style="font-style:italic;">Leases</i> in the notes to consolidated financial statements included in this Annual Report on Form 10-K for additional information relating to the Company&#8217;s leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, we are obligated to make quarterly interest payments under our Credit Agreement. For additional details, see Note 9, <i style="font-style:italic;">Debt and Credit Facilities</i> in the notes to consolidated financial statements included in this Annual Report on Form 10-K for additional information relating to the Company&#8217;s debt payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to exercise its judgment. We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and contingencies at the date of the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on a variety of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the attributes of our products and the regulatory environment. We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We define critical accounting policies as those that are reflective of significant judgments and uncertainty and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies are noted below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Stock Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company has granted stock options, restricted stock units and profit units to employees, directors, and consultants, as well as warrants to other third parties. For employee, director and consultant awards, the value of each grant is estimated on the date of grant using a Black-Scholes option-pricing model. The Black-Scholes pricing model incorporates the volatility of the price of BTI&#8217;s stock, the risk-free interest rate, the estimated life of the award, the closing market price of the Company&#8217;s stock and the exercise price of the award. Management bases the Company&#8217;s estimates of stock price volatility on the historical volatility of the Company&#8217;s common stock, as well as a peer group of comparable companies. However, these estimates are neither predictive nor indicative of the future performance of the Company&#8217;s stock. For purposes of the calculation, management assumed that no dividends would be paid during the life of the stock awards. The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Research and Development Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As part of the process of preparing the Company&#8217;s consolidated financial statements, BTI&#8217;s management is required to estimate prepaid and accrued expenses, including research and development expenses. This process involves reviewing open contracts, communicating with personnel to identify services that have been performed on behalf of the Company and estimating the level of service performed and the associated cost incurred for the service when BTI has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company&#8217;s service providers invoice BTI monthly for services performed or when contractual milestones are met. BTI management makes estimates of prepaid and/or accrued expenses, including research and development expenses, as of each reporting date in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Company&#8217;s consolidated financial statements based on facts and circumstances known to management at that time. BTI periodically confirms the accuracy of its estimates with the service providers and makes adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to contract research organizations (&#8220;CROs&#8221;) in connection with clinical studies, amounts paid to contract manufacturing organizations, and fees paid to sites in connection with clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company bases its expenses related to clinical studies on management&#8217;s estimates of the services received and efforts expended pursuant to contracts with multiple CROs that conduct and manage clinical trial studies on our behalf. The financial terms of these agreements are subject to an initial negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to vendors exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing certain service fees, BTI management estimates the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from management&#8217;s estimate, management will adjust the accrual or prepaid accordingly. Although the Company does not expect management&#8217;s estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</p><a id="_5b0ddb8a_4bbe_4753_851d_69f39b40ec37"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Foreign Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, we had $65,221 of cash and cash equivalents. Our cash and cash equivalents are primarily held in U.S. Government money market funds. We do not participate in any foreign currency hedging activities and have limited exposure to other derivative financial instruments, primarily resulting from the terms and conditions of the Credit Agreement. We did not recognize any significant exchange rate losses during the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. While we believe our cash and cash equivalents do not contain material market risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash at one or more financial institutions that exceed federally insured limits. In the event of a failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The loans under the Credit Agreement bear interest at a variable annual rate of the Secured Overnight Financing Rate (&#8220;Term SOFR&#8221;) (but not less than 2.5% or more than 5.5%) plus 7.5% payable quarterly. Consequently, we have material interest rate exposure due to our indebtedness, however this risk is hedged in part by the floor and ceiling on TERM SOFR rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Capital Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently do not have substantial product revenues and depend on funds raised through other sources. One source of funding includes future debt or equity offerings. Our ability to raise funds in this manner depends upon, among other things, capital market forces affecting our stock price, and on the state of the capital markets generally<span style="background:#ffffff;">.</span></p><a id="_bcbbebca_8269_436e_9c30_a5ba38f861c9"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The financial statements required pursuant to this item and the related report of our independent auditor are included in Item 15 of this report beginning on page F-1 and are incorporated under this Item by reference. Our independent auditor for the years ended December 31, 2023 and 2022 was <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:AuditorName" id="Narr_ilUlPJ4wHkyKT7HW5pli-w">Ernst &amp; Young LLP</ix:nonNumeric> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:AuditorFirmId" id="Narr_ktC_J4tAaEmr6CnAq-Ah8g">42</ix:nonNumeric>), located in <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="dei:AuditorLocation" id="Narr_Xqki8CskQEWjGqWN2NkT1Q">Stamford, Connecticut</ix:nonNumeric>, USA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_50ebb85c_eb8f_4a01_94ba_a2792624e3de"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_58519dfa_228b_4670_a91c_f2d9611c6012"></a><a id="Item9AControlsandProcedures_710755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Controls Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control-Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Attestation Report of the Registered Public Accounting Firm</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting as we are a &#8220;non-accelerated filer&#8221; as defined under SEC rules.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_4e2dfe74_f572_424c_896a_790b4cd76cd1"></a><a id="Item9BOtherInformation_895714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span>On March 20, 2024 (the &#8220;Effective Date&#8221;), we entered into a Fourth Amendment (the &#8220;Fourth Amendment&#8221;) to the Credit Agreement and Guaranty (as amended, the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent (the &#8220;Administrative Agent&#8221;), pursuant to which the Lenders waived the covenant that we not receive a report and opinion from our independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to our financial statements for the year ended December 31, 2023. Accordingly, while our independent registered public accounting </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">firm&#8217;s report contained in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Fourth Amendment includes a covenant that we will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require us or any of our subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024 (for the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, the Fourth Amendment provides that if we have not, after the Effective Date and on or before September 30, 2024, received at least $40,000,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that we are required to maintain at all times will increase to $25,000,000 from $15,000,000, unless and until we have received, after the Effective Date and on or before November 30, 2024, at least $50,000,000 in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the Fourth Amendment, on the Effective Date, we granted new warrants to the Lenders to purchase up to 100,000 shares of our common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $3.0723 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of our common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. The 2024 Warrants were issued, and the 2024 Warrant Shares will be issued (if at all), in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), contained in Section 4(a)(2) of the Securities Act. The Lenders have represented that they are acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof, and appropriate legends have been or will be affixed to the securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On the Effective Date, we amended and restated our Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, we agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The foregoing summary of the Fourth Amendment, the 2024 Warrants and the Second Amended and Restated Registration Rights Agreement are qualified in their entirety by the complete text of such agreements, copies of which are filed hereto as Exhibit 10.22.4, 4.5 and 4.6, respectively.</p><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_VfXAGLu4fUqQYeyeGuXIig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>On <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw" name="ecd:TrdArrAdoptionDate" id="Narr_YHrK3BKvE06-QuOA9uXysA">December 14, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw" name="ecd:TrdArrIndName" id="Narr_8qvmH6yYNECXr7zTax0ROw">Vimal Mehta</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw" name="ecd:TrdArrIndTitle" id="Narr_U35vWvwAQUGpBXHv5ycM7g">Chief Executive Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw" format="ixt:booleantrue" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_f01ikmy5IkirkTGoiPbppg">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember_uCqLAxkpTUCf_97fB1ROog" decimals="-3" format="ixt:numdotdecimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="3" id="Narr_Ft2kftlgr0-wl29niVLm3g">34,938</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_T9C6dk96bkuwZda1PrS6Dg" continuedAt="Tb_T9C6dk96bkuwZda1PrS6Dg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg" name="ecd:TrdArrAdoptionDate" id="Narr_ZX7JBV7vYUygloNSJX4mZQ">December 14, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg" name="ecd:TrdArrIndName" id="Narr_6201VV_hLE6-BvEI2-AZjQ">Richard Steinhart</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg" name="ecd:TrdArrIndTitle" id="Narr_jDbXazBPU0GCmAHHg7QbEg">Chief Executive Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg" format="ixt:booleantrue" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_nlKlIO2sakyTYefX-ojTtw">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_Hr72ObP9Ykyp9_0xmJWLlQ" decimals="-3" format="ixt:numdotdecimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="3" id="Narr_TKpsvkjIdkm91P8kvV86sw">25,000</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_T9C6dk96bkuwZda1PrS6Dg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_mu3dFPpFNkqdVq-o59ZOzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA" name="ecd:TrdArrAdoptionDate" id="Narr_0M8yeF5X-Eaf-_oNGyG_1w">December 14, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA" name="ecd:TrdArrIndName" id="Narr_men-ZErc10ea9-Upt7MrfQ">Javier Rodriguez</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA" name="ecd:TrdArrIndTitle" id="Narr_SmlDUse_BEmJvakDXKe-1Q">Senior Vice President, Chief Legal Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA" format="ixt:booleantrue" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_mL7z2qYhckO-yK8XCtgTXg">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_8dg2ROr62EmFMKrYPCbbVA" decimals="-3" format="ixt:numdotdecimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="3" id="Narr_nOo901_WdUKEy33vSulg4g">25,000</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_FgWliStOX06G9Qb_7Gd1xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA" name="ecd:TrdArrAdoptionDate" id="Narr_UcB2-RHmkU2p3gWJK2esQQ">December 14, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA" name="ecd:TrdArrIndName" id="Narr_1_-kR_cqk0eSBQcR7tde3g">Matthew Wiley</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA" name="ecd:TrdArrIndTitle" id="Narr_r8-oygCvek2eA5azu8I13Q">Chief Commercial Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA" format="ixt:booleantrue" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_-iTaaN23C0et7x6CLp8Ypg">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_T5Zf7K9_uEKO9VCroUlqcA" decimals="-3" format="ixt:numdotdecimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="3" id="Narr_TZAQ28iChU6rKCSiFLlORQ">25,000</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_l5xTBQA5W0yeideFlK2PKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw" name="ecd:TrdArrAdoptionDate" id="Narr_1MC3K9NXwk6iz4YklCFnHA">December 14, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw" name="ecd:TrdArrIndName" id="Narr_Js7E5LJcwU-YkIqUTaCR2g">Frank Yocca</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw" name="ecd:TrdArrIndTitle" id="Narr_3hVNNx1upkKtAqVssCW77w">Chief Scientific Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw" format="ixt:booleantrue" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_sVCEegUkkUOluhsOXXhUCg">adopted</ix:nonNumeric> a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_YXURVutUlkePgjsTcxszAg" decimals="-3" format="ixt:numdotdecimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="3" id="Narr_ExcRMVZ3sk-NMDuhn91qyQ">25,000</ix:nonFraction> shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p></ix:nonNumeric><a id="_39e37fdf_ec2d_4e8d_b147_58842c525a11"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_50ab2fb7_bc83_4aa1_a3e2_f8a8fe4596ff"></a><a id="PARTIII_44466"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 10. Directors, Executive Officers, and Corporate Governance.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">INFORMATION ABOUT OUR DIRECTORS &amp; EXECUTIVE OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The following information with respect to our Board of Directors (the "Board") and executive officers is presented as of March 22, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:105.7%;"><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:14.25pt;"><td style="vertical-align:top;width:23.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;"><b style="font-weight:bold;">Name</b></p></div></div></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;"><b style="font-weight:bold;">Age</b></p></div></div></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;"><b style="font-weight:bold;">Position at BioXcel</b></p></div></div></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:14.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;"><b style="font-weight:bold;">Principal Employment</b></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2.75pt 0pt 1.5pt 0pt;">Vimal Mehta, Ph.D.</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:2.75pt 0pt 1.5pt 0pt;">63</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2.75pt 0pt 1.5pt 0pt;">Chief Executive Officer and President, and Director</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2.75pt 0pt 1.5pt 0pt;">Same</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Richard Steinhart</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">66</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Same</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Matthew Wiley</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">52</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Senior Vice President and Chief Commercial Officer</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Same</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Frank Yocca, Ph.D.</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">68</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Senior Vice President and Chief Scientific Officer</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Same</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Vincent O&#8217;Neill, M.D.</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">54</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Executive Vice President, Chief of Product Development and Medical Officer</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Same</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Javier Rodriguez</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">52</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Senior Vice President, Chief Legal Officer and Corporate Secretary</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Same</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Peter Mueller, Ph.D.</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">67</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Chairman of the Board</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">President at Mueller Health Foundation, a private foundation tackling globally lethal infectious diseases</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">June Bray</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">70</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Director</p></td><td style="vertical-align:top;width:1.22%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Former Senior Vice President, Global Regulatory Affairs and Medical Writing at Allergan, Inc., a pharmaceutical company</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Sandeep Laumas, M.D.</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">55</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Director</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Chief Business Officer and Chief Financial Officer at Instil Bio, Inc., a pharmaceutical company</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Michael Miller</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">66</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Director</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Former Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals, Inc., a pharmaceutical company</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:23.72%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Michael Votruba, M.D.</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.75%;margin:0pt;padding:0pt 0.75pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:3.75pt 0pt 1.5pt 0pt;">58</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Director</p></td><td style="vertical-align:bottom;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3.75pt 0pt 1.5pt 0pt;">Director at the Gradus/RSJ Life Sciences Fund, a dedicated fund</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to our annual meeting of stockholders to be held in 2024 (the &#8220;2024 Annual Meeting of Stockholders&#8221;), which we intend to file with the SEC within 120 days of the year ended December 31, 2023.</p><a id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a id="Item_10__Directors__Executive_Officers_a"></a><a id="_8a48c414_6223_42f5_8219_c087dd56dea7"></a><a id="Item11ExecutiveCompensation_58666"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7a844522_ab8d_43cb_bdf8_96eb07f49951"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2023.</p><a id="_3c55392c_3d9f_47be_abdd_af24a23797c6"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_63b1b7cf_5ad9_423a_ab41_46e9ef03fa4d"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;14. Principal Accounting Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2024 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2023.<span style="visibility:hidden;">&#8203;</span></p><a id="_b67c5707_cdb3_4ded_82c8_93a4a989b567"></a><a id="PARTIV_900935"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsFinancialStatementSchedule"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;15. Exhibits, Financial Statement Schedules</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following documents are filed as part of this report:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: 00042)</p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_688394"><span style="font-style:normal;font-weight:normal;">Consolidated</span><span style="font-style:normal;font-weight:normal;"> Balance Sheets as of December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_773604"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_770795"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:91.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#NOTESTOFINANCIALSTATEMENTS_564668"><span style="font-style:normal;font-weight:normal;">Notes to C</span><span style="font-style:normal;font-weight:normal;">onsolidated </span><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules:</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits.</span></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/10/2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/13/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of the Registrant&#8217;s Securities Registered Under Section 12 of the Exchange Act</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918001032/a2234645zex-4_2.htm#Exhibit:http://www.sec.gov/Archives/edgar/data/1720893/000104746918001032/a2234645zex-4_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Stock Certificate evidencing the shares of common stock</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/26/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Warrant Agreement, dated December 5, 2023</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/06/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Agreement, dated December 5, 2023</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/06/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex4d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Agreement, dated March 20, 2024</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex4d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Registration Rights Agreement, between the Company and the parties thereto, dated March 20, 2024.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1+</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/btai-20191231ex102ae7793.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Amended and Restated Separation and Shared Services Agreement, dated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 6, 2020</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, by and between BioXcel Corporation and BioXcel Therapeutics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">10.2      </span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2#</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837021002916/btai-20201231ex1034633bc.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">F</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">irst</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Second Amended and Restated Separation and Shared Services Agreement, dated March 3, 2021, by and between BioXcel LLC and BioXcel Therapeutics Inc</span></a>.</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/12/2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023008597/btai-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Second Amended and Restated Separation and Shared Services Agreement, dated March 3, 2021, by and between BioXcel LLC and BioXcel Therapeutics Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4#</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Asset Contribution Agreement, effective November&#160;7, 2017, by and between BioXcel LLC and BioXcel Therapeutics,&#160;Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918053383/a18-21149_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated as of August 20, 2018, by and between Fusco Harbour Associates, LLC, as Landlord, and BioXcel Therapeutics, Inc., as Tenant</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/23/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020013632/btai-20200930ex1018d184a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment, dated August 19, 2020, to Lease Agreement, dated as of August 20, 2018, by and between Fusco Harbour Associates, LLC, as Landlord, and BioXcel Therapeutics, Inc., as Tenant</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/12/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2017 Equity Incentive Plan</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Non-Statutory Stock Option Agreement under the 2017 Equity Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020010611/btai-20200630ex101dd8d33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BioXcel Therapeutics, Inc. 2020 Incentive Award Plan and forms of award agreements thereunder</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/14/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465920064759/tm2020394d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/14/2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement with directors and executive officers</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918016770/a18-8090_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated March 7, 2018 by and between BioXcel Therapeutics,&#160;Inc. and Vimal Mehta</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/13/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated February&#160;12, 2018, by and between BioXcel Therapeutics,&#160;Inc. and Frank Yocca</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000104746918000756/a2234454zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective October&#160;2, 2017, by and between BioXcel Therapeutics,&#160;Inc. and Richard Steinhart</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-222990</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1720893/000110465918038902/a18-14962_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated June 1, 2018, by and between BioXcel Therapeutics, Inc. and Dr. Vincent O&#8217;Neill, M.D.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">06/07/2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001720893/000155837021002916/btai-20201231ex101943a8b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Javier Rodriguez and BioXcel Therapeutics, Inc., dated February 15, 2021.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/12/2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022003335/btai-20211231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Matthew Wiley and BioXcel Therapeutics, Inc., dated January 12, 2022.</span></a> </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023008597/btai-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement BioXcel Therapeutics, Inc. and Vincent O&#8217;Neill, M.D. dated July 1, 2022</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/08/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">@</sup></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022013353/btai-20220630xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Program</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022007805/btai-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BioXcel Trademark License Agreement, between the Company and BioXcel LLC</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022013353/btai-20220630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Credit Agreement and Guaranty, by and among BioXcel Therapeutic, Inc., Oaktree Fund Administration, LLC, the Subsidiary Guarantors from time to time party thereto and the Lenders from time to time party thereto, dated April 19, 2022</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.1+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023018917/btai-20230930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Waiver and First Amendment to Credit Agreement and Guaranty, by and between the Company, the lenders party thereto and Oaktree Fund Administration LLC dated November 13, 2023.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/14/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.2&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924012333/tm244487d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement dated December 5, 2023, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/08/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.3&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465924014028/tm244487d3_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/12/2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22.4</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex10d224.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Credit Agreement and Guaranty, dated March 20, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto, and Oaktree Fund Administration LLC, as administrative agent (as amended)</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23+&amp;</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837022013353/btai-20220630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial Supply Agreement, between ARx, LLC and BioXcel Therapeutics, Inc., dated April 1, 2022</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/11/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465922092973/tm2223745d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC Management Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/19/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465922092973/tm2223745d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Profits Interest Award Agreement under the Management Incentive Plan</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/19/2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26@</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000155837023008597/btai-20230331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of RSU Agreement pursuant to the OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC Management Incentive Plan.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/08/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27+</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1720893/000110465923103556/tm2326812d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Compete Agreement, by and among the Company, Dr. Krishnan Nandabalan, InveniAI LLC, Invea Therapeutics, Inc. and the other parties thereto, dated September 19, 2023.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-38410</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">09/25/2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of BioXcel Therapeutics, Inc.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP </span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">**</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">**</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="btai-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy for Recovery of Erroneously Awarded Compensation</span></a></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline eXtensible Business Reporting Language (XBRL) Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL </p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="4" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:36.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.8%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th colspan="3" style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></th></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"/><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">*</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:4.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">@    Indicates a management contract or any compensatory plan, contract or arrangement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">+     Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">#     Confidential treatment has been granted for portions omitted from this exhibit and those portions have been separately filed with the Securities and Exchange Commission.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">&amp;    Annexes, schedules, and certain exhibits have been omitted pursuant to Item 601(a)(5)(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">*     Filed herewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="white-space:pre-wrap;">**   Furnished herewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item16Form10KSummary_689937"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;16. Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7e4d087f_fac1_4417_b64f_35480343f7bc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="SIGNATURES_328256"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">BioXcel Therapeutics,&#160;Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 22, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 22, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times';font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times';font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">11</p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></th></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/&#160;Vimal Mehta</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Vimal Mehta, Ph.D.</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Executive Officer and Director <i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/&#160;Richard Steinhart</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Richard Steinhart</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chief Financial Officer <i style="font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</i></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/&#160;Peter Mueller</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Peter Mueller, Ph.D.</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Chairman of the Board of Directors</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/&#160;June Bray</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">June Bray</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/&#160;Sandeep Laumas</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Sandeep Laumas, M.D.</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">/s/&#160;Michael Miller</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Michael Miller</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:center;border-bottom:1.5pt solid #000000;margin:0pt;">/s/ Michal Votruba</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Michal Votruba</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:37.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">March 22, 2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ee6d790c_bb5b_40ba_943a_380419417697"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 4.69pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the Stockholders and the Board of Directors of BioXcel Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have audited the accompanying consolidated balance sheets of BioXcel Therapeutics, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in stockholders' (deficit) equity and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">The Company&#8217;s Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations, has used significant cash in operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the Audit Committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgment. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosure to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:4.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:82.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">As of December 31, 2023, research and development expenses and accrued research and development expenses includes clinical trial expenses and related accrued clinical trial expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Description of the Matter</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">How We Addressed the Matter in Our Audit</i></p></td><td style="vertical-align:top;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.5pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Clinical trial expense and related accrued clinical trial expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">As discussed in Note 3 to the consolidated financial statements, at the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives, and depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. As of December 31, 2023, research and development expenses and accrued research and development expenses includes clinical trial expenses and related accrued clinical trial expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">Auditing the Company&#8217;s clinical trial expenses and related accrued clinical trial expenses was complex because the evidence is accumulated from multiple third-party service providers and in certain circumstances, the nature and amount of services that have been rendered during the reporting period does not correspond to the timing and pattern of vendor invoicing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.5pt 12pt 0pt;">To test the clinical trial expenses and accrued clinical trial expenses, our audit procedures included, among others, evaluating the significant assumptions used by management to estimate the clinical trial expenses and testing the accuracy and completeness of the underlying data. To test the significant assumptions, we inspected the Company's contracts with third-party service providers, corroborated the progress of clinical trials and other research and development projects with the Company&#8217;s internal personnel that oversee these activities, and obtained information directly from third-party service providers which included the third parties&#8217; estimates of clinical trial costs incurred to date. We also examined invoices received from vendors and cash disbursements made to third-party service providers subsequent to December 31, 2023 to assess the completeness of the recorded accruals.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stamford, Connecticut</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9c54e66a_9831_416f_a978_2da772cf228e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="BALANCESHEETS_688394"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts)</b></p><a id="_5ca8df52_6219_44d8_bcae_a98041ff4c46"></a><a id="Tc_C4A78G7SFEWr_WxxS72CsA_3_2"></a><a id="Tc_FZhWBzkCpUaOI1ekJpWlSQ_3_5"></a><a id="Tc_U9BHzMoFh0CNPoztoMSRFw_4_2"></a><a id="Tc_A2YKyBtvwUK7GVnEW8z3KQ_4_5"></a><a id="Tc_sC1Q_v38A0OUG_HyCuvMNg_5_0"></a><a id="Tc_m-zvI1nVi0O4OYkp93uyEQ_6_0"></a><a id="Tc_3WPVqya3z0mD_0yuD3aSWg_7_0"></a><a id="Tc_uqTIIvzUu0KJgU3UqU9rLw_7_2"></a><a id="Tc_b_XUCXGwhUOHhFenMGw1rw_7_5"></a><a id="Tc_ZeN4VSM7oEmrpoF51rW-wQ_8_0"></a><a id="Tc_JeM7Wrya40aWJWbqzbgInw_9_0"></a><a id="Tc_Gs8biGziy0SP65LhDARVPQ_10_0"></a><a id="Tc_RcnntKwctUq6Pi72zNHUdw_11_0"></a><a id="Tc_xLst34Nd7kCbpXeykiB9Zw_12_0"></a><a id="Tc_lSHZSUM1_kmzH1HniWB_Kw_12_2"></a><a id="Tc_0Phg6p8ypUm-wZ7RnU-Muw_12_5"></a><a id="Tc_D0W0HotjVEC7dUtkvduLtw_13_0"></a><a id="Tc_-JiBdHfcZ02zBK-yzeYFOg_14_0"></a><a id="Tc_c6EM2uUjQk60NF_e0BSRVg_15_0"></a><a id="Tc_Fj7F7DuOtk612qux6hxXJQ_16_0"></a><a id="Tc_3aEvAV9gQ0CnIz5H_Ucq5g_16_2"></a><a id="Tc_ih-WKKLJc0e0BiVYCz-cEA_16_5"></a><a id="Tc_Z9oMEeXMvEGnGvvOfEdL3Q_18_0"></a><a id="Tc_qjxSAl_U_E2bW_WH5A41Jw_19_0"></a><a id="Tc_5BEhbPyOy0mJ_RdOxz_Qlg_20_0"></a><a id="Tc_ZWZbqnH9R0KMoBhf5k0mjw_20_2"></a><a id="Tc_xmucl9UJeUepEB_luuDRUQ_20_5"></a><a id="Tc_M7aJnhgNWkONB1jUfxzx8Q_21_0"></a><a id="Tc_rf_9jkP9DUa0KqstoSmepw_22_0"></a><a id="Tc_B4Ijo05UcUafWfZq39RMYg_23_0"></a><a id="Tc_cPP4q5fDXUq-dFIW6Rww_w_24_0"></a><a id="Tc_p6nnLlDFw0OXr6vQ3z-l2g_25_0"></a><a id="Tc__1dFvlPr2U2KSEwYpSFwog_25_2"></a><a id="Tc_-LFe5Yd3CkKKDDuqZ0broA_25_5"></a><a id="Tc_4FGr0mQi6Uu5Dy2tcxDdEA_26_0"></a><a id="Tc_oFqLa-AQ-0iyc_rrNnO87Q_27_0"></a><a id="Tc_wrNiiV60n02RUsuUm98f7g_28_0"></a><a id="Tc_q-OjWsX8nEuQfjH_rPRabQ_29_0"></a><a id="Tc_ElhVuaUtFES9FF8BsdhQUg_29_2"></a><a id="Tc_JRYcjUPx9UiOS8dMkgueYw_29_5"></a><a id="Tc__8429n7zmECA9cVH6b9kGg_31_0"></a><a id="Tc_dtqzA0hC5Uqs42HtU47awA_32_0"></a><a id="Tc_1Xlc3e2VLUi5BxZeaWLiTg_33_0"></a><a id="_5a5b6730_efdc_4e82_a030_06f6c9b1b6c8"></a><a id="_5a5b6730_efdc_4e82_a030_06f6c9b1b6c8_2"></a><a id="_5a5b6730_efdc_4e82_a030_06f6c9b1b6c8_3"></a><a id="Tc_Hb1lPxgvjkS82aIhpOC3VA_33_2"></a><a id="Tc_AfBPthQwm0K4bGYW4VRT9A_33_5"></a><a id="Tc_vjNnYQ0Bz0m_U-f-Fk2ySw_34_0"></a><a id="Tc_qL0cRawYTkiA20VI_W3a8Q_35_0"></a><a id="Tc_NCsc9qvMFUGZM5WKCh7TJw_36_0"></a><a id="Tc_wtV3yyfz8kmm94gFNXecAQ_37_0"></a><a id="Tc_qW3CHBLoz0KCRKLC9WEcgA_37_2"></a><a id="Tc_70ES0Y8-vkiZ14DAXgbeBA_37_5"></a><a id="Tc_KUYYixumqky8X4bnzif6Sg_38_0"></a><a id="Tc_jHvHQBMKe0a1AcXOL6m_eA_38_2"></a><a id="Tc_sO5Dm2I5rUGpkOyrHCCDSA_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_BWRZZSWKiUSodaymszfN7A_7_3">65,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_9-4ztyealEGYxAN6ECyftQ_7_6">193,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_BSEqc0KIokWFUBfAQfZiwA_8_3">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_toAFGZF9B0WWI1IoGRsCiw_8_6">248</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_USKiHEOw60Ke6JIwDSAZ2A_9_3">1,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_4aVzCLM1ckSq3hV9GuaI8w_9_6">1,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_sDSUIATHn02SxkHWz9VEUQ_10_3">2,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_8MyJa5zFzki1ypXVCvfexw_10_6">3,067</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_oTrTvvjoYkue4w7nSo66DA_11_3">2,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_Z58MBupPqEChzb8f_ggpRw_11_6">3,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_qWsZsiIop0qplBAjVP8T5g_12_3">72,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_pzgq8Sr8i0qg7JYmkDPOWw_12_6">202,868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_R8S2z5a7kkKEkaP6h-APkQ_13_3">784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_kDsn7xx_q02oFVyVAOzfwQ_13_6">1,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_KSoxuDYmXU-vQpW2Wdi4Eg_14_3">688</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_oKQMKhlNHUKBWjTMT837ZA_14_6">976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_mNqVsKIvo0-CCezeNEK96A_15_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Aj4APlFLMkKJmTi_oW-zkQ_15_6">925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_7bf_Fu7m1kmaCOmTPF3rEw_16_3">73,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_IUu7iYkHoEqXJXn8nqe3rw_16_6">205,853</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_LEHIBspiZUiriEbV56kZFQ_20_3">13,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_0e7DBqYjWkqE6S3VDmKdkg_20_6">10,228</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_AXLEqQ08xk-4w7tPNoDX2g_21_3">12,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_LEdyF7D6TEOtDnW1Z1bOSg_21_6">18,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_C6w_xNcT_EqUj9i8wEs-yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_4BfkSwOS1UKCdXd0Uu8e6w_22_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Pe0_O6hXxUaHjPzlWLuThQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_DKNDgyvb5EuZWE2R7HUeSA_22_6">422</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_lJdbgksAgEOKAdDX_9_lnw_23_3">736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_q1Hw8sn_XkKvItBN6V2K7Q_23_6">3,175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_CBA1W1BLL0GwUTYi-6y_ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_TclyUhmkbEeZyhqEt8xVsg_24_3">346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_7EMAZ25l10i2MUh_SEohkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_8R0yjgi_DUWqVeNEgrmxXg_24_6">404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_UN0aovcI_k2vysuvf8OeGw_25_3">27,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_XTF4oh1MmUmWRNbj4s_9bg_25_6">32,898</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_MVSzAd3gp0yOb2MFz7McUg_26_3">440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_-MnQ0qdqxUmJMGtAhZB-dg_26_6">786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_ugLEkdhASke76Lci9zVkfA_27_3">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="Tc_vHDEcrnxeU2fZDSLPr5lbA_27_6">2,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_ab-XteufdUa8E9pPKNcJHw_28_3">100,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_HGCqGt0sz0GOthtJecydvw_28_6">93,051</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">     Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_MGjf_cIdmU2TtIjT-JBNMw_29_3">130,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_xr0rpPCYzkirEfnV-j5nJg_29_6">129,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_9wbbroIKd0CkXLx0jZmnoQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_FTWH6w-eKkW0iuUTB-4nAQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_YS90i04BYkqGvsAyfROFEg"><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="Narr_TKiWECNySkm9jCZsl5BmmQ">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_3JAuSjMDVkqYEEVZhWEG6w"><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="Narr_AQcR-ScKTEG-XznGjPYJHg">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31,&#160;2023 and December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_XzcQek6kG0WjzoawbI-6aQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3ul1BO7V2EW5KZOaIYDk9A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_iVA5A_CXbEKYkrg-5XpIcQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_C-8GCiBrjUqFKoHpp8NkDQ">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_iritMafr6k64OvPvDDp2pQ"><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="Narr_n8cDIHR9w0Opl8azfGjkqQ">100,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31,&#160;2023 and December&#160;31,&#160;2022; <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Narr_T8U_SKX90EKtdO3SWnd2Og">29,930</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Narr_JU0knSwYAUWohhAs4NDUQg">28,147</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_5tpEl_7wWkyfmmgg0VxDAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_PcWL0v_iXEK7OCLk66t6LA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Xn-0_zITWkuYPYIn0UVNHg_34_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_uGkKO9mS6EqHMyRkMl3cAQ_34_6">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in-capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Fls-goDxLUekNu_gd2_Sig_35_3">534,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_9UipIyQMWEuA57xrBqnTHg_35_6">488,292</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_CQZNugyA1kWIgdGsHAPSig_36_3">590,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_jfWhj9fEsUi80yIOK5oh-g_36_6">411,545</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__dkoaZ3A1U2X8JlSoS_1lw_37_3">56,508</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fT8giltOuUGT-wWF6eqChA_37_6">76,775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total liabilities and stockholders' (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_7cV0BNllpkajEp75s-uzjw_38_3">73,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_E1V_8opXDUKbw-DqNcLgnA_38_6">205,853</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b61364e8_f157_4bcb_8866_38fa0980ab17"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="STATEMENTSOFOPERATIONS_773604"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts)</b></p><a id="_7d904eb2_cd1b_452c_b415_1dc164155aa1"></a><a id="Tc_If5H_hZ9wEqHvXq_DvwBGw_1_2"></a><a id="Tc_AcQxgszRw0eWvqT87XATAw_2_2"></a><a id="Tc_T3dpThUhi0ae6ujEIby8Kg_2_5"></a><a id="Tc_c76LZqfMOUWF9_WLF4bPcw_4_0"></a><a id="Tc_EIP2n-vs20qlHevuiV_l7A_5_0"></a><a id="Tc_cCnWLkU2D0eBeLIaS4XXhg_5_2"></a><a id="Tc_Ehh4l9OkOEWJHm2RX60idA_5_5"></a><a id="Tc_kU_qs5bZsUeMG3cxcu-A6Q_7_0"></a><a id="Tc_7wVhSp6HzUOzLbq5ErUIsQ_8_0"></a><a id="Tc_99gGrKLoOEabSTIjJ4leLQ_8_2"></a><a id="Tc_837LX-QHB06tMHfbHfubDA_8_5"></a><a id="Tc_X3FMVwBhTUqmu26Ws7PuiA_9_0"></a><a id="Tc_1UhDQNxwO0-CUA1ViJaAaw_10_0"></a><a id="Tc_K8QsQje94UOlokUXvrK1OQ_11_0"></a><a id="Tc_IqT9f6qAKUqYL02YU3YJAg_11_6"></a><a id="Tc_YEe2QM-0LUmzqht81U3qWA_12_0"></a><a id="Tc_lqbGMqG1OEKtOOWsemvccA_12_2"></a><a id="Tc_HQexMM_Yr0y844M4qcwfpg_12_5"></a><a id="Tc_I4o4O0AUEEykM1JQfSs2fA_13_0"></a><a id="Tc_23bJraGcb0yLHnTIWkheiQ_13_2"></a><a id="Tc_Q2NBi5dEyU-w5hNV58VT3w_13_5"></a><a id="Tc_ethRMCYytEGNoMHa_64spg_14_0"></a><a id="Tc_l92E4iKDjU218ZjzNjI86w_15_0"></a><a id="Tc_yDZHieufCkuAV1QQFVQG3Q_16_0"></a><a id="Tc_mkR9km4mf0CO9Q1vPUKzCg_17_0"></a><a id="Tc_zlgIyZecX0GxnqYgmmukQA_18_0"></a><a id="Tc_gUrqHz6Jk0u-48VZV8dZQA_18_2"></a><a id="Tc_xxM1n9Ke4E-urFh7Ae3kNQ_18_5"></a><a id="Tc_Y0vkWKZsXkSkXJ_EE2h_dg_19_0"></a><a id="Tc_Gopo0jwF2EG_9oTesRzbPg_19_2"></a><a id="Tc_Bc-Fd1IcPkmHZXJYV0MS7w_19_5"></a><a id="Tc_IlxysQ9jMkSHvhodnHXO6A_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Product revenue, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_KEg05O2E-EW_VmHlGrcPFQ_5_3">1,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__rYiyt-BAUOtUntV31trlg_5_6">375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_6kK3VKWBE0uvzrtoN5Jv-w_8_3">1,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_uYDksjD5pEOTFqCd0eStug_8_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_LNdVDfPITUK1T0kwe_lARA_9_3">84,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_2atI2YnDR0G5wDWwpHTDtg_9_6">91,239</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_R9FCX9vrQU6SP-K-Zu9CCw_10_3">83,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_6CyaYeg4xkmDlE2wp1JGOA_10_6">68,761</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Restructuring costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="Tc_EPYUHURmO0KAkRV8xQ9l7w_11_3">4,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_nUkMDuIApEuUt5jKsYX48Q_12_3">173,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_PbUfZFw8I0iuAY5vW3zwAw_12_6">160,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_IcDP2pFH-kSy18WiDkF3Nw_13_3">171,782</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_VbAgf_1dp02RFA02N_2Jqg_13_6">159,645</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other expense (income)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_-0lqJXKDn0mH5K1WdFem8g_15_3">13,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_dQtVAU06fEq7UZOq-XWEwA_15_6">8,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_3sn8jG-kWEG-2IvOwwzSoA_16_3">5,649</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_Ytt_XHcej0eZvn8oXpcGNA_16_6">2,528</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_R4XuOWfWEkuH89JITIhOJg_17_3">394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_QgOQwsh4DEy1zORXlRiDMA_17_6">427</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ncNFrmsnMUqwC0SN-DMWFw_18_3">179,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uHE_pEjmHkSCdK1H6PZvPg_18_6">165,757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_0KkHPx86O0a2v5bmBcxgJg_19_3">6.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WpN0nRgEEEmPmbuu-YIjPw_19_6">5.92</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_x72pgrQvj0W9umNboJie5w_20_3">29,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_m9JXwXesPE2GcUrF7Zc_Ow_20_6">28,015</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aeaf0602_1666_4dad_bfcb_69cc2d566802"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; (DEFICIT) EQUITY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><a id="_40fa7b67_9cfc_4dcd_9a63_d1374915c3a8"></a><a id="Tc_1Gj8EAozQEyvYe__dEcexg_1_7"></a><a id="Tc_8Xkwf0o7k0ygJXvemVQGtQ_2_2"></a><a id="Tc_g4-uFV5H6UWRJZ9k-iVelA_2_7"></a><a id="Tc_sl6IUtTvgES4aDkx2ZXl4g_2_10"></a><a id="Tc_Xn2hwNCHQE-l7qKmv8fiAQ_3_2"></a><a id="Tc_XRiqmxVW0k25YeWak2DlXA_3_4"></a><a id="Tc_GOjamuLdwEarbWjTc-lZAA_3_7"></a><a id="Tc_fAdFA60UpUCRdDsL_kFQCw_3_10"></a><a id="Tc_buNU4optM0mmVPvw_X0NFw_3_13"></a><a id="Tc_gBqgo-ziqEWC0zed72XUIA_4_0"></a><a id="Tc_sKYixDHUhUm7YFIzm3vXhg_4_4"></a><a id="Tc_ANXFZhoA_kqd2DlAitaSSw_4_7"></a><a id="Tc_2UWb04m7akOleFtTmYpTwg_4_10"></a><a id="Tc_-fDlg-NF10K86Z7PCBjN8w_4_13"></a><a id="Tc_MiSD-kbXFESE1rWyq1GK5g_5_0"></a><a id="Tc_Tll2Pz7jG0iaf2mmfdL-Qw_5_2"></a><a id="Tc_H3Ycla6-skOYG7QD8WJw2g_5_5"></a><a id="Tc_vLVlQuLD7UWA54qqx1OAVA_5_11"></a><a id="Tc_LtJeS6D5iEqaKjOpVdpCug_6_0"></a><a id="Tc_wUj2AIk030-mkYWe31fsHw_6_2"></a><a id="Tc_nXEOAvGSu0qIBDjTpI9i2Q_6_5"></a><a id="Tc_xRVsW_dYCk2QuvF8wbCjDQ_6_11"></a><a id="Tc_Ji-Nf9NoM062D8OsRuewfg_7_0"></a><a id="Tc_odP-lpu-0UWI9kV5rMMeGg_7_5"></a><a id="Tc_J_1un0QKRUq5BwmrstSyuA_7_11"></a><a id="Tc_aBtwfr2LF02oQLsUH0Ckug_8_0"></a><a id="Tc_BOaRGP8Im0Wt3vAUjKqp8A_8_2"></a><a id="Tc_T2_AsxavEUK3dn9t1hDQvQ_8_5"></a><a id="Tc_kiCxvY_x7kaMCy38wE0h7g_8_8"></a><a id="Tc_ardMt_4cKE6Tlgzf8kDfNA_9_0"></a><a id="Tc_gs8XJDbcUEyDdmrDrHV1Ag_9_4"></a><a id="Tc_e9B93BlQV0iy1ZGYBfLrYg_9_7"></a><a id="Tc_rEQMYkmYSkS0is5hax_HpQ_9_10"></a><a id="Tc_DIw6ObQpL0aI_YAnB91_TA_9_13"></a><a id="Tc_Vwoup737oE-bfhc27KWqrA_10_0"></a><a id="Tc_hcEzyaDQdkqq5wLTXsVa5w_10_11"></a><a id="Tc_Ajo5GT9yr0GFsUQEmpmFPA_11_0"></a><a id="Tc_ufZAJyvq80WHtLAVxqcJjQ_11_2"></a><a id="Tc_Qd1kFevxpkWSeOZpRojJUw_11_5"></a><a id="Tc_Nbh3y1kLe0eLsf8LqRpLbg_11_11"></a><a id="Tc_rJW3OI6EhkO_fxJxrkxiRg_12_0"></a><a id="Tc_oxbJ4-wim0CWQt2Hf_9eaQ_12_5"></a><a id="Tc_GmDr_vh1BUOVTZH9BFPgEA_12_11"></a><a id="Tc_jopI3ZAL602jOv302MvcwA_13_0"></a><a id="Tc_XZwfiTELYkyVZB-9ITOXfQ_13_2"></a><a id="Tc_ocu2qKMTkE22BnzrbCWc1g_13_5"></a><a id="Tc_XgVc3MskWkmuVxHagEITpw_13_11"></a><a id="Tc_LmFynxjAqEi0uXgHThkxEg_14_0"></a><a id="Tc_W1T4sVtyR0-LBV4IcMV3Hw_14_2"></a><a id="Tc_PskEhLE6uUGg5Qedb9cl0Q_14_5"></a><a id="Tc_FYMC_2cmWUexY63aE3-rkw_14_11"></a><a id="Tc_6iuWH2hkTkKZGrY8lb35qQ_15_0"></a><a id="Tc_eo_7amCjFUys7hKm3mRJXQ_15_5"></a><a id="Tc_vgmu9piNvE2ikleXsoPhqA_15_11"></a><a id="Tc_bjdSMHR9o0OddnF70kjqwA_16_0"></a><a id="Tc_9IdWwXiLfkW1fokeoKxDrQ_16_2"></a><a id="Tc_OlaCwaGwDEW6SZwnBdXf9Q_16_5"></a><a id="Tc_iPv7cHazyEmBcCpU6Igu2Q_16_8"></a><a id="Tc_OvlfFJQwF0SDsW1Aq3o-VQ_17_0"></a><a id="Tc_qYdgES5IyUW7FM0RQ9avew_17_4"></a><a id="Tc_382pFPfRxUqZzK9mbCdU7Q_17_7"></a><a id="Tc_RZZm79Mg4UW0K6_9l3mnMg_17_10"></a><a id="Tc_rdvodCpkZ0q6Yh5Kunv6Zw_17_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_Rr1KiZZB10G0VGZqnI--tw_4_2">27,980</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tRuZX6gMx0-1NLonU-djOQ_4_5">28</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PRtGyQfymEacLjG_UJArXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Q4aB0H5MpUafRf3qFVn2gA_4_8">467,427</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_spu6vwv6wkeAKS8ZgaBZyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_buc0tJiJpkiL85MQ8VDT7g_4_11">245,788</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CQTBE1Z7m0Ci3wZsN3ibXQ_4_14">221,667</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_U39kaL-MCEawWm0fyoIohA_5_8">3,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_-jO94JcmBUqaZ_fKd7Nacw_5_14">3,245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_89R80t4SEkavA56gt5nCCg_6_8">17,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_clZm2OUdu0SLYghBVaGWNQ_6_14">17,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xHeZV4Ol5U-qHZKumtzK4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_XXNs-VVhcUqJUiBV4d8JOQ_7_2">167</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_IwbtiSEubUq0Wi_gQLOyzg_7_8">283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_3RK091sZ9E--qw2PA-nk6g_7_14">283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_owHhLehS_EmtWcsJidsnPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_e7CkU6UcHE2n6yrrT9w02w_8_11">165,757</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6wD_IVna-Euboph0fagwtA_8_14">165,757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cC-JtWvLskOqp8xXQ1r_1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_P2a29rXiS0iZUzeeGbVLcw_9_2">28,147</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cC-JtWvLskOqp8xXQ1r_1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VlKp70YIZk-EOH8sLaAlSg_9_5">28</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yGTb9URg5keSwgCiIyKD1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VXN7QOeSVE2gFU7q-VXg0g_9_8">488,292</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAiZHn3hQE6KSYUOLwW1Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zyfwKfwOW06zsy9Uax4O6Q_9_11">411,545</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xigK2I-_YUSO1UzwmYgfEg_9_14">76,775</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_Cwr2BVq4GEKFrDfdkeVdMw_10_2">1,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_kdiJvqkeLUWJqcfi9FUmlQ_10_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Nau4QcAQL0y5M1HcYm8CYw_10_8">26,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_k3XxPJNmk0-KCTaRsovLig_10_14">26,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_rFAmHJwXAk2oin-B6Ydynw_11_8">18,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_x6icEqzX6kKZYV3KxkN64A_11_14">18,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_G22iAp9NtEKUYVpPs-dgYA_12_2">310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_yzAE5CZ3GUi0h2u-Q9vpjA_12_8">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_miUft1IZv0adbACxcgJRlA_12_14">508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Repricing of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_oBIwLqshGUOOxxVQwFue0Q_13_8">254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Tc_Nis9jd-orEalM-2fsBsQmQ_13_14">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_onKqFmI6H0yKjaNQpptiKw_14_8">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_PYFABgDBuUKnU1UaYo5VPQ_14_14">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vesting of restricted stock units, net of employee tax obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="3" id="Tc_FxY3F_W7IE6SY8hfblYxcQ_15_2">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_i3r0Uhg0U0mmOZpTkMthzA_15_8">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_9jSczZuYr021VM2slz4q2Q_15_14">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AXJr0CJxhEq-UxVe_rzlPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_aq_pv4kmJEuyujJkjInk_Q_16_11">179,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Y0qojS7eSU2-aqnFoHLpgw_16_14">179,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jfJvbh6zN0ezSU9wjtHC3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="Tc_XkrXVri52kGSMdyu1Z7xaA_17_2">29,930</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jfJvbh6zN0ezSU9wjtHC3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-mCKqzSye0We8DsUsThFXA_17_5">30</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eqYihjzZTUmciy86aDfMcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2bYrAFY53Uqh32qqusleSw_17_8">534,060</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e3G2VXdksEeqw2aI3K5qYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_irWr3LpIY0yzhAS5p33sSQ_17_11">590,598</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_CGzATqg7GkOZyGDz-zXgXA_17_14">56,508</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_20ded290_045e_4058_b979_13cd06f7576b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="STATEMENTSOFCASHFLOWS_770795"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><a id="_df2869d6_2136_4086_83bf_410edcbe9eb5"></a><a id="Tc_r7qKaelacUujavIyNzWAew_1_2"></a><a id="Tc_FCY1XnHInk2BDmnGAo-ppg_2_2"></a><a id="Tc_MQsWF9Gxk0WiukCNdxK1xA_2_5"></a><a id="Tc_fBt1LCEOKUm9j6M6l3SChQ_3_0"></a><a id="Tc_d4FlQOyus0e_k-_wPnw5Nw_4_0"></a><a id="Tc_02TmjqajEkOrsjhXHutoVw_4_2"></a><a id="Tc_tEEXdCugpEymhnkTHD-2Cg_4_5"></a><a id="Tc_Kj6hYNyUIEizXvubwwzuMQ_5_0"></a><a id="Tc_42ubtPZQ3UyOACedBtsL5Q_6_0"></a><a id="Tc_CMSdTCUfIky6IoWhDjGSPQ_7_0"></a><a id="Tc_kPQNPYOFmESgRILsIEqmkg_8_0"></a><a id="Tc_9LKiBuV0-0mSXzkuSviKgg_9_0"></a><a id="Tc_4RDqUXKhYEymQfUjet6SrQ_10_0"></a><a id="Tc_e1UUBW9hi0WmwKgw3bsUxQ_11_0"></a><a id="Tc_iz0tIliYeUq2sBWdBmp27g_12_0"></a><a id="Tc_NwDYOYgp40-5LKfcUQBCGQ_13_0"></a><a id="Tc_qgRXBbyvaE6SsKGDFaF6bg_14_0"></a><a id="Tc_5I7LAvdVj06Fmc5VNKg5Kg_15_0"></a><a id="Tc_BQERgWKOpEGkHVdbl4Bi0A_16_0"></a><a id="Tc_npRVSkMwzUKNweTMoWp9zg_17_0"></a><a id="Tc_kVRYUJgi0U-lrbAQLMrs9A_18_0"></a><a id="Tc_MivoobJCekSbnfpktyPiIA_19_0"></a><a id="Tc_mqKyNOC9_Euy_Z7XR_hvjg_20_0"></a><a id="Tc_RjLBFJdmMU6snS8tTyVCYg_20_2"></a><a id="Tc_9pnk0VrXPEK7Mf9CNgfaAg_20_5"></a><a id="Tc_4R4m2nJnZEKpr6tLBtJRXA_22_0"></a><a id="Tc_B6dDiMYghk2mlGgr7gSAuQ_23_0"></a><a id="Tc_xCHOMzic-0OLh7fAwB-Eog_23_2"></a><a id="Tc_0d6g2eNyl06xYUPRNZ61SQ_23_5"></a><a id="Tc_6dUjG_HGQUOZiqqClDsGkA_24_0"></a><a id="Tc_9HtaPHcG8Ueqc9fXl_H3Hg_24_2"></a><a id="Tc_N64WMv122UassOXZKk1Z2g_24_5"></a><a id="Tc_jSoA6-DJCEGoQis050T-ig_26_0"></a><a id="Tc_4KSD5Kw37UyTH4ncurY0vA_27_0"></a><a id="Tc_73NlMI6UZEeyYt_7jAG5fg_27_2"></a><a id="Tc_NIaUegW4gUyuJdsNPg67jQ_27_3"></a><a id="Tc_u-CJ4fU1lE-CjcE99VIZdA_27_5"></a><a id="Tc_aSHKCyVlEkiAys8X5MZd1A_28_0"></a><a id="Tc_mD9IeGBQv0atpylUoDWjHA_29_0"></a><a id="Tc_L9VfQ4fwOUG1deUB0w43VQ_29_6"></a><a id="Tc_AdRhmls57ECE-Tkv1XyrKw_30_0"></a><a id="Tc_a9OsndRm7kSqi3SidtIVCQ_30_6"></a><a id="Tc_ZpqwC0XuYEC6keZ9zVoBqg_31_0"></a><a id="Tc_v5W6ZGcjTUaw2latPsKg6A_31_6"></a><a id="Tc_kcL9s9Ex70KOK5NYvvri6Q_32_0"></a><a id="Tc_uTQx-w078UmGIizhS8m0hw_33_0"></a><a id="Tc_JS_CTaSPFEm4v-O7ME4lkg_33_2"></a><a id="Tc_pkV_ezBPXkixMwypqeKgbA_33_5"></a><a id="Tc_wW9v37rd5EWZ-rrmWPgJgg_35_0"></a><a id="Tc_yFRBbreLnUOmNettpbV1Ag_35_2"></a><a id="Tc_f2pYKlet70eWknxbS2VsTQ_35_5"></a><a id="Tc_lPJdKSfJwEilfgMG7t5Zaw_36_0"></a><a id="Tc_jTFQWunXuEu-1OYzpq7R8Q_37_0"></a><a id="Tc_uCvKGWyATEKeCiYySZgfkg_37_2"></a><a id="Tc_xlXONe1CO0ql6tK6mHfzWw_37_5"></a><a id="Tc_-533WYtvCEK4yoDFd_k3Zw_39_0"></a><a id="Tc_Y2JoR1WBpU-111vZyB9nEw_40_0"></a><a id="Tc_60gL97w8sEuyDYkrabZyAA_40_2"></a><a id="Tc_XXIFwcT2bkaUlmz6hY6QBQ_40_5"></a><a id="Tc_t_xygWnny0WqkyoCDg2ZTg_41_0"></a><a id="Tc_64zDp7lwgEGTkS2LVJ1-BQ_41_2"></a><a id="Tc_b7vzuNsc9EOyL703c8m8BQ_41_5"></a><a id="Tc_RaLN-SGBSEWweGPSJ0nSjQ_41_6"></a><a id="Tc_vOB8GveFPk6AmiMm50OH8A_42_0"></a><a id="Tc_P560a2u7e0GQiOjrch6HkA_42_2"></a><a id="Tc_F7rf0HTPl0GUKGcuXe4Puw_42_5"></a><a id="Tc_KYvkSEMtX0OP9lxiA7kxkw_43_0"></a><a id="Tc_DQQ9Z9xPz0iyLyjDVMXZ8Q_43_2"></a><a id="Tc_qNSef8zLrkWDCJ815DOtKA_43_5"></a><a id="Tc_8cycACzbV0KwddDaeNdCmQ_43_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OPERATING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_sNgSpYUFRUmZo8BLPJ0BEA_4_3">179,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_SxZxaOMFNkCP6-VEWfrYFA_4_6">165,757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Reconciliation of net loss to net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_KaThfFBI-UWMOmaVqWU7wQ_6_3">318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_zWbNIma2hUuwrWsZ9yRwOg_6_6">327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_t2w6b0YTZEGODpWjpFhyDQ_7_3">1,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_ppJtMtdOPUSHVXiALnukgg_7_6">860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of derivative liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="Tc_JAriI6SaT0q9Yi63ieUFwA_8_3">438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeGainLossOnDerivativeNet" sign="-" scale="3" id="Tc_TGZ3JkMypUK6zx-M-J0tFw_8_6">389</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_q44nHzQE8E2glZdCBCCXWA_9_3">18,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ue91O4fkbUe16u1LA45yrw_9_6">17,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payable-in-kind interest on Credit Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_-E-AVMr54UeS8H8MzsPrhw_10_3">1,872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_2FWIwnJ8PkmH7ZnuiZom7Q_10_6">807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_5rYcvkCcb0qT47sqLS0sdw_11_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_-AvDGR4YG0am4vt-2hEvTg_11_6">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_m7eBQaR3t0q1iFBLox6W7Q_12_3">288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_NHg31Maa-0C1VzHrgdB_ww_12_6">271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">   Accounts receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_1gfot_2Uk0SzG4guPS6jlg_14_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_2Bje9d97zkWnuBKXdh3nyw_14_6">248</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_xiS5n6-b_ESiBpiu5ivBTw_15_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_6DkKJesCnUGQWj1NsRxRdg_15_6">1,985</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses, other current assets and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_8mAz7NAoTUio42OE_LtwDw_16_3">2,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_nwdwoPVlYEa2NwHkbCubhg_16_6">3,905</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable, accrued expenses, due to related parties, and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_h-vxGdFfykO54ydcqOeiEA_17_3">3,219</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_8bJcCzzpKkidj1PWqTgFoA_17_6">13,030</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="Tc_0bdXNvsU_U-uEq7wmSswwA_18_3">2,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="Tc_5JshPmRCSUy0-WxSZwqGLQ_18_6">3,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_H4WMlOe0n06AtL4ljP_wpw_19_3">319</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_gOCEFqDllEy4s2Hq5y_n_A_19_6">293</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_wmdaTns4f0yqaqTG1wzHww_20_3">155,006</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Msj0Gm2od0u6Ch9UkWeHvw_20_6">135,341</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INVESTING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases of equipment and leasehold improvements </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_uaqUaC7SmEGFro-FaZYguw_23_3">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_VkkCI07LkUylK6cat2Hp4w_23_6">139</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_GUpieyjcA0inLnwVY3mVPg_24_3">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_t3GTVA1hhkGjI0K-fI6W7A_24_6">139</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FINANCING CASH FLOW ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Tc_xOa3C17n0Uyg-LBsWjYN1w_27_6">98,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_0JNJwNGpQkOt03yUl-njiA_28_3">180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="Tc_aMSrC3KjpEGAFJWN2TdH2g_28_6">2,646</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Jr5XqDyFv0GZLI8RWkVvLw_29_3">27,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Offering costs for common stock issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_GBZkGfXsikKBKgwJH0IL3Q_30_3">811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Payment of employee tax obligations related to vesting restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_sM-W5eOljE23WC8EwqJ_bA_31_3">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_Ci0USBsH4EqKEbj24mNb3Q_32_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_p2QyrZ2DOkynP1uFz49e4A_32_6">283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_xSj-aHnSFUKOy9NHmM78mw_33_3">26,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Pa17OazklUSeugw7OLW38A_33_6">96,237</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_RqzqjhyaA0q7bVJZ59Ay_g_35_3">128,504</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_hd-sMYFwIUOPD5BiXzCw9Q_35_6">39,243</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of the&#160;period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_haHglmmfn0aVs4_eHp-g6w_36_3">193,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_u61etzBwwkSIr2xmgRobUw_36_6">232,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of the&#160;period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_DjpsF3DgcEi_L4rihfE_XQ_37_3">65,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_qK024r6wxUCs1saxHx4ozw_37_6">193,725</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_5o8oCIalMkW122bXl5Kaag_40_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_MRAQc4kvn0ea9qUUFU1Mrg_40_6">3,245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Repricing of stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_AByLwnyBCkyNwXt9WeJ2fg_41_3">254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_xrmsrv8nx06ZK3zJWi-Vqg_42_3">7,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_eKF4R2Aas0Wa6lYasNhybQ_42_6">2,697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Conversion of accrued interest to long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="btai:ConversionOfAccruedInterestToLongTermDebt" sign="-" scale="3" id="Tc_Er5KVB9jJ0eluRGGZPHHNA_43_3">767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_16b1c5bc_de39_43b7_bdd5_61388f0bd1bf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BIOXCEL THERAPEUTICS, INC.</p><a id="NOTESTOFINANCIALSTATEMENTS_564668"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share amounts and where otherwise noted)</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:NatureOfOperations" id="Tb_b36l4uXTFEaHOHMAL2Aeog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#8217;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#8220;OnkosXcel&#8221; refers to BTI&#8217;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (dexmedetomidine or &#8220;Dex&#8221;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#239;ve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#8217;s principal office is in New Haven, Connecticut.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_lXmPQqYeJU-ascS7WVO3Zw" continuedAt="Tb_lXmPQqYeJU-ascS7WVO3Zw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2. Basis of Presentation</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_e6HnBbkJeEiWQcRBteNOHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#8220;U.S.&#8221;) Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_M5bKhZStek6xy96RRQKtpA">65,221</ix:nonFraction> and an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_yu4KA6OkmEO5vETAAZRJ1w">590,598</ix:nonFraction>. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr__zlU52Ct5UijVgoYQCbAKA">179,053</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Narr_ohMqUMEzr0aMTOCNj0vNJQ">165,757</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively, and had net cash used in operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_ZQt30byNx0mevvuIn9KeGA">155,006</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_KzaY8_oKIE6DTPwzG-Lj1A">135,341</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lXmPQqYeJU-ascS7WVO3Zw_cont1" continuedAt="Tb_lXmPQqYeJU-ascS7WVO3Zw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This going concern evaluation takes into consideration the potential mitigating effect of management&#8217;s Reprioritization (as defined in Note 4, Restructuring). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#8217;s Board of Directors. The Company&#8217;s Reprioritization was approved by the Board of Directors on August 8, 2023; however, such plans will not mitigate the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, Debt and Credit Facilities) or other potential sources of debt or equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through debt financing and/or restructuring of its existing OFA Facilities; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>reduce overhead and headcount to focus on core priorities; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_lXmPQqYeJU-ascS7WVO3Zw_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_Jay4NB1yfEenoTGT-T1KKg" continuedAt="Tb_Jay4NB1yfEenoTGT-T1KKg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:UseOfEstimates" id="Tb_GNrYA0rcHEmRZscaMTotqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_V0_8QrFcrkqX9LhCU9TjVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_VTKYEu1h20a4LnKY_9jz-Q" escape="true"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounts Receivable, Net</b></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Accounts receivable arise from sales of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> and represent amounts due from distributors. Payment terms generally range from </span><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_LbKlmh1ElU2MfLJqOKFfxQ" format="ixt-sec:durday" name="btai:AccountsReceivablePaymentTerm" id="Narr_kqFvR4KcpkC6i5vJCeIXjA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">30</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> to </span><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_KcpdD2ZAMkKgL8-kiMrvzw" format="ixt-sec:durwordsen" name="btai:AccountsReceivablePaymentTerm" id="Narr_1PPQDkeIWEuRfKdj2gllnQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">75 days</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2023, the Company determined that an allowance for credit losses was not required.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_2pV7PjiEgUK48NXPMsbAGw" escape="true"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company sells </span><span style="font-weight:normal;">IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-weight:normal;"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#8220;GPOs&#8221;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:InventoryPolicyTextBlock" id="Tb_J0hn7f3M70GAK_dP9Sf7VA" continuedAt="Tb_J0hn7f3M70GAK_dP9Sf7VA_cont1" escape="true"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BTI capitalizes inventory costs associated with the Company&#8217;s products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0c3ae8bf_0e34_45f9_84ae_7a0727287831"></a><a id="Tc_79WkI4wxIk6LEREdOdcANg_1_0"></a><a id="Tc_nWIp5tKAoEypErBdUfmjgg_1_1"></a><a id="Tc_j0u06936tEizVAjpXDgVzA_2_0"></a><a id="Tc_n-PH6x9yfUWzfRAwr5tE_Q_3_0"></a><a id="Tc_FJPRXAL_a0-b1YWIKBfa5Q_3_1"></a><ix:continuation id="Tb_Jay4NB1yfEenoTGT-T1KKg_cont1" continuedAt="Tb_Jay4NB1yfEenoTGT-T1KKg_cont2"><ix:continuation id="Tb_J0hn7f3M70GAK_dP9Sf7VA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="btai:DeferredOfferingCostsPolicyTextBlock" id="Tb_ru65vK1H0kCVJD1VCxYI9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Deferred Initial Public Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Deferred initial public offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="3" id="Narr_MsbwejWR_EKu1adaMWD1rg">2,570</ix:nonFraction>, consisted of legal, accounting, and other costs that were directly related to the Company&#8217;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_ht0Oq7QrjUmx8B6IB6j9uw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="Tb_LxlWHhHzskeJoZQvrYJkZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DPrRJZyMuUC3HpIpzHgSwA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_c8TMIEzUSkeg19Gvwq-OGA">3</ix:nonNumeric>-<ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_qZV9TJRkVkSO1q1Z2RQAKQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_b2AY4BY9rUSNHrYuhjoM1Q">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lfv86wIfO0uGyrJUEO6W4g" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_YLyFczBaYUywqG1xKcxw2Q_2_1">7 years</ix:nonNumeric></p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Selling, general and administrative expenses in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_h0r6LEToy0CZmXBYUR8xtw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ROU assets represent BTI&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#8217;s leases do not provide an implicit rate, it used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and excludes lease incentives. The Company&#8217;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:DebtPolicyTextBlock" id="Tb_d57HbJUd8kWt1XZPq36Vgg" continuedAt="Tb_d57HbJUd8kWt1XZPq36Vgg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Debt and Detachable Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#8220;<i style="font-style:italic;">Derivative Assets and Liabilities</i>&#8221; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jay4NB1yfEenoTGT-T1KKg_cont2" continuedAt="Tb_Jay4NB1yfEenoTGT-T1KKg_cont3"><ix:continuation id="Tb_d57HbJUd8kWt1XZPq36Vgg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions of the debt.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_QrH1IYMAg0SwjqBjVuD6QA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Derivative Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" id="Tb_8aljX-WYMkuBcq_XgKXh7g" continuedAt="Tb_8aljX-WYMkuBcq_XgKXh7g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#8217;s behalf. The Company believes the hospitals are its customers.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jay4NB1yfEenoTGT-T1KKg_cont3" continuedAt="Tb_Jay4NB1yfEenoTGT-T1KKg_cont4"><ix:continuation id="Tb_8aljX-WYMkuBcq_XgKXh7g_cont1" continuedAt="Tb_8aljX-WYMkuBcq_XgKXh7g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is to deliver the quantity of product ordered to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#8217;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#8217;s Consolidated Statements of Operations.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jay4NB1yfEenoTGT-T1KKg_cont4" continuedAt="Tb_Jay4NB1yfEenoTGT-T1KKg_cont5"><ix:continuation id="Tb_8aljX-WYMkuBcq_XgKXh7g_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:CostOfSalesPolicyTextBlock" id="Tb_Ef4cBfL1zEmdy3hnC0KycA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cost of Goods Sold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_rhFoKI21QU2jFAPot9xN3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#8220;BTI RSUs&#8221;), OnkosXcel profit sharing units (&#8220;PSUs&#8221;), OnkosXcel restricted stock units (&#8220;OnkosXcel RSUs&#8221;) and BTI performance stock units (&#8220;Performance Units&#8221;). The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) became effective in August 2017. The Company&#8217;s 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#8217;s closing stock price on the grant date. The estimated fair value of stock-options, OnkosXcel RSUs and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Black-Scholes pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards, and expected term of the award. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_YT5EIL9cV0i9ZfyaBOMiFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#8217;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Most of the Company&#8217;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#8217;s estimates with the service providers and makes adjustments if necessary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although management does not expect its estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="btai:PatentCostsPolicyTextBlock" id="Tb_BFpZ3vXp7EK6EHcpUIMjdQ" continuedAt="Tb_BFpZ3vXp7EK6EHcpUIMjdQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jay4NB1yfEenoTGT-T1KKg_cont5" continuedAt="Tb_Jay4NB1yfEenoTGT-T1KKg_cont6"><ix:continuation id="Tb_BFpZ3vXp7EK6EHcpUIMjdQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_TQQ3wVnFUUqk_zagWNHR7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_MlgLYJPiRkS6PoEnlvM8HA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#8220;more likely than not&#8221; that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#8217;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#8217; full knowledge of the position and all relevant facts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not have any unrecognized tax benefits as of December 31, 2023 and 2022. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_LBnX0ugemkeUxEjJhJ1gYQ" continuedAt="Tb_LBnX0ugemkeUxEjJhJ1gYQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Earnings (Loss) per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Earnings (loss) per share (&#8220;EPS&#8221;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jay4NB1yfEenoTGT-T1KKg_cont6"><ix:continuation id="Tb_LBnX0ugemkeUxEjJhJ1gYQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_5rWg85NMkEmFbHYXUTfIVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#8217;s chief operating decision maker has made such decisions and assessed performance at the Company level as <ix:nonFraction unitRef="Unit_Standard_segment_laXuDs1PtUqwsUSCfciCQA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_hJYHgsA0v0CTAt5haaOnxg">one</ix:nonFraction> segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_ERl-_RilREe9rv9asTG2bQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance (collectively, &#8220;Topic 326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) - Effective Dates, which deferred the effective dates of Topic 326 for the Company, until fiscal year 2023. The Company adopted Topic 326 in 2023 and it did not have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_G1gw2rqa9EKtbCecS9hvpQ" continuedAt="Tb_G1gw2rqa9EKtbCecS9hvpQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4. Restructuring</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">On August 8, 2023, the Company&#8217;s Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). The Company took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend its cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for </span>IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="background:#ffffff;"> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;background:#ffffff;">As part of this strategy, the Company&#8217;s Board of Directors approved a reduction of approximately </span><span style="font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_8_8_2023_To_8_8_2023_3YScg74_R0ConxpN-Oxzqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_AOKpDy8BY0OJtwAThtnxGA">60</ix:nonFraction>%</span><span style="font-weight:normal;background:#ffffff;"> of the Company&#8217;s workforce. The Company notified impacted employees on August 14, 2023 and recorded total restructuring costs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_mLAZyGcQJEqoMEFLFyn8yw">4,163</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> for the year ended December 31, 2023. These costs consisted of severance and benefit costs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GDQlj4QAs0O-w3hPNOGBnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_bCJRB0ZXSEOdzjagGDUOxg">4,063</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> and contract termination costs of </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_j_3iRADS3U-7NdeM4T4eaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="Narr_0-PWvBqhDkO5thZPToJN_Q">100</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;">. The Company paid $</span><span style="font-weight:normal;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GDQlj4QAs0O-w3hPNOGBnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRestructuring" scale="3" id="Narr_ZcFhwtKZLky7n1Oa82tsIw">3,998</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> of severance and benefit costs and </span><span style="font-weight:normal;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_j_3iRADS3U-7NdeM4T4eaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRestructuring" scale="3" id="Narr_JLpB1YZXYkCCFsjpRBMpIQ">100</ix:nonFraction></span><span style="font-weight:normal;background:#ffffff;"> of contract termination costs in the year ended December 31, 2023. The Reprioritization is substantially complete as of December 31, 2023, and any remaining costs are expected to be paid during the first quarter of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_G1gw2rqa9EKtbCecS9hvpQ_cont1"></ix:continuation><a id="_43adc588_173f_4edc_96cf_54fa1edbae91"></a><a id="Tc_Vo2XHbl7xE6M_WfO3xRMYA_1_2"></a><a id="Tc_zNFFOMhhFEmKlk1_9Is0CQ_1_5"></a><a id="Tc_483g5a0NpkenaMrGZOylvQ_2_2"></a><a id="Tc_kxkdIPtfXUSYJAiog5_O5w_2_5"></a><a id="Tc_N91AERmpE0CPxyCK6Sln3A_4_0"></a><a id="Tc_Y7kST0knnESXnUS3mn03bg_4_2"></a><a id="Tc_twm_ZEMQ7ESJHF7h-S6Xtg_4_5"></a><a id="Tc_J7H0fFu30UGVHPSgYCP1UA_5_0"></a><a id="Tc_kO1jaggE40WIoMengbu_9w_6_0"></a><a id="Tc_fMXDHMiQ3kmRMMCsSdAWFA_7_0"></a><a id="Tc_IHeVQXagfk6qfQIRkxUEcQ_7_2"></a><a id="Tc_kN5zAhhO-EaHkJR8RXh_7g_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_9aimq17fbkqIyBG0qsWnCQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inventory consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_dsBmmFXh2EmQHr3fkOocVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_yKEpIg2pyU2sWRxbJA378Q_4_3">935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_WB6urcufvUq2q9Xjmdamig_4_6">682</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_xAfWKUk6skWIeyckzLBuSQ_5_3">651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_dOG_b6VdrkeLwNUoRyBpJA_5_6">708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_NUNOf6OFOkakYc5WCHL7YQ_6_3">405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_aWtVXo7P5UqwyxfiEQcvHQ_6_6">595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_BIAXUTf9OEuiWXbD6UiJbA_7_3">1,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ADkkPV-NDUWb1DrKDgDykg_7_6">1,985</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">The Company recorded inventory write-downs of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="3" id="Narr_MmDEbZ3AfEmlflbezAqMAg">1,191</ix:nonFraction></span><span style="font-weight:normal;"> for the year ended December 31, 2023. </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:InventoryValuationReserves" scale="3" id="Narr_gKIcbdSfU0eUKBFpzv0USQ">No</ix:nonFraction></span><span style="font-weight:normal;"> write-downs of inventory were recorded for the year ended December 31, 2022</span>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_RJZX_T5OXEGTMqkfUw-WsQ_1_2"></a><a id="Tc_B0L5x-lfF0-VoEka6a2gCA_1_5"></a><a id="Tc_2P0IvUiPFkSov5RfGWjwbA_2_2"></a><a id="Tc_MDmal67Q2kOStDDJLg9pZw_2_5"></a><a id="Tc_uTCWSqV3NkGIqM4QvyameQ_4_0"></a><a id="Tc_pM6DPwzWBE2IddcCN5yjpg_4_2"></a><a id="Tc_1rFF2s1A0Eyf5YhC-HKoFg_4_5"></a><a id="Tc_ZMrPqwYxUkOqRIAMazqk1w_5_0"></a><a id="Tc_taOyLSAFXU-bCmFw_2IWGQ_6_0"></a><a id="Tc_mrhcKvGYaU2E8urhs5Qo8A_7_0"></a><a id="Tc_1o7JUBc7ckW8h_GCIXCysQ_7_2"></a><a id="Tc_8-b-BYiabkO6BjrkkTA_kg_7_5"></a><a id="Tc_RNSbVLPvKEWK7zn-yLmO1A_8_0"></a><a id="Tc_2XFMFGdPB02UH8-cBO9SDw_9_0"></a><a id="Tc_FiOjzQkudUOhv6DnwC8jaA_9_2"></a><a id="Tc_Je0PHhTs-kO5JQzsjbYKYQ_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_T_eXlG2qgEWvHlDdmCEvVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment, net consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_mIcf7XVPbU6sfkBkpIteVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Q0FkyLMLpE6C08_6RQv7GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_pg8EVHNOgECFdEnWFBbLbg_4_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ALKhxrCkjkOwdbr4SCwncA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DPbirmTZoE2hj6KIW-K3-A_4_6">213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lfv86wIfO0uGyrJUEO6W4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-SYQ3VWUcUeP1m7x0ND9Gw_5_3">575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_hB0HP0jhXkSZURCC-uucwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_jr5oycoZdkWwyeQCdp71BA_5_6">575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_dxjhG7eFUUSaXMpZC0s-aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nxKyt8SvQ0ehngOSOb7NGQ_6_3">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-GBUxd3EAE6_mzgWpsJOzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8xEyuQhfm0uS-TSy7Mgnfw_6_6">1,181</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_3ZQ2j2j4CkyIc5HAkF2u9A_7_3">1,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6qju0MkLdUuylKkIaBbFGQ_7_6">1,969</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_M7cFQA3i7EOdluNnBCczlQ_8_3">1,193</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc__t719AI0dEWbbVrD2_B4fw_8_6">885</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_dbF6p_vM4U-9RB6ny-5Cmw_9_3">784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_02Ov6ERGw0e5x_On3QcaSA_9_6">1,084</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">Depreciation expense was </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_-EC1dJ3DJ0COJDNSIcJYCA">318</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_Fxg3lLieK0WHpzzU43Y2fQ">327</ix:nonFraction></span><span style="font-weight:normal;"> for the years ended December 31, 2023 and 2022, respectively</span>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_bqDEAxLByUmtaDUNOCVGzQ_1_2"></a><a id="Tc_UMIIaObQR0qr70OIHXNusg_1_5"></a><a id="Tc_VqxAjz3YQkmnP9UImNNGPw_2_2"></a><a id="Tc_M1gor8u8NkCaDi2IfY3ndA_2_5"></a><a id="Tc_0cQ2sq_rykKXZJzLz8wygg_4_0"></a><a id="Tc_SZksjUTEK0-Ws3Sv0BC_pA_4_2"></a><a id="Tc_iY5yARsmTkGqbjxRQNNn1Q_4_5"></a><a id="Tc_o8KIHh3NJUippxYYBh4Cxg_5_0"></a><a id="Tc_hkSxOqn8Y0y797t9XVBEIw_6_0"></a><a id="Tc_6h_qLAPJfUy0V14nVyWw3g_7_0"></a><a id="Tc_6v8kojjo_EOawfucJST3Qw_8_0"></a><a id="Tc_M2JpccLe20i84z881gdG3w_9_0"></a><a id="Tc_qJY4HcCfhEq4i5nFIJ4q5w_9_2"></a><a id="Tc_JFGVS2_p20e27Ny3kPEsyA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_ht_J-hw7aEmXFOi4-SRanw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_RStWZ-_b40y4I63DXdNW1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="btai:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_Zy_ny3IZLUmRgEWcrgIjEQ_4_3">6,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="btai:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_gvry4W7upUebtE2JOa9w1w_4_6">8,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_9dfgx6hcqUe77-RFFcI3Uw_5_3">163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_JhsXTZPkDEi3hDd_rBlYQw_5_6">6,370</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_KdwtDKtKBE-QWHEychFFSw_6_3">5,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_tCs9SbmJpUi7j2IH4rOkfg_6_6">2,738</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_T1R2wB0M6kGusdT7PtCfWw_7_3">116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_BdKZLeGjxE209aFH9fjuWw_7_6">82</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_scf5LvU2KE2285vZcC0jQQ_8_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Ec6h63fjpkyW5baBvj2Zew_8_6">820</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_wyiSGyk0F0i6UHavyVBe5w_9_3">12,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_D-MvTW0Znky9nlOfOoQtHg_9_6">18,669</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_rGcFaxfBRUKRNLv7VO7KVw" continuedAt="Tb_rGcFaxfBRUKRNLv7VO7KVw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8. Transactions with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which BioXcel LLC has agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the Services Agreement, we have an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. We agreed to pay BioXcel LLC $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3yVQCurUjku_rn_lePc8vw" decimals="-3" format="ixt:numdotdecimal" name="btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" scale="3" id="Narr_3X5z5CvkRkmyLGTKKPPqew">18</ix:nonFraction> per month from March 13, 2023, to December 31, 2024 in exchange for this option. We agreed to negotiate any such collaborative services agreement in </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_--un8hs_RUO-u_dIw2tIdA_1_2"></a><a id="Tc_6P4Y8qmYf0Ope0KhJ-CkLw_2_2"></a><a id="Tc_9jmHCePrRkqqGBgLLD-oLg_2_5"></a><a id="Tc_AJ8NUbNIskO8-syBknvG5Q_4_0"></a><a id="Tc_uIhnJ18t6UCAdcNgogMaZQ_4_2"></a><a id="Tc_xkEtTQ5a2U6_nau1UpvqnA_4_5"></a><a id="Tc_GxqGUzsBqkOoe7RPj5eBVw_5_0"></a><a id="Tc_IAFRBDlCp0q-45jejCBOqQ_6_0"></a><a id="Tc_GpKOrn_yBEupsnEBsHa7sw_6_2"></a><a id="Tc_fIgP1cLG5ECPEJ4OR0GLPQ_6_5"></a><ix:continuation id="Tb_rGcFaxfBRUKRNLv7VO7KVw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_mAbI1B8ghUiyZZyzM0aMpA" decimals="-3" format="ixt:numdotdecimal" name="btai:CollaborativeArrangementMilestonePaymentsPotential" scale="3" id="Narr_Pts-AyVcwEyRqE-PBnmmXw">10,000</ix:nonFraction> in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember__S0J6TAmqEaBUKJsiY7Iag" decimals="0" format="ixt:numdotdecimal" name="btai:CollaborativeArrangementMilestonePotentialPercent" scale="0" id="Narr_vA74-qr_vkyS9xVmXP8JTA">3</ix:nonFraction>% of the applicable net sales level, and not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember__S0J6TAmqEaBUKJsiY7Iag" decimals="-3" format="ixt:numdotdecimal" name="btai:CollaborativeArrangementMilestonePaymentsPotential" scale="3" id="Narr_-UGCosIHiku3lOZBH6lIXw">30,000</ix:nonFraction> in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement for the years December 31, 2023 and 2022 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_7EzeZIFam0yP_o2CZPEVHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_idIS74rsW0iLgmnVSYQ-hA_4_3">1,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_T9op7jta4EOUSOjB6QCl_A_4_6">1,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_RZvch9VBG06h-4ALt2yWkg_5_3">211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_O5eZu35xQ0OY8I4tHIVjVQ_5_6">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_oacgvWYcfEO2DCYHG-liXw_6_3">1,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_X8ogqfKUa0ioIYYlaReeIQ_6_6">1,401</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023 and 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aNHYV9yCoUm00_-U0XfV2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Narr_lYYt4QUhMkafIxumF8eb4Q">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vn8IA3nckU24niIfjblXlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Narr_Gfl_ayPde0eOF3XOFA1g4A">310</ix:nonFraction>, respectively, of these service charges are included in Due to related parties in the Company&#8217;s Consolidated Balance Sheets.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_5539d5f6_fa3b_4ed0_a750_b08d5e0ea52e"></a><a id="Tc_NpEQQicSYU2yl0TZOBX4NQ_1_2"></a><a id="Tc_UOVVy9BYV0uJcxYkxU7MOA_1_5"></a><a id="Tc_k5DB6HWZ3EWrcSp3ylBXRA_3_0"></a><a id="Tc_J7kF0DmPXUuVLpf9zg7yhA_3_2"></a><a id="Tc_zBX1AZDBl02MtNSuIsFJMg_3_3"></a><a id="Tc_Fq4UXZbiHkCiHtCd3rH2Vg_3_5"></a><a id="Tc_bvlG_lc1RkaeNia5XqQkHw_4_0"></a><a id="Tc_b9zlmIEJBkSwy6iawbMF3Q_4_3"></a><a id="Tc_OeNBQQzg2UiGPtNsZjy8Rg_5_0"></a><a id="Tc_Xqn4quYTAUqF_zj1lMACag_5_3"></a><a id="Tc_Odyv90ERrUiwtw8hqhaHwA_6_0"></a><a id="Tc_JEauf08fy0m3yt0Ra5WgBw_6_2"></a><a id="Tc_7PBerwYkXkGvfbp10Jhz2Q_6_3"></a><a id="Tc_wWSmXHHelk-PBkoBr2v-Ug_6_5"></a><a id="Tc_AaxGK67MkUmlHDAh0EeQ6A_7_0"></a><a id="Tc_1wN3mVFmRkuCcIEF9_Qf5g_7_3"></a><a id="Tc_gLiNMrRG_EOdiSC8HbBK0g_8_0"></a><a id="Tc_t8fjrORYLUa7ZUWtv8Aikg_8_2"></a><a id="Tc_Gt6SfyJm6E-11tcysYZS_w_8_3"></a><a id="Tc_1NBbq7y1506WKfkMtwRROg_8_5"></a><a id="Tc_OPa1n7rIx0ugs5DEXuEAag_9_0"></a><a id="Tc_G0nIU9zfGkObUMbVYTFkBg_10_0"></a><a id="Tc_FGQdb-yoQ0a-tGpwFb5ISA_11_0"></a><a id="Tc_gXVIIpeZNE2UHnT4GG5ypQ_11_2"></a><a id="Tc_U0tLBC2HK0u_Zo3R2U_aUQ_11_5"></a><a id="Tc_rWrdO_QaHUKiTYVbpa7aHw_12_0"></a><a id="Tc_gYPer0C_HECdV-XrmDQU_Q_13_0"></a><a id="Tc_Gg7tLA1f2U2pyxJCzxMZ-g_13_2"></a><a id="Tc_YGrPJjyTXEyUMa4SyKCcKA_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:DebtDisclosureTextBlock" id="Tb_l6zc4q-qiUKtzbi-UdQFNA" continuedAt="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9. Debt and Credit Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Debt, net of unamortized discounts and financing costs, consists of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_grVppPvl60u0uKzkDeXTkA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Interest Financing Agreement ("RIFA")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Tc_sXbmQk2qF02AdMbUe67xqw_3_6">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIFA accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_PfOMnn2r6Em4dZ9LbC_GWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" id="Tc_AJbDUkXNv0uXFx5EzBaO-Q_4_6">2,041</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIFA payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_PfOMnn2r6Em4dZ9LbC_GWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_8Fo-ewt4eESfMLNfSyceOg_5_6">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     RIFA debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_sLmPPKU0RUqB-EZ84dL-jQ_6_6">32,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated Portion of RIFA debt liability to be paid within one-year </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="3" id="Tc_C2BE3XBvvUW06t-gVpS8Yw_7_6">1,401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     RIFA long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q" decimals="-3" format="ixt:numdotdecimal" name="btai:LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" scale="3" id="Tc_jvCMCoQV5U-F1TJ_j2p4IA_8_6">30,630</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_68Fuy5qz-Ee8C82obZkBOA_9_3">102,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_v1M2BA7xuUyhRRqLClhhMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_dWlLE0v_jEGWl_T5e6FqhQ_9_6">70,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_W29nsD5d7kyN70aN7TzDxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_zf2HCUQ6hUSk2tAJjLXvLQ_10_3">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1XLHPADP90S8ZwGclsNpbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaidInKindInterest" scale="3" id="Tc_FrRgUqoOL0eHIxKCOZkHRQ_10_6">807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_AoERJqcMpkO4k_Ya4o6bEA_11_3">102,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_Am589OBhj02aqp51oP9FCQ_11_6">101,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_XLB8E3fj_0KZhkGf-IPaCw_12_3">2,082</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_Qh-KJRzscUqNbRZ0RQnuVw_12_6">8,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_BcT1-68uGEih3vHeBz7AXw_13_3">100,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_t6XSANplB02uF_5Os6J8gg_13_6">93,051</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#8220;RIFA&#8221;; and together with the Credit Agreement, the &#8220;OFA Facilities&#8221;) by and among the Company, the purchasers party thereto (the &#8220;Purchasers&#8221;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_vfYLl0s_aUWnm54pgYQgKg">260,000</ix:nonFraction> in gross funding to support the Company&#8217;s commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#8217;s disease, and for general corporate purposes. The Lenders and Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and First Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont1" continuedAt="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fDwcE2NcAkalD934EMLcKg" decimals="-3" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_OV_RXp2ku0uR2AepwzpyqQ">30,000</ix:nonFraction> at any time outstanding in OnkosXcel, increased from $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ORjQlGmsX0GTKU-h12WP4g" decimals="-3" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_poE5-9WMiUq9l91IfqPjTw">25,000</ix:nonFraction> at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#8217;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fDwcE2NcAkalD934EMLcKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="Narr_AOt-gnuUFUS-_ikaKTK7OA">180</ix:nonFraction> (representing <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_NXCCj7glw0uPyaR6Y2-w9w" decimals="4" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityAmendmentFeePercentage" scale="-2" id="Narr_I3l_VuTETU2itLAeYgytog">0.25</ix:nonFraction>% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_NXCCj7glw0uPyaR6Y2-w9w" decimals="4" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityExitFeePercentage" scale="-2" id="Narr_gZAGRMvsNUWlQ1y5KP0ggQ">0.25</ix:nonFraction>% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, (the &#8220;Second Amendment Effective Date&#8221;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1kRdDymbCUqa9XieGI09Zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_NvtkvD7jEUe-Lv526_XjyA">202,319</ix:nonFraction> in senior secured term loans, including the initial Tranche A of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_N1udVxFwqUa9M9O90JMIFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_F_a_cnu3Ek2O1E2shnNSew">70,000</ix:nonFraction>, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_lqY8_zjpaE6CKAXuo279Ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_WjPmiPkQikCZcj37ztBU0Q">72,319</ix:nonFraction>. In addition, the $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_73tBnm99SkWJuAHEaVzHcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_PYMwCB5Ts0KQeeBnY3CogA">30,000</ix:nonFraction> in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1kRdDymbCUqa9XieGI09Zg" decimals="-3" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_Cod_Q230gEGNr6Cryn3s2Q">30,865</ix:nonFraction> at any time outstanding in OnkosXcel, increased from $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_4_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qN1X0eAfCkKStJDFYn04Lg" decimals="-3" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityInvestmentAllowed" scale="3" id="Narr_KhPepcFZdU-GSF0RblZqiw">30,000</ix:nonFraction>. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_Ku-HMoUhaECwUSnCUZw31A" decimals="4" format="ixt:numdotdecimal" name="btai:LineOfCreditFacilityExitFeePercentage" scale="-2" id="Narr_1u9P2vaBYEuT6Recpq6EdA">0.25</ix:nonFraction>% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the First Amendment). As of December 31, 2023, $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="3" id="Narr_vl3yE3YG3US0pRmigjJLnQ">100,000</ix:nonFraction> in commitments under the Credit Agreement remains unfunded, and Oaktree has an Equity Investment Right (as defined below) to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg" decimals="-3" format="ixt:numdotdecimal" name="btai:EquityInvestmentRightAmountUnfunded" scale="3" id="Narr_5fArKjUXZEi38YBOAjMKsg">5,000</ix:nonFraction> of Common Stock from the Company. The blended effective interest rate on the Tranches A-1 and A-2 as of December 31, 2023 was approximately <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_yR8vJ6DdUk-wCmSUqP9RmA">13.5</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 0.1pt -0.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The remaining tranches may be borrowed at the Company&#8217;s option prior to December 31, 2024, subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_huSrkOX7SUmY8-_tuWQFpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_BlKRzxf6Ok2APyS1NapN_Q">20,000</ix:nonFraction> and is available upon satisfaction of certain conditions and financial milestones. Tranche C of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V-ADkks9QE-9-kuUtA7EMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_uJKEG_V200K2jG27Z0zPeA">30,000</ix:nonFraction> and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FwZJLNhx_0moyuSOcfdYXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_UJL4NWosBES-760Ux0SACg">50,000</ix:nonFraction> and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_anIgAQjD802S5HzYHrjq2A" decimals="4" format="ixt:numdotdecimal" name="btai:DebtInstrumentInterestRateDiscountRatePercentage" scale="-4" id="Narr_xUkvY3J0zEuPJMk2gh83iw">200</ix:nonFraction>-basis point original issue discount and bear interest at a variable annual rate of TERM SOFR (but not less than <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_h7P1Xd1OZUajABk9uxWk4w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_3F-uV4rOSEO4l3zNEWeuVw">2.5</ix:nonFraction>% or more than <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_gIbrrmF-LU2BVh3G5muq_w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_G0fnUYl7pEGd_rJth5XxnA">5.5</ix:nonFraction>%) plus <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_wzQDKTToGUu0fupDsFLSUw" decimals="3" format="ixt:numdotdecimal" name="btai:DebtInstrumentIncrementalOnVariableRatePercent" scale="-2" id="Narr_U-_0oilp1UmlZDsGlpONTQ">7.5</ix:nonFraction>%, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cSh0m3wu4kefKlStrPWJ1w" decimals="2" format="ixt:numdotdecimal" name="btai:PaidInKindInterestPercentage" scale="-2" id="Narr_L7JGEcNHxUKexFt6FwFMBg">8</ix:nonFraction>% per annum is, at the Company&#8217;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through<span style="font-size:12pt;"> </span>March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_anIgAQjD802S5HzYHrjq2A" decimals="4" format="ixt:numdotdecimal" name="btai:TickingFeesPercentage" scale="-2" id="Narr_wb6DOkSr00WV0af61LBb3w">0.75</ix:nonFraction>% per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s obligations under the Credit Agreement are guaranteed by BTI&#8217;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#8217;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont2" continuedAt="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">a pledge of all of the equity interests of all of the Company&#8217;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#8217; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A" decimals="-3" format="ixt:numdotdecimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_7G8MxNHU7kCrfymguUmaQA">15,000</ix:nonFraction>, (b) from and after the funding of the Tranche B loans, $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_V8-C-RxYK0aXAjUC8xvmzw" decimals="-3" format="ixt:numdotdecimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_0XbnkPJCfkydIejzA1dKFQ">20,000</ix:nonFraction>, and (c) from and after the Company&#8217;s satisfaction of the funding conditions for the Tranche C loans, $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_UZzwa5c1w0eu9CL07OEeQA" decimals="-3" format="ixt:numdotdecimal" name="btai:NetCashRequiredMinimum" scale="3" id="Narr_XtSZ4FyyOE6RwFCPvUWE4Q">15,000</ix:nonFraction>, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A" decimals="-3" format="ixt:numdotdecimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_xdpqseZIqUaTV2qK7aW8DQ">37,500</ix:nonFraction>), provided that the minimum liquidity amount will in no event exceed <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_qDjBignJyUitVErr7JersQ" decimals="2" format="ixt:numdotdecimal" name="btai:PercentageOfOutstandingLoan" scale="-2" id="Narr_OhLMkr69qUqkLutMfP9crg">50</ix:nonFraction>% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#8217;s fiscal quarter ending on December 31, 2024 (such six-month period the &#8220;Revenue Covenant Measurement Period&#8221;), that requires it and its subsidiaries&#8217; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#8220;Revenue Covenant Measurement Testing Date&#8221; and the covenant described in this clause (ii) the &#8220;Revenue Covenant&#8221;). The Company&#8217;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#8217;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such minimum required revenue amount and the Company&#8217;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#8220;Employee Holdings&#8221;), a subsidiary of BTI, and their respective subsidiaries, the &#8220;BXCL701 Subsidiaries&#8221;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#8217;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#8217;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events (&#8220;Permitted BXCL701 Release Events&#8221;), including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A" decimals="2" format="ixt:numdotdecimal" name="btai:SubsidiaryOwnershipPercentage" scale="-2" id="Narr_sSQGFILJhUq0OPoKv23IcA">20</ix:nonFraction>% of the equity interests in the BXCL701 Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#8217;s secured creditors.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont3" continuedAt="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Revenue Interest Financing Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As noted, the RIFA was terminated when the Company entered into the Second Amendment, which amended the Credit Agreement (as amended by the First Amendment). The $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_7_8_2022_To_7_8_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_V64yF2oxIU6GdMLQcz2BkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="3" id="Narr_dOPWwxTRekKlOJg3boEm5A">30,000</ix:nonFraction> Tranche A previously provided to the Company under the RIFA was converted to the Tranche A-2 Term Loan. Prior to termination, the RIFA provided up to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_RWFw3r1oWUC3XL39vHaqqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="Narr_ay4SO4_18kKHXqHOOag8sA">120,000</ix:nonFraction> in potential financing in exchange for a capped revenue interest on net sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and other future BXCL501 products, if any, that received regulatory approval for sale. The initial Tranche A of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_wzC_0CZ3tUyxRyd-2zvgHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="Narr_M7W0GqQrWUKTcaAy19Ucmw">30,000</ix:nonFraction> was funded on July 8, 2022. The effective interest rate on the RIFA as of December 31, 2022, was approximately <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_ZZFS75tw0Ei4s785m1rH-w">14</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the RIFA, the Purchasers were to receive tiered revenue interest payments on U.S. net sales of IGALMI&#8482;, and other future BXCL501 products, if any, that receive regulatory approval for sale, equal to a royalty ranging from <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_dIkd-uFGvk-VmaG81kxPvQ" decimals="5" format="ixt:numdotdecimal" name="btai:BorrowingsBasedOnNetSalesPercent" scale="-2" id="Narr_NgD34CTYaU-8cDhMn7V8WA">0.375</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_oxNFZAw51EWZ3rfLAxMbLg" decimals="5" format="ixt:numdotdecimal" name="btai:BorrowingsBasedOnNetSalesPercent" scale="-2" id="Narr_hcGF5dHneEOkYc5y7YmDlg">7.750</ix:nonFraction>% of net sales of IGALMI&#8482;, and other future BXCL501 products, if any, approved for sale in the U.S., subject to a hard cap equal to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_bpv_lNdtNUaJOmv6QXYrHA" decimals="2" format="ixt:numdotdecimal" name="btai:ThresholdRatioOfDebtToRevenueRatio" scale="0" id="Narr_pvgGtc9owEudmTbqR8iu_A">1.75</ix:nonFraction>x the total amount funded. The Company would also have been required to make certain additional payments to the Purchasers from time to time to ensure that the aggregate amount of payments received by the Purchasers under the RIFA were at least equal to certain agreed upon minimum levels as of certain specified dates, subject to terms and conditions set forth in the RIFA. Revenue interest payments due under the RIFA were payable quarterly based on net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants and Equity Investment Right</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_Pu0kdhhF7UKG-_yJkqwL_g">278</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Tw5vLrfd2U6WGfe6OC_03A">20.04</ix:nonFraction> per share (the &#8220;Original Warrants&#8221;). Pursuant to the amendment and restatement of the Original Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Original Warrants&#8221;), the exercise price of the Original Warrants has been reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_-bm2mPRg-EeiZn13fUr0jQ">3.6452</ix:nonFraction> per share. In addition, the Company granted new warrants to the Lenders to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_LxCPLzm9okOLdFn3Z8l8lw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_bCWOdbYeJESfgkoRKumgYQ">70</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_LxCPLzm9okOLdFn3Z8l8lw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_bhMA1my51kSgs9bZTj_3Fg">3.6452</ix:nonFraction> per share (the &#8220;2023 Warrants&#8221;<span style="font-size:12pt;"> </span>and together with the Amended and Restated Original Warrants, the &#8220;Warrants&#8221;). The Amended and Restated Original Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#8217;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA" decimals="-3" format="ixt:numdotdecimal" name="btai:RightToPurchaseStockLenders" scale="3" id="Narr__peyA2OnGkuVkLGcLvee3w">5,000</ix:nonFraction> at a price per share equal to a <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_fZkIV0wemUSj8D-mDkwN0g" decimals="2" format="ixt:numdotdecimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_ZUCtKAxWi0iRKkH1tsz3_Q">10</ix:nonFraction>% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). BTI entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of BTI common stock issuable under the Warrants (including the Original Warrants and the 2023 Warrants) and Lenders&#8217; Equity Investment Right was <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="3" id="Narr_7cO2nGyvrEmFBO_4mhSwRQ">5,852</ix:nonFraction> as of December 31, 2023.<span style="font-size:12pt;"> </span>On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" id="Narr_kEK6kUEIbEOQ1EQ3shGZ-Q">175</ix:nonFraction> individual limited liability company units (which number of units is not in thousands; referred to herein as the &#8220;OnkosXcel Warrants&#8221;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g" decimals="-3" format="ixt:numdotdecimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_UOFdiIw2s0yabPm3C6Zwrg">20,000</ix:nonFraction>. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g" decimals="-3" format="ixt:numdotdecimal" name="btai:ThresholdLiquidityEventAmountForExerciseOfWarrants" scale="3" id="Narr_SJGegqBoN062CxBb7TkP2A">20,000</ix:nonFraction> to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ" decimals="2" format="ixt:numdotdecimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_lVXfIn70gkC0WIj9KFf8eg">10</ix:nonFraction>% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ" decimals="2" format="ixt:numdotdecimal" name="btai:PercentageOfFairValueConsiderationToBePaid" scale="-2" id="Narr_-VIqjHCWVkmdVKSbOndluA">75</ix:nonFraction>% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ" decimals="2" format="ixt:numdotdecimal" name="btai:PercentageOfValuationApplicableToInitialProfits" scale="-2" id="Narr_XWuaE9OfB0-7Se6KxDIPBw">150</ix:nonFraction>% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6c5fc411_4b95_43c2_b8a5_527345c8e46a"></a><a id="Tc__cAfiCnABU-5ffusyNoEJg_1_2"></a><a id="Tc_1LfS-gKSEkmC6XhH6_iV2g_3_0"></a><a id="Tc_vbtr6zp_dUSi9zVIa2RstQ_3_2"></a><a id="Tc_0MKlWUXcOUy3cbw-sE2A3w_3_3"></a><a id="Tc_f3CrLSglj0OXCwd19qZzsA_4_0"></a><a id="Tc_bG3GXP9rHkWHGAg3Y1t6JA_4_2"></a><a id="Tc_Vfdo_-bJfUWyISaPUmza7g_4_3"></a><a id="Tc_XaEvDrzxC0Cf8ZtFoAJIaA_5_0"></a><a id="Tc_RndoDea5IU2SXd3CjRzjpA_5_2"></a><a id="Tc_JlOrh3P-KE6dg6mGJLY1kw_5_3"></a><a id="Tc_jQ8H0XqJqEur3txSZkr2jg_6_0"></a><a id="Tc_wjBRSCiABkS6kZpLY8Bgqw_6_2"></a><a id="Tc_EZE5TPh5WkeVhbYJo8_FEA_7_0"></a><a id="Tc_IjRXLA6JDUavlcQd_MYWVg_7_2"></a><a id="Tc_FN3GR3K_lEe_b8kb_rZ9kA_7_3"></a><a id="Tc_e2GaGfhHe0W0-iZPmfxk8w_8_0"></a><a id="Tc_2drib1EkwkSJyH8itqKjiA_8_2"></a><a id="Tc_uXhfdc872EKyhtG0wQvHyg_8_3"></a><a id="_e384deda_270c_4c3d_b742_581205ab41a6"></a><a id="Tc_z1JS-YbU5keYSay77wacOQ_1_2"></a><a id="Tc_qov4oeeqf0OLQVBirhKkEg_2_2"></a><a id="Tc_blwKWK0pNU21ldkDxF_oHQ_3_2"></a><a id="Tc_0t9sdIFarECe1mwtsUEE9w_3_5"></a><a id="Tc_D0-159Cmr0yBr0lWtCH3yw_5_0"></a><a id="Tc_FUwmeBf6yUCWbJU4gEeeqA_5_2"></a><a id="Tc_freKKBep7ke4j9wvpAiajA_5_5"></a><a id="Tc_9qNo95OHQEiByqNOhfPXJA_6_0"></a><a id="Tc_sFBntV22HUewdLkF8HDJxA_7_0"></a><a id="Tc_IWTrfYmtEkW84tD_1ocfbg_7_2"></a><a id="Tc_Oqx7RC-8dEKjs-dExC8sxw_7_5"></a><ix:continuation id="Tb_l6zc4q-qiUKtzbi-UdQFNA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Maturities of long-term debt are expected to be as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_pinmGz_jr0GJg5eY9MdxjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="Tc_hLFP91Lj-UqFsOAoIlZJ3Q_6_3">102,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" id="Tb_V4yxO7bD00KBXWx8n_awKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_TPCSWpbarUqSTCknp2eLQQ_5_3">11,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_27fQjTB8S0qwjF0qKtP-lg_5_6">7,353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_NhF3FtaxYEyg0psjgwbDkw_6_3">1,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_qa7kVVridUOV0ZH8Tq6OOA_6_6">860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_9rmOQSepwUakCV8aWgkUmQ_7_3">13,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_Lw5F8kHyvEeBX0MzO1CCYQ_7_6">8,213</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:12pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Tb_HWnbiOATUUmpcT-VZQ-biQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10. Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options. The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#8217;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheets. The respective derivative liabilities are recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="btai:FinancingActivitiesDisclosureTextBlock" id="Tb_7M3rYJTu2EKGjrmvrE_SFg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;11. Common Stock Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">In May 2021, the Company entered into</span><span style="font-weight:normal;"> an </span><span style="font-weight:normal;">Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_CyJ8S634XkOrnMXvZQo-Gw" decimals="-3" format="ixt:numdotdecimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_MpvopprF1Uy9gO17cjhotw">100,000</ix:nonFraction></span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#8220;at the market offering" program to </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_qQIgqhjIAU-25A9Enh5x8Q" decimals="-3" format="ixt:numdotdecimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_Z0t-eyayLkq6ZPcPw9d9YQ">150,000</ix:nonFraction></span><span style="font-weight:normal;">. The Company sold </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_P2WAahEr9ku9jvMIwlxm7A">1,408</ix:nonFraction></span><span style="font-weight:normal;"> shares under the Sale Agreement in the year ended December 31, 2023 for net proceeds of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_6o0YoULu4kCvEc_9CM5-Jg">26,221</ix:nonFraction></span><span style="font-weight:normal;">. For the year ended December 2023, the Company sold shares for the gross amount of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_O13gEwksdEyEGGJ5M3MMAQ">27,032</ix:nonFraction></span><span style="font-weight:normal;">, and incurred issuance costs of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_Bz9WxKSogU-giAidGUpB2w">811</ix:nonFraction></span><span style="font-weight:normal;">. The Company did not sell any shares, and thus did </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_Vc2MKw-dukuwAowcKM-VEQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_tTTtcEcwK0ansq31yLe-SA">no</ix:nonFraction></span><span style="font-weight:normal;">t receive any proceeds under this program, for the year ended December 31, 2022</span>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_mSAckiN4hky3V5UhNTcblA" continuedAt="Tb_mSAckiN4hky3V5UhNTcblA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">2017 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_50d2ok6PFEOXFwbv7MwQ0g_2_2"></a><a id="Tc_IaOz92VAI0yizu42ak0-TA_3_2"></a><a id="Tc_auiHa0QCM0WGjphz4Andgw_5_0"></a><a id="Tc__Q-DKlIVUUOyj8YyOZdzrA_6_0"></a><a id="Tc_xxBHP50KzEmL7EBYLsAp1A_7_0"></a><a id="Tc_cE3HgMvCaUy3265II9Y9xw_8_0"></a><ix:continuation id="Tb_mSAckiN4hky3V5UhNTcblA_cont1" continuedAt="Tb_mSAckiN4hky3V5UhNTcblA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Incentive Award Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2020 Plan was approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_u28NxTusVku5UX5Tspxcdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="Narr_lRosr2ZdgU21dRyvzJoIVg">911</ix:nonFraction> shares of the Company&#8217;s common stock and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_EzEfX9_flUy4assVwEUnZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_VQ3Ck2z0Qki8fV8rCcgmWA">233</ix:nonFraction> shares of the Company&#8217;s common stock, which represents the number of shares that remained available for issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg" decimals="2" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" scale="-2" id="Narr_L-xOEwJtpUqPm8U10KmTyw">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_SZqxVW5oU0abbZ9IElW9dw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_m7ymKrejtkCtzxH1doj4Aw">1,126</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_Y3C2KLUibEGjwn_Zo1eoew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_eH6zoW9_q02TwZhT5vUuRQ">1,119</ix:nonFraction> shares on January 1, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-based awards granted under the 2020 Plan have a term of <ix:nonNumeric contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_nR8Ol0H6r02jIwJYBPGN4g">ten years</ix:nonNumeric>. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally <ix:nonNumeric contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Qzk6fFBbSkymUv0WpZv4TA">four years</ix:nonNumeric>. Stock-based awards granted under the 2020 Plan include stock options, BTI RSUs, and Performance Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ZWLEjeNqVUifL0AxwuMoJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_d-0RaiPjaU69XbJKXTlp2A">664</ix:nonFraction> shares available to be granted under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to BTI RSUs.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_Q5AKhFSDbEOxbYSKGi4aqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_p2sWFHswF0-DPdbaZVQ8aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_2Q4QIHNZg0-19n-aXsHLfA_5_2">119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Tc_r_siLFE8QkS5SlyeZQ3lBg_6_2">133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Tc_j6sVDuXlVkGyv_bvBLYRyA_7_2">67</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_h6CnSCl4dECh1YLUxQk6ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_9R8rciSuq0uDYmpT35JVZg_8_2">185</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2023, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_5q9HVIUgyUeUlZWGNrFN8A">133</ix:nonFraction> time-based BTI RSUs to certain employees. All of the BTI RSUs vest over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ODa3EU-15EqPg6LSYs-8sw">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_7kdciTq9P0ChwZep8WboaA">25</ix:nonFraction>% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. The weighted average grant date fair value per share for the BTI RSUs was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_3qbtS_0rhE-DYbESZY9ehw">19.62</ix:nonFraction>. Unrecognized stock-based compensation expense related to these awards was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2023Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SiWlKh8skUWL3uCUhIDNLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_zUeutilYMU-ogFV15mDFBQ">1,417</ix:nonFraction> as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2022, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_HIcuh8LU9UatecNs4rJlgw">122</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_p2sWFHswF0-DPdbaZVQ8aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Narr_vW9iNuloskayMX6QfSlqRg">119</ix:nonFraction>, net of forfeitures) time-based BTI RSUs to certain employees and consultants. The majority of BTI RSUs granted to employees vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_hQq_EHMacU-nn51XSEQRPA">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_8ppD3PRQ0kuJJFcJpRniMw">25</ix:nonFraction>% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. There were <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IX6hI-H8FE6Sxk8kEK1KPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_uyPiX1BFHUiSgl8iDvplrQ">25</ix:nonFraction> BTI RSUs granted to the employees in May 2022 which fully vested at the <span style="-sec-ix-hidden:Hidden_ENbZ6Viv9kSPsLzsnlVWSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span></span> anniversary of the grant date. BTI RSUs granted to a third-party consultant vest <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENmMDZVWL0Sj71YGtPStYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_hVMO5qsCFkuEhOAVWcM1eg">50</ix:nonFraction>% each on the first and second anniversaries of the grant date. The weighted average grant date fair value per share for the BTI RSUs granted in 2022 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ta-CtRtqhk27TCmgBdefwg">14.38</ix:nonFraction>. Unrecognized stock-based compensation expense related to these awards was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2022Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9upi1ce5e0qUxLvJvKR5mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_P32ujpSzwkempbq7G4csXA">298</ix:nonFraction> as of December 31, 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_tiA2Hki3IEm6dLnZiZ0vzQ_1_2"></a><a id="Tc_vCHtfw1Z10ilUw1eyDcZFw_2_2"></a><a id="Tc_8EtsGeYLxUO4EabOMTWHWQ_4_0"></a><a id="Tc_VXI153tdjkq48NEm_zOCPg_4_2"></a><a id="Tc_STN2YiNPKUagdMbu1E27Cg_5_0"></a><a id="Tc_cWsihzbW1U2pJrZ4hwjFTg_6_0"></a><a id="Tc_NfJMVtJ9IkS-mCCFjbfNOg_7_0"></a><a id="Tc_0Ytcx1ohwkyQGvfjrOU3KQ_2_4"></a><a id="Tc__Q_uKOGqHUCuL60Ol3FyrA_3_2"></a><a id="Tc_thOe61FL4UCfISwAhmoWxw_3_4"></a><a id="Tc_B7QnzrS530uUqV7fa2vVIw_4_2"></a><a id="Tc_n5DOzGLpFUy7rSaOn_qRDA_4_4"></a><a id="Tc_vTG5plaaUkWRDCV1Yp0UBw_6_0"></a><a id="Tc_elAxDnKfiUCBTUyzh01u7Q_6_4"></a><a id="Tc_96mXlzTtcU62qLZS3OiF_w_7_0"></a><a id="Tc_-rJShfofOUOAONO2tNmn-A_7_4"></a><a id="Tc_r6CtjRzt9keJkhKrnziDFg_8_0"></a><a id="Tc_hZAUCSIdr0enunBTtB4Ydg_8_4"></a><a id="Tc_Ok8tGiRPcE6R4DajlDx-Hg_9_0"></a><a id="Tc_O25bdxbGXki-GlqxQ1PzuQ_9_2"></a><a id="Tc_aMYpb8irQ020oljCNPTolA_9_4"></a><a id="Tc_uWt6mSNz80mYPHDquavCGw_9_5"></a><a id="Tc_bT0x1k5p_U2uka6GJucvTA_10_0"></a><a id="Tc_H7O-GVtCGEOj40elURHkNg_12_0"></a><a id="Tc_tNwPwbA_jEuVw8YWNI0J2Q_12_4"></a><ix:continuation id="Tb_mSAckiN4hky3V5UhNTcblA_cont2" continuedAt="Tb_mSAckiN4hky3V5UhNTcblA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Performance stock units </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes activity relating to Performance Units related to BTI common stock.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="Tb_KN0gzo-L5EqipSDhxCWlsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Tc_pyZliU9SFUCAiJWY1fvo0g_5_2">543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="Tc_c3VtU_gtok6YFAEmguGQpA_6_2">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_a1Cs0RhSBUWu9ebIk9a4Uw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="Tc_S4Xm8sKxtkS1tE7TPDmyjA_7_2">527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In October 2023, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_UWn9MaHj40m9ggi57C5_7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_y-whzeCLAkufai43IpoueQ">543</ix:nonFraction> Performance Units to employees. <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5JKcWlgs30ac0qBkTIeQIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_AyGbgDJcnkKo_S7WX91NLw">209</ix:nonFraction> Performance Units vest on the one-year anniversary of the grant date, and the remaining <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p3_hhWFiREeo8nnIsabskA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_D5jqdzi_Xka0zpYIG5eJ9g">334</ix:nonFraction> Performance Units are performance based and vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value of Performance Units granted and cancelled during 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw" decimals="2" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" scale="0" id="Narr_JFYdWGKeD0a5yWVXKQ9oCg">2.43</ix:nonFraction>. <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="Narr_USSs7RZKlE6C7TICBuZUPg">None</ix:nonFraction> of the Performance Units had vested as of December 31, 2023. Unrecognized stock-based compensation expense related to the awards expected to vest was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_a1Cs0RhSBUWu9ebIk9a4Uw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_l1rUaSukEEmUskfXNXNMyQ">515</ix:nonFraction> as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OnkosXcel Profit sharing units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" id="Tb_Ebf61CA_LUerYTJd0WDlSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_owEIm-zEdUysPQOKMlfGRQ_6_2">1,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_6OcyRfO6sE68aBGJgItvqQ_6_5">5,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_h30eqbPawk-Hc0WLL3qsmQ_7_2">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_RP42BkKUmE22qj8rWEBCfg_7_5">10,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="0" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" scale="0" id="Tc_v6rbPuIzIEaKeittyXoa4Q_8_2">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="0" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" scale="0" id="Tc_wLlaVoF1YEWzlLP2dAsIxA_8_5">5,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_bX-Jb4qjY02sCaMxOt3ahQ_10_2">1,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_qd1KTC2ltUGSCOtqJTAQEQ_12_2">676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc__2hgc7BOr0uECqOudYbUZw_12_5">5,533</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During 2023, Employee Holdings, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_5QIi6CwIw0m7EWTNIksmJg">30</ix:nonFraction> individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. In 2022, Employee Holdings granted <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_VRCkfH11u0yQPf850NGkwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_vPWbVG0qDEqpkW23L-kK3g">1,310</ix:nonFraction> (not in thousands) PSUs to employees and a consultant of the Company for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. All PSUs, other than those granted to certain </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_fVUHj57N_ky4mWE8R8KgxQ_2_2"></a><a id="Tc_lXoYmIEmfki03OcyjXiwXw_4_0"></a><a id="Tc_Uqp1NV3lJki_FbsPik06_Q_4_3"></a><a id="Tc_dECZ1gzjVkud8nrTlq1-LA_5_0"></a><a id="Tc_mBv-WzmPk0K4FaJlepT9mQ_5_3"></a><a id="Tc_eIeB2UKBtEmHAsoUMEvxDw_6_0"></a><a id="Tc_fPcJU-RJE0SHJDVE8Cv8JA_6_3"></a><a id="Tc_UXFDZSLyPEGG1N2XTkxw1w_7_0"></a><a id="Tc_JmICWTHYFE6toW1Tx_75NQ_7_3"></a><a id="Tc_SygW6O0PYUuhT76LrockLw_2_2"></a><a id="Tc_1C67XraoWUCwiZAAxBUsig_3_2"></a><a id="Tc_ZWyroPvjAUuep-aDyfAYZg_5_0"></a><a id="Tc_HSljM-YXw0KNPGq5dMlF8w_5_2"></a><a id="Tc_jutcKf3pGUmzNq4_JonujA_6_0"></a><a id="Tc_gLTmjzwXsUSWhF9nQnTcAg_7_0"></a><ix:continuation id="Tb_mSAckiN4hky3V5UhNTcblA_cont3" continuedAt="Tb_mSAckiN4hky3V5UhNTcblA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">executive employees of the Company, vest ratably over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_xiXAEv6gykWPYQxj3vMLYg">48 months</ix:nonNumeric>. PSUs granted to certain executive employees of the Company, vested ratably over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_us-gaap_GranteeStatusAxis_srt_ExecutiveOfficerMember_7KyW7kaoLEujFskhyoTCJQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_dzsQEmMrpUy1L1VjHoXV6w">24 months</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair values of the PSUs granted in 2023 and 2022 were $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_H_y6MGc5ukelIxWGb4E8OA">8</ix:nonFraction> per unit and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_VRCkfH11u0yQPf850NGkwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_HNzAOUWQG0-MDOIawMGsZw">4</ix:nonFraction> per unit, respectively, and were estimated at the date of grant using a Black-Scholes option pricing model. The total fair value of the PSUs vested during the year ended December 31, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="-3" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" scale="3" id="Narr_CQzZViI1iUaQ3KndtCXPpw">1,942</ix:nonFraction>.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_NCeaFdPS7USzgBRgNL92Yw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_1WPT-eemIk-5oW-Lk83GOg_4_2">97.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc__Tda7uRFGUOFfr1-G828Qg_5_2">3.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_wfC7LzRkYkG34Rx9wbSIUQ_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_XPopO7EUR0CwS4S_nHcbRQ_7_2"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized stock-based compensation expense related to the PSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_hjtD8fThK02S4vdaBd7zRA">971</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_ACQrzGigL0K71bKRJTfhBA">4,588</ix:nonFraction> as of December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the OnkosXcel RSUs.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_rR2fEzb6W0GzwTim7c9a2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_-xEp0YxPJ02tt-tZwkKsog_6_2">225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uLG7LMwfw0CKpBUSpaBN1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_nP_3eZ5mDU68HIRXDGRCTQ_7_2">225</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2023, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_9Tp5oHvd3UqTqQRNf9GNmQ">225</ix:nonFraction> individual (not in thousands) OnkosXcel RSUs to certain employees. <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_LFEwrHLb3k630YwocgejDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="Narr_sq_NRDN5TECX7XzvMKDHlg">125</ix:nonFraction> of the OnkosXcel RSUs vest upon the earlier to occur of (a) <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_LFEwrHLb3k630YwocgejDw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OxilrCKCHkGmd0FLiJp8Og">180 days</ix:nonNumeric> after an initial public offering of OnkosXcel, or (b) a change in control of OnkosXcel. The remaining OnkosXcel RSUs vest over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0uPjNo82rUCxuxmCApfRtg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ju017TyH9k6SzMcIpf7OYQ">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0uPjNo82rUCxuxmCApfRtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_NendxdHg9kWtcxStRzLPrw">25</ix:nonFraction>% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. The weighted average grant date fair value per unit for the OnkosXcel RSUs was approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_aYgvWVQDPEW3hWFzAi5Q9A">10</ix:nonFraction>. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uLG7LMwfw0CKpBUSpaBN1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" id="Narr_87_xhLiUqUO8u6RNTETqLQ">552</ix:nonFraction> as of December 31, 2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_XoU71J1QCEOzjwdkicXvxg_2_2"></a><a id="Tc_ofYW7zQFmEytb7Y-SJUuLQ_2_4"></a><a id="Tc_YsEivUGOjEmD-89vz1Lnuw_3_2"></a><a id="Tc_r-092z7JAkm8NjIHfyY7Eg_3_4"></a><a id="Tc_Ua_Z_g1LyEWrvlbN6jgjdw_5_0"></a><a id="Tc_drwu0ngseEKuAYn96WpnBA_5_4"></a><a id="Tc_Y27mtZpPFUGwXi7F5-mbag_6_0"></a><a id="Tc_IwYu3e77vkK10S4VhuhIAQ_6_4"></a><a id="Tc_fby_X0M3cUyZ8WldCb1N4A_7_0"></a><a id="Tc_GzVliH2Im0Ck7_KK5-6CbQ_7_4"></a><a id="Tc_k4wcMCeb50iKMCDB202Tmg_8_0"></a><a id="Tc_AymlufDz90aZX37q3lCWQg_8_4"></a><a id="Tc_FoEIIQoitEelsPz9v755yg_9_0"></a><a id="Tc_y_ErnPvaPEuGSZDu2S9CmQ_9_4"></a><a id="Tc_3EtKlGjfxk-rGOSq5mtGnA_10_0"></a><a id="Tc_g0DiivSOQk61P0axHjNnsw_10_4"></a><a id="Tc_Bw3sqiBEd0yQJ5l2GxrC-w_12_0"></a><a id="Tc_IDTa0WIYmECI82HyLntQ8A_12_4"></a><a id="Tc_OXntvMmx7kWcdrW1HninFw_2_2"></a><a id="Tc_gTzqnQxlpE-M3xMS5s1aSg_2_9"></a><a id="Tc_y3jYqlCqy0K8taruV307OQ_3_3"></a><a id="Tc_ccnU2UOFxkafk_R4T8fmWw_3_9"></a><a id="Tc_34TmYQTJ9kyljLuHSw_7MQ_5_0"></a><a id="Tc_S3tDyJlVjEKlPd59y9McmA_5_4"></a><a id="Tc_nEu6yKj-fEqZ6WpGGJNRbA_5_5"></a><a id="Tc_Wk9CmjQNiUShI2dJbOyujQ_5_7"></a><a id="Tc_7IlUbuldykq8jHs12xlryA_5_10"></a><a id="Tc_XNWb-TzMK0-5323nI6aQFw_5_11"></a><a id="Tc_GwvfiajVoUmZqd5hx2_haA_5_13"></a><a id="Tc_2RZ0OhbWMEe7iKOW1rckxQ_6_0"></a><a id="Tc_EH6XPzptWkWZNeBT7Q4L_Q_6_4"></a><a id="Tc_KHLmdFYrD0OQL1eWjtTtbg_6_5"></a><a id="Tc_F3xFR782xECfpeN5bCgWaA_6_7"></a><a id="Tc_04zV-UlO_U-6YHasAToBTA_6_10"></a><a id="Tc_j9I_CZbIbEmE8thG5B3pnQ_6_11"></a><a id="Tc_yRrtf1O-6kGn26irV8RY6A_6_13"></a><a id="Tc_ox4h0bXpAkqbKiVCuwvp7w_7_0"></a><a id="Tc_hR2MlzJQ9UuKvX_tr2tbYA_7_4"></a><a id="Tc_VH23teI_Eki0xk8vQqN0Ow_7_5"></a><a id="Tc_qpm8xn31zkqbEJXnwlbNRw_7_7"></a><a id="Tc_DaYbAGVctkGKszPordyOJQ_7_10"></a><a id="Tc_WYAVwZDhbkid7Dc310ji5g_7_11"></a><a id="Tc_52gJqRRUwkurvkWfFI0SYw_7_13"></a><a id="Tc_dzCs6FpRW06DMdmJTgX6og_8_0"></a><a id="Tc_2IdLnj3-_U6a_fg_HcMMrQ_8_4"></a><a id="Tc_C0mr8v6GsEKEL7NS_ze3_Q_8_5"></a><a id="Tc_ElPsoe5igUe1uziwZwhs2A_8_7"></a><a id="Tc_pCCvCIwPLUqZbnsyx8p47A_8_10"></a><a id="Tc__2q8XgW6D0K-jajxd8CaFA_8_11"></a><a id="Tc_gOuNfrkBuU6G-YWb46hUiw_8_13"></a><ix:continuation id="Tb_mSAckiN4hky3V5UhNTcblA_cont4" continuedAt="Tb_mSAckiN4hky3V5UhNTcblA_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A summary of the Company&#8217;s stock option activity for the year ended December 31, 2023, is presented below.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_rlZHxGp9jEGKn5OLvqNwjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="Tc_q_r7tB2vG0SC-IxMc_pE1w_5_2">4,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0laVdB89eESOrmnVenvTnA_5_5">17.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="Tc_q0dAuxCmUk6gDThhs6OnOA_6_2">1,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Zdy4Vb6xuUGLAnlUdUMdVg_6_5">19.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="Tc_2oQfGpTyF0KcQnr0bYrkIA_7_2">651</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_HI34gZSdM0Caru7hoVkMiw_7_5">17.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="-3" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" scale="3" id="Tc_C8RjaylxzEqe5-S6PG8IuQ_8_2">36</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7HY5l0VA0ESPo2eW5COA9g_8_5">24.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_4krTelo520arTRCGIKZWew_9_2">309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_sWo-QhwXLEqzMWR78J6utA_9_5">1.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="Tc_kgxRP7z1m06UsiKaiocF_A_10_2">4,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9aMxu812qUqZiDg9_dNmQg_10_5">18.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="Tc_UMtNOdoUAECOR9G5qwJjmQ_12_2">3,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_3EgQY3QsTki2UzDavGKAQQ_12_5">17.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, the intrinsic value of options outstanding was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Narr_CSM2LRV82EewpIj9XZ248w">3,149</ix:nonFraction>. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#8217;s common stock as of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The total intrinsic value of stock options exercised for the years ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_DnAuPrcRjEylW-3R328tQA">5,928</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Narr_8vGg6XL-Uka6Jg3pQo4xrQ">2,437</ix:nonFraction>, respectively. The total intrinsic value of stock options exercisable as of December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_GKF-bIbFA0-pSxcULfHk6w">3,148</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_kKhtcip1AEqs0AGXnHTF1Q">40,255</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_YpsLWUdtjUi2kKabzqc6Iw">15.53</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_rmzYshSQF0e4zped8l2EWQ">11.62</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options vested as of December 31, 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_3jbd_C0b5Ei2jigfRpskQA">12.86</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average remaining contractual life is <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr__S1E3LohL0WPVuLBwwbqWw">5.5</ix:nonNumeric> years for options exercisable as of December 31, 2023. The weighted average remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_d0poiiyit0WC3bSaELlL_Q">6.4</ix:nonNumeric> years for options outstanding as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized compensation expense related to unvested stock option awards as of December 31, 2023, was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_avYhochPdkCIgK1gg1ugLA">9,478</ix:nonFraction> and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_YIkmg_L0jkOYTw-cEox3Tg">1.1</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of options granted during the years ended December 31, 2023 and 2022 was estimated using the Black-Scholes pricing model with the following assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_88qxIVFcgE2I8SmNBdTXIg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OTZS4zpsIUmXN4c6tbKJVw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_4mDqRI6h60CMUh9mz-ZhCA_5_3">5.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bVD8ivCGrESTiF07tgD9xQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_zWlLo40z8kSw4hZHKxxWQw_5_6">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pKAAtUPo1Ey3Co1MIzsM-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_wfh33KOlTEiL59Fn8A3njw_5_9">5.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WnuQlcoII0qSBZBbrHkrEg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_tXErJON81US1nXT_VeoMcg_5_12">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Tc_lcsKYo5p3US4B6kX0IeXJw_6_3">96.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Tc_f1lhHW4ofUeJUh1MAuT21A_6_6">109.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Tc_Hfwyz4zTXECJhgefG1nARw_6_9">92.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Tc_kaavVxHZe0uKsdGaTJ8axg_6_12">99.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Tc_Jr41-ZstYk6rHuqzzDSKXQ_7_3">3.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_444eHLHcrUGE7jj5sXYoBw_7_6">4.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Tc_JxTa1VZLikG28Uu8r0mbBw_7_9">1.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Tc_2kE3Jpemek-q1uwvGgyheg_7_12">4.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OTZS4zpsIUmXN4c6tbKJVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_yiQ4J9VYuk-YKiWah1Yw8A_8_3">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bVD8ivCGrESTiF07tgD9xQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_3Mf9OoIf-UuiSSjMfMHcKQ_8_6">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pKAAtUPo1Ey3Co1MIzsM-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_RWTaPLsrz0Gn7VsR-yQUwA_8_9">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WnuQlcoII0qSBZBbrHkrEg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_jrCYY1ZqeE2qzYDocrT9Uw_8_12">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In 2023, the Company began using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#8217;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the term of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_nlVkDI2VI029a9Cd6txknQ">zero</ix:nonFraction> percent as the Company has no history of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_KWScFFte40KFYr9THVPR2A_1_2"></a><a id="Tc_uqBfWkeKO0yUZ1pPiWujQg_2_2"></a><a id="Tc_V81YMxbsLkGGf2xqFaBzrg_2_5"></a><a id="Tc_E_bR94pemE-i_TQMN4Qgyg_4_0"></a><a id="Tc_ccr1KfQ1f0eJZCydbRVy2w_4_2"></a><a id="Tc_tQM5MqA1MEeWap_ZbnPuVQ_4_5"></a><a id="Tc__mpkWiP7W0Gl7iGNeljnNA_5_0"></a><a id="Tc_ohAUuxaqk02C11jbKT_ekg_6_0"></a><a id="Tc_qiknemr67k2NiHSeeYlkQA_6_2"></a><a id="Tc_aHQW54ZnaUSFCxhK0JRBhg_6_5"></a><ix:continuation id="Tb_mSAckiN4hky3V5UhNTcblA_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel PSUs and OnkosXcel RSU&#8217;s, of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_7Nsm2jSr80iXG67T10cIQg">18,614</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_9h1xuVneFkulBXYqApNPsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_rWJo4J5bV02zjvnNUlNRhw">17,337</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively, which were comprised as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_KpqfUl0JsUuJkHH7wfqqKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LO90L5PoDEivpd5VLIVaEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_L_JAjxn4wU2MPhZ4wl9HQw_4_3">6,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YNOnCMIhzk-zL6WUrMzXvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_X9wNPBA6QkO5j5vDGy6LiQ_4_6">4,558</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jlMfMWAUtUG3OTUw8vN1rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_r7V2RhISsE2DivEeAynOjQ_5_3">12,290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_o3kSuLNg7k-AKoYTLeldyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fvDFKNRj0Ey4skoMa1iLaw_5_6">12,779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_an4boZm7Q0KyDpSjidC6QA_6_3">18,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vccsPtlmEUqJuff-JPZXQQ_6_6">17,337</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was also approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#8217;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that may be issued pursuant to rights granted under the ESPP is <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_QZPms-_JDE62jRgrcbtUIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="Narr_HMfxwv7J4UmZqiNolnVXyw">100</ix:nonFraction> shares of common stock. In addition, the number of shares available for issuance under the ESPP will increase on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg" decimals="2" format="ixt:numdotdecimal" name="btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" scale="-2" id="Narr_wSvQMzt2ckqSOr92TKlJWQ">1</ix:nonFraction>% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#8220;Section 423 Component&#8221;) shall not exceed <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg" decimals="-3" format="ixt:numdotdecimal" name="btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" scale="3" id="Narr_Fv8b46VO-UKJJvTjW_eUDw">500</ix:nonFraction> shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_8YJ3pkxw6UiwCNtdf5bFlg">85</ix:nonFraction>% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Y1r3H-NssUGDKP2nkYl0gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_0qyYPCUUT0WEmJibevKalA">281</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v-MW3gW6_0OhWwhL83cZBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" id="Narr_xcpHmIyVr0KUPy1msZahgQ">280</ix:nonFraction> shares on January 1, 2023 and 2022, respectively. To date, <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_x7P2HSC51kqvtDIeyiG1VQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Narr_6YWyyetGw0mmhveZWJ8zCA">no</ix:nonFraction> shares have been sold under the ESPP. There were <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_kttjLkP_lUGbpgLUyc0SDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="Narr_6rWhvjEGv0SYyl9VBSk9MQ">905</ix:nonFraction> shares available for issuance as of December 31, 2023.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb__RCR3SL9eE2jiL4OqP3LTA" continuedAt="Tb__RCR3SL9eE2jiL4OqP3LTA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;13. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;) under an operating lease that expires in February 2026. The Company has an <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_Dd3zCmKItEmXat2oge76gw">option to renew</ix:nonNumeric> the HQ Lease for one additional <ix:nonNumeric contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_1tBvtStaKUufSo9gYdjZbA">five-year</ix:nonNumeric> term. Payments under the HQ Lease are fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also leases equipment such as copiers and information technology equipment.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_jbhNMBp-IkWf92v7HYLjyg_1_0"></a><a id="Tc_rRoW_teVPUuj-1AhhKOsRg_1_2"></a><a id="Tc_BpcWaMCEPE-R3E0Z-lFyYQ_3_0"></a><a id="Tc__UyMgLqbckaWQ7oIHJ3vow_4_0"></a><a id="Tc_I2T7qapeTky6PK47tsbGbQ_5_0"></a><a id="Tc_pEyI5Bzmwkaohe88YPJoIA_6_0"></a><a id="Tc_2aUnGs4UC0SpGdfhSRnuRw_6_3"></a><a id="Tc_UKUmcdMhVk6fGJZDGN6Xyg_7_0"></a><a id="Tc_d-A5b-qYu0OXICPTZIlJhw_7_3"></a><a id="Tc_oEvgt_sbLEWiLfBtcSw0Zw_8_0"></a><a id="Tc_yTH23tQP-UWDru7h-dJAzg_8_3"></a><a id="Tc_vm9ohg5EGEW31Sxpf_l3Cg_9_0"></a><a id="Tc_kY1s39AR50KbDIpiu8Q3Gg_9_2"></a><a id="Tc_45-gSFT9OEGZtF3p8Z--ow_10_0"></a><a id="Tc_vUd2kUgUdkuX3vSyYgXOFw_11_0"></a><a id="Tc_ZH6X-ZQ88kSaaqKA9vBO7w_11_2"></a><a id="Tc_S60BzBuWnEKyOTbHCPSlvA_12_0"></a><a id="Tc_srvbewh_00i4uWeaFKZZfg_13_0"></a><a id="Tc_cASkdd30zUCTm5CcXs17NQ_13_2"></a><ix:continuation id="Tb__RCR3SL9eE2jiL4OqP3LTA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The future minimum annual lease payments under operating leases, as of December 31, 2023, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_5Fb7vqCESEWtdVT9I_WZ6w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_oujHAnTL2kSApiJqoByfQw_3_3">381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_3t7Y5PQZtkS85YoEL31FNA_4_3">391</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_Nswn9keCAU6TDRJxkb5Lww_5_3">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_xsQuQShtKkKaHb59j4G33w_9_3">837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_S-3mLuc76EmUAq27ZgpE2w_10_3">51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_WM9TXVkJ-Ua-vHHIswPoIg_11_3">786</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_d-iWJJ4_HUe5MkJHzVU7wg_12_3">346</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_lgdDx5ZDFkuQawSlFYsOeg_13_3">440</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current portion of the Company&#8217;s operating lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Narr_E2UcdRq4pEa1Wg2tCMegng">346</ix:nonFraction>, as of December 31, 2023, is included in <span style="-sec-ix-hidden:Hidden_YDje09iS6UufW2YFrYa5Ng;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span> on the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lease expense was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_ecX48SUZ8E2UWZ9eKGgCog">392</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_PxR2EfwZQE2V3n1CuwWKew">410</ix:nonFraction> for the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lease renewal options are not included in the ROU asset or lease liability.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:DefinedBenefitPlanTextBlock" id="Tb_idxdCA1nYkSU-Mdyh9nYDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 14. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company maintains a defined contribution retirement plan for its employees that complies with Section 401(k) of the Internal Revenue Code (the &#8220;401(K) Plan&#8221;). Employees are eligible to participate in the 401(K) Plan and can contribute a portion of their pay into the 401(K) Plan, subject to annual limits established by the U.S. Internal Revenue Service. Participating employees receive an employer matching contribution equal to <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_z7CoYZsPUk6ioJ-82dje3Q">50</ix:nonFraction>% of eligible employee contributions on the first <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_8iEZKLABsUOCxgsZhOH2eg">5</ix:nonFraction>% of eligible compensation contributed. Employer contributions to the 401(K) Plan were $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="Narr_IjVDJhEBJEGqUW0xPZAUdQ">788</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="Narr_tefBzOlRNE6lzN_lpYskyg">568</ix:nonFraction><span style="background:#ffffff;"> for the years ended December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9a46bd27_9319_4583_83b1_f1cae431eee2"></a><a id="Tc_ga08Ax--OkS0RJQLkGwS7g_1_2"></a><a id="Tc_cbOYyKm4QkSfL03uQbvang_2_2"></a><a id="Tc_QPzziFVe8kOiXwURP-0UIA_3_2"></a><a id="Tc_uLrWQYamREa0GjzATM54rA_3_5"></a><a id="Tc_OVJd-SvtQ0-88xmw93eyBw_3_8"></a><a id="Tc_E8bwMY1Q5EOeUq_J3SDJsQ_3_11"></a><a id="Tc_ZDnkIeqPc0CptuRaZdWHyA_3_14"></a><a id="Tc_4IoYCIpwc0OKyzC134p7_g_5_0"></a><a id="Tc_UsIhwk1FlkCAAzyIR6b5Tg_5_2"></a><a id="Tc_AgYdP8rutUmpAGDKJdxIuA_5_5"></a><a id="Tc_dCE-yhgydkyFaeAV5qmH7g_5_6"></a><a id="Tc_qj9rq4LWmU6u3v12DueFCg_5_8"></a><a id="Tc_yrZ4VoHQ30CdcNyJom070Q_5_9"></a><a id="Tc_ifRLhSxtek-SpqIOVoQ5Zg_5_11"></a><a id="Tc_DKBC5YjhFEaC5Q7x-In_tw_5_14"></a><a id="Tc_J-83PPXaYEGQxbXooOjdIQ_6_0"></a><a id="Tc_6Bk9CbZAEkeEyTVwsDcjHg_6_6"></a><a id="Tc_Qw59jLG6Rkqlinwy8rFd6w_6_9"></a><a id="Tc_bHA1-yhQYkWzEiBH-FidEg_7_2"></a><a id="Tc_CJI5Ga0acEiciwObN3rWEg_7_5"></a><a id="Tc_JeiLWFz_cUKwF6LACOMEpw_7_6"></a><a id="Tc_xq4lDVKgzkyC6K1ZrJDk2w_7_8"></a><a id="Tc_m4GFLbeLREyCAwOsOIxL9A_7_9"></a><a id="Tc_N0XPIuGGQ0isHX1UQUYCrg_7_11"></a><a id="Tc_AryoGxKnqUeRALtQFNFWZA_7_14"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_uOaOp-TM1EKXArrMRD6JVA" continuedAt="Tb_uOaOp-TM1EKXArrMRD6JVA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;15. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, Summary of Significant Accounting Policies, for additional information on the accounting policies related to fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts of Cash and cash equivalents, Accounts receivable, net and Accounts payable approximate fair value due to the short-term nature of these instruments. As of December 31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Z17gbjnh30i21j6FjyTHjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Narr_b-8qfp22ckW3mio3LrpedA">64,860</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_r3W4hkyAb0-K4kHx7gA8ng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Narr_t7csAPozNEKT9CQKcH0SPg">191,022</ix:nonFraction>, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in Cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities measured at fair value on a recurring basis are summarized below.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_EJyycNpVrUiI3NE3kOk-zg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - Equity Investment Right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Wce1URlIPE-m9fYpV9zeJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_SvNv9jx6z0qfW9mdXY0k2g_5_3">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VGlEMLwpK0G_B3i2obOKVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_vp02gghESk-dzyRILGK20w_5_12">1,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__Ry2HIqDsUKb1qJ9uR4b3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_Lyi46rPtLUyriWrwAJj32g_5_15">1,193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnJ5CJh_wUO7oAOB1qWnWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_c8MWGq9Ay0uRHycaFEO_3Q_6_3">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7hC-g0hRVUyUylsJ4F6ZoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_9zheJjuY3UuCusNDACsUKA_6_12">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_S6sTUJ5nc0O-S3nh1hH-8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_Ea_1diUXdEOWzxtGM29vEA_6_15">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lFagk5bTnEemlWdu4CgnkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">     Total derivative liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_If0SwRWVoEKPCeiBpygDpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_TF69AxboXEy9ljk0AJQ9eg_7_3">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BBwsCn9q10ez32Xp3IZYGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_SWLCiWIe7kWyu66Se_4U7w_7_12">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z8wGFoFQHkGh9pMeSDi2Ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="Tc_ExxI2hNtoE6iDMAF1jlVmw_7_15">1,905</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_250f3ea2_69e6_4a4b_bb5f_e6214034625f"></a><a id="Tc_-Hg-f2LXJE-dUTvi050BzA_1_2"></a><a id="Tc_nEgo1pnuC0ODAFhMdut6ZQ_2_2"></a><a id="Tc_j7-00SYUwEyQA5jsmhe7fA_3_2"></a><a id="Tc_jsVQBFGng0aQmQQCisLV4g_3_5"></a><a id="Tc_7n48uQeiUEmZoIVUBWHhJA_5_0"></a><a id="Tc_3CFViJu_JU-bpsOLQOxJ7w_5_2"></a><a id="Tc_-KgfUWSFVUuD7NyVbrhIrA_5_5"></a><a id="Tc_QPsMtyleC0CO4Ifv3NfESg_6_0"></a><a id="Tc_W96froYnxE6HLEKgC6JK9g_7_0"></a><a id="Tc_xeMYa8l0TUWJxN7LyNbI1g_7_2"></a><a id="Tc_neWBaf7coUue9Q8HrLwhcw_7_5"></a><a id="_6b9bb593_b1f3_45ca_b18f_40c7d8d983cb"></a><a id="Tc_VopuZFrPrUelJ3zZudbB0w_1_2"></a><a id="Tc_vImQKmxaEkCB_lSWnSysOg_3_0"></a><a id="Tc_FvF0tTmH9EK6F5vnKQ0-Wg_3_3"></a><a id="Tc_Qp7EYKDdoUmNb9uKir2vEA_4_0"></a><a id="Tc_18XSbkUaVU2Ld8NdFmtckQ_4_3"></a><a id="Tc_rntsYxp8y0eMnaDPP_LMpA_5_0"></a><a id="Tc_OAJTh5wDfEqkBtU_D_prdQ_5_3"></a><a id="Tc_egs98R-7PkGg066YURF-KA_6_0"></a><a id="Tc_CO3ycBfJqkqzilpAuzH1eQ_6_3"></a><a id="Tc_u7kNAQmuCUikF_KAcnjoCA_7_0"></a><a id="Tc_BQxbAlVCCE6FzjrI6O5DAw_7_3"></a><a id="Tc_kOWqlnRpK0C3kXQiHsWcWA_8_0"></a><a id="Tc_li4Ya7tm-USV5NlW_cJBPA_8_3"></a><ix:continuation id="Tb_uOaOp-TM1EKXArrMRD6JVA_cont1" continuedAt="Tb_uOaOp-TM1EKXArrMRD6JVA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities are comprised of the OnkosXcel Warrants and Equity Investment Right held by the Lenders. The fair value of the derivative liabilities was determined using Monte Carlo simulation models for the Equity Investment Right, and Binomial Option Pricing and Distribution models for the OnkosXcel Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2023. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="Tb_uwZ0jWHmLk6krSRZtFTIog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_8lEUU38T2Um4yVWzcVCGeA_5_3">2,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_4j4Tsidu-ECCbyVYDCgUlQ_5_6">1,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Change in fair value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" sign="-" scale="3" id="Tc_IAHDWMrEHk2VXqkwg67NYA_6_3">438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" id="Tc_bRGAyO6gLEyvViJmtnKsvg_6_6">389</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_K17OfBjfJEWEcedQhN3j3Q_7_3">1,905</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_ehyMRMpNoEWBiV6Vy7m_Aw_7_6">2,343</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The derivative liabilities were reported at their fair values in the Consolidated Balance Sheets. The changes in the fair value of the derivative liabilities were reported in the Consolidated Statements of Operations as Other (income) expense, net, for the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inputs used to calculate the estimated fair value of the Equity Investment Right were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_HT7qBQK3BkGVDH_zXjxyHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Investment Right</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Strike price relative to volume weighted 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_nhdn74qyc0WhUslR4qua3g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_HaC7igu9ZUWEAYpJZqVq3g_3_2">110.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility (annual)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGhzkv0Pn0-_E2xmVYozig" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_j0jyl7sPgEqXzjNOMtPU2g_4_2">99.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probability of exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember__t5_rrWTAkSvW4vx2R3MKg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_dsdFwnqo2k2SEeQdWCVuBA_5_2">90.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Time period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_EiQqzjUCAki7PrEDtNqD5g" decimals="1" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Tc_HFf440RA90SSqCFOyNJFnw_6_2">3.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated premium to 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_l5-tles4rk6AJ38rbZ5qDQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_HoMZpmpfw0qS29VeDPoXIg_7_2">24.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_UWym6eYkO0i2Db4epU9hOg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Tc_SdxOtaFVekemPOrWimLZmg_8_2">4.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CZOqcLp0PUKVcyA1bGHQyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_w5lH-Yt4K0mp24ZjcH_oLA">100</ix:nonFraction>% based on the historical volatility of the Company&#8217;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated fair value of the Credit Agreement as of December 31, 2023, was $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="3" id="Narr_pjURN-RQpkuyFNs2A18mDg">88,210</ix:nonFraction>. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_xk0Q89gawUCTwiTOaOpAWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_OJVNgWcP4UO9C8Qm9yHEXg">200</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 3. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_zrIRZIK4QUyE2BqXAHd39w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_1tqEQKcbzk6S3pgaVaQwFA">3.6452</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_n9fLqTrqZkCK8GBCnlZSGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_mDk1vGKhRkG3qZxOBos7fw">3.71</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_A6wlGoCQXEKa2GVlvoBZ6A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_La9foYiGMU-I6RC46q55xQ">99</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mA8YOGT8Mk-UH8QN9ncEhQ" decimals="1" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_I-oHWsxW9UmCuUi-WZZHoA">5.4</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_NC_OkAZruUWuB05QvPr4mA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_pV3lioHCJEugQDvAhf8CAw">4.14</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the Original Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_JQIv3PvyeE2jLl13TCtVDw">3,245</ix:nonFraction> was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 3. The inputs used were a strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_7PDK9HAQOUe7s0Ry8BL5WA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_CLU9czgWh06vDUOrlbskVw">20.04</ix:nonFraction>, the Company&#8217;s stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2iBcLPYPak63zB2SGjujoQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_vFLvU335XESCZ8mRT5FpBA">14.93</ix:nonFraction>, volatility of <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wGIdAt1pk0uCvgXve4GiLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_-4pA-ytFUUGhNfhV0cKvpw">95</ix:nonFraction>%, term of <ix:nonFraction unitRef="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tz8ZkPV9rEagiQzVm1c8XA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="Narr_heKBBB8mK0evLfPFBmFuIg">7</ix:nonFraction> years and risk-free rate of <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZjevHEcIPEOgTS172gTu_w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="Narr_1MLGrTz11ke1pR5DzvPYQw">2.95</ix:nonFraction>%. As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment<span style="font-size:12pt;"> of the </span>Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Original Warrants granted to the Lenders to have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_5jfXnpGwr0Ov5YYjFNBdBQ">3.6452</ix:nonFraction> per share.<span style="font-size:12pt;"> </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uOaOp-TM1EKXArrMRD6JVA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Amended and Restated Original Warrants&#8217; fair values at the original strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_GpdoISruzku_097J5reooA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_GzLy33kGwEG01njDoNOA_Q">20.04</ix:nonFraction> and the amended strike price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_U3FPRNp3MEuqZZWeSvsSlQ">3.6452</ix:nonFraction> were $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_GpdoISruzku_097J5reooA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_XujKl_OTekGFl_8mMf96Kg">548</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="Narr_21H0KQb4f0WeBd7kaIVBMw">802</ix:nonFraction>, respectively, as of the Second Amendment Effective Date. The Amended and Restated Original Warrants&#8217; incremental increase in fair value for the repricing of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_PntQCMUJZkeGnizT8u1Fug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" scale="3" id="Narr_c04CF5aBJkuIO1RC6GIZEg">254</ix:nonFraction>, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><a id="Tc_3zAoJrXY8kS2S08gOGvlVQ_1_2"></a><a id="Tc_lK6x2AyWYk2nQOKICQbX8A_1_5"></a><a id="Tc_4aJV-wQufEiCugMeqP-WYg_2_2"></a><a id="Tc_EOR5fKq_k0OYWKfwAo3q7g_2_5"></a><a id="Tc_kCpF4dc6D0Sc_rx5bMvkJA_3_0"></a><a id="Tc_PXfNnPHgPUSbovK6LXq_Bg_4_0"></a><a id="Tc_RI47vh3O_kyCvTornwLyOw_4_2"></a><a id="Tc_wrLHyFffVU-eI3GqBrwggg_4_5"></a><a id="Tc_y3iumi8mbk2V-kAV4eCalQ_5_0"></a><a id="Tc_DpJgV9o-LUiUrystqIhP8Q_6_0"></a><a id="Tc_zJUaoPMQa0GRMkYkd1quhA_7_0"></a><a id="Tc_4ddrs6CAikanVvoss5-s2w_8_0"></a><a id="Tc_H7YGV2P86Uisj33h_H0y3g_9_0"></a><a id="Tc_UbZhJ4pj50CUERkPBByl_Q_9_3"></a><a id="Tc_5iEfJhFTxkesxJLk0xjHtw_10_0"></a><a id="Tc_F3g6R6li7EeQP8IPyPMZKQ_11_0"></a><a id="Tc_tdxpSZbrWEC1qtg2MWAQCw_12_0"></a><a id="Tc_vo8diNZfr0WxPu6z0gVqWg_12_3"></a><a id="Tc_cQpwEFsfoEOpA2qo_CZp_Q_13_0"></a><a id="Tc_LAihwxMJOEKo8P_5bjYzEA_14_0"></a><a id="Tc_Won9x2Kx0kKdUlPV3XhzEA_14_2"></a><a id="Tc_yqYRzV7WHE2aeY7WVYh0Hg_14_5"></a><a id="Tc_d2IDmPYU-UKSNDkKs4Qfzg_15_0"></a><a id="Tc_PiELSsmk8EKYHUKqgp9qfQ_16_0"></a><a id="Tc_mRJIqNy_kEG8Wo7kRnQA8w_16_6"></a><a id="Tc_eBFbdtlMkU60JmabZ2HK4Q_17_0"></a><a id="Tc_E6kD8YxwDEuKuoldHYPj9A_17_2"></a><a id="Tc_dwnVfHfsy0SfPIZdn7LtuA_17_5"></a><a id="Tc_fvvUjGWjL0OtLRPGymytAw_18_0"></a><a id="Tc_CrGZB5YUEEifK3OwX3wghg_18_2"></a><a id="Tc_m92W90JKs02IIonHsPDscA_18_5"></a><a id="Tc_1mIB5a6Dj0a63vPh1Yn28A_19_0"></a><a id="Tc_S59v2OWUh0uTATLnX8Bg6A_19_2"></a><a id="Tc_DrWA_7YgQEKO820JUjpnpg_19_3"></a><a id="Tc_BVo5blb_eU6zKNvyBfxx1Q_19_5"></a><a id="Tc_3zEPUwoRHU-0yULrWmzU9w_19_6"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Ug6q8k-x-0qcoEyHNkGErw" continuedAt="Tb_Ug6q8k-x-0qcoEyHNkGErw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;16. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There is <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AccruedIncomeTaxes" scale="3" id="Narr_Ah7jMeqp30alwKKV5rl0dQ">no</ix:nonFraction> provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the years differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses primarily because of changes in valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For tax years beginning on or after January 1, 2022, the 2017 Tax Cuts and Jobs Act amended Section 174&#160;of the U.S. Tax Code to eliminate current-year deductibility of research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the U.S. and fifteen years for research activities performed outside of the U.S. For the 2023 tax year, the Company capitalized $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="btai:CapitalizedResearchAndDevelopment" scale="3" id="Narr_E_EYA6GrNEubMQPGYlb8Cg">78,002</ix:nonFraction> of research and development expenses. This resulted in an increase in the deferred tax asset associated with capitalized research and development of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="btai:CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" scale="3" id="Narr_190h41raN02j4Q9ORoH2mQ">20,985</ix:nonFraction>. In determining the realizability of the Company&#8217;s net deferred tax asset, the Company considered numerous factors, including historical profitability, estimated future taxable income, and the industry in which it operates. Based on this information the Company has provided a valuation allowance for the full amount of its net deferred tax asset because the Company has determined that it is more likely than not that it will not be realized. The significant components of the Company&#8217;s net deferred tax assets are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_-CEelx_t3Eagxd_OEcrr7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="Tc_1UKC_Rattk6NN7saRnPQUw_4_3">73,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="Tc_nlAPatuptkm_g7Wwd_RjGg_4_6">46,695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="Tc_5sObLXNtkEaO3WuU_emp6A_5_3">21,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="3" id="Tc_8O5T-VU-s0mr82kyBY6dMw_5_6">11,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_U8Z9_5jTPECuO2_JpZlNmA_6_3">13,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_yCRQCj6rn0q2kTh5CytkLQ_6_6">10,705</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_ktkqgXFvrU-7o9lFBZQ0dA_7_3">15,048</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_C-cBITydLUiICKbr0z6XmA_7_6">10,689</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_he4tx3mrgkuCNf7-sBS5Wg_8_3">49,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_l_EiM2F7BUubH5AlmdLqhA_8_6">36,663</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="Tc_nhKNmcczaEaH3wM0Qii4yA_9_6">2,171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_k7c2dX_RlkuxEl87LCP7QQ_10_3">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_e06DajOXo0qw3EF1S_fx2g_10_6">42</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="btai:DeferredTaxAssetsLeaseAccountingLiability" scale="3" id="Tc_0eDsaBTqlEGC08hTCkuYig_11_3">212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="btai:DeferredTaxAssetsLeaseAccountingLiability" scale="3" id="Tc_nsY3K0qp4U6ik-r34dX2iA_11_6">290</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" id="Tc_ajBhG4GO2k6x4b19pJR9Yg_12_6">103</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_MLGIxIqfsEmLjeNtnvFLxg_13_3">173,679</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_2M3LYXJifEOOMp6DsMGhJg_13_6">118,373</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Ff4Y39QqJEeaYCTQqxvGWQ_14_3">197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_Hma7c0kwk0uhrUY397GM3g_14_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesDerivatives" scale="3" id="Tc_T2raM4U900-YAegYDaz8OA_16_3">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_yB3g1BEUSEW_0iIs0zPkNg_17_3">185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_cf3Tb9HzLEqr5TU2a_8VlQ_17_6">256</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_glJvVmzy8EWc6Z4ZdQhU8g_18_3">197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_T4Y-aGut3Um0RuSrU2IxrQ_18_6">256</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset (liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The income tax benefit for the year ended December 31, 2023 differed from the amounts computed by applying the U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_GDdiXJekiE-hlCWC0UXDmA">21</ix:nonFraction>% to loss before tax benefit as a result of nondeductible expenses, tax credits generated and increases in the amount of the Company&#8217;s valuation allowance.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IUXPJuJsfEmccEq2jPPSPA_1_2"></a><a id="Tc_iglg8BjOm0WjJ-yv7IKsag_2_2"></a><a id="Tc_vWNx2JLkN06mupcdwr-k-Q_2_5"></a><a id="Tc_bqg1PkXVEkad9PAyJkxofw_3_0"></a><a id="Tc_yuTEkS6YLUCjLzbIjJqiAA_3_3"></a><a id="Tc_BDRV29BQNUir_SuIpkSncA_3_6"></a><a id="Tc_le_XmH9GcESk37F8JmcZSA_4_0"></a><a id="Tc_2oTsQhnsiUSWbiabFm871Q_4_3"></a><a id="Tc_yiSL-RWVK0ysSKTZIk8Bdg_4_6"></a><a id="Tc_cwYuK7DPsk6HwtJIwoSTvA_5_0"></a><a id="Tc_dx4OxJYbjkKLeQ7HLLF-ig_5_3"></a><a id="Tc_blebKs1phU2Z-tX9QsNYMQ_5_6"></a><a id="Tc_JHHO-dsVjEC5Qa3e3fpcyw_6_0"></a><a id="Tc_KBCyGeDKMEKKH0SRIKbjyg_6_3"></a><a id="Tc_IbbS8bujIUGNH06K2DgozQ_6_6"></a><a id="Tc_UZUrHxm8pEOf1ttoJR4XwQ_7_0"></a><a id="Tc_88wM75VdGU2iWYPrhCcWDQ_7_3"></a><a id="Tc_DduD_dEsfEecBEsRGngCrQ_7_6"></a><a id="Tc_Bi2JrzrY0UmPWJGYIiED_Q_8_0"></a><a id="Tc_YjuDLLyJxUi7-OAcyJlwuw_8_3"></a><a id="Tc_GeIoBh6A40KeTI4PMHjjBw_8_6"></a><a id="Tc_ddTzKFYUcUOk7N8bQFXyzA_9_2"></a><a id="Tc_hIUHcG_1o0SC3A4kEEWZWA_9_3"></a><a id="Tc_wAVbL-ywq0uuuBBNEFHuoQ_9_5"></a><a id="Tc_7k1Smcqijk28mfP_pAWZ2A_9_6"></a><ix:continuation id="Tb_Ug6q8k-x-0qcoEyHNkGErw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_3zW6X2RetEeRdgSq55vEPQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_GZDVRvICCEuTYVZ0au4cjw_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_gqtLJUPkh0CdxkdfE-MSqQ_3_5">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_4hbtG-Jt7k-9CV1AtyWpzw_4_2">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_V3upSTn0i0m0OYcPoHcvpw_4_5">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_jnoJfXx3QUOFEIO3VNKMLQ_5_2">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="Tc_m5q9_0luNE6mRapodF8ALQ_5_5">2.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_5nXWUd8fZkqRc4MVbJ9LRA_6_2">8.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_wjM2UhFfFU6Y5k9ZjYZC_A_6_5">4.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_aixN2BPN6Ei-rRCiJVjyyw_7_2">0.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_6yYJL38IBEGP4-2fGlbgNA_7_5">1.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_Xf2b--WTs0SHR49eOUlWaQ_8_2">30.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_SAjA-9n1_kCs7vU2YImUNQ_8_5">28.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2023, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_W2i9WK1SZUeMOgcqPDEO-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_LcNf9Ly87EWia-AeSxjvvg">351,284</ix:nonFraction> of gross federal and $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_yu4AYaDZ_Ue7i6ZZWzIm3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_0RQJJkT3qkiWqyADR99oYQ">360,081</ix:nonFraction> of gross state net operating loss (&#8220;NOL&#8221;) carryforwards. If not utilized, the federal and state NOL carryforwards will begin to expire in 2037. The federal NOL of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt:numdotdecimal" name="btai:OperatingLossCarryforwardsNoExpiration" scale="3" id="Narr_PAvNB56MBEKJ0Z-J0S2bhQ">348,638</ix:nonFraction> incurred after December 31, 2017, will be carried forward indefinitely. The utilization of such NOL carryforwards and realization of tax benefits in future&#160;years depends predominantly upon having taxable income. The Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_W2i9WK1SZUeMOgcqPDEO-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Narr_TJKhzoyoz0eDF5mbg1_ivw">14,345</ix:nonFraction> of federal orphan drug and research development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_yu4AYaDZ_Ue7i6ZZWzIm3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Narr_9r85Fsy8OkqjldcMvN1u5g">1,206</ix:nonFraction> of state drug research development credits which will begin to expire in 2040 if not utilized. &#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Utilization of the NOL and research tax credit carryforwards may be subject to a substantial annual limitation due to ownership limitations that have occurred or that could occur in the future, as required by section 382 of the U.S. Tax Code, as well as similar state and foreign provisions. These ownership changes may limit the amount of the NOL and research credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change," as defined by Section 382 of the U.S. Tax Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock by certain stockholders or public groups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December&#160;31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_YOF5gbkWAk2sZ8f7Skl2ww">no</ix:nonFraction> uncertain positions. The Company's U.S. federal and state NOLs have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of NOLs from prior years opens the relevant year to audit by the U.S. Internal Revenue Service and/or state taxing authorities. BTI did <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_FtL5qDTu2Eys3VrD_0WYWg"><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_fVgu62CClkewAaWim32Wxg">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits and has <ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="3" id="Narr_vjPPEcIvdkGRYKMm0wUCCA"><ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="3" id="Narr_bmYIy4WhfkyVUJbfKRVc0Q">no</ix:nonFraction></ix:nonFraction>t accrued any interest or penalties for the years ended December 31, 2023 and 2022. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_NPseQtmmG0y7a0__rGs3xQ_1_2"></a><a id="Tc_nY9Ir7bfi0Kz-P5B6azUSA_2_2"></a><a id="Tc_RE95SMAf40SOukNb1noqBg_3_2"></a><a id="Tc_yyIY9dLJ_kep-1xv9-4LYw_3_5"></a><a id="Tc_9eLuV4C1_0Kgi-R0TxcuVw_5_0"></a><a id="Tc_EXCXYHuQfE2ye3yjEl97rg_5_2"></a><a id="Tc_4QWaQtzhe0Kg8Klwp-1vuQ_5_5"></a><a id="Tc_ZZHpx7R7Pka_1xG9VDGlTA_6_0"></a><a id="Tc_cuh0d6eK8kucIvjJ0Ul6Gg_7_0"></a><a id="Tc_bnQjE2XUME-qfgs7m3Ev5Q_7_2"></a><a id="Tc_M9n6widpRUK6P5fRChyGfg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:EarningsPerShareTextBlock" id="Tb_lFkZ8RsLEkyeUxxBM1sgog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 17. Net Loss Per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Basic and diluted net loss per share are as follows</span>:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_rgn3W3IFsE6VZBluTq3Qvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DzTJhKBsFEyYDZFOQuOyrg_5_3">179,053</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sDY0q0dKM0q6OwJl0NRoaw_5_6">165,757</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_QemXQII2KkysM7FxeU2Pqw_6_3">29,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_r8qKtqDZA0--dSRB3VOmTQ_6_6">28,015</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_J4L0h73f-E-zrNVQZHRFMQ_7_3">6.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc__9QNt-3U2EeWuVWLmQoZAw_7_6">5.92</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding as of December 31, 2023 and 2022 of <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="Narr_XtKCtWRBk0CtDJ2VBuDr4w">6,036</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="Narr_0Giq832W60-r9iqYIfBOgg">5,280</ix:nonFraction> shares, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_FaWCWFW4P06L0Kn-882lCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 18. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned Martin v. BioXcel Therapeutics, et al., 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. The amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. Defendants filed a motion to dismiss on February 6, 2024, which has not been decided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Panancherry et al v. Mehta et al, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation, 3:23-cv-1554 (D. Conn.). The above-captioned consolidated action is currently stayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Smith v. Mehta et al, 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Derivative Litigation, 1:24-cv-00041 (D. Del.). The Company expects to seek a stay in the above-captioned consolidated action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_4_30_2022_GlNf8HOiWUu7zXkTvkFBsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted" scale="3" id="Narr_GqHV3VzUu0Kzi9zxi_yXkg">10,000</ix:nonFraction> for the <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_30_2022_TCiII9VhN0SRNqnqQ9rjQw" format="ixt-sec:durwordsen" name="btai:AgreementCommitmentPeriod" id="Narr_OoEu7gQYNEqUFFRK8lWR9g">three-year </ix:nonNumeric>period<span style="background:#ffffff;">.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w" name="us-gaap:SubsequentEventsTextBlock" id="Tb_2oy11pNaOEuj-BthIpRoTg" continuedAt="Tb_2oy11pNaOEuj-BthIpRoTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 19. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#8217;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KN9Fx05BHkKau-z8hNvRxg" decimals="-3" format="ixt:numdotdecimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_khtmQw8FNkKdEVEV0IEQoA">40,000</ix:nonFraction></span><span style="background:#ffffff;"> in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants</span> on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2oy11pNaOEuj-BthIpRoTg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 20, 2024 (the &#8220;Effective Date&#8221;), the Company entered into a Fourth Amendment (the &#8220;Fourth Amendment&#8221;) to the Credit Agreement and Guaranty (as amended from time to time, the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the Lenders, and OFA as administrative agent, pursuant to which the Lenders waived the covenant that the Company not receive a report and opinion from the Company&#8217;s independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to the Company&#8217;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#8217;s independent registered public accounting firm&#8217;s report contained in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QEq2Y_AI2EClDFuZWnDU8A" decimals="-3" format="ixt:numdotdecimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_fnR7PvC7w0SS13pOQhF7mQ">25,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eky2EVddxU2Zk8lYvRBFDw" decimals="-3" format="ixt:numdotdecimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_ZM0sP8wa7kyvA0nIOliCRQ">50,000</ix:nonFraction> (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cxmDc-hxWEiaxO1wwjZa8g" decimals="-3" format="ixt:numdotdecimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_oOv1S4GnQEu1RWTkuyxIqw">40,000</ix:nonFraction> in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i38r8XQuQEOi9Le4Y7r8lA" decimals="-3" format="ixt:numdotdecimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_9d9oAqrOYUezILR0tfIF3Q">25,000</ix:nonFraction> from $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5UeYbgXGDEaW_6Z1qh8tGw" decimals="-3" format="ixt:numdotdecimal" name="btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" scale="3" id="Narr_sNGwNrBLLkGcTfX90IuHJQ">15,000</ix:nonFraction>, unless and until we have received, after the Effective Date and on or before November 30, 2024, at least $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eky2EVddxU2Zk8lYvRBFDw" decimals="-3" format="ixt:numdotdecimal" name="btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" scale="3" id="Narr_elJTal3_o0aQpzCgUDlc0Q">50,000</ix:nonFraction> in gross proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, on the Effective Date, the Company granted new warrants to the Lenders to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_MibmYLJhpEiokQkpjq1Arw">100</ix:nonFraction> shares of its common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A" contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_n-mB1hKa-UqOoW9qnFBNBw">3.0723</ix:nonFraction> per share (the &#8220;2024 Warrants&#8221;), which represents a <ix:nonFraction unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA" contextRef="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_os9ZcTj60EKmwN-8QTANZA" decimals="2" format="ixt:numdotdecimal" name="btai:PremiumSharePricePercent" scale="-2" id="Narr_HZpgkPXfKEWMSaWDE7go7Q">10</ix:nonFraction>% premium over the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 11, Common Stock Financings Activities, the Company has previously entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), as amended, pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_qQIgqhjIAU-25A9Enh5x8Q" decimals="-3" format="ixt:numdotdecimal" name="btai:SaleOfStockMaximumValueSharesToBeIssued" scale="3" id="Narr_cShbXD1dvkqzQ3VZL1YTAw">150,000</ix:nonFraction>, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. From January 1, 2024 through March 19, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ" contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Narr_dGy5B-vzWUmHuLuLPYYK1g">647</ix:nonFraction> shares under the Sale Agreement for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Narr_uFCJKBHwN0WnGwN358DILQ">1,743</ix:nonFraction> and received proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="Narr_5rBBO6cmrUGCaJ5-hdc3iw">1,691</ix:nonFraction>, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA" contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_0zClK0avoEqMFjSDpWYRvg">52</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>btai-20231231xex4d1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">BioXcel Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to BioXcel Therapeutics, Inc. and not to any of its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation (as amended and/or restated from time to time, our &#8220;charter&#8221;) and amended and restated bylaws (as amended and/or restated from time to time, our &#8220;bylaws&#8221;) are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which have been publicly filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). We encourage you to read our amended and restated certificate of incorporation and our amended and restated bylaws and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are authorized to issue up to a total of 100,000,000 shares of common stock, par value $0.001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. Further, holders of our common stock have no preemptive or conversion rights or other subscription rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon our liquidation, dissolution or winding- up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of one-third of the voting power of our issued and outstanding capital stock, represented in person or by proxy, are necessary to constitute a quorum for the transaction of business at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action unless a different vote is required by law, the charter, the by-laws or, with respect to a class or series of preferred stock, the terms of any resolution or resolutions adopted by the board of directors. Pursuant to our charter, the election of directors requires a plurality of the votes cast by the stockholders present in person or represented by proxy at the meeting and entitled to vote thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges, and relative participating, optional, or special rights as well as the qualifications, limitations, or restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, can issue convertible preferred stock with voting, conversion, or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms calculated to delay or prevent a change of control or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock, and may adversely affect the voting and other rights of the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Certain Provisions of our Charter and Bylaws and the DGCL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Delaware Law</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are governed by the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly traded Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A business combination includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An interested stockholder is a person who, together with affiliates and associates, owns (or within three years, did own) 15% or more of the corporation&#39;s voting stock, subject to certain exceptions. The statute could have the effect of delaying, deferring or preventing a change in control of our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Classified Board of Directors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter provides that our Board is divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. Directors may only be removed from our board of directors for cause and only by the affirmative vote of holders of a majority of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Board of Directors Vacancies</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and bylaws authorize only our board of directors to fill vacant directorships. In addition, the number of directors constituting our board of directors may be set only by resolution of the majority of the incumbent directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Stockholder Action; Special Meeting of Stockholders</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and bylaws provide that our stockholders may not take action by written consent. Our charter and bylaws further provide that special meetings of our stockholders may be called by a majority of the board of directors, the Chief Executive Officer, or the Chairman of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder&#39;s notice must be delivered to the secretary at our principal executive offices not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#39;s annual meeting; provided, however, that in the event the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which a public announcement of the date of such meeting is first made by us. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Authorized but Unissued Shares</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval and may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitations on Liability, Indemnification of Officers and Directors and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors&#8217; fiduciary duties as directors and our charter includes such an exculpation provision. Our charter and bylaws include provisions that indemnify, to the fullest extent allowable under the DGCL, the personal liability of directors or officers for monetary damages for actions taken as a director or officer of us, or for serving at our request as a director or officer or another position at another corporation or enterprise, as the case may be. Our charter and bylaws also provide that we must indemnify and advance reasonable expenses to our directors and officers, subject to our receipt of an undertaking from the indemnified party as may be required under the DGCL. Our bylaws expressly authorize us to carry directors&#39; and officers&#39; insurance to protect us, our directors, officers and certain employees for some liabilities. The limitation of liability and indemnification provisions in our charter and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against our directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. However, these provisions do not limit or eliminate our rights, or those of any stockholder, to seek non-monetary relief such as injunction or rescission in the event of a breach of a director&#39;s duty of care. These provisions will not alter the liability of directors under federal securities laws.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>btai-20231231xex4d5.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Exhibit 4.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">[FORM OF] BIOXCEL THERAPEUTICS, INC. COMMON STOCK WARRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE OR CONVERSION HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;</b>),<b style="font-weight:bold;"> OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED EXCEPT (I) IN ACCORDANCE WITH THE SECURITIES ACT OR SUCH APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM, OR (II) WHERE, IN THE OPINION OF COUNSEL, REGISTRATION UNDER THE SECURITIES ACTS OR SUCH APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[</b><font style="font-style:italic;font-weight:bold;"># of shares</font><b style="font-weight:bold;">] Shares of Company Common Stock No.&#160;[</b><font style="font-style:italic;font-weight:bold;">warrant #</font><b style="font-weight:bold;">]</b><b style="font-weight:bold;letter-spacing:-0.85pt;"> </b><b style="font-weight:bold;">WARRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.85pt 12.25pt 6pt;">This WARRANT (this &#8220;<b style="font-weight:bold;">Warrant</b>&#8221;) is issued as of March 20, 2024 (the &#8220;<b style="font-weight:bold;">Initial Issuance Date</b>&#8221;), by BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), to [<i style="font-style:italic;">name of purchaser</i>], a [<i style="font-style:italic;">jurisdiction of organization</i>] [<i style="font-style:italic;">entity type</i>] (&#8220;<b style="font-weight:bold;">Purchaser</b>&#8221; and, together with any assignee(s) or transferee(s), &#8220;<b style="font-weight:bold;">Holder</b>&#8221; or &#8220;<b style="font-weight:bold;">Holders</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.75pt 12.5pt 6pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company, certain subsidiaries of the Company as guarantors, the Purchaser as lender and the other lenders party thereto are parties to that certain Credit Agreement and Guaranty, dated as of April 19, 2022, and amended as of November 13, 2023, December 5, 2023, February 12, 2024 and March 20, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<b style="font-weight:bold;">Credit Agreement</b>&#8221;), pursuant to which the Company may borrow from Purchaser and the other lenders party thereto (collectively, the &#8220;<b style="font-weight:bold;">Lenders</b>&#8221;), and the Lenders may loan to the Company, up to $202,319,447 from the date of the Credit Agreement through the Maturity Date; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.95pt 12.5pt 6pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company is issuing this Warrant to Purchaser as a condition precedent to the effectiveness of that Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024, by and among the Company, Purchaser and the other parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.8pt 12.5pt 6pt;"><b style="font-weight:bold;">NOW THEREFORE</b>, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Purchaser agree as<font style="letter-spacing:-0.6pt;"> </font>follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_1._Definitions.__Unless_otherwis"></a><font style="color:#010000;">Section&#160;1. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b>. Unless otherwise defined herein, capitalized terms have the meanings set forth in the Credit Agreement (as in effect on the date hereof), however, the following terms when used herein have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.95pt 12pt 6pt;">&#8220;<b style="font-weight:bold;">Aggregate Exercise Price</b>&#8221; means, in connection with any Exercise of this Warrant pursuant to <b style="font-weight:bold;">Section&#160;4 </b>(whether in whole or in part), an amount equal to the product of (i) the number of Underlying Shares in respect of which this Warrant is then being exercised pursuant to such <b style="font-weight:bold;">Section&#160;4</b>, multiplied by (ii) the Exercise<font style="letter-spacing:-0.45pt;"> </font>Price.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.95pt 12pt 6pt;">&#8220;<b style="font-weight:bold;">Fair Market Value</b>&#8221; means, with respect to any security or other property, the fair market value of such security or other property as determined by the independent members of the Board of Directors of the Company, acting in good faith. If the Holder objects in writing to the Board of Directors&#8217; calculation of Fair Market Value within ten (10) days of receipt of written notice thereof and the Holder and the Company are unable to agree on Fair Market Value during the five (5) day period following the delivery of the Holder&#8217;s objection, the valuation dispute resolution procedure set forth in <b style="font-weight:bold;">Section 20</b> hereof shall be invoked to determine Fair Market Value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Market Price</b>&#8221; means, with respect to a particular security, on any given day, the last reported sale price, regular way, or, in case no such reported sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case on the principal national securities exchange on which the applicable securities are listed or admitted to trading, or if not listed or admitted to trading on any national securities exchange, the last quoted bid price in the over-the-counter market as reported by Pink Sheets LLC or similar organization. &#8220;Market Price&#8221; shall be determined without reference to after hours or extended hours trading. If such security is not listed and traded in a manner that the quotations referred to above are available for the period required hereunder, the Market Price per share of Company Common Stock shall be deemed to be t<font style="letter-spacing:0.1pt;">he fair market value per share of such security as determined in good faith </font>by the independent members of the Board of Directors in reliance upon an opinion of an accounting firm of nationally recognized standing retained by the Company for this purpose and reasonably acceptable to the Holder (or if there is more than one Holder, a majority in interest of Holders excluding any Holder that is an Affiliate of the Company). &#160;For the purposes of determining the Market Price of the Company Common Stock on the Trading Day preceding, on or following the occurrence of an event, (i)&#160;that Trading Day shall be deemed to commence immediately after the regular scheduled closing time of trading on the Trading Market on which the Company Common Stock is listed or, if trading is closed at an earlier time, such earlier time and (ii)&#160;that Trading Day shall end at the next regular scheduled closing time, or if trading is closed at an earlier time, such earlier time (for the avoidance of doubt, and as an example, if the Market Price is to be determined as of the last Trading Day preceding a specified event and the closing time of trading on a particular day is 4:00 p.m. and the specified event occurs at 5:00 p.m. on that day, the Market Price would be determined by reference to such 4:00 p.m. closing price).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.95pt 12pt 6pt;">&#8220;<b style="font-weight:bold;">Trading Day</b>&#8221; means a day on which the Company Common Stock is traded on a Trading Market or, if the Company Common Stock is not traded on a Trading Market, then on the principal securities exchange or securities market on which the Company Common Stock is then traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.95pt 12.5pt 6pt;">&#8220;<b style="font-weight:bold;">Trading Market</b>&#8221; means any market or exchange of The Nasdaq Stock Market LLC or the New York Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.95pt 0pt 6pt;">&#8220;<b style="font-weight:bold;">VWAP</b>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (i)&#160;if the Company Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Company Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Company Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)), (ii)&#160;if the Company Common Stock </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 5.95pt 12pt 6pt;">is not then listed on a Trading Market or quoted for trading on the OTC Bulletin Board and if prices for the Company Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Company Common Stock so reported or (iii)&#160;in all other cases, the fair market value of a share of Company Common Stock as determined by an independent nationally recognized investment banking, accounting or valuation firm selected in good faith by the Company and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_2._Issuance_of_Warrant;_Term.__I"></a><font style="color:#010000;">Section&#160;2. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Warrant; Term</b>. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company hereby grants to Holder the right to purchase from the Company [<i style="font-style:italic;"># of shares</i>]<b style="font-weight:bold;"> </b>fully paid and nonassessable shares of the Company&#8217;s voting common stock having a par value $0.001 per share<font style="letter-spacing:2.15pt;"> </font>(the<font style="letter-spacing:2.25pt;"> </font>&#8220;<b style="font-weight:bold;">Company</b><b style="font-weight:bold;letter-spacing:2.45pt;"> </b><b style="font-weight:bold;">Common</b><b style="font-weight:bold;letter-spacing:2.5pt;"> </b><b style="font-weight:bold;">Stock</b>&#8221;).<font style="letter-spacing:1.45pt;"> </font>The<font style="letter-spacing:2.15pt;"> </font>shares<font style="letter-spacing:2.2pt;"> </font>of<font style="letter-spacing:2.15pt;"> </font>Company Common Stock<font style="letter-spacing:2.2pt;"> </font>issuable<font style="letter-spacing:2.15pt;"> </font>upon exercise of this Warrant are hereinafter referred to as the &#8220;<b style="font-weight:bold;">Underlying Shares</b>.&#8221; This Warrant shall be exercisable at any time and from time to time, in whole or in part, during the period commencing on the date hereof and ending on April 19, 2029 (the &#8220;<b style="font-weight:bold;">Expiration Date</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_3._Exercise_Price.__The_exercise"></a><font style="color:#010000;">Section&#160;3. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</b>. The exercise price per share of Company Common Stock for which each Underlying Share may be purchased pursuant to this Warrant shall be $3.0723, subject to adjustment pursuant to <b style="font-weight:bold;">Section 7</b> (the &#8220;<b style="font-weight:bold;">Exercise Price</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_4._Exercise."></a><font style="color:#010000;">Section&#160;4. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(a)_This_Warrant_may_be_exercised_by_the"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font>This Warrant may be exercised by the Holder hereof as to all or any portion of the Underlying Shares, upon delivery of written notice to the Company, together with this original Warrant and (x) payment to the Company of the Aggregate Exercise Price or (y) instruction to the Company to withhold a number of the Underlying Shares then issuable upon exercise of this Warrant with an aggregate value (determined on the basis of the average Market Price per share for the Company Common Stock on the last five Trading Days for such stock ended immediately prior to the applicable Exercise Date, as defined below) equal to such Aggregate Exercise Price (collectively, the &#8220;<b style="font-weight:bold;">Exercise</b>&#8221;, with the date of an Exercise being an &#8220;<b style="font-weight:bold;">Exercise Date</b>&#8221;). The Exercise Price (if paid pursuant to clause&#160;(x) above) shall be payable by delivery by the Holder of a certified or official bank check payable to the order of the Company or wire transfer of immediately available funds to an account designated by the Company. This Warrant shall be deemed to have been so exercised as of the applicable Exercise Date, and the Holder shall be entitled to receive the Underlying Shares issuable upon such Exercise and be treated for all purposes as the holder of record of the Underlying Shares as of such date. Upon the Exercise of this Warrant, the Company shall, within two (2) Business Days of the applicable Exercise Date (the &#8220;<b style="font-weight:bold;">Underlying Share Delivery Date</b>&#8221;), execute and deliver to the Holder of this Warrant (a) a statement confirming the total number of Underlying Shares for which this Warrant is being exercised, and (b) (i) if the Underlying Shares are issued in certificate form, a certificate or certificates for the number of Underlying Shares issuable upon such Exercise, or (ii) if the Underlying Shares are issued in uncertificated form, a written confirmation evidencing the book-entry registration of such Underlying Shares in the Holder&#8217;s name; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that if the Company fails to deliver to Holder such certificate or certificates (in the case of Underlying Shares issued in certificate form) or written confirmation (in the case of Underlying Shares issued in uncertificated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">form) by the Underlying Share Delivery Date, the Holder will have the right to rescind such Exercise. Any rescission by the Holder pursuant to this <b style="font-weight:bold;">Section&#160;4(a)</b> shall not affect any other remedies available to the Holder under applicable law or equity or pursuant to <b style="font-weight:bold;">Section&#160;14 </b>hereof as a result of the Company&#8217;s failure to timely deliver the Underlying Shares. If this Warrant shall be exercised with respect to less than all of the Underlying Shares, the Company shall deliver a new Warrant covering the number of Underlying Shares in respect of which this Warrant shall not have been exercised, which new Warrant shall in all other respects be identical to this Warrant. The Company covenants and agrees that it will pay when due any and all state and federal issue taxes which may be payable in respect of the issuance of this Warrant or the issuance of any Underlying Shares upon<font style="letter-spacing:-0.55pt;"> </font>exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(b)_In_the_event_of_any_withholding_of_s"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font>In the event of any withholding of shares of Underlying Shares pursuant to <b style="font-weight:bold;">Section&#160;4(a)(y) </b>above where the number of the Underlying Shares then issuable upon exercise of this Warrant with an aggregate value equal to the Aggregate Exercise Price is not a whole number, the number of the Underlying Shares withheld by the Company shall be rounded up to the nearest whole share,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.15pt;"> </font>shall<font style="letter-spacing:0.35pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.45pt;"> </font>payment<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>Holder<font style="letter-spacing:0.3pt;"> </font>(by<font style="letter-spacing:0.15pt;"> </font>delivery<font style="letter-spacing:0.1pt;"> </font>of<font style="letter-spacing:0.35pt;"> </font>a certified or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of Underlying Shares being so withheld by the Company in an amount equal to the product of (x) such incremental fraction of Underlying Shares being so withheld or surrendered multiplied by (y) the value per share of Underlying Shares (determined on the basis of the average Market Price per share for the Company Common Stock on the last five Trading Days for such stock ended immediately prior to the applicable Exercise Date).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(c)_The_Company_shall_not_knowingly_effe"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font>The Company shall not knowingly effect the exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant to the extent that, after giving effect to such exercise, the Holder (together with such Person&#8217;s Affiliates) would beneficially own in excess of 9.99% (the &#8220;<b style="font-weight:bold;">Maximum Percentage</b>&#8221;) of the Company Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Company Common Stock beneficially owned by such Person and its Affiliates shall include the number of shares of Company Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Company Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its Affiliates (including, without limitation, any convertible notes or convertible shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act. For purposes of this Warrant, in determining the number of outstanding shares of Company Common Stock, a Holder of this Warrant may rely on<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>number<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.35pt;"> </font>outstanding<font style="letter-spacing:0.3pt;"> </font>shares<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.35pt;"> </font>Company Common Stock<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.4pt;"> </font>reflected<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>most<font style="letter-spacing:0.45pt;"> </font>recent<font style="letter-spacing:0.45pt;"> </font>of (1) the Company&#8217;s Form 10-K, Form 10-Q or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or its transfer agent setting forth the number of shares of Company Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall, within five (5) Business Days, confirm to such Holder the number of shares of its Company Common Stock then outstanding. Furthermore, upon the written request of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company, a Holder shall confirm to the Company its then current beneficial ownership with respect to the Company&#8217;s Company Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_5._No_Fractional_Shares.__No_fra"></a><font style="color:#010000;">Section&#160;5. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Fractional Shares</b>. No fractional shares may be issued upon any exercise of this Warrant or as a consequence of any adjustment pursuant to <b style="font-weight:bold;">Section&#160;7</b>, and any fractions shall be rounded upwards to the nearest whole number of shares. If upon any exercise or adjustment of this Warrant a fraction of a share results, the Company will pay to the Holder the cash value of any such fractional share, calculated on the basis of the Exercise<font style="letter-spacing:-0.85pt;"> </font>Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_6._Securities_Laws."></a><font style="color:#010000;">Section&#160;6. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Laws</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(a)_Holder_acknowledges_that_the_Underly"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font>Holder acknowledges that the Underlying Shares are being offered and sold by the Company in accordance with Regulation D under the Securities Act and that the Underlying Shares will constitute &#8220;restricted securities&#8221; as defined in Rule 144 under the Securities Act. Neither this Warrant nor the Underlying Shares have been registered under the Securities Act, or any state securities laws (&#8220;<b style="font-weight:bold;">Blue Sky Laws</b>&#8221;). This Warrant has been acquired for the Holder&#8217;s own account for investment purposes and not with a current view to distribution or resale and may not be sold or otherwise transferred (i) without an effective registration statement for such Warrant under the Securities Act and such applicable Blue Sky Laws, or (ii) unless Holder shall have delivered to the Company an opinion of counsel to the effect that the Warrant or such portion of the Warrant to be sold or transferred may be sold or transferred under an exemption from such<font style="letter-spacing:-0.05pt;"> </font>registration; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that the foregoing conditions shall not apply to any transfer of this Warrant from Purchaser to (i) any Affiliate, managed fund or account of Oaktree Capital Management, L.P. or (ii) an Affiliate of Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(b)_The_Company_covenants_and_agrees_tha"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company covenants and agrees that all Underlying Shares will, upon issuance and payment therefor, be legally and validly issued and outstanding, free from all taxes, liens, charges and preemptive or similar rights, if any, with respect thereto or to the issuance<font style="letter-spacing:-0.65pt;"> </font>thereof. The Company will take all such action as may be reasonably necessary or appropriate to assure that the Underlying Shares may be issued as provided herein without violating any applicable law or regulation, or any requirements of the Trading Market upon which the Company Common Stock may be listed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(c)_The_certificates_representing_the_Un"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font>The certificates representing the Underlying Shares will bear the following or similar legend, unless the Company determines otherwise in compliance with applicable<font style="letter-spacing:-0.85pt;"> </font>law:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;<font style="font-style:italic;font-weight:bold;">ACT</font>&#8221;), OR UNDER THE SECURITIES LAWS OF ANY STATE. &#160;THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. &#160;INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. &#160;THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_7._Anti-Dilution_Adjustments."></a><font style="color:#010000;">Section&#160;7. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Dilution Adjustments</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(a)_If_the_Company_shall_at_any_time_pri"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font>If the Company shall at any time prior to the expiration of this Warrant (i) pay a stock dividend or otherwise make a distribution or distributions on shares of Company Common Stock or any other equity or equity securities, (ii) subdivide the Company Common Stock (by stock split, recapitalization, or any other similar event) into a larger number of shares, (iii) combine the Company Common Stock (by stock split or reverse stock split, recapitalization, combination of shares, or any other similar event) or (iv) issue by reclassification of shares of Company Common Stock any shares of capital stock of the Company (with the exception of any reclassification that constitutes a Fundamental Change, as hereinafter defined), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to (x) the record date for the determination of stockholders entitled to receive such dividend or distribution or (y) the effective date in the case of a subdivision, combination or re-classification by a fraction, the numerator of which shall be the number of shares of Company Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Company Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the Aggregate Exercise Price shall remain unchanged. Before taking any action which would result in an adjustment in the number of Underlying Shares for which this Warrant is exercisable or to the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.<a name="(b)_Not_less_than_five_(5)_days_prior_to"></a><a name="(c)_If_the_Company_shall_at_any_time_pri"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font>If the Company shall at any time prior to the expiration of this Warrant (in each case, occurring after the date hereof) be a party to any merger, consolidation, exchange of shares of Company Common Stock, sale of a majority of the Company Common Stock, sale of all or substantially all of the assets of the Company, separation, reorganization, recapitalization, winding up or liquidation of the Company, or other similar event or transaction (each, a &#8220;<b style="font-weight:bold;">Fundamental Change</b>&#8221;), as a result of which shares of Company Common Stock shall be changed into the same or a different number or class or classes of securities of the Company or another entity, or the holders of shares of Company Common Stock are entitled to receive cash or other property, then, upon the Exercise of this Warrant by the Holder, such Holder shall receive, for the Aggregate Exercise Price as in effect immediately prior to such Fundamental Change (subject to all other adjustments under this Warrant), the aggregate number of shares or such other securities, cash or other property which such Holder would have received if this Warrant had been exercised immediately prior to such Fundamental Change (collectively, the &#8220;<b style="font-weight:bold;">Fundamental Change Receivable</b>&#8221;), which, upon the Holder&#8217;s election, may be received net of the Aggregate Exercise Price (for the avoidance of doubt, without payment by the Holder of any cash in an amount equal to the then Exercise Price). In the case of any Fundamental Change, the successor or purchasing party of such merger, consolidation, exchange of shares of Company Common Stock, sale of all or substantially all of the assets of the Company or reorganization (if other than the Company) shall duly execute and deliver to the Holder a supplement to this Warrant acknowledging the Company and such party&#8217;s obligations under this <b style="font-weight:bold;">Section&#160;7(b)</b>. The terms of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">this Warrant shall be applicable to the Fundamental Change Receivable due to the Holder upon the consummation of any such Fundamental<font style="letter-spacing:-0.05pt;"> </font>Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font>If the Company, at any time while this Warrant is outstanding, shall otherwise distribute to all holders of Company Common Stock (and not to the Holder or Holders) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security (for the avoidance of doubt, excluding in each such case any Fundamental Change Receivable), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction, the numerator of which shall be such VWAP on such record date less the then Fair Market Value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of Company Common Stock, and the denominator of which shall be the VWAP determined as of the record date mentioned above. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="(d)_Not_less_than_ten_(10)_days_prior_to"></a></font><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font>Not less than five (5) days prior to the record date or effective date, as the case may be, of any event which requires or might require an adjustment or readjustment pursuant to <b style="font-weight:bold;">Section&#160;7(a</b>) or <b style="font-weight:bold;">Section 7(c) </b>(each, an &#8220;<b style="font-weight:bold;">Adjustment Event</b>&#8221;), and not less than ten (10) days prior to the record date or effective date, as the case may be, of any Fundamental Change, the Company shall give written notice of such Adjustment Event or Fundamental Change (as applicable) to the Holder or Holders, describing such Adjustment Event or Fundamental Change in reasonable detail and specifying the record date or effective date, as the case may be. Such notice shall additionally include the Company&#8217;s certification of the following computations, as applicable, each of which shall have been made by the Company in good faith: (i) in the case of an Adjustment Event, if determinable, the required adjustment and the computation thereof or, if the required adjustment is not determinable at the time of such notice, the Company shall give notice to the Holder or Holders of such adjustment and computation promptly after such adjustment becomes determinable, and (ii) in the case of a Fundamental Change, the number of shares or such other securities, cash or other property which is payable to the Holder or Holders upon the Fundamental Change, the computation thereof, and the computation of the then applicable Exercise Price.<a name="(e)_Notwithstanding_any_other_provision_"></a> Except as otherwise prohibited by applicable laws, to the extent that any notice provided pursuant to this <b style="font-weight:bold;">Section 7(d)</b> contains material, non-public information regarding the Company, the Company shall disclose such information regarding the Company in a Current Report on Form 8-K and file such Current Report on Form 8-K with the SEC no later than the second Trading Day following the date such notice is delivered to the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font>Notwithstanding any other provision hereof, if an exercise of all or any portion of this Warrant is to be made in connection with a Fundamental Change or a public offering, such exercise may, at the election of the Holder, be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the consummation of such<font style="letter-spacing:-0.05pt;"> </font>transaction.<a name="(f)_At_all_times_on_and_prior_to_the_Exp"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font>At all times on and prior to the Expiration Date, the Company shall at all times reserve and keep available out of its authorized but unissued Company Common Stock (or other equity interests then constituting Underlying Shares), solely for the purpose of issuance upon </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the exercise of this Warrant, the maximum number of Underlying Shares issuable upon the exercise of this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates or effectuating the book entry of uncertificated shares to execute and issue, or enter, the necessary certificates or book entries (as applicable) for the Underlying Shares upon the exercise of the purchase rights under this Warrant. The Company shall not increase the par value of any Underlying Shares receivable upon the exercise of this Warrant above the Exercise Price then in effect, and shall take all such actions within its power as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Underlying Shares upon the exercise of this<font style="letter-spacing:-0.2pt;"> </font>Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_8._Transfer_of_Warrant.__Subject"></a><font style="color:#010000;">Section&#160;8. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Warrant</b>. Subject to compliance with applicable federal and state securities laws, the Holder may, from time to time, transfer this Warrant or the Underlying Shares, in each case, in whole or in part, by giving the Company a written notice of the portion of the Warrant or the shares of the Underlying Shares being transferred, such notice to set forth the name, address and taxpayer identification number of the transferee, the anticipated date of such transfer, and surrendering this Warrant or the certificates or book-entry records representing shares of the Underlying Shares, as applicable, to the Company for reissuance to the transferee(s). Upon surrender of this Warrant by a Holder to the Company for transfer, in whole or in part, the Company shall issue a new warrant to such Holder in such denomination as shall be requested by such Holder covering the number of Underlying Shares, if any, in respect of which this Warrant shall not have been transferred. Such new warrant shall be identical in all other respects to this<font style="letter-spacing:-0.1pt;"> </font>Warrant. This Warrant may be divided or combined with other Warrants upon presentation hereof at the office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with this <b style="font-weight:bold;">Section&#160;8</b> as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated as of the Initial Issuance Date and shall be identical to this Warrant except as to the number of Underlying Shares issuable pursuant thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><a name="Section_9._No_Impairment.__The_Company_m"></a><font style="color:#010000;">Section&#160;9. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Impairment</b>. The Company may not, including, without limitation, by amendment of its certificate of incorporation or bylaws, or through a Fundamental Change or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and the Company shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder or Holders against impairment. Without limiting the generality of the foregoing, the Company shall take (a) all such action as may be necessary or appropriate in order that the Company may duly and validly issue fully paid and non-assessable Underlying Shares, free from any taxes, liens, charges and preemptive rights, upon the exercise of this<font style="letter-spacing:-0.15pt;"> </font>Warrant, and (b) use its best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be necessary to enable the Company to perform its obligations under this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><a name="Section_10._No_Rights_or_Liabilities_as_"></a><font style="color:#010000;">Section&#160;10. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights or Liabilities as a Stockholder</b>. This Warrant shall not entitle the Holder or Holders hereof to any voting rights or other rights as a stockholder of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">Company with respect to the Underlying Shares prior to the exercise of the Warrant. No provision of this Warrant, in the absence of affirmative action by the Holder or Holders to purchase the Underlying Shares, and no mere enumeration herein of the rights or privileges of the Holder or Holders, shall give rise to any liability of such Holder or Holders for the Exercise Price or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the<font style="letter-spacing:-0.1pt;"> </font>Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_11._Successors.__All_the_covenan"></a><font style="color:#010000;">Section&#160;11. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Company</b>. The Company hereby represents and warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font>As of the Initial Issuance Date, the Company (A)&#160;is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, (B)&#160;has all requisite power and authority to own and operate its properties, to carry on its business as now conducted and as currently proposed to be conducted, to issue and enter into the Warrant and to carry out the transactions contemplated thereby, and (C)&#160;except where the failure to do so, individually or in the aggregate, has not had, and could not be reasonably expected to have, a material adverse effect on the business, assets, financial condition or operations of the Company, is qualified to do business and, where applicable is in good standing, in every jurisdiction where such qualification is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font>This Warrant is, and any Warrant issued in substitution for or replacement of this Warrant (including pursuant to <b style="font-weight:bold;">Section 15</b>) shall be, upon issuance, duly authorized and validly issued. &#160;This Warrant constitutes, and any Warrant issued in substitution for or replacement of this Warrant shall be, upon issuance, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or other similar laws affecting the enforcement of creditors&#8217; rights generally and by general principles of equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font>As of the Initial Issuance Date, the execution, delivery and performance by the Company of the Warrant does not and will not (A)&#160;violate any material provision of applicable law or the organizational documents of the Company, (B) conflict with, result in a breach of, or constitute (with the giving of any notice, the passage of time, or both) a default under any material agreement of the Company or (C) result in or require the creation or imposition of any lien upon any assets of the Company. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="color:#010000;">Section&#160;12. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</b>. All the covenants and provisions of this Warrant by or for the benefit of the Company or the Holder or Holders shall bind and inure to the benefit of their respective successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_12._Survival.__The_rights_of_the"></a><font style="color:#010000;">Section&#160;13. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</b>. The rights of the Holder or Holders under this Warrant, and the covenants and agreements of the Company set forth in this Warrant for the benefit of the Holder or Holders, shall survive exercise of all or any portion of this Warrant and shall inure to the Holder or Holders of any Underlying Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;"><a name="Section_13._Remedies.__If_the_Company_vi"></a><font style="color:#010000;">Section&#160;14. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</b>. If the Company violates, breaches or defaults under this Warrant, the Holder may proceed to protect and enforce its rights by any action at law, suit in equity or other appropriate proceeding, whether for specific performance of any agreement contained in this Warrant, or for an injunction against a violation of any of the terms hereof, or in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 11pt 0pt;">and of the exercise of any power granted hereby or by law, in each case without providing any bond or other security in connection with such action, suit or other proceeding. In case of any violation,<font style="letter-spacing:0.4pt;"> </font>breach<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.35pt;"> </font>default<font style="letter-spacing:0.5pt;"> </font>under<font style="letter-spacing:0.35pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>Warrant,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>Company<font style="letter-spacing:0.05pt;"> </font>shall<font style="letter-spacing:0.45pt;"> </font>pay<font style="letter-spacing:0.2pt;"> </font>to<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>Holder<font style="letter-spacing:0.35pt;"> </font>on<font style="letter-spacing:0.45pt;"> </font>demand all reasonable costs and expenses of enforcing the Holder&#8217;s rights under this Warrant, including, without limitation, reasonable attorneys&#8217; fees and legal expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="color:#010000;">Section&#160;15. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss, Theft, Destruction or Mutilation of Warrant</b>. The Company covenants that upon its receipt of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Underlying Shares (and, in the case of mutilation, the surrender and cancellation of this Warrant or such stock certificate), the Company shall make and deliver to the Holder a new Warrant or stock certificate that is identical to this Warrant or to such stock certificate (as applicable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_14._Article_and_Section_Headings"></a><font style="color:#010000;">Section&#160;16. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article and Section&#160;Headings</b>. Numbered and titled article and section headings are for convenience only and shall not be construed as amplifying or limiting any of the provisions of this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_15._Notice.__Any_and_all_notices"></a><font style="color:#010000;">Section&#160;17. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</b>. Any and all notices, elections or demands permitted or required to be made under this Warrant shall be in writing, signed by the party giving such notice, election or demand and shall be delivered in accordance with the notice provisions in the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_16._Severability.__If_any_provis"></a><font style="color:#010000;">Section&#160;18. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</b>. <font style="letter-spacing:-0.15pt;">If </font>any provisions(s) of this Warrant or the application thereof to any person or circumstances shall be invalid or unenforceable to any extent, the remainder of this Warrant and the application of such provisions to other persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by<font style="letter-spacing:-0.25pt;"> </font>law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_17._Entire_Agreement.__This_Warr"></a><font style="color:#010000;">Section&#160;19. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</b>. This Warrant and between the Company and the Holder represents the entire agreement between the parties concerning the subject matter hereof, and all oral discussions and prior agreement are merged<font style="letter-spacing:-0.2pt;"> </font>herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="color:#010000;">Section&#160;20. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valuation Dispute Resolution</b>. <font style="letter-spacing:-0.15pt;">In </font>the case of any dispute as to the determination of any amount or valuation hereunder or in connection with the amount or value of any Company Common Stock or Underlying Shares to be issued, withheld or otherwise determined, the calculation of the Aggregate Exercise Price or any other computation or valuation required to be made hereunder or in connection herewith, in the event the Holder, on the one hand, and the Company, on the other hand, are unable to settle such dispute within five (5) Business Days, then either party may elect to submit the disputed matter(s) for resolution by an accounting firm of nationally recognized standing as may be mutually agreed upon by the Holder and the Company. Such firm&#8217;s determination of such disputed matter(s) shall be binding upon all parties absent demonstrable error, and the Company and the Holder shall each pay one half of the fees and costs of such<font style="letter-spacing:-0.95pt;"> </font>firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_18._Dispute_Resolution.__In_the_"></a><font style="color:#010000;">Section&#160;21. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</b>. This Warrant and the rights and obligations of the parties hereunder, and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Warrant and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="color:#010000;">Section&#160;22. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction; Waiver of Venue; Service of Process</b>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font>Each party hereto irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against any other party hereto in any way relating to this Warrant or the transactions relating hereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof; and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court. &#160;Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font>Each party hereto irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement in any court referred to in paragraph (a) of this <b style="font-weight:bold;">Section 22</b>. &#160;Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font>Each party hereto irrevocably consents to service of process in the manner provided for notices in <b style="font-weight:bold;">Section 17</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_19._Governing_Law_and_Amendments"></a><font style="color:#010000;">Section&#160;23. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</b>. No amendment or modification hereof shall be effective except in a writing executed by the Company and the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_20._Counterparts.__This_Warrant_"></a><font style="color:#010000;">Section&#160;24. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b>. This Warrant may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same<font style="letter-spacing:-0.3pt;"> </font>Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 11pt 0pt;"><a name="Section_21._Waiver_of_Trial.__EACH_PARTY"></a><font style="color:#010000;">Section&#160;25. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</b>. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). &#160;EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS WARRANT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <b style="font-weight:bold;">SECTION 25</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Page&#160;Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF, </b>the parties hereto have set their hands as of the date first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:53.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page to Warrant</i>]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>4
<FILENAME>btai-20231231xex4d6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:24 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 4.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Execution Version</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This<b style="font-weight:bold;"> SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT</b> (this &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;) is made as of March 20, 2024, by and among BioXcel Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), the purchasers identified on <b style="font-weight:bold;">Schedule A</b> hereto (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Purchaser</font>&#8221;) and such other Persons, if any, from time to time, that become a party hereto as holders of Registrable Securities (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to the Credit Agreement (as defined below), on the Closing Date, the Company issued to each Purchaser a warrant to purchase such number of shares of Common Stock (as defined below) as is set forth opposite such Purchaser&#8217;s name on <b style="font-weight:bold;">Schedule A</b> hereto as the Shares Issuable Upon Exercise of Closing Date Warrants (as such number may be adjusted pursuant to the terms of such warrant) (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrant</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to the Credit Agreement (as defined below), on the Second Amendment Effective Date, the Company issued to each Purchaser a warrant to purchase such number of shares of Common Stock (as defined below) as is set forth opposite such Purchaser&#8217;s name on <b style="font-weight:bold;">Schedule A</b> hereto as the Shares Issuable Upon Exercise of Second Amendment Warrants (as such number may be adjusted pursuant to the terms of such warrant) (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrant</font>&#8221;, collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to the Credit Agreement (as defined below), on March 20, 2024 (the &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Effective Date</font>&#8221;), the Company will issue to each Purchaser a warrant to purchase such number of shares of Common Stock (as defined below) as is set forth opposite such Purchaser&#8217;s name on <b style="font-weight:bold;">Schedule A</b> hereto as the Shares Issuable Upon Exercise of Fourth Amendment Warrants (as such number may be adjusted pursuant to the terms of such warrant) (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrant</font>&#8221;, collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants</font>&#8221; and together with the Closing Date Warrants and the Second Amendment Warrants, the &#8220;<font style="font-style:italic;font-weight:bold;">Warrants</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Warrants will be exercisable for shares of Common Stock from time to time on or after the Closing Date, the Second Amendment Effective Date or the Fourth Amendment Effective Date, as applicable, and on or prior to the close of business on April 19, 2029, in accordance with the terms thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with the execution and delivery of the Credit Agreement and the issuance of the Warrants and the consummation of the transactions contemplated thereby the Company has agreed to grant the Holders (as defined below) certain registration rights as set forth below; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the mutual promises and covenants herein contained, and other consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="white-space:pre-wrap;">.  Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in the Credit Agreement.  As used in this Agreement, the following terms shall have the meanings set forth below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Additional Shares</font>&#8221; means any shares of Common Stock issued to the Purchasers pursuant to a stock split, stock dividend or other distribution with respect to, or in exchange or in replacement of, the Underlying Shares, or in connection with a combination of shares, distribution, recapitalization, merger, consolidation, other reorganization or other similar event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221; has the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Business Day</font>&#8221; means any day, excluding Saturday, Sunday and any day which is a legal holiday in the City of New York or is a day on which banking institutions located in the City of New York are authorized or required by law or other governmental action to remain closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Change of Control</font>&#8221; means an event or series of events (i) as a result of which any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Securities Act, but excluding any of such person or its Subsidiaries, and any Person acting in its capacity as trustee, agent or other fiduciary or administrator of any such Plan and excluding any Permitted Holder becomes the &#8220;beneficial owner&#8221;, directly or indirectly, of thirty-five percent (35%) or more of the Equity Interests of the Company entitled to vote for members of the Board of the Company on a fully-diluted basis (and taking into account all such Equity Interests that such person or group has the right to acquire pursuant to any Option Right); (ii) as a result of which any Permitted Holder or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Securities Act) including any Permitted Holder becomes the &#8220;beneficial owner&#8221;, directly or indirectly, of forty-five percent (45%) or more of the Equity Interests of the Company entitled to vote for members of the Board of the Company on a fully-diluted basis (and taking into account all such Equity Interests that such Permitted Holder or group has the right to acquire pursuant to any Option Right); (iii) that results in the sale of all or substantially all of the assets or businesses of the Company and its Subsidiaries, taken as a whole, or (iv) that results in the Company&#8217;s failure to own, directly or indirectly, beneficially and of record, one-hundred percent (100%) of all issued and outstanding Equity Interests of each Subsidiary Guarantor (other than, in the case of this clause (iv), as a result of any Asset Sale permitted by Section 9.09 of the Credit Agreement, liquidation or dissolution permitted by Section 9.03(b) of the Credit Agreement, the issuance of any Equity Interests in BXCL 701 Subsidiaries pursuant to Section 9.09(o) of the Credit Agreement or a Permitted BXCL 701 Disposition Event, or any interest in or exercise of any 701 Warrant). For purposes of this definition, &#8220;beneficial owner&#8221; is as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that a person or group shall be deemed to have &#8220;beneficial ownership&#8221; of all Equity Interests that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an &#8220;<font style="font-style:italic;font-weight:bold;">Option Right</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrant</font>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Shelf Effectiveness Deadline</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Shelf Registration</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Subsequent Shelf Effectiveness Deadline</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(j)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Subsequent Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(k)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Termination Date</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(l)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221; means shares of the common stock of the Company, par value $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(m)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221; has the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(n)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Company Indemnified Party</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(o)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Controlling Person</font><b style="font-weight:bold;">&#8221; </b>has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(p)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Credit Agreement</font>&#8221; means that certain Credit Agreement and Guaranty (as may be amended or restated from time to time), dated as of April 19, 2022, and amended as of November 13, 2023, December 5, 2023, February 12, 2024 and March 20, 2024 by and among the Company, the subsidiaries of the Company party thereto as Guarantors, the lenders party thereto and Oaktree Fund Administration, LLC, as administrative agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(q)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Default</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(r)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Effectiveness Deadline</font>&#8221; means the Shelf Effectiveness Deadline and the Subsequent Shelf Effectiveness Deadline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(s)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">End of Suspension Notice</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(t)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Effective Date</font>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(u)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrant</font>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Shelf Effectiveness Deadline</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(w)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Shelf Registration</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(y)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Subsequent Shelf Effectiveness Date</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(z)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Subsequent Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(aa)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Termination Date</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(bb)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Holder</font>&#8221; (collectively, &#8220;<font style="font-style:italic;font-weight:bold;">Holders</font>&#8221;) means any Purchaser and any transferee permitted under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u>, in each case, to the extent holding or beneficially owning Registrable Securities or Warrants exercisable for Registrable Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(cc)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Holder Indemnified Parties</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(dd)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Indemnified Party</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ee)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Liquidated Damages</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ff)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Option Right</font>&#8221; has the meaning set forth in the definition of &#8220;Change of Control&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(gg)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Person</font>&#8221;&#160;means any person, individual, corporation, limited liability company, partnership, trust or other nongovernmental entity or any governmental agency, court, authority or other body (whether foreign, federal, state, local or otherwise).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(hh)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Prospectus</font>&#8221; means the prospectus or prospectuses (whether preliminary or final) included in any Registration Statement and relating to Registrable Securities, as amended or supplemented and including all material incorporated by reference in such prospectus or prospectuses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Purchaser</font>&#8221; has the meaning set forth in the Preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(jj)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">register</font>,&#8221; &#8220;<font style="font-style:italic;font-weight:bold;">registered</font>&#8221; and &#8220;<font style="font-style:italic;font-weight:bold;">registration</font>&#8221; refer to a registration effected by filing with the SEC a registration statement in compliance with the Securities Act, and the declaration or ordering by the SEC of the effectiveness of such registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(kk)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Registrable Securities</font>&#8221; means (i) the Underlying Shares, and (ii) any Additional Shares; <i style="font-style:italic;">provided, however</i>, that Underlying Shares or Additional Shares shall cease to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be treated as Registrable Securities on the earliest to occur of, (A) the date such security has been disposed of pursuant to an effective registration statement, (B) the date on which such security is sold pursuant to Rule 144 or (C) the date on which the Holder thereof, together with its Affiliates, is able to dispose of all of its Registrable Securities without restriction or limitation pursuant to Rule 144 and without the requirement for the Company to be in compliance with Rule 144 (or any successor rule).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ll)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Registration Expenses</font>&#8221; means any and all expenses incident to the Company&#8217;s performance of or compliance with this Agreement, including without limitation: (i)&#160;all SEC registration and filing fees, (ii) all fees and expenses associated with filings to be made with, or the listing of any Registrable Securities on, any securities exchange or over-the-counter trading market on which the Registrable Securities are to be listed or quoted, (iii) all fees and expenses with respect to filings required to be made with an exchange or any securities industry self-regulatory body, (iv) all fees and expenses of compliance with securities or &#8220;blue sky&#8221; laws (including fees and disbursements of counsel for the Company in connection therewith), (v)&#160;all transfer agent&#8217;s and registrar&#8217;s fees, (vi) all fees and disbursements of counsel for the Company and customary fees and expenses for independent certified public accountants retained by the Company, (vii) securities acts liability insurance, if the Company so desires, (viii) all internal expenses of the Company (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), (ix)&#160;<font style="white-space:pre-wrap;">the expense of any annual audit, and (x) the fees and expenses of any Person, including special experts, retained by the Company.  &#8220;</font><font style="font-style:italic;font-weight:bold;">Registration Expenses</font>&#8221; shall not include underwriting discounts or commissions attributable to the sale of the Registrable Securities or any legal fees and expenses of counsel to the Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(mm)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Registration Statement</font>&#8221; means any registration statement of the Company under the Securities Act which covers any of the Registrable Securities pursuant to the provisions of this Agreement, including the Prospectus, all amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits and all documents incorporated by reference in such Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(nn)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Rule 144</font>&#8221; means Rule 144 under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(oo)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">SEC</font>&#8221; means the U.S. Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(pp)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrant</font>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(qq)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Shelf Effectiveness Deadline</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(rr)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Shelf Registration</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ss)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(tt)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Subsequent Shelf Effectiveness Date</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(uu)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Subsequent Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vv)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Termination Date</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ww)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, as the same may be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xx)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Shelf Effectiveness Deadline</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(yy)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(i)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(zz)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Subsequent Shelf Effectiveness Deadline</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(aaa)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Subsequent Shelf Registration Statement</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(c)(ii)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(bbb)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Suspension Event</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ccc)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Suspension Notice</font>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ddd)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Trading Day</font>&#8221; means a day on which the Common Stock is traded on a Trading Market or, if the Common Stock is not traded on a Trading Market, then on the principal securities exchange or securities market on which the Common Stock is then traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(eee)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Trading Market</font>&#8221; means any market or exchange of The Nasdaq Stock Market LLC or the New York Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(fff)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Underlying Shares</font>&#8221; means any and all shares of Common Stock issuable upon exercise of the Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ggg)</font></font>&#8220;<font style="font-style:italic;font-weight:bold;">Warrant</font>&#8221; has the meaning set forth in the Recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shelf Registration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date Warrants Shelf Registration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Filing</u><font style="white-space:pre-wrap;">.  Within 45 days following the Closing Date, the Company shall file with the SEC a Registration Statement on Form S-3 (unless the Company is ineligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form) or the then appropriate form for an offering to be made on a delayed or continuous basis pursuant to Rule 415 under the Securities Act or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">any successor rule thereto (a &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Shelf Registration Statement</font>&#8221;) pursuant to which all of the Registrable Securities associated with the Closing Date Warrants shall be included (on the initial filing or by supplement or amendment thereto) to enable the public resale of such Registrable Securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act or any successor rule thereto (a &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Shelf Registration</font><font style="white-space:pre-wrap;">&#8221;).  If permitted under the Securities Act, such Closing Date Warrants Shelf Registration Statement shall be an &#8220;automatic shelf registration statement&#8221; as defined in Rule 405 under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effectiveness</u><font style="white-space:pre-wrap;">.  The Company shall use its reasonable best efforts to (A)&#160;cause the Closing Date Warrants Shelf Registration Statement filed pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(a)(i)</u> to be declared effective by the SEC as soon as reasonably practicable, and in any event by the date that is the earlier of (1) 120 days following the Closing Date and (2) five Trading Days after the date the Company receives written notification from the SEC that the Closing Date Warrants Shelf Registration will not be reviewed (the &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Shelf Effectiveness Deadline</font>&#8221;) and (B)&#160;maintain the effectiveness of such Closing Date Warrants Shelf Registration Statement, including by filing any necessary post-effective amendments and Prospectus supplements and by filing one or more replacement or renewal Closing Date Warrants Shelf Registration Statements (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Subsequent Shelf Registration Statement</font>&#8221;) upon the expiration of such Closing Date Warrants Shelf Registration Statement, if required by Rule 415 under the Securities Act, continuously until the earliest to occur of (1) the 30-month anniversary of the Closing Date, (2) a Change of Control and (3) such time as there are no Registrable Securities remaining or issuable upon exercise of the Closing Date Warrants (the &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Termination Date</font>&#8221;). If a Closing Date Warrants Subsequent Shelf Registration Statement is filed, the Company shall use its reasonable best efforts to (x) cause such Closing Date Warrants Subsequent Shelf Registration Statement to be declared effective by the SEC as soon as reasonably practicable after such filing, but in any event by the date that is fifty (50) days after such Closing Date Warrants Subsequent Shelf Registration Statement is filed (the &#8220;<font style="font-style:italic;font-weight:bold;">Closing Date Warrants Subsequent Shelf Effectiveness Deadline</font>&#8221;), and (y)&#160;keep such Closing Date Warrants Subsequent Shelf Registration Statement (or another Closing Date Warrants Subsequent Shelf Registration Statement) continuously effective until the Closing Date Warrants Termination Date. Any Closing Date Warrants Subsequent Shelf Registration Statement shall be a Closing Date Warrants Shelf Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Amendment Warrants Shelf Registration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Filing</u><font style="white-space:pre-wrap;">.  Within 45 days following the Second Amendment Effective Date, the Company shall file with the SEC a new Registration Statement or an amendment to an effective Registration Statement on Form S-3 (unless the Company is ineligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form) or the then appropriate form for an offering to be made on a delayed or continuous basis pursuant to Rule 415 under the Securities Act or any successor rule thereto (a &#8220;</font><font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Shelf Registration Statement</font>&#8221;) pursuant to which all of the Registrable Securities associated with the Second Amendment Warrants shall be included (on the initial filing or by supplement or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">amendment thereto) to enable the public resale of such Registrable Securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act or any successor rule thereto (a &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Shelf Registration</font><font style="white-space:pre-wrap;">&#8221;).  If permitted under the Securities Act, such Second Amendment Warrants Shelf Registration Statement shall be an &#8220;automatic shelf registration statement&#8221; as defined in Rule 405 under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effectiveness</u><font style="white-space:pre-wrap;">.  The Company shall use its reasonable best efforts to (A)&#160;cause the Second Amendment Warrants Shelf Registration Statement filed pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(b)(i)</u> to be declared effective by the SEC as soon as reasonably practicable, and in any event by the date that is the earlier of (1) 120 days following the Second Amendment and (2) five Trading Days after the date the Company receives written notification from the SEC that the Second Amendment Warrants Shelf Registration will not be reviewed (the &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Shelf Effectiveness Deadline</font>&#8221;) and (B)&#160;maintain the effectiveness of such Second Amendment Warrants Shelf Registration Statement, including by filing any necessary post-effective amendments and Prospectus supplements and by filing one or more replacement or renewal Second Amendment Warrants Shelf Registration Statements (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Subsequent Shelf Registration Statement</font>&#8221;) upon the expiration of such Second Amendment Warrants Shelf Registration Statement, if required by Rule 415 under the Securities Act, continuously until the earliest to occur of (1) the 30-month anniversary of the Second Amendment Effective Date, (2) a Change of Control and (3) such time as there are no Registrable Securities remaining or issuable upon exercise of the Second Amendment Warrants (the &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Termination Date</font>&#8221;). If a Second Amendment Warrants Subsequent Shelf Registration Statement is filed, the Company shall use its reasonable best efforts to (x) cause such Second Amendment Warrants Subsequent Shelf Registration Statement to be declared effective by the SEC as soon as reasonably practicable after such filing, but in any event by the date that is fifty (50) days after such Second Amendment Warrants Subsequent Shelf Registration Statement is filed (the &#8220;<font style="font-style:italic;font-weight:bold;">Second Amendment Warrants Subsequent Shelf Effectiveness Deadline</font>&#8221;), and (y)&#160;keep such Second Amendment Warrants Subsequent Shelf Registration Statement (or another Second Amendment Warrants Subsequent Shelf Registration Statement) continuously effective until the Second Amendment Warrants Termination Date. Any Second Amendment Warrants Subsequent Shelf Registration Statement shall be a Second Amendment Warrants Shelf Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fourth Amendment Warrants Shelf Registration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Filing</u><font style="white-space:pre-wrap;">.  Within 45 days following the Fourth Amendment Effective Date, the Company shall file with the SEC a new Registration Statement or an amendment to an effective Registration Statement on Form S-3 (unless the Company is ineligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form) or the then appropriate form for an offering to be made on a delayed or continuous basis pursuant to Rule 415 under the Securities Act or any successor rule thereto (a &#8220;</font><font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Shelf Registration Statement</font>&#8221; and together with the Closing Date Warrants Shelf Registration Statements and the Second Amendment Warrants Shelf Registration Statement, a &#8220;<font style="font-style:italic;font-weight:bold;">Shelf</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-style:italic;font-weight:bold;">Registration Statement</font>&#8221;) pursuant to which all of the Registrable Securities associated with the Fourth Amendment Warrants shall be included (on the initial filing or by supplement or amendment thereto) to enable the public resale of such Registrable Securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act or any successor rule thereto (a &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Shelf Registration</font><font style="white-space:pre-wrap;">&#8221;).  If permitted under the Securities Act, such Fourth Amendment Warrants Shelf Registration Statement shall be an &#8220;automatic shelf registration statement&#8221; as defined in Rule 405 under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effectiveness</u><font style="white-space:pre-wrap;">.  The Company shall use its reasonable best efforts to (A)&#160;cause the Fourth Amendment Warrants Shelf Registration Statement filed pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1(c)(i)</u> to be declared effective by the SEC as soon as reasonably practicable, and in any event by the date that is the earlier of (1) 120 days following the Fourth Amendment Effective Date and (2) five Trading Days after the date the Company receives written notification from the SEC that the Fourth Amendment Warrants Shelf Registration will not be reviewed (the &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Shelf Effectiveness Deadline</font>&#8221; and together with the Closing Date Warrants Shelf Effectiveness Deadline and the Second Amendment Warrants Shelf Effectiveness Deadline, the &#8220;<font style="font-style:italic;font-weight:bold;">Shelf Effectiveness Deadline</font>&#8221;) and (B)&#160;maintain the effectiveness of such Fourth Amendment Warrants Shelf Registration Statement, including by filing any necessary post-effective amendments and Prospectus supplements and by filing one or more replacement or renewal Fourth Amendment Warrants Shelf Registration Statements (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Subsequent Shelf Registration Statement</font>&#8221; and together with the Closing Date Warrants Subsequent Shelf Registration Statements and the Second Amendment Warrants Subsequent Shelf Registration Statements, a &#8220;<font style="font-style:italic;font-weight:bold;">Subsequent Shelf Registration Statement</font>&#8221;) upon the expiration of such Fourth Amendment Warrants Shelf Registration Statement, if required by Rule 415 under the Securities Act, continuously until the earliest to occur of (1) the 30-month anniversary of the Fourth Amendment Effective Date, (2) a Change of Control and (3) such time as there are no Registrable Securities remaining or issuable upon exercise of the Fourth Amendment Warrants (the &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Termination Date</font>&#8221;). If a Fourth Amendment Warrants Subsequent Shelf Registration Statement is filed, the Company shall use its reasonable best efforts to (x) cause such Fourth Amendment Warrants Subsequent Shelf Registration Statement to be declared effective by the SEC as soon as reasonably practicable after such filing, but in any event by the date that is fifty (50) days after such Fourth Amendment Warrants Subsequent Shelf Registration Statement is filed (the &#8220;<font style="font-style:italic;font-weight:bold;">Fourth Amendment Warrants Subsequent Shelf Effectiveness Deadline</font>&#8221; and together with the Closing Date Warrants Subsequent Shelf Effectiveness Deadline and the Second Amendment Warrants Subsequent Shelf Effectiveness Deadline, the &#8220;<font style="font-style:italic;font-weight:bold;">Subsequent Shelf Effectiveness Deadline</font>&#8221;), and (y)&#160;keep such Fourth Amendment Warrants Subsequent Shelf Registration Statement (or another Fourth Amendment Warrants Subsequent Shelf Registration Statement) continuously effective until the Fourth Amendment Warrants Termination Date. Any Fourth Amendment Warrants Subsequent Shelf Registration Statement shall be a Fourth Amendment Warrants Shelf Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Default</u>. In the event that (i) the Shelf Registration Statement filed pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(a)(i)</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(b)(i)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(c)(i)</u> is not declared effective by the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">SEC by the applicable Shelf Effectiveness Deadline, (ii) a Subsequent Shelf Registration Statement (if required to be filed pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(a)(ii)</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(b)(ii)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(c)(ii)</u>) is not filed by the applicable Subsequent Shelf Effectiveness Deadline, or (iii) after a Shelf Registration Statement has been declared effective, sales cannot be made continuously pursuant to such Shelf Registration Statement for any reason (including without limitation by reason of a stop order, or the Company&#8217;s failure to update the Shelf Registration Statement), other than, in each case, during the time period(s) permitted by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(b)</u> (each such event, a &#8220;<font style="font-style:italic;font-weight:bold;">Default</font>&#8221;), then, in addition to any other rights a Holder may have hereunder or under applicable law, on the first day of the occurrence of the Default, and on the same day of each succeeding month (if the applicable Default shall not have been cured by such date) until the applicable Default is cured, the Company shall pay to each Holder an amount in cash, as liquidated damages and not as a penalty (the &#8220;<font style="font-style:italic;font-weight:bold;">Liquidated Damages</font>&#8221;), on the date of the Default and the same day each succeeding month, equal to 1% of the aggregate purchase price paid for the applicable Registrable Securities held by such Holder. The parties agree that in no event shall the aggregate amount of Liquidated Damages payable to any Holder exceed, in the aggregate, twenty-five percent (25%) of the aggregate purchase price paid for the applicable Registrable Securities held by such Holder. If the Company fails to pay any Liquidated Damages pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(d)</u> in full within five (5) Business Days after the date payable, the Company will pay interest thereon at a rate of 1.5% per month (or such lesser maximum amount that is permitted to be paid by applicable law) to each Holder, accruing daily from the date such Liquidated Damages are due until such amounts, plus all such interest thereon, are paid in full. The Liquidated Damages pursuant to the terms hereof shall apply on a daily pro-rata basis for any portion of a month prior to the cure of a Default, except in the case of the first occurrence of the Default. The applicable Effectiveness Deadline shall be extended without Default or Liquidated Damages hereunder in the event that the Company&#8217;s failure to obtain the effectiveness of such Shelf Registration Statement or Subsequent Shelf Registration Statement on a timely basis results from the failure of any Holder to timely provide the Company with information requested by the Company and necessary to complete the Shelf Registration Statement or Subsequent Shelf Registration Statement in accordance with the requirements of the Securities Act (in which case the applicable Effectiveness Deadline would be extended with respect to the applicable Registrable Securities held by such Holder).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Selling Stockholders</u><font style="white-space:pre-wrap;">.  At any time and from time to time that a Shelf Registration Statement is effective, if a Holder of Registrable Securities requests that such Holder be added as a selling stockholder in such Shelf Registration Statement, the Company shall as promptly as practicable amend or supplement the Shelf Registration Statement to cover such Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Provisions Relating to Registration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If and whenever the Company is required to effect the registration of any Registrable Securities pursuant to this Agreement, the Company shall use its reasonable best efforts to effect and facilitate the registration of such Registrable Securities as promptly as is practicable and, pursuant thereto, the Company shall as expeditiously as possible and as applicable:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>prepare and file with the SEC a Registration Statement with respect to such Registrable Securities, make all required filings required in connection therewith and (if the Registration Statement is not automatically effective upon filing) use its reasonable best efforts to cause such Registration Statement to become effective as promptly as practicable; <i style="font-style:italic;">provided</i> that before filing a Registration Statement or any amendments or supplements thereto, the Company shall furnish to counsel to the Holders for such registration copies of all documents proposed to be filed, which documents shall be subject to review by counsel to the Holders at the Holders&#8217; expense, and give the Holders participating in such registration an opportunity to comment on such documents and keep such Holders reasonably informed as to the registration process;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ii)</font></font>furnish to each Holder participating in the registration, without charge, such number of copies of the Prospectus included in such Registration Statement (including each preliminary Prospectus) and any supplement thereto (in each case including all exhibits thereto and all documents incorporated by reference therein) and such other documents as such Holder may reasonably request, including in order to facilitate the disposition of the Registrable Securities owned by such Holder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)</font></font>use its reasonable best efforts to register or qualify such Registrable Securities under such other securities or blue sky laws of such U.S. jurisdiction(s) or such U.S. self-regulatory bodies as any Holder participating in the registration reasonably requests and do any and all other acts and things that may be necessary or reasonably advisable to enable such Holder to consummate the disposition of such Holder&#8217;s Registrable Securities in such jurisdiction(s); <i style="font-style:italic;">provided</i>, that the Company shall not be required to qualify generally to do business, subject itself to taxation or consent to general service of process in any jurisdiction where it would not otherwise be required to do so but for its obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2(a)(iii)</u>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iv)</font></font>notwithstanding any other provisions of this Agreement to the contrary, cause (A) any Registration Statement (as of the effective date of the Registration Statement), any amendment thereof (as of the effective date thereof) or supplement thereto (as of its date), (1)&#160;to comply in all material respects with the applicable requirements of the Securities Act and the rules and regulations of the SEC and (2) not to contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and (B) any related Prospectus, preliminary Prospectus and any amendment thereof or supplement thereto (as of its date), (1) to comply in all material respects with the applicable requirements of the Securities Act and the rules and regulations of the SEC, and (2) not to contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <i style="font-style:italic;">provided, however</i>, the Company shall have no such obligations or liabilities with respect to any written information pertaining to a Holder and furnished to the Company by or on behalf of such Holder specifically for inclusion therein;&#160;<i style="font-style:italic;">provided further</i>, that each Holder of Registrable Securities, upon receipt of any notice from the Company of any noncompliance event or material misstatement or omission of the kind described in this&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(a)(iv)</u>, shall forthwith discontinue disposition of Registrable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">pursuant to the Registration Statement covering such Registrable Securities until such Holder is advised in writing by the Company that the use of the Prospectus may be resumed and, if appropriate, is furnished with a supplemented or amended Prospectus as contemplated by this&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(a)(iv)</u>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(v)</font></font>as promptly as practicable (and in any event, within twenty-four (24) hours), notify the Holders: (A) when the Registration Statement, any pre-effective amendment thereto, the Prospectus or any Prospectus supplement or any post-effective amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective amendment thereto has become effective, (B) of any oral or written comments by the SEC or of any request by the SEC for amendments or supplements to the Registration Statement or the Prospectus included therein or for any additional information regarding such Holder, (C) of the issuance by the SEC of any stop order suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceedings for that purpose and of any other action, event or failure to act that would cause the Registration Statement not to remain effective, and (D) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any Registrable Securities for sale under the applicable securities or blue sky laws of any jurisdiction or the initiation of any proceeding for such purpose;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vi)</font></font>in the event of the issuance of any stop order suspending the effectiveness of a Registration Statement, any order suspending or preventing the use of any related Prospectus or any suspension of the qualification or exemption from qualification of any Registrable Securities for sale in any jurisdiction, use its reasonable best efforts to promptly obtain the withdrawal or lifting of any such order or suspension, and each Holder of Registrable Securities, upon receipt of any notice from the Company of any event of the kind described in this&#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(a)(vi)</u>, shall forthwith discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Holder is advised in writing by the Company that the use of the Prospectus may be resumed and is furnished with a supplemented or amended Prospectus, if applicable;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(vii)</font></font>not file or make any amendment to any Registration Statement with respect to any Registrable Securities, or any amendment of or supplement to the Prospectus used in connection therewith, that refers to any Holder covered thereby by name or otherwise identifies such Holder as the holder of any securities of the Company without the consent of such Holder (which consent shall not be unreasonably withheld, conditioned or delayed), unless and to the extent such disclosure is required by law; <i style="font-style:italic;">provided</i>, that (A) each Holder shall furnish to the Company in writing such information regarding itself and the distribution proposed by it as the Company may reasonably request for use in connection with a Registration Statement or Prospectus and (B) each Holder agrees to notify the Company as promptly as practicable of any inaccuracy or change in information previously furnished to the Company by such Holder or of the occurrence of any event that would cause the Prospectus included in such Registration Statement to contain an untrue statement of a material fact regarding such Holder or the distribution of such Registrable Securities or to omit to state any material fact regarding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">such Holder or the distribution of such Registrable Securities required to be stated therein or necessary to make the statements made therein not misleading in light of the circumstances under which they were made and to furnish to the Company, as promptly as practicable, any additional information required to correct and update the information previously furnished by such Holder such that such Prospectus shall not contain any untrue statement of a material fact regarding such Holder or the distribution of such Registrable Securities or omit to state a material fact regarding such Holder or the distribution of such Registrable Securities necessary to make the statements therein not misleading in light of the circumstances under which they were made;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(viii)</font></font>cause such Registrable Securities to be listed on each securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on any securities exchange, use its reasonable best efforts to cause such Registrable Securities to be listed on a national securities exchange selected by the Company after consultation with the Holders participating in such registration;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(ix)</font></font>provide a transfer agent and registrar (which may be the same Person) for all such Registrable Securities not later than the effective date of such Registration Statement and, within a reasonable time prior to any proposed sale of Registrable Securities pursuant to a Registration Statement, provide the transfer agent if reasonably required by the transfer agent, an opinion of counsel as to the effectiveness of the Registration Statement, together with any other authorizations, certificates and directions required by the transfer agent which authorize and direct the transfer agent to issue such Registrable Securities without legend upon sale by the Holder of such Registrable Securities under the Registration Statement, subject to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(x)</font></font>otherwise use its reasonable best efforts to comply with all applicable rules and regulations of the SEC, and make available to its stockholders, as soon as reasonably practicable, an earnings statement (in a form that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act or any successor rule thereto) covering the period of at least 12 months beginning with the first day of the Company&#8217;s first full fiscal quarter after the effective date of the applicable Registration Statement, which requirement shall be deemed satisfied if the Company timely files complete and accurate information on Forms 10-K, 10-Q and 8-K under the Exchange Act and otherwise complies with Rule 158 under the Securities Act or any successor rule thereto;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xi)</font></font>(A)&#160;furnish to each Holder all legal opinions of outside counsel to the Company required to be included in the Registration Statement, which provision shall be satisfied by filing with the SEC any such opinion as an exhibit to the Registration Statement and (B) obtain all consents of independent public accountants required to be included in the Registration Statement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xii)</font></font>cooperate with the Holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates representing the Registrable Securities to be sold pursuant to such Registration Statement free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">the Holders of the Registrable Securities may reasonably request a reasonable period of time prior to sales of Registrable Securities pursuant to such Registration Statement; <i style="font-style:italic;">provided</i>, that the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company&#8217;s Direct Registration System; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(xiii)</font></font>otherwise use its reasonable best efforts to take or cause to be taken all other actions necessary or reasonably advisable to effect the registration of such Registrable Securities contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>As promptly as practicable after becoming aware of such event, the Company shall notify the Holders of the happening of any event (a &#8220;<font style="font-style:italic;font-weight:bold;">Suspension Event</font>&#8221;), of which the Company has knowledge, as a result of which the Prospectus included in a Registration Statement as then in effect includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, and as promptly as practicable, the Company shall prepare and file with the SEC a supplement or amendment to the Registration Statement to correct such untrue statement or omission, and deliver such number of copies of such supplement or amendment to the Holders as the Holders may reasonably request so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus will not contain any untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading in the light of the circumstances under which they were made; <i style="font-style:italic;">provided, however</i>, that, for not more than forty-five (45) consecutive days (or a total of not more than one hundred and twenty (120) Trading Days in any 12-month period), the Company may delay or suspend the filing, effectiveness or use of a Registration Statement or Prospectus, to the extent permitted by and in a manner not in violation of applicable securities laws, if the board of directors of the Company determines in good faith, based on the advice of counsel, that (i) proceeding with the filing, effectiveness or use of such Registration Statement or Prospectus would reasonably be expected to require the Company to disclose any information the disclosure of which would have a material adverse effect on the Company and that the Company would not otherwise be required to disclose at such time or (ii) the registration or offering proposed to be delayed or suspended would reasonably be expected to, if not delayed or suspended, have a material adverse effect on any pending negotiation or plan of the Company to effect a merger, acquisition, disposition, financing, reorganization, recapitalization or similar transaction, in each case that, if consummated, would be material to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Upon a Suspension Event, the Company shall promptly give written notice (a &#8220;<font style="font-style:italic;font-weight:bold;">Suspension Notice</font><font style="white-space:pre-wrap;">&#8221;) to the Holders to suspend sales of the affected Registrable Securities, and such notice shall state that such suspension shall continue only for so long as the Suspension Event or its effect is continuing and the Company is pursuing with reasonable diligence the completion of the matter giving rise to the Suspension Event or otherwise taking all reasonable steps to terminate suspension of the effectiveness or use of the Registration Statement.  In no event shall the Company, without the prior written consent of the Holders, disclose to the Holders any of the facts or circumstances giving rise to the Suspension Event.  The Holders shall not effect any sales of the Registrable Securities pursuant to the Registration Statement (or such filings), at any time after they have received a Suspension Notice and prior to receipt of an End of Suspension Notice.  The Holders may resume effecting sales of the Registrable Securities</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">under the Registration Statement (or such filings), following further notice to such effect (an &#8220;<font style="font-style:italic;font-weight:bold;">End of Suspension Notice</font><font style="white-space:pre-wrap;">&#8221;) from the Company.  This End of Suspension Notice shall be given by the Company to the Holders in the manner described above promptly following the conclusion of any Suspension Event and its effect.  For the avoidance of doubt, a Suspension Notice shall not affect or otherwise limit sales of affected Registrable Securities under Rule 144 or otherwise outside of the Registration Statement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Notwithstanding any provision herein to the contrary, if the Company gives a Suspension Notice pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2(c)</u> with respect to any Registration Statement, the Company shall extend the period during which the Registration Statement shall be maintained effective under this Agreement by the number of days during the period from the date of the giving of the Suspension Notice to and including the date when the Holders shall have received the End of Suspension Notice and copies of the supplemented or amended Prospectus necessary to resume sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Notwithstanding anything to the contrary contained in this Agreement, the Company shall not be required to include Registrable Securities in any Registration Statement unless the Holder owning the Registrable Securities to be registered on the Registration Statement, following reasonable advance written request by the Company, furnishes to the Company, at least ten Business Days prior to the scheduled filing date of the Registration Statement, an executed stockholder questionnaire in the form attached hereto as <b style="font-weight:bold;">Exhibit A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Registration Expenses</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall bear all Registration Expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The obligation of the Company to bear and pay the Registration Expenses shall apply irrespective of whether a registration becomes effective or is withdrawn or suspended; <i style="font-style:italic;">provided</i>, that the Registration Expenses for any Registration Statement withdrawn solely at the request of one or more Holder(s) (unless withdrawn following commencement of a Suspension Event) shall be borne by such Holder(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall, to the fullest extent permitted by law, indemnify and hold harmless each Holder and any Person who is or might be deemed to be a &#8220;controlling person&#8221; of such Holder (within the meaning of the Securities Act or the Exchange Act) (each such Person, a &#8220;<font style="font-style:italic;font-weight:bold;">Controlling Person</font>&#8221;), as well as their respective direct and indirect general and limited partners, advisory board members, directors, officers, trustees, managers, members, employees, agents, Affiliates and shareholders, and each other Person, if any, who acts on behalf of or controls any such Holder or Controlling Person (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Holder Indemnified Parties</font>&#8221;) from and against any losses, claims, damages, liabilities or expenses, joint or several, or any actions in respect thereof to which each Holder Indemnified Party may become subject under the Securities Act, the Exchange Act, any state blue sky securities laws, insofar as such losses, claims, damages, liabilities, expenses or actions arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in or incorporated by reference in any Registration Statement or in any amendment thereof, in each case at the time</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">such became effective under the Securities Act, (ii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (iii)&#160;any violation or alleged violation by the Company of the Securities Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to the Company and relating to any action or inaction required of the Company in connection with any registration of securities, and the Company shall reimburse, as incurred, the Holder Indemnified Parties for any reasonable and documented legal or other expenses reasonably incurred by them in connection with investigating, defending or settling any such loss, claim, damage, liability, expense or action in respect thereof; <i style="font-style:italic;">provided, however</i>, that the Company shall not be liable in any such case to the extent that such loss, claim, damage, liability, expense or action arises out of or is based upon any untrue statement or omission made or incorporated by reference in any such Registration Statement, any Prospectus or in any amendment thereof or supplement thereto in reliance upon and in conformity with written information pertaining to a Holder and furnished to the Company by or on behalf of such Holder Indemnified Party specifically for inclusion therein; and <i style="font-style:italic;">provided further, however</i><font style="white-space:pre-wrap;">, that this indemnity agreement will be in addition to any liability that the Company may otherwise have to such Holder Indemnified Party.  Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of any Holder Indemnified Parties and shall survive the transfer of the Registrable Securities by any Holder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In connection with any registration in which a Holder of Registrable Securities is participating, each such Holder shall furnish to the Company in writing such information as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus and shall, severally and not jointly, to the fullest extent permitted by law, indemnify and hold harmless the Company, its directors and officers, employees, agents and any Person who is or might be deemed to be a Controlling Person (a &#8220;<font style="font-style:italic;font-weight:bold;">Company Indemnified Party</font><font style="white-space:pre-wrap;">&#8221;) from and against any losses, claims, damages, liabilities or expenses or any actions in respect thereof, to which a Company Indemnified Party may become subject under the Securities Act, the Exchange Act, any state blue sky securities laws, any equivalent non-U.S. securities laws or otherwise, insofar as such losses, claims, damages, liabilities or actions arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or in any amendment thereof, in each case at the time such became effective under the Securities Act, or in any Prospectus or in any amendment thereof or supplement thereto, or (ii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, in the light of the circumstances under which they were made) not misleading, but in each of clauses (i) and (ii), only to the extent that the untrue statement or omission or alleged untrue statement or omission was made in reliance upon and in conformity with written information pertaining to such Holder and furnished to the Company by or on behalf of such Holder specifically for inclusion therein, and, subject to the limitation immediately preceding this clause, shall reimburse, as incurred, the Company Indemnified Parties for any legal or other expenses reasonably incurred by them in connection with investigating, defending or settling any such loss, claim, damage, liability, expense or action in respect thereof.  Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Holder, or any such director, officer, employees, Affiliates and agents and shall survive the transfer of such Registrable Securities by such Holder, and such Holder shall reimburse the Company, and each such director, officer, employees, Affiliates and agents for any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">legal or other expenses reasonably incurred by them in connection with investigating, defending, or settling any such loss, claim, damage, liability, action, or proceeding; <i style="font-style:italic;">provided, however</i>, that the indemnity amount contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4(b)</u><font style="white-space:pre-wrap;"> shall in no event exceed the net proceeds actually received by such Holder in the sale of Registrable Securities to which such Registration Statement or Prospectus relates.  Such indemnity shall remain in full force and effect, regardless of any investigation made by or on behalf of the Company or any such director, officer, employees, Affiliates and agents and shall survive the transfer by a Holder of such Registrable Securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Promptly after receipt by a Holder Indemnified Party or a Company Indemnified Party (each, an &#8220;<font style="font-style:italic;font-weight:bold;">Indemnified Party</font>&#8221;) of notice of the commencement of any action or proceeding (including a governmental investigation), such Indemnified Party will, if a claim in respect thereof is to be made against the indemnifying party under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u>, notify the indemnifying party of the commencement thereof; <i style="font-style:italic;">provided</i>, that the omission to so notify the indemnifying party will not relieve the indemnifying party from liability under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.4(a)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.4(b)</u> unless and to the extent it did not otherwise learn of such action and the indemnifying party has been materially prejudiced by such failure. In case any such action is brought against any Indemnified Party, and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof at the indemnifying party&#8217;s expense, with counsel reasonably satisfactory to such Indemnified Party (who shall not, except with the consent of the Indemnified Party, be counsel to the indemnifying party); <i style="font-style:italic;">provided</i><font style="white-space:pre-wrap;">, that any Indemnified Party shall continue to be entitled to participate in the defense of such claim or action, with counsel of its own choice, but the indemnifying party shall not be obligated to reimburse such Indemnified Party for any fees, costs and expenses subsequently incurred by the Indemnified Party in connection with such defense unless (i) the indemnifying party has agreed in writing to pay such fees, costs and expenses, (ii) the indemnifying party has failed to assume the defense of such claim or action within a reasonable time after receipt of notice of such claim or action, (iii) having assumed the defense of such claim or action, the indemnifying party fails to employ counsel reasonably acceptable to the Indemnified Party or to pursue the defense of such claim or action in a reasonably vigorous manner, (iv) the use of counsel chosen by the indemnifying party to represent the Indemnified Party would present such counsel with a conflict of interest or (v) the Indemnified Party has reasonably concluded that there may be one or more legal or equitable defenses available to it and/or other any other Indemnified Party which are different from or additional to those available to the indemnifying party.  In no event shall the indemnifying party be liable for the fees and expenses of more than one counsel (together with appropriate local counsel) at any time for any Indemnified Party in connection with any one action or separate but substantially similar or related actions arising in the same jurisdiction out of the same general allegations or circumstances.  No indemnifying party shall, without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed), effect any settlement of any pending or threatened action in respect of which any Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party unless such settlement (i) includes an unconditional release of such Indemnified Party from all liability on any claims that are the subject matter of such action, in form and substance reasonably satisfactory to such Indemnified Party, and (ii) does not include a</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">statement as to or an admission of fault, culpability or a failure to act by or on behalf of any Indemnified Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>If the indemnification provided for in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u> is unavailable or insufficient to hold harmless an Indemnified Party under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.4(a)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.4(b)</u>, then each indemnifying party shall contribute to the amount paid or payable by such Indemnified Party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 2.4(a)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.4(b)</u><font style="white-space:pre-wrap;"> in such proportion as is appropriate to reflect the relative fault of the indemnifying party or parties on the one hand and the Indemnified Party on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities (or actions in respect thereof) as well as any other relevant equitable considerations.  The relative fault of the parties shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or a Holder or Holder Indemnified Party, as the case may be, on the other, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.  The amount paid by an Indemnified Party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u> shall be deemed to include any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any action or claim that is the subject of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(d)</u><font style="white-space:pre-wrap;">.  The parties agree that it would not be just and equitable if contributions were determined by </font><i style="font-style:italic;">pro rata</i><font style="white-space:pre-wrap;"> allocation (even if a Holder was treated as one Person for such purpose) or any other method of allocation that does not take account of the equitable considerations referred to above.  Notwithstanding any other provision of this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.4(d)</u><font style="white-space:pre-wrap;">, no Holder shall be required to contribute any amount in excess of the amount by which the net proceeds received by such Holder from the sale of the Registrable Securities pursuant to the Registration Statement exceeds the amount of damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The agreements contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u> shall survive the sale of the Registrable Securities pursuant to the Registration Statement and shall remain in full force and effect, regardless of any termination or cancellation of this Agreement or any investigation made by or on behalf of any Indemnified Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restrictions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Restrictions</u><font style="white-space:pre-wrap;">.  Each Holder acknowledges and agrees that the following legend shall be imprinted on any certificate or book-entry security entitlement evidencing any of the Registrable Securities to the extent that at the time of issuance such Registrable Securities are not covered by an effective Registration Statement:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;<font style="font-style:italic;font-weight:bold;">ACT</font>&#8221;), OR UNDER THE SECURITIES LAWS OF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">ANY STATE. &#160;THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. &#160;INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. &#160;THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This legend shall be removed by the Company from any certificate or book-entry security entitlement evidencing the Registrable Securities upon delivery by the holder thereof to the Company of a written request to that effect if at the time of such written request (a)&#160;a registration statement under the Securities Act is at that time in effect with respect to the legended security, or (b) the legended security can be transferred in a transaction in compliance with Rule 144, and, in the case of (b), upon the request and in the reasonable discretion of the Company&#8217;s transfer agent, the holder of such Registrable Securities executes and delivers a representation letter that includes customary representations regarding the holding requirements and whether such holder is an &#8220;affiliate&#8221; for purposes of Rule 144. The Company represents and warrants to the Purchasers that the Company is not currently a shell company (as defined in Rule 405 promulgated under the Securities Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule 144 Compliance</u><font style="white-space:pre-wrap;">.  With a view to making available to the Holders of Registrable Securities the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration until such date on which the Holders no longer hold any Registrable Securities, the Company shall:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>make and keep public information available, as those terms are understood and defined in Rule 144;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>use reasonable best efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>furnish to any Holder of Registrable Securities, promptly upon request, a written statement by the Company as to its compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies; Specific Performance</u><font style="white-space:pre-wrap;">.  In the event of a breach or a threatened breach by any party to this Agreement of its obligations under this Agreement, any party injured or to be injured by such breach shall be entitled to specific performance of its rights under this Agreement or to injunctive relief, in addition to being entitled to exercise all rights provided in this Agreement and granted by law, it being agreed by the parties that the remedy at law, including monetary damages, for breach of any such provision will be inadequate compensation for any loss and that any defense or objection in any action for specific performance or injunctive relief for which a remedy at law would be adequate is hereby waived.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waivers</u><font style="white-space:pre-wrap;">.  No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u><font style="white-space:pre-wrap;">.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="white-space:pre-wrap;">.  All notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile or e-mail as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If to the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">BioXcel Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">555 Long Wharf Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">New Haven, CT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Attn: Chief Financial Officer<br>Email: RSteinhart@bioxceltherapeutics.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">With a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Cooley LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">3 Embarcadero Center</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">20th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">San Francisco, CA 94111-4004</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Attention: Mischi a Marca</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Email: gmamarca@cooley.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">If to a Purchaser: To the address set forth opposite such Purchaser&#8217;s name on <b style="font-weight:bold;">Schedule A </b>hereto, or to such other address and/or e-mail address and/or to the attention of such other person as the recipient party has specified by written notice given to each other party at least five days prior to the effectiveness of such change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">With a copy (which shall not constitute notice) to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Sullivan &amp; Cromwell LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">New York, NY 10004</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">E-mail: blauta@sullcrom.com<br>Attn: Ari Blaut</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Notices or communications sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received, notices or communications sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient) and notices or communications sent by e-mail shall be deemed received upon the sender&#8217;s receipt of an acknowledgement from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail or other written acknowledgement) (except that, if not given during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="white-space:pre-wrap;">.  Section headings herein are included for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed counterpart of a signature page of this Agreement by facsimile or in electronic (i.e., &#8220;pdf&#8221; or &#8220;tif&#8221;) format shall be effective as delivery of a manually executed counterpart of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Disputes</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="white-space:pre-wrap;">.   This Agreement and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction.</u><font style="white-space:pre-wrap;">   Each party hereto hereby irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or tort or otherwise, against such other party in any way relating to this Agreement or the transactions relating hereto or thereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable Law, in such federal court. Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Venue.</u><font style="white-space:pre-wrap;">   Each party hereto irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such party is or may be subject, by suit upon judgment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</u><i style="font-style:italic;white-space:pre-wrap;">.   </i><font style="white-space:pre-wrap;">EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B)&#160;ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 4.7</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service of Process</u><font style="white-space:pre-wrap;">.   Each party hereto irrevocably consents to service of process in the manner provided for notices in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u><font style="white-space:pre-wrap;">.  This Agreement and the rights and obligations evidenced hereby shall be binding upon and inure to the benefit of the parties hereto and their respective the successors and permitted assigns.  Neither this Agreement nor any right, benefit, remedy, obligation or liability arising hereunder may be assigned by any party without the prior written consent of the other parties, and any attempted assignment without such consent shall be null and void and of no effect; </font><i style="font-style:italic;">provided that</i> that, (a) the rights (and related obligations and liabilities) offered a Holder pursuant to this Agreement shall be assignable (in whole or in part) by such Holder to any transferee of such Holder&#8217;s Registrable Securities or Warrants exercisable for Registrable Securities and (b) any such assignment shall be effected hereunder only by giving written notice thereof from both the transferor and the transferee to the Company and the transferee&#8217;s execution and delivery to the Company of an executed counterpart to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</u><font style="white-space:pre-wrap;">.  No provision of this Agreement may be amended, waived or modified other than by an instrument in writing signed by the Company and Holders representing at least fifty percent (50%) (by number) of the Registrable Securities then held by the Holders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.10</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="white-space:pre-wrap;">.  Any provision of this Agreement held to be invalid, illegal or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">enforceability of the remaining provisions hereof, and the invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.11</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><font style="white-space:pre-wrap;">.  This Agreement shall terminate with respect to any Holder upon such time as such Holder ceases to hold or beneficially own any remaining Registrable Securities or upon the dissolution, liquidation or winding up of the Company or a Change of Control; </font><i style="font-style:italic;">provided that </i><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u> of this Agreement and this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article IV</u> shall survive such termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.12</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</u><font style="white-space:pre-wrap;">.  This Agreement is intended for the sole benefit of the parties hereto and their respective permitted successors and assigns and transferees, and is not for the benefit of, nor may any provision hereof be enforced by, any other person; </font><i style="font-style:italic;">provided, however</i>, that the parties hereto hereby acknowledge that the Persons set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u> shall be express third-party beneficiaries of the obligations of the parties hereto set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.13</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Language; Currency</u><font style="white-space:pre-wrap;">.  This Agreement has been prepared in the English language and the English language shall control its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the parties regarding this Agreement, shall be in the English language.  All references to &#8220;$&#8221; contained in this Agreement shall refer to United States Dollars unless otherwise stated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[The remainder of this page intentionally left blank]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties hereto have duly executed this Agreement as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">THE COMPANY:</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">BioXcel Therapeutics, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a Delaware corporation</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Vimal Mehta</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vimal Mehta</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PURCHASERS:</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TCDRS STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-FORREST MULTI-STRATEGY, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND C, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND F, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND G, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TSE 16 STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INPRS STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE</b><b style="font-weight:bold;letter-spacing:-0.8pt;"> </b><b style="font-weight:bold;">SPECIALTY</b><b style="font-weight:bold;letter-spacing:-0.8pt;"> </b><b style="font-weight:bold;">LENDING </b><b style="font-weight:bold;letter-spacing:-0.1pt;">CORPORATION</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree<font style="letter-spacing:-0.15pt;"> </font>Fund<font style="letter-spacing:-0.1pt;"> </font>Advisors,<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">LLC</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment Adviser</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE</b><b style="font-weight:bold;letter-spacing:-0.65pt;"> </b><b style="font-weight:bold;">STRATEGIC</b><b style="font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="font-weight:bold;">CREDIT</b><b style="font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;">FUND</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree<font style="letter-spacing:-0.15pt;"> </font>Fund<font style="letter-spacing:-0.1pt;"> </font>Advisors,<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">LLC</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment Adviser</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE GCP FUND DELAWARE HOLDINGS, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Global Credit Plus Fund GP, L.P.</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Global Credit Plus Fund GP Ltd.</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE DIVERSIFIED INCOME FUND INC.</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree<font style="letter-spacing:-0.15pt;"> </font>Fund<font style="letter-spacing:-0.1pt;"> </font>Advisors,<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">LLC</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment Adviser</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE</b><b style="font-weight:bold;letter-spacing:-0.7pt;"> </b><b style="font-weight:bold;">AZ</b><b style="font-weight:bold;letter-spacing:-0.8pt;"> </b><b style="font-weight:bold;">STRATEGIC</b><b style="font-weight:bold;letter-spacing:-0.65pt;"> </b><b style="font-weight:bold;">LENDING FUND, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree<font style="letter-spacing:-0.05pt;"> </font>AZ<font style="letter-spacing:-0.2pt;"> </font>Strategic<font style="letter-spacing:-0.05pt;"> </font>Lending<font style="letter-spacing:-0.15pt;"> </font>Fund GP,<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.2pt;">L.P.</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree<font style="letter-spacing:-0.2pt;"> </font>Fund<font style="letter-spacing:-0.1pt;"> </font>GP IIA, <font style="letter-spacing:-0.25pt;">LLC</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree<font style="letter-spacing:-0.2pt;"> </font>Fund<font style="letter-spacing:-0.1pt;"> </font>GP<font style="letter-spacing:-0.05pt;"> </font>II,<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.2pt;">L.P.</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing<font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">Member</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Matthew Stewart</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Mary Gallagly</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Oaktree LSL Fund Holdings EURRC S.&#224; r.l.</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26A, boulevard Royal L-2449</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Luxembourg, Grand Duchy of Luxembourg</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R.C.S Luxembourg Number: B269245</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Eckel</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Eckel</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Flora Verrecchia</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Flora Verrecchia</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE LSL FUND DELAWARE HOLDINGS EURRC, L.P.</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Life Sciences Lending Fund GP, L.P.</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:top;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Life Sciences Lending Fund GP Ltd.</p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:27.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:21.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:21.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:27.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:28.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Q Boost Holding LLC</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:59.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:30.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ahmed Nasser Al-Abdulghani</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ahmed Nasser Al-Abdulghani</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Schedule A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Exhibit A<br>Form of Selling Stockholder Questionnaire<br>BIOXCEL THERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Plan of Distribution</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A-20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22_4
<SEQUENCE>5
<FILENAME>btai-20231231xex10d224.htm
<DESCRIPTION>EX-10.22_4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:24 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.22.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Execution Version</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FOURTH AMENDMENT TO CREDIT AGREEMENT AND GUARANTY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Fourth Amendment to Credit Agreement and Guaranty (this &#8220;<font style="font-style:italic;font-weight:bold;">Amendment</font>&#8221;) is made as of March 20, 2024, by and among BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Borrower</font>&#8221;), the lenders party hereto (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Lenders</font>&#8221; and individually, a &#8220;<font style="font-style:italic;font-weight:bold;">Lender</font>&#8221;), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent on behalf of the Lenders (in such capacity, together with its successors and assigns, the &#8220;<font style="font-style:italic;font-weight:bold;">Administrative Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Borrower, the Administrative Agent and the Lenders previously entered into that certain Credit Agreement and Guaranty, dated as of April 19, 2022 (including the exhibits and other attachments thereto, as amended by that certain Waiver and First Amendment to Credit Agreement and Guaranty, dated as of November 13, 2023, that certain Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing, dated as of December 5, 2023, and that certain Third Amendment to Credit Agreement, dated as of February 12, 2024, the &#8220;<font style="font-style:italic;font-weight:bold;">Existing Credit Agreement</font>&#8221;, and as further amended by this Amendment, the &#8220;<font style="font-style:italic;font-weight:bold;">Credit Agreement</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Borrower, the Administrative Agent and the Lenders have agreed to amend the Existing Credit Agreement on the terms and subject to the conditions set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, each of the Borrower, the Administrative Agent and the Lenders party hereto hereby covenant and agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Existing Credit Agreement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</u>. &#160;Subject to the satisfaction of the conditions precedent specified in Section 4 hereof, the Existing Credit Agreement shall be amended as follows:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Section 8.01(b) of the Existing Credit Agreement shall be deleted in its entirety and replaced as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>&#8220;(b)<font style="display:inline-block;width:19.9pt;"></font>as soon as available and in any event within ninety (90) days after the end of each fiscal year (i) the consolidated balance sheets of the Borrower and its Subsidiaries as of the end of such fiscal year and (ii) the related consolidated statements of income, stockholders&#8217; equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, in each case prepared in all material respects in accordance with GAAP consistently applied, all in reasonable detail and setting forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of Ernst &amp; Young U.S. LLP or another firm of independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent, which report and opinion shall be prepared in accordance with generally accepted auditing standards and such report and opinion shall not be subject to (x) except with respect to the report and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">opinion delivered for the fiscal year ending on December 31, 2023, any &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote or (y) any qualification or exception as to the scope of such audit, and in the case of such consolidated financial statements, certified by a Responsible Officer of the Borrower; provided that documents required to be furnished pursuant to this Section 8.01(b) shall be deemed furnished on the date that such documents are publicly available on &#8220;EDGAR&#8221;;&#8221;.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The definition of &#8220;Company Warrants&#8221; in Section 1.01 of the Existing Credit Agreement shall be deleted in its entirety and replaced as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="white-space:pre-wrap;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Company Warrants</font>&#8221; means (i) those certain warrants, dated as of the Closing Date and delivered pursuant to Section 6.01(h), evidenced by an instrument substantially the form of Exhibit J-1 hereto, as amended on the Second Amendment Effective Date and as further amended, replaced or otherwise modified pursuant to the terms thereof, (ii) those certain warrants, dated as of the Second Amendment Effective Date, evidenced by an instrument substantially the form of <b style="font-weight:bold;">Exhibit J-1</b> hereto, as amended, replaced or otherwise modified pursuant to the terms thereof, and (iii) those certain warrants, dated March 20, 2024, evidenced by an instrument substantially the form of <b style="font-weight:bold;">Exhibit A</b> to the Fourth Amendment to Credit Agreement and Guaranty, dated March 20, 2024, by and among the Borrower, the Lenders and the Administrative Agent.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The definition of &#8220;Registration Rights Agreement&#8221; in Section 1.01 of the Existing Credit Agreement shall be deleted in its entirety and replaced as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="white-space:pre-wrap;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Registration Rights Agreement</font>&#8221; means that certain Second Amended and Restated Registration Rights Agreement, dated March 20, 2024, by and among the Borrower and the purchasers identified therein.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reaffirmation of Loan Documents</u>. &#160;Except as otherwise expressly provided herein, the parties hereto agree that all terms and conditions of the Existing Credit Agreement and the other Loan Documents remain in full force and effect. &#160;The Borrower hereby confirms that the Security Documents and all of the Collateral described therein do, and shall continue to, secure the payment in full and performance of all of the Obligations.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent to Effectiveness</u>. &#160;The effectiveness of this Amendment shall be subject to the following conditions precedent:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment shall have been duly executed and delivered to the Administrative Agent by the Borrower and the Lenders, which constitute the &#8220;Majority Lenders&#8221; as defined in the Existing Credit Agreement;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each of the representations and warranties in Section 6 of this Amendment, Section 7 of the Credit Agreement and in the other Loan Documents shall be true, accurate and complete in all material respects (unless such representations are already qualified by reference to materiality, Material Adverse Effect or similar language, in which case such representations and warranties shall be true and correct in all</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">respects) on and as of the date hereof with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all respects on and as of such earlier date; and</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At the time of and after giving effect to this Amendment, no fact or condition exists that constitutes, or with the passage of time, the giving of notice, or both, would constitute, a Default or Event of Default.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Condition Subsequent and Post-Closing Covenant</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In addition to the conditions precedent set forth in the preceding Section 4, the effectiveness of this Amendment shall be subject to the following:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within two calendar days of the date hereof, the Borrower shall have issued and delivered to the Lenders warrants, evidenced by an instrument substantially in the form of <b style="font-weight:bold;">Exhibit A</b> hereto, dated as of the date of issuance, exercisable at $3.0723 &#160;per share and for an aggregate number of shares of common stock of the Borrower set forth in <b style="font-weight:bold;">Exhibit B</b> hereto;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within two calendar days of the date hereof, the second amended and restated Registration Rights Agreement in form and substance reasonably satisfactory to the Administrative Agent shall have been duly executed and delivered to the Administrative Agent by the Borrower; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within two calendar days of the date hereof, the Borrower shall have paid all costs, fees and expenses of the Administrative Agent and the Lenders, including, without limitation, the fees and expenses of Sullivan &amp; Cromwell LLP, as outside counsel to Administrative Agent and the Oaktree Lenders and the fees and expenses of Shearman &amp; Sterling LLP, as outside counsel to Q Boost Holding LLC, incurred prior to the date hereof, to the extent invoiced on or prior to the date hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Borrower shall receive, (i) after the date hereof and on or before April 15, 2024, at least $25,000,000 in gross proceeds from the issuance of Borrower&#8217;s common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the date hereof (so long as such partnering transactions would not require the Borrower or any of its Subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made), and (ii) after the date hereof and on or before November 30, 2024, at least $50,000,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of Borrower&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the date hereof. Failure to perform this covenant shall constitute (A) a Default under the Credit Agreement and (B) an</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Event of Default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024 (provided, for the avoidance of doubt, that failure to perform clause (ii) of the preceding sentence shall constitute an immediate Event of Default under the Credit Agreement without any cure or grace period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In addition, if the Borrower has not, after the date hereof and on or before September 30, 2024, received at least $40,000,000 in gross proceeds from the issuance of Borrower&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the date hereof, the definition of &#8220;Minimum Liquidity Amount&#8221; in Section 1.01 of the Existing Credit Agreement shall be deleted in its entirety and replaced as follows effective as of September 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Minimum Liquidity Amount</font>&#8221; means (i) from the Closing Date until the date on which the Tranche B Term Loans are funded (the &#8220;<font style="font-style:italic;font-weight:bold;">Step-Up Date</font>&#8221;), $25,000,000; <i style="font-style:italic;">provided</i>, that if the Borrower has received at least $50,000,000 in gross proceeds from the issuance of Borrower&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after March 20, 2024 and on or before November 30, 2024, the Minimum Liquidity Amount shall be $15,000,000; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">further</i>, that upon and following the occurrence of a Permitted BXCL 701 Release Event, the Minimum Liquidity Amount shall be $27,500,000; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">further</i>, that upon and following the occurrence of a Permitted BXCL 701 Control Event, the Minimum Liquidity Amount shall be $32,500,000; (ii) from and after the Step-Up Date, $20,000,000; <i style="font-style:italic;">provided</i>, that upon and following the occurrence of a Permitted BXCL 701 Release Event, the Minimum Liquidity Amount shall be $32,500,000; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">further</i>, that upon and following the occurrence of a Permitted BXCL 701 Control Event, the Minimum Liquidity Amount shall be $37,500,000; and (iii) from and after the Applicable Funding Condition for Tranche C Term Loans is satisfied (as evidenced by an officer&#8217;s certificate delivered by the Borrower to the Administrative Agent) (the &#8220;<font style="font-style:italic;font-weight:bold;">Step-Down Date</font>&#8221;), $25,000,000; <i style="font-style:italic;">provided</i>, that if the Borrower has received at least $50,000,000 in gross proceeds from the issuance of Borrower&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after March 20, 2024 and on or before November 30, 2024, the Minimum Liquidity Amount shall be $15,000,000; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">further</i>, that upon and following the occurrence of a Permitted BXCL 701 Release Event, the Minimum Liquidity Amount shall be $27,500,000; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">further</i>, that upon and following the occurrence of a Permitted BXCL 701 Control Event, the Minimum Liquidity Amount shall be $32,500,000. &#160;For the avoidance of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 108pt;">doubt, the Minimum Liquidity Amount shall be the highest applicable amount at any time. Notwithstanding the foregoing or anything to the contrary herein, the Minimum Liquidity Amount shall in no event exceed 50% of the aggregate amount of Loans outstanding at any time.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</u>. &#160;The Borrower hereby represents and warrants:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">None of the execution, delivery and performance by the Borrower of this Amendment and the documents, instruments and agreements executed in connection herewith (collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Amendment Documents</font>&#8221;) or performance under the Amendment Documents (i)&#160;requires any Governmental Approval of, registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (x) such as have been obtained or made and are in full force and effect and (y)&#160;filings and recordings in respect of perfecting or recording the Liens created pursuant to the Security Documents, (ii) will violate (1) any Law, (2) any Organic Document of the Borrower or any of its Subsidiaries or (3) any order of any Governmental Authority, that in the case of clause&#160;(ii)(1) or clause (ii)(3), individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect, (iii) will violate or result in a default under any Material Agreement binding upon the Borrower or any of its Subsidiaries that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect or (iv) will result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of the Borrower or any of its Subsidiaries.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment and the other Amendment Documents have been duly authorized by all necessary corporate or other organizational action including, if required, approval by all necessary holders of Equity Interests, and duly executed and delivered by the Borrower and constitutes, and each of the Amendment Documents when executed and delivered by the Borrower will constitute, a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors&#8217; rights and (ii) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In consideration of this Amendment and agreements of the Administrative Agent and the Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Borrower (the &#8220;<font style="font-style:italic;font-weight:bold;">Releasing Party</font>&#8221;), on behalf of itself and its successors, assigns and other legal representatives hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges the Administrative Agent and the Lenders and their respective present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives, in each case solely in their capacities relative to the Lenders and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">not in any other capacity such party may have relative to the Releasing Party (the Administrative Agent, each Lender and all such other Persons being hereinafter referred to collectively as the &#8220;<font style="font-style:italic;font-weight:bold;">Releasees</font>&#8221; and individually as a &#8220;<font style="font-style:italic;font-weight:bold;">Releasee</font>&#8221;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which the Borrower or any of its successors, assigns or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the date hereof, for or on account of, or in relation to, or in any way in connection with the Credit Agreement or any of the other Loan Documents or transactions thereunder (any of the foregoing, a &#8220;<font style="font-style:italic;font-weight:bold;">Claim</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Claims</font>&#8221;). &#160;The Releasing Party expressly acknowledges and agrees, with respect to the Claims, that it waives, to the fullest extent permitted by applicable law, any and all provisions, rights and benefits conferred by any applicable U.S. federal or state law, or any principle of U.S. common law, that would otherwise limit a release or discharge of any unknown Claims pursuant to this Section 7. &#160;Furthermore, the Releasing Party hereby absolutely, unconditionally and irrevocably covenants and agrees with and in favor of each Releasee that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis of any Claim released and/or discharged by the Releasing Parties pursuant to this Section 7. &#160;The foregoing release, covenant and waivers of this Section 7 shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment or prepayment of any of the Loans, or the termination of the Credit Agreement, this Amendment, any other Loan Document or any provision hereof or thereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each Releasing Party understands, acknowledges and agrees that its release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Each Releasing Party agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Expenses</u>. &#160;The Borrower agrees to pay on demand (a) all out-of-pocket fees, costs and expenses of the Administrative Agent and the Lenders accrued prior to the date hereof and (b) all out-of-pocket fees, costs and expenses of the Administrative Agent and the Lenders incurred in connection with the preparation, execution and delivery of (i)&#160;this Amendment, (ii)&#160;any Amendment Documents, other Loan Documents or other post-closing amendments, agreements, arrangements or documentation, (iii) any other instruments and documents to be delivered hereunder or thereunder, in each case of clauses (a) and (b), including the fees and expenses of Sullivan &amp; Cromwell LLP, as outside counsel to</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Administrative Agent and the Oaktree Lenders, and Shearman &amp; Sterling LLP, as outside counsel to Q Boost Holding LLC, with respect thereto.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Except as otherwise expressly provided herein, (i) all provisions of the Credit Agreement and the other Loan Documents remain in full force and effect and (ii) the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the Existing Credit Agreement or any of the Loan Documents. &#160;None of the Administrative Agent or any Lender is under any obligation to enter into this Amendment. &#160;The entering into of this Amendment by such parties shall not be deemed to limit or hinder any rights of any such party under the Loan Documents, nor shall it be deemed to create or infer a course of dealing between any such party, on the one hand, and the Borrower, on the other hand, with regard to any provision of the Loan Documents. &#160;This Amendment shall constitute a Loan Document.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment may be executed in several counterparts and by each party on a separate counterpart, each of which when so executed and delivered shall be an original, and all of which together shall constitute one instrument. &#160;An executed facsimile or electronic copy of this Amendment shall be effective for all purposes as an original hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment expresses the entire understanding of the parties with respect to the amendments contemplated hereby. &#160;No prior negotiations or discussions shall limit, modify, or otherwise affect the provisions hereof.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#010000;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Amendment and its contents shall be subject to the governing law, indemnification, venue, service of process, waivers of jury trial and severability provisions of the Existing Credit Agreement, mutatis mutandis.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[SIGNATURE PAGES FOLLOW]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the day and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BORROWER</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vimal Mehta</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">555 Long Wharf Drive, 12th Floor New Haven, CT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">06511</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to (which shall not constitute notice):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cooley LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3 Embarcadero Center 20th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Francisco, CA 94111-4004 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: Mischi a Marca</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: gmamarca@cooley.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADMINISTRATIVE AGENT</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE FUND ADMINISTRATION, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Fund Administration, LLC </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">333 S. Grand Avenue, 28th Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">333 S. Grand Avenue, 28th Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn:&#160;&#160;&#160;&#160;Aman Kumar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  AmKumar@oaktreecapital.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn:&#160;&#160;&#160;&#160;Ari B. Blaut</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  blauta@sullcrom.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LENDERS</b><b style="font-weight:bold;">:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TCDRS STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.2pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-FORREST MULTI-STRATEGY, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND C, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND F, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TBMR STRATEGIC CREDIT FUND G, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE-TSE 16 STRATEGIC CREDIT, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INPRS STRATEGIC CREDIT HOLDINGS, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE SPECIALTY LENDING CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Fund Advisors, LLC</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment Adviser</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE STRATEGIC CREDIT FUND</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Fund Advisors, LLC</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment Adviser</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE GCP FUND DELAWARE HOLDINGS, L.P.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Global Credit Plus Fund GP, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Global Credit Plus Fund GP Ltd.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE DIVERSIFIED INCOME FUND INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Fund Advisors, LLC</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investment Adviser</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE AZ STRATEGIC LENDING FUND, L.P.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree AZ Strategic Lending Fund GP, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Fund GP IIA, LLC</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Fund GP II, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Member</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE LSL FUND HOLDINGS EURRC S.&#192; R.L. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26A, boulevard Royal L-2449 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Luxembourg, Grand Duchy of Luxembourg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R.C.S Luxembourg Number: B269245 </p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Eckel</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Eckel</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Flora Verrecchia</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Flora Verrecchia</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Manager</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OAKTREE LSL FUND DELAWARE HOLDINGS EURRC, L.P.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Life Sciences Lending Fund GP, L.P.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Life Sciences Lending Fund GP Ltd.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Partner</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P. </p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Matthew Stewart</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mary Gallagly</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Managing Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for Notices:<br>Oaktree Fund Administration, LLC<br>333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.<br>Los Angeles, CA 90071 <br>Attn:&#160;&#160;&#160;&#160;Oaktree Agency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Email:  Oaktreeagency@alterdomus.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oaktree Capital Management, L.P.<br> 333 S. Grand Avenue, 28<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Fl.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Los Angeles, CA 90071 <br><font style="white-space:pre-wrap;">Attn:   Aman Kumar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: AmKumar@oaktreecapital.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sullivan &amp; Cromwell LLP <br>125 Broad Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, NY 10004 <br><font style="white-space:pre-wrap;">Attn:   Ari B. Blaut</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: blauta@sullcrom.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Q BOOST HOLDING LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ahmed Nasser Al-Abdulghani</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ahmed Nasser Al-Abdulghani</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address<font style="letter-spacing:-0.1pt;"> </font>for <font style="letter-spacing:-0.1pt;">Notices:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 71.65pt 0pt 0pt;">c/o<font style="letter-spacing:-0.65pt;"> </font>Qatar<font style="letter-spacing:-0.65pt;"> </font>Investment<font style="letter-spacing:-0.65pt;"> </font>Authority </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 71.65pt 0pt 0pt;">Ooredoo Tower (Building 14) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 71.65pt 0pt 0pt;">Al Dafna Street (Street 801)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 105.95pt 0pt 0pt;">Al<font style="letter-spacing:-0.65pt;"> </font>Dafna<font style="letter-spacing:-0.65pt;"> </font>(Zone<font style="letter-spacing:-0.65pt;"> </font>61) Doha, Qatar</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 5.9pt 0pt 0pt;">A<font style="letter-spacing:-0.35pt;"> </font>copy<font style="letter-spacing:-0.3pt;"> </font>(which<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>not<font style="letter-spacing:-0.35pt;"> </font>constitute<font style="letter-spacing:-0.3pt;"> </font>notice) shall also be sent to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Counsel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 81.7pt 0pt 0pt;">Qatar Investment Authority</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 81.7pt 0pt 0pt;">Ooredoo<font style="letter-spacing:-0.65pt;"> </font>Tower<font style="letter-spacing:-0.65pt;"> </font>(Building<font style="letter-spacing:-0.65pt;"> </font>14) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 81.7pt 0pt 0pt;">Al Dafna Street (Street 801) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 81.7pt 0pt 0pt;">Al Dafna (Zone 61)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:13.75pt;margin:0pt;">Doha,<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Qatar</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:<font style="letter-spacing:-0.1pt;"> </font><u style="letter-spacing:-0.1pt;text-decoration-line:underline;text-decoration-style:solid;">notices.legal@qia.qa</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4.5pt 5.9pt 0pt 0pt;">A<font style="letter-spacing:-0.35pt;"> </font>copy<font style="letter-spacing:-0.3pt;"> </font>(which<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.3pt;"> </font>not<font style="letter-spacing:-0.35pt;"> </font>constitute<font style="letter-spacing:-0.3pt;"> </font>notice) shall also be sent to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 82.95pt 0pt 0pt;">Shearman &amp; Sterling LLP </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 82.95pt 0pt 0pt;">535<font style="letter-spacing:-0.45pt;"> </font>Mission<font style="letter-spacing:-0.55pt;"> </font>Street,<font style="letter-spacing:-0.45pt;"> </font>25<sup style="font-size:7.5pt;vertical-align:top;">th</sup><font style="letter-spacing:-0.5pt;"> </font>Floor </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 82.95pt 0pt 0pt;">San Francisco, CA 94105 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 82.95pt 0pt 0pt;"><font style="letter-spacing:-0.1pt;white-space:pre-wrap;">Attn:  </font>Michael S. Dorf</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 81.7pt 0pt 0pt;"><font style="white-space:pre-wrap;">          Tomasz Kulawik </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 81.7pt 0pt 0pt;">Email:<font style="letter-spacing:-0.75pt;"> </font>mdorf@shearman.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">           </font><font style="letter-spacing:-0.1pt;">tomasz.kulawik@shearman.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><i style="font-style:italic;">[Signature Page to Fourth Amendment to Credit Agreement and Guaranty]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[FORM OF] BIOXCEL THERAPEUTICS, INC. COMMON STOCK WARRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE OR CONVERSION HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;</b>),<b style="font-weight:bold;"> OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED EXCEPT (I) IN ACCORDANCE WITH THE SECURITIES ACT OR SUCH APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM, OR (II) WHERE, IN THE OPINION OF COUNSEL, REGISTRATION UNDER THE SECURITIES ACTS OR SUCH APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">[</b><font style="font-style:italic;font-weight:bold;"># of shares</font><b style="font-weight:bold;">] Shares of Company Common Stock No.&#160;[</b><font style="font-style:italic;font-weight:bold;">warrant #</font><b style="font-weight:bold;">] WARRANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;">This WARRANT (this &#8220;<b style="font-weight:bold;">Warrant</b>&#8221;) is issued as of March 20, 2024 (the &#8220;<b style="font-weight:bold;">Initial Issuance Date</b>&#8221;), by BIOXCEL THERAPEUTICS, INC., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), to [<i style="font-style:italic;">name of purchaser</i>], a [<i style="font-style:italic;">jurisdiction of organization</i>] [<i style="font-style:italic;">entity type</i>] (&#8220;<b style="font-weight:bold;">Purchaser</b>&#8221; and, together with any assignee(s) or transferee(s), &#8220;<b style="font-weight:bold;">Holder</b>&#8221; or &#8220;<b style="font-weight:bold;">Holders</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company, certain subsidiaries of the Company as guarantors, the Purchaser as lender and the other lenders party thereto are parties to that certain Credit Agreement and Guaranty, dated as of April 19, 2022, and amended as of November 13, 2023, December 5, 2023, February 12, 2024 and March 20, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<b style="font-weight:bold;">Credit Agreement</b>&#8221;), pursuant to which the Company may borrow from Purchaser and the other lenders party thereto (collectively, the &#8220;<b style="font-weight:bold;">Lenders</b>&#8221;), and the Lenders may loan to the Company, up to $202,319,447 from the date of the Credit Agreement through the Maturity Date; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company is issuing this Warrant to Purchaser as a condition precedent to the effectiveness of that Fourth Amendment to Credit Agreement and Guaranty, dated as of March 20, 2024, by and among the Company, Purchaser and the other parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;"><b style="font-weight:bold;">NOW THEREFORE</b>, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Purchaser agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;"><font style="color:#010000;">Section&#160;1. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b>. Unless otherwise defined herein, capitalized terms have the meanings set forth in the Credit Agreement (as in effect on the date hereof), however, the following terms when used herein have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;">&#8220;<b style="font-weight:bold;">Aggregate Exercise Price</b>&#8221; means, in connection with any Exercise of this Warrant pursuant to <b style="font-weight:bold;">Section&#160;4 </b>(whether in whole or in part), an amount equal to the product of (i) the number of Underlying Shares in respect of which this Warrant is then being exercised pursuant to such <b style="font-weight:bold;">Section&#160;4</b>, multiplied by (ii) the Exercise Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.25pt 0pt;">&#8220;<b style="font-weight:bold;">Fair Market Value</b>&#8221; means, with respect to any security or other property, the fair market value of such security or other property as determined by the independent members</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the Board of Directors of the Company, acting in good faith. If the Holder objects in writing to the Board of Directors&#8217; calculation of Fair Market Value within ten (10) days of receipt of written notice thereof and the Holder and the Company are unable to agree on Fair Market Value during the five (5) day period following the delivery of the Holder&#8217;s objection, the valuation dispute resolution procedure set forth in <b style="font-weight:bold;">Section 20</b> hereof shall be invoked to determine Fair Market Value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Market Price</b>&#8221; means, with respect to a particular security, on any given day, the last reported sale price, regular way, or, in case no such reported sale takes place on such day, the average of the closing bid and asked prices, regular way, in either case on the principal national securities exchange on which the applicable securities are listed or admitted to trading, or if not listed or admitted to trading on any national securities exchange, the last quoted bid price in the over-the-counter market as reported by Pink Sheets LLC or similar organization. &#8220;Market Price&#8221; shall be determined without reference to after hours or extended hours trading. If such security is not listed and traded in a manner that the quotations referred to above are available for the period required hereunder, the Market Price per share of Company Common Stock shall be deemed to be the fair market value per share of such security as determined in good faith by the independent members of the Board of Directors in reliance upon an opinion of an accounting firm of nationally recognized standing retained by the Company for this purpose and reasonably acceptable to the Holder (or if there is more than one Holder, a majority in interest of Holders excluding any Holder that is an Affiliate of the Company). &#160;For the purposes of determining the Market Price of the Company Common Stock on the Trading Day preceding, on or following the occurrence of an event, (i)&#160;that Trading Day shall be deemed to commence immediately after the regular scheduled closing time of trading on the Trading Market on which the Company Common Stock is listed or, if trading is closed at an earlier time, such earlier time and (ii)&#160;that Trading Day shall end at the next regular scheduled closing time, or if trading is closed at an earlier time, such earlier time (for the avoidance of doubt, and as an example, if the Market Price is to be determined as of the last Trading Day preceding a specified event and the closing time of trading on a particular day is 4:00 p.m. and the specified event occurs at 5:00 p.m. on that day, the Market Price would be determined by reference to such 4:00 p.m. closing price).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Trading Day</b>&#8221; means a day on which the Company Common Stock is traded on a Trading Market or, if the Company Common Stock is not traded on a Trading Market, then on the principal securities exchange or securities market on which the Company Common Stock is then traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12.5pt 0pt;">&#8220;<b style="font-weight:bold;">Trading Market</b>&#8221; means any market or exchange of The Nasdaq Stock Market LLC or the New York Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">VWAP</b>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (i)&#160;if the Company Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Company Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Company Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)), (ii)&#160;if the Company Common Stock is not then listed on a Trading Market or quoted for trading on the OTC Bulletin Board and if prices for the Company Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Company Common Stock so reported or (iii)&#160;in all other cases, the fair market value of a share of Company Common Stock as determined by an independent nationally recognized investment banking, accounting or valuation firm selected in good faith by the Company and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;2. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Warrant; Term</b>. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company hereby grants to Holder the right to purchase from the Company [<i style="font-style:italic;"># of shares</i>] fully paid and nonassessable shares of the Company&#8217;s voting common stock having a par value $0.001 per share (the &#8220;<b style="font-weight:bold;">Company Common Stock</b>&#8221;). The shares of Company Common Stock issuable upon exercise of this Warrant are hereinafter referred to as the &#8220;<b style="font-weight:bold;">Underlying Shares</b>.&#8221; This Warrant shall be exercisable at any time and from time to time, in whole or in part, during the period commencing on the date hereof and ending on April 19, 2029 (the &#8220;<b style="font-weight:bold;">Expiration Date</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;3. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</b>. The exercise price per share of Company Common Stock for which each Underlying Share may be purchased pursuant to this Warrant shall be $3.0723, subject to adjustment pursuant to <b style="font-weight:bold;">Section 7</b> (the &#8220;<b style="font-weight:bold;">Exercise Price</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;4. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>This Warrant may be exercised by the Holder hereof as to all or any portion of the Underlying Shares, upon delivery of written notice to the Company, together with this original Warrant and (x) payment to the Company of the Aggregate Exercise Price or (y) instruction to the Company to withhold a number of the Underlying Shares then issuable upon exercise of this Warrant with an aggregate value (determined on the basis of the average Market Price per share for the Company Common Stock on the last five Trading Days for such stock ended immediately prior to the applicable Exercise Date, as defined below) equal to such Aggregate Exercise Price (collectively, the &#8220;<b style="font-weight:bold;">Exercise</b>&#8221;, with the date of an Exercise being an &#8220;<b style="font-weight:bold;">Exercise Date</b>&#8221;). The Exercise Price (if paid pursuant to clause&#160;(x) above) shall be payable by delivery by the Holder of a certified or official bank check payable to the order of the Company or wire transfer of immediately available funds to an account designated by the Company. This Warrant shall be deemed to have been so exercised as of the applicable Exercise Date, and the Holder shall be entitled to receive the Underlying Shares issuable upon such Exercise and be treated for all purposes as the holder of record of the Underlying Shares as of such date. Upon the Exercise of this Warrant, the Company shall, within two (2) Business Days of the applicable Exercise Date (the &#8220;<b style="font-weight:bold;">Underlying Share Delivery Date</b>&#8221;), execute and deliver to the Holder of this Warrant (a) a statement confirming the total number of Underlying Shares for which this Warrant is being exercised, and (b) (i) if the Underlying Shares are issued in certificate form, a certificate or certificates for the number of Underlying Shares issuable upon such Exercise, or (ii) if the Underlying Shares are issued in uncertificated form, a written confirmation evidencing the book-entry registration of such Underlying Shares in the Holder&#8217;s name; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that if the Company fails to deliver to Holder such certificate or certificates (in the case of Underlying Shares issued in certificate form) or written confirmation (in the case of Underlying Shares issued in uncertificated form) by the Underlying Share Delivery Date, the Holder will have the right to rescind such Exercise. Any rescission by the Holder pursuant to this <b style="font-weight:bold;">Section&#160;4(a)</b> shall not affect any other</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">remedies available to the Holder under applicable law or equity or pursuant to <b style="font-weight:bold;">Section&#160;14 </b>hereof as a result of the Company&#8217;s failure to timely deliver the Underlying Shares. If this Warrant shall be exercised with respect to less than all of the Underlying Shares, the Company shall deliver a new Warrant covering the number of Underlying Shares in respect of which this Warrant shall not have been exercised, which new Warrant shall in all other respects be identical to this Warrant. The Company covenants and agrees that it will pay when due any and all state and federal issue taxes which may be payable in respect of the issuance of this Warrant or the issuance of any Underlying Shares upon exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In the event of any withholding of shares of Underlying Shares pursuant to <b style="font-weight:bold;">Section&#160;4(a)(y) </b>above where the number of the Underlying Shares then issuable upon exercise of this Warrant with an aggregate value equal to the Aggregate Exercise Price is not a whole number, the number of the Underlying Shares withheld by the Company shall be rounded up to the nearest whole share, and the Company shall make a cash payment to the Holder (by delivery of a certified or official bank check or by wire transfer of immediately available funds) based on the incremental fraction of Underlying Shares being so withheld by the Company in an amount equal to the product of (x) such incremental fraction of Underlying Shares being so withheld or surrendered multiplied by (y) the value per share of Underlying Shares (determined on the basis of the average Market Price per share for the Company Common Stock on the last five Trading Days for such stock ended immediately prior to the applicable Exercise Date).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The Company shall not knowingly effect the exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant to the extent that, after giving effect to such exercise, the Holder (together with such Person&#8217;s Affiliates) would beneficially own in excess of 9.99% (the &#8220;<b style="font-weight:bold;">Maximum Percentage</b>&#8221;) of the Company Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Company Common Stock beneficially owned by such Person and its Affiliates shall include the number of shares of Company Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Company Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its Affiliates (including, without limitation, any convertible notes or convertible shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section&#160;13(d) of the Exchange Act. For purposes of this Warrant, in determining the number of outstanding shares of Company Common Stock, a Holder of this Warrant may rely on the number of outstanding shares of Company Common Stock as reflected in the most recent of (1) the Company&#8217;s Form 10-K, Form 10-Q or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or its transfer agent setting forth the number of shares of Company Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall, within five (5) Business Days, confirm to such Holder the number of shares of its Company Common Stock then outstanding. Furthermore, upon the written request of the Company, a Holder shall confirm to the Company its then current beneficial ownership with respect to the Company&#8217;s Company Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;5. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Fractional Shares</b>. No fractional shares may be issued upon any exercise of this Warrant or as a consequence of any adjustment pursuant to <b style="font-weight:bold;">Section&#160;7</b>, and any fractions shall be rounded upwards to the nearest whole number of shares. If upon any exercise or adjustment of this Warrant a fraction of a share results, the Company will pay to the Holder the cash value of any such fractional share, calculated on the basis of the Exercise Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;6. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Laws</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Holder acknowledges that the Underlying Shares are being offered and sold by the Company in accordance with Regulation D under the Securities Act and that the Underlying Shares will constitute &#8220;restricted securities&#8221; as defined in Rule 144 under the Securities Act. Neither this Warrant nor the Underlying Shares have been registered under the Securities Act, or any state securities laws (&#8220;<b style="font-weight:bold;">Blue Sky Laws</b>&#8221;). This Warrant has been acquired for the Holder&#8217;s own account for investment purposes and not with a current view to distribution or resale and may not be sold or otherwise transferred (i) without an effective registration statement for such Warrant under the Securities Act and such applicable Blue Sky Laws, or (ii) unless Holder shall have delivered to the Company an opinion of counsel to the effect that the Warrant or such portion of the Warrant to be sold or transferred may be sold or transferred under an exemption from such registration; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that the foregoing conditions shall not apply to any transfer of this Warrant from Purchaser to (i) any Affiliate, managed fund or account of Oaktree Capital Management, L.P. or (ii) an Affiliate of Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company covenants and agrees that all Underlying Shares will, upon issuance and payment therefor, be legally and validly issued and outstanding, free from all taxes, liens, charges and preemptive or similar rights, if any, with respect thereto or to the issuance thereof. The Company will take all such action as may be reasonably necessary or appropriate to assure that the Underlying Shares may be issued as provided herein without violating any applicable law or regulation, or any requirements of the Trading Market upon which the Company Common Stock may be listed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The certificates representing the Underlying Shares will bear the following or similar legend, unless the Company determines otherwise in compliance with applicable law:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">&#8220;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;<font style="font-style:italic;font-weight:bold;">ACT</font>&#8221;), OR UNDER THE SECURITIES LAWS OF ANY STATE. &#160;THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. &#160;INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. &#160;THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;7. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Dilution Adjustments</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>If the Company shall at any time prior to the expiration of this Warrant (i) pay a stock dividend or otherwise make a distribution or distributions on shares of Company Common Stock or any other equity or equity securities, (ii) subdivide the Company Common Stock (by stock split, recapitalization, or any other similar event) into a larger number of shares, (iii) combine the Company Common Stock (by stock split or reverse stock split, recapitalization, combination of shares, or any other similar event) or (iv) issue by reclassification of shares of Company Common Stock any shares of capital stock of the Company (with the exception of any reclassification that constitutes a Fundamental Change, as hereinafter defined), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to (x) the record date for the determination of stockholders entitled to receive such dividend or distribution or (y) the effective date in the case of a subdivision, combination or re-classification by a fraction, the numerator of which shall be the number of shares of Company Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Company Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the Aggregate Exercise Price shall remain unchanged. Before taking any action which would result in an adjustment in the number of Underlying Shares for which this Warrant is exercisable or to the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>If the Company shall at any time prior to the expiration of this Warrant (in each case, occurring after the date hereof) be a party to any merger, consolidation, exchange of shares of Company Common Stock, sale of a majority of the Company Common Stock, sale of all or substantially all of the assets of the Company, separation, reorganization, recapitalization, winding up or liquidation of the Company, or other similar event or transaction (each, a &#8220;<b style="font-weight:bold;">Fundamental Change</b>&#8221;), as a result of which shares of Company Common Stock shall be changed into the same or a different number or class or classes of securities of the Company or another entity, or the holders of shares of Company Common Stock are entitled to receive cash or other property, then, upon the Exercise of this Warrant by the Holder, such Holder shall receive, for the Aggregate Exercise Price as in effect immediately prior to such Fundamental Change (subject to all other adjustments under this Warrant), the aggregate number of shares or such other securities, cash or other property which such Holder would have received if this Warrant had been exercised immediately prior to such Fundamental Change (collectively, the &#8220;<b style="font-weight:bold;">Fundamental Change Receivable</b>&#8221;), which, upon the Holder&#8217;s election, may be received net of the Aggregate Exercise Price (for the avoidance of doubt, without payment by the Holder of any cash in an amount equal to the then Exercise Price). In the case of any Fundamental Change, the successor or purchasing party of such merger, consolidation, exchange of shares of Company Common Stock, sale of all or substantially all of the assets of the Company or reorganization (if other than the Company) shall duly execute and deliver to the Holder a supplement to this Warrant acknowledging the Company and such party&#8217;s obligations under this <b style="font-weight:bold;">Section&#160;7(b)</b>. The terms of this Warrant shall be applicable to the Fundamental Change Receivable due to the Holder upon the consummation of any such Fundamental Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If the Company, at any time while this Warrant is outstanding, shall otherwise distribute to all holders of Company Common Stock (and not to the Holder or Holders)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security (for the avoidance of doubt, excluding in each such case any Fundamental Change Receivable), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction, the numerator of which shall be such VWAP on such record date less the then Fair Market Value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of Company Common Stock, and the denominator of which shall be the VWAP determined as of the record date mentioned above. Such adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>Not less than five (5) days prior to the record date or effective date, as the case may be, of any event which requires or might require an adjustment or readjustment pursuant to <b style="font-weight:bold;">Section&#160;7(a</b>) or <b style="font-weight:bold;">Section 7(c) </b>(each, an &#8220;<b style="font-weight:bold;">Adjustment Event</b>&#8221;), and not less than ten (10) days prior to the record date or effective date, as the case may be, of any Fundamental Change, the Company shall give written notice of such Adjustment Event or Fundamental Change (as applicable) to the Holder or Holders, describing such Adjustment Event or Fundamental Change in reasonable detail and specifying the record date or effective date, as the case may be. Such notice shall additionally include the Company&#8217;s certification of the following computations, as applicable, each of which shall have been made by the Company in good faith: (i) in the case of an Adjustment Event, if determinable, the required adjustment and the computation thereof or, if the required adjustment is not determinable at the time of such notice, the Company shall give notice to the Holder or Holders of such adjustment and computation promptly after such adjustment becomes determinable, and (ii) in the case of a Fundamental Change, the number of shares or such other securities, cash or other property which is payable to the Holder or Holders upon the Fundamental Change, the computation thereof, and the computation of the then applicable Exercise Price. Except as otherwise prohibited by applicable laws, to the extent that any notice provided pursuant to this <b style="font-weight:bold;">Section 7(d)</b> contains material, non-public information regarding the Company, the Company shall disclose such information regarding the Company in a Current Report on Form 8-K and file such Current Report on Form 8-K with the SEC no later than the second Trading Day following the date such notice is delivered to the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Notwithstanding any other provision hereof, if an exercise of all or any portion of this Warrant is to be made in connection with a Fundamental Change or a public offering, such exercise may, at the election of the Holder, be conditioned upon the consummation of such transaction, in which case such exercise shall not be deemed to be effective until immediately prior to the consummation of such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>At all times on and prior to the Expiration Date, the Company shall at all times reserve and keep available out of its authorized but unissued Company Common Stock (or other equity interests then constituting Underlying Shares), solely for the purpose of issuance upon the exercise of this Warrant, the maximum number of Underlying Shares issuable upon the exercise of this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates or effectuating the book entry of uncertificated shares to execute and issue, or enter, the necessary certificates or book entries (as applicable) for the Underlying Shares upon the exercise of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">purchase rights under this Warrant. The Company shall not increase the par value of any Underlying Shares receivable upon the exercise of this Warrant above the Exercise Price then in effect, and shall take all such actions within its power as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Underlying Shares upon the exercise of this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;8. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Warrant</b>. Subject to compliance with applicable federal and state securities laws, the Holder may, from time to time, transfer this Warrant or the Underlying Shares, in each case, in whole or in part, by giving the Company a written notice of the portion of the Warrant or the shares of the Underlying Shares being transferred, such notice to set forth the name, address and taxpayer identification number of the transferee, the anticipated date of such transfer, and surrendering this Warrant or the certificates or book-entry records representing shares of the Underlying Shares, as applicable, to the Company for reissuance to the transferee(s). Upon surrender of this Warrant by a Holder to the Company for transfer, in whole or in part, the Company shall issue a new warrant to such Holder in such denomination as shall be requested by such Holder covering the number of Underlying Shares, if any, in respect of which this Warrant shall not have been transferred. Such new warrant shall be identical in all other respects to this Warrant. This Warrant may be divided or combined with other Warrants upon presentation hereof at the office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with this <b style="font-weight:bold;">Section&#160;8</b> as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated as of the Initial Issuance Date and shall be identical to this Warrant except as to the number of Underlying Shares issuable pursuant thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;9. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Impairment</b>. The Company may not, including, without limitation, by amendment of its certificate of incorporation or bylaws, or through a Fundamental Change or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and the Company shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder or Holders against impairment. Without limiting the generality of the foregoing, the Company shall take (a) all such action as may be necessary or appropriate in order that the Company may duly and validly issue fully paid and non-assessable Underlying Shares, free from any taxes, liens, charges and preemptive rights, upon the exercise of this Warrant, and (b) use its best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be necessary to enable the Company to perform its obligations under this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;10. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights or Liabilities as a Stockholder</b>. This Warrant shall not entitle the Holder or Holders hereof to any voting rights or other rights as a stockholder of the Company with respect to the Underlying Shares prior to the exercise of the Warrant. No provision of this Warrant, in the absence of affirmative action by the Holder or Holders to purchase the Underlying Shares, and no mere enumeration herein of the rights or privileges of the Holder or Holders, shall give rise to any liability of such Holder or Holders for the Exercise Price or as a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;11. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Company</b>. The Company hereby represents and warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>As of the Initial Issuance Date, the Company (A)&#160;is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, (B)&#160;has all requisite power and authority to own and operate its properties, to carry on its business as now conducted and as currently proposed to be conducted, to issue and enter into the Warrant and to carry out the transactions contemplated thereby, and (C)&#160;except where the failure to do so, individually or in the aggregate, has not had, and could not be reasonably expected to have, a material adverse effect on the business, assets, financial condition or operations of the Company, is qualified to do business and, where applicable is in good standing, in every jurisdiction where such qualification is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>This Warrant is, and any Warrant issued in substitution for or replacement of this Warrant (including pursuant to <b style="font-weight:bold;">Section 15</b>) shall be, upon issuance, duly authorized and validly issued. &#160;This Warrant constitutes, and any Warrant issued in substitution for or replacement of this Warrant shall be, upon issuance, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or other similar laws affecting the enforcement of creditors&#8217; rights generally and by general principles of equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>As of the Initial Issuance Date, the execution, delivery and performance by the Company of the Warrant does not and will not (A)&#160;violate any material provision of applicable law or the organizational documents of the Company, (B) conflict with, result in a breach of, or constitute (with the giving of any notice, the passage of time, or both) a default under any material agreement of the Company or (C) result in or require the creation or imposition of any lien upon any assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;12. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</b>. All the covenants and provisions of this Warrant by or for the benefit of the Company or the Holder or Holders shall bind and inure to the benefit of their respective successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;13. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</b>. The rights of the Holder or Holders under this Warrant, and the covenants and agreements of the Company set forth in this Warrant for the benefit of the Holder or Holders, shall survive exercise of all or any portion of this Warrant and shall inure to the Holder or Holders of any Underlying Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;14. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</b>. If the Company violates, breaches or defaults under this Warrant, the Holder may proceed to protect and enforce its rights by any action at law, suit in equity or other appropriate proceeding, whether for specific performance of any agreement contained in this Warrant, or for an injunction against a violation of any of the terms hereof, or in and of the exercise of any power granted hereby or by law, in each case without providing any bond or other security in connection with such action, suit or other proceeding. In case of any violation, breach or default under this Warrant, the Company shall pay to the Holder on demand</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">all reasonable costs and expenses of enforcing the Holder&#8217;s rights under this Warrant, including, without limitation, reasonable attorneys&#8217; fees and legal expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;15. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss, Theft, Destruction or Mutilation of Warrant</b>. The Company covenants that upon its receipt of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Underlying Shares (and, in the case of mutilation, the surrender and cancellation of this Warrant or such stock certificate), the Company shall make and deliver to the Holder a new Warrant or stock certificate that is identical to this Warrant or to such stock certificate (as applicable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;16. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article and Section&#160;Headings</b>. Numbered and titled article and section headings are for convenience only and shall not be construed as amplifying or limiting any of the provisions of this Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;17. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</b>. Any and all notices, elections or demands permitted or required to be made under this Warrant shall be in writing, signed by the party giving such notice, election or demand and shall be delivered in accordance with the notice provisions in the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;18. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</b>. If any provisions(s) of this Warrant or the application thereof to any person or circumstances shall be invalid or unenforceable to any extent, the remainder of this Warrant and the application of such provisions to other persons or circumstances shall not be affected thereby and shall be enforced to the greatest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;19. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</b>. This Warrant and between the Company and the Holder represents the entire agreement between the parties concerning the subject matter hereof, and all oral discussions and prior agreement are merged herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;20. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valuation Dispute Resolution</b>. In the case of any dispute as to the determination of any amount or valuation hereunder or in connection with the amount or value of any Company Common Stock or Underlying Shares to be issued, withheld or otherwise determined, the calculation of the Aggregate Exercise Price or any other computation or valuation required to be made hereunder or in connection herewith, in the event the Holder, on the one hand, and the Company, on the other hand, are unable to settle such dispute within five (5) Business Days, then either party may elect to submit the disputed matter(s) for resolution by an accounting firm of nationally recognized standing as may be mutually agreed upon by the Holder and the Company. Such firm&#8217;s determination of such disputed matter(s) shall be binding upon all parties absent demonstrable error, and the Company and the Holder shall each pay one half of the fees and costs of such firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;21. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</b>. This Warrant and the rights and obligations of the parties hereunder, and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Warrant and the transactions contemplated hereby shall be governed by, and construed in accordance with, the law of the State of New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;22. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction; Waiver of Venue; Service of Process</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Each party hereto irrevocably and unconditionally agrees that it will not commence any action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against any other party hereto in any way relating to this Warrant or the transactions relating hereto, in any forum other than the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof; and each of the parties hereto irrevocably and unconditionally submits to the jurisdiction of such courts and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by applicable law, in such federal court. &#160;Each of the parties hereto agrees that a final judgment in any such action, litigation or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Each party hereto irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement in any court referred to in paragraph (a) of this <b style="font-weight:bold;">Section 22</b>. &#160;Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Each party hereto irrevocably consents to service of process in the manner provided for notices in <b style="font-weight:bold;">Section 17</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;23. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</b>. No amendment or modification hereof shall be effective except in a writing executed by the Company and the Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;24. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b>. This Warrant may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010000;">Section&#160;25. </font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Jury Trial</b>. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). &#160;EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS WARRANT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <b style="font-weight:bold;">SECTION 25</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Page&#160;Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF, </b>the parties hereto have set their hands as of the date first above written.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">Exhibit A - 1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>btai-20231231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:41 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OnkosXcel Therapeutics, LLC (Delaware)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">OnkosXcel Employee Holdings, LLC (Delaware)</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>btai-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:43 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title>Consent - Form 10-K or Form 8-K</title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:14.71%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent of Independent Registered Public Accounting Firm</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the following Registration Statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-3 Nos. 333-265277, 333-275261 and 333-276488) of BioXcel Therapeutics, Inc., and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Registration Statements (Form S-8 Nos. 333-235282, 333-238580, 333-266922 and 333-270652) pertaining to the 2017 Equity Incentive Plan and the 2020 Incentive Award Plan and 2020 Employee Stock Purchase Plan of BioXcel Therapeutics, Inc.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">of our report dated March 22, 2024, with respect to the consolidated financial statements of BioXcel Therapeutics, Inc. included in this Annual Report (Form 10-K) of BioXcel Therapeutics, Inc. for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Ernst &amp; Young, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> &#160; &#160; &#160; &#160; &#160; &#160; &#160; <font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Stamford, Connecticut</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 22, 2024</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:14.71%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:73.53%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>btai-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Vimal Mehta, Ph.D., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">1.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023, of BioXcel Therapeutics,&#160;Inc.;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">c.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">d.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 27pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">5.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 45pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 22, 2024</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>btai-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:50 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Richard Steinhart, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">1.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2023, of BioXcel Therapeutics,&#160;Inc.;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">3.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">4.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">c.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">d.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">5.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:96.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">a.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">b.</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:88.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:2.25pt;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 22, 2024</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>btai-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:30:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with the Annual Report on Form 10-K of BioXcel Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(1)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or Section 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 42.5pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(2)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 22, 2024</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Vimal Mehta</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Vimal Mehta, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:47.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>btai-20231231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:31:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with the Annual Report on Form&#160;10-K of BioXcel Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(1)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the Report fully complies with the requirements of Section&#160;13(a)&#160;or Section 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 42.5pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(2)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:90.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><font style="font-size:10pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Date: March 22, 2024</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">/s/ Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Richard Steinhart</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>12
<FILENAME>btai-20231231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 08:31:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">BIOXCEL THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">BioXcel Therapeutics, Inc. (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">), effective as of October 2, 2023 (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">). &#160;Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Persons Subject to Policy</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy shall apply to current and former Officers of the Company. &#160;Each Officer shall be required to sign an acknowledgment agreement pursuant to which such Officer will agree to be bound by the terms of, and comply with, this Policy; however, any Officer</font><font style="font-family:'TimesNewRomanPS-BoldMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s failure to sign any such acknowledgment agreement shall not negate the application of this Policy to the Officer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation Subject to Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy shall apply to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">received</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> shall be determined under the Applicable </font><font style="font-size:12pt;">Rules, which generally provide that Incentive-Based Compensation is &#8220;received&#8221; in the Company&#8217;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recovery of Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the event that the Company is required to prepare a Restatement, the Company shall recover, reasonably promptly, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee has determined that recovery would be Impracticable. Recovery shall be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by the Company. &#160;For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any person</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s right to voluntarily terminate employment for </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">good reason,</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> or due to a </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">constructive termination</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> (or any similar term of like effect) under any plan, program or policy of or agreement with the Company or any of its affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manner of Recovery; Limitation on Duplicative Recovery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Committee shall, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by the Company or an affiliate of the Company of Incentive-Based Compensation or Erroneously Awarded Compensation, reimbursement or repayment by any person subject to this</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Policy of the Erroneously Awarded Compensation, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by the Company or an affiliate of the Company to such person. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already recovered by the Company from the recipient of such Erroneously Awarded Compensation may be credited to the amount of Erroneously Awarded Compensation required to be recovered pursuant to this Policy from such person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose. The Board of Directors of the Company (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and in such event references herein to the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">Committee</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> shall be deemed to be references to the Board. &#160;Subject to any permitted review by the applicable national securities exchange or association pursuant to the Applicable Rules, all determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company and its affiliates, equityholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of the Company, as permitted under applicable law, including any Applicable Rules.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy will be interpreted and applied in a manner that is consistent with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with such Applicable Rules, it shall be deemed amended to the minimum extent necessary to ensure compliance therewith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Indemnification; No Liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Company shall not indemnify or insure any person against the loss of any Erroneously Awarded Compensation pursuant to this Policy, nor shall the Company directly or indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s potential obligations under this Policy. &#160;None of the Company, an affiliate of the Company or any member of the Committee or the Board shall have any liability to any person as a result of actions taken under this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Application; Enforceability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Except as otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any other clawback, recoupment, forfeiture or similar policies or provisions of the Company or its affiliates, including any such policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">equity-based plan or award agreement thereunder or similar plan, program or agreement of the Company or an affiliate or required under applicable law (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Other Recovery Arrangements</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">). The remedy specified in this Policy shall not be exclusive and shall be in addition to every other right or remedy at law or in equity that may be available to the Company or an affiliate of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The provisions in this Policy are intended to be applied to the fullest extent of the law; provided, however, to the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate automatically when the Company does not have a class of securities listed on a national securities exchange or association.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Applicable Rules</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder, the listing rules of the national securities exchange or association on which the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on which the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s securities are listed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means the Compensation Committee of the Board, provided that, for purposes of determining whether recovery of Incentive-Based Compensation that is Erroneously Awarded Compensation would be Impracticable, </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">Committee</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> shall mean the committee of the Board responsible for executive compensation decisions comprised solely of independent directors (as determined under the Applicable Rules), or in the absence of such a committee, a majority of the independent directors serving on the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Erroneously Awarded Compensation</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means the amount of Incentive-Based Compensation received by a current or former Officer that exceeds the amount of Incentive-Based Compensation that would have been received by such current or former Officer based on a restated Financial Reporting Measure, as determined on a pre-</font><font style="font-size:12pt;">tax basis in accordance with the Applicable Rules.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means the Securities Exchange Act of 1934, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Financial Reporting Measure</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means any measure determined and presented in accordance with the accounting principles used in preparing the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s financial statements,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP/IFRS financial measures, as well as stock or share price and total equityholder return.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">GAAP</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means United States generally accepted accounting principles.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">IFRS</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means international financial reporting standards as adopted by the International Accounting Standards Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Impracticable</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means (a) the direct expenses paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation; provided that the Company has (i) made reasonable attempts to recover the Erroneously Awarded Compensation, (ii) documented such attempt(s), and (iii) provided such documentation to the relevant listing exchange or association, (b) to the extent permitted by the Applicable Rules, the recovery would violate the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s home country laws pursuant to an opinion of home country counsel; provided that the Company has (i) obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in such violation, and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Incentive-Based Compensation</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures and received by a person: (a) after such person began service as an Officer; (b) who served as an Officer at any time during the performance period for that compensation; (c) while the Company</font><font style="font-size:12pt;"> has a class of its securities listed on a national securities exchange or association; and (d) </font><font style="font-size:12pt;">during the applicable Three-Year Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means each person who serves as an executive officer of the Company, as defined in Rule</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#160;</font><font style="font-size:12pt;">10D-1(d) under the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Restatement</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means an accounting restatement to correct the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Three-Year Period</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs the Company to prepare such Restatement. The </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">Three-Year Period</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> also includes any transition period (that results from a change in the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence. However, a transition period between</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">the last day of the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ACKNOWLEDGMENT AND CONSENT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:12pt;">The undersigned has received a copy of the Policy for Recovery of Erroneously Awarded Compensation (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">Policy</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">) adopted by BioXcel Therapeutics, Inc. (the </font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8220;</font><font style="font-size:12pt;">Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8221;</font><font style="font-size:12pt;">).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">For good and valuable consideration, the receipt of which is acknowledged, the undersigned agrees to the terms of the Policy and agrees that compensation received by the undersigned may be subject to reduction, cancellation, forfeiture and/or recoupment to the extent necessary to comply with the Policy, notwithstanding any other agreement to the contrary. The undersigned further acknowledges and agrees that the undersigned is not entitled to indemnification in connection with any enforcement of the Policy and expressly waives any rights to such indemnification under the Company</font><font style="font-family:'TimesNewRomanPSMT';font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s organizational documents or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Signature</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>btai-20231231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (9 [L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&#DJ/O#+"O5OV2OVH?$/Q6T[Q;X7\90);>./#43O)*D0C\]5)1RR#A71P 0
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M)IKN24445YYN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?'G_  4[_P"2*:#_ -AM/_1,E>+>
M(AG]I;]FKC_F7M%_]&RU^C>N>'-*\36R6VKZ;::I;HV]8KR%95#=,@,#SR:K
M/X)\/27ME>-H>G-=V2+':SFU0O J\JJ'&5 R< =,U]#A<TCAZ$:+A>W-U_F5
MCAJ89SFYW[?@?$O_  5+^_\ "O\ Z[:C_P"VM=S_ ,%+;>2;]G71G1&=8M?M
M7<@9VK]GN%R?Q8#\:^I==\)Z)XH\C^V-(L=5^S[C#]LMTE\O.,[=P.,X'3T%
M6-9T/3O$6ESZ;JEC;ZCI\Z[9;6YC$D;CK@J>#T%9T<RC26&7+_";?K=W*EAW
M)U'?XK?@?#_CK5M/^._[ ]AIW@^XEU74O!^G:4NIVL43AHW@@42K@CYL ,<C
M(^7VKQ'PWK'[/EM\&;.[UJ?Q5>>,8H5@N?#]O?2Q)-)G#%6VE%3'///;%?I[
MX0\ >&OA_936GAK0K#0K69M\D5A;K$KMZD <UC/\#OA[)KG]LMX*T)M4W;_M
M9T^+?GUSCK791S:E24J:4E'FYE9V>NZ?EZ:F,L+*34KJ]K;'R)\4O@W#K/["
M%FW@WPWK&C6UOJ"^(_[)U.3S[KRMKH[<#IL;S!QG Z55M?VV/"^H_LN_\(9:
MZ=J5WXU.@MI!L(;8F-2(C&9B_(V!1O/?C''6OKSX[>'O&/B/X8:I9^ -6_L7
MQ2FR6SF#!0Y1@3%D@@;@"O/'/.!S7Q?#?_M"1^"=5\&3?!:SF\0:G;3V%QXG
M2RBAD>*4%6R\96+< ?O;L< D'OU8.K#&4KUK.T^9)SLU?O?=?.YG5BZ4O<OJ
MK;7_ .&*7P.1A_P3S^*K%2%:XEP<<'_4U](?\$^@!^RYX;XZW-[G_P "9*W?
MV6/@)-\(?@?!X3\3):ZC>7LTEY?VI42PHS[?W7(PVT*,GIG.,C!KV32-&L-
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M.]L-\O QR*\3_8R_: \.?LUZ3XO\ ?$?S_#FHP:H]XKR6SR;G\M(WC.T$_\
M+)2IZ'<>:_0+1-!TWPWIT5AI-A;:;8Q<);VL2QHOT &*P_%OPI\&>/+A)_$7
MA;2=:G3&V6]LTD<8Z<D9K&./PUJE%TVJ4K:)ZIKK=]^I;HU/=FI>\ON/B_\
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M]XPU;Q]\8M<4'4/$-_);VP[*N\R3$?[.YD0>GEGUJ']JZ3XY?&/5-4^%^A>
MO*\+2WT9_MX'$=U"I5TW.QVH%;!;&6)3CT/U'\&/AI;_  @^&/A_PE;R+/\
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M/?P'X7\4?$#Q]X8^ FJ-(NE:-XCNWNH8V(*X(%P3R1\JQ2;2.AD8]Z_8
M 8 ["LJ#PEH=MK<FLPZ/8Q:M)G??);H)VR,'+XR<CWK'"YM+#NJW&_-JM=GK
MKY[E5,,JG*K[?BCY0_X*2^!+S4/@KX?O=(LB=-T"_7SX;=2$@A9/+4[1P%!V
MKGMGWKYWUK6/V;XO FC36J^,?$VN7?E1W&@IJ$D1A;'S$EE*'##@+G/'2OU*
MFACN89(98UEBD4HZ.,JP/!!!ZBN-TCX)^ - UO\ MC3O!FAV6J;MPNX+&-9
M?4$#@U>#S6-"A&C44O=;:Y7:]^C_ . *KAG.;G&VO=?D?'/[;7AJS\(?LE_#
M;2;#3;S1K2"]C,>GZBX>XM]T,CF.0C@L"Q!K6_;+^&.J>-?V5?ASKVE02W;^
M';2"6ZMXADBWDMT#28[[61/P9CT%?:>N>&])\36R6^KZ9::I C;UBO(%E56Q
MC(# \U=BM(8+5+:.%([=$$:Q*H"A<8P!TQCM65/-94E2:C[T)2EZ\VZ_X)4L
M,I<UWHTE]Q\5>-?V\? /B?\ 9KU.R$L@\9:KHDFF2:+%:LJQ7$D)C9@V-GE
ML2.<D # KSVR^&6K_#K_ ()N^-9M;MWL[O6]0M-1BMI#AD@-U:K&67^%FVEL
M>A7//%?<L7P0^'L&MC5X_!6@IJ8.1=+I\0<'Z[:Y+]KWP)KGQ)_9Z\4>'/#5
M@=3UF[-IY%JLB1E]EU$[<N0HPJL>3VKJH8_#QJ4Z-"+C%SC*3;[/;T7F9SHU
M'&4YN[2:5CYO_9R_;/\  _PT_9NL] \0-=6NOZ/;3I;6*V[G[<K.[(4?&T9+
M8))&,=ZY']G/P7JN@_L1?&C7+ZU>VLM:M7^Q&0$&5(D96<?[.YBH/JIKZF^
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M= CU*5&MR1SRR%7PV  .N>U?IEI?@_0M$LKFST_1K"QM+G_7P6]LB)+QCYE
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M;V R[GW9BS'W)K?HK.5=NBJ"5DG?U>WX(UCA8K$RQ4G>32BO);V^;U^XYY/
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MJ**F4Y3?-)W9=.G"E'D@K(****@T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[
MU_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0 ZBF[U_O#\Z-Z_P!X?G0!AT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%-DD2&-I)&5$499F. !ZDT .HKQ;Q'^UW\.O#VI2V2W]SJCQ$J\NGP>9
M%GV<D!OJN1[UE?\ #;'P]_YY:Q_X"K_\77JQRK'22DJ,K>A\_/B#*J<G&6)C
M=>9[]17@/_#;'P]_YY:Q_P" J_\ Q='_  VQ\/?^>6L?^ J__%U7]D8__GS+
M[B/]8LH_Z"8_>>_45X#_ ,-L?#W_ )Y:Q_X"K_\ %T?\-L?#W_GEK'_@*O\
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M[@_UBRC_ *"8_>>_45X#_P -L?#W_GEK'_@*O_Q='_#;'P]_YY:Q_P" J_\
MQ=']D8__ )\R^X/]8LH_Z"8_>>_45X#_ ,-L?#W_ )Y:Q_X"K_\ %T?\-L?#
MW_GEK'_@*O\ \71_9&/_ .?,ON#_ %BRC_H)C]Y[]17@/_#;'P]_YY:Q_P"
MJ_\ Q==G\//VB?!'Q,OQI^EZD\&I,"4L[V,Q._\ NG[K'V!S[5G4RS&T8N<Z
M4DEY&]#/,LQ-14J6(BY/97W/2Z***\P]P**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKRCQU^T[X"
M\ ZI)IMWJ,M]?Q'$L.GQ>;Y9]&;(7/MG([UT4,/6Q,N2C%R?D<>*QF'P4/:8
MFHH+NW8]7HKP'_AMCX>_\\M8_P# 5?\ XNC_ (;8^'O_ #RUC_P%7_XNN_\
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MW!_K%E'_ $$Q^\]^HKP'_AMCX>_\\M8_\!5_^+H_X;8^'O\ SRUC_P !5_\
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M%=QP)%'(IP4,DB1;A[C?G\*_-)F+L68EF)R23R37Z)_M8_\ )O\ XI_[=?\
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M7[/7Q%L-#O;J\ACF%M%_:%WIZZC')<Q*1_K7A#;LX/7&:[KX_?!'Q/JGQ/\
M%/BZ(6D?A\S_ &LWHO(F9(E1=S^7NW$C:3C&3BO2+WP]->2>(-8\4W&@-IDF
ME/Y?CK0K]K&\NAY8"K)&LA#[B%!4X!P.O2MZF:/V=*I3E%MK5;N^FBU7=Z7O
MV3U.:CD2]OB*5:,TDWRN]E;WO>>C[+6RCO=K0^+3JEZUS'<&[G-Q& J2F5MR
M@= #G(I;C5[Z[GCGGO;B::/[DDDK,R_0D\55/6DKZ?E78^$YY;7+2:I>1333
M)=SI+.")9%D8-(#U#'/.?>JM%%.R6PFV]PK[]_8R_P"2)VW_ %_7'\Q7P%7W
M[^QE_P D3MO^OZX_F*^1XH_W!?XE^3/T3@3_ )&S_P #_-'N=%%%?DQ_0844
M44 %%%% !1110!X]^UO_ ,D$\1?[]K_Z41U^>%?H?^UO_P D$\1?[]K_ .E$
M=?GA7ZMPK_N,O\3_ "B?@/'W_(TA_P!>U_Z5(]'\(? 'QAXUT*TUBQMK.WL;
MV1HK1KZ]BMVNG!P1&KL"W(Q6/>?"KQ)IV@:]J]W9"UMM#O%L+Y)7 DCF8@ ;
M>XYZCBO?_A/HNJ>)/AKX1CA_X1KQOH]M/()K+4)?L=[HK%\G9,),X_BSM],>
MUJ_TC2O&^C_%WP/X6\11ZOJ4VJ6E]:/J=_O>Y5%02*LKG]YL92H.>FWGO74\
MSJQK2C*UD]='HN9)WUT=G?5)=5=' LCP\\/"I!2YI1=M5[TN1R5E:S5U;1M]
M'9GB'AG]G[Q?XLL-*O;&"S%KJ=M/=P23W:1CRH659&;)^7!8=:MO^SGXVMIM
M)EM$L+Z*^O%LX+S3M1BFC2<@E59T8[3QU-?37P\AM_"__"*>";J;3]3UO3?#
M&IF]L4NE\L--)$4A9P< M@CKP.>XJ]X5TRRT'2]!M]0T;3/A[.OB*WG@TW3=
M32Y74&VD$OW&T$GK_#FN"IG.(C*5DK:VTW5Y6>]]DGHFN]CUJ/#6#G"/,Y)Z
M7UV=HMKX;+5M6<D^BNSY7L?@C\0;CXG7_A&!63Q+%!Y]PWVS:&C(4Y,F><[A
M3?\ A5GQ&:.RM89+FX%WJ<VBPV\5\3F>+.]<;L!0 >3Q@5]4VWBC25UG3O%D
M=W'_ &UJFO1>&9?G&5AAU"5RQ/N@1?H*Y&ZU#:N@&S\1VGAV['CS5FBU"X02
MQH2'VAUW#Y7^[G(^]51S3$3>L$K*VSW2=_.UT9SR+!TU[M23N[Z27PN4;+6R
MO9ZW:5^Q\]>./@IXT\(Z'!J&I+#?Z7#/]C$EE?)=);RD_P"K(5CL)/:M#7OV
M>/B'I^BSWE]!#<#3;83S6"ZA'+<VL)&<F(,64>P%>L?$+PM'HGPPU:;Q%;Z/
MX&U9]1M?LW_"-:B[6VH?O/GD>U#D8C7Y@?T7OU>H^')K@>)M6\53>'UTZ72Y
M/*\<:!J#65W> H-JR1*Y$FXA05X!P.M;?VI54(RNMVMM_AV]ZSW>SOY;G/\
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MOT6/%F&LN:G*_P O\S\9GX?8U2?)6BUYW7Z/\S\U**_2O_AG;X;_ /0H:?\
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M+L#3RW"4\)2=U!6]>K?S84445QGHA1110 4444 %%%% !1110 4444 %%%%
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M@Y'7VIM/\Y_F^8_-U]Z42_,FY0P48QTS0!'13_D*]PY;\,4-$5+8^<+U9>E
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M=.O?W%PI_N[6^\?]TD>]?CG3D=HW5T8HRG(93@@UX>)X=P=97I7@_+5?<_\
M@'93Q]6'Q:G[NAR!C.5SG':G,5DWM]UL\*!Q7Y<_ S]NSQG\-)[73_$DDOBW
MP\N$9;F3-W"OJDI^]C^ZW7ID5^B/PN^+GA?XQ>'4UCPQJ4=[!PLT)^6:W?\
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M/" *Q8@$'[IZFG,@A#*X(DX((/2JM_J$%C;3WEY<1V]O$ADEGF8*B*!DDD\
M 4;@66EY8(-B-U7-<WXR^(/AOX>Z<;[Q)K5GH]MSA[J4*6_W1U)]@*^/_P!H
M'_@H5!ISSZ)\-(X[R<$I)KMPN8E[?N4/WO\ >/'L<YKX;\6>,M<\=ZS-JWB#
M5;K5]1E^]/=2%SCL!V '8# %?78#AVMB$IXA\D>W7_@?UH>76Q\(:0U?X'Z
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M.G3? S]FC4/B7=_\)?X[DN3873>?'!,Q\^]).=[D\A#^9[8%?1?Q*^+7@?\
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M>"45]!1RG T/AI+YZ_F9RQ5:>\CTRX_:8^*MTY=_'^N@_P"Q>,@_(8%6=/\
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M7CNKZ5(2XEC!&2&QN;H3CGVS7VGX6\5:5XUT.WUC1;Q+_3KC/ESH" <'!&"
M0001@U\X:M^TRVK1&*\^&6KW,)ZQ7, D0CT(*8KV3X(:UI>L>!+632]!;PQ"
MTLS?V5("#&3(VX@'H"<G X&:]3-J<Y4(5*E)Q:=OB4EK=]V]_-GA</U:4,74
MI4:ZG&2O;D<&K62V2C:V^B=_F>@4445\D?H04=*#T->%?'#5]8M_@IXSG?4+
MM98DM_*D"&%DS<Q@X8*IZ<=:Z\-AWB:D::=KM+[W8\_'8Q8*C.LXWY8RE_X"
MK_B>S:U9/J5AY$4PB?SHI-V>R2*Q'XA2/QK!M_"5W%>-,U\I4JZ[<GN8\?\
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MOXGFTCPYHLFG:;=0M#HT]BAL2#;1Y4P@!<98G&.O->BL6I5Y8>,=4F_NY?\
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MVG#"  &8CVP57_@=?ES7T.08>5:4\QK:RDW;]7^AZU>-/"TH8.@K1@DO\O\
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M^F1"BY0<[Z'Q+17Z!>*?#WA+QY^TUKGP[NO OAG3/"_A.Q3Q(PT;38[2\O\
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M.\%>&YKBXOIEMK:\U+Y(W=C@ *",_BPKTGP-)XFT[P]:2^))HCKX>1Y6M\;
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M  G?@+3-:>%;>>X1Q/&@P!*K%7(]B1G\:YC4=%^/TL3QSZOX?964J=JCH?\
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MLM?%73-?F-QK&B6/DFX8?-)'(=HW8ZD%6&?I7YX5^C%W\%=4^'?[*?Q/O-<
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MU_K/PQ^'U_J=XFV;4)])D>=B$"!MYE)R  !]!7':M^T5XKUGX(:;\+9S;?\
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M1&68#DUV7@;P$+0IJ.I1YG^]% W\'N??VK2\,>$%MY%OKU-TW6.)A]SW/O\
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M++ZKC,!CGM&?*_25OT3(/^"G?A@IJ7@7Q%'"Y62*YL)I@/E4J4>-3[G?*?\
M@)KX:K]5/V\_!3>+OV>M4N8HO,GT6XBU)< DA5RCD8_V78_05^5=?6\/5O:X
M&,>L6U^OZGM8Z'+6;[A1117TIYX45TVL^!I]'\$>&O$AN%FAUN2[C2!5.Z+R
M&13D]\[_ -*O^.?A9J7@MK(@MJ,$VC6FLSS01-MMHYR H<]OF*KGH2PK)5H-
MI7WO^&C*Y7V.*K6N?%NM7FD:;I4^JW<VFZ:[265H\S&*W9CEBB]%)(R<58T[
MP%XDU=[9;'0M0NVN;<W<(AMG<R0A_+,BX'*[_ESTSQ5V[^$_C2PBU&2Y\*ZQ
M!'IRA[MY+*0"!2,@N<<#'-*4Z5[2:O\ T@2ET1NK^TE\55  ^(?B0 < #4I?
M_BJX^?QCKMSXH'B275[V3Q )UNAJ;3L;@2J05??G.X8'/M5GP_\ #OQ1XKL)
M[[1O#^I:I9P9$L]I:O(B8&3D@8Z5+H?PS\6^);)+S2?#>J:E:OYFV:UM'D0[
M,;^0/X=PS]:S4</3O9171[%-U);W+=Q\8_'5UJUOJDWB[69-2MXI8(;IKV3S
M(XY#F10V<@,3DCO6%J7BC5]9TG2]+OM3NKO3M+5UL;6:4M';!R"XC4\+N(!.
M.N*T?AWX(G^('C_1/"L<ZV%SJ=XEF)ID)$3,<9(Z\5TMA\*M(\3Z#XAO?#7B
MC^T[[1;,ZA-I]S8/;O+ K 2,C;F4E<@D$@D=,TG*A2E:UFK=-KW2].OX@E.2
MN>:T5U4GPI\917EE:OX7U9;F]+BVA-G)NFVG#;1CG'>J4O@7Q%#XC'A^30]0
M36V( T\VS^>2?]C&:W56#VDOO)Y9=C"HKTKP!\ ?%GC?XA)X2FTN^T>\6"6Z
MN6N;.3,$21L^XIC)W;=J^K,!7!Z[IRZ/K5]8JTKBVG>',\1B?*D@[D))4\<C
MM2C5A.7)%W=K_)@XM*[11JYHNDSZ]K%AIEJN^ZO9X[:)?5W8*H_,BJ=>X?L7
M^"7\;?M#^&4\OS+?3';4YB1PJQ#*D_\  R@_&HQ%94*,ZK^RFQTX\\U'N?IK
M\2KB'P5\&O$!B;RXK#1Y((3[B+8@_/;7@?[!FDA;?Q=J97)9K>V5O3 =B/U7
M\J[7]M3Q-_9'PGCTM'VRZK>1QE<\E$.\_JJ5>_8Z\,-H'P;M;R1-DVJW$MUR
M.=@.Q/S"9_&OS:G^XR2I.6]227W:_HSAKOZWQ11IQVHP;?K+3]4>XT445\F?
MH!)!N\P!0"3Q\W2HW0,&1@"#P0>AI1C(STIT@ <X4J#R : /P_\ B%X9D\&>
M/?$>@2@A],U&XL^>X21E!_$#-<_7T9^WMX);PG^T%J5ZL>RVUNWBU"-@."V-
MC_\ CR$_C7SG7[E@ZWUC#TZO=(^.JPY)N/8***?!"]S-'%&-TDC!5&<9).!7
M69GN"_$'0?#OPN^%L.H>']'\6K;3:A)>65W-(LL:&="$S&XV;AD@L#T[BO5]
M*\7:'I_Q6\8:O#K-EJ(UCPY"/"CP:G#I3VL&]-UHLVUEM9DC#K@@%B.""^:\
M8UW]G^QT/6-7\.OXTL3XMTRS:YETV6UEBADD2/S'ACG8!6<#.,@!CP":\S@\
M'ZY=:C:6$.DWDM[=V_VNWMUA8O+#L9_,48R5VJQR.P->)]7H5TW&>]WK?9OF
MZVT\UNCKYYP>J_I:'U5J?CJRU#Q0RP7=CI'CA?!T]II^JR>)$U"XCNFN%9%F
MO?+C19O(\U%;<<!@"P-7;C5[[3+?P/+XQU^TO=3D\ ^(X'OI;Y)O,=EN%BC,
MNXAWY"]22>.37A>A^"?'OP[T;1_&?A>"ZO;35-*>XN9H+#[1!#"9GC:*8,K(
MP)A#8(QT]*R=>TOXC_%6*#7KS1M3U6SAM"8)K33]EM%;JS9\M8T"*H;?G:.N
M:P6$IMVC-<JNK];V:MKLM=KE^UEU3O\ \,>\W?B^'7?@])8:EXBM-+LXO"B0
M0S:1KT<MC<NB*$MI-,E&^.<L,,Z#.06!P2:-!^*-_IWPBTF^L_%H@:Q\"W>G
M0Q?VHOFP7WVM@H6+?N600E=K  @ 8/ KYK_X5OKMAKVA:;K>EW^B#5YHHX);
MJSDRRNX7>B ;GQNZ*"3T')J0?"[Q+?76M?V1HFI:Q8Z7<2P37EO8R[5V$@E@
M5RIP,[3@CO6SP="UG-6O?R[?U^1/M9WV\CZN^!/C2VT^S^'%QJ7BYM3M+N26
MXUF:]\40V5O:227#^9'<6F/,NG8$'=(3G</X16#\*?&:I\(_!EC<>)+>&UTJ
M#Q3;7]C/J:+L>6U7[*#$7RP)\T*0" 6..O/S!X>\ ^)/%L%U/HNA:AJL-K_K
MWL[9Y!'_ +Q XI8?"CR^#KG7/-E$D.H1V'V46LA!+(S9\W&P'Y<;"=QSD# -
M*6 I.4O?U;[;7YO_ )+RV!5I66G]:?Y'T[X4\8%+_P"&=UIGB[3M.^&-AHL4
M.OZ*VIQPJ7&_[6DUJ6#2R2$DJ=K9W+@C%4/AO\6IM#\3_ 71K?Q,MAX96W==
M7LQ=A+8B2]N0RW*YVG]WMX?H#D=:^==8^'/BGP_]@_M/P]J=A]O94M?M-JZ>
M>QZ!<CDG/04W7OAWXH\+V$=]J_A[4M,LY)#"L]U:O&A<'!7)&,\'BK^IT9JS
MFG>_;^]][UW\A>UFNFW_  /\C(U58EU2\6';Y(F<)MZ;=QQCVQ56M[7_  #X
MD\*V-K>ZSH6H:7:77^IGN[9XTDXSP2.>*P:]B,E)7B[G*TT]0KZ^_P"":GAF
M34/BSXBUPJ3;Z;I)@W>DDTB[?_'8Y*^0:_2S_@G%X*;0O@]J6ORQ[9-<OV*,
M1RT40V#\-QD_6O!SZM[' 3[RLOO_ .!<[,%#GK+RU/K: '<Q"A\ D@U%3QM$
M;$[MW8CI3*_(CZ@**** "N-^*/PPT_XKZ/IVE:K-)'86U\E[+'%]Z8*CKLS_
M  @E\D^V.^1V5%:TJLZ,U4INS74PKT*>)INE65XO==RGHVC6/A[3+?3M-M8K
M*QMT"100KM51]*N445FVY.[W-8Q44HQ5D@HHHI%!1110 5X5^T_XQ\":;8:?
MH/C31M3U+[4K7-M/IJ(7@93M)#,ZD'GIR#WKW6O'_CA\1_%&A:_X;\)>#+>U
M?7M;\QQ<7G*11H,G ]>O)SP.ASQZF6)O%1:6UW\7+:RO>]G:QX6=R4<#-2=K
MV7P\][M*W+=7;V6NFY\E6]_\*DNE:Z;QMJ-JIR+6=( I]B1)FOL_X+7^B^+O
M!>FZWI%E+9:=\T%K:SHJF)8V*= 2/X>.:\3MO%WQD^).L:S::3-IWA^]\*JL
M=^BX*W-QE_NE@W!"=.GKUX]Y^"/CRY^)7PRT;7KV)8;Z=7CN%087S$=D)'H#
MMSCMG%?19U4G.@F]TU?W^:UTVM.5+5:W/C>&:5.GBY1CLTVKT^6_*TG9\TG[
MK=FFEKJ=S1117Q)^GA7SS^T-]G_X0CXL;%TH3^5IOF-:NQNS^\BQYX(P/]G'
M\.,U]#5QWQ+^&MG\1/!VN:(LD>ESZLL2S7\=N'D/ENK+NY!;A<#)XS7HX"O#
M#XB,Y[7C^$D_T/&S?"U,7@ZE*DKRM*WFW"45Z:L_,"BOKC4OV%['2].NKV;Q
MI/Y-O$TS[=,!.U02<?O?05DR_L>:+#+;QMXTN]T\LD28TH=464G/[[T@?]*_
M5XY]E\E>-3_R67^1_/\ /A/.(.TJ27_;T/\ Y(^7:*^F[S]DC0K&PU&[D\9W
MGE6,<DLN-*&<)YV['[[G_4/^E6;C]CC1[:]:U?QI=>:O)QI0QTF/_/;_ *8/
M^GK5_P!MX%?;?_@,O\C-<+YJ_P#EVO\ P*'_ ,D?+=%?3<G[)&A1V4ET?&=Y
MY237$!_XE2YW0^?O_P"6W_3M)C\/6I;C]C_1+9[U'\9W>;2W^TR8TH?<S,./
MWW7_ $=_T]:/[;P/\[_\!E_D)<+YJ_\ EVO_  *'K_,?+]%?4+?L>Z*DJ1GQ
MI=[GNGM!_P 2H??02D_\MNG[A_TIK?L@Z(BW+'QG=XMX9)W_ .)4/NHTJMC]
M]ZPO^E']MX'^=_\ @,O\A_ZKYK_S[7_@4/\ Y(O_ +!/_(5\9?\ 7&U_]"EK
MZ4\1I$WBS3"T;LX\K#"T$@'[P_QX^7^G6N,^ 'P$M_@V^JW<&N2:NNIQQ+M>
MU$/E["W^VV<[OTKU6YTBVN[R*ZE60S18VE974<'(RH.#SZBOS7-<72KX^I7I
M.\6E^274_;<@R[$83**6%KQM--MJ]_M-[J_0^+?VL_#]Q\._C-I?C'3%\H7W
MEW8*Y"_:(2 W3'4!"><DECWKZ@\5:+HW[0'P8O;%'+:9XBTW=#(>6A<C=&Q
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M_!:#X0>$0ERD<GB"^ DOIUYV^D:GT7]3D^E>JUX&;XZ&(G'#X?2E3T7GW?\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <)\8/A!H_Q@\--IVH*(+V++V=^@^>!_ZJ>A4\'Z
M@$?(G@GQ_P"+OV4O'-UX?UVWDNM'=]TUHK921<X$\#'U'TST8 CC[VKE/B-\
M,/#_ ,4M$.FZ[9B8*#Y%RF!-;L>Z-VZ#(Z' R*^@R[,XT(/"XJ//1ETZKS7]
M>9\?G.1RQ52./P$O9XB.SZ27:7^?R>FV6X\"_M%^ I;>:.U\0:+=H!)"_$D#
M$?\ ?4;CU&#Q7PA\?_V"?$OP_:XUCP7YOB?P^"SM; 9O;9>3RH&) !CE>?\
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M5;>RD*HZ*3S5+5=)L]9L+BPU*S@OK*X0QS6UU$)(Y%(Y#*PP0?0U])E^>8C
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MF+^PKX2&=VNZN>>,&(<?]\U#HY(WI5G;T_X!HL5Q0E9X>FW_ (G_ )G6:O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>btai-20231231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '0 \L# 2(  A$! Q$!_\0
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MGEOLDX5B1M8$?-CVS4OA_+E+E=[^H?7:]K_H?HY_P]#^&O\ T+7BS_P'M?\
MX_1_P]#^&O\ T+7BS_P'M?\ X_7YC&:-5#&1%4]&+  _0UTNB_#KQ+XBL].N
M].T:YN;34;TZ=9W'RI'/<A"YB5F8 L%!)YP.YIRX?RZ"O)-?,%CJ[V_(_13_
M (>A_#7_ *%KQ9_X#VO_ ,?H_P"'H?PU_P"A:\6?^ ]K_P#'Z_,JYC-G=26T
MQ6.XC=HVC9AD,I((Z\X((XJ/S8]VWS$W9QMW#.?2J_U=P'9_>+Z_6[GZ<_\
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MU^9=S$UG>2VDVV.YB<H\18%@P.".#ZU>\1>'=3\(7-O;ZW92Z3<7%NEU%%>
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M&M#0)HTUBZ;2KZ6]TZ:&&#R&%NKQVD2JEL)?**^>2X(.[-?GKMYSMY]<<T!
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M$ /J%IV#Z'\J]'"8986#@G>]OP27Z&%6I[1WM_6XE>@ZQ_R07PS_ -C#??\
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MKH.KZ#<ZMHLM@UI<6DL[6.1YH C^? .=P/S8Z\8K\_\ RP3G8,^NV@1@'(0
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M* YZ_+UI=@./D''3Y>E6\I@W=S;V_!I_UYW?47UEI6L?H'XU\2_"H^+?"?\
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MZY,KSO#)GS"/+7:A495221D@^M2X4TFTP/6:***Y@)3_ ,>H_P!_^E15Y_\
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M%0T?\-V>'?\ H5-7_P# J&C^Q\?_ ,^G]Z_S#_6+*O\ G^ON?^1]-45\R_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%/BE>"19(W:.1"&5E."".A!IE% 'VO\ LU?M*IXNBM_"WBFX6/6T 2TO9#@7
M8'16/]_W[_6OI&OSG^!7P3U;XM>(4:%I+#1K1PUSJ*C!7N%0]W/Z=:_1*QM1
M8V4%LLDLJPQK&))G+NP QEF/4^]?EV=X?#X?$6H/5[KM_P /V/W;A?&8S%X.
M^*CHM(RZM?\  []2:BBBOG3[(**** "BBB@":S_X^HO]ZN@KG[/_ (^HO]ZN
M@KCK[H]/"_"S(UC_ %Z?[O\ 6J%7]8_UZ?[O]:H5T4_@1Q5OXD@KQ[QUIWPX
M@\5ZGJFOV4NHZNDL ^S^7(/WFV,#9M(#Y"PL021F)<<BO8:Y_5/A]X;UN^EO
M;_1;2\NY<;YID)9L# YSV%:HSB[,\PL]8^$<EL#)I@CBFFDFAADCGE"LS@EH
MUR1%N*;@%QT)P.:O&X^%C106=GHL&HJ+4SQP16[D&*&*<C&XC.%EF4#_ *:_
MEVNH?"GPIJ&FR6)T6VMX7_BMD$;K_NL.5ZGIZFK=E\//#.G2K);:'90NJE0R
M1<@$$$?B&8?0T7+YEYGF>C-\*]7U+24DT9UO[9Q:6@NFGG "MO 9BY!"N[8W
MYP=P'%,\20> M%CM[(^"Y]6LK..6TMI!=%D$<Z0LZ+OEW!"IC(R,*44#!Q7J
MMKX'\/V5T+FWT:RAG$GFB1(@&#_WOK2ZIX*T'6[N6YO])M;NXE4+))*F2X!4
MC/K@JI_ 47#F5SS>TE^$]FTMA;Z4&:WR\BBTN)"?*$JM(6.2V//F!<DY,AR3
MG-9GB>/X8^&[C2)_^$0:Y MX[NTDMRT2E?EV J7&2#;18## *J1S7JEY\/?#
M=]O,NC6@D;?^\2,*XW9W$'WSGZU#'\,O#"Z=964NCV]W#:1B*(W69'V\]6/7
MJ3]3FBX<R\SSBU3X2?8;&PD\.);274*[+%+2:5E:6)$V!D)!;8B#Y3D;01@B
MO0?AS9:"-.N]3\/R3S6M_(F7N"Y8"*-8U7+_ #$ #.6))W$YJ[-\/_#4\<22
M:'9,L041@Q<KM "X/48  J[X<\-V/A33/L&G1M%:^;),$9LX9VR<>@] .@H$
MY)HTZE/_ ![#_?/\A452G_CV'^^?Y"I?0E=2*BBBF2%%%% #9)4BV[W5-S!5
MW,!DGH!GJ?:G9'K7F/QWTZ35;7P1;17%Q9L_BO3_ /2+7'FQC,F2I((4^^.,
MUX]J?Q0\<P0"W;6IK%+.VU);"]NKE8&U"Y@OYH8U=1;R&Y98TBS"@5GWEAD\
MCHA1=173 ^I]0MX;RQN;>=MD,L3QR'=C"E2"<]N">:\-F^ ^L:D^C17OB[2I
M+72].M-*L!#:,))(H;N"Y5Y#YF"[);JI"\9^8<'%<3XN^*/B._\ $=W82:JZ
M6]Y<ZEI=[HLTF7CC6PF9<6PB_=)YB*5E>0M)O&% .!C>"-!EO/$_AFQ&L:I8
MW4FNZ=-B&9?-MX3X>P&C#(=@)#)NQ_"0.173"E.FG+FMI?N&^AZR/@!JJZI+
M?6VMZ=I @NX]1LM.TVVN%L)+M+@3"::!Y65"1N0B';G>S<X4#1M_@/+=ZIJ6
MH:MK4<T^KVFJP:@MI R*&O%MT'E;F.%C2W ^;)8G/'2N1\!_$?5-;%BWBWQA
MJ'A^6*RMCIJP11H=7E^T3QS%D,9\]OW<2%$QMWE@!N##B'^,OC2XCOQ9>);D
MF]T87@"RI<7%E<?;H(R"@A"6[B.5P8,R%0 6.>2*%9MJ_P#7W >F:G^SUKWB
M*_34M7\2:=/?V=OIT%DMK;7$$9^R-*=TI64/^\64YV$;2 1FNK^'7P>?P-XC
MAU9K^VE8V-U;S6]O"ZJ99KE)BP9W9F "!<N2S'DGM7$6_C+Q=8_%PZ))JTP%
MMKD.GQ:=>WF][K3C$I:<P+;EG)S(WVCS JE IV@$&3XI^/=7TCXD>(=/T[Q5
M=V>IV>F:9<:+X>B5#'?W$L\RR*5*%I-P15(##:/FXZU#565H7Z?\ #LD^#\Z
M?$Z?Q7_:\/E27TUY]E\AMP#V"VNW=NQP5WYQTX]ZBO?A#J#?"7PUX2AUN$S:
M-Y'G2RK+'!>I&&#1/Y;B14(;/#?P@'(R*X:V\6ZZES8S:_XQU;1M!O\ 6=;@
MN=1WQQK;_9IY$M+=',>$5E!Y/,AC49YP8='^('Q N]3\-Z#J,U];W?B.SMM9
M%V;18_LMO K_ &R/!7"&0+;G8>0;AP,8&#DJ/KM^E_RU#8LZ?^SEJFB>$M4L
M-(\5:';)K=E>:=/+]@86R07$[S1F!1)]Y#*Z $D,"O<<[TOP%UAKV."/Q!8)
MH\>K/K'EM9R&X,KV1MFCW;]H0'YP<9['UKRJZ\8ZIXD\(>'(M?UZ\M]5%YX;
MDLM#6%(XM0A:2"22<H$R?WN\%E(">6HP,\W!\4_'T_AW4[@:Y+;ZI):N]_;Q
M3BXFTNX-Y%&BK%]G ML*TB;)&8N &&=I:MG&L_M+?^N@M#T*W_9\O[#2)+%;
MW0]2C(TZ1'OK6Y22*:VLUMC)'+%*KQ$[ P*G/+*>#FNNU;X:ZM>^"?"FFKX@
M^W:[X>N[6]74M3C:1;N6+(/FA6W88,1G)/ )SSG/^-%]J/A/P]HD=EXJ_LR.
M*Y:.YEO]0%G/>H(WPJW9B=$D# , R@/MVY&:\_\ ^%RZTP:*35=1TZ\O[SPX
M^GV&H0HEVUO.4%T=BIC!(?>PX4]-N0*YTJM1*2?];%'1V'[.^HPZ1XDMKCQ'
M:2W6LZ5?:>TL5FZ)&]Q=O<;]N\DA=^W&<G&<TFJ?L\:CJR6^D3>([9?#$5]>
M:AY2VK_;"US;R1.GF;]H"M*S@XR> ?6O/--^+?B^3P3#J&@^*+[Q1?S:7<3:
MT95C;^R'6[2-)%"Q?NR(S+P0V0F_:<<]/X8\2^*O%7BK0]$'BN]319[[4$2_
MTR\6Y>:..UC=5:Z-NBR!92V&0$8^4DD&MFJT;MR77^MON%H;^A? *?1;W2+R
M^UK3DNK.\TXHT23DSQVS.VW=-,[;G+<(IVK@X!S7M<EQ%"4$DJ(7;8@9@-S>
M@SU/L*^9-/\ B/XWUW^SY;J\N=/;2M9L?#=V9;-7CGO$,QN;G:4)*E1 1M(^
M\P'6JNG_ !-\5_9--M;35)O$NJQ:A:,UY#=0W]C=,]O<'9$_DH\+,T:LT+#<
MFY0&P><Y4JDW[SV ^J<CUHZU\PP^/_$M_;Z-:Z/XQU74H+]-(_M34!'$9;"[
MFNTCGMT/EXC)0R Q$9CV*>,\^S_"/5M1U+0-4AU*[N+^;3]9O=/CN;L#S9(H
MY,(7( #'!QNQS@5A.DX*[8';T445@ 4444 ?._[9_A76O%/A7PU'HVD7VK21
M7TK2)8V[S% 8L D*#@5\F?\ "HO'7_0F:_\ ^"R;_P")K]0/^78?[_\ 2H\U
M]'@<[J8*@J,8)I7_ !/C<UX8HYGB7B9U&FTM$ET5C\P_^%1>.O\ H3-?_P#!
M9-_\31_PJ+QU_P!"9K__ (+)O_B:_3S-&:]#_6:M_P ^U][/'_U(P_\ S^E]
MR/S#_P"%1>.O^A,U_P#\%DW_ ,31_P *B\=?]"9K_P#X+)O_ (FOT\S1FC_6
M:M_S[7WL/]2,/_S^E]R/S#_X5%XZ_P"A,U__ ,%DW_Q-'_"HO'7_ $)FO_\
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M_P#\%DW_ ,31_P *B\=?]"9K_P#X+)O_ (FOT\S1FG_K-6_Y]K[V3_J1A_\
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M,U__ ,%DW_Q-?IYFC-'^LU;_ )]K[V'^I&'_ .?TON1^8?\ PJ+QU_T)FO\
M_@LF_P#B:/\ A47CK_H3-?\ _!9-_P#$U^GF:,T?ZS5O^?:^]A_J1A_^?TON
M1^8?_"HO'7_0F:__ ."R;_XFC_A47CK_ *$S7_\ P63?_$U^GF:,T?ZS5O\
MGVOO8?ZD8?\ Y_2^Y'YA_P#"HO'7_0F:_P#^"R;_ .)I1\(/'9SCP7X@./\
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ME1?[U=!7+V%]/)>PJTF5+#(P*ZBN2ONCLH0Y$T<YXD_X_(_]S^IK*K5\2?\
M'Y'_ +G]365713^!#EN%%%%:$!1110 4444 %%%% !1110 5.?\ CP7_ *ZG
M^0J"IS_QX+_UU/\ (4F-$%%%%,04444 %%%% !3O+?\ N-_WR:;7SQX[\$Z9
M_:?B]M-LH0^VQ-FZ3NR[WD/GE0'YX^\!T'I7=A</'$2<92MMTONTNZ[F52;@
MKI7/H@HP."I!],4F#Z'\J^<6TS4+33=6\*Q6R-+?ZHAN(M/NOL]@+2--VZ&>
M1VVF0X!!.01C%+>7?B74/[+U"%FCU72]"GM+FVDF 2[*R&-D#9P6:,AU(ZD<
M5W?V9?:HOZ6G7J]#'ZQ_=/H[8QS\IXZ\=*3:?0^O2OF"\N&TGPZ\FJ:;J>H:
MV+&V&CWMK.V+!5AY)VMA&649<,,D'/.,5OC4;N6V_L:19YM0EU]-4-W"0;5[
M<HK%A,&V]C\O7/:G+*VM5/\ #\=^GR!8CR/H @CJ"/J*<(W/1&/X5X%\-_$J
M>$I9(]5AU#==:190QF*W>91(H<,&(^Z1D9S1:>%-+U/1?APVI6D4UT)S!J/F
MW#!EA D(60!QA<D<G';FLY9?R2:E+3H[;Z-]_*Q2K76B/>]I&>",=>.E+L;&
M=K8]<5Y5X#T6UTKQIJOGZD'TO2"(=&CGN%\N-)AODVL6^?:?D!.<#BN-@\$3
MW:^)-<.HVEG+'=:@T4,187ETI5E1"QDVF,[L@!,\<&HC@H.33J62MTWOLM_O
M[/[QNJTD^7\3Z'*,N,JPSTR*-C XVG/ICFOF6PT'4]#TV]MP$A-QIMH[1:/*
MR+=P[T:X5R\K%;@#*[1MR"V/2M5XK=I[N32[._MO 'VJV:ZT=Y6CFG #^8T<
M3/YFS)CW*/O8.,UL\MBKVJ77IZ>>^NB\GJB%7?6)]"B-R<!&SZ8I-IYX/'7C
MI7S.-'O?$$>E6UKI5C9VD=S>S6]MJEW/):E3$"H(9D>(%@0H;OD\BIKF?7;O
M2/#\>EVUU+_PCMI]J)NKQ+=Q=&4DH%9LRJJ*R *3PPYZ57]EK1>T7G>VF]NO
M=?B'UC^[_7W'TGM/'!YZ<=:2OEWQ3'K.J:EXK^PK<)INN3F9@9"I01(LJ@#.
M1NR4P.I&.U?27AT,/#^EA\[Q:Q;L]<[!FN/%8/ZM",N:]_PT7ZW7R-*=7VC:
MML:%%%%>:;A1110 4444 3G_ (\5_P"NA_E4%<M\1_BAI?PQT6PN=4M[NX2[
MN6B06BJQ!"9.=S"O/?\ AK+PE_T#=9_[]1?_ !RNZC@,57A[2E3;1E.M3@^6
M3U/:Z*\4_P"&LO"7_0-UG_OU%_\ '*/^&LO"7_0-UG_OU%_\<K?^RL;_ ,^F
M1]8I?S'M=%>*?\-9>$O^@;K/_?J+_P".4?\ #67A+_H&ZS_WZB_^.4?V5C?^
M?3#ZQ2_F/:Z*\4_X:R\)?] W6?\ OU%_\<H_X:R\)?\ 0-UG_OU%_P#'*/[*
MQO\ SZ8?6*7\Q[717BG_  UEX2_Z!NL_]^HO_CE'_#67A+_H&ZS_ -^HO_CE
M']E8W_GTP^L4OYCVNBO%/^&LO"7_ $#=9_[]1?\ QRC_ (:R\)?] W6?^_47
M_P <H_LK&_\ /IA]8I?S'M=3/_QY1?\ 71OY"O#O^&LO"7_0-UG_ +]1?_'*
MD;]K;PB;=(_[-UK<K%O]3%Z?]=*/[*QO_/IC6)I?S'L]%>*?\-9>$O\ H&ZS
M_P!^HO\ XY1_PUEX2_Z!NL_]^HO_ (Y1_96-_P"?3%]8I?S'M=%>*?\ #67A
M+_H&ZS_WZB_^.4?\-9>$O^@;K/\ WZB_^.4?V5C?^?3#ZQ2_F/:Z*\4_X:R\
M)?\ 0-UG_OU%_P#'*/\ AK+PE_T#=9_[]1?_ !RC^RL;_P ^F'UBE_,>UT5X
MI_PUEX2_Z!NL_P#?J+_XY1_PUEX2_P"@;K/_ 'ZB_P#CE']E8W_GTP^L4OYC
MVNBO%/\ AK+PE_T#=9_[]1?_ !RC_AK+PE_T#=9_[]1?_'*/[*QO_/IA]8I?
MS'M=%>*?\-9>$O\ H&ZS_P!^HO\ XY1_PUEX2_Z!NL_]^HO_ (Y1_96-_P"?
M3#ZQ2_F/<A_QY-_UT'\C4%>,#]K;PB+<Q_V;K6XL&_U,7I_UTJ/_ (:R\)?]
M W6?^_47_P <I+*L=_SZ8WB:7\Q[717BG_#67A+_ *!NL_\ ?J+_ ..4?\-9
M>$O^@;K/_?J+_P".4_[*QO\ SZ8OK%+^8]KHKQ3_ (:R\)?] W6?^_47_P <
MH_X:R\)?] W6?^_47_QRC^RL;_SZ8?6*7\Q[717BG_#67A+_ *!NL_\ ?J+_
M ..4?\-9>$O^@;K/_?J+_P".4?V5C?\ GTP^L4OYCVNBO%/^&LO"7_0-UG_O
MU%_\<H_X:R\)?] W6?\ OU%_\<H_LK&_\^F'UBE_,>UT5XI_PUEX2_Z!NL_]
M^HO_ (Y1_P -9>$O^@;K/_?J+_XY1_96-_Y],/K%+^8]KJ>/_CSG^J_SKPW_
M (:R\)?] W6?^_47_P <J5/VM_"*P2(=-UK+$$?N8NW_ &TH>58W_GTP^LTO
MYCV:BO%/^&LO"7_0-UG_ +]1?_'*/^&LO"7_ $#=9_[]1?\ QRC^RL;_ ,^F
M'UBE_,>UT5YOX&^/GACQ[JXTRT^U6%XPS$E\BH)3Z*58\^QKTBN&M0JX>7)5
MC9^9K&<9J\7<****P+"BBB@ HHHH **** )X/]1<?[H_G4%3P?ZBX_W1_.H*
M2ZCZ!1113$%%%% !1110 4444 %%%% !4UM]V;_KF:AJ:V^[-_US-)[#1#11
M13$%%%% !1110 4444 %%%% !1110!9TS_C_ (/]X5U]<AIG_'_!_O"NOKCK
M[HVI['.>)/\ C\C_ -S^IK*K5\2?\?D?^Y_4UE5T4_@1$MPHHHK0@**** "B
MBB@ HHHH **** "IS_QX+_UU/\A4%3G_ (\%_P"NI_D*3&B"BBBF(Y7XC?$C
M2?A?H<.J:PMU)!+<+;K'9Q"23)#,SX)'RHB.['LJD\]*UK[Q3HNF7MC9WFL:
M?:7=]C[)!<74<;W&2 /+5B"V<CIZBN0\:?#6Z\?>-[.YO[^XL= T_39H8%L)
MT$TMQ<'RYMZO&PV"$;1W)D;ICGF?A_\ #KQ?X,EDCU'3]'\2+=6MEIK75U>[
M6@ALWD2*1E,3&0M$R/M7!613ZAATJ$''?7^OZ_ B[N=]XK^*7A;P;X=.MZCK
M-F+ HLL;0SH[3(9%CW(-WS*&=02.!GDUL6WB;1KW5I=+MM7L+C4XHQ*]G#=1
MO,J$ AB@.X AE.<="/6OG^?X%>-+K0-.TI[;2431M$FTRWE%^2;R0WT%PC$>
M7^[5DA(.<D,>XYKJ_"/PE\0Z1X[MK^^E$NG6VLW^LI.=15@3<J_[L0K$&WCS
M-C,TC(1&"!R M.G34=):Z_\  $I2OL=Y_P +5\*1ZWKFE7&NV-E=Z-)!%>?;
M+F.%4>5"Z*"S#)P.??CUQ<M]0\)WM[?VL$^A3W=BOF7D,9MVDMUZ[I .4'NV
M*X75/AAK-[\5%UH0V<FD?V[I^L&22X'F!8+.:!E$>W[P9T8'.,9Z$5QH^ /C
M&+29].2XMKIK2WU)+*ZO[M98;HW,N['D"#Y"P/S&5I0'52 W9QC#I*VP-OL>
MGWGQ#^'EI+HD8O\ 0;E-8NWL[6:V^SR1&1(S(P9QP,*/S9?6K]MXK\ WLT4-
MOJ_A>XFEE6"..*>U9GD(RJ  \L1T ZUY%:_ _P 7QZYJ&JR10NUQJ@NUBO=:
M-S.4;3IK1VDE,87<'=6VJ NWA<8Q5W_A0FNQ>'I[2"'3(KEO#NA:3"Z2;0LU
MG<>9-@[.%Z%2.I["M'&&GO\ X_UL*[['K7]K>#A<:C#]K\/B?3EWWL>ZWW6J
MCO*/X![MBLNZ\=> K>YT.%+O1+PZU?MIMF]H+>5'G"%V4L. 0!]<LHQR*\GO
M?V>O%5YH6J:/+<17>RSU:WM;BZU &.Y:[D+#,*P@IG=F3S&?YE!7.<CMKGX8
MZW#\1UUZVALWL8]=L[]8%G$3>4FGR6LIQMQN#."%[A>HJ;07V^X]>QWEY<^%
M].U.TTV[?1+34;O)M[.<0)--Z[$/+?@*QO!?C#PGX\TS5=3TVSL1IFGW<UG)
M>S16PC=HB1(PVDE5!!Y?;D<@8.:YOQM\+]=UO6_%"V45A+I_B3^S@^ISS%9M
M-^S-D[8]I,F?OIM9=KDY]:G?X<:]'\(_$WAZ Z>=6U#4+^Z@6<K+ R37;3*K
M%D(!*'&2K!6YP0*E6Y5[VKMU_K^O4>M]CJO^$A\#'1UU;^T?#7]E&7R!?>;;
M>09/[F_[N[VSFLO5?'W@;1]2TNSN#I).J7%O;64L(M9$F>8.4(P<A<1M\Q !
MXV[N<>1GPCKGPQ\3W'BG6+5+\7E_/+#97M_/?LXDL%@9Y9U@8+*#&<#:%*R%
M5P1@S^"O@IXKLM+\*:C]BL[.XL[?17-A/,8VC,$5VLJLI7C;]I0A3U (X-:\
MD4KN7X_UL3=[6/5_$/Q ^'WAK2-1U&YO="F@T^:.WNDM?L\KPR/((U5E'W3N
M..<8P?0UI'7O"$,<+W<N@V'GW,EI!]HDM!Y\B-M(0@D$YQ\OWAD @'BO$+;X
M!>-61FE@LS-'HL&GJC:L&26:*]M[C$4:Q*EO"1"X50N06^;<>:W3\&O%%G)X
MGDBL](U ^(;?4[%H[J[P+!+B[>9)1\AWC:_SHN#F-<$]1+C!+X_Q"[['K4&H
M^$;K67TB&XT&;5EW!K",V[3C;][,8^;COQQ3[R[\*Z?JMKI=W)H=MJ5T,V]E
M,($FEYP-B'YFY!Z#M7G7ASX/:OH-WILA>RE-MXM_MF2XW_O);;[%]GR?ESYA
M(&5ST[UG_$OX2>*_%?BN_NK);5[">]TR[B8:C]D0+;R(SB:)8RT[_*VPLQ1=
MWW01DPE%RMSZ#UML>EKXA\$/'J$BZAX;:/3SB\82VQ%L<X_>'^#D$<XYXJ]_
MPF7AR"#3&_MW28X=1^2P(O(@MSR!B+YL/R0,+GG KR*+X-^(@-0M$TV--#0*
M]CIJ:[F>WN!="59;.Z$ D@5!EEBE++N(&  28S\(_&SZ=K4=\ND:M=Z_I<ND
MS2W,J1MIJ&YED1SLB"SMME!<HJ%GC4\YW <(/>7]?U_D%WV/7M4\=:#I-Q>V
MDFK:>VI6<1GFT_[=!'.J  Y*NZ[1@@Y8@<]:BUCXB^&=!CU0WFNZ>DVEVSWE
MW:K<QM/%$J[F8QAMW0CMW'K7F.J?"?Q,W@/Q)X/@T[2+]+V6[N;?7KN\V3,T
MQ! :/RRRO_"6W8*@=>E8FI? SQAJGB$SR_8A;+-JQ\Y=1V0E+NWFBC*6J1@*
MX,B^8SEF;;D-CBB-.F]Y W+L>W:3X\\/:W_9:6NLV#76IVJ7EK9FZC\^6)EW
M!@@;)XSTST/I56Q^)/A_5?&1\,V%_#J&I):RW4IM)8Y4A$;JC)(58E7RX^4C
ML?2O);3X(^*9]2Q=RBWM+R?3;R5X=47;9O;01QE0BP[Y&!B)1ED5?WAW#@AN
M@^&?PU\1^&_%^AW>J6.DVUCHWAZ30UNK.YWRW;&:-UD*;!L4A"2"20S'US2=
M.FDWS#O+L>Q4445R%G@_[7?_ "*7AK_L(2_^B:^7*^H_VN_^12\-?]A"7_T3
M7RY7ZAD/^X1]7^;/G\9_&?R_(****^@.(**** "BBB@ HHHH **** "BBB@
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M_"C_ %F7_/G_ ,F_X ?4/[WX?\$_.?(]11D>HK]&/L\7_/*/_O@?X4?9XO\
MGE'_ -\#_"C_ %F7_/G_ ,F_X ?4/[WX?\$_.?(]11D>HK]&/L\7_/*/_O@?
MX4?9XO\ GE'_ -\#_"C_ %F7_/G_ ,F_X ?4/[WX?\$_.?(]11N'J*_1C[/%
M_P \H_\ O@?X5.\$7V*/]U'_ *P_P#T'M1_K,O\ GS_Y-_P!_P!G_P![\/\
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MHYY(+$&-RI,ISCZ"DRD5,T9JQ]ON/^>S?I1]ON/^>S?I1J+0KYHS5C[?<?\
M/9OTH^WW'_/9OTHU#0KYHS5C[?<?\]F_2C[?<?\ /9OTHU#0KYHS5C[?<?\
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MBBOH#B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KI/A_P",-8\%
M^)+:]T4N]RS"-K8 E;@$_<('7-<_;V\MW/'##&TLTC!4C099B>@ KZT^!WP.
MB\$P1:UK4:RZ](N4B/(M >P_V_4]J\G,L90PE%^V5[[+O_P#IH4IU)^[I;J>
MLZ7<SWNFVMQ<VK6-Q+&KR6SL&,3$<J2.N*M445^3-W=T?2!1112 **** "BB
MB@">#_47'^Z/YU!4\'^HN/\ ='\Z@I+J/H%%%%,04444 %%%% !1110 4444
M %36WW9O^N9J&IK;[LW_ %S-)[#1#1113$%%%% !1110 4444 %%%% !1110
M!9TS_C_@_P!X5U]<AIG_ !_P?[PKKZXZ^Z-J>QSGB3_C\C_W/ZFLJM7Q)_Q^
M1_[G]365713^!$2W"@$CH<445H0&X^I_.CMCMZ444 &2>YXH))ZDGZFBB@ R
M<YSSZT9YSGFBB@ HHHH *G/_ !X+_P!=3_(5!4Y_X\%_ZZG^0I,:(****8@I
M0Q7HQ'?@TE% "AV'1B/QH+$]23WY-)10 ID<@ NV!TY/%4-)T2QT/[=]@MQ;
M"^NGO;D*S$2SN &<Y)Y.T=..*O44P%,CGJ['MR32F5SU=C]6--HI  8IRI*_
M0XK@[OXK_8-5\1LUM//IFD7,&F#[,,S37CH)9,N[K''&B,F6<@9))88 />5Y
M?K/P=;7-=UH2W?V?3+O4K?7K:01QS^7>)%Y,J202*4D1E5&!/1AQ@@&M:?+K
MS"=^@_P5\<(?B#XRL--T>QGDT6ZTJXOVOY)(\I-%<^0T9"R$, 0?F7<#E2"1
MDU7T?X]V]M?ZS#XBM+G2K:UU?4-.@U5$'V61;:/S=I/F%]_EASG9M)7 .>*T
M_ _P;L_ FK6FH6NLWU[/%'>Q3&ZBBS<"YN/M#%BJC:5DSC;C@X-1ZI\#=#UJ
MU:UO;J\FM7U:]U>2+Y!O:ZA:*2/(&0H5R01SD#FMFZ/,UT)]ZP3?'?3+?[+;
MSZ+X@AU*]EM4M=+>WB\^X6YW^3(/WNP*3&P;<P*'&X"JUK^T9X??3S?7-EK>
MFVTEO// UW;H#=-#,L$L2!9"2ZRNJ?-A6SE6(YJQ9_!6U75M*U34=>U+5M2T
MV:S:WN)XXH\16WF&.$JB@$$R$L_WF('3%4M3_9WT#5]%L=,NKZ^E@LXKY(R5
MB)W7-RER7(*D$I)&NT$8(X8&A>PO9A[QI-\7XWEL98(7MX4UF+1=6M+EE-Q:
M2S*/(8-%(R,I9H^A8$/P05(KT02.HP&8 =@:\Q3X1FQATG3[>XCN++^VH=8U
M&<P0VH)@ :&*&") B@NJ$D>C$DDBO3.O6L9\NG*4K]10[+T9A]#2^8^<[VSZ
M[C3:*R&4K;1K*SUB_P!4A@$>H7\<45S.&;,JQ[O+!&<<;VZ#OS5[>V?O-^=)
M13O<!=[ $!B >HSQ1O;.=S9^M)12 4R,1@NQ'H2<4E%% !1110!S_CKX<:)\
M1=(LK?6XIY8[6X:2,03F(ABF#DCKQ7$?\,Q> O\ GTU'_P &#_X5Z\?^/%?^
MNA_E4%=E+&XFC'DIU&EV3,Y4H2=Y139Y1_PS%X"_Y]-1_P#!@_\ A1_PS%X"
M_P"?34?_  8/_A7J]%;?VCC/^?LOO9/L*7\J/*/^&8O 7_/IJ/\ X,'_ ,*/
M^&8O 7_/IJ/_ (,'_P *]7HH_M'&?\_9?>P]A2_E1Y1_PS%X"_Y]-1_\&#_X
M4?\ #,7@+_GTU'_P8/\ X5ZO11_:.,_Y^R^]A["E_*CRC_AF+P%_SZ:C_P"#
M!_\ "C_AF+P%_P ^FH_^#!_\*]7HH_M'&?\ /V7WL/84OY4>4?\ #,7@+_GT
MU'_P8/\ X4?\,Q> O^?34?\ P8/_ (5ZO11_:.,_Y^R^]A["E_*CRC_AF+P%
M_P ^FH_^#!_\*D;]E[P"+='^R:CDL1_R$']/I7J=3/\ \>47_71OY"D\QQG_
M #]E][&J%+^5'D7_  S%X"_Y]-1_\&#_ .%'_#,7@+_GTU'_ ,&#_P"%>KT4
M_P"T<9_S]E][%["E_*CRC_AF+P%_SZ:C_P"#!_\ "C_AF+P%_P ^FH_^#!_\
M*]7HH_M'&?\ /V7WL/84OY4>4?\ #,7@+_GTU'_P8/\ X4?\,Q> O^?34?\
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MA["E_*CRC_AF+P%_SZ:C_P"#!_\ "C_AF+P%_P ^FH_^#!_\*]7HH_M'&?\
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M^TI_S[1?^/?XU"JLYPJECZ*,T%&4D%6!')!'2BP7)OM*?\^T7_CW^-'VE/\
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M<TQ2,W<OEJY"Y(&3R<5@_P#"X/ __0QZ#_X&#_XJO*_VN_\ D4O#7_80E_\
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M?_ P?_%4?\+@\#_]#'H/_@8/_BJ^",T9H_U:H?\ /QA_:$_Y4?>__"X/ _\
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MB@ HHHH *GC_ ./.?ZK_ #J"IX_^/.?ZK_.DQH@HHHIB"BBB@ HHHH ****
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M,_\ SS_\>'^-'V&?_GG_ ./#_&J^*,4:AH6/L,__ #S_ /'A_C1]AG_YY_\
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M_FI_V7FW=_\ @7_!%]8PW;\/^ >^?\*5\(?]"?H__@,E'_"E?"'_ $)^C_\
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M_P \_P#QX?XT?89_^>?_ (\/\:KXHQ1J&A>ALIA#."G)48^8>M0_89_^>?\
MX\/\:2 ?N+C_ '1_.H,4E<>A8^PS_P#//_QX?XT?89_^>?\ X\/\:KXHQ3U%
MH6/L,_\ SS_\>'^-'V&?_GG_ ./#_&J^*,4:AH6/L,__ #S_ /'A_C1]AG_Y
MY_\ CP_QJOBC%&H:%C[#/_SS_P#'A_C1]AG_ .>?_CP_QJOBC%&H:%C[#/\
M\\__ !X?XT?89_\ GG_X\/\ &J^*,4:AH6/L,_\ SS_\>'^-36]E,%ERF,H0
M/F'^-4<5/;#Y9O\ KF:3O8:L+]AG_P">?_CP_P :/L,__//_ ,>'^-5\48IZ
MBT+'V&?_ )Y_^/#_ !H^PS_\\_\ QX?XU7Q1BC4-"Q]AG_YY_P#CP_QH^PS_
M ///_P >'^-5\48HU#0L?89_^>?_ (\/\:/L,_\ SS_\>'^-5\48HU#0L?89
M_P#GG_X\/\:/L,__ #S_ /'A_C5?%&*-0T+'V&?_ )Y_^/#_ !H^PS_\\_\
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M;[JC#<D]O7M47B+XM>$O#.FZ]=W.NV4S:';R7-]:VTZ23Q*F PV ]<D+CL2
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M^_P_^)H]C4_E_+_,/KE#^;\'_D6Z*J?VW;?\^DO_ '^'_P 31_;=M_SZ2_\
M?X?_ !-'L:G\OY?YA]<H?S?@_P#(MU.?^/!?^NI_D*S?[;MO^?27_O\ #_XF
MK#:Q;_V<C_99,&8C'FCKM'^S4NC4T]W\BEC*#O[WX/\ R'T54_MNV_Y])?\
MO\/_ (FC^V[;_GTE_P"_P_\ B:KV-3^7\O\ ,GZY0_F_!_Y%NBJG]MVW_/I+
M_P!_A_\ $T?VW;?\^DO_ '^'_P 31[&I_+^7^8?7*'\WX/\ R+=%5/[;MO\
MGTE_[_#_ .)H_MNV_P"?27_O\/\ XFCV-3^7\O\ ,/KE#^;\'_D6Z*J?VW;?
M\^DO_?X?_$T?VW;?\^DO_?X?_$T>QJ?R_E_F'URA_-^#_P BW153^V[;_GTE
M_P"_P_\ B:/[;MO^?27_ +_#_P")H]C4_E_+_,/KE#^;\'_D6Z*J?VW;?\^D
MO_?X?_$T?VW;?\^DO_?X?_$T>QJ?R_E_F'URA_-^#_R+=%5/[;MO^?27_O\
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MVW_/I+_W^'_Q-']MVW_/I+_W^'_Q-=O]N8__ )]Q_K_MXQY<'_._Z^1\=?\
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MT^)_LLF#(PQYH]!_LTGGN/5OW<?Z_P"WAJ&#?VW_ %\CXR_X9R^('_0$C_\
M Z#_ .+H_P"&<OB!_P! 2/\ \#H/_BZ^Q?[;MO\ GTE_[_#_ .)H_MNV_P"?
M27_O\/\ XFG_ &YC_P#GW'^O^WA<N#_G?]?(^.O^&<OB!_T!(_\ P.@_^+H_
MX9R^('_0$C_\#H/_ (NOL7^V[;_GTE_[_#_XFC^V[;_GTE_[_#_XFC^W,?\
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M -_A_P#$T?VW;?\ /I+_ -_A_P#$T>QJ?R_E_F'URA_-^#_R+=3Q_P#'G/\
M5?YUF_VW;?\ /I+_ -_A_P#$U9AU>W-C<-]ED 4KD>:.>?\ =J71J+[/Y#6+
MH/:7X/\ R'454_MNV_Y])?\ O\/_ (FC^V[;_GTE_P"_P_\ B:KV-3^7\O\
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M/_B:/[;MO^?27_O\/_B:/8U/Y?R_S#ZY0_F_!_Y%NBJG]MVW_/I+_P!_A_\
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MM36O[EG_ -^3_P#%5QU%>K]1PW_/M'SO]K8__G]+[SL?^%J:U_<L_P#OR?\
MXJC_ (6IK7]RS_[\G_XJN.HH^HX;_GV@_M;'_P#/Z7WG8_\ "U-:_N6?_?D_
M_%4?\+4UK^Y9_P#?D_\ Q5<=11]1PW_/M!_:V/\ ^?TOO/9_!WC.+Q+!Y4NV
M&_09:,='']Y?\*Z:OG>UNI;*XCG@D:*6,[E=3R#7L/@WQG%XCMQ#,5BOT'SI
MT#C^\O\ 45\WF&7NA>K27N_E_P  ^ZR7.EBTL/B'[_1]_P#@_F=/1117@GV
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MH7@30]-CT#_A%XK.V6!-'^TI<_957("^:GRN<<DCN?6NDHHK!ZZF;U"K;?\
M()C_ .OAO_0152K;?\@F/_KX;_T$5$NA<.OH5*R/%WB:V\&^&=2UN\1Y+>QA
M,K1Q8WN>BJN>,DD 9]:UZR_%'ARS\7>'M0T:_#&SO86AD\LX8 ]&4]B#@CW
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MH,DX(&2"*SK7XX^%V%K AOYY9)(K1/L6ESO$UP\"S)"AV\L8R"%].#@UB_\
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MI_$BI1115F84444 %%%% !1110 4444 %%%% %_0O^0Q:?\ 705Z97F>A?\
M(8M/^N@KTRO!S#XX^A]+E7\.7J<?XRL9KK486C"$"+'S2*O<^IK _LBY](_^
M_P G^-:_CH9U2#_KC_4US>!Z"O1PRE[&-G^'_!/*Q;A[>5T_O_X!=_LBY](_
M^_R?XT?V1<^D?_?Y/\:I8'H*Q?%7C;PYX%LHKOQ'KFFZ#:ROY<<VI720*[8S
MM!8C)^E=24WHG^'_  3DO!]']_\ P#I_[(N?2/\ [_)_C1_9%SZ1_P#?Y/\
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MR?XU2P/048'H*+2[_A_P0O#L_O\ ^ 7?[(N?2/\ [_)_C1_9%SZ1_P#?Y/\
M&J6!Z"C ]!1:7?\ #_@A>'9_?_P"[_9%SZ1_]_D_QH_LBY](_P#O\G^-4L#T
M%&!Z"BTN_P"'_!"\.S^__@%W^R+GTC_[_)_C1_9%SZ1_]_D_QJE@>@HP/046
MEW_#_@A>'9_?_P  N_V1<^D?_?Y/\:/[(N?2/_O\G^-4L#T%&!Z"BTN_X?\
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M?\ME_D:J8'H*B*EKKU[?\$TFX::/;O\ \ N_V1<^D?\ W^3_ !H_LBY](_\
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M_?\ \ U[;2[A;2\!$>60 ?O4]1[U5_LBY](_^_R?XTVT ^QWO'\ _P#0A53
M]!414KO7\/+U-).%HZ/[_-^1=_LBY](_^_R?XT?V1<^D?_?Y/\:I8'H*,#T%
M7:7?\/\ @F=X=G]__ +O]D7/I'_W^3_&C^R+GTC_ ._R?XU2P/048'H*+2[_
M (?\$+P[/[_^ 7?[(N?2/_O\G^-']D7/I'_W^3_&J6!Z"C ]!1:7?\/^"%X=
MG]__  "[_9%SZ1_]_D_QH_LBY](_^_R?XU2P/048'H*+2[_A_P $+P[/[_\
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M&>:7(E>[V)Y5W/:M7UBST"P-[J$ZVMH)(X3,X)4.[A$7@'DLRC\:O&-P0"C
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M0_LQ_P#GO:_^!"T?V8__ #WM?_ A:.>/</9S[%"*&.")(HD6.)%"JB*%50.
M !P /2GX'I5S^S'_ .>]K_X$+1_9C_\ />U_\"%HYX]P]G/L4B >U&!Z"KO]
MF/\ \][7_P "%H_LQ_\ GO:_^!"T<\>X>SGV*>!2  =JN_V8_P#SWM?_  (6
MC^S'_P">]K_X$+1SQ[A[.?8I8'I0 !VJ[_9C_P#/>U_\"%H_LQ_^>]K_ .!"
MT<\>X>SGV*=%7/[,?_GO:_\ @0M']F/_ ,][7_P(6CGCW#V<^Q3HJY_9C_\
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MM'/'N'LY]BG15S^S'_Y[VO\ X$+1_9C_ //>U_\  A:.>/</9S["+_R"I/\
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M]EIN?7NDZ[INOK=-IE_;:@+6X>UG-K*)/*F3[\;8Z,,C(/(J1M6LEU-=--Y
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MZ(TEM'T_5A1115F84444 %%%% !1110 4444 %6[#[EW_P!<6JI5NP^Y=_\
M7%JB?PFE/XD5****LS"BBB@ HHHH **** "BBB@ HHHH OZ%_P ABT_ZZ"O3
M*\ST+_D,6G_705Z97@YA\<?0^ERK^'+U.'\=?\A2#_KC_P"S&N<KH_'7_(4@
M_P"N/_LQKG*]3"_P8GC8S_>)A7*?$_XFZ9\(?!USXEU>&^N+*"6*$Q:;$))W
M:1PBA5++GDCO75UY'^U1X%UOXC?!G4M#\/6#:GJDMU:2I:I<I;LZI,KOB1B
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M5QY"%ER0_8C.2!C$^&EK\4$^%MC\./$WPBM5T>UT%M.DNYO$\2K=LD6%C81
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MYU4JW!_R#+O_ 'D_G43V^:_,TAN_1_D5****LS"BBB@ HHHH **** "BBB@
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M -:C_A"]2](?^^__ *U=]11]?K>0?V90\S@?^$+U+TA_[[_^M1_PA>I>D/\
MWW_]:N^HH^OUO(/[,H>9P/\ PA>I>D/_ 'W_ /6H_P"$+U+TA_[[_P#K5WU%
M'U^MY!_9E#S.!_X0O4O2'_OO_P"M1_PA>I>D/_??_P!:N^HH^OUO(/[,H>9Q
M/_"):C]@$(\H/YN_[_;;CTJ#_A#=3_Z9?]_#_A7>T4ECJJ[%/+J+[G!?\(;J
M?_3+_OX?\*3_ (0O4O2'_OO_ .M7?44_K];R)_LRAYG _P#"%ZEZ0_\ ??\
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M/^$+U+TA_P"^_P#ZU=]13^OUO(G^S*'F<#_PA>I>D/\ WW_]:C_A"]2](?\
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M4O2'_OO_ .M7?44OK];R'_9E#S.!_P"$+U+TA_[[_P#K4?\ "%ZEZ0_]]_\
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M6<G3:<'S?$NS_FL]!9M&EGOO#^H1Z=IFJE=&$ M[R<)*N=A+*""-O&#531/
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M*1K'YGGK#NRSE>!'G[WM5&S^.WCRQ\/:MYTT>I012VS:=XAN](.FM>1O*J2
M6CN6( /$@ %)97B&KZ:[>?FM+?+?R!YIADW&^V_EZ]?T\SZF)P,GI59=4LW$
M)6[@83,4B(E4[V'4+SR?I7FOQ2\3Z_!XS\/>&M%U&#34U>TO"]Q+:BX,;)'E
M&"DC.#V[UXA\,3J?@WPE\/[C6)M-\11'6[V2$RZ2D<MF$$I<Q.&.&8@G/;.*
MBE@74I>T<M7LO_ OE]DVJ8ZG3FX/IO\ A_\ )(^PZ0D 9/ KP[P?JOQ:\7:=
MIOC*TU;P^=*OW$R>&9;)D*6Q/!^U!B?-QSC9MSQ7/>%?$?BOXG>+-2\-^*->
ML=)9VF<^')M*FM;FW5'_ ';Q2D[;E",%B#QGBDL#+WKS7N[VN[?A^.WF)XZ"
M4;1?O;;*_;K^&_D?2=%4])T\:5IMM:"5IO)0)O;J:N5YKWT/16JU"BBBD,*@
MGLK>Y</+!'*P1H]SH"=K8W+SV.!D=\5/10!G3^'-*NHTCFTVSE1)$E57MT8*
MZ#:C $<$   ]0.E27&B:?=WR7L]C;37B1M"MQ)"K2*C?>4,1D ]QT-7:* ,N
MW\+:-:6C6L&DV,-LT;1&&.V14*, &7 &,$ 9'0X'I4%SX*T.[%DKZ; BV;1-
M"L*^4!Y;;HU(7&Y%8[@ARH(!QD UMT4 4;W0].U*Y@N+NPM;JX@SY4LT*N\>
M<9VDC(Z#IZ5'<>&M)N[8V\VF64T!"#RI+=&7"9V<$8XR<>F3BM*B@"E<Z+I]
MZ]H]Q8VT[6C![<R0JQA8# *9'RGW&*:-!TU2"+"U&%VC$"\###'3IAV'_ CZ
MFK]% &5!X4T6UEM9(=(L(I+5/+@=+6-3$N=VU2!\HSS@=ZBM/!NBV&HVU];:
M?#;3VR2)"(1LCC\P@N1&,*&; RV-V.,X)K:HH HS:'IUQ=S74MA;27,T/V>2
M9X5+O'G.PDC)7/.#Q4DVEV=S.)Y;2"68#:)'B4L!@C&2,]&8?B?6K5% %"70
M-,GM9[:33[62WG18Y8F@0I(BC"JPQ@@#H#TJ/_A&-'WR/_95EOD@%J[?9DRT
M(Z1GCE1C[O3VK3HH YF7X;^')M?M=9DTR-[ZUB:&#+-Y42L&#;8\[!D.P)Q_
M$:T;?PIHMJD"0Z180I;G="L=K&HC/R\K@<?=7I_='H*U:* ,V+PWI,$;I%IE
MG&CM([*EN@!9QAR1CJPZGOWHB\-:3!=27,>F6<=Q(XD>5;= [,,88G&2>!S[
M"M*B@#&U3P?HVL?;#<Z?#YUW&8I[B)?+F=2,8\Q<-TXZ].*AT?P%X>T&QL+2
MRTBTCAL!(+;?&)'BWDE\.V6RQ)SSSGFM^B@#,G\,Z1=1".;2[*6,#&Q[=&&-
MFS&"/[OR_3CI3Y_#VEW6GPV$VG6DME 5,5L\"-''M^[M4C QVP.*T** ,\^'
M],,31'3K3RV5E9/(3!#*%8$8Z$  ^H %,_X1C1QI\EA_95E]BDQOMOLR>6V.
M1E<8./I6G10!5_LRT\F:+[+#Y4YS*GEKM<X RPQSP .?05&-#TY8R@L+8(0H
M*B%<<,6'&.S$D>YS5ZB@#+NO"^CWTEX]QI5C.]XJK<M+;(QF"_=#DCY@.V<X
MJ#5?!>BZQ:7%O<:?"J7$8AD> >3(R 8V[TPV,<8STXZ5MT4 8.D^!/#VAV]E
M#9:/9Q+9Q>3 QA5W1,EL!V!;J2>O))-6XO#&CP?9?+TJRC^RL7@V6R#RB1@E
M>/E. !Q6G10!F7'AC1[J)(YM*LIHTV[4DMD8+MSMP".,9./3)J270=-GL'LI
M=/M9+-VW-;O AC8]<E<8)X%7Z* ,P>&-(5IV&E60,\ MI3]F3]Y$!@1MQRH'
M\)XIUKX=TJRN8+BWTVS@G@B\B*6.W16CC_N*0,A?8<5HT4 4?[#T[[3<7'V"
MV\^X*--+Y*[I"GW2QQDXQQGIVJIK7@[1/$2W0U'2[6Z:Y@-M+*T0$K1D$%=X
M^8#D]#WK9HH Y^#X?^'+;4;&^BT6SCN;&$P6K+$ L"%@QV+]U22 <@9]^36B
M-!TU9K68:?:B6U#+ X@7=$&^\%./ESWQ5^B@#/D\/Z9,+42:=:.+63S;<- A
M\E^3N3CY3R>1SS4,_A31[BSU&U;3K=(-15ENUBC$9G# @[BN"2<GG.>:UJ*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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-R71;+H%%%%<9Z!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>btai-20231231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &. X(# 2(  A$! Q$!_\0
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MH_\ ($^'/_8M+_Z6W=92X?P*E%)/7S\BECJS39^@'_#S[X6?] #QA_X!VO\
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M)MW_ .J=L8WKUQUXK@J*>09;5BIT[M/JI702QN(B[2T?H?I[_P //OA9_P!
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M2M)J?0] HHHKX\]4**** "BBB@#Y8_X*1_\ )N#?]ABU_E)7Y5U^JG_!2/\
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MUS=$91E\+N#36X44450@HHK?\2_#[Q3X+M[2X\0>&M7T*"\S]FEU.PEMUGP
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MEB.,UE?$OXL^(_BAK5Y<:KJ^J7&EO>375EI5YJ$ES#8J[$B.(,=JA5(7Y5'
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M<@*81'OV^7@ ;<8P ,<5R_V162C'VETK;WW7+=[[MQ?WFGUJ-V^7\O/_ #_
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M.D&QOE"E1CY0:IZSI_@SX::7X\U9?AOX2UN:/XGIHEM#J6E1-%;6TEO"61%
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M_P"G&^K@JPH?!\W^;+GO]WY!1116Y 4444 %%%% !1110!;TG_D*V7_79/\
MT(5U'QI_Y+'X\_[#U_\ ^E$E<OI/_(5LO^NR?^A"NH^-/_)8_'G_ &'K_P#]
M*)*P?\9>C_-%_8?J<91116Y 4444 %%%% !1110!WOP@_P"/[Q5_V+6I?^B#
M7!5WOP@_X_O%7_8M:E_Z(-<%6$/XL_D6_A04445N0%%%% !1110 4444 %=[
M\4?^0)\.?^Q:7_TMNZX*N]^*/_($^'/_ &+2_P#I;=UA4^.'J_R9<=F<%111
M6Y 4444 %%%% !1110 5WWP5_P"1IU?_ +%K7?\ TUW-<#7??!7_ )&G5_\
ML6M=_P#37<UAB/X4_1EP^)' U]Z?L;O:ZI^R]?\ @^]REIXS\77_ (>>8$ P
MF31O,1QGOOA4#W-?!=;6E^-?$6B6-M9:=KVIZ?9VUZ-2@M[6\DCCBNPNT7"J
MK +*%XWCYL<9KFQV%>+I>SB[.]_N-*-3V4N9H_3C4]+T'5].^'W@&;3[35]
M\*^/+7PVT%Y$L\-QY.@22.61@0?WDC9R.JYKF_!'PY\)>,M'^&6B:_9VSZ38
M^)/%%S9Z48@8)Y(;N8QPF%?OHJ@MY0X81X(*Y!_/:U^)OC&RE:2W\6:Y;R-J
M#ZL7BU*92;UU*O<Y#?ZYE9E,GWB"03S4,OQ"\4SC3Q)XEUB0:?=M?V8:_E/V
M:Y9][31_-\DA?YBZX)/.<UX:R:LE:-6WGYVDF_Q.OZW%N[C_ %I_D?>'B/PI
M\-=)^*G@?49/AQ<:]J<MA?V][I^C_#K4+&RW;XA!>'3IAB5(A*RR;6=B70@
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M_OJ;_P"+KU:BCZS7_P"?DOO?^879Y3_PRE\(?^A TO\ [ZF_^+H_X92^$/\
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M  RE\(?^A TO_OJ;_P"+H_X92^$/_0@:7_WU-_\ %U\I_P##4OQ/_P"AG_\
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M  RE\(?^A TO_OJ;_P"+KY57]JCXHIG;XGQD8/\ Q+[7I_WZIO\ PU+\3_\
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M7E^C(S*?K7HM3VG^L?\ ZYO_ .@FHEB*SBTYO[V5%OF1Y%_PRE\(?^A TO\
M[ZF_^+H_X92^$/\ T(&E_P#?4W_Q=>K45?UFO_S\E][_ ,R;L\I_X92^$/\
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M(?\ H0-+_P"^IO\ XNFP?M%:7<ZN;./PSXA-L=;N_#D.HE+58)]0@\[,"9N
M_P _D,%<H$RRAF4YQS_P_P#VF;C7O /AJ_U'PGJNI>)]3T^?4YM+T&* A+6)
M]AN!YMP J$X55+^8S9PM5S8JU^=_^!/_ #\@NSHO^&4OA#_T(&E_]]3?_%T?
M\,I?"'_H0-+_ .^IO_BZAN_VF_"T7]HW-E8ZMJ^C:=I$&MW>LV4,7V:&UFC=
MX6(>19"S^6R[0A((^;: 2.X\$^,V\96UU))H.K:!+;NJ^5JB1$3(R*ZR12PR
M212(0V,JY(((('&9E5Q,5=SE][_S"[.-_P"&4OA#_P!"!I?_ 'U-_P#%T?\
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M&5.V>N%V_3/@CX2Z)X&T3Q'I5N]UJ-KX@U*[U34/[0=7:26Y_P!:ORJORX&
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M)'[O^ <;_P *F\#_ /0F>'__  5P?_$4?\*F\#_]"9X?_P#!7!_\179;[?\
MYY2?]_!_\31OM_\ GE)_W\'_ ,31]8K?S/[_ /@A]3PW\D?N_P" <>OPE\#E
MA_Q1GA_K_P! N#_XBGW7PD\#+<R@>#/#P <@ :5!Z_[E=<CV^X?NI.O_ #T'
M_P 33[IX/M,V8I"=YSB0>O\ NTOK%:_Q/[_^"5]3PW+\$?N_X!Q/_"IO _\
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M/3Z5%OM_^>4G_?P?_$TEB*UW[S^__@E/!X:R]R/W?\ XW_A4W@?_ *$SP_\
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M_P#GE)_W\'_Q-&^W_P">4G_?P?\ Q-*[[!9=R"NOL?\ CRM_^N:_RKE]]O\
M\\I/^_@_^)KJ;/!LX, @>6N 3GM7%B7HCT<$K2>I-1117 >N%%%% !1110!F
MZ]_QX?\  A7-UTFO?\>'_ A7-UZ>&^ \+&?Q?D%?(7[3GC?7_!WQFLKRV\37
MLNFV]O8&/POI>JSZ9J,DK7)_>6L;H;:_#':KQL)&P2N$^]7U[17HTJBIRYFK
MG$?%&@^/]2D^($\5CXPUJ^\:+\6+K3(M!EU6>2)M%\R43+]D)*&%(Q(WF[#Y
M9C7#+@+4/A_XA^*9[?0)[;Q-K%YX_N4UT>,M$DOY7CTR&..0HYMR=EIY;K (
MW0(7+D9?<:^PO"W@K1O!2:JFC6?V-=4U"?5;L>:\GFW,QW2R?,3C)'W1@#L!
M7-7_ ,>_ FD^/=1\(7_B2PT_5M.LA?7C7ES'## I(PC.[#Y\$,5[*03C(SU^
MW4F^6%_Z_+7[P/EWP-XK\40:/#'%XVUV"XU?X3OK<U]J%U=ZB(+Y;E8Q<+&/
M,="$?!,2\ ;BK$$FKX-^)OB,^&#IU]XBU(^&[?Q7I=MXB\56'B66_P!/%K+"
M<_9KUO\ 2+6-G2 2AY<QF7AH]Y ^N+#XP>%-5U>\M+/6M,N[*STU]4N-5@U2
MS>VBB21DDW 3&10I0EG*",8(W[@0*>H?'7PA;S>%UT[4HO$=OXBU7^Q[6\T2
M>&Z@CN-A<B1U?   YQD\CCFG[9MO]W_7W ?-WAC6_$'C/XD_#_P_+XI\12^"
M+SQ%XC@TZ\M]7N8)=4TV"VAD@+7",LDR++Y@64L6*@C=W.7X+\<_$N]O-3>Q
MU\S>-8;3Q&=1\/2ZK>WUV6C1Q9@6!MS#9[)!;['\P><)&&69MJ_9'A_QYX9\
M67U[9Z'XBTG6;RQ.VZM]/OHIY+<Y(Q(J,2O((YQR#6[4/$6T</ZU_P _P ^1
M/V:M3TG6/C[87>D^([WQ0)?AK8O=WM_J,E[(MR;K,J&20D@[CDIG",S+A<;1
M]=T45RU:GM9<U@"BBBL1$]W_ *U?^N:?^@BH*GN_]:O_ %S3_P!!%04H[(N7
MQ,****9!Q/Q:\<W'@/0M.NK>2SLQ>ZE!8RZGJ2,]IIZ/N)FF"LN5^4(,NHW2
M+E@*SM)^)SZ+I;WOBN]TVZTVXNHK?2-;T&)Y8-4,BL0D<*-,ZN&1EQN8,=NW
MD[:ZCQ=:^(I(K&Y\-W=HEU;7 >>PO_E@O8B"K1M*J,\3#(=74'E<%2#QYC;?
M!#5#KD>L1V^B:#YNOZ?JDVCZ9([6T26Z2J[J_E)OED,H)RBCY1DGJ<WS7T-X
M\KC[W]?U]QW&C_&;PCKVH6EE9ZC.9[JY>Q3SM/N846Y0.6MY'>,+',!&Q\IR
M'Q@XP1GG_%WQ\T6#P7XCU#PU="]U73]+EU.UCO;&XB@N8T8+YB,RH)8]S*-T
M;$<CGD53?X/:X;:!(KZQAEC\:W'B02AG;;;N)MH *<R#S%.T_+P?FKB;S]G;
MQMJ]C/\ ;]1T^?49O#MUHLUW=ZS>WC3S2&)EGS+'^Z4E&S$@PO4%LX$.4[;%
MQC2ON>Q?##QK?>-8_$K7T5O$=-UB33X?LZL-T:Q1."V6.6S(W3 P!Q6'X?\
M&GC?Q=HMMXLT>RTJXT"[G#6NB-&ZWTUGNV><;EI1$LA&9/+\LC&%WY^:MSX8
M>"K[P5'XE6^EMY3J6L2:A#]G9CMC:*) &RHPV8VZ9&".:YW1? _CGPIX?A\(
M:+?:5:Z%:W 6SUUIG:_@M-^\1FV,1C>1>8PYDVD ,4ZK5ZZ7(]V[L=<OQ/\
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M_P IEY_\9H_X;(^#_P#T-_\ Y3+S_P",U^8]%']D4/YG^'^0?ZQ8K^6/W/\
MS/TX_P"&R/@__P!#?_Y3+S_XS1_PV1\'_P#H;_\ RF7G_P 9K\QZ*/[(H?S/
M\/\ (/\ 6+%?RQ^Y_P"9^R/AKQ%IOBW1K#6-'O([_3+R,2P7$1^5U/UY!'0@
MX((((!%:MW_Q]S?[[?SK\V/V5?VDIO@[KR:-K,K2^#[^8&88R;*0X'G+W*X
MW*.PR.1@_I#]K@U#_2K6:.YMI_WD4T+ATD0\JRL."""""*^<Q>%EA:MGL]F?
M8Y?CX8ZAS+22W7]= HHHKC/1"BBB@ HHHH **** )[7K)_US;^505/:]9/\
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MX\Y/^NB_R:H*G7_CSD_ZZ+_)J@I+=ERV04444R HHHH **** "BBB@ HHHH
M**** "NOL?\ CRM_^N:_RKD*Z^Q_X\K?_KFO\JXL5LCT\#\4B>BBBO//8"BB
MB@ HHHH S=>_X\/^!"N;KI->_P"/#_@0KFZ]/#? >%C/XOR"BBBNHX0KY6_:
M(^#OC;Q9XM^(D^@^'I=7M/$GA.UTRTN(;NVC6.XBN3(R2"65&&5 P5##D9(Y
MQ]4T5M2JNE+FB,^8/BY\)/'EWXRU35?".B6D\0\#Z?H]L+D6DL;7$6I":2%8
MYR4W"'+*SJ4W <YZ<CX7^ OCZU\;6>I'PWJ5OIT?C:+65.LZW#<W0M!9-$9)
MI1-(Q?=@-M+$9^7( -?9M%;1Q4XQY;(#YB_9K^$'C#X:>/F$^C7.E>$8=)DM
M$CUVXLM0NH)3/O$-G=PXE-K@%]DJ1@,<[2Q)KZ=HHK"K4=67,P"BBBLA!111
M0!/=_P"M7_KFG_H(J"I[O_6K_P!<T_\ 014%*.R+E\3"BBBF0%%%% !1110
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MDLYM?U6744MYXS'-'"$2&$.I *L8X58J>5+D'G--7NA2LTSMZ***T,0HHHH
M**** "BBB@ HHHH ^ O^"AW_ "6+P]_V+D/_ *575?+E?I+^T7^R=_PO;Q?I
M6O\ _"4_V']FTM+'[/\ V=]HW;9IGW;O-3'^LQC';KS7E7_#N3_JH7_E$_\
MNBOK,'C\/3H1A.6J\G_D? YCE6,K8N=2G"Z?FNWJ?%]%?:'_  [D_P"JA?\
ME$_^Z*/^'<G_ %4+_P HG_W179_:6%_G_!_Y'F_V+C_^??XQ_P SXOHK[0_X
M=R?]5"_\HG_W11_P[D_ZJ%_Y1/\ [HH_M+"_S_@_\@_L7'_\^_QC_F?%]%?:
M'_#N3_JH7_E$_P#NBC_AW)_U4+_RB?\ W11_:6%_G_!_Y!_8N/\ ^??XQ_S/
MB^BOM#_AW)_U4+_RB?\ W11_P[D_ZJ%_Y1/_ +HH_M+"_P _X/\ R#^Q<?\
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M%WW#ZO2[&G=O;^:N97!\M/\ EG_LCWJ'?;?\]I/^_?\ ]>H;W_7+_P!<X_\
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MUN+J;,K@[VR/+]_K6<GWU^M2WW_'[<?]=&_G2UON5["G:UB??;?\]I/^_?\
M]>C?;?\ /:3_ +]__7JE13N^Y/U>EV+N^V_Y[2?]^_\ Z]&^V_Y[2?\ ?O\
M^O5*BB[[A]7I=B[OMO\ GM)_W[_^O1OMO^>TG_?O_P"O5*BB[[A]7I=B[OMO
M^>TG_?O_ .O1OMO^>TG_ '[_ /KU2HHN^X?5Z78T[9[?,F)7/[MO^6?M]:AW
MVW_/:3_OW_\ 7J&T^]+_ -<V_E4%)-WW*]A3ML7=]M_SVD_[]_\ UZ-]M_SV
MD_[]_P#UZI44[ON3]7I=B[OMO^>TG_?O_P"O1OMO^>TG_?O_ .O5*BB[[A]7
MI=B[OMO^>TG_ '[_ /KT;[;_ )[2?]^__KU2HHN^X?5Z78N[[;_GM)_W[_\
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MY[2?]^__ *]&^V_Y[2?]^_\ Z]4J*+ON'U>EV+N^V_Y[2?\ ?O\ ^O1OMO\
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MKTQG/;!SGD>-A%SY4[=F4L92;2N?1M%-1UE171@Z,,JRG((]13J\$[ HHHH
M**** "BBB@ J>Z_U=M_UR_\ 9C4%3W7^KMO^N7_LQI/=#(****8@HHHH ***
M* "BBB@ J>R_UK_]<I/_ $$U!4]E_K7_ .N4G_H)J9;,:W(****H1YUXF^(O
MB&U^):>#O#OAW3-4N!I U>6ZU35Y+)%4S-%L4);3$G(!R<=:YKPW^U#H-_K%
MA9>(%L?"44MA=S75WJFII'#!=V]Y]EDME9U59 6#LK@C(7[H.<:'B7X4S>+?
MCJNN7Z:G!H4?AM;)+O2]9GL'-Q]J9RC?9Y4D8;#GG*_C65??!;^R/'2#0=!A
MC\-6O@F^T:US*K;;F6='V'>Q<LXWEG;.23N;)Y[8JBTD][?UU_0R?/<]/UCX
MA>%O#U]866J^)='TR\U *;.WO+^**2Y#'"^6K,"^20!C/)J5?''AQ_$[>&U\
M0:6WB)%WMI O8_M87:&R8=V_&TALXZ'-?+/BKX0_$^]^'*>&K;1;I9)/!^BV
M 339M,BBENK:-C-%?3R9N&96 \KR6\K+#+*&=J[^\^'OBL?$F1]&T?4-)TVZ
MUYM3N9KVXL+W2E5[9HWNH0P%Y!=G=@+'^[#[OF9&)+="FE\:Z]?07/+L>T:/
MXV\.^(=5U#2]*U_2]3U/3G,=[96=Y'+-;,&*E9$5B4(8$88#D$5R7Q,^)NO?
M#JWU+66\)Q7GA/2HXI;W4'U,1W3HS 2-;VZQN)-BD'$DD18@@ C!/FGP+^$'
MBCPGKW@V/7K/6E'A;3[NP%Y<7NFKI[[RJ_Z,EO#]HE23;YA^T,C*0"=[$UU?
MQ(B\3^)_':Z=J7@;6M<\!::8;F*#2KG3PFK70PX-P)[J)A#$P7$6W#NN6)50
MK3[.$:EKIKU_+S_KS'S-QN>ST4U&+(K%2A(R5;&1[<4ZN,U+"?\ (/E_ZZI_
M)J\XG\2^)]6U'6KG1I-%MM*T:[^R2VVIQR>;=%%1Y6\]7"P##X7,<GW=Q(#8
M'HZ?\@^7_KJG\FKCM:^&/ASQ!JTVHWUC)+-/Y?VF%+N:.WNMGW//@5Q'-@8'
M[Q6X '0 "->A1BZC\;M'TF/4;BYTW5$TZU%WY6H".)HKQ[8D3I$!(7RNQ\%U
M4-L.">,Q_P#"[;*":XCO?#FNZ:+=Y8)FNDM\)/':O=^3\LQ)9H$W@@%>0"P.
M0->[^$GA6^N=2FN-.EF_M!)TGB>]G,(\[F9HX]^R)G_B9 K')YY.9_$OP[TG
MQ%8ZE&8O(O+R26Y%UN=O+N'LVL_-V[@#B%MNWIWZ\T>\&AR&J?$#PSXDN-(E
MU3P->ZCK"74 TRUOK.SDN%$\<DL4\3-*516%J_.Y6#1C*C%4K[]I31M1TW5O
M^$<3[9J%D8I(HY)()1<PF[B@=E2.8O&?W@PLHC/S+P<-CL_#?PH\/^&[>P$=
MO+<W=I)%.MU<74TC^;'"\2D;W;"!9) L>=B[S@9YJ6+X6>'(8[F%;>\^R3LK
MM9-J=TUJA$JRCRX#)Y<>'52-BK@9'0D%6D&ARVM?M'^&O#L*#5+2]TZ]#SI/
M8W4UI%+ (2 Y):<))]X$+$SL>R\&M5?C3I;W\\2:3JTEE'-/;KJ4<43P3316
M[7#1H!(9"3&I()0 ],YXK.*_#SQ%XC6UAEU&VU*[N;CRK^REU"QCNI3@RQQW
M<91)?]5DQJY&8R0,J<=C_P (#H8C95MID)NY+[S4NYED$\D#0/('#[@QC=AD
M'@G(PP!H7,^H:'%6WQ^TG4;*TU.VM[@V'^E&>&$VMV^(8XI&;S(+ED3:LNXJ
M=S$ \+QND\2?M%^%?"]Q-%=>>WES3Q>9YUM$LBP[1))&99D\P!V*;4S(61\(
M0 3NZ3X(\(Z;XB>VAAENM:A@:YD:_O+B[F,4P\KYWF=BRD0E0I) VG &3F9?
MA/X9BTW3;&VM;NPATZ-X;>2PU*ZMIE1VW,K2QR*[@M\Q#,>>>M'O=PT%\2^)
M=0?4-!TOP_+91W.KQS7"7]]"\\,<,:J21&KH79C(@ WK@;CSC!Y[Q'\9X/AG
MIMN/%ZP3W;-<;KG29(H[=HXB,L!/*I\PAAF!&DD!! W#!/:Z_P"#]+\36MI#
M?Q3L;-_,M[B"[E@N(6VE24FC99%)4E3AN02#G-8-Y\%_"-[:K;R:?<I&8Y8I
MC!J5U$UTLIW2BX9) 9]QY/FEL\YZFFU+H&A!/\9])L]4OK:[TW4[6RM);J!]
M4D2(V[26\32RJ LAD^XK,"4 .,9SQ6=XB_: TCPC:VSZ[HFKZ+>7!D,=EJ+6
MEN[1HB,TBR/.(G \Q!L60ODD;.#CKF^'WA^16633EE5KB>Z9997<-)-$T4I8
M%CG<C,"#QSTS69'\'/"T,4:Q6VH13QL2M['J]XMW@JJ[/M E\TIA5^0MM^4<
M9%%I!H7_  QX]L_%^JZC;:;9WDME9"+.J,(UMI6DABG14^?S"?+F0\H!U&<X
MSZ]IW_(/MO\ KDO\A7FVD:!8Z$UXUG&Z/>2I/</),\K2NL,<(8LY)SLBC'OM
MR<DDGTG3O^0?;?\ 7)?Y"N>O>RN7#<L4445Q&P4444 %%%% &5XE_P"0;_P,
M5RE=7XE_Y!O_  ,5RE>A0^ PGN%?$7[1/C7_ (07]K62]_X63_PK#S?",,/]
MJ?V%_:_GYNG/D^5M.W.W=O\ ]C'>OL'Q=XVT7P)86M[KM[]AMKJ[AL87\IY-
MTTK;8TPBDC)XR>!W(K<KT:-3V+YFKIZ?U=-?@83CS*R9^?&@>*+.Y_9M\9^%
MCIB>-M2\:^+;JV\.:@;9[-M=N9#&7O\ RF/[H1'!RN$!"H0,.:LV/A_4;/\
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MSP?/IFI7S:A=VPTZYAL[BTO-+N[>\$TVWR8UMI(EF=I-PVA4.[MG!IQ^-/A
MZ+::G'J5Q/'=7<MA%9V^G7,M\UQ&&,L1M%C,X= C%E* J!DX'-<5XM^">NZO
MX[UWQ1876G&<ZKH^K:;:W$LBK*UG%+'+%,P0^6&65MKJ'P0"5.,&MIWP:\6:
M-K]KXS@.BW/B<ZWJ&JW.CR7<L=D([FVBM_+2Y$#/N1;>%MYA^8EQA<@C+DHM
M;_U;;;OU'>78[/4_C_X#TBQL[R?6I'M+FS74//MK"YG2"W9R@EG,<;"W7>KK
MF79@HX/*MBW=_&KP?87^OVD^J31OH(/]I2_8+@PVS;58(91'L+L'3:@8LY.%
M!/%>4_%CX)?$OXI6&IV]_J^D2C4]#6S%M!JU_9V6GW8:5F(MD#+=JP:)/,F(
M(*;Q'TCK9E^ VN7GAKQU:RWNGPZAJVNV6O:;M9Y(EDMH[4K'-E 0K26Q!*@X
M5@<$_+5>SH65Y?UIY>H<T^QOZC\>M#37-,^SZM;6>E11ZA)J]KJFFWL&HPBW
MMDGRD+1 IA'#D2*"RLNS=6QIOQV\$:I8ZG>1ZQ);6VG64>I3/?V%S:;[60L(
MYHA+&IF1BI :+<"2H'++GAOB%\*_'_Q1N(KO5#X;THPZ;K&GP65I=7$WE_:[
M(0QLTS1+YG[S<QQ&FU< ;SS47C']GO6_%#P,FHV%NUMX8T_3(2S2,&O;2\CN
MEWKMYA8QA2?O#).W(%')1:5W;_A_0+SUL=Z_QV\$Q:4U_+JEQ BWZ:6UK-IE
MTEXMVZ%XX3;&(3!W494%/FR N20"FA?'GP3XDU2RT^QU2Y:YN[N33X_/TR[@
MC2[0.7M9))(E6*<"-SY+E7Q@[<,N>+NO@QXH\0>+%\4ZE)I%AJ,_B/2]3GT^
MTN99XH;6S@DCPLS0H9)&:5FY1 !@9.,E[? [Q#]FMDBU#3X)HO'USXJ$H9VV
MVT@GVJ 4YE!E4E3\O!^:ER4;;Z^O_ "\SO\ PA\7_"GCO5SIFBZA-<W9MFO8
MO-L+B".YMU<(9H))(U2:/<RC?&6'S#GD5V5?/_PH^"/C+PM\0_#_ (E\1W]I
M?S66BW.E7MR^MWNH3W<KO"XN%\] L2L8WS"F%3J"V["_0%858PC*T'=%Q;:U
M"BBBL2@HHHH **** /EO]K;_ )'_ $7_ + T?_I1/7B%>W_M;?\ (_Z+_P!@
M:/\ ]*)Z\0K]7RG_ '&EZ'S>)_C2"BBBO6.8**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHK1\/>'[[Q3K-KI>FPF>\N&VH@X ]23V ')-*4E%
M.4G9(:3;LCW[]F7XD:A?N_A6\BEN[>"(RVUT!GR%'_+-S_=_N^G3IC'T)7(_
M#/X<V/PW\/I8VV)KN3#W5UCF5_\ XD=A_4FNNK\ES&M2KXF52BK1?X^?S/I:
M$90IJ,WJ%%%%>:;A1110 4444 %3W7^KMO\ KE_[,:@J>Z_U=M_UR_\ 9C2>
MZ&04444Q!1110 4444 %%%% !4]E_K7_ .N4G_H)J"I[+_6O_P!<I/\ T$U,
MMF-;D%%%%4(YOQG\0]"\ #3O[:N9X9-1G-M9PVMG/=2SRA"Y1(X4=B=JDXQV
MJA:_&'PE>^)1H,6IR?;S<FQ#O93I;&Z$?F&W%P4$1F"Y)BW[QA@5R"!#X_\
M U_XJ\8?#_5K2:VCM_#^J2WMTLS,'=&M9H0$ 4@G=(IY(& >>U>;:#^SMJ>B
M>-UD<6>H:#'XDE\0PWEUKFI>9'O9IA&NG(RVPD65R!,6(*\F,DFNJ$:3C>3U
ML9MROH>EZ1\:/!VMZO)IUMJS)*L-S<)/=6<]O:SQ6[!9WAN)$6*94+#)C=@
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M1]D7_GYA_-O\*JZ%8KT58^R+_P _,/YM_A1]D7_GYA_-O\*+H+%>BK'V1?\
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M !-=7]D7_GYA_-O\*/LB_P#/S#^;?X4?6*O\[^]A[./8Y3_A7'A+_H5]%_\
M!?#_ /$T?\*X\)?]"OHO_@OA_P#B:ZO[(O\ S\P_FW^%'V1?^?F'\V_PH^L5
M?YW][#V<>QRR_#?PD6'_ !2VB]?^@?#_ /$U)>?#;PBMY.J^%M% $C  :=#Q
MS_NUTRVJ[A_I,/7U;_"I;RU5KR<_:(AF1N"3QS]*GZQ5O\;^]C]G'L<=_P *
MX\)?]"OHO_@OA_\ B:/^%<>$O^A7T7_P7P__ !-=7]D7_GYA_-O\*/LB_P#/
MS#^;?X57UBK_ #O[V+V<>QRG_"N/"7_0KZ+_ ."^'_XFC_A7'A+_ *%?1?\
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MC[(O_/S#^;?X55T*Q7HJQ]D7_GYA_-O\*/LB_P#/S#^;?X4706*]%6/LB_\
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M+3?V9?%2:'X8\+WFH:0OA_PE_:<NF7L$\S7=\]PDB0+/&8PL(43,797DW;0
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MH2-S<X)Z<'\JS_\ A*M$_P"@Q8?^!2?XU483:ND#:[FK165_PE6B?]!BP_\
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MGJ7]MKK\D]S<0*9;H0F(Y\N%-JE6SA-N"!M( Q7LM%:*M42LF+DCO8\U\&?
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M!2"H\D\=>$-8N_A;\9[4^'M6OFO_ !U9WD%G:6\@GO+99-,+O#@ LN(Y/G'
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MC_WHO^_J_P"-'V1_[T7_ ']7_&L:BCZOYA_:#_E-G[(_]Z+_ +^K_C1]D?\
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MJ]2GCW9/E-G[(_\ >B_[^K_C1]D?^]%_W]7_ !K&HJOJ_F3_ &@_Y39^R/\
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M7*7_ +(_]Z+_ +^K_C1]D?\ O1?]_5_QK&HJ_J_F3_:#_E-G[(_]Z+_OZO\
MC1]D?^]%_P!_5_QK&HH^K^8?V@_Y39^R/_>B_P"_J_XT?9'_ +T7_?U?\:QJ
M*/J_F']H/^4V?LC_ -Z+_OZO^-'V1_[T7_?U?\:QJ*/J_F']H/\ E-G[(_\
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M,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT+3]&N[2XT6.]=]1AE>0.UQ<(0"DJC&(U[9R3S7B7_#PKXB_] 7PO_X"W/\
M\D5:_P""BW_)8O#/_8LP_P#I7=U\K5]A@,'0J8:$I03;_P S>25_N_(^G_\
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M#$]K+/CEZ%NBBBO$/H0HHHH **** ,/QA_R"/^VB_P!:XBNW\8?\@C_MHO\
M6N(KZ# _POF?,9C_ !_D%8>L^"=%\0:Q9ZI?V7GW]I!/;02^:Z[(YEVR+@,
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MNK?S-0Q_?7ZBIM1_Y"%U_P!=6_F:A_$C1? _4KT4459F%%%% !1110 4444
M6M/^]/\ ]<7_ )55JUI_WI_^N+_RJK4+XF:/X4%%%%69A1110 4444 %%%%
M!5J]_P!7:?\ 7'_V9JJU:O?]7:?]<?\ V9JA[HTC\,OZZE6BBBK,PHHHH **
M** "BBB@ JUIW^O?_KC+_P"@-56K6G?Z]_\ KC+_ .@-43^%FE/XT5:***LS
M"BBB@ HHHH **** "BBB@"U'_P @N?\ Z[1_^@O56K4?_(+G_P"NT?\ Z"]5
M:B.[-);+T_4****LS"BBB@ HHHH **** "BBB@ HHHH *](TG_D%V?\ UQ3_
M -!%>;UZ1I/_ ""[/_KBG_H(KRLP^&)[66?'+T+=%%%>(?0A1110 4444 9G
MB&PFU'3_ "80"^\'DXXKF/\ A$M1_N)_WV*[JBNNEB9T8\L3AK8.G7ESRO<X
M7_A$M1_N)_WV*/\ A$M1_N)_WV*[JBMOKU7R,?[.H^9PO_"):C_<3_OL4?\
M"):C_<3_ +[%=U11]>J^0?V=1\SA?^$2U'^XG_?8H_X1+4?[B?\ ?8KNJ*/K
MU7R#^SJ/F<+_ ,(EJ/\ <3_OL4?\(EJ/]Q/^^Q7=44?7JOD']G4?,X7_ (1+
M4?[B?]]BC_A$M1_N)_WV*[JBCZ]5\@_LZCYG"_\ "):C_<3_ +[%'_"):C_<
M3_OL5W5%'UZKY!_9U'S.,O/#%_-,K*B$".-?OCJ$ /ZBH/\ A$M1_N)_WV*[
MJBDL;52MH-Y?1;OJ<+_PB6H_W$_[[%'_  B6H_W$_P"^Q7=44_KU7R%_9U'S
M.%_X1+4?[B?]]BC_ (1+4?[B?]]BNZHH^O5?(/[.H^9PO_"):C_<3_OL4?\
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M\\%?$'P]!;VGANXO+32KF_U*2[M;<VK?9(/MK-:K;*SQA=\;DL-_"@C@A5H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **BNIQ:VLT[ L(T+D#O@9KS+X!?M%>%_VA_#]UJ/A\7%I<V3K
M'>:?>J!-"6SM/RD@JV&P0>QZ5M&C4E"52*]V-KOM?8ASC&2BWJ]CU*BN.^+O
MQ,LO@]\/-6\7ZC:7%]9::(C)!:[?,8/*D?&X@<%\\GM5_P"'WCW1_B=X.TSQ
M-H,[3Z7J$?F1%UVNI!*LK#LRL""/4=Z7LI^S]M;W;VOY[V#GCS^SOKO;R.BH
MK,L-=AO'N5?;;F*[:T0.X_>, #Q^&>/8UH>:GF^5O'F;=VS/./6LVFM&4FGJ
MA]%%%(845&MQ$\\D*R(TT8#/&&&Y0<X)';.#^1J2@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>)#+.-.8K,L7ED,01SCG!V_-@G'.*A-IK?\ :)V_VU_PC'F?ZKS)/M7D_+D
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M>6SD5;66<3VLI1?-0F(+R!C)]B<W@,0HN;CHO-=+_P"1:Q^&<E!3U?\ P/\
M-'N-%?//[1WQ*\4)X8^)WA_PW;V]G-HNBVMZ^IM>R0S+'.+@.8MBG#J84QR
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I-%9SQ-6<'!M6?9)?DC2G@J-*:J13YDK:RD]_5O7SWMIL%%%%<IW'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>btai-20231231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'E Y # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPM2=12YG==':UPHKXX_:H^-?CO7OC;X>^"GPSU(Z)JE^L;W^IQY$L996?:&
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M?VE]E\O#E=N/)?/3.<BO$O\ AZQ_U2[_ ,N#_P"Y:^_J^#_V7?\ E()\9?\
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M_P !6ES9851GS)Z7OLOS"ORFT+QAIOASXT>-O^%Y^ ]>\?>+9I]FD6#EF5)
M[DJ(RP!C8%-I4. %X4ALU^K-%<6!QRP:FG"_,EL[-6[-=^O<UK4?:V:=K?,_
M/K_@G()=!^,OQ.T35;$:)K+6Z2-I;*$,.R9@Z!>P4R*,5=_X)T?\E@^,'^^G
M_I1-7WQ175B,U]O[;W+>T45OMR_+J90PW)R:_#?\3X/_ &7?^4@GQE_Z]]3_
M /2^VKB?A!\0;_\ 8&^)WC3PSXS\,ZI>Z!J\J-87NGQ!FF$9D$3QERJNK+)A
MANRI7IG(/Z3453S:,W)5*=X2C%-7_EV=[?H"PS23C+5-O;N?FW\"?&.K?$/_
M (*$1>)]8T>XT&YU6&XGBL+I=LL=N+$I#N&!R8T0YQSG/>OTDHHK@QV,6,G"
M48<JC%1M>^QM1I.DFF[W=SQO]L/_ )-F^(/_ &#_ /VHE<=_P3R_Y-AT3_K]
MO/\ T<U?2M%0L5;"/"\N\N:_RM:W_!*]G^]]I?I8^!_^"='_ "6#XP?[Z?\
MI1-5C]J+_E()\&O^O?3/_2^YK[PHKOEFO-BY8KD^*/+:_E:][&"PUJ:IWV=_
MQ/S1_:!\2)X=_:\U6Z^,_A_6O$_@= 1H^FP,PA9"@\EHAO16 .[<-V=Q;.2,
M4W]F2\@T[]N.TNIO"[> K'6;2XDTO19X_*,<+P$Q<8'+*A/N3WS7Z845T?VR
MO8.C[/>/+\3MZI6MZ]^Y'U3W^?FZWV_4^!_AS_RDW\6?[EQ_Z2QU]\445Y&,
MQ7UN4'RVY8J/?;J=-*E[)-7O=MA1117 ;A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO<_R@KY*_.OK7]O+_CR^'7_7O<_R@KY)_P ]*_9N'O\ D6TOG_Z4S^9>,/\
MD>5_^W?_ $B)[Y^Q+_R7.W_[!]S_ "6OT+K\]/V)/^2YV_\ V#[G^2U]C?M!
M>,=5\ ?"/7M>T69+?4K18C%(\8D W2HI^4\'AC7Q?$5*5?-(4H[R45][:/TS
M@S$0PN15,14^&$I-VWLDF>BT5^<__#9GQ3_Z#-I_X+X?_B:TO#7[7WQ.U+Q'
MI-G/K%JT%Q>0PR*+"(95G (SM]#64N%L=%-N4=/-_P"1T0X\RJ<E%1GKY+_Y
M(_0:BBBOCS]'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%>E3_P!)/S7_ ,]*V?!?_(Y:!_V$+?M_TU6L;_/6MGP7_P CEH'_ &$+?O\
M]-5K]&J_PY>C/QBA_&AZK\S];2< GTKSA_C_ .$T=E,EYD'!_P!&/^->C/\
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MGB%(KJ>-!';85)" /W"=LUXU_:U]_P _MS_W^;_&O7?VPO\ DX#Q%_USM?\
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M,/2;ES);]VVCZ'AW/IYO@JN+Q$5'D;6E]DD[_B=!17Q5_P / ]6_Z$VS_P#
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MUCUL^"_^1RT'_L(6_P#Z-6OT:K_#EZ,_&*'\:'JOS/UK?[C?2OB*X_X^)?\
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M+7_CZ@_ZZ+W]Z_7ZW_U$?^Z/Y5^05K_Q]0_]=%_F*_7VW_U$?^Z/Y5P\7_\
M+C_M[_VT]7PZVQ7_ &Y_[<?%_B#_ )#^I_\ 7U+_ .AFJ%7_ !!_R']3_P"O
MJ7_T,U0KCC\*/GZO\27JSZG^!_\ R332O]Z;_P!&M7QE^V[_ ,EQ?_L&V_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KD/C!_P DH\8_]@BZ_P#135U]<A\8/^24
M>,?^P1=?^BFJH_$A/8^7?V\?^/+X=_\ 7O<_R@KY*KZU_;Q_X\OAW_U[W/\
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MXK]!_P!B#_DAT7_82N?YK7N<4_[@O\2_4^7X#_Y&S_P2_-'A/[>/_)7-*_[
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MC:/^!?G(Z7X9?\E)\)_]A:T_]')7ZG^)O^1<U7_KTE_] -?EA\,O^2D^$_\
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MUM/_ $&6N@_;C\6:WX4T'PI)HNKWVD2374ZR-97#1%P$7 .TC-<__P $^O\
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M:\=_]"?K?_@!+_\ $UUGPE^'?B[PG\3?#&LZEX3UV'3[&_BGGD739G*HIR2
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M445XA],%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(0M&KI(6;!#!B!C!8YSP0, G /85@>-;[3[/2(H]4LX;ZRN[F*U>*YV^2-[
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M2-BQ5XR&7CY>O)8#O4QW&RQ\.W:3PC9L\K22;YMRMOS"?-?,/S_-^[/R9/\
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M(]8L;[-S)(DT>HV\R/$5ES'%$IWJ2I@R,#_5L23GGVVN(\(Z%XHTC6;^:_\
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M:1X4BDLK6.VGGDD-T%@\IED$K@QD9)^0Y09)X4<UV=9OAQ+:/1K9;2PDTRW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8E7)(^\JCU6-2>2:[RN<^'DEQ+X/L&NDD28>8O[T2@NHD8*^)6:0!E 8!CD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUW_SV/Y4>SD'UB!U=%<I_:UW_P ]C^5']K7?_/8_E1[.0?6('5T5RG]K7?\
MSV/Y4?VM=_\ /8_E1[.0?6('5T5RG]K7?_/8_E1_:UW_ ,]C^5'LY!]8@=71
M7*?VM=_\]C^5']K7?_/8_E1[.0?6('5T5RG]K7?_ #V/Y4?VM=_\]C^5'LY!
M]8@=717*?VM=_P#/8_E1_:UW_P ]C^5'LY!]8@=717*?VM=_\]C^5']K7?\
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M.8&^:!N)74@1M)QR00JJ>QP :EL=!\/:M/;:U:65G<.H'DW42<#9E%([97!
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MU!/)!XS5RUT#3;*5)8+***1',BLHP0Q0(3]=JJOT HNK VK%^BBBI("BBB@
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M/]?\*/\ A'9_^>D?Z_X4<T>X>RGV,FBM;_A'9_\ GI'^O^%'_".S_P#/2/\
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M"5QO&<X5CR.X]*\*V]S;621WJ79U-;2W6XNKDY65PF,@!B,@YW8ZD]379_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML8] 34FF_%_PYK'A2X\0V,US=V,%Y%821Q6SM,)Y6B6--F,DGSXC[!N<$$
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MUZ&VFMAK"Q7,(GA>71[E=X:W:Y10-F2S0H\@7&2![C-6+]I;PE<W=MY4D_\
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MC5A"2\1EM/FDP"J2HP1B&4*GE&-K4E7A"\7UO'_/Y>NFX.I%.S9[/17B]O\
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MYI;6:9&V.7"JT;<?*P*]^.?:O3/CKX2G\2V>FO#KNJ:0(O&]G%LT^1%4EW@
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M@MC_ %<$2]/X<]22>>_X41X(,:H=)F;:" S:C=%BI2)-I8R9*A8(E"DX 7
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MM?@KX^L?$B:[;^*O \&H(_FH(_".HK DGE>3Y@@&L^4)/*_=[PN[;QG%5T^
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>btai-20231231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '8 T4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRG!Z<=!7OW[)/A[2K#X*>'-3MM,L[?4KR&47-Y% BS3A9Y H=P,M@#C)K?\
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MD:7:#[_,*^H]'^%&GVWPCMO .JS?VKIZ6(L99Q'Y1D Z.%RVT@X(Y."!7&_
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M!?!C]FK2/A-JMSKESJ=SXD\27 93J5VNS8K?>VKN8Y/=BQ....<I\$OV>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BD8[035$W<A[@52BY;$2FH;E^BL_P"U2>M'
MVJ3UJO9R,_;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**
MS_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(
M/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3
MUH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4
MGK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-
M"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G
M(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]
MJD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_
M[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0
M-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:
M/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)Z
MT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL
M_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#
MVT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I
M/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U
M2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV<@]M T**S_M4GK1]JD]:/9R#VT#0
MHK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'VJ3UH]G(/;0-"BL_[5)ZT?:I/6CV
M<@]M T**S_M4GK1]JD]:/9R#VT#0HK/^U2>M'VJ3UH]G(/;0-"BL_P"U2>M'
MVJ3UH]G(/;0-"BN>U#Q.FF:GI]I+RUX7"_\  =N?_0A70*=R@^HS4-6=F:Q:
MDKH6BBBD4,E_U;?2LRM.7_5M]*S*WI=3DK] HHHK8Y0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZ[KEEX
M:T:]U74I_LUA9Q-//-L9]B*,DX4$G\!5ZN%^.O\ R1OQG_V"Y_\ T UO1@JE
M6,'LVE^)S8FJZ-"I5CO%-_<BCX:_:-^'7B_6[72-+\2QSZA=-LABEMIX0[=E
M#2(JY/0#.2>!DUVOB?Q-IO@W0KO6=8N?L>FVBAII_+9]@)"CY5!)Y(Z"OGWP
M=\-/'GQ'\+_#,:_=^&[3PGI$=CJ5J=.29K]T2%?*1RXV@D8#;2!GG!P!7'V+
M^(KOX/\ Q \;2^-_$_V_3M0N+*TM4U.18(T$D?S8SDL-Y Y  [5[\LMPTZB5
M.>B:35[ZMV6JBDMNSMYGR,<ZQM.BY5J6KBY)VY5:,4W>+DV[7[J_D?7UA?0:
MG8V]Y;/YEM<1K-$^"-RL,@X/(X(ZU/7R)KEWXC\2:]XP"^,_$.EPZ-X.MM8A
MAL+]XQ)<+:H_S<]&);=C!)()/%6_"?C/7O#'BOPCK&K^+M<U*SU_PQ=ZMJ4,
MLBR1P&.%I ;>$KL4J(QC@Y.<\,16,LIER\T9J]KVL^W-;[CHCQ#'G49TFE>U
M[JWQ<M[7OO;Y'UA17QQX4\=WL'Q#TU-#\9ZWJVCZOHVH3O;:KKHOKB';;R2)
MYD:(%MY R @*S,!W&2*OZ#9^*-,^!.C_ !/3QIXEU35+6YBO;G3[K4I7M9+:
M.X9'C\O/S94 L6/0'I3GE$J;2E42O9+1[N]EY;"I\11K*3ITF^52;U6BCRMM
M=])(^N**\H^ NMZCXV'BWQ?<W]W<:5JVJ/%I-M.S>5%:0Y17C0G"ECNW8')7
MDD]/ O'GQ(\<7'Q.\6_8];N-.NM)U+[/I\$_B6TTVS2)'R/,M)MOV@,O.[</
MO#.0 *PH99.M6G14DG%*]^^FGR>C.K%9[2PV&IXETVU4;LEJ[*]G\TKKUU[G
MVI3)IDMX9)9#MC12S'&< <FODGQ WBGQ)J'QBU&7QCXBT-_#<4%S;Z=I^H,D
M*2-$S,AP3\HVD84@$G.3BI=3\<W_ (P\16*>*O'5_P""[&'P?::M:-9W*VB:
MA<R1H[LZD;9AN+KY8'.T@ ?-G993)V:FMKO1Z72:]=^AS2XA@KITFKMI7:2=
MI2BV[[:Q>Y].^$_%FE>.?#]KK>B77VW2[K?Y,_EO'NVN4;Y7 8892.1VK7KX
M=\#:PZZ+\)-&O/&NI>#- O;'43=7-E?FU4L+N<KEC\JDD ;B/;O6W:_$GQ+/
MX:T[1+CQA?P^$)O%LVDMXS$^RZ:U3:Z#[0?N[LD^8>RD9VJPK:KDLE4:ISTN
M]T]DY+>UF]-D<M#B:,J495:>K2V:^)QB]F[J/O;O1'U9XN\::-X$TM-1UR\^
MPV;S);K)Y3R9D;[HP@)YQUQBMNOC+7_'VOZ3HOBS2=#\9ZKX@T#3-:TZ.Q\0
M&]+3MYH<RPF9<&5<C&0<?+TPPK5\6-XCUG4OC1J<?C;Q'IB>&9TDL;*QU!XX
M<D-D,,YVX7[JX&3GFI_LBR5YV\]>O+;2UT_>UO\ \/HN([RERTV_+3HIN7O7
MLU[CM;_AOK%K^V6^2R:YB%X\;3);EQYC1J0&<+U*@LH)Z L/6L_PQXNT?QG9
M3WFB7\>HVD-P]JT\.=AD0X8*2,,/]H9![$U\R>%+*U\2?M":)?>(/$-Y%)K'
MA*SOW@ENTCBO)9/+#6>PC#PN-[&$#D@GIQ7K%G\/;7PCX6U.QUKQ/_PB=G=^
M);C4K2XTG4!9?))(6BMV9E Y'!0<<<$XKEK8&E02C*;YFD]N][^MCOPV:5\4
MY3A32A%R6^NEK>2O=[W/5;R\M].M)[JZGCMK6!&EEGF<(D:*,LS,>   22>E
M<)X3^/O@#QOK@T?1O$D%SJ+ E(9(I8?,P0"$:15#GGHI)(!(& :QOVIK34+S
MX)ZZEA%).J&&:ZCB^\;=)%:3WP ,G'8'MFJTWC_X3Z[K7P[M8'L=8O1*%T2&
MR F.G'RAM\V-3F/ " !A\K ' V%ESH86$Z'M7&4F^9>[;2R3N].M^ZT3WV-<
M5CZE+%^PC*$4E%^]?WN:35HNZM:W9ZM+3<]BHKXMF^(VM2>%M0\9/\0]3M_B
M%%K7V:'P<MR/L[*'6/ROLF/[I)WXP2/[_-6?&&M>*_LOQ7\3Q>,=?TZ?PSK<
M"V6FPWS&V DG5&1U_B4 C"\+P>#NKM62SO9S2UML][I?-7DM=MSS'Q-2Y7*-
M)O3FW7PVE*[UT=HN\7KMW/LFBOD/Q#KOB?P3<_$?1T\7ZYJ2KX;MM5CN;R\)
ME@G:6(,8BN/+7]XPVKCC .<"GZ%XUU3PUXB\+R^%?'>I>/KS5= N[O5-+O;T
M726TZ6OFQ[5_Y9$R#&P_,-NTGYJC^R)N/-&:?5:/^7FU?3YFO^L5.,U"=)IW
ML]5=>\XZ+>6NKMT/KFBOD#PAXYU&WD^'>NZ;\1=3\3^*/$&J+!J_AN>[66".
M%W8R%8 ,6^S  .!P<KA015CP3XPU'PY\6=)B\0>-=0\3OJ.H^1%<Z!XGM[NP
M=Y6PJ/8%-T:#=@L" I V]J)9/4CS6FM$^C3=KI[V[?/HM[$.(Z4^2]-I2:5[
MII72:NU?775=.KU5_I7P]\0_#OBG2WU'3M5BDLEO/[/,TP: &XW!1&/,"DL6
M90,=20!FNBKX<U6:Z\4>$?!^I:]XJU>%(_',EB]Y)J)46L)*'SE=\[&C )5L
MX7)XJ3Q-\1?&<GCGQ NF>)KM)-'O$MM,>Z\4VEC:O!&?E>6WFV_:?,7YBX8
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MR_ZMOI696]+J<E?H%%%%;'*%%%% !1110 4444 %%%% !1110 4444 %%%%
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M .L. ;C3J-J4M+-==/SNK?C8^G;.SM].M(+6U@CMK6!%BB@A0(D:*,*JJ.
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M_  L-U=V<<LL8!+ *S D8))&.YKGOC+IWB+5?!-[;^']5@T5##,U]=O$9)A
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MII^HZ%IE_86@"VUK<V<<D4( V@(K A<#CCM6E;6%M9V,5E;VT4%G%&(8[>-
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M_)?@8%Y\!O#=_P##/3?!,TE\UAISB2TOA*@NX'#EMZN$P#\Q'W>A]>:K:E\
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MZEB?2].O/[1T^UN_(FM?/B67R+E-DL>X [77LPS@CL:L5BL9B8+E4WH[_/\
MX?7U.EY;@JCYW23NK;=+6_+3O;38***X7X:_%[3/BG+J)TC2]7AL;1RBZC>V
MHCMKDABI\I@QW=,D$ C(SCI7-&E.<)3BM([_ #V.R=>E3J1I2E:4KV7>V_W'
M=4445D= 445R_C'XB:;X(U7PY87T%U+-KMZ+"V:W165)#CE\L,+SVR?:M(0E
M4ERP5V95:L*,>>H[+_-V7XG44445F:A117._$+QU8?#7P?J'B34X;F>QLO+\
MR.T56E.^18Q@,RCJX[CC-7"$JDE""NWHC*I4A1A*I4=HQ3;?9+<Z*BL#1O%Z
MZSX@O]+32-5MDM88IAJ%S;;+2X$BAML4F3N9<X88X(-;]$H.#M(<*D:BYH.Z
MV^X****@T"BBB@ HHHH **** "BBB@ HHHH **** .(\;_\ (X^$_K<?^TJ]
M*B_U2?05YKXW_P"1Q\)_6X_]I5Z5%_JD^@KEG\3/0I? A]%%%0:C)?\ 5M]*
MS*TY?]6WTK,K>EU.2OT"BBBMCE"BBB@ HHHH **** "BBB@ HHHH P?'^D77
MB#P)XDTNQQ]MOM-N;:#+;1YCQ,J\]N2.:\%\)?'CPWH?PU\.^#;KPW=:KXOL
M_LVGS>%38,)#+&PS*=R%,C9Y@[[L=.6'TQ17H4,3"G!TZD.97NK.VOW/3[GY
MGD8O!5:U55J%11=G%WCS:-WTU5GZW7=,\3_:G8MX4\&L5*$^*;$E6QD?++QQ
M6=XE\16OP?\ V@M5\4>*$GMO#>MZ7#:VVK1V\DT4$R=87*J2"PC9L '/![''
MOM%:4L:H4U2E&ZLT];;M/31VM;S,*^62JUI8B%2TKQ:NKI.*:U5U=-2?56[G
M!_"'QS9?$'1]4U72_#TVB:;)?RF"YDB6,:B.,W   ))(P21VQN)! ^=M<_X1
M4?$GQJ?'1\2#QP-;0^'/['$IO/LWFCR/LV?W7_??&,[?FK[%HJJ&.CAZDYPB
MTI=I:JWG9W3Z]_(C%Y7/%T:5.I43<+MMQNG=-7Y4U9J]XN[L^Y\6?$$Z,?%/
MQ /CL:VOCTRK_P (@$\[S!'EOL_D^7^[QYF-W;.[;\V:N)X#3QQXY\7Q>-H)
M;K5;#P=:7<B>>Z;;Q;9/WC;2-SJ=W!R,EN#7V/17:LYE&-H1L[6WV^'X=-%I
MMW=[GF/AN$YMU)IJ][<N_P 7Q:^\US:.RT5K'QC_ &KK/@3X=>!/B-IWGW5W
MJ&BW'ARY*-\_F$R_9)"<Y;:R@?1% /2J/QB\&3?#UO 7A_5%L!X;MM&S(=9-
MX;)]1:1VG)^R?.7^88_V>I-?;E%..<N,U/V?5]==;VUMIRW:3L3/AJ,Z3I^U
MZ12NKJZMS:7U4W%-J^C6[/C71/! \9^+OA%H'BZ[_M^QFTB];SH7N8?M,"M(
M\.3(D<@& N.!E54@D')S_&]EX=\ _&*9[,0^,-6CU&+R=&G35+/5+7!588;:
M5#Y3HJA"K-G*@!<C!K[:HH6<R4[N+Y;-64K+5M]%YVTMMOT'+AJ#I\JFN?F3
MYG&[5HJ*6LM=FUS<R5]KZGQUXJ_MG[)\;_[)^U_9O^$@MO[4^P_Z[[#B3SMN
M.<?=W8_AW9^7=6-K0T+^SOB$?AG]L_X5[_8"_;?/\_[/]N\^/;Y?F_-OV8SG
MMN[;:^WJ*(9QRV_=]NNCLHK56U?NZ/I?J%3AOVE_WN]]>757<WH^;1>][R^U
M;='RU\/O">G^ OC1\,?[%6>V.N^&WFU(M<22?:I/)+[FW$_Q ' P!@8 K?\
MC!X%T/Q)^TG\-8]1L?M"7]O>"Y'FNOF>1$TD7W6&-K<\8SWR*^AJ*Y7F=1U5
M6L[\KCOKK>SOY77W'?'(Z4<.\-=<KG&=N716Y;JU_M<KN_[ST?7XM\*^ GF^
M"'CCQ9H%I<2^,HM1NK2*[@FE\V.U\R/S4B13C.UI"3C.&;GI2Z6GAMK[63\*
M?[2_X1=?"-\?$?GF81>;]GE$._S.#+N/\'&-VWC=7VC174\YE+FYHMW;ZZ6=
MM&K:VM>.UF[G N&H05-0FERI)OEUNFW=.^G->TM^9)*Z/BGP-\,M#OO$WPGL
M)5O!:^*-%N'UE$O94^V+&I=$8AN$!C0;5P,(._->R?LN:A-:_!.\_?@IIU[>
MQVYN"S+&BG< <<[02>!7N5%<^*S26*@Z<XZ73WOLY/MV:7HE\NO 9%#+ZJJT
MY*Z36D;;J"[]XN7K)^K^3M#\5?#KX@>,]"U?QQ\0CXF\00W"?V=IMAI-Q9V5
MM*[*1&K>5OD"R8VL[#( W#K7):!'X?TWQCH!T'3]9T;XC6GB1YM7CO;B281V
M ),[2.L<:>65/9<X+9)RN?MZBMEFT8748.UK6YE;KI912MKJK:OJ<\N'Y5.6
M4ZD>9.]^1W>VO-*<GS*VCO9*ZMM;YK;Q/?>#?V7M9\31/(FM>*+R>[C8X4J]
MU,54CTQ%@CWQ7J_AW_A'/@EX4\(^%[JY2RDN7CTZV\N)W%U=MC<<JIP68DY;
M Y[5WM%>?5Q:K)Q<;)R<G9^5DMOL_KT/7P^72P\E.,[M0C%76UG>3WWEIZ66
MY\4:[I^D/XWO+?2-)UG3OB^WBWSHUEN'F+6[$NTJLL<<:P$9;D%@IR6*9Q[-
M^UM:K>^"_"MN[O&LWB:SC+Q,5=05E&01T/O7N-%=4\S<JM*IR_!YW^YVT79:
MVUU."GD:A0KT.=?O.T;;=6D]9.^KTOIIH?#WB7X<:+IVF?&>"V2ZBM/"MS:2
MZ/:B\E,5K)*0)'"EOF8A%7+9X'L".V\*_%?P_P" /C?X@U/Q9JIL1?Z#I@69
MH99C)(;>)FSL5C[Y-?5=%;2S958.%:#::M\6NT;[I[N-WZ_,YZ?#SP]2-7#5
M%%IW^#3>=KI26RGRK7:*]%YUXRU'0OBU\#M?O=,9M7TB]TZYDMV5)(C))%NV
MX4A6R)(^F.<=P>?EO0?^$7_X07X=_P!J?;/^%=?:;G_A(_LOVC9_:?EKL\W'
MS8V^5C9Q]['.:^Z:*Y\+F*PL94XQ=F[KWM5HUVWUT=MUL=F/R9X^I&M.:YE%
M)^[=.TE+;F^%V:<;O1M7/$OV7A.-*\4_8/M?_"#G5'_X1S[9OS]GR=WE[_G\
MO.W&>^[/S;JYKQ5\-/$^E^,;K7_&.C2_%_0EG2:TAM[EHI=-11\^VPR(I=WR
MC:"2WE@G&XU])45G_:$XUYUHQ^+?O_X$K.[ZM6OU70V>3TY86GAIS?N:IZ6O
M_A=XM+HG?E5K-/4^,OC)9:!%XY\;I<:5KEK\3;B]LYO#DZ7,DIN/F4+);^6B
M*H"H%PY<@C"D%3CUOP%X@NM,T_XK^/K]HIKB!_LVT'Y'-C;;6P1QAI3)T]>.
MU>Y45K4S)5:4:3AM9;WT]W1::)\JTUL[G/0R5T,1+$1J;MM6BEJ^:S=G[S7.
MU>RNDNUSQ?X.3:9\+/@A%XO\37?D2ZMMUC5-1>-I7D>X<>62$!8\.@QS@DGC
MFO)/CW#X1N/'GC&76M+UA/%-Y8VC>&;F&:22*[DVJJ^2B1J48-@$.S@G=C!P
M#]AT4J.8^RKRQ#B^:5]I6TNFEMY6?=:66Y6)R;V^$A@U-*,4MX\UW9IMZ[N]
MU:S4E=MWL>*?'!-0B_97U!-6+-JJZ99"[+G+&;?#OR>YW9KQZ/X5: WC;5]$
M*WO]ER^"%\03VWVV7;<7R\+-)\WS$&1V Z D\8)%?9E%/#YI/#4W3BMVWH[;
MV_*VGJ3C,BIXVM&K.5[**U5]N:^M^O-KZ>9\8^#_ (@:=X2\1?!S7_$VHO;V
M4/AZZA>Y=))B!YDT:#"AF/ 4=.*^H_!?Q1\-_$72K[4/#5\^KV]FVR41V\D;
M;]NX*!(JY)'X5U=%98O%TL7:7(U)>>EKM[<OG;<Z,NRZOE]X>U4H.S?NN]U%
M1WYK=+_#\SX?\-ZQH6J?%7P3XC\.6$F@ZA<Z]]GU:VWWLT\+R,P"W%U,^QVE
MQ*=BJ#@,"6P:S[+PGI^G_"&V\;6ZSQ>);;Q8+>"]6XD'E1;\[%4':!G+9QG)
M/..*^\**])YVTURP=M-Y7NE?1NVJUMKT[GB+A=-/GJ*[OM"R4FHKF2YK)^[?
M2VKTML?#/Q4/A\:G\5_^$K&HGQ]_:#_V'_K_ /CQW#;MV_)L\K.=_P##TYKM
MK9==\0> /'^O^&S>2:C9:+I6A6+VQ;S L<<<EVL>.<_O&Z<]?6OK"BLI9Q>$
M8J&UMW=:<NB5M$^7:_5F\.'+5)S=725]HV>O/JW=WDN?>RV78^,/"R^'#JSG
MX7?VE_80\,7A\4;S/Y'F_99?(\SS./,W[ON_+C=MXW5[+^RKX#T30OAGH_B&
MTM"NLZK: 7EV\KNT@61MJ@$[5 &!\H'09S7M5%<^*S.6(INE%-7M=MW;M?=V
M5]_N2.S 9'#!UHUY--J]DHV2;Y=8J[Y=%KW<F[ZV/D?Q+XT^'_Q!UMC\3?B(
ME];6-VS6_A_1])N8+:W*DH0T_E&63<H4G!7#%L'&*]$^,EM\0;OP=XSBUO3]
M&U3PB8V:"UT">>'5&B$Z%2S21R1@B,$OA3T.,=:]THI2S"/-!PAI'HVK+5/2
MT8V>FKU;*AD\W"K&I4UGNTFF]&O>YI3YDKZ+1+5)6>GPM?>'+'Q%X>^(:_#"
M#4Y/!:Z19230R+*RRWJ3Q.X ;DLL8=CC(!''!4UZWX,FT'X]_&;Q/K%K:S:C
MX0D\/0:=/)+&\ >X\Y)0N>&#IMZJ>"H(/0GZ.HK:KFSJ1:46GT=]=>6[>BN_
M=5GI8YL/P^J,XMS3CO*/+9.SFTDKOEC[[NM;^6I\R3WL'AS77\5:%#:6F@6&
MLC0=/U#5'DN((9)Y&-_J,S-*&D)?$0=I!D <]J]:T/Q5>^-_@>==U"R%A>7V
MD32R0J"%/R, Z@\A6 #KDGAAR>I]!HKBK8R-91O#5-:WN[+I\WJWWZ;GIX;+
MI8:4K5/=DGI:RN^N_1:)=M+NR/E7X/\ P9UWXE?!WPO#JOCB9?!TCF=O#\&F
MQ(V$G?Y?M .XY8%N0>O3@&IOV@=9\.^'?B+?:K;:_KO@'QM:V:/#?K:-+8ZP
M@7<L6%)W?,$4EP$&W!5L U]245U+-9O$.K./NZZ*RW=W?W6GMK=.YPO(:<<)
M'#TI>\N6\GS2^%-*WOIQM=M*,DEMM<^6+[7O'?Q?USP%I5K::9#K^AV(U[5+
M;6DEBM?/9C'")$0;@VP[PHQ_K#T'%=M^S9=:CX3G\2?#G7A;Q:KHMQ]LMUM'
M9H#;3X?$6X9VJY/7GYP.H->XT5E6S!5:3H*FE'I;H[WOZ:M6[/<VP^42H8B.
M*=9RFM[K1QY4K6OOHG?NMM3X3^*#: '^*(\6+J3?$DZHXTLCSO+%AN385Q\G
ME^7N'S_PE<<YK-\=QZC<^+&CUZ^T[2KG[!IYT*[U3^T3)#$(EVM:?959,[A\
MV]3\W3G=7W]17I4\\]FDO9O3^]MMMIHM-M=V>+6X6]JY/VRU?\N^LG>7O+FE
M[V^FRT/C?QFF@GQUK2_&*?5Y+H:/9?V!-IRSKOD$ \\P J )#+C D4+N+;@.
M,,\<N\FJ_%1I%U!'_P"$1T[(U7;]K_Y8<S;>/,_O8[YK[+HK".;\O*^39)6O
MIHXO16TORZ[ZNYUSX=YU->U6K;OR^\[J2]Y\WO6YM-K)6\SX^M/ >C^/_B->
MVNM0RW%M:^!+.ZCBCF>,>:L,85CM(SC)(!XSU!KA->U'4M1\"_"^379K6;PP
M-,N(T;7&O6LOM"7,R -]E_>;UB6,+V R.E??E%7#.I1:O"Z5K:[:-.VFC=[_
M ",JO#$9J7+4LY7O[N]Y1DKZZI6:MY].OEOP-T*ZU+X'V&E>(;Y-=L[RVE@2
M>/[1&)K-\JH_>I'(!L. <#Y=I!(P:^7/"_@;1[_X=_#E7MWC?7/%PM+Z6.9P
MTD:L44#G"D*[#( ZU]ZT5RT,TG0G4E%?$[[V[^7FG\ON[\5D-/%4Z,)2_AQY
M;M7OK'N[[1:W>DGKW^0OB'X9\#>#?B-?:-X]M=1LO UII(7PM! ]P\*R':T_
MEE2<R[SD[SCE=W&VJ/A?P7>^/?&WPTT3X@Q7EQ)/X=NFGAGFDCG>,33&'S2"
M&R!L.,_PKGN*^RZ*V6<35-12?-:U[[.S5UIHW>\M=7KH<SX;I2K.;DN2]^7E
MW7,GRRULTK<L=%RQ;5F?#WPUTF+3['X,>*8IKHZY?:\^FRW+W,C?Z*K>6L*J
M3A4"Y& /XCGBO6_VN3IJS_#PZP;@:2-7/VLVN[S/)VC?C;STSTYQG'-?0U%1
M/-74Q,,0X?#S=>CO97MI:^AK2R!4<%4P<:B]_EUY=+Q4;MJ^O-:[UZ]3XLT_
M6?#VA^'?B#-I.CZAK?PCFU&QM[>WEN;JWABE9?WLI<#S/+5@@*GDEH@><8I>
M$M-T.Z\*?%/1U\1S:#X6\_3;RVN+;3KPP21$2[F-N7>81/A 6+'^ YZ"ON"B
MMO[9T:4'=M?:OMRZZQ:YM-7;6^J.7_5N\HN52+24E;DM\7-=)J2:A[VD;NUM
M&KL^&=-UF^D^#/CC3_!VBP6]C#<6TFI:MH$]^UE/;D'S4"7)\U2HV^84ZIG(
MVC)I6\<D?P5^)K:9JFDS^''2Q/\ 9^C)J'V>"Y%W -P-W&#N9?O .3PO& ,?
M>=%:+.TF[4_M*7Q7O:V]UJ]-'I:^QD^&&TDZWV)1TC:U^9:)25E[VJ=[VNW?
M4^-?B;_R$?C;_P!@71?Y6]/U7PI=?#[QEIT'@)+RWU;6O!<US.(KB226YN"K
M,9!N8GS.,@#^(# S7V/16$<XE&*AR:6U5]'[L8JZMY7_ *N=,^&XSFZCJZMW
M3MJO?E)V=^JE;Y7\CXU_96AD;XDZ?/I6J:3%']@9=7T_3EU(RS'8=KSF:,Q"
M02$<JZKDMMSG!^RJ**\_'XSZ[6]K:VEM[_C9'LY3EW]EX?V'-S:WT5ETZ7?Y
M[ZA1117FGM!1110 4444 %%%% !1110 4444 <1XW_Y''PG];C_VE7I47^J3
MZ"O-?&__ "./A/ZW'_M*O2HO]4GT%<L_B9Z%+X$/HHHJ#4:XRA%<)K?B;6-,
MNS%;: MY&/\ EH;O9^FPUWM-**>HJE)K8B4%+<\S_P"$X\0_]"JO_@?_ /:J
M/^$X\0_]"JO_ ('_ /VJO3/+7T%'EKZ"GSR[D^RAV/,_^$X\0_\ 0JK_ .!_
M_P!JH_X3CQ#_ -"JO_@?_P#:J],\M?04>6OH*.>7</90['F?_"<>(?\ H55_
M\#__ +51_P )QXA_Z%5?_ __ .U5Z9Y:^@H\M?04<\NX>RAV/,_^$X\0_P#0
MJK_X'_\ VJC_ (3CQ#_T*J_^!_\ ]JKTSRU]!1Y:^@HYY=P]E#L>9_\ "<>(
M?^A57_P/_P#M5'_"<>(?^A57_P #_P#[57IGEKZ"CRU]!1SR[A[*'8\S_P"$
MX\0_]"JO_@?_ /:J/^$X\0_]"JO_ ('_ /VJO3/+7T%'EKZ"CGEW#V4.QYG_
M ,)QXA_Z%5?_  /_ /M5'_"<>(?^A57_ ,#_ /[57IGEKZ"CRU]!1SR[A[*'
M8\S_ .$X\0_]"JO_ ('_ /VJC_A./$/_ $*J_P#@?_\ :J],\M?04>6OH*.>
M7</90['F?_"<>(?^A57_ ,#_ /[51_PG'B'_ *%5?_ __P"U5Z9Y:^@H\M?0
M4<\NX>RAV/,_^$X\0_\ 0JK_ .!__P!JH_X3CQ#_ -"JO_@?_P#:J],\M?04
M>6OH*.>7</90['F?_"<>(?\ H55_\#__ +51_P )QXA_Z%5?_ __ .U5Z9Y:
M^@H\M?04<\NX>RAV/,_^$X\0_P#0JK_X'_\ VJC_ (3CQ#_T*J_^!_\ ]JKT
MSRU]!1Y:^@HYY=P]E#L>9_\ "<>(?^A57_P/_P#M5'_"<>(?^A57_P #_P#[
M57IGEKZ"CRU]!1SR[A[*'8\S_P"$X\0_]"JO_@?_ /:J/^$X\0_]"JO_ ('_
M /VJO3/+7T%'EKZ"CGEW#V4.QYG_ ,)QXA_Z%5?_  /_ /M5'_"<>(?^A57_
M ,#_ /[57IGEKZ"CRU]!1SR[A[*'8\S_ .$X\0_]"JO_ ('_ /VJC_A./$/_
M $*J_P#@?_\ :J],\M?04>6OH*.>7</90['F?_"<>(?^A57_ ,#_ /[51_PG
M'B'_ *%5?_ __P"U5Z9Y:^@H\M?04<\NX>RAV/,_^$X\0_\ 0JK_ .!__P!J
MH_X3CQ#_ -"JO_@?_P#:J],\M?04>6OH*.>7</90['F?_"<>(?\ H55_\#__
M +51_P )QXA_Z%5?_ __ .U5Z9Y:^@H\M?04<\NX>RAV/,_^$X\0_P#0JK_X
M'_\ VJC_ (3CQ#_T*J_^!_\ ]JKTSRU]!1Y:^@HYY=P]E#L>9_\ "<>(?^A5
M7_P/_P#M5'_"<>(?^A57_P #_P#[57IGEKZ"CRU]!1SR[A[*'8\S_P"$X\0_
M]"JO_@?_ /:J/^$X\0_]"JO_ ('_ /VJO3/+7T%'EKZ"CGEW#V4.QYG_ ,)Q
MXA_Z%5?_  /_ /M5'_"<>(?^A57_ ,#_ /[57IGEKZ"CRU]!1SR[A[*'8\S_
M .$X\0_]"JO_ ('_ /VJC_A./$/_ $*J_P#@?_\ :J],\M?04>6OH*.>7</9
M0['F?_"<>(?^A57_ ,#_ /[51_PG'B'_ *%5?_ __P"U5Z9Y:^@H\M?04<\N
MX>RAV/,_^$X\0_\ 0JK_ .!__P!JH_X3CQ#_ -"JO_@?_P#:J],\M?04>6OH
M*.>7</90['F?_"<>(?\ H55_\#__ +51_P )QXA_Z%5?_ __ .U5Z9Y:^@H\
MM?04<\NX>RAV/,_^$X\0_P#0JK_X'_\ VJC_ (3CQ#_T*J_^!_\ ]JKTSRU]
M!5"745CD=/)!VDC.[_ZU'/+N'LH=C@O^$X\0_P#0JK_X'_\ VJC_ (3CQ#_T
M*J_^!_\ ]JKNO[47_G@/^^O_ *U']J+_ ,\!_P!]?_6HYY=P]E#L<+_PG'B'
M_H55_P# _P#^U4?\)QXA_P"A57_P/_\ M5=U_:B_\\!_WU_]:C^U%_YX#_OK
M_P"M1SR[A[*'8X7_ (3CQ#_T*J_^!_\ ]JH_X3CQ#_T*J_\ @?\ _:J[K^U%
M_P"> _[Z_P#K4?VHO_/ ?]]?_6HYY=P]E#L<+_PG'B'_ *%5?_ __P"U4?\
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MHYY=P]E#L<+_ ,)QXA_Z%5?_  /_ /M5'_"<>(?^A57_ ,#_ /[57=?VHO\
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M  /_ /M5=U_:B_\ / ?]]?\ UJ/[47_G@/\ OK_ZU'/+N'LH=CA?^$X\0_\
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M%_YX#_OK_P"M1SR[A[*'8X7_ (3CQ#_T*J_^!_\ ]JH_X3CQ#_T*J_\ @?\
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MCV+[A_KGA_\ GR_O1]W45\(_\+'\6?\ 0T:U_P"#";_XJC_A8_BS_H:-:_\
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MXB\.V=EJ.OZ=:ZC=?8K":X2.>X_YYH6 9N>!QW/2OMWXC_\ )//%'_8+NO\
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M3PS/=_N-2GC1R2@0;%8 ;0&SUW;AD?**^<G^(7B"276Y6U#+ZTH2_/DQ_O@
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M.,_*" 2">N#7C_Q'U5=.^*.L1/XCT7PZEUX7AB+ZS%Y@E!GN1M0>:G(SZ/\
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MBB@ HHHH *P+G_CYE_WS_.M^L"Y_X^9?]\_SH CHHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110!]5?LJ?\D\U'_L*2?\ HF&O9J\9_94_Y)YJ/_84D_\
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MC^SKC_GG_P"/"E=]QGG=]\(M+BTC5;;1#_9UYJ5D=.GO+UY[YC;D$;<22\D
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MG_CIH_M&W_YZ?^.FL6B@#:_M&W_YZ?\ CIH_M&W_ .>G_CIK%HH VO[1M_\
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M_P &$/\ \519A]:P_P#S\7WHZ*BN=_X6/X3_ .AHT7_P80__ !5'_"Q_"?\
MT-&B_P#@PA_^*HLP^M8?_GXOO1T5%<[_ ,+'\)_]#1HO_@PA_P#BJ/\ A8_A
M/_H:-%_\&$/_ ,519A]:P_\ S\7WHZ*BN=_X6/X3_P"AHT7_ ,&$/_Q5:NE:
MWIVO6[7&F7]KJ,"N8VEM)EE4-@':2I(S@@X]Q19EPKTJCY833?DT7:***1N%
M%%% !1110 45SO\ PL?PG_T-&B_^#"'_ .*H_P"%C^$_^AHT7_P80_\ Q5.S
M.7ZUA_\ GXOO1T5%<[_PL?PG_P!#1HO_ (,(?_BJ/^%C^$_^AHT7_P &$/\
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M;=JD*ZA@HR#SG./P8TQM'NM(.L:U_9$L300Z>+E!#:H91)A $^8@C ,F\@<
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M#W8X+):O-*-=JUW:]K::6YHIR?2WX[7\ZUGPKJ>@1+)>VZQQF1H2T<J2!9
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M*N-K^\)E;4?B5>Z5]C2X\.7*3ZI:Q2:7!YOSS7+ ;[:8%?W+)N!)^8;%D;^
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MA:63<0FX +M'SGKQA-6^'^L7&O>([[3->M;"#7;>*WGCFTYII8@D;)NC<3*
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MHHHH **** "BBB@ HHHH **** "OJK]E3_DGFH_]A23_ -$PU\JU]5?LJ?\
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M@**** "OEGQCXQU^U\7:Y##KFI0PQWTZ)''=R*JJ)&   /  [5]35\A>./\
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MM].;6].74+A5>&T-W&)90PRI5,Y((Z8'-*S&;?VF;_GJ_P#WT:/M,W_/5_\
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M(WM_WAGR,J(P/O$CD8[<] 35BV\16,WAVWUN:=+'3I;9+HRW;K&(T90P+DG
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M_P#Z '_DY;__ !RNBBTKW/SOB["XC$^P]A3<K<U[)NWP]CSNBO1/^&?/'_\
MT /_ "<M_P#XY1_PSYX__P"@!_Y.6_\ \<KHYH]S\\_LO'_] \__  &7^1YW
M17HG_#/GC_\ Z '_ ).6_P#\<H_X9\\?_P#0 _\ )RW_ /CE'-'N']EX_P#Z
M!Y_^ R_R/.Z*]$_X9\\?_P#0 _\ )RW_ /CE'_#/GC__ * '_DY;_P#QRCFC
MW#^R\?\ ] \__ 9?Y'G=%>B?\,^>/_\ H ?^3EO_ /'*/^&?/'__ $ /_)RW
M_P#CE'-'N']EX_\ Z!Y_^ R_R/.Z*]$_X9\\?_\ 0 _\G+?_ ..4?\,^>/\
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M5Z'-'N?SQ_9>/_Z!Y_\ @,O\CSNBO1/^&?/'_P#T /\ R<M__CE'_#/GC_\
MZ '_ ).6_P#\<HYH]P_LO'_] \__  &7^1YW17HG_#/GC_\ Z '_ ).6_P#\
M<H_X9\\?_P#0 _\ )RW_ /CE'-'N']EX_P#Z!Y_^ R_R/.Z*]$_X9\\?_P#0
M _\ )RW_ /CE'_#/GC__ * '_DY;_P#QRCFCW#^R\?\ ] \__ 9?Y'G=%>B?
M\,^>/_\ H ?^3EO_ /'*/^&?/'__ $ /_)RW_P#CE'-'N']EX_\ Z!Y_^ R_
MR/.Z*]$_X9\\?_\ 0 _\G+?_ ..4?\,^>/\ _H ?^3EO_P#'*.:/</[+Q_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %><:K\"- UC5+R_FO-26:ZF>=UCEC"AF8L<90\9->CT5
MM3K5*+O3=C@Q> PN/BHXF"DEM<\N_P"&=_#G_/[JG_?V/_XW1_PSOX<_Y_=4
M_P"_L?\ \;KU&BM_KN(_G9Y?^KN4_P#0/$\N_P"&=_#G_/[JG_?V/_XW1_PS
MOX<_Y_=4_P"_L?\ \;KU&BCZ[B/YV'^KN4_] \3R[_AG?PY_S^ZI_P!_8_\
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MPN2 .!C5M_"FIC7='D\B#3HH/#DVG226#YBMIV:#:L0.UBHV-M.!PHS@FH/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>btai-20231231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (2 \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>K5]HM79*Z=GIOITNO,\._;Y_P"1$\.?]?[_ /H%<5^T+X7U#5/V<_A?K5K
MTUKI5L%N2@SY:R(FUC[93&?]H5]8^._AKX;^)EC;V?B73%U.VMY#+$C321[6
M(QG*,#TK6T[P[INE:#!HMM:1KI4,(MTM9,R)Y>,;3NSD8]<USX;-HX6C0C&+
M<J<FWV:=U^O8ZL=P[4Q^*Q=2<TH5H1BK7NG%IW:VM==SY]L/VMO \?P@C+W;
M+K4=@+7^R_+8N9!'MZXQMSWS7FW[.O@S4+#X)_$[Q/>0O;VVJ6+0VBL,>8J*
MY=Q[98 'V-?1C?LR?"]]2^W'P?9>?NW[0\@BS_USW;,>V,5W][X>TW4-"ET6
M:TC_ ++EA-NUK'^[3R\8VC;C QZ5<LRPE"G*GA(27/).7-;9.]E;]2(9+F.*
MK0KYA4@W3C*,%&^KDK7E?\D?,_[ 2*/!WBE@!N-]$"?7"'_&OJFN7\!_#+PU
M\,K.YM/#.F+I=O<N))46:23<P& <NS$<>E=17D9EBH8S%SKP32EWWV/H<DP-
M3+<OI82JTY13O;;=OJEW/B/]L&".Z^/?A.&:-98I(K='C<95@9L$$=Q7;_M,
M_LQZ6_AQO%'@C2X=)U73?WL]G81^6D\8Y+*HX#KC/ Y&?:O<?%GP<\'^.=?M
M-;US1EOM3M HAN#/*FS:=PX5@#SZBNS90ZE6 92,$$9!%>K_ &S*C##*A=.F
MFFNC_'\SP?\ 5J&(J8UXM)JLTXM?%&RWVT=^SUZGSM^SI\8C\9?AIJWAF_D1
M/$]G926[8 7[1&RE5E ]02 WO@]Z^8/A1X9\#P>(=<T7XCZQK/A>ZMI/+BDL
MY!&NY20ZR QL<],?C7W7X<^!/@7PCXF_X2#1M"73]6R[>?#<S ?-]X;-^W!S
MTQBI?&OP0\#?$34!?>(/#EK?WN IN0SQ2,!P S(REL=LYKJHYOA</5K*E&4:
M=2STM>+7;6UC@Q/#N88NAAY8B4)U:-U[W,XRB]N;1-->5^]SPO\ 9]\)?""3
MXD+J'@[7O$6IZY91R/Y=_M,;J1M))$0]>.17,^,-;^!/Q3\7:M'KMGJ?@G64
M=Q-J 7RA+*"0P>/##=D<_*"?6OJ_P5\./#/P[M)+?PYHUMI4<IS(8@2[^FYV
M)8_B:QO&'P(\ ^/=1:_USPS:7EZWW[A&>%W_ -XQLI;\:QCFM'ZU*K*52UDD
MTUS+U6S7D=,\@Q2P,,/3A1OS-RBXOD=]-'K)-=U:_P"?R%^S[J-SX<_:*L]$
M\$ZW>:WX9F=DN&D0HDD 0EG9.@VG&&XYP.^"WQGXTMOA]^V'?:]>HSV=K?YF
MV#+!"@!('L#FOM/P1\+O"GPWBFC\-Z);:5YW^LDC!:1QV!=B6(]LXKY'?3[7
M5OVWKRSO;>.ZM)[J2.6&90R.IA.00>HKV<+CZ..Q%>JHOE5)IWM>5MV[:7/F
ML=E.)RO!X6@ZBYY5TU:[C&^R5]6EN/\ VM/C+H'Q<M?#?AOPC,VLS"Z\]I(H
MF'SLNQ(QD#).XY^@J3]K3P-J7A71_AMJ_DFXM](T^#3[A@/E62,(1D^AP?RK
MZ<\*_ ;P#X)UH:OHOAFUL]17)2<L\A3/]T.Q"_@!7::GIEGK5A-97]K#>V<Z
M[);>XC#HX]"IX->1#.*&%E1AA8/DA>_-:[YM]M/0^AJ<-XK'PQ53'5(JK5Y;
M<J?+'DU6^KOU/G/XE_M:^!]8^$6K)IEV]QK&J6$EHFG-&P>%Y$*DN<8PNXG@
M\X]Z\^\">$+_ ,,_L9>.;N^A: :JRW4*.,'RPT2AL>AQFOHFQ_9F^&&G:FE_
M#X0LOM".'42/))&"#G_5LQ3\,5W/B+PMI7BOP_<Z'JMFMSI5R@CEM@S(&4$$
M#*D$<@=#6:S+!X:$:6%A+EYU*3E:^CV5C=Y+F.-J3Q&/J0YU3E"*C>UY*S;;
MU^21X5^QI_R02Y_Z^KG^0KR_]BV^73/&?Q"NWBDG2"S,ABA7<[ 2DX [FOKG
MP?X T#P#H3:-H.GC3]-9F<P"5WR6^\<LQ//UK/\ !'P@\(_#G4+V^\.Z.NFW
M5ZNVXD$\LF\9ST=B!SZ5,\THR^M^Z_WK36W1WUU_*YI3R+$P>7OFC_LZ:EOK
M=6TTU^=CY)U2Y_9^^*>H:G<W U'P#J 8MYD8Q',W))\L!@.>PVU;_8_U?4K/
MXQ:QH>B:G=ZMX/6*4F6=2JD!@(Y-I)VL?3W-?2WB7]G;X<>+M3EU#5/"EI+>
M2MNDEA>2 NWJ1&R@GW-=-X-^'_AWX?6#V7AW2+;2K=VW.(%^9SZLQR6_$UU5
MLXP\L+.A!3ES*UI--1\T]_0\_#<-XR./IXJJZ<5!MMP3C*7DU\/J?GWX7\&^
M%/#_ ,5O$/A[XC:GJWA^&&5T@O+"0)E@_!?*,2K*<@@?SKV3X1^#/@I>?%32
MF\-^)O$FJ:_9S^?;"Z*M#*4&>2(0=N!ZBOH_QQ\'O!OQ(ECF\1Z!;:E/&-JS
MDM'*!Z;T(8CVS4O@?X4^$OAN)CX;T*VTMYAMDE3<\C#K@NQ+8]LU6)SR&(HM
MWFIM6LFN7U[_ "(P7"M7!XB*Y:4J2ES)M2Y[7NENEIT?X=#K*^'OC?IFI_ C
M]H^V\?QV;W6BWUR+H,HX+%0LT9/9LY89]1Z&ON&J&MZ%IWB339M/U6QM]1L9
MAA[>YC#HWX'^=>#EV.^HU7*4>:,DU)=TSZS.LK>:T(QA/DJ0DI1?9KOY'C]]
M^V)\-[;PZVI0ZI+<W.PE=.6!A,6QP#D8'/&<UY%^R3X8U;QY\6M=^)NHVK6]
MF[W#0L,A&FE/*KGJ%4D?B*]WC_9:^%D5U]H7PA:F3.<-/,R?]\%]OZ5Z;I^G
MVNDV<-I8VT-G:0KMC@MXPD:#T51P!]*[Y8[!X:A4I8&,KU-&Y6T796/)AE69
M8W%T<1FE2'+2=XQ@GK+N[]O(^!O"/Q%T[X8?M6:_K&K[ETY[R[MII4&3$';A
ML=P"!GV-:O[2OQ"TOX\?$GP;H?A%SJD=L6B^T1QD;WE=,@9&<*$!_$U]5M\
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M-'\/V(T[3D=I%@$CR89CDG+DG]:W:\[$XJ-7&RQ,8W3E>S]=F>W@L!.AEE/
MSE:2@HMQ;T=K73T?H?*7P8_:H\.^)?"LVF?%&_MWU:.1@;B\LE\J>/J 51,
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M"_=&[O@#/>NXHKC4Y)63.EPBW=HX+P]\!_A]X3U"^O=(\)Z=I]S>Q/!.T,9
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M^ =:\):9KGAAK.YUJ,/<@7ZN+#]X$.2J$.!D'((J_9RO85T>Q45SOC_QG;^
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MS52LYT8\J;T78^_HPE3H*%:7,TM7W*/B'X>Z1XJ\!R>$M3B>XTJ2U2U.&VN
M@ 5@PZ,"H(([BN2\._ '3[#5FU+Q!KVK>,KM+&73+5M8D0K:V\@Q(J*BJ-S
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MTN%(D?(&U>>3DCCW%;=92J5'\3_J]_S-(P@OA04445B:A1110 4444 %%%%
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M_!WQOJ6M:WXI\/>(=,L+/Q)HTL7VNZTP?N;L.N5?/4-CJ">_;D!GQRNM ?\
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MU>Y$L/%VL> Z#^SQJ6D:1;?N/#\>K6NI6%WOC:X>*ZCM@R_/OR8V(=L!00.
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M /HI@E1C@.I/H#3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *>J:>VI6PB2[N+)@P82VS*&^A# @@YZ$&L.
MR^'NFV%S:RQ3702!HY#"779+(F[:[?+G(W'H0.!QQ7444[M %,\F/^XOY4^B
MD SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">
M:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\
M/-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,
M\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY
M4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7
M\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C
M_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'D
MQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*G
MT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\
MGFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_
M #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]%
M#/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \U_*GT4 ,\F/_ )YK
M^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR8_\ GFOY4>3'_P \
MU_*GT4 ,\F/_ )YK^5'DQ_\ /-?RI]% #/)C_P">:_E1Y,?_ #S7\J?10 SR
M8_\ GFOY4>3'_P \U_*GT4 ,$2*<A%!]0*?110 4444 %%%% !1110 4444
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MC?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]9/\
MOXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(_63_
M +^-_C0!-14/V2/UD_[^-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD
M_P"_C?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]
M9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(
M_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V
M2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1
M]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345#]DC]9/^_C?X
MT?9(_63_ +^-_C0!-14/V2/UD_[^-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW
M^-'V2/UD_P"_C?XT 345#]DC]9/^_C?XT?9(_63_ +^-_C0!-14/V2/UD_[^
M-_C1]DC]9/\ OXW^- $U%0_9(_63_OXW^-'V2/UD_P"_C?XT 345$MLB,""^
M1ZNQ_K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <K\1;YK70PD5RD$QE1F1KH6Y>,'Y@'/2JGPWNH+E+WR=W!7.
M[5!>_P ONU8^(MK =)2ZD61I$=8D/VAX8TW$#<Y7G:*S?A/=QWEE.Z1%6:.)
MV=9WE3)'*_-T(/;T(K3[)/4[^BJ>J:K!H]L)KCS"K,$58HVD9B?15!/0$_A5
M"'QEI-Q=6MO'<EWN A1A&VW+@E5+8P"=IP#SQ4691MUQ?QK_ .2->//^P!?_
M /I/)7:5Q?QK_P"2->//^P!?_P#I/)6U#^-#U7YF-;^'+T97^+7_ ")&F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F<4GF+_>'YU1U60@(
M 2.>U9NX^I_.@#H/,7^\/SH\Q?[P_.N?W'U-&X^IH Z#S%_O#\Z/,7^\/SKG
M]Q]31N/J: .@\Q?[P_.CS%_O#\ZY_<?4T;CZF@#H/,7^\/SH\Q?[P_.N?W'U
M-&X^IH Z#S%_O#\Z/,7^\/SKG]Q]31N/J: .@\Q?[P_.CS%_O#\ZY_<?4T;C
MZF@#H/,7^\/SH\Q?[P_.N?W'U-&X^IH Z#S%_O#\Z/,7^\/SKG]Q]31N/J:
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M,<*N]X@H)/J:[FKG3G3=IQ:]="(5(55>$D_1W(?LJ?WI?^_C?XT?94_O2_\
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M\:/LJ?WI?^_C?XU-10!#]E3^]+_W\;_&C[*G]Z7_ +^-_C4U% $/V5/[TO\
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MXB^,^K6-SJNN6UE:>']-FAMM-UJ\L8Q))<Z@)'*P2H&8B*,9.3A17M7E3?\
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MA^P_]'"O<:\.\6_\??A;_L/V'_HX5[C7?F'V/F>)DO\ "GZ_H<1\2/\ D,^
M/^QA7_TCNJ37_P#DL/@W_L%:K_Z'94OQ(_Y#/@#_ +&%?_2.ZI-?_P"2P^#?
M^P5JO_H=E7-#:/\ AE_[<>O+>7K']#N*\;U[_DNWB+_L6](_]*M3KV2O&]>_
MY+MXB_[%O2/_ $JU.M,O_B2]/U1PYO\ [M\T:/P/_P"0O\3O^QFC_P#33IU>
MIUY9\#_^0O\ $[_L9H__ $TZ=7J=98W^._E^2.G+O]UA_74\2T7_ )'#Q_\
M]AW_ -L[6NN^!/\ R3.P_P"ON_\ _2R:N1T7_D</'_\ V'?_ &SM:Z[X$_\
M),[#_K[O_P#TLFKTL;_NT?\ MW_TEGBY=_OU7_M[_P!*._KQ_1_^35I_^Q9N
M?_1#U[!7C^C_ /)JT_\ V+-S_P"B'KS*&W_;T?U/H:V__;LOT/4=!_Y >G?]
M>T?_ *"*Y;XQ?\BE8?\ 8PZ%_P"G:TKJ=!_Y >G?]>T?_H(KEOC%_P BE8?]
MC#H7_IVM*SH_QX^J_,JK_!EZ/\AGQ%_Y&_X7?]C'-_Z:-1KNZX3XB_\ (W_"
M[_L8YO\ TT:C7=TJOP4_3_VYE4_BGZ_HC@OB:EU?:UX(TJ#4[[2[?4-4EBN7
MT^;R9'1;*YD"[AVW(I_"JFBZ9<^%OBM8Z6FN:OJ5C=Z+=W,D.I79G DCGME5
MER..)''XUH>._P#D=OAO_P!ABX_]-UW1??\ );=$_P"Q>O\ _P!*;.NB+?)&
M/3E?YLPDES.77F7Z'<445S/B?XD^&?!E]#9:UJ\%A=S1^<D+ABS)G&[ !XSQ
M7%&$IOE@KLZI3C!<TG9'345A^%?&^A>-H+F;0]2AU&.VD$4QBR#&Y4, 00".
M"#^-;E*490?+)68XR4US1=T%%%%24%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN9)L6<LML69A^\)\LD<\XZ>U6='LO[ ^(GPKU?4M)N9;>7PO#:-(MFTA%UM
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MO/\ O(]O_",W/'EG/^I?WKV6O']'_P"35I_^Q9N?_1#UYE#;_MZ/ZGT-;?\
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M]^S_ /%4;+C_ )ZQ?]^S_P#%5-10!#LN/^>L7_?L_P#Q5&RX_P">L7_?L_\
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MJ2BZ;CMT:1Y^7^VA2:Q%[WZZG;T5Q']L_$3_ *%+PW_X4L__ ,@T?VS\1/\
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M<9*+H1LT]NODSY_ TIPQ564HM)W_ #%^+,LI^%?C+,) _L6]YW#_ )X/6/\
M%J60_L^>,P82!_PB][SN'_/H];OQ:_Y)5XS_ .P+>_\ HAZQ_BW_ ,F]>,_^
MQ6O?_21ZX:'_ "[_ ,7^1ZE;[?\ A_S.^\V7_G@?^^A7G7Q]DD;X>0AHBH_M
M[0^=P/\ S%K2O2Z\X_: _P"2=1?]A[0O_3M:5GA/]YI_XE^88W_=JO\ A?Y,
MYG5"5^('PU*KN/\ ;D_&<?\ ,*OZ]G\V7_G@?^^A7C.H_P#)0OAI_P!AR?\
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M5#]K3^[+_P!^F_PH^UI_=E_[]-_A0!-14/VM/[LO_?IO\*/M:?W9?^_3?X4
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MVW^%'VN/_;_[]M_A4U% $/VN/_;_ ._;?X4?:X_]O_OVW^%344 0_:X_]O\
M[]M_A1]KC_V_^_;?X5-10!#]KC_V_P#OVW^%'VN/_;_[]M_A4U% $/VN/_;_
M ._;?X4?:X_]O_OVW^%344 0_:X_]O\ []M_A1]KC_V_^_;?X5-10!#]KC_V
M_P#OVW^%'VN/_;_[]M_A4U% $/VN/_;_ ._;?X4?:X_]O_OVW^%344 0_:X_
M]O\ []M_A1]KC_V_^_;?X5-10!#]KC_V_P#OVW^%'VN/_;_[]M_A4U% $/VN
M/_;_ ._;?X4?:X_]O_OVW^%344 0_:X_]O\ []M_A1]KC_V_^_;?X5-10!#]
MKC_V_P#OVW^%'VN/_;_[]M_A4U% $/VN/_;_ ._;?X4?:X_]O_OVW^%344 0
M_:X_]O\ []M_A1]KC_V_^_;?X5-10!#]KC_V_P#OVW^%>=?'VX23X>0J-V3K
MVA]4(_YBUI[5Z77G'[0'_).HO^P]H7_IVM*Z\)_O-/\ Q+\SCQO^[5?\+_)G
M,ZHXC^('PU8YP-<GZ#/_ #"K^O9_M<?^W_W[;_"O&=1_Y*%\-/\ L.3_ /IJ
MOZ]LKKS'XX?X?U9YF2_P)?XOT1Y7\69EE\7^ PN[BYN^JD?\NS>M5?",JQ?&
M20MGG0#T4G_EX7TJ]\7/^1N\!?\ 7U=_^DS53\&_\EEE_P"P ?\ TH6NJ'^Y
M?)_^E,XZG_(U7R_(]6^UQ_[?_?MO\*XCP5=1CQ_\0S\_-]:?P-_SY0^U=[7#
M^"O^2@?$/_K^M/\ TBAKQZ?PS]/U1]+4^*'K^C(O 5U&/&/Q)^_SKD'\#?\
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MM[6:;O>WEM;]#SO]9Z7-=TI*-G>]KW4HQM:_5R6M^J\[?8%%>+^ =9\?>./
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MYT?]]?SH ?13/.C_ +Z_G1YT?]]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/\
MOK^='G1_WU_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_P"^OYT>='_?7\Z 'T4S
MSH_[Z_G1YT?]]?SH ?13/.C_ +Z_G1YT?]]?SH ?13/.C_OK^='G1_WU_.@!
M]%,\Z/\ OK^='G1_WU_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_P"^OYT>='_?
M7\Z 'T4SSH_[Z_G1YT?]]?SH ?13/.C_ +Z_G1YT?]]?SH ?13/.C_OK^='G
M1_WU_.@!]><?M ?\DZB_[#VA?^G:TKT3SH_[Z_G7G/Q_D1OAW$ RD_V]H7 /
M_46M*Z\)_O-/_$OS./&_[M5_PO\ )G.:C_R4+X:?]AR?_P!-5_7ME>)ZFP7X
M@_#4D@#^W)^3_P!@J_KVGSH_[Z_G77F/QP_P_JSS,E_@2_Q?HCS+XN?\C=X"
M_P"OJ[_])FJGX-_Y+++_ -@ _P#I0M6OBVZMXO\  6U@?])N^A_Z=FJIX.95
M^,DNX@?\2 ]3_P!/"UU0_P!R^3_]*9QU/^1JOE^1Z[7#^"O^2@?$/_K^M/\
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M10!QGQ2_Y VG?]A"/_T%Z]#\._\ (*@_W17GGQ2_Y VG?]A"/_T%Z]#\._\
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M]W'U;!Q^58^KZGK?Q!^)FB>&/$ME9>%_[-F3585CG:X>^V9P(WVJ  >HZ\4
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M>Y)$(N'V[R.N/S%)KWC_ ,.^%[^SLM6UBTL+N\ -O#-)AI 3@8_'BO"OVKM
M;Q3XM\%Z4B[IKF*\2(?]-/*)3_QX+7CNMZ[=?$B?P_XKN%*)I]]I>B*#GE_+
ME>0_FBG_ (%7UF$R:EB:-.M*;5T[[=VHV];.Y^>YCQ+7P6)K8:---Q:4=]59
M2G?T35O4^]J9-,EO"\LC!(T4LS'H .2:^2-=^(/C?5M?\5:Q8W>O1SZ/J@M;
M6"VN((M+B16'R7".P+%LD9_4]!U&O:SKOQ#^)/BO3+KQ/J'A.ST+1H[F"RL9
M5C69WA5W:7.0ZY;&/3'3G/&\GG&SG-6M=];?#T7^)?B>BN)*52ZITI-WLKV2
M?Q:W>GV'^'R]NM/B1X8OX],>WURSF34Y&ALBKY\]U.&5?4@BNDKX[^&.L7VG
M^'_@U;VUY-#!=:M>K.D;E5E'FM]X#K0GQ)\2OXJ\.^)-,\1:[>Z5J7B$61:]
MFCBLYXS(%,<5H-Q"A#]XMD9!P#S754R1^TE&G+17WZV<DNG]TXJ/%*5*-2O3
MNWR_#TO&#;U=VDYKMY]+_8E%?+.J2>)?$6K_ !>NT\::]ID/AS=<65K976V/
M<(V;:V03M^7&T$=<U[+H7C#4G^!]MXDD/VG5!I'VHLR_?D"$Y('N*\NOETJ,
M8M23;:771M)K\SW<)G,,3.<73<5%2=]'=1DXO;S1V&M>(],\.K:MJ=[#9+=3
M+;PF9L>9(W11[G%:-?'NK66H7O@_X9^)M0\9:CKESK.M02SV%U,KP1ON;_5+
MC*;.5."0<]N!752^.]9@\&_'">37;M+C3=8E@L':Y8-;+YI"K'S\HP. /2NV
M>3VBN2=W>ST>_,H_FSRZ?$:<I>UI67+S+57MR.>NMM4M#Z8HKYJT\:_X^^(W
MAG1)/%^NZ3I\OA*TO[@Z;>&.268J,MD@C))R3C)Q7'?$#XA^([75=2U_0?$>
MOO9Z?K:V"M+=)%9#:<")8/F:8_*<LQ&>I!S2IY-*K-4U45[7Z]=$K^9=;B6G
M0I.M*D^5-K=7=E=NW9:'UG-XFTJ#4+FQDU"W6\MK?[5-!O&Z.+.-[#L*ET/7
M=/\ $NF0ZCI=W%?6,P)CGA.5;!P<'ZBOFT>&I[7]H'XB7*:SJT,EIHYO4"7(
M EW*,(_'*#.0.,$#FJ/@_P 7^(/%6E?##PB_B*_T2VU>VN;F\U6VE"W5P4D;
M9$DC [3\O;KN QCJY93%P4H3Z)OR3BY/3KMH1'B&<:KA5I6UE%)=6IQ@M6[+
M5ZW_ . _JZBODO7OB%XJT[X<>/-*A\27EY)X?UNWL['7%DQ<21NS95W7[V-H
MR?\ :],5Z'X._MOPA\=8O#<_BC5O$&GWVBF_E75)1)MF#X)C  "+Z*.GJ:PJ
M95.G"4G-75VEKJDD_EI);G51X@IUZD(1I.SY4W=:.3E&V^NL7JNFI[C5#7->
MT[PSI<VHZK>0V%C#CS)YVVJN3@<_4BO)_BGK.K:[\5_#'@>#7+SPQI5Y;RW<
M][I\@BN+AE!VQ(Y!QT[=>X/%>-_$/4]7\1?##Q)IVHZ[?ZI;>'/$$=E:WWFC
M_2XW8<3$#]XR=FXY-7A,J==TW.=E*S?>S=EY7OT(S#/UA56C3IMN',D]+.48
MJ35KWLD]^NW8^O-"U_3O$VF0ZCI5Y%?V,V?+GA.5;!P<'ZU?KSGQ!9S>"O@9
MJ$5AJ%ZT]GI3-%>S2YGW;<[MR@<^X%>-ZQJ'BCP=\'O#&MIXJ\0ZGJGBA[6"
MX9[I7^S(X+8MPP 1R %W,3SZ9K&CEZQ+;ISLG+E5_O\ R.G$YP\$DJU-MJ'/
M*UK+I9:]_P#ASZJHKY?T?Q#X\B\,>.M'M]8N]/:W6)M/O/$U];_;8"V!)&\@
M8A2>2I.,=L&I_#7B?6M \/\ CK3=0USQ-;:Y'X;GOXM.U]EFF@=86S-#<H1\
MN[H-H/ /6M7E,DG:HG9K;71VU_'^M#GCQ%3DXIT9)-/5V237,K:]7RZ=7=66
M]OIFBOE#1O$/B3PMIGPN\31^--7U^Y\07JVE[I=W<++ Z$@$(F,AAW8DG)'3
MO8N_$_B37_"_CCQZ?&NH:-J&A:@\-GHT,JK9HL; *DL1!WE^@SW]:MY--/\
MB*U[7L]^;EM:U]^IDN):;C_!ES6YK7C\/*IWO>VSVWOY:GU/17S#)JWB7XA?
M%FXTY_$NM>'+-O#<.HO:Z;<^7MEV*>,@A?F.3@ D<9YK.T_Q5XY\:?#+P6\&
MM:A/(MW<V]]'I=]';:G>QQOM1D+CYRHZ^O!/)S2_L>=HMU$KVOY73:UVZ/\
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MC&W]:K?$#X=P^.#I-S'>R:5JNEW(N;6^A0.R?WE()&58<$9KJ/L-M_S[Q?\
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M'3ZC?W&HW.MZUJ3*UWJ-W@.X48554<*H'0"NF^PVW_/O%_WP*/L-M_S[Q?\
M? H P-!\$QZ%XM\1:ZMTTSZPT3-"4 $6Q O!SSG&:Z:H/L-M_P ^\7_? H^P
MVW_/O%_WP* ,$^"XS\1U\6_:F\U=).E?9=@V[3,)=^[/7C&,5HV>FZC!KVH7
MD^KO<Z=.J"WTXP(JVQ PQ#@;FW'GGIVJ[]AMO^?>+_O@4?8;;_GWB_[X% &
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MO^?>+_O@5VK%35'V-E;\=[]S@E@J4J_UAWYOPVL3UP_@K_DH'Q#_ .OZT_\
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M?H<V)KQPM"=>:NH)MVWLE<Z#6?!6B^(-:TK5]0LOM&H:6S/9S>:Z^46&#P"
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M#6]5U+1KNQU32+M;*ZTEY49UE;.S]X#M*D#.X<?6NM^'_CV^\9->Q7_AJ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI)M<JCOT5K?DM]/+5GAN@_ O5M&\#:]9P6WABQUC490PM8K62:R\I<XB8O\
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M5G2='11?9>=[>E]3SZ>58>G7CB=7)=W>[LU=]W9VOV.,^*7_ "!M._["$?\
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M\O\ W\;_ !H^RK_?E_[^-_C4U% $/V5?[\O_ '\;_&C[*O\ ?E_[^-_C4U%
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M;^26R273U\SW,MRIY?6K5>9-3=[)6ZMZMMM[[;=DKA1117DGT 4444 %%%%
M!1110 4444 %%%% '&?%+_D#:=_V$(__ $%Z]#\._P#(*@_W17GGQ2_Y VG?
M]A"/_P!!>O0_#O\ R"H/]T4 :=%%% !1110 4444 %%%% %74=4LM(M_/O[N
M"R@R%\VXE6-<GH,D@9J"#Q'I-U);)#JEE*]R"8%2X1C+CKM /S8]JAU@:O\
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M=;7G7Q<=/(MXP@CG,4C+.TC)N P?+7:#EF., ^E*.K!F[\.'=_"UJ9;^2_N
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M9I.HIJVF6M[&C1QSQB15;J 1T-<IK6FS7/B&]NY;N$-;+']DMIVC,4BD?.K
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M%Z[.S-/;PK$K$GT4D9]ZTJ'N!YWXP\;PKJ-SI<5MLN+=U)GDF2+=M"R,.3D
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M@_#KO@_PKH#:G)"F@W=O=+.(03,8E90I&>,[O?I7(WO[*^DSP>,8X-6EMO\
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M<5?'3_=I/JM6O=5_\2]]^>ATE%%%?.GV84444 %%%% '&?%+_D#:=_V$(_\
MT%Z]#\._\@J#_=%>>?%+_D#:=_V$(_\ T%Z]#\._\@J#_=% &G1110 4444
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M!45U:Q7MM+;SQK+#*I1T<9# ]014M%(##TCP3H.A&![+2+*&>$82X6W02_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAQ$-2UJ'2;B"PAU;1TFA^RZS]C1([=KG,1?(6.,'RFC#;0&!'%>W?\*7N?\
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M!I#3P&RCO;N)H[AL>3YA#;BV#(<'I@9%>U?\*7N?^B@^*?\ OWIO_P AT?\
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M9>RM+<1$R0,FW<P*D('7:I# Y)]Y_P"%+W/_ $4'Q3_W[TW_ .0Z/^%+W/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHK%U"_O[?Q1I-K'Y7]GW$<WF_*2^]0"O/0#DTP-JBO-O''Q*
MU+PUXAN+&&/3[6.&W2>%=49HAJ3%OFBAF)$<;8P!NSRPR .:M:E\8-.M+RXM
M$LKQ67S((KV5$^RM=I"93;[@Y;?M5N<;3M(#$U7*Q7._HKSKPQX[UR?4?"T6
ML1:?);>(K5YH'LD>-H)$C$A1@S-N!4GD8Y7IS753^+K&WU7^SW@U0S[PF]-)
MNGAR?^FHC*8]]V!2<6@N;=%>?_$+Q]J/A758K6#^S["V:TDN%OM55Q!-*O2
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MZK(\6X2,&>9551MXWE2V1M!YQ@V'QUCU#6=OV&:TT>2>SC@O)8E8NLT$DIW
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M[E$O%0&6%\[)%V.V <?=;##NHKK:EIK1C"BBBD 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>btai-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" () \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5MY*9;@QCH.]2Z+XN\5^"=*U;6/BSJ'A#0]%MT0PW>FW4RJK$D,)#,JCGY0
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M&-]UNO/[SRLU5>6"JK#4U.=M(RV?=/;I^)X)JO[#VJ6;IJO@?QBDL3J)K4W
M:&3:>1B1,@\8YP/I6[^RM\9?%<WQ!U3X=^+[J34KBU$RQW$S^9)#+"VUXR_\
M2\'GU'O6!I'PN_:2\):.?#VE:LJZ2!Y:-'>P,$7_ &'<>8@_W<5ZA^S=^S1<
M?"K4;KQ+XCOH]0\2W4;1A8'9T@5B"Q+, 6<D<G&!S@G.:^RQF)IO"588NO"J
M_L6^*_=VV\S\URW!58YA0J9=A:F'2=ZG,WR-=DFW?R_+J>-_LG2+X=_:0\1Z
M9J3"*^DCN[= YY:190Q ]20I/X5]G>+/%%AX*\-ZAKFJ2&*PL8C-*RC+$#L!
MW)Z >]>!?'K]E>\\7>)3XQ\$7ZZ5XC+K+-"\C1+(XZ2(X^X_ ]CZCOY_K7P0
M_: ^*$=IHWBO6HDTB)AEI[N+RR!_$RPC,C>A;GW%<N)AA,VJ0Q<J\8*R4D]'
MIV[G=@JN8\/T:N7PPLJCYFX2CK%WVYGTMU_IGT3/\2_#OQ0^$WBC4_#FH"_M
MH["XCE!1D>)_*)VLK $'%?(WP-^$"?%[X+^-K2WA1M<L;R&XTZ0X!+^6VZ/)
MZ!P,>F0I[5]=>&_@_:?#SX.ZCX0T(&YN)K.<--)A6N)W0C<>PSP!SP *XO\
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MSC;OKLSOX>AC(8R7/2?L^6W-*FJ<[WTCI\2MU_I]U1117R)^BA1110 4444
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M /%5\[44?V9A_/[P_P!=,U[Q_P# 3Z)_X:"\.?\ /O??]^U_^*H_X:"\.?\
M/O??]^U_^*KYVHH_LS#^?WA_KIFO>/\ X"?1/_#07AS_ )][[_OVO_Q5>AZ/
MJD6M:7:W\ 98;B,2('&#@^M?&=?6_P /?^1(T3_KU3^5>7C\)2P\(RI]6?:\
M+9]C,VKU*>):M%75E;J=#1117B'Z05)+N7SWCBMS*$QEMX')&:3[3=?\^?\
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M_:;K_GS_ /(HH^TW7_/G_P"115RB@"G]INO^?/\ \BBC[3=?\^?_ )%%7**
M*?VFZ_Y\_P#R**/M-U_SY_\ D45<HH I_:;K_GS_ /(HH^TW7_/G_P"115RB
M@"G]INO^?/\ \BBC[3=?\^?_ )%%7** *?VFZ_Y\_P#R**/M-U_SY_\ D45<
MHH I_:;K_GS_ /(HH^TW7_/G_P"115RB@"G]INO^?/\ \BBC[3=?\^?_ )%%
M7** *?VFZ_Y\_P#R**/M-U_SY_\ D45<HH I_:;K_GS_ /(HH^TW7_/G_P"1
M15RB@"G]INO^?/\ \BBC[3=?\^?_ )%%7** *?VFZ_Y\_P#R**/M-U_SY_\
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MJ0@5(#$EM,LBX3(>,JJD#Y\]:] _:1N=,LO%_P ,Y]8UZ?PSIRWMX)-3MYQ
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M%+.ACE95 X92P( [C- 'T%KGC/2- \/ZKK,]Y%-9:;$TUP;>1790HSC&>IZ
M'O4&D>-+;7]3M(=/CCNK*>S^U&\CNHCY397$;1AM^2#G(&!C&<U\O>$_L?BK
M3?&T&F1Z+=V]WX++OI^B:>T4,,Z.Q6)RQ/FRINY; .<9'2M"1=/U/5(;OX>0
MV:75W\.[X0R:9 (C)<AD7^$#,@;@$]#0!]4P:K972S-#>6\RPY\TQRJPCQUW
M8/'XT^VU"UO'D2WN89WC.'6.0,4/OCI7S!I4_AG45U*?P+%;1Z;;>!+VWUHV
ML!C7[1M3RDEX&9AB4G=D@;L]177_  E\.Z=X8^(WAJ+2[..Q2[\#137/E+@S
MRB:+]Y(?XW^=OF.3SUH ]N?5;*.Z%L]Y MP6VB%I5#DX!QC.<X(/XU:KYL\7
M>'=-N/%/Q4UJ2QADU:U\1:$MO>L@,L(\JQSL;JN=Q!QC(.#72W/P\U"3XGKJ
MH\!,]N-42X_M;_A-KQ?E$@/G?8P/+XZ^5]TXQT- '7V'Q6DD\;:;X>U/PUJ6
MBKJWVD:;>731E;DPC<X**Q:/*Y8;@,BI;7XLV%[\6;CP+#9W#W,%F;E[\$>2
M'786B]=P62,G_>%>63:]8ZE\=="U+PCJ][XLU4F]@U#1]0+&/28MA.Y,J/LY
M,BHG.=P;%9_PVM_%6C_&[PG;^(O#+6&IW.E:E<7]V+V&1))9)8W>10A.%#;(
MPO7!7L#0!].T444 %%%% !1110 4444 %%%% %;4/^/;_@:?^A"K-5M0_P"/
M;_@:?^A"K- !1110 5\H_%/_ )*#K?\ UW_]E%?5U?*/Q3_Y*#K?_7?_ -E%
M>YE/\67I^I^:\=_[C2_Q_HSE:***^I/Q$**** "BBB@ HHHH **** +&GV%Q
MJM]!9VL9FN9W$<<8(&YCT&3Q5OQ!X:U+PM>K::I:FUN&0.%+JV5/?*DCM7<?
M K07OO$5UJBQ>:=/@9HE)P#*P(7GZ;JVOBCX9U6Y\ :3J>K1!=7T]S!<%6#;
MXF/RDD=<87\S7GSQ7+B%2TM^-W_7XGU=#)'6RJ6.M+FU:_EY8M)WTWU;6NT6
M>2:5I=UK>H06-E%YUU.VV./<%W'ZD@5'?64VFWMQ:7*>7<6\C12)D':RG!&1
MP>1VKV;3]%T+P?\ $7P[HT.F-->-$LS:B9WW>80W1,[=O'IW]N<O5/"%GXP7
MQ-_9]L!X@M=<D1W\QOGB>9@"5R0 "3R!_#26,3EJK1:6OJ[=]BY</S5%J,TZ
MJE)-*_V8J32]W66KZVTT9Y/17L,/@/PY>>)M<AM[539:):*KQO=-&MQ/@DLS
MEOE4=."!Q4$7@GPY>ZUX8*"S5KN9H;W2[2_^T*,*Q#!@Q8#CU[BJ^N4^SVO^
M%_R,?]7L5TG'>V[_ )E%N]K:/YV3:31Y+17J=CI7@^[\;:EI5U96^F6]GYD<
M!FNY0MQ(#@;V+?*.O3'XU<UCX664FK>'+=;%M.6\F,5S+:3^=;, I;Y&9BX)
M"GJ,?ERWC(1=I)K2_P"O<F/#^)J0<Z4XRM+ET;WNH]4K:OK;NCR"M#0M O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ!_S[P?^!,?^--_5VV]-28K.(QC!1G:.VC[-=NS:79/0IGQM?_\ "/Z7I"I
MD&G7/VJ&0*?,+Y)Y.<$98]JUI?BSJLNJ37PLM-1KF(Q742P-Y=R",?O 6.2.
MV".IJK_PJ[Q!_P ^\'_@3'_C1_PJ[Q!_S[P?^!,?^-#6&>]O^''#^V8)*,9K
M;H_LJRZ=%IZ:%+Q%XSO/$5E9V+P6MC86F3%:V<92,$]3R22>3W[U@5UG_"KO
M$'_/O!_X$Q_XT?\ "KO$'_/O!_X$Q_XUI&=&"M%HY*V#S'$3]I5I2;]'TT7W
M')T5UG_"KO$'_/O!_P"!,?\ C1_PJ[Q!_P ^\'_@3'_C5^VI_P R,/[-QO\
MSYE]S.3HKK/^%7>(/^?>#_P)C_QH_P"%7>(/^?>#_P "8_\ &CVU/^9!_9N-
M_P"?,ON9R=%=9_PJ[Q!_S[P?^!,?^-'_  J[Q!_S[P?^!,?^-'MJ?\R#^S<;
M_P ^9?<SDZ*ZS_A5WB#_ )]X/_ F/_&C_A5WB#_GW@_\"8_\:/;4_P"9!_9N
M-_Y\R^YG)UM^"?\ D:M-_P"NG]#6C_PJ[Q!_S[P?^!,?^-:WA3X<:Y8^(K&>
M:"$1H^6(N$)Z'L#6=2M3<)>\MCKPF78R.)IMT96YET?='GIZT5UI^%WB#/\
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MJK26G,CQGEV.DVW1E=^3.3KZW^'O_(D:)_UZI_*OG3_A5WB#_GW@_P# F/\
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M"R!BL8!]]\"ZK_;?A#2;W["FFK+ NRUC.411PNPX&4( *\#@CBMZB@ HHHH
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MJS0 4444 %%%% !1110!!]H/VWR,#;Y>_/?KBIZI_P#,7_[8?^S5<H ****
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MBT//UC58H8O^$.TI#&^HC+R7MQG'EVX! 89P-W()Z>H7UJ?<?]FT>WXG2_\
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M)A020N H[>]%V"43H=+\?WEA'OOO[3UNZLM.M!>V&F:<LC&>4;_,!!!Z=5P
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M?%&O7?\ ;VF:!IDRVUS<*;N[NB%8VUJA&X@-D;G/R@D$#YCSBN?^'WA+7?\
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M %*?2LZFQO0^)DE%%%<YVE:W_P"/N[_WE_\ 015FJUO_ ,?=W_O+_P"@BK-
M!1110 4444 %%%% %/\ YB__ &P_]FJY5/\ YB__ &P_]FJY0 4444 %%%%
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M\9Z+XOTVUM7N%>U:&*^61/OQ^0A[;6SD^G/4#9T'XTV?B3PZVMV'AKQ'-8$
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M;IXD7XE6.B6WC&]U"ULXA>ZJL]K; !"<1Q I$"&<@D\C"C/<47'9H]4 C4
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MCWKJ\K_=/YT97^Z?SHM8&[]3A/ ,8U'Q5XQUZ+FSO+J*T@?M(+="C,/4;V<
M]]M=S2HL<:A4C"*.@7@4N5_NG\Z:$]1M:5O_ *E/I6?E?[I_.M"#_4K]*RJ;
M&]#XF24445@=A6M_^/N[_P!Y?_015FJUO_Q]W?\ O+_Z"*\<\::)XHN]>\;/
M8-)%I\UYHY5!8R22RA7BWM#('"@+@EOD;H<XH ]LHKY^A\>>+I+.T&JZMJ%@
MT>JOHEPVEZ<EQ+-);VLYDF1/*<XDD5&P%P H QDU3U?5?B1X@T+4+"Z&K1ZG
M/%-#<6$.G*MLML=.+"6.8Q\RFX*KM#D_,PV#&0 ?1M%?/^M>)/B/!<:RNCSW
MDEA;Z9-)8O=6<GVBX86;,A$0LMOF>=C :5<[<>6<C-B?Q!X^L9;J"X?4]4MX
M-2:T6'^SPDUS"]O:N)-PMFC=$DDG4J3'D*?G+)M(![Q17@^B^(/'$.B6*8U6
MVU&.QC T]-(5+98QIP8OD1 +(+CY=@88(V[,5WGPMN_$<AU>V\03W=V(3:O;
MW%Y;+"S;[:-Y5&Q%!"R%QTR.03Q0!X;^W?JM[I6G>%6LKRXLV>68,8)60L,#
MK@U\@_\ "7Z]_P!!O4?_  +D_P :^M/V_O\ D&>$O^NTW_H(KXTK];X>A%Y?
M!M=7^;/A\TDUBI6?;\C7_P"$OU[_ *#>H_\ @7)_C1_PE^O?]!O4?_ N3_&L
MBBOI/9P_E1Y/-+N:_P#PE^O?]!O4?_ N3_&C_A+]>_Z#>H_^!<G^-9%%'LX?
MRH.:7<U_^$OU[_H-ZC_X%R?XT@\7:ZO36M0&>>+J3_&LFO2_A#X=U75M.\0W
M=OH$>L:3;6["Z(TT7DY=D<11Q?*QC.XABR[<!<D] <*SIT8.;BC2FIU)<J;.
M<7Q;KG]D6[?VSJ&XSR@G[4^<;8_?W-0?\)=KO_0:U'_P+D_QJ@O_ "!;;_KX
ME_\ 08Z@K\>SE)9A52[_ *'W^7ZX6GZ&M_PEVN_]!K4?_ N3_&C_ (2[7?\
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MVH_\>,W^[5F@ HHHH **** "JMQ_Q^6GU;_T&K55;C_C\M/JW_H- %JBBB@
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M'%==5+8B5FW8****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6E;_ .I3Z5FUI6_^I3Z5E4V.BA\3)****YSM*UO_ ,?=W_O+_P"@BK-5K?\
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M\O\ SR?_ +Y-?KK_ &79?\^D'_?I?\*/[+LO^?2#_OTO^%'^MB_Y\_\ DW_
M#^Q'_P _/P_X)^17V>7_ )Y/_P!\FC[/+_SR?_ODU^NO]EV7_/I!_P!^E_PJ
MIIVEV92?_1(/]>__ "S7U^E'^MB_Y\_^3?\  #^Q'_S\_#_@GY3K;R_V-;_N
MW_X^)?X3_=CJ#[/+_P \G_[Y-?K5_9=GC_CT@_[]K_A1_9=E_P ^D'_?I?\
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M)!_K3_RS7_GF_M5K^R[+_GT@_P"_2_X46#F/R5^SR_\ /)_^^31]GE_YY/\
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M>8/[B_K3**+!=C_,']Q?UH\P?W%_6F446"['^8/[B_K1Y@_N+^M,HHL%V/\
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M #JY5/3?N7'_ %W?^= %RBBB@ HHHH *K:G_ ,@V[_ZY/_(U9JMJ?_(-N_\
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M^[_@G445R_\ PD-]_P ]$_[]K_A1_P )#??\]$_[]K_A1]5J>0?VE0[/[O\
M@G445R__  D-]_ST3_OVO^%'_"0WW_/1/^_:_P"%'U6IY!_:5#L_N_X)U%%<
MO_PD-]_ST3_OVO\ A1_PD-]_ST3_ +]K_A1]5J>0?VE0[/[O^"=117+_ /"0
MWW_/1/\ OVO^%'_"0WW_ #T3_OVO^%'U6IY!_:5#L_N_X)U%%<O_ ,)#??\
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MOA_2WN+E]9N0-2U&[E#3%&/[R1CQD[5V@*.XXQDUWUO!':P1PQ*$BC4(BCL
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M+_\ %4?\-Y>*_P#H7=&_.7_XJBX69]NU5B_Y"-S_ -<X_P";5\6?\-Y>*_\
MH7=&_.7_ .*J-?V[/%2SR2_\(]H^755(S+VS_M>]%PLS[AHKC?@_XVNOB-\.
M=&\17EO#:W-\CN\4&=BX=EXR2?X:[*F2%%%% !1110!5TW_CT'^^_P#Z$:M5
M5TW_ (]!_OO_ .A&K5 !1110 4444 5M1_X\9O\ =JS5;4?^/&;_ ':LT %%
M%% !1110 55N/^/RT^K?^@U:JK<?\?EI]6_]!H M4444 %%8WC#Q&/"?AV\U
M5H#="V4,8@^W=D@=<'UKC=+^-EOJ/A&\UK^R9EECO(-/M[-)@S7$\SHD2[B
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M"PX) (Y/8GUS6BQ#;2M_5[&$L$E%R4ME?;R3U^_\#UC5O&NFZ/XETK0YI/\
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MU_W!7GE>AZ-_R"[7_<%>9C_@CZGT62_Q9^GZEVBBBO%/KBM;_P#'W=_[R_\
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MJT'L92PE6+M+3KN>DT5YGK7Q*UV35/$$>@Z59SV6@*#>O>S,LDK8W%8PH(&
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K6E_P#'_#_O55JUI?\
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MZ3\:9M.L]5OKRRCL5:5&LR@+%C@@[E/I7F__  P?X._Z#VN?]]0__&Z^B_\
MF+_]L/\ V:KE [GS1_PP?X._Z#VN?]]0_P#QNC_A@_P=_P!![7/^^H?_ (W7
MTO12L%V?-'_#!_@[_H/:Y_WU#_\ &Z/^&#_!W_0>US_OJ'_XW7TO118+L^:/
M^&#_  =_T'M<_P"^H?\ XW4%I^PMX0N%E)U[6QMD9!AH>@/_ %SKZ>JGIOW+
MC_KN_P#.BP79\Z?\,'^#O^@]KG_?4/\ \;H_X8/\'?\ 0>US_OJ'_P"-U]+T
M46"[/FC_ (8/\'?]![7/^^H?_C='_#!_@[_H/:Y_WU#_ /&Z^EZ*+!=GS1_P
MP?X._P"@]KG_ 'U#_P#&ZBN_V%?!]O:32KKVMED1F +0]AG_ )YU].56U/\
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MD6)"R^<SN)1N?)B0*-O+A@QZ+X4:S_:4?B6V?6VUR2SU>:))I9D>01[4*@[
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M:?XDZ3!KFIZ=B9HM*A\[4-0 46UIQD([%@=V.< &G];EV0O[+I]V1_V->_\
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M;_=JS5;4?^/&;_=JS0 4444 %%%% !56X_X_+3ZM_P"@U:JK<?\ 'Y:?5O\
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M"L9;<W)'(! [USMC&MS\/'L[<3:A<Z[XHBCLM1N0?M%]%'-')Y[YZ@+&ZY
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M>A?^#"+_ .*H_P"%U^ /^AST+_P81?\ Q5?EY11<.4_4/_A=?@#_ *'/0O\
MP81?_%4?\+K\ ?\ 0YZ%_P"#"+_XJOR\HHN'*?J'_P +K\ ?]#GH7_@PB_\
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MJ[5( !^8CO7S7_PRI\3O^A;?_P "(O\ XJI9:V/):*]:_P"&5/B=_P!"V_\
MX$1?_%4?\,J?$[_H6W_\"(O_ (J@JZ/):*]:_P"&5/B=_P!"V_\ X$1?_%4?
M\,J?$[_H6W_\"(O_ (J@+H\EHKUK_AE3XG?]"V__ ($1?_%4V/\ 99^)DH8K
MX<8[6*G_ $B/J.O\5 71Y/17K7_#*GQ._P"A;?\ \"(O_BJ/^&5/B=_T+;_^
M!$7_ ,50%T>2T5ZU_P ,J?$[_H6W_P# B+_XJC_AE3XG?]"V_P#X$1?_ !5
M71Y+17K7_#*GQ._Z%M__  (B_P#BJ;+^RQ\3(8WD?PXP506)^T1\ ?\  J N
MCR>BO6A^RK\3B 1X;?!_Z>(O_BJ/^&5/B=_T+;_^!$7_ ,50%T>2T5ZU_P ,
MJ?$[_H6W_P# B+_XJC_AE3XG?]"V_P#X$1?_ !5 71Y+17K7_#*GQ._Z%M__
M  (B_P#BJ/\ AE3XG?\ 0MO_ .!$7_Q5 71Y+17K#_LL?$R-D5O#C N=J_Z1
M'R<$_P![T!IW_#*GQ._Z%M__  (B_P#BJ NCR6O5="UC3/\ A3\^GRW%K#@7
M;3A+Z2&Y,Y,7D 0APLR-SDE&"A3RIZR_\,J?$[_H6W_\"(O_ (JC_AE3XG?]
M"V__ ($1?_%4"NC[%_95_P"2#^%_]R;_ -'/7(^.+*.[USX@6=GHFL[;ZXTR
M62Y_L*ZG@<Q2GSI-IB*W*KN7,2D[UR%X!(]#_9^\+:GX+^$F@Z/K%L;34;99
M!+"6#;<RL1R..A%>B51#/E(?#?6='\/66KZ5INJ+=PVBR7VGSV+M;7"?:E12
MMLBK-EHXUE:W5QA(ECV@N2?I/PQ=7M]86ESJ5N+/49K&WDN;=>D4I4ET'7H<
MC\*VJJQ?\A&Y_P"N<?\ -J!%JBBB@ HHHH **** *NF_\>@_WW_]"-6JJZ;_
M ,>@_P!]_P#T(U:H **** "BBB@"MJ/_ !XS?[M6:K:C_P >,W^[5F@ HHHH
M **** "JMQ_Q^6GU;_T&K55;C_C\M/JW_H- %JBBB@ HHHH **** *MO_P ?
MMW]5_E5JJMO_ ,?MW]5_E5J@"MJ'_'M_P-/_ $(59JMJ'_'M_P #3_T(59H
M**** "LV?_7-]:TJSYW82L,]ZUI[G/6V1#13O,;U-<+X)^+5KXJ;61>I!HHL
M-6?2(C/=J?M,@)"[<A?F;!PHR?K6]SDLF=Q16(GQ"\-/9)>+XDTEK1YOLZW
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M6OT%.IL?^K7Z"G4 %%%% !1110!5O/\ CYL?^NQ_]%O5JJMY_P ?-C_UV/\
MZ+>K5 !1110 4444 %58O^0C<_\ 7./^;5:JK%_R$;G_ *YQ_P VH M4444
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M,B0$R/'LZMG<,],5@?9]9;X1:=H>KZ9=7:^%?$,46IVD,;-Y]FK$_+Q\Z\D
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M_P @V[_ZY/\ R-6:K:G_ ,@V[_ZY/_(T 3Q_ZM?H*=38_P#5K]!3J "BBB@
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MY2JY(4,^U3@;B<468[QL=M1115F04444 %%%% !1110 4444 %%%% !1110
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M_A7HO[3'W-%^K_TKPJOM,MHTIX:,I13>O3S/ Q=2<:S2;.P_X6_XP_Z#D_\
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M"Y8JH& ,DDG\35FJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_B3K^@>+_B!-J&G+<Z=I]WIUM!"+_B+SC%&-H\O^(2F0^XV\]1T/CSXO?\
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M *K:G_R#;O\ ZY/_ "-6:CGA%Q!)$V0KJ5./0C% #H_]6OT%.I%&T >G%+0
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M6U1XO,^RQF.&*.-2(T0,2?XF))/):MKQ!JKZ'HMW?QV5SJ,D";DM+1"\LK=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#%4 7J*H_V-;?]-O\ P(D_^*H_L:V_Z;?^!$G_ ,50!>HJC_8UM_TV_P#
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M2?\ Q5 %ZBJ/]C6W_3;_ ,")/_BJ/[&MO^FW_@1)_P#%4 7J*H_V-;?]-O\
MP(D_^*H_L:V_Z;?^!$G_ ,50!>HJC_8UM_TV_P# B3_XJC^QK;_IM_X$2?\
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M+2VUZPFN6/14$P&X^P8J?PKO*I:UH]IXATF\TR_A%Q9W<30RQMW4C!^A]^U
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MM2:YIT30J^H6J&8 Q!IE&\'IMYYS@]/2@:YIQM)+H:A:FUC;8\_G+L4^A;.
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M@@BN+_2[2#]YN,&F6K1.=I.2&)5^.IP#0!Z/9>-M!U"74H[?5K1SITHANR9
M%B8@$ L>#]X#(.,Y'4$5LQR++&KHP=& 964Y!'8@UXZW@;Q!%X6NK9-)/]MO
MJ]YJD=[#<PA%F:1S Q5L[HMC ,#\PQP#P1ZQI%FVGZ39VSI!&\,*(R6R;(@0
M #L7LN>@]* +E%%% !1110 4444 %%%% !17@'CWP#>^))_'&NRZ?J,VIR:C
M9Z?I$40E C1#$#<JJXR!OD.\\#:WJ:]/^(=AKEYH=I:Z+;SW<XE!E>'5CI\@
M4*1]\1ONR3R,#ZT =A17&^ -.U?0]!O9=7BO?MI=G6WGU5M1.T+QM<QIC)S\
MN.PYYKS+P;\.KW1M2\ :F^GZ@=9O);S5-4NG,G[A61G6V8$[4RTH^4X)9#Z&
M@#W^BO _!3:S?+X*MKC0M:A;1XKS5-0FOK26-9+MD<+&I89<[I21V..,\U1\
M._!WS+_P'%?V>J>?=VEU?ZY<EYD4;]K+:.<@*-TC93@G8Q[F@#VSQ7XLB\+'
M1T:W:YEU/4(M/B1& (+Y)<^RA236]7SFWAJ0:)X#L]8T'76T2VEU"^FM+*UG
MEEB#NP@@?:-RC9(1CCA2.E4F\*^*;32O#NE7MA=0^''-[>FPDL;G4%@+S?N(
M)$B8-\D;9 8[<Y!Y% 'TS17C.A_#&/4?$NBZ;JJZEJ&B:)HJ-%)=I)"D]Q+*
MS%6YYV*B?(2=N1GD5?\ B=8G4_&VEVVMZ7JVJ>$(M/DE^S:;;RS)->;U"K*(
MN<!,D;N,GVH [3QEXQ'A1--AAL9-3U+4KD6MI9Q.$+MM9V)8\*JJI)-;UM))
M+;1/+%Y$K(&>+<&V''*Y'!QTS7AGA7P!#?\ B;P1IWB&P\Z[TG2KJ^:&X/FF
M /< 6\;,<YV*7 YZI5OXIR6>M_%/3K+4]-U;6-(TK29)Y;/2K>2;S)IG 1)!
M'SM*PMC/&>M 'MM5;G4[2SNK6VGN8H;BZ9E@B=@&E(&2%'? YKP"Z\-:AI^C
M^'-+\2Z'K6NV-EHDDL-C8QRS(;UI&(CE=#P8TVJI8XY)'(J3PQ\.8X->^'$&
MO:!=7JVVAR2S7$MG),%O))%DV3/CY"F9"-W<GKF@#W?3=5_M*>^C^R7=M]EF
M,.^YBV+-P#OC/\2\XSZ@U>KYTU/0=?N-!\-0W6GW26%Y)?:CJ%M+I]S=@S23
M$Q)+%$5;*HW ;"Y49J\/AHTUW96>H6^L:UH?A[P[)/%'.DL7VRYF<OY04')V
MJBCR\DCY0>V0#W.;5+.WO[>QEN8H[RY5FA@9@'D"XW$#OC(S]:M5X/X:\%Q6
M7BCPC+X@\/WFH7%CX:A"7/V*28+<JQ8AY.BNJH  3DE\=:W?@SH4^G>(O$$\
MMA>/$^&CUG4+>:UN;HR.SM'+'(?F*84!P ,' H ];HKY\N?#^KZ]\0=3O=?3
M4;=K?4_-LY;;2;J>2*VB(*)#,I\I5<*2<*6)8@CI6>/[6\,0>+M:U32]3T^P
M@T^YU+PW;.IV6DD[.K+)@82;<R$(2=JLP'0Y /I.BOG;PYX4U'1+:]OO"NEZ
MU8WEGX;DM9I]1BE26]O6*%-J2?>V!&P5&.5 /6JD'@34H?"'B";3AJG]J:C:
MP:0\$.F75J)/-E DN)#,Q>1@NXE^ H)['@ ^AK[5?L-]86WV2ZN/M;LGFP1;
MHX<*6S(W\(.,#W-7J\1\0^![WPG?:@GA'3;N/[!H,S6]P"\ADO)Y$1G!.=T@
MCA)P.?F'3(KG(?A_?GPEK:Z:FI1WFL"STB2"'3KJU15:<>9<OYQ9Y&";MTAP
M ": /I&J>IZE_9J6[?9;FZ\Z>.#%M'O*;CC>WH@ZD]A7B&I^#]1\)CQQ!X?T
M[58=-D;3;0M:F62>>,X:YGBSDN^URA*\Y![BMBP\/V>GZIX9?PYH&JZ;H\4]
MYJ4\5U!.,21VXCC&Q\E2YD) (!8H3CB@#V.BOGWPU\.]3T/4_!.J6EEJ+:V;
M*^U'4KBX:0+YCQ_N[9@3M4>9)]S@_*3ZFJGPVTR.;QYX)-QINKVGB1;.YU'6
MKW5$EA:XF*!"@1C\RJTK88#& -IZ@ 'T;17BOQCLI-0\1WO]H:#K6O65MI&[
M2K73H)GA:\9GWL[1\!E"QXW>IQDUST/PUO;VS>'5],U&]M_#OA"%(+=O-"WE
M_(LDD@&W!D8,J# R02.^* /HNN5\._$G1O%'BC7M!LFF-WHVSSY'0")]Q8'8
MV>=K(0<@<^O-96HOK_AGX4:78:5!/?>)'M+>PA=D9Q',4"F64X.U5P6)/< =
M2!7GVA>$?%7PZU>XE?1X)T3PG<6L<FDO-=&>>%S*OF$QJ?-D:5L#G=SCI0!Z
M5X4^*,7C&\@2Q\.:ZEC,SB/5)X(EM6"D@MN$A."5('R^E=M7F/P2TFWTK18+
M>*7Q*);:TBBE@UJ&>&!6QSY2R*HZ@],X!]Z].H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>btai-20231231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (; \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"!;#4- MI#]FO9K65FDC SN)$Z@]^PKSOPC^U?\9?'LMS%X?\ !^AZK);
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MP*2'.,Y)WJ<8^;KGI7J'QB_:4U#3_@)X9UO16%CK?B2'894'-L5!$Q3T.X$
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MN_-96DKW>GGYW/L^BOD_]C7Q_+HNB^,?"VNRO'<Z$[WI6=CE$&5E'/3# ?\
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MQ7,**P2XW-G<[[B<8/O[I^T?X?UOQ!^S;>VT2G7-0AAM+F\CLP3]MCC='F"
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M0C!T\+2Y5*2E*[O>SNDNRN71R#%3JQK8[$>T<(RC"T;6YE9MZZNQ\P?L!_\
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MY,O?'H"H_"O3]5\.:3KK1-J6EV6HM%GRS=VZ2E,]<;@<5?1%C4*H"J!@ #
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M,D!N.",CGZ5@^+OB0?BQ^T3X;\11:?/I^GR75M!:+<##/&CXW'MU)Z?3M7Z
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M;2_@KX.L[.R;3;2"YCBALW;<T""$@(3DY(''4].M=CXR_P"3*;?_ +%:P_\
M14->X:KH>FZ]"D.IZ?:ZC$C;ECNX5E53Z@,#S3Y-(L9M,&G265N^GB,1"T:)
M3%L'1=F,8&!QCM7%',DJ-&FXZPGS7OOK<]2622>)Q-:,TE5IJ"5MK*U_^ ?(
M?P5\$W?Q$_9"\4Z#8<WMS=,\*DXWO&\<@7\2F/QK,^!_[4=I\&O!4GA'Q3H6
MHK>Z=))Y A0*Q+,6*2!B"I!)YY[<5]G:7H]AHEN;?3K&VL("=WE6L*QKGUPH
M S5;4O"FB:S<"XU#1]/OIQC$MS:I(W'3D@FNN6;T:SJPQ%+FA.7,E>S3VW]#
MSX\.XG#+#U<'74:M.'(VXW4HWOM?34^3_P!EWPOK/Q#^,.N_%#4K%[+3I9)F
M@W@J)))#]U?4*O4]*Y'X:>+9?V1OBIXDTGQ-IEW/IER!''<6R@LZ*Q,<B9(#
M J>1G@\=J^[X(([:%(H8UBB085$4!5'H *J:KH&EZZB+J6FVFHJGW5NX%E ^
MFX&C^VE4J5%6IWIS2CRI[*.VHEPQ*C1HRPU:U>G*4N9JZ;G\5UV=EU/GOX.?
MM$>+_C'\4;NTTO188?!T*O(]Q<(1)"@7" L#@LS8X';)[&OGBT\1Z)HOQK\3
M7?Q9T2_UU_-E1+<$Y23?\N5)7*[>!SWZ&OT0T[2K+1[<6]A9P64 .1%;1+&O
MY  55U#PMHVK72W5]I%A>W*8VS7%LDCC'3!(S3H9MAZ%2?LZ/+"44M':6G6_
M=]18KA[&8NC257$\]2$G+WHIQ=^G+V72]]V?"/P5O[:?]J?2K^'1_P#A&M/O
MY))++3V39LB:,B/ ]P,Y[YSWKO-,_P"4@%W_ +S?^F\5]:7'AK2+O48M0GTJ
MRFOXL".ZDMT:5,=,,1D8^M*OAS25U8ZH-+LAJ9ZWHMT\X\;?OXW=..O2KJYW
M"K.4U3:O3<-[_.YGA^%ZE"G3INJGRUE5O:U[+566B_(\0_;/^'>H>-_AG;7V
MEPR75UHUS]I>WC&YGA92KD <DCY3] U>8:3^VG#X?^%%AH]AI%Q_PEMI EJI
MF0-;?* -_7<3Q]W'XU]G=:QQX,\/B]^V#0M,%WG=YXLX_,SZ[L9S7'A<QH1P
M\</BJ7.HNZUMOT?='HX[)<54QD\9@*_LY3BHRO&^VS6JLSY[^*/B/Q-XN_9'
MO]7\5V$6F:G=M'(MO&I4B+S%V%E/0GDX]"*XK2?^3!M<_P"OE/\ TLAK[)U#
M3;/5K1K6^M8+RV?&Z&XC$B'TRI&*K+X9T=-);2UTJQ73'.6LA;)Y).0>4QCJ
M >G45=+-84Z:@J=K5%/3:RZ&=?(*M:M*JZUVZ+I7:U;?VG_D>*?LJ_\ )MD?
MTO/YM7E_[#VF?VWI7Q4T[?Y?VN&UM]_]W>MTN?UK["L-)L=+LOL=E96]I:<_
MZ/!$J1\]?E QS4.D^'=)T S'3-,L].,V/-^R6Z1;\9QNV@9QD]?4U$LT3AB8
MJ.M5IKRM*YK#(I1J8&4IIJA&47I\7-'ET['P_P#!?XG7'[*WBGQ'X;\8Z+>K
M:W$JDR6\8+Y3(5TW$!T8'J#6CHTFH_M4?M$:7XAM-,GL?#.D/#))+,.D<;;P
MI(X+.W&!T'/:OM'5= TO751=2TVTU%4^Z+N!90OTW XJ;3],L])MQ;V-I!90
M#I%;QB-1^ &*ZYYU3<IXB%*U:2LW?3M=+N>=2X8KQC3P=3$<V&A+F4>77>Z3
ME?:_E_P/C&[_ .3[[;_K\'_H@U9_:G_Y.E\ ?]>EC_Z63U]=GPQHYU4:F=)L
M3J0.1>?9D\[.,9WXST]Z6_\ #6D:I?17M[I5E=WD( CN)[='D0 D@!B,C!)/
M'K41SF$:U.KR?#3Y-_Q-)\-5)X:M0]JO?J^TVV5UIOY;GRU_P4 _Y!'A+_KO
M-_Z"*Y;]K.XUA/#'PT259V\,_P!F0-*D1(1Y0B9#'IG;TK[0U;P]I6OK&NIZ
M99ZBL9)07<"2A?IN!Q4EWI%A?V(LKFRM[BR "BWEB5HP!T&TC'%3A<XCAH4(
MNG?V;EUWYNW:Q>8<-SQU7%U%5Y?;*"6FW+WUU3/SD^+OB/P1XF\,Z?%X!\%W
M&C6=BX>_U*X3+,S#:J%\GON/49].*^\_@O<1W7PF\)21.)$.FPX93Q]T5O#P
MEH8TQM.&C:>-/9@YM/LJ>46[$IC&??%7K&PM=+M8[6SMH;2VC&$A@0(BCV X
M%99AF<,90A0A%KE;=V^9N_=LWR?(JN6XNIBJE2,N>*5HQY4FNR6EK?.Y8HHH
MKYX^R/.?CG\>/"O[/O@\:_XHNF19I/(M+.$;IKJ7!.U1Z #)8\ =>HS\.VG[
M:/Q+^-_Q'71]'\&V7B/PW?*;=_"KVPF2:(GEI9"."!_$<**^H?VS_P!EN3]I
MKP1IL.FZBFG>(M$DEGL#/GR)O,"AXWQR,[%PPS@CI@U^=_PX^*GQ4_83\>W>
MF:EH?V>&=Q]LTN_C_=W2C@-%,!Z="I(]17U>64L/*A)QBIU>S=ON_P _Q1\I
MFE3$QKP3FX4NZ5[^O]?>?0?Q]_X)H2:IIG_"1?#6%-,U&2(37'A2YN0\:.1E
MD@F.!P<@!N#ZBO%/AC^U;XL^#&JV?@[XL^%SXOT71KE6CTWQ%;!KW370\-"T
M@)X[ \8Q@@5^B_P$_:T\ _M Z0LNCZB--UF./==:-J#".>$@<D<X=?\ :7\<
M=*\-_:F^+O[.GQ'\06WA+Q;%-JMV"8I/$NC1ACIC=LR Y<9Z@!@*,-7Q%63P
MV)I.=OO7]??ZCQ-'#T8K$X>JH7\]'\OZ^1]/?![XW>#OCIX976O".JQWT*X6
M>V;Y)[5C_#)&>5/Z'L37>5\0?L8?LAZM\&_B]J/C/3O%]EK_ ("O-+:'3[BS
M8A[[>ZE?,3HNP*><G)88QS7V_7@8NG2I57&C*Z_K0]_"U*E6DI58V?\ 6IPH
M^*GPU\.7]YIX\6^%M+O?M+_:K4:C;Q2>>3A]Z[@=^1@YYSUKLH-/M;:XN+B&
MVABGN"#-+'& TI P"Q')P..:^3?V?_#?B/5O%OCF2+P?X,U7PP?'>KBYU/5)
M'.I)B<[@B>2RD#C&7'?I5V?XP_$)?A7>?&:+7;!="M]091X0>R7#6:W?V<H9
M\[Q.1EAVSA<5M/"^]RP?9;]7LM/U,X8CW>:2[_<MW_PQ]+:5X1T+0KR\N]-T
M73M/N[TYNI[6TCBDG/J[* 6_'-)HG@WP_P"&;BZN-'T/3=*GNSNN);&TCA:8
M^KE0"WXUXKJGQB\1V_P_^-&K17,2WGAG4Y+?32T*_NHQ#"ZAA_$<NW6L^;Q;
M\1_&WC?XD:?HWBZV\/67A:RT^[MH_P"RXYVGDFL_.979CPFY3T&?FZ\8K)4*
MCNW*RZ[^7^:-/;05DE_6O^3/;C\-O")L9++_ (171?L<MQ]K>W_LZ'RWG_YZ
ME=N"_P#M=?>J>CV?@CQ_HVJI9:9I.KZ9+?2PW\3V*&.6ZA?8_F*RX9E9<9(/
M3@UX]X>^*GC3XU7_ (/TK0=9MO!CWGA2W\27UV+-;IY9)6V"*-7. @96)/7!
M4<5Q_P .O%NM>'OA<='C\42V7BZ]\3ZTSQ>'M(&H37S)<-YC0QL=L<88Y+,<
M $#.:T^KSMK+7Y^?^1'MX7TCI\O+_,^I=6\#^&]<:Q.IZ!I6H-98%H;NRBE,
M&.@CW*=N,=L5?L-6T_4)[NVLKRVN)K&007,,$BLT#[0P1P#\IVD'![$5\AZI
MXQ\:?%'P[\"-8;Q+/H.H7?BB73;I(+1 'FCANQYSH21G$>#'DJ"V>H%=1>_%
MCQ)HVM>.-%TM]/M=6NO&EGX>M=4>S0"$264,CSRJN/,?[P&X]U'04GA9_"Y:
MZ_+6PUB([VT_/2Y] VOP^\+6.O2:W;>&M(M]:D)+ZC%81+<,3U)D"[C^=.@\
M!>&;:4RP^'=)BE-R+TNEC$K&X'2;(7[_ "?FZ\]:^=_B/\6_'WP<TWQ]H=SK
MUMXCU/3= BUW3-7DL4B>(M<")XIHU.UAW4C!P2.V:[KPYKOC7P=\9=!\,>(O
M$L/BC3O$6F75XC#3TM6LYH#&2%VDY0B0C#9(P.34NA44>;F]-]4E?]>I2JPO
MR\OY:7T/7AH6FBQCLAI]J+.-@Z6_D+Y:,#N!"XP"#SGUJK?>#M U36;;5[S0
M]-N]6MAB"_GM(WGB'^S(1N7\#6Q17%S-;,ZK)F/<>#= O-=BUN?0]-GUJ( 1
MZC):1M<(!T D(W#\ZT+33[73Q*+6VAMA+(99!#&$WN>K''4GN:L44-M[L+)!
M1112&%%%% !1110 445Y5<?$OQ?J_B[Q!I/A;PQI^I6FC3);S75[J!@+2%=Q
M  1NF?7N*I1;V%<]5HK-\/7&IW6CVTNLV<%AJ3 ^=;V\WFHAR<8? SQCM4.I
M^,= T6>2#4=<TVPFC"EX[J[CC90WW20Q&,]O6E;H,V**R=4\7:%H:V[:EK6G
M:>MP-T)NKJ.(2#U7<1G\*N3ZG9VU@;Z:[@BL@GF&Y>11&%]=Q.,>]%F!:HK,
MTCQ/H^OV\L^EZM8ZE!%_K);2Y254^I4D#H>OI56/QWX:FFM8H_$.E/+=#-NB
MWL1:;DCY!N^;D$<=Q19@;M%5-4U>PT.T:[U&]M]/M5.&GNI5B0?5F(%1Z?KV
MF:O8&^L=1M+VR4$FYMYUDC&.OS D<4@+]%8B>./#DEU;6R^(-+:XNE5X(1>Q
MEY5;E2@W98'L1UJYK&OZ9X>MA<:KJ-IIEN3M$MY.L2$^F6(%.S OT5Q?A'XB
M)XL\9>(]'@AA:UTM8&BO(9O,$XD7=G@8P/8FMV'QAH-SJK:7#K>G2ZFIP;-+
MN,S ^FP'/Z4VFA7->BLC4_&&@Z)/)!J.MZ=831JKO'=7<<;*K'"DAB" 3T/>
MF7_C7P]I<T$-[KVF6DLZAXHY[R-&D4]"H+<@^HI68S:HI 0P!!!!Y!%48->T
MRYMKJXAU&TEM[5F2XE2=62%E^\'(.%([@]*0%^BLT^)=(&E1ZH=5LAIDI 2]
M^T)Y+Y.!A\X.3QUIFK^+-#\/R0QZIK.GZ;)-_JTO+I(B_P#NAB,_A3LP-6BJ
M5[K>G:;!;SW=_:VL-S(L4$DTRHLKL,JJDGYB<' '6J]OXLT.\TN;4H-9T^?3
MH25DNX[I&A0CJ&<' ZCJ:+,#5HK/T?Q!I?B*W:?2M2L]3@4[3+9SK*H/H2I(
MKFOC#\0I/A?X#OO$,5DFH/;LBB!Y"@;<P'4 ^OI0DV[ =K17*?#/QTGQ"\%6
M6NF 64L@=;BVW;O)D5B&7.!TQ7'?#7X])X_\4^+;!M-6ST[0X_.CNQ*7:>/+
M#=MP,<+GJ:KD>OD*Z/7**\<TSXN>-_%.D?V]X?\  L-YH+[FMWN-1$=Q.@)&
MY8]I'.. 36U)\==$7X3_ /"=+#<-:G]W]CP!+Y^[9Y1[9W=_3FCDD%T>DT5X
M]JOQ:\;^$]+77/$7@6&UT%-K7$EKJ(EN+="0-SQ[0.,C.":]:LKR+4+."Z@;
M?#/&LJ-ZJPR#^1I.+07)Z*R-8\8:#X=F2'5=;T[3)G&5CO+N.)F'L&(S5B;7
MM,MH+2:;4;2*&[94MY'G4+,S?="$GYB>P'6E9C+]%9>D^*=%U^::'3-7L-1F
MA_UD=I<I*R?[P4G'XU7USQGHVA226USJMA#J/E-)'9372)+)@9 "DY.?846>
MP&Y17G^C?%5;WX/-XYN[-;8+:RW!M5D+#*LRJN['<@=N]=#'XOL],\/:;?\
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MTN:V^'<.K7:XO]=N)=5G)ZYE8E1^"XKTNH+&RATVRM[2W01V\$:Q1H/X548
M_(5/6$G=W*6@4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ^;?VY?A=X]^+7P]T31O! -S&=14ZE9+.(O-C*X1F)(!16
MY(]P<'%>;_#[_@F3X33PG<1^.=1N-3U^YBVK)I[^7%9-ZIW<C_:X]J^VJ*]2
MGF6(I4%AZ;Y5>^F[^9Y53+,-5Q#Q-1<TK6UV7HC\A/C#^R;\4OV1/$L/C/PK
M>7&HZ192>9;Z[IB?O;4>D\?.!C@GE3WQTKZ._9J_X*6:1XI>S\/_ !/6+0]4
M<B*/7(5(M)6Z#S1_RS)_O?=]<5]U2Q)/$\<B+)&X*LC#(8'J"*^._P!HO_@G
M#X4^)\LVL>")X/!NOR-ND@\LFQG)/.57F,^Z@CVKNCCJ&,BJ>-6O22_4XY8*
MM@Y>TP3TZQ?Z'V)%*D\22Q.LD;@,KH<A@>A![BG$ @@\@USWP[\)?\(%X$T#
MPY]K>^_LNRBM/M,GWI-B@;OTKHJ^>DDFTCZ!7:U/'T^!VJV_@_5?!$'B95\%
M7=M=6L%L]H&NK:.8-A%EW8*H6XR,X !J;0?@IJ%OXRL_$VLZ_'J&I0W+W#K!
M:^5&VZT:V  W''#;OTKUJBM_;U-5?<R]E#338\?TK]GV/2_#FN:5_:[RC4[>
MT@,AA \OR)'?.,\YWX_"N8^"7AGQ5X?^(3KJVB7OV&%;Z**6ZPD&F0R3>8L4
M!#$3!R$R0,@(,XZ5]#T4_K$VI*6MQ>QBFFM+'FOBGX/'7M=UG6;?53::A=7&
MGWEJ6A#I!+:"0+N&?F5O,.1QCM7DGQ(^$OBG1]9^TV<5]KQU>"Z.KMIL 6._
M>1X\6KJ'!BC*IC?_ +39(KZEHIPQ$X/N$Z,9GB.B_L[QQW6H75PUI NHQ74P
MC:#S+FQGN8RL@27=M(&]QD*"0<9K4MO@;*]MJ O=9$US>QZ4CO%!M4?8F8@@
M$G[P(^F*]:HJ7B*CZC5&"Z'A.C?LO6NC6)T^.^M6M8+B&6SN3:?Z5'&EVEQY
M;/NP0=@7( SP3S7MME'=1B?[5,DVZ5FBV)MVIV4\\D<\U9HJ)U9U/B=RH4XP
M^%!11161H%%%% !1110 4444 %%%% !7@_Q\\>^-]'$<>CV)T30H-0M89]6>
M4>==%Y -D2C[J]<D\G&.._O%>0_M0_\ ).+/_L,V/_HT5I3MS*XGL>O5YSXE
M^-5IH'C2Z\+6^@:QK.K06Z71CT^)&!1NX)<=/?\ #->C5Y%X< _X:=\7G'/]
MA6G_ *&:44G>X,VM8^,MK8ZU<:3IV@ZQK]_:1K)>Q:;$C"UR,A7+,!NQV&:?
M<?&SP]%X)MO$L?VJX@N+H6,5G'%_I#7))'D["1AOE/4]J\8N;'3/!OQ(\:)X
ML\6>)?!B7]\;ZRN-,N#%;7<;#ID1MEQTQ5]-%\)VWP<FFO\ 2?%-SX?U#6Q=
M-J%U*IO8&Z"\&U00G!Z@GYO>MN2.A-V>M^'?B[9ZUK-YH][H^J:!JUO:F]%G
MJ42JTL0SED*L5/3UKF=/_::T?5-$.M6_AS7Y-%B)6ZOUMD,5L0<'=A\G P3M
M!QFN0^'?B&\;QG/I6@^+KWQWX4.E3O<WE_;EGL9 I\M/.(!)/I^E8_PQ^+GA
M_2_V>V\-203MKTMO>6MMIL=L[/?/))(%:/"X89;:3V*FG[-=NP7/<O$_Q<T?
MP^FC):PW6O7VL1^=8V6EH))9H\9WC) "X[DBD\,_%O3?$1UFWDL;_2=6TF$W
M%SI=_&$G$>,AA@D$'ID&O(O#=A/\$/$/@K6/%22QZ4?#W]ESWBH9$LI]XDVO
M@' P,9]JUK;48OB-\4O$7B[0Q*?#MAX9FTTWXC*1WDS,7PN0"P4=_514\B_X
M(79T%M^TKI%UH-OKZ^'M>'AY]HEU4VR>3 3@$-\^3M)P2H(]ZZKQ=\5;#POJ
MFGZ5;Z??Z]J]]$9XK'3(U=_*'\9+$ #ZFO)44#]B5\ #_B3Y_P#(E:,6N6OP
MU^).D>)/$!>#0=4\-VME'J+QEH[:5/F*$@'&X'/US1R1Z+N%V;?PQ^),OB'Q
MM\0+N^N+RSTG3D@<6FH?(;/",9,KT'3)Q5^']H32VM[?49] URT\/7$JQ1ZW
M/;*+8[CA6/S;@I/<K7GEC,OQ8G^,X\/QR$:C80I:,Z&,W!$;8(!YPQ& :YB%
MO"6J^";+0[OQ5X\O]9E2.TE\)1W0#AQ@%=C1;0@(SDGIBJY$WJNWY"NSW?Q+
M\;;'0/&;^%[?0]6UK51:)>*FG1HX>-L\@EATQWKJ_%'BM/"O@^]\07-C=316
M=M]IEM80IF"@988) R!G//8UYCX4MEM?VF]5A"LHB\*6R!9""PQ*HY([U[)?
M64&IV5Q9W48FMKB-HI8VZ,C#!'X@FL9))HI:G!>+?CAH'@^Q\*7=TEQ/!XB:
M,6S0!3Y:L%.]\L, ;QG&:T]2^*.DZ7XKU30YTG#:7IO]IWEV%'DPIG 4\YW$
M<@ =*^:=(\*:CXOT+QCH-ZN9?!6CRZ;:.RY+RK<>>C#T)6)!GT:NZ^&NOZU+
M\*/&_P 1K6P-[KNK -;P2CS-T<,>Q>.IY,C8[\5JZ<4A79W"_M 6,,>GW=]X
M9U[3=&OI4B@U6YMT$!+G"$X<L ?<5L>(_B[:Z-XDN-"T_1-5\1:C:PK/=1Z7
M$C"!6&5W%F7DCG S7S3\0_%$'B3P1;7#>/\ 6/%.H&6WEN=/AM1;6=GAUW>:
MJH ,=!SUKTCXH_\ ")V_Q$GN=0US6_A[KHM(?)URT9A;7Z;>A4 [BO3!QT^E
M/V:[!=GMW@GQEI_CWP[;ZSIAD%M,64I,FQXW4X96'8@UX9\>OB!XB\'?&?0&
MT[4[F'1K338K^^L4<^5,GVDQN64>BL#]%KT?X!ZYKNO^!C<:ZQN&6ZECM;Q[
M;[.]U #A)63 P6'/O7)>.]#A\2_M(VNE7"AH;SP=<0,#_M3.*B"49NXWJCHO
MC_XSOM#^'J)H%T]OJVJN(K2:(X=%"F1W'IA%-<-<_$?Q)8?L\>"=275I+:ZU
M2:.WU#7YT\YK2)I&#2D'N!W]JR/ D^I>-+;48]6BD7_A!= N]+?S5'SW;>8A
M;_OU&GT)/K6[X/\ $^J^$O@!X!OK?1TUO0BICUBW$!FE6W+."Z*#@X/4$'BM
M.5127F3>YIVFA>(K,Z9J_@3XB7?C1UFC^VZ;JMY#-%-"3AV4@*8R.PY/OZ[^
MN>(=3@_:/\-Z-'?3II4^B3SRV8<^6\@=@&(]1BO(?'%_\.?$R6DOPOM+B'QZ
M]S$]J-$@DM_*.\;S,H 0+M#$\?CUKT77([EOVF?""2RA+P^&;@/*B@@/N;)
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M@?;=)Z?5:.6/PV_JP7>Y[Q1117*:!1110 4444 %%%% !1110 4444 %%%%
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MM_\ %4 7Z*H>5J7_ #\VW_?EO_BJ/*U+_GYMO^_+?_%4 7Z*H>5J7_/S;?\
M?EO_ (JCRM2_Y^;;_ORW_P 50!?HJAY6I?\ /S;?]^6_^*H\K4O^?FV_[\M_
M\50!?HJAY6I?\_-M_P!^6_\ BJ/*U+_GYMO^_+?_ !5 %^BJ'E:E_P _-M_W
MY;_XJCRM2_Y^;;_ORW_Q5 %^BJ'E:E_S\VW_ 'Y;_P"*H\K4O^?FV_[\M_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=8\2ZKKEYJ\!9X;Z56BA*RNN4  (R ,YS0![917C&EZEXAL?VGY](OM?FO\
M2+G0)KZ*P$8CA@(N(U7 ')(!.6)YS73_ !V;6;?X7Z[=Z)K$FB75G;27+7$,
M8>1E5&.U2>%)..<'@'UH ] HK@/#.M7US\"[#59;F2347T 7+7+'YS)Y&[=]
M<\U\X?L^_%S6T\2^&9=9\0>(I-/OM%N+N^7Q#"%@N9HUW_Z$P'S *&)R>@H
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M0BO9J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!YCX*_9X@\#-+#8>+]?.EK;2VME8,\06S5P1E6";F*Y^4L3CWJG;?LNZ/\
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M6_"JP^%UEJBV]_>ZOJ.K79OM0U'4'4RW$Q &2%  & . *[>J'F:C_P \+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*DXJW-&[]4VOQM<^IRW$SKRKQF[J,VD_)QC)+Y7M\@HHHKS3VPHHHH ****
M"BBB@ HHHH OZ1_K9/I6I67I'^MD^E:E !1110 52L_^/^__ -Y/_0!5VJ5G
M_P ?]_\ [R?^@"@"[1110 4444 %%%% 'B.N?"+7=;\6:W=!(K<WZW<3:A]H
MS&]O);F..,08^5P^PE^I"GDYQ7<_#_1M:@U/5]7URS@TZYO([:W2T@G\X*L*
ML-Q; 'S%S@8X %=K10 V2,2QLC9PPP<'!JE_8MMZS?\ ?YO\:OT4 <"WQ#\
M(Q5O%>GA@<$'4.A_[ZKJ;2PL+^UBN;:9Y[>50\<B3L593T(.>E?DQJ0']H7G
M'_+9_P#T(U^I_P (_P#DE_A7_L&P?^@"OJ,WRB&6TX3A-OF[GCX''2Q<Y1E&
MUC>_L6V]9O\ O\W^-']BVWK-_P!_F_QJ_6?JOB'2M",8U+4[/3S)G8+JX2+=
MCKC<1FOF$G)V2/7;2U8O]BVWK-_W^;_&C^Q;;UF_[_-_C3-+\2Z/KDKQZ=JM
MCJ$B#<R6MPDI4>I"DXK2H<7%V:!-/5%#^Q;;UF_[_-_C1_8MMZS?]_F_QJ_1
M2&4/[%MO6;_O\W^-']BVWK-_W^;_ !J_10!0_L6V]9O^_P W^-']BVWK-_W^
M;_&K]% %#^Q;;UF_[_-_C1_8MMZS?]_F_P :OT4 4/[%MO6;_O\ -_C1_8MM
MZS?]_F_QJ_10!0_L6V]9O^_S?XT?V+;>LW_?YO\ &K]% %#^Q;;UF_[_ #?X
MT?V+;>LW_?YO\:OT4 4/[%MO6;_O\W^-']BVWK-_W^;_ !J_10!0_L6V]9O^
M_P W^-']BVWK-_W^;_&K]% %#^Q;;UF_[_-_C1_8MMZS?]_F_P :OT4 4/[%
MMO6;_O\ -_C1_8MMZS?]_F_QJ_10!0_L6V]9O^_S?XT?V+;>LW_?YO\ &K]%
M %#^Q;;UF_[_ #?XT?V+;>LW_?YO\:OT4 4/[%MO6;_O\W^-']BVWK-_W^;_
M !J_10!0_L6V]9O^_P W^-']BVWK-_W^;_&K]% %#^Q;;UF_[_-_C1_8MMZS
M?]_F_P :OT4 4/[%MO6;_O\ -_C1_8MMZS?]_F_QJ_10!0_L6V]9O^_S?XT?
MV+;>LW_?YO\ &K]% %#^Q;;UF_[_ #?XT?V+;>LW_?YO\:OT4 4/[%MO6;_O
M\W^-']BVWK-_W^;_ !J_10!0_L6V]9O^_P W^-']BVWK-_W^;_&K]% %#^Q;
M;UF_[_-_C1_8MMZS?]_F_P :OT4 4/[%MO6;_O\ -_C1_8MMZS?]_F_QJ_10
M!0_L6V]9O^_S?XT?V+;>LW_?YO\ &K]% %#^Q;;UF_[_ #?XT?V+;>LW_?YO
M\:OT4 4/[%MO6;_O\W^-']BVWK-_W^;_ !J_10!0_L6V]9O^_P W^-']BVWK
M-_W^;_&K]% %#^Q;;UF_[_-_C4]K8Q698QE\MUWN6_G5BB@ JE/_ ,A:U_ZY
MR?\ LM7:I3_\A:U_ZYR?^RT 7:*** "D/2EI#TH YVN'M_ABMC\6KGQM::B8
M!>6(L[S3_)R)F!&V0/N^7 "\;3TZ\UW%%:TZLZ7-R.UU9^ASUL/2K\KJ*_*U
M)>377\2G!HNGVMTUS#8VT5RW69(55S^(&:P/'GPWTSXB_P!D)JLUT+?3;Q;U
M;>!U$<[KT$@*G*^P(ZGFNKHHA5J4YJ<79KJ%3#TJU-TJD4XO=!6=<^&](O)W
MFN-+LIYG.6DDMT9C]216C14*3CJG8UE",U:2N4)/#^ES0102:;9O##GRXV@0
MJF>3@8X_"KL<20QK'&BHBC"JHP /0"G44.3>C8*$8NZ13O-&T_49%DN[&VNI
M%^Z\T*N1]"13[O2[._A2&ZM(+F%#E8YHU95/J 1Q5FBCFEIKL')'73<JWNE6
M6HJBW=G;W2I]T31*X7Z9'%,.B:<T)A-A:F(R>:8S"NTO_>QCK[U=HHYI+2X.
MG!N[2*EQH]A>7"W$]E;3SJ,"62)68#ZD9IDFA:;-;16\FGVKV\1S'$T"E$^@
MQ@5>HI\\EU$Z<'>Z6I2&B:<(6B%A:B)W\QD\E=I?^\1CK[TZVTBQLVE:WLK>
M R_ZPQQ*N_ZX'-6Z*7-+N/V<$[V13.CV!LA9FQMOL@.1;^2OEC_@.,5+9V-M
MI\/DVMO%;19SY<*!%S]!4]%#DWHV"A%.Z1P6G?":TM?B5XF\67<\6H)K44$?
MV">U!6$QHJ9W$G=G9G[HQFNRN=(L;V"."XLK>>&/[D<L2LJ_0$<5;HK6I7J5
M6G.6R27HE9?@84L+1H*4:<;*3;?6[;N]_-^G8JQZ38PP2P1V=ND,O,D:Q*%?
MC'(QSQ38M%T^W\CRK"VC\@DP[(5'ED]2O'&?:KE%9<TNYOR0[(I3:)IUQ="Y
MEL+66Y!R)GA4N/QQFIEL+9+F2X6WB6XD&UY0@#L/0GJ:GHHYI=PY(K5(I'1=
M.:R%F;"U-H#N$!A7RP?7;C%))H.F3/$\FG6CM$ L;- I* = ..*O44^>7<7L
MX/[*.*MOAJJ_%6\\:W6H&ZD:R2QL[+R=HM4'+'=N.XL<GH,9QS7:T4552K.K
M;G=[))>B,Z-"GAU)4U;F;;\V]W_6VR"BBBLCH"BBB@ HHHH **** "BBB@"_
MI'^MD^E:E9>D?ZV3Z5J4 %%%% !5*S_X_P"__P!Y/_0!5VJ5G_Q_W_\ O)_Z
M * +M%%% !1110 4444 >0ZS\8KK2M8U]Y$>&PL#<V]JCV9\NZGA@,I7SL\'
M@\8QA3SFNK\!:]K5YJ>K:5KDMK<W5G%;7"SVD1C4K,K':02>04;GN,4MY\*-
M"U'6[K4;E;F<7!D=K-YB;<2/$8GD"=F*$C/N:TO"7@JQ\'I=?99KJZGN2GFW
M%Y*9)&"+M1<^BC@#ZT ;TDBPQL[L%11DD]JH_P!O:?\ \_<?YUH44 ?D'J1S
M?W>/^>K_ /H1K]0?A/K=A%\,O"R/=1JPTV $$]/D%?E]J7_(0O/^NS_^A&OU
M/^$G_)+_  K_ -@V#_T 5^C\4_P*/J_R/D\F_B3]#=_M[3_^?N+\Z^0/V][V
MVO[KP@89$FVK/G'..5K[/KXX_P""@'_'UX._W+C^:U\SD'_(QI_/\F>QF?\
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M ,_<7YT?V]I__/W%^=:%% &?_;VG_P#/W%^=']O:?_S]Q?G6A10!G_V]I_\
MS]Q?G1_;VG_\_<7YUH44 9_]O:?_ ,_<7YT?V]I__/W%^=:%% &?_;VG_P#/
MW%^=']O:?_S]Q?G6A10!G_V]I_\ S]Q?G1_;VG_\_<7YUH44 9_]O:?_ ,_<
M7YT?V]I__/W%^=:%% &?_;VG_P#/W%^=']O:?_S]Q?G6A10!G_V]I_\ S]Q?
MG1_;VG_\_<7YUH44 9_]O:?_ ,_<7YT?V]I__/W%^=:%% &?_;VG_P#/W%^=
M']O:?_S]Q?G6A10!G_V]I_\ S]Q?G4]KJ-M?,P@F64KR0IZ59HH *I3_ /(6
MM?\ KG)_[+5VJ4__ "%K7_KG)_[+0!=HHHH *0]*6D/2@#G:XKPI\7?#WC/Q
M)?:'ITDYO;0,6\V+:KA3AMISV/KBNUK$T?P3H6@:I=:CIVEV]I?7.?-GC7YF
MR<GZ<^E/0XZRQ+J4W1:4;^]>]VO(VZ:YPC$=0*=2.,HP'4BD=A\>CXR>*D\+
M:[K9^(L::U9ZH]M:^'7MK=FN4#X "A?,Q@GGIQUKN_'?Q$\0?\+'\'Z1=>+5
M\":=J.B"]O)9$@"QSY?@F88&=H&,UDV/[/&LS?#/Q$DVE16/C&/5I-1TFY26
M/S6 8%5\Q3P&&1AB,$@\5J^,/!OC75/'W@WQ5<>!8/$OV31!;:AIT][;(BW!
M,F1ER0<;@<@$>]?>SG@9U/<Y-.=?87V5RVOHU?9OJ?DE.GFM.C^]]IK[-_\
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M/YUQ:R) ZQKNDV2%=K%5() -6?"?C;3/&<-P^G_:4>W*B2&[MG@D4,-R-M<
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MU?\ F:]OA/>M_P!N_J>=G?\ R[^?Z'ZF_!__ ))1X._[!%I_Z*6NOKD/@_\
M\DH\'?\ 8(M/_12UU]?#8C^-/U?YGT=+^''T1YY\6?CGX<^#)TP:^MZW]H>9
MY/V2$2?<V[LY88^\*J_"K]H3PM\8=4O+#04OUGM8A-)]K@$8VDXX(8UX1_P4
M$_UG@?Z7G_M&L+]@?_D>_$G_ &#T_P#1E?40RO#RRCZZ[\]GUT^*QX\L;56.
M^KZ<O_ N?<-%%%?'GNA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSA+.5+L7VA< A4P ./6H(/$OCGQEXS\7:%8^+1HD/A6VC0S"TB:2]EPV9&#
MX4E3]T#&1ZUZCIGPBT#2]<T+6(Q>3:AHT,D%K-<7+2':X8-O)^\?G;DU4\6_
M WPKXQUR?5[N"[M;^XC$5Q)873P>>OHX4_-QQSZ5A'&X56BXK2._)'XN:][>
M<=/(ZIY7CWS3C-ZSOR^TFO<Y$DN;=-2U;MKU9X19>/=0^(VK_!S5=55/MZZI
M<VTLD:[5E*$ .!VR,9]\UZM^TGXW\0>"="\/2>';X6%W>:I';.[1JX92#\I#
M \9QTY]ZZP?!_P +Q-X:,%BULGAYV>PCAD*JC'J6'\63SSWK1\;_  ^T?X@V
M]A#K$4LJ6-RMW#Y4A0B1>F<=1[4JF.PD\12FH>Y'FTLNK;6GS15+*LPIX/$4
MG5_>SY;23:=U&*;OOT9Y#\0_%OB'P1<Z1X>E\<:G>ZS)!)<2)I&B1W-W+DG;
ME<;508(Z9P":\U\1^*?$?Q,^%_@K5M3UF2*YB\3KIY"VT:[G!!28C'#*"1MZ
M'N*^E_&GPA\.^.]8M=5U&.ZAU&WB,*W-C<O [1G.58J>1R?SJ@/@+X07P6?"
MXM)QI7VLWR 7#>9',<?,K]1TKHP^8X.C"G)Q]].[?+'SO:UNZT.+&9+F.(JU
M8*?[III+GGK;EM>]]='=KOU/-?B+\1?%OA_QSIG@FRU76[EK;3OM5UJ6E:/'
M=W=T[,V#Y6-H08 ) ZUTG@74?B-X^^']B]W?3>$];M-1VSS7^G>6UW;CMY;C
MY2<]1Z5U.I_ SPQJL&E++_:$5UIL1A@OX+Z1+K8220TH.X\D]?6I+KX)>%KS
MPYI^B207)LK*\%]&?M+^8TW]YFSEJYY8S!NE"$8VDGJ^1/O=[]>ST738[*>6
MYE'$5*E2;<&M(^TDOY;*]FTU9^\M7UWTQ_VH;N>S^!_B-[=RCL((V(/\#3HK
M#Z$$BN2\#^+/$'@OQOX*\*:M;:)=Z;J>G&2R?2[<QO:C'()).0<#)&,U[EX@
MT"P\4Z-=Z5J=NMU8W2&.6)NXKD_!GP4\+^!=775-/ANI[Z.'[/#->W+SF&/^
MXFX_*/85SX?%T(8.5"K&[O)K3NDEK?2S7S.S&Y=BZN8PQ="5HVBGKTC)MZ6:
M?,G;=6:N<#XME'Q2_:&T7PY%^^T?PJHU&^V\H;@X**>W&5_4=JYWXB^ M1\%
M>-;*[T_4[?4KZ_UN74]+T=;?$_VAQ\SR/G B3[QX[8^GNG@_X;Z)X'U#6+_3
M8IC>:M.;B[GN)3(SL23P3T&2>*MP^"]+A\57/B(Q/-JL\(M_-E<L(XQ_"@_A
MSWQUK:.90HR4:?P1C:UEJ^M^UVWMK;0YZF2U,33E.O;VLY\UTW[J6B2[VBEH
M]+Z^3\?^!/Q#TZSU.S\.'2KU+O6WN;H:Y<2(W]HSQY\UMHY4#:< ]@*]]KA?
M#'P7\+^$?$K:YI]M.+T"01++<,\4'F'+^6A.%SST]:[JO/Q]6A7K>TH)V>]^
M_P![Z6_2R/8RC#XK"X;V.*:;3TMVLO)=;OO:UVW=A1117FGM!1110 4444 %
M%%% %_2/];)]*U*R](_ULGTK4H **** "J5G_P ?]_\ [R?^@"KM4K/_ (_[
M_P#WD_\ 0!0!=HHHH @OPS6-P$E$#F-MLIZ(<=?PKYS_ &8+W5+GQ;J\%WKM
MI?V]O;RXCM]2>\-R[2IF;D (!M8 9_Y:XZ"O=/'&NKX?\/RW#VS74<KI;LJR
M1IM#G:7)<@8&<D9YQ7DO[.\FJ6VJW&FW&I:C=:;:V6VWM[Q+ )& Z@8-N2YP
M./FXQ[XH ]YHHHH \I\3^%_$7C+Q+KD5]I(AT]M.N=/TN]%W&4A\V+#2/'][
M<S87V ]S6_\ #[1]:BU36-7UNQATR>\BMK>.TAG$VU858%RP 'S%S@=@!FNW
MHH ;(@E1D.0",'!P:I?V-!_?G_[_ #?XU?HH _(/4N+^[_ZZO_Z$:_4+X3Z3
M#)\,O"S%ILG38#Q*P'W![U^7NI?\A"\_Z[/_ .A&OU/^$G_)+_"O_8-@_P#0
M!7Z/Q3_ H^K_ "/D\F_B3]#>_L:#^_/_ -_F_P :^0/V][..TNO"&PN<K/G>
MY;NOK7V=7QQ_P4 _X^O!W^Y<?S6OF<@_Y&-/Y_DSV,S_ -TG\OS1@?L'6J77
MC?Q*KEP!I\9^1BO_ "T]J^U_[&@_OS_]_F_QKXN_8%_Y'KQ-_P!@^/\ ]&5]
MP5KQ'_R,9^B_(C*O]UC\_P S.DT> 1O\\_0_\MF_QK\E+\8OKG_KHW\S7Z\R
M_P"J?Z&OR&U#_C^NO^NK_P S7M\)[UO^W?U/.SO_ )=_/]#]0/A'I,,GPK\(
M,6FR=)M2<2L!_JE]ZZW^QH/[\_\ W^;_ !KG_@__ ,DH\'?]@BT_]%+77U\-
MB/XT_5_F?1TOX<?1'QI^WW9QVDG@G87.X7>=[EO^>7K6'^PA:I=>.?$2N7 %
M@A^1BO\ RT]JZ/\ X*"?ZSP/]+S_ -HUA?L#_P#(]^)/^P>G_HROOZ?_ "3K
M]'_Z4?,S_P"1K]W_ *2?:7]C0?WY_P#O\W^-9_B+3([;P_JDL<MPDD=K*RL)
MFR"$)!ZUOUE^*?\ D6-7_P"O.;_T U^=P^)'U,MF?E_-\7_' +X\6:N,$_\
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M\IF'J V,BG:5X^\/:Z91IFJV^I&+'F"S;SMF<XSMSC.#U]*^/?V^@#X]\-Y
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MC3;"VDN+JX-M;Q+NDFFC9$0>I8C 'UK(B^+'@V>5(HO$NF2R.0JHERI9B>@
M!Y-8_P"T/S\#_&W_ &#)?Y5^;_P\5?\ A/O#? _Y"-OV_P"FBUZV5Y/',*$Z
MTIVY?+RN<.,QSPM6--1O<_53^W+3UF_[\2?_ !-']N6GK-_WXD_^)K0HKYD]
M@YG4/B7X6TBZ:VO]=LK&Y4 F&YE$;@'IE6P:MZ9XUT36X&GTW4(]0@5MAEM
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M^-,\:Z)K<+3:;J$6H0JVUI+0&50?0E01FM.UOX;PL(BY*\G=&R_S KYR_8.
M'PMU; Q_Q,W_ /0%KZ6KDQN'6$Q,Z"=^5VN;X>JZ]*-1JUPJE/\ \A:U_P"N
M<G_LM7:I3_\ (6M?^N<G_LM<)T%VBBB@ I#TI:0]* .=KSOP/\%M-\#>+M1U
M^VOKFXFNPX$4@ 5 S;CR.O2O1**=['+6PM&O.%2I&[@[KR84V3_5M]#3J*1U
M'RC\'/A+-\2O#.OVNH^(=0M- _MR8SZ/;QHJ3E7!!9\;NN..G /6M;X]0?#F
M'59+:>74_#OC#2;2--/O-/MY ;C" QJK*,-C.,\$<C/ KZ8HKZ!YO4EB?;23
MMT2:6]KW=M;VUNM3Y!<.TH8+ZK!IR=KRE%RO:]K+F7+9NZL]'TU/DZ+5/'/C
MC6?AMHEQ:17WB'1K1M9OH=3D:%6?>P@\PJI(?8$;&.IYJYX,\::E\$/&GQ M
MO$>FPQF[B_MV&RT^;="69\,J.5'][ICL:^I:H:]IG]LZ1<V>VW;S5 VW< FB
M;!!PZ'[RG&#T/H0>:O\ M6G4_=3HI0>Z3:^US?=Y6O;J9+(*M%JO3Q#=6+NF
MTG?W.1)]W;5N]KZV.3U/XF3Z/8Z*+K2%.JZU=+;6%C#=AQ)E=Q=Y-H"!1G/!
M/3UXYN[\?^"O&D_@G4-9T>ZEU.349[6P4*S_ &2ZC*K(&*D CA<$@YZX%16_
M[/\ -8ZA#JUIJ]K9ZI!JPU."&"R*V47[O8T:PA\@$<DANM=_\/?!<?@/PVFF
MK/\ :IGFEN9YPFP222.68A<G YP!GH!6$Y8.C'FI-N7E=;IWWOIMYO7H=5.&
M9XFIR8B*C#S49+1Q:VMJ_>\EH]UK>\5>+=)\$Z-)JNM7?V*PC8*TWEN^"3@<
M*"?TKP+]C?Q9I7]@:SHGVK&J&ZEO?LYC<?N?E&[=C'4CC.?:OI2BN2EB:=/#
M5*#BVYM:WVMMI;S[GHXC U:V.HXN-1)4U)6Y6V^:U]>9=E;3OOT\$^!L#?$7
MXC^+/B-=H6MBYTS2@X^[$N-SCZX _%JQ/$7PVT'Q/XQ\06WA#P_%:VFFQR/K
M%_&7/VRXVEUM(P3@ D#?M Z@=^?I:BNG^TYQK2JTU9622OHDMK]_\W<X?["I
M3P\:%:2D^9RE+E5VW=NV_+K:]KZ*Q\W?!+QKXK\<7]WHZ>(KB2V_LE&EN1IJ
M0_V3=[L&% 5 ?:!WS7HW_"MO&W_14]3_ /!7:?\ Q%>ET5E7Q_/4<Z4(Q3Z<
ML7^<?T-\+E"I48T\15E-KKS3C^"E^;?W:'GMGX,\2Z+%?7.I^.;W7[46DRFR
MFL;>)6)0X.Y%!XKYMT_1H=:^'?P6L+VV^T6DVM7T<T3 X93.>#7VI16V&S2=
M"[<4W>^EH_9DNB_O7OY'/C<AIXNR4VDDU9WG>\H2WE*_V+6\[^OR3XF\+W6E
M^*?C;HGA&Q^Q0_V=9O'8V4952ICB:4(H[G+\#U(HN+_X?ZC\#==B\+:0UMK]
MOH,4>H3):/&5821[UD<@!W+ G// ZCI7UM170LX;4>:#O%Q?Q6ORI+736]K^
M5^IQ/AM*4W"HK24U9PORJ4I27+JK6YK>:70^2M,UF#X=_$7X<>)-:2>'1YO#
M2VZW$4+2?O-I&S"C.>1Q[BN;ACN-0^"VJW;6=V^D+XZ>YU*V$;!_LWE1$[EZ
M]<9K[9HJXYTDU+V>JMUZ)MKIH]=[^=C.7#+DI0]O[KYM.76\HQ3N^;5>[M;J
MU<^0K*3PUJ'Q2\37O@W3&L-#G\)7@0I:M!%-($8,\:D#C[HX Y!K-T[0K?7M
M!^ FGZA:_:;&>>>.:%P=KKY[$@^U?9]%']M-6Y8/3JY7>D91WMO[U_D'^K"=
M^>HM6VTH66LX3:MS/3W;?/RU^/O$NFV_AS3OCW8:?;?8=.BETWRK:V39&@:1
MMV%' 7UQVK;_ &<(/#>L_$RYU>.?P];7Z::EO;:5I=O(N"N-\P,D:X8@<[>3
MDY/7/O\ \1OA_I_Q,\,2Z)J,LT$+2),LMNV'1U.01GC\ZY_PC\%K7PYXMB\2
MWVN:EX@U:"V^R6\U^4 BCZ8 10.A/7UK=YI1JX2I";:G)6[WM&*[=>779KS.
M19#B*&8T:E.*E3B[ZZ6O.<M-;KE4K+1IVUL8GQTF^&;WUE%\0+"Z>1+>1K.[
M2*?8,GE%:,XWY .&&.E0_LIV>LVGP]N/[2%VFGO>.=,COL^8MOVX/0?_ %Z]
MHHKQGC?]D^JI/IN[I6O\*MI>^NK/IUE?_"A]?<DK)JRC9N]OBE?WK6TT5CXU
MU^]\&67Q*^+I\6:8]]<2OY6FR>0TJI*4/RJ0"$<D*03V4\TW5[N[\-^$_AII
M_B;1+ '^S9B-5UZQEO4@#2$K"(E/WMHCZC(R.E?4/A3X>6?A+Q1XGUNWN9YI
M]?FCGGCDQMC*!@ N!G^(]:ZNO7GG,(N*C%R22ZVU4.7333K?=,^;I<-59QG*
MI4492<MHIZ.IS^\[KFT2M\+CW/AJUT(W?[+]_<2:;Y]QIWB=CN-O\]O#MCW@
M C*+D\C\Z]62_P!#UGXY?#>[\)6T5MHSZ5J MUMK7[/&#LER0F!CGVKZ/HK"
MKG+J\UX;\_73WU;:W3?IU.O#\-+#\BC56BIW]W5^SES*SYM+[-:[)]+'P5I6
MC-<1#1]7O;73/%JZMYS+_8D\NJ/)YGWA.#@H?3@?SKT6P\$Z9XA^(_QHDUG3
MH=3N+&Q9K>2>/=LD\MOG4'HV5&#UKZPHK6KGLZEW&%KKOMJGI9)VTM:[WW,*
M'"=*ERJ=122=]8O7W915[R:O[U[I+;8^*EL],M/!OP4U_P 0:?%/I,+S6^H7
M,]KYP\H3/L20;264#.%Y]A5[XEW6@Z?\1I=1T:Q@URZO_L<:^'M0TF3?Y>Q"
MCVLBC]V -HP"#U&*^QZ*2SOW^=P?VM.;2SES=NGE;RL-\+_NO91JK[#OR:WC
M#DO\5M=[--*[O<9 [2P1NZ&-V4%D/\)QTI]%%?+GW:+^D?ZV3Z5J5EZ1_K9/
MI6I0,**** "J5G_Q_P!__O)_Z *NU2L_^/\ O_\ >3_T 4 7:*** ..^+WBR
M[\$?#O5]8L8H);N$1QI]J1GB3S)4C+NJ_,54.6(')"FO&_V:O%7]O>/]3:2'
M1)+BZTUG>32=-DMC:"*98UB+N3O5PP<="-O>OH^\=8K29VC\Y40L8\9W8&<5
MYO\ ";XG3_$"\EW:5I.FP&W\Y%M-5BN+D?,!MDB4 IUYST/% 'IU%%4M7N+Z
MVLF?3[1+VY!&(I)?+!'?YL&@"T)HS(8PZF0#)3/('THCE29=T;K(N<94Y&:\
M'\87FEZMXXUU-!:*Q\16.D7J3B!B+B\N9(,K&.[",+NSZXQWKJO@U_9;:CK[
M^'H_+\/F.S$6Q"L9G$;>=@'O]S<?7.><T >HT4V0L$8H SXX!. :I>?J/_/K
M#_W^/^% %^BJ'GZC_P ^L/\ W^/^%'GZC_SZP_\ ?X_X4 7Z*H>?J/\ SZP_
M]_C_ (4>?J/_ #ZP_P#?X_X4 7Z*H>?J/_/K#_W^/^%'GZC_ ,^L/_?X_P"%
M %^BJ'GZC_SZP_\ ?X_X4>?J/_/K#_W^/^% %^BJ'GZC_P ^L/\ W^/^%'GZ
MC_SZP_\ ?X_X4 7Z*H>?J/\ SZP_]_C_ (4>?J/_ #ZP_P#?X_X4 7Z*H>?J
M/_/K#_W^/^%'GZC_ ,^L/_?X_P"% %^BJ'GZC_SZP_\ ?X_X4>?J/_/K#_W^
M/^% %^BJ'GZC_P ^L/\ W^/^%'GZC_SZP_\ ?X_X4 7Z*H>?J/\ SZP_]_C_
M (4>?J/_ #ZP_P#?X_X4 7Z*H>?J/_/K#_W^/^%'GZC_ ,^L/_?X_P"% %^B
MJ'GZC_SZP_\ ?X_X4>?J/_/K#_W^/^% 'E/QP_9JT_XW:WI^I7>MW6EO9VYM
MQ';PJX8%BV3GZU;^!7[/=C\#)=:>SUBYU4ZF(0PN(E39Y>_&,=<[S^5>E^?J
M/_/K#_W^/^%'GZC_ ,^L/_?X_P"%>@\PQ+P_U5S]SMIWOZ[G*L-157VW+[W<
MOUSWQ#TFYU_P!XETRR02WE[IES;PH2!N=XF51D\#DBM+S]1_Y]8?^_Q_PH\_
M4?\ GUA_[_'_  KBA)PDI+H=$ES)IGY]:?\ LA_%""]MI'T*(*DBLQ^VP] 1
M_M5^B%NA2"-3P0H!_*JGGZC_ ,^L/_?X_P"%'GZC_P ^L/\ W^/^%>KF&:5L
MRY?;)+EOMY_-]CBPN#IX2_LV]>Y?KX'_ &ZO^2OV/_8*B_\ 0WK[I\_4?^?6
M'_O\?\*^$?VX7E;XN6)G18W_ ++CX5MPQO>O2X:_W]>C.7-O]V^:.W_X)^_Z
M_P :_P"[:_\ M2OL:OC+]@:2X2?QG]GB27Y;7.Y]N/\ 6>U?7WGZC_SZP_\
M?X_X5S<0?\C&I\OR1KEG^Z0^?YLP/B[_ ,DL\7?]@JY_]%M7Y7VG_'Y;_P#7
M1?YBOU#^+4U^?A?XL#VT2K_9=SDB7)'[MO:OR\M/^/N#_KHO\Q7T_"O\"KZK
M\CQ\Z_B0]#]?1T%+6>)]1P/]%A_[_'_"E\_4?^?6'_O\?\*_-SZP^%OV[/\
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M?LT9-C=JR@W<MTP&"Q?=U/3@< 5Z5^U;HU]KOPGDM=.L[F^N#?6[>5:Q-(^
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M+\D?7Y9BJN,PL:U:/*W?\&TGN]_5^K+^D?ZV3Z5J5EZ1_K9/I6I7">J%%%%
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MQ_W^;_&K]% %#^QX?^>EQ_W^;_&C^QX?^>EQ_P!_F_QJ_10!0_L>'_GI<?\
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MV<5E>I<26L\<!)C+ICE<Y('(X)/UJ/0?A%%H7Q#B\5+J;S/'I46F?93" "$
M&_=N[XZ8_&KWPF^&T?PK\+RZ-'?MJ*O=RW7G-%Y9&_'RXR>F.M>)B:F"E0Y*
M27,N6SL[O?FO^!]1@J.9PQ?M,1)N#<[J\;)>[R6MK_-^O0\D\??%'Q?XWT;X
MB6VA:1I;>%]'CEL;J:ZD=;J0[#O:/!V_+UP1_.KOPT^)>HZ&WPF\(PVUJ^GZ
MKH:SS32*WFJR@@!2&QCCN#6YK/[.DEYJGB-M+\7W^BZ-X@8R7^F06Z.)'(YP
MY.5!SR!U'&:GU/\ 9\\[3_!ATOQ+<:/K7AJU^R1:G%:K(9H\#K&QP.^.OWCU
MXKTG7R]TE1323\I:/DM=]WS=KGBK"9Q'$/$M-R5E\4=5[1-J.NB</YK:_CS&
MO_M&:_H^A>/[]-/TV1_#VNC2[9623$D6]UW/\_WL(.1@<]*U_$7Q/^(/A;2+
M&768/!VA75ZY=9-1O91'!'@$(R@[F?)P2O%1-^R[%)X0\2:')XHNKA]:OX[^
M2]GM@TBNNXG/S#<6+$YX^E=9\3O@ZWC_ ,0:+KMEKLFAZKI:ND4OV2.Z0JW7
M*/QGWYK-U<M4XQBE:[N[2_EC;[Y7Z/T-8X?.W2G.;ES65DI1ZSES?-1Y;:J_
M>^WAOQ$^,/B?XA?!RUU2V^P::UIKHL;R6RFE'FN,&)HB#_JSEMP))^[CO7:^
M(M8O++XG_"Y?%%AI<^K"UN)I+VR>?9"HY&P%AGY0,[@><XK;A_9GM$^'>J^%
MIO$%S.][J0U1-0-NH>*48ZKG#=#Z=?:MD?!6>]\0>$M8U?Q)+JUYH44T,C26
MB(+L.>,A3A,#C@'-;SQF!2Y:3M%.=K)W]Z.FO:^FOET.6GEN;2E[2NG*4E2O
M=Q:O&=Y:7WMJFO/6YPLW[07CB[\*:AXYT[P_H[>#;.Z,)AGFD^VR1API<$?(
M.2.W'OC-:]W\:/&/B'QY=:!X0TO1YK<:7#JD5SJK2(51T#88(W).Y0 ,8/4X
MH;]E]EL+K08/&FI6_@VYNC=2:(MO&223DJ)NH' [=L]:[71?A'::%\0K_P 3
M6MX4BN=-CTU+ 1?+"B  $-G)X &,?C6%2MEL4W3BF[.VDO[MD[[O?78ZJ&&S
MR;C&K.25X\SO"_VN9QMM%^[9/7R1/\&?B#/\3O -EKMU:1V5T[R0RQ1$E-Z,
M5)7/.#CH<UYYJ'QN\;:ROBK5O"NB:/)X;\.SM;S2:E))Y]RR %_+VD*, @\^
MHZUZ9\*OAXGPO\(1:%'?-J*I-+-Y[1>63O8MC&3TSZUPNK?LY3R7NOIHGC*_
MT'0]=E\Z_P!+BMDE#L?O;'8Y3/L/8YKEHSP"Q-5NW+?W;IM6OKHM;VVN=^)I
MYM+!8=1O[1+W^5Q3YN735Z6YM[?*^QYUXX\0Z[\4/B%\,-1TVST1[34K2:XL
M+/51*Z*X0"83[>N&!VE?3FO:?CG\0K[X4?#XZSI-I:W%PEQ#;I#<JWE[6..B
MD'H..:$^"VGV?B#P1?V%V]I:^%K>2VAM#&&\X.H&6;(P>,G@Y)K2^+7PVC^*
MOA%M"DOVTU3<1S^>L7F'Y#G&,CK]:NIBL)5K8>+7[N&ZL]N9[]]+;&5' 9A0
MPV,FG^_J6Y7=;J$5==O>NE?HD>9^+_CUXJ\#Z=H=KJ]CX?LM>UN0RV[2SRBT
MM+7:N&F/4ODD?+QQ5*Q_:>U>Z\!^)+^/2=/U#6=%O(;9Y[!Y'L7CE+;9A_'M
M&QLCZ=*]&^(WP9MO'B:#<P:I-H^M:+Q:ZA%"LO& "&C;AAP#^?K56V^$&MV_
MA^\MAX\U#^U[FY2X.H)9PI$H4$",0 ;-IR20>O'I6L*V6NC%R@N:^OQ?S>2>
MG+IO?R9SU<-G<<1-0J2=.VC]Q_9\VO>YM=K6TND<9J_[0?B/1?AU:Z]]G\/:
MO=RZI'9AM+GD>"6-E!. 2&1\Y'S?7%:VF_&SQ'X;\9:AH7CO2=.M"FE2ZM!)
MI,COA(T+NC;CRVU3R,#(]ZX3XI_ BY\(?#V.ST^>_P#$.H:GKL5W>W%M:A"N
M<@LL<8(0#)/I7J.@? 98?$.H:SXF\1W?BR]N=/?2XVN8$A\J!UVL/EZL5XW<
M=3ZUT55EL://9-/FM9.^EK6Z)+7>U^W0Y*#SN>)5.[3BH7NXN*OS7OU;>EN6
M]GN^KY%OCSXYTS0=$\8:IH.C)X0U6[2!(H)I3>Q(Y(5F).T]#T'Y4[4OCEXZ
MN];\=P:#I&AS:?X7</)<WK2JS1$,0NT-RYVL<\ 8]ZU;']FF58-*TG4O&FHZ
MGX4TNY%S;:,]M&@!!)4-(.6 ST([G&,UT=C\%(+*X^(4@U5ROB[;N40 ?9<"
M0<?-\W^L]NE9RK99&[C%-]-)6MS+OU4;WZ>IO3PV>324IRBNOO0O?DE>UM.5
MSY;+=:['$>)/VCM9BT7P7>:9I^EZ:FO6C3S7VMM+]EA=3M,8:/GD@X)[$5/X
MV_:(U+0[SP_I%H/#]AJM[8+>W=YJMT[6,61PJ-'RV2#@UJWO[/E_)X,TKPW9
M>-;JRL+6R:RN(FL8YHKA2Q8L$8G8WS8W YX%.O?V;K6VB\/3>'_$%UHFJZ/:
M?8EO9+:.Z$\9.3OC?Y>I/^11&>5)JZ6\OYO/E;T]-%?\T*=+/VI6;U4.L-].
M91U]=6X]M=&NB^"_Q/E^*O@^;49+>"VO[:XDM)A Q:!G7&&0GDJ00:\0\"ZU
MK/ASXF?%7Q3K5GHMY'HTJ/J#(LAF4XD$:VQ/W02H#%O08KZ.\!^$I_!VB&SN
MM7N-;N7E:62[N(UCR3V5%&% ]*YG3O@E86]]\0)+R^DO+7Q>Z-- (PAMPN_A
M6R=WW\YP.E<M'%86E/$)*T)62WVYE>STZ7WMT._$8#'XBG@Y2=ZE/F;;LM>2
M2BVKM/WK)VONSBX/C=XXT1?"6L^)=$T:#PUXCGBBA%E)*;JW63!1GW':>"#@
M#\C6QX)^)_CGQO\ $#7=-M-*T:/P_HNJO9W-W(T@F:,,0 @W$%\#))X]J;HW
M[.MQ!=>'XM;\97^O:'H,JRZ?I<MM'&J%?N!W&2X&!P?3' XKM?A_\.4\!ZEX
MHNTOVO#KFHOJ!1HMGDEOX <G=]>*O$5L!&$O913E;2RE;?SZJ._3U,\'ALWE
M5I^WE*-.]W=Q<M(ZZJ_NN6R6MNQV5%%%?-'VY?TC_6R?2M2LO2/];)]*U* "
MBBB@ JE9_P#'_?\ ^\G_ * *NU2L_P#C_O\ _>3_ - % %VBBB@""_:1;&X,
M(S,(V*#&<MCCCO7@7P+\*K?^(?MWB'0M176+>'[1YFIZ!96D$,^[EH9(D#EO
MF;&X]"2>:][U,*=-NP\I@3RGS*.J#!Y_"OF_]F/P?I6E>.]3U?1TOS8W&F>6
MEU<Z--:I<DO&6D\V0D/DKD #HS$]!0!],U3U76+#0K-KO4KVWT^U4@&>ZE6-
M 3T&YB!5RFO&LJ[74.OHPR* /)=4^,TUAJ^NR$!--L!<16RM:/LNYHH#*5$^
M=H)P<#'(4\YKJO ?B#6;_4=5TO73:2WMG';W"S6:,B%)E8A<$GE2C#/?BH[[
MX2Z+J>LW5]=/=307#22&P:7_ $=99(C$\@7'WBA(Z]R:U/"/@JU\(+=M%=75
M_<W13S;J\DWR,J+M1<X'"C^9H Z"218HV=B0JC)P,U1_MVS_ .>C_P#?E_\
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M,Q7D[D9?YBOG/]@__DENK?\ 83?_ - 6OI6O*SG_ )&%;U.W ?[K#T"J4_\
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M_-WMW/:-!\9:-XFU#5K'3+T75UI,_P!FO8PC+Y,G/RY( /0],CBH]6\?^%]
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MKZ5KYA_87-W_ ,*PU7[.("O]IOGS"<_<7TKZ6M3=9;[0(0.WE$G\\UY6<_\
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M /&];^%7B#Q%)>Z5,;"UT22ZN]22Z6=GG,T]N\8B*;  JM(S;MQR !@9KL/
M&@:W9ZAJVK:_%9VM[>QV]NMM8S-,BI"K ,795Y8NQQC@8&37:44 -D02(RDD
M C&5.#5/^R(_^>US_P!_FJ]10!1_LB/_ )[7/_?YJ/[(C_Y[7/\ W^:KU% %
M'^R(_P#GM<_]_FH_LB/_ )[7/_?YJO44 4?[(C_Y[7/_ '^:C^R(_P#GM<_]
M_FJ]10!1_LB/_GM<_P#?YJ/[(C_Y[7/_ '^:KU% %'^R(_\ GM<_]_FH_LB/
M_GM<_P#?YJO44 4?[(C_ .>US_W^:C^R(_\ GM<_]_FJ]10!1_LB/_GM<_\
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MKNK_ -6/=:*\9\4?%#QGX3N=$\,/9Z)JWC?6)G:$6@FCLX;< ?.X9MV<ANA
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MIEGNYFED8*-JJ6/.%' % &W+(L,;.YPJC).,U2_MZQ_Y[-_W[;_"M"B@#/\
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MW_?MO\*/[>L?^>S?]^V_PK0I"0H))P!U)H H?V]8_P#/9O\ OVW^%']O6/\
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M"?M!Z!X[\1W>A)I/B#0M3M[07K0:YICVK-$7V!E!))&X$9QC@^E.\??'_0/
M&NV&CRZ7K^N:C>V[W,=OH>FO=.(T8*S%000,L.<8YK*M/^3O=3_[$>V_]+YJ
M->_Y.P\)?]BKJ'_I1!5>RI>TVTY;VOY7W(]O7]B_>7-S\M[=.:VQ7_X:DTS_
M *)_\1?_  F9O\:CE_:Q\/V4EO\ VAX1\<:3;SSQVXNM0T"2"%7=@B[G8X&2
M0*]L#J6*[AD=1GI7CW[5+J_PJMV4AE.NZ5@@Y'_'[%4T?85:D:?):[MO_P
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M$F@L;A1#8R!)9E9XLMD@C:,#\6%6OA]X<T_P^^MBRUN]UJ::[S=F\F5S',%
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M@<DTM1W.S[/+YO\ J]IW?3'- 'E5FO@+PEXMOTNQX?TZW\1)"+#?*-][DDR
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MIYJ^<['(RNT,0&RI*C@XKI/"6LZ!XCTY]5\.W5G?6=U(6>YLB"LC@!221W
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M("%5+X.=PZD<<UL^!OC%I'CG5-2TQ+#5=$U'3T62>UUFV%NZJW0XW']<5O/
MXF$7.4'9;_A_FOO.6GFN"JSC3A53E+9??_D]/)G=T4V.5)D#QNKH>C*<@TZN
M$]4OZ1_K9/I6I67I'^MD^E:E !1110 52L_^/^__ -Y/_0!5VJ5G_P ?]_\
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M! MY21D!3D>O%?/7_"3^"[[P+I5_X@\+V]AK=C96[V>ESS,1=P?*8EBD _?
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M+PO('(9XV(!96(R#CO755RWPROM5U'P7I\VLZ5%HM^5(>QA&$BP3@ =A74T
M%4I_^0M:_P#7.3_V6KM4I_\ D+6O_7.3_P!EH NT444 %(>E+2'I0!SM%%%
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M%_2/];)]*U*R](_ULGTK4K(W"BBB@ JE9_\ '_?_ .\G_H J[5*S_P"/^_\
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MY?+_ -7CCC9_#Z=L4 >#:C^T=JUKX&BUQ9M$-[J%S*MGIL>Z2:%(Q*S),-P
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MQ3418D5$4(BC 51@ >@IU !1110 4444 %%%% !1110 4444 %%%% !1110
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M:$RQ9P'4X8<^AK4JI1<7RR5F1"<:D5*#NGU10_M9?^?6[_[\&C^UE_Y];O\
M[\&HI_$^EVWB&VT*6]C35[F%KB&T.=[QJ<%A["A_$VEQ^(H]":]C&KR0&Y6T
MYWF('!;Z9I^SGV>U_EW]"?:T_P"9;VWZ]O7R)?[67_GUN_\ OP:/[67_ )];
MO_OP:OT5!J4/[67_ )];O_OP:/[67_GUN_\ OP:OU6U#4K32;5KF^NH+*V4@
M--<2"-!DX&23BFDV[(3:BKLA_M9?^?6[_P"_!H_M9?\ GUN_^_!J_12&4/[6
M7_GUN_\ OP:/[67_ )];O_OP:OT4 4/[67_GUN_^_!H_M9?^?6[_ ._!J_5:
M+4;2>]FLX[J&2[@56EMUD!DC#?=++U /;-.S8FTMR'^UE_Y];O\ [\&C^UE_
MY];O_OP:BD\3Z7#XCBT%[V-=8EMS=):'.]H@2"_IC((_"M2FXN-KK<F,XSOR
MN]M/F4/[67_GUN_^_!H_M9?^?6[_ ._!J_14EE#^UE_Y];O_ +\&C^UE_P"?
M6[_[\&K]% %#^UE_Y];O_OP:/[67_GUN_P#OP:OT4 4/[67_ )];O_OP:/[6
M7_GUN_\ OP:CN/$NEVFOVFB37L<>K7<3SP6ISOD1/O,/8477B;2[+7;+19[V
M.+5+V-Y;>U;.Z1$QN(^F15\D^S[_ "[F3JTU>\EH[;]>WKJM/,D_M9?^?6[_
M ._!H_M9?^?6[_[\&K]9^O:_I_AC2YM2U6Z2RL8<>9/)G:N2 .GN14I.322N
MRY2C"+E)V2%_M9?^?6[_ ._!H_M9?^?6[_[\&I++5['4I9HK2\@N98-OFQQ2
M!FCW#*[@.5R.1FK=#36C&I*2NF4/[67_ )];O_OP:/[67_GUN_\ OP:OT4AE
M#^UE_P"?6[_[\&C^UE_Y];O_ +\&K]9MSXDTRSURTT::\C35+N-Y8+4YWNBX
MW-]!D52BY;(F4HP5Y.W_  1_]K+_ ,^MW_WX-']K+_SZW?\ WX-7Z*DHH?VL
MO_/K=_\ ?@T?VLO_ #ZW?_?@U?K*\2>*-*\(:;_:&LWL>GV6]8O.ESMW,<*.
M/4U48N;48J[9$YQIQ<YNR75DW]K+_P ^MW_WX-']K+_SZW?_ 'X-7Z*DLH?V
MLO\ SZW?_?@T?VLO_/K=_P#?@U?HH H?VLO_ #ZW?_?@T?VLO_/K=_\ ?@U)
MJ6JV6C6WVC4+RWL;?<%\VYE6-,GH,D@9I+[6+#3(8I;R]MK2*5@D;SRJBNQZ
M $GDGTJE&3V1#G%7N]AG]K+_ ,^MW_WX-']K+_SZW?\ WX-7Z*DLH?VLO_/K
M=_\ ?@T?VLO_ #ZW?_?@U?JM'J5G-?2V4=U ]["H>2W60&1%/0E<Y /J::3>
MPFTMR'^UE_Y];O\ [\&C^UE_Y];O_OP:OT4AE#^UE_Y];O\ [\&C^UE_Y];O
M_OP:OT4 4/[67_GUN_\ OP:/[67_ )];O_OP:LW=Y!I]M)<W4\=M;QC<\LSA
M$0>I)X I&OK=;$WGG(;01^=YRME2F,[@1U&.<T[,GF2=KE?^UE_Y];O_ +\&
MC^UE_P"?6[_[\&DT'7M/\3Z1:ZII5TE[I]RN^&XCSM<9QD9]P:T*&G%M-6:"
M,HSBI1=TRA_:R_\ /K=_]^#1_:R_\^MW_P!^#5^LQ/$NER>(9="6]C.KQ0+<
MO:<[UB)(#?3(--1<KV6PI3C&W,[7T)/[67_GUN_^_!H_M9?^?6[_ ._!J_14
MEE#^UE_Y];O_ +\&C^UE_P"?6[_[\&K]% %#^UE_Y];O_OP:/[67_GUN_P#O
MP:OT4 4/[67_ )];O_OP:/[67_GUN_\ OP:OT4 4/[67_GUN_P#OP:/[67_G
MUN_^_!J_6;X@\2:9X5TTW^K7D=C9B1(C-+G&YV"J./4D"JC%R:C%7;)E*,(N
M4W9+J/\ [67_ )];O_OP:/[67_GUN_\ OP:O*P=0P.01D&H;V^MM-M9+J\N(
MK6VB&YYIW"(@]23P*23;LAMI*[*_]K+_ ,^MW_WX-']K+_SZW?\ WX-7(I4G
MB22-UDC<!E=3D,#T(-/I#*']K+_SZW?_ 'X-1QSF[U.!U@FC1(W!:6,J.<8_
ME6D2%!)Z#FL[P[XDTSQ9I,.IZ1>1W]A,6"3Q'@D$@CGD$$'K5<K:YK:$N<5)
M0;U?3TW_ #1I4445)04AZ4M(>E '.T5/]BG_ .>;4?8I_P#GFU $%%3_ &*?
M_GFU'V*?_GFU $%%3_8I_P#GFU'V*?\ YYM0!!14_P!BG_YYM1]BG_YYM0!!
M14_V*?\ YYM1]BG_ .>;4 045/\ 8I_^>;4?8I_^>;4 045/]BG_ .>;4?8I
M_P#GFU $%%3_ &*?_GFU'V*?_GFU $%%3_8I_P#GFU'V*?\ YYM0!!14_P!B
MG_YYM1]BG_YYM0!!14_V*?\ YYM1]BG_ .>;4 045/\ 8I_^>;4?8I_^>;4
M045/]BG_ .>;4?8I_P#GFU $%%3_ &*?_GFU'V*?_GFU $%%3_8I_P#GFU'V
M*?\ YYM0!!14_P!BG_YYM1]BG_YYM0!!14_V*?\ YYM1]BG_ .>;4 045/\
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MY>&!+?)]WGITK"\7?%GQOX5^'7@N^NO&3_VMXC$]XLD5E9Q+'&D47[O=+A
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M.BLFHZZG@#?&O7E^.6C:=-K]O'X>O?LD:Z3;QPO*'EMED(E!_>CYG!#+E<$
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M?^B::;_X4B?_ !FCZE4_FC_X'#_,/[3H_P L_P#P74_^1/4J*\M_X37XJ_\
M1---_P#"D3_XS1_PFOQ5_P"B::;_ .%(G_QFCZE4_FC_ .!P_P P_M.C_+/_
M ,%U/_D3U*BO+?\ A-?BK_T333?_  I$_P#C-'_":_%7_HFFF_\ A2)_\9H^
MI5/YH_\ @</\P_M.C_+/_P %U/\ Y$]2HKRW_A-?BK_T333?_"D3_P",T?\
M":_%7_HFFF_^%(G_ ,9H^I5/YH_^!P_S#^TZ/\L__!=3_P"1/4J*\M_X37XJ
M_P#1---_\*1/_C-'_":_%7_HFFF_^%(G_P 9H^I5/YH_^!P_S#^TZ/\ +/\
M\%U/_D3U*BO+?^$U^*O_ $333?\ PI$_^,T?\)K\5?\ HFFF_P#A2)_\9H^I
M5/YH_P#@</\ ,/[3H_RS_P#!=3_Y$]2HKR:#XK>,=,\5^'=*\2^"+71[76KI
MK2*ZM]96Y*N(V?E!&.,*>]>LUA6H3H6Y[:ZJS3\NC9U8;%TL5S>SO[KL[IQ:
MTOM))[,***\8\?V_C30U\9ZN^L7J:)]C/V..&>,/&RE<'"H&7.]\;2&_=C<6
MR,<YV'L]%>*_\)NG@C6S=M_;T>FC2)+B2SU>:24W,JN@7R3(S%3\_/(&"..*
MV/$WQ?U7P<\=IJGAV#^U)_LS6\%K?EXY%EF6)@7,8PREAQC!SUH ]2HKS9?B
MY<6&NQ:;J^DPV@74?[.NKFWNS+'"S0F6%AF-20Q!3D#!QUS4OB+Q?>:O\%]5
M\06Z2:7/)9R36YAE)=5R=CA@!@D8/MF@#T2BO&Y-1U+0_L>LZ1:^(?LME9SW
M>I)K-W*T$R+"6"KYK/ABP&"HX&:W=-^)&OZS]EM[3P_9-J$VG)JC0R:BRI'$
MX&Q"WD_ZPG(P!M&/O4 >CT5Y.OQON=6\,:IX@T/0DO=.TN!9+H75YY,H<KN9
M$4(P.T$9)([XS4DGQGO(K*_O6T2!;6'4O[*@_P!+=I)9B%()58CM3#')R3\I
MX- 'JE%>3W'QMN[6TD>;0?L_DW'E37L[S)9*FS>)/,\G?CL<H,'OWJQJ7QCG
MT^33%;3;&*.Z@BD:XGU(+;O(S$-'%,J-&Y 5C\S)GC\ #U"BO,-(^)MQJ.N7
M.B:+I(N]3-S=NWVS4'\E882BF3>58C<TB (HP,DY%5H/C5J&J7,L.F>'H97M
MM*?4[K[3?>7L*321/&N(VW',9(/ .>U 'K%%4=$U6/7-&L=1B4I%=P).JMU
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MS6KE#AMC*5.#CK@^E8-[\-K&=+$V>H:CI-S:V(TX7=C(BRR08 "MN1AD8R&
M# DX(S7744 >->*/A#?S6VH:'X?@;2=%O88+=V@O@(W"8!>6-D+E@!U1UWX
M;/-=LOPOTA=&N]/\RY N+T:B+A) )8;@;</&<<8VC@Y[@Y!KKZ* .3;P [YE
M/B?Q!]M:7S&N3=(01M"[/),?DA<#.!&.><Y.:H2?"#3#HB:/#JNL6VE&W-O<
M6D=TK)=*S,SE]ZL59R[[C'L)W8Z 8[NB@#AHOA!H]C+'<:;=ZAI5]'/-+'>6
MLJ>8JRJ \7S(RLAVJ<,"05!!!JQIGPJT32))GMC<J9M,.E2;I0VZ,N[LY)&2
MY:1B3^E=C10!3T;2X=#TFRTZW+F"TA2",R'+%5  R?7 JY110 4444 %%%%
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M/_P>W7_Q=>IT4?7\5_S\?WA_9. _Y\Q^Y'EG_#./A;_G^\1_^#VZ_P#BZ/\
MAG'PM_S_ 'B/_P 'MU_\77J=%'U_%?\ /Q_>']DX#_GS'[D><:'\ _"V@Z]I
M^L1/JUW>V$AEMS?:I/<)&Y4KN"NQ&<$BO1Z**YJM:I7:=63;7<[:&&H86+C0
M@HIZZ*P4445B=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>btai-20231231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (W \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3P].55\JF^1+2+V>K6_1;GV-2;AZBO';7QO\3&^!TVIR^$9!X[3,"67R /R
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MA4M4NHNRU:Z+7\=C[@!!Z'-!('6OD7X2_%3X@^#?CTWP]\8ZS_PD,,SF+SI
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M2,W3YAC&, D5\>_M!?\ !/7QK\&[]_%7PTN[[Q%HUHYN$2V8IJMACG<-F/,
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MO)Z6L=N,R'Z[BZ]:I.T*E/DTW3O>Y\S?#+]K?P3H7PAL;/5+B:VUO3+1;7[
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MP?8@FOQ$^-?@[0?A+\5;D?#'QC=:[86$OF6^I6ZM!-:2 GY%E4CS-O\ ST7
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M=9 FX[5&X9&>#TS71>-/AQHOCN2PGU!+F"_T]F:TU#3[J2UN8-P <+)&0=K
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M&2,-M!QVZ5S^M? _0;N^U75=.26QUFZ%Q/;L\\LEI;WLL31-="VW;/,(;E@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#?1_PKY2S1FC^R:7\S_ /]>\=_SZA^/^9]6_\ "U/"7_0>L_\ OH_X4?\
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MC^R:7\S_  #_ %[QW_/J'X_YGU;_ ,+4\)?]!ZS_ .^C_A1_PM3PE_T'K/\
M[Z/^%?*6:,T?V32_F?X!_KWCO^?4/Q_S/JW_ (6IX2_Z#UG_ -]'_"C_ (6I
MX2_Z#UG_ -]'_"OE+-&:/[)I?S/\ _U[QW_/J'X_YGU;_P +4\)?]!ZS_P"^
MC_A1_P +4\)?]!ZS_P"^C_A7REFC-']DTOYG^ ?Z]X[_ )]0_'_,^K?^%J>$
MO^@]9_\ ?1_PH_X6IX2_Z#UG_P!]'_"OE+-&:/[)I?S/\ _U[QW_ #ZA^/\
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M('F3V[HN3T&2*SZ](U6*35+C2]/N/'1\26UW>10RVL)8%5)^_P DCC^M:/\
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M:S;^+'T/V+@3_<JO^+]$0Q?Z^;\*FJ&+_7S?A4U>$?I@4444 %%%% !1110
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M@&.O?BJ?+9V%J=[1116)04444 %%%% !1110!#!_K9_]\?\ H(J:H8/];/\
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MVT+[(NR&\%YY_F')/]W;C]<ULS?%>>XUW4KV;3(9;+4;=;>YL'E;:P4$ AP
M0>3VKAA&[*S*C,J]6"D@?4]J#%($#F-PAZ.5.#^/2M'0I/=?T_\ ACBAF6,@
MDHSVMT6T4TNFJLVO.^MSL;;XCK8Z_IM_9Z):6EM81M'':Q.<MD8+/)C+'ZBJ
M5GXWDM-$\0Z<+-'76)"[2>808LDG &.>OM7."WF*[O)EVXSNV'&/7.*&AD5
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MG4I4G>6C-</A<9C8J-)-J]MTE>U^K6R7]71!X:^+NO:#.#/=3:E;K$8DMY9
MBIQ@$$+VJ?2_BJEKI%W97^APZLUY*9;F:>Y*M,>VX!>@'%8%UX1DT_2]1O+R
MX$/V6Y^RQ(J9\]P><'/  YJ.#PP;OPG<:U!<;S;3"*>W*X**>C YY_*L'2PT
MM;;M;76O38]*&,S>E:GSMVC)V=I:;/25^WK:]M&5=?U*TU743<66F0Z1 5"B
MV@<LH(ZG) ZUG445VI**LCYVI.56;G+=^27X+1?(Z;X9_P#(^Z)_U\"OK*OD
MWX9_\C[HG_7P*^LJ^8S;^+'T/VC@3_<JO^+]$0Q?Z^;\*FJ&+_7S?A4U>$?I
M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11535KI[+2[RXC&Z
M2*%W4'N0"10!;HKS*+5=?FLIS!?R2QVXCN))G9%8!D#%<[<$ YXZ\CFNE\$^
M(CK44RSR2M=Y,I5X]JJI. %]0,8YJG&PKG44445(PI*P/&+ZB+2U73A,2TP\
M[[/*D;[ I)P7XZXKDK[Q'JT!M[V"[G_LV]B58 ^QI!]T$[<?>!R,YP=R\52C
M<5STVBJ6D:C%JNG0W,)<HZ_\M%VMGOD>M7:D844C9VG;C..,UYS+KNLN]W9S
MWY1VU%X/M%M&J>4@B+A5SGN.IR>M-*XCT>BO+Y_$>O6]O:7TUR4@OH$5%CVD
MJ2%RP3&=P.>2<?,M>AZ/J,6JZ=#<0L[(PQ^\7:P(X((]<TVK!<NT45D^*I;Z
MWT"^ET^:.WN8XG<2R)OV@*3P,CGCOQ4[C-:BO.SK6K+<V-S<RW2V<L$$4<L3
MQ^69W4\R)]XC) XQ3=*\2ZCIFL1V>L7,Q2-R&V!9,LVT .P  4%AT_O@=C5\
MK%<]&HHZT5 PI*Y;Q-<7D&KV@T^]N'N=P=[-54Q+",[V?C//0<]>G0US=KJN
MOW^G2_9]1=F^S07TDDC(GEAU?<%.W 4$*<'G (S5*-Q7/3J*Y+P5XG;6)9XK
MJ24W;DR+&T>V-4&!A3W(XSGN:ZVDU884F:&&0<'!]:\^N;C6YGO$TF[O=1M3
M+#$)V:)&+AF,OE,0!MV@#H><XZ&A*X'H)P>M+7F-YXEU6"UM]1M[N9-/EB,"
MBX*.Z. 0Y90/F92I;<#M(&.]=]H6I1:IIL<L1E.W,;B==KAE.&##UR*;BT*Y
MH4452U>*2>PD2*XDMI#]UH657)_N@L" 3TS4C+A /7FEKRZP\4:O+Y+27LK2
MV9@CDB"IB5GN7B<.<?,0%'*X&1GO5BS\2ZIH>K)::U=2ND;F65H0LAY4#!P!
MM0$E\=0"@R:OD8KGI-%("",CI2U PI,UR_C6[N]+C@O[>\FBC@EB$T:E/+5&
MD 9F4C<V1P #QUK CO\ 7;C[7:-+>6^J2AKM$>XA\LVXE(Q&P!"$ KRV<C/?
MI2C<5STBBN,\$^*I-6N98;V:22YD4&,"/;$515R5/7+;PY]G4=C79TFK#"BB
MO,+[QW=7_B*\MK345BM9%MX(DCV^9'NNA%)(<C@X)P#T&#CFFDV(]/HKS*77
MM?M+"VU+[5YEM"\UJ/,91YK)+*@+*%RQ("'(Q@(Y(YKMO"VJ1ZII$3)---)%
MB*5[A DA< ') X&00W'8BAQL%S7HHK/UW5X]#TN:\EQA,!03@%B<*">PR1D]
MAS4C+]+7E=AXIU.?2;'4KJ\N+RPMEN#>W&GR1(-XN-JY4\E0G0#J#W-6Y/$>
MK:!K1M]6NI6A$IN7\@+(?+ D.  !M4@;L') C;GD5?(Q7/2:*:C!T5E.5(R#
M3J@845R/C6_OK"ZMIT^UII=M#)/=O9RQJV 5QPW) &XX'7UK&@UC6M4N)5L[
MV1WO%NBL1V*(UBG10$)7Y24)Y;/)![52C=7%<]'HKB/!OBB>]U VNH7$DLQ4
M0Q%$'E,5#$MN'5FPWMA,CK7;TFK#(8/];/\ [X_]!%35#!_K9_\ ?'_H(J:D
M!\3T445^BG\CA1110 4444 %%%% !1110!8TZPEU34+:S@4M-/(L2 #/).*]
M\N=:\,Z!XQTBQ?5[B&;3+<6 M%M]T+;P,[GQU/RG\*^?8II+>59(I'BD4Y5T
M8JRGU!'2EDGDFE:621Y)6.XR.Q+$^I)YKDKX?V[5W9)/\3W\MS7^S(2]G34I
M.47=WM:.MM&NMGVTV/9M-T"?PM'X[M-'1_[=C*O9^4,R_9V.<IW[D<=P/:K6
MLZ_J?AGP_P"!]0U4.EXEPPNE889D8$'=_M;3D]\UXK_:E[]I%S]MN?M &T3>
M>^\#TW9SBF3WUS=($GN9ID#%@LLK, 3U.">OO7/]3<I)S:??37:WW=3U%G\*
M5-PP\''2T5?W5[_.G:V_2_8]@\:V=AX&TI=+BD0QZ[J0N9F4\"U# [3[<_J:
MZ;Q"4AFUR.:WU.YT;[" L3I"E@BXX:-RP);Z<_I7SQ/=SW6SSYY9MB[4\URV
MT>@R>![4]]1NY;9;9[NX>W7I"TK%!]%SBD\$VE>6O7\/\BUQ%",JG)2M%I<J
M3V24KIZ:IN3;/4_%FMZAIO@OP+:VMRT4-S;XGC+[$F VC:Y_N\G/;FNSUM)-
M:T_6H)8[[2G-GN>*^B$VGJ O'E./E!^ASQG%?.TUW/<1QQRSRRQQC")(Y8(/
M0 GC\*D?4[V6V%N]Y<O;@8$+3,4_[YSBG+!72L[--].[N*GQ%RRJ<\&XRC%6
MOMRQY>UU??1^J>Y[YH@2WTOPH-*35);$VQ:6*PCB-K*V!O$[.1@]:\1U+[/_
M ,)9<_9(_*MOMA\M 00HW= 02"/H:H0ZC=V\#PQ7=Q%"_P!Z..5E5OJ <&JX
M)4@@X(Z$=JVHX=TI2=[W_K4\W,<VCCJ=."AR\MNMULE9::+2_P#5W]!>/(-4
MDUYC:^ ['7HO)3_39T!8GG*\GM_6N<\$Z:/%^F:CX7U.,6%QI]Z+V.$_\LD+
M9>,<] #C\:\O_P"$@U7_ *"E_P#^!4G_ ,55>._NH9WGCNITG?(:596#M]3G
M)K&.$E&GR75]+/7I\STJV?4:N*]NZ;<7?FBW&S3Z744][/5O8]MT#7+;Q)KW
MC"\A>X^V00B"Q^PJKSK"N03$&.,D_P ZMVDBGQMX4,T%XNHBUFWS7PC6>5-O
M!D5"2#]?>O!(+B6UE$L$LD,@Z/&Y5A^(YJ3^T;O[4;G[7<?:3_RV\UM__?6<
MTI8'5\KTM;\+#I\26C'VE.\E+F>NC]_FVMOTOV^X]837[_6O GC.:[G>1[.[
M#6W;R"&.-G]W&*WM4O=7?Q7X2N%AFU"Q-DKF.24)&\Q3J&;Y3)R2!UKP9;RX
M2*6);B98I3F1!(P5S_M#.#^-/;4;MX8XFN[AHHSE(S*Q5#Z@9P/PIO!J^ENO
M3NDB(<0M12FI-I1UONXS<NJ?1VUOL>P?$VV-]X&DNVGOXE@NN+?6H,3[B>5C
M?NOTR,=Z\7JQ=ZC=W^W[5=W%SM^[Y\K/CZ9)Q5>NK#TG1ARMW/$S3'1S"NJT
M8\NB6][VZ^7H%%%%=)XX4444 %%%% !1110 5N>$/^0A=?\ 7G-_Z :PZW/"
M'_(0NO\ KSF_] -9U?@9VX+_ 'B'J80Z"EI!T%+6AQ'1?#O/_";Z+C_GY7I7
MJL6K7>LZ]X\TZ\E,]A!;GRK9E&Q",<@>OO7A44KP2+)$[1R*<JZ,5(/L14JZ
MA=I)+(MU.KRC$C"5@7'^T<\_C7%6PWM9<U^GZW/H\NS?ZC15'E;7,V];73BX
MV?WW.K^$ C/CO3_,QN <IG^]MXIND>+=;T37[^SL!%-+=WA_=W,/F8DW$*PR
M>"/6N;T759M#U6UO[<XEMY X]\=JN:OX@-SXEN-7TT2Z<\DAE4;P61CUP:J=
M+FJ-M737XIF-#&JCA:<83<91FWINU)).WI:WS/39- TSQ*TMK>/=7,&F3):G
M[(X7?<2G,DI.#G!XQ65X6T]=)T+X@61D$L,$117/0D'C\:\_TWQ%JFC2326.
MH7%H\W^M:)\%_K5^#Q3]F\*7FDQQ/]HO9Q+<W+L#N4=%'?KU-8/#U$N5.ZNO
MSNV>I'-<+.:JN'+-*=WWO%J*_%+7:WF<^.@I:**](^..F^&?_(^Z)_U\"OK*
MODWX9_\ (^Z)_P!? KZRKY?-OXL?0_;.!/\ <JO^+]$0Q?Z^;\*FJ&+_ %\W
MX5-7A'Z8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 8$$9![
M&EHH H0:!IMK:O;0V-O';N_F-$L8"LV<Y(^M2VFEV=C//-;VT4,LYW2.B %S
M[U3\4:R/#VC3Z@T;3+!AC&C8+=L9K@/^%]6O_0'N/^_R?X5239YF*S+"8*2A
MB)\K>NS_ $1ZK17E7_"^;7_H#W'_ '^3_"C_ (7S:_\ 0'N/^_R?X4<K.+^W
M\M_Y^_@_\CTK4=*L]7@$-[;1740.X+*H8 ^HIDNB:?-&$DLH'01^2%,8P$_N
M_3VKSC_A?-K_ - >X_[_ "?X4T?'BV#L?[(N,'MYZ_X4^60?V_EO_/W\'_D>
MHVEI#8V\<%O$D$,8VK'&N%4>PJ:O*O\ A?-K_P! >X_[_)_A1_POFU_Z ]Q_
MW^3_  I<K#^W\M_Y^_@_\CU6J%SH.G7D,\4]C;RQSOYDJO&"';^\?4^]><_\
M+YM?^@/<?]_D_P *0_'FU_Z ]Q_W^3_"GRR#^W\M_P"?OX/_ "/2IM'L;D 2
MVD,@$9A 9 <(?X?I4UI:0V-O'!;Q)##&-JQH,!1["O+H_CQ;(@!TBX) Z^>O
M^%._X7S:_P#0'N/^_P G^%'+(/[?RW_G[^#_ ,CU6F30I<1/%*BR1NI5D89#
M \$&O+?^%\VO_0'N/^_R?X4?\+YM?^@/<?\ ?Y/\*7*P_M_+?^?OX/\ R/1/
M^$=TP7<-T+"W%Q"H6.3RQN0#H!]*=+H.G321O)8V[O'*9U9HP2'/5A[^]>;R
M?'>V9<#2+@<@Y$Z_X4[_ (7S:_\ 0'N/^_R?X4^60?V_EO\ S]_!_P"1ZK17
ME7_"^;7_ * ]Q_W^3_"C_A?-K_T![C_O\G^%+E8?V_EO_/W\'_D>AS^'-,NM
M0%]+8P/>#;^_*?/\O3GVIT'A_3;:"XABL+>.*X.946, .?<=Z\Z_X7S:_P#0
M'N/^_P G^%-_X7O;>86_LBXQC&//7_"G:0?V_EO_ #]_!_Y'IEOI5G:W<UU#
M:Q17$P DE5 &8#IDU;KRK_A?-K_T![C_ +_)_A1_POFU_P"@/<?]_D_PI<K#
M^W\M_P"?OX/_ "/5&4.I5AD$8(-8T?@S0XH7A32K58FQE!&,<=,#M^%<)_PO
MFU_Z ]Q_W^3_  H_X7S:_P#0'N/^_P G^%/ED']OY;_S]_!_Y'I T6P$44?V
M.#RXHVB1/+&%0XRH'8' J:RL;?3;9+>UA2W@086.-< 5Y?'\=[9$ .D7!/J9
MU_PIW_"^;7_H#W'_ '^3_"CED']OY;_S]_!_Y'JM5[[3[;4[9K>[@CN(&QF.
M1=P..17F7_"^;7_H#W'_ '^3_"C_ (7S:_\ 0'N/^_R?X4N5A_;^6_\ /W\'
M_D>AIX<TN-[1TT^V5[08@(B ,8_V?2GW&@Z;=G,UC;RGSA/EXP?WF -WUP ,
M^U>;R?'BV="!I%P#ZB=?\*=_POFU_P"@/<?]_D_PIVD']OY;_P _?P?^1ZK1
M7E7_  OFU_Z ]Q_W^3_"C_A?-K_T![C_ +_)_A2Y6']OY;_S]_!_Y'H]WHEA
M?W<-S<V<$]Q#_JY9$!9><C!^O/UIEOX=TRT^U>386\7VH$3;(P/,!SD'VY/Y
MFO._^%\VO_0'N/\ O\G^%-/QWMO,#?V1<8 (QYZ_X4^60?V_EO\ S]_!_P"1
MZ7!H]C;7C7<-I#%<L@C,J( Q4=!GTX'Y"KE>5?\ "^;7_H#W'_?Y/\*/^%\V
MO_0'N/\ O\G^%+E8?V_EO_/W\'_D>JU3N](LK]I6N;2&<RQ>2YD0,63.=I]L
M\UYM_P +YM?^@/<?]_D_PH_X7S:_] >X_P"_R?X4<K#^W\M_Y^_@_P#(])CT
M>QBBMHDM(5CM@1"@08CR,' [<$C\33]/TVUTJV%O9V\=M "2(XE"C)ZUYBGQ
MWME!!TBX/)/^O3U^E._X7S:_] >X_P"_R?X4^60?V_EO_/W\'_D>JTG6O-]&
M^-%OK&KV5BNESQ-<S+$',JD+DXSC%>DU+36YZ6%QN'QL7+#RYDO7]3+D\,:3
M,\#/IMJS0,6C)B'RDMN./JW/UYJ6[T'3K_S/M-C;S^8ZR/YD8.YE&%)]P.*L
MW1*P,0<'(Z?45-1=G<(!@4M%%("C?Z)I^JR0R7EG!<O$<HTJ!BO^<#\J6'1;
M"WNKFYBLX([BY&)I%0!I/J>]7:AD)%S$,\$-Q3N!7@T33[:YBN(K*".>*(0I
M(L8!5!T4'L*O444@(8/];/\ [X_]!%35#!_K9_\ ?'_H(J:@#XGHKW;_ (1;
M0/\ H!6'_?#?_%4?\(MH'_0"L/\ OAO_ (JON?K/]T_G;_5RM_S]C^/^1X31
M7NW_  BV@?\ 0"L/^^&_^*H_X1;0/^@%8?\ ?#?_ !5'UG^Z'^KE;_G['\?\
MCPFBO=O^$6T#_H!6'_?#?_%4?\(MH'_0"L/^^&_^*H^L_P!T/]7*W_/V/X_Y
M'A-%>[?\(MH'_0"L/^^&_P#BJ/\ A%M _P"@%8?]\-_\51]9_NA_JY6_Y^Q_
M'_(\)HKW;_A%M _Z 5A_WPW_ ,51_P (MH'_ $ K#_OAO_BJ/K/]T/\ 5RM_
MS]C^/^1X317NW_"+:!_T K#_ +X;_P"*H_X1;0/^@%8?]\-_\51]9_NA_JY6
M_P"?L?Q_R/":*]V_X1;0/^@%8?\ ?#?_ !5'_"+:!_T K#_OAO\ XJCZS_=#
M_5RM_P _8_C_ )'A-%>[?\(MH'_0"L/^^&_^*H_X1;0/^@%8?]\-_P#%4?6?
M[H?ZN5O^?L?Q_P CPFBO=O\ A%M _P"@%8?]\-_\51_PBV@?] *P_P"^&_\
MBJ/K/]T/]7*W_/V/X_Y'A-%>[?\ "+:!_P! *P_[X;_XJC_A%M _Z 5A_P!\
M-_\ %4?6?[H?ZN5O^?L?Q_R/":*]V_X1;0/^@%8?]\-_\51_PBV@?] *P_[X
M;_XJCZS_ '0_U<K?\_8_C_D>$T5[M_PBV@?] *P_[X;_ .*H_P"$6T#_ * 5
MA_WPW_Q5'UG^Z'^KE;_G['\?\CPFBO=O^$6T#_H!6'_?#?\ Q5'_  BV@?\
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MQ:Y3IPW#U6%:,O:1T?G_ )'SV.@I:]V_X1;0/^@%8?\ ?#?_ !5'_"+:!_T
MK#_OAO\ XJM/K/\ =.;_ %<J_P#/V/X_Y'A-%>[?\(MH'_0"L/\ OAO_ (JC
M_A%M _Z 5A_WPW_Q5'UG^Z'^KE;_ )^Q_'_(\)HKW;_A%M _Z 5A_P!\-_\
M%4?\(MH'_0"L/^^&_P#BJ/K/]T/]7*W_ #]C^/\ D>$T5[M_PBV@?] *P_[X
M;_XJC_A%M _Z 5A_WPW_ ,51]9_NA_JY6_Y^Q_'_ "/":*]V_P"$6T#_ * 5
MA_WPW_Q5'_"+:!_T K#_ +X;_P"*H^L_W0_U<K?\_8_C_D>7_#/_ )'W1/\
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MIX=S+:Q3E8YP\FXAQW&>.,''&<5?UOP/I^O3W$UP]PLTNP>9%+M**JLNU>.
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MX8-=U/\ Z"5Y_P"!+_XUI&+:W/F\SQ&%I58JO14W;=I=_-'L_P#PJ;PM_P!
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M_C2_V[J?_02O/_ E_P#&CD?</KN7?] D?NC_ )'LW_"IO"W_ $##_P"!$O\
M\51_PJ;PM_T##_X$2_\ Q5>,_P!NZG_T$KS_ ,"7_P :/[=U/_H)7G_@2_\
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M;%=1112.JCAZ.'35&"BGV27Y$-W_ ,>[?4?S%35#=_\ 'NWU'\Q4U!N%%%%
M!4$G_'U#]&J>H)/^/J'Z-0!/1110!#!_K9_]\?\ H(J:H8/];/\ [X_]!%34
M <1_PC$W_/>']?\ "C_A&)O^>\/Z_P"%=#17K_6:G<^8_L^AV_$Y[_A&)O\
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MY;B;4KU+&&.#:2'8$Y;)&  "3WJ;5?$MGI&JZ5ITQ9KK4I6B@1 /X4+,S9/
M 'YD"E]:J=P_L^AV_$I_\(Q-_P ]X?U_PH_X1B;_ )[P_K_A70!U9BH8%AU
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M)_S3_P"*H_X0#Q%_T")_S3_XJBZ#ZK7_ .?<ON9S]%;[> O$*C)TF<#ZI_\
M%4O_  @'B+_H$3_FG_Q5%T'U6O\ \^Y?<SGZ*Z#_ (0#Q%_T")_S3_XJC_A
M/$7_ $")_P T_P#BJ+H/JM?_ )]R^YG/T5T'_" >(O\ H$3_ )I_\52?\(%X
MAW8_LF?/7JG_ ,51=!]5K_\ /N7W,P**Z#_A /$7_0(G_-/_ (JC_A /$7_0
M(G_-/_BJ+H/JM?\ Y]R^YG/T5T'_  @'B+_H$3_FG_Q5'_" >(O^@1/^:?\
MQ5%T'U6O_P ^Y?<SGZ*WU\!>(6&1I,Y'U3_XJE_X0#Q%_P! B?\ -/\ XJBZ
M#ZKB/^?<ON9S]%=!_P (!XB_Z!$_YI_\51_P@'B+_H$3_FG_ ,51=!]5K_\
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M2;$)R54GU(%'*Q<RWL>>^.=:A\8VWA_0=)O%FM?$,A:2Z@8X-F@W2E3_ +0
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M-$$SOY%]@@#_ %2__%5XY11R(/[:Q?=?<>S_ /"Y-#_Y][[_ +]+_P#%4?\
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M_MJ>%)+S&D1W\S2OM PY#.2VTGGDUOV5I%\1]=UV?4C(=%T]VT^WACG>(,X
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MM57P[X3OM,\2)*0T6FVRRK$C3*X)<CD84'M_%^%=Q11S,+',_$?_ )$[4/\
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M%OIM,U2SMEDM[NW(#QMYBC()![$_G7Y7?\-=?&7_ **/KO\ W^3_ .)K]/\
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MF7[5'YAAE8_(% !<8.Y"0=HRPY\1A\+0INI[&+MY+_(Z*%?$UJBA[5J_F_\
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M^"2Y_P#B*_9Z;XI>'73"WDN<@_ZB3U^E/_X6IX;_ .?R7_P'D_PH_P!;*_\
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M +IJGI>K66MV,5[IUY#?V<N?+N+:021O@X.&'!Y!JU^)H =L?&-K8]*/+?\
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MB=J'^Z/YBO ATKWWXC_\B=J'^Z/YBO ATK2&Q\1GW\>'I^K"BBBM#YH****
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M?EE^$ 7<<C^[CM4/A[QU>KX)\ Z9X)-QX4MKS7Y=)DCN)DOVVA0Q.YUQU8D
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M-U+"4)[_ ",.?>D]5H5%I/4YWX"^&=3\.^#KBXU:V73[G4[N2^%@@PMLK=%
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M_AX-\<_^AKM?_!1:_P#QNC_AX-\<_P#H:[7_ ,%%K_\ &Z]7_5?,/YH_>_\
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M.?\ T-=K_P""BU_^-T?\/!OCG_T-=K_X*+7_ .-T?ZKYA_-'[W_\B'U_*/\
MGT_Z_P"WC],HO@O8R1JW]IW8R,_<3_"G?\*4L?\ H)W?_?"?X5^92_\ !03X
MY(H4>*[4 ?\ 4(M?_C==5\*OVZ_C+XH^)GA32-0\46T]A?:I;VUQ&NEVREHV
MD 89"9'!ZBHGPSCX1<G*.GF_\BXXW*)R452>O]?S'Z%_\*4L?^@G=_\ ?"?X
M4?\ "E+'_H)W?_?"?X5W'VN7^\/RH^UR_P!X?E7RG+/N>_\ 4L#_ ,^_S_S.
M$E^"]C&F?[3NSR!]Q/7Z4_\ X4I8_P#03N_^^$_PKMGN)'&&;(SGI3OM<O\
M>'Y4<L^X?4L#_P ^_P _\S/\->$(?#6GM:Q7$LRF0OND !Y^E:WV%?[YJ2UD
M:6,ECDYQ4U0Y23M<].G1I1@E!:$,-L(6)#$Y]:!_Q]G_ '!_,U+40_X^S_N#
M^9J&[[FZBHJR)J***104444 0VG_ ![K4U0VG_'NM34 %%%% $-Y_P >[_A_
M.I1TJ*\_X]W_  _G4HZ4 +1110 5"W_'VG^XW\Q4U0M_Q]I_N-_,4 34444
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M0_1J )Z*** (8/\ 6S_[X_\ 014U0P?ZV?\ WQ_Z"*FH R:*@_M"T_Y^X/\
MONC^T+3_ )^X/^^Z[^678\;VD/YE]YX+K_PN\7:$OB+0=,T'2O&/@[6KTZBM
MG>W[VDEK(6#,I92"PW '@]NW2CP]\"M=\,:7\/[/;9WATSQ ^JW_ -G?;'!&
MR@87=R^,#H,U[U_:%I_S]P?]]T?VA:?\_<'_ 'W4>R?9FGUB/\R^\\,^+?P[
M\>>,];\0VT:MJ>AW=J@TV/\ M;[-!:2 98R0CF1B<@$_+\PSP.+-CX"\8^$-
M?MM8TG2;359+_P .P:3=6]S?+']CFC4#=G!#IZA>>#[5[5_:%I_S]P?]]T?V
MA:?\_<'_ 'W1[)]F'UB%K77WGS=8_ CQ#INB^"[NYT=-7N=-M+BRO=)BU<V;
M?/([I(DZ$#C(RN>?Y>V_#GPLWA3P3::;_9]II$V'D>TM;B2YAB=R20'D.YN3
MSVSG'%=)_:%I_P _<'_?=']H6G_/W!_WW35-KH)UXR^TOO/'!X+\;>)];\+6
MNN:3H^F6>@:HVHMJ>FR*J7*C.Q(X!\R%L_-D]J]JJ#^T+3_G[@_[[H_M"T_Y
M^X/^^Z%!KH)UH2^TOO)Z*@_M"T_Y^X/^^Z/[0M/^?N#_ +[JN678GVD/YE]Y
M/14']H6G_/W!_P!]T?VA:?\ /W!_WW1RR[![2'\R^\GHJ#^T+3_G[@_[[H_M
M"T_Y^X/^^Z.678/:0_F7WD]%0?VA:?\ /W!_WW1_:%I_S]P?]]T<LNP>TA_,
MOO)Z*@_M"T_Y^X/^^Z/[0M/^?N#_ +[HY9=@]I#^9?>3T5!_:%I_S]P?]]T?
MVA:?\_<'_?='++L'M(?S+[R>BH/[0M/^?N#_ +[H_M"T_P"?N#_ONCEEV#VD
M/YE]Y/14']H6G_/W!_WW1_:%I_S]P?\ ?='++L'M(?S+[R>BH/[0M/\ G[@_
M[[H_M"T_Y^X/^^Z.678/:0_F7WD]%0?VA:?\_<'_ 'W1_:%I_P _<'_?='++
ML'M(?S+[R>BH/[0M/^?N#_ONC^T+3_G[@_[[HY9=@]I#^9?>3T5!_:%I_P _
M<'_?=']H6G_/W!_WW1RR[![2'\R^\GHJ#^T+3_G[@_[[H_M"T_Y^X/\ ONCE
MEV#VD/YE]Y/3H_O?@:K?VA:?\_<'_?=/BOK5F.VYA8@$\/2<96V&JD&_B7WD
M@Z457_M"T_Y^X/\ ONE_M"T_Y^X/^^Z?++L3[2'\R^\GKSSXC^#]5\1>,O!&
MH6,*2VNEWIFNG:55*)CJ >3]!7>?VA:?\_<'_?=']H6G_/W!_P!]TG"3Z%*K
M!?:7WD@@C$A<1H')SN"C/YUPWBI&TKXD^&M7<9M989K DG 61AE!GMDC%=K_
M &A:?\_<'_?=13W&G72!)IK69 0P60A@".AY[T.$NP*K!?:7WGEN@6'C!O&;
MZUX@\)F_NO-,5I,-5@\FP@)Q\D?)+$<D]3T&*Z3P\AU/XI^(M3AYM+6TBT[>
M#PT@.]@/IQ^==G_:%I_S]P?]]U'!<:=:J5AFM85+%BL9"@D]3QWJ53EV&ZT'
MU7WENBH/[0M/^?N#_ONC^T+3_G[@_P"^ZOEEV)]I#^9?>6X/]:GUK2K&MKVV
MDN(U2YA=B>%5\DULUS54TU<[L/)23:=R&+_7S?A4U0Q?Z^;\*FK$ZPHHHH *
M*** "BBB@ HHHH **** "BBB@ HHK)\0ZX^BQVOE6QNIKF80(GF!!D@G))!]
M*-P-:BN<M/'.G&$_;YHM-N%D>)HI90>5."01U'O4NJ>--*TV*4?;;>2X7I!Y
MRJ6/'&3P.O>G9@;U%8.F^-M)U(3;;E87A9U=92!]P98CU ]:O67B#3=2N6M[
M6]AGF"[MD;Y./7WHLP%UO48-)L3>7+%((F#.R@D@?05SW_"U?#?_ #]S?^ \
MG^%6OB/_ ,B=J'^Z/YBO ATJXQ31\WF>8UL'5C"FE9J^O_#GN?\ PM7PW_S]
MS?\ @/)_A1_PM7PW_P _<W_@/)_A7AE%7R(\?^W,5VC]S_S/<_\ A:OAO_G[
MF_\  >3_  J-?BGX=$SL;N;:0,?N)/\ "O$**.1!_;F*[1^Y_P"9[G_PM7PW
M_P _<W_@/)_A1_PM7PW_ ,_<W_@/)_A7AE%'(@_MS%=H_<_\SW/_ (6KX;_Y
M^YO_  'D_P *#\5?#>/^/N;_ +\2?X5X911R(/[<Q7:/W/\ S/<(?BGX=2)0
MUW-D#G]Q)_A3_P#A:OAO_G[F_P# >3_"O#**.1!_;F*[1^Y_YGNG_"UO#G_/
MW+_X#O\ X4?\+6\.?\_<O_@._P#A7A=%'(@_MS%=H_<_\SW"?XI^'73 NI<Y
M!_X]W]?I4G_"UO#G_/W+_P" [_X5X75ZPTEM0@GD2YMXS"AD=)"X(4=\A2.>
MW-'(BHYUBYNR4?N?^9]!Z%X@LO$=HUS8R-)$K%"60KR/8UI5P?P<_P"18F_Z
M^'_I70R^+K%=>ET:$2W6HQP-.T42C&!CY=Q(&XY'&?KBLFM;(^OPE65>A"I/
M=HVZA'_'V?\ <'\S7*GXFV$;ND]C?V[I.;=PZ1D*5V[CE7((4NH."3D].#6[
MI&K0ZUNN;</Y!RB.XQO 8C<O^R>Q[T6:.LTZ***D HHHH AM/^/=:FJ&T_X]
MUJ:@ HHHH AO/^/=_P /YU*.E17G_'N_X?SJ4=* %HHHH *A;_C[3_<;^8J:
MH6_X^T_W&_F* )J*** "BBB@"&U_U;?[[_\ H1J:H;7_ %;?[[_^A&IJ "BB
MB@"&[_X]V^H_F*FJ&[_X]V^H_F*FH **** "H)/^/J'Z-4]02?\ 'U#]&H G
MHHHH A@_UL_^^/\ T$5-4,'^MG_WQ_Z"*FH \OS1FBBOK3\O#-&:\.^)/C37
M8O&FH7NCWTL6E>%4MVO;6.7"W+.XWAEZ-M4_A5GXS^*?LVO>$2OB'5=$T6]M
MIYI9](+&1AA3&=HZ]0/8$URO$12;MM_PQZ,<%.3@K_$G\M+_ )6/:,T9KSOX
M.7MEJ-CJ<UEXDUSQ%&)41FUN,HT1 )P@(Z'//T%2>%-6O;KXM^-;&:[GELK:
M&U,%N[DQQ%EYVCH,UHJJ:B^YA*@XRG&_PJ_;M_F>@9HS7GWC?XO6WA'6Y-*A
MLXKVZ@MOM5QY]_':*J=E0O\ ?<]=H[5)K7Q1EM- LM:TO1&U#2KBS^V-=W-[
M%:1QKT"9;)9\\8 _'FAUH)M7V!8:JU%VWVU1WN:,UYZOQ;_M$>'8M%T2?4]0
MUBV:]6U>X6$0Q*2&+.01G(( [^U<;X1\;7<NE: ^ISZM<7-YXEN+5-M^8S&H
M*X208.]%SC9D#WJ'B()I+4TC@ZC3;T_I_P"1[IFC->5R?'*6*WNKY_#,XTJT
MU,Z;/>"\3AMVT,J;<MZD<8XY.:T-?^+DFF7FOKI^@3ZM9:'&#>W:W*Q!7(R%
M52"6 [GMSP<<U[>G:]R?JE:]N7\5Y>?FCT3-&:Y76/%-[_PKB7Q!IMHINWL!
M=QPR2C$>4W<DC!VCG&.<8[UR7A;XGZG#X3\,6]QI<FK^(=50FWC%VB^?&O+3
M2.5Q&.ORX/2FZT8NS)CAJDXN2Z.V_P SU?-&:YSP5XSB\8V=VWV233[ZRG-M
M=V<K!C%(/1APP/8_I7FOCWP]K.G>.=!M+?QKX@AM]<NY%>-+C:MN.H$8]!G'
M-*=7EBI15QT\.YS=.;Y6O^'Z'MN:,UY9X;^)%QID6K6$]C=7VG>'7>&^UJ]O
M5,L@&2&V;<LQZ8SQQS5SPC\9K;Q1JJZ>^G+!<SVS75K';7T5TTBJ,E'"X\M\
M?PG\Z%7@[:CEA*L;NUTO3^MM3T?-&:\SB^+E])K,FBS^'18ZK):2W-M"=1BE
M.54L%E"C]V2!GG-<_P"#_B_KEKX9T1]0T>36+W5KR2""5+Q$,AR>-NW"@' Q
MGIS2^L0O8I8*LU>R^]>?GY'MF:,UY2?CC<PVMU<W/A6X@M["]%C?R"]C80R%
ML#8,9?WZ=JL>(_CII_A_6KZT%E'<6FGND=U.U]%%+ENOE0M\TF ><8H^L4[7
MN+ZG7O91_%?Y^:/3LT9KSG6?BY/9:SJUCIWA]]533K..^>Y6\6)#$R[L\J><
M'@<Y]JR6^)&LZWX^\)QZ7:$Z/?V1NOL[7"QM)G(8L<?P=A_%0Z\-D$<)5:NU
M96ONNUSUS-&:**Z#B#-&:** #-&:** #-&:** #-&:** #-&:** #-6M._US
M_P#7-OY55JUIW^N?_KFW\JF?PLUI?Q$5<T9HHJC(,T9HHH ,T9HHH ,T9HHH
M ,T9HHH O:'_ ,A:U_WQ7H5>>Z'_ ,A:U_WQ7H5>+C_C7H?7Y+_!EZ_H0Q?Z
M^;\*FJ&+_7S?A4U>8?0A1110 4444 %%%% !1110 4444 %%%% !61XB\.0^
M(TLX[@H8H)UF:-XPZR8!^4@_6M>BFG8#F-6\"6NH.! Z6$"VSVZPP0@*-QSN
M&,=QTK+'PRDDFNII]5#RSQM&?+MMH&0HR!O/]VN[HI\S0K'$S_#J9A)Y.J+&
MS--@O;;L+(H##[XYXX/Z5=\/^"Y-"U%;A;\-$J%3#%$8PY./F8;BI/'4*#ZD
MUU-%',PL<S\1_P#D3M0_W1_,5X$.E?1GBG2CKFC36 E$)G(7S"N[;WZ<>E<#
M_P *1D_Z#"?^ Q_^+JX226I\MF^"Q&)JQE2C=)=UW\SS&BO3O^%(R?\ 083_
M ,!C_P#%T?\ "D9/^@PG_@,?_BZOF1X7]DXW_GW^*_S/,:*]._X4C)_T&$_\
M!C_\73%^"LAE9/[87@ Y^S'_ .*HYD']DXW_ )]_BO\ ,\THKT[_ (4C)_T&
M$_\  8__ !='_"D9/^@PG_@,?_BZ.9!_9.-_Y]_BO\SS&BO3O^%(R?\ 083_
M ,!C_P#%T'X)2#_F,)_X#'_XNCF0?V3C?^??XK_,\QHKTR+X*221JW]L*,C/
M_'L?_BJ=_P *1D_Z#"?^ Q_^+HYD']DXW_GW^*_S/,:*]._X4C)_T&$_\!C_
M /%T?\*1D_Z#"?\ @,?_ (NCF0?V3C?^??XK_,\QJY!?K!I5U:A&\R>1"7[;
M5SQ^9KT"3X*R1KG^V%/('_'L?7_>IW_"D9/^@PG_ (#'_P"+HYD5'*\;'50_
M%?YFS\'/^18F_P"OA_Z5T5SHDTOBNTU59$$4%I+ 8SG)9F4@^F/EJ+P9X6/A
M/2WLVN1=%I#)O";.O;&36_6+>MT?<8*G*EAX0FK-(Y+_ (0DGPE!I;_9I[P-
MO:ZFCW;'9LR.F1D-@G!]:7P7X9O?#=Y>QW%Y]IMF51 F]FVJ"W.&X4XP-J\?
M+GO765"/^/L_[@_F:+NQV6)J***D84444 0VG_'NM35#:?\ 'NM34 %%%% $
M-Y_Q[O\ A_.I1TJ*\_X]W_#^=2CI0 M%%% !4+?\?:?[C?S%35"W_'VG^XW\
MQ0!-1110 4444 0VO^K;_??_ -"-35#:_P"K;_??_P!"-34 %%%% $-W_P >
M[?4?S%35#=_\>[?4?S%34 %%%% !4$G_ !]0_1JGJ"3_ (^H?HU $]%%% $,
M'^MG_P!\?^@BIJA@_P!;/_OC_P!!%34 >7T<]L9[9HHKZT_+SRJR_9]T2\CU
M"Y\1G^U]9O+B6=KV%Y(@F\_* F[''OUJ/_A47B.VM/"IL?%%K:ZEH,,\$5VU
MD9 Z2'@;2<9"Y'.:]&\3:['X8\/ZAJTT3SQ64+3-%&0&8#L">*X73/CA!/<:
M:=3\,ZQH6GZ@ZQV^HWBJ8'9ONC(['UKBE"A!\KT9ZD*N+JIRCJOEVV2?D]D=
M1X/TGQ/I;71\1>(8-=#A?($-F+?RL9W9QUSQ^5<UJWPX\3KXTUC7M \46ND#
M4EB62*6P$YPB@#DG'7)X'>NVL=;:XN]4BN+464-E($%Q)=1,LH(^]A6R@'H^
M#5^&YAN8?-AFCFBY_>1N&7CKR#BMN2$HI7>GGJ<JK5*<G)):^2MT>VQYK>?"
MG6I]2BUA=<TV?7);3[+>SWVE+-%)@Y62./.$<# [CCI2^)/@[<ZSJ]G?0:M:
M9CTXZ>ZWVG)($SG,D**52-CD]L"O2+:[@O4+V\\5P@."T,BN ?3()I(;^UN(
MY)(KJ"5(_OO'*K!/J0>/QJ?8TW_PY:Q59.ZZ>2_R/.-/^$NIZ'#X9N-+UNVM
M]7T>TDL7FFM&DAGA9BWW-P(8$^M0Z5\&;RPM-"BEUJ&XDT[69-5DE^SE3,'Q
M\N,\'CKTYZ5Z7'J5G,VV.\MW;;OPLRD[?[W!Z>_2N9L?B19ZUILMYI%JVHI%
M?&R9#<PP-P<&3YV'RYS@=3C@5#IT8V-%7Q,[M?DNM^OS9S]U\';FX\':GH@U
M6!9+S6&U03^0V$4L&V$9Y/'6N1\?6=WI.K^,;#2_[5A36H$,EL-'>=;F7;M'
MDSH2J*>C;QQSCM7NCZE9QN5:\MU8/Y9#3*#N_NXSU]NM2_;(4D>+[1&LB+N>
M/S "H]2,\#W-.5&$E:+L%/%U(N\U?^EY>2,#3?#LDOP^M="NR;>9M-6SE*X8
MHWE[3]<5R=C\*-7T_3_#[PZY9QZSH0:&TN19L89(&&"DJ%\D]>5(KT:34K.*
M".9[RV2&3[DC3*%;Z'.#^%9&L^.-+T/6M(TN>8&ZU-R(MK+M50,[V8G 'IZ]
MJN4*=DY/8RIU:UVH=;O;UO\ @0^!O!O_  B%I?-/=_VAJ6H7!NKRY">6K.>R
MKSA0.G>H_%'@R7Q#XF\-:JEVD":1.TK1-&6,N0!@$'C\:U](UIM0MKN>YMAI
MR6\SQ9DN8I RK_'N1B%!]&P1WJW]OM?LPN/M4'V<G F\U=F?][.*M1@X\O0S
M=2HJCGU_X%OR..T[X8I%;>,+6]O%N+;Q!<--B)"K0@C&.3R1UJEH'PNU+3["
M>QO-9LOLWV)K.!].TN.WG&00)'E.6+8_ND ]Z]!@NX+EG6&>*9HSAQ'(&*GW
MP>/QJ6I]C!V*^LU=4WOY(\F\*_!.\T#5M(NYM3TYHK"WEM?*L[ PF174C>S;
MCN?)ZGCCBI-%^#FI:9_PCT,VM6<]GHM\UW"J6CK(ZMDE6.XC/3G%>JT4EAZ:
MV_K^K%O&5I7;?X+S_P V>9:C\'[B^T/Q)8#584;5M5745D,#$1 $'81GD\=:
M?=?"B]AU_4+W2]3T^WM]1>.2Y6]TM+J5'48)B9^!D=B#7I5%'L*?87UNMW_!
M>7^2.%N/AM++K/B>]6_B6/6-/CL4C\D@Q%1C<<'!'L *H:?\*M0T>\\*7EEJ
M]J+G1K5K2436S,DR$Y)4!@5//?->DT4_8P)6*JI6O^"[6_(****W.4**** "
MBBB@ HHHH **** "BBB@ JUIW^N?_KFW\JJU:T[_ %S_ /7-OY5,_A9K2_B(
MJT4451D%<]XLN?$D9LX?#UO9#S'/VB]OCNCMT'?RPREOP-=#7G_Q?M_%>IZ3
M!IGANSEFBN6(O9X)HXY%C[JN]AR?6LJKM!M?@;T(\U1)V^>QH_#3QC=>,=(N
MY+Q+?[59W3VKS6F?)FV_QH#D@>V35'7O']U8Z'X@U.W:VBMK.=;.U>="0TN0
M&9N1\H)Z<=.M:OPZTS^Q?#46GKH4^@1VYVK#<3Q2O)ZN3&2,DU@:%;7]IX=U
M?3;.RM+_ %&RU-Y&M+P#;(C-N!!/ 8C.">,BL;SY$F];'5:FZDFEI=?=?[O^
M'+NC>)=5U#0]3O;?7=%UV6V3<J6-J\84CEE;+D\C./ZUUVC:I#K>E6E_!_JK
MB,2*#VSV_#I7&PQ7MMJ>O>*=3T[^Q8#8BW6UDF1Y),9.YBA([X')-;W@#3YM
M+\&:1;3@K,L 9E/4;B6Q^M53<KV9G6C'E<EW7;MKMIH=!11172<1>T/_ )"U
MK_OBO0J\]T/_ )"UK_OBO0J\7'_&O0^OR7^#+U_0AB_U\WX5-4,7^OF_"IJ\
MP^A"BBB@ HHI#0 4M>6:?:ZG=VUY?0M+"L,UR9+MKYV+J <((^@^O:J^G_$'
M4;S3GLX+B($6+ND^S,B,@&2<N2WU*K^-:<G85SUNBO)+GQ[JE_I\ELS1!1M0
MRQ.L<@P5^?\ UA8@Y_N@>YJ6\^(&LWJR11F"Q5)E!?Y2\:API##S,D'U*K^-
M'(PN>K45R7B>>-M9TR#4+IK;2Y(W9G64PH\@Z N".W(&:QW\<3:?(EMI\RWM
MK'L2/[6K&>X# G<IXR%QC.#GUJ>6X7/1:*\VC^)&H7T]O;VIL \BIN<HSA&*
ML2,!QZ=,U8\/^(M0UG3_ !#/=72#%J)(H8AM\K,9Y4Y)QFGRM!<]!HKS"QUI
M-&AM;K2[A[^0:<\UW!]H:9=P VDY8[3G/ITJUI_Q"U&\,4<TFG608L3>3$&,
MX .S"RG:W/=B?;M1R,+GHM%>;S?$/5HM(LKO99$W3R[7"8C4)T7+R*,GUR/H
M:2;XEWXU P1I9#,;_)*0HC=5!Y?S.1S_ '0/]KO1R,+GI-%>9Q_$W47N88%C
MM9'&/,8JL:R$OMVJQFQP.<J7SZ5;A\27>J>,M.B>YB@C6:YB-E&2) % PS_-
MSGJ.!^-'*PN9_P"TWXSU?X>? SQ7XCT&Y6SU?3[=9;:=HED"-O49VL"#P3U%
M?FE_P\$^.G_0WP?^"BT_^-U^B7[:'_)L?CS_ *\U_P#1B5^,=?HO#.$P^(PT
MY5J:D^;JD^B/A>(,57H5X1I3<5;HVNK/HK_AX)\=/^AOM_\ P46G_P ;H_X>
M"?'3_H;[?_P46G_QNOG6BOL/[,P/_/B/_@*_R/E_[0QG_/Z7WL^BO^'@GQT_
MZ&^W_P#!1:?_ !ND'_!0+XYABW_"76^3U/\ 9%I_\;KYVHH_LS _\^(_^ K_
M "#^T,9_S^E][/HK_AX)\=/^AOM__!1:?_&Z/^'@GQT_Z&^W_P#!1:?_ !NO
MG6BC^S,#_P ^(_\ @*_R#^T,9_S^E][/HK_AX)\=/^AOM_\ P46G_P ;H_X>
M"?'3_H;[?_P46G_QNOG6BC^S,#_SXC_X"O\ (/[0QG_/Z7WL^B5_X*!?'-%"
MCQ=;@#_J$6G_ ,;I?^'@GQT_Z&^W_P#!1:?_ !NOG6BC^S,#_P ^(_\ @*_R
M#^T,9_S^E][/HK_AX)\=/^AOM_\ P46G_P ;H_X>"?'3_H;[?_P46G_QNOG6
MBC^S,#_SXC_X"O\ (/[0QG_/Z7WL^B7_ ."@7QS<8/BZWQG/_((M/_C=!_X*
M#?'('!\86P/H=)L__C=?.U>M_#?7KGP[\)O&>IS1VES:CR]+L8+JPMY5%Q/N
M:24.\9;<D:' R,%\CD"L*V7X*G'F5"#U2V773L;4L9BZDK.M):/J^GS/T@_8
M9^,'BOXT?">]UOQ?J2:GJ4>IRVZRI;1P 1@*0-J*!W/-?1M?('_!,;_DA&I?
M]AF?_P!!2OHN]BG;XBPV]QJ$\EC<Z=,?LF[9&F&09&W!)Y/S$Y],5^2YK3A3
MQU6$%9)[(_3,NG*>$IRF[MH[.HA_Q]G_ '!_,UY2-)NAX6CUNVU&>TCDN6N$
MMY+B9OE+*(53YCEL #!^4ER372_#C7VU4WEM,)C>0?//)+('W.S-D8'W,$$!
M#T&/6O+<;*YZ%SMZ***@84444 0VG_'NM35#:?\ 'NM34 %%%% $-Y_Q[O\
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M:%&TB01[4=\CENQ;W/->N4;CC&3CTHKIIP]FK'!6JNLU)]%8****T, HHHH
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M?^&R?@K_ -%%T;_OZ_\ \31_PV3\%?\ HHNC?]_7_P#B:/\ 6'&?] <OQ_\
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MTJ*\_P"/=_P_G4HZ4 +1110 5"W_ !]I_N-_,5-4+?\ 'VG^XW\Q0!-1110
M4444 0VO^K;_ 'W_ /0C4U0VO^K;_??_ -"-34 %%9=[XGTS3[W[)<7B1394
M,"#A"QPH9@,+D],D9K3S0!%=_P#'NWU'\Q4U4=2O[>V,%O+*J37+[(D/5R/F
M('X FK4T\5M$TDTBQ1KU=V"@?B: )**S]4U_3]&$1O+E(!+G:6R>!U/ X R.
M3QS5\$$9'(H 6H)/^/J'Z-4]02?\?4/T:@">BBB@"&#_ %L_^^/_ $$5-4,'
M^MG_ -\?^@BIJ .3_P"$9MO^>LWY"C_A&;;_ )ZS?D*UJ*]/VU3^8^>^J4/Y
M#)_X1FV_YZS?D*/^$9MO^>LWY"M:BCVU3^8/JE#^0R?^$9MO^>LWY"C_ (1F
MV_YZS?D*UJ*/;5/Y@^J4/Y#)_P"$9MO^>LWY"C_A&;;_ )ZS?D*UJX+4_BJE
ME\1;'PU!IYN;5Y4M;K4!+@6]Q(C/'$%Q\Q*KD\C&12=>HOM#6#H/:!T__",V
MW_/6;\A1_P (S;?\]9OR%<?K_P <_#WA[5/$5E/=6I?1;19W7[6@>>8YQ"B_
MWA@ D]"PKH(/B/X<.GV=Q<:[I=N]U#%*B->)AC(I90ISR#M;![[31]8G_,/Z
ME1_D-#_A&;;_ )ZS?D*/^$9MO^>LWY"N6@^+=C:ZS8V.M2Z7I4=QIR7K7AU%
M6@+R2%8HXV(7S-P5CGCITKM3JMD+TV9NX?M0A^T&'S!O$6<;\?W<\9H5>;^T
M)X*@OL%/_A&;;_GK-^0H_P"$9MO^>LWY"L0?%30I_&6E>'K2^M+N:_MGNDFC
MN5(VC[H4=6+88C'96-;6B^,-"\27-U;Z3K-AJ<]J<3Q6ERDK1<X^8*>.:/;S
M_F#ZE07V!?\ A&;;_GK-^0H_X1FV_P">LWY"N?U3XK:0FI:7I^BWEAKMY=ZD
MFGS1VUVK&VR&+,VW/("G@XSZU<\2_$32_#7B;0="N)X%O=6E**LDZH8UP<-@
M\G<P"@=R:/K$_P"8?U*C_(:G_",VW_/6;\A1_P (S;?\]9OR%-L/&>@:IK$^
MDV>M:?=:I!GS;*&Y1IH\=<J#D8K/\?>+KOPG9:?_ &=IR:KJ6H7D=E;VLDYA
M5F;))+!6P  3TH]O4WYA+!4&[<AI?\(S;?\ /6;\A1_PC-M_SUF_(5RNG^/_
M !%+/KNF7OAFVM]>TZT2]BM;?4?.AN$8D!?,\L%6RIX*TI^+4&K6V@Q^'K,:
MMJVK()?L;2^6+2,<2/.P!VA3E<8R3P*7UB?\Q7U&C_(=3_PC-M_SUF_(4?\
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MC:*=Y;_W31Y;_P!TT7068VG1_>_ T>6_]TTY(VR?E/0TFU8:3N1CI13O+?\
MNFCRW_NFG="LQM>=_&SQCKWA7PP(_#6E7FI:M>-Y22VMJ\XMEQS(0H//I[UZ
M-Y;_ -TTOEN/X32>O4I:.]CS'X#^';'0?"4I@BU,ZA<3>9?W6K6<EM-/*>20
MK@':.QJGH+F/PGXNO)="/B.2;6)A=6"D,\L:E1@ @AR%Y"]^E>M&-S_":H:=
MH%KI,][-:6YADO)?.GPQ(9\8S@G X]*FR'=O6QX]<WT37^L^*K70;C0-)@TH
MZ="EW9_9)KR5S\JB(X("] 2._%>G^ ]'E\/^#='T^?\ U\%LBR#T;&2/P)K2
MU#0+75;BTFN[<SO:2>;"&8[5?LQ7."1VSTJ]Y;_W30DD#;:V&T4[RW_NFCRW
M_NFKNB+,=!_K4^M:59T,;"525(&:T:YZFYV4-F0Q?Z^;\*FJ&+_7S?A4U9'2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <)\</AVWQ:^%
MVN^$$OQI;:M$(!>-#YHB^8-G9D9^[ZCK7Q9_PZBO/^BF0?\ @C;_ .2*^Q?V
MB_'NI?"_X,^)?%6CI;R:EID"S0+=H7B+;U7YE!!(P3W%?GK_ ,/-OBW_ ,^'
MA;_P7S?_ !^OL,EAFLJ,G@)I1OK>V]EW3/F,UGET:L?KD6Y6TM?:_DT>B_\
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M2JU7>3W/9I4H48*G35D@J$?\?9_W!_,U-4(_X^S_ +@_F:P-2:BBB@ HHHH
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MQ)QQF>9#Y&>J45X;;^--?TK7FGTK2K[6;'2M MYKJTNM4.V)Y297)D<$RRA
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MZ1_]]BOU#A/_ '6I_B_1'YYQ(F\3"W\OZL=13?,3_GI'_P!]BCS$_P">D?\
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MCE?E;YAQP:Z.AJP!1112 *A'_'V?]P?S-35"/^/L_P"X/YF@":BBB@ HHHH
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MHHH AN_^/=OJ/YBIJAN_^/=OJ/YBIJ "BBB@ J"3_CZA^C5/4$G_ !]0_1J
M)Z*** (8/];/_OC_ -!%35#!_K9_]\?^@BIJ "FAU+%0P)')&:S?%-[=:=X:
MU6ZL;:6\O8;662"WA7+RR!"551ZDXKS/X>?#A_"WB_P^D>GO:Q:9H!6\OU0C
M[9=S.A=6<\OM\MFQT7>,8JDKJXCO9OAWX8GU3^T9-"L)+SS?/\QH ?WF,;\=
M-WOC-7;CPIHUUIU]8S:9:R6=],9[F%HAMFD)!+L.[953GKP/2N7\6>"+[6M<
MFNX;/39HW50'N;NZC<X&.5C.W\J7XD:!<^)K3PUX?^R2S:=<ZA$^HM$6\M8(
M5,I5FZ@,Z(H[G-5O;4#6C^'7A0:9-9)H6G"SGF6>1%A7#RKPKD]V'][K3I_A
MYX5DTN.PDT+3A8PRO,D(@541V^^P Z%L\^N>:\KL-%O]#UG3[]_#U^FD?VYJ
M6J+8V-D3Y;)$MO:KY8X0.N^3) &[DD9K('@36;O2KR^U/PY<7U[!H=S>Q6LL
M6\/J5]*S,NT\,T2K&ISP.WK5\OF*Y[SK6HZ5X6\.7ES=B.WTJQMRTL<<6Y4C
M"] BCICC %1^&/#VB>'K%GT;3K;3H+@"1Q#$(\\8&[OP.,=J\+\0_#:^T\7V
MGVF@W]Q9?8-+TBXDM@2UXOG>;=RLV<OB- H8G(+$#KBK6K>#=5EGDO;#2+C2
M_"=WK,<TFDC3FFW11VY59)+164E7EVDIUPJLP-+D5MPN>O-\._"IO9=0;1;#
MSYI3<22F,8>0\EV'0GW-7-3\(:!J<=X;[2[*=;MXY9VEB4^8Z#",3ZKV/:O*
M?"7PYNK_ %K0H-9TR=M(MS?:I]EN[=4MXGE9$BB$89E&%,K^62=N[GD5T?C[
M3BWC'39]2T*ZUWPY;Z?,L%G:VWVB-;O<H4O%T^YN"LWR@D\CK2MK:X&EK^D^
M"K&XT7P[=Z%;W4LIDDM+.&S\TQKQYCG ^5?F&23SGO6SK'P_\+Z[-&^I:'I]
MVZQ"W43P*?W8Z)CH0.P[=J\]^%OP_P!0T_Q/:76OZ:&N=*T6&UAN)D60+(\T
MDC)'(<EO+3RTW?7'7G!\0:6?&_B3QV8-"GU'4YIH-)TN_P#++0VC1+EY?,Z1
M%&DW9X)P ,\BG;6R8'LK>"_#O]M1ZD=)LAJ2!2L_E#?\HPI]R!P#U&/:LWP]
M;^%(]4O+_0]-MVO#>/97-S9VW*2_><%NPR>2.">O->4RZ!XAU/QKITTNB3QW
M@UWSKJ\.GR%H[>('81=M(<I($4;$7:-[ X.2<Q/ OB.7PK81Z/HUSI.HV^FW
M]Y*Z6OD2?:YI=OEKTRZQO(%.>@&#C%/E[L+GT;%IUB-2EU%+>'[=)&L$ERJC
M>44DA"WH"Q./<UG:W>Z%X>=]:OQ;PSR!++[1LW2/N?Y8ACDY8]/>O%_^$#U&
M[L-2L[#3;NUTW56LM*=(=.-A$T(DW33-&9&D!"$H9&P3D=<9JQ-\/-_BQ"?#
MDB:(_B"/;;): QB."U;9*1@X#ROM+D<A1D]Z7*NX7/5#X T6ULM3@T:UM-&N
M[V(QR7%M;1LP!)."K J5R2=I&#FLSPE\)M%\+274T\5K=W5U+#( +988HS%_
MJA'&"<;22<Y)R?85Q_PV\.7EMX_-\^BWL4<HN;B:YO[=K:YM)7('D-*IV7<9
MYV\':%7GI5'Q[X/US7/&GB'SK6YN?M0MX=+F33_.^S1;1O>.<R*L#!]S'(W'
M"XSP*+.]K@>P7GA#0K_6(]6N=+LY]1B*[;F2(%P1]WGU&3CTSQ3(/!GA^#6I
M=3ATJR349"6>=8AO)88+'W(X)ZFO'+O3KNV\8ZGXBU/1+V+PPD4UW!'<C:GV
MZ&/'VN:+'R!U!"9[J#@$BLK3/!.O7'A;3)O#&DW>BZY:Z5</?WTT?E274TPR
M(D8D>9R2P.<+M7D$T<OF%SW'3_ 'A?3@PM-%T^%?,23$<*X5D;<N/3:>0!T-
M,C\)^&X]<NKA-#MEN[B)VFO!;C:P;AP6Z;CW[D=:\;B^'^HWVGW<%IIU[:Z?
M?)::7*D>F?8?-0RJTLSQF1G+*@8&1L9W'&>M6/$O@+5!XAO[NSTF2S\/+J$%
MO):P:?YXFMXXF8$P*RF2,S2#=SSC)! -/E_O!?R/<+30-*L9;2XM[*VA>UM_
MLUO(B >5#Q\BGLORC@>@I_\ 9&F+/=W'V6W\R^58[B0J,SJ 0H8_Q !C^9KQ
MC2/ =]=2Z)::GI%S)H\,MYK+6<EN(XHV*A(8!&KLH!)9_+)."2#Z50\/^"KJ
MSLXK;Q%X5U#6H+BPSI^G1QCR;::65VE0GA8&4-& QQ@!@#VI<OF%SUR3P+X7
MN[>WTB3P[:?8M/3-NC6H$,8;.50]/J/>M>#0M)M=1_M.&SMH;QH5MOM"(%8Q
MC[J9'8=A7C%GX#O]:\3QIJ>BW?\ 9C:G)=RB;<P:*W@$<"LQ.6W,2>>N,U@#
M2U\,:5<S>(]$N+C3TT^YN[73EA#I8SRS,0'0<1'8%"L0 /FP0:.6_4+GT9:Z
M/86;WDD%I#$UX_F7#(@!E; 7+>IP *R'^'WA:ZM[.)M#TZ2"TR($\A2L8+;B
M .F"W..F:XZ]T+4O#_P0TG1["RGNYQ;6\-S'&':1%8@RG:C*SD;FX!!/K7%:
M/X)U;5I;_3KC1)[31-2UFU#Q16#6,7V6%"[2>4'.W><)UR<#-)1ZW"Y[9>>"
M?#NJP3QW&D65Q'/*L\F8@=TBC ;/J ,9]*YW21X"A\8KX:T[3K*+6-,C:Z6*
M"TVK#OP&PX&W<1C(SGIFL[PE9WW@OPKXIU*UT.Y2XN;^62RTFWB"_* (XR$'
M"[BI8GT.37/:7X \2>"M:\/ZI-)_;-R_VR2_:RM"KK++$6.YMYW .J*.!P!3
M2W5P.GT74/!T4FIQ:-X6N)H9I7M+J:TTEC%(0Q#J3C!4$G...M=CX?\ !^B>
M&/-;2-*M=.:=5$C01!&<+]T,>IQGC/2O./A5I4.G:9I$5[_PE5OJKN9[B&2*
M[2U$KL78-E=F,G![5[#4ST=D-&#<>!/#]W%>1RZ/9NEW*)YU,0Q)(.CG_:]^
MM:%IH>GV.E#3;>R@@L A3[-'&%CVGJ,>^:O45%V,YW1_A[X;T">.;3]%L[22
M,;8S'$/D'^S_ '?PJQ=^#=#OM*CTV?2K22PCD,J6YB&U7R6+ =CDDY'K6U11
M=@<'XD^$VGZMI]II^G_9-)T^#>1:)I\4B!FZNN0"K]>0<'/(-=7X=T&T\,:'
M9:38H4M+2(11ACDX'<^YZUHT4-MJP&4GA;2(XEB33;58UN?M@41#'G9SYG^]
MGO4=UX.T.]UE-5GTJTFU%,%;EX@7!'0Y]1V/:MFBB[ YT?#SPR-4.I?V%8?;
MC(9O/\A=P<\%AZ$]R.M26O@3P]8QF.#1K*)#$\&%A _=L<LGT)Y(K>HHNP,@
M^$-$974Z39E7MA:,#"I!A'2/_='I4-AX&\/Z9#!%:Z/9PI!,+B,+"/ED P''
MOCO6[11=@8W_  AVA^?%,-*M1-%<-=1R",!EE889P?4CJ:V:**0!1110 444
M4 0Q?Z^;\*FJ&+_7S?A4U !1110 4444 %%%% !1110 4444 %%%% !117 7
MVOZK:PZQJ(OV,=G>F!+0Q1[&3I@';NW<YZ_A32N!W]%<%#\3([.WL%GA>Y:6
M(,\GF() 2I8911QT]13-8^(&H?V>AM-/-O</%'<;FF1@J-(% QCDG]*KE8KG
MH%%<,_Q0BAE6WDT^7[6C,L\2ONV@-MRN!\Q[XXK3T7QO#K.NS::D.TJAD219
M0X(!P00.A]LFERL+EWQ;JKZ)H<]]'&LKP88(Y(![=OK7G/\ PNK4/^@;;?\
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MTI:* $P!VHP,TM% $-W96]_;26]S!%<6\BE7BE0,C ]00>"*D5%10JJ%4<
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M (]V^H_F*FJ&[_X]V^H_F*FH **** "H)/\ CZA^C5/4$G_'U#]&H GHHHH
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M. _X=R?&C_H':+_X-E_^)H_X=R?&C_H':+_X-E_^)KO_ /AZCXO_ .A'T/\
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M_F: )J*** "BBB@"&T_X]UJ:H;3_ (]UJ:@ HHHH AO/^/=_P_G4HZ5%>?\
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M5#=_\>[?4?S%34 %%%% !4$G_'U#]&J>H)/^/J'Z-0!/1110!#!_K9_]\?\
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M:Z]:?9KM7*!@ZM&Y1E8="#VKZ8_X5-X6_P"@8?\ P(E_^*H_X5-X6_Z!A_\
M B7_ .*HYT7#A?,*<E.%2*:\W_\ (GRS;^"]+@CO4*33K>(%G^T3%R^.^3SG
MWI(/!.EPQ74;"XN3<QB&1[B=G?8.@![8KZG_ .%3>%O^@8?_  (E_P#BJ/\
MA4WA;_H&'_P(E_\ BJ7-$ZO[!S=W_?K6WVI=+>7DON/EW3_"ECIMW;W4;W,D
MUO$88VGF+X0]N:?9>%M-T\ZAY4!Q?$F=7;(.>P]!S7T__P *F\+?] P_^!$O
M_P 51_PJ;PM_T##_ .!$O_Q5'-$F7#V:RO>M'7SET=^W?4^5K'P/IFGW5M<1
MM=O); K%YUP7"J1RH![<]*6W\$:9;+$J&Z\N&X%S'&TY*H_/0=ASTKZH_P"%
M3>%O^@8?_ B7_P"*H_X5-X6_Z!A_\")?_BJ.:);R+-Y.[KK_ ,"EY^7F_O9\
MLW/@O2KN]DN'CF E<22VZ3,L,C#H63H34[>%[!Y=0DVR!K^,1S8? VCIM]*^
MG_\ A4WA;_H&'_P(E_\ BJ/^%3>%O^@8?_ B7_XJCFB3_J_FUDO;+3^]+R\O
M)?<CYNL+&+3K*&TA#>3$FQ0QR<>YK%/@'1C836?DR^3+/]H;]Y\V[V..GM7U
M7_PJ;PM_T##_ .!$O_Q5'_"IO"W_ $##_P"!$O\ \51S1(AP[FE)N4*L4V[O
M66_?8^7-1\(Z=J<ZS/\ :()!&(2UM.T>]!T5L=15F#0+.VU*.^B1TFC@^SJ-
M_P H3Z>OO7TU_P *F\+?] P_^!$O_P 51_PJ;PM_T##_ .!$O_Q5'-$;X>S1
MQY'6C;;>6WW'RTO@[34OS=*+A<R^<8!.PA+_ -[9TS6CJFE6VLV;VMW'YD+<
M\'!![$'L:^E/^%3>%O\ H&'_ ,")?_BJ/^%3>%O^@8?_  (E_P#BJ.>(I<.Y
MI.49RJQO'9WEI^!\L#P3I9L[JW<7$QN@%EGEG+RL!T&X]J6R\%Z78R.X2>=F
MB\D?:)V?8G]U?2OJ;_A4WA;_ *!A_P# B7_XJC_A4WA;_H&'_P ")?\ XJCF
MB:/(<W:<?;JS_O2_R\CY;L?!^G6-PLV;FY9$,<8N[AI1&IZA0>E)I_@[3M,G
M$D/VAMJLL<<D[,D0/78O05]2_P#"IO"W_0,/_@1+_P#%4?\ "IO"W_0,/_@1
M+_\ %4<T1/(,VE>]9:[^]+_+S?WL^9K#0[33M)_LV)7-KA@5=MQPW7FJ]OX3
MTRWT-M)6%C9,22K/EL^N?6OJ'_A4WA;_ *!A_P# B7_XJC_A4WA;_H&'_P "
M)?\ XJCGB1_J[FEV_;1U=]Y;]]MSY=MO">GV]K=0,)[I;E=LK74S2,1V&3TI
MFF^#M/TJ_AO(FNI+B)#&K3W!D^7TY].U?4O_  J;PM_T##_X$2__ !5'_"IO
M"W_0,/\ X$2__%4<T2_[ S9J2]LK2W]Z6O3MV/G:BOHG_A4WA;_H&'_P(E_^
M*H_X5-X6_P"@8?\ P(E_^*I\Z./_ %4QW\\/O?\ \B?.U%?1/_"IO"W_ $##
M_P"!$O\ \51_PJ;PM_T##_X$2_\ Q5'.@_U4QW\\/O?_ ,B>"Z#_ ,ANP_Z[
MI_.OJ@5RL'PM\,VT\<T>FE9(V#*?/D."/^!5U=9RDF?7Y%E=;+(5(UFGS6VO
M^J1#%_KYOPJ:H8O]?-^%35!]0%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 9OB'P]IWBK29]+U>QMM3TVXPL]I=Q"2*5>N&4\$9P>?2N&_
MX9H^$O\ T37PI_X)X/\ XFO2Z*VA6JTU:$FO1F4Z5.H[SBGZH\T_X9H^$O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 1/;1R,69?F/4@D4W['%_=/_ 'T?\:GHH @^QQ?W
M3_WT?\:/L<7]T_\ ?1_QJ>B@"#['%_=/_?1_QKF;_P ?^$],U%K"ZU>""\#%
M?(=WWDCK@=_PKK:\WU*Y>7XHZA?,D@M]$T=F5MK$%W))QV)P*J*ON)FS%\1/
M!\UPL":W:-(T@B'[XXW_ -W/3/MFMBXU;1[36+;29KV"+4KE#)#:--B211U(
M7.2!7B4-KJ^D^!M MM:NHH?#6K3M/>O!92"ZA+,9%5B7(VM@ L%!'I3%.K-X
M@TCQIJ&C3Q0SZDHBG,JLT5IL*QIY8&X9QDY]:UY%T8KGKLOCKPM#?R61U6 W
M,<GE/&KLQ5_[IQWKHQ:0L 0"0>?O'_&O&?A=K4,6EI-_PF+"[NKF:[?18X8&
ME9BQ.P KOR0!QG-6OA+J=WJ'BR]\S4;[4HC$\IN!<2&([G.$F@D'[F5>F$."
M.HJ7"UPN>N?8XO[I_P"^C_C5 ZEI(TZ>_P#MD)LH-WFW FRB;?O9.>U>':SX
MQU2Z\8LT#WB7'VR<26K7L^^&".-OD:%4$:AN,$L6/8UO1:;'8?!#2=/L!),V
MJRPQL?,=^9)-SY+$D# (-'):UPN>OPPVUQ"DL9WQNH965R00>01S3_L<7]T_
M]]'_ !KY[TC7O$4%\]R+FY?4+/[3)=6=O-<.4A4$)$86C\J/'!4\DX/6J=GX
MFU.9=6CBURYM+9K2W5[Y;NZO(?.=]Q:1RJ^4,#:QB "YI^S?<+GT3</8VDL$
M4TJ123MLB1Y""YQG &>:G^QQ?W3_ -]'_&O#/ :CQ#XW\/R7PU"-+6"XN;>.
M[OI9XRQ?;^XD.#(F!D;\G!YJ7Q#KESJWBOQ#]BU+4CJ\%];VFF:?;7,BQ?)C
MS7* [2/O!B00.*7)K8+GMWV.+^Z?^^C_ (T?8XO[I_[Z/^->#P>(-1=+6\CU
M'63KZFYDUF.(2RK9Q8*J/(^X"IP5 &2 3S67;ZW?)H4\1UN]3_2(E-\U]<2:
M;>%5W,#/_K;=FS@C) 88I^S87/?=3U+2=&!:^NH[10AD+2R%5"@@9)Z=2*?<
MWNF6;6BSW,<37;B.W#RD&5B,X7GDXYKYZU+5;W5M+6UO[G6K72Y?L5LZWTSR
M/"&<RN^X ;@%"CS",XQDUH-#?ZS=3Q6MSJ+Z;:0WVH:9<3SR>8B!0L;"1CNP
M2KD9/0^E'L_,+GT#]CB_NG_OH_XT?8XO[I_[Z/\ C7G7@;6M0U'PKJ7C"\DN
MA%-:;K.T=F^6*-.&V=-[D$YQGD"O/M2CUW1;?2EO]4OVBNM--PTESJ-VCW%V
MQ.U8_*5B2@*XCXSGG/:5"[M<=SWQ;C3FU)M/$Z&]6,3- )#O"$D!L9Z9!_*G
MS26-M<P6\LJ1SSY\J-I"&?'7 SSBO )=5U2TN;J?5)ITGGG@T^XOFGEM$(AA
M#,K.J,Z[F)X4 D@\^N5;7NLZE8VVJ+<7BZO::5+-8F26X8Q))<[#RPW/LC&<
MLI(X)!Q5^S\Q7/IO['%_=/\ WT?\:J0W>FW$UW%%<QR26AVW"K+GRCC.&YXX
MYKPVPU;45>/SM7N8?"-U>QP7-W;WEU*JE8\MLN)%5@KM@$I@ @@'FM+0]]M\
M%?%VIJ;N8ZA+=/&UP)!-L+;$+=&X7!R>PYJ>2P7/9;,V>H6L=S;2+/!(-R2Q
MR$JP]0<\U2UW6=&\,P13:I>164<K^7&99"-[8S@#J3BO%+%I;*-].LK_ %6+
M6+:YM;?1K&"XF\O[,-A:4KG#H1ORSY X QQ75_$S4(C\0/"UK=ZTN@1V=O-?
M&\=4*^8<(JC>",XWT<FM@N=UIWB?P]JSVB6FIVUP]V',"I/DR;/OX&>HSR.U
M,N/%OAJU6],NK6J"RE$%Q^__ -7(1D(>?O>W6O$+U]2U_P -_P!F^'+6YN/$
MT-Y/JXUC:862/+8E(92!),I(6,#'(/  KJ-%;0_#^H^#=2*-9^&4TZ4P7%TK
M8CO'(+M*Q'$C#/S-R?FIN"07/2[;Q+X?O+2SNH-3MI8+N7R('6?B23GY!S][
M@\=>*BU_Q;X=\+2;-6U&&P(3S"9G8 +ZD] *\VOM>T)OB#X>OC#_ ,(_8/+=
M:G)<W@,0NW"K$DG/W=P+$ X) SCFNM\37,?C?Q#H&CVLYGT9T.IW<D1)CG16
MQ%'N'!!;+$?[(]:7+8=S?7Q3X=;4;6P&J6QO+I \,/G_ #.",C SW'(]16B)
MM/.H-8B9#>+&)C )#O"$D!L9Z$@C/M7C5C;R:G.NB>4Z^(+GQ$U_J $1S;01
M.2C$] "HC5>>03CI75_#;P]!9>-O&NI0I<?O+J*U,UT[O)*8XQN;<QZ;F.,8
M''2DXI"3/0_L<7]T_P#?1_QH^QQ?W3_WT?\ &O#]2\17\>I7-W]NU/\ X26W
MU:9Y+!9)1#!81!OO1#Y-C*%(8@DLPP:Z",7O@SX*W^K7-]J-UK=Q8%WFN;B1
MW263A0BDD+M+C  '04<EAW/4/L<7]T_]]'_&C['%_=/_ 'T?\:^?K_5-6LX'
M_L/5[ZYT%OL5O?ZG>7DY3S,.TQ$N&:/.(T9E  )QP<FG6]]JMW##'/J>III-
MO#?ZLJ6]Q= O H"11&5PLCJ6WLI/) &*?L_,5SW;4IK#1[&:\O9DM;6%=TDT
MTA55'J235A+:"10R@E2,@ACR/SKYHUF/4X[&RTO4=3UF2*ZLM/BU66YEEDVR
M/*9789R%V1Q8+ # /S9/-=+I::GK>M1:?87^L/H"RWE_:H;R96N851$C0RYW
M[&D,C*,YP!VI^S\PN>WW$=K:6\L\S"*&)2[N[D!5 R23GIBJ^FWNFZPA>RG6
MY3:K[HW)!5E#*0>X((-> 7^J:A=>';9-.U'5;_5;W3Y+?6UFFE>.*:=DCCC*
M-\L;JS/@* 0H.>U37NK12Z:FC3:O>:3=ZC?W M;M[Z>WBTVRC<1;EPRAF;R_
MD7U8MT!R>S"Y]"_8XO[I_P"^C_C1]CB_NG_OH_XUX=J/B6Z@U+6M#M]3U'[3
M-J%EIEK%YLKRQ6L:+)+<Y[;@)!OS\W'.:S+5]3D^PZG?:AKDJ3Z9?ZY>0?;Y
MXT,18?9[=54C9CGA<-GC..*7)YA<^A/L<0_A/_?1_P :JV5QI^HR726LZ3O:
MRF"98Y23&X )5N>#@@X]Z^?)?$NOI+I%G<WU[_;%O/IUDOF7LZRX)C:6;R43
M:Z,&92\K'IC@]=/X>:G'_;=CJ]O?WEO)=7VH:CK<4\SI!;6S%O*$BM\JG/EE
M3C) 8YQ3]G9!<]Z^QQ?W3_WT?\:/L<7]T_\ ?1_QKC_BCJ,]OH^F".[GL=+N
M;Z./4+^U8JT%N0Q)WKR@9@BEQT#=1UKS:VUF6/4VAU74=;A\%3&[FTLQS3BX
MNF#1K'&L@/F-DF1HU)RP(Z@"I4;JX[GO/V.+^Z?^^C_C1]CB_NG_ +Z/^->+
M:5J,J:G=PZGJGB2;7=/N@+*UB9A(UK%$K[IHP/+*R<AG(.68!<$#'.'Q3K&O
M>'M&T_3M:U%[_P"P!KNZMY)1BZNYTC5=QZM$IF.#PN!TQ3]FQ7/HBY2VL[:6
M>8E(HD+NQ9N% R33TMH)$5U!*L,@[CR*\,U?2KZ.\UI;75M<2-=5L-&LB+^X
M;RR2C7$_WOF8AW!S\HV]JHWNJ>)AIMEKFE76JSZSJ-SJ>I0V\DDKQ16<:.L<
M0AS@[LQ,,C.[IZ4<GF%SZ"^QQ?W3_P!]'_&H8/LES+/'&V]X'V2 ,WRG ./R
M(KR_X:7=OJ7Q!O1I.NZGJ^DV6DP"9KJYEDBDNY78NXWG[VU%X'"DD #FN:BU
M?4M<O;N[N[[6DTJU@U76Y88;B:(S1&8Q6L(VD$ +$[!01R0>_)R:V"Y[W]CB
M_NG_ +Z/^--DMX(D9W^1%&2S.0 /7K7%V]EJS_"_0H+M=3O];%K;^8]G=""<
M3;!N9I&(&,YSG=GT-8/Q!T;7)_@YK=KXAN1J-[(#'!#9%@7,A\N-)2@3S/F<
M$X51P,Y .94;O<=SN;[Q7X;TW3[*^N=5M8+.] :WF>?"RK@'<ISRN"#GH,CF
MIH]?T*777T9-1MVU5$\QK03_ +P+@'.,^A!^A![UY7XD0>&M7\1V'V=Y[^3P
M];:/X>MO++F<,'5P,<</LW],*JD\8K!\5>#!X7M;V#2YKW5$TNU9]1\T[8XC
M.L221JZKO+2!%+')\N(,!@LI%J"?45SWW2[G3M:L8[VPG2[M),[)HI"R-@D$
M@YY&0:74[C3]%T^XOK^=+2S@0R2SS2%411W))KS\>*M=G^#FKZC86D<5];+/
M#82Z?;L$EA1]B3Q1,6(&P%@I)SM!&017$:U9P>(M3@T/3+[5-7\*WU]IEL]Q
M<7<\HEG1I9KADD+9(\I(U?!VAF& &'"4+A<]YL6L]2LX;JV;S8)5#HX9L,/7
MFI_L<7]T_P#?1_QKRGXDZU:P>-;#2[W4M1L].L]%N+IH;.ZF1KJ9V5(8R4(9
MG^20J,Y)]:XS7/$7B4G3;"ZNKRV\2PII.GI&U[,DGGR>49KA88DV2(2Y5FD;
M:#&PP.XH-A<][_M#2S<M;K<QO.LPMV19"2LA7>%..AV\\]JO?8XO[I_[Z/\
MC7S7'=ZQ8V^JZAX:GOH-0E_MG4[E \SJK_:5MH@R'<"4CS(!@GY1P<"MBSN=
M9U%X]*TW5[Y=.U74;.T6YL[VYN67RM\MU-%<RJO#(BH=ORALXY)%/V?F%SW6
MX>QM);>*:5(I+A_+A1Y"#(V"V%&>3@$_0&I_L<7]T_\ ?1_QKYR^TM/KYO+N
MZU:&VL4U>\TN13/<2PH)([>-XU+9DV[9I"#GY7QTXKT;X(SW-Q::J)[JYO!
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6 !B@#%%% "T444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>btai-20231231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 btai-20231231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &T Y0# 2(  A$! Q$!_\0
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MB1\,?BUXK\*Z?I'A:ZL=*OY+>"6YL[GS6C!RN\BX +8(!( !QG Z5Q'_  ]
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M/EG :N5X3*%'FY8_UTMO<T]KBKVNSUC_ (>@?%/_ * '@_\ \ [K_P"2:/\
MAZ!\4_\ H >#_P#P#NO_ ))KR?6?V4_',?BB^TG2-(N9XK1[.!I]8GL=/WW%
MS&KQ0H3=/&\C;AM1)&<@KE5)Q6#:?LZ?$&[TB343H*6D,4$MW)!?ZA;6MU'!
M'+Y4DS6\LBRK$DF5:0H%&#D@ U2P>425U&/3KWVZB=7%+2[/=O\ AZ!\4_\
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M1/-]F+^=Y:N0"^S:.I..:KZCE-[<L?O[[=>HO;8GNSWW_AZ!\4_^@!X/_P#
M.Z_^2:/^'H'Q3_Z '@__ , [K_Y)KP[4/V:?B5IEYI%G/X7F:[U6]CTZ"W@N
M8)9([EXA*L,ZHY-N_EL'VS;"%#,<!20_XK_ ;4?A'X'\$ZWJM_!-?>(GU!)+
M"V:*:.U^S21IQ<12.DN[S,G;C:05.2#A+!93*48QC%N6UM>[_1C]MB4FVWH>
MW?\ #T#XI_\ 0 \'_P#@'=?_ "31_P /0/BG_P! #P?_ . =U_\ )->6:O\
MLJ^)O[*\.7WAV:'78]1\,P>)KYKB6"PCTZ&1V4AY)I@K*NW)?C R2 !FJ.A?
MLK_$'4O%]WH=_HZZ0NGW=G:ZC>7%Y;"*W-R5\KRV,H6=F# JD3,S$@#DBH6$
MRAIOECI_PVVX_:8J]KL]A_X>@?%/_H >#_\ P#NO_DFC_AZ!\4_^@!X/_P#
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MQHY3@94HR=)7:14\364FE(^O_P#AZ!\4_P#H >#_ /P#NO\ Y)H_X>@?%/\
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M;;7=V6WF+VN*[L]<_P"'H'Q3_P"@!X/_ / .Z_\ DFC_ (>@?%/_ * '@_\
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MS/*(Y6DW *J,Q).,9K;ZEE&_+#[UWMW[Z>I'ML5W9[7_ ,/0/BG_ - #P?\
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M/F/K_P#X>@?%/_H >#__  #NO_DFC_AZ!\4_^@!X/_\  .Z_^2:^0**V_LC
M?\^D3]:K?S,^O_\ AZ!\4_\ H >#_P#P#NO_ ))H_P"'H'Q3_P"@!X/_ / .
MZ_\ DFO&/!GP?\.ZI\)&\?>)O%E]H.G?\)"OAX0V&C+?,KM;^=YSDW$6$ #
MA0QX& <\>@>+OV%?%>AV-^FD:I9Z_K5MXADT./30\-I]H06RW"2QO-,N^1D8
M9A4,PPQ!8*37!/#913ER3@D]M4[:;Z[&RJ8J2NFSI_\ AZ!\4_\ H >#_P#P
M#NO_ ))H_P"'H'Q3_P"@!X/_ / .Z_\ DFO +/X"^.K[PK/XBCT15TZ"TN+]
MTFO;>*Y^S0/LFF%LT@F9$8$%@A (ZU<U']FSXDZ7INGWT_A:=H[ZXMK6.&"X
MAFN(Y;A \"2PHYDA+J00)%7J >2*V^HY2G;EC]__  2/;8GNSW/_ (>@?%/_
M * '@_\ \ [K_P"2:/\ AZ!\4_\ H >#_P#P#NO_ ))KYM^('PJ\4?"^XLXO
M$>G):"\$OD3V]U#=02-%(8Y4$L+NF]'4JR;MRDC(&1GM?$OP)T>#X3ZIXZ\+
M>,F\3V&CWUMI]^9-)>RA:26-6)MW=R\H1F"'?'&?XL8QD> RM*+]FK2T35VN
MVZTW#VV(U]YZ'KO_  ] ^*?_ $ /!_\ X!W7_P DT?\ #T#XI_\ 0 \'_P#@
M'=?_ "37R!173_9& _Y](CZU6_F9]?\ _#T#XI_] #P?_P" =U_\DUT/Q _X
M*+?%'P5XPU+1$TCPC=I:,JB9K"Z4ME%;I]J/][%?#]=]\>/^2M>(?^ND?_HI
M*Q>58%58Q]DK6?Z%+$UN5OF_K4^@?^'H'Q3_ .@!X/\ _ .Z_P#DFC_AZ!\4
M_P#H >#_ /P#NO\ Y)KY HK;^R,!_P ^D3]:K?S,^O\ _AZ!\4_^@!X/_P#
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MUZ9-7# 954G[.$(MVOIKII_FB76Q,5S-NQ]&_P##T#XI_P#0 \'_ /@'=?\
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M_AV_\4O^@CX8_P# V;_XS1_P[?\ BE_T$?#'_@;-_P#&:?\ PE_\_/Q[V_\
MD4'/7[?UK_F?/7Q-\2VOC/XD>*_$%E'-%9:MJUW?P1W  D6.69W4, 2 P##.
M"1GN:YJOJK_AV_\ %+_H(^&/_ V;_P",T?\ #M_XI?\ 01\,?^!LW_QFO4CF
M."A%15561S.E4;O8\3T/_DA/C+_L8M%_])M4K@:^TM-_8#^)%I\,?$.@O?\
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M^OM&TK2]:TFSTVPMVMIM8N+2TA4"9X&D13O^<$JVU"P^_MPW$?\ #M_XI?\
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M$_LS3+6&./[,87 N(T,]W*K.[(\C1C "D<Y'A_QB^(W@_P 0_#+X=>#?"/\
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M;S1[>-;VYZ/<W%RETQ+X)( BZEN>1MZ'_AV_\4O^@CX8_P# V;_XS1_P[?\
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MBVZU6>R\1VD$?CG3_%]LD=E;RM+'!8QVTD#YN%"-E796&X$  @9..<_X=O\
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M>BC_ %8_Z??^2_\ VP?Z\_\ 4-_Y/_\ :GZT5+<?ZYJ_)*BE_JQK_&_\E_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYW][#ZIA_P#GW'[D<E_PJ'P)_P!"5X=_\%4'_P 11_PJ'P)_T)7AW_P50?\
MQ%=;11[>M_._O8?5,/\ \^X_<CEH?A!X#(DSX)\.G"G_ )A,'_Q%1_\ "H?
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M#M?M.I7UMI]MN"^==3+$F3T&6(&::CS.R#EBNB-?^T3_ ,\8O_'O\:/[1/\
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M6R\5:+J/VO[)K%A=?9%+7'DW2/Y(&<E\'Y1P>OH:'2FMXO\ $/<\CH/[1/\
MSQB_\>_QH_M$_P#/&+_Q[_&N8'CGPV;!KX>(-*-DL@A-R+V/RQ(1D)NW8W8Y
MQUQ5A?%&C/;V4ZZO8M!?2>5:RBY0K</G&V,YPQSQ@9.:;HS6\7^(O<\C?_M$
M_P#/&+_Q[_&C^T3_ ,\8O_'O\:P9?$^CP1WTDNK6,:6+!+MGN4 MV)P!(<_*
M2>F<5HHZR*&4AE89!!R"*AP<=T5:+Z(N_P!HG_GC%_X]_C1_:)_YXQ?^/?XU
M4HJ;(.6/8M_VB?\ GC%_X]_C1_:)_P">,7_CW^-5**+(.6/8M_VB?^>,7_CW
M^-']HG_GC%_X]_C52BBR#ECV-"[OREU,ODQG#D9.?7ZU%_:)_P">,7_CW^-1
M7W_'[/\ ]=&_G4-)+1#<8WV+?]HG_GC%_P"/?XT?VB?^>,7_ (]_C52BG9"Y
M8]BW_:)_YXQ?^/?XT?VB?^>,7_CW^-5**+(.6/8M_P!HG_GC%_X]_C1_:)_Y
MXQ?^/?XU4HHL@Y8]BW_:)_YXQ?\ CW^-']HG_GC%_P"/?XU4HHL@Y8]BW_:)
M_P">,7_CW^-']HG_ )XQ?^/?XU4HHL@Y8]B_)>[(HF$,>7!)Z^N/6H_[1/\
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M)%I.3LA-V.HHK!O_ !]X8TK5Y]*O?$>DV>J06S7DMC<7T23QP*I9I60MN"
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M-L>[<V5(;@=#GI4^J>,_#^B:U8:/J.NZ98:MJ!Q9V%U>1QSW/./W<;$,_/'
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M'D2K+:1FZ:0QZ?((IEG:50'NH0OEKNCP=SRU6:MSK37^M!^[V/1[?X17EO\
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M/W6MB#_AGC63%K"#Q38I%>2++:VD=KJ2VUBPF,I>)1J>^%\X ^SO"H&X%6!
M6S;?L_:I!"EO)XO6\MKR.RCUA[RPDGN;C[+<R3Q^1,]P6BYD*_O/.; !W;RS
M'GOA#?>.-=^(GAG5?%CZ_$JZ7JMD%FTYDMY2+N)HFF8VD)1GB"D$I#N\E0$!
MWJ8K6V^(W@[_ (2>\T ZE=&^U#Q'+;Z-<:?']GCD#/):S*WEB0EW' :38X8
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M],_^_B_XT7069#14WV.3_IG_ -_%_P :/L<G_3/_ +^+_C1=!9A-_P >]O\
M[I_]"-0U<FM9#! /DX!_Y:+ZGWJ'[')_TS_[^+_C230VF0T5-]CD_P"F?_?Q
M?\:/L<G_ $S_ ._B_P"-.Z%9D-%3?8Y/^F?_ '\7_&C[')_TS_[^+_C1=!9D
M-%3?8Y/^F?\ W\7_ !H^QR?],_\ OXO^-%T%F0T5-]CD_P"F?_?Q?\:/L<G_
M $S_ ._B_P"-%T%F0T5-]CD_Z9_]_%_QH^QR?],_^_B_XT7068MKTG_ZYG^8
MJ"KEM:R*)L[.8R/]8OJ/>H?L<G_3/_OXO^-)-78[,AHJ;[')_P!,_P#OXO\
MC1]CD_Z9_P#?Q?\ &G="LR&BIOL<G_3/_OXO^-'V.3_IG_W\7_&BZ"S(:*F^
MQR?],_\ OXO^-'V.3_IG_P!_%_QHN@LR&BIOL<G_ $S_ ._B_P"-'V.3_IG_
M -_%_P :+H+,AHJ;[')_TS_[^+_C1]CD_P"F?_?Q?\:+H+,AJ:]_X^I/\]J/
ML<G_ $S_ ._B_P"-37=I(UPY&S'O(H[?6E=7'9E.BIOL<G_3/_OXO^-'V.3_
M *9_]_%_QIW0K,AHJ;[')_TS_P"_B_XT?8Y/^F?_ '\7_&BZ"S(:*F^QR?\
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M&,[3MR@&<$#C(-0W/Q?\06'A+2M<,4&H/=R6OF62Z-=6F%D4LRQS22%)#@$
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MJ7XN?'W5/A]\4]'\.6@TI[6<V!EMKDQBZF6XN3$[)ON8F"HJELQ0W RK;_+
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M3_D&0_\  O\ T(T4:)_R#(?^!?\ H1HKS9_$SJ6R.?U7_D(3_P"]56K6J_\
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MK'B_Y8_<_P#,/J-/N_Z^1\6-^SI\0U56/A[AN1_IMO\ _'*3_AG?X@_]"_\
M^3MO_P#'*^VIO^/>W_W3_P"A&H:%Q'B_Y8_<_P#,?U&EW?\ 7R/BO_AG?X@_
M]"__ .3MO_\ '*/^&=_B#_T+_P#Y.V__ ,<K[4HH_P!8\7_+'[G_ )B^HT^[
M_KY'Q7_PSO\ $'_H7_\ R=M__CE'_#._Q!_Z%_\ \G;?_P".5]J44?ZQXO\
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M%'^L>+_EC]S_ ,P^HT^[_KY'Q7_PSO\ $'_H7_\ R=M__CE'_#._Q!_Z%_\
M\G;?_P".5]J44?ZQXO\ EC]S_P P^HT^[_KY'Q7_ ,,[_$'_ *%__P G;?\
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MZON#Z_#^4^_O)B_Y^%_[Y;_"CR8O^?A?^^6_PKX!_P"%E>+O^AJUO_P8S?\
MQ5'_  LKQ=_T-6M_^#&;_P"*H_U:K?\ /U?<'U^'\I]_>3%_S\+_ -\M_A1Y
M,7_/PO\ WRW^%? /_"RO%W_0U:W_ .#&;_XJC_A97B[_ *&K6_\ P8S?_%4?
MZM5O^?J^X/K\/Y3[^\F+_GX7_OEO\*/)B_Y^%_[Y;_"O@'_A97B[_H:M;_\
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MG\FJ&DNHPKB++XR^%=0\0?V/%<Z@+C[=+I@N)M'O(K,W4;,K1"Z:(0EMR,H
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M ;H<'!-5?A3\+W\$ZCXBU;4X[2[UO5+B(C4M_GW9MTM+:/RY)S&A;][%*^
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M!7P'$,,,JB</XG6W;S\SVL$ZCC9_";5%%%?''ID]KTG_ .N9_F*@J>UZ3_\
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M^;_XU1_PR;XN_P"@CHG_ '_F_P#C5?4/]NO_ ,^MO^3_ /Q5']NO_P ^MO\
MD_\ \51_:^8^7W!S8/S/E[_ADWQ=_P!!'1/^_P#-_P#&J/\ ADWQ=_T$=$_[
M_P W_P :KZA_MU_^?6W_ "?_ .*H_MU_^?6W_)__ (JC^U\Q\ON#FP?F?+W_
M  R;XN_Z".B?]_YO_C5'_#)OB[_H(Z)_W_F_^-5]0_VZ_P#SZV_Y/_\ %4?V
MZ_\ SZV_Y/\ _%4?VOF/E]P<V#\SY>_X9-\7?]!'1/\ O_-_\:H_X9-\7?\
M01T3_O\ S?\ QJOJ'^W7_P"?6W_)_P#XJC^W7_Y];?\ )_\ XJC^U\Q\ON#F
MP?F?,+?LD^+T1&.I:)AP2/W\WKC_ )Y4S_ADWQ=_T$=$_P"_\W_QJOJFXUIU
MM;5OL\!W*QP0W'S'_:JO_;K_ //K;_D__P 54K.,Q?;[AMX-=SY>_P"&3?%W
M_01T3_O_ #?_ !JC_ADWQ=_T$=$_[_S?_&J^H?[=?_GUM_R?_P"*H_MU_P#G
MUM_R?_XJJ_M?,?+[A<V#\SY>_P"&3?%W_01T3_O_ #?_ !JC_ADWQ=_T$=$_
M[_S?_&J^H?[=?_GUM_R?_P"*H_MU_P#GUM_R?_XJC^U\Q\ON#FP?F?+W_#)O
MB[_H(Z)_W_F_^-5+:_LF>*&N8A<ZII$=N6'F/%)*[A<\D Q@$^V1]:^G/[=?
M_GUM_P G_P#BJ/[=?_GUM_R?_P"*I?VOF/=?<@YL'YE3P=X.TSP-H4&E:5!Y
M4$?+.>7E?N['N3_]8<"MNL_^W7_Y];?\G_\ BJ/[=?\ Y];?\G_^*KY^=*M4
MDYSU;.U8Z@E9?D:%%9_]NO\ \^MO^3__ !5']NO_ ,^MO^3_ /Q53]7J=A_7
MZ'=_<:]KTG_ZYG^8J"J]GK3NMQ_H\ VQ$\!N>1_M57_MU_\ GUM_R?\ ^*J5
M0J7>A3QU%).YH45G_P!NO_SZV_Y/_P#%4?VZ_P#SZV_Y/_\ %57U>IV)^OT.
M[^XT**S_ .W7_P"?6W_)_P#XJC^W7_Y];?\ )_\ XJCZO4[!]?H=W]QH45G_
M -NO_P ^MO\ D_\ \51_;K_\^MO^3_\ Q5'U>IV#Z_0[O[C0HK/_ +=?_GUM
M_P G_P#BJ/[=?_GUM_R?_P"*H^KU.P?7Z'=_<:%%9_\ ;K_\^MO^3_\ Q5']
MNO\ \^MO^3__ !5'U>IV#Z_0[O[C0J:]_P"/J3_/:LG^W7_Y];?\G_\ BJLZ
MCK3Q7DB_9X&P1R0V>G^]4^PJ7V*^O4;7N3T5G_VZ_P#SZV_Y/_\ %4?VZ_\
MSZV_Y/\ _%57U>IV)^OT.[^XT**S_P"W7_Y];?\ )_\ XJC^W7_Y];?\G_\
MBJ/J]3L'U^AW?W&A16?_ &Z__/K;_D__ ,51_;K_ //K;_D__P 51]7J=@^O
MT.[^XT**S_[=?_GUM_R?_P"*H_MU_P#GUM_R?_XJCZO4[!]?H=W]QH45G_VZ
M_P#SZV_Y/_\ %4?VZ_\ SZV_Y/\ _%4?5ZG8/K]#N_N-"IO^7+_MI_2LG^W7
M_P"?6W_)_P#XJK/]M/\ V=O^SP?ZW;CYL=/]ZI="HNA2QU%]2>BL_P#MU_\
MGUM_R?\ ^*H_MU_^?6W_ "?_ .*JOJ]3L3]?H=W]QH45G_VZ_P#SZV_Y/_\
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M%1&5I6"K@DE/%W[.6I737%OH&F>'K6Q34[B\TV)GAC@L8Y8+5<"UDL)T+>;
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M@"W8?=NO^N)_F*J5;L/NW7_7$_S%5*A;LTE\,0HHHJS,**** "BBB@ HHHH
M**** "K>J_\ (0F^H_D*J5;U7_D(3?4?R%0_B7S_ $-%\#]5^I4HHHJS,***
M* "BBB@ HHHH **** "K?_,)_P"V_P#[+52K?_,)_P"V_P#[+42Z&D.OH5**
M**LS"BBB@ HHHH **** "BBB@ JWI/\ R$8/K_2JE6])_P"0C!]?Z5$_A9I3
M^./J5****LS"BBB@ HHHH **** "BBB@ HHHH ]$\)_\@"U_X'_Z&:*/"?\
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M .?63_O]_P#8U4HHY%_38<[\ON1;\^S_ .?63_O]_P#8T>?9_P#/K)_W^_\
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M_P#8T>?9_P#/K)_W^_\ L:J44<B_IL.=^7W(M^?9_P#/K)_W^_\ L://L_\
MGUD_[_?_ &-5**.1?TV'._+[D>C^&61M#MC&A1/FPI;)'S'O13/"?_( M?\
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M'_@%6AW?W?\ !*E%6_[5O/\ GYD_[ZH_M6\_Y^9/^^J+R[?C_P  +0[O[O\
M@E2BK?\ :MY_S\R?]]4?VK>?\_,G_?5%Y=OQ_P" %H=W]W_!"Z_X\[+_ '&_
M]#-5*U+G4[M;2S(N) 2K9.>OS&JW]JWG_/S)_P!]5$'*VW?\_0TFH7W>RZ>7
MJ5**M_VK>?\ /S)_WU1_:MY_S\R?]]5=Y=OQ_P" 9VAW?W?\$J45;_M6\_Y^
M9/\ OJC^U;S_ )^9/^^J+R[?C_P M#N_N_X)4HJW_:MY_P _,G_?5']JWG_/
MS)_WU1>7;\?^ %H=W]W_  2I15O^U;S_ )^9/^^J/[5O/^?F3_OJB\NWX_\
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M0[O[O^"5**M_VK>?\_,G_?5']JWG_/S)_P!]47EV_'_@!:'=_=_P3N?"?_(
MM?\ @?\ Z&:*?X8E>?0[9Y&+N=V6/7[QHKY6M_%EZL^TP_\ !A;LOR.(\0?\
MAJ\_ZZ&L^M#Q!_R&KS_KH:SZ^HI?PX^B/C:W\27JQ'#%&"$*V."1D _2OF[X
M%>)_!6A_#/PYX/\ &/V%_'$.J2?;-"N[3[3J']I><\@N# %9SP1()\;0I!W
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MK*$$Y1D]8_Y>?YGO-%-C#B-1(0SX&XJ, GO@4ZO@S]@04444#"BBB@ HHHH
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M_D(P?7^E1/X6:4_CCZE2BBBK,PHHHH **** "BBB@ HHHH **** /1/"?_(
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M=)XBPZ$JX(R/I51_ GAJ34=,U!_#VE/?Z9$L%A=-91&6TC7.U(FVY11DX"D
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M_P#?Q?\ &C_A$-4_YX+_ -_%_P :/;TOYE]X?5J_\C^XQJ*V?^$0U3_G@O\
MW\7_ !H_X1#5/^>"_P#?Q?\ &CV]+^9?>'U:O_(_N,:BMG_A$-4_YX+_ -_%
M_P :/^$0U3_G@O\ W\7_ !H]O2_F7WA]6K_R/[C&HK9_X1#5/^>"_P#?Q?\
M&C_A$-4_YX+_ -_%_P :/;TOYE]X?5J_\C^XQJ*V?^$0U3_G@O\ W\7_ !H_
MX1#5/^>"_P#?Q?\ &CV]+^9?>'U:O_(_N/G7QU_R._B'_L(W'_HUJPZ^KM0\
M+:C/?W,J0J4>1F4[QT)-5_\ A$-4_P">"_\ ?Q?\:^BI<04H4XQY5HE]K_@'
MPU?@VM5K3FJCU;?P=WZGS-H^CW.NWR6MJF^1N23T4=R3Z5[5X;\-VWAJQ$$
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MX+_W\7_&K]O2_F7WD?5J_P#(_N,:BMG_ (1#5/\ G@O_ '\7_&C_ (1#5/\
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M_"VHP7D4CPJ%4\G>*B=>DXOWE]YI3PU933<'OV.>HK9_X1#5/^>"_P#?Q?\
M&C_A$-4_YX+_ -_%_P :OV]+^9?>9_5J_P#(_N,:BMG_ (1#5/\ G@O_ '\7
M_&C_ (1#5/\ G@O_ '\7_&CV]+^9?>'U:O\ R/[C&HK9_P"$0U3_ )X+_P!_
M%_QH_P"$0U3_ )X+_P!_%_QH]O2_F7WA]6K_ ,C^XQJ*V?\ A$-4_P">"_\
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M/_135^=WP$^$_P 1?C'\,;?0_!&I2Z58+K5S+JERUX]O;@>1;",2;,ESR^
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MYEB38=I#&0+ES\N""HR HS\N3'LJ-_C'[:M;6!U^G:M#JDEZD(;_ $2?R'+
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M9^8#&2,?+D\M8?M)W>I7.EV4&FZ:U]=7$5K)%]L;Y&FE\J)@=NU@&(+>6TG
M;I@&O>Z* /F[P5^T!XIU3P[8PWMMIJ7P@M))M2O;V*/[TEJ9))(5 9(BEP<,
M%P %.3NX]$M/BY<R>%?$FKW6G0V1T1UL9EFE8(U\'*2H"%)\L%HMKXP=QR0
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M7O/C)XAL[V]M[+2+;4TM[E[<":X*322/?W]M"BA4"[1]D3D\X?\ B(R?:**
M/#;K]HV\>[MY;#P_;W&EW47VFUDNM1CM9;F$RR1 HKX)(,+2-M#81TZ9YQ[C
M]H[5RUC>"SM3;B*9Y+"SN TT\D89RJL4967;L!,9;#,,-U%?150W=I%?VDUM
M.GF03(T<B9(W*1@CCV- 'A5W^TI<6-U]D$&AZE,FHK9M+I]^SQ2QLMN?,B8H
M V#.P(!)!3&"#N#=$_:!U2/3!+>PZ==S@),\GVO9'/\ Z+9.;>U 3+S%KECL
M8G!&,X8;/:]"\/6'AJS>VL(G1))&FD>:9YI)'.,L\CEF8X &23P .@%:5 '@
MNK?M':GH7ANVO+[2=,2_N]-M-7MH5O'"/!/',P3<R "0& YR0,.,;BI!Z:U^
M+KV'@C3->U P^3?:OJ=H9+EUB6**$WK0@D<9Q;1Q^Y;/)Z^J44 ?/UM^TWJ%
MU:N1H>GQ7#RQ1QB;4T2*)625FDED;"(#Y0 5F5MT@&#C+=7X'^-ESXKO=:AN
M-$2UDL; WT=G;70N9WV@93* KDE@ "5.>@8?-7JU% 'C7@CXJ:]XZ^(VD:?&
MVFPZ1'87-Y=MIUQ]H2=MEL4CWM&"&0W(W*-O8D\[:P)?VHIFU2]M8;/1EAA7
MSX[JXU!HXY(_+N7"<IN$A^S$895/SCY>.?H2JEUI5I>7MG>30+)<V;,UO(<Y
MC+*5;'U!(H \:/Q_U:?4+>RL]'TZYN[J^NK1;07C_:+40S-'BXC"$H[A=R+W
MVM]1-8?'V_O(H672+*[-WY%O;MI]X9HTO+A-UO;2L57:R[7$A_AS&<#=@>PZ
M?IMMI4#0VD*P1-++.RKT+R2-([?B[L?QJS0!\^3_ +2&L7OAB]N8M)TS2;A[
M:2>"XN=4C>.$^1)(() H;;< H!Y;A<Y/'RD'JM>^,=WX<O;*T>'3[EVTNPO&
MCFNC%=7#W$DL;>3&%(81^7O;T4GZUZS5:/3;:+4I[](56\GBC@DF[LB%V1?P
M,CG_ ($: /%?^&@]4M+>T:^TK2(KBX:"(VZ:B^^$36Z3K=.#'D6R+($>3'#*
MWTJM'^T7=Z-X?O)[^WL-5U".:1H(K.Z&+M/M]_#MA.WY@J6D>&QSO!/O[Y10
M!X9J_P =]6T>:\D7_A'-3@C@@"&RU/*,[/+OD1F5=ZJJQJP4DAF&,D[:W=8^
M*.J:?XGTF:"*WFT&ZT[3KB>)RXDC-U=B /'\@9L;U)#;>%/&3QZM10!X5X<_
M:.O-?N?)CT6VE6YN(K2RFMKDR1M--M,*O\H8#8)W)(4XB'RC=@:GA_XY:CK?
M@;Q'K[:':02Z=;PW$-LNHQRY,F[]S-LW&*1,#<& /S?=&#7L-% 'B%W\>M7@
MN+[3FTS3(M3LIFLWB^UN7N9C)+&LEO'LR\:>4K/G! +?W06MZG\7=3TC5_"'
M[_3+RWU31X+F:V6<*UQ-)/#&3;84ES^])"\ @=LY'LE% 'STO[3NKO913KX7
ML 98S<@2:W;HJ*$+&W<EL)<=!L;!^\=ORD5W&E_%C49;SQ$MYH\3PV-OJ-U9
MI93,\LZVEU);E&4J,,Y12,9ZD5Z;10!X7:?M"ZI<+HZ2:/I43WUZ;0SQ:M'<
MQ<BWV%1#O8\W!!P#@QC=L#@K@W7[3.I>1HMG$VC_ &FX&G+/J NML222/;/+
MO#+\L925P64,%X(;)VK])44 ?.=]^T-K=GKL\BP6MU:B/;'!%=1K;,1*8FE6
M5U4NC8\Q!N7(( SD5H']H+6;""_U-],L]1TRYEBCL42X:(PR-8V<[;V>-0(0
M9I&+M@@#)  X]\HH \.TWXY:QX@USPY8K:Z=I7VC4H[6YC6^2XEN4/V@%X0H
M96B)A7Y@Q()*Y^4[O<:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%%>4>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
/!1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>btai-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 8:30:45 PM-->
<!--Modified on: 3/22/2024 8:30:45 PM-->
<xsd:schema targetNamespace="http://www.bioxceltherapeutics.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:btai="http://www.bioxceltherapeutics.com/20231231" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>40501 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40701 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" id="DisclosureDebtAndCreditFacilitiesDebtSummaryDetails">
        <link:definition>40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" id="DisclosureDebtAndCreditFacilitiesInterestDetails">
        <link:definition>40906 - Disclosure - Debt and Credit Facilities - Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" id="DisclosureLeasesMaturitiesDetailsCalc2">
        <link:definition>41002 - Disclosure - Leases - Maturities (Details) - Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" id="DisclosureLeasesMaturitiesDetails">
        <link:definition>41301 - Disclosure - Leases - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" id="DisclosureIncomeTaxesDeferredTaxDetails">
        <link:definition>41601 - Disclosure - Income Taxes - Deferred Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>41602 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31203 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" id="DisclosureRestructuringDetails">
        <link:definition>40401 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" id="DisclosureTransactionsWithBioxcelLlcDetails">
        <link:definition>40801 - Disclosure - Transactions with BioXcel LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" id="DisclosureDebtAndCreditFacilitiesCreditAgreementDetails">
        <link:definition>40902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" id="DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails">
        <link:definition>40903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" id="DisclosureDebtAndCreditFacilitiesWarrantsDetails">
        <link:definition>40904 - Disclosure - Debt and Credit Facilities - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" id="DisclosureCommonStockFinancingActivitiesDetails">
        <link:definition>41101 - Disclosure - Common Stock Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" id="DisclosureStockBasedCompensationDescriptionDetails">
        <link:definition>41201 - Disclosure - Stock-Based Compensation - Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" id="DisclosureStockBasedCompensationNonOptionsDetails">
        <link:definition>41202 - Disclosure - Stock-Based Compensation - Non-options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" id="DisclosureStockBasedCompensationOptionsDetails">
        <link:definition>41203 - Disclosure - Stock-Based Compensation - Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>41204 - Disclosure - Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>41205 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" id="DisclosureStockBasedCompensationEsppDetails">
        <link:definition>41206 - Disclosure - Stock-Based Compensation - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" id="DisclosureFairValueMeasurementsHierarchyDetails">
        <link:definition>41501 - Disclosure - Fair Value Measurements - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" id="DisclosureFairValueMeasurementsLevel3Details">
        <link:definition>41502 - Disclosure - Fair Value Measurements - Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" id="DisclosureFairValueMeasurementsInputsDetails">
        <link:definition>41503 - Disclosure - Fair Value Measurements - Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41801 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41901 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>10401 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>10501 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10701 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" id="DisclosureTransactionsWithBioxcelLlc">
        <link:definition>10801 - Disclosure - Transactions with BioXcel LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" id="DisclosureDebtAndCreditFacilities">
        <link:definition>10901 - Disclosure - Debt and Credit Facilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" id="DisclosureDerivativeFinancialInstruments">
        <link:definition>11001 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" id="DisclosureCommonStockFinancingActivities">
        <link:definition>11101 - Disclosure - Common Stock Financing Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11201 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11301 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11401 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11501 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11601 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11701 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11901 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>30503 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30703 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" id="DisclosureTransactionsWithBioxcelLlcTables">
        <link:definition>30803 - Disclosure - Transactions with BioXcel LLC (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" id="DisclosureDebtAndCreditFacilitiesTables">
        <link:definition>30903 - Disclosure - Debt and Credit Facilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>31303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31503 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31603 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31703 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" id="DisclosureDebtAndCreditFacilitiesMaturitiesDetails">
        <link:definition>40905 - Disclosure - Debt and Credit Facilities - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>41302 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>41401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41701 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20231231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btai-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="OrganizationAndPrincipalActivitiesAbstract" id="btai_OrganizationAndPrincipalActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredOfferingCostsPolicyTextBlock" id="btai_DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DevelopmentMilestonesMember" id="btai_DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SalesMilestonesMember" id="btai_SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentsPotential" id="btai_CollaborativeArrangementMilestonePaymentsPotential" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BioxcelCorporationMember" id="btai_BioxcelCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementMilestonePotentialPercent" id="btai_CollaborativeArrangementMilestonePotentialPercent" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PatentCostsPolicyTextBlock" id="btai_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="JefferiesMember" id="btai_JefferiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncentiveAwardPlan2020Member" id="btai_IncentiveAwardPlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlan2020Member" id="btai_EmployeeStockPurchasePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" id="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPlan2017Member" id="btai_StockPlan2017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="btai_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FinancingActivitiesAbstract" id="btai_FinancingActivitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancingActivitiesDisclosureTextBlock" id="btai_FinancingActivitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" id="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsLeaseAccountingLiability" id="btai_DeferredTaxAssetsLeaseAccountingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OperatingLossCarryforwardsNoExpiration" id="btai_OperatingLossCarryforwardsNoExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AgreementCommitmentPeriod" id="btai_AgreementCommitmentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CreditFacilityMember" id="btai_CreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingAgreementMember" id="btai_RevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaidInKindInterestPercentage" id="btai_PaidInKindInterestPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TickingFeesPercentage" id="btai_TickingFeesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdRatioOfDebtToRevenueRatio" id="btai_ThresholdRatioOfDebtToRevenueRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" id="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityInvestmentMember" id="btai_EquityInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantOaktreeAndQiaMember" id="btai_WarrantOaktreeAndQiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsBasedOnNetSalesPercent" id="btai_BorrowingsBasedOnNetSalesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PremiumSharePricePercent" id="btai_PremiumSharePricePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RightToPurchaseStockLenders" id="btai_RightToPurchaseStockLenders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" id="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheMember" id="btai_TrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheBMember" id="btai_TrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheCMember" id="btai_TrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnkosxcelWarrantMember" id="btai_OnkosxcelWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdLiquidityEventAmountForExerciseOfWarrants" id="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfFairValueConsiderationToBePaid" id="btai_PercentageOfFairValueConsiderationToBePaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfValuationApplicableToInitialProfits" id="btai_PercentageOfValuationApplicableToInitialProfits" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DebtInstrumentInterestRateDiscountRatePercentage" id="btai_DebtInstrumentInterestRateDiscountRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfOutstandingLoan" id="btai_PercentageOfOutstandingLoan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfaAdministrativeAgentMember" id="btai_OfaAdministrativeAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetCashRequiredMinimum" id="btai_NetCashRequiredMinimum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SubsidiaryOwnershipPercentage" id="btai_SubsidiaryOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MeasurementInputProbabilityOfExerciseMember" id="btai_MeasurementInputProbabilityOfExerciseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TimeBasedProfitSharingUnitsMember" id="btai_TimeBasedProfitSharingUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" id="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MeasurementInputEstimatedPremiumMember" id="btai_MeasurementInputEstimatedPremiumMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CapitalizedResearchAndDevelopment" id="btai_CapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" id="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDate2022Member" id="btai_ShareBasedPaymentArrangementGrantDate2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementGrantDate2023Member" id="btai_ShareBasedPaymentArrangementGrantDate2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsOnkosxcelMember" id="btai_RestrictedStockUnitsOnkosxcelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheDMember" id="btai_TrancheDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LineOfCreditFacilityExitFeePercentage" id="btai_LineOfCreditFacilityExitFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityAmendmentFeePercentage" id="btai_LineOfCreditFacilityAmendmentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LineOfCreditFacilityInvestmentAllowed" id="btai_LineOfCreditFacilityInvestmentAllowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsReceivablePaymentTerm" id="btai_AccountsReceivablePaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EquityInvestmentRightAmountUnfunded" id="btai_EquityInvestmentRightAmountUnfunded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ConversionOfAccruedInterestToLongTermDebt" id="btai_ConversionOfAccruedInterestToLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" id="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NewWarrantsMember" id="btai_NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheTwoMember" id="btai_TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockMaximumValueSharesToBeIssued" id="btai_SaleOfStockMaximumValueSharesToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VimalMehtaMember" id="btai_VimalMehtaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RichardSteinhartMember" id="btai_RichardSteinhartMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="JavierRodriguezMember" id="btai_JavierRodriguezMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MatthewWileyMember" id="btai_MatthewWileyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FrankYoccaMember" id="btai_FrankYoccaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" id="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FromAndAfterFundingOfTrancheBLoansMember" id="btai_FromAndAfterFundingOfTrancheBLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" id="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" id="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Warrants2024Member" id="btai_Warrants2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentIncrementalOnVariableRatePercent" id="btai_DebtInstrumentIncrementalOnVariableRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodOneMember" id="btai_PeriodOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodTwoMember" id="btai_PeriodTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodThreeMember" id="btai_PeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>btai-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 8:30:45 PM-->
<!--Modified on: 3/22/2024 8:30:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureInventoryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesInterestDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureLeasesMaturitiesDetailsCalc2" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxesDeferredTaxDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638467362421629575" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638467362421629575" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467362421629575" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467362421639577" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467362421629575" xlink:to="us-gaap_ReceivablesNetCurrent_638467362421639577" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467362421629575" xlink:to="us-gaap_InventoryNet_638467362421639577" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467362421629575" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638467362421639577" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467362421629575" xlink:to="us-gaap_OtherAssetsCurrent_638467362421639577" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638467362421639577" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638467362421639577" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638467362421639577" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638467362421639577" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638467362421649588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638467362421649588" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638467362421649588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638467362421649588" xlink:to="us-gaap_LiabilitiesCurrent_638467362421649588" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638467362421649588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467362421649588" xlink:to="us-gaap_AccountsPayableCurrent_638467362421649588" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638467362421649588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467362421649588" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638467362421649588" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638467362421649588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467362421649588" xlink:to="us-gaap_InterestPayableCurrent_638467362421649588" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638467362421649588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467362421649588" xlink:to="us-gaap_OtherLiabilitiesCurrent_638467362421649588" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362421659582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638467362421649588" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362421659582" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638467362421659582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638467362421649588" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638467362421659582" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638467362421659582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638467362421649588" xlink:to="us-gaap_LongTermDebtNoncurrent_638467362421659582" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638467362421659582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638467362421659582" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467362421659582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638467362421659582" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638467362421659582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467362421659582" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638467362421659582" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638467362421669574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467362421659582" xlink:to="us-gaap_PreferredStockValue_638467362421669574" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638467362421669574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467362421659582" xlink:to="us-gaap_CommonStockValue_638467362421669574" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638467362421669574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467362421659582" xlink:to="us-gaap_AdditionalPaidInCapital_638467362421669574" order="4" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638467362421669574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638467362421669574" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638467362421669574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_638467362421669574" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638467362421669574" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense_638467362421669574" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638467362421679576" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638467362421679576" xlink:to="us-gaap_CostsAndExpenses_638467362421679576" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467362421679576" xlink:to="us-gaap_RestructuringCharges_638467362421679576" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467362421679576" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638467362421679576" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467362421679576" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638467362421679576" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467362421679576" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638467362421679576" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467362421679576" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638467362421679576" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467362421679576" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_ProfitLoss_638467362421689599" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638467362421689599" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_Depreciation_638467362421689599" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362421689599" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638467362421689599" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_PaidInKindInterest_638467362421689599" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638467362421689599" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_ShareBasedCompensation_638467362421689599" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638467362421699565" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_IncreaseDecreaseInInventories_638467362421699565" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638467362421699565" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638467362421699565" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467362421699565" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638467362421699565" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_638467362421699565" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362421689599" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_638467362421699565" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467362421709570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467362421709570" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467362421709570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467362421709570" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467362421709570" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638467362421709570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638467362421709570" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638467362421709570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638467362421709570" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638467362421709570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638467362421709570" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638467362421719570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638467362421719570" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638467362421719570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638467362421719570" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362421719570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362421709570" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362421719570" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638467362421719570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryRawMaterials_638467362421719570" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638467362421719570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryWorkInProcess_638467362421719570" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638467362421719570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryFinishedGoods_638467362421719570" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638467362421729571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638467362421729571" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467362421729571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467362421729571" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638467362421729571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638467362421729571" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_638467362421729571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_638467362421729571" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638467362421729571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638467362421729571" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638467362421729571" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638467362421729571" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638467362421739568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638467362421739568" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638467362421739568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_2" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638467362421739568" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638467362421739568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_2" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638467362421739568" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Debt and Credit Facilities - Interest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638467362421739568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpense_1" xlink:to="us-gaap_InterestExpenseDebt_638467362421739568" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362421739568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpense_1" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362421739568" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2" xlink:type="extended" xlink:title="41002 - Disclosure - Leases - Maturities (Details) - Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638467362421749567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638467362421749567" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362421749567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638467362421749567" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362421749567" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638467362421749567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability_638467362421749567" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638467362421749567" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467362421749567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467362421749567" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467362421749567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467362421749567" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467362421749567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467362421749567" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467362421759567" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Income Taxes - Deferred Tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638467362421759567" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638467362421759567" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638467362421759567" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638467362421759567" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638467362421759567" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467362421759567" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467362421759567" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="btai_DeferredTaxAssetsLeaseAccountingLiability_638467362421769566" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_638467362421769566" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638467362421769566" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638467362421769566" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467362421759567" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638467362421769566" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638467362421769566" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638467362421769566" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_638467362421769566" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638467362421769566" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638467362421769566" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638467362421769566" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467362421779570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467362421779570" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467362421779570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467362421779570" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638467362421779570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638467362421779570" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467362421779570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467362421779570" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467362421779570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467362421779570" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467362421779570" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467362421779570" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>btai-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 8:30:45 PM-->
<!--Modified on: 3/22/2024 8:30:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureRestructuringDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureTransactionsWithBioxcelLlcDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesWarrantsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureCommonStockFinancingActivitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationDescriptionDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurementsInputsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
  <link:roleRef roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:title="us-gaap_OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OtherLiabilitiesCurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesNoncurrentAbstract To us-gaap_DerivativeLiabilitiesNoncurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_1" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_DerivativeLiabilitiesNoncurrent_1" order="3" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:label="AcceleratedShareRepurchasesDateAxis" xlink:title="AcceleratedShareRepurchasesDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:label="AcceleratedShareRepurchasesDateDomain" xlink:title="AcceleratedShareRepurchasesDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AcceleratedShareRepurchasesDateAxis" xlink:to="AcceleratedShareRepurchasesDateDomain" xlink:title="definition: AcceleratedShareRepurchasesDateAxis to AcceleratedShareRepurchasesDateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember" xlink:title="btai_VimalMehtaMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_VimalMehtaMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_VimalMehtaMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember" xlink:title="btai_RichardSteinhartMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_RichardSteinhartMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_RichardSteinhartMember" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember" xlink:title="btai_JavierRodriguezMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_JavierRodriguezMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_JavierRodriguezMember" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MatthewWileyMember" xlink:label="btai_MatthewWileyMember" xlink:title="btai_MatthewWileyMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_MatthewWileyMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_MatthewWileyMember" order="4" priority="0" />
    <link:loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember" xlink:title="btai_FrankYoccaMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="btai_FrankYoccaMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To btai_FrankYoccaMember" order="5" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_NonrelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AccountsReceivablePaymentTerm" xlink:label="btai_AccountsReceivablePaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="btai_AccountsReceivablePaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Restructuring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Transactions with BioXcel LLC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="btai_BioxcelCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="btai_DevelopmentMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="btai_SalesMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_OfaAdministrativeAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_RevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaidInKindInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" xlink:label="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_OfaAdministrativeAgentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_RevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_TrancheDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_LineOfCreditFacilityExitFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentRightAmountUnfunded" xlink:label="btai_EquityInvestmentRightAmountUnfunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_EquityInvestmentRightAmountUnfunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PaidInKindInterestPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_TickingFeesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_NetCashRequiredMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_SubsidiaryOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfOutstandingLoan" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_RevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_BorrowingsBasedOnNetSalesPercent" xlink:label="btai_BorrowingsBasedOnNetSalesPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_BorrowingsBasedOnNetSalesPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ThresholdRatioOfDebtToRevenueRatio" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_ThresholdRatioOfDebtToRevenueRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Debt and Credit Facilities - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_RightToPurchaseStockLenders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PremiumSharePricePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common Stock Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_JefferiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation - Description (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_IncentiveAwardPlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_StockPlan2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation - Non-options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedPaymentArrangementGrantDate2023Member" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AwardDateDomain" xlink:to="btai_ShareBasedPaymentArrangementGrantDate2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedPaymentArrangementGrantDate2022Member" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AwardDateDomain" xlink:to="btai_ShareBasedPaymentArrangementGrantDate2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="srt_ExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation - Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="btai_TimeBasedProfitSharingUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Stock-Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="btai_EmployeeStockPurchasePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_EquityInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Fair Value Measurements - Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MeasurementInputProbabilityOfExerciseMember" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="btai_MeasurementInputProbabilityOfExerciseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MeasurementInputEstimatedPremiumMember" xlink:label="btai_MeasurementInputEstimatedPremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="btai_MeasurementInputEstimatedPremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_WarrantOaktreeAndQiaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_EquityInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_OnkosxcelWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_NewWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OperatingLossCarryforwardsNoExpiration" xlink:label="btai_OperatingLossCarryforwardsNoExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="btai_OperatingLossCarryforwardsNoExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="btai_JefferiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="btai_CreditFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="btai_Warrants2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="btai_PeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_PremiumSharePricePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>btai-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 8:30:45 PM-->
<!--Modified on: 3/22/2024 8:30:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrelated Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 18)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 100,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,930 and 28,147 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in-capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product revenue, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseAbstract" xlink:label="us-gaap_InterestExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseAbstract" xlink:to="us-gaap_InterestExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense (income)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (income) expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss (numerator)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share attributable to common stockholders (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share attributable to common stockholders (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares (denominator) - basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding - diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares (denominator) - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of offering costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repricing of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, net of employee tax obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units, net of employee tax obligations (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash (used in) provided by operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of net loss to net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of debt discount and amortization of financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payable-in-kind interest on Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payable-in-kind ("PIK") interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses, other current assets and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable, accrued expenses, due to related parties, and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Interest Payable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INVESTING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of equipment and leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCING CASH FLOW ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs for common stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of employee tax obligations related to vesting restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Disclosures of Cash Flow Information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repricing of stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ConversionOfAccruedInterestToLongTermDebt" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ConversionOfAccruedInterestToLongTermDebt" xlink:to="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount of accrued interest that is converted into long erm debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Accrued Interest To Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of accrued interest to long-term debt</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OrganizationAndPrincipalActivitiesAbstract" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OrganizationAndPrincipalActivitiesAbstract" xlink:to="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OrganizationAndPrincipalActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Credit Facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Credit Facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FinancingActivitiesAbstract" xlink:label="btai_FinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FinancingActivitiesAbstract" xlink:to="btai_FinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Financing Activities</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FinancingActivitiesDisclosureTextBlock" xlink:label="btai_FinancingActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FinancingActivitiesDisclosureTextBlock" xlink:to="btai_FinancingActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for Financing Activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Benefit Plan [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DeferredOfferingCostsPolicyTextBlock" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DeferredOfferingCostsPolicyTextBlock" xlink:to="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for deferred offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Initial Public Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Detachable Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xlink:to="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Service [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods Sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PatentCostsPolicyTextBlock" xlink:label="btai_PatentCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PatentCostsPolicyTextBlock" xlink:to="btai_PatentCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of Property Plant And Equipment Useful Lives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property Plant And Equipment Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property Plant and Equipment useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of service charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities on long-term debt</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:to="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of interest expense associated with long-term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long-term debt interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI PSU</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RestrictedStockUnitsOnkosxcelMember" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel RSUs</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TimeBasedProfitSharingUnitsMember" xlink:to="btai_TimeBasedProfitSharingUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to OnkosXcel time based profit-sharing units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel PSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TimeBasedProfitSharingUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel PSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of activity relating to PSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in Level 3 liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value unobservable inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective tax rate and statutory rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AccountsReceivablePaymentTerm" xlink:label="btai_AccountsReceivablePaymentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccountsReceivablePaymentTerm" xlink:to="btai_AccountsReceivablePaymentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccountsReceivablePaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The credit period offered to customers or receivables by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccountsReceivablePaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Payment Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccountsReceivablePaymentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable payment term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Restructuring and Related Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance and benefit costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Termination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract termination costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees eliminated (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Valuation Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-downs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computers and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AccruedResearchAndDevelopmentExpenses" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BioxcelCorporationMember" xlink:to="btai_BioxcelCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents BioXcel LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BioxcelCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioXcel LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative services agreement</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DevelopmentMilestonesMember" xlink:to="btai_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones defined by the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestones</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SalesMilestonesMember" xlink:to="btai_SalesMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones are payable when annual sales reach certain levels.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SalesMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with BioXcel</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fees per month to be paid to enter into collaborative service agreement option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Fees Per Month to Enter into Collaborative Service Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly agreement option fees</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential maximum payments that could be paid under the collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Milestone Payments Potential</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CollaborativeArrangementMilestonePotentialPercent" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum percentage of net sales payable under a collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Milestone Potential Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone (as as percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OfaAdministrativeAgentMember" xlink:to="btai_OfaAdministrativeAgentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents OFA as debt administrative agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OfaAdministrativeAgentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OFA</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CreditFacilityMember" xlink:to="btai_CreditFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to financing agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Agreement and Guaranty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CreditFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Facility</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RevenueInterestFinancingAgreementMember" xlink:to="btai_RevenueInterestFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Revenue Interest Financing agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue interest financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount borrowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Increase, Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, gross</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" xlink:label="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" xlink:to="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt, Before Unamortized (Discount) Premium and Debt Issuance Costs, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt classified as current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt premiums, discounts and issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheMember" xlink:to="btai_TrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheTwoMember" xlink:to="btai_TrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche A2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A-2</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheBMember" xlink:to="btai_TrancheBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheCMember" xlink:to="btai_TrancheCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche C.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche C</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TrancheDMember" xlink:to="btai_TrancheDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Tranche D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TrancheDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche D</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the statement scenario, from and after the funding of Tranche B loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and After Funding of Tranche B Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and after the funding of Tranche B loans</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the statement scenario, from and after satisfaction of the funding conditions for the Tranche C loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and After Satisfaction of Funding Conditions for Tranche C Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">From and after satisfaction of funding conditions for tranche C loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Rate [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SOFR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityInvestmentAllowed" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount the Lenders agree to permit the entity to invest in subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Investment Allowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum investment allowed</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Amendment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_LineOfCreditFacilityExitFeePercentage" xlink:to="btai_LineOfCreditFacilityExitFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The line of credit facility exit fee, expressed as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Exit Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exit fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Remaining Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentRightAmountUnfunded" xlink:label="btai_EquityInvestmentRightAmountUnfunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EquityInvestmentRightAmountUnfunded" xlink:to="btai_EquityInvestmentRightAmountUnfunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EquityInvestmentRightAmountUnfunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount of equity investment right in the OFA that is currently unfunded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EquityInvestmentRightAmountUnfunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Right, Amount Unfunded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EquityInvestmentRightAmountUnfunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Interest Rate, Discount Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental percentage points added to the reference rate and variable rate on the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Incremental on Variable Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PaidInKindInterestPercentage" xlink:to="btai_PaidInKindInterestPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-kind interest rate for funds borrowed, under the debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PaidInKindInterestPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt paid-in-kind interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_TickingFeesPercentage" xlink:to="btai_TickingFeesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents ticking fees percentage relating to debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ticking Fees Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_TickingFeesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ticking fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_NetCashRequiredMinimum" xlink:to="btai_NetCashRequiredMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Required, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_NetCashRequiredMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash maintenance in controlled accounts</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum liquidity required per the financial covenant of debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Financial Covenant, Minimum Liquidity Requirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Liquidity Amount</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SubsidiaryOwnershipPercentage" xlink:to="btai_SubsidiaryOwnershipPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of ownership of common stock of subsidiary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Ownership, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SubsidiaryOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary ownership (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfOutstandingLoan" xlink:to="btai_PercentageOfOutstandingLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Outstanding Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfOutstandingLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding loan (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt extinguishment</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_BorrowingsBasedOnNetSalesPercent" xlink:label="btai_BorrowingsBasedOnNetSalesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_BorrowingsBasedOnNetSalesPercent" xlink:to="btai_BorrowingsBasedOnNetSalesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum borrowings allowed based on a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings Based on Net Sales, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing allowed per net sales (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ThresholdRatioOfDebtToRevenueRatio" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ThresholdRatioOfDebtToRevenueRatio" xlink:to="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents threshold ratio for debt to revenue ratio.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Ratio of Debt to Revenue Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt to revenue multiplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_WarrantOaktreeAndQiaMember" xlink:to="btai_WarrantOaktreeAndQiaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Oaktree (OFA) original Warrants issued April 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="btai_WarrantOaktreeAndQiaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_NewWarrantsMember" xlink:to="btai_NewWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the warrants issued per the credit agreement December 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_NewWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OnkosxcelWarrantMember" xlink:to="btai_OnkosxcelWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to OnkosXcel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OnkosxcelWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OnkosXcel Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RightToPurchaseStockLenders" xlink:to="btai_RightToPurchaseStockLenders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity investment allowed for lenders in entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to Purchase Stock, Lenders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_RightToPurchaseStockLenders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum equity investment allowed for lenders</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PremiumSharePricePercent" xlink:to="btai_PremiumSharePricePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents premium percentage for share price determined over a specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium Share Price, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PremiumSharePricePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium share price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of  liquidity event for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Liquidity Event Amount for Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of liquidity event for exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfFairValueConsiderationToBePaid" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fair value of consideration to be paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Fair Value Consideration to Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of fair value of consideration to be paid</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PercentageOfValuationApplicableToInitialProfits" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of valuation applicable to initial profits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Valuation Applicable to Initial Profits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of valuation applicable to initial profits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_JefferiesMember" xlink:to="btai_JefferiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Jefferies LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies Sale Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_JefferiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate net offering price of shares permitted to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Maximum Value Shares to be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value shares to be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_IncentiveAwardPlan2020Member" xlink:to="btai_IncentiveAwardPlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2020 Incentive Award Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Incentive Award Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_IncentiveAwardPlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Incentive Award Plan</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_StockPlan2017Member" xlink:to="btai_StockPlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the 2017 Stock Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Equity Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_StockPlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in shares available for grant (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in shares available for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI RSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BTI RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Date [Domain]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedPaymentArrangementGrantDate2023Member" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedPaymentArrangementGrantDate2023Member" xlink:to="btai_ShareBasedPaymentArrangementGrantDate2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award granted under share-based payment arrangement during 2023.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Date 2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Date 2023</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedPaymentArrangementGrantDate2022Member" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedPaymentArrangementGrantDate2022Member" xlink:to="btai_ShareBasedPaymentArrangementGrantDate2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award granted under share-based payment arrangement during 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Date 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Date 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonemployee consultant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonemployee consultant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive officers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested aggregate (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted average price ending balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted average price beginning balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted average price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation costs recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of non-options granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of vested award under share-based payment arrangement. Excludes share and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Fair Value, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of PSUs vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares under options that were cancelled during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end balance (in dollars per shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning balance (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options cancelled (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options vested and exercisable (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value, exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of options vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining unamortized expense period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest, minimum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate of interest, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EmployeeStockPurchasePlan2020Member" xlink:to="btai_EmployeeStockPurchasePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the 2020 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum number of shares issued or transferred under ESPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares issued or transferred under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price as a percent of fair market value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current portion of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to renew the lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer matching contribution, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution percent on eligible contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contribution amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_EquityInvestmentMember" xlink:to="btai_EquityInvestmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to the Equity Investment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_EquityInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Investment Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value money market accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 liabilities reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strike price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (annual)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (annual)</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MeasurementInputProbabilityOfExerciseMember" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MeasurementInputProbabilityOfExerciseMember" xlink:to="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using rate at which there is a probability of exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability of exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Time period</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MeasurementInputEstimatedPremiumMember" xlink:label="btai_MeasurementInputEstimatedPremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MeasurementInputEstimatedPremiumMember" xlink:to="btai_MeasurementInputEstimatedPremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MeasurementInputEstimatedPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using estimated premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MeasurementInputEstimatedPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated premium to 30-day average</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MeasurementInputEstimatedPremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated premium to 30-day average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value warrant classified as equity</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CapitalizedResearchAndDevelopment" xlink:label="btai_CapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CapitalizedResearchAndDevelopment" xlink:to="btai_CapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" xlink:label="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" xlink:to="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development costs deferred tax increase (decrease).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development, Deferred tax Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D deferred tax increase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxes" xlink:label="us-gaap_AccruedIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxes" xlink:to="us-gaap_AccruedIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research &amp; development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:to="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease accounting, liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Accounting, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Derivative Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset (liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation between effective tax rate and federal statutory rate, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax credits (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State Taxes (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Tax Rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OperatingLossCarryforwardsNoExpiration" xlink:label="btai_OperatingLossCarryforwardsNoExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_OperatingLossCarryforwardsNoExpiration" xlink:to="btai_OperatingLossCarryforwardsNoExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward with no expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, No Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforward with no expiration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry-forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax related interest and penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock equivalents outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supply Commitment, Remaining Minimum Amount Committed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum annual payments</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AgreementCommitmentPeriod" xlink:label="btai_AgreementCommitmentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_AgreementCommitmentPeriod" xlink:to="btai_AgreementCommitmentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_AgreementCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period covered by the agreement commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_AgreementCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Commitment, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_AgreementCommitmentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment agreement period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_Warrants2024Member" xlink:to="btai_Warrants2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2024 warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_Warrants2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Warrants</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodOneMember" xlink:to="btai_PeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the first period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">April 2024</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodTwoMember" xlink:to="btai_PeriodTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the second period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">September 2024</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_PeriodThreeMember" xlink:to="btai_PeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information reported for the third period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_PeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Gross Proceeds From The Issuance of Common Stock, Warrants And (Or) Pre-funded Warrants For Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum revenue required</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_VimalMehtaMember" xlink:to="btai_VimalMehtaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_VimalMehtaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Vimal Mehta.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_VimalMehtaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vimal Mehta</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_RichardSteinhartMember" xlink:to="btai_RichardSteinhartMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_RichardSteinhartMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Richard Steinhart.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_RichardSteinhartMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Richard Steinhart</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_JavierRodriguezMember" xlink:to="btai_JavierRodriguezMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_JavierRodriguezMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Javier Rodriguez.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_JavierRodriguezMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Javier Rodriguez</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MatthewWileyMember" xlink:label="btai_MatthewWileyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_MatthewWileyMember" xlink:to="btai_MatthewWileyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_MatthewWileyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Matthew Wiley.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_MatthewWileyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matthew Wiley</label>
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="btai_FrankYoccaMember" xlink:to="btai_FrankYoccaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="btai_FrankYoccaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Frank Yocca.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="btai_FrankYoccaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frank Yocca</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>btai-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 8:30:45 PM-->
<!--Modified on: 3/22/2024 8:30:45 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureNatureOfBusiness" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureBasisOfPresentation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureRestructuring" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureInventory" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureAccruedExpenses" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureTransactionsWithBioxcelLlc" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilities" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDerivativeFinancialInstruments" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureCommonStockFinancingActivities" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureLeases" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureNetLossPerShare" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureInventoryTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureTransactionsWithBioxcelLlcTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureLeasesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureRestructuringDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureInventoryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureTransactionsWithBioxcelLlcDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesWarrantsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureDebtAndCreditFacilitiesInterestDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureCommonStockFinancingActivitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationDescriptionDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationNonOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationOptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurementsLevel3Details" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureFairValueMeasurementsInputsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxesDeferredTaxDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="btai-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638467362422829594" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638467362422829594" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638467362422829594" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638467362422829594" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638467362422829594" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638467362422829594" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638467362422829594" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638467362422829594" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638467362422829594" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638467362422829594" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638467362422829594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638467362422829594" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638467362422839588" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638467362422839588" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638467362422839588" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638467362422839588" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638467362422839588" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638467362422839588" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638467362422839588" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638467362422839588" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638467362422839588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638467362422839588" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638467362422849586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638467362422849586" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638467362422849586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638467362422849586" order="22" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638467362422849586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638467362422849586" order="23" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638467362422849586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638467362422849586" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638467362422849586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638467362422849586" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638467362422849586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638467362422849586" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638467362422859594" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638467362422859594" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638467362422859594" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638467362422859594" order="30" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638467362422859594" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638467362422859594" order="32" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638467362422859594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638467362422859594" order="33" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638467362422869652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638467362422869652" order="34" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638467362422869652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638467362422869652" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638467362422869652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638467362422869652" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638467362422869652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638467362422869652" order="37" use="optional" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467362422869652" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638467362422869652" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467362422869652" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467362422879591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467362422879591" xlink:to="us-gaap_RelatedPartyDomain_638467362422879591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638467362422879591" xlink:to="us-gaap_RelatedPartyMember_638467362422879591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638467362422879591" xlink:to="us-gaap_NonrelatedPartyMember_638467362422879591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467362422869652" xlink:to="us-gaap_StatementLineItems_638467362422879591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422879591" xlink:to="us-gaap_AssetsAbstract_638467362422879591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467362422879591" xlink:to="us-gaap_AssetsCurrentAbstract_638467362422879591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467362422879591" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467362422879591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467362422879591" xlink:to="us-gaap_ReceivablesNetCurrent_638467362422879591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467362422879591" xlink:to="us-gaap_InventoryNet_638467362422879591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467362422879591" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638467362422879591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638467362422879591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467362422879591" xlink:to="us-gaap_OtherAssetsCurrent_638467362422879591" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467362422879591" xlink:to="us-gaap_AssetsCurrent_638467362422889586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467362422879591" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638467362422889586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467362422879591" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638467362422889586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467362422879591" xlink:to="us-gaap_OtherAssetsNoncurrent_638467362422889586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467362422879591" xlink:to="us-gaap_Assets_638467362422889586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422879591" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" xlink:to="us-gaap_AccountsPayableCurrent_638467362422889586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638467362422889586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638467362422889586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" xlink:to="us-gaap_InterestPayableCurrent_638467362422899592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" xlink:to="us-gaap_OtherLiabilitiesCurrent_638467362422899592" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467362422889586" xlink:to="us-gaap_LiabilitiesCurrent_638467362422899592" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362422899592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638467362422899592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_LongTermDebtNoncurrent_638467362422899592" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638467362422899592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_Liabilities_638467362422899592" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_CommitmentsAndContingencies_638467362422909587" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467362422889586" xlink:to="us-gaap_StockholdersEquityAbstract_638467362422909587" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467362422909587" xlink:to="us-gaap_PreferredStockValue_638467362422909587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467362422909587" xlink:to="us-gaap_CommonStockValue_638467362422909587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467362422909587" xlink:to="us-gaap_AdditionalPaidInCapital_638467362422909587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467362422909587" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638467362422909587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467362422909587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467362422909587" xlink:to="us-gaap_StockholdersEquity_638467362422909587" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467362422909587" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638467362422919585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638467362422919585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638467362422919585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638467362422919585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638467362422919585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638467362422919585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638467362422919585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638467362422919585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638467362422929596" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638467362422929596" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_638467362422929596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467362422929596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_CostsAndExpensesAbstract_638467362422929596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638467362422929596" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638467362422929596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638467362422929596" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638467362422929596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638467362422929596" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638467362422929596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638467362422929596" xlink:to="us-gaap_RestructuringCharges_638467362422929596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638467362422929596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638467362422929596" xlink:to="us-gaap_CostsAndExpenses_638467362422929596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_OperatingIncomeLoss_638467362422939589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseAbstract" xlink:label="us-gaap_InterestExpenseAbstract_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_InterestExpenseAbstract_638467362422939589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseAbstract_638467362422939589" xlink:to="us-gaap_InterestExpense_638467362422939589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseAbstract_638467362422939589" xlink:to="us-gaap_InvestmentIncomeInterest_638467362422939589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseAbstract_638467362422939589" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638467362422939589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_NetIncomeLoss_638467362422939589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_EarningsPerShareBasic_638467362422939589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_EarningsPerShareDiluted_638467362422939589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638467362422939589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638467362422939589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638467362422929596" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638467362422949589" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638467362422949589" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467362422949589" xlink:to="us-gaap_StatementEquityComponentsAxis_638467362422949589" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467362422949589" xlink:to="us-gaap_CommonStockMember_638467362422949589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467362422949589" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638467362422949589" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467362422949589" xlink:to="us-gaap_RetainedEarningsMember_638467362422949589" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467362422949589" xlink:to="us-gaap_EquityComponentDomain_638467362422949589" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467362422949589" xlink:to="us-gaap_StatementLineItems_638467362422949589" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467362422949589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_StockholdersEquity_638467362422949589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_CommonStockSharesOutstanding_638467362422959589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638467362422959589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638467362422959589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638467362422959589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638467362422959589" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467362422959589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638467362422959589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638467362422959589" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467362422959589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638467362422959589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638467362422959589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638467362422959589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_638467362422959589" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_638467362422959589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_NetIncomeLoss_638467362422969589" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_StockholdersEquity_638467362422969589" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467362422949589" xlink:to="us-gaap_CommonStockSharesOutstanding_638467362422969589" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_ProfitLoss_638467362422969589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_Depreciation_638467362422969589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362422969589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362422969589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_638467362422979589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_ShareBasedCompensation_638467362422979589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_PaidInKindInterest_638467362422979589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638467362422979589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638467362422979589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638467362422979589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" xlink:to="us-gaap_IncreaseDecreaseInInventories_638467362422979589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638467362422979589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638467362422979589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_638467362422979589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_638467362422989591" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467362422979589" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467362422989591" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467362422969589" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362422989591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467362422989591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467362422989591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467362422989591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638467362422989591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638467362422989591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_638467362422999588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362422999588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638467362422999588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638467362422999588" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638467362422999588" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467362422989591" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467362422999588" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638467362422999588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467362422999588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467362422999588" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467362423009591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467362423009591" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638467362423009591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638467362423009591" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638467362423009591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638467362423009591" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638467362423009591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638467362423009591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638467362423009591" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638467362423009591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638467362423009591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638467362423009591" xlink:to="us-gaap_InterestPaidNet_638467362423009591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ConversionOfAccruedInterestToLongTermDebt" xlink:label="btai_ConversionOfAccruedInterestToLongTermDebt_638467362423009591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638467362423009591" xlink:to="btai_ConversionOfAccruedInterestToLongTermDebt_638467362423009591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OrganizationAndPrincipalActivitiesAbstract" xlink:label="OrganizationAndPrincipalActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638467362423019588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationAndPrincipalActivitiesAbstract" xlink:to="us-gaap_NatureOfOperations_638467362423019588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638467362423019588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638467362423019588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638467362423019588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638467362423019588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuring" xlink:type="extended" xlink:title="10401 - Disclosure - Restructuring" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638467362423029592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638467362423029592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventory" xlink:type="extended" xlink:title="10501 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638467362423029592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638467362423029592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638467362423029592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638467362423029592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10701 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638467362423029592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638467362423029592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc" xlink:type="extended" xlink:title="10801 - Disclosure - Transactions with BioXcel LLC" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638467362423039593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638467362423039593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities" xlink:type="extended" xlink:title="10901 - Disclosure - Debt and Credit Facilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638467362423039593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638467362423039593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments" xlink:type="extended" xlink:title="11001 - Disclosure - Derivative Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638467362423039593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_638467362423039593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities" xlink:type="extended" xlink:title="11101 - Disclosure - Common Stock Financing Activities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FinancingActivitiesAbstract" xlink:label="FinancingActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FinancingActivitiesDisclosureTextBlock" xlink:label="btai_FinancingActivitiesDisclosureTextBlock_638467362423049591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="btai_FinancingActivitiesDisclosureTextBlock_638467362423049591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11201 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638467362423049591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638467362423049591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11301 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638467362423049591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638467362423049591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11401 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_638467362423049591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_638467362423049591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11501 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638467362423059591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638467362423059591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11601 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638467362423059591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638467362423059591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11701 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638467362423059591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638467362423059591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638467362423069590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638467362423069590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11901 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638467362423069590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638467362423069590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638467362423069590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638467362423069590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638467362423069590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638467362423069590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638467362423069590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638467362423069590" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638467362423069590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638467362423069590" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638467362423079589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638467362423079589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DeferredOfferingCostsPolicyTextBlock" xlink:label="btai_DeferredOfferingCostsPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_DeferredOfferingCostsPolicyTextBlock_638467362423079589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638467362423079589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638467362423079589" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638467362423079589" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock_638467362423079589" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure" xlink:label="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure_638467362423079589" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_638467362423079589" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638467362423079589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638467362423079589" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638467362423089591" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PatentCostsPolicyTextBlock" xlink:label="btai_PatentCostsPolicyTextBlock_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_PatentCostsPolicyTextBlock_638467362423089591" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638467362423089591" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638467362423089591" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638467362423089591" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638467362423089591" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638467362423089591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638467362423089591" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_638467362423099592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_638467362423099592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="30503 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638467362423099592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638467362423099592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638467362423099592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638467362423099592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638467362423109595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638467362423109595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables" xlink:type="extended" xlink:title="30803 - Disclosure - Transactions with BioXcel LLC (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638467362423109595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638467362423109595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Debt and Credit Facilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638467362423109595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638467362423109595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638467362423109595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638467362423109595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock" xlink:label="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_638467362423109595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock_638467362423109595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423119602" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423119602" xlink:to="us-gaap_AwardTypeAxis_638467362423119602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638467362423119602" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423119602" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423119602" xlink:to="us-gaap_PerformanceSharesMember_638467362423119602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423119602" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_638467362423119602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423119602" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638467362423119602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423119602" xlink:to="us-gaap_EmployeeStockOptionMember_638467362423119602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423119602" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638467362423119602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_638467362423119602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock_638467362423119602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638467362423129593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638467362423129593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638467362423129593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638467362423129593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638467362423129593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423119602" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638467362423129593" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638467362423129593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638467362423129593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31503 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638467362423139591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638467362423139591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_638467362423139591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_638467362423139591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638467362423139591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638467362423139591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31603 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638467362423139591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638467362423139591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638467362423139591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638467362423139591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31703 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638467362423139591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638467362423139591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467362423149591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638467362423149591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss_638467362423149591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467362423149591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423149591" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423149591" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467362423149591" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467362423149591" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423149591" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638467362423149591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423149591" xlink:to="us-gaap_EquipmentMember_638467362423149591" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423149591" xlink:to="us-gaap_FurnitureAndFixturesMember_638467362423159588" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423149591" xlink:to="srt_RangeAxis_638467362423159588" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467362423159588" xlink:to="srt_RangeMember_638467362423159588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423159588" xlink:to="srt_MinimumMember_638467362423159588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423159588" xlink:to="srt_MaximumMember_638467362423159588" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423149591" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423159588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AccountsReceivablePaymentTerm" xlink:label="btai_AccountsReceivablePaymentTerm_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423159588" xlink:to="btai_AccountsReceivablePaymentTerm_638467362423159588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423159588" xlink:to="us-gaap_DeferredOfferingCosts_638467362423159588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423159588" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638467362423159588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638467362423159588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423159588" xlink:to="us-gaap_NumberOfOperatingSegments_638467362423159588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Restructuring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467362423169592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467362423169592" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638467362423169592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638467362423169592" xlink:to="us-gaap_TypeOfRestructuringDomain_638467362423169592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638467362423169592" xlink:to="us-gaap_EmployeeSeveranceMember_638467362423169592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638467362423169592" xlink:to="us-gaap_ContractTerminationMember_638467362423169592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467362423169592" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638467362423169592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638467362423169592" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638467362423169592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638467362423169592" xlink:to="us-gaap_RestructuringCharges_638467362423169592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring_638467362423169592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638467362423169592" xlink:to="us-gaap_PaymentsForRestructuring_638467362423169592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryRawMaterials_638467362423179597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryWorkInProcess_638467362423179597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryFinishedGoods_638467362423179597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryNet_638467362423179597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_1" xlink:to="us-gaap_InventoryValuationReserves_638467362423179597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423179597" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423179597" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467362423179597" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467362423179597" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423179597" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638467362423179597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423179597" xlink:to="us-gaap_ComputerEquipmentMember_638467362423179597" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423179597" xlink:to="us-gaap_FurnitureAndFixturesMember_638467362423189594" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467362423179597" xlink:to="us-gaap_LeaseholdImprovementsMember_638467362423189594" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467362423179597" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423189594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423189594" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638467362423189594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423189594" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467362423189594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423189594" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638467362423189594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467362423189594" xlink:to="us-gaap_Depreciation_638467362423189594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AccruedResearchAndDevelopmentExpenses" xlink:label="btai_AccruedResearchAndDevelopmentExpenses_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="btai_AccruedResearchAndDevelopmentExpenses_638467362423189594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638467362423189594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638467362423189594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638467362423199594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_TaxesPayableCurrent_638467362423199594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638467362423199594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638467362423199594" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Transactions with BioXcel LLC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467362423199594" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467362423199594" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467362423199594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467362423199594" xlink:to="us-gaap_RelatedPartyDomain_638467362423199594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638467362423199594" xlink:to="us-gaap_RelatedPartyMember_638467362423199594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467362423199594" xlink:to="srt_CounterpartyNameAxis_638467362423199594" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638467362423199594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638467362423199594" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638467362423199594" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_BioxcelCorporationMember" xlink:label="btai_BioxcelCorporationMember_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638467362423199594" xlink:to="btai_BioxcelCorporationMember_638467362423209595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467362423199594" xlink:to="us-gaap_TypeOfArrangementAxis_638467362423209595" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638467362423209595" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467362423209595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467362423209595" xlink:to="us-gaap_CollaborativeArrangementMember_638467362423209595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DevelopmentMilestonesMember" xlink:label="btai_DevelopmentMilestonesMember_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638467362423209595" xlink:to="btai_DevelopmentMilestonesMember_638467362423209595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SalesMilestonesMember" xlink:label="btai_SalesMilestonesMember_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638467362423209595" xlink:to="btai_SalesMilestonesMember_638467362423209595" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467362423199594" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement" xlink:label="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement_638467362423209595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CollaborativeArrangementMilestonePaymentsPotential" xlink:label="btai_CollaborativeArrangementMilestonePaymentsPotential_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="btai_CollaborativeArrangementMilestonePaymentsPotential_638467362423209595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CollaborativeArrangementMilestonePotentialPercent" xlink:label="btai_CollaborativeArrangementMilestonePotentialPercent_638467362423209595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="btai_CollaborativeArrangementMilestonePotentialPercent_638467362423209595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638467362423219591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638467362423219591" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="us-gaap_CostsAndExpenses_638467362423219591" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467362423209595" xlink:to="us-gaap_OtherLiabilitiesCurrent_638467362423219591" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_2" xlink:to="us-gaap_DebtInstrumentTable_638467362423219591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638467362423219591" xlink:to="us-gaap_DebtInstrumentAxis_638467362423219591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638467362423219591" xlink:to="us-gaap_DebtInstrumentNameDomain_638467362423219591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember_638467362423219591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638467362423219591" xlink:to="btai_OfaAdministrativeAgentMember_638467362423219591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638467362423219591" xlink:to="btai_CreditFacilityMember_638467362423229594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638467362423219591" xlink:to="btai_RevenueInterestFinancingAgreementMember_638467362423229594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638467362423219591" xlink:to="us-gaap_DebtInstrumentLineItems_638467362423229594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_DebtInstrumentFaceAmount_638467362423229594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_638467362423229594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_RepaymentsOfDebt_638467362423229594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_PaidInKindInterest_638467362423229594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638467362423229594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent" xlink:label="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent_638467362423229594" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_DebtCurrent_638467362423229594" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638467362423229594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638467362423229594" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_LongTermDebtNoncurrent_638467362423239595" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467362423229594" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638467362423239595" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_7" xlink:to="us-gaap_LineOfCreditFacilityTable_638467362423239595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423239595" xlink:to="us-gaap_DebtInstrumentAxis_638467362423239595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638467362423239595" xlink:to="us-gaap_DebtInstrumentNameDomain_638467362423239595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OfaAdministrativeAgentMember" xlink:label="btai_OfaAdministrativeAgentMember_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638467362423239595" xlink:to="btai_OfaAdministrativeAgentMember_638467362423239595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638467362423239595" xlink:to="btai_CreditFacilityMember_638467362423239595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember_638467362423239595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="btai_OfaAdministrativeAgentMember_638467362423239595" xlink:to="btai_RevenueInterestFinancingAgreementMember_638467362423239595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638467362423249591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423239595" xlink:to="srt_StatementScenarioAxis_638467362423249591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638467362423249591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638467362423249591" xlink:to="srt_ScenarioUnspecifiedDomain_638467362423249591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheMember" xlink:label="btai_TrancheMember_638467362423249591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_TrancheMember_638467362423249591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheTwoMember" xlink:label="btai_TrancheTwoMember_638467362423289593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_TrancheTwoMember_638467362423289593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheBMember" xlink:label="btai_TrancheBMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_TrancheBMember_638467362423299593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheCMember" xlink:label="btai_TrancheCMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_TrancheCMember_638467362423299593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TrancheDMember" xlink:label="btai_TrancheDMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_TrancheDMember_638467362423299593" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FromAndAfterFundingOfTrancheBLoansMember" xlink:label="btai_FromAndAfterFundingOfTrancheBLoansMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_FromAndAfterFundingOfTrancheBLoansMember_638467362423299593" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember" xlink:label="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423249591" xlink:to="btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_638467362423299593" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423239595" xlink:to="srt_RangeAxis_638467362423299593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467362423299593" xlink:to="srt_RangeMember_638467362423299593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423299593" xlink:to="srt_MinimumMember_638467362423299593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423299593" xlink:to="srt_MaximumMember_638467362423299593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_638467362423299593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423239595" xlink:to="us-gaap_VariableRateAxis_638467362423299593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_638467362423299593" xlink:to="us-gaap_VariableRateDomain_638467362423309596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_638467362423309596" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_638467362423309596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423239595" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityInvestmentAllowed" xlink:label="btai_LineOfCreditFacilityInvestmentAllowed_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_LineOfCreditFacilityInvestmentAllowed_638467362423309596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="us-gaap_DebtInstrumentFaceAmount_638467362423309596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityAmendmentFeePercentage" xlink:label="btai_LineOfCreditFacilityAmendmentFeePercentage_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_LineOfCreditFacilityAmendmentFeePercentage_638467362423309596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_LineOfCreditFacilityExitFeePercentage" xlink:label="btai_LineOfCreditFacilityExitFeePercentage_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_LineOfCreditFacilityExitFeePercentage_638467362423309596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638467362423309596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="us-gaap_DebtInstrumentFeeAmount_638467362423309596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638467362423319590" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_638467362423319590" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentRightAmountUnfunded" xlink:label="btai_EquityInvestmentRightAmountUnfunded_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_EquityInvestmentRightAmountUnfunded_638467362423319590" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638467362423319590" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentInterestRateDiscountRatePercentage" xlink:label="btai_DebtInstrumentInterestRateDiscountRatePercentage_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_DebtInstrumentInterestRateDiscountRatePercentage_638467362423319590" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638467362423319590" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentIncrementalOnVariableRatePercent" xlink:label="btai_DebtInstrumentIncrementalOnVariableRatePercent_638467362423319590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_DebtInstrumentIncrementalOnVariableRatePercent_638467362423319590" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PaidInKindInterestPercentage" xlink:label="btai_PaidInKindInterestPercentage_638467362423329593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_PaidInKindInterestPercentage_638467362423329593" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TickingFeesPercentage" xlink:label="btai_TickingFeesPercentage_638467362423329593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_TickingFeesPercentage_638467362423329593" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NetCashRequiredMinimum" xlink:label="btai_NetCashRequiredMinimum_638467362423329593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_NetCashRequiredMinimum_638467362423329593" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638467362423329593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638467362423329593" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SubsidiaryOwnershipPercentage" xlink:label="btai_SubsidiaryOwnershipPercentage_638467362423329593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_SubsidiaryOwnershipPercentage_638467362423329593" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfOutstandingLoan" xlink:label="btai_PercentageOfOutstandingLoan_638467362423329593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423309596" xlink:to="btai_PercentageOfOutstandingLoan_638467362423329593" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_5" xlink:to="us-gaap_LineOfCreditFacilityTable_638467362423339594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423339594" xlink:to="us-gaap_DebtInstrumentAxis_638467362423339594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638467362423339594" xlink:to="us-gaap_DebtInstrumentNameDomain_638467362423339594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RevenueInterestFinancingAgreementMember" xlink:label="btai_RevenueInterestFinancingAgreementMember_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638467362423339594" xlink:to="btai_RevenueInterestFinancingAgreementMember_638467362423339594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423339594" xlink:to="srt_RangeAxis_638467362423339594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467362423339594" xlink:to="srt_RangeMember_638467362423339594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423339594" xlink:to="srt_MinimumMember_638467362423339594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467362423339594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423339594" xlink:to="srt_MaximumMember_638467362423339594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423339594" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_638467362423349595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638467362423349595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_638467362423349595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_BorrowingsBasedOnNetSalesPercent" xlink:label="btai_BorrowingsBasedOnNetSalesPercent_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" xlink:to="btai_BorrowingsBasedOnNetSalesPercent_638467362423349595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ThresholdRatioOfDebtToRevenueRatio" xlink:label="btai_ThresholdRatioOfDebtToRevenueRatio_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423349595" xlink:to="btai_ThresholdRatioOfDebtToRevenueRatio_638467362423349595" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Debt and Credit Facilities - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_6" xlink:to="us-gaap_LineOfCreditFacilityTable_638467362423349595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638467362423349595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423349595" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638467362423349595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638467362423349595" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638467362423359601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423359601" xlink:to="btai_WarrantOaktreeAndQiaMember_638467362423359601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423359601" xlink:to="btai_NewWarrantsMember_638467362423359601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423359601" xlink:to="btai_OnkosxcelWarrantMember_638467362423359601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable_638467362423349595" xlink:to="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638467362423359601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638467362423359601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RightToPurchaseStockLenders" xlink:label="btai_RightToPurchaseStockLenders_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="btai_RightToPurchaseStockLenders_638467362423359601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="btai_PremiumSharePricePercent_638467362423359601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ThresholdLiquidityEventAmountForExerciseOfWarrants" xlink:label="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="btai_ThresholdLiquidityEventAmountForExerciseOfWarrants_638467362423359601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfFairValueConsiderationToBePaid" xlink:label="btai_PercentageOfFairValueConsiderationToBePaid_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="btai_PercentageOfFairValueConsiderationToBePaid_638467362423359601" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PercentageOfValuationApplicableToInitialProfits" xlink:label="btai_PercentageOfValuationApplicableToInitialProfits_638467362423359601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="btai_PercentageOfValuationApplicableToInitialProfits_638467362423359601" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638467362423369591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems_638467362423359601" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638467362423369591" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Debt and Credit Facilities - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638467362423369591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638467362423369591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Debt and Credit Facilities - Interest (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638467362423369591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpenseDebt_638467362423369591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362423369591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638467362423369591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638467362423369591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_InterestExpense_638467362423369591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common Stock Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FinancingActivitiesAbstract" xlink:label="FinancingActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638467362423379588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638467362423379588" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638467362423379588" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467362423379588" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467362423379588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638467362423379588" xlink:to="btai_JefferiesMember_638467362423379588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638467362423379588" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_638467362423379588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467362423379588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638467362423379588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362423379588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638467362423379588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638467362423379588" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638467362423379588" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation - Description (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423389591" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423389591" xlink:to="us-gaap_PlanNameAxis_638467362423389591" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638467362423389591" xlink:to="us-gaap_PlanNameDomain_638467362423389591" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_IncentiveAwardPlan2020Member" xlink:label="btai_IncentiveAwardPlan2020Member_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467362423389591" xlink:to="btai_IncentiveAwardPlan2020Member_638467362423389591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_StockPlan2017Member" xlink:label="btai_StockPlan2017Member_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467362423389591" xlink:to="btai_StockPlan2017Member_638467362423389591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423389591" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638467362423389591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638467362423389591" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638467362423389591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638467362423389591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638467362423399597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638467362423399597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423389591" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467362423399597" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation - Non-options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" xlink:to="us-gaap_AwardTypeAxis_638467362423399597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638467362423399597" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423399597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423399597" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638467362423399597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423399597" xlink:to="us-gaap_PerformanceSharesMember_638467362423399597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638467362423399597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423399597" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638467362423399597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RestrictedStockUnitsOnkosxcelMember" xlink:label="btai_RestrictedStockUnitsOnkosxcelMember_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423399597" xlink:to="btai_RestrictedStockUnitsOnkosxcelMember_638467362423409594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" xlink:to="us-gaap_AwardDateAxis_638467362423409594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_638467362423409594" xlink:to="us-gaap_AwardDateDomain_638467362423409594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedPaymentArrangementGrantDate2023Member" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2023Member_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638467362423409594" xlink:to="btai_ShareBasedPaymentArrangementGrantDate2023Member_638467362423409594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedPaymentArrangementGrantDate2022Member" xlink:label="btai_ShareBasedPaymentArrangementGrantDate2022Member_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_638467362423409594" xlink:to="btai_ShareBasedPaymentArrangementGrantDate2022Member_638467362423409594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" xlink:to="us-gaap_GranteeStatusAxis_638467362423409594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638467362423409594" xlink:to="us-gaap_GranteeStatusDomain_638467362423409594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638467362423409594" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638467362423409594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638467362423409594" xlink:to="srt_ExecutiveOfficerMember_638467362423409594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638467362423409594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" xlink:to="us-gaap_VestingAxis_638467362423409594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638467362423409594" xlink:to="us-gaap_VestingDomain_638467362423419593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638467362423419593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638467362423419593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423399597" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638467362423419593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638467362423419593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638467362423419593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638467362423419593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_638467362423429592" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638467362423429592" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638467362423429592" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638467362423429592" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638467362423429592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467362423429592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_638467362423429592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_638467362423429592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638467362423439598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638467362423439598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638467362423439598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638467362423429592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638467362423439598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467362423439598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467362423439598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638467362423439598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638467362423439598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638467362423439598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638467362423439598" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638467362423439598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638467362423439598" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467362423449598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467362423449598" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested_638467362423449598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423419593" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested_638467362423449598" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation - Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423449598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423449598" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638467362423449598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423449598" xlink:to="us-gaap_AwardTypeAxis_638467362423449598" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423449598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638467362423449598" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423449598" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638467362423449598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423449598" xlink:to="us-gaap_EmployeeStockOptionMember_638467362423449598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423449598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423459601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467362423459601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638467362423459601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638467362423459601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_638467362423459601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467362423459601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384673624234596011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384673624234596011" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638467362423459601" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638467362423469594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638467362423469594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638467362423469594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_638467362423469594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638467362423469594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384673624234695941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384673624234695941" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638467362423469594" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423459601" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638467362423469594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638467362423469594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638467362423479600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638467362423479600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467362423479600" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638467362423479600" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638467362423479600" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638467362423479600" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638467362423479600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638467362423479600" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467362423469594" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638467362423489594" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423489594" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423489594" xlink:to="us-gaap_AwardTypeAxis_638467362423489594" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638467362423489594" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423489594" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_TimeBasedProfitSharingUnitsMember" xlink:label="btai_TimeBasedProfitSharingUnitsMember_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423489594" xlink:to="btai_TimeBasedProfitSharingUnitsMember_638467362423489594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467362423489594" xlink:to="us-gaap_EmployeeStockOptionMember_638467362423489594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423489594" xlink:to="srt_RangeAxis_638467362423489594" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467362423489594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467362423489594" xlink:to="srt_RangeMember_638467362423489594" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423489594" xlink:to="srt_MinimumMember_638467362423499596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467362423489594" xlink:to="srt_MaximumMember_638467362423499596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423489594" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638467362423499596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638467362423499596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638467362423499596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638467362423499596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638467362423499596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638467362423499596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638467362423499596" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638467362423509595" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423499596" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638467362423509595" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423509595" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423509595" xlink:to="us-gaap_IncomeStatementLocationAxis_638467362423509595" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638467362423509595" xlink:to="us-gaap_IncomeStatementLocationDomain_638467362423509595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467362423509595" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638467362423509595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467362423509595" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638467362423509595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467362423509595" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423509595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638467362423509595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467362423509595" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638467362423509595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Stock-Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638467362423519598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638467362423519598" xlink:to="us-gaap_PlanNameAxis_638467362423519598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638467362423519598" xlink:to="us-gaap_PlanNameDomain_638467362423519598" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EmployeeStockPurchasePlan2020Member" xlink:label="btai_EmployeeStockPurchasePlan2020Member_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467362423519598" xlink:to="btai_EmployeeStockPurchasePlan2020Member_638467362423519598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_638467362423519598" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638467362423519598" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant" xlink:label="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant_638467362423519598" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred" xlink:label="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred_638467362423519598" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638467362423519598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638467362423519598" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638467362423529594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638467362423529594" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_638467362423519598" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638467362423529594" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467362423529594" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467362423529594" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467362423529594" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638467362423529594" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467362423529594" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467362423529594" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_OperatingLeaseLiability_638467362423539602" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638467362423539602" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638467362423539602" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638467362423539602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467362423529594" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638467362423539602" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Leases - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense_638467362423539602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638467362423539602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638467362423539602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638467362423539602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAbstract" xlink:label="us-gaap_DefinedBenefitPlanAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638467362423549604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638467362423549604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638467362423549604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638467362423549604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638467362423549604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanAbstract_1" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638467362423549604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638467362423549604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638467362423549604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638467362423549604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638467362423549604" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638467362423549604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638467362423549604" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638467362423559604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638467362423559604" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638467362423559604" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638467362423559604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638467362423559604" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467362423559604" xlink:to="us-gaap_FairValueInputsLevel1Member_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467362423559604" xlink:to="us-gaap_FairValueInputsLevel3Member_638467362423559604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638467362423559604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638467362423559604" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember_638467362423559604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423559604" xlink:to="btai_EquityInvestmentMember_638467362423559604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423559604" xlink:to="btai_OnkosxcelWarrantMember_638467362423569665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467362423549604" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467362423569665" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467362423569665" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638467362423569665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467362423569665" xlink:to="us-gaap_DerivativeLiabilities_638467362423569665" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilities_638467362423569665" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_638467362423569665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details" xlink:type="extended" xlink:title="41502 - Disclosure - Fair Value Measurements - Level 3 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638467362423569665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638467362423569665" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638467362423569665" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638467362423569665" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638467362423569665" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_638467362423579599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_638467362423569665" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_638467362423579599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Fair Value Measurements - Inputs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638467362423579599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638467362423579599" xlink:to="us-gaap_MeasurementInputTypeAxis_638467362423579599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638467362423579599" xlink:to="us-gaap_MeasurementInputTypeDomain_638467362423579599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638467362423579599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638467362423579599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MeasurementInputProbabilityOfExerciseMember" xlink:label="btai_MeasurementInputProbabilityOfExerciseMember_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="btai_MeasurementInputProbabilityOfExerciseMember_638467362423579599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638467362423579599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638467362423579599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MeasurementInputEstimatedPremiumMember" xlink:label="btai_MeasurementInputEstimatedPremiumMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="btai_MeasurementInputEstimatedPremiumMember_638467362423589597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="us-gaap_MeasurementInputDiscountRateMember_638467362423589597" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638467362423589597" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638467362423579599" xlink:to="us-gaap_MeasurementInputSharePriceMember_638467362423589597" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638467362423579599" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638467362423589597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638467362423589597" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638467362423589597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_WarrantOaktreeAndQiaMember" xlink:label="btai_WarrantOaktreeAndQiaMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423589597" xlink:to="btai_WarrantOaktreeAndQiaMember_638467362423589597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_EquityInvestmentMember" xlink:label="btai_EquityInvestmentMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423589597" xlink:to="btai_EquityInvestmentMember_638467362423589597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OnkosxcelWarrantMember" xlink:label="btai_OnkosxcelWarrantMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423589597" xlink:to="btai_OnkosxcelWarrantMember_638467362423589597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_NewWarrantsMember" xlink:label="btai_NewWarrantsMember_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423589597" xlink:to="btai_NewWarrantsMember_638467362423589597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638467362423589597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638467362423579599" xlink:to="us-gaap_DebtInstrumentAxis_638467362423589597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638467362423589597" xlink:to="us-gaap_DebtInstrumentNameDomain_638467362423599606" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638467362423599606" xlink:to="btai_CreditFacilityMember_638467362423599606" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638467362423579599" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_638467362423599606" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638467362423599606" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" xlink:to="us-gaap_DebtInstrumentFairValue_638467362423599606" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638467362423599606" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638467362423599606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638467362423599606" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_638467362423599606" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Income Taxes - Deferred Tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CapitalizedResearchAndDevelopment" xlink:label="btai_CapitalizedResearchAndDevelopment_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="btai_CapitalizedResearchAndDevelopment_638467362423609600" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease" xlink:label="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease_638467362423609600" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxes" xlink:label="us-gaap_AccruedIncomeTaxes_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_AccruedIncomeTaxes_638467362423609600" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638467362423609600" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638467362423609600" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467362423609600" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638467362423609600" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638467362423609600" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638467362423609600" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638467362423619598" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638467362423619598" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DeferredTaxAssetsLeaseAccountingLiability" xlink:label="btai_DeferredTaxAssetsLeaseAccountingLiability_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="btai_DeferredTaxAssetsLeaseAccountingLiability_638467362423619598" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_638467362423619598" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638467362423619598" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638467362423619598" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDerivatives" xlink:label="us-gaap_DeferredTaxLiabilitiesDerivatives_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDerivatives_638467362423619598" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638467362423619598" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638467362423619598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638467362423619598" order="17" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638467362423629596" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638467362423629596" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467362423629596" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638467362423629596" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638467362423629596" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638467362423629596" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638467362423629596" xlink:to="us-gaap_DomesticCountryMember_638467362423629596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638467362423629596" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638467362423629596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467362423629596" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467362423629596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467362423629596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467362423639599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_638467362423639599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467362423639599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467362423639599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467362423639599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638467362423629596" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638467362423639599" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" xlink:to="us-gaap_OperatingLossCarryforwards_638467362423639599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_OperatingLossCarryforwardsNoExpiration" xlink:label="btai_OperatingLossCarryforwardsNoExpiration_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" xlink:to="btai_OperatingLossCarryforwardsNoExpiration_638467362423639599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638467362423639599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638467362423639599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" xlink:to="us-gaap_UnrecognizedTaxBenefits_638467362423649597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467362423629596" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638467362423649597" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss_638467362423649597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638467362423649597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638467362423649597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638467362423649597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638467362423649597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638467362423649597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638467362423659603" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_638467362423659603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_AgreementCommitmentPeriod" xlink:label="btai_AgreementCommitmentPeriod_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="btai_AgreementCommitmentPeriod_638467362423659603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638467362423659603" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467362423659603" xlink:to="us-gaap_SubsequentEventTypeAxis_638467362423659603" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638467362423659603" xlink:to="us-gaap_SubsequentEventTypeDomain_638467362423659603" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638467362423659603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638467362423659603" xlink:to="us-gaap_SubsequentEventMember_638467362423659603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467362423659603" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638467362423669596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467362423669596" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467362423669596" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JefferiesMember" xlink:label="btai_JefferiesMember_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638467362423669596" xlink:to="btai_JefferiesMember_638467362423669596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467362423659603" xlink:to="us-gaap_DebtInstrumentAxis_638467362423669596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638467362423669596" xlink:to="us-gaap_DebtInstrumentNameDomain_638467362423669596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_CreditFacilityMember" xlink:label="btai_CreditFacilityMember_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638467362423669596" xlink:to="btai_CreditFacilityMember_638467362423669596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467362423659603" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638467362423669596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638467362423669596" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638467362423669596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_Warrants2024Member" xlink:label="btai_Warrants2024Member_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638467362423669596" xlink:to="btai_Warrants2024Member_638467362423669596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467362423659603" xlink:to="srt_StatementScenarioAxis_638467362423669596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638467362423669596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638467362423669596" xlink:to="srt_ScenarioUnspecifiedDomain_638467362423669596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodOneMember" xlink:label="btai_PeriodOneMember_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423669596" xlink:to="btai_PeriodOneMember_638467362423679607" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodTwoMember" xlink:label="btai_PeriodTwoMember_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423669596" xlink:to="btai_PeriodTwoMember_638467362423679607" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PeriodThreeMember" xlink:label="btai_PeriodThreeMember_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638467362423669596" xlink:to="btai_PeriodThreeMember_638467362423679607" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467362423659603" xlink:to="us-gaap_SubsequentEventLineItems_638467362423679607" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt" xlink:label="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt_638467362423679607" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement" xlink:label="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement_638467362423679607" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638467362423679607" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638467362423679607" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_PremiumSharePricePercent" xlink:label="btai_PremiumSharePricePercent_638467362423679607" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="btai_PremiumSharePricePercent_638467362423679607" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_SaleOfStockMaximumValueSharesToBeIssued" xlink:label="btai_SaleOfStockMaximumValueSharesToBeIssued_638467362423689597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="btai_SaleOfStockMaximumValueSharesToBeIssued_638467362423689597" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467362423689597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467362423689597" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362423689597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467362423689597" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638467362423689597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638467362423689597" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638467362423689597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467362423679607" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638467362423689597" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638467362423699601" xlink:to="btai_VimalMehtaMember_638467362423699601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638467362423699601" xlink:to="btai_RichardSteinhartMember_638467362423699601" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638467362423699601" xlink:to="btai_JavierRodriguezMember_638467362423699601" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638467362423699601" xlink:to="btai_MatthewWileyMember_638467362423699601" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638467362423699601" xlink:to="btai_FrankYoccaMember_638467362423699601" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember_638467362423699601" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_VimalMehtaMember" xlink:label="btai_VimalMehtaMember_638467362423699601" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_RichardSteinhartMember" xlink:label="btai_RichardSteinhartMember_638467362423699601" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_JavierRodriguezMember" xlink:label="btai_JavierRodriguezMember_638467362423699601" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_MatthewWileyMember" xlink:label="btai_MatthewWileyMember_638467362423699601" />
    <loc xlink:type="locator" xlink:href="btai-20231231.xsd#btai_FrankYoccaMember" xlink:label="btai_FrankYoccaMember_638467362423699601" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MF#*0\RM*Q:ZC+A+EQ='] U!+ P04    "  4A798C:C)]:T$  "9$0  &
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M:&5E=',O<VAE970U+GAM;+59:W/:.!3]*QJVL]O.E-J27] ES"38V3+;)ME
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M()%OF 2U+B73Q%2G5/F#93>T*1-V0VL[M*WZ!*131R UM[IODFN9!%E9,"]
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M@-]70N2'+_H!U7]'3/X#4$L#!!0    ( !2%=ECE51:[S 4  ,$,   8
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MOJ T)Q%(%28:MX#&V'7KF>LNG2KVR17H_Q=K63;$R>JS*B1F6"ID>&3/CFH
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M\L;' G]CD.,-6,\LYG+WP@[ZOUIF?P-02P,$%     @ %(5V6%[TN3GL"
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M3[1I-<X @ COS3)WW)T<!*WLY+!5U^B'>7S3'OZN:$A(7=W);"DS46;T_H7
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M!B#=W;OAM"&=+S]!:$B1-8KCJF2R-'_ :(9UL"^+B25;", 8Y7.>F/( ?FB
M#4MPKL>VY&7*'7U-P"Z(F0Q!$!1H--EAH=_'>BT2*<X93 WI$MABI1Y.YYTH
M]D'L,NB3Z-1%%;(DX[(B$6MR%;(TBDI3/RLLG-%;,M<+X2 ].):A*1W +<$,
MSI1])1Y-30Y&:UD2_"#O5KY(O>#KZ/L2C7[;&17^W%;0Q]#7CE5*4$N)!K,W
M-%%4-W-$H%>=T*LF!Y%XW91P=-@UQZ^T=F-K!OJ6'$BB<&UO:1N8J$^541MB
MEP0S,4U8#N(D MSTB2V;\I\_M.Y"OXDB8L&GPS4]GX2PSXQ7$-DHR%DU4(?7
MP'4R2"PMZ1E'2KUE<M)I*S*=Q#HD6$(T=2; B[2;Y_ZUM34)D&WK?X(,7EI"
M4$6,"I8XD(4(1<!"B*9BX++<)ZQ-PK[RAE2]X\2J@<?8>U^5-[;G!4F5=&#K
MWYE7%T*T4]#,Y6(.)WEI$O/RTE!T J%XU='RM-_;<4F19/$;HA:PP@L^1!C6
MZ+"=#+-^F)R5]OJ/R\7C)^<+D3<'/,+M,&O(<AGB53'M+$,ZE;4A!PM!6Y-G
M4JKH'5$@.^ON@ E4ZSY:]U^5:9EHSGB:<%#"K),L_P6T]_*""7N2[,(@GS(7
M$3FU8_.@P<[7=+P]@A32?D0^\VF0Q50L(,@4RPBW)6 ';J8EKLGD,S;5'1;7
MKB:VA)TID6;SF@8A 2&,HMD]CT*P*:HH^]B$CS,WO!S$HH@:HQ!$M3MTC 0*
M&T3UO:H?$O_>(!&)L[:&0TJ2%HF:<N4P.D,V4+TOF!T C@3>*9(A8G!PU)6%
MV^2>%J#_^<-G!__& ST\?<S$<<7/8T\$@&Y_HI^\!C ;%ODM3(P2^34\&(;>
MNX')UQ(NAT.$#8'8FI>7* $')AJR:Z>Q&JDI'['X.$G6Q9I"<49?P,*-<5&%
M.]@>T!#Z?<:Z4.B#$('$^.]D)=-1K-0LJ#! SA>ZH,A3H"3)X[@=Y<- 57;_
MF?9;@K,.O@O3-$)4)>$.[()D0D#O=2GQ,<<:C?,!6E"_7\.T7ZF87]MN?0HD
MUBDR>G/3F%N5M,1VP+4P8&#-_\ ;WR \YFVS4(0=T@J!,>LICAW*OM_CO!*(
M<Y2J-& U"V(O$T.,6.+=@556,,6[D Q'QT)1 W5;XCI.6R"@XQ :&0*Q-Y^#
M@98D+U_#4AQ>G!PXA)Q:64&<IOZ-D&3P9$?(0["(V#>.U"W;(+)/!Q8XZ L*
M_O^(#JD"1O!'&W\7U)*X$>6YHBW48]#S\ABDH1*D"5QB9P0&33!.7>+9K?OI
M3FQ9U219CJG.1&GD.;G@+!-K"/@]9U:\YU*JQB@15U=F)VA37O5*49 6Y -B
MDP^@N!V:T*Y.004?@KS[[8./0)1_%MZ4:L:@;83%&A]$"R)(.%B#L9LG7#3=
M,)DY*WO/RY;UVS7J'"1Q!(OGX9B:HO @6&D^ 3,C\Y%$GJW0@"F^4AHD&A80
M'X(3UY_S!BP9V+5H+Y^8EB4T$^$XN89M0S#&WQ\0)3W2/""'G,X1!Z%%4D%0
M$UD2VL,=>'D"6;"B$0>YKS\ZX[Q[C#P_Q738! H,?F6-?&IP2%G37+F,"LIN
M:H-@@9J:R9$MN$#VDW4/ONFJG@]$&GII^][> D7]P>&RM%'(*LTBA1C*0^F=
MJ,^@1M P9=) (0GT58 <VR$N=33U%,5;CM'AX'S2P3*@X>P*S&Z&\2GBH-!]
MHM'ZZH9-+3@/?":QH!\QE>[IX1.69U)*R!D27A1!H/C 8EBR5$DP83XANG5J
MBZSJ%E92,:YT*8L>=:QF.>^E68I_\-(,%!<R/?_.^HTC@?#9K?^,_1)04"P'
M[&A+].$DL/ %&9J&-13\RX'3\4,_,FD6A):^N1&[GRDN^!")V)&' G\+CKUP
M'IP1[*$Y;E7Q"E51KGOCHZE#:^Z=,AP5/HISHT]6"(BG_@CX6 ^Z\,DKL5%!
MD6 V:T4"@5<$0B1V1;*O2J.8VB-W ,43@'TU)O..HV%2_DQ4=P;+P3X9<=1;
M\\$&Q4XD(J=P<B0I("Z8P.9=!MDONO%^*TY\KL:>R4F^R5B)?Q(SX*0W&!+Z
M$) L&QI=A3B9DP@4+-4U>YV>]%@7D,[AZVR6ZQ("<30UQT3SI_?.7*UY4+6K
MM$M8XRH:@-?)<C[(YTJD+)X>9V5*"0=8V,%:D<]%6C7RSI#">4TIT*)X&%QK
MM8S;R?'R2I.N/JDC(,7).H>P&&LPB8^BO!PD1\3!%W'2$DY:T&4%ZG,6"]5M
M;%.C<YD5<Q93M<?)5UK"*ZH%/#%B:4W4);&OEQ7/5\QWM^2/^=AZHF.69K@U
M)%+>!V+;/75Y'"L#/<+=@*=9?,FO&>0<#$P<9AXF9D9V+V[(S["C8]O0=S&#
M0Q:P)*54@FBS'@PAFRSQCOE2*V%TA!WY6QT';3ZI*?TSS(]<'G#$4G1@U.)2
MF,FRCP.SHF)<M69P@3//.J@E"?G= :'T=.(RC(#1<&$?'!G&@H-S3H0Q4]QA
MFQ!N!,/\V01D)@Y<#M<8+=0W2(+JWT>I@GNU<00XL81$Z1#(LAU<:.V<L-PC
MR+5B9Q K5F')";_E^?E Q;O9+T7WV1?HFV1$ZI+..*.<ILF;'O[;W>6[1W.3
MQEE=5@(.AHT)(:$TQO%.3+*EKBE]:SP/&;Y6'*%4_4FM9QA:4TOR8]>@D8(1
MGX3=DW#,2_64-5R6![.:>24AT<R*\*QF''[CK^_+]R=1]4#J__D$?&V-%.L0
MV23Z.3TT>!:LAB0+OMN-/8)5SC406VVX$X7@L8[-!GV$V/P4L7G!&256':C>
M0M;5&XP*?556G@\RE:^6-Z@"]5Q7Y!'!!1*5/6=&0.@'0."!1<NLE[=6249W
M8J0BMS[(W3A6P*E%B,3.]==(7,3%)7$L.; SU:9K2-LI.-OR4[.E,3Z%Q@'M
M$@U>["DT'2DJD1CL-1TY=H=CO?: 7T\6P9+ :^+FQG3$CN_$IV9HYL*%7L8Y
MG_[FKIJLNR'KZ(!+']ST,-L' TFUG([%I.>:IFUUV2VWU$@9 XQ&AVDJ-;K0
MBI+C4,JM4,IWH><*M3#%JL]H!>^!E;23DAR*F1RY4>"TD=X1=DN(BP]W)@&Q
M,342SM-'K"VFC3>AC,6"STE>X4ZX(8/9N:<DN">^!K3/RO;WW4E0W(JI9S1Z
M.ERW$ \]I F"MO&K\52:&^%G#RDVOZ!269G4[8&M9_;),+J0E- >"]Z<!)=V
M?CG/<E\,)-CY/BT;^"9GF_OLXIYD!'6TEENQM3BRSUEQE?B&PA)>:W &A[FA
MK,75(9UQ0'IM;^ ,-8>G/@T0:1.D!"X=,M.::8Z]/$F15F/H7.4&7Z)9:3.=
M#[5#2B/TWL7,D_32:(<)T$>SG5U(K;#L358;GB>#@!$";X0QTXVTM'80;)2!
M=L76UHG_D'S;=&/F5(09O$;4L=Y\',%*$IW,$"@H#+6*;+_#3MRJP.T]XO$D
M$F1]JH';/8XCJ$G[8WPL@0:+Y>_J;&5%4Z?^YO'.4E_9=]J/-.D,.:X!I7*M
MV&!/1(9(I.7'!$/&O40^F!=?HG2B R<$D9[/5N#?-#LNJJ5 '.R0\%9 KS*K
MM 2)?LMXE.*NT(,0X,+ZR1E]0D4;DU">9Y]B+8=FM6@U1G>68LU41'W.,.;K
MYL2$->F1RNNVD391UF>KA.=2$*>+HETEQKF^K!_1+_#JZ@>J;\+TJE7=$;5Z
M/ZD^<#],:O*:(35R)+6 A#U3Q,L I4R@/K!]Y@[6.^&\($1K7E)"D*4V7\L:
MOEUF5I??M1QPJNJ]GD]A^H#=\_(AKG"J7!O$E"K%V_-6#N>,-9T9WR%!JW0,
MA>8GD[:IY=%BP(OWFKQ'M?"MH#D0%$=Z_DU:"Y-,P1'@D]X"GV1->DPU[NQ'
MM)T%J4D:I"085A', EN-H\AW1Y6U;3YR2D?X<$NR:>O%829SV.\">8[Z%.H2
M?KY?7A3ESC:=A#?-5OG)>X]>:-U40A<^#^0 $EDJ&.5;GZCT)-D06I<(RFJ#
M6FL?DW4'EIYEE/V+]U$<TY3X/$-JOQ82UEU<7:>#6Q5,SMV&=BXA5):\ O?T
MY'A+M__6AV$3Q_0/-HK$+XCFN'EH7I)LU^Z/RF%H4F( <Q]_VIKYGEL&7V8]
MPTG+<2H2:BM$4:3M@V+B0J>E:/R8A 40DQYE3B=QJ[<)C5KIDHML/8Q&LV,J
M*ED?=-[+*2(>Q'^3-!:3M]%CYW[0!C%3]IWZ;WG?M+16:W:<0A:+ LI ?":=
M@M*JJ7WOK*;7/9H,)KHB3QNE[?4B&2P0*'GE6MB?4U<Y*WY!=:1CU+TSRS)7
M6R^2%F^</-#) Q-/AD _-K%.6B.]]@&JYYO!-69+]A/W?&K#E!F%4MX?EE+=
MN/.*)JV4E#O4_O3B0?3^55G_>W#^5I=]9X81;>.SHI![8QB8!"EYW!QC-=[.
MAP0ZRQ]"/6+7? HW9&+<SIFJ:+O''1:XN/0CR]4@3LMD<&:%N/.DX^QBE?1#
M"Z_7Y;9<2U:L-CYMJ0LN/FMC>S)-9\6;Z#W[KR.%!)4RG#,A:,8;-J.;)B#*
M @VPB._R)O7I4BE1T7L/WP%J@Y,[',CK-2D)A)7A<+6%J&;[D!?"4 H;N#4Q
MP;C?1M.">5Z(%;4D?(6+[X)46Y5]I4C\&59_7"2>TX%6;7K9:>@#01ZYP9VB
MD!O?-8QO$LUX2U386,XLA73AXFM;]+PS_X7)R)_O.(=8R1F@)"C)2F<S_; $
M2-H^\(4 ^85^X86NL=!LKZWZEN+<ITDRJ3#4B9WADE'271PCF#91=9FGF/9H
M)AUKDC<^FX,H[R*0YI]D VUY)H0>=#SOT])#Z$5.!/]@L5F:>"+F5[BN!UM]
M/)7[)^!^XI%RFGGT+6)N&E<XGBSJOTHG^]QX:.*8JS9+XH&.X.A,1I<I"?9:
M6RF ENVNM7NVV)WM3OVO(?I3==U[+<=MO;;/ZH8,I4_B+%0= 0?L2\NW8P>9
M\,U/&/+N^D.X@[&(/;[8$2$S8,;B^<2W1R9]9K\X,-V53\1F/_$&YZ:_3;[_
M@&_BW9$Y#_/R_.()=[(.N.:AK2G%VY:4$0>TNBH/PZ<!GJ6IRFU>]BJNQC64
M) 8?V^WR/-GF"O2=VXQ&?7:S-^6>UR.U%)*X>2$NO5<8ULQU>V68T=8H\+,N
M$(Z3*KW,TX,_(Y?J%LY]6L?FJW>Q'AOVTCD^U<;<NV;G3JS3.(2JB.[($!AU
M0WG[>0RF4J93H9VT2(;[/4=K:VOI4NGT8E@R,._=*9UTAW_]?9'8W<-)-M<,
MB7!*@74,-P3)=R-_O=?+1-'+EYA5\Y]!4V2U8R^2?)@#AL=Q[KR27;7615T@
M : .%1S5H:H\JZH("B%#4".YS I8^$&Z[B=!/)^@);_Z]+KB\(=!X J_I0!W
MEFQ@\MX37/.;;(KBX94I_)7AR)8YQW^-Q@Z!.+E;N*R<WO=)]5#8"X)JMR:&
MR(+%NTZ+'"Y+;.S?F>5Y7PM)3%W:*-*;==EG)9+$%9=+@8BUVV;;B%T4K$ 3
M?S2>!U::\/752>UB;]S'4U0RM64QR[ZD/'1C$>U+H[47!+F%H.$/DV^A78&^
M#7HZ((_)D/K@=TS$F&O P]:2_EL9O0T@'2KA(M)RKXD(?Q$ZD);=GTA75L"-
M\VLA<?8NO4'V,KE!)A=SWGWF@EEHOR?F9]]$\\IJM+D3_!CC+9+Z\H(OWK;\
M4^ALB07'BGQ<I(MHK;'>+Y#,'^'KC\GEH#3EYH</**"XY#)0 #MFW;[P.M#1
MJW9IN\R5Q QHV@RW+/+&@EP\\QB<;\_"%1PL4PK(:DV:# E <"P78;"^!,)G
MG<D :FZ+S0$)A=Q>"DTR>N0#SXJ+3M((H2U,TOPJ5:,>-L@K#ZE&)7GF(]AB
M6ND]N_Q=C43/:38<0A]+@FDCL%<\H< P26UX*M\-1G['Y8TZ[K,ZZ0 S*#_A
M$RXW(U+GIP*0Z.![0*NL,B;*<Y) 3XZO]^Q3A#J]_WVL"^:+GS<)MG'%=Y79
MA\F:5?%DB3:UAQB_U+*^W! [+*D3(VOVE@!8-;Z^C@L_?5GMCZ$QGCA<VSW$
M+/=3E!^!@1#[<$6V,XB3RGZ?/-"2@!7Z9439,E(3^9+LQ/3A%$R4@HRFH"3M
M(^\^,&,LYNX$L\L6G#K_F 4A?703&3MD BWPW83ZE6::OG0Z9/(&K_4(HOS5
M*'"$Q#=>X?@C!54W6,O/NT@ES^+JBK1R["5[BC:B/@2R;\LAVH$74Q6[DBY%
MSOF.O1M9P\D,S?O%=$!HI?I7WLX*/61S-]@*AT;\F5O+G'XTZ4V[!M35K"GY
M8? #_^;]P)^#@+U*>IIFP^4J;Z;"08\TV U9BU(HD-1D1CLYA=@&KGCR+5:^
MB;STST@(/1Q[2?Z:$S)5/G'C*ZAEV':O#3S\)@ >14@*)+XA3EO#A"^:7=)
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MJX;?8 Z-OASGJ7(>Y.?2-S<T?-4IQHV_CR3Y=5/%?JQI^#][+J_> \?JE3D
M6?G;9Y6P'!O'>'3@<-SZ)#M-X&.,9*=[YE+=6*Q8]C(KLZ*N(Y+8MK&AB#,E
M1R[C;,H;N90Y=@F?L[1KYO/8PWV%?\7T3.-TO!HB'0,3BEJ2?\<XD&-1@&9*
MJ0$[GQU&7R9YHZ5<R(_:"@"(F8!+OB5Q4^D-?!+.'>)(7<APYSH)8]L:DD=B
M_I_*'B8*OCA9@A-(;W&-BFWR31N^X5INJ$S^]/8Z%/30;U>VE3X%PY=Y;QIF
M.KDBY>]5R?.16AT*?9=VNR5H.8N,EW60(]+2P2T_Q0VO'U$]D;8;&>5@%0#C
MI*$SSB_B,U!)58[L0]/RG4,"^A!8\?L]F_T?[1E:?6MLS5D/5<"3V=D#N:^Z
M<#\MJ/Z2D>A?P_&Y%N3?_9+T,>('3O+M+"R[3X'IULY48^_S\,%AU=F!3> 9
M^BEGQ;41!_=5$L^F$B/M!^K78]5UBXW408N/8NA'^II![')D3T/?='7ZA@M?
M0N.7?C4.%PR$ZV)Z\2-W4R-X39(PEJ;D:&Z4HU#Y2E\M"2H1&<E>XH^/Z1=I
M+<IWPOOF\:!<PENI21E-[C*%$M-!U?)N0*#DN5&"56($)FXWN6PR,1*<$&!-
MU254P<NYDW>_>]O945_9<#H '<>UW;$0))='\J'$JG\=.RZ/?R-'C-FS9(-K
MR /7.9];U#R\^OCYZOIYHC_X^839:1]V')[Z>5?7\?&:7^T9;W]Z\7 QG[L[
MU<=.7\OSJ/??VUU3%0\OOSEY6KQ)XO;X+*J.)$+,+BBI) 12<FNZ*.GC.JNR
M^#?;UF,C;Z'?UW=P.2Y;>+\F@))T=/B/DELM"9!)AX[W<XX\[3MQH\7_P>M0
MZ1ZH9FN;?>BQ6/&;7].KLDNS;CJ.9:19,9B^B\<P?1??Z35<<ED]Z^AE_"T%
M?S TQ"R_XC4T3)()S##$ X'VUQ\\/;\[O3@_0L_BM#A*T45RVUD$Y2_D#@!J
M'?3MQ>,3H9\^R.0_?W1Y0@O_%+#P4IXG\$]\>%?RH!N%U59$J-?X*H,+O<F\
M(J5%I^#G_N G3-*I*FAQ&=)!P9U \W)3)XY)O#6FE\OM%[;UG]TA]5DCCKIG
MGO8YY?SSQ%/*X9O3\R>+8#4"$WDT!HY69QA[2!@77@E2-96I="LW4;MNU%("
MYTV:K7])]KW495A7\'NK&2M+$/49]L69TI6_D.LO'TGE/^?YQJ5LGQ*Z"7?[
M:;PW3%F3$QM!7H@_AE7W*N3+J4ST"H!^CEXDAJ_25PP'FX35":'<9XA(OY7K
M->RD_&&&&)E+E8)L;QH\+,C.;Z0VF>SA(\A(01]TLM+KT$D03:Y<A323J_LT
MX]37L)*E_>V1H*DY@LXX13GLBVG_;Z&MOAPY]T=''B1_.(:"@C7_>1PG^1OY
M&S+AT\+_!9XK^<,S<;C\^9XW94^'Q]-5*YIZ?O;D\3UI?/>_#';'?X9F:8?!
M;OG'C2%?I<< ^GYER0?57[!!^+M$/_X/4$L#!!0    ( !2%=EA79^8)400
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MU9K8R_+V*;AC<E-P14K($.I.HJE%9&NO[4"+NK&TM=!HD$TWQQ<)I%F \YG
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MO1G6H=B=T-WLNSEQ!+GQ&"U#!0G!1J?WQG?Z@1:T5;C)ZZ3/J7W\BM2Z2!*
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M 'R_,*;Q'W"#\)- K_X/4$L#!!0    ( !2%=ECN!7BTW0,  .P(   9
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M'M!)10LZEMCRFH;R[< 6X$O!V:8GMKVR52W,\>6+BVSRYJT'::N*FB+U%_D
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M#30=XV-)GR/HV(#."TO=K5LP0?^!L_@;4$L#!!0    ( !2%=EAK23TOIP,
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MCL:<?VWH?P4:=J#OE:8>-2XXP?1/9?,O4$L#!!0    ( !2%=E@QN!F ?A
M *D^   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;-5;;7/;N!'^*Q@W
MU]HSC"Q2+Y8N+S-Q+M=+9^[.$R>]]B-$0A(:DE  TH[[Z[N[ $%0HF39SEW;
M+XE% HO=Q>ZS+P!?WBK]V:R%J-C7(B_-JY-U56V^/S\WZ5H4W S41I3P9JET
MP2OXJ5?G9J,%SVA2D9\GP^'TO."R/'G]DIY=Z=<O55WELA17FIFZ*+B^NQ2Y
MNGUU$I\T#S[(U;K"!^>O7V[X2ER+ZM/F2L.O<T\EDX4HC50ETV+YZN1-_/WE
M&,?3@+]+<6N"OQE*LE#J,_YXG[TZ&2)#(A=IA10X_'<CWHH\1T+ QA='\\0O
MB1/#OQOJ/Y+L(,N"&_%6Y;_)K%J_.IF=L$PL>9U7']3M3\+),T%ZJ<H-_<MN
M[=AD<L+2VE2J<).!@T*6]G_^U>DAF# ;[IF0N D)\6T7(BY_X!5__5*K6Z9Q
M-%##/TA4F@W,R1(WY;K2\%;"O.KU=:72S\\O0:Z,O54%[+7AJ*Z7YQ50QS'G
MJ:-T:2DE>RC%"?M9E=7:L'=E)K(N@7-@R_.6-+Q=)@<I_B#2 1O%$4N&R>@
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MR%BRG_D=#"6W@7]Q@;K,A3%,<)U+5!PH1Y8<Y5G<T4J7"GD'6C](#3PH;2(
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M%*F@T1U-6)^^/ -C R69 M #6+E_JPWD8!;/#J&91:B'[VFSG40ZCN)DZHD
MN_ @GGO.RJT='-$8^".) $S,QF)[?M=$XP71/>!0#1-KCB&!4)L4*DK2F!/J
M1A@*!)BO9W5.L164=PQA>9SR&MB$X2M1"DW OE2U;MAXH#S6C$5C/QL*SA&[
M_/B>?;C^9&S(NA*:2@[<F4^EK! %:?LA*Q1D%$UF&-F@;*%J.AWO;C,XP$(<
M8FE@%P=-:IGB&,M:C>N2DBNBL\ :QM4O$-*,K2DP==(BY[0+L%0CQX"APPQ'
M+Y[\_R_>"YHG3L1]$WX-$QC2VK9IHN'^U2FDF15#,/T[Z"!X=#J]..NAMK,'
M+8W9Q/_]OFSWQV=TS2[@8A64=\YL&J6A E.A*TPZ1+')U9T0N/6Y#V!^)!H^
MPZ0ML$7,6BI(3";?>;]PN90JQ7.',R6XH3:H#4?21@A*3-'T\-&"YV1Z#17-
MT03N['HXP*8'^ H*'X!975'V90DVLS8"0G%F_?26"D3*)\"%5IU5EUQJ!D$:
M,E&88G>7P*DC,.:-S^+Y8 H)_:<2G%.M2LJL3.!_:9C=BZ_XM[#FB=DK10)X
MX+S44HS&$&OW;.S [6*R9Q>3A)V"+46L%!42<#&_!NL\.WI_FSS=0"D-=!VP
M%?Q?D#E6M$M^NL_#53#]_\L2&JA*)KUB4;7D19--.@^*MBB\K!%^;ZR?;HN$
M!$/D? J.[2!P:$:X4!B('P]VN^!V),@]'/0H@4G:&=L .!FW0/86Y88<),#"
M>'IV8+']F#A)+G:8!:_Z%8(KCM^/D<C/[BZ$IH]%Z+QGC/6(\@'V'GF#;^UY
M-!KWT$9LV@1/7=R'V8]9%:L3F2%P.50(2:?@_^ XG-8L1+4'22UR O%=9AM5
M$L+X+<UJC?+1+A$&)H,Q0-TOP'3#XRZI-<^\V^T#RZ? <@/*^#9UCTFCQ.$D
MGNQ?]M?RLS+_ .'8E59+69'KH(2/\WR2'V&)&Z-223P2FK;K4-YM8'\6F#DB
MU6^7[CSU_]^V[>-^R(&2.;6Q%S7F'UOU>0  Z[R%REBP3.4YQ)BS![-V1&(6
MC>*A'_^,3:+)<+J#5*-P2#R,XHMI+V(-AV<[M'[T97G(78B+S_R3!Z5^43(>
M?K--=(FHW8'[EIZ"^!TQ1^V['UI?C]@[!YSL)Y6C4%AL0*)1@I44 C!I;1^3
MNR(2U\;ZX9*G,I<5Y@4M@&%%;SNG$C8'0I4%9VP'DS599+.Y0.LY#2+!%DI0
M+ S!&OV4NB (G:HVH/!N]D3.&*!%2ZTWG>J6[4@6DRODQ>(/9I:.2],"<$@W
M2/MV5-8F?V2J/9Q?N42OF^#Q(,7;9O$8CCXVJ.3;=Z1 +%)W]P$8"J9B^7!%
MI:7"6A%;5,2P$6'FY17Y5:0U]6'WJ32RP-Q)!<<S5M#YQ\!R^03",*M#.AE[
MTJB$MEKPTSLKRK+;?K#IYK-9BV_XYMG8_^[V)VPF0',P>2UXD&@VS7O74S.$
M"^PRYQ#HKE/$1N,*>H)4?%VHK-F]2E5@ZD&Q$W+O!'>A&1]3^B#P,*G']5WI
M,A\G?US@H86MZ)LVS@JK4Y3(NI<L-W5U?-[:_/^NB?LW"D-QC@;=O)M?#,;L
M.__S@S2?GR\U.*5V&])8?ALA!M-@@J=-@ ,Z97=2Y+L1H&<&M9U\*CN8V?)J
MA_LG93Y7OKR=7\3..J/);+87^/=UUEI@U-^FF8/<M41_[[9.-]]X?(&SG2XD
M4&L^))3C^*WX>9]#]E<P2.APE.LJ=T_[)P8R#BNVQA,.UQM7=/@#+L54FM:V
MV<W/6#P;8CL:]G@)YLRH!RDK"1QMZD4N4QBW%-H=I_D5(CRW.%V<8>2"@+$2
M+I)66N6=@1;=VKJIC\?_F_;$0QI5!'Q-GVI+:G_*^95""+#T+![^CA72UEJ3
M2;*_7L+NQ778?69OFFLI^\X\PF9U"Q6-[(<]0V).0QG+_TZQM L^]Y9-KA_3
MUDHV^CV6@_OA;!S-9DE8Z%P, I#::5]'PWFG+)H/1BV,[58]I]-)?-:E/AO[
MWSW5U&@:#D_&@VG;UWGGCS7;X<-YA_Q@.CD@^WXP'D?S3GD3SP:3Y-%:]QPX
MPV\Z&GC8:&6@Z+B/J5$TOIAWE3;:9>;020VF*@"U!E#7)X&-%X9GB90.C*)X
M/+>PM#V-2H:.#X.;I3Q/:PL9%E5<8,@D KR@=I6H;H5P\<+MFK5ICXIT0I3?
M!=<_&K3]4JLVH[".<-1]!4\::A>E"7(13\.TN$<M7?':D_,0=<S>#+E-_ZE_
M%,V3F4VMDF@\NMC.G![.R$$[Z2Z.V^@6'P^C9#+I6_W(N!.82Y-E;-4,QZHD
MG@PF]MFS&+QS)YE\'%.'6X1NY60PF^Y9H(W7E&I J,',*9=+@08.+#L9T0@>
ML",/7PTYG4+9L;N<NA^]M@+]?<&]+IW:NF'6.=\^-+$5 R"2M2VZ@+% NG[=
MGBRHF_+L]_FNPIXW"K/3+&%[($,7%CH"RFZ*TF4)7L:#N'MTWG,QKUOH?SNK
M;TMZ6[W3"6.G?N\4[C9-I4L=_CX?-Y K66:^_Z_G,0_]_Y]MIG;@D2]^]D;E
M[3=/C\B/[A=T*O2V4F^ XCEX<;Q5M?>_]13#^-;3C?!=B>E@SKX#$O%P3G_Y
M%\G@@E[,Y]2W.*)?T?8M)C1S3!1\;N>?(KECNAGX_W PI%GV_\-/>R\K+,0*
M:L764=82- -: 8@,U(+B5%L1'[N?SM."H0-VU=S-LXL%5/J<$UNFQ0*O:B(D
M.*3:RX2M9:'X 1Q'8]X(,$_;R9:BR6'X=N^U-V.QX"<Z%M9<%[.@+$-N.[F6
MD5"XRZ6$)X6 2C]K[@_YY,RXY"ND;DGX2KZ0V4;)ME&\PX%/R?I*V+=M^][T
M\T1W;N$U[!S+%(S"S@1=M#+U<@D B.UE%X9\E@A1G^/>N08U; ]>#E.E[2=Q
M SHA :RXH0GLR+NEX"U#!D+_%EJA3'B[&"-@:)9KCOPZ0[!;SRER-63PM;9R
M!8<;=C42@-\%8WV0#%, >X'::ARO,UJ\=YT.[\[>C35M*Y:#W1ME6C1YMROA
M/PVN@0CJK0;6K;AIK>T%<G?'V'5"\ #$-YM=PP2T"6&O(GOV!;^_9-YGKYW<
M=;N!WA/].V[<N?(62.8V),T5^>GQE8"+[+]PD_$O4&1N)*;</W/]6?BC\_!X
MG(3NGM[ ,K=KX<XQL$LO<9?IG#R'?2]=2TN6]I,=J=R5W%35:%K '!H!/FD=
M.- (T"[1*R2=.-'EQZY3/;)_XW%C[TW?QJ.#;P% S[<BSQM]!^?<=#P-$SI=
MIT;G$2KI63R+IO'8)?@7T6AT\<#*:?M<Q/HUG8R@M-I>8S8N-?H=DJ%_[FDK
M;8_K-F^?DHQ\ &>GN_VH@TR W&I#X-&6_--HE(R#W^-H,IFQ:]@F<(6H\1=[
MY)>!NP!*H>7>M)VB.(F2^>Y1,3R^N)BSCU2%AOT.VL:PYT![&<@[;$\I;5OO
MJ@89\!KVX<\Q#LXZ14/!\<GPQ;OKJROZ,WYQ9KN-N5%_V$<<UO^0!WMEU\A5
MZ9S*0- !1\[E2F(0VGL&[--XM<$&!#9N[R@2-"+?W\, 7(:@80!&2I1,JWH%
M9I*F=>$Z+A!5-'@",)C5J:U57(T")5(J@-4;T7;:7?UE93MP!YV0JN"8C#7@
M 4SCG6T*91KKL[[[QHVZXN%PS^7Q;W+_GY9YZM7_G;OCW^3V__9=^7U? ^ !
MB?\:H)G[+6_U+^Z[U?^@6_S'6 C"/%B$ 5O3QQH,0KHJ19MSTM82<6DHTRG=
MI034HUS:[O^2WRA-!D*9S5)DA'X5_PH<"%X1>-I%KMV7J&, :[?$>\R?4*T?
M &KQ0[2W4'1WD"><]+;AT$,1:"#/*7<57U.!5P:]M5ME>?^V*4K3(MG5=@#5
M2G<T %L8D:A :Z-,BRV]K$4!3PMK9O:ZQ6SB;:R;?W%WCM!Q&RQA;)?T#C?3
MO<OY]BM7$6P@NT]I%[;PQ05M_# 0=Q'"-'ZY]W%]_,<@%D?"[T"261Q^!9+,
MAH_X!N2C<AD>)/)N-I4?"^Q-&X@#6RQTK@[/AY-[^-_7ENO[//4\^'RX$'I%
M'TDC^@/0VR^)_5/_'?8;^_EQ.]Q^Q V)+& :Z%DL8>IP<#$YL0[7_*C4ACY&
M7JBJ4@7]N190K6H< .^72E7-#US ?YW^^C]02P,$%     @ %(5V6%XF813Z
M P  H@D  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULE59K;^(Z$/TK
MHVRUVDHL>0%E6T#JXZY::1^]W9?N1Y-,B+6)G=I.*?_^CFU(H;2L]@O$CW/F
MS-C']F0IU6]=(AIXK"NAIT%I3',:ACHKL6:Z+QL4-%)(53-#3;4(=:.0Y0Y4
M5V$21:.P9EP$LXGKNU6SB6Q-Q07>*M!M73.UNL!*+J=!'&PZ[OBB-+8CG$T:
MML!O:'XTMXI:8<>2\QJ%YE* PF(:G,>G%P,[WTWXR7&IM[[!9C*7\K=MW.33
M(+*"L,+,6 9&?P]XB55EB4C&_9HSZ$):X/;WAOVCRYURF3.-E[+ZQ7-33H-Q
M #D6K*W,G5Q>XSJ?H>7+9*7=+RS]W#@-(&NUD?4:3 IJ+OP_>US780LPCEX!
M)&M XG3[0$[E%3-L-E%R"<K.)C;[X5)U:!+'A5V4;T;1*"><F7U"2DE/0D-<
MMB?,UK@+CTM>P<4)?);"E!K^$3GFNP0AB>B4)!LE%\E!QBO,^I#&/4BB)#W
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M]F1&92?0>"'IA%\W;(#N63;['U!+ P04    "  4A798VOMX\2H#  !"!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RE56UOVC 0_BNG[$6K5)$0
MH$4M()5NTZ:I$RKK]ME)#N+5L3/[*./?[^R$E&X=FK0/$)]]]_AYSK[S9&OL
MO2L1"7Y62KMI5!+5%W'L\A(KX7JF1LTK*V,K06S:=>QJBZ((096*TR0YBRLA
M=32;A+F%G4W,AI34N+#@-E4E[&Z.RFRG43_:3]S*=4E^(IY-:K'&)=)=O;!L
MQ1U*(2O43AH-%E?3Z*I_,1]Z_^#P5>+6'8S!*\F,N??&QV(:)9X0*LS)(PC^
M/. U*N6!F,:/%C/JMO2!A^,]^ON@G;5DPN&U4=]D0>4T&D=0X$IL%-V:[0=L
M]8P\7FZ4"_^P;7S3-()\X\A4;3 SJ*1NON)GFX>#@''REX"T#4@#[V:CP/*M
M(#&;6+,%Z[T9S0^"U!#-Y*3VA[(DRZN2XVCVKJJ5V2'"'#6N),%""3V)B:&]
M0YRW,/,&)OT+3#^%&Z.I=/!.%U@\!8B94T<LW1.;IT<1WV+>@T'_%-(D'1S!
M&W1"!P%O\+]"&YCA\S"^1BY<+7*<1EP$#NT#1K/7+_IGR>41DL..Y/ 8^K^3
M/ [SV1!"?]B#9_'@2XEP;:I:Z!WXNB7^.1#^,C-0 3F?I)79AIK"(VF1RY"@
M]L'<!T"2 VRA'5 IB&/8EFQM)96P;&MNF/3?W)^ 6;$3PD=-:+50<(L/J#>>
M1('PQB^]?C%.T^32^W\Z"2S#3/_RY%$$4[0(J.1:9@J!#-3"DLQE+5BNU&&/
M P00FK7PM].#++(V-E!K.$G+(#L.9K3?PD^Y467?68C?26B]8>)*5D&[(Y$I
MR5570+8+@7>]9>]/@4N^'S+''BPZIE*O#W)G,4?N2HR_G[1\))27WNW).> /
M3X"IC))7GGR7ASW8$W<'ILG'2EI','H:X@^+^ZH(P(_9*;I<V]_ _LP.;)$/
MX^7Y>!S2_')T-@Y7P[OM4%A.DF\$P&6,5<: ^U(.[CQ(3UF\JS%T9;7K/5<]
M\4%?J]"N0_=VS&VCJ6EQW6SW0%PU??'1O7E=;H1=^UNN<,6A2>]\%(%M.G9C
MD*E#E\P,<<\-PY(?.;3>@==7AHNJ-?P&W;,Y^P502P,$%     @ %(5V6#J_
MCLK="   Y1P  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULW5EK<]NX
M%?TK&*VSD\S0>E!28B6V9VPGF4UG4WOB)-M^A$A(Q)@DN !H1?WU/1<@15*O
M..U.N^T'6P0(7-S'N2_P?*7T@TF$L.Q;EN;FHI=86[P>#$R4B(R;OBI$CC<+
MI3-N,=3+@2FTX+';E*6#<#A\.<BXS'N7YV[N3E^>J]*F,A=WFIDRR[A>7XM4
MK2YZHUX]\4DN$TL3@\OS@B_%O;!?BCN-T6!#)9:9R(U4.=-B<=&[&KV^GM!Z
MM^"K%"O3>F8DR5RI!QI\B"]Z0V)(I"*R1('CYU'<B#0E0F#C]XIF;W,D;6P_
MU]3?.]DARYP;<:/2WV1LDXO>68_%8L'+U'Y2JU]$)<^4Z$4J->X_6_FUX:3'
MHM)8E56;P4$F<__+OU5Z:&TX&Q[8$%8;0L>W/\AQ^99;?GFNU8II6@UJ].!$
M=;O!G,S)*/=6XZW$/GOYGDO-OO*T%.RCX*;4 AJWYGQ@09R6#***T+4G%!X@
M- K91Y7;Q+!W>2SB+H$!N-JP%M:L78='*;X549^-1P$+A^'X"+WQ1M2QHS?^
M]T7UA";["9&?O#8%C\1%#XY@A'X4O<N??QJ]'+XYPN9DP^;D&/4?8?,XH;\J
M*]AHVF<'*++/B6 W*BMXOF9+K<K",(EI;HR@GSQFJ>1SF4HKA6&9WQHS;MF"
M*#XZBC)G-M%"L%0\BM0X%XF9HEG!<FZQA:F%&\F\*"O".*/,"O)+PTK:8!5\
MR0H-B(L6^3[[)!9"TVLGSCA@]SY\$-%[N<SE0D8\M^PJBE296YDOV9U*9026
M X:@Q7@<2SJ(IV# 1S$*!Q6'O-E65-L0:U)N/4]M3DA=$==Z38MY1ML,<7'#
M3>*$BNA!_%Y*;" %!S531#(2F)ZG(F Y0BTMW[PL^)K>,%X46GV38+"M A;C
M#ZP0MR91VIZ2FKJJ-:1<8W7I#-MG5XXQ.)#(YM!>[43N6#R$@:-6VS[A,3MY
M.0G.7@[=BI/1;!2X54!W(5S<3-<!*S1XTS)=D]$SE8LU(I%^@#B+,H\-: (:
MB4IC]J5_WV=+]2AT3AQM:Z;-+'LN\R@M$3*(ZD%=OF"K1$8)6PD([?02-U#[
ME:#'1A7 G*6PRBW-H3C-<P,0 9O"KH3(:ZBNI$VDAT$BA>8Z2M;0MB;[TN1:
M<&P2%,Z.Z+*/=QILDI:>XC"4B@@/I78'00@)GP"K/B_*?Y!DE"S[[.>?SL+A
M^,V?[O?O4$REE^U7NWK:7M&*1O54;;_N.-P:-Z0^*PMO_F]K88_9U^R4O0-H
M\? A?Q3&.O2[2F>S[82-@M%LW!K3TRA\<W1F>X\?'V#A-G]0YF\1=/8;XA4G
M+]MF_M4HW"M8^]3OS>^C07/>//%^KVB+,!M.?U@-W3W=\0%').>*$.NT=/'"
M)Z,].B*//F2]1""LS==NZZ\$?>WC3,>S/>4#@J^X:5)<C*Q'WD\E$P(QUZEB
M1F9EZI-3IF(*4)2^B.(!I@+'\;7,52:A\%N73]F=1A:C#(5W;R7BK)R7^XCN
M*J 22*4(/BX&NJSD2AQ23Y3P? E!9+YQR">$N_JX=1,S=F)$GUTKFS UIUK*
MIT(P7^:MB:IV<#%]MV"P.X8HE)&^O'!9J9ON($N*"@2E PBULD M5H0,O%1Z
M_<='X*=&SNV7G4A*6>>/C%JN5+KF*<\C@>CQ%YZ75&"-6GX6!N-)-_S,IA-V
MXQ!!@&@I?_O YY/QV8N=V?'9[ FLM'1R) ATF?M\Q 4)/5H4**(\3F%T\-TP
M;UB%A!L@!^5@[.K FI][ZK(J+VDYPR[XCD6!#@O[3KNW^/&E$4C=%BA,/) !
MVUNLUJYB4IEXP<0W].;&EY1!Q].>4K9\\"Y5>U/$TXCBC_<F!!I7B,9[1#L4
M(YULW%01Q+S^ES'ZO11ZZ!?=CWR@B"4CX:MX4C]D>U0IJDTP2&0@TWAX&O,U
MXRA0^;*![&@T[ _9,_95T5:73)_S'-Z0-@">S?HC++G3:EXG7*A%?!,Z0GII
MEGE*GR6.A0FE:AQ^W!]7-GJW43*";";+C'@]P%LX<001T5W7P#19JGXYZ4_P
MKAY]R&OSU97LD^"Y;C<^^S-$4,?A3<V.V*GCTX)K;&^=4L/'8WA#)Y69I .:
M(Z,J*)>Y:SU3!8XI(CL&'AL[.+85%.P7/J^Z :#-4#MEV6@X?-9M/A,D/P4H
M(#5N$]HD U=AO'H#*E9%#T&; 0Z[P7%<8TR['*?:I\1RCE81?1!:"U*"%P+N
M_<*G9#H \M=9N.ABA=Y"T^*1N\ZHD%0MN2:%1][3551U!S[6'//%&V1<B>YW
MB1;<>0K?W_H%3E<G9V=!")#_\?F6].8;TUC,$8P:^SPUU>XOIES,:N#GR5+#
MA,XN/VW:J&9GL%UI>8TXT)//X%D:4[J([HLPSJY3'CV<WD=H7@'9HJJ@7,&T
M,6B7MY-P.'0'@06E8W\,=TA 8PP[8(W#%/7#*!8KH+F6UKH&^FIS+P'WD?&I
MS$]K,'P_"06-DZC%@ER@RT=<AXGZFJ.ZKJ!&G8I/*F#WXH?L /5VE9LUMT:D
M^Y9%<5AE26] V<HI/ATPTP[*I+EQ_^5DVKV"Z+IA9^TK +CKOK/9,VPFJ&$P
M1>3SP93LA K_X71!MU&Z,O6D/YH\ZW>*@UV0W6JYE'1!M VT%?\3(&T<A)/I
M_P/6;M]?H?N/JE+H/X"T$$EX\C2@C2;]V7@':=,6TEX=Q5G8QV)W\4;J*(WQ
MU9V[M)P%B,=S?^E7^5NC!DJI,&6>5Y\I-KJ.4N4P4R'J'CJG2T.H)LXJH]-\
MC>POWP=8]]:OA=M-B^2HD[)QTB>D'8>&'>^H\=6NFRL"JEZ[WQ8;B//JH /!
MP5OT9#HY\Q>29\.=R\C&UW8T\VZQ\.O86PC@X?)CDJ&\\2!T#H)G;K;;G+K:
M1BU?Z=A).9T$_X.NJL4">@"=HZEAW\>-0>O34R;TTGU@@^,27?\5:C.[^89W
MY3]=-<O]!\"/7,,:AJ5B@:W#_JMI#X[F/JKY@56%^Y U5]:JS#TF @68I@5X
MOU#PMFI !VR^;%[^$U!+ P04    "  4A798;9C"2/<)  "%&P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6RU66V3VS8._BL<-\GMSBBV)+]N]F4F
MFS33=-HTDTUZ<Q]IB;9YD425I-;K^_7W@)1LR=9NTG;Z(5GS!2   @\ ZFJK
M]%>S$<*RASPKS/5@8VWY:C0RR4;DW Q5*0JLK)3.N<50KT>FU(*GCBC/1G$8
MSD8YE\7@YLK-?=0W5ZJRF2S$1\U,E>=<[VY%IK;7@VC03'R2ZXVEB='-5<G7
MXD[8+^5'C=%HSR65N2B,5 738G4]>!V]NIW0?K?A=RFVIO6;D29+I;[2X'UZ
M/0A)()&)Q!('CC_WXHW(,F($,?ZH>0[V1Q)A^W?#_9W3';HLN1%O5/9OF=K-
M]6 Q8*E8\2JSG]3V)U'K,R5^B<J,^Y]M_=YH/&!)9:S*:V)(D,O"_^4/M1U:
M!(OP$8*X)HB=W/X@)^5;;OG-E59;IFDWN-$/IZJCAG"RH$NYLQJK$G3VYGV1
MJ%RPS_Q!F*N1!4>:'R4U]:VGCA^ACF+VJRKLQK ?BU2D708CB+*7)V[DN8V?
MY/A6)$,VC@(6A_'X"7[CO7YCQV_\%_7SU)-^:HJ(5Z;DB;@>P.6-T/=B<//B
MAV@67CXAVV0OV^0I[M^4[4GJ?MD^*"M8-!NR-F_V>2.T8-*P0K%2JWOI0@H1
MS:3?9MVVI4AX93#:"/9&Y24O=FS##=M(N*&6"<^R'5%46HN4 1<TM[)8LTP9
M W)>I(Q@P.(?1FQ591F[YUG%??QE  !>)(+Q->VP3%I(!-Q!$ G'$F(P#EZ
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MLEIF,B%TKDISB( ?X:NN^'.YGV)R[TX41[X*@0URE"[.X:@ 03=:O^.DTB2
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MJG8":4*XN/QB/"GBX/5>Y@B-Y)9\SCR_^@0;IC63=!' 58EPJJJ:R3LH64'
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M<G=TO'K?)&___.+%E7_[K/A#"#/QD 3V >* $GJC[H&TVZWI3/'R_1LZ.J$
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M3&Z0\ $M2<SC&..RX>W6DF(AY0*V(RDNL+78;R6XUT!XWXD\$P_TI%Z(=?!
MPJQ?!I)8/7K:!FYS<75V']A7WQD?-[$!)#[8$/![[Q] ZFRW*=OZGXKX$*A<
M_>IBH$**"_JZ,E-Z0? 3# 8K^V@TA$'70[.N03>E C'^TFS+9CV*^>8X\]O
MF=_.LM*;%AZI[>ZFN/">KQ;Q+XJ,V9^NO(]%<D9,!0_80DET;$U(GS2$1.@/
M\G(&DO!75E1(G:Z4""[T(5FRSO6G-5E ^0LJ9(EH7 B\*IDGZG_"G0GK8%]6
M&I:\% #&])YRV)4!\4<-4EB"<S,T)2]3[NEK G:!\) @".8D.E-AH=^&:B/Z
M27QX&%[2K/"2E'5P.N_>LG=HET&[1M\_*M0EF=HUR7>=*]2E452:ZEEA$;/<
MDO.R$/;5@V,9>J4%N"4XT9FR6XFO69'KUU@60_^0CSY>I<'2=0R1B$:_[HUJ
MGMQRTL>P7HX5;%#2B3ZW-_2B&#+FB$"O*J%71:X["9HIX8)R!(=_TMJUK1CH
M6W+MB<*5O:5M8+ _K8Q:5+LDF(EIPG*09=$>=9=8]C'_^4/K+O0OT8*L=>AP
M=<<G(>PSXQ5$MK8G_XJ,0W$-7"</B=]!2LZ1B6N8G'3:%3D2Q#HDU4(T=:W
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M'&*LD'MA5<KA:=EU7&V07 \G0I0&;+M [&7BW2!<?7?@ZBB8XK))0J]EH:B
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M):84CD5#+,.%%V%5LKPU*TTXW#V7X_IN8&Y9$*6Z^D8<H4R7PJE*- &Y;'!
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M\\)!4V1=!UXD^3 '#(_CS-XLLFJLB[I  F-]5'!4A7Z$255%4 @9@AK)95;
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MRCI+AFGMWD#4/L'METK9W<(7&%[5[ ]02P,$%     @ %(5V6,J2H.I? @
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M#$@3@.]S(?3>, ?T/ZWD#U!+ P04    "  4A798BHFE$'D"   1!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RM5=M.&S$0_961J5 K(?:60 K)
M2@1:40DD1.CMT=F=9"V\]M9V$OKW'7N3);0A#Z@OL<>><^:,)S,[7&GS:"M$
M!T^U5';$*N>:LRBR184UM\>Z044W,VUJ[L@T\\@V!GD90+6,TC@^B6HN%,N'
MX>S.Y$.]<%(HO#-@%W7-S>\Q2KT:L81M#N[%O'+^(,J'#9_C!-W7YLZ0%74L
MI:A16:$5&)R-V$5R-NYY_^#P3>#*;NW!9S+5^M$;7\H1B[T@E%@XS\!I6>(E
M2NF)2,:O-2?K0GK@]G[#_CGD3KE,N<5++;^+TE4C-F!0XHPOI+O7JVM<Y]/W
M?(66-OS"JO7-/C(H%M;I>@TF!;50[<J?UN^P!1C$KP#2-2 -NMM 0>45=SP?
M&KT"X[V)S6]"J@%-XH3R19DX0[>"<"Y_,%Q9'E[(4FA7P5CH'P5*N+FYA/</
M?"K1?AA&CF)Y1%2L><<M;_H*;Y+"K5:NLO!)E5B^)(A(9*<TW2@=IWL9K[ X
MABPY@C1.LSU\69=Y%OBRMV2^*^&6KK>;SC?/F6UX@2-&W6'1+)'EAP?)27R^
M1VRO$]O;QYY/J!G+A430,_#<HD H*F[F:'=)W4]V>#!(X^P<_M?Z$[D!]&4&
M*A+64S2A4'_[^<)M&^F;(][3 W-35,!523VXI-G2T*1PG<,[2([BT_X+.^DG
M,*'V%VI^!'-4:+@,!+RDQA+6&>XGQ+/")/DWA7X,#]H1<)LY'9R\L'MQLJOF
MT5:;UDBU\\/(0J$7RK4=VYUV\^ZB;?-G]W98WE+I!?UO)<X(&A^?]AF8=@"U
MAM--:/JI=C1"PK:BF8W&.]#]3&NW,7R [BN0_P%02P,$%     @ %(5V6&P\
M8[7H P  E@P  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULK5=M3^,X
M$/XK5O:T:J5 G*1- [25>%GNT&FE"M@[W4<WF;86B=VS'4KOU]\X:;(!0@0K
MOM3Q>.;Q,Y[Q>#K=2?6@-P"&/.69T#-G8\SVU/-TLH&<Z6.Y!8$K*ZER9G"J
MUI[>*F!I:91G7D!IY.6,"V<^+64+-9_*PF1<P$(17>0Y4_L+R.1NYOA.+;CE
MZXVQ F\^W;(UW('YL5THG'D-2LIS$)I+012L9LZY?WH16?U2X2\..]WZ)M:3
MI90/=G*3SAQJ"4$&B;$(#(='N(0LLT!(X]\#IM-L:0W;WS7Z=>D[^K)D&BYE
M]C=/S6;FQ Y)8<6*S-S*W1]P\&=L\1*9Z?*7["K=T<@A2:&-S _&R"#GHAK9
MT^$<6@8Q?<,@.!@$)>]JHY+E%3-L/E5R1Y351C3[4;I:6B,Y+FQ0[HS"58YV
M9GX%2T.82,FE@I0;<LT2GG'#09/!/5MFH(=3S^!&5MU+#J 7%6CP!J@?D.]2
MF(TFWT0*Z7, #QDV-(.:YD70BW@%R3$)?9<$- A[\,+&[;#$"S_L=I>W%=:H
M&\M>FU.]90G,'+P7&M0C./.O7_R(GO4P'35,1WWH\SN\AFF1 9$KS+:EZ>+7
MC_#U2QS0\(Q\UHBQ@'P)JHG'*TGPR]BW\ BB '(C#.!98F"X8"+A8DW.UPH
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M;W)K<VAE971S+W-H965T,S0N>&ULA55K3]LP%/TK5I@02!MYMLV@C41ATY!
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M)JKJ4BO!R,)UAE-IL,]TPP4V]J#L IR?26DV@MV@_JLP_@]02P,$%     @
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MFI(HR,TW3C.JAA!;D6@K^"F^&.&+\QW( ;O0\W"XAS+J*:.#E%]UT[YA&:\
M'7_A4IX,,49O8WNQA@QV&(?L(ASC>)@Q[AGC/S+:VVZDKJ7N"'J>"/VFLV7;
MD:FB,'C]\9N+/?4PUK-FAWO(+L!!Z.UPNUL]KP*QM*- HHPW3+4MI#_MI\V5
M;;([YQ,]A=JA\5NF'6&W1"PIDZB$A98<G<6:2K1CH=TH7MO.^LB5[M-V6>A)
M"L(8Z.<+SM5F8P+TLSG]!5!+ P04    "  4A798?FZ"0$T#  #Y#@  &0
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M$&:#?A]QKK83DZ#N=B?_ %!+ P04    "  4A798^B=/M"@#  !S#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RMEUUOFS 4AO^*Q:JIE;;PE9"D
M2Y":=--V42EJUNW:@9. "C:S3=+^^]E ""R$C96;Q#9^7Y_''W \.U#VS ,
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M*F3*G14#>2L"ICK(YUM*Q;&B!BCO6>YO4$L#!!0    ( !2%=EB@3-V=@@(
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M^O6+'WO?AWS])[)W+L/.97B,/;W%M;XA"@3!=/"?-?#(PDV6[])9&"7N;M]
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MD;5"!I<3-:EXM=-5'4BV*_=^'IF4+"_?;@E."=<-U.=KIB9O?: ':/8;%]\
M4$L#!!0    ( !2%=EBAYVI*704  #8D   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;+6:W6[;-AB&;X70BJ$%FEBD;-G.$@.)I73%5BQHU^V8EAF;
MJ"1Z))6TN_I1/Y%,62&BX%L.8OWP>TB^I$B^$B\?A?RF]HQI]#U+<W7E[;4^
M7$PF*MFSC*IS<6"YN7,O9$:U.96[B3I(1K=54)9.B.^'DXSRW%M=5M?NY.I2
M%#KE.;N32!591N6/&Y:*QRL/>T\7/O/=7I<7)JO+ ]VQ+TQ_/=Q)<S9I*5N>
ML5QQD2/)[J^\:WP1DVD94*7XB[-'=72,RJILA/A6GGS<7GE^62*6LD27"&I^
M'MB:I6E),N7XIX%Z;9YEX/'Q$_VVJKRIS(8JMA;IWWRK]U?>PD-;=D^+5'\6
MC[^RID*SDI>(5%7_T6.==C[W4%(H+;(FV)0@XWG]2[\W0AP%X/"9 -($D'[
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MW'AUC%K-4'IY7/9YM>J&!S< &J&B6M1H>R^W)]-@OP70#!75%*II5#.49K=
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MN :<@C -=/V2<_54,'?8YD>.^3]02P,$%     @ %(5V6#<P8 B7!   3!D
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M2V?F@ AO44[E5W;XA*L)C;5>R*@H/L&AZNLY(,R%9$EEK#Q(2%I^HZ<*1,,
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M5_=E0[*L>)F]85*RI+B,,5)+37=0S[>,R6-#OQ^O_T!9_0=02P,$%     @
M%(5V6'N0:4[U 0  '00  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL
ME51A;YLP$/TKEE=-K;3%!):TR@!I251M'RI%S;I]=N 2K!J;V4=H__UL0U F
MI97V!?OL>^_>@SO23IMG6P$@>:FELAFM$)L%8[:HH.9VHAM0[F:O3<W1A>;
M;&. EP%42Q9'T9S57"B:I^%L8_)4MRB%@HTAMJUK;EZ7('67T2D]'3R*0X7^
M@.5IPP^P!7QJ-L9%;&0I10W*"JV(@7U&OTT7R\3GAX1? CI[MB?>R4[K9Q_\
M*#,:>4$@H4#/P-URA!5(Z8F<C#\#)QU+>N#Y_L1^'[P[+SMN8:7E;U%BE=$[
M2DK8\U;BH^Z^P^!GYOD*+6UXDJ[/G<\H*5J+NA[ 3D$M5+_RE^$]G 'B^ U
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M1...;EB8]PN4#3#["REQ.[$)NA<Q_0502P,$%     @ %(5V6-IFT&3* P
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ME*RH7C/ *7#=0/V_8TP^%?2%4GM%N?D/4$L#!!0    ( !2%=ECIPZ=X_0L
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MNY$T#J4)*$VB:&; K@[8[;+9><_L25<KV3Q9K:(T8YMBW[%:X>SK&]E0[Q\
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MIIAQ'11;XHN!PF8-"(9*EVQGWNK/H;RU1(%646"L:QU ,U]A&,(FX&0X]MJ
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M?JKN7OBPU$'WNX3N2*P"/2B@!\;E_?*>J)*CB"7PJ([4'#Y >Z!<H#&*LEV
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MHBR3RX;BN:D#-UQA56E>8Z!X,O0 _+[C7)T:>H+ZGQ7S_P!02P,$%     @
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M+B6(#3C)QP_CR/LRQ/B?Q%X13SKBR3'U';'0?TB5%H3E*-5?6)!5;8[H.:I
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MV7FJN8];,H@]1^L)[@+)D$$R-.J@Q9U2F"NU>@4,A2'[PZ\6+3X^B4&Z0*K
M(%5@1ZJC+7X:AMC56[]CZ8+' L-C >S@)9-3$'.E5J^  ;' _A3L].8NA 96
M#+%G:^O&K[PIUJ_I/V.^IJD ,5DI^=[%4 V&']Y\'W8DV^8OCQ=,2I;DFQN"
MEX3K$]3W*\;DRXY^'UW^_\'L7U!+ P04    "  4A798I(QB=Z,"  #N!@
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M_7&)ZL]'SU:^VR*"?D15^=[D:SE75X.RM.4J>U"#V7__XXZ=7_M2@X1Q)$R
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MY=]OT[38/:DZV-]=:/9_4$L#!!0    ( !2%=EB.=J6^1P0  -P0   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*U8;6^;.A3^*Q9WFC;IIF!(('1)
MI+:YTR;=255?ML\N.(E5P)GM)-W]]?<8*"1@W*[:EX27\_(\SO%Y?#([</$H
M-Y0J])1GA9P[&Z6VYZXKDPW-B3SC6UK FQ47.5%P*]:NW I*TM(ISUS?\T(W
M)ZQP%K/RV;58S/A.9:R@UP+)79X3\>N29OPP=[#S_."&K3=*/W 7LRU9TUNJ
M[K?7 N[<)DK*<EI(Q@LDZ&KN7.#S*]_3#J7%=T8/\N@::2H/G#_JFZ_IW/$T
M(IK11.D0!+[V](IFF8X$.'[609TFIW8\OGZ._KDD#V0>B*17//O!4K69.U,'
MI71%=IFZX8<OM"8TT?$2GLGR$QTJVS!P4+*3BN>U,R#(65%]DZ=Z(8X<<#C@
MX-<.?M=A/. 0U Y!2;1"5M):$D46,\$/2&AKB*8ORK4IO8$-*_3/>*L$O&7@
MIQ9?BX3G%-V1)RK1""WIB@I!4_T ?5A215@F/\*+^]LE^O#N(WJ'6('N-GPG
M29'*F:L @X[D)G6^RRJ?/Y /^^@;+]1&HG^*E*:G 5P WS#PGQE<^M:(2YJ<
MH0#_C7S/#PR KE[O[EO@!,V"!F6\X!4+:EJ>RGML]M:;]EQN24+G#NQ*2<6>
M.HOW?^'0^V2B]H>"G1 =-T3'MNB+*[)EBF3L/Z@6'9V(9(.@*& 3[:$[;&&O
M*],"5%$G953=9/:+:.IYL/3[8V;6W&]D-FF835[-[.8]R;>?EKHS5!M#P<9@
M10(M4U(3O2IT>$3/]^+II$//"N"-],*&7FBE5U>H)I(Q\L RIIBY5L,>%Z_#
MPYKIC3RBAD=DY?&9IE20#!4@=B!K@BA6K%'&I32SB7ILHB"*NHRB7GF.PS!N
M?[\3J-,&ZM0*]58115\-=-HO(>Q/NB74M\+8C[ 9:-P C5\ RI-' *DEUH@M
M[F<-8MS%9K#R(F]@$;'7:I5G1:=%"79>RI19>;Q^VHDWGG; F<R\<!H/H#M2
M4OS[#;%L'R^UQ#KP,:)Q''I!%WC?+ C#,!@ [K? ?2OPBR01.P!-G^!P:.YJ
M]@B_*UMUM-,*'RI=W"HOMNH=2#DD3QC1Q6LD$1@Z0'>-^S9C?P!8JY38+I7_
M:K%HFNTO([:Q:=-WP1F,8F\ 7:MVV"YW]P6(656VNB<9T?TAO:II]#42>T-5
MW*H:MLO:=Y+M2#4:9#"<D"(Q5W)?U$8X"L(H[BZVR1!/@V@(::M;V"Y<=QS:
MQ.F)@H 6##2UOFSA..IB[1OYDW  9RM:V*Y:1X6QAH'0B*ZO0J-^V5K3O/&4
M@%M)PW9-*T?3$5^-=K )+0O=%ZT1[AW<3%:#2^VWRN:_H&S]DGCA;%8'G)S
M[16&R:H/USV:'W,JUN58+5'"=X6J1LGF:3.Z7Y0#J]N:5W/_-R+6K) HHRMP
M]<XB2"VJ4;JZ47Q;3J,/7,%L6UYN*(&3G#: ]RO.U?.-3M#\H;'X'U!+ P04
M    "  4A798BZ4_9%,$  !G$P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6S%6&V/VC@0_BM6KCWM2BV)G1!@#Y"Z;*OKA]ZM]J7][$T&B#:Q.=LL
M[+\_QX$$0C O0NH7R(OGF><9>SP3]Q=<O,HI@$+++&5RX$R5FMVXKHRFD%'9
MXC-@^LV8BXPJ?2LFKIP)H+$QRE*7>%[H9C1ASK!OGMV+89_/59HPN!=(SK.,
MBO=;2/EBX&!G_> AF4Q5_L =]F=T H^@GF?W0M^Y)4J<9,!DPAD2,!XX7_#-
MB'BY@1GQ,X&%W+A&N907SE_SF^_QP/%R1I!"I'((JO_>8 1IFB-I'O^M0)W2
M9VZX>;U&_V;$:S$O5,*(I[^26$T'3M=!,8SI/%4/?/$WK 2U<[R(I]+\HD4Q
MMJ,'1W.I>+8RU@RRA!7_=+D*Q(8!#O<8D)4!J1L$>PS\E8%OA!;,C*P[JNBP
M+_@"B7RT1LLO3&R,M5:3L'P:'Y70;Q-MIX;?6<0S0$]T"1)]1@\0<18E:4)-
MD*_N0-$DE=?ZU?/C';KZ<(T^H(2AIRF?2\IBV7>59I%CN='*XVWAD>SQB GZ
MP9F:2O25Q1!O [B:?JF!K#7<$BOB'40MY.-/B'C$;R T.MZ<6.CX94A]@^?O
MP:O%\ 74 H A&(_!K%FDZ!()J@#I *(QQ"!HBJ2B:JZX>#>O/J$9B B8:HIO
MX3YH=I_G_8V<T0@&CDYL">(-G.&??^#0^ZLI-A<"VXI44$8JL*$/OS5J1U=4
M(KH.P'53! K8GH'--ZJWH=<BN.^^;2H[,&B+<;MDW+8R?E0\>C7[1HQTXNC-
M5*XRY2#G AA[6WP\SZ^QMON_\EJ!]_':$ONP5!(>%?M\,48"XD3)(T2$C2)(
M7<2>87N"WRDI=PX$/U\=Q59UF&JG8?J];HUHIY%H0)J)=DNB72O1?]44Q!$4
M[2AZKCL[<UW0[C;2QGOBVRMI]ZP.?])T7JQFFNKR3EET3"[:,:]\K]7;H^*
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M1,X0,BR,8R#VM<<%,N:(K(V_)\Z@EW3 R_C,_MW7;FO9$HT+R?[0TM19\"6
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M#!IR],:';'9$B2=RD[K/QY']I>%^0#_I]9.K^F_- E(I1!\UJ*@LASQ<)YO
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M+EU5B&$[HAASSM*5/Q<7/36HI$*N16_VZR_6>/![FQE(F(N$422,(6$<"?-
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M)6<Q5^8!N#^74F]/3 /-/S!,_P-02P,$%     @ %(5V6 V$OO1H P  >Q<
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MNO:/.<NO5EP_T-]"L[FM["IVBHQZQZ^Q/L0<N\CX%$2>Q'+WCU]DE!R_QOI
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MDL3M 9];011A'MB-N =3 !HP3Q29Y^#.\RA8/Z>"]M_MH[]02P,$%     @
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M_&7YO1/O%\T%Y_JVHCS]!5!+ P04    "  4A798I,C#=_H!  "T*   $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %(5V6)E<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  4A798(-/"G9,'  #_,0  &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %(5V6%8YER<]!@
MAQT  !@              ("!U0\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( !2%=EA/9-5\X@(  $0*   8              " @4@6
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  4A798C:C)
M]:T$  "9$0  &               @(%@&0  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ %(5V6'H**_V0!0  Y1\  !@
M ("!0QX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !2%
M=EC#JV3'E0<  "DA   8              " @0DD  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  4A798Y546N\P%  #!#   &
M        @('4*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ %(5V6%[TN3GL"   ;1@  !@              ("!UC$  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !2%=EA,=A5N,R$  *-H   8
M              " @?@Z  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  4A7985V?F"5$$   )"@  &0              @(%A7   >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !2%=EC)%OIUI@(
M ,<&   9              " @>E@  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ %(5V6+K0PXW5 @  ?P<  !D              ("!
MQF,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  4A798
MHK?V-:8"  #O!@  &0              @('29@  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( !2%=EAF6+*5)P4  ,$,   9
M      " @:]I  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ %(5V6(QDZU>O%0  'D@  !D              ("!#6\  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  4A798[@5XM-T#  #L"
M&0              @('SA   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( !2%=EAK23TOIP,  +4(   9              " @0>)  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ %(5V6#&X&8!^
M$   J3X  !D              ("!Y8P  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  4A7987B9A%/H#  "B"0  &0
M@(&:G0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !2%
M=EC:^WCQ*@,  $('   9              " @<NA  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ %(5V6#J_CLK="   Y1P  !D
M         ("!+*4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  4A798;9C"2/<)  "%&P  &0              @(% K@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !2%=EB3SRO1# ,  '('
M   9              " @6ZX  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ %(5V6(T+%9R%!P  /A,  !D              ("!L;L
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  4A798'Z7U
M;3<)   $'0  &0              @(%MPP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( !2%=EAP #>*+B,  .QU   9
M  " @=O,  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M%(5V6.+7*NIA @  804  !D              ("!0/   'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  4A798RI*@ZE\"  #S!0  &0
M            @('8\@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( !2%=E@:4^#)F@(  ,T&   9              " @6[U  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ %(5V6"Z3V]V> @
MP 8  !D              ("!/_@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  4A798BHFE$'D"   1!@  &0              @($4
M^P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !2%=EAL
M/&.UZ ,  )8,   9              " @<3]  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ %(5V6"8+GS/*!0  &QP  !D
M     ("!XP$! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !2%=EC'\-]DT (  *<'   9              "
M@945 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ %(5V
M6'YN@D!- P  ^0X  !D              ("!G!@! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  4A798^B=/M"@#  !S#0  &0
M        @($@' $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( !2%=EB@3-V=@@(  $4'   9              " @7\? 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ %(5V6&#W>X!\ P  . \
M !D              ("!."(! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  4A798+>_BDK$"   S"   &0              @('K)0$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !2%=EC-#RE5
MQP0  'L<   9              " @=,H 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ %(5V6*'G:DI=!0  -B0  !D
M ("!T2T! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  4
MA798;V.NQ#P,  !IM0  &0              @(%E,P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( !2%=E@&J[&&=0,  / 0   9
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M970U,2YX;6Q02P$"% ,4    "  4A798STS26+(#  "N%   &0
M    @(%@40$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M !2%=ECIPZ=X_0L  -&*   9              " @4E5 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ %(5V6+L^GO1N!0  .QL  !D
M             ("!?6$! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    "  4A798B7"?_RX$  !C%@  &0              @($B9P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !2%=E@_0T50_0(
M !8+   9              " @8=K 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ %(5V6(2V/!6] P  N!   !D              ("!
MNVX! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  4A798
MXP$\IC8#  "T"P  &0              @(&O<@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( !2%=EA-"#M!B (  $,'   9
M      " @1QV 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ %(5V6#_Y0\&/ @  :0<  !D              ("!VW@! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  4A798M%!(N:H$  "+(
M&0              @(&A>P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( !2%=EBDC&)WHP(  .X&   9              " @8*  0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ %(5V6,8?'#UF
M"0  :6@  !D              ("!7(,! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    "  4A798CG:EOD<$  #<$   &0
M@('YC $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( !2%
M=EB+I3]D4P0  &<3   9              " @7>1 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ %(5V6.#8Q-L@ P  B D  !D
M         ("! 98! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M    "  4A798HX488T "  !+!0  &0              @(%8F0$ >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( !2%=ECWUJ _&@@  $1;
M   9              " @<^; 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
M4$L! A0#%     @ %(5V6'!43'I+ @  I@4  !D              ("!(*0!
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  4A798<8S9
MAYP%  #,(   &0              @(&BI@$ >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;%!+ 0(4 Q0    ( !2%=E@-A+[T: ,  'L7   -
M  "  76L 0!X;"]S='EL97,N>&UL4$L! A0#%     @ %(5V6)>*NQS
M$P(   L              ( !"+ ! %]R96QS+RYR96QS4$L! A0#%     @
M%(5V6(Q[6KV2!0  '"X   \              ( !\; ! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( !2%=EC;=K!Q,0(  (DI   :              "
M ;"V 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !2%
M=EBDR,-W^@$  +0H   3              "  1FY 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !. $X 614  $2[ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>190</ContextCount>
  <ElementCount>354</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Transactions with BioXcel LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc</Role>
      <ShortName>Transactions with BioXcel LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Debt and Credit Facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities</Role>
      <ShortName>Debt and Credit Facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Common Stock Financing Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities</Role>
      <ShortName>Common Stock Financing Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureInventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Transactions with BioXcel LLC (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables</Role>
      <ShortName>Transactions with BioXcel LLC (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Debt and Credit Facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables</Role>
      <ShortName>Debt and Credit Facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureLeases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureRestructuring</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Transactions with BioXcel LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails</Role>
      <ShortName>Transactions with BioXcel LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails</Role>
      <ShortName>Debt and Credit Facilities - Debt summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails</Role>
      <ShortName>Debt and Credit Facilities - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails</Role>
      <ShortName>Debt and Credit Facilities - Revenue Interest Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Debt and Credit Facilities - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails</Role>
      <ShortName>Debt and Credit Facilities - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Debt and Credit Facilities - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails</Role>
      <ShortName>Debt and Credit Facilities - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Debt and Credit Facilities - Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails</Role>
      <ShortName>Debt and Credit Facilities - Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Common Stock Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails</Role>
      <ShortName>Common Stock Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stock-Based Compensation - Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails</Role>
      <ShortName>Stock-Based Compensation - Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Stock-Based Compensation - Non-options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Non-options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Stock-Based Compensation - Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41206 - Disclosure - Stock-Based Compensation - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails</Role>
      <ShortName>Stock-Based Compensation - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Leases - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails</Role>
      <ShortName>Leases - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Fair Value Measurements - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Fair Value Measurements - Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details</Role>
      <ShortName>Fair Value Measurements - Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Fair Value Measurements - Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails</Role>
      <ShortName>Fair Value Measurements - Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Income Taxes - Deferred Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails</Role>
      <ShortName>Income Taxes - Deferred Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="btai-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>btai-20231231.xsd</File>
    <File>btai-20231231_cal.xml</File>
    <File>btai-20231231_def.xml</File>
    <File>btai-20231231_lab.xml</File>
    <File>btai-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="btai-20231231x10k.htm">btai-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>btai-20231231x10k001.jpg</File>
    <File>btai-20231231x10k002.jpg</File>
    <File>btai-20231231x10k003.jpg</File>
    <File>btai-20231231x10k004.jpg</File>
    <File>btai-20231231x10k005.jpg</File>
    <File>btai-20231231x10k006.jpg</File>
    <File>btai-20231231x10k007.jpg</File>
    <File>btai-20231231x10k008.jpg</File>
    <File>btai-20231231x10k009.jpg</File>
    <File>btai-20231231x10k010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="599">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "btai-20231231x10k.htm": {
   "nsprefix": "btai",
   "nsuri": "http://www.bioxceltherapeutics.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "btai-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "btai-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "btai-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "btai-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btai-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "btai-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 309,
   "keyCustom": 45,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 36,
   "memberCustom": 36,
   "hidden": {
    "total": 15,
    "http://fasb.org/us-gaap/2023": 11,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 190,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 632,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 599,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://xbrl.sec.gov/ecd/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:ReceivablesNetCurrent",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness",
     "longName": "10101 - Disclosure - Nature of the Business",
     "shortName": "Nature of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation",
     "longName": "10201 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring",
     "longName": "10401 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventory",
     "longName": "10501 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet",
     "longName": "10601 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses",
     "longName": "10701 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc",
     "longName": "10801 - Disclosure - Transactions with BioXcel LLC",
     "shortName": "Transactions with BioXcel LLC",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities",
     "longName": "10901 - Disclosure - Debt and Credit Facilities",
     "shortName": "Debt and Credit Facilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments",
     "longName": "11001 - Disclosure - Derivative Financial Instruments",
     "shortName": "Derivative Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities",
     "longName": "11101 - Disclosure - Common Stock Financing Activities",
     "shortName": "Common Stock Financing Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "btai:FinancingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "btai:FinancingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation",
     "longName": "11201 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeases",
     "longName": "11301 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan",
     "longName": "11401 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements",
     "longName": "11501 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes",
     "longName": "11601 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare",
     "longName": "11701 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11801 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents",
     "longName": "11901 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables",
     "longName": "30503 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "30603 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables",
     "longName": "30703 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables",
     "longName": "30803 - Disclosure - Transactions with BioXcel LLC (Tables)",
     "shortName": "Transactions with BioXcel LLC (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables",
     "longName": "30903 - Disclosure - Debt and Credit Facilities (Tables)",
     "shortName": "Debt and Credit Facilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
     "longName": "31203 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables",
     "longName": "31303 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "31503 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables",
     "longName": "31603 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables",
     "longName": "31703 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
     "longName": "40201 - Disclosure - Basis of Presentation (Details)",
     "shortName": "Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "btai:DeferredOfferingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "btai:DeferredOfferingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails",
     "longName": "40401 - Disclosure - Restructuring (Details)",
     "shortName": "Restructuring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_8_8_2023_To_8_8_2023_3YScg74_R0ConxpN-Oxzqg",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_8_2023_To_8_8_2023_3YScg74_R0ConxpN-Oxzqg",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails",
     "longName": "40501 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "longName": "40601 - Disclosure - Property and Equipment, net (Details)",
     "shortName": "Property and Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
     "longName": "40701 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "btai:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "btai:AccruedResearchAndDevelopmentExpenses",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
     "longName": "40801 - Disclosure - Transactions with BioXcel LLC (Details)",
     "shortName": "Transactions with BioXcel LLC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3yVQCurUjku_rn_lePc8vw",
      "name": "btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
     "longName": "40901 - Disclosure - Debt and Credit Facilities - Debt summary (Details)",
     "shortName": "Debt and Credit Facilities - Debt summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:PaidInKindInterest",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
     "longName": "40902 - Disclosure - Debt and Credit Facilities - Credit Agreement (Details)",
     "shortName": "Debt and Credit Facilities - Credit Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A",
      "name": "btai:NetCashRequiredMinimum",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
     "longName": "40903 - Disclosure - Debt and Credit Facilities - Revenue Interest Financing (Details)",
     "shortName": "Debt and Credit Facilities - Revenue Interest Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_7_8_2022_To_7_8_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_V64yF2oxIU6GdMLQcz2BkA",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_8_2022_To_7_8_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_V64yF2oxIU6GdMLQcz2BkA",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
     "longName": "40904 - Disclosure - Debt and Credit Facilities - Warrants (Details)",
     "shortName": "Debt and Credit Facilities - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails",
     "longName": "40905 - Disclosure - Debt and Credit Facilities - Maturities (Details)",
     "shortName": "Debt and Credit Facilities - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
     "longName": "40906 - Disclosure - Debt and Credit Facilities - Interest (Details)",
     "shortName": "Debt and Credit Facilities - Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
     "longName": "41101 - Disclosure - Common Stock Financing Activities (Details)",
     "shortName": "Common Stock Financing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
     "longName": "41201 - Disclosure - Stock-Based Compensation - Description (Details)",
     "shortName": "Stock-Based Compensation - Description (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_u28NxTusVku5UX5Tspxcdg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_u28NxTusVku5UX5Tspxcdg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
     "longName": "41202 - Disclosure - Stock-Based Compensation - Non-options (Details)",
     "shortName": "Stock-Based Compensation - Non-options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IX6hI-H8FE6Sxk8kEK1KPA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
     "longName": "41203 - Disclosure - Stock-Based Compensation - Options (Details)",
     "shortName": "Stock-Based Compensation - Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "longName": "41204 - Disclosure - Stock-Based Compensation - Assumptions (Details)",
     "shortName": "Stock-Based Compensation - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "longName": "41205 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LO90L5PoDEivpd5VLIVaEg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails",
     "longName": "41206 - Disclosure - Stock-Based Compensation - ESPP (Details)",
     "shortName": "Stock-Based Compensation - ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_QZPms-_JDE62jRgrcbtUIg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_QZPms-_JDE62jRgrcbtUIg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails",
     "longName": "41301 - Disclosure - Leases - Maturities (Details)",
     "shortName": "Leases - Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "41302 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails",
     "longName": "41401 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
     "longName": "41501 - Disclosure - Fair Value Measurements - Hierarchy (Details)",
     "shortName": "Fair Value Measurements - Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Z17gbjnh30i21j6FjyTHjA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Z17gbjnh30i21j6FjyTHjA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details",
     "longName": "41502 - Disclosure - Fair Value Measurements - Level 3 (Details)",
     "shortName": "Fair Value Measurements - Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
     "longName": "41503 - Disclosure - Fair Value Measurements - Inputs (Details)",
     "shortName": "Fair Value Measurements - Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg",
      "name": "us-gaap:DebtInstrumentFairValue",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails",
     "longName": "41601 - Disclosure - Income Taxes - Deferred Tax (Details)",
     "shortName": "Income Taxes - Deferred Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "btai:CapitalizedResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A",
      "name": "btai:CapitalizedResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "longName": "41602 - Disclosure - Income Taxes - Reconciliation (Details)",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
     "longName": "41701 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "41801 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_4_30_2022_GlNf8HOiWUu7zXkTvkFBsQ",
      "name": "us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_30_2022_GlNf8HOiWUu7zXkTvkFBsQ",
      "name": "us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41901 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "btai-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r611"
     ]
    },
    "btai_AccountsReceivablePaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "AccountsReceivablePaymentTerm",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The credit period offered to customers or receivables by the company.",
        "label": "Accounts Receivable, Payment Term",
        "terseLabel": "Accounts receivable payment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes",
        "terseLabel": "Income tax liabilities",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r113",
      "r118",
      "r468"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "btai_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r145",
      "r475"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees per month to be paid to enter into collaborative service agreement option.",
        "label": "Additional Fees Per Month to Enter into Collaborative Service Agreement",
        "terseLabel": "Monthly agreement option fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital.",
        "terseLabel": "Additional paid-in-capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r611",
      "r790"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r497",
      "r723",
      "r724",
      "r725",
      "r772",
      "r792"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r322"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of stock purchase warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44",
      "r108"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of net loss to net cash (used in) provided by operating activities:",
        "verboseLabel": "Reconciliation of net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r645",
      "r655",
      "r681"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r658",
      "r684"
     ]
    },
    "btai_AgreementCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "AgreementCommitmentPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the agreement commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Agreement Commitment, Period",
        "terseLabel": "Commitment agreement period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r649",
      "r659",
      "r676",
      "r685",
      "r689",
      "r697"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation costs recognized",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r360"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Accretion of debt discount and amortization of financing costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r423",
      "r599",
      "r600",
      "r717"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r147",
      "r173",
      "r211",
      "r224",
      "r228",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r386",
      "r390",
      "r414",
      "r467",
      "r528",
      "r611",
      "r623",
      "r735",
      "r736",
      "r779"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r153",
      "r173",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r386",
      "r390",
      "r414",
      "r611",
      "r735",
      "r736",
      "r779"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r641"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r641"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r641"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "btai_BioxcelCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "BioxcelCorporationMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BioXcel LLC.",
        "label": "BioXcel LLC"
       }
      }
     },
     "auth_ref": []
    },
    "btai_BorrowingsBasedOnNetSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "BorrowingsBasedOnNetSalesPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum borrowings allowed based on a percentage of net sales.",
        "label": "Borrowings Based on Net Sales, Percent",
        "terseLabel": "Borrowing allowed per net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "CapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized research and development costs.",
        "label": "Capitalized research and development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized research and development costs deferred tax increase (decrease).",
        "label": "Capitalized research and development, Deferred tax Increase (Decrease)",
        "terseLabel": "Capitalized R&amp;D deferred tax increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r143",
      "r581"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value money market accounts",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r97",
      "r170"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r97"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Common stock issuable (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative services agreement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "btai_CollaborativeArrangementMilestonePaymentsPotential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "CollaborativeArrangementMilestonePaymentsPotential",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential maximum payments that could be paid under the collaborative agreement.",
        "label": "Collaborative Arrangement, Milestone Payments Potential",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "btai_CollaborativeArrangementMilestonePotentialPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "CollaborativeArrangementMilestonePotentialPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum percentage of net sales payable under a collaborative agreement.",
        "label": "Collaborative Arrangement Milestone Potential Percent",
        "terseLabel": "Maximum milestone (as as percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 18)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r69",
      "r469",
      "r515"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r255",
      "r256",
      "r578",
      "r734"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r614",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r723",
      "r724",
      "r772",
      "r788",
      "r792"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r516"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r80",
      "r516",
      "r534",
      "r792",
      "r793"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 100,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,930 and 28,147 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r471",
      "r611"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers and equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r131"
     ]
    },
    "us-gaap_ContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractTerminationMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Termination [Member]",
        "terseLabel": "Contract termination costs",
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r595"
     ]
    },
    "btai_ConversionOfAccruedInterestToLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ConversionOfAccruedInterestToLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of accrued interest that is converted into long erm debt.",
        "label": "Conversion Of Accrued Interest To Long-Term Debt",
        "negatedLabel": "Conversion of accrued interest to long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r451"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r274",
      "r302",
      "r439",
      "r583",
      "r585"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "btai_CreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "CreditFacilityMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to financing agreements.",
        "label": "Credit Agreement and Guaranty",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current",
        "negatedLabel": "Debt classified as current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt and Credit Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and Credit Facilities",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r172",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r286",
      "r293",
      "r294",
      "r296"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r74",
      "r75",
      "r117",
      "r120",
      "r180",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r424",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r120",
      "r297"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount borrowed",
        "verboseLabel": "Revenue Interest Financing Agreement",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r271",
      "r424",
      "r597",
      "r598"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value debt",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r413",
      "r597",
      "r598"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt instrument fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "DebtInstrumentFinancialCovenantMinimumLiquidityRequirement",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum liquidity required per the financial covenant of debt agreement.",
        "label": "Debt Instrument, Financial Covenant, Minimum Liquidity Requirement",
        "terseLabel": "Minimum Liquidity Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "btai_DebtInstrumentIncrementalOnVariableRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "DebtInstrumentIncrementalOnVariableRatePercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage points added to the reference rate and variable rate on the debt instrument.",
        "label": "Debt Instrument, Incremental on Variable Rate, Percent",
        "terseLabel": "Incremental interest rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_DebtInstrumentInterestRateDiscountRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "DebtInstrumentInterestRateDiscountRatePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.",
        "label": "Debt Instrument Interest Rate, Discount Rate Percentage",
        "terseLabel": "Discount rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (as a percent)",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r64",
      "r299",
      "r424"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r424",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r180",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r424",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r45",
      "r46",
      "r63",
      "r64",
      "r66",
      "r70",
      "r106",
      "r107",
      "r180",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r424",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r718"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt premiums, discounts and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r282",
      "r298",
      "r597",
      "r598"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt and Detachable Warrants",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r119",
      "r372"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs.",
        "terseLabel": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "btai_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred offering costs.",
        "label": "Deferred Offering Costs [Policy Text Block]",
        "terseLabel": "Deferred Initial Public Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Unrealized loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research &amp; development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "btai_DeferredTaxAssetsLeaseAccountingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "DeferredTaxAssetsLeaseAccountingLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease accounting, liability.",
        "label": "Deferred Tax Assets, Lease Accounting, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset (liability)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Depreciation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock options",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Derivatives",
        "negatedLabel": "Unrealized gain",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesDeferredTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r768"
     ]
    },
    "us-gaap_DefinedBenefitPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r450",
      "r604"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer contribution percent on eligible contribution",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r42"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value of Derivative Liabilities",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDerivativeFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r393",
      "r400"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r413",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r529",
      "r531",
      "r532",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r585",
      "r789"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Assets and Liabilities",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r60",
      "r61",
      "r179"
     ]
    },
    "btai_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones defined by the collaboration agreement.",
        "label": "Development milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r325",
      "r353",
      "r354",
      "r356",
      "r606"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r641"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r641",
      "r677"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r196",
      "r198",
      "r203",
      "r204",
      "r205",
      "r209",
      "r402",
      "r403",
      "r464",
      "r479",
      "r587"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r198",
      "r203",
      "r204",
      "r205",
      "r209",
      "r402",
      "r403",
      "r464",
      "r479",
      "r587"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r206",
      "r207",
      "r208"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Tax Rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation between effective tax rate and federal statutory rate, percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate (as a percent)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r367",
      "r380"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r769"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent",
        "verboseLabel": "Stock based compensation (as a percent)",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r769"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r769"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State Taxes (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r769"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "verboseLabel": "Federal tax credits (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r769"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining unamortized expense period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance and benefit costs",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "btai_EmployeeStockPurchasePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "EmployeeStockPurchasePlan2020Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2020 Employee Stock Purchase Plan.",
        "label": "2020 Employee Stock Purchase Plan",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of shares issued or transferred under ESPP.",
        "label": "Employee Stock Purchase Plan, Maximum Number Of Shares Issued Or Transferred",
        "terseLabel": "Maximum number of shares issued or transferred under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r138",
      "r159",
      "r160",
      "r161",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r193",
      "r210",
      "r237",
      "r238",
      "r306",
      "r357",
      "r358",
      "r359",
      "r377",
      "r378",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r432",
      "r481",
      "r482",
      "r483",
      "r497",
      "r559"
     ]
    },
    "btai_EquityInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "EquityInvestmentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Equity Investment agreement.",
        "label": "Equity Investment Rights",
        "terseLabel": "Equity Investment Rights"
       }
      }
     },
     "auth_ref": []
    },
    "btai_EquityInvestmentRightAmountUnfunded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "EquityInvestmentRightAmountUnfunded",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of equity investment right in the OFA that is currently unfunded.",
        "label": "Equity Investment Right, Amount Unfunded",
        "terseLabel": "Equity Investment Right"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r645",
      "r655",
      "r681"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r642",
      "r652",
      "r678"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r413",
      "r597",
      "r598"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive officers",
        "terseLabel": "Executive officers"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt extinguishment",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Repricing of stock purchase warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value assets and liabilities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r410"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r410"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair value inputs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of fair value unobservable inputs",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Hierarchy [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r406",
      "r444",
      "r445",
      "r446",
      "r597",
      "r598",
      "r602",
      "r603",
      "r604"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r62",
      "r284",
      "r597",
      "r598"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r408",
      "r409",
      "r411"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r311",
      "r316",
      "r406",
      "r444",
      "r602",
      "r603",
      "r604"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r406",
      "r446",
      "r597",
      "r598",
      "r602",
      "r603",
      "r604"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Level 3 liabilities reconciliation",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r444",
      "r445",
      "r446",
      "r597",
      "r598",
      "r602",
      "r603",
      "r604"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r411"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of changes in Level 3 liabilities",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15"
     ]
    },
    "btai_FinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "FinancingActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Common Stock Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FinancingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "FinancingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Financing Activities.",
        "label": "Financing Activities Disclosure [Text Block]",
        "terseLabel": "Common Stock Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r685"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r685"
     ]
    },
    "btai_FrankYoccaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "FrankYoccaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Frank Yocca.",
        "label": "Frank Yocca"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FromAndAfterFundingOfTrancheBLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "FromAndAfterFundingOfTrancheBLoansMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the statement scenario, from and after the funding of Tranche B loans.",
        "label": "From and After Funding of Tranche B Loans [Member]",
        "terseLabel": "From and after the funding of Tranche B loans"
       }
      }
     },
     "auth_ref": []
    },
    "btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the statement scenario, from and after satisfaction of the funding conditions for the Tranche C loans.",
        "label": "From and After Satisfaction of Funding Conditions for Tranche C Loans [Member]",
        "terseLabel": "From and after satisfaction of funding conditions for tranche C loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r641"
     ]
    },
    "btai_IncentiveAwardPlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "IncentiveAwardPlan2020Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Incentive Award Plan.",
        "label": "2020 Incentive Award Plan",
        "terseLabel": "2020 Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r247",
      "r543"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r543"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r363",
      "r368",
      "r370",
      "r375",
      "r379",
      "r381",
      "r382",
      "r383",
      "r492"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Income tax related interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r365",
      "r366",
      "r370",
      "r371",
      "r374",
      "r376",
      "r489"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r716"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, due to related parties, and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Common stock equivalents outstanding",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r205",
      "r324"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r649",
      "r659",
      "r676",
      "r685",
      "r689",
      "r697"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r701"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r701"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r701"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "terseLabel": "Interest expense",
        "totalLabel": "Total interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r123",
      "r162",
      "r215",
      "r422",
      "r544",
      "r621",
      "r791"
     ]
    },
    "us-gaap_InterestExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense [Abstract]",
        "terseLabel": "Other expense (income)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r290",
      "r300",
      "r599",
      "r600"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Net",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r168",
      "r169"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net.",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r582",
      "r611"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r142",
      "r150",
      "r239",
      "r240",
      "r241",
      "r449",
      "r586"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory write-downs",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r711"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r214"
     ]
    },
    "btai_JavierRodriguezMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "JavierRodriguezMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Javier Rodriguez.",
        "label": "Javier Rodriguez"
       }
      }
     },
     "auth_ref": []
    },
    "btai_JefferiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "JefferiesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Jefferies LLC.",
        "label": "Jefferies Sale Agreement",
        "terseLabel": "Jefferies Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to renew the lease",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of the operating lease liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "verboseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r173",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r387",
      "r390",
      "r391",
      "r414",
      "r514",
      "r588",
      "r623",
      "r735",
      "r779",
      "r780"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' (deficit) equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r121",
      "r473",
      "r611",
      "r719",
      "r730",
      "r774"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r141",
      "r173",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r387",
      "r390",
      "r391",
      "r414",
      "r611",
      "r735",
      "r779",
      "r780"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityAmendmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "LineOfCreditFacilityAmendmentFeePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.",
        "label": "Line of Credit Facility, Amendment Fee Percentage",
        "terseLabel": "Amendment fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityExitFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "LineOfCreditFacilityExitFeePercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The line of credit facility exit fee, expressed as a percentage.",
        "label": "Line of Credit Facility, Exit Fee Percentage",
        "terseLabel": "Exit fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_LineOfCreditFacilityInvestmentAllowed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "LineOfCreditFacilityInvestmentAllowed",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the Lenders agree to permit the entity to invest in subsidiary.",
        "label": "Line of Credit Facility, Investment Allowed",
        "terseLabel": "Maximum investment allowed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowing capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r718"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long Term Debt, Before Unamortized (Discount) Premium and Debt Issuance Costs, Non-Current",
        "terseLabel": "Long-term debt liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r180",
      "r288"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "btai_MatthewWileyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "MatthewWileyMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Matthew Wiley.",
        "label": "Matthew Wiley"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r318",
      "r448",
      "r480",
      "r506",
      "r507",
      "r565",
      "r566",
      "r567",
      "r568",
      "r576",
      "r579",
      "r580",
      "r591",
      "r601",
      "r605",
      "r612",
      "r737",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "terseLabel": "Discount rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "btai_MeasurementInputEstimatedPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "MeasurementInputEstimatedPremiumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using estimated premium.",
        "label": "Estimated premium to 30-day average",
        "terseLabel": "Estimated premium to 30-day average"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strike price",
        "terseLabel": "Strike price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time period",
        "terseLabel": "Time period",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility (annual)",
        "terseLabel": "Volatility (annual)",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "btai_MeasurementInputProbabilityOfExerciseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "MeasurementInputProbabilityOfExerciseMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which there is a probability of exercise.",
        "label": "Probability of exercise",
        "terseLabel": "Probability of exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free rate",
        "terseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price input",
        "terseLabel": "Share price input",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.",
        "label": "Minimum Gross Proceeds From The Issuance of Common Stock, Warrants And (Or) Pre-funded Warrants For Debt",
        "terseLabel": "Minimum revenue required"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r318",
      "r448",
      "r480",
      "r506",
      "r507",
      "r565",
      "r566",
      "r567",
      "r568",
      "r576",
      "r579",
      "r580",
      "r591",
      "r601",
      "r605",
      "r612",
      "r737",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r137"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING CASH FLOW ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "btai_NetCashRequiredMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "NetCashRequiredMinimum",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.",
        "label": "Net Cash Required, Minimum",
        "terseLabel": "Cash maintenance in controlled accounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss (numerator)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r99",
      "r122",
      "r139",
      "r156",
      "r157",
      "r161",
      "r173",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r202",
      "r211",
      "r223",
      "r227",
      "r229",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r403",
      "r414",
      "r478",
      "r536",
      "r557",
      "r558",
      "r589",
      "r621",
      "r735"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "btai_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the warrants issued per the credit agreement December 2023.",
        "label": "2023 Warrants",
        "terseLabel": "2023 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r659",
      "r676",
      "r685"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "btai_OfaAdministrativeAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "OfaAdministrativeAgentMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents OFA as debt administrative agent.",
        "label": "OFA"
       }
      }
     },
     "auth_ref": []
    },
    "btai_OnkosxcelWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "OnkosxcelWarrantMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to OnkosXcel.",
        "label": "OnkosXcel Warrants",
        "terseLabel": "OnkosXcel Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r223",
      "r227",
      "r229",
      "r589"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturities of the operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less current portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetailsCalc2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureLeasesMaturitiesDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liabilities",
        "verboseLabel": "Long-term portion operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry-forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "btai_OperatingLossCarryforwardsNoExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "OperatingLossCarryforwardsNoExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward with no expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards, No Expiration",
        "terseLabel": "Operating loss carryforward with no expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "btai_OrganizationAndPrincipalActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "OrganizationAndPrincipalActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r114",
      "r486",
      "r487"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r611"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r611"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r647",
      "r657",
      "r683"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r660",
      "r686"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r660",
      "r686"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Payable-in-kind interest on Credit Agreement",
        "verboseLabel": "Payable-in-kind (\"PIK\") interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "btai_PaidInKindInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PaidInKindInterestPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid-in-kind interest rate for funds borrowed, under the debt agreement.",
        "label": "Paid-in-Kind Interest, Percentage",
        "terseLabel": "Debt paid-in-kind interest (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r715"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Offering costs for common stock issuance",
        "verboseLabel": "Stock offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of employee tax obligations related to vesting restricted stock units",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment and leasehold improvements",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "btai_PercentageOfFairValueConsiderationToBePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PercentageOfFairValueConsiderationToBePaid",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of consideration to be paid.",
        "label": "Percentage of Fair Value Consideration to Be Paid",
        "terseLabel": "Percentage of fair value of consideration to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PercentageOfOutstandingLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PercentageOfOutstandingLoan",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding Loan.",
        "label": "Percentage of Outstanding Loan",
        "terseLabel": "Outstanding loan (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PercentageOfValuationApplicableToInitialProfits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PercentageOfValuationApplicableToInitialProfits",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation applicable to initial profits.",
        "label": "Percentage of Valuation Applicable to Initial Profits",
        "terseLabel": "Percentage of valuation applicable to initial profits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "BTI PSU",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PeriodOneMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the first period.",
        "label": "Period One [Member]",
        "terseLabel": "April 2024"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PeriodThreeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the third period.",
        "label": "Period Three [Member]",
        "terseLabel": "November 2024"
       }
      }
     },
     "auth_ref": []
    },
    "btai_PeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PeriodTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for the second period.",
        "label": "Period Two [Member]",
        "terseLabel": "September 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r301"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r516"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r301"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r516",
      "r534",
      "r792",
      "r793"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r470",
      "r611"
     ]
    },
    "btai_PremiumSharePricePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "PremiumSharePricePercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents premium percentage for share price determined over a specified period of time.",
        "label": "Premium Share Price, Percent",
        "terseLabel": "Premium share price (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r490"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent.",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r156",
      "r157",
      "r166",
      "r173",
      "r184",
      "r192",
      "r193",
      "r211",
      "r223",
      "r227",
      "r229",
      "r236",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r385",
      "r388",
      "r389",
      "r403",
      "r414",
      "r465",
      "r477",
      "r496",
      "r536",
      "r557",
      "r558",
      "r589",
      "r609",
      "r610",
      "r622",
      "r713",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r132",
      "r135",
      "r136"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r144",
      "r476"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "verboseLabel": "Equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r466",
      "r476",
      "r611"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r132",
      "r135",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r310",
      "r318",
      "r348",
      "r349",
      "r350",
      "r447",
      "r448",
      "r480",
      "r506",
      "r507",
      "r565",
      "r566",
      "r567",
      "r568",
      "r576",
      "r579",
      "r580",
      "r591",
      "r601",
      "r605",
      "r612",
      "r615",
      "r732",
      "r737",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r310",
      "r318",
      "r348",
      "r349",
      "r350",
      "r447",
      "r448",
      "r480",
      "r506",
      "r507",
      "r565",
      "r566",
      "r567",
      "r568",
      "r576",
      "r579",
      "r580",
      "r591",
      "r601",
      "r605",
      "r612",
      "r615",
      "r732",
      "r737",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r642",
      "r652",
      "r678"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r436",
      "r437",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r533",
      "r535",
      "r564"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r436",
      "r437",
      "r438",
      "r439",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r533",
      "r535",
      "r564"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Transactions with BioXcel",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r543"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions with BioXcel LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r436",
      "r437",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r533",
      "r535",
      "r564",
      "r778"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Transactions with BioXcel LLC",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r437",
      "r440",
      "r493",
      "r494",
      "r495",
      "r541",
      "r542",
      "r543",
      "r562",
      "r563"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Payments",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r274",
      "r302",
      "r439",
      "r584",
      "r585"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense.",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r362",
      "r787"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r643",
      "r653",
      "r679"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r644",
      "r654",
      "r680"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r651",
      "r661",
      "r687"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "btai_RestrictedStockUnitsOnkosxcelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "RestrictedStockUnitsOnkosxcelMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument associated with OnkosXcel, which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "OnkosXcel RSUs",
        "terseLabel": "OnkosXcel RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BTI RSU",
        "terseLabel": "BTI RSU",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r246",
      "r249",
      "r254"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Employees eliminated (as a percent)",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r250",
      "r251",
      "r733"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r251",
      "r252"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r253"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureBasisOfPresentationDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r108",
      "r472",
      "r484",
      "r485",
      "r491",
      "r517",
      "r611"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r193",
      "r237",
      "r238",
      "r357",
      "r358",
      "r359",
      "r377",
      "r378",
      "r394",
      "r396",
      "r397",
      "r399",
      "r401",
      "r481",
      "r483",
      "r497",
      "r792"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Product revenue, net",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r222",
      "r225",
      "r226",
      "r230",
      "r231",
      "r232",
      "r307",
      "r308",
      "r451"
     ]
    },
    "btai_RevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "RevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesDebtSummaryDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Revenue Interest Financing agreement",
        "label": "Revenue interest financing",
        "terseLabel": "Revenue Interest Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for recognizing revenue from a transaction on a gross or net basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RichardSteinhartMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "RichardSteinhartMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Richard Steinhart.",
        "label": "Richard Steinhart"
       }
      }
     },
     "auth_ref": []
    },
    "btai_RightToPurchaseStockLenders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "RightToPurchaseStockLenders",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum equity investment allowed for lenders in entity's common stock.",
        "label": "Right to Purchase Stock, Lenders",
        "terseLabel": "Maximum equity investment allowed for lenders"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds issuance of common stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SaleOfStockMaximumValueSharesToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "SaleOfStockMaximumValueSharesToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate net offering price of shares permitted to be issued.",
        "label": "Sale of Stock, Maximum Value Shares to be Issued",
        "terseLabel": "Maximum value shares to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "SalesMilestonesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones are payable when annual sales reach certain levels.",
        "label": "Sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r319",
      "r704",
      "r726"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r45",
      "r46",
      "r63",
      "r64",
      "r66",
      "r70",
      "r106",
      "r107",
      "r597",
      "r599",
      "r722"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective tax rate and statutory rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation charges",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]",
        "documentation": "Describes the details pertaining to each employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406"
     ]
    },
    "btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest expense associated with long-term debt.",
        "label": "Schedule of Interest Expense Associated with Long Term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r86",
      "r87",
      "r88"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of maturities on long-term debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Property Plant And Equipment Useful Lives.",
        "label": "Schedule of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of Property Plant and Equipment useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r539",
      "r540",
      "r543"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of service charges",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r252",
      "r253"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of activity relating to PSUs",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of activity relating to RSUs",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r231",
      "r590"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "terseLabel": "Selling, general and administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Cancelled, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled, Weighted average price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Fair Value, Vested",
        "terseLabel": "Total fair value of PSUs vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted average price (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, Weighted average price ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, Weighted average price beginning balance (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility (as a percent)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum (as a percent)",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum (as a percent)",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate of interest (as a percent)",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free rate of interest, maximum (as a percent)",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free rate of interest, minimum (as a percent)",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in shares available for issuance (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Options"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period",
        "negatedLabel": "Options cancelled (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable (in dollars per shares)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of non-options granted (in dollars per share)",
        "verboseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value, outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end balance (in dollars per shares)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per shares)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested aggregate (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested, Weighted average price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Of Increase In Common Stock Available For Grant",
        "terseLabel": "Annual increase in shares available for grant (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled (in dollars per shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per shares)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per shares)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche One",
        "verboseLabel": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two",
        "terseLabel": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedPaymentArrangementGrantDate2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedPaymentArrangementGrantDate2022Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award granted under share-based payment arrangement during 2022.",
        "label": "Grant Date 2022",
        "terseLabel": "Grant Date 2022"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ShareBasedPaymentArrangementGrantDate2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ShareBasedPaymentArrangementGrantDate2023Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award granted under share-based payment arrangement during 2023.",
        "label": "Grant Date 2023",
        "terseLabel": "Grant Date 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee consultant",
        "terseLabel": "Nonemployee consultant",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting (as a percent)",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Terms of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual life, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options vested (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percent of fair market value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r171"
     ]
    },
    "us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Minimum annual payments",
        "documentation": "The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r69"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r138",
      "r159",
      "r160",
      "r161",
      "r181",
      "r182",
      "r183",
      "r185",
      "r191",
      "r193",
      "r210",
      "r237",
      "r238",
      "r306",
      "r357",
      "r358",
      "r359",
      "r377",
      "r378",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r432",
      "r481",
      "r482",
      "r483",
      "r497",
      "r559"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r210",
      "r451",
      "r488",
      "r498",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r537",
      "r538",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r616"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r319",
      "r704",
      "r705",
      "r726"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r210",
      "r451",
      "r488",
      "r498",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r516",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r535",
      "r537",
      "r538",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r616"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r646",
      "r656",
      "r682"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under ESPP",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r108"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r108",
      "r490",
      "r559",
      "r577"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r108",
      "r334"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r79",
      "r80",
      "r108",
      "r497",
      "r559",
      "r577",
      "r622"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r30",
      "r108"
     ]
    },
    "btai_StockPlan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "StockPlan2017Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationDescriptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the 2017 Stock Plan.",
        "label": "2017 Equity Incentive Plan",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' (deficit) equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r101",
      "r518",
      "r534",
      "r560",
      "r561",
      "r611",
      "r623",
      "r719",
      "r730",
      "r774",
      "r792"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' (deficit) equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r442"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r442"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r442"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r442"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r442"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r443"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "btai_SubsidiaryOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "SubsidiaryOwnershipPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock of subsidiary.",
        "label": "Subsidiary Ownership, Percentage",
        "terseLabel": "Subsidiary ownership (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureCommonStockFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Shares issued",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosures of Cash Flow Information",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry-forwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "btai_ThresholdLiquidityEventAmountForExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ThresholdLiquidityEventAmountForExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of  liquidity event for exercise of warrants.",
        "label": "Threshold Liquidity Event Amount for Exercise of Warrants",
        "terseLabel": "Threshold amount of liquidity event for exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_ThresholdRatioOfDebtToRevenueRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "ThresholdRatioOfDebtToRevenueRatio",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents threshold ratio for debt to revenue ratio.",
        "label": "Threshold Ratio of Debt to Revenue Ratio",
        "terseLabel": "Debt to revenue multiplier"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TickingFeesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TickingFeesPercentage",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ticking fees percentage relating to debt instrument.",
        "label": "Ticking Fees Percentage",
        "terseLabel": "Ticking fee (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TimeBasedProfitSharingUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TimeBasedProfitSharingUnitsMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to OnkosXcel time based profit-sharing units",
        "label": "OnkosXcel PSUs",
        "terseLabel": "OnkosXcel PSU"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r233",
      "r234",
      "r235"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche B.",
        "label": "Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche C.",
        "label": "Tranche C"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TrancheDMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche D.",
        "label": "Tranche D [Member]",
        "terseLabel": "Tranche D"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TrancheMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A.",
        "label": "Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "btai_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Tranche A2.",
        "label": "Tranche A Two [Member]",
        "terseLabel": "Tranche A-2"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureTransactionsWithBioxcelLlcDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureRestructuringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r251",
      "r252"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r369"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r129",
      "r130",
      "r133",
      "r134"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureStockBasedCompensationNonOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763"
     ]
    },
    "btai_VimalMehtaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "VimalMehtaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Vimal Mehta.",
        "label": "Vimal Mehta"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfChangesInStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Down Round Feature, Increase (Decrease) in Equity, Amount",
        "terseLabel": "Repricing of stock purchase warrants",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305"
     ]
    },
    "btai_WarrantOaktreeAndQiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "WarrantOaktreeAndQiaMember",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureDebtAndCreditFacilitiesWarrantsDetails",
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Oaktree (OFA) original Warrants issued April 2022.",
        "label": "Original Warrants",
        "verboseLabel": "Original Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "btai_Warrants2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.bioxceltherapeutics.com/20231231",
     "localname": "Warrants2024Member",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 warrants.",
        "label": "Warrants 2024 [Member]",
        "terseLabel": "2024 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureFairValueMeasurementsInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Fair value warrant classified as equity",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)",
        "verboseLabel": "Weighted average shares (denominator) - diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r205"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.bioxceltherapeutics.com/role/DisclosureNetLossPerShareDetails",
      "http://www.bioxceltherapeutics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares (denominator) - basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding - basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715-20/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482236/912-715-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001558370-24-003784-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-003784-xbrl.zip
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M3SN.+8*Z1J*R"4E_?279!ALL6S(.%M"9G;V)(QWK.<^1+!T='7WY^7WF&&^
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MN' V=Y@L_FQ*P.2F\N*9D&)IMAI-'\E?1QXEDME(#R,7.]!FO'XU'=:.T10
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M4LQ'*%5RV6B?@841ZUE\JE,P8(%P9<P6M?V%PX4,Z-\"G.R]!4]N(SH%[QY
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M\=:?'(0M/'07(4(8C=U,C\8>C>D_#_W'\<@8WAG#I_YS=WQ/"V@;E_T(/#^
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M\ ?,=_1F/D@A%R9?3DPE)VT2,L).TE9R*R9T'-6UG3^FYLV*+J<R0F 5Q9R
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MH 8[\Y(H#2SA5]-9^'PX#EZR^'E9$]BN>=S<2^*5N]2I)-I76Q[RKK"D*@=
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M4M@+O)_C2\UG*5C[_O0_4$L#!!0    ( !&%=ECJ XRP7S@  #NX P 5
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M;T=%Z-'[H&Z=E?Q)MGZ&@I%8PM7URCZJ%^+M%E6@:(&C5?82!O42I,?N0F@
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M*U-HO42?820/).]# 3A\,]"[_<K\"BE6V7^51H1]9,4B!%SY;_23_#A4U@!
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MXD8*RQ4?CT!PPOIH+*R/@.HU>A'61Q#"F@5.',\7OSDT1)K,HWOZ0I!D;93
M#[\<"@[M>UT.)0R )TCI>B=M 6-U4VJG4C)])NW^D?K)YIH]Y$(M@B1/5P )
M8!W24)M=)HN C!YX.P^_X)B>B>2(B7DK@@2P;)CP5D0&C)6\A2&M'=?U<*!R
M R!9NA=><7V(]JO:^!*K9TY,JYCI?]0*O3A!Q07;11]$:YU^>P"&HW==,F '
MG&R+"Q013&F]<XD; GD+8 $D'_<N6P'ID.6X*4KAYXLK/W1"UW>".QS[625J
M0GU&8K@NPW2%(I;1H2WV)ET#<,NDNBZ7=A.*H2:W9-MET\R6C_J9+=D 7T=:
M"VW/Y/V(W&7H_Y'*2X'['7)8DU.2.I.XXJ%!,?B[2G-1*439SHA98G4MX:$E
M#7K(&L"(>:AT5245$ '[?<0NWXB"^WFA@306K-42P JMUCR9H+A4@9(8PVQW
MD[B1S 1M >RLVDE-0%</\:_ZR/@I=^_FBZWRB(-B1LT!;(KTQ&).&J@957ZM
MQ] $UAL"J(UL:P'K1 TPD;8Y+-X=^=(7/'9GU!) %6&+Z2.B"M3,H9LYG(;9
M#=8F,X?7$$#=7;N9PR,*E+BX%X^;B$W6 8#ZMW;BDQ$'2HRL%,K<8:\W U!=
MUDYD=9+@'?6/)6>CQR,/DWC&(8WCD,:1>8C;@9PO";'*1*_^[CMBKU &#2 J
M89)R("/EJT^7Z2"EXY N8Q8$L)TN(^#M+7K-!^%?0RX" K!#-^$HAP++I\1/
MQ/F*DRAE-?IB[X8'^*XJ,TS<&AXS (E1>4.L&!R&)R/62K$4>KX[=D8TR$^N
M'%<<IY?  ?!95"I2F"@^!://D.3,[YL!DB;EPXXZCU*'HUVG5HJM]/BR+3E)
M1?LA$?T$K'I+ 'Z\#2W3X@V<-#VN\U@YMRY^C/-?XU.!6C3L"\"FQ(:B-.06
M'-6IKN@%"[5\OA(T@!V4'3LAX << 6^U[Q8G#RA) D17NNN0YI/KY^2;=@+@
MH-6&.IBR"9R67.#7\!ZGH7>%G(2@N+WV^@)MK[_.(F73%3W5%"TA33L#<-QK
M46N,V04@$SQ['>_1>4/T?B<<TNU>]CZ>41[XGT_.]O/ LYXGK&OR9[5W^$G@
M\S5+V ^?;W <SXB -PL<T<LKI7G<RE8VGE(E(LAO^4UD5P^*@,&D86N*I/Z&
M:ITF  _<EI'2>-N6!PXC3"=7,KDT0.1/$R103 SDC)KE2)Y]*X %$-E3:57%
MZ^538?G*;R>A!Z,WI/?@;VGDQY[O4E3D[]&J6@&(?YA(1DF/51F)+; JB*K5
MTEH<U("NLK"4"]+XHI&7BP5R:=BL4%J:,C<C&/MA2BC-2<9AG/]4]>NF3_29
M9%<4L>RL=P"SNJ'.=,8".%M//DE[>"=7R*/O:5,#EQ(<-A5@(WTQ[!G VMSQ
MK%+KDR&+QJ5+9+].]J I :.EU=G;R?RW"&8X-C-%[08"8)4L:YHIQ\:E>.3+
M[%A<^.*H82< SEPL*TR9&^-2AHJG7@JCM5 -<9< 3F<L*XJ8-^-2FSF-R$Z]
M?Z59GFH;=:EW!>#4QK*:U'DR+O68+>GC2=?A!<K>HZ11 W:049Q)3(, OSJA
MV\9G-AH%P*&.9:4R8A=T?>-QK?5V'42IX.!:PN<$' 40ARB,HW0@?-7.PW3]
M/_<L'OL6D_V1S[UAS:@E -?04"Y&Y,&93<56I8QM=I8OF$[2%@!\M8;S24H6
M''E]IED=^#FD;]L2E,]12#@M=+B%T #<GX9R$I($1T;%<GKYYJS\D,WY.T00
MH=DZ9+>WK=N?NFZ4"I^.-NX%@+/24*;&I +(,7I(GV+VY%QR^4+W9&:I13_4
M'T_==3C)>H2?3K3' UD.$1]TX,/X/1SD5S@*H<&D#LG87SE^%U&RFT9GMO,D
MZBA*TX<D\##RAQ2ZIA /B RB/;SD&2M\6 "GE$K-DH@"1'H*Q<GW?"?:/#@!
MFB_8\^8*NR6 !W-7BXGE$M!B5R8[;&BUZ7SQ&#EA[+"<)KG=TF@(QX!)U:XB
M)PVR>HA#_ TM%BAB*?"BFN4:" 23I*T]16"A1@:@ZJRQWJR@:X0.-R+T:VD.
M-R(<;D1X-Y?3"8+)NK;F<*G<X5*YRJ5R,?GE6^5E<A4H .:GP25R%1*ZU_4X
M2DIZ3O[:Z3CYX_?BQ9L'%X5.Y&..O9' #6]G!(<?*CLCH6%XGN?#?P[C-7+]
MA8\\KD51P-JU)4KE*;@NIJ 'ZW%'-@O8FX>2&_YK(!;MAI8Z%!:CAGEO#'Q\
MQ2H&ED L9DHW86 )\_X82&"4.E@!LIB1T8B)9=RMQPE+IO]&4;LF!K=6L*:B
M0!8TMU2:)GHS@C!NE:Y^B7 <WT781<B+KPBMUW&<TH2Z^6*&5RN:_XO=+UL'
M:!IZ\^@N0E<I/3+<?GN%([J9X\V>/D8!4.VAHP:]T=]WZM3>U3S;UQ5GF)!*
M;Z'-2+KQ_TA]LB_?W!-&^-GU7CP-:-,;@-0W;4FWH1-.7@AW5W2;4D[-%P_T
MLA9VG\N,F$KDG6_V+^@RV6B;] H@U\[$\K>F%[A"O-\+\O3VK.;"'_!B.Y&S
MFSU]M'OE@SB'KL!FBV$!).5I6V0Q%7WSNG1Z]LEYHW:?W8S%,(D?\3FBRW\M
MJ\ZL*8!4.FU):!,%Q^XQ9#.T+E)Z05FVE\I0OD6O["?AQD6S,8 W@XPV-)ID
MP9&BTN46"%"CW9"R^Z&][#0H@B.VDKV8X3#VO;S(YQZYR'^AUPB6TA'4:2PZ
M?0P:63SI8"Z:D0='MG?.AA6(YLAO=9%>2R RI_(F@TJN@["0G)H&:>,_'6=,
M\[/\ZK_\?U!+ P04    "  1A798Y$[4=PU_  #PEP@ %0   &)T86DM,C R
M,S$R,S%?;&%B+GAM;.R]>W/D.)(G^/^:W7? U9WM9)F%JBJK9G:F>F=F3<]J
M72L5&DE9U7UI9VT4B9"XQ2"C288>_>D/#O =! F2(.!4MMGN=)8"\!?=?W@Y
M'/_^OUZW 7FF<>)'X7]\\_&['[XA-'0CSP\?_^.;?;HY^K=O_M=__A__[=__
MSZ.C/Y_<7A$O<O=;&J;$C:F34H^\^.D3N8]V.R<DGV@<^T% 3F+?>Z2$?/SA
MNW_Y[H?O_HT<'?TG)W'B)*Q+%!).Z\?O/N8_G&;4HO /Y*?O?_SQ^Q]_^/&?
MR;_]X:<?_O#/_T)N/N7M/C')-GY?P\ /?_\#_)\'QH\P#</D#Z^)_Q_?/*7I
M[@_??__R\O+=RT_?1?$CZ_[#Q^___.GJSGVB6^?(#Y/4"5WZ#6'M_Y#P/UY%
MKI-R\U2ZOS[$04[@I^\+7M(6\%]'>;,C^-/1QQ^/?OKXW6OB?9.)"#\K,,F;
MPZ]>6G2H-OZ7[\6/1=,#TIGZ'W_^^>?O^:_?_.=_(^3?XRB@MW1#^)_^D+[M
MZ']\D_C;70!<^=^>8KII%S*(X^^A__<A?82/"5K^#%I^_!^@Y?^5_?G*>:#!
M-P1:?KZ]E.K[<XU6UHEKHV2B[TVI<\]BAX[2J=H3HV)1Z@3C%*OT'*J8"%WH
M>\7^5=./OJ8T]*B7:P@L.RASB0K/!M*16Z,70%Q'\:'!DCR:$NI^]Q@]?^]1
M'W#F)_C'$?R#VXG]QU]/(X:=QP])&CMNFE/BXO_'-VV_#[,&" VTCN.ZY$[L
MYKS8/WOLD+7XWHT8KNW2HR#[,+S[)HZV[9(*=E'+CW\-'H9_V%R5FAXQ3:)]
M[-)!7[0JOLS2A8BL!0QD-#SZ?#= YO\\RX<Y)_3(>9CZZ1NY##=1O.5#P;\+
M,69TK%R >T:Q1=O&SWC=JDV/W*NJO^%TJE8))_L44#/G0<=AN'>"6[J+XC:$
MDC3#[U%M>C4]J]H&MX>U2CK9TP15(LB:<[D;&ON1=QYZ9VPZT*%TLQU^IVO5
MK.EUM4:XW:Y=U,E^)\BR@=,C0-C@<!D[8>+#$-T+>"U-\?N?3+^#(;71#K<7
M2J6=/M06E(V!H)@M7O@!O=YO'VC<HG=+$[RN)],G=[GF[SA=32KE6!?+%@5
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M47U9T#UJ]W;"'8QJ.M=6L)T]\ :FHMS39IM5^L4"-V.A=XVK'K)&%,^GU_D
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MW+&_B))2/9OQNFCCCFRM%JP]EZR#,%[\T*O>V$@\<1(_$>^OERP7%XCEZ06
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M:_W\7M8:+T0HR#S^Q#I)X7CAERCR1'S?T?C9=_$$M#'E[Z+ LW1)NO7I M7
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MN_3GAL;,8/?.:YL]!^Y0#*6&&T4G6DE6.70 *;Q(-U4A'7&5<X9WE65;"4A
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M!\@^T_'#U;R5ION?*YK? I7KL'?^8^AO?!<,<>RZ4+P +EK<1('O'B;[:[&
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MM+V)4O8_OM-JJU%4$(/T>*L4P#R<!'(PGJ"0AH/4M';M<I>S(%OGU=_NM[!
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MBQ@MAEJ@P!'5CL@19K :FJH$)_G6.4F*/4;X+#RIP %I>+.-$ E.98KY(0E
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M)[@,_T*=^()]&HF)Q]+"#5>3+%1[>'X,(;RP-$V=L4$$7(^ ;5;9)N/\MB+
M@@ /.X_.6[$&"^=_M8$:^2,7YZ\[&B84E);8I;TE[HCOT*X:SRW-\$9KE[#C
M[_]EKY!D1%<\)JV$WZSJ44'41J!5JFK&XCWV3S1]BCSQ*#NE4)N&35]@2G'R
M=M@X;W8/4PV)Z32SP!W:<]BSB@DZZ>,%DUFTU%$:-B:" Q'RD)S3BA>6XJL4
M/OMF*Y/6;GE[\H7+9J4H1"E8Q8P=Q4RZVB\E&"6:MD=6H_$2PD0F\FB?KWFS
MO0(F%;VNG2W[YSU;,">."UMVG75,E#HB]UYEW6MNW-L+L3^KRZ[)L;77-?E_
MZ&9#8[8RDU\//FR"TP^[]"F.K1J_(S^6DDFKN;! _?IOP91<79V:/7/2K6^I
M"H^CX[PB@OEC(TN:V9N@7?DAO4SI=M LK=H))\@,T[EWOE;T0#S(J<D]?;72
M7)-\ 2:$<VD.>&;V4.;6G!]R9,5;-#XA5,J:73+A.3V"&R3S7'*&;2"EWA5G
M<([1OWQ@2*T?\AG#4"VFWE]R'MG(\PAO;T/)YH@/2FP:L<OOGHJ3O,KKE2*W
M2SB]X0>(#)FFAF)P(",L)3+_LJ 75KAL"WT#DQ'33B+2_)*JZJ-13^<2O9;G
M>$M=ZC]#B?/**JY_X:=$ R=<3K*(9 W?3P#Q3&>4&II@HIX2G+.$9P J3.U,
M@XR:!1X]V,612ZDGYD;%0\B5;!$;N''#%()=GHZ=YT83W%'?ID\UJ*N_XXW9
M5BE'YUJR?@2H6=Q!SA7JW"T^:+0,5Y/O M=;X'<W3;N[%8?3OK-[&4+>, /H
MXQ<G]H 3:_.#?)NWISU.#U/6M%CF=35&OK93$GW6K6'@1PHQ")>#@"!F5W*S
M&D*JH_EU&@H]IVQ%P5Q-B/WQ7^7(T]X,,>!TZ%5N)QVV00XO71+/4!$?N&0[
MO>819 Y=N4)%WDP>5W:0PZI^9K9Q8#>)OTEW&FTA'5%<Q((+"H_\).SDK6QR
M(Y*..<855QSX=M3Q/GV*8O_O!QOB<_+!"6VS6[:V9:2;"=XUPWRJ3CIY.H)_
M>Z0J$ZD(Q5,"*^TRP<0\H7;-26SKEN+9V:1"9^225+;SO624?';\ !) +Z+X
M%[@"-O-7:&'W=6"FS,YS0&>3U_M'4*G&J( TEY*7".)R+AI1M1N];J!'?I-V
MVJ51V?)UK 6J-0+83#FFK,%E**Z[BISG'CRUP!XGOMKZ#N4RWAQO[-L#%BRA
M83,3MAKJ3\A74E8*[,UR$QK'C"3:ITGJA!YL?T(Y4W@V9[NEGL]Z!V]0)]6E
M_$?7@5*]3DS>X-(MKY?I9ZK"?D>-J-."7WNH\RMD-;\7LJ /JV' K11466](
M+C?[!\GJ$8@]J7*4N; R#"_NTQR'X=X)2K<O1N16AY]<4];^TNC8\WSHX@2F
MMI(Z.>(<P U:6^L:2<[N'2^3%)1&L5(JY7PONT\S6OZR#Y"+)"O+E7>XY@_]
M1GQH&O'\=>>+E+0;7GF^ZR-IHK\ L-5IR0-HU4$<.9!J5=$B;)8R$2&4/81$
M85(H2L17>@Z07]3,D_^?7VD"CT +:\C>H-/,8@%PI]F>6B:3+?21@YYN+2WB
MGDAHRN2R#GU8#)O;8]=F#R/H=\LDB'TWI1[?B/@<^FER>_>Y-3U,M0]N?%+2
MN HXG1WP(HB:V&,]]^3^DC!J5D+8AF9&@I%#S)F3=MUJ:;;!'6RM&E6#J]8
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M#4J);&#CJ9,\,;7A?P"RF7BUS99RHUUBXB']<6/:8$M4\4JY,UXL&J["V$
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M5E#+].X*Y6:?Y02P5/+1!W5 4)S3B74'BL@UKN:2$SRO#!3,[&&+&S),V=U
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M/%#@"E)H&/) :1G8A\^O8+7E PWIC#.VQ]F@2"M4[HD\AW"X'J/'M"VO6?1
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M*&BB5J=921>V"=DH7 #<!U[/'X-EX_RR2[1+LY<"_/4 VZBI5O[GSIGK/3R
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MA2Y(J_%> M<?P//^X</X^@%8$72;SDT4)835.*;](+3#ST&A)M)RO)?8]9?
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M41<J4+Z14*J0DEY<BV9)C-[==+*7I3#;<H1. U(2-QN%UI3O.DPATR&Z >^
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MG4$)H8!"$&Q>BH-<8W1?;F*2RJE\$8JO#5#3]R%86V[QEAQT@#.T<U\1( 8
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M4RF0,O(;6NH&#$Y--F78L/$H=3]<R:22%^<B7LG8:6:<]ID8-&O3>^(X;L;
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MK2SY8QA!#^4$0#S3@H)&?'FX_JNW)^NUEPK5\@JAWOB+(%QE&B6?)C'V'BJ
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ML5\W< NB"(#JFPQ4*R=WTL6(FZ5>-LH6?!AD<U>KM1>\ W !?+!P8W2FR6B
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M<QJD'@9=@RY^9E6_HB4G^KI+$/YGB[3Z:[KPG5J>!YR+]\+;Y0VYPG1VJD/
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MQ60'\4A]H*EWD%WE96\>0/CBYI6::^+8Q%BIK*/'(+:\\N_H-8Z[(/X7B.?
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MY!(K0@FCKYNOH:FQ[FWDBF+(98$VDKEX+[F"ZQ#\G@#??B<4BF+HJ2UPI,"
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M"! 8-0D$5V\@M-W\*5IB'BE#SR' @J!7.C!8>1[\!MTNXRG#OP1H38+6!%Q
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M+%%=FQHXSI2#XPXPQQ6PJ2GJQ[%2Z+OS3G,06YY6L64IJ-YZ1H:9HKG?\''
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M8_NJ>,Z4WV'MZ)O9>104^GI*M+_E[\Y:P3\^AI8?66G5"K([IW;4$0_L2FT
M13N.Q;AXS'KU[V !$9:^F]S@LIN::*>5=E+=6:NR,#EX3WT)GN)M<7B"BZXW
MU$[K[7TS(W."#D>5..4JB\@LB*X8UUPWI3-JCJ9R"H."S+R-XG$/.J=9Q->6
MG;[[@??43>WTUB%%%3M.FIF_P7OJJ6=%T6SQPT(';?$LG*-D#X+#QK;73?T=
M_#8?CX*2'92X[T9.B1Z<T$,W!/"ID1$&@W+G^= C^,L)WIG76PU"D^S>G)%!
M/7UY%,8E2X9_VUHQ_$M6R!%-< \V\*W0#1I\-[:=;GINX;/Y>!.4HR3.5].T
MFS/TW8_6P'87+G :O3.QK2Y:YE/5CHJYF-//$V?'T3,?X-WP3I,J8U\A[M6D
M"_)+?\?[LO"EVO42M?;X&M"TMFEBF-;(?*DN"$S6&FQ#M;92(],T1^%,PCUQ
MI0>!MY0*SKCFNJA=_#$]F46MJMI@##E/TOLY1-<LT:OJP(FNH;1NHBA!Y7IF
MBSR3&&W)%T'^Q'=FX7T(KA.4 %7\ZW40HOV@)D\@_BN:8XH,C!UOTI-TI-:_
MY2U;@7U)NKRA>.WZD'\79;-#H4+^<DG=NK\GK@._.X<B=[.4]R;8M:=F$KP$
M2T'J%<7>JY\T;GML+FX".PG3!]&FEN<!Y^*]L+.\(=<.+CM50] G4QIFU>!I
ME-#5&PAM-P+WH8OF@%VQ'/)@CT;K(R"NE0RDEO$1-&G"*&#E)JOT8E?*'%R>
MV)@I$=?6$ #P\RBU'(\@!9>R8KY9;VBV1G4ULXKPT6-P 5"D6+NNQ-.U*IIS
MY15UNJB_"\N]7'7L\94N*(.,VTLXR?K+;-\BD\0=>$U_PJ[FF3H; AP!3(NJ
M)JH'=*CK4 QJJ/T, TP[?G.L='Y&N1$K_=_]V#K<:>!'KI-7W9T#&[@OP)GY
MI2Q.>@(QG89A&.K.>XZGL2&^)ZM+$.4R*<P*/76#FZQ(70Q#"S>KQ;[?@:2J
M(0(J.*1?BX#]TS)X^0)L)_O@368+$/RHZ%%3U0_B3=SQ^/3DY+3^.'M*=)13
M'>V0Y;R+VR-\H%A^G7C>C>^X+ZZ36%YC=OL8PN:P%A+_XJXL[QMXCBU"'SDG
M^@.1T-RU88SG/,3 ]>$?&N]X5>4D^(+/0.3T=^O%!>$\<$)WF8 _Z&(2G'(_
M$#%]L^+X&;S^<#W0F-I<E9'@O-:!R.@:.M[?_A78-H-34IY-5IZ<LA#&=K:1
M"TX,.]$*E[1$;!SM^OVF'2*FN4'$8)I=;-.0.)RQD&MS33ZM:5SLSD_(T7S-
MAS0>K;-Y&A$#VC78IN$P&34V7/S+EXQ@'F7]Y_\'4$L#!!0    ( !&%=E@"
M%APU)10% !* *@ 5    8G1A:2TR,#(S,3(S,7@Q,&LN:'1M['UG=^I(\^?[
M_13:^^S^GYESC*\D\IV9NX=H8Z*)-F\XC=2 C)! @>!/OUVM@$@VML$6'CUA
MQH#44E?_*G95]=__;SF1F3G6=$E5_ODO=\W^E\&*H(J2,OSGOZE&IE#X[__[
M_;_^_M^A$",]I.LE1E0%<X(5@Q$TC PL,@O)&/UBFNITBA2FC#5-DF4FK4GB
M$-NW<.QU])J]3C"AD#U4&NGD3E7YY5QQS:U_S-@#P\_AGSS_DV?Y")/X%69_
M\3&F5EY?:=U<DOH:TE;.+'Z1T<C#XFSXFDO$$XGMRQM8FTL"9N[4/E/(_F)B
M(I?D.3X6XI-B(A3!@W@()1'Y"_63_3Z/$@(;M<88&816A%Z*_JMO(.F?'R/#
MF/[Z^7.Q6%SW)74I8-D880U-L6E(@GXMJ!-X]S!'_O?#OM'40T.$INZ] Z3W
MKU5M^-/^@=[@7"Q+RGCC*<N^)M.K>98-_X2?^X22SN5+??.=%F'G6N[G0[G4
M$$9X@D*2HAM($=9WD3%%P[W1^XCH3^M'YU)I:81T+&P\A'R^'JKSGY)"7@<#
MA7\:&E+T@:I-D$'6@PS$14-L(K0F@JX9NP0@7VY,7EH>FCH7]CS-N5S#@X.D
MBOTDOWKG*[U U6WZB%C:)(XS8_+#Y@OK:H3GXB\-;5UAW[!OK;AD,OES"4!S
M1L6"N/_QY(>-QR]WT+(Q)ORZ!LH[<$(6?__47EMY/L3'-L F[05;S *;]./W
MWR.,Q-]_3["!&$%5#")M_OEAX*7QTR(,W!S",U.:__/#_CUDK*;XQ\_??QN2
M(>/??_]T_FT-U5?%U>^_16G.Z,9*QO_\F"!M*"DA0YT2L3(U_B(/_4E^WKA&
ME/2IC%:_%%7!<(&T_ 6C8<WZ4Q)%K- _R05Y#0DP9<94)*,.4&R1/WH-0D$1
M:6*OU<CV6OE,=&K<3A)C=%=]DJJ3:8VOIPAE]%^*)),9:B8A-IW0TAHCI?>J
M@Q[']\)<#Y:Z5[OKB\N)ME):J[ME_V%8549"E RAH EY85N$_,JHDXED@)#6
M4XJ8(0,2:4ZDNH3U'XQ$X'1+W[V'<W*T60@5NZS)CY_NZG*63W<70,5/G!3?
M2X\>0L/20W<QGDWG0@J'HL-X]_Z]DUJ6^B5T6Q[RN5@-LS.]N4AGII\]J6-7
MJD;D$M&86&P8JC!N(QG&]4SFX5FXQ^/8^(;M/#VK:-$OA&+HWJ<K]-IDPJ;,
MI:OQ-I_K1(O=*BH\9L?)U'HR%6)7:)*P\2I94Z.BI,?U;,(V52^98]-VI/"L
MA.]:O)2K15?"W;3#+9PW(Q+Z5XX Q5AE"&XT)!<4$2^+>&6]5U/HI:OYB"$6
M5U76S-YG*R6]Q]9SPQ[?XW[\9HD\C/-L(AG^^^?&&Y[WA;.V@967= ')CQAI
M>?*-[K[R;;F>T[5.O9631@FU]A!?#<NC12\"KPR/^,*7K9$GJ.+FZT::"E]N
MF<(X9V:0T$D]X:B)[WM1>-W\XZ>^;(J\J4C?5D9#]P5KHU0Y4LDON%RQ,9X6
MPVC:B<NI7@Q><(!D'1]XQ]=X3Q\A#>N]9C3*5>^RRCW;4 9"3QAR]9%V_TZ&
M$[$@3<@[_?,C%-XG(%6%\EZ#/KJ@ZR86-U@P:DQS<B^^Z(Q7@\ED.&3;RVPJ
M17"3X")Q@G=GJL[<SC_7PY+R37.MF@98*^"V;$RX)G1*[+PG/>2*\6JF-([%
MC%@))IQ,AMDOF?#[%G=3MKX\Y]9S-EUMYX<9-I01,HU8?A*>M\F<+V9UWS)9
M7"\VRW?/\GC<R8KFH%!\O+T9+%Z8[#[1LO/6]IOT\DC2J")+K\H8Z::&J?C0
MB/%)3(]5:BGIN]=ZKM3K6#")1ZP,RWC2QUKO.;&XR:OY^]OQS2@Y+>-&5N(+
MPVT"9,D;SHFPF^.2A/J23!0860R##ED=Y"6%V.42$;>J+L'4<DMB NM27\8Y
M!69'Q>0&E>0\&HZC_::2PQ.Y(YJ1S% 9W__X_9(3^I_=MR"V5D558$;D1=X@
MNM]I'56G="[*L$0HNB9%QGK^<10I2;JQ08K'[!-FDU(CUC(''?XQKSVB:&7X
M"BFJX-=[J)!Y,PE<[17MV6* :*^H*Q,<$*46A.&:Q)?9@%8=ZP89T+ Y KA3
MKS=:-J:<JVZ(\V5@#'0Q]8W[*0O1F$L-K8!D*8U<.Z34(PN*)U-976%LCY>K
M3,K9;IL(SL93G'N\,6H-XW''VEN/283QE%";3L\S<'JU^UB8'?U'F\R(+*QE
M,' ;"Y2K]+NQMC1/CALUO?2L*W*[TR!8K7&[UL+/34>,R@W"F%C__3?XN[]T
MZLJ2!6"H__L+O,1_?N@2F3#XM?2[$8T<0$ GY 1KKI>Z"';ISZTQZ4==-37Z
MB082?MF+3&=P4(YD9*3KU4$' 7F,JE:7AB.#+A$\MU?!"_LGW5Z#Y9B]3R2'
M:-'*-!=2LXJJTU2'$,%^**9&K?-)$N'S0,(:0R>,]P9H,H7BIDV[?;,SG(Z'
ML%C61Y$\;#F5)4$RK%=C1&D"O*4J'G5\:'H_?L/\?NW,[^^?>\?^[;R4^PH_
M]\UW2E'CSI[&*0QJ^X8X/A3FW*G9OSB?G?M^;JS<OH5<VYH\85*/L1E]T[HZ
MWZ.QH6%,W-9["=D+7%.,^TRY==<=XQM%>FXF3"YO#B]U@0]/])0K3593,[)$
MZKMKS4;=<=S?7 J*!RYU?OD(+#Q"W&/9N?+644VYF0D*BPA((F4A<N&5RAXC
MUN'Z6]QM1ZIRM!6:W7:+YL1X+D9\"XH79_GC]QY;_<R0((O,D?\= PE^4U*<
M#A+;7JFSV#49*16B0-?"(6=K74J9&M$I(Z(IX3)R'^L (E[C;QN9*#>>S8UL
M :^D&Z[M6S7@G:,M&(Z8Y!DEQ-%P")\*#@<M@.-$0AT3HBE8S"%-(>:18PW@
M\ W??A#'>@[/%CPJA(O1V6/*KS X4B[LGZO?+8,/+G!*%*F#0EP5)(D%)8.F
MDH%D9YUGC]+HZ;G;;$T$:96(H>R@+%RZ_']QRA>VW&]5\0?XN9Z2NK=*>'2?
MBQ4;CZUJ:='A,I>^SI_*S[Q/%OAE?E[=-/O)5GT8'>/&8IB1"JMBEKOT=?X*
M?C[7<G.GX6=]:L;FBWEL,<:I8B/1':)T=[6X\'7^5'[F?++ +_-SK6[<K.X'
MJTD.":6GFU[K+J4]7+H=]A7\?.+ECO3"K"6];^3*('%;E3HM,_[\,&[.Q_FT
M?G:'Z:W"C(V$PNP9==?^*/*&+U:=PIK;N%9S^!G?Q*=A]D:?=&JSV* !.1,^
MQ?7&[-8X/CB]"]-)+\4,"HH ;S?'E 9;P8)NIY1[PI59NR4-2FQJN3#+ZIUO
MK8T]P8*79G=ACL)' S]CPW@JC6L]N773GPY+K97 -K*^U31?'_@YWY)"Q!]6
ME'UA1:U)TLEQ<6<7[3DW>$CV!G)K%4&ZWE[D6DK7MS)USPKNF=295HP-L=$0
M?S*%>,R*O2A(33Y1639-O3TVHZV':%.?+@4Q$*1^6\-CY.A]MS;10[V[;"[&
M/]6'FM W6H5+6LJODZ,G6]']6R2]CQD[C>YLV>Y$U1:+^OUNLI"3.TGQDL3K
M9_'H^[=$-BX]]0[9Z\M_#'L_<EKX-E31]=9-MECCE?&CS X#]KX<,/ >,/#O
ME06/X0Q?++6D?N[F::'TNBJ'51S(@E>6_TV[Y5^\_,?(@GFHW D/.[$>6QUU
M%J-2(BQTT\%>^:6!X>/1K$PI>=><SU;1UJ33K6KE2&P12OM6*7QE-,OWV3.Z
M9O3JD%!*EQX^E25%FIB3K=37MT*DVNPV(L]3O=":/%0B0LSH%^_:OM,89+Z_
MW-G_^ T?-Z9_$ J7![ZOR-5Y!_C0\@3@Z[>S"6F>N=%RC::49^/&,)M<^DY1
M[0.?=_H!^,ZJ_,XE^:;%5,IHU50NMPIG5*Y<>-;+H8L WS>5?'Y0NT> [R22
MKZ.8][*@%@KLK)'NIOO:[5C+^<XR^Q=)OJ\ W\&=LO?4/HUB&:61D2-B+C/B
M'DNMY?TXAGR'J%?6_<4I7L8NV=%NV\O+.>7U3OY67^394+8F]E&W?9] OMWV
M]-%RGBP98:T:V)<+&O8O;PUKM/V+(F"K;G=+8]AU?P>J$S<J">GX&AEIA)L+
MU0%(N#<:=?)2/8?5A*(4=-37QY<&D -$^KA>\5!W_;0WD/>,%C;'?IV%O8%D
M]DN17%6<*MOH75'HR$,]S"*!G:7'S0*^+_@N!'%A2';)ZQ,DLWY&<JNC),OH
M]BG"3I+#H12-9Z*]^'>7I1>]_J?O'5!XB(T*H=M$/A=K+,>)<:[(%6N7AH%/
M,[BV?:?H\5LFT4]QW/=#@6ZA-0DYK5X,FCJ0#& 6(F IK6PLM.N9\>"6XTQV
M=5\;)*)LY6:\\%UHZ  6Z [:JW/\5H[TL:7'[P+#X:8B$ [*+;%@PH9U=3"0
M!*S9-\6+JTY\C-12SGS*Z^/12FUF[OXE"#KZL3L4M4),^TGZK6/>;P#L/A%?
M5<:J#DUW3^QCLF;MJ:(F>*V569K+228U'=2-2XDI410?0:UO[6P&T#[@=);R
MN85V6^J'Q[$P^[A0A2%^REZ*T^E[:'^&]WDIT#[._>B6.H_]VX<[-L?/<*0H
M+XJX@B[%8/A:]^-+H7"Q3>S^#<CZB"6Z*^R.(';@8A\)\G(].JM'QJL*&QJ)
MS^4[PQ"5:!!M^88.]C%&77S4%N;/L5IF?!/-)"2EM\JFQ$M!PX>-L8O6?PGR
M7P<0[M_AQX8PC$=Z=3:C*LMI)51=/L_.[C>^@VX)\K_CZ+9QZ?D9Z;U]$^OL
M\T-4BJ5[K=6H7KU+1N]+==&WRMYW?1-]T2COV(3'FJ:2IQ@K*(PP4HH(1)S"
MO-.KW4PTYS=[C&Q-J]]U5V6SE0G?3@O3Y]MA8^$[B7O^Y,<C:.C)2MLDXID2
M6,[7B.'89,:/ &O6;2>;=_5Q>]RH<C.NR]?O4T7?":#S)S;^JX#U'N#03O8C
M518+DZFFSJU# FP0B<NGT4T<YUNM!GHH3[L95@_Y-QCRIJ5^8=K_BF7/FQJQ
MC4T-6F/GI27\Y:RZ/)@G8HO"H,J:-ROMKI6KQCK^[?G\IE4_/.M_Q:*#86<:
M6-M6%O=L?KPJE4O37"S#)GJQ^OT\?N,[*^1=*WY@RA>VW/S)17OH)MU:BN%<
M*A?K39Z'G:E^5WW^'DS^^:+]_+U?3R3:1VGVML8^C1[&C6ZKGLF$3%/P;T*-
MOT6[OQ;]D&A/E8JCI989/XVK"[&O11J9A2($HMT7]0RO'-EA]G5)E)"V:B 9
M5P<T[K*.Y][AP8 \TV7MML"7BXN0:([-14I=",5RJ)WS+6L?G)P=Q]V:W;<.
MXD<  'R/BUD?O.M/3W4S<G/RCQV.W_I]*W;P1O2L> ')<NF^SF8RZ1M##B]6
M==FW8N( :3R;A?MH\_%@@E]0&SD>M1$X[9J+?6+$_&W XU=RL36)*8M<:-F*
M-/NQ:+^X]*T=ZA< ^#GKAF[!F0(QP"1EF%%UT./D.ZS-#Q1EXSF&;"4G3^(F
M>R\_1>Y3.EL-+<*C6J5ZDU9\J\A>F>V>4NK-Z080>0$B<*8Z');:Q-I$4I"G
M;O^I%Y;JJ6PCW K%*R(N1YH1C'R;-G@T2 Y.^%\)DRSN&P4%2$?S?5P=DM&P
M*!EY)-##5VU$=/BDHF>C8GR\JL195(DWG[/^ZV'C+/3NU&P-LF]NWWKQ#[D_
M;UI\[J%T6TME:TFVD>@N;@19KTS[P>+[SO79NQ6:44URA38ESU]M-EE,2RKD
M[614;:IJ7O&_5B0R>1&Q!K="RK-NG:RMIU?>7[;RX=8_V*.ARNUC.[G*J*T)
MR_9"+?9AT.9]9X/"YN@^4MG8.42KCWL]QQ/9FY*W3>4+B[B'3XRQ3&S16U:$
M9B\W:STEI<0BIX?\>R!3L.1O7?**JFA[5CV=XCI<NE1B;Q:MYJ,4BJUZ7=_J
MI?>L^MYY7]C"\_Y00VTE44B%%6'<XB.*5!@\]>4'V7=@"=30UVP&G09C-<SV
MJK'1P[*%;I]JSW*G9#9'OL-8L.2G54/Q7#G5Y:,RQTI\N37J-7+J:/RM5OTS
MU=#YCUDK*((ZP4VT3)G&2-6DK46FZ=HI12RI I+O3$W214GPJ*65&4D]HFRW
MU\)Q*=;M=IX+D[!O-W/V3]:SE_/R;"_,UCAZD;/D1]V0!*IKM7642TIVBERC
MV\+EZE"8U;*Y:NABEW;O'/V^H*<M'3EP?F_JX4YC,W?+46X6:BW;N*<]RS7?
M2FS?G-][,='-#X%#7=R.2GC4Z.4F1D?0[R115VJ^C27X$QQ?%_V,]+CDVNMT
MJ=,0L(+(2)Z62%8/A^R6L_FFP'A^T;TK54;+'CM15V:C*@S$1_^=#PT^Y5Y"
M.#V0-BCQ<5?RRP+PVV<N<\E3&1AO157F(ZAJAU+9\5A/WN="R=#8;!DIXF'X
M,F!^!*HR :I.AJKT1U U,AO:N/H0;[0FCXE0SS []_GII:(J':#J"%2]AI,Z
MGF/%Q 6(-A)/(2\IA+C0!VFH8>S)<JYW\HNPQJF=5B;\4 HGY[=H=OY"]_=:
M1 >7],CI^GV572,X;C4BH$:P^_>IUKP=BZSRO+HLM&(W8KET+SSS:?\V7O?3
MFF\;PO$CNR]L7?II!VX</K[%4/O:^"&K/(T;G?2H\ZPNFBO>MQCXRD-6/C6T
M12<*V%AS]4OMFVC7)[@<!MFR(-[3U*@A=>3B**&/6YU2V,RT1H5LI>1;_WB#
M6,Y)]V^CUL>MC*_NK'0I\.1/ ,^D.94X 4<Q.VLM2_.[>;$>G?C66/D(//D
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MFW+ZX7&6FE9JNF_%R\8DW;3O5V?YK0%QR'HY;G\G)8H2C(;D&I+$@I)!4\E
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MHL=#Y8^SBT%0!"GRGELP7T5NYWPDU:Z-8[-!?F2&^6X_L1N+>>G=(_'H!Y7
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MYRUOZ$MFK'?TB%DSU[J_%U&OSYHW8VZUB#R4].$)Q.P1+6@^H>?'NY;W,YN
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M-:=M>DTF6(-L%RH R0V"J6E.=<S A)W/ ',!YMZ'.1WC,?R;;MM I)2(/$!
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M(A$I$;9%Z(:3MUXUGTTY-S@G%1)W1K-2!0B7$/I"_O-(=>I?"4O(6!D:(^)
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MDE(W,I]IY*"/ [<A8/(=3WUKPW_3'-L387=1FZ->@I8J;%3<N[N>4/JN2=B
M(-@4@$?(9!I6K/_@(PG'$[?W"L);"TQL.V25J4 3M50!-H0-*$P&YE'( +(M
M&X##L'WV W194FEF%_1>@U19&CMVB@_ P+/-Q_7YIBL//P\\6P8,%-<$+D_
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M26$<.1@?\R9@ ,^D+XDC3C#4(;W"VN'V%O:UU9F2@2"O-LG/Q.[7,D"7XEB
M0J<$0V@J7G) U8"8B/3N0=?1RV@!U!WGW"Z6T/N+FF=A9B/)[+E)HLJ  0R.
M82A:725QS!Q,8[,C1:=#"Q-<2\,)K7\)&PBMR@49UU:XB!:"=VLE>X/KVW^;
M\__YXQ;I/0WU;9D<D(P4R?-!LKNSNSL(>9MG$J6\(U+;#3*%6X]+)T]FV4<2
MBXP,>5)T)/U/O/X^RC[:2)Y"FN@59RON85@L[IBZ@ /!,X G1G<W]SQ@JY
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M:()(ZGQ5\S$C@ZVZ'%A8/%(UO%^S;%K))<T='[[E Z ^Q'?=;T@\@^0VGP5
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M? ?B7QSVM1;PP,_21F%9D'EUN;PZ6Z1<?JT]2R $XC6$F$2]=:UYB8S:M5M
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M\R-,WVPM%MU:BBE1'<<K;D!Y);(0%M4KJU+KS'?S@B50 Y'GKZ!"RF:,Y<T
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MI(5/P)G!8&PPH9 G4:]$1-A@797:;H26':PU OA4H"@>Y1K4^C*2&]"\/ME
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MD<W.')]:^"Y9&:AL(=>?TVK'Y4&V+A*N6< K]N7Z#8UI&G?79AA)9^=(_:-
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MW48+(W 28\[VC5;L((,KS!7G1ARUL *U47' GK3Q*,BPV3:?/.VO,@$Z?DR
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M!*^YTID5J*Z?NF])<VXPB,V-9YW3/:3B>K5<4);Q9BTD;T?R]^_[.PD9,H4
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M=0R N$:B3E\9Z@G8K":X9"CK]_8NAJ'&++KG"*F@$*P+<8N!"0K'-7NWR<[
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M"G,ZBD768:!-+AA >[N2IW>'B;N[3+X/M($A1;SQJ/9F8(PRU5X-O9"?,9;
MVKEV%ZTU*O0Z\W?,+)P'#8[NJ%51I+[\SK$XI:NVLJ'CQ/P/WR.-7[ZDA,$
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MPR66"4.,[%21-NSA<M\2O%A*O<(K5IKM;5B9#RO[867SRNYB51NG_'QRFPM
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M;#3+9+]P6NT\=$RG+O:;$+' E>8,U9,4JCCT]#$8B%P.:GY:A;4?.3Z="P8
M7?[R@.AO!BSD4B^B+IT:)Q9Z(?M-?L/TK3J?J;!)8\=8A-"9.X2;$IA>S=P,
ME*(Z^J2XJ_Q6]<&&EW.Y?0-.);L+L\N=6!39;'OAU2 ;0J!%>'6$X^QI77 [
M2(:,7-3P%(3UG)]2YZC?7EXRWI1B <<H230"T2D' K2/XR4"6(RG#K:N[ 0_
M)C ]=S/QF)F$E!UF@;?>]<X)::/?R@DK610=#?^J11>/.E1')DPFB[I+8")
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MY=1*7M F!#?4LPJ_J6;!S+YRFE<T5<MR32]G6JG0UOP!V/Q/F"MG>HV3/RN
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M.THOKK?5U#O82;D<"#*G?L,DJCP DRD*;LZTW$"W.@,8Q<.$*?WW%(0<>8.
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MR1RUB\41;@;F62*[&:VA<,]#4F9B @JIGHRC8;36P[!DQLOF>3MW< ^P*[%
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MHBU2?H.^JBFC^:/P@;(W\PX1>960&_7I%6V4=IK"U:(5-B-@S,3X^"_!N)J
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M$VY+;_'=ZW#A[?I_\A./)R01AXM#&I-\WR9-@01_Z,+#/7UR\H0+@Q=<N0:
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MLL+J- BM^FG<\UP&G;]:Z97SLIX1]LETWNY+YK3I[_MP=ZO#QV2B;THT@,(
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MW2(E$ZD$NT.W*S5[B3<23_BD":6O><QI@QNK7&]G*I1ZB)7Y1$MT./[SE80
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MD0' /*6T7#/J"G@E9Y55\J11%+V48)J/ X2.R4D'YAUF86YH>)"K**,W,11
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MA-;0Z!<5E2:R-UF32LK@ YZK C%IABQ>=\TL//!518AP_X*C&GR4_(E:/ZQ
MR/H'%=V'M$"E]SD?4%'I?4E3]*AOU?Q-B^1AQ]<'^[TT=7OZ6:O!7\5:#G$#
M<4W66+Q!W"W#[,:N:MQ<,7C@4Z\NVV;O>#95ELOWL*7:V7G:<Z<FIU]%O^&R
MAWP;*F)@@K132TH&YB/*Y>A[PGZ'0PG9B_#61<K':!9.E=.J7"MJV'BYJ)AA
M;=OP'2HALJ$#I%\3P\N.V]8ZWDH/?*3AC8+B+F10VUVR *//>#?:ZSW@&F4R
M=ZM:-XY+>?U>O@@B52P,YT]HB5:Y,P+.7&\JX$:DPDK1FL)ZVNT;!;*\UY7J
M+XY'81'C)W!8-S?'4Z9G1P>:44?X6AL; Q;$^9!%&D=W2*>1)^A4-9,6\F+&
MOKK2](5M*VP;<R<>*L37=MST80SA?BX+5MOMRWCU#E+;@;HE?5RR8LD)YGLE
M=152P8UM/24.]M2KOH9"(5&S!F9FI*!2;+<EQH-O67=".4OIRF&G7<90BW."
M$MW>2&_UG-@::3SO'D0[ _A#EEX<<H/C; YK18R,SXEF%UD?%;X P13]5S=M
M'T<,Y/B//AO7Z>9F 2;T4N>YO^5$RC? [8Q.F.55D*7/KILRZQ)9\"$]G^?^
M]#9:7>! ?-V^&RO<S^[%\+E?M'3U<!W>5ED,3[(=WI5L%2EMIERR]V]Y>)W.
M(M\Z#MJ$7W?\[!_10^F3D4M(* L4 YZ(M?,G9A((1%&4+ HGHBH&;.$2Y\7F
MAH^ 6$J@ AU1FO2,Y3'C,:7672,X#WSQ@XB5^AEQGV888J&/3<L_?PVN^F/[
MWKVJXV*7Q+CL<:"O+W=9N7T/E$M[Q5$]TQ+[&-H)S<;D-MJI$Y]U#Y$!7V)_
M<[6_ZEY(KLVUHC7ALO2(KL9C"@Y\'CWXZI]5?%3Z//_V275'H<S[UZ>]G1KM
M3\&D2 R;7;$T@9[2=@G.Z2 ]XD1<[$=Y6T\,3_L!*>OB+%6%1V@;5TBTPK9=
MMOL+=@3V9/RC^'CO+W?YD4YW76X4;[DVW^>D&P,PDZ,LA6JNJJ^:]17W_B#_
M6$!+0,O-*.LPJX77?$,XG)'E'!4G.P XNI6V.Z3KV7-)[7DY*K6'.*SA=R/(
MPG(YCL4?$?80AAGR040GTRR(JQMC,8F,5D^>$V7>D/904Y'(A1D3PVW3<JDT
M?5JE(J6S/H8\WO%67QI"T_2E#>\P78:YU%A#<+C8K9EDEHNS/,<3?%5X.WI+
MX2\*BU_)M>WV2X5.\FV%:#JA(/P8&Y>?/Y@:EU/C\H-J7,8U$()0Z1Q%HM6P
MG>%U056NHI^BXN2]&-#JO.>IO2%C%/4B&"@4%UV0'C7['$D,<6S193DW'7*0
MAIM38G8BRU.*=4DT?>])T6,9==AW=-X=7]E7KW^Y""2%G-!">1;XY\]G/UZ2
MOLBG["8158MP&M)68U,=R#:N"RZ8S(WA+*Z^#0:U,DTUPMR,=])'P18+PDCM
MPGO?:0A57,B0U.P>J=,LB[#B]P>S>DL>GBK "1,^'LGOJ>"+_76V_CTXBA <
M&V8K!#AD8'<QO3+RAD>*>-\T)+*F:66,RT Z%T=:=+Z5]@"2. Z+N,PCYZZ=
MV,%-,(7.$;M(CW<$.)*)X2Q.1VH9YZ4%E'(X3PFCH@N=SKB\-7+O%),YP:3S
MLJQ3H1RK-CUZ\.@1 >ZI"[05^:CPG(!=^><<4YCJ/7;ZN.$NSU0BGC6=-'JI
M.O>%<T7]2[F+UH7^1;6\D\^^_%0+T0<N!Q&R,_XQVK*4%VORS]T7_S,K_<CB
MYA?-;-KUCXOEI2C7XJ5 1ETJE8+?%.ST511M>A[5:%&9O*J"S7_=D%(5"H>6
M+T3&.'DU8;M=-AWX2$/@T-FJM+@&Y;MQ\F!9_F-/"2WDC:2G*+S<B@6-F_B&
MJ_)T8_JDSBII$'Q=<&5;+DT<B="YX3)$^;*@X<OX'A>5AI8WK#6W"G%%6DRM
M]X'(VGU,N:@V34U=;93C:+JO"+NXNJC6"-V[8D5-]G 2+9N6Z:]G/Y\]FT>Q
M;]Z_NMIZ*@JH\;KH('NFCEZOL]^1C)?^\://9I?T6YX.8Z@]%68$/"@VD&X#
M2R 8"SFR9]F!4\DZV7?,ZKV,UDOKFU@W[46IN/F[HH9<N#I5CW_1[17W>%MN
M4/!KMB4UI;5J643[" Z,\SW;D\^47AD'R_-X,2Z_W^TA .SL03HS).5<;.Q5
M4D.QQIVB[(=5[NCW(Z]"5O.H;\-9CQQS59Q3/Q\E@ V-,B#MXK=&=ED@J8CO
M1[43DQ<"R"ZMHH0:X30FQ'-KO81T6S:MJL0':XXP>41R-VP,#^CF'2(S(.%4
M),ET9IB7LX(08?3-M'UX4^LTDO//$L,D]]]=0M)4;ER^FHZEX#L)55TN=1;L
M=/;K%@9IDV%R/ #N9&6!L(<V6TIECQR?,3XM[8L*_]['-U]\A\AR<^^Q=XK$
MX"XBH^T'X0%H84=?B2R(@M*JG?2V> -*'T4N0JN&$US>N%43"@=,O-GQ'(L6
M>*>CR,(*8E+=.2@".[VLN&=&(\2"1;B'/?4X21SLVNA-;SH"RG!T-(>R522,
ME4I@! N<_<[WO2_<SNL$F3]7UEJ@=Q7;;=QI"\YXVW'30B'FNAZEM-6+]=XZ
M>SH4N\HY(WX1ZLR2(\-UF;6<(]_+E:'KTAK"NBU:N4^86>UO4,YYN@L7$-..
M:8O]THG;5S7SQ# ^M"\+;U4F*CU=M()$)=A3$>4JL//688_PC^;BN-B]E-2R
M+A8'O@SG1:RFF;%[C5AQ @+L-?O@,Y1$J9G<J[8$F983P!]JV''L+=!$":I%
M.+98'SIFDD,BJE4^^@$R7*G+AG<2]AC\D+E\FKXR34/NPDA"2;=BTJ3>8JP_
M+6EB[_U*F[(/HKUH&E<)WA*TDEJ!.N7^UR<_VI1[,O8G+SJ^WWFV.TDJBBR]
MV**\FL9\?(\792W(J>S^\3"((BV%*.<X@\[DX1U,1J_GK! ,J83H/B][GY2F
MNGV4VL?/5WK7OB;K[]!=&B5Y2F5#;J&,"5DWH5+#T&@L6_0[)8&@03LB2"@Y
M.R&, H%2%HGL)'?1HF#Q>6GJMO0H\5+7Y7I](IV =3R5,-#-A>=96?&)PF4I
MA9FJ2*5EW&!)!+%=RQ*=Z?.+X+"T"VSN#KC".JF0) 42LHY!>8,K)ODBB6@#
M)K61FZLA>(U)OQ/!02S=X^7V7Y^.X(EL5Q=-!\6_]XZ-RC5FI*VM01ZM]RJ\
M.JJ=)_/[ R!&OT0B#==>_D@ GO*\W1.6P0F1A].II,+E[)?#MIQ]_<G75'97
MO$E(;H(#);5',EA^A:HK;V4*! Z4!H4T.3PAO1$*5[O2PC7[$Q:N%1HC>SCI
M0_&7,'T!R0(T'?;RR26Y'&J;"'Y:R[8R A;,G>8,KX0"C<NW=J*%6'#;5"RL
MZO%A.*57 B6R0J!="L#*KK.Q=+N>(;<7E\&9E)"GQ6QM//;5?P>?$+:)8*[B
ME>V.N&2![P&67[\B+,VH^<?MI3@079]RM\.MG'7(0J@/AK>[:A9[>6[)6H%E
MRQI6"BOD=T H AR ]E71H>.=\*P/IT&2XBJ,NL'!$)Z:/11D@T%' 8@4^GFS
M:XYI#++ VS<W#<[9&-U)]WVX67>2K M:?7JL<*?JDW8VZWAS[?9HO?9&GS2C
M4K.^CPA5F!N2;MMLJ;XL$$;$5&0@\LXPDHU>;<5:[(RH *P*V4#9S=TK"J<3
M'[#\Z4I1%1Y8I*=P@G#R05[*&Q*RH]W)1]EV?#BU':>VXP?:=KQ-8K)L>.;&
M[TP?(HNO@^OK.N:JB&5$R@NUL%+LG-,N>SG=N6]4FJBYC8+3];YXD!2U7<X*
MGZF>\?,'L\WBPL=^P:,E@3%<?1HJSUU\JR!0'\&58&%B2"L/((57Q'-IYV@&
M],X'=&AX"4(V7'6Z -[ST3-%\&::X0)'3@+LANB.@!")DK4)*\B1L=,VB>-R
MKZ6T\-ONS,3<]=3$/=WPUJ.[QHE]BT/)WF;YDBTBTOIPV9[9/!1CC2!&RD12
MY=N!7(8670.XX%?V$0>DV8>Q>F@,)-%L1^0/RG8@G[;;S)YS5M=RK!WZW13-
M[[$::1$FN:K&-3&H-FNG/DLMP77N?-2NHID*X$?Q#<T'\X;&;$3&="+&=%#C
M$#CMHFV"'7=4?I!2C 47^TY[,C\^>]*/G>PV9+X)&Q^1G-@B6VPO)T5(-L1]
MH<=$N1:OH83;81^NNUAD3;E3\E9*L9H"$_*)P%E(JN84!G&E%;7*.AS!"^7,
MNK+FZ*<1*4PQLW]!,5=-00#Y?3B_51 ZN^<7ZVPW^_=PB?OS&87E;DE599QU
M,36C) \Z9CEC%I/Q,PZ%=R(52</A<\U[A1X)XXG#/S.W?$HGHO=12.?3')Y@
MV3N,9#O.4*Z;ZCA+;SK-R#TU=S$\=Q>AP P7Y@#6Q@JY"GOI1R*2:_OWJ<7/
M/C(OT^BW+/8L^X@>S2=_O0M'<;E3Q^>B[BXVE%P?AE\4I<CZ_A0^:.XMA%0T
MRRT>.O+J> ! -&^%B=S0M[=2(%WH@J 2M8 E7;\%?(8)8="<QS_/BU;R%_P@
MTHBC*L<]0U7:&^\0S'76<?S[CUYYWRDG@[Y1[C;W56/'BD72@5C:LQFL'OCO
MFZ>3Z09&N)/]S(I0/3#_8)SA&:%]R,UOW#\V^VS8HG=<0'K;**P^O#JBA\G0
M)0Y)E54RVR5? ,S%27?=O3[;7Q"7I8T6QCVK&I;2PHXLV6[\H.U/<!E]P4TL
MGCK<X(EJ^_-@D;'6<51F)L/"'5U6*V"J4=/AL14ZX\("ZK?F7@B?9#0D(H')
M@!,A?5LR7MD[MVZ%@1O4?RW6D6+O+>)6/75O^J)N<5G]WFQ#FEF'ZX/;HMHV
M5.2]N4;FHI,>E!V!6C&$CB-2T1[BTB<_#![PN*08E?2V67]WR55B3&R[[<A>
MHN".N\GA=&OCETAR)<]1]"."7K2A5]USF;;W/._Z);]7SIKH"?Q[9\;^'EG"
M3651'*CVDFC>%IS+/,JF#;DR\:AJ/S&]BVD='$E=&LL/97V=EDICFPSES;Z+
MI;>G_"(AO^LJ]&D4BN%[G-I.8K@.SSBO):8QK%MR?XM+=Y-]'%JX[1\6NX9B
M^(=^7#LJ?6<7$;=V4Z$@Y VT'H6,PZ3<&>/IL3FGGC43LH%L^&@;ZFWXK-A[
MR_E3,HR^.U4OERGC7(-S,\16^0GAF!KE@VDD+PIVT)0(X'4T1_K-_KA:(WV_
MM.JN^.D;NH"P(1> W]&&QQRG\ ]N]>@F0ZV3$<7C2'1)1(@%%B];1S@Y 7>#
MG',]XH_/;TX0^-> P%=_47Y/EF,!IDH466Z>/(:?M^<=STK>7523/\P]&3?Q
M1&V717_XA%[E^QMF]">DC5F_E6YT!GL#Q UCFK32*DW@3E")Z"*C59:<!*6"
M96=4[.>"871T8_G)ZW<!7^<@*'H]OJ2%:K%<BO!NI!ULX"R/%QZ>$EI9Y@(O
MAQ!FJ#T2]T+Q*8)@IJJ?CC7)*X@+QZ\"C7BP/U-ZOV\E4P\QSCG@89$IW<7;
MTL)$<>3CG&1\-+44IY;B!]I2Y&3"M].&244GX',*UURQ,3H7#S313"+FK-Y+
M]Z")UW;RT@RY(FELM^MD<Z[49VW)6/.;=8+H;=Q4-!H!26$WW#2UD98AB;Y*
M69@TACY8ON P;3J/WW>XO[C' _XKI:#CA%## P\G<<'M:._0@F,/DV-&HYAM
MZS@)BM7AN<Z>9BK6N2R_Z/5(CC6Q<L>AMB1>I8=%%*$[E$L)N(K737?@$URM
M<?$QG7#OZ-_U4HH;HK LD/#FL_C_M5-X[BSU[<>(E^^T^G6K.)%3=V;,T<?P
M2*F<96B3.<'!CU>!8C^%3-2OL3Z3 S4=0XSZ;<#\J/V]D "D )"F&MQ(;_U6
M;LE@H"P?Q\2>PV9IFEQE*@Q%Q-)AF-4J/STXMDZ4#F'4#JR1AKT&-/= 1%S6
M _>54(*_AN?*Z <A SR=_1PN\V-P$0!8/-^5F]G#,TM!B0QF]@US^<+('GWU
M-OAAY%*OF>!2</AZ"2[]Y?_A!-?GMZN4>\K-:@'[;&,#3=GY$8;7L?EQY1TK
M,CD2K%Y%4PBB^?R^]D@+2AQI\H@G8ASIL'(F2/=$N:*Y=>A:34F!5#>C/XSY
MHN0]]FTM%\]2+\3VH,9KGOK[[@I39V#%"79)ZD)5?*M@?V9$5E?VAU!B?Y0F
M@KH,Z"N!YB*>LD#131(D1\"'DS@/\V.;<W&9M(VF6/:K3Y/FO\>2WL$,Z$W+
M<$=6\ENFM/+SLY^>?9_45>C8I4C6X_B?S+[+H'/H;&01'-:2^LRC\:68[%'Y
MJ6U=LJB9'!P1K6]W])S\"QU(CWR',:=U(RVIB,V7GH?')RTX1V..<;A &0V(
M?J+7!4A1.]PU"7_RSOCZ'SXB<;J%TML9!=@K[)3Q)F98"M0%K(O9['>:)\16
MX+MZM!"3%>OP",M#Y&"0\ 9/O;B8 ;IJ<6F:96A<YF R<3"L$D@I@S(( Q<\
M0[D-S\M4 +9: #H-0(2],3,;O8SOG+;^.UN9#'RV<%K9C$V),W??_O!K;/#7
MC?5?E7LX.ILV@8[)Z2J4".3.E&.%49DD^4=OX'3V5(C8PUY-][8X@AQ,CPF,
M>;.5(WVFZ\MRQQH,MVD<BU7<$HF7N%DC<"^ 55TWK8BL1?=0K5QJJ<@CC=8%
M+YH)&300A%>(!"F1V?<]V(MN%ZJ_T"M,%I!9J&5X1877_0T&\W%H5_TIN?($
MZ:KX3A#[X@*)4]91]4'^-W+JV3:773Z&1/BM-^W<XWE& GC3XW$"RT(M<XZ=
MV]U<L[C(XQ)]J+@*] B8K*-4'4)?H.#I)#[Y3R$MIB4,D<%.UTCPI9VO81#5
MI,4)='U9KS$4JJ]YT ?>N5&Q_59=Q/B8F;GC8M^52M=;4<Z@ZMIEKQBBBRE1
ME[3.?>_EZ.MP6I!^[7UB'3)8K:D,K/RW:,9:M-&8Y&)?,8-D;T!-D\#4XB4P
M<BXSX;^X#:8]V@O[+]D^]%69: >GI=A4(G=7G#<Z^^;-0E8'R35]<7'5M ;)
M$'9K' ()J[6]!$2VFL+JKLHE:I($W%6*4P?7WBP-O]H98X=&E&G'+\XSFSKH
M6B2&% _-#IRQ!<E%&-+&N27'CIVP@%IC42U]Z9+;VG])]@CI?-IY.OO)3\W?
M+DUVQZ<KK^F&:-*B*G]E'V/1#0K1274NAW>N!KE4-YJ#*Y_I[66!8KE%@-Y#
M>.SI1]G[^W3J_4V]OSOM_;T1:[9($M5$=D0E<FL;14E>B:LDR'F7Z7'$N"W3
MJO(*D@(I.;8GQ+8A-?Z/1_P?7P37IP)Y7SQXI/KF*9V]XB_Y$,A08N-[K<>3
MH6)5[YHAO^8&AL2&*'-&^/<[C/4*%6% *)1;,$6<K 5+RLP; /R%"*2U>0_N
MQ#DJ=3\<A(,0!\<2:%::XO(2<+%.["8WUS150X1C=U4@\V5GG%V0-Z=UT(7"
MN7\).B_!I^8Z :821JTGWQ547+T[X=EJ\MS@G>FLIVP>/%N#<D=<<D=< NYA
M;:0FHGIQC$JI P93!^^RQM6?:)![7;W1YD5?[)I5ZT;M&@W '"UJ?X B0N#=
MXH++C>)K(X:750P/T^RTR?&^5S('UT;JQ7%71K]2';:R0&L8ZQNMUNY]M_*D
M5>]T =<(9>LF'M03G1^^J'>:%,?7&6XOY'\8E\%8GDS+A" BQ*UTK'[R'$U5
M%!"?ENL*#=#OR]UUT[ZPTMWSI]\;798JE<(S\F"0RO2$QR9R1EK_,U:WGSVM
M2!H@>-Q[3\Z>WL?=,/+DHHG);P@,Z2G"'80/\1U7N$W<!*Z]IA!_%NY#^F0M
MU<ZZ8AW,8K^K@M5R"36LP\FRN1;,0K&X/)W] *4(S'N*]6!*WBT1>QNI'3!I
MCM4._*2CU^TQ2L4Z?,VR<Y3*R?P+.TB&FJ I _V<TA+8#24[[6G4<^K/R>34
M/GJ#A8.].[>#TF4G;?^T2@(A5ZZ:,R.;]!@B^7IZAL;S8'Y#"(%)X/%@(1-=
M$.;"C8)XY(:UR!0Z=5<I_2_O,W*,Q64[0^Q4N3$H\E5%>M4ZUB7JQOT)."L5
M_1D+RX>[9GU(T< M56R[\L_Z'U^]A5S'1"[=CW2)<!,G(2AK]KL_0\?7)UV:
M.')ZM&O#_RV-:X0_1N_R#Y_X7[S1'?=?&9D-O3?/;%(WX#5Q-R 9J-SHO_[+
MGS[_XD]?_=LGNZ6_K_1#P^SN+213QU)#1E"HIEZ?^;988_H<7LC1%,9CXONG
M=DRX&A9FIOUU'3C1709U+T)/43/51Z;[W26.3NJ+:!USGQ2=^I6FT91*3^Y?
M3W\^G3$%LW[CW_=MU06W@EN)\E7T>CXAH_H$5CCMB'^R'1$+KG,NIT,#G.%8
M<X?<<:6_VUMC*J>92R+<('1]T,QT48#]1+;8Z/16GX#!8!*@(R!@;CQ9Y59[
M@!+=7T-8;[8>ZTJM'JX2\<'3MIJV%6\KUTR45D:^_SJR<<2Z.Z*1716F)V(]
M?:'T< ?-D8-%J)][?:5A.#M9[V2];+T.D0L77K: 94EX@W:2$TS.)%"3)YQL
MR=E27<!").$V]/&6B@71#PWB"DWZ**.N=M:*=8J-^3!Z,K[)^-CXRD1K!XB"
M+<EN%VU+$-=-1.[O+JMV>4(USF"@Q;7UQ3O^DXK@F=PZJ/=T(@=[GKS<9&BC
MAG;<PA(K\M#LX &[RU)$CI/&%B&/*% +N8H(#A2+%\6%*@X4ZW*RQLD:I<RE
M7#]*6"1<0*81DWHX4]56@X/^7:ZGKIFUZRZ@23&9WF1Z;'IQ#(]/2U9:!,%@
M086@>8CN2!ZP*Q>DJ4. 2^GZ<I7)XKGR)0:BKI"_@OS#US9-?[N6RNWZ,-G@
M9(-L@\ZH)%T%*LZX9\EPP)"UYZIDR&]W!V T5LVZ:B9#F@R)#<D-"*R+?;VX
ME.Y.<O8Y]#D=C:]45_O84+.?3:C9"37[FJC9R7?^4_G.PL!$2VV/X_US'R1X
MQE6U+M_$=T[V]$]E3^[8=6B+\X/Q ##^337.Z>/[6IE5?.UE&UY6VWU%/_^
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MUK,]D6"$J_]:>SVC9[^:G!'#U/TVUC (.G<M9@%^ WP5&V01K@<BV5SOHK.
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M%]56L/$2>ZNMY#6#F5CK&F2(U\(Z;V.:GMC)BIS*,$\SFDKPTA,>J>K5>L_
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M4+#C>*F85>&#BX=02QL8&LYB !=%"+!PL77U(CS<)1&U<K),=<C3V6_*RI#
M+8@VYJ OY95>B%M0).YT?G(B7JXJCQN/ S1<PO+]QY(GSS"CD<R3V2/Z5XD[
MKCK&%L;E"#^F/GQ-H067Q(;7<Y>1&1E9<MN##D@&3!2%(N$I"'UCT!YZO'?5
MY)U3D@!D9O;V=/*VVQD=!XB(Q)S$!XST^:LN3H0A86WIC>VB\]*1/45M1$C
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MI\&I=+O[V.SF^\ES.M@?F4*ZVUC1AZQXXLJVU%@4/A@Q[XUD)E/&%%[R!/J
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M'9C]4BE+N$0^^7(- ;XS'% R4[L:O1WR&9@RL)G;F^^%.SQ\'@EN9*$0W]0
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M06.MM>1S*7G"9&>3G:F=+02Q/N5<DVVDMK%B-!VE7M7.4JJ08ETTK;3ZV6[
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M;:XD)&LY$D@A?WOF185HL@;D,T&W!?^XHMR-7(9 /(R0X\;]?2^>\[Y+148
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MLC51-C&4=_MQ$J* '$YRWZIW"8&OW:X2Q$[2XVZ3/GE1OZ"T5+</([J1R K
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M5QBBF&WD/I'O)MYAI]Q%:^B^ 1UP'CQFMW+99<,^H#*KI9^DQD?(KYJY;ZC
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M\3;&QY]D5?-WIZKFJ:KYD58U[],H!H1;?\UQTY:V*N_@[!0XYRU*$0)E8#8
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MQ8,F*N]C#9ZK$\\NNVT-C4Y3$*!EAY"F2WW^NQUX =@RB!Q.N!:[+ &J;'L
M\9*C6%6,2\;6E/38R/M'13KM$OP']841>='%FN"%L3GP']%YUV#I]1X%S=?+
MZVJUW\2$T9]>QS["+&\:,WC5XA\7GX=OCO-XXA_15_[6-F=ZMPO)5+WPX=C+
M)%.%K^?I*N_U6X<JWY_+/F+VYH9T%&OH ST5$XUG<'ZN\U#-Y=4GFW>4-<1
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M#:<95S"*'PT!EHUURB8\XT.HA)@C:U*5QB([Y",A6&0/,DK*J >I#314V?I
MKID<X_XE$E8["+V%DU; ><+2(H1"G6+V''E%(8QN7.'8@ ZQU&\=)6^M@F6]
M_N<^+#GJS=@$UYZ(4H-?1^$#3IO#[KH5VCQF2;VM2@%-Q_%=UZQE@OXNS[+?
MWE8F*.C],:4FBA\I:XZC8(R&1^7W>!Z;LVVY F ZA Z,9[V<7$7<3A1> *]2
M;<)K=VU#!*95;/NE W&/YW9T2>]A+G#DW.PWU%LLEF)5;GF<PDNNI>=[N83]
MD 1:04U<(5QG]M?LI.0HA-XW_*G?%DSAZ%Z30:H;*-OL&\-7QT&?'^%%,L2D
MN5BA/W#$>3;B!C2V%?DF=8V%%=8-FEC>,$\H^6"W9.XC-94=ANW2G8"7R4GM
M"M(2DQP\55?4]>V]:+0V.2J%T@1SVUK(+YN%],_UBT^2UN1W)US9"5?VH+0F
M\X=]E.1FT6WEM079<=XX6+.",;=&I-Z!-$:EG(T;]I:G6?;4FRW&;J4/M%R0
M/.9?4^:N2%25J)+!J6;[:7ZW^YR[XHL%F)I%\COE=V2@5J^MW YFDW"S%I,>
M>5132,7A/?-+QG"'H SE91'J8ZLL/E9.));[W5'"AQWK,3M8\$K;3H7/$G:'
M"3^,&P^I"9V;_AA"Q%$#/>@#I<W^6K^I;FN1VT3:LS-*T&1.8D[EXM7;0MC*
M9 %5B^=_OOCKB^?_T^_3%\ C_?Z<C!$QSJF!P@;5,D*>MF]W9 E>A*V_W_UA
MH7U.$UI)TJ-M$5F^[GE:N(]=M0UZ\7SB1HU=G2U*,6781KOK1/*>NT)SWZY
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M?.TL0ORM!6V[+'-5E.O*>["438EM'UU#PX/'.$9#AV=2J4U]Q>VS?5T)MEI
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M5TQ*T^+#K;#A'18"GK9C[EF#=6"X-_VG--&'Z,\,#$%& _\4]L:PN#"2?S
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M<1RV&Z\!*IAYEX_(&OTA<=S/1_IYZQC6:IF:,0]RU679U%R;AHHYGEGP'0-
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MZ4LXT_ITM4(]V0N T\JHVQ5)=Z)F'*4.:*N9%0<PX!NQ7P,O18ALZ V/W%\
M3X&^6U,@W3D ,Q<$0L03=[NMKS ]PIB-#QFY7H#L^:/)-?!X<'T8'NFTU-1M
M8LI:=@1^B?&4&#A,JU\:($BDTTE7_N#8UILA67_"Y/BGL [P]I];5=Z7K,K[
MJ6!O2617J]E:S-X*!W4GHXYVE(G06P,M"F-NKB+\"E$9Z30W!EQXM1P'8Q5
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MK7#8,']J"%0K%E,H,O_T5Q\Y4,X^T4B9UEF6U<H&8RQCI(]YL7, O%(80/.
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MX *>H8&LQ2?5^7ZS>/Y?\>V)R@;]HTC=&TJM+6C(:)YMW\H+;% NOJGKM]D
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M3FLAG]3N2RA8AC6<5@O $;E?+$" \8*4\4VDG8PJ2N H=7IF$L=S<C!2.<P
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M1YSQ".YO,L> JLOD(RZ"C/LM[I,8G 9"'5-9G;]W+1DAK9;U-0*9 $E<-"2
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ME@JZS7'15.NK%>I0#XPTT86[.W+N6RP<Q[^Z=+@^5XW/0J@I@.JK4DP3.7B
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M^\IG'QB =HW*H@U3+2BU7O)/%3U-\IOV&0(]RKJ)\K*QR13-/&P(B37FSTS
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MGA7C7'J8S2L)&JR386-_)YP!3B?"Z;V#$7:^08+'3?R6]H.UCLVX[2+?P:W
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M&:<FKD!+P^/UG%KM7+>I"UAX[!H9J9,-]&.XXA+!Z>H5%10(+K<'2\I738U
M97>#V\"%#_0^F8$=>1,C9UFNC&0K0E6CN!6OG$/\])ERRCZ>>SQSC^>SX92]
M]3%,XZ;F$3_2R!::H/EO'8=)'RYYE479^C#@\)>R@CKMO>6V7KU%XS/#*"GD
M<&1TQ<RHX"LFMV2*ZGK8RX$EIU7(-\>.*/;L:8"4Q96S@#8 D@=&.$N^W]3
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M4ZT4'B;% ;14<H^$K#\J8YRD5$L%V?\*^&=>S)([GL1]'>ELSM-S>RJ/G6-
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M+$^"[#5VIU-2M8*8)]]";E,+XI\'G\A?5::&:BP61KDX(874YK3".W5TR+S
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M(84^,4#'/A$C#?%G<)G&@Z%IS!6ED1W L1U$LIU<(&"G4RNBPV^]"+-*V$E
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M9'](J/[#9M"6F74?TF2JL@Q,("]RIDJUX:P'[=I<L^A]$)Z;?M\=]%K/_F-
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M_:BL#Y>_K;^U"<76R7)N0;U_FU3>:/,I).UI)+/X)AOC+K(%G;.+ESB=*A_
M6F1,(82BY)XNV#> %QB!F$F9/K1ID*>A=J=WG-^!/R0@(X#*5!0JC.T@V83F
M?>= D><>F#- (D 4^*BB%R/QX9O24O0EI>BS<)-1 ]%/91A.#3K.ZP:I9U[I
MI5=.&F9?,^V^G!9H/\&++E1<*)M!E6#YJ%WHSK&?NTY6"NN_A:LDR3^4%R$!
M>/0"P&9@" !&LM?\I(C0M4^O@QW/:0<Y[6F>)OA"># .P@ @ RI.^(N(:UL7
MS@H?:#7K:+$/)/8!&)QSZCJGN9HYO>..J[?Z$4[MO 8YGJ1&30"M6UV2-"<7
M(I#Q<1P7L#!H!.B1A1._QEWWNOO_=^_RFI'S30A<%ZCXBO#LQ)LC=%'U 4#Y
MDD)^[Q1S3!C9$,2\5(3/R^4&AD7'(Q>@#S].TJ^D,\FA\+OAT#T\&-.SY!,X
M!^@HOC"\^T!-0S\DXGLZ&KNC[F$'3ICS>PJVYJWP4*FUD?![VAN-L$,F+0]:
MP\@=#'L5F9$M%3;X"$L/P-ZYPH55=$4T#MRAH#A7E&29HC-Z<\#A;R%2-3"3
MI[V#([<[&LA[X?P'HX,??^]E&$4@?E@ ,NL"N9"!V14"E#P@)DU(AKKAAYY_
M3JP(XX0 =LX:Z9"B#00 U(&J0645/A9*NC.65@3M:91<9FRAEJP)%)@$@_E(
MG#&<B[6 4L+[H):#I,OW Q!]"A3M&9"9UKKGWA7+L@39$IPM5?*1DTPB"4=J
M#H5\HB[?6$E*U5D!C L/(BP%1>W40W\.L.>S,\"G%7J8*PY@U%80AU)$WY15
M-+W]U<]'X2Q$.1P9TDTUN3J$*7&.^A>R?U3YV!N%C@"%3BCA_'(QQ*8GN0=H
MC0X."2F)NH R(*&-TB.6A*#\%O8<\ NM+2 W5M_.O2*#3;IH*H'^R*I%3KP0
M+AT$%MHV/ACS\.K\RH6]7B@11TQEP%) :\(3&SO*0SS)"%):2476F@&?GF2Y
MQVB!Z:"YO+5V4!\84@AXRBZXLX0-*@!*&HLMQ^*.* R#OEZ&U3>H9>;G6>DM
M";.L((=>0-%B-OI*%0NVDBO&-,#,J CX0#?B_SN707789E"U&52[DD'UB?4Y
M8/[:[;[":Q.@US29$[L!87:6>K.,C6CTGK+H98G@Y<C%9B(+M."+5(5CILIP
MX=PIYO!>48U)B(!D8UY!-@ Q9%(P I .R&0J'%D'])MV3;:#]A@I#C@:?05,
M^+CCO%WDK/@%2>]P!MLG0V)QZ:BB*E+>BR(_0OD"77DHRAGK79:$,QS11=&,
M1R59"*PQ/D/A7J1901"(%4IID-XE?TVBB)P<<#HUI\VF7I@I6V[)&UT,_-"#
M+'9$X)P57@I" A4:9/8(>I '*6I0:-)*E'\1H'&>)M'S#=FV-MV"S047=?4\
MC,D]/HE @:TL9HD$<<8QQ>J8QK6+\</]H\[1V'Z> :TUEOP<./H9NP PRV09
M >&U [)D"G0$4I)?M#!<A&&8!OOH-;N2M#A-)HBC3!U4UZO.,(EMSLP$E163
MQ-9"=0&JY#4M628PHY^3M.9)1Z\% %I] Z.$_/LU/?M1@Q4@!0(L!#.,(LF3
M1(LQ\OV5-A@B;HSV#AI^P04IQ4VL0!N*\W"N\.TM<&\ W#*TJ\'\J,$F"@=H
M)^FY0J<FIN["/WPP+W(R5!._R"BL@&J##KFA9X$9P&,&'L9Q0.6=2+BG5*I2
M17;PAESWGQ.RH<6QAZX?,=$I/@K&A'\N_HM2%[>=;N<AJ!_D*3"^<_0=:6NC
MX_PCN81'4WJ!Z*$51X<6'"N= SHDZW%$ULLDH<>$J=A5!BIF5AH8*,%+/3XN
M57G*QL +L 04*\R7YRHFAQN[W/A[5?>]P.VAUPL>@7?-=54&1A)0JP7X1%$M
M&YC6-<X2B985L?&^T(.QH^"XR0S4C""YC$%*D@H23D4+83,%GOZJ+$V%C@G[
M*Y4\.%^6H8-2>=BHI..<3A%""+LBUINEGZL2)@U7T@ 3C)R79TY2RU5/M0=>
MEL@;$#YTYS/OBA$+7UKZ'*EZ &C'=3(?-5CT4^""&-70>(#T4<&[V$Z^L5*H
M;6-E,;2  4ES/E>N :%QX:58R !;]--DWP _3\%&S"1 I,,P):KP[2'J)QBG
M!C%;1G.J!IJ8EPU^QDQN0Q  06V<6'AGEE]KM<NJZB6VO7"+%\J.R+ !&5B'
MT]:B=>%T@QS(F2C.VXLBI@VR%&&A"*XZ9J^Q*,>6(>V21$5'(+E,)= =HN&/
M8* ,J"(E[,98 3!#7UGU'"[_FS@+X)H$Z/0-+W,/:#U(NP.(*57"=_RS14QQ
M=7,?]EMFF6)?=:84Q3'JUH!U^*R2XO*1 G ?RWJ8U\8W^4$X(VWA'=X:VA+'
MY6U)!&AUX(U>U.N_N-?[I^NAXPCI:H4 >!/>;TQ(:X7W&F^HPC4T$>L:"VUR
M7>*&$.S+H*WCA96@8.<!! 5%Z_@DOGS WS) N!D5X7?1#,H$"-+S5%"IC@&@
M(1K9X3Y$MTD11H&)93->9%IF:6/$9:\>QI+)>@2D,]$NB6RQ[Y]*:JS,R'I*
MI)7D^'WYBX3P$M)'5YJ?5T)OK-:L#)#I6A4,CI$8!,80:B4"_S%G)EC3*0C"
M$P64)TJ'G7)#KP#@^4"45A1$NWX6W#P55R:]MK$2CY*1+NA<F%DTT_%;SH"8
MS9*80[1(Z&=@I"L,@>J'E_P2M)CW<SC%6]9Q/N$6RPRH/=0I9A0)=<F)RG)
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M=LUAIG@(E^2E*..B,EV,^+UV[^M.D4T-M&[6WOD8]DA99:@4<5'PK0]F4$Y
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M@MM@TTV$U8,4(W>'1O<72UQ66%!C/:[V+S38@=]G^?>ZW9N6.Y+PN+VIWST
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MZ)!6!217ZUFI';K";R'=46H<,2,[-KP7.\ASOU=8V&89[W"WPOA,Y?-JH]&
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MR!O_<0 +XOOYWWUN;;KB,K7FKC+3_@E9"+9R[SCOJS_ GEK3"'908#\0"PV
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M:&YVN1:L8A$,SY@"Q1X(&81"DI9!N'F"G$WJ;V( O;4P0Q0/*10L%4G+[&R
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M05J*AA<$\N\(CV0U$YD _26RE"XG\BP\+T-X'AP,<#!B-EL I>!@Q&5^X&"
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M/(B#FP/)@\C[+H+@-QV AM'@ED3/+8'D07P\&$@>) @$0_(@47@9 L[)0=7
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MV2:_P)8-^8"XN$)PD% ,'!PX2"@6O@L1EBPP*-(."1PD!+Y&A'T-R C$QXF
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M1YR0H5D'48 \071\I%<-(20*HNX*0:(@#DX.E94"<"C2K@OM=T!W&HCO3>F
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MFR5 (.\ O@KX*N"KQ$F>P5?91TZ"KQ([.Q1+7P6.K8*D0]0<%T@Z ) '( ]
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M,^Y",WHM9&,(R@.6!RR?J.D# @0L'XOI 98'+!\U+ ]!>0C*1PS50U >@#P
M>0#R^PS_ ,A'>7H Y '(1PW(0U ^",J?E"L WR,;E#_!;<W0("8/4!Z@/$#Y
MF,HS0/E]Y"1 ^=C9H5A">8C)0TP^8J >8O( Y '( Y#?9_@'0#[*TP,@#T ^
M:D >8O)!3/ZB> SP/;(Q^0O4PCJ$XP'% XH'%!]#>084OX^<!!0?.SL42Q0/
MX7@(QT<,ST,X'H \ 'D \OL,_P#(1WEZ .0!R$<-R$,X/@C'7]^6 ;Y'-AQ_
M;6&;, X.K@$P#V >P'Q<Y1G _#YR$L!\[.Q0','\?Q*"QB'H'AO4#D%WP.F
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M*LY;GM &M+=3M+>BRB BMC[N8&\AT?QV?+?X4XH3I]\7%85(I$,F 0 0 "
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MW5-?]7JYZVS$#6+C.AMQBTG^L^[,'>3 NYXMZS.X,."X_S?VIP*FFJQY?\7
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M4^GC"5#TI.I()7E";.IEJU<9Z% KMM'0HPFTJ69.2RG<1D@$J5FSG\KT>W2
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MSWF)\U_)&V@S<KUC(P7?D=!S1%+<G?_JV8>GP9A%/UG96G15H#2NE=K(U<6
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MRG6Y00!*K6Z5L+IS//0(,"L^ERFM0+&E,ZRI-<P4P9<S< =. *:58@B)\M.
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M&8ATV->-B:>H*/$?"89SQBRNO=+;D0O7Z:SR,;G0DL@T+VUU0^@"7PW2?'U
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MC^3NQG:_XU6MZ4"[XS$@M]O3^4Z0H2P0CS!6GWT"AC7F(541OG,(%UD2=#-
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M#,_;0+I>E]#!:V8UZ5:VZ,772+M3,04[AT]:4">]R,-C?6KGQ$6_-ZKVQJD
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MA2D[?94<UX^_G:/CSG$KFMS)09VF29_CWH:D#$!GJ6M?=@K<X;C\W.P/QV-
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M%O;?#^B/$%FS/)F7+GZ[J J(//R^38<KF>GF&0][YJ%YE/8_"'KU9GDIZ14
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M*=(/E(]H%&0;'-GE%Q1D6/"!M-;:R$W",U"1K17IB#BTAH>  1-T"3TB:-N
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MNHE"G?@L"G4L=I6,GC5F?\!ZOP;A_R@+QD9?[E=;UWPP[?_<>/FHY'9AT!/
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M9SRB(OQ7W5*!7[%*SH_Z]@Y JJ"?.%]TK0/PYH9791B?N043\,JN,E7=;\I
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M9W$3XXUTKH8EFQ3?OKY0O^C=4:RPVS6I1,<LY%H;>D#%VF\(M>-7/!V\#DD
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MG/# Q4>%I0=LX1.[,17@ZSJ_B?"V=R#[2TDC?Z)\LR9LH][2&2\VL=.![\A
MI&ZM";U-"UWN!01@="<Y#;Q'*_<$(S)O4.?$8JPWX0BK@IQW=PP:6-:KU3V>
MMT(:$[J<'+.#]$#(2.B]3C;"PD*"ZO)0%.#?>9NPA\*EUQ#;K+V#A((+.23[
MS]FXGOTK#YZ"&[6Z.I_C-19$)LX2!."#2XRA\1;/O/&HX[9)'WLP@@3C;?TX
MIK .47SQA*5G #DA^A6,!VRKX@'%"@R:8+@;08DE?UB$&DE/UOP<*4^?[!X!
MQO?MJYOW%"@!IYSDL9YG\#-,IA\XQ*N$7^61@ <=1$D^G-=X&FE/UG%\4&0J
MAL1%Y@R,K*U=M'*Q,$F+)':NJ/H4ICSLHC@TL@<I*7A4:C.^M00-QFM+!AT/
M,>XKH'LY(;/=K64]=6*C&5O'!8? VBW8LQ3>&TG\OTZ;^BR^.74K$)22,)WR
M*@^C4P<B'+W@8<?MG3O9>D=83BD/%#8J"+*NMIQC=,,SZ/YD7>F\2)"Z^!\<
M>G&05Q$,V@G1;&>,@PH">5N(@$C(().X8N9;B\7V[Z_3R_G/D0PLGO.NV%D
MXL)#%_=K/7JOFZD;9:D:B@[WR+6C2"4IP. J*($4J(6M1(;F=6>/T?</7U"
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ME;Y[8O6J-*!?V":](]F)&=4H(D.:X$KR],HIF5-KW9FTP)HO.9/#T^O17LL
MJ^%[^J1(%E]::;4D#DK%S(P<XGJB J_T/;T_Y91Q=%*9TH-=N<NTZ.6>2<[
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MYN!9'EU]Q*66D<O^997*:6!C);"4]\50 V2R_*JWO"K+4_JXO#FBAF[]76?
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M\!$2-?-^O1E?:[F":%#S9J8_8.LX#WR;N'_.S'\L;*TCT"UK_A7$%/:PDW!
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M28Q*-3-__)OR1RP.IBBBXK?0[B>&FI>D76.?:=*#=A&+UO/-,F/6B]H(:(B
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MVJ#+N&R_9X-T1NDXU?HTJ438BC[H5H$JN1]] P%5R5OE\I5Z>TYR;LQ2])I
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MG"DN#>';?>M@X=Q/'P5 $WES%_#%>#/$URBP=&3O;AS.: E(G0P9ZP_.HA[
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M_1LZB(^L)J$?W!,3SQC(L\[T.)):3@R:%I4^LY!UIFH:T"S^^)6(/:029[+
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MBX#BVVJIR446Z<G Z*6WH-SZ P"[G>$YN ]_KLS<JKY*SS>)+;F<]-,+Z7%
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M<L(,]!26(].K\NB,55E47<(V!22BGHC)P/K'JV:)7@"E<U? TCA.Z*-OH1Z
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M^+H>Q[<P1Q\ZR5U&_=.% ]_7>\!ZALZ)ZB+J)V!RXE9C7'VLVPHG-)B^PX_
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M8@Q,@J$>"!25$)(\@8LG_&IBZ@O<7%@@J $+^C<+P['A-V.7$ Q#=5'=8]2
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MP6N<44\A3]3O?R1Y]>M_X3\[^1=5*'G(:LU\X=U;)22WOBTFR;^N8GM$J#C
MW&D-'3MP'3VMR4?HM#<//&[\[W\=#O\IK(F(NJJ;/W<6]&!>,\]FT=B83D%D
M#"FK1(0)?/5/05T+KK7SD]-19F><?^Z-,.-I<I2)_T4<_(X($J#F0MA$#FCF
MV^Z("B;00'B/[3[#=G?_H6[)B'T_3:#B\P*H]Z-^,6MLW?A)4U&T\;B ?_H3
MBU'19/Q*S#HQ:,S!PB 0,Q.I_G]W&]ESOC#^'0H?U&GUW\/%P_\(%3=#Z@!%
M.HLLB88V3GT++?PZX/ISTGI,ZG,4%';!5HE_;):=LC7A%J+(+>EYL]EILLA4
M_?#>MF\I3]5I*C-O+,C^O!QQ5\E2Q1*F(SK8<M6O;^AR5:F3B85CB-+:C"B1
M%FP9/VTY7DZIIO+8XQ1!2C=9MZQL],EZQ(S(TY:NT^643F)0Y;/SZG9<FI>7
M,LN.\!W.XY:97+M'IS.M.B^;HXY3,I2.)J*6B=.6*A@]+HKI@LAU%":93Y47
MXK##CF+!M]-ZUVK--$OF._TQC,WRBU22:HUBP;>[<J<::?=[%=*U.I7NL*2D
M,M)T% N^75P/G$HRU[241'%METMKO=-=H8+@@;=+FUAC4QZ,YTJE"EK)8K6:
MC\A3KW3X"3U5,*Y8E#'CZ6'$?DRWK/J@UO)J&!^W+!>+C8AD]>9<-MX2&,!,
M#-%=CQ+!MU<R6;< <I4:5ZD4R4Z[5!G/W:E72?2X96D\[J3&SKS$%^I%,E&A
M<U-]ZU<?/&[)#WFSN%FD#*XQH:!1+;=CC^O6*!E\>RJUKB7C/:D E\?^H&G.
MLF(_U_*JB1VWS$E.;B1Q4)*!F.&L=D&;9LV65[;H1$)DNFQNS0')+YK]<F%0
MDKG<J#5*!=\^F#NY:M4M;W@Y&6FPHEM6U\[:JR-RW+( 2GIFEF!C9 5T2[%F
MK3B?9]9>?8(3;DK=;24_X$6^H23KJ7$K_^AN$0AS0(]F);XH%D:43G:R#!M3
M.*X_[*.6@;>OV=ZX&G'72])QG$RFSN6+CMZ"+0,:EU2HSD)<RG.%3BTFS9'!
M]H>T#P&-6\)E$;DOLN8OF_BY\8B?)I8I);*)D$M1Y]QB72EPYGJ$FE*770#?
MYC6RT(DX=&J@@V&O =#..@%@YQ4]>7K(E4!-=YZ@M?.%_*]-=&0%^EW(:?#O
M)1PY#!?Q\8Y]MXXX@ZZ0"AJ3MWAQ>(GHPA%D5%U4?NSXQ&S[B4>Z#6P.M*5I
M9QF/K[AFZP<!H%-GP)?9I@,NMP8^+;5D] U)(/PD^O*-L0B.E/8.C1<:0F=&
M%0P+_-S]<C@HM/[[ T*KH.BMGL?>QD'HZ+L:07_.-G=O]7NCO!F]/:O(O)2'
M.%BW#_K789\3*&X[DNS^CJ @^:?GFZTA$5[UB7P_%;]XUU086[H* Z(K^T+/
MLYUZ.]L/7-H_3PBE0T;< 2.2T7C(ASO@ QU-OKCA$3(BM$S?BQ'0,E$A(^Z
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M9.;-;["T<AN#ZFJY)1!W<$GTSW&1NB[->+*)J]!1MWBVFRXL=CGX>>D7E4^
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MSPN<" Z1@?5[W7H40(,V!3"W/ARA'9&D&<ZF?\1]9H^8EYS,&QR.2?QG;/:
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MB?JF,&M 8H']?[\(2Y?BWS\-JL9!&ONNVL8+F=7J:9[+-/EI'F4V*=O@"K]
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M:%<Q/DLUS".AV5/M;RU\"P=!)5MJ'YGB>'[0L7BI$@3G(9?'5A+H-$H^RZH
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MC])2%LNQ+@5P:1,W0_Y$#]YUVLD@LTU@ZTD7V.$+,_-*QV.?J'6X$L&_P7/
M>0I@>9^:9_>?L1$\\EN8>)* )9M2 )<I *I< __X(V/44:Z"?QP%\)?&??8D
M4'W/T\]I1Q*$ 7*%*7QYLIYQCY$02*  CDB,U$R1/2H87,XG,74.NY$DN4@;
MWL6#[D^OGS1PC44^IG.%(@;4_]P@]VD6'&.@#"-GZ/>5"@/=;RV1#I=U749%
M/'A&D]H0US06_-N^+:WZ&N*D[I.!<[)YQZW6NQ[EV[O5"FGGK<]CG2ZN2LDX
MU-T3-$/2KY<_[ELU&-* ?%-YZ>H:OT$JN1S^Z*>2Q7<-!1;>/QWY\6;=5,*M
M[<U)-%5M[H^..RBI5ZH2;KXLV=31T=@N'XUT!F&LBY+%O$WM%,LD0JM:PYNT
MVDWS3/.((FK :,T6W/.=CG#.()62^XUG/,YH@0YH6N!T1):Y"3QJF"B6,ST-
MGJFTKJCYXPK'\T0[T-\/%21#*?3^II"M*Q4,;_V!9LQIO-;E@X?JN_#$?]SC
MP_#"KY"C0^%F8L?_+EP54&% [H706_1[G/$[W:ZL@W1VZH\3G[<AS=YS%C]8
MCKB;T0K5&<3_@;5$Y[-R#USQO] 88F2O"FA?HB&M-++Y$8PWN\#'(R&XO[W2
MMG>"C(Y^.?MJGG/6[!>7G>_?=\5+F/:GC\G>O#DY1S'J[XH/;K*=Z('R#^#1
MR$E_6PU(%ORO4/U[\\3^8XZ)J/\9?J!]Q)\FQY]GZM_F]%=X"_B/,T\KU$P+
M_K8Z:8$RDKG04OV*P;)ORL).19RW712KP%HK=&Z0C+_.FE49$%6JR-%=A;]9
M\30P?'Y_U["%IG)?<"C2?D0;6A+)@W\](Z$ZWK8O(]=RHK"YKI106#33M7H5
MRM0,QP42A)\-2!P%JI>&3-8?AOP\0_:H46 Y*EM8YI=T[)L00(??44P65^E>
MH,9<3ZC890;\+Z93K40KG/G,97]60N"3BO;QHN]G+[\\%<5E_H10<HJ 67+,
MRC9>P>R-00P[;;QH8N/98O-Y&+X'0 J&NPDY6/A'HH,SDGTY<$,,%,?Q;+=%
MYK?/M>NW?2U1^7R]]:4\=[5YH$@_B1<$(5YL8*H*RTJ/HHL.QA+A_\U@@XC\
M!SBT6Z4 _IUQK)HH@#\-P3\:<]&_P;^9?),,)L/E_RT3SYYF" GT%V[Z,UF2
M[*EU]57Y Y?^$Y&_2"M%-%N&O\?%?3C-^)O&W/>@2 N+V)C!==$SS'<9@J_G
M5L>0)*<@W3?FN[HX8?6I:M:5.1=F%SL%!0?@*6$6#5#"4#C8CMYI>!^I:DQ$
M636(_@/O8/4WWA3_/^H=Q L%^>NK0J;'62LKXS[<UA"P?.L#H-."9,)+,>^V
M4%PP@8']_(,',Q4GWX+Z<-(I$_!3[PDZRY_EF*'@QH0TNP&8I*FI5]C%(.Q9
M!2Y<^VU_EF%,CY7DW._O/]'AZ2D'4Z6;E7:?4E4U]4+V-+_IZ(P)IVX_3@\!
M+?3U/_V[3Z 9^.=U/V03 G$U+>ST%7+#;@"H2)NYDCZS/R^ :+<GK8$N*@M=
MW4 X+)37O.]2OI2G'17XZ@EBQ&>1J(6K;_(7KS(,=VO&2\5UA:=[O^6VE*9O
M/A-ICQDV'YO!FUNH9#I=V\Y>3:-IJ;V_U]E4Q_9S**2B1LQW?QQCM5CW/^TW
MB/K?!DJ.X_\[P/T9&\4PJQ-)F&A,TW%T9Y8>P5LF^N7/'!NJWG*ZYW(TK!3R
MJR0Z\G;Y/@7P\*XS@]QE*MMZFL#SBH^F%/Q#H;IX%X(-X^?]8;5KW4;J-Y\/
M)6])\+#M/<RADX460OZ,NJMS!??,,;>IQIRC%N2BB?^%P?Q#MLSY#SL@?P+<
M'=H@@'GJ.]U5W3_E1UC7GX'18=<)V_8RH.QF#[;)Z#+I+NX6QU[&RDQ"*;V3
M9S)BEVI+!I8L5MYC<.V(&B3+K..E"!X_"?P-$LCCK)IQ8SNF@LXS&9>*[W[Y
M&#'6#<P&S=Q)KY=NG;,*0TCM3;\@Q0@UH+N=8W&Q*4,L=3[(/5,%9EVVE3\?
MZ?V?)<W9J&27]<?G%9Z;O18JFKF_&O$DZVI>2<GWV3>?ET5/<3-F"<>/\=AT
M+.P,)OQV>"^R&Y DSW-5V2Q^O<\ (%-QY*^UYWZ8.:X(E=$,OLYR%-F-3HU%
MF3F 4L]W,@.Z[D*DW>(]Z-L>#'ZY>_\QPW72W!0M0$GA4=MC?K97+I7NV?^Q
M8:HW+1*C$MIDT+T>=33^<%S%B:=1^L>X5QB#CU66_8A7L+ E&@;.-3:TV<R;
ME'>Z'36:,UWY)C.HG0ZAWE:6L]..0>^LF!E,=^EN'$-PZZM#+00-\.<M?Z#U
M($&1Q@Z[%!Y><*_@0OAF)5=+\M94)[]<^8@N>);>8-L8YYG@Y_NC$UN3^[9[
M59.T#KMZ>IZ&$_"X87:_Z$-1':EL>VIK&U,/,<G64_4S22ETU"Y9-'0/'?-V
M_^-JA8;_YS0B"-0R#1H@<F1U_ESW"4=]LP#J6SE7R;WSX!]U@X@2%4G(PL*4
M#2)K%JGBQ?SFX6P!''>]G7^'9\5NL'%QM,"M_)RQU^IAJI!9\JSKSQD6#?X)
M3[(JI/^XX(O4CE%;W8Y\DPFKIYI6BX%';.B(I!"K,U$DB3 G*#&?T)ZY9QZC
M$:B<D/-UJ7?X_;Z)1&0#1AN+&%5]5:G!5S]G[:"N11]V5HM0RD*S*[8)-W^#
MF]FNC$VS7J, $%%[%X/<[GD10YT?NOBJ.,7!(2)C!^#Q>FS\UT7&(#5TQ,A(
M226Q:?Z@0++>03C0Y3D+Q^M$."K^*S"?1KNL;S2FP=-6#NV1#T&ZW5X+V-5F
M*09N^.$&6.E>U#AYUL*&)FY]3L@5KB&?RI%@>3U\5^-DYNA3VF8 KG<Q5CEO
MRF"9[#.F0@WA80'&CE$[RUA\95=%*@@=BE2(A]PAJX5@$6 SQD#=N\\T;'4R
M#R.V'U$ J/=%$BW 7_Z)=Z6M4_FK*V"PXIF&D@]^%P6,_!4_*?'D9]J^Y,ZC
M3B6F%A<U6F^-'"VB8 ZAS$_!QML)?KK'0<;K\J^N3J;/6ONWLA&?EDG)9&$B
M*$EUAMY$U?GR%K]BC845S8A(^,P+]@$<8C-P7OVL+8WZ3NH7L>OS#M'!M\0Q
MRNL39TXNRZ4'FS_,2\:)F6EXCI$:&>Y%<*NDV@2FG#TNAY+PQ!@Y3'HED,HX
MG+4\.\JGK8^C"W'&/:9N)U7M ^K3W/-B,[H]PQF:'R?OMK;BK<:Q.Z(N[L,&
M3)JA:RE-(7<*7G[Y'WZG$7OZR0WGNT_8\]\J-H"BD$F D 1F'/:IJ>+BFKID
MYL-B!JFSDC=>G?:V?RF>//^HE8/#VIZ3Z9W-BR(]KO8;9I*;RG6_SKZDN_$*
MH/'^1D 49OR;^E[:TE%D#V8Z5G6/;_$2LQF7R.,K ^I'%PX9#'&M]%<T1X^:
M#BQ6'U_ZNV:<2J ]<Y5-T6S<ZY)GN]@R!4"S163QQMJUXP0S]%??'FLG2>B>
MZ6F;WXMV5GS0^V!UL.ZLH@#'PUS74S>5X+8+_JS0T%<[PH%;0F+ "]U8MN@M
MO9$NQTLA#+ &<<3T;?QRD9I'$[G)=WR],,$8 T$O>0][^R-5\'59>$,_\?B!
M/75XU"@UANGPN?EOU,&BJS5LOV_(AO"X^-.^\*;FKKKTQV?<F4DVXAL?QT-J
M/!7R0$M]011 1='['^<=8 +6XP>SLT;=7S=CCRD [_I+?G:=/#N0=L;(EYW9
MWT[\Q"+8"MZ75G"WO:!"("W+C^M2(-,C7X--K4AO:7_@LMG<CI'N^RRM45.M
M0JTR%FJ,N%N%_UP_/\, ->31P=P3Q7-NI&*UZ^\M53KHXK,(%IDX,F_$8GV-
MW9D2<EZF?_GL-"?I,^S)S\J$%NZ;9>AFSI()'J/GZE6\2O,Q)N&9Y.;I"Z7:
M$M7QA3^59PZ#V=.^7XPZ&MD^'_-J,/N6%GP*L@S_O:@?>/5M><;'3V*D(V-2
M9PZ!W0M2$=C\S2UH<6C+;ZZ4A^J&;Q48D$<I 'K'!TN0Z?$_IIED.VF77@XX
M>H@MD$^1VI5?.XQ\-4ENJV?@/\-;2*0;%J)FOV\#;V)"'Z:]VVRU@TS6"T/7
M1=/&^;&]I<@-,JA8<^K:;!G_KC.H!NT1RF4YJ6[J3;M!EQF_2P?YS7Z$-"1]
M)$J[%KBG75D3%XZ@'5*66L:-VO66,XZ!YJS>"R6=-$L5>&GF3,6HU=C9!.TO
M ^-M"LYJ!PU^YFVE#H1_]4V9"7"374BC0'LM<#5?;BX=Q3$(MND+ 5_T.(,F
MZN?(?8]*EI'*I+_4"A_[PN"?*>;'BD/CDW!6+8DWRR)PJ^QEE:?;B!_O30?-
M>*!2U+-<WNX:F5R3&YP<V.;2/4K-AK2,><KYMR>B<XFE5(&2T'4H:QERJJ,C
MO99IK>G?)5A56G",M3B99B1S1X;>[7MAE83+G;?Z#Q]Q/)?LE;IB+&9*F-&J
M&JCESS,96]E&3#:?-T?S+$P"M_8EB9&#%3_@=AQ>Q@Z$_8,5M[<.&_S^?1X>
M2&T,NJ@%SI@]("1S)5T9VU$;?K[PU5B;_.GB^7=>;FF%[BQ16"[%>5U<6X*W
M5Q8JV$VV6B;)/<UG,NJ0D2:GWX_6;C"?J RI68>W(W[B\/C[2(L2Y,LI62FJ
M ]?G^E_^,E3E%#_ O#]/_QV7VG/UF(:NWX48F5>G[^9]<I5W^Y"RROY4_L[1
MJ^3-@OHKA)@7N-1PKP([B?[5<8\\-O[J2N>? 9,4P,L#G%5['^&.Y8\\-;E(
MW(A(SMBE_'6O!P&B@>3$FUBE&O.T)S.#C1:$,%B5=:$4*FBYT(19>Z&O' ;?
M\6J<N5A(WQXB\\0J,[PF7@#RL)("L'P0[]2@VT66_>-_U5O':W;3?91YX)&[
M^<BP3N7):8E*A6ZS]8!-"(V=U/2/.<&7?DK:J,HAIRT.&%)"D^VVVYK>KFV<
MWQ;K9]Q0W#I2XE!XCZA^+5LN$T7/F$FD:EK:TX3RN6NFIGXY4$^> ?<37L_V
M&M7Z_59OTN&FZHZ5ABL:>J*O"5\.([\B?KFPVP6:R4G "H">QOHON*C4Z3OQ
M^3@@-\5V# ::E>9)[E'CJA4N1^(*GO[LI&KR?8*GA0U,@:'T @703:_2Q:=U
M8$[]DW  HP 47N,>&80,9K'N/M7.4[(!UY[D-,)Q6OK#\Y&MJ9>57M+T9:H%
M'%SI)")UA^"7X#9I@9!K@\S]M?*G9SK.NJ_/3!H)D+=&3MI)@TIU_I+HJ'$)
M7<4[7:YL+\^)8>>@7G3Z)G&SQ'*(&P7PSE.K?3BP-?>DFO-]V*);LF?. WT)
MY)0][KL+) %, W;L8R.*IF+4=VY'$Y#-W1\MJF(DG!%Y*OYX</64C[GN2F33
M=F@J*Z$5.S0B\R!7R9?NHBC_8M(4!5!SRT/KF'L,$="^J!=6-YU>ZUM8/\L]
MS*DF10$PD")Z!C(<"N[["93A3MY?>M@.?" KP.7YP"@@8CX+NOQJ_ ]E] -1
ME'[,_;U:OID[[XV+[2'@:TO-R\'1S63MXYX=L01\9*"'-&23;K!VW8;GQ%VM
MO' WT_L=G@>!U64,-^HJ)"47CAWYRUY T45"0IN27*'IAOKE6."QUEC8,T/^
MZX=M(A$BR2Z&<;TPJ<&SGV93^%KL2@AQ;T/#=6QHRAMN?YEX+\DYZPJEB3'F
M,K;SU3>L&=/WFY*]A,/@+]=M6]343.2O$8^I>EDOY:8)VTX[/F. S'9>M [8
M-0)3ZK!^_UN\?>2I5!I>2<8M A1$R@3;GK\G)"3#,UO5/;W0[)7[V-7,\?.C
M8J)QJ.>*Y(("[B)>)?A60(N)]/OL*M?; 4JQSG7-:FOPT<T9R8;C6B%C^8L*
M9B*"3 2S$0@.C("\:U]^5.!_2]]1M2"A56NC'5U#3DA(A4*PD!;X.$3?V*Z%
MM=1@]?86*_)=@:GRR:]G4N2 H274=X+7B0R4!^OQJS*D3?J$T+8\5'Y/FM&9
ML2M@161-[15A]40-*H&'HW4N'M%NE0PXE@_8=UR]TG]MD]TE+*V!G;A(&#C1
M)NS-&Y4:KDD%HT7%[8NBWK3>;'=8+@@D;<D"$"H7[_=JOB(-<P?;Y*P3>.RY
MU=YU96W:DH]KAKL,:HAX(B3QF'9'"3],,,-U6B#9<W>N_0QT&G5WYFVD &R?
M/A5>3K,]RF\#XC0I "83T6!LVL75<7NKK>Z?SP\9P+1W18XP;<RZR$ LD85V
MNSV%&OM$K0ZUZZ3VMB/7TRK2VF0]E83GV0HR'*/TQIO/07Z<K]GCJ\H%VZB'
M1*.6=LCU:7BG9,8.]CT#T%C$17I:Z\&0(YZXX9^',2=]AFBP'3AT7/YL0'O2
MMR@* "S-#XP-&5Z=ODJEES"8ZH"X4H'!*O?-(+_E^,E& 0K@O>+3R),EE$YZ
M26["F[7\E['^Z_X*BG5ZFWS^L;!'?[P$Y6A!7C& IJG7X@JVV\>#3A0J_+K"
MNZG"=7X(4S]I0Z8A8+$[ L;"K>SV 1=EA#@1 T-;6OLW,'.M[JDTA,@YR&>#
M05O4]1$A]]!6;!+=D3EDJSKUNN]ENX86YT7IDQ><D[<K-@^WZIERS5B>5T.#
M<A6V/8[M_19WY/&/AF4>;A;"P'6I>QU.]_4Z;ZA^)<V[O!O=GSTV1Z.N^(^,
M(SX=G"-*[EP5R(S@WWV9OA-7B90%^U0>O3N@ 1M QK;Q%, @S&1D'-C"'/AT
M>#1H?MAL;M 5RM%.+)'<[CH).60,@P-@TCN1ZA+/>",JJ?I!:?@&8&M^\:K9
M-F)-6C=!B_51?>[RZZUJ];R]>DA?M56O3L?RQYAV9^(1[\@W@L6B8R1N8V#5
MP"3?JG 5![$YU##1[ZV93V6]%"'[A,46=0$GT:+.2NXBBR4TCY,*D.PBE=X%
MH;""G$BYLS*>QYQO9G?EL+CZX/T9-FMQG[8H]X1X5F64Y*OET8"5)QT\Q6=T
MWW]=C&DH?X2R=2685U, C7*!?'T"EL5QDDK197)W9#%)N\3JI%@-!6@.^D_Q
MK<R-"ZU!9X#5/DEN-SX^K+SU\MR-_3SD\<=KXNAI$R,E)Z>K;+RIEA>"OIM'
MJP-.*<[JVWB_"7@KH=WCYO^0$("M#ZQV0>WPE5ME3+@%5L<*.!TJ:?J]0T12
M -9 PIW7[&Y]Z3#1".G.1@&^&N>J8%__1<9I"@"ZL^&61'!J37V(D?$JZ,F'
M!FA7#Q^P^>\?:K(^VJ![0_?F/JV?)TV@W=NKJ3=WE9 0 G D,,$0>,Z&'C+K
M_PXF3X5<-%15H3()T^3#NQQDS$"[V'@B2K_U_<."G[9=(\R0ZM,8"5D(5K4[
MJ_Z<022TC2U?K)^!9@,%,',+]28=U?59^=WWLIS?Q ,JN@G<KW<\<O"%*SZH
MC!,=HM$P9]FT['!LVM&AQT?_Y[1:@?AX0KXC-J;]&*]TB# .7+#KN8-0,[V_
MJJ\5.1D!M],Z2IOV1092  XS83YG.F9P<2DJ+.NTI,R'(#^].TZ=^6,R7-0&
MB8R\@:);N:^6UKZDZ<GZW8\<XHD'%L)4%5Q&NIS%4'=5%W,6S?3F[.1M1 XP
M6*]-7US?7'HS?6IE]<M<?N#8^*]=7KK^JYX21-IP7Q64[J)37!WCV?IS3QH[
M9C&UQ,ND$I@7SF73/K/:Z0K!]1;S:L+N50W96S'1J<U?9$&+Q;4BYHL?$SK)
MD43RWF#65_<\E-7ZRX4OT:.1%QLTAM!L; \JS7ANU:)GD9LT6&!$M;0QU/_0
M8>,N_4BBRZ?*=VG:6^!Q-I;5$ *=\U3;6745@FU9CJ)CBH)EM<AH6"Q&U+B_
M2Z#WVSF. )=4@?*H)U0I16,^M5CQFZYQHB;;U[+*Z3..@**_BH59R8:W93MF
M/A![=_.9Y-&363<,KLV[*%M[AJEH+O&,(Y=2G4O:^5H9% =NL:>:4 2_#II6
MY9^PBGUNUKET7UYBBB<J-1,'RKZ&%QD_-!9;+UT]3A:31)6^Q)1G#?.B/6IV
M_>2L[!28=1],,FN8T)XH^0]^@8E^5J-Y#-VJ5;M+W/[2:<[HR349$;IU?E_V
MZPM>(P=MQ9 :>. WF8WF^\V+7[W?NCPLTYV>L5CR@+/56PLS$F\66V=Z#'E@
M@%5H4Z>O\/*;9!:2NBGDWA.+'3"^"%,[9HP=N*:.&@MI&V5H@'/X6ZU(N<_0
M@"W#Y>>,9XB\9.GHA5%CB31.I@=[V\J2TPN[E\E6%;1^K#N@.<Q["L#*Z=Q$
M9[X:PS?[X,4Q&\\@F;%?<AO68$UGR84]B%Z>Z6ZB'X06:&>\LFB7><)+\D8%
M-C9?C)B#X,.:7D9P>)S96*CII/J'9MZJ/MA#4FPMQRQMQ-HQ(^&YAT8 /A3[
M=1Z\H83>L4_+,B DGFC!1 A/+L4?1U31]Q!Y;%=]#(*S.\B<PEUIN%N@640$
ML (3(7=/U<,T^R7Y&FXA\8F5Q4TFE;3]08T/;I-"=(YVRZZJ5Y4[97N\-#MV
MKG?ZVG?E.Y60"U!*@P/QK,(Y&\ZBL;H'>W"1+48V>*.:V'F39SC$1\%--(%O
M./LA,/=9._F3B<@<>")FGC7(TE*=B2_F/ 40S^Z1_#QCY7?!#.$ RLNRS^R:
M3,_X.?IH_2BQF\7 MV._.W+<;*X0G0 'KG^G (JA'>";[W7<*8#QC+GI).R/
MG:U?+? ^[V?-N\YV73^+,!^;RZU>@ET?XLO!B:1EM!P3E3 ^PG1Q1PI#1:)]
M5UKD#B<*6IPB+4/?$!L1'C@Z(G-^<W4R;H)0TXST$7"E,=&KK R6[<*-'I^5
M&SZ:5_ >WC6B]5L=.[*A1O,XB<]"97+#)/5QM8NMTP#"XH_J5<RX;H@]FRLN
M6?H&>%KQ*);T6&P.R$P!O/T&*JL<DF%TM2]2-++QTF3B &YEI+X^=KSM&T*<
MP%$ 00?J%VQ'CK/#?QJM^GRJ<0Q9&I'G^(&_A1HFT% Y@SZ5[<< BD^1[R/6
M#%-HUBQ,\@QC4#I1/>(NW]OK?G"DA:_R4[IS$$FD3^OZW<?ZN7LOR%?&0\P_
M>JV.>WU7S!_H/V B1N M$ Z$.5EX^>6T//WJV";TQB0QO&\&\O;Y_ ?01N0Y
M0I_BSG3XM=P?,ZUPJQLG.ZFO*0"/0&VYMJIZ=B@-5:YPPW@=>!L#-,J2P.+M
MKTN=]6D8V#@]N+_O0&[,V) ?D:)DH,C+DC6#0H87"+?&C^_[KS-BG1F'K,("
M^BYF?.I%XU7'YEC'5H75P:LS;HW:.T1!7LX7*?8\XQ!;[CK,?F'QX2)+!TR(
M\".#.D:_#5 Q0M=A"=>*E!*=^"1U@!V'12B47);DP+<<#?W"@6-!]J$=T7F#
ML*H,02TJS>A88O6F'T0:)C2S1Q-<5:'ES5=.>*8NM0&G*^SHVJO?C,"X\O7%
MB_D#1ZS97N8P;=BYD(@+9GM @Y&XNDRG*?=Z+*9_N04RVCLQMK&!7SGVV1>$
MZHM!B9(Y0K7XW?5;M*Q.MN>".B-4ELMM=20"1+<WTB[8B,/'2^P^<)@_R7UQ
M,KY@MAT3DWR\0%*S'_QOA+UG5%-/]/<;146IHB"=J""H-*7WJ(@T 0$!J1$1
M$4(1D!X2 :E2I"LMTCNA=P@= >DE$&KH+9!0 R3AX7>?]3QWW?^;^_J<==;,
MF3U[?S][9O;D.WJ9-NR1:-+AUIQ'I@U-#8>'- \S*J3^WS.#!?4)^3:9QII>
M< _Z^")E4<4./R;5? $_+?[9G\FZ1HY_JU0\X3_. 1#DM<]ZR8K,9L3<M^Y[
MBS6CH\L>"I<:3\\!Y9P;%E'XP0YO] \%H&T!Y%3^LUPX[AZ$>F!]2/9&RL)R
M'O6?K9$&NP5GYD>/JZQZT]##Y&G2H"ACTGN"VQR045=;W7SZ;;,/N/=8+NEA
M1JW.V_]=$"=\Z)(*>Z8$0/?5YWX LVZ2V/]):24\74'^,C#689, /-F+RZ?Y
M-WG/;\,,T8$(E6-M0]RP(/[H,/*?:)MR :RJ(XA6*A1^@6\@!;JD*;1D Y!^
M'5U?DNV2D.2;(JRP__=+7IB8.K('C/$X"AF#@3SG-.-M'1HE/^!X?K]?8WM]
M#BC^(C,W>>6PFTJ 76G5($'S::%-UIW= PL;'H&;>:K]VRIGRI21.5XB&5DQ
M^Q<##_X#/Q"^SW]RT]V#LH^P"/ASN1$6)GA8+V&+7<@?,50["1W03Y1(2[\P
ME([_3];?#4%'>4B,P@J$X@[GZ3<9K3W8.9=ZGFK_7N&S",\]!XP'F*6RB'^W
M4VFSVXB09OT*:X$-("K= \^>$=_/8+9+T<7/6#'Z2A:\Y$/*'D\W7G+[X?2W
MB!"# 8\/**9F#I+J!(79LZV](^GJ<#6JRCY>(2L/=N HG\\%R_PI>+B[4-,Y
M"UP"?[-74,_Z^^>O0D.A^92/;0MGIM/@W>,K/(<G%FYQC5?(Q:)85.N%/N7=
M>/(+85]G3>!M4 "::,35_$*( ]Y8OI(;,]BG_L,2<>'CT['<-F<>J9S;,>2*
M77@^QH,\YVV3*UEAW,S?).=Q 9'I[T_S@S#J2NT<.Y#P1TKON'LVB!-Q%)EI
M5'H$Q.<1N&+6'(H&*]_&RN*'B3Z9\+:[U_&["?/6]"B0;XT-O#]UN@*Q8N[@
MBF X=$5Z"JHWRW$U<^QG#!Z]S6,JQJM-?[M&S<[%<'W!2-4H!%6=NNO3-#M'
M!O_O90$3A'!Q;[6AZ5>=MPTBR5>ALV=&)%_XM2G@#4_O+<<Z=\2&:V>?20?\
M.\_ S)G?X)4 BQK"CT4#9!OR,G@K-L[GIT*A&MN%<:3Z85#:-Y1:T'W "H&V
M!L2/9JDF0G>8P:Z]<,GKNN3L\0D/JUDC?U7M@!S(NEB*\,,7QD&/8#N<HJN)
M3ENDP>A%+E_O^'NQ"\!=NYV+N*,(CC\'B$I%/2<G@FSN88G")*O%'PZGE;U\
MY17)B(K\9;7VL^6OW'Z'&T9'->0RX>:;K:! DB"?4?.3)+$'OR((&RV1;$=B
M'K1#7]2Z+FV ((,8/:"?$H,I]^.7<%:[$,->A<O"HYFOVZ?_< ^62IX8Y]FQ
MRA4?'"?6W)J=G9%-,%YUV>6-C?FGPQ<[UU1TC2''V7B)@&*<,@=A$Q<'-MF\
MV:78WY?^&#]T:MB'^XE4%<\3HPSJQJHT>Y"[.V8]DAT[QK-1+EIZ&6%G'3&&
MJB+8_YG- K^E](*J/V7B2W;0[4HBM8FZ^.^1^=S_OC?6>]@CW:/&?=P/0(*Z
M9K^*A(6LI37*Z^'!Z=ER,=DBGRN.7!?![5&,4'>\V(O13K$^-H3VN$,(7#CD
MK[4B3=HE[N[T5N!#J""!TG3VE/2Z_@)/E'-"A5I%%F6MG\%P_V"37<YC'ZWN
M6D63@T%VJGBI"J<%4>8Y/VS#AM2DN?:,L7;W=X%*1_A5 <4;R&*X[:!_&507
M_V-3ZF;LHJ*(5,QT'[MXKF'(Z5K>\2FZ7:_9U,384=I$?.IHW[SQ3-'7TS7E
M"D$WTB'1IS8,?B)FFCNOU5 L;SKE4&+95!VV./<VZ<9;!9=7+D59'V_Z!.@9
M]:+*HKKX496Q+4E%=6E3KS'VD3.5T,0?B)U#GLXFP<V"$WL8C2?=RSR=G,'Z
M]<'<7M?'QM4,; 7F'N8( _+7L0L7N3_X_C]'^=C,2SV!9KJ;ZR KU/GW$_:W
M>XS>05Y+_H_XXQ,>_F3]9/7MCXNZ4MREU$7X[0T8PQ#2K=CN2!CTNB*\3_%?
M-TT8Z/<!52PX$5%Y#L"Y%D.=Q[)'*G,3U?'V0B_=P]Q[/ ;GDX$9!]Q[=L>X
MV#.=&>A'PLLTX%!)J@)[CL9+2X9AWX<+O7,%LC2*LIN>)P4HK1Z7S]C%,K;
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M##.L\M$3U2FE= ,_D5EBI^?E;JC+;G:LZ!_EHD8U@Q:R>M3SZC$N=33%MG7
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MNYF^1;Y1:&;1J^$/&XVX/W^9?CQEEP%X&]GO7]5X$_ANJF?:+:?W'.#SZG%
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MA?O@K\_1]B/:?W+&BYO1XBD.Q=#(B)V%=*2Q$@-RB*[*PX= %D]1O:9D]<9
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M=05D:3SIS7[C)Z4$,A=[VJS*7),/:H6WJOYM]74*^[A2Q6$W5W[QD_EAON>
MUF>-+I3'Q'WG[*+L8@G.=]O#EQ;4VO_]),/>@Q;N-W\N02P&AYEVG0-N*>@B
M*^YP)&0[?ZW;CN!E 3ZK!0:ZLIQ*T42-X\<VW#5WMXAI@<9G&C&)+G-1^4H1
MA9.;3 6-";%9F\5#\>];@+U-P:\OA)QZ#LF   X_!U04B=PCO-2Y5I@^P%TL
M$!'K>'W 12X@;=D#>3NC*O]%O-/BJU/3%=1Z:/@*,##M'.!S9C"Y92(=?$!V
MPGH$'K:F;PQMN+O.5;5&OX_X4J#V!:11G$L91P>\"GXYT4B/C;JU[B[>B#%(
MR+X204XJFMK+_++PJQLH:/-GM9$_;.TTDF=BA03&EB#NDZNTUX:-@-6#/Z O
M)#5!S)ZN[6D/\>3=^ J5ALJO-95[K3>6<5_ZOJDMQ^[J&E.F>.[IW-ZLCU@+
M/)"?%3E^"6;D]^>-D9?WN=O96$4SM2; =]%8C1%R".R>.H0@K8P7[O+[LYGT
MJ@IJLNC[JD7+Y5<X/E*;&9H9SG.X#::A\)E!7U03F_+[,TF*0VZ,#,GRBDJ[
MAJ/08CD)2 ]+DF]#LC,XCBGJ%]*.X$P3Q.,27&IHN.4PFY#*/=&D7>LZIKY_
MO#&MWR)\#K"K@TKF0IB(TBW>U/Z2BMK_)IL+LR2VG+FLQR/;!KZHZPZ6EGCO
M'\41@IKP:WIX>,@.9\?$L?00>'INTZ4Q\4[,*Z_K'>0)JBM _2WP2R*\#7T.
M8+W 5,O#0+Q R &"?N.88WP,=JD&_ECEA93R0S?.U*S)RZ>WS4M^XW,>P6T9
M@WADQQKO.62](R8JUW%$!DK^>5>,7*AQV'P3#FBWM0 %1BAW6CX">2.:'!UV
M=DI&&M#6&\=Q^>,)(Z-.6[M*S\;. ;9 %C.2:^)B6DH"QK!YD>7)RR*\V(/Z
M9[IQ*?'6SZ/3<L.=32B/R 62W$9M]7.!V%UJ(J25"5)@->[X5=XH$I(W^&[O
MWXOTGEZ_N>9^HA$^JJV9DSB+],S94BFK'R(Y"Z=XT]U^%L7\R=36,1>3]=[R
MS_LG,E>\T:M!U>F2R8=O6%0ZOET:HN]J>!+;MF33Q^&^K%NSCL)-U!\^+2C0
M,W*916VM>F/)!20CZDXMZFY#PZ-J(XQ%XK7("=O&5@\'COA'#P5^3O7P_&$:
MJ>MG7)*88Q\G^7IDK;O?D9H3N0B^=?;1*=VV7/^*ND1<6RTN_04L-JZ&'2;<
M\C?474_LL6M>2L9H_7=\L#Z\#:5U#EA(;9:!WX+>0KQ,>K'_67KP\F67EWHP
M IPND52X?[_Y8E[ZVQ"SMV'\GIGMVY,!NB,3VY>]>^C" .> YD_PWF8?4":N
M]+:OE0T96N+Q/K?'V&O=#<SU/A'KA%.!%'<HY'VJJQZ_&4GUR*&<L:,PJJMY
M*\@@C2^>8=F-+G>,)WY/%+>6Z>>&%38PBHF=EO>E*8\:+]R !YF4HINY/:W>
MT-?.;%3O/3T'?.ZJ Z9!EBI4<7LD?M[B%'"?TU]"^8/#UTM/6H5+<E X''@U
M,J$.$?KSL[02U40&0:'?Z4]5':M+^KUXF>7WMU.6_DB.&LD3&/4JATFWBRS
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M9OK<$6#G #<KM:\Z05N"TRV.*TI9H+>2%G)%@O;,7TY1:ZA3&'J$(-&U2/!
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M@_T\(8F3]A/Q]Y%L_\1E['Q?[*7&@(4NG4NENL_#C537E/SR;1Z;A[S%[HK
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MV9T8-F0YT[$O/X'CHWN>^3FZKY$BF_E3KO<(7 +8$0UPZ"#ZO>*-,*>?,Y>
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MO]Y]5QN[4<&4X-"TOZ2:\>= S]RCQ?HVI;&[)'3GZ7S+/K$;6-TTNHRGCUB
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M]+AG! <BS?&TE-M#D,!%P'1-@3#J17,+(^(M_RNYPFD\*?EV7BRVP(L9UN(
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M,_Q@$J9?]?P==,D$4/Q/^$_X3_A_-QS[3R7D/_S#/_P_ 3%A]K\!4$L#!!0
M   ( !&%=EC_^7#FP/,   ]( 0 8    8G1A:2TR,#(S,3(S,7@Q,&LP,#(N
M:G!G[+D%5)1K^R_\("722+>D2HETCHI(B4@WJ(B4@/20(Z!T* @H*0U2TMT-
M*MT]=,^0 TQ\X][[?=^SW_W^S_9_UK?.65\\S"P6U_,\]WWE[_I=-YA)S")
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M4L!RQ-#/^5-UP%P8Y=5\%#W\*UV7PS+5,DS<D-OY4L8M?I5-?U/!7-A"Q[1
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MR,>P:G]983BG>I,ZJ*/.,1@ILC3'.J$6;&P'J>YYT]@:9AUUH&>87/IP_<D
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M(B<%<7+JG'!_7O]2P3 &($]),&L>^\%@)?G11T>TL0G$UY0BOR_JZQC4(D-
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M"!\LCUAWBH?Q!R::=L[M-)_V8,O^#^2/^3\@[?7' $H.=/OD2ZQQM']T"YU
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MB3*Z^JXFMZN6(S_Q*\LYA77"'3L7J!#FCV,UO!MY39(>)GP+UJ?UIPRW29#
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MQW&GW<8Z;L@TH:0])8>Q/I3?;R>JY198QY1:<;)A"N?E5-?MC.@&8^RA$J_
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MWK0P4!X&JL)&+%?*$>VA1K'R46!9^9EFL3)7&_^V]TWE)R#.ER<9;'EYRD@
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M8/YZ@9K$/41G5-@^<8.?I#S,=-+55-6:;'48,8-FFPW<>%:3/^AY0_W=@&:
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MD2FFTEAJSIV81X[U+XZUM')-2E"2A&Y4%$GPS$B=^+!'Z=^70-'X^/DQ,88
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M#IH/AG[;DFH,*.$H)]\3NT!/??_ OYR$9F*XTXB@]."QD>C+;Z3X*"^)V0<
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M4CLWI9X'/>_H8HC7F/H7;[B37CC]D_,[T7Q-H[A7NT*3)SN)VNZZ<7-S!"
M6)!7Y2?6XBZOHPYDK&R#)ZQK!Z38I0/Y%Y9>8W7-H:FLFL.4,WW<L6A\1J50
M5)W@C3D-V8&37K/+XWD%T2?!;.7V;I#@0PY,<XKYC/H[,#HG\O?M_"<W)<D<
ML*W+6-GMG^[TI\I.@BVE<@JZ/3C+'V-DE#>;<:HRV=$[FH/F*0835@2DGE>6
MA=/.LRQ+A%"=^#A.MLYKN@*+98+J&BY2S2SO![VJ#M^544N[:Q@NRK+C5AA^
MG]:!X<W<S2OYNV)[&/VNQ%E&\MK-?%K=#BP)*]WZ0:ZGVC)Y>+?)Q6 WY2CM
MNQ\DE;URK<6$.(Y*(_,T]W.U*HU:IHXF-LV@ISU23E0 O?A 5B'4%_E"VYIE
MT9 "V;J1TFJ,P^FG& SY9MMF>6B!W2[6^\('7&>"4V^RWZUF\%#;I@_ L1N,
MYRQN.IJ[/;Y?EGL^("!XS7NF\7IVR@R-$^>;9X_0?&D^$X1\<D6K&.6HCG=0
M&64X$GBE$9-_2W_ M_A&V38FU9,'4Y.>YM,U-QL'_6][E[^HY/UP B)WO?NZ
M\>+AF>-7C>INBTP9:BN_\7#*)>8.M:&,F63OZP3&2,O\6H,A^0C]Y6KL7(AL
M[$J)JB9U >^5F&'5-Y)'BQR]ZXE7S ZK>?+FAX_3PM>+0J,D2;Q+XC.XE2@!
MRVUSKJGGK=1#P_6&IEKB2D-V:$-F:17U45L=S"7SEGYD^_0AC*[-5_H\4#B7
M[U:*O)4=.@_NXZ7?#:HC+2/QF/RP.<ZH[JB44A0JP@\1666GHR-5\W=M)+MU
MJLB+VQ)/_WR0JJK">YU)+W@< 2C.R\T(7\8J@SMA/?(@L'9 "=3EIB&0K[LV
M&<]*BC:<IN%8:GS$@E;E629E0=4Q]X:%IXUHN^1&9\BQ6[PR'E.MJ7/[L9V+
M1BU#NR&M_Y!&EJ/K;NR;*PT,CWE.)?CO^%B>X"KUV4T"\=;*U,MB+9E*SMO>
M]4DG!6TXDU&(9^"FZ^2[S)^\JY]'W5,.F8?86[3$HX<R20M344[)/O5XO#GI
MOV9*8[IF<-*W &=& -I*TQ& T4T$8*UJW^0XT7<"[;A^?A.U\)UT_PP;"Q,A
M2F>KC;8# G!CM0EXL%!_<@%JJ:NG;Y+/]);_..#@IF)S@,P+T/SR0MZO#T0H
M!V=Q]9,-$PP@ %\K(>@P:,$% B '2843]/J"5IO!NV?@(.=9C49DHM!\DKH*
M*BZL/UC1@6(B %1Q*54Z4!5!2@0@D0 !J%^'LX-_ZF+3$7P*K3L$CH_-GAXP
MP] 0@+!N>2UF&'WB37"O/S*].$0 2$#SFE!/N*L*' &@@?8?U8!@,!UGW*TM
M"]AI-/PJDMA5JJ",,'G\ZL(O2L34HWF.P"^;R2DS,[2FQ\"'Q[[@((KK>ZQK
M3YF9E;1A%\,]3T0FA\Y'=9$YQHK@R*%1O4/.+@* <B"X2=TN6/!:]K[+!:$%
MU^JI\Q8RSCYHG?#2B(8+/0./&B  ?:**.=;(\1[BGFU=UH2BUD9(I?I^B_Q_
M^0GR4;B0 GA4'RZ6K52*C+H5$X_&P6'9D;<V-XP%$][^,F'0\(0+18-W:0ZR
M(\UQ3Z]I(0 UB3TI+JZC*\;8LZDP__>_RDTN4QKS03A_0?T4\.PFLN4/U[>F
MD<G-K;2RD,R-K_ZT.6S_9J%%^<L3)F0H&8!,H?YVI2@WSYX)N9>.+Z]L\,=M
M1)<_G;[ZI4?&R&[1G/6=$KP0@+L!<F=K](/T#5V"W&= J4@PCG8F<)&>.+^4
M2)WEW?7" XF<J;.X+_"VRL.0WR9QI#[8VTX"M!ERQ-$]YWSCT+)#NX43[ /#
MZVBN<''2 M7#KSB<WUL= )W#$A?%CT5[T\ GIZ"6K!?.-YHA*D$U/',:M/DP
M\7SC*NS<@N56SG3;4/HRMI([5#3K6I(R:XF77[]:J@&*GR  7WC!6P&)$L@L
M=Q\<!!PG% Q#2M424JJZ/M>4#;^>JRY*H.]4ZY/$/]ZAEL3?)U:U%#HB$)PZ
M)(;1J2.YCPN]5\-WB<?F%W@*.6IM9/9&H@73<W0TC.-LB0[,=Y9N-5-(H-A0
M7)-$@62LNU,.E'9^.'?C>U9:7S&X<BXPI3R04UI3+?+:4G#SA:?GV&#)2?TE
M6@<?PTNP7. B)C<JI*:T(S5%3_-,' $ 1\!,\21&;;O=S#](UY4-H>4U3O28
MZ=UV>DXS&U38[RTFM*08E#W&]*G*N+J<)$#8_,Y@%X6Q[\WTXZ,)#!0!5J.2
M<SAP3WAO"\EYZ+7Z;^!#OK/E^02Z?,C7")0^A9)JY+.BCO9@,.SJ[K='\SBC
MK2YB GP/5@L1 /7$:8JCL+=K#R>O7$0 @?N7U=&L\*@X9$,9ROG\$',$8 _]
M.W:C[[,^S( K)(:>E//;(-*[.+U(O7NC]?W__1=A-NO "[@<)%N5PB,05T@T
M??;RHV2$O_,&*9M_T6O*P"X4W(#96'R. ,P1_I*-)E'H2:DH??+&#C#0G-?\
M.-($[6'6_R 2H&^M.*20S[U=H_T-ZM]XAS;[:T%*1S[WY1#_=VFY^T?>_<!F
M!>132 EF1!+B [OYNUC]F9BS"*#=B08WPJ]KDR?.(@" ZF^\2?W60O&S !H1
MA4> U&\2Q/P_F)\HFNL.P''_F!"'Q,2CK$&+D>P?L)OB-<W0E.[5^9C=[V+M
M>%"E?Y62];KT03A]% +@59P.[HU?74J$*=G*-RR8M";<JD*Z% _+!1O^:Q29
MQ7E\DO>1GG*.PN\7_+UTD)B&3Y&^BZ^W_;>C15ZOZQRL.IW2(  $6L!Q:.\R
MDO"/B9-JAC 8#'S^O!_T2^WMW7:G6R<DO-72I_DEUU(O3,7D_"/9J)X7];,.
MI4AO(3(/ =.X?(I:3!=1TU-P Y\E=.H!(Y>PYLBL#A1M]Z]X1.#U^X3:_[\1
M$I.A.*V&P9>:XF'TP*.L-8%-*I0^I<K'\ [/D-/7E_XP/'*D'FG$5;G5UHZ1
MPP <_D(+JG\'U/$_4[<X1J4JX-UV34ZL64B+F> S\Z/ &F>C'TM_!'=>!@9(
M.+Y9I@7:LWLR#^8S?C.>?ZU"#[=_(Q&/[[^&9OXSLZ&</+!S+=$V33Q*KW7W
M^>BF&I+1^8_1C_5749"!#U**RK<'>X<&< C'M\Y.G3'_?';R?[-1;/_RV?Y/
ML:38+F9,\V;,5VXMAUXY'SJB.%+Y!E>F!&7+H08,0$:D7HI(,W!+H7IT;_^(
M/<(K-?4<-AOV%ZS0^AVXX7\?5?K) @U'15L&V(0!']U\]!#XN^ 8S[VNG@-G
MF?AE:2"!8*1SX>BG7G+Z?ZW<Q -E$LB5AZ<>]%/VW']^AJ+MHZV??.6BT+ 5
M5D*P7CJ_N-M+>BP8PE!>'%G]$11<OT2'?F&% (P'V43V0S?APJ'@4>!%S"B/
M=CXA]!&_M.%YT]<Z ^@TR*>&'++1V0RZ!>.R6<"])H4D^;/Q*&9Z63I:Y%I,
M2?;>&\N!!RQCVZ/^9P:5<OY /-O9=X(XE1"F/.RCYO>WFS$"9 (E^4J";PEG
MZ?=2.^2O<2;$RQI5LRV%^*IOQ8$;Z]&,*6[WU3S?FY2H&BB5$9$M"=\_DDN@
M[I+WW1:/I2ZZJG9;\C:'"FJ.;K0I;Z8_3"/5<5#]0U,=77GU0!V%,4ES^/K)
MX&3+Q%N_@#9Y%O(BG*46'%FA1>!C1_!Q<C_'$@3+=+Z :#T.F0J1JVL!GP]@
MYRT/?S++HZ;M09D[IG8Q*'$%G4M"F9NY"+<S-@@)2;0_I+;FZVP*B8_E+H0Y
M,%@+;OE]QJ"]0H7.T=][_QB<,S496U#D6@]IU1[BF&9KW8-F*D'8G6&?C7'G
MMQ\,:6)BYCR0T';"DLB@$7P9[0+JJB!JH4\;A8GD:SA&-]_:F"CWM9U%"0$V
M7RMVR6BW(BL;T7DI<CLW+(256WH,2[? >,]A6V>>F=#$QABB!HT0B\]],,S0
M4I AD+*A#&$Z"9^*:H15\"]2^N\<ZOCQ:A?O38RVR@MTE_EQQMCIL[TI:D6/
MTN.YXHL.V,/5/N3IH(]L/=L?[-S%,2@Q@H:/:@V]=J4\,TAT69 B!RE"S"L9
MU)N*9A\/L+8"QYMRS#V<TEV7\4M,6J,>%*RKS%";Z33.T'OL:GQHC4MLO,/[
M.O\@PB:KJ2?OEO1K0]7AQ$[P^RKOAM>&ZYN@"3[IZ(9PQXR#QH2' [;KV+G*
M5X\''C%EWF]H>J21+3T9$\[]*@DEHL6*8':;;[X:C#-N\LBXCJJNMKJZNM ,
M9Z+1#H:GGG\>&8OY3H?14G)&"-6LQR1>$LQ\=&$N: C+Q#Z_9RI(.;P#$QXE
M:9HH\!D9Z4N9TMH@#"*8?[ZRX-*FR_/2 W+W8> U;H[#> .H:=,Q!?O>3FS^
MNH/8B?206?C&B$U8'1?Q<\^V,WN.=,V(:/8/I<%.?-5>&A:GJ*T(@ [VY1O$
MK!]7@A1&"R>/]OV;-WS$O"<![& LF8SF[(V;8^U96HR1<9V)L]*-=Z]=65JL
M0Z\UW3*K+BN;U213"88]A;HLX/K5T0R'T[T:L+T /3U_D"BP'!LC8\.&06'D
M&\E)!/ND^ @]?(R@Q8@^%UK=[#P]M[>3I;OX9+@D5J\FS+\A\U.97WZ*X70I
M@4\,)\#AU-=I.\7#Y(1=7L;<C3![0[F*W'-F X\Q/D77=F")MOV&8"4U#E^8
MS$"IJ8PUO=_K!X3RDU.=AO3WRNX839IF4GWB5^D8A'%!E'-,7:,%B8<I,//H
M*(Y[I!BH9L1=L*H=V -/6%_CO3+@?F&9Y#:Q];H.7TM@+=284%W1.:,R+R/9
MKJ*I/;,;/T$$U+V?])*4=JN1GVS0TO]<9$DJZQ"MJ=,,I6L>5J+0^HHM'%WS
MH8?D,2#.67]![2JW&,"C35RGX"D$%U4=ZMFL@^:JD3N=>P#UU"R*FYG@UFNW
M\T"QP!,3 C@%%TE<WUS!,<'%A*)K#+J*Z.9*IFNW?D( OLH11ZTOO6J4Y7P8
M E/=KVEH:YU9)5Z)OJ=2/9:@-'6<IZ-:W,> O9/,.S&!0?6N:RX29^<6X1LG
MA@X028VNY6/:+PGH'4YG*IZN\GOV>7F.GHH.>SNIN3/MG];9UDF"/D]CQY=8
M)U>(\;V1OKGUQ;.&=9%[,3)Z?C;(O*0ZQRF7X\'0?:RXDK+C[JNS/'5!C:<K
M\X'0QUNY_A^>17+W3)A@I.]B"W%4'I&*;;"V=0@\#1-_?]K2.CU**FNZ*J,[
M#_8];,SJG)=A7909FM0:2BFJ5%-3IB<LLKI)[,H@9GT=)94,,O(AV95[A+D4
M&P?CT 5:PW.1^>HDSK7,3/_F..J",<F#BK"8V_WTE7QZE&1D>%*1ZK"&MNJ$
M4ZM\-0T3[!<'>,YA:=T69.;[#]FVE!\FA:87L3K.K;Z1,2+0!T2^P!46OU;W
MLAAJM: AN<TD[E-ZY=-%PL X$SYY?S/.Y]W"I>E(H.%^&WIVH'VS;2)Z#<>"
M&<T"@\/HF79ZIMK4.ALC A!ONBQR7,^C)B(QP#<EB+E@,.?I=8,[8RZ\*I0[
M?[6F7Y0@[,<JU95FF X"$&8JA0 4C"( _79+PYL@0@1@27T  =@\0@ .M9PX
MW.KDX6NU.BON,DV)^X^BT\#4^/*B+C1=:/9UUR"=QEA17#WJS<&W1=I]$0 (
MJ*,BNS!S_80D?<I^I#_6('2.%@Y^NM*DD*G^(4BKGIFM&LVOP*N ) 8<4 YF
MCCV\Q]OV]KVW,C$JF0>=*7TC+]L:[Q/.<$V.Q@+JB*\1XVXYRO5\<8%Z0UJC
M-L<3"N_76YX'?5#/;Q#%5R3Y3>7_?Q'PGRD"_KS(T4Z;M=@T2.S.[:\Q 43A
MSS*SCG*!6TB+FW!<#[U9NC:?22#&91@9\"[>B=W?;BFQ5/PM1SURKJ_9,>(V
MCJ _'[Y?51+)J+S,V)DMG0\-\[UA[]F[K-U[$8, ',P@I>KJG9#OO8V3% :^
MCQA;>A;G4 BI_ZKCC0#@U9%NUM%"**+G^.)YQ?LF>F:?CM0HW2GFN%C]4'6;
MQBV#*!4M(-]RZ@5>H/I>R%;_(A 32M4RB_,@;N+D"<3]/?,'K:!7@:HFT&NJ
MVH^\'=4B[2/1C="YN]W<?@TAIUE'"S1?ANQ>=S7H-C@0SG!@VWO+D5EH;R3"
M.'E:M9W?V4-;!FS9MQ6RM:3;)MP9#BPD;B=["6,OAJ8"OVX"?00?0,7UV%VT
MT$K6F58@3TS*7X>]U'UYG9DH-*CZ?7SE80'2%!8#X2X3R !1N/\'%)F3K:;,
MK;#V$@3@/72!^8T@+8W"J"T05</Q0<^@0K\=/1!-_-.7A0T-5@3 *,+YD1^%
M:(1)N/NKV-<&5;1U0.B)S!Z-;]Z.*YY%@1JT5WVHE-RPL= 4T\+%D"S9O>OV
MG$3A([0KH=?X;Q+R>QXQ'^LB +TN.K#KZJ!O:(;Y94X^(P".9V3,7T&XIH)X
MT)?S;H1-7"Q:F\IW;FE,2[U&CU(3 Q"A<!-ISAD2[VK9:<*[P*>[I@C 6TSQ
M[STV# 4X5'[(Y-Q]%?^3?];YSF?]DE5XE^A!7O%J86]"Q7EJ[9-,<@XF_.7\
M>*SLAZN_!'?06IE8G/@JGL#F'.GC5VL+X*B,P/$0!$!@&[QWUV@UQ/+89NMY
M2C[8  0[06KM%Z_4[P^2078H>MS\;95ZOV$H^>'!!('&\=Y"V=3@"5J]L$5_
M=B><5?W'F!]?W!9_'LR3A_L7;:2,#O';\Q8JO1:BJ*-HT-1Y\%D_"PBA>PCD
MB/P%S&?^1'-^]_SN<(<)9]_S4D)Y R #"-!!*2+_BC8%2HJARR+,+R6WQ*:U
MPH7GF&Y. 8!N\M>/O'!^!B#/WOT5D_M[*>:W5L<R17\]L3R+4P(?S_'7<A*_
M8_OA07X7G__@! 7C+=2FG;B3#CZY*<6C,4K]Q*OPO-YDOW?+303NRE2_VX@
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MZT!0TDFET5G"V0J Y7G@X'+?JZ.$+B]@7CA(0V""=,,PJ3OUU"0B4+!$*5X
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M+VH5__ZC,/+@:BN"#N()4OOSK1GU>+4N=P =K1]_[V5[/\X#A1#_Z;:*^_8
M^=N$Q<!O,0?WXV'WKRN=X@O[4P'O?XHG.?\4;!K?LB,,7:>'ST,"[#.>(.FW
M,S \*!Q6=/7(=L,8Z4*?/$W!CW6Q('\1H-J?+GN@J^M&!5=9TK5=X6]-DY=
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MINQGK/1[DZ8/,SRA1 : 3<#[BALZ1.K4%']$CM19TLJ1GE2LJ.CM3-]RD_0
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MF&44U0;L_&GD/T7PS?<]NOXI O@YCBQQ%,IXX-KLS %S"4Y;?]$TX NL084
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MJ0MUHO85KO,ORI_LWLMDQCZHC_=E'Z;7@X?)W,S#/-CGWR<4$Z4J:*)[V9!
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M.%I!,C?WQ>SYFZ^7G]S;BJNJ2TR=R#RH^9%VA6J&8 OX7K5.M@$&@FQK05!
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M:M\UEF*;*0DP>G+'/R?E*?%Y]+4PY(;'5-Y!Z:D$ <VYTG3I<SY[\OZRYU%
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M4SAP';Z\J;8G%!YPL10]$['O3]D"H7&OPRB0/L<#Q6"D3$I]9*[ZVR$'<FB
M02-@W+G>8)GPE'0W68X?,R<K0G7;SVKN[.!LB?UUAW,YDA'2G@_S*;*P))<?
M,1"3 #=;I'4P5?/Y3BKE R4@5F@('E"OH"@RF+(KZB#YZ+EY/FKQ@7B!B.2X
M+*],+BWOKE2DUXSZA&[!\9GF!CY7N+LB*JCQVQIC+0F8<L\V@!X<U)HKU)Q5
MUO(CM>N6?_:)LK1+.<T4#?)V6\*./@B6H9!C!R?&<6# R.RFKGR((2H@>8ZO
M1K^9U?R<MQZ/ZU6H\Z+J\T30S=BO>D=>Q.AV3-#<:Z0"TF7.U 3Z9+\_8$;H
M!PX/)..R/?OJ=O=.)O>S:#@P"1ZR?-J<EX>5TC,F,@O>>PI9[>8AY>\J4VYU
MVU2E4F00Q;\J*7;M[-S2%:HIF^Z;]MF>R0H+#8L<!R=-!B1BV)3ZW87"\,!9
M/P6:YWLQY]=]-E)&DMPO-H%_%"J%GW\5EYF3,"XA]^#[1DO*;7@P]9FCOA 9
M(0]0B Q1GL*)',;MT8B,*:++8:[+MEIN4?1ZG N%,OUYU6(JFFV)LDZ:[OHM
M!K1&6PL>X)B:FIC2G'>BU7!S<':<3='0\X1F\7WMS(/<6%0U;7KG,O#>&AW:
M5ND_DNYF/P^CG3!9N\]Y;.-A_](WB[*81<6O@K+56,;%@/]3X>A[B=UM'@?6
M?C>A=UK9(Q^. \P@BQBX,=9PT.\B"C3K%,:#:@N2$9CCS4(G' 0YY-@;^7D5
MCLM;/&U4"7AJ,^:98^$2%.N-"+%7@URTOP@-X*#0T#O6H&/IZ?:Q-*DH50V[
MU/[-VN89G011FKUX334G"S+]*J^;^*'DVI N:V$AQ6G5:1H>6'B!%<4#WZSO
MXX$!@W4T79TC'K"N.[H$HP)O& Z"]Q*EC@)X<51"^D><KTS17=_W**Y_JKLM
M._LIXCI &,2+,1A>$#8U"/;#8O1(%9+@<9Q#\ ,7'HAW=CHY;X0'>/EV"NIT
MD(A#T(DW+K1G'@]$[Q#>4?MY-S#B^H<SOPSJPWD(-OK8FM"3DN)2!/@""WX5
MY!$(<T/H)VPDO+DQXGI^.^%=SW]W2,^$S^P(^OTTF)#%JZW'Y3?^?!20 D3:
M@WM6L7T8<.??#F'^X]PD83#NP8\HQF"C3_# ]V /$"MLX1MF%]<TB@>.M:ZZ
M'FMB@Y_5K1?"5NY6QD2#=PRPWGC ?!T/G%Z/^PIK-8O953P-77-YHZ7H*/^/
M(PM_'%N8QE[" S';#+ ?)3FPE2 3AE\;=0,%3-$1(XZ>_I<G@;_O7\QUYD-S
ML<DN8^\8Z+6,8_]Y>E418)CQ8\ #K[/U":MA;XH'!DU[G,7^+#,/P]&?LCAC
M7M>/3L._58VOP0L)'530MFMBVBVT!QX(37LL+YPLZG23W;H6\XC&#7)V9"1I
M'D)KDR@^8N19D[-ZX#F:KATX/;*C,A^Q(=CO_"7O3"=3]/Q2&TO!,T^&N55?
MR2KIF2W1=)TQ]>3TO7F=@3T.R .,_RQ+\8D&1!Z%B!'P$_]N=J^HR65AA4YE
M\?4+TL,X<5>I OM4E'(3G!S:I8RQ^F1_X-F7\0,3W\(D[J,5QLP3QU81Y?Q6
M?_O39X%%:F;E0(H%4)\])+SV9F%"1AGZ:843EQU-+E.D=K)JC<>-P]M4N(J$
MY/MP:. =F2$1 JNX/Z])!TTRB+4]=( ]9<7I'-@G^F^*PB0Z+L/>5L[&][J9
ML7;D7K49+H._STC%/JC+;ZDJ_Z,L'(:&87E1HZJ8G%E_)<U0)M:#;('@TYHM
M>#I6:HC_69E3V!VH^VK(5967>84.UA:F9,!+XFP4.&1;A@A=90B5X9DM*QW%
M,GEX9%^+1E:]%YF#74[OUC'HWC"?'F1XPM[.===9B739?[2%AL4,DSC:[,4I
M,.HHHV +BG?*5<^Y/^J<Q>R@JNZD%1I U-8]G94VPR!CA[NJ22L1);:$/J.X
M()CG<;MGH*VO_>I4N1!/U'S*@*&BK7+"4&VT]/&49S],19V!9+MKZ"2W$4+E
M?E"!<4A71"G<'9$!SQO[ILXPVHNLOK(:<(0[IXRSN*4R/"]HN1^4,%X>>^MB
M_30(XX],EB/#:,_4IUU$Z\9$;)54W=[?5-<,F5LR]O6>5+C2#ISO%N=8 +TQ
M=WD7\S(?QX-I'=08=E^1,2Y0R%X;4!?_:,N9*=+BS9U.5]W.1G?K.3$C2>SM
MGCNV:.(61E(E\6GNX<W>R"68U9'^ .*'Q"FAD:<ZR9\ZF)==RTS02QC,F:FS
M-=SN+]FY:_!6(/W(&Y8T%Q".X9K5;ZP[CY4=Y%]&;=969:UYL;[S2>@.H*T=
MV3_'=ZN1CJWK<6MW6_%Y!NX$;O.RF]C18?/2LJ'M*X7E$IXNW>LDBVI'KT,N
M&Y.<$1%VEE\W]H1=E#'/MDW)2K6=JW$<?3!L9BA&J>+!$L?7^MJS?>##,Q43
MYY87[;-+%5_VG"6ERFT?Z-ZX[09K^+F5V%AB,*2J)/YM>A6\<P>K@P<L!5_C
M@8S*!&?=OQ!-:<[!$2M15@2^=O?_$>I^%\8QK_X!X[5_!>.O,1]G'8CGF()[
MX^<T;E!9:NP..!69,%+6N 7MQ$([$)?Q0(@V1@$/W#V7A ?\-?! RVB-_0P:
MB0?.,/2,%KW,UZ/?)!=%]!=#H6UVV6_P0!.O'^&AC\3J>* VB]"\K/S%&W*U
M3.L,$82%N7I8MRM9T,?[YWOZ\<#Y3%0H[B65$.XX%0]$(O0^Q>01$!<>=S)S
M%#RV"$9U0LA@*_($O-O.J<-4@I%O:B\0\/E%)AZ8T8&A/=:&M/93\,#N#L07
M#PA7R63C6-21-*=DK)#3?0D\P*2,%4EJ!!U?$*T[67/""=881<@507 !ZMNP
M)2;KWS9$><0>#_1U^&]C&S=VX!@KH9?@O4NVL,.A&:PIZ!<5]^VN'_? CHZ$
M:O# 6],T#T1 -QZ@%(O\D5V#4DIU$S&:,,ZM4G_-_C##!4'3K\6@_#5O^S^^
MT6=SYG@8#Q38XH$/$8&?)",Z>7GK:A*N'27_QGH,+]:Q^6D48#S7FR!/*D?<
M8>=[!-H.6DN0I_QV$IZIEP7(=J)N.42'^0]X:Q1_.5^P,?(UW\PIX1',]]I&
MS+]>O$(9/G2#^R9(H<SW  -W*9B>:ODXC;$Q3G9TF%-\0YG?<U[KP9=N9JK<
M'7?M"7L((2>*'8/FV:+9%3YA AN[#+Z5UPPB'#>^Y_>7/9*XD.'2ONL=9IIT
M3KC TDG@G8- >AJO?X7_AF#3O]:B0C,,5*PXUN_XK+A'P@#E%;XIY*YJ53)B
M7N+-V;NU?YF;;"'Y40)UAOBH2="+D4IP2!V]&*\<!2:^E16;_0BN4CF2<5GK
MBA!5?C/R@L-#295AMT#?=RF.!IF<UEK;#C],$W]=4W?8KT&R.DT]('?%Q!!J
MV:PO)Q2CG8@'NLJ'BZ4C52Y_#237=S%6>B4D(^/],,N075*O=ZJ^0*GF1&GU
M$'=QV%$T4E;GOD3ETQR)T)*N<G/QRI<CWU2Z+4PWYCF-I8Z^??"XJZ2LNWF3
M:ER,[>AKE1CL;W590]2#0/;3XD/5QHPEL(,?&_HJXO,=KV33/),<9.H\E+Q4
MN<INMSH+ PR+E>!-RGGF &KH<,G[NY)^NF??C^1_L(LDD3<UNCHH7]]6]A1C
M>C=6F8];HT- +XVW-$%Y,'>-R;K@3W/^19(,3\S$L'+$A#N*C@Z6Z UL>DCN
M&2-H^;5@UA/3[>?:F9-),K:@WRM;M0R';E&KA(-MP-2UH<C-1X9V<.M1(<3>
MB=5.^G2<D7]ZCZ!,]UFP5;PC.0]?K(@+O+@%)E-[B#/WU/\-^,@R#.@7E\J*
M^3AM@%%H'BWS6:R:6:U\='/<_\M2!Y>^_5>J>MV8P]>?J;NX;D5_5A:[NKP)
M0A99VGJGVQ[7A6\N$%Y8MI6J%L+_X\?""^Y&0R[I<$,@FKC=K^P(RG(;#>G[
MMZ0._W7>]%]"5@L2,##-63)4(HD<$,O=Y+I?/KBY[;%N,WO"?F;_DJ^WG.W+
M@@R3:YY*+<ZJP.-W3NQ8[PJX&6HS-(2_1*5X&>U?&NR!>"LPW;H2.N'BF.SY
MYH*7T%M+W>YG#'UL*8F\IQ5_(-'T;ZQ(MBVX&!9<PO3*-]5?7:7?,6]KGPIL
M4AMRT_:S\<29IW$"KWH!>1-R6LKKG4'WJTX_YHM.<8[@3AH"^ M/_$I?VZ+4
M;1V-,).)!O<<B]X.1UX_R^WN,9GYACBV FWLUO4312U^"T1'K@6C]WZLC;^"
M>V=#8R C0M6*+ED_5KZ/&2J*12I;.CD?M-YQ6ZS\\'JBQWHAD8-!_9G"B?)*
M96)"ILD*#H0^5^7O;^_A,ZX1)8X';$M"IO5"GB9U)ULR)Q@"^A;-?A]#12>_
MJ6_^H9 E'OC;K%GO][L]QR'=4GGN?;XMDZIOYMJ%JSTEC6=(7I>??4!&XNQS
M@6Q%7BS=H%K1(_U=[<%_L53LYAL?6&,,/X^O:IE"N312I/D@11.YHN418''E
M<;F U/=]6+(1K_\(;]7;![F8OGFA4#/I_KT9&GO0V('V*NVD#,0JQ*3=^KUJ
M5SIG6+4UNWXD02%MK"9!(3BA#3NHP]K5;(@;QC1K11OH%OI@M0GT:>%;M6Y0
MP]S5T!QR"0Z.-PYE.?O6_W&RF/]8>/RR\0"5.AJ,"X%AL\?Q /H+&)D3P$-8
MR3X\\.8$@A,SA?P8B\$26OR.3)PRS?'R<YSJ*2'F%F)R_QXUUQ?!&#L((7?V
M;N&!13E"E8_6^M-\WXI 1P3J%Z^.#3IUJX=QXPBKO*,\#/^[NK<#QXH)-1-:
M-1;"_7"""UH_$]R3B2$LC@(8I[,)PPR#_JGZ'5S%+#@.Y@X[XEKK^]?E_$@3
MQYHT!SL]CP>.-$OPP/PCV"_K'K/QK T'@RT0GB"T>B8H4 >X$HQ]O>\'+BQK
ME,R*'JR7,JK\>BDD*0A^N#9==2+B=V-$K.<N[K!^W*%G<;@YON]6<57&Z[=%
M-YOVN>,A7#3CJ7//;^.!E_\^00(>L(N)$)&^!87SMW$3J-\?2P7?,&D]/.@B
M4+2D(P9<Y6,!QW^XXDO=_Q57(/YIUA78J SICN96#![@]C?\._"#\/XI-&/^
M--MI]%M"FFQC4R +H/4TXB.>0V4\$">7]SL<D9"+OX2E\I^<CVOMABT?XC2$
M=FCV^XBP\2?I!,>#]'ZGE(UVPE!#=1?QP(HU'NCT)S!8UO0_Q8#E4_#N"1ZX
MEG1$^G]D <(=,@9'/HV_.F^(X=(HL]VT*GN3J[[;NAZBD[2BS/#^3Z8DZ!]\
MQGQ*GICS>_(8#S37CF:?'F?]:?DRGU1$.)Q8X8$7ZM@0S""1O>O_35_H_A_&
M4/Y/3[K_+,!MUC($C%8>O$>0R3BXG>9G3%[(6I*&SB=^QP-0 F%&?&Z%MJ\&
M)=S/%LDFO:I]L)+)APL9@M8)Y6K=R5$Z-=(S*WUVZ/0?)[%9PP-%X,8>-2H1
M:02);5'F^\]E97JV,"_0V^UBOU,):5!KU92$=LD(_Z6:;^416[WN=(HR_"P<
MFG?)UO6W A9 ^WW'*4<Y^@4IU8N'19OI@C:E,5=^KW?*71?# \L+!+YD\=^P
M%=+Y5>-\#LJ?]3%]JD\L*5!TPO9)27F9EU+2M=M7H MFD'0N$7B^CX"F+>X;
M'E@GW+]R[9-!1*_ ;4(OQ'CT>@'R][VA[NG3.BPVB4"4NE.+.O^>3*\/YW;!
M;&F8UZ9),5Y.GVV.$WH3W 2_98]U>%C9)>GDB4QFN'J[B+J>\\]S/G.S5YA\
M[@O#MXMQ$9_W=\T]E?\N&4U@X5B= @.HETK\/?1RU$+\([1X<GJ7VQP-C?$/
M#2?Z@838^KA55 BW\%&RR9ETYF594WA$"21DA@[2-,V%%N@+<^?KH5XV"M4>
MVMR<2^N>D+&7JBA[)6K3V9DGIU&?^R162<RM^2I6^;!=L..W.H<^$#35;,A#
M0+KU0<YGR'C#G.P-&EXNFV>"(G+=GC')'SV(PCM.UYZDE6PPO%NWN"RHKW6Z
M(?B[C7SZ_PY&<T_O(3 A)=JK9;VRL@-%A[^FK;&%/Z82'(T33="*Z7OW@C\(
M1V(O_<MZF576H9=Y3MTA"\-G[S;K51W.3'?%>RK_=JCJ__/+@,CO:?TYX#)T
MN=6(IV4[M%(VCU$*%BRFH6>L'MZ=YC%UP)_Y!@@6;V*MW/%BLDC?NBYG9>K;
M'' -!6MUHC P@:8M/QPL65\/6_Y:.<A5,BC@T"U24JG@MKCEFX^^?C/Y_3LF
M)T&Q!M,W:.J9:I_<K<:-[[^A4$%DZPR]0#4H;VQE9/Q:_IR#Z]*(,3)K)8=2
M+;$_03\A:J#U@Z/'0V)&"V?ZV7D*/' 0\IW?@_(EKG-D<2 O;8!#TY QAZ,T
M6:Q=A_U6WJLBTC,JD<'1+P,L0F\HG$W0H=O7^2,Y!-O_GC.L?@WH-S+M+7@V
MC^H+T_@VLH6]3?U)>_@Q_&%0;S=YZG,\ (YM,/EPOS#$ZG8;&$50);E\M)H8
MF7NJW.A3D#GGKZD)UTE5_V[Q_&5)^ ';BZ5)X/,#AD=U;WO>">B+WQA=AF$(
M-1=\J4I*Z%^C2LCV02JJ&#(N(:XG58I(MQV_QSHU761U'O(T9,1F"FG!J1A;
M=/2LZBX=V5'I<Y4MF8OSXNB$DJ$X&ZG2%P)57XZ,/MV[U]Y>4*C(+Z)*'Z9@
M>6,AD.R22W*"R7W=R<7#NEW*HNC?"_"B?PEN"!_42+SU!ZB;VJ#HND?QX$;^
ME=*RLKMJ+:R7'FF]>P< RP,5E>L;L/G.&5P%8@<AS:*7J9)Y6V)M0I;_8G6R
M++V6F=9Z\#_V)E@J#[%06'VPF\? /[_+98=@:"A9L)!8_9:98J^P$OW3K D%
M!\VY=)L<9)CCJ ;&TAGGT^W(<;]0^?U'<90Q2V\#Q&8T!JMRFKR'")L&<]Z$
M,$.;&E-&?US4L)6YE9/Y%JH[UOAM9^R58:'2AE_Z*[ZAIE[1I<DJ=I6C77FT
M5X10G=4,/2:X]K*]D7*8'^F<>F3D'<2D!L=*F9("0TC&.^^^RZZ =,C2/1*@
MD_L[[B:F<?[ %\W3 JW6Y\9QHSW+SB58V\7+))JQ175?H8@%=RP].XI\;.UZ
MDX?'J]0HH*V6,E1IT+VJ1ATR(O!XQ-BL#C=8K3IC6#7+6VW)^427F$C?YK;%
M1/BULFNGR=5,'CF8-<.Y:K@Z^H/R\)[X6TJ>]P:2Y?+T4FH&COP@EMNM\FV6
M".4RX\U!#3"DGIIS!LD3$4!KO^IFA0XR&17M>L^(F;$UXQO2F.K>56;45I<+
M$<XLNTF2T!A4Y=4U$M!=EA)#"(2GFA1=N7;'T:WIGU<'VL0_C_*/>EN_]@HW
MYH$R-]QN)<W41H5N1"(AY^TC\R#0H)8 P:$/A7&-K3"ZM<"-572EB$2L^/7_
MQ=U[AS79=7VB4510I'>I4J2#=*4%1)J(-"%(BU*D"9$>:A2E-P$!Z=($I-?0
M(UVZ= F]2T^0$B D$]\Y[SP^W_LZ\YUS9LZ9<_[(=>4B>^U[K;57^:U[K[W1
M-PQ=H92[H.<'/(^KW@N>1$JFZ'3$A);DV^L7E_\8W?K\@N7*[&J3('7@VW4!
ML;24+K?\.]6KI2G38Q22J*XWGZ&BA# @=<Z^1!'=I)6-51S>I519TO;8W=F3
M4GFQ+_[^VF=]6@&2IX^.+OG/V?O=F/#S7BQC@K+=D7<LA-;^[,:19CYQ!-.8
M*W0F9'RDU*)2^BBI=W&1R:#69]'S7&(AYFT#[^MJ':H-HSV/ B3FC7[CN!3%
M#C'(GJ<>#S!!")3UO7XENUQ?:K HLXU8!+]EN^7O]6C,8]9B1V@PTS)E]AAI
M-2H<L7=[6F2X0K-;_Q$Q\9K3V%9K(7A_7N?G&#GXR&RL"<0;HRBZH2B$5IT,
M%SEH-D'29NA:!<G<>_+V]DJQ5II?T49\/%AEDGUA* @)>MVDMW3NT[:T[SA$
M,]OM#4T2B6)Q#BLG^:*KU%T(*?&DZS9YX+9F 7Y'< WCT(R]<P<\8%*2$+U4
ME0UF\8 2\.E:YBE) ;^ZM5G++;H>3'=;PVYAD7T*/$3^@;O@F63B5>$RX92?
M.HWAVKDGM5M"ZOU&JOR<#;%)Q"\M!8NS2V08W)576E@QUY# R(,8VIFM[#VC
M$(.6\9H+=,GAI,FE3G'S5+P?YAYDWT^CN6E);IHA'K(]@ ?0A@15BV(T5R/.
M:!Z.'^S5M-I7:BK.,O-^0#3)W5"88O?E]BR3G_ HVQ&E\GL>[#@4"IKCJAS+
MF%>.:*]RI'!R[NJE#U-Z=9X \^D,38UV;;<O4TI:WJU?] 73JI="74DS,?>=
M7G".[6:-20]X^;I!:-19;H>&OWJ>]$R8XQK)L\9W<LB2?$$LHK26*<CJC,,_
M8<6E;(.>S5K66OA*Q.)XY9MS<I19R'=>2XN'XE5BO,*Q7T@M2A9$@Q);*%%L
M.8N.6['%4^!9!YI!$RX2Z&Y^G%KDJPX4CV#:STCT2!V"$C=\(^:MY<1V#>+Z
ME/%6@^%N)N3E.L@MM_/R DQ@T[3=^09?NRKW"Q,V=ELYTY>#E9CQI73(DLXK
MU9+2Q SF<7<%_=,C9!\H<,<F;LY:"?VH8MN&R/YA#^,S0>] ";;K/:""YO5/
MYW+@?:(B0O9H@]!LN&"\'C2AIV>A5DKI/-7PFM&!DO,.%VMELH&1?J/[ADA&
M;KV35+5=TBO+U113-#JH;09/(Z\4NN97%6,O=D2R4)T-FX@-#71A7;.0B=Z-
M!YOR-4$?G&8ZG,D&H=U'Q1.'P"O04B!YZR)&:A;XL'K\9LMP#>;0%)H3MZ(J
MI'\'OM^Q\;[?RF?)?+J+P<NP##<A"PMN OOFS)O8#7?FS9O8^X2G^]-C9QYR
MS4W4.E'ZAEJ)?Q2G8;KS[C-KVJ3(3:?)T=--8E]4V2(0*R@WX /; >^([JB6
M,P<,K7J#GU<&3YX-I,\]PGV?C7:)[X:6'9E7H4&M1127M$J;:[/R9W1<[$M5
M'$-B!A/5$B78\(!D)AYK0<2E(.?/8L-8TS'1,NR3!5'B:0<O6=5HA/?+R6-I
M\0_.UL%S1**Q+)]5U-=8KEC?;"MR$O F&\,-H]15T%?RZ2L]HIARJ\^$D\(\
MRO@E)[SV<^/,[ZVIPWC"C) JE0E/7\,%1 0,&N(22R=.[*Y<GMSN))2E5*)^
MJA#IH"/'G2=28;CYQ2+? 4T>9BUULI6W)RY5?'?$JD1,K?@YPGO.)#;Y16()
M5?/5M^KM2.G\0@=I>O 4$ &NY?GJ'@>1HZ@I-2XD:;I([GJM2OD\7Q3[Y#S"
M)@MC^W!<*DK=I&58.<2<5X?,Z>(,4]R*:6+<K:C7E]33#BZYF<A2[! 504?Z
M5."HR;=/6]!TAWF'.^-1N\5.)25Q$QLE9D)+Q.(2#W,Y]L<HKUHVDY=MD<)&
MAW#D'^V444"];^YE%WL6$=2MGS Q;:>4*/081'+4#>+MN-I1TG!!G XB3K)B
ML$:I^%1EA:IW,[/RRCNN$?($CUPM%]OLT@BA.;YOG!->EST]ZH+,ART_2,;%
M:;C+O:<]\4[J@-5T)2TB:"WLDWP",FWIDZ42/N4Y^9>JT!?$#U(V3$]]AB.I
M;PI 7#@#[Z<2!?7Y\+8#0U,R.P2'J)I2>&J3<S=,2G9CZ;Z,W;#?Y:FMLTON
MM]!_>X^6ZF=\G-IM(B;G9JG^HQ.8N=+J(7!J1'"6H:O!^L9"[9L.D(EVA[4Q
MQYG E/J+U](YG+5H1^S-BWM?S$1O:Y_)S44]&)R8[!137F0&4L?0M.>T)*T]
MNB7N'7?/^?I'1JVF7 HA\3VFYZ1O$MQD(G <&%Y=-%N82![L,AX0'NEF+_O\
MTXM=\AA'.62UT8AD:(7&#E7Z!UF)*]9SMU^YX0&HU!F5'/"/##8T>UBUYJ&3
ME]:(]0A6YWK99XRW,],(2"LBY%W_+2JQ*+A&>,>.Y>TB1Z33 ,9'=.MG'6MT
M^IEXA_L 4&E"_AXR)D@R2D9WI+J(V5<%XL;"X/+!="CMZY*11G+LM6[&E<3K
M+E%76ZY#<TQK4#NES<L?1$O<!<^E]R=(%6A-BS-MXKW%$Y.G\E[2>0D*7*=9
MC8.V8<87%506X>T4+ X$[CP;[>V0S$&5#>,B$!'.>FJ1Z0_.SQ-6(Z[U%X=[
MIF6=:,A5&"PE(IXM02YB8"9-=1 JC)<AHFHB"QZ;K6U$.^*\5ELG.)RH&X[A
M"(IEH:C7]-4LM>L].SAY/;<!OH"H4N1272K;&9*P#874[%7ZQS.=:;_US# Z
M)Q0GJWNST6Z1UY_7,Y=-L8T75WO&Z ]+L3YHE6*\GL&)6O%)*.KT\.8927B=
M9Q[7-?*.Y>XE6\$WKZM0W:VG^>%^EQ?968!1AQYHHT+63R5N<G,#(BE]?$9Q
MPR_\6@$Q5HSC"2K!U\XBK-FJ%DM+O(C#FUP631OKRY+46L*7!GW#3#15:_H#
M'+KZ.RJF.)*5>7??LGYFV50[2IP#BXZ1E[4%L$6T63"-'-BQ<H>WS0J/C\P)
M>CCE,%%U%-VP+1W3)7YF,J9GYC0[&\J7':[D!SY[B0?TZ'U#;!,QX-[/3 X>
M'JCOM.,!/.KW\(#RZ^!3 S>PW.1F/>@L050%)80'X-02SF'W:?54?;J'@GYK
MKOG/?8SP@$ _BF*_>Y,+(Y*F:@T-[U93&362&AMAUV+ 7UQ5'^8QJO8^ZF%X
ME/:YY]ZUG>V81^<I 2+0I+8 OBK484)>5W,N6"MXU+(5&K8E9(VJVU2^J3'X
MTIO=V^S\*W K\U!J#4:L>,T.#R"I?L;:4+)6)8X'Y&V*U-EN[(L>ZU*-(@PL
MDMV..?" 4MC8Y&IRZ:UH0:HA-6GSLY/,9FM&ED=$Q-MHB<8?B*1>/&!D6UF5
M%A3G#_B]9^?Q4>86.ZX>@0MTN)8Q>FY%P"6$2O:;]L-:F^ZE7VK1NV 6TX$'
MA! <J>) D$QF!P^8FK<9?U$#E.GYZ>6?X9[Z7$9$YD676Y?;FY&FG.7,B,-,
M$BP$993C5&0Q_</$(DD!5YBO(A$J\LQQ6@ODS47LZ&WO/G)1G0U,-Z".;MEK
M!](%<$&'],<@95@NQURM\]3<;H\(JR/?CJJYUZ&JXF9"4_&?)BPTF!3>Y<CQ
M=Q+,=?Y9QA;:=/%\OD.!71->/OYL>*]ZP&(4%+BTUC][WX)XKF XC(N;)G+Q
M=:DZ&$-3#)U;UFM" \-W(*)[)<]&,L_D-!T=H0?S"K?J7W-YK\BM[[=)1FY?
M?/UV.<,.]SU%H3:AB/1#-=.AKUP?L\;T0S2+EZS6>5% =QRF(YLCX_'<4[&X
M+)#S>5O5PGFN5!DKM+NUUH+-G,]8L;#0/@7YW:'/ W(WN'^PS,E5>/"0I(^S
MG$3K#3- ?-PEWT*@QV0NXZ./._A"D]1'Z'Q[!@\J,2D7<V]=6Z+;FSXIK_/:
M)OU^=W4G;U)5@D?4>/0V'1>[6-F#LB1YIC,MAP90^_O$]K:?6XDFQ&^WFY1A
M_B68T.:5=[T\O;OTW8/O2<)ZOC.G)2PK($+Q +NB<P6I$AT-5)P#CG%$2DZ8
M<TLW2?],GO!+W6WK7#8MYRC%44;A)NJI"P\"QVERGC1J@5-P#:]WWNNINH2F
MPY8'=4Y_('H^7_OMJY:G62W!B PX5OQL?QTGI-ZCA8H:G\&F@(O,8]R(?;]T
MPNSS$"$Y&6=FL37G08J'5FD3Y(6H,C":-\R]OF:/\5;>XJR@T8V!C(P4?16/
MM=*'8GTORVIR(BN^&">$DM:G7H)_ @WT+*5[ &V&(F334EJR&YJ#YD/CYM"E
MU@ST.,..+4;UP97OM)<!476,78*?,N5K \#0H<?H_/9F4R.T?TAXDT39] _9
MG>:W2+,2__S4+>^2%8_X<^-$3E;S"V2-C$+7TB)?@C(K:VJ&(D1J\L<._-6<
MU$RUTM6.35&=>4?9MF\YOQ[]K.5Z;6,\R??L96Z]=FY478"4#J6Q@^RGPB48
MYA'7MT\5%>;L'6RT+<E+(V*0Y-R&RF!#[_#^&VK/PVWX>O,O:)0]0N^%0;@P
M;,<ICXI%#\V-NI"][895*@SI+AZ5C*5<NIK@%#T. (K80L*$ )0+^ORESY6&
MX!BR%97\[O/ZQNT,J7IT<$#/,78RO67H&-.=&2/1,M\@T7UCOE+@5OSB#UB-
M.]FC8]7*NI$%?]]VP0)39E!2?^2)Z)T.= 6PZ3K11>4'NP&B8/ /@C-?<RH6
MW7L:#J&;GIIYG]Y:%[(-LL[-94_7$J!FYGA'H2O8AP?8Z[ ZLE&C@5%K\$DI
M5HE'Y:BN$.\(TV2]F[83UIK6A@;MDH[5[\1[Q;XN?4XMNO7>!G$R?4@T*B^'
M$L8*$^"3\JB?DK#UA*0Y4#-<P[W(FKYKW);-]CU#CPT,^*'#X>-%8K,(!(DB
MA6C;UA#E;-A!KK_YPJWV]E.]D0.,?)[-]43<B[K88]:]QK5K;XB<'XFV(JC,
M_$#H6_7+@LWJ>J/+E77^(J-M^M6U _D"K[3FE#QWZ^)O?GEJ2%F@_VA-L=/X
M<=K2#/=QS:\K%=<H06!"&&,CA.;# 5B"*]WD=SR@.P%Q[@9>-3,NB=U8"."G
M&5:E6\_X\L^6Q]0R6'<(E@0D8WZKF4#)CKII-NL#A;Q"561VGER&SG<.$"8#
M85I1ZU\02)G31T'%J@5@BYY/L\VYQVJS7/P7!YB>4+F>I5I=5"*Z,^#+XX83
M0Y$'+4\[:G@4R:07KS'0PZ6/J:?-3#7NS-,.B_<P=2D+M'.\<Q5L27MOX^G"
MYK'$"GJ",2_&_+H[8)QWK QK4 #6A!1"*S6EZ$:=%B,&XSA4N*O(7V98YP4O
M)PE\SND#'96A!^$\ Y]2K1;/%8\U4;MEA0X0+T<7%Q:XB=\.32B!)ZJ>:DIF
M'AF6I.F?OO48X@6#'.5/I5'<CF1GFQ'^K.>]X/.2J@8W*#=-U;L'B>(T<-)O
M /KY!?97)1S!)/(*+%0J.3J+AQJEM_2.^#]4#Z<!^P<[JC3<;EIJOHAS_"3%
ME[<GB,# @$KRQ";GQ4W^BSLWCARC9-J30),WV**6R.YR!B_=R0H_^G'_V\.'
MN5][2^MB[UT/]*148K5H/+L';6R7/0YM8O8\I9N/>"'EI#C8M33TL-X&$;Z)
MU Q4MU_/G"L,>RWJPJ)T^[G'%[()/ZWSQ";^Y3+2VN3\K@;6J<K1@[PF%QYD
M!+/FB/&"6/5KC1.Q.NS,OLZ#&3P@V U%_#V2_?NQFD% 2N;1Z_$R,CP J0_D
M9S$_F8,B,_G,,40?BXX^^(*34 >$#$X<]F.^1B=&WC 7ZO[]"12F/29RH&"K
MWRQ3Z_8P0BIR^[6>_L(S,]&[SY&F'.5FTN\1->KAUM6C)1RCDF\G_?3R?LC,
M,88M)2QYB[*H0^,#4/24M6O,GMBZH<+# 8HC=XSW8IWPS5$_>6'+ZJK&\M>7
M5]M)%AHL1S_VAP1SIQVRMX=GL6^?Y:FCB;\@D9J.Y"$+$5>+#Q0X!4'B72/<
M+KN)BZM6 ME9WQMI@YTZPVA]'\KYJ)_BBEM0<K.D73A6M"HNRRK'\=2BQ#<?
MF.3K9.7-,F(JK3'-640=(M!.%OWXU&A<_\9:BD=5#MF]L<TM9Y'!S'51Y*7+
MX5?]FG:GZNAF(ZVITL:1"Y;7^+)SK^[B 1-EYVXZYY<>T[DN9I&GYGA"A,55
M7BG^."J 3^,!0_S O04\8,F!\\#D1H^(;>%E.L4SV,DJ[SF6':O-3, 'Z^\S
MCU$PM!3(/ZQRU[6%#L43\E8*0N- [V;6)Q,J=:'07&@[3U]'X$[Y![V@:>HT
MZD>:Z^7=XP3L[&NN>(=AP%L^0/3L+B)F\!JGG:7QLMV#5[UJG2_B IYEI(&R
M(' \($,?-M^*!W0,M\SCO#7Q !@Q'D!C]%E;[F/EKG<D\/+-5PXR$4M[U&5A
MHKM.N[QH6K?I;O>V2];A-#>4A)$<E9K[DMS4J]'&@M</SE.;I!$VGF-2H'K#
M<?JC=;\+AZ([%S]M#78H74_0E\]BFW%IY3@]^O<"6B#S#Y]6[D+SL>*X(#<K
M7T@!-+[#I\C<+NRC]Z2!Z97@<6Y-SN^%%S]:6R\DW)WQ<EYF;E](KS;9&<QS
M7"JCMD?/FYG..7A*,]R>;B^8Z0C-< _B)(_<8K%4)NTJ@R>LK(]Z_:9P0F+%
M ^1S\0#$&SP@+&NB  _(I3<?U.E6O%".7DT/-)LQMY\\]1BQV#C]E+&9).TF
MHK8B5)Q+)U1<6EQ<K,)_I5YP;^JGQGA68]V8U(XS07]>#(E>?4N:*=,[Y0I%
M(7#C;TH<CPT0*_OE#Z,?&:_X#/Y;J25SC%R,E&UF]LNNXX9.18/]U&U*1<I*
M'&2C:HL\BI-%GP>]A8/HBR 2MXV3KAEZ73;/,EY44J)4<3R3W[BAD/&A@3U4
M:H=(KYQA^%.1%4]]71QS8V)](@/U/70"M?3C[>N-:LSQF:9_DS7''X'=C\?A
M*'"W,FL+STU/-^G-AX3A&*I\>V0:7-8VK$DG=]J\IC@E*J$T6ZR@#V#XQ"9Y
MN)2H,M=A[:X!5+GQ[HM#BVLHA9#7PE):OE>=;VFK/VX<SY,1*C8R#3-Y0O<R
MYQI3*&!EN5#!L>!/#\X;3TOX\,0+.\0ZHDA17=L0'08];C S>=0L#5]L]M5.
MD<J8,4M*O*\[W2KPTZRCAU-<TCG]T3W[ 12S\MC!K(\P0=\&DX?:UDHB4HWU
MEN%'0(Y$^.T/7%&<8F(B>92L'8FS%IF_F[/:7\HW*%'  \JV"GX]_=8$T'96
MM-.HH1*3U&&R%R9:=G T,JK;XFB\6@6W)=^ZV'[)I=#3<*:3*=20Z<M%^"$>
M\+:!(K2%!PKN!EU<8H6U;\@;[2LMZMNMA&L</2"1"PRS%@PD$?)NY3@V_6V1
M?W>SD:,J7%-;'V+-6R%I^R3GB:KC)SS :2L>HS:!LFA=O)OW:N-K[_2PQ*KW
M +5FB'&*_JO/47E*)DA"W&N^-V2*]@JM\76SA96""\._-50$3I!TZ 8+:,Q,
M6Z@$NJR]1C;N'.$!/WMUSC! 3(K,[P;O\7STH5#C.SV#O3\Y_9/9(U*1%=K'
M9W]@?=CKNU#CAPQN%#!$7DLA;Z)B\5S4L%[CDJ/4X7LWV8^>-U7$XR/C7'8=
MN7!T,J_Q@!\/?\'::[^>+EA7!Y56_I +;%P^?G/6C<SZFV64W+0H-HR'P; T
M-SZ8T"1)YM"? Q=8(%@!"!&A?$I>Q .P=+\8T"/@K]0O>,#!+2@,#[C\$H:F
MF_IC"#,\#)_OQ^$!F%LP@W88=\ >AICY7^AI86V?4,#SJQGL>$"K&3M6U?-/
MZS;\S^EN'LK+[*L3 OLK%P2JL(D"#[AG^ZN@ Q$>2J7^+SR#;/Y@B.S&)=BA
M/4+"9/]?Q=X6*NG+:@A6+X-]"P]0J@-BPOTGVW2(A/L_0B7:OQ!S7,A3WL*M
M>GP].@O9S24,4?C%H4X#5'%4VO)=^OJ==SYX0*/6%ET9&HC 704;M+MBJ<X0
M"RPZ__<61F>+#I%\3M"8YFD&\PG7,>S+G7G,XSG"3UD2[00)! DF$9KSKR94
M^:=H$E-LA+,])FB(HG 1$0?TPA)%X0%!V@NP4QIY($'!OR0'+AI V7%OAPC+
MM5!*@>-L%/Z3GYQV0M8(IDCYOXRY^%J,YL)S<=O6 +8[:O(;NCZP^E]W:_Z'
MA3X:NF+=H4\1V_!503&!_B^SX0DM\=K[M1XZQ,&5Q_\3&,R<$(1)G!'4$O__
M&</^5_9,D QO#X"D8<%1.?:G&JELMM^=]%DQ&XUV3%TZ)C-_$OU]T>.XZE3'
M2=Q5O7;=-VN1^@&9*!(!W\QZXG,WW*>HWRPD97%A^HKE.]Q>I(:"3LW3Z89O
MFYI/-O6S\_\T]>>]"FGSKWR%QW_$'-E[Y4^\./X\0T1+J\U,8'CF7W_YG2&1
ML\M)KG][R?0[EI(J:EV3YGP7L'/Z%=C@_]EZ-B-(5<2F\,&?9BMJZ9CRN@-F
MQ/(.R[L5F<UO1KFNK=]K0AV4<Q5$E91:W(HM?YR^T%%W]TO/ CK:1W0*WB:8
MI9*K<1IYI(?QEU<(J;N Y'G_D%?H,T7F&N#L-1&PW0+^!_.P^SSVH'>1 'G.
M,E\?(4L3W"!%&'C'Z<"9^3389!/NI1M6? L^]'X"W7VM+21QYN']EB7VEP!B
MF59!K9!A$8B\WI*PNN'((=,A[5B9R,VX)P^'&:W?%D;T1=,P35=RQS#.D%@:
MGWK^>[3E:X\'&)&*K$=M *L8@JIAI%LFUV5.&Y]LSK'!46-[W,-,]$@J/I ^
M%T##;ZV'(YJX]^[0Y>7Y0-S-"7EU[VR[AD?UGWZD!-?DS<V:MWZ>DHX7-_UP
M/4F\K1?.N9![03ZW_T4?<WS:\B;K'X*+H\:2@.K\R\J]D_]>'C8[]@_LJQ/%
M>O?@ >8,)U+*(+J%,^[,AGCFR9C;/C(UJK\/UD]M_%;(8_,_*!R4+6R*L1='
MI/(GA,&F$R58F1*+U'.=]G>:Q-]+5Y\;Q0L-,PU;6U^.NVNH*=S=/W6H_0<!
M''+T=3'W^NK7D).MJ4[JAA.[!WO46W,LM9,OD:7I>3W.3KOS3Z-R.[Y]'993
MHWN29<UK!_1=*YEJ8;/;R\> =(+YA27GR89HCZ1?RNRB:46O:YQ<2M!=#":1
MR[FGR41<_"=G2"V4)J!S<+<B<07Z*)8L8>782'_:K-O7UM^*0W-'A.NNINZ[
MOMBXV[V]RAR!5^EZS+$7AFO\>3OH3UNJBK=DHQMY4BVV9'0NSHJ;]%:V4H<N
M:L02\7\U;I7['J=YR:?TWUN+6O%2<6!?_5=86U-YR!(3.B%]?"ZS4,=.J&QG
M)_ER2W:X9NA@GJ8HV]KW3<-7EKD)2PU_\J^D6\?_760UTKA-;_Y5L*P"#X@1
MA)VN(7KK_7\CWWR!>K'PA</;\=4C7Q ]SX\8]4LEO(52M'IFQ*7_//+Y?.N_
M=89H_O,-C$4&\X*\D"TZ0!E\,V T0V82RXI.Z=V?[IBLW*@].KH")-WP*3Y]
MGL-=X@KS=F3.JD5<]RSJ:E-K%7Q[-GZX0_=CI*"P+[DH3;WS!D7,(;\BAPY=
M3*14T=X-T<Z($G'A*^9&WIQ.#/WO'R*LN;."N*AE4LM/GDNUBUP<4V3'A"PE
M[QQ<W6G2+K: XE:EAI>%J;5.+!3$&9??Y:2Z>IIX.Y>3S%YD$%$#NY25-PDO
ME#"W:G[^%&5[)#4N=?70M&*M*<.IO]N]TJ]CF=M_^)7<!;-Q/* ;<=%>46',
M[R9L28L,:#1:''2X;&'6??TV/Q?)X+:B'V6G+_^E92Z%@%G-%F/P*;;F[,N)
MUY<Y0?3]&_)BG<M.GJ11X$6Y+3>P P/()S3PQ-E([&5%C-BWMWXTU*@K2\7*
MM\K>!-S"1&*>;DS.<8[%!.]@07G3T(A.(S:>1#Q A[ZRS>W(<0(/T*B)2N>@
M#DD22X;:';]3K"O'M"YJ@T!-U543U7V-@@I2AUI11F3Z SO98=S6\2]IF&CY
M[SWI)>DBF:^CY-]D9_6["9$)FGPTEHUF1836@+=]30>HH<X?HY>?N7)[^ $
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M4HGAW^\UX*W9XCUW@ZSJ/CYJML8#2IVPOS;#33&Z>JJT?[\((6-]5YD "O"
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MIA";N4U\AYNJ"#4);AD_V#'J?OQAUL'G5IYTLL*PH8I+M5!LKZ&2[@!M;!R
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M="MS8=W/K![LS828;5J*/>H'F7T0]+MA\.S)O6=3#4@07'<G1<$Z7$0;5O7
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M!&#6JT+W0IU7G$NVJ4H&(YGGRV=P]VTS:XY&UYX-U9$MDBV^/?_D&-#-R*G
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M8KWY :Q@R2 HZ?0OU)ONR9:R+VXQ+L9P[FU!<M#I>C1)3JQ\_#"I]MJB[#6
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MHNS8XFKO'7@(A4^LV.#"4HN<K9;BE.N^DE=?&[D10+4FV 3GB5 I9Y6U#[%
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M>W<PE(%')%"6@JWM8:1"D-+8GDLRGC4UM87-;DFFUIOJFC Y&N7\&\IJ#H4
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M+'A';^9]>HPG"6*7@/7K(,609'WLL%&=:[A?PEQB@HVSK?N$WH8QVH0UFR!
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MD^10Q28$2-]1<>]&/9YS%9_W^[JBE/\U<S=5+5AX>_)$&HI\]OK=(L[(495
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M-U? ;-A.$PQOR*IL:+Z_N)X/Y '<IR]J<ZVJAR3!IMER.PK=<+ *URQEL%*
M\]2$G:OFSV.5&EYDS$PC2W+%<4\3[QWE$;7>]=8Y]-5KNSJ7SS\\SO>_KZ5]
MG"-;_YD.0ROV'7UNHL,*&(Y*%'(YSA29O<V6?3?)\NGX7EW$6T'G>UTC?$:
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M>(O&G;2Y4N=K)GDR9]+S*57ILV#]T?7,2)3<U3]F0?\GEB:]BPS%9_[ "*1
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MB9&EDY0BE9CM<?5F7]]3I1%!WFR+Z_?2LV[G,&2DUE3.&!\RQIA(?VELR<Y
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M)9Y-X2Q"T2NA\(?GN-0S%<3?)_&B37OCWXU0!A%[B<A(*G X84*K*QYK"\S
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MTO"9<&5UTG=<0R"RVSQ1M/13YC5SCVWMOL-&V'0&)N_W[3(,,2F_56QK,&"
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M1(OH!G:VA%0B"1SIDJRU080^;?]C$P7'M.(UX2<-8L*I66Y?SNQ_=?CSV_:
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MG=5E3[&MVKU4/48%/A:$=IS4<"@BHW-LA^*^V5>0S0@21&W*\![4=Z+:0>V
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M@91%ITBH(E2*[R+A6Z%([;NWV.S02KB +A5B=!K@=]%?L *9!\K[__WO9&Q
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M[EAIPY; P AL2R87X%O<(6RB?(-6C\.WP)8_T6LQD"WO&*P:.UYK+$6_#]?
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M&HM%LZ1ON)%^\C"<&X.D[120JO LH&R[3)@\OGY#I0M]3XJ>\1,JP17M]7G
M2@C]!'<^)@]ZB_#L(YAM4]T(CS@ R>CW[ "+052KK;7BPQ3>X' #H[>C+B]K
M*!X 11W#+Z?/O:\?,DMT:>"8=^@LSC:<FUBS;T488PDY%[EV1W2SA@%@M6/O
MW,^U6L%]".%1V',,[\E:G/#LM4@OFTF:M^AAC-Z:/[G*R0%8SPH-:GS;N[9
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MU'-CJ^%SE<9LEF %O"JV?DONNYP"83I;2V@!7U;!7V8'!%*4#KCT>0B?;[5
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M>*F'.DO *;\<[E/8PP)'UAJWLE=-/)..483C<DH.+:ILEM)K41??#9=7%"V
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MYL1W;F?/]RG1"[4Z69[:-]V[_6K HJ55O^HW[F$*. -PNJ742IOQ)D%S]=\
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M.<\2E_HZN9P\2E9ZP<5=[?9?:HM:5^\R7UFLD78-\&)EC4_J7XN<.41(D,Z
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ME^0F UQVT\&"^XTP%NP;<P@]_3E8=PRI1R8.-6>:F-XL"#U#/"L]5H-OUSW
MM1#O>SL9IZY^!1A-N8ZFS-H+ &N5RV+F+Q9!N1DKIND")CZ *]\$HD6X[%F[
M3,='LYFC*P[E'.T,N4@V71+7AD&RA#2/5Q2"03*6.8JKIPNQ5;[ <B/K&-.
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MSBL$&1ER:UI;*"\%_?H*?(VNHO]UCM]'V;Y'"?M0LZTAB2(WP5\C"'/S6V
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M T]!.RT.!JWL"P9SQY+L-+L<*IB N6V P,5R%X3+-86+J+(>B/UZYFGT$H"
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M"$#]4=:K_=[M:Z6OTH8?A5KD#AR,ITKL/(S#)?)#TK2AQ39-D),N1OG\!7M
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MP6^ J5#X"6=A>M^RWG*:^BO[ZJ=S58V.7-IDB==4$SI8>$A#M"[S.8T<CU6
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MH#?LWY],EC28$-.^JCXU9ILZUJ*8PDY$T5DC2Y"EB1>*G&=F*;NQS__491)
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M0'I_]FH(;5JR/S6.#!W<'XS[3JG13D3C"W.G^O7!13>#)6WQSP^8D)2MZ&"
MW/QR^1%N*%ER:!H"=G"@30@I/.;SZ?182G,Z QI-OO6!M-YK\N?K 9'A6E5P
MAB1?4)_*'LG4U,@-9_<*DEPCB?6SW)D%7Q2.YCG,QBC=Q[6V0QDA+Y&LRL3V
MRC15 ?K -&,0<1SJK$;C:.ZH\SLI^1/UEY-C>';\H $.V%.#X)N]\BW!Y>&G
MQ'[PB)'*!VY__\6>KJXL^OP4^; 3"9W7WS+#5&^%-\EC2$S0U:<+3S4W*H>
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M6<ZD]3UO?\-P 'XE$K!P<F .3+!\XALB6&V99J&B,J@7K7V(\VBNF>P[&EV
MXC7";SM,;#WRPX@1X4=:&9J\T6<:*9.]3]I7B_=L?#SF3TV:PZFW\QZ&D(RQ
M :=;V93HH!T;:!7T&38?JWSQCS>G_:5RYIE[S]+@K**[22OEU:,; "G5EQ,0
MY34,M3Q?,^B,S10;/!9?=M)5^B6)GH=-'>$F_LPJ/_5RN# )[.BY)5ULDJL<
M[L>TZ*L$_>JE4]T1;&UB[%T,2;N07I!RQ7)TU4D#?FSJ\*'FH5,'RNC#-CV=
M;8BY:X:N)O(9FUZ'<D@@P_0-P+J5?F^V0:IZI!IK<OFU-9%0A_9%E!5I[P]F
M\^<];NXI%\5KWD'052L?JG?HY05HY0V@RI(ZH'C@&-+Z4]KKP/3DE'[ AWO%
M^^I1*[$4*.SVK?]TZ5F]T8J-G9?^=#R=K&1^G-[8X,3<ZU#TOMC'%B6H;"\8
MH1=0TFA_=$7:97W/*GO?+E]-TH;87UZS%KQT6(;WSU2^$L* 0D[TYFEPN)&.
M/>"$<@UB1E$.L:FAT_65IZ Q\4<(T5/J>"73E;3[6X%*#@B>&3R9CY$]A"+?
M1[G=9>E%@U9DIA*Z^.6C-QFD:H;""Z&;CS1'C<_2A;#:D[]Q4IXK[.IF22=*
M.9[/I)C KT3(&^]0?6]T8B*GXI9O]"PQ<\<^GU$ KOI3,)K@4@,*%NQ=A8VM
M;75>12RI$&Z^>6PMK_):V_J./#FP6%N\39UFSU^O!M%T*=6D/W%] +/:VEN?
M;T*_Z;@4._=DVM[)'TI'R2H:F]&9P5H-.->@[<K45^IH[XY1&CN&F93]!J-8
MN\IM^-=&FI5/T1=)KU7:R64$>IXXLJIA\H.;A)"H>U=0M*48X>Z$1C&XT#C+
MY/5N)PWI<\-S;=%WSMRQ#J?.K/@A1V0L*<Y$)[4[&2M7$VQ/G^87\H<^U";*
MXOWOY<](PDURJMDH"[O,\JW,M50*VYX6^=M@BGU,1=^\)A&D0B3T=/#10EP?
MT["[?N\J.\G]4P_3&4U-;2.L_5'5#:"I67=1S>"G.EW1JLM%BW:]G%O(A&9-
MRJ8.U+-E^P@63O(:HX<*ASHJ?YWM4>NG%O$@2UVOB7EE8N/B7;=0*SP![I5M
M'Y6:PK&N*L=*0N%4_V!"PCKKKNA_:R ,3Z-;2L$*&E$A9D'9E$^K:P31;RV;
M#9 R^^-Y$*/9VT6H38F9CU67BV#^ HHV$-WJD4B>[[+-] 09XR).U0&=+\5S
M^#2 :!T03Z>;#(KKN"'[&.YXZ<WGUNZ/"+_4K?AYM M/4J+#7VAJ&JR[.CCA
MD^)C&I>*8Y@I13Y*)+Z3803"!0H-C$R*$939-3,ZJN<<\R"!*W?<;<\Z&(K>
MCN50E^J3XTT*;8.0OXU^FBRUJBKC::<;ZJV3&8\FRZ0"" W^5C7)>4Y/E_Q5
M]2EL:ML/,7I>SPS7>-:W,P4<"N2\#J\^O-<OF<+9G:ZN%O^!J#1_KI_@.^67
M"-,HO-2ZC1B)EGYI>(H^Z+Y]=>#!8+[5-BY4-M'G)450WB(OIFY T AO.#0-
MFSZ1JX<0KMSF3TBLQU35*%WOXTH;%\-3^FJOD$,G]N1/=@,#[6K3[.H#)1KK
M$>CE2#E$==G5G4E6/31%V-= SFY/UITC31\GT?28 Q6%U19+;?*XQ=FQ!NC^
M@C?TED5 Z-HH!?<B7+,4,U<* KOG$]\_^4R@Y;W$/848"0G%7G'_RX<.%[W!
MX";Q(HA.2]/XOH3'I>KD&ZXOE>VNF[2/"3X06$1AOK1CG_Q<Y!7,F*AVLG<_
MEI[:GZZ-, ;E%8-C4X?<FCJ:Z=4I0M?#*C8TY2#]R_::NTAPP&S+M9[^=899
M#HY[I6+HW0W@8Y>$K@\A(-!PE;.V]>IK(.L-8-9D>0L,TH1(H*U;J2 DV3@W
ML^<.L?DO+!@M.?G\#G@#=8:C[I 8I'VL@\5" =!5'U.<$PAUN _:M_U5CE6N
M\D58?+L!C*HNQ HMRV*W^MO6"EX/!Y;+&C,FU008U"2UFO>.??P5*$3_/4#K
MAQ@P*:5Z9J>[V1DL?''!P7?Y;KNFA><ZIX7-GG%@U"8PR:NRJ&;"RK_7"(!=
M21F\+E1@SX+(XF!H+++3S[ FMJGGD#V%-#%%-L'Q Y11(2._.8  P[="=26L
M'(&GQ<"P9U@HEFRA=BZP=],7_W83U+I)43^BM--K[O=6F15JFXDS#>1%'\"N
M6Z_CKK^3'@5V;YVWRM6"Q+VN%SVD=BV>:M%EL$@4VO5(Z!O##[ [L)?M0Q+"
MACY(V_L"(YX/5PY9YXVQX)U9=:NYO4WG<"@%GA$_#GK@J2BCAZ&#@V(E3V^7
MJ5X5%ETZ?P_>TQL.H"6B)Z<^Q.8Y=N"% @?\@%V<])ET=A<;RU^KSREWRCXA
M$15/F*BJ)!(_>3ZJ/QG11+L-3&T;N2>JZRQHBAA>3:>/G\X?L)2)4;%X;*M5
M.=5G\WV<]1G8G3 /$(7< $KMEQ_< *RB_543%5YR%*]>SILPO.GK$0A*1)32
M!O1T4OT*4%<LSL/%E9CX$&*7)TZ77!DH! U#DGQ#'W O,!']ZE6%I&$7X,U4
MG9GE&W48P[Q&I#+S;J!,QG0B,N*4V3#B>FPCQTOPR;.^$<5G,'5</UJF<YFE
MZB>XVH*W]+1&IRP+'"LM?&J0P:S';+#33G]B,.R2 5<X3$V1B-I@.EI.F9D<
M6)[I[='O<^<LUM&/Y0K1T$V4U4Y9K&T V_V _6G5\4_)D,?!5F%A&?3.#QQ2
MHO3?TU/<-^Z+Y1W1!7QS8FU5^,"";H7[]\*!7:/S?Y9!X_]L=B#?A@-1#WXN
M"YKID<"X"WC\3TNN^?#W+O,6=L7["WT&-K%]3T2(FX/:]NMWFOI6 KQF*R"O
M<;06R.60FD"2B8/)SI2 M#@%,?;:-/K7U-&-LSQ;O.$C;KKNY@%\22O%X^F"
M96!-Z?T)[4FO42MJML.G'6OVLUDLKBX.XIOZ3F;G9?'F^0,IO2&>8E_Q##@;
M#+330?U"F-I!G/)!G5FVE^P"UYWH Q)9A^7K1/:F]S (R)]T/M7@[X]V5K1F
M7"Z<JG5(:%>1<U4M$XR.66B3*UF&-_B]BV2VI3Y7>R[WS+1F@I)T?>6+J7,;
MU7P5A&S:,[)]30Q57O BCG0X.6X#9>F>*5XY.P;T_&<MY!.OCP[^"!M9>98]
M['GFN_"R/[OS9XF214BAKG)#]699\WR=6W^IY^:DX]ZZK]X^Z]JPD$X-1BS,
M6=2B<N9Q?8S/A_0@A38!_2(J_1R/O6.//?,]9"R<NST#@''*7!U^<>08K;6/
M$K)@2C,I_U!402Q+KOD,0-O[T-HV!%=YR8SS7I-N=2W=2<EI89D23>OW*%\(
M7XD;!=ZKURI?3Y.^)]MKVH\.P\K=DF"G&/7"7NU%"8)KJI1)L<#?E4A<65EI
M>$B;DE1V)0KYC#N5WD"H>RI).E?371/",(.M[:YNA7$WBF5GVDQ9).EG<VBT
MKLD*N2%N '?/\$VCOXLW%(5ZDUCRNT<9Q#IBPUP= [ELXZ04_0VGTIZWU5.^
MD'] ][<-#GP8L.AQ4=$"O0&$ IO&%&Q+'3/(,1N'7W]/GT6F:I3$>Q&DNA-]
MKUL(3L]G32Z'"8D4A^45%1U5.FH?NS4'SHK"!O/=$2/;5D)R5&24-LPR0F[N
MI9*N[N.^S:CRS=:_M>F,,5?^Y%^X+=C\D6%<3SJ ;%0J";$._=?12JPXYU[C
M&T",4Y-*SH(#RFJ]FPAHQQ/]*@^\98_T/I@E*=BB/[@!$"E_/,7QK37;&E1C
MV%)RD[))XD7XJNYQ/5A-C,H:09Z%+3$OH8!*=R"W*YH03O<U36AM:TUKC3E#
M[QQ^=/W\H\$-0)'5"[+\R6HYUILYY77RS,:+O,JWYY]2%M9.QLY-&[FZ.R^5
MF(H$>A**-KP9DF4Z9TU:!G5KE"QQ(@&>JY*X+<=L$KV*'1DEC1>:4>K<ORUB
M=DMT_2V;J; :./653*8KSJEJ"N]7%5,'!V*/:U,VU^_ZO#$D)5T^&HK:XB;)
MJ.OV\^YHG:^A"N,0Q9A7NI>6U8)AO<+Z<\W)/PHJ-)N"$%9.3#P>]#V:ES3=
MMH7+9>'()= K].DQ-,?^B9JFQXC7TW# !WFGE[B9N:A!LF^>%BPCE*:QO_A*
M$U,F06,;[>L_KUBRC/*8#5\;<O=ML,OF>HHXU8R?'LG> .9H^'\WXZ+9:'S'
M>)*$V#*77SNY0*G-MRY?^: A\KB7:Q2ZLD3>E2^Q\KKUQS;G*AR[9#)7=RN5
M" -'QZ[(&S%/%_;XWM9.(QAB'E<?13?TV'0D(19PR<QMERU7FI@;P(I-;Z^(
MLL9?#FXY]L0HF$(<F;+RB!O  %_N6N6T'WCJ^ZQ$C98^]=)W] P8Z32: ]0&
M>8)C_[2M').34%X;I2LOY_(DSJ1->'DW5^E>XOGZ.*E:!'UH.UOO-.FM#(-T
MI[=F//-\C0]F2%-X/ GWKZH^K[YW"P2M?0+"\ -0VC*G0&+<X(L8+_P,^C1W
M>#I9UED$Z666??V+$+JL#3*RNS!L"<YYMY-DIS\Q0%03HF>M>C_[Z$Y3; >H
M\CO:N2< U,O \9#,HH@9/_F'E3,Q"?0K>>A8//;)W<OTNXI[%66.7WOT2^^U
M=]>.E"W">"?!HE7[OG608/'!XM4B_8*\'V:RQH(BJDN( _/37!B4NU_9BC,$
M0849_0)Y6;AWH9-16Z1X:?RD^8X!G9+I)V:5C?>_,K?8KIHX*%R5B:QO %^5
MC7"+$'FA)?5\N]E^*U=6L&6XP#W^PX[/RR'^'+F7#)W.:^PO#CL0,M,* CG+
M&[:38.Z/ [0)'!BNC:=C3S[YSQJ@_;$6DWAJG]@NQK^[J&)[O]+R2I: X0)B
M+F%*]K/OYVR<B2JC*A,->Q]]C(JGL".F5Z4J^;DI#:@S.]^Y3Y%/(CO>^'A2
MV8RDJ_(O+4GF@O'7D%HE%QSKRL(A#41L>F)TE1X6;7QA_T'N!#[=W#2S3^]2
M7AS=]_;[/)'3TBC]G#&.LP=$V6J=^4V.+](#F5^D1X[5<K),W?#]@R!)&@(L
MUK?W"CN6M5R'#^=N9G.&!C[<;6$?=^ZGW2FFU2@+PS$GO25O#MU0.H>]@,[O
M3G &^<5V+NAXG3$NO#\56G%B?B<G,\BQ01#X_$Z0>-J1W\^T60K9GM<%::;(
MQZ7RQ5*EBRE'9T997U:OP'+Z(5HBNI+Y1.>%1_W]4HYJ@CHRI5LBS*L<U#B#
M59/8N=[7&!ZX8A/\9.9,!@JG>?A4#6,J]U!MM[CZ[O.5]<UZ_]@'N]*9Y?3I
MU55EWX?7'E=DVBMTAB5S=/J CAQWHUE7O+'J;9I*+#< L&\C*K\6/W7Y>-&W
M4N'746U&*B9Z$:E@J$>('S%6#PND-O<A-&FZ'> PO88,3?B*"M9;#=RH%3T<
MJE]/HOPF*CA^>-O<K9!/;-F=%]:Y!'+FS9K >3,@=>D^9$&4>=)G>W,G:\H.
MO<IBE5)78CO;+X5O /;0C^]YY\:@5:'E1^>WIT?>-X"27;4;0+*M;MO'II?O
M,>;UROL!?^;ZA4LM;@#WZ))L1GQ#N(YI)/S+CKJHL'?E@-54<T&@1QXUN-CB
MVE BA#-6_;O7EB)T9G\)/S. U0&N.(=(@4+Z5[@_CMFY/GSP<^&L7..>DITE
MU6B\IN*1VA-7G8\^IO+1NPVUF=*%E\7FUYX[61)]Y7-]HTE!G?"$T&@E;\]6
M,1VYO<(M*VP #E@,X4%G.\S,&-/=1<!7=L=&V9MJ:10^)/K^9%\-'WFZ4TL?
MA\GLXB!&YT<TD?PV]E&#LN.*)F:(QRW 6BKDFFFOWAT([G<3G/]8!VCV"/X)
M[)PT57?,=U"F/C59IES0;!$1V^\V5/3:-#)46A6JPISMPW)QD:_1([FKZ1^=
M278;B)N,:FH?F @/Z$N\)Q/=& S2?9?AWB<URJ;+(/5GUS)7ZE"Y*KYE]M+X
MM'Q6F,%"07*:C5Q@<-&D0]<49L)WL--D&DLR+0K1=+\$X5YL=;.8Q426Z"D6
M*Y9EBOTL"G-A355^^D"6.\JRQO/POGW&T^LFF.2PY;28Q_&&#F_5;[KO>6E1
M65]V)>ZJ^YWD7/_PY,/%9N,09VO$(X5EQF:]GNZ\B)1<)^DG'8(E$5QFOZ/(
MD0I^0$/&-DXA;'#J&A2+A70M7"=BE3*W.ZA.6VQK#AM1AV9/A]#EWOGZPV]<
MC/3-3Z?C&UJS+T<$?3GD')-*'T]VJ65ONH [1E#S\.N)\\>QM->%5='/(" <
M:&6S-DP;[>OSTMBX:*&=*6GO4Q=Q!VS@:<8\7[,_5<0-P+8UY&57"T=+?<1L
M)V/-%D/2C(SX/%G>BQR:N\SSNK+Z5,/]"D 5#&SE8SBF4JVF9LHFOO-UI>5,
MRM?[9-UI3OI4"(,OO6Q?@F1'?VUGED>Y^83I3D$LD-':/=)88DBQ_,]?C XG
M495:6[:$@N+=K@8]XX6A.>F^!C_H$C1EA@.;J_?<)TL3U^R0C@//-&9"U.^F
MVO/GQ%?JF8GD"T*S>GVV\'JMSR\6H-O![UF\OU9EL@0N-&QFELZK%\S=V_RY
M\,]3UHJV^P?L/;[M*\@,(83GZ/S6I2.R.:PK%G4#X-O/>WK]"RNR4*-F<.W\
M4SQMZV \"S^J/-?*?HCG@3J?+SM(<.Z/EH,76IYD[D$ZTZR4O1JX?ZVNZO"/
M3+SU]8+28Q<P"T/(#/6H0K/ZB29S/K@#$FWB#T(O]V'2250FFY@O?;KS[&K>
MV,,A<7T=,XN?HLG>24;1JP.<F'M5,L2[WURG7\GF7@%QI\B%&P#+N_82!X91
MGG(XB-]GN@D5)IY!^IS^^<,O&;^Z_:=: 9!E."5G^ U@8>YHTAD+G+NX 60S
M*<^<9URV'-8V6URI7R?L0]XC!2# U5::99R86?I0PJAU;F?]Y4B=AXW5,D7P
MSDSQI1Z%Y._=9_7Z4:8E!SFI8*6&4X?U&X %TEYS.IJ>OZ-ILQ AH$6CJ5H6
M 9^7A\2*5HSOXYGQ"\:!<:M,JKDAZUJU7@^<Q'_[,"^Y9@ Z^K>?[8N_:ZUP
M_MRDC(2&(V3 4,V:Z8EQD_[0(W$>!W,CXIJ,>VTK6-1P #':"NLPH43K4"NW
M,9+OOJ9'8WK7H-"L;#ABV=_AP"IA*9(VYMF6 %H;ZWN;M,FN@:@=;K'> ."W
M986*;]]</?&XTO.8U1O1JZ)5X_AR;CI?-]MM_>O;DLD$G:5SNXM0UH?=U[94
M1M5T62A!G8Z= @%5_K)10ZR!QOGR;5KFO#K*>)N@1!G/)( +X3OCB;4U#7H2
MDB("IB@%FCLKMC.PP,&4F%^K5$P0D]#SC.5.K)=!TQY;5 E7!-!4@(A]X=UG
ME1'78//3_RT/WR/N7">57/&6XF;V7L]25EJM^?NB/E8Q!&J&6[MUA2'FN178
M*'U+Q67+6)K*[QNR1OT0:=4VA]M=__-7]JX,&3E;MJI AR%;=<R$CAK6K[0*
M6*&@KT<S7 9Y@('<)D0L\]L<=[C4FZ:JA; 9MIZ$/XQX:PEJV2J"_$YA'ZZ_
MO:MM)R**OYOK<M<_8&!H$FHMHOT/>N/6Z3^XA(+\KTZ;Q\O:,>WTO_Z*-YBM
MQ[4-?";HU3W=R;S30J.#!K5/^@2<)LZL.=;6QUC88]V^)*KHR[3XFF[%5 __
M1+HD/DGD'T]?B'=<:S2J*3.#4O9ZZ21]E'1G>9>F(T//XB1F;,_G#Q</'4?E
M'OIG1*O2 7LR<__CCX[_"V6KWNIH)7:0 7MZKU+<W=V)V<P 2Y"XN:<E":5L
MHX17)E'9-=5!\HX^R0XO[Q.]XOA,"2@L*.75=]?4TIGKH;,W<'H=H8,UNL__
MIU+Z=O?YO_3_12K A"*:IO5^=$"L'YG4I>7 FKQ=<@.HUMQ3A^><%F'=GF+'
M)/G_YY7L^3[%*HK[0LHH?;]Q;*&B'=:-"DSX(F+T\FU&54"1GK%B6O#"\[$_
ME?AIOE).AX296-N'_V7AORS\_\5"QI2";LK'_'RX]J Y(]D-@& A\YH4^#S?
M+7CWZ>OI]%\EQO$-#!'\.:_[H=.U$Y5"NJ!3\$G) "+9(+[U^9\((:L?_'\B
M /^I"L8TEKWW<51KGO84P ];V-+J*2PP8[FB$D*(,ML,=U<#Y6X _:R8S.N@
MK1O &(6SVOW<=^W[<%#X<'C1]EBAD7RWS!E7;&BKW7*8N=@,RB-:K*M\M,!,
MNL\R">[SLM:&@DMP_810EN]+@ADL_$HG#R?SHG'&,S*S?*<F@L7^JB;@\_?L
MC=>:ZS%!+0%H[TX]#H@ZNK53'+:$<YKL\'OE)9=8.!G_L=5# SB@+BH=I$8(
M?FB;QD9@&A")BSA<N0%T4;%J(Z&TUZVZ4Z+"I2(&!G$?HHGBKN9&M"G6*9\3
M5OL?#;I,%B3*;J?HF%_4VA1%:#N-(&S[>N5Z)O]L&">5B6HN)!J+ZR!$=1I!
M#:UQIZ<A)RSIT<T;E>=)L]0EXTJDBR42E%3<07)3IT>/Z[W7E&D<$4_(D,H/
M=ERV$90U,X]".ZZ1-*8B1<K#HVJ\M59$\?<4#%OOX4;-T;T15]PE#GC162DA
M16@GHU]-+GF%<%R;54C.701-(UU!E%5P0AJZRTABP&9PF+D8CJU$#3O7;<<^
MZ$U7\T@!5A^48MP0LRW8<\YW;T!L/@:]WG\A+R<-7F(R:HOM+EJB"W2Q\+(&
ML;)'"\X\X9MJWQ@0S_M([P^U>3-SP;:E _DGE8BV;P"TDST9O--2VB8_84X>
MEZ5:P.IXN'RH>NS@Z' BH-QJC./'U@^M5"U#FN;X\8-#FXV_A1@Z1P$YC]0-
M?6?#/[%"8.\)C8NUB*/8SPV(;*3%VC+CXO+2HKUQ30'&7GJRTO>-\<L?P.A[
M'4GRM1_<@/%Z>G<P6UVQ;*8078SSW&ECM-R>YE3+:'Z[<CA8<D$RG)-[J"K5
M&4XH)E]+U?3T.Z"$WR:AU-CC;;RKUMEA7B9?MESY>Y2P-$L&[R3XK5._PS[,
M]EAK;]9\"_ZC/T_;QSKI98VD_I!K&D$_+![R'"& >9R%B7R3W*/$-;;<Z:KB
M[IQO?Q',(\#]:JC/16] .B[D(8U[0D2R 6;X!A"EH&J9(8B9O@$$[5N@ _)*
M[6:\A>Q20H;BLAOEXFHLZAK./[A7?2893D\RX/N85],XON.1<KJ<-2SZ**C!
M(Z71WBPG/9>_YK"FW#]3%Z?7G0*,@2@[EFXG@\ 3![7G3\^=.5!E;UJ !*',
M&NM>I7XX[S9X9UDD.D&M"5.6NS)\!]O[1@8H#=R<UB:K']B('<CY?G=-L7%F
M"=:523.Z6BK_J@X3<J7T(+6[TEX$*:XTF%>M4Q:,(CDXZ%>RV,^Q=?A;6K1>
M8<B2KRAZIF>]7EN=.FGM-K9F-_##QBBC5"0%EV:)==I5PAZ^"GB_=LABAR":
MF'PS*Z;4^?&8MZ%_0^%77,MVQQW?7E/+FCVD"+07CD_X@ZO4'+NR+<(%/Y^4
M*I63YWS .C%9F\(V>.^7BXUIE#4;I/E)1S7D'8)[QE,LFB4M4!K#\3.#.9VG
MO*)\BN.9VTOK)R->JX&[*]9;*9G[D;R^"Z/F3343LWJ(F1L ^D*4NREW4*=5
M1$Z@WG^VTAQ9W;K:4NYX:=.B_;C^F[D"6,(DF<-*+>>N2[-6T,"];3(JXU%T
M;V05E'E>S_</J+< _M(%6ZH@.V?],O2^1B<5-E1E7P?2OZHM!*()'$OA/?NF
M\-*7+J7W:\DAXI[3Q#,8;\(@A>W?* 51F?*OE!I\^?1[#% J,(1[%:S;:XQ1
MON+R\@[DK9LJ%95,?_X>$J]A+.3U\;4L&QV;:_NS,N,YEK<T47GG*7I.9ZVE
M,5?2]B"ZC6<&6M1N)GNYI>LP[^91PZ:FVLE2OH:&#'G'=]2Y2;YI7&H1$D-#
M/@" )E^N2P8M[G*%BG4O6'V\29-XY$_;CU"-W+"A=L!7>_J7&7X"/)\UF.Z6
MMSHXZKPX7LEH2*+6E,L*=2Q8N^Q9XC%*6 :0IWF1U#A4(91Q>F5[($K4!W]V
MRQ,MQE>A??=BTB!9M</1NE9MI "+H[\DA!8V(Z$,M%DH4YO'Y\F-8.&$QLG2
MRU+:92M3(Z5<8=#?J"RZ'Z!FJ'^*CK'H[DRM;;&VSJCEGQ:1U#7I:KZ0:BIF
MY2Y%W>4U.N/9^2RTVV)L9478NRM8A=5E3CJNG?OR:CJ3R=%<Z%*L&TK;C62'
MZF9VRBV2V>1U0GKF[O&]M?;$\P*BQ,C:5P[*IN-'L.[:)I_.&D!2OB)>B\><
MM/H;;M&/3S:7(-(_RD['X:(8/]3BY>.(<ZHNN</P*UIW#*>Z'N->2CPL%%7]
M[L!9[%[2/?B[8*8(Y" (\01>AP1LW<G,\IE]BY[]UB0F%@+Q+O2Y.#8<$STX
MU1'%GICQ5NTX;O960S?B),@_*3]9J,I,R;[D<E(83PDPBCWWK0Y0^MBZ1_]L
M^(5'BG?EM)G_B)S(1EG9$E69'>R[PB-DNAI"+\SO(!7#:(!1CE!0*1)F:0W=
M:GS_(8;12X+^,[G)?AM@Q<6M[K7J.[1>E!0G)>3]A"6&)-J3BK8EN^"<VG2;
M@Z^V\:]WXM\"++&,6K 7V9T[WZ6Q?]XK:AP;.[ZZD%PJR\"BCK=KRRFY<Y6T
M)^TU<_WS$B<<4" S3S.Y9D-\(OJL2YD2EZ\=H*X[;1G?[ZQ<.31Y]S-K=/LK
MJZ'[V@PVA.R:@(\-@CAWPY2];@YJ=& NS*<8&,*-&4H2\WW\YZUQAQ:GK-EQ
M>38@\=.JFT^A@@Z&L<?-9ZN++,\G!<4S?DBS\(\_C [^#MY$G9FX47O+N)#N
M\\A0P %S7UM9<KS[P-06^&S'%GS2>IK5R<&/==6M?GPXZ&2V-.FL8[Q?'5AP
MR=C#(3%^19RE4[)7FVDQ:6$#S!SP??(N!)1(H*B!,H6%*-N!PA RLP_'3YRI
M>]T+1C,%F47RPGP)G]U]]5JOQLWQQW6)=8;S_/&;^,U'Q(.*V=H/'NZ["UI;
MTZ:QQ50/.CS%-9K@EE=08FL:XU65>><-,9&BD71![/HKQ-=M*4:\I/*:Q&JN
ML6LO3>L^4;#4>>N#C_T7I+#Z?D+RAV5%@P9CO1_K4IBZ7\2;MC8BQ%#]^;[N
MO.P,R9&-D_Z<_[P!T5Z)XA*0S?Z]+'?S'U>[B@S/%'%-"<,@.G9_FR@>S\:(
MR XT/&,G[>=QD2T+[FAY,@41QX#^47J(*<M:LP@H\J7663VD75B:?ZK5Q>.<
M3X<HD'@IL2+0@W %&O 6Z@PH[%3!;*ZA[4<2V5U3CFJT;W.R!8P/52=!O9.C
MCM>NJA Y!=<".$Z^2XF+DTXJ!^/UJTS2B(,CX'F3>^\FC(*,QMJ4X09@3;P0
ML=L$0NKH&<ZT<)OC(GOAR5].1RF_S:J/?8*]>C#Z5;0^L@1OL= W0ABUX?49
MH?U&WAU/U6#B:7XT:VG5-97+>BD3@.>'SR1,(_HO8>IE"*_;6'W^>.0&T)U)
M S$ISLM?RWS@XXJZ>@0NELI+]!L3@T-RY"-BZ-_%=[\E["/"O/4$T>.*NT!4
M"H3%HTCH(]UTKD5[%Y\,=L;7#=]U>!R54[D2/1=8@AO3@F,TI83X$R<\Z4]:
M$R<=S1I8E+A"<GG5C( U<+B6F,YT656E[=S_(TI'0\ 8=^!L*838,<<!\2CX
M>=U$3GI>_2SX)'(P')FDD3K4Y#%W^8)R67I%;]C\-FC<-JZ&!3\P]8GQ$9.B
M#_5IF77VII@8B7AO&!7W5$B&57/$+5]ALQ[#;/./%*^1FW&C21DJ,.PCE7QN
M#$R0[O=)].&D]=GYSH6]WW?\=.;]K41N$#V_[8??S=$349GZEFT<6Q&G/KF:
M:YK<GO$R!(E3ZT\4216[(<HY#DI2P5CG,<F]J?'2%M;=A.;<$1A]52UCBA]K
MSU!%'KKN6.9#@<('EZ[;<#F_5DPAZ>#%P8*I:<TSQSGJ5 4)N9;U6CE*,$UU
M?0CG%O/8T-V4?4W *2T=<5)L0[=AJ/\;<61R_&EBIO_]TF[U%6S- A=192<W
M5Y!_T)V3+-24D*!UE"Q1,6',![-U+M'-<JC=LW2R8"RE_@6."AX2#R)P:?8*
M:K/-TS@MW$-:-]=5XVI]UV2;M M>EO6O%)RFV@W#U<3$R/D[IAX_P<23^3[W
M9$89W0!L1]E\>HTP9V$VR>_KIO9/Z5(O=9=?8W1RYR%9-CZ?CBI4JD.U/O<Z
MWZ;4TQ*^:JF%S,6\W@%2E5X@;X37Q-HSW2J[@82FG(F:!C.A1G#SLLTR;';J
MC2ID!ZNB2O>:X/] 2:B1T',V"-]IW0T ;KCS!EJD]QLFA6F]BE&BO5B$H@1/
M"EJG^<: POC'?G0M1$H1_ 52S&(7-1=&-O:#^-*6Q%\F$[MNP&VZ-ZJ?W/ZS
MO^.!@S> *J^0&\ ]OEYEDCEHA]CM8<RUH/MUW'46EE.&?$O)24WZM!=BV?C7
MQR:B>'^QI&3I9!LVG7M6Y?L^2?K=?8Z9)YO@7+!?HX<^E"=5Z?>?EM<8SM 2
M/"?D654\-)2AA2'^L&OF32I9LP-8Q;I#:3ZX5S#Q@S8@!UE/$F7M,]J%4)BM
MBHU.:EC"IGOF["!4F[ZK36S>/5;_(3)UE:5!XNO\\WNSXT2H <ILU4 ;?K T
M,3$1[W]V _BR-K5&]2&E4//8& O$O]<VM^LNY5YH27'$2JE +<!%[W5L_<'T
M2SG;5DGWQA3<!'9+\H.HLF#I'GHQYOPXKXN/J6O-8AK@QWKDZ?IM]O$#MG?X
M*\H'AJ23Y%V\"@!_91^RC*#%4#;%N&##E!Z,)&N]J&1C\9[A)'>#6E4*/X>S
M('(8H$RJ(IYFS<;A*+:?9IBV4I94JW<![[D![%$2U$T6P']459IY7!V4XN8N
MO$9&EG6K@F9F2%&E'U0C^!\]#V?A[R@J6 $  )2)*1F48]P33E758R?3DZ*+
M@Z[6(MP/AM:#WD\R66JPQ<T!J=%B/4I2N.#5.<C+-0U)(3/!"P#V]4ZQ3&:=
MN)&$L^5O]GH C>\ZQCQ@52],CJ\7R@9Y.=7D,+E[F.OXU)Z!0=DAGJ<RZ&F(
MYUONI"L504VVS8H8^LET5:/<'R+^CJ6HI4]7(^%(I%$Z8UCNT"XH47O)J'KI
M)*'21,C!OP\=& 3S0+Z:#%XR(9,/98C;M+N#HE;FE  C[9%LEM^:N+-4I'Z4
M;S=XN,UU@%%F8&X*9VHF >;>@1R:)T]D8;%.U>D!)5=/_QB;<CX876WEJ$G/
M,0=I'RUR@<6SZW8)>C3X[K>1 X0*<+D8*Y,Z] W@VY40,I9JVQN.B"UX-Z34
MR]M7D23@\C9*H^*NOKI1^ZA0K^*A(&R8J2?W\ R.;4X%+GG5]'ZOO!+CV1)4
MJ(%?RM@^+DNH'%_PAU_'9N_CV7!Z>N^29CLNI/Z&IR,?[& >]WC"URU\A'\+
M*+:U%P6*H(5V PD;T*UA?'_1W;E#>I\0YFF\,<],GWC&2'D86C7*KGLB^;@[
M6QX%SC+B&3$SE?GS*MFBJ=FFD>\_':KV-[?80+3&&L02F=@!"9?U6_+J^LM,
M5][(V =[_>BSE^.PJG2J_3U)XRH8^S2R+_?;MU#2GX#8-&34^I9=YR[3MMMT
M:@7BR,^C^C#?\-IT%S\]L%N_NB/4;#EET(C ;LS:M2HR>D*-T7I?]Z_(5A6%
MGO\5GFF D-UOO-[B/I0]L]14K,\'^0AUPO,J*6&^OW>2_4J(681V]I&^2$&W
M$&NAN@>^3 K $?ARU)4G%$.R%I)4(KE3Q:[<":35^3/*TZC/4.,=39+4QJPM
M41+=F+<2!3!UP(&0GK.?)=GO4ACH3.XKR+BOBJ$4>8Q+YF6H'XJ!ZY<J>[GK
MR.OY2FD&,9Q=48<"CODFQ8?+&TZUI!]QRJNZF2+/S!QJ-B#%VG:P/][-)^6'
M(JLZU#%YNK$?H-4 QO-JO9._!(3#R*V5N&/;P@(Q",5JLZ;D22,:G^B1XD:Z
MG^3/OVC"W\.@ .N[.[WJ.N8'' T4NRZ :*]&.E/-F>:'>32[[6F:&6'!:F0U
MM7?5E R;[!DVJ2KMA7N=W"3D@,7;"#E0.)2@#*(ATM(W"]<9]R%T(MVMX 8$
MR CT5EL9$$=V]D@]1C'LI^-!\9<Q1<P9H,BT;7W- ?%->Y@:?O/T^.#I.QQM
MUFZ&-/J@K.8BH"4\QUC/\?JSY+KTY#UO&M?OQ:'@.;B;;]E\$]\?I>#K4+AT
M!ESTS@W@8^K;2VE")\+!GN7F4=VFV0X6CLQ5_^4[.%N=<0AOV1Q$Y[^Q]YYA
M379;NV@4!96FTKL*"-*E=T1?NO2> !$%*3%T"#V*TIN @'2E2Y426B#T+B U
MDE ,O1-Z:,EVG;7/M==:W_J^O:_KG'.=/]^/^>\9]QSSOL=XQAQ/G;!_5KBY
M_WQJJGJ@9C50;VQ;UH#<E&(H3K72CO#NW-P91;47EI</$HGFD>=^=GT"&&(5
M7:ZM&J_0YSC1R^2F.%(IAU%ZKFX9E;FHESF3Z=JDXX"*G=M&RE2<C'+2T"FT
M&17)3W[C?^0Q6[B4\2F8R;=G2%U@SQP$,J_\6?K;E;HPGC,1Q346ELR.\K"(
MYK\(39*;HW/Y.;T;,S&$$Z9&&YN-UAY;ZY-?L%GLP>*R7;E4C$]JIII%>U1J
M92(/=YFPH&FU+[ZPSM0J#"HG:.&S*#WXM*JT2NNK6>155U/H*N5$]E=O*1(@
MB@2X[<T5X7\2WLSE@,N(ADKHOC<Z5_]R()9@(]9MF/#60R>PZ):8G&+40?#7
MZ&J/Y"3SR=.*EAWTR!#G_'$%&,;<L:T,XM^LF7:%\.UCU?TW"1*=^];K)[I?
MG<J]B]2K+)^_611UCCXQD^XQH&EWCZHO7?-W:75).2O,@7Q[DBA4RC C*% :
M%T-V]0K+;_0'1Y5:VNC@AZUAM2/7UED5Y8=V4A]^@XL@> HQU[72KY;047EL
M?O3#A3<RJ.#R+BS+?_FJ8]5':S]+7>H8(T==;5O]6.<4/INI9+'<N"_Q<$&L
MEPR0=,!TF1&]4N,#&8$2M]-4L)8P;G?='C.,O/9%R2#2:O!,8_0H,I? UAG,
MADHYT<(34POF!D)Y&JJKXU@XM*Z%#'SYJ$G!^<4\7*5WEU,5YWJ'VY'5NC>B
M5@GJA<66:E:\_EY?C_EQ(A*9YB/2F:C OLCM!-W=5H#G!XK6316VX@N_E<X[
MZ]A?PT!F+U.F;[P<FWFZ]M :23L@]T+50,-([K5PP/>-[;S3RD[#0<7!C)5O
M10(>DU '!\@1*MUI):#F;XQ"2 !L[!]*RY>XMKD=6!K[K+^<?IX]";9ID<W/
M:0_F;*R?>)'Q=)SWO=%'G0"VZ1ZS]?8^)U5FCQL4PMF0$;C#?*R,"N.V]R_1
ML!S>G21)9[2_T8\4],U[+\NBQ>Z*2(LIM$C8@ I]HWN(=_?">X(@'75 X<FP
MK.*,EB?.E7R?UR*V_KI_@^46<V)O0X^>8QC%[0V]3ZN#_+S(G4G$>LO/DM>?
MI=13'F0I.YIX3$-R83YU2$D2P'@N^'Z@\-B%.ZX<HA_&IBMH.+'-.'1DL36Y
M8C&9'))X*\6P-A!9-3Y6J\CRIZ*HX75CJW^MU]UQ%H1RM Q_=77\..AE^D1H
MB2HS(?.N7^6]ELM"T<-!KMMSUD['D71KTNES;T.M).?<+3!RP:Z9915Y2Y0?
M\_<^:KS:\X>J+Q[[H)<GQ_@16I+0$\.V D-> 4J!$"T >YS6NK9%H D]OTER
MWB/> Z=@H--,\0*>@=>8X2E3Y@/L>JY'?<$LQ@<)S)H,?Z^H4@!A8D6DA!9.
M;]1?_X&>.G;/WV>4>SE,OIC4W[\T+JQ(C4-20X\R7&G7?<Z0R#[,!S/#\DX)
M!W?QZS-:_?TC<E)[E>&UKC3.J6#:PQQR7WTK/+I+CG7L3-?<,+D<EWT])FTE
M1K&\A8VJTYGJK?NL7G+E.SA.F)"V]Q!,,./"Y_C);VT>QQ,T56J"1U)>U;O@
MD$J>F):;]IGE!V80O3H]=+UE@</8[I(O?H1^PD]L%#JH(R<5;.. X!.QGQH=
M6Y\YPX"O^+Z&/CKL5U3([R]L[EDNP_1P4VK[]QF[R, 1,:,J;R\D/(LQ&W2^
M,*T4XD]UX9WLGH<IMW,VCA];5<Q0O=C#--\CJ.CMU7=3D^'F$+;2"3AKIDZG
MXLHPH\MISN5?Y+0"WYT46WY1\"7SN/V@T>_>#6^"=^:$ N.R\C=K-H#@"UY&
ME/KG [^$]2?+/R@3?]P\D.'HLA//=!":^=[AJ2?94F.4W.3T>KLI &M6=^#@
M_;PS)5F;!#"+_B!27]-LNNU OQV0?[(YD'"X4Y7K-'?_>P"'60?:N-J#$F3S
MM+JGBSW$]!T%17J\.7XE:8'LC;>NR*"1=+7?=[9!K]0!^.[#WS[9\E&G\\<)
M>*DC=/R]/<YZW)\]-0N!WVG>SM&K'Z.0Q7MBOW.''C<\4V<!E;T2%6H$O=#&
M_U$??JZHL? K&%NA7^A8UN125#R\Z?%5[\:G^R8PJAL\W_JO+1W)C;?WIL1<
MEM9FU9K7!"GS5@9@!U:./!]Y+CQJNG4XN<WGP%_12CF.:$2,[M?,0B\8<)O6
M[HAB20YQ#OOI- 3SUB(HQ,(V\J/(UD=-Q0/=.KQ,V-91SU3YA4I!>YE$;6RQ
MACWK#..+9W3WK*?O968>)%F9M]&&H=CP#N\.H6"-<51O,835-!,][K>ODKER
MKPOW.73Y\\47[TJ5[V,7&K;G9H1@5SKGG\XR,*#US/=V)Q9-X?L_WG$_W^\E
MXXV@X&-_2^W RCGF_8JU8E0_:#9E"CF^2E0?ZPX0,!$PZ2R=2)PNS/LQIK?-
M%V0VN&KO.8IBO: :#:2XWCG7:5OIK&&485 _X3 ^^KINSN2#.F]$.TL?=Z6J
M=5SY[U9:R%D,:UC15Z?TV N D(RYC_N@T(N[;8)B/"\2U1725U'BZW,/)@/I
M EQQEV;4#%024D?8+KO/3QYXF-WY*7&[M"&A]J[&/3.9+20)P,/6 3\:<+WD
MXE73AQA%]V@7+ > )E42L780G5\&74)-]%!.<\&6K'2SJ>U=Y*'Y^AH4-\2+
MH"P]*)C.V"P.'G'W@HX/I8ON*+P20O5&C2 )?CC0I?R(?B-^.-[=U@&Y-57]
MZZ]1U8;END=6(OI\9.G[0W0+Z"XPVP8FK@CG2KUV%OZA3.KUN,T<)"S>,,V8
M;5G]M47;$CMG@.=4X^Z=0+V]HNC#^2@#G4)?%]<;!'^=3;;/.]<'9F9*2B,F
MWGR$4396-\L,]I5_?=?US7)($$@\+LTU0YU-PSLS$1)6=.'BA;.[KC MD-DN
MM!8)5W@3,%?T-P:!WH4YQ6M ^\O0+Y10B*<#>\)3 .:JX%4FLC@%LV1$*"(K
MQLSL>%35@?XE\_;BDZK\%R_N&;89R/8^-Q_$P+JXF-:590FPZV48[_C0!_AD
M5 G&2EBZW?F>L;)'5W/)G0\!G]]>75JJD@EF#9Y*G1/>FXLMW!!;FW\Q]=KW
M0>UX]PA6B#EGUF_D040^Q=?]2\\>Z8QL\R@WC^B5*/-Y* G H:*39C3R_59N
M#)HG_]0LXT(I(&!@#C@MB%WS;1;,5?V2=5>)LT.)_IMQD7 )92"CD$9J; -/
MHN^&ITEX9^4MH5%MQ<=Y-U^^Q?0LZD=[/#7Y&L/1?-_,7G"<2L/_-+ZKE4'Q
MU1[9[S=$OCWI<%Q *XV.)[O8=!%FS"'+@;*E[KG86Y=%'RW X4(+[:)H3SQS
MH&+KI,AA$@ZJHS:>SIL]I#8[= B*BI^7A"R#4F;W3S_8D<7V1L&G?Q7PZDF<
M9#AM%DPVG:"ME5]:#I,;>!?IS\2\G$J?/I JJ-5)V1@Z$T%U!#+A%F%%LUF4
MSV6 7A#J3R3 J_B@,LB)D72/H;HOY5O^T3_YO$OK3 =V M*D%<[K%=@WUM3$
M/>*Y%O),O)CG[I75AA(;OCWA[OBWJU-E+I+ERLOEBRDL".Q[ZLSGRT\.K*@6
M5]8>)[U+R(RGXJI-C:EMX>LU=$[WB7Y8^=42.P?2<87 J.[>Y/WK?EZ.77AX
MGVVM>X_JD,?/C@5WP^"A(QVX9*LT;&&/P$ZUN/VJ5$^K8%KF!,,W+FD^4I?#
M%6B-"_)M7U025),VM^'* -=8<RP?,!A:?C"26&*\[Z;)?.U]HFR%CLD>7VPS
M:%$TY*PWJJP6!.+0,3A_G=ED/+C"XU+UG8Z"Q^Z;T:T<J[?NP$Z!DGG4F)G+
M2<M6QOC.Q.JW'-P$',:X[)5>8X:,0F[O/42><IF/@L4).@LBK87K328V+..'
MFY7T@:I3" X]IHG9[I:69NA;L LS<4?Q+:WJSZ0H1$7PZ)S(SPN%$HQ^WCH7
M/G7M;+DNR:>J-M[>+4FH+)[30IQK]MT!W8:&+-E ::-'Q\BJ2UT+TM/)O8P$
MN/5UQ%"JX!@*'8*<+#N;7>KG\Y>YWJ"]'4M.2] &/9<?%5ZEYK!C;'-1>'H:
M[J[@GNC>KYRF(+4XH%CMWK(51,\[PB (O.0D <1RHP1TKT;Q?_D_'33</23
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MY0]EH8;TE=.8R";I)(4/X(> U=CV5E8O+A8O2*SX, XJVKT]_/V,Z=CFU]"
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M!C1I2;MOO'8GP14,$"SD/:)IKQ6Y)=$L'KKAP_=D+.6,S9H-JDC,N SZ^A9
M"T1@D@*_J".JCY"3&C 'IQMN=DO[$-&IV0'.Z681A]P]9D]/! ;/[(CYMYUT
M/>:4U>54N&QYV7C4V0[%@OQ>29G!(NO"CC:07*&>.#5MVR%"-^3];D%P>$</
MS846,"GQP8P!O8-M#3T&GW<OLS/VB!F_S33G^G0TKV,V\I9%U%TM^:<?X,@;
MX;R285O&&2I CJ9+&HK'KL4;I+6[CK'H;4N9%VSUSIL,'8. SYPS[/%DNSIY
M>D.8X[F<IM%[$_M\'0B)(^E" Z392ACP^]A&D=3C,IA::L0&7+6P,JPM.K&@
M&&!^,'V1FG+SYG"BL: W0\MIKF 6_;B_(,":5<30?]'JI5LCOY6-RZ/(;V[X
M%<7W )\(>9.V(S.'&H81<+<5&_(S74TN/8#TF8S]I83H!N(L9/$@\)F304OD
M9J4VKG;6]9<Q]C77&!]I[BPLPX>T5OOW=X<(4+3(##Q0F+IZ"41A7E,1#Q4:
MXX0E73\%[Y5\S"E.?MV$L5BPZ[M">I%\PLC&RUTS-AH1F!A?>?!<=S<147!N
MYL:Q9U?= TU" W\:+8?60BS$WHF L<KEWOV$D3CT61WTWJ1;)WQ9)=I(P =W
MSN,\"/U"I70TO9[$,4);VMHJB'KX2=5@3$+"HD$"?FK@*1S-34J/\.9CV=@^
M1OQO)XM.!6%;+9VYWVH54VUT?K1=[=^O<X=>B]]!5L((!8+<(+GFN[+@7#^G
MXS<?#'QHO'Q?+J^Y\@11*0**[B;QJ'3RREW9=:+.2FL"&RTNWFRF!(Y=EFX7
M3JO<R:ZGW@.^RH)./_'MCJ^ 2C)O(ONE[UHBX)N_H-.Y7IEM@PLEG)?$0Z=_
M[E\J-O1W*Q[R<))0ES&W)S<['D4<\)5UO8O!D]]8FW]%UA<^/@JM7,ZU_"&<
M7XZHH ^&(C\0'Q*R='C)S.Y] :[AB]L#+&DI\V$Z;KJ32MI;^A22XP/)6=.]
MKOBQ]HXX[-E*9+ E UK.=>F$Z@=M.F35,[YZ83NU68A;@QI>'H;EZ,*-IK8"
MTK8<XGS'0V[SYEU%0[N!7PX@WFL,<LQBW/A.VPU<D+GW[HLS4.OL?J*)K&%%
ML[3Y>*V"9^">&<< ^A5::AV[]*X#8Q(QQL CK+-\.;E#BT*GFHQD:/YFW J#
M7SC<%GA2TUW:6Y(4?=*7LYIJX5X[Y'^)SSAR%M1O^^GP&ZQ UZ1=.'AD._*]
M:#B%0RC3SVG)R%\2AH2)M3J[!@G%O)>/-\J&=3\OJ\:WU$1'&62BHK?7L=W>
M9_H511RM(R8$-'##Z$5$.E]!FO5"*<A(GQ@LG_V*E/+,M[#<.\N=7A[]1CZC
M7%T1P!!5O"XL2><W59OT4X&$2+2FD&OV8+,0Y\A^/S4%%&18.6$O?_>R<O1Y
MD]BNST>(M\Q)@34/:$ZD^1PP^=72-N_M49\V9'O0-J,_>5;GK<%STN0@DF<L
MT12A%VL-MJ'X ,JU*F??P0\I=6'+?LEPSA]N[U\*I^\G4@<M.8SOH2>VOL,;
MC.7LIU5&"T1CX1?7P)VUC=LK9S43_;S$BA.KD!:J'[HO)T^]LULR2Q5[7-??
MHVKDN3091?;-D*@7^J9Z2!<I#3?C*\MGZ63YP]A+(Z )-&?WZH]K+SP3)WA+
MG*6?_*AFNT"BW?;)+$2GUY;75VH<0U;KUW=AW$7#11NHUU =-'OS'O"$#T]7
MRV.FP+0((LVR@&$L^]7AL9 ,;>WKIWE--VTO(A,F/C42N>E]Y<]F:',!3M1\
M'C6JTLQ?EXX6J5##\NEZ5V+48(-E(:Z6LQJ=_73S/(>UUP[TX^HN?QE$P!4F
M#\'4'BO'>9WRK(LC1<XH'G>P+IMM*$)"%Y,R,IP@F*&F#E4Q@3':)IP?86JM
MP'8JKSJ-]G/V8X;4/4#&A_([IK+3RVJ^4JI!S90Z[Q:D0W6!D]=D:P/SN#T6
M^./P[VHGMH-5S_WT:%D-VWY"=3C[YV<W4VRR0@-0:$O-0++ ]QL-]/;=2173
M28$)XHMC@8,T&<^IOE8RZ\3T*F"!HA"O(#A+YU2;=2.11FN<C;<0;S9 ]&UZ
MXOO621MYZYQM2[LXG^5A0RD?YY'+3UC.C^AXODL1O*U>[!6J,UO&VBL7 VL=
MC[9<05K<8]2J*]M*V.)7Q<'?^ZRXP6+,-0X3R]5[:O'N2SM4<JI%8QSZS@7?
MR!"S9$F]4BRJC3&)OA6E@+;GCP3I^=8N$*_'"^X!QOUR&N[OK'/:36R"X"\N
M;8I#34(,<:N:7[WM.LMGMQYLA9-N9G1^KG<7OQHYG9LQ1R9</"L,)XDK.?BC
M:WAQ3;.0]&LSK?(J_)?.V5/6]K)[0+#PU9Q"):N!*Q2*%W+6WN8"F0NX%AWE
M5=Z5G>&L7+-FFF,A-1#CY:,)0 #)OVFG/=.:-AU-G^L3]D'"^F>->2._L7)&
MS"3C?N\RHLW"S*1$]/L.[_!J/#F25JX6YO1?*J^.-1SC>TVX9]?K%^K:55%:
MI]3W=&_)T9+M>\Y/38MF_R5XT/?#B9B,;0WRT.1<;./*:+UBG8%71K%CDKQW
MND.;R6I! D"+;C0NG8))JC_UQ%OQ*/$>X'FF&.#80#>NIQ$FQZ_X_-'JNWPV
M.)MUMC&A5U]0A&+N"VW0HQMIZT(S77KPG@N>QQ6>KM(H>!;;0-7P78.>J.3/
M:U<K]ZTJW@(2,>' UWD=_^LTJNG#B#^>.;PK3]>J =U4W(#RS?[]!D4B1S1W
MLAN!H%T2^WM BG8#V4-VG:BG5%%<^F/0WIJN_:7<^*^$1_WN_?]"5XZ3R'@W
M?SZ@[K4]+QG-K)%3)(11D[4[V%/5&K/#*W1>T>@\A$1Q7'Q >:9MBM,609T9
M:BME?YN@B5ILXY,I8-&&1XG7M[OT/P19$/S)Y?T 7.)&L\.,WZ/-#$5QGUI%
MK:JYH@>6>OPH3P8M&CXT"#:.NUEGH()TJZ/OH*Z_&,*C5*G"BT34I%Y:$3QY
MPC0;=YJ$Z^96-.SF7KA-PE]INTGNLV#N1TA.MA1O*M]$TM2SCYFDZ%)M:R?J
MUN"L;\'G06,:9_-QFQ7BHK4[@5Q([C&C0;</<9F@**L;.2VKC_Y05#YF$:P"
M\16\12YN9%&N%&^^%4T/\SG#62!J79K\4#:&V-GU-1%4C718^/7=:= Z[A0&
M6H[QM6=5Q.]=9@>IP>1:!Q8,[@9-VWBRC$QOYCIIO7Z[-6PD+'Y!:;3Q.)6N
M6$3E#I*W,ZSG4F;P"6'A!'.X+GXQCK.9V&#7$7^L$&S:LZ\<Z')JIGME.EH#
MWKJ(@.H]L>\GGU@W:ARQ9RJ+?55;653#+0>M^UE(MX>N$5: ;_W=>MA4[_$^
MK]YSL>B"*_QJT/0J?'=LG-'O0Q/:1X?.*OQ6>DP^:-L]X%D=W^(>N(,XCB\T
M\S8_VYR1XKS&T)1><QW.E=(\*V=X.,<S&4S9JQB$%*4AY2LD*B\_&BV$X1*V
MT2OR"L20KX:@.I1.F<KEUX>W7"ES"=0%S&^ZQ2PBZ@K.M#=3[29";D+AK8WH
M9XV$9L0:+2=RHW'W .?BLC&.NNS]EC.N#'SI#)E=EV<?9]S(QN-;CZ$D2$1X
M*EB:=V(@+F0XI*TX&H^TY:?FWC> @A745A*5M 3-%V@Y1@4IC ,G1/EKV4&E
M<V@O<J*X8@6HFKQ21=RQ-T2D3$(]F,&HT>8W#\&GJ';F>=[D<6+NJH\-2DVH
MF_8-I>=(SG%UV^::5>I@O[/-9L&90^B5Z8&[<&']*,I@"4:O6C%YUN]NG/1Q
MF%96=P3C]23^[KM77[O0O+!)14.AZFB'F$&6=1QQ%I&VJ>8"Y&7\E2YZ2"""
M^8N)$KA?'PM(:>T]&1JBJ8<O:FNV]#Y7TWQ"66_3I>[Q_+X@*5NNET/-BV9Z
M)B]IW3KU7J?>IBO*>2KY)Y*-1L7C=(W58^4T;',EN5X&$OYFI)2/)58R9'E%
M9H-Y#W<(T)W@KK&Z&NLC Y.5[#4SKJE58W<43C9WED1;K<T"\^3^GRKBH# /
MN>HXYD^&!H\5__"C]CE"2&N?A 4WD(R*,B_C<<Q\K+AFXS&STI%I,!#?(JU8
MB0:>4]KE4(NB_+-1E5KC<6(J*C#B[:6TP([UI0H6BQZO^,!@ZZ:MP)CES!"V
M.NM\L\EH0AU)HH8DO-0@7S7]33#P"T+HI:0LG^TG!U9TW1#-$2]E>2TDR_:!
MT<NHB(K:ADPRR9?JF3W_;KLR&C6/GJ1C13Z:ZZ>R#^;D:Z%Q(=EM%&@580XZ
M?QEY#_C0JMNO0R3.Z'$;#N^J\/_]Y^>?]O^VP?]<H@<^"Q?S.> -?D%;3!^^
M(_%R,Q<T/4ES,G@/H'X)-]&!#X)NG)30S5D&S^T[;TX>[O*E^>?U1]J!I;>)
MUO< T7O T9+T/RD ZBEY]X#_N/GS?U)(4"9>M/8_49Z$5W"P)9X]X25!;^_+
M\9.!CPM)-,OJA$<(4ZI8>% Z>:PI?%OS4W%F1R&0^Z;&6NFDX=$?K+9)[97>
M(027:PYV=\(N-^X!84]!I06@C:0[49;J)&O-Y<Z6QJ?I46LI9MA$Y6MIZCSM
ME"5T95P1GYTLWL@*D3*)1FKK @]#8Y?;2\F#54JU>C=FNF'V['7AXB.UWFT]
M<Z2A]3LI=P-5]P $''68>BV\<N=\#UAI"3699;,1=FS-?R(7/:+)MF;&;I%6
M+XW8-PO2$?8QTW--XCH/24YBD'JWPICD>'@A40]Y:U1,JP=A.&W0.9:N6 +@
M\+IJ.BM;<7>7(=+BMN\!_R'TZ__D%7N!0VG8B',C)!:DW6UF<UT0<58@?]N)
MU#:$9*W#>?H8-#RC%^UR)QIP1_8D_=3W-Z=FR^=J=1<4;;J90U+98ZD"+B'?
M,6D-?SY:K]'[E]YYO>[>TLF9BR)X-UEN>L:Z0\^'Q&JF,R-D(&Q M87GHO]D
M=6MU$A1CN3;E)RCLS"?ER>[\-@$5/U]FM+>IM0VKR[$-/IJH@/^+V.D./#%'
M-)Z\(&*=5O%L0PN& %PMK;1@6>K%>1U/4NP7-M[%Q]5[W=E\<(PM[5TC2X.J
M*-].9&J4)6.HC"'R!9=PE:G?_!N?)]$KZT);H']I/N6@BK)/%V-HZ3!MGD(.
M4,,[7*<\$T##0</0*^[X7!98+ 0\R[(0IW;RV.*<@(!L%O)+9@F$W]:!$UIO
M=&#T%3P+?!/P?QV$TCS[F+%;<&R/WI7-.EEK]T>:3%4U?B,#V"EZPD:O!V8V
MPGG*XT4(!?BQMP+W2-X50^S/PC'XF"K 4DFNML^+K?[LD;8-LHW\;W_3N'QW
M?;M!W&0=29I3Q#YR_QP[^GQ:BZZVM"9ZPEYEW*TK%FQVMR5XGLM/33'*6__(
M3DY.<.^T/. W\=$J7G[B[%EW-W#CS\)<O\7?-/[QX&N"0M)A8:NV:8A!64TL
M7;FKH/+!Y^HJ33K[I[W/N^FQCG]S:&!2FF!$K"QI^.T#9='K]TK9$QQH-ET2
MQQLVZ='HWH1*S@*8#@Q/((U_H\^7Z;/J4N@'/J<A[UNYG5S I!W!A^Z_IML^
MF=-W\(>D/1/WR]*^$1Z"^=Y=0X,FZLNAS*MCEIFUMD],[,Q':E^J#[Z2&<"P
M]0RM_:?NA/US,&JX=SC/7;2P<[#3JU4,$YS;KZ<;VFT=<.JZKO.O$E8^E^L&
M_$R+(,G 6B[GO"-'P97+BBL0 WH< Z.[A#\XTKW=&P#':<?3;FV7TCW35$ZK
MDU__SO*(FSD2!>/9MB!-?N2Q[Q[  KSF/\0]L61M.A3V(DIUZBEYADVF+ BT
MX^/W7+H%M9+K:'O$6K#GT[,U"_!$],GQ\'"QM47( B-LP?]J!95KR_T,M$R)
MR1T>7+_ZH;-C34#PG%Q]6.Q:P=AB BZ^X)/YF(]#>792]?Q*SHSG:_L;E].5
M/4T8%K(=#J$8F%2L!G_3+1Q-^9):?V-T?A)E_;]AB#7_69?)-JLX!E\B]/<&
MN+K$RQW^;9F&VTTK7;[024-KE'WZN>L,<WZJ&?93LJ$L)D""X17Y9>$=F4I[
MTBGA,/S@9N'&O"$GI8#'>NJ(!S<))[:'IXW)/J6T^+CPACLS"+1)GW(/6+AL
M1(W3'/8@V.X!OT.#[@'P]8='5#M3(_*8D(ZZRS&J3YIWR[T'X&8O#UYA;39>
MW%G>\4G_Y7YW-4GJB;?_3?S?Q/^>^$%[FA7]K\):X4_GS.(2)DH'V7=F<[5%
MN'V9R1?WU81ZJ.>C-E]^UA)P=' 7IR# 92 =2C_L_/"0!=*G_=WG*EG#&E"5
M2V+\Y\LC&VK'^^RKIFF*I1\=2A((?_X2#1V?TNC2%;P'A$^VT9P_>]#BX1!=
M!"8.KFI:QGQB6,CRMPW"R,^9*@2DE8RCZXV6C&')]X E.R>!.V^:2U:!>P"A
M] U'&,8]8,C@'L!@? ]89EU#LD[==2?/W=&L>KC?U1OKG>S3V#5>TF]SHB#4
M> \*U'GW\2'Y:_M\#\!);6X\);T'=&LUH@(O'0)!)::.</]+S*NS6/A@E?O(
M/6 U+*OQ_X[=Z__@1K,S870/$%^ZD+L'1(@_=*WO\.+"%2Y\-6_A1A)J2BTZ
M5/?YP609Z[EG=LVL>ZQ_F*D5O.[A&9KL.MO1>P1:%[D'? .=I]LLEURIONY)
M ]><'FRZ5M,0K92*MB">E]&FLLYW+\A43BA6&LS!RV#W@(W,.V'3N^'*!].7
MA-K*TV;="!L/*=RC@%]NW0-"XT#_H($2!P*0_Z1+O99:N'.!KV04F_[&^V_J
M_X^HY_V618(O8;543G3I>7,T=V /FHFRK/^8D][X$_VD>.<70G(/P'CVX'%4
M]VR9QS,_SA[+C4]M9A4XWA&#?.X!FZ;#\,.O!/\!7<)^&'7##Z-JL87FCB6(
MAS/_ZP.WY>OAX<\Z!W^]_">&[<6?"#7)/Q%JH!LUXJ]G>:";&ST781;6Q#^A
M4TN@*W)>O1O2]W]"IQXT@:8%?LIKVHAZXW\/"$SI$R__$Q@5=" M*6G;>%A\
MP_0G+NK!\7ACP?\O7-1_D5[+?Z+H'G!RY+[Y?R;\FZL)FCL/SGHJ(J*!/X%=
MATFW>.2<=[BO_@'L^B_2&=-H_PF^:[](34FI7OCKDYEO:<\G%H++.V+AT*RF
M @,S&*.6*O\CY,<('B]\L79BHY9ZEK#H%_*7O)"40&:*?R9S_P><54J%//Y_
MTP\T?Y6.K75'$WZ):CBU4]40^>L;3OVK<)*_W*$/_R"2^=# P-=I]O^2\!*A
MSYU5)-'$VEL3E<$78EL(^B9$W"0.:RI&E^5I!9(;@D!71"(\S!.9\D@;N?'X
M4S4PE7JO"MKT/'C.<ZR9I0%$KYY-SLS,FFGUH .D_P7)]E<'H*<[^2\^X?SS
MT>#036T8:"X+'G GQ?#RLYZ"QYM_KN+\7PVH,[O+9)/B9>@]8(;@-EO7P>!N
M!Q2S'E:P!+JD4KH'5#:>!E!72K[4:$\:_I_@#EVQ%;V@FAC_NK?+M3+V>@1(
M*BI:5WGN*Q)H_8>ZMSU2'WI/GCL$2\V&QYV3=X^*\D'3H34#^;B1? ,Y0V7;
MJR_UV/DYAC"DJ6P4Q:.LS2P8K3M7!OWI)]9&,EY(V[\0Y1#MDGT!-)8*ZST1
MG><O.7C]K*AC7TK?>V4@DM9W=>BL5Q/H-[$S&$?Z+K^^S>MU!NU'L)EM, "<
M/1,*-5?T(Y96:HQC!ZM7E-3'@6/+ICB(V)%F]%/[5O$#'N<M[0*V%;FS-U3#
M!7DK%:[Q1^1F%=J:=!\&HZ"<\63724Z5N"Z$0_CE'HOE7+R-H>=%IA'ST#BC
MO>*W;D>*ED\O2=Y-3PE+QN)88&$X^BJK'3KE!XASF0W)E[C3JWO278-F&$R7
M68TVBC7=9F44^[\OT,*28QQ&VU7@GN1LYRK3L^8N]?VIZ<OO<4NE*\9F(XR=
MCDB%A&@M9C$4R8")$)4EA9B<;66(V-K-FUF<K\Y&N#]>U?%O<)%Q^_H)#G0H
M6?$D*-W^,K?U($#U.N=I071TS?J=&<H+D29^+8*_-0U."E[T<0_:Y*BRT=,_
M(1N0 7$,WG! .%@I:N,36=5+H& Y<#=L_U6($;9HQNL.-/_UKFZT0ZR#<-5E
M%$$:$ITX;J#8K.VK%U]MGB=#M!IN(0XKX.2%%]=Q\C:/!E^2=X7+S;&B>R&4
MN]\:3?W"(M\B":J9SMU>QT;[. _N;2'1/"AD&5XT5NA\U"I?5EOM:2=FOM(=
M=XX>\7IQAA49N>$[]UKT-1LV@+"IUZW<864%(QR:O4D<H:W+ O60**TR]GP?
MJ\I]M]O#0&NAI*64Q42V.!9V&"D=H?=F=L%D<(Q#,%S\;)'N\X4P7J=EIMOX
M:W%LTW-D5/JL=FB&U[P<F=OWHV_A>\^ ;)V]LQY*;R'-'L:T3[Q(JLA#4= C
M):>>!3EOI=&-T3.*&5F.E*A4M<H:PBI9T<+$^#6V:MQ'S5U=Z\E'TB$WTDMX
M]O(]9AI7KNESW:-[SS_;X^5Q\03,*\]8:;*$%WWI^DV\H^V!C]+(=.(_'G&R
MQY-6(E8_UIYN=P=^B\ZF]X\T'E.)-B)CDVUJ:EI.KT19OQ1NR'>YFL^TQ<C9
MMV3+!!M09JEF!<$CUWV4VEX3=(IGLAPUQ&-DTD"/--KDT!Q(E+:29D@BMO2,
MJP/)T.O,G"A_#L?B"(5U1_[<J65M.8'PQQ_1[R816-Y(%LR\C)&+6T:>BQ!U
MF?@9!\2]Z1^*&L!>$>SN^.0 Q^3-%1/6!)79"Q7B5D1(9LL!C9<)2G$ELG^T
M/&L4F%=GKZ\D[C<5:)5GKD.W7N(4/M@E>;H,3=RV #K:'+R"5<WVR8(XA!8?
M!<*:_3(^Z5'PIHV%)-Z%YVY10X9*$="I%&RT_$>)3W;#X]<E@<_P!><J^;*7
M: (<$)QC!B5A<F.G6XS%D(_$#:%\6K#IBMR0T#;#C;4O6$]^<O,0EQ\6RDY8
M'A1F0F/3:QJ"/CN1JVDB9/9":I(OL;&43L8V?KJJ2[<J^@MW^IY=\N$I'XH^
MVRHV<W!H_'8-EGY>;6%X_&K1"L#2/\GA],@U!(*1G.+V::Q 5 Z7W(??>NO%
M=DUT1&D*-Z]RD^/[ZJ!GCBERX9XGKSMU5&,6"/F@<)^XRN#G\V.R 1QVFVD!
M+?&6/,_*O#UD#5L3TPA^&2S(J:'D4G>H*<?*S HX(W#VI.25!E_FE+3S=-?M
MBEAA,EB]74S*_^;DW8R$_ZA[9;U4+3HCSV]*/.7^Z_O1[X['T6C6GF/DG!2_
MQYJ#VFOF/9>+DW=D87EB TD,9PEQ\JG@VCH;%EX&:@TR<?UG:^/2_;4 XYPM
M.)4H*$>K?J39D:B&#RF:_CN:#^JD;$*Q$A55$A;%(G,)!NH7F.MA?[/?@<GS
M)>JICN]SYJ.'(0MPL0Y;*&74B 6CA+ZD1:LSF6)Z!O:,>^"Q3<AF@N=E'<T<
M<S.RLW3T>E+46$E#VN0H/S;624Z]?:7*A11^"@W?)T^4#A15<<]P(G9W_#0R
MO[VJ[9X.*X#H'_OUKW9W7Z=FZ40X4:<(B=KC1QY>*QXQ9KZH583!7E66ZM1%
M]!:Q6><** \ NJ\09XVY6^%0;?G])!'A]XY/9FJE)+[DI<N2H9E@CI3P<3XQ
MNRKT_GTX.Z+#GD;XGE( :U&10K*LDZZ"J^JERBCUU'*RS1E9WP[-<S[Y]ZTN
M!:F_I\J]MTA>@!<Z<[3$QE(^A&"%T%5&KO?*_.ZN-?<U\'IC#J-?40]RB7XS
MESNC.\C+?XQF&/&26R(B ,VS2/]R7,!^5AI@^VFH@<2<7QW9YBC..,Y>P%&N
M56C04)2(-B()Y.I05S.MJY_^%))]O ACC7A=C2)<RM:/$R0_[Q&RJ[++KSC.
M>AI>(]S%G7D1&\+=2;NWE1#7:&O,+D-[^[N.BS\U0ZMF3KO7I:+SEN%W2#+/
M8AL5;NW 6RD&HJCW(6VVP?4&YR'#&</VV;R,H7+7(@[5E=!J.M-,R5@#XQG*
M]-&#QVB>I*'6WZVGDOP<N*!ZEL5C]F(L3-<@)%N>!9K5K/.3;ZX#(XLP9!IK
MUI=4VI.$E4.#3S#J'1GACO+;<#9Y-&&GZK=X.60??DF\6*<-?L)XC D(?)%!
MGL@1OGQ-!9:(!,.N/"(>18CT+A<#B[YC);@ML!G:X.P);I#2_G)C6+G%["2<
MY0_+!D.ZT4HZ@5R*%%W)0-/6GWE6(94VB.VW!^HW DNYECC:<]K3O3S:_;8,
M/6^9T=DO$OLIOSSRF:OZ;AO2]B3XD:W\R)Y=D*/7""<+4QS8#])>"BSAC:"6
MW=[OI,*P>L,J\'5;.R601>K?UCSU$L^N7CT<1J6S+V/([P%]H-OZ>T#%0^@)
MD5Y_]7<54;V_UB6BH']=_1*BYW--_?(A*(HX-2G]+$G4YC'VC^C'PW%8DF@K
MJ<_S[PJMFP]L=;_>\O]GM58GLRWL![$>?IT01ZIM@ 4%,^P; 7?WE#NFLKO8
MD3QK+3WY>/;25D^^AFD^F-UIM-,%]+VLU#57YU)B5?(IWLA'=R)XX=O9R?X&
M_MNT.LEE$B?>8%-U:5K2T*TIUT9+%+YX1MU&NR[KV(U)GGSV=B6>M343P$YS
MLB1K%]U0PY"9H1JU#VVK2C!,>+/7DA1],'X7=,2F9TZBG=X[JZO3[RB24%9:
M[0!2-J]_J=[94;&ZW]ELS9[7R\8MRIW<4_=-S?.<KIZUN;&,*?"&;8MJ?/!\
M[<<.WE:OYUU?DA--@72Y<Q01.U/UI%^'_AN;C=;^]DN/7),3\464ZY'B!U28
ML9[B'ZVNI'T3/#\9%*UOURZHIYN7:Y_>7(Z4@_L)E+RN6I;EP%44;K925JH/
MV=[<SB[(NY'H-RHR)2K)D'S\]^-U]$7!/;JP?<1*\4H54W2Z.$2]<T>+Y%E>
M^ZT>8;I"8OH] +-W7PP_\'4>0?G3U%RH@_9+)5EW@9^1?15'B<$S:98U@IBC
M6QHYH=D,;7##8P[VO0L=NNYSSR0NH9Y"^G6QAD26E$B77Q-_I&(L-2Z@(!X&
M)I.[[*$IP"3+<S=]<%)X6'2ZW)-1Q*.M.!<HL0VDU;S46W2(XM<HYGH8K<4
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M\7XUZ]LQ'G)4HT_DBL<N"_*N3] '+WAFENY5$6+%N5HN$##'JCG!>=!?G@Q
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M#6' C"Z3'-G\V?W$L-4Z*EW&?%#?%)'=]'.%E_*';QG:6Z&MT.=WE2E ,[U
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MY>TP2%#Y7>C#+&+P2M<<$TA&(WS@AE>LO\KI>Z\OSYGJ$S4X39C@D/7X!DG
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M0>0 OP Q45J 3CKQ)*B&!&X.V[!&+,&Y#N,/E7^"Z/4R69#TX25Q5PM@K,$
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MI-EFF]B^6_;=;67Y0 (A39";#><8Y-WO1 8/+W&#%E8P8NJ1<T8H\=DU#+!
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M \"0WGW=^(V%"\I7=;DU:XVLJR7G\)RURR@RH.AFSE?=YQ/718P2%YV_^%U
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M0N>1WKMP0<ZR'A-YRI:DC4Q>RBDX_2&.K?Q/QQ;^M_RG! ZV_#\ 4$L#!!0
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M'<]9WLS4.9[43%U%Q&##>G#\V-XK<2Q,94I69Y4(PY8<N 76E-%\].GSM@1
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M'TKBWTLB8JA4O?D&D09%]F80Q=0N4_Z]A..BB9 KV=JGU<^9?5R"ONJ_/[V
MYI8+23U3I]D2TQ7V<!2M-YH=(NBE$?(MUDUA[#30[*TMVZ\X"T%O3=$8=<L3
M8,-6EQ-,SRKY"S#N. HIW;>F.Q@\)DFI#@8?!@8\CN33RES<?<<<ZEJ_]K"^
M)GAJ\R^63)[9+:K!6<F1EQNJ6\F)QJO'L+#8LQ3VO^6%I9#A4H7$R31/?&^N
M_MFQ-(Y*QZ!RQ^L!\;4-GR!66DP;',.YJM)_"XAINML;>.4A[QV0)M9;_5R1
M7J6N_".Y50/;1$X+6"Y,6-\2.;;I%D"">V(1XC@L,>0:>- X?G9HE0D4;CA=
M9S%,'G!^G9PF&S"QZ7FEQC"Q"A8SQ436),&XO+A3S\V;W8,#178'_]T"8MN9
MP5)H9XV$+=,DM8HMHOT9N@Y&NWZ(ZKU@M1OG,1Z4J]<4V.*FIG!2K&QAI\X_
M8LYU]KI-G^<<$OZ)$^%9)ES&*FNA-EAS_H2>TW6QB=4$9V<FD*_%\*&UP.2%
M\M7SRW;%1NWYUDG7GKL*>+0Z,7L+Z)]M&V7KZ**_!;!5YD*8P'KH6T!O/+Y3
M$\&D&E-6]?S?GQ_#6UF]/$_QH8%++>C#M)!?;6F>L'D-F#0#<CJ/S417*"Z8
M9PTX-]V.LL1-!YZ'BYZ[[Q>OM]0:+R2'0WT2<[SNK\EO-D^ST%E'ELK*26CY
M(,0/"IN.IH[M8OX>@S^R90LWE6O5;&#US3^<P>LM84U8\K.OMX O\VMLI2L*
M6!5([QE0 ?<<Z/9/XN(#^2G$N,_[9@T:>%9RC9[4CBV\*;C6L5M)IUJV:&MJ
MKC-+)Z)0-N._. AM]0C$C/# W:.6:4+LM6.D#;/6-#VOE7XM'PALOK6+7^.K
MK18!# X&].\,^]D<2VIY&ILH2>!?N!V>3)_*[C?'..G"I&Q_<BGI>VZI>?5:
M#LB8N34%;\WK&PTLUT;V55+,@W4F9.D+G&\!Z(CMXVZ:R3UFK<U_PHH?O&@
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M[Z#Q84%15O4&!S5UQPJS"J40[6-Y]0 RQUA]#RSR3O0-R/ODU/HA#PX@%;>
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M%KES+ZF \CS7[#60JD4>)Z\Y/#E:+<"9R&A!+::'[_0#&5F<BCRQ2PKGIOL
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MEHXADH@Y-ISC:9Z4'5'=ZU"CQBP5MT749LTD 8_92<#!9Z'#LCT[;FC_$W*
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M6)M-RU?3SR34L8K]WM<,$Q.B!1.XC&WIX,/70][[YD#.'+\7>(-G6!<_)^R
MQ%4FLK$<[(Z8S7?V&4[:L07VY^WGC*4U 6P*VB 4W,!VV_I;T4D^OSU,-#\6
M=.SO5WYV?=.W*;K0N6"&,WZK1*2R QCPXDT\IT2EV:.>-9\C.MC:9#?=VM,9
M]*7[ZRU7H[/O=U-E%9.UBI$9+=H7!J.S"85^JW1YF_M4*E0JK6\9S_$!QP>#
MWM*VE]MJQ[9'Z)3-*WX<9?+X[FF\>Z!R7$[IL,\8.).RSZ/&GW8O6.EOJVCG
MPN=DJ^>_#>7"KCI](W8@4"XD(._?)S7G'M@)H^3"&?VZW:EO;=5>RQGRAW?R
M^8VI;#!6\1<)> 7]93C2C!#R/$&3@*2+WD3F,+N5*QJXY.'PXO=_OBY^@^@2
M/V,G8YI1W7R+)@9\IAX]"?A=_V=$-WUOUB;-5U6-^5:;W8?GK_&J!^W3C$'
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M)HS2;PTM4WA@ U>.P+#U+3#@FMC-#!IK,(3CF8*:B)^KAQ9K0C.J8O</!8O
M'%-?<9G<0SW<#AU[%A?8=$?3]"%'>2N/>]3GL@-[=QMW1MJL:N%UX$MXJZ7^
M4.$2/62.D;E#\0_)8P5$:(/]C=L?+R6U;M5@Q2-;-,*0:*[?5E:SFB7]BP-6
M]K>IF;2*0!(4!_Q1]I.M?B;?,64%J:&E\Y,A$% 0I&P</;.[O^[<<&)0-+WJ
M-CCE=I#7<% 3OAD<8 ?.5U1"01EP-9#86ANW/N.,&1YO2]V:J_MO[IQ#?2K&
M1?9:LD5Q4$[XA2B)%E]ZPN8C$M*)\K\3U*L>#M_/;$?0S]OBU7X=,B/&K#>"
M72-6&*)']2*D'FND[@6]^#83K7K^&:ID9Y0X;.8O#6(D7K7>-&5T,Y70\=^;
MZ6'XT'V.30$<S^VU8^M;,ZU]]<MPFMO@R7IV7:FGQYR>4ZZ?K<73ZJ\1\88)
M?L$6WX5.9> +-I/?CH3!W($!^K]6)]SAS30'[WQ6Y_N>%_'W6=<]%P89XGJ6
M.$$7W7*O15K6CHM(KOQ /,[A?[+0&;E*X>,+I&2=#!G6CL^HXN)AZSQ<*8H*
MI9L3J]/36WKB488/TBJ;Z8/6SD/95L2C%"7$"A98%B.X=8FB&EU$]_3>3\4G
M5)LF9OU)2A]Y%SIA^A(3S:Q&,7$^'^;2+%T),\6KC7ESU6O:L5X^;UV-BF "
MHG[P2;!(IN^)F5XM?)HX_"G4KP[+'\Z0VOGSN_&D37Z.E<EK_J]>"27W*;1F
M#_0O5$TP\. \UFS=&44#]-+,#56JK:+N1,CQ>?C82;@<#96!.\P/"'=VV9_=
MR.#LA<C$#V32#C#F$T\K/&D"!2TR348D.6=:=6?,X1/3*Y65>/D$_6C^[Y/1
M#[Y?#M.SC6&I?%1.)PP7T[9KAC*GSY_R9[H?HZ-X>/M4TV5#=)VY?;47(UW=
MR[W#YD9KZA9,-D',+:!"&SWW(*2[V 22)O3UDXP-EE2]W3=ZU)$]#IMY' =T
M=Y&FV8MKN7P^0=0?)G7D8U%.?9D\\AFA$=1<5R:E4.Z+2V&"?0/E.>S%C:G/
M+ 9$JYWLSSI#:S044<5PB^%MQ!?EZZ'"XX>B-U:M@D+%Z?(?UKE?8[.ZIX\/
MK;@C]\QAHC$_T_Y);I7ND([,LJ'IV;:_GGR?9M]<@E'JQ-#241+],?HI>FU?
M:7,(*1AUR.U>&V)WV762HZQ:U9G[N^2G&(-ZN6]E\XS8S<#L;F7^8<>OTC*G
MHIW=ZT_G!1*C#>\]OWUAYW<2?-_Y5>T"3DW1,]\<%_)PS$]VTHRRUO/R^B?G
M+\N>[STO[\AV\/KVZ0=/5N ,+BW4+B04P@U%/X^XYS<H)10LA[^8,$]H2F11
M-H,&O)>9TQ1M0:\V2_LNW?V@>\/X!)EV]*%2U$CW3LA6&<0FI_[AD>7-SVW/
MSO0_Q]VD2,"1TS"ONP*Q\PH)6!>WC5E:.*%4(:[#%/^3B8]T\G_YM=Q_&G(,
M'"(3EE$99>ZB,%'1)RDV'L7FX^RQ79<BT\;"I4 O/!"U:#\%W&,XO"[SR8GT
M5VK.7N]NX/9#OGHW.*J\V;.F"W(K5^Z<S!,7$ZMOYFT.?%2++S?FRW%41CZB
M!\<ZWGZW3*6]O!C5SC[3W&>1/=P:=#U2&YO"^F=(Y=%MLK99/=JA94XTKUH#
M=KBNY'IU(!N9,<3/32LOI0V9VGI5O'I_&][\_;#@2 [%?6R6;V!8^/A+S%^>
M161 <4:YBC]24@B1T#=\X'VTX)G)["0;%D9\.)D,WCX')0$%>Z:UX$0&DY/W
MID2N5G9MY'<R$+R@F_.>C^_,1W6#C $_%A:?F<QM-Y" W&KHPE<2T&/&]#</
MD9<T_NTALEYOSUL(Z%)]TVT2\"I#E^4""7BGF[\+ :O1A\OA AR$\G :4N$6
M9% @;NG<4*GW?Q6TACCVX0_CB80\HE!+?F^G"C;^T?SW!>RU/$XST!Z6K1%F
M Q/ 3N(S1,6)[7=)P,8#D[5%<.(>-&73:6$W]= N2P!GR:^LB.WM4^-\=K=1
MDP1D>(?$'1 R0?L3XF='4%S9?_\8D ITI8T7?2W[3&LF_2IHCP%^7!6_:/DC
M]$I S0.3/]](W"2S?1/5U^IS1);:4/D:]+?6#!F0'<%'0LGZ2.'8(G9E(8@?
M_O-G% O/_EKC_<(DX(8Y>#L/NBO?U@)[,TE\] 4ZI4P"9OU,C8X0/2!"@\4Q
MOOD@<SW,O09%#"8S#2<;DL5:L$_M0R@(Z[%!MJ?RHY?LW(AYF,I_"8"9D/AL
M&.T.K\P1(9J&';05%>(TD'RRQ48X ^-- HOCH2ATY\(1B P8ASM;>YOW&:KW
M%1]EXHP."?2T2/DA0O4B5S\(GR"</)=WLD]&\FZ)0<XD(*IC$3VOD;==:4:T
MR$-/0>%&_R5TMOXU#5[*W S>F[>M)M /_)7%0RSIE>4#DT.$03CU@R03KS^]
M**\1YOS?@&4;'']-CC/2OT\-A$GMZ[H&WJ<9;>T)3OJWK05EMI. $UJ\+AF_
M98$)DAOCFWX9,CCTR@E?L1@)\(LY',-R7[B-#4BNOVQU%I!*18T/FIXTP4@X
M@>F>^?=?M8,O+#+SDX"^Y?G# 1?$GFP@"2!V(<Z<(38![7DG-_Q!A\?D U>8
M9E:80 +\DPEDN%WPM6< L4!V[)F%4X/9?W?&WKALR>#OM)" EF1//)^,8I S
M>--NOC6C!4H&S&FF><2>[#S"Y<-5_1GB?/)F&)T["=B9"H\I<A'V(L04AQ^!
M<4?)9%7O)A^59^ ZR2P[!>S?\X&Q^NLV?. #UEJR89IV_DL(_C,9B]I$W"%+
M1V6;O">,?V!! I;$<7;OR?I-27H6ODT"?O$9D/DT5_[;T4&V72<!WQ8PS<1>
M.<3!<,ED@%9QA]XH"?!P-,(5;YWR16!'R(Y) ^M*Z.>!PG<ESLBBW=M"')6T
M_<G>;SVO)1F,2;8C 0/DLPN6ANX8MRF0UYM90A"BQ< '<P%JQ_B,.29BSQ8)
M(-SZ6HFJA7:2 +FKK2M$@5/NC+^RITP\17)"']E1MB]@X7_Z"6-(UN'IGC@;
M">AW!A\!R60W>5K>#F4YO9LL339P>/F^")Z?,8\%=^;P.;ENFK L2+3A.V;9
MF!$#KU78'9/WBS5915P +[MAR6M#+<FQA=]DDR7W_V#OO:.:;K9&__A84!00
MD%ZB J+25)K28@,$!*2&%J(B-121%FI$!)2J(*"T2*\A=)06I2.]AAY"[R34
M0$)R\SSWG/.>]SGG/>]=Z][[6[^[UODC:[%FUG>8V;._>W_V[)GY*OZA)(XU
M1\- K#$\+CHJX-+JP$J9J<,43TE9U9!4X;,0?\89[]_NN0E?-VU>^>U1M"BC
M C:-(DMDSI@%AEIR8C>U"\&)V7$P?P7SA@[>VH]BQ4\L/GRWBHAQG< FP8%4
MI5T,F=LC^NCV!-B#($I]%-VX2>:B3^'1E:B:DG(\(SA"'[MCFQ*/+3"N>]2M
MG46UM?U[*Z#V'U+1[.30$ 6<B[5\B2P'!0H7:^%S5X!/X4T-:TL)#4#QB-"I
M9^-5_!O=-[N\998&"Q"VG.NC%OOYQCF:4_T:T)J2)?/_$(;AWYLHPT'C*YF*
M_V7EDQ/_KOL_6Z=9=HHO,P+]\GP09<7LZC_?Z0*@PP^@$,I#4FMLM>2KZY.5
MNF$&N6H,?\1VB>'2IP\O[PFXFAL:-;S*$;E=(V.KGWS]YT!N46*9Y4,Y8YQ5
MV1M<5PSBNFQTUZ<WFX$1E0 >91U 7FYZ5DU-?%S<!SW5"R'_[#0+1Q<\] <O
MXKV? 7[=9P7V>5-&+@X5PZG']^6WD"G&F("EEM-%\6']'"+:V_=&5TE+-,#Q
MZ^5I9DIQ'$,#!SD>^[(OT\/$I'_'MC]Z7^3;:'FZF%"?AUJ1VYJPL%S9!]E_
MBY^/>_>C(1VO=H$9<.<0^T#5PO9JSH4=WR^:GT2O=FMN*'K;N[1=30\+^C]"
M?S0 YU*B2I9C F_SC_*JMQSV9@@1'@T>-=$W.<?#=,^N\$H6>.1"EA-C'-Q^
M37?B&QWYU^^U MSTX!L-VT8#;&/]W;!04\ZGA';>.&NE<Z!37Z;#(<:C=&A<
MSZH2CDRU?[N(/8+N_KZSUD-&S^)4E9=[JD+43=F&KKWP>TZ,TDYPNDM26E^Z
M"YC;^[&L']?BM?L/1\=&'UFHM<B>FQ;(;P6D_DCF#S!:$%2H((7/T(TW//1>
M=*,E7Z5"-M+U>173S+7QCFVA%^? :Q:SGJ[(ENH;J_L?XX9B(?HW"PJ%$PR[
MH']*07CKAJ^I",$S[E<.8!L#>*MNX$8L#T*;#"I5*R:DXUI'U*>V*A<KU[8C
MC&F O9XFW<,+M?)TAT^')4J0F8+3@%YU'<YH?N$Q)'NR6C(U6_1?G_SXM"E@
M!V*E6'OCO;&-4[SEO)*Y8^\-9GAP7:>Z%W!/:8#[W O3<M[D;YL?S1H;,*QK
MM;[9I&CR\4:=^$3KA52Z&\1?3.:4[H!==,(]GW49?==R!S?.?^@^SXT_X(];
M.RRJVE92&/$I;<W_)96@K0O[,ROVT0".E(<T0)I6(X*D3[>>;;)ML"E^4C0*
MWCT $002!L5.(442/OC=NR-<_HY<MB>UYQKA5:3$[Q]G:5\>AS0:']SL?':=
MY,7HL*G;.4@RH &$%J,0D[_STBMP'C@:KG6/%(V/1%@.)M'']XWW<]5O-V=X
ML!U;0Z'0$OY%KV4(^,]2- @/+2^</Y4XD+]6V_&CQ? E\>U0(F:A6^%?GGE[
MU4?2FGD8<(4H6' 4A(^IKN@$_R9%>B3::2XQ$\I#YKJS539>I&B,?.V.>4=E
M[+492&I,Y:V10GC[+K"<[_[,/M%^P\+_[1%.FF<S@@CY%LJ#_R0D@O#*7RH\
M3/5D"S:#C\79<J8?8#B_K!K]IRV_:8C*@,N(WBP\AG*-CGYSO,0^ FSF">FB
MTK&C)'RT/)45MR9514<""Z>>T=IH>=N10P3G!-FF0/*3'71,0^+Y/D0J(+V+
ML.NJE/I+8HP&B(S.A@61UFD 8:]FW!Y+[($A9AS$"EK2)^"H%^CV<(OI*?RP
M<48^TH^GT$X+CV$RDSVJN2NJ<CFEP;9>I4'Z )MP/RG81%/;5';(:U>YNB?U
M4P9'@6[:^S_G>H:5^(A"ADD:KFEP&U#Q"N=^DT" 6ZT:OI*.=0D\+=(0[)^G
M!O*Y*7]K2T,12L<DZ8Y?RX:-#9J%3IY -M"<]#0+F9L^%8\V\F3I9"FNPD0#
M%!L7T%5KU%CT?2%5"/YFOW$ '5(K"^BO8 TP)(5Y;@-"3.@!0VLT<-4MU<>W
MWX$3P8JNM4U?S6BTY%4=0$FN1P )'W6T#KJ.=0<TMBBE?E[TJGC&;:JV;I=9
M!7%9\+E54Y\"QEL-B;7L;AY(3M%9K,2%SMG]*)UJW#KR'7+G&MR%!F"DH];!
MJ6]T &6DJ-<1][)F0&LL3)<M[>-]X/1Y>?OFE>%/B<'@??_P%)S]<>Y96S]B
M-K/*KU=N]O:37I:V5ZQT/)9>&8"]Y%08Z.\'=,;K*(+^VBSGZ* -T *$*T%$
MX,^JU&LIM<KX@A*40WAN?O3Y[M0GG)[#9)9#UAZY^;+6J5;'5#39=D;TB-&2
MC\ZF\0CJO4+BD[TXB_2A\I4:*6D_-O=B EW+;Z?\ZVS4[!H]NKG<8TID(O;6
MWFHTPI#M=-</6N.5/F>,(TO<J 5W9M$5,!*##BER&G-V?)F%KAV0<@,+K85H
M5IW7![%*WUI'=+5)%+&J"[/Z;Y_QB)'KP \'5KP_7^>P?[YBF&RFLW=0DUIB
M"<J@*WB!+@WPO*N'^LYGY<\J/NM8>Y-X>0 OD\JDP!!BIM8_/U _2N?<$]._
M+75@7$9JG+NE+62>_:J P>NP6@>IS;K>2]4JJ:$H.]#6\0',ZACHZ 18@AA.
M516C:XV[U)&BF:&"/PW09"YV%N:&UV7Z'B(2[441CHV8/H8D$0N1O*84-:)-
MM,N+>E["4$FX?C%FRD]5\84YI/$E&/@,"%>M4JZR37Z>GB+/6Q+K@(6 $?K9
MFQK-$DXCH_^8'_,&OQ</$((=]@2[A-+U\72?K.@@#\N[')?;LBE=E;T!C:WR
MQ\IZ)EO](C?_K$6?EJNXA8?#JS<HK0SV&A4UZW-OB3A*%(ZN[&LWZ=2=O5HM
MA9FK7$+N2?WNJK13GJWN(5@K4&Z-"J\)V) T7N6Y!!OIF6L]2?5C=IZ+:TI6
M79.I 1N*?:ZV1%X7_A%2$)45S72R<J!(G E#$3:8CRAM(%?YAU;%1EB1Z@I,
M&GXIH(-1PX<'!U]J)I>'0&V[FG]"_**D/RE:$<B4@&WR![?@QF<;J;SO$67#
MK6TJ%Y.3W_/LVZY!UZVXUXV"HDOSNN1BRE8PG0M_,><;2UC2/;KDP/165P_I
M\:K&9?03-)#@'$H$-E17O7/AH]OS[[R%Q,?GX2$>6WOW2V9!S^]T3^RM0G3_
MP:*'_6[1.5$Y1J/>B4\SKIO &QRZ$%]^DOXEZW^#,/Q$L,G8N60H<(58DW4R
M? -.8Q?Y'N[?>LQ%5?H^OF"E3$P5\_TA!V6MY9B&,I.\*;+X@LI^]U7?XR^5
M5!7./-;+=Q[?8X]8[[[E@W66:$&IF&C(!ZSV=&Z_.N2P R>OJ&;2 )V[?-&D
M_82C 4K!/.:@XC-H38\^8HV3OGZ)54VF0M9T Z';:/52"$2(T?W=/<Z#"'E4
M$41#;O1/S*@E]S:7.D1L'3E>Q=WV5IVN^4=E$509ZPT9EW7A^(+\9<2-+CNC
MIF^^5ZM@U-"^W1;*LR%T.2B4MVLAR4LD>$L<)M!Y3ZNUVE#_[E.UE[I/'*3^
MK'#%2K[/B'PMJ>SU?0ET'"F'I7S^3 KS.ENIZHQ\!IQLG;6TYC7.XY)#>?B#
M#U+7-2R9U/:KOKP1)3('SK@PEA"CRG)_>N6WPI11TY4WV_G4+UU<"S9YE9&&
M=D>?'_S=F)#U>C="@O&?>)T.+>.HN.2#0".L"\7;=;^:#'8]*B.R4X.EZ-J-
MUP+1X1%K>>MFWM5J9T5W>\$ Z'J:1J'J9D!U2AU'$^)/&"'SYP+913*/%]2'
M[C<&%J']MBZJKL _>37K<=)VJY?EU4&9"X2 UU+BCNOH3+>9.[6EL;5+KX$E
MMA?'-5(5..;F\/GL7@YCWNAM]CP.&/7Q3K58EPQ"@+1ICAE>OTA_LG29*]SJ
M3FR3&Z#[:<A+,*>ZD./2G=:+Q-X4W3]+-_2^JZ<G&7OP)H\KG_)EO,_RGC71
MJP6,-?O$2I)797GFN?<JGGCAF^17-O#1V1RA(I6X++PN$+[:(@@L&Q:O!7YM
MA;EG?;0E\O]LX49?-&4=%-S-+/;X^CTSQK* TOGL?9:^SGDOF'^/=GKM;).*
M#'$SI)Q)%UQ-" V=&M>MB-\P"F]RX[K&R_GTZ\AKG6,MC_*G+I-"9Y'G2(H&
M1 ELT Y7\<":R*#UHUKUFQ]:^6W4&)D^G"QF/G;1MDZST3 .Y>0^B?A24,#A
MN[-EFZMGH?[G]\ZD7HH4/HL\:=>1AX.#[L5,%JV+OQDG1=DX[7.QCJ?]+#U^
M;%[?>XGYF!('O[)&NYI<S39T@:V 6_67F<A<CUYZ;0@B//56D$GOSC#!.<QV
M:".U^Y3@Y02'ZO&N.^(!S3_&CT<=FXL:%<JACI+>TUDU(80&(&0A:8 /#CG!
M!=I9BF('Z&WIK'=9IFX&7I81ZTMH,2)7$X:/9*O7[UA4*Y"F5)T<HWXFO,F
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MJ6H_^D[JE5EF\]C 8,'7C#DN9&6X_GACL5W;8<XHROED5V;V 65<G6Y<)"B
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MA K>+QY0B:?^M,[JB7)5G7.MDN"\0JFIQ+K7[U?NU)]*3'^YYN$6PN,]1M*
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MKS9PQ.IK; QD[C,#IXC%9'RU\:69?B)%6O:\ )X-C&PMN_&XGJ*(RRP1/.\
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MA*+(O@)?E]5K YL6@Q^)"1T?[9XJW@2&/M%Q5F?@".O:,<LSDUM)!D)R'K,
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MWO="">=EU]:W?A]BPZ6'J8+3CDG+^F MLBCQ(Y:0M#0VEV)F+(V/).SC/>;
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MZ<&)E$QQ 6N%MD%.9XMI"=^;C;=GDS^B_*=CA]@WQ-(MA_1X"M0Z6)@S*JB
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M9(>/09Q]-R8.WM\#I&=1:JCW_P[4@P/_%5*]X'N XYR?ON^*03/+RH$"TCZ
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M9]6QB/%=BL8F&_&*\*)9^-*B(Q\/]V&^LI%@2!T7XSXE>U.ETIC1[OX] ,B
M:>9EKC&=+#]CM#OJS_ET<M57><MJBL&J)C3&(\IO'K^@BT,+]S_@SO2_1FCT
MEN?FX[;TL]FSD9>7G0&,Q[>>C=.S8=&'V3QO7RQWD XB1)(EJC"?Q.WBGD8%
MIW-G07DC6.,I\AQ7'1W@=A[4T9=AY>5OB>7*O@GQ[GY5&J'X@YD\(C\8'*A.
M]@_JG,G\:^I<979=S")T$R^#FM7+D>8:]%13 ?2@3OU?MM0&M1XA=3DB[$?L
MEO2]+-H!M\2)BZGG8\0!\TOHQUNQ#K<"+YK21K+>0;,T%;]\@"8@T1VHA>-4
MV@_?5C-A+HD0C]#/,)P>@#:6-^E'S4?O 40G$F/_VJ"50QE[,#T==H_/)%+=
M_+O:,0IZC3YJ-H(Y,JE:==L"B^*,:K!>:&\?LM!SCSV K()=^SI>V@20(5CK
M?-?JA93!#CQ:\Q\#Y\AO7@^.O<R6$<'@QZ8<5<*XJ+P'9-G? QZ2RXL+5Y3G
M@U;OM/V/;/GKD4F25B7(7^8D\WOB:H7Q)=M&J3LP1<N V;B!QLFE/Z8?;3[(
M>/S1"4HGETP]^717+XG/;?;G\YU5\PA)ETE5>!=URZVG/H]#U1O\X,N(%X]W
MYP#5*W'V$P$4#<D]]P#R]#P%X^Y*DNAIT)IJH;/]FU4MTDN2ZM;DPV2]F[BI
M'/:;D<4KCP %,S#"O =TG.3U365"DB//W'#[TO:3$X3 Q]B0Q:,NU/6-K34[
M "?P9DM">2WW@5DI""+4UPI\T*JVRP."NV,PF0U_9.P]X'U_V]F"I7'B@2)1
MV$;T#CC9T%UU^(KZ*I23O(AR[ U\WO.,XQ[0.8P,>X@A_5"9XY+ZAQAR9SBN
M^>L@H/'$U=A;3B>9*U-]KC\R40R4M^IYMU:(V3"'9BM0=D\^T@FF.5&[1\"[
MM'>0G"#8GI^V$C^8$?ZB+$-=2* @-*BIL/4*="*K2A/]"QZMW@&*/\>^Y1X+
M!YVQ>%D^N#\M%J6O>0_ $UACN,,QHWRPHW#]'I XO4I==$!3+)?K%?:Z8<+=
ME*^GD2WD_<RYJ<H,GC?X[#+IJ86>&*LV$Y?",BL_+/WC-V$9B%Y(@8W&D+]C
MJ=U,JF[2S^M[0/A#X4W)G=\4*A(^Q)!23T'"1/S$.:U/4FOC0:#&()=#MT/7
M,^\G'W2C_^((:9CUY!ZPK7+<AR(78;@MST-16'?+7),T\_]U8&3?0]26QAXK
M]I2"Z+V&>HP(8B)*Y!C"^ A"EHJ<WS^1[-"%9I,\E131RG:VW[)"KJX/+9/N
MQ6\OL;5,0_88: IC@:M"DP?P25.984TFR5) /&ZOZ64**/ 1H:T*I<$]8.C!
MFGM PN,/")BCKZKQP -.8_\9G$[-$F\,18+\!,KMI/GJ6F;I98CMDH2'BA2!
M5)'P^>3RK2A^M!\N26(7K-F(>\"!-8@)N3NF #L2-&52/O:O"S^X5243OOS.
MEFELZ9^JK/%$.!'^3O5C1O8C?5Z2Y2YSO[;ABK)/! L/+= 5@]I_AB5F M@'
M^CER:P.2$M+?P/V.0L8\N'L&)]G&5HT-=<HY$GZ+2(LY4>W@V2C2DEP43)IN
MUD^MR"9NIS'79-DK3^<XWU4I?M\XC<PS22YL+*F#$!9U\A)3OZ:SK?*!1REI
M/9MX!S*-,AL^R?\I=*")-ZXVXC-A6&#;%1"Y5-DU9E_$^N!\T&<D58*M=_U*
M*:_PW>9OX>!1*>O>:_!8>"O9T!H1H?WE-8XXZ (,64P7/CQA2S EGO'*-RWB
M? =P$F5*C\RD4-E-O?F#>L_]29J 8W29_:%0G0/]:VC,N?L0GGVMM$C%8]7N
M/M,I/^U?R#Y3V.H4]]),K["755W*TF/A'I)L[DA/ 2?*FW9]V^* ^5:"RN.P
M,/>Q_3OEC9D/;2F"6[XVUE^X\VW*/5-8=%A,54+T/LS3R.;GA.RI\:6W#==%
M#%/ V@9 R?&'YG\W0/'OF.DG&J-@1H1%Y0.6!3;7T%*KIV&.MYJ\)8\Z*UE^
M()JZG4^XDI[SUW+<=$&5MK@?RAT97%.DM?9T:$BY-SR@P+)@H*@7>O+VQ+32
MP)"*A7TH:8L@RU)]?E4FWO_D'O!2C^\%R/9NXB$E+LFL?O*3>ZB'N;H8D#J_
M02>-L7^/MXKG81>EQU-&&4E9OW:,H!'NO&#W7%.\GJ_@Z-_"O1N*7/E1;<W1
M!CFOV^.#(\] 89E_E?,K8*;N&0]//6&?]$=KCX&Z>AIAATFX2E2TYT<Z)>^M
M<O\2GQ22/LN5"@X4\8,=YO\(ZN)_*F>#O/[T0QX_/?CK)@3X#KBM;V]OF5 *
M=5T@AMTEWBGW$0FC"8=:^T6!?@<#.SY?VF_L'P@W@Q@?SWG!?<[+=YMK5LUO
M?Q#1@F;I9.X!LJDM[YK?FC"]JXDB3\I*./0/>%2V]WY=/.9@^?2]//GZ,@D&
M2A )6V7 Z"FU:W3*H(@'@7<ME:98JN,[!S H!B??#,[Q,(]$K5P%3/=Z9G;)
M^S5GU48?=?&ACSBZL<2&'SI I#[ X?< L^F/M0(&AK\E[;D3Y($23?C>QA?O
MHZQ2OD@N--_EN0\!R<SV[(L,V4)CP@J$,D)0OV9._*%G@@M6NG6NDO7C2>P?
M+?*^?G &2"?E-H^MAO4V >EOA:>;C7T=[0LZ"M0\"6#&9H(7W:]>'M%.RI.2
M]7I[P3!>,$7-9B'=+FJ;$!19:SF.JQ(2(Y8J-35-M;"S@P_*(0,-WKK/XU.G
M<55*\9JX55_ <;3NV-&W![F&:[.B740Z%BKH[:D_"T\LX'@:[7AF.2@;?N0O
MCE%0&O@]1_GY-4X76N2I>00#I22H='[9BY&!8,[+MU>?9$>-N!K!72A3O3CT
MH@].,2ZI#<H=+L/XB&DQN.\%8%"=,)-=WPMK0H2%-I.RUA5O-[*TQKN4[GHF
MU9W(NS!K.$3+F3YB1G=+^M3/$Z-N@L0*>0C+ -YQ/YZRO1$P?-M'.BM;L<2.
M@KH>!B3X<]--L0KNYDYF]HYWBGP=$>K'10H-E%[*;8Y=4_^VB=@*=G*4Q"P9
M\"Q9V'W1YVUEY>P = *OQQOMXGE_7(#*T3NWQ[[J5WJ_ =_Z=FY<0>!EW[5$
M.^5G53I2AJQ<&,A5]KR0<GL'J8-X'Q[D-R6Y<XODK@X%0ZTTC(->24-R6QT0
M[CU](6=$.+8D\[=R,,*&LOY9J&J9>HE=!,:+)KKJ#LFRJBH=#*;8EO[-1N#7
M5K9[P%>C>X V9*;"_8:.S6A*UT_,<BTY<UV#,Y[Q[?!8PP2U2:(A)7T^H(P=
M?<&F(N-6@+=>FL6>>*=5NG7Z?0S>ME#+I\L,SM%KPU?50?#%K _-8G.#T:<6
MV!)I,<$KJG8STD*(S3#?$GM]O<:W27'YXG='\$,SA:@:D])''8P_'*VB1(:"
M3XH6LXEL_EJ!8.KFXZ;H-<@]G5?\/2J G,T<66_YP&&H&/H-X)(%69>Y(FPQ
MC1/MH"+'J0I\2(-"M\7H@VVK,C.@;0,9)-4] +[]<$/W ,,'[;"X!ZQ8WP/L
M*W1O,!A.1T"<TAW8MZ?F@X&2I2C2.VM42/ ]X$O677DL4OT\ZYJ""(4%NF@\
M-Z^4O0=(SI[D[3\!C?W?Z?_O]/_'3M\GY*^JBX@T,AS(32./6?UT*OF0?K*9
M*.%2]K."!M3+[R)H@LAT0ZI#WKVQ(YHL!*!]>87W'VTL_OOXVU*:D2[F0:[Y
M_)CC<T:Q/)NYDHX.2M';W=Q]&*F^&H/0'*IW"0V9<OR@(4JSS-.LP3U;:K.\
M5LJY)/.+\HZX3,;\4?LTVMC.#J'OTVGUS<&H@4S2&<C-PM&!J4>?VK11KQI0
M%E(?MB\^G!1)@<-&0*I49)=;&:04_-5TM<K4+.6X5'OB;$$53R9\B3-T<H8Y
MB/(6S ]E#/SUTF% %.!>*G-<(=1VS6'&>0]HHS:_!SS7?[.*HSR@9K^'4I1D
M$>UAPT:"4MBBI<EL4.((F2#WA9VC9XW'T6>I(5\]RK_1)DCRX1C*:JD<N 46
MO'NU!>&+:B7?D19!5'RY5?=W\25_\!GO(9\#4]UG@WQO\!(V25!^'/D C<II
MC-*_-5'>X'O A I"_PXY>0^XPHU%ZJ<NWY%5D(.6H_GN 7&_I-)E,@)D-LQK
MDT]DNFY'<4 ?9?#G[$CLX SAMZJK8\3"I<5VEL:P38A]B/&2DR-T!,BLAO<D
M"EW!5(5#'UMLZ9AA'[9*%+HD.GZKF2.< _3,]_JDCB=KS[S'S.=TR>%ZTJKO
M^_;C*U6G7LK;EL?+_]JBX@MGE#ORX86O,HCI5F98!ZF8UX>H!D8^VKQ!D>#X
M23&$IL[U9UG=O#1I:7=N$O%.^QUUU,M_LI6ZCN(.&,PD0W:L'<AU-Y87@>?L
MZGQTDWY4V\(Z2YV@=;&>^,45I,'/XOLE+I]K8(V>SS[4U<TS#S5;@5<IZM86
M=!NB>,LU D1%ZD>V'?4FWP/Z=7Q%0>*WH'ZI_+9X%,.F]U+$#9V7FRP%;,&K
MID>]3&[-6]+XKD)P!NA\.2G_1SU1>,ELX*F81K"M964V 'L[JZHBJ)9J(W59
M>S8CZ^V,8"YS_==8+JWDD7JGYPPOZQ[[H$V)&)TQ_!V!_P D:Z(M\]@K[/_'
M2V,O$$3[BBMWH'=AZNHD7D4JU=)T=<<]^\)/*?)N7D]B+>*D9"[^%(<26K(3
MOF@O>7:H=L.*?&T_=),TY9Y]V?JL$L$<J$Z(.9*O2J8DXXXJ^Q74E:"N0,=5
M\U_WCC2M'\-X*Q72S7A\GWI+$W8>K7*JTQBKQ<&ZU>@Z64A.YK 1^)B-3KF,
M#Q P=G$/(*RH_0&[!:[=9!%L#S'[Z(<<5N104&A"7\O_7%7>4IHZD*]/TL@F
MS'\D EHULP>=:34_1'F 8!OJ=1Z*?+/N'B#/U6-^N:YZ#]C@_'^I2S]IWG\/
M(#J5W'MH@JO4NX[PMWVPHF#VU*V)>=M&66%ZLQKU4>"1@MM>XR\<,8(2U=T<
MK^OI(C:3NBY$CX?I\1\BR.FF1YIKAB?I1JTE<NUB=T[Y296[%Z-NS"+30N+5
MSYSX$]>-E=@W_W5T-ACO?C0_IT-E?)YM[ 9;KJ7%4N2[JA$K-J:R1:R__^-&
M,4^#^V*^;]B.CRC@07;&@3Q^(\9FT[7^PDO7L_+CYWCA1C"%F*.(KYB,AB8'
M+&1CS 5D<?D?9VT?VIU3XWM ;N):Q0VBX!YP0L[P=YG1W%^]W7MHD9]=)* 4
M'R1F<SR@IY74G* G=]'K>S<\NE::/+FC<LA%*'> (KV;7/// CMO(*;>LPVB
M-)<!L-7=#TD>X+JC1'>2T5BXX#S/9 ^0V^'PN9*0<*U:G%"7MYG3ZT"J#PE"
MSMDO*]>:9/ZK%!Y]:G 7+\GQR\O']"4/L%O<X1YPG-06S7/.I7PPTE.>/=R]
M3X3W9F+UIT,\0_"LY&S:;E:5U6'T^E$(%$6.X&VQ6@7C,A +YY6G-6F7]/!F
M5\57"F*QX7>^\E1P)O0)5!PW_P<>_\2,?I1AM(WAA,B6;P,4=I7)L78T+PW3
M0F8<BX\ICNO!.D"$ZZF&0F)'P6ING93@0?\=&5_JP>$Y0(QXZ@5?*.A$W.\A
M659E$MT)V"9:_X.>L&/](,9C@YF/J*FV&:"0[RK(T[OX2MJR_UDH ! I.HY&
M2QR%N:\\:C?+(JKFQN;NU +;3?[ (/B'P6,FP#3U:-.[-^6APSOJ!MT0RM\#
M"A>H?Y?Z5'04']W*E]E=!'#/GEE/6ZNF?;-__FG"^QN^\Q^_!<_WB1&BBU%;
M,SD/^/.Y/9B#W2-S>:3V8([X!5-DWA#9GVI5ZPF6N2N[>3-6=VO!Q#1@P'YD
M YW :F9R@=^[F5MW_$O'TMUK?VB&).^NA<&*]4?.'$\L5H4!;D5T@/Y#38!K
MMH6*)(H$'2VE/>CC9U!G<L,#IL%K63>7A0^8THE$9%\FKSQ\-&+E!?%EJ4C9
M]-EJCT8W1V#'"'W[UJ+,ZV>>UY.[G*_52R)J28)I\^6U'.J\VJ!RQ<7D8&P_
M9Y4KC)A U2A,N3ZHD\Y843GGAK?F0E#I +[%_[3?8!U[T*;+$>T+K7[=/R[,
M<%QP"-K.1A:A[G;:;L,T]E:SX+<,5]3<;=30VU&9#G."L[%'=DL<4]QL3:E
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MLB2)5%Q5CZ@Q'%B3$E;=A.A%/3YBJS/\\ &OZV7W+FL(-'I"B8J&MJ30[AZ
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M JT  N;3IGXD *TA!M!>'OJ_MIWEOSZJW/%N;D!DML)55^;SE\0CF[?YK>>
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MU_5H8)+;OEHBT%6D@;[MX5&,CO_?! !02P,$%     @ $85V6'][6;>M"P$
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M+SWNA[7IAF&"&3-B$<;1?O.G+UQ?&#17YL9VD==W12'=0O>#^%>&97BH((%
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M.ZNTI5C]I4(U3/HK_)Z"G:N*.Y?Y:WLV5L *^V<-'*C:=GQE5P/=F^[[2*,
M>P]Z6[W@I548$OS5JK;B>?B]>_;&=\GVZL,[@OW5C0>TM\'050)@-#5*5W>3
M *"^TDR%*,+3K<QW:;&4AC:RUGKB+R:]D]/OT7]?T(]: U+'2Y$>].S=7#B!
MF>;'H;,6%I??=J[9E=/],;.%QABJ,V6\5F=\0?3?J60B6+D>8_P3C,]2 JAR
M$1*R9YZHY2,BN?16M)KCCHB0 @!F>[R^?%/5?I%G]7Z';(=*A1>*RU?]K75%
M3!^(U:W]Z5HB>O$#^TFK2&..')U._'=,:I[8;";^],QV,-U:M->\#\YFQE+&
ME;V4*X*\\FV^=K0O(/1_P-/_)_6F>5RU= 60:JL.U&EP(NI;*[/1;#/QY6GV
M1;1'/!88P\-:#R6'1*/XM_'BDSXBRA1^Q/,&;5!9,T_]H.^23W,>%M9P=T3O
MD<4I*3I>)R.-2\#]_/B31PGM:77E6?2)1?JT=F/^!MW71+,[EVBFNGY$JGP;
M!G<YCZ&53-H;>*2ANLBF/ R#B@Y,]#SURE[(&2D9/<./D\8,_,P2JL]O<H,^
M"S'85N7I%''N9"$ (H-18E#K:.UZE9>9-IM.Q>H$0(ZK!9FP:NL@TW'2CN:%
M"%X!5Y#?@]KUZI/-$6Y^SHQ9:V-D3MIT+Z$:_ 5@//\.@UTIA8QRW[C,\\[E
M[<M\]<$DAJ<.Q Q)W&+8;,,A+M.&SKE!A]8HQ$X7%G3R"*N !48U4(YDLT_@
MAY0T"]:>@W+;/'@4-=]P>/+8SNQ,#@ZRJ?_*$[>7P^&O:17DV',]HKJ&";W[
MIHLV_2@)4:6H5S^Q<Z>VIC'NY\_%&Q[6W:'T,ES$H=U,#IW&EU$$ &A7\R3I
M^\P1D.XWW UEP\WZ-[#B2:-(\Y?=Q28<*_<W=Z^!1^8SJ=CCC6GXM/>6:U)-
MGA739GG*B>-GO,.L&UE\" _$4\\,_01SU>#GG1EY7-_Y+%G:G27JM^ZLJD2M
M)[G=V@HWB*,OESD?]WR)=^*=SE8:4C:4N0:D4E"J-+F@S3]:(ZW^._GICNT?
M_&^8W:RWLF*?&;W%5B,S,COEBSC8GV*$PZ[8-)3I(P% A;_+WU%(O6K#]*V.
M2@P-5KGW/4H!'.XV\GEXT*IT.EHX/FUYO6M#Z*F?J_CY58,2Z"7NN$J3JQ'V
M(/5=FMGY24VQM3KUG_+)KR*@O^*")#<DFEZP9-%;*P!,3@F >O,8;TYK$+OM
M!WL//\>B+69$[U]C9Q#U3NTSE8E4ZA2G[A\K<E^Z_&X@FK17]>B=GADYG=#>
M3K/LE2EGHM=BU<$-+KGOL1[?_:HP7.V%XND%\PXB]1HJU$".8NV->]7OT*E\
M6A;U[D/1'"BJ_K"W '=-F?PR]?HL;P(@3*W$]/YT?(*JZ70G'YZU><8GXNNS
M]C216-352'/F8MC 3U[W!5D$!:<CFQD;TYHM,6ZD"F*]NI?2>&5;H9P>?K3/
MO,T2<F^Z2,KV:\Q7;[/"\# J&F@K58S$H4/'^NKZ^S<8EBB^B80C9*&D@?3N
M2>A%/;W$?<$I/CXU^5O)@(K3$%+,XKGSB-?JY8-5[QF3&LMW!:]=*A+R16%#
M-R?>-P^0%?&;9?GGS\P,;(X5[CO:P6$$@(O8&\0+Q/UH>..I54ARZX>%.=XA
M<;#1G,; E]3?86\V3-8C5?M_SFNBQOO &@94@P]2BS;$?6#];P^'!=,HA[B1
ME@_S+#,H:E\E:X08R?/15&A?YHIZPS@Z.ULK*WE>M$SS)[PRR=P89966HP_/
M>&U#  @_7+E'A6]8>((Y[&UL=9Y:Q<Q^H@[-< T9X8K79<GL\M7+\VA^]>J8
MR;/LJ>Q:PM"+RBLA'A6(,7HPII,+PHP,=C0(?UG7TC@+$^77;9+CWX7I[&1D
M@2F>%=P([LY:;_+("[+!#A0$YE_S&_:I^D4UPVG^)MVR:B^2'DYBAT^F;%\>
M<GP&T7T.SV(_3L5TQM? V3=E[\F;F<2JU[YF5LMX&N_.>=#MLY\9KHLQCZZ7
MS_^@_ZM^GASEERS=4)_X,'ZDX0LIR0W8#P./_F<51JG+]UL)@.X'TELB#\#4
M$3Z?F";""ZBBC#^J/\IO:(CZ@10)A"0O+?'?XC04-%$G 0#D 30S8AY<3_Y?
M4+7_;]?GF:Q[]R!%ZLD"1I6)DM=U)Q&5JP[PX*&]HH (K-J65;FH,&*.BV-]
M*A\-0V;+'WMV -AZ$[5[5]Y^MNE@--4Q^MJ>/2<1_ZJ*Z>UU-Z#]Y"6LGR>6
M7;-7E0C$+8K@0NA/O3EDXV7S9_U8&J=L&4.RO6EC:@_)U9R0Z:#_N]QG)LL>
M];'B[SA-$84N@/+0U=[=/-Y1H%A$)Z@=NVYN/CO_.RYK(>G3W)'*TVO>N9)_
MV%_NA. 6P@$K<(Z]C]I[%?4"G+,_3>=V$L6:ON?,KH0<P[0NOT%!-9@/ R<J
M%!A$. P?B)K;[5]H#0Z7/)/(0N\5U+PC=F<)#3.06<L1CS*8=^L_9XD(XBTJ
MSL8X]OIM\R_5K)$7M*=)"]YM_.?GDM*!FQP"K"^\@VX$P7!"/(EFF,B,(\,3
M#X$;L/1;9U J!&*$,JQ+L<B154>?<[QUK6U14;%A(ZC=@[7"4SC=*#DN-=TQ
M4"QS<C@G'3-_,H093%2AP:4/6D5&_HRXXN"747Z@0:_+00 0EZ$5DTCN>&4=
MP42G5%<*S"5LG>6N[N',*S=4J&8$#JI\UE,S^-@&UF[RFP\:,8VC7X0,LYM]
MJ,8[7!;=F=[9<<,_.)\]B3KG2YXN7WC9:"$O\IXX)\!.&C(K<%G;KET H>T.
M,+$RZ-FG7.8%0L($;[B_5++C5L\'L#@9AR;MOWT/H)IE(#6@,\K6L475@1M3
MC.-\;1874_?=(5DV.K>SA -_;O*EMT]7^<U9!R<9XBXO;,5[@4R;W(R8\0BW
M]D 46&,:*)807KL3L0X**MW1IM GQMP$55QF$@!.BU(G\9CJO%+DYM1&:W&&
MNQCL:#YJZ5<-FQ$'R9W5Z,>>)7&."<:]R/48MW:>5?';&SFLN-K,@/Z;A=*X
M:A]*W5>WLUP!'^UX2=RW:%VP7;_9SWEN0<)1;G#0B'PQ]D%"&<>'RP"V3(/=
M>S:?O5S7=#Y-71;O9YW]C.*&W-*71I9Q*"XN%I\V+G0P-72><_UH@-C9L>G)
MZVS-FNF)P3HNEM5V7 3S.]U/G_Y'_\KS'ZWM%^BNWOFN^&5J&7%R)"X*2/W@
MFZ%C>]3R3X<8SOI /QCU>UIE247$MPDKXS)A*=.[K3-LTQ$N/;V!RK1Q1VXX
M@9*X=L42]9)-((^2=K&%6NZ#V9](BS?/L[*$%P&2VDHTQUNY]2P[X45!8*QR
M=-S1,MV6"@76I_#I\H6U'FE\#=6*9)1Q,_'C5_#P\!R)(U*FS1'9 ?W\\O5]
MD2/=X'U[V,_U&YX+HJ\V2YUV9XZ0R,T#%:])53L]N=Y<(I_]:!4NK,Q2=B!,
MJ]8EY&[.@IXT ?!0-(^DE,($/("&<_[)0F0Y 3$&0$:<PP\.+@$T(N9HGES?
M:/(?'U_^KSX&5^P^$HP")T3+E& 5VPJ/S[ZE64;DBJW6UM:!##ZK^.#0%^R;
MN2S'5;Q]:=Q"T^V\:$K*MPU@EQY=F5[A7=+W/J]^#RWPY-U9C_?IJNO:F5E=
MGIM_UAG^O*5YYCA!NR\S"N8?*OK'$4!T:O(VZVU6LK;,=KVY4@TNX]=Y>\F>
M[U5#4]HUY5U=-9\?X#Z%;L.^7'<'W;Z1C(:/2?]5W=E/![)IX<B.V6POZGD#
MUWG.@3AS^7'."P04*(@W)@"2PZL(  3T,L6\Y#T<3F<X$)P4CXI',*2LELW
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MW%GE/R<03B5G^Q7'Z$'N5Z;HS7)>.D%(JE62R-"'2$,KXME$B= <6[[Z>;B
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M%%31F&+:/34\;%P-X>D2C6JSY#.T^&X*SO/E3-=-?A# ID\F56X]\RT)MY-
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MT!%2T-"YIQ_DL[NX7G0=0[M*$3$G3;"B#]!9&Z>^%TK"O(9<=X*-+XL\.M"
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MCN(;'DT;:K%S#5*KD/<*K5*?W_1J3E@FU5AN;F0<S1K;L2GO-BX=%5<@3).
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MW2E MM]L-XHIOP(V)*B!]JI@0B^ZFKNYL/$/^//86BO$"ZRG60N'PSJVB,J
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M>,"7A'.@D_*G@-_3M-"?)46QPAQYGV72Z=M]]5TKEOLL38D@QF-T\62/^!1
MFXBA M5.[C(,@S;3H*AQ%RXQ"H*"A=]2K>!#>YPT3P'56!$Y:W,I=8UCFL#S
M<[23!NW[]U2&CKBG ,W5Y96?44V^ET9V4O]K)A3>5(@8GJ5=0=J=X!=U'Z\
M?\\5<[[:D3:,G=*@\RS-#=%9FAOLPNWR[!30M,(&_Z%2N[\?^J)\OUB-Y,N%
MGGWJ4T",S>Z\\L I8([6#LM3["$-MFX7P?%E>_[/P/5UJ^#8JK..)O^-ILZ+
MWZ.JQ-S7#O\&PK_075UV9/EO8W?O+"\1?B-'N;^3QFT)5LN>K>V\WU( \?V]
ME[R_'$K_[P^.]=^JY28O)=3:.O?^;<;$RV'!6[=AUT&,3I H?1@G=CX%](.,
MCVPS&D\!MVACCQ:!.\;LE/J@^LV+H\X"2-?H:03U0EE1GK)B^"SM#PJ.+@"]
M1E\Y*TO*GT'H%WXY"L\XK[3\)4?8C$%;LWS'1?J9?Q9^BIAS^2:-!Y5*3P&!
M[7*9T"5N'.,S#T6ADSBA9VFHU].4GVRT[BZO%1'8AR7$")F^TI*@WN>9T<%S
M9;>'-T#QT&(9Q@*##0</P,JVEL;LL&X](Z9@]NTT7)3">/Y3Q$$@8'@POR'T
MEA3)^V>#JN]IWBL'/:5E,F^FX9M0>H)S!,.S-T8K5??8^&8+RI;Y["*DG8X1
MF9F'<X,XJK<+;:ZW9&5[4>*;0Q"R%C6U\;G.[[?PLJ>T9.]Q<E<QK+8.S(1L
MJ.X?5K\0R[NUO:'U2GFG]+84OVRT=P_)#X1HE&Z)#^5%B"+@S1X:"6*56UM5
MH&G>-W0N$@QSSG-S>1(G\1G-A@J<X:*PGU7IW]C]PE'H!!4A_]Q^O=1_.OB=
M:/OBH]+/ILY?@E@0[5Z$CER>--W[GUWO%+M BEK9]QP2I)*_,CQE&& EJ@%0
M<_@!!(:UP)"KQG8%[)+YQ37OK^*2%%K$UK@JO9MHF^C)<[\<SW'@9T@)TI3'
MY3EGI#R7F/-W@:1"DK5L9V4<010DR,C[%#>7'#%D<@I8C5K5LG<,^!8E$140
M3_><[/W1-[-]GDWTL=2APHF_TRE I,]5:5A!"[MRQ;ZWCQWY#/\:0Y#N?'EX
M88LH-\.H^LX MT5Z"U,D@9.%QP>W1Q4QJ3N9K4AZ#G8T'_B]Z1M?\<IC(Z/K
M@F/\3=)T?C<"ZI&Y)@EY^[Z'4-".P 1]881@?W]1!3A^VC&BQO^9QE#VA@V'
M^O91W<2<IAB$H]#5<BHD??%DW2TF)@8], R_:/,H8[(S>54@P#]UA9+-SL8
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M,G@$'!)E;\KD+_KL_OAQF:M))FD6'@XUO;$1AFGY/C@R)MHGDH,5*"@_ %"
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MG8[513-UXE+/I?+N1AUB'^8TGP+$JM0S2F*W=G2Q) (QOHY%/U/ */EB1/E
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M \N8)J*[9L8Z+S)U^LE';+<[B6B%;KP=A;[U7VZ=L /ZJ^.VEM0T-QO%]
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M]-QOLD<JG/1#O"E'JBC4U>^FJNI@HZA72M,LM#$QM2C4/!A* '+C<2ODY=*
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M>1+L2+MK*+#0:+E2[@%H5<JND;,JW\9'>K'I6L=IIQ*O@RAJC]L_2@$ :%W
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M-^687^OPHC"E?*9Y1DF\_S$\_0R41. P#JIW@+1E:2[NR OR 8^J(L %M1U
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M+L^K;YD2#C<Z7DZ<1J$_J-FMO:,ZB=H&]P"SQ=4?Q:V<(@S=7A&#Q+S$?/T
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M)B2Z%N[SLG*HCVZ4[YW]LA-.:1>34>)FA0CP?)_5\GBM)+!A(!LS8BI"2T7
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MM$_*9QW8/MR"J\W@;+@+H$TUP"@7]CW;^J!E<4YTPJF&@%^P?Y_KP2C<12T
M3-*LZ#_;5K^@)%1@Y/10H,BKG=DGXGA9V67-MW,BDZ'(Q+0TV$9R0U6T*3]Q
M) '.VWSZ:23[T<A\O1_$*%+ZUY.G=T</R$&BX:QA+JX+Y:@?B%FA*H72.35
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M\4NEMD#=;T[/>G,;5_^FP] BYI:5R2/.P%6*&=+NONXP0GGZRAGQ]J:$46M
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M;0_=H_>R9\T@P8:E+]\^@0Q/3X=-BM@U?%80MY80H\71*D*_&J[I5<7")&\
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MAT"7]))\=E5Z_1296D>S[\O+G$-C]WQN #46]XUZO$F A VST[/[#=_>7%Q
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MRX- :,P=>'D])SP<=#+-R;*CDT76Z]?'AOP^.;"J-S>AWD)EBC?[S_A[K]P
M9FX UZKY#VX 4RO(<P#L%4ZI8U!DF:*#E52O(8[/UPCEFMU_^7V!["-M.V_5
MV$C<L;5EU[E-6TH)M 3MS,_8+S1+RF>X)4T0UT@F-M.9\C*>1J- _Y&MT4,
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MP,?%;_6(F>5G3:KXED*/G2J.>%'UJ)[N/*RS4NW\(%CP<]'!W8J@QU14EU?
M/6A]E*4W07?R'>LHGM=&L%=V)0KETGK8T(BBV:L??2_'*O:4UBM;BSR1:T1@
MIF?C=LH2SKVFB;L#TJSRN_\VNCVZ5^/S.#XMIFM+%>N*UUH>(.J&LVX +A>D
MKB*+L(B*G9T<'?C'-9F"6K_9D<>?/GQ:60GO,QRK]%-\>@/XPH^X 51;=-T
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MEN!R)?:OI5Q*?1I@W3-F/H;!>P">OS2\QE'+%'3RNXG.AES+M<RBJ^%U47[
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M8<Y:XF7K95US>9U>KFU4B?+[@VX#OX..ZUR#UPW$1F1(<1JQ&B<ORRCT%]3
M+1=:[RY)3I,T#LWGXUI^0*WGDWYS\BVOJXDY!3R%*\6=)H^<ZTZXR^K9+,E2
MB[&<'K@'4"P)D+YU>Y)H'J[>F-9.*A8T+A+4=17@:N6I^5B' OR$/ZF5=V2
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M,S@*IC_TN_X, %SHAH$Z>JBBXH- OD4QZ;G/$,OLNS(?+TJ?9Z6?*<]R!MT
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M=MV*KQ]T\Z)<2E'NNHN_&[MXY;7-:KPVC(<&12?KPVR<UT1QKY]O49TK_L<
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MHW&L'[3@,GJRI$M?LD#<!]O!X1CFU77[K"_MMD>'9"^YOVQNYD:N0EJJ%;!
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M%BBCP/WV;N[;XHWGUPSZ]PJ\J&S+5 92QA3BDI>Q3J2*XGSGJ_(138%( 55
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M*7*4E=!QZH<XO(.=+/2*HJK?W8%\YC0^*@A ?&E##(!^XV=ETXX%XR&[ S3
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MD>6NB/S9?=[A!U1':B_0V.R5.H?4)/:S9 6+U@41I2B!W=U<2>PY+[/MAL2
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MT=,K_X.]]XYK\MGV1J.(2!?I(D0% 4% I=?8Z$($!80 49$:0^@=HJ(@74!
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M'6N5GE:$=\@V^0UDZ$[AN>NGA^01I+M9*;=-'4\^QSVE<UO]?E-Q8J4#R40
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MN@(.G3:,2"?%&? LS4/>%%SJM?M@\]-(4XC96;EC]=SS8]/9!$0T7,TNZ8F
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M/7"CDRRSI374?(C;@>9N3'Q%DN/&(-0ZQ-%:(A4H"94/.D(?F_J>B$/&HP'
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MA9F>N+>KJL-J@G@92P[R\D8].,PO.F2"L4J8%9N_=% 84M(N%S[N5/P28"S
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MQ37ZF0@\DY.0<D\5**,\^-EZI"C_?/Q:L=:YRR[:/Y2%RX5([; QL@,QYDV
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M_F.OD',:]3T"=2I /;H3G':T?*B$Y!0V>ON[PIU.%[HQ7W%]>9HE?LDZXU/
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MHBZ>"=T(XXHJ_/.?YID/;#4M(]E3?0\HDHNNRG>6>I-*XF;-^JK1\.TMB&B
M%_.;W/YT@_Y@$Y&,ITF-[?YN8VOKU<,CO_:.WUAV?5BN<;T+K7;?<:H%D2"?
M_RW9!ZYP33JB=X%/D/T^5"Q EQ0ZS1X&99';Q\R7'>$F\JTKTHE\;O$Z5XTU
ME2?9W+XMA*]6F3^>_D8#.,B<'+Z9_]!@&K2:VV^@!S'^^B+ITJN;,1=\Z-32
MIDNCP3_P@7*I.3G.)O[CPX44Y%W;AK0N&J#$V%DQ)[\LS[G=8KG=?"2K!Z]/
MD;7<S2(*U/G)DQ-50L.V80*#/]CA[E\TSX6#SW/;G? L-)NTCY%'G5WRVU8A
MEB<9=>TH>^RE#2F(5-Y0+=M=L6:8@35_)54336>H'*?4S)G,<][;/04^H7_@
M^^GJ%>2D6C^?9<GP0.ZM_'Z) WGT,*12.L<4I+;+IZ>4QX'[,MRG?B5S/+;R
M4('LI5'4IP9)7_0Z#76RZ$#E#%G:M%3@<-'BLS]^#/^\H>;>*!HV(TC7D*NZ
M='8^):^ [CHV8=3]5/,A1+=Y!BJQDGRY*XB1+!+"$-IX'.ZF/%-N.L)U."NU
MZ_*4CT[L\>A5-C?)3-(8,G<13[_!1)*>F"*7'[SC,>,P-Z#[,"FQZO;K.:#U
M1?!R("SC4#3%]95]0>9,($_'P%S0UOXYY JK0U.6>4_Q*V'1)-EQM?YY_018
M=B4Z=ILM=0;#"N-ULQCT"=6KP;WA.3)?G\3^8LO\\N0&]U6BURL/Z-H+M.."
M3@L0P6M$09U? U5UC'^*KH8E84EF4^RL#JY6CA92[\P4%(R9_0<SCM\Z*VK<
M&#K^PV9 '59;I4K8LB1VKNY,IJ2R,0?JP86-*ROC=7'/M+W4]I64)V.#:W?D
MV[497F,V+G]KU)6L]#1&?MZNJ10<C&P3?.WT,?>R09.QGE3U1UX8/JQ:L;AL
MH;N;K$GXJ.)A\2I-K"OC:\)/US&%]--AHRP)K)4G9LH</6+>6/,0Z3?-'8,N
M=>U(-I] 5Z>2C7]\9XGC?IA&[RM3#]>NLU8G8"*NS!$T$X,+EM 7\#UVY=IW
M4FP BZ?JTDY-LOCW@&S&&.Z"F-'8VSD6@G>M.E[N_8 JR= )$#_ZVZ4^HY>0
M<^JP;+WG"#',Q98;:#R=VGJF)<9QZZ/R.0DM8]S\H91HP5IAM6EBB?IN^":0
MG[31:(%I?!_ /*6\6MIR_JO*ZS'*MH9WV]OC>;/VB="?!Z:>>]%D[X* &V4$
MH03/+,?AZNC$<EQ:E@BK'/A"<]O9,VP3'P+W-1+:SM5DQCGK6KD[[<9XY\QY
M>7<JIS/J29SQ2KI8;-%6W ?OJY02RBGOEJ4_$?]<663@IR*RU#Y"F!0H7]?X
MI.9\S\Y4YJB.L"CC@-A;4*C21=QE,FSF$,1%BJ\=3D1GJV\NRN2-0(>'WG[E
MMF5)T=TO9@: BYJ=%GTU?0+@4@?;II4C\/O*P@T/]1)W7>.K<5)CJUC_&M-*
M*!JK+J--:IY$>Z\U]30D7KIBJR.6Z*CVOE][K.CV-Z:&U6=PL2RO\R& X+>^
M)\R:5"Y4'SW+]B VR[%"5.[@.*R?.#+<[AC,?GW]26V-&_AVD_)*\LZ88K.&
M(E&F"<-!NJ];W?-,#LY7+RFWVSA[;<HM(KBOV%?]FA5?0?;5=]61U8-;5N7D
M0LG/XQNP@/$%'KHW8J9R_:)"V[W//N-:]/2]MDN]\7D0&;?/-1;0*.@9&37!
MZ4[.$:LEQL=3%$WT\-B:;MS3<2Z6!3K^<SO*&@G]#D >-6@V::&>9UPDQ0"E
M2Q1*4LCA,G6YCOWTT.)1987,9J%L]$ZGVN<JSH NKYJD 4VOLC4,F;,LB6-*
MHE4R45=ON!2]H=NHOCMO2@.\R-V0-S/ID_(P4)BG[AK19Y7:F=N>3\T[J?M]
M81.3*'=D)D0TF&5WFH5O=DP+1$QQ^GA)74<J*#';((>O?2U3I1LOJS(G,C<!
M.=8T+FEG6"[U:PC\RH#9E^->1 Z<SW>^@'\^I;LTRG[?@@9X,GVY7:)?/W\
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M'9&=1K\L;N P7Y:TLS=RA5P^VC5+8F"W6Y)$D.1S;.WZRGIK"<C@*P&\4\Q
M-HNJ<@6>6#Z30AWI95TQ+X!@I].6#@U@"V:M9T47PRP6>]:D&^>P8=\BZYE#
M.NGL#%VC=94VK'LT-=6<+[[+$C?($?.>IP&RVR5MWZO=N<!4VG//U%K?0%T.
MZEH_0K[8#5\/<+P^.LY#--489"X4KBNF;LS-A*B[/TR"EC2]4(B?RH<$:IOT
MK&^?&I8TT.M^JI_Z:C9?\+VPR.XZK'<QYYSS1>EE!)7?C6IQHKB*JR]+UY-L
M^_-H<X<'&DI.-==%24Y%#O],MFU?:W,JSNQ)&;H3ZO?R.MNQV3A#]Y9\%61]
MH*H!*?0+J4EY'6)44P8QOV '%9%X>Y/.V;T9[?G.U+BA_V.6LKZY)$@^9U_8
MX9%+[Q23RTNC8)Q5&HXJLZ$L(T!6C6E*4C"3+(2=Y>[+*[Z",_D1XU9VG>_Z
M5W5U6<M2: GR]<S7HE+%LZ_R3WZ6UP\33;#:R!94FS9[>]V';QG6]P5]><:5
MZW,Z8VEL@F4)@W5&KFDR?&\?&;>C!.8*X"=LA'FRGJ$J&4;Y9HZA1SD=8YLY
M98^S#>P;FD4GS/!:>)5,(=EA5%Y"[^F5)_#KR],&I@,&<=V[0S\_E;(UIOA*
M?GOTB @U,K+B"VC*XFX#^4J:@Z0"_?:4BGSE6>Y\7/*/\S9 KW9;K15;#-7T
MJ[E/8E^ ^7U"MNZ^0*LI'02ASFC/R>D,2/)O,>72O;W*=Q [4%[4I>GV!%:E
M"7;H*]5?-U6_PL/]:/%09",_L!R^B)/2/] ^&-)(R#7W^]NW98[+?R6CME'_
MMCJH(?GIL%>^[<ET&P6U-O]7;%$O3_W0>'5<O5'5H&O5PU_?'R:@)"6UEK&9
M'LU75^#8W/K)XQR;>M[<[UR2CWV2FBR\7SO+?9,)V$TRPNGK\)S2GWK_G%DH
MO$(X#JD"&!V6_<AR\(M+_#N W6EZO49JT51EKA_EDO3V-F(^PTF&X>!RG-+/
MXCM 9>G3UY:B3S&HF28%5[G;S^BLUW0Z!N9T/KO_LZSWPF86TTH%D!\DR::M
M'NVB)4Z7\7_5@>M_XT/WB@C]/G'<9\8\WG0@0!&6ZW1=(G]4KX/O^54&%GIG
M']GO?@SU[=<-5.MQ3RU,WL5]&.?3/VWYG-D-; M,0'19G6DP?<>M;/!MM[)\
M]&GN_<B*7I/#P7]W,MBZWAIT"!$&?0=RYN7:@>PG65 D4C3N^L9>*V@Z9CZR
MZ-^"DXC]!\%)\+4"CDDS[,&,X3=.HN%Q#VB SIO07.Z=<R9DOR!4[LPLO@[U
MQ6S!?NT##7!IPI@&P.@C*2<&%E.#O(*&4)M6.S('VW]%/G4C-/_.0L1,[BIS
MI:Y7FRW[[ZT":0"1<E,:X&L*#;#(#-4;:(?^BV?//YMX+_XIVTD^]L],*,3H
MS;^<=RXLZ>OXW6-0_<T!W'T?RQQ;R^2X_>KD":&;T\\U'I+@>3[O ^2(X.AY
MHD9Y'G1)QB<Q.6#@V2Z)26OAEB$E*YAE>^2%28W BK4&=8#@7"HC'[9-T?V!
M3WHX(#6'K;C?6\]&3K<.NB?;&"CSB21[A]"4I)&:[?AK>+!C0^0K2W&EXKB8
MR$Z!%>]D\TLUU?RH^X:$L00T2:2@-7--K/"8"/MWL]ZJ_E?5Z"4RQ*$,B\XP
M'8 L!W"YL5AJ8-H@D_HIXTCN'C>SB.IN;/68RO B8>(4*:+!CR&:!\CI$_P0
MA^NC'TWV[,O^G'36MM<I\L;#VCJ.R-G :Y;6J&D\QS"9IXA83+[5+SH@Y2E?
M9J !F?<9\[9_]D976F=AOI..>X<UIS:&87& MWQ8ZX6M31Z8ZTVY1&:"=.:9
M8R)LU:]=:8!3>#L*;YVU4$]H6&FJS'TB:V;[Q?';U0,"Q7@?:9T][J%SG0RM
MRTHK/DNMV'+YOL+5,C TZ79[;NR\)?%33L;]O8JL]?(6NV&]30.%PFJK'>4/
MV$#(-+BAD]/1+R=\!W1J>''XJ1G/KA]\"&MO9] I'+OW,NW30?C,%)$&B" ;
M3 %#B.5A\@*2$=7.*^# 6\/&&$^F5::U(6)%B*$O_PI4EU0R!7X5X.XO.%^9
M;K&L:%38EWS#I&A1+Q;5A#8@;-2[-_X/]MX[K*FG71L-HJ @H"C2B_2.TGNP
MT$1 $0@=!:DQ(+T3! 'I34"Z]$[HH2.]"4B'4!-Z3X"$T#]^>^_SO;]WG_WN
M\YWK?.>_[X]<:^9:*S-K/?/,,_<],VO=V2\1<N5ARE#AMGM4AJ[8-[>/]HW>
M_$;_"8>ZU5175AX;C#7/JB]BY*3KF:1SUBYJ=[<'^?JDNE7%JCW,4G4:C\;1
M85[[#ZV9'N,+ERZ W=2.-1&EU<D07*,G+2I6)R(TQ#13IC_*&R3B@I'I]+V-
M]T U<HR+X<]UK#A*FQ%;4V WG.F3Z-$.+DFR<()9%BPLKX;B&B5.V+MX-0XR
M+:PMZT:PMG@(>V,5;@0,OR\>8^0EHT8J?Y65RS&U\80&[_PL;S&&/_F^P,$8
M\*A/<G=3@S;OT6)3OML>/&LBEWY[9F;3KEF,,T\QTM$VPD['-D3>1H9'2C*G
MM*%A*B6WY C<WG2_ '_X"D/:Z<)WILYZII1L*M.9O%HS$_G^:PD&V:<]],?]
MU_RP[0R>&$4&TL#,+3!BY//+C, '-FO(K.96PP&I+^]?_HGVU2"@.1;;:J!N
M@]W$6\^G270DZ'9O<?J;5U>XS^X+_=8@P!6;4.(-D9HWY@==?FZX-D ZBVM6
MPRD[7;I5)9G:LUK,@XI)8M[@8VM#;!O@UP.YX0G]!V$C.Z92VH;$MY#JE85(
M!,< TX)NXQRJU;;+%*_5,/;>;OX>,</R;ZHHU#ZA+=,3O!.Z=E^EL3Q8>Z0K
M?K>Y)9.S=X_6+*+6"H:.E!,QR5AF#C*AP7\1*$E_//IX@FE<N-W"DI[07!*A
M;$0RS'SSG%P6>!%\[=>[%:--^]4^/ZJBV;LEK%R=HCS7.Y9MWF1JW&FQ[FN.
M,R@V1('&QJ!),^']VZ@*G2+)KO;/X:"FL29382AI+6S8#EZQNDC$.>'2BJ#N
M1I2>ZY*,V(P8&J4)OF,GY?GXV.V>A/C]JA[;9@RM2\9]WY$&B2"!)O7B#4^=
MH2^XD.PQ.P.YWQPIT=)$,MIVW9_YIIN$D&34;9YNTZ)RXF3B8Z[+#*01/>/I
M.1<VENCT& >4NZPB1SBD])D=Q+R)?4^O4F.AKEN_T2U+/U#B6[Q>CX:)W@;\
MU36Y!96_X"HI_]PQY&:7+UOCF<]7G5PUJY%X(/\\P!@3@C=&F=Z7B'19]D V
MO]$W^-D@PVY\GN35ZW')?P13NER8D.<Y5QL737O191 5Z+S-^(ATX_%HV6#Q
MZWT:M^CRK>+T9[LFG?)4[J^M/2,C156(4@HT<2G%/H,A'WME0H:\7//<HY#4
M 4V&.,U=GQNC1XB7Y>U#MS\J/*%F\5<X+IM9J[.-M8\=-A3-=O$U29%[=S8L
MF/ L,I>F!U$HY+K9KQNG8=ALH'L==7Y]FHA*&N[4I-Y.)T>+ONAL"&P:Q8?Z
MR)QI+&C!G&XCJ#(8Y(4]5W1QA40PF])S?;3Z< BV^=VK\E&V%G^UQFZ/B7XV
MJ@4/A%LT*)/JB/T*0-;TU,$FQZ E[)/ 49+W-DTTE1[SV:\;4J=KI5S^U2^G
M7 0^VHQ ;;:>D((; V(MPP$W8E+- >1IA6KBF3B>6;?*Q3158&S#2:2L7%@E
MKJ8^/:1Q (FS$]8]C-,<%# >CA&+N,_?:KE(-/>LV&1.'5KP:XTO+$I:YCF3
M(I,6T[V/E,J.?..BFTW/EEK#3-C1OTV$QH5*33N$MY[.;2?*FQG.A1-P&GY5
M4&5W)MPT28.@U7Y-NE+J/T,.Z.U^K%/+#U%;ZD]"+'K5:L+%ZKV6(DC?3@JZ
M&*:)TV))4\3'UI(.U&;A"^'AR\2;BI\0$2;6U0@[3>V&ZJGY]QV?<:P!X>/?
M/WY_%)LPHJ6UT<*7OUJ(R@#47.AV]#S >W6>YC7*MW)\J;.VAR4<#'UH5DEX
M1+RR'.XL)1]_).>X0(DW19K>,!IV^O?^/%"S^HVRRRGU8ZS"\(=-8W7WZ7-%
M675[&U5]?0_P9FD+SD?\[=?2+^U%8JNN*5L+:8((D,]\XL^WBE3K3+W_A43X
M_Q>->B7Z[^$Q,>&1->LM4NB6YHN87 -WWWFQH "MH$O01 UGA%]$!T3W8%&J
M6\:LF3P4@&FV1X*^77>DO?BGY34C[ V-X[&;5E:I@W*-W:P\Y8"B41&[.4<
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MB=I[IGC-;L1+-_A;_1Z70FOA9X!899(O:9'$G,TV3<_>%^G]GB8$;LV>\PT
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M,DR1DNU%OB];9B3XRWK11QHFBTAL6F0A<G._R:;41/-NY@XR?5/\%9(<1$#
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M<O]G(._JRSOIO']W3KV0_]0BY25:O,+)>:N4$39$]>-T_;'3OI'%/Z'XHBL
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M:5P]9#<$!_&XZ#2?*]\!0DYWW>&]K!]C/(NE%TLD(7H.T]#%\X;F9!."[)L
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M8AS,N>6%WX2[F[S\16T0KHC;1G_:IFM&8-Y<#UX_K9%57(3,[?9EQHN!I#;
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M2OX?-JT/= *WW/G\;&ND<4Y5N,SANEP>+G^,%B17&FK37088WIM?H@'?P@
M0#G1E"B>-$)LV(_DC U"56)CI)RH"Y//Q%.E5*[D0XW!A->?V_+TB%O6)JIG
MR]>%&?$C9!T_;Q:?8$9#UL2O\ E/LM)])AU);K#@#A)DS.F_R:(T@I535*J
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M)IY\:*O]:_7^-FGT'15E'[>^8GY9=]6TOW]KO6OGH,G#;EET;S*4.=7]I$5
MCK;]*R<+:\Z<[3BRI;5P12Y\L29V N,WY_XZ04K3@8F"M;[-V[V- \8BM7'_
MXZ[0P>Q269@\R/[\Q<R,)>SSG)-W0B]OS&Z'XN_HM0%S[UG+8!RXBXN.0.*<
M2=4X 7?T0TP/M4-EB%E8S.*#ZE= 94Z'@C95:^2TV3KN0\);_KX;V<NC&-_#
M34Q!Y(_+#%G^#:@GI+066IK&99,86T62=KIW_!/?YX,6#3<5@CGK) SH3^6J
MUJ;]C=EB)*&3X?[VT;(,FSE@] OO]T.D.5 QK[C/I=+<W/R.<:5[K (1<4M
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M1N_*9(9\@\W%BTWOA"2<&"T57VHC-9+6^!>,\ ZM+WH]ITL)C!?.N)[&GQ?
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MR"2+>(-)D3;\.!Y;0J )\P-3]OXT>Z1G ?U3PK4&;Y7AXW ^=*GWVPLEW)E
M]94VB>?^E4K8J7ELH@*/_X:6.?59B]QH:VLK TK^N1]W[")0:@"QV%L+_'.T
M_R@S7V\G:86Q0,2VOR0EK=C#(B[E"N (CERX0Z"%/Q^38GN:FMC^ZYW71\@(
M=SE0'O3P-@MS[X.*%OZ R>N\ G==-!LPD9=V+W1*O?-+F>KH!Q%)?,R\B[;X
M9A-RJB$LW;'85-W9'T*U4A5,0XD+5^%<Q#JG5.&E%I^R53?48EU"J3HR.EZ.
M_Z"D*9LKC58$WF#6.YX R\MUHPBMJZY+CZ.'/)W]S>B:,[26I 8'"%RBPG')
M 32J2Z)AX$I@M+QJ0:=4R4D"]TP*Z"LWB?.?(M56,E0=A,8,[UX*EYV0XF+:
M1*U%-/F+?BDW^0N2C&J*BT_E$N"L!X8&1%315BFJQ[PR\]H6?+(TSID\N+%
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M/?W%R!6@XF@VXOL8@JH)9=L2[\V?.;9!FZ"9U$#!_N%WKL"+.L"M/C*&^<W
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MP%X.@3[PWTL,^RD.@UPSDJU?"42$YJ76M0D@UX$BXG]N-N OQT")"Y)+O][
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MO&JJ"K_GDSC;( )22A!2;.8VB-327=(<WY7W@*M#O'WH'Z,ZC!ET ZX /+%
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M8/-,?7T#7=GA+FNB;U6RN*)?>NGR"[5]!&)'7\#O?V,;GM3]5*>P_N!M#Q/
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MFA]T+A],U:OB&#LVK!K>Y':C'3L?LUFK,C"OJ_9TWL)5[, :=@Q3Q9S126@
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MN3JD'_VYW'7T^UM H/*2[>5=NFMLU#IA^5VM:;@WZ:5G;V8KZ$Z//-+.BKK
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M9T-AFP=YY^+->6:#A?22O@6@F:PZI/U%=BT*E!_;VQ7=?+'33$-Y2/1946&
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MC%&)1>3!NIN;)W)P)G2OEH>\BI9@?F/H6ZLQJ]/#H]U8QN.+S7*&S2DL,F.
M2.F;I[PYBS@2RXJ3Z67Q(Y8=[?>-ZQ(<Z_7RA>_UXY$*0@<^:-]S2#P]H<:U
M6B]0D2+^U&T+7/YF914TBA*=R/V9JW++'O,$#<!=5XV,(UY'>D&6D)LJ(V])
M+M-8,G[/-DW\XPJ0^%N.RZV_V/,9?UGM_IG;_X=!7_C'6O>OQ)C?\C>5E.4P
M'IKR!<5;IDLWX2]Q6>465#7HI OE_\@*T),9*H3G(U@ZVBN2I8M8\IW9*<IS
M5VOQ# XS'='O\/&XOG%7I5LHTXQ@Q7B=]BWO.,(:9A<&=M=Z,<F19W"3%5G\
MQFJP>K?)J4X:=LV9B=Y?$$R:NJZ+,'T- ]\QL$0Q5@4KCS.,5>[BN;\:TN_N
MWB&/J[NB!'#:M*IW-^KP[(R&#]*2ZUH)Q;4A/J^EV$]"8X1?!M@GO96XAXL5
M:4WSVBDKAIWVJ<(R].YLER5#,_W(2_F.!1NH#QYAJ</'A\TFJ5R/;$$=ND9!
MBYJ0,;;M5W':LVT.CM$\/["^/55B2E\6E?+>W2OM4Q[CA1!;'*>2Z E$O)/H
M758:4NB?>:L2$^1-'$BZM@A8X,1BNMEK"9D68ZH8\Y9;&I T'*W"O:TWK<VF
MZS1'MJY."3/Q-S5-:YS:&GN9QLT4;0$U@;MUB'*V&UX9%5$KE+=>ZK.&]1;X
MN(<6MGQVW;5-CZT1Z'#%GY,2K5<B+!ZJ#]:A%PY@(;^./^;#NF+ W9HX'A7<
M3+VPB;<9KZO1%+%:F4M-9M1CS?U\?:W&V;ZYEK)Z;]M( DDUC!O43&E9[<"1
MW9TI=S],,X2N5N,56V%O>(N,R%TX+IU:>-)PJ(.\^BM+6G([#J1&]H9G6B#8
M65[TE>72:&GIZE4=78Y<V3M!X31=3"):N5I^<OE&B#987J"+K7";T& 8C%7^
M,_M1($3&RZ+X:\LL/2Y;?#==%Q1L=3+C8!O+$U=,I"*E\[^\E^GWGV+4KN_-
MI)]E[)2U0U8.T;V/:@RKWM;+U/)M"10^N=%+#1"\^?DG &G4"_PK8STLFMC;
MT0-.?$84=D<E-",&M*U:9T%@]I5XM>G;$FW6#WR6&9:>!QX*K&4BCI93[-L\
M%:KCTG4,1=>RG\OEZ\W("\U(#2?=RF.'7JWU6B"L:5L(=!5B\OO!FU34-VTH
MG**X+ENG%1)UUA-*-*<DXG Z8=N0U,DO+SF%HG$_!M)L:&G1OHQ5:*RH]9(O
MDJ.26^UN>NK0ANM]IZ#$6UZ!JZV=-/[,HS'@N7.-)O<[4L+D5T]:.KFX/+9&
M\I%X(X<^E"W6K[,I3W7,V%V<\J?EK=D.:'2JN].COULGC[+;KB!<2J8W$ZE0
M="0S8[G[G5@FC")?6^""-E?O#4\2&4PEL5:41W7Z/J@9WMFU1S)>#ZFRW3[\
M)F5/\=HTG.K!CVMU@AV2MGNDJG(N7J*2;;FC&J/;FB<_AN:+>W@8%N/>9*W1
MO//E;9NV5D8\.FG7Q2@5$6$0B?_QGB2.O[;\':A+6G.9[1P1;F.+1PD:$.P9
ME.)@7VKEED Z6?_C>$WO/&F STL[YO&]!V']4I2DHP6;EHR=L ::V!PKU[/!
M)%L?J_/M'7H=4WME::MQAX5;=/$+2X.AY?[%W3OIX28Z4^#O4JZ\A>/D3=0A
M=!A_*$UWI'@*.)$W45ET)RG%F<_L5QI?X6_V:,C(0[*<S+>$1"_C0P$_E["N
M/)%FL4B_GOGS7EX*P,C<P4X$^)1%5*E\]66XZO!3&M%S@PW2F9,?&\L&P!?E
MM6/VZU4:01,CC/$ZN)_R[A3>9HILA3  EZ2\GV/,#P\8!$F@CP;L$9\'E%@]
MMN1CW%\-Q3B KH 8+$7_.C0 H9M*B='(/2 XC1(<G-M[4/C9G$4MD)>U(8T[
MT?C-5&%9G%5C!'OE[IHO)Z@U%!&'!CP[Z  A&#!U89<Q/.(]5E3(>B@: )=S
MPBA#K6U<)+L2#D;SKD 0N$R_/GW;!CHXY41=ZT$1_T #2C @UGO/IV%H@.DB
M\/M#7]I_ LV"H0 I-PA<,D04T=<</X2B ?A&E4;P*A%^-  8@P8LBJ0MJ8 [
M..^%I$2L-,B27;2G+<F<31NAO,%-P<=BUU#^6DNHU\ND2&9PB-&ADH@6&N O
MGX9Z$(50,2* ?$]U!Z,!UQ. 2"G?H9^?BEU HN0Q>O_G$41_:^0_@<)._O>!
M8L'R@O8PZN??@7Y'D.X]#))I6R#&W^2Y!)J (M)J!Y\QI;*B 2V_&% QY*T*
MATF$3L:LW ,Y,"$NMT19N=NC0 _1@*\>P-:HHW((\M3("_>'-];%=7 ;$MJQ
M^U]1HX5G-C\$#8OL&:%N<X 0H1<9/S]T"SE%)J !5U9^^\#N?PMS%,X)DR4'
MXGJK W=N7TK],KOQOPB0]=C3/M20VKEU7CXY )6I=!G_),D+PLA^WPB)]?/<
M'ST,8="XDR^HKJ^@H>=(8#_2\#\[E"JM'RV!MDDS-:(@.&-H1PDU"IX=H&VO
M]VVPLF-;M7QP5SE>VE"FC-AKV\$SK7L858V121KK[NMG[B!<AAR*&>^HP5T$
MXTE;%(F[,"SO_8[++O:6+G5EHFIGK)6N]\3W@;5U"XYTPLCQ,PR]G*\O6I #
M0H(CJA(Q2B.)P&5,?ZT%?@;']CN4]S^YU[C\:F1TZ"S\'HF T)V/#YWK8V"A
MNJS]HK_"CDJ($]W$C$HT(,KE]YR[_R]',)$UJ(VL/M!.HCW, JG@NNFA>^_6
M<N:7,V7\+BD3[?J%\$-<' 4JH>:ZO TGV888X;[LD$^>;]L==+\H48\]&;@;
MQJ;*;!;#-U>,*W%KD^5N@FG4DA4?,$L-1*@0(Q7$Y_;F?7H%-Q4 2]6"Y%T2
MK6#;ZXDH=C2@WBHUH4C'VO6)X<;DAX7IOC0.V(PX@WU 0! 5C7B144@ZEHVW
MJ;7IR*]WP\\FTJP+]"Q'C?0Z\O6+>$C S 2]6*I%R1]$"]>7GW9YV%^,RL2C
M =]X%MJ'$8F>8>+S>FB \_ JY$2!?X_'ES%"\O]/3T:S(BI.E"154(PIM&J'
M/"D_>*V#?U)_R0<%6C49F.4F.Y:-P]#C,]7M6(RS*/0:9A59 ;9,I:XX-RS*
MG]F(K\->GU<L8_3A:K\CR7-'<+/8MTIB\FEUV3@G[ZW[[CMVK:<=VMN.3??F
M/Y\4\&PKCFI71.ZT[E#.RDFK>GE<RXIZA74SLW&R\IN ?E*3Q,R4'EV\$T]O
MLRI-^+0(KM-3"DK:X8HM]:,("G8WQ<3./8:8&9.J8?W2I8WHF0J>71IW:ZU(
M'39OR5S#+GP5>KUY^G<]7WNPPA._(4&Z>D&MDC;L,-FL,#.+# UU8X#0%:7]
MA?/<)(S+1:BD8B%_YW&<8[:3+F\2UMG8V42<B9I3>5#_;X=I_Y9752XD\2_9
M\7?!>-;VF1TV+ZOYU?1??'G@X7=3EHDA+>?5K/OFU+>JJA4CDWBZ5@>&0M?'
MH@"J+V+IFL'OG76JWF^+A+VK3IQQ2=&5#0^5O6[\MF]K2_\"VC;;8Y?3&*6-
M-S](IO!@-J68;)\(ZX;T3:'87<T26ZF"*F#$H;9MC$G^;'UW=L?YU^O!J5=$
M7,CRIA 0^88GSR:KX=^$[!^3QX7N)9LYC";VU<-]LYR--<?8)FZ9/'E8/UW[
MC %/'Y=_U_AD0!-X-RNFH\1LC#S+@WBJ6)L)_T>746?8,][+#3"<P]XYL>>*
MLZ9\7[U;)DK$2Z;T%T23M3[T. <P/GRC1]P=%:2:#>3(HM!_<^-KD-)C (#,
MB>/'HO/@PK&UT0OXQQG?6GO4PJ=NX<Q(KE1+NKN0?O54H<#K)XQ!67.\A# @
M,F0F^#SK-!1^?Z3IY&^WE4%=[:\7NH+S-EM#F4MP$_]Q!7-HM+(6O%UJ;@VA
M^QHDK?DN.O*M'5:!:)G.D1WKP;W/#A8%_2.L%>OE 7Y1!0/TS^U8SOLDQ\2(
M0=TU3!?>P,/28;SN%O%K6_I&K>!3$HQJ @>CXF;H;=Y\<U"P\>G$OIA/.2><
M!I78YY@CHCJ4W1U1O8+L.QPT.[*+:G?-"NUL[%R_8P'59JK8(!,U(_F(8 G4
M@K6[-QI WY-*F;S]+25242BRN2J\F5W)*NJK<=_>\QGBSS.]4N\_DXS/F-$X
M1(I3[J 6;_CU;,?.$E<L@4AE8!^@]K8/GD5GB81_??N#^XMIP34L44'BY]"O
MEK@AKR9>Q8S(O7#LHN@P*XMM]'^133N/_U;8(4TW6 ;A<A$+GMT$S;"S9L8R
M/S')=DJ9V_FJJNBZG$^U)_^MK#KOM121ING]7^JC\)<R^37A_YG(I*Z5MK?S
M,[])YCE ]Y+!@9#E;>"</489_'[%?-7J-^[_OY,._M&%?"/Q.6OE?E2B"$N.
MI=!V33N[J2:\T9!O+UQW[(M\CM(#MN&66C9?'5^\&W..P(;(<=S@1A?/YMOP
M>Y\78QV6Y*T'? T897<8Y8]GB)X(ISB,AP",'0R[,/:A'^KVWD2^"[OI,[G=
M3R;K05J!V8<+7R+:/1-':>\BN:(M5"2S.ZSOA3@=-]PJ"7M6)A]N=U]I  VX
M.F#>.W"Z/+9/&X(2WL,-!%79.D>1;WI&9F3JR## 9RV&N(*8&/7J/ET'^ -D
MO])'XO*FH[CV9-II"<6B7Q=W+?7IV>-T%$*KQQE(57NS'G4<O \"!6.!Q5+]
M8+0!AOA[FB5N!5:Z>@HN;F2AR^;]9=F+=UF<->^TNS*8X>$JL[C8!Z023'0F
M'0\\^5;,+O61(T&U<P! MK]B;FRF[VIS)%;I6.Z1-057NN9^T.XJA@/'#3R\
MDM]VG$39T&,^8IN>NG'<OZ3Q;(5.9;SAL,/G"AP-,)SD$+EQ PT(LTE3&D^7
M$QNG^8I]G0FW2@Y0'KY(4V4(\I_'JQTZ;&+8B'E8&J\_W:CEV,4CW,-QO; %
M+B=(WN&,HH6C4I9L'\S*CY30EWVI-B@3QUOR42I@V)=;270(D_B8>2S3YTN-
M",A#!"_7!'FK^11)YYY PW4_3)6'W:![OW<R^S"$RKRI:$LQ+L)G"8=5=8\O
M!88=YNJCI12Q7/WI^=<'D'E*\19H;4EB?FZ@((MNBQ21!M[_]"37__K[F:%<
M^;,4#:JA$%)YNB'%)8$9 ["+W4 18.Z,-8J^W$!BLP5Z[%+'-L#0;OPH]TW[
M>4#HX9W51DMX7]L"GGEYK'Y5XNJ/GL<\_*JMRJF8\7[/9T-4,U J^TAPX6TS
M^1A2>'$K+$)WVOD\17%'?LDX -NF9/CI]F$Q<^4&TF21VE<#4OX%,NX2%+(V
M1KG"'$ELNASS1L#P%*P,[WIWB ;<FNZQSJ.L((I:XY_E?%AG<\X3WHYK,_$P
MKZW/E>+X<[XXSII?OCYV;09;"^S#!>I3%QV>>'=^1578VGC%G:_SS5DPX"UK
MAXT:G='F4>JUM-?'-AG=,QNQW?1T:_51013)9UUO>>0;XCF%9P-?V954QO4@
M;VB!@H]G:/P*9Q"N]^]EY#,E//QVU!\K*_,BP;'_#;??2#WU->F MAGV^"1;
M5.;$PQ"Y7;_)/9'14,N0RF'?4.8BNAC<HX*CDD>_;3+[WTU'_O-WTRB$)WOB
ML(#-+#I3KEOU^Q5Z""C' 03/80-]9W)# [R9$!KV,_:=GI VJ%_SHSV: ,?J
MQ.8TN_)9Q3TV/TK/\&UC\<743 @O<&EQ@0ICY%ICYJD6*8Q[0@E.[ROW5C15
M&,M@B'&=0 -6H(D#3P0H>%^6*3NZ;LR@\B]X, X"BREF&A*&G"]=9DJHQ@,/
M"3$F<3,ADO6 $T6#LP=%!348(8DPGO]>_3\TH76AU0],!'IAH"M1;IW*(,]
MDQ>-OHF@UH]E&,LX9>$"GK;TPBB A%%3:5NX&0!T +9"N"'_ 2B;%JZL%"D>
M!FK5LHY=.'\PB09$#*.*UF@':)O0@'WZ,Y02&B"6=H0&V-/F0O[*G<N=_*I=
M*'\WT$DK*-#7' UH:VD61 .&)JTQ[F28$8I?!BE"N9QV@>,*03!C&EQV!A6>
M!A_([(*0[YLA'T'0O O0;-=&'I)%GO;L]F46RFT4$:U_/#WJY?\CF#X@C#.6
MIG2&!M1$C3(W8T_U4-0<ITQU0^>4+L]1_0M?C#YCW-D;UQ$KH43NI6-7T #E
M2] &6JW@6? R9Z@8H[N:[)B(BJUHX'&!O:T#Q89KKR[?AYODMZ-;-A\QM0D@
MI'IZA3P@^QP"<YF.*NJID,D#V@S0OS/'C=8ZX;QM/VO;$0UP]]783Z[8P0A.
M]?)( 0@4.4A@Y'_\)!=4N0.E\VD_.KOTAI]K8XA6W$4AE."ETSL,#D$VX>LY
MPK_JJSM":WWD+P\PP'CW!]Q(WJ5;WKQY5<5:!/VY$N?9 !K?N))C8M1I ;N9
MI>G#2$4'-75!.6']PXWA'+*'-S+N\K62,#P1/$H'=6'TWQL0M^J8)$H,>AF-
M#]JMJP\-+<<X<"Q$E[/8;WDLZGP8?5W%^W-BD_S3 \P'_Q']_@BHQ/Q'C WJ
MF@'5+O2KC_]^I7Q][+<94=(:50)9 %W<&AO_:X[RKZ^E\8/V=A94D!T*RG]F
M*/^L17P];>\(=[C0\Y<Z'[LB>IG&_&><^R]NH?)-0YD3K#6+;M0B<H O]$?9
MZISKGP_<8Q'+,-QV'"6#M)9R"T_I@.QOHJ'Z5M\'3V+RYKO, 8M.FZS98;!)
MY(-YHB$[I+W9C"$XO]_6MR^/I4&-F9QL2I'KR?Y*<K+Z-])>J-Q/D.2T<[2?
MP<+C*$&$DZ0&?_Q9_XOJ#1='R+0:X6M**I:TJ&\7.$HP2+@8+7Q+RBJ!<-Y(
M?YKR>WSOB+P?E4#O ./P?IYWZM?1>E*V!NJ=/S'U(/5#\4N@ ?>0O 7N[P8\
M2JV*N$MRHU\>R&Y1?GF-SRBK 3";S$9XM7NZA3KK&>B]J-,KPHY;H$K'_R&.
M]4&\F^ZPXW8N#H^5&>B-[ZOPJ!W<_LE ;QY$5;[[24=Y!U-899A 9(:0GL5K
M!4:/[>'W9&GN!NV>5]TW#-<E+-_%1H:[_I6+1?@.TY=D9M&?!QSPS#!_T?_;
MWVRDU-$7+:>)7,!:(+="9MB-KC];';7(;/D_73GO/CF0^;M78F0*[3P2A[&2
M153RS1^BRXW\J%;&_U<P8+H]I4YJU5E89.!2$[="# Z?_)*U&\@-JX_;].$#
MP1]"5?+E+(S'HL$_<?K98&.#)"(OWPI$;-_(_S"N7D?Z#H/_DE)_8YEFU^!4
MIYI_<VY]&J%[Z.:H_C"/K7 ?:<((3XQ(6"T#,]<Z35[ZV;!+K4Z>:?Y?^A/G
M.%)JF?;NG.594(Y+3B5_O?\,1QA.'9>'S=2-5]\.'E-%UQ"/8:2OQ4_S<.)0
M>#_"Z54?#X%TDG<W;:Y,/OWUH41*!6JQO\O045OV0&NU2ZPJ2^<+J$2IQ%)+
M5&&P]W\MA1-O,KZKT#IM>L*>:)CGM;JSC,<*!^+;.Y-PV^5<Z[%-%O9H&#/@
MQ?J-I]UB6?,%PK<6S1 A/J)-Q? D2F&/=8OKDZ&SZIFKD/<@DJ>%6A#\*NLB
M\G:5%LLG$F'W.KFO5;@E"IY#@AT&7+>61$6D3,DC4FRF4_BI=DS':DJL?!(?
MG".S%VKLMK,$#J$Y&I/&8P<AOO2;KNRKM[;MWCV^S]:AW/O"J\;?;)![BN4L
M-%&)UNKX>Q_GL>OA_K=L#?I5,]RW$71S'IN48J'60S>2KWQ\;]I;.N1Z#RMO
M)(2=+LZU\4G]"A67/Y>0ZIJ!?U?21C.P(73V<9A/4J)R#0Z]:*?Y;+GHP(>G
MZV0"A\1U2T#2A2W=<.5O)?F17JXIUYE[>X)9_>6I#@^))Y(LY"1>2BBO*@ZW
M'!&M!N+YYQ<^[7R:436%2W)1"5R90F*F34.,#LLB@)!M'7L=]X>L77QN=([.
MDMU^E?Z(Y27(/04 [H3^\)%$>7.@ 7!J-* 5HK3$%T^2@P8D'<JL-\HFM;<N
M])V5YQ#;G],J8Q0=-@2)!8)G_?4&7+,6Y;129SY5(*6'ZAH#KK?NH@%7%I#,
MJ"[(GS421=OB#4(_:D#^UEK4W^XB+4[NZ;@^4M%$ \J.<$_A&-/DJ]ME3/5O
M=X)9<X+F4R-PZJ:FA8C*6W:+J9OCNXL$+;:X*6Q%C01A--*PIYWSIV"/L<K@
MJ.7)UF\V/-75,Z5@PI;L^0T\RP0^V00]B<HG;Y27'ZW'B,4=Y(_P L1)^(TC
MQ4EV4<3S2++J\5(4GSL-;)_R=,Z:SRNG5HYJ\7F33K"XH>LCJLG\G$JC%;>E
MO-XX?NH9H)44D>_-J*^3L. -/U6Z^[?I6:%V1]0<2DV,/#_T,;I?W;>JU[#K
MS0*^24WM&%-,Y[KBIXL/_/$A0>+1-==3E?J51HDG,%JW$*C[J3.GAOA&6?AR
MLI9(2O;@&>BJR"=+MX#6C9)9*[69CH=]^@\;:[CY>W6>/4I[TF=LBK7ZL(=W
MQ%M@<E;SW+QRWLE0_ #*4'ZSCYOO*0#YB>YM<'I7B6L0$7-!F6OIXR=?\U\&
M"8#-F$,#Q[B) 7:"(FFZBEK2\6S#4L37?OJ[_]?YSJ$!YQ*C*-]%C"+^CAK"
MH)]6"]RMWUU-,.T\_H R/TG%!B,Y]ES?-3\8<A[ >KX7%5!5-)I?DK)]/B-G
M?=^X/^>C?]L;K(#9FN<BHG!6 WAG AP%M4U9&A5Y>E:"!DPOV+R1[KU)ZL89
M?B^ =]=HAB3MX 3KXD3F.# />=&"L23&O)BF$WU> ON;#]K$V)'">^OA1Q"\
M6>F2@N]NKOD\4VA 5?/ C>RWYN$?(LU>.EX!<O9S?X4-1+UM-%W"\9W5'G%.
M4M#$F(3W6K*_Z<TML(%,$WFON;Z1S,LW=!<;W_Z'%H=_I+VBU0XL<3E)X]=&
MWMJ[EY2)X-A9EU$P7%>HK"UO&GDY/I#DO2^<'2*$)]#=NYZVN@VYY\TV3P17
MR$VZ2+/,5@B.WF:W8Z@+8G*4N[(BG!0+M5FGTI*[R,"87, WH 5GD(4N"#I'
M>_*-5Z'4WV69L[+YH O+'VD+\[%OG:A?B\W:B/>\F3\39N5I$UK@F"5,((#5
M'UAQ8'8,MLH'5K(#UW=PSW>BMK&53L\#4.<9XA@@&1@@^YZ/<']_F/6'V#8Q
M<T::)>Z:D8<H,=:?1/Z)C6/?%R]9$-=YS_=_ )X5;Q P(WF:,*\D)?X/!%"5
M_Z 9H>W_EZ:_KR88_^PEL</*?U2A_8/C; U8E<$'G(VI_]S),-./:#;PL\_*
MH3KM/TBICZ-E^SZR;Y<I,_W/.G\0$*GCBOM_FNB?B9&%"[_CKA1Z-OYINR[P
M_77X8;*Y;5"A."3$9R4@A]CHC[H;H-]Q26-K(/Q%'E@$$;5XH76Y(TPZP_2.
MO'7._.?2E!P-YD^;5U8N;KBE_2=O1M[$?E<MNG&<,"]+%RZK+^W7,[B8!4QY
M,_](>J29 6&MY9"D8Y+X->8-B32Y>.HT/?$,&O [<5*BG2G.?HR)$V;7'^O<
M,K[UW6-7\EW#U9_0/.S\3)9O[B5M&=+!/T/J#UYHQN)HXC*V7G78E^EADV$X
M$KW)F@W?IU:"I;VO$O"HK*H,4YS'Q:$3GL+-HTUQ!?V.J4J+0YYN@?:KJD!Y
M$E;R.[=%E:@W-01=*4NPQGU6Z_^Q$Y_^WHGM?L4(.JN;JF-@O/*?#$*6-/85
M;"9YU4>UA+_LJRKD.?[=]&G?^M?=*\S%:7A;49E=UJMZE 6EK_!^"[E_\&&>
MP[%B3:[<&TPV =HGLO,MF;DGLIACQ0DPX(]YC=7G1?"4\+'(S-JNU!I^\.C-
MB:(R@PN=Y+VZ>40<D(N8E1M[-VNG21J88F!.Y],23S^&J]MD#L/A5ZVS]M*;
M>OV)8SNZ65'4YWO%%9<F:1S&]GG],MD'QH.]M^E\;C@MP*LNSVH'.H$N%V$U
MF^G1@.Z4?% ]\!/X*O6C9:+A X]44STLS<>Y<8G-$/AZ'4:CC\,7D!<#?RP-
M_Z6^(;F4T0,1T':_EL4%% EU0@,"BY8@I^=)OZVC1OBR()Q?_+!;FWG:M<.
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MWR!2,6#"]Y)$ SY4@<]A37<:3_YRK0_J;,(%]X ".(V&_IZ1V=CV_9<@67
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M8WYCS-Z_,6)6RA6Q(IGN*=C4E%^&^2QGDWX(.[B<&J$G]^U$!"8TY-VDPQT
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M5O\A%2<YYV"&GR_PGSN#NDH<2>G+9N<-5I+NTFMU%KXUT2LF5[+T?LH;O):
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MYYQKB!>(E4@2(@SG]>2^DU K/PIUXN.L2M2NJZUBXR"@8/,S,6C]_!CQ?6K
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M\Y_\-#HU4K$F7'^Y(/%=(RPCY2?)#?DONAL'?!.%8,<$ <'EFUM1$MYSU*7
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MUC_[YO 'W$UY;$FKI/(I<:3$+2GE\[_32$:-_C^A5K&%D J1U725^LT<^N+
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M&% 7L.MK))5U\WH-^@T[9S3JW@%6@$$$BJ/KKL4<-S(&%4'SE 3X[2>OB;5
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M*<O1-K(:O)A?-QL5B99^'*CNAMBC24J,-VQ"A^M8BG5LM>:\B",@E:<#-5#
MW:XG3\&5LR[%/ID/D?Z63P5(*>"SU^!C"7$<?# I2"<;W__578:S33"9P9FL
M4:GF($V9.DT%D3:IG(=P5V%Z_N%P>EXI$CGOA/7YQ;@/NI6!++J@$+]+!C<:
MW><$DY/O7)-46%BRAN,KA37AG"WX&"]1QG/\F#@M<C\7%]#48,V*4^!0&F1N
M7KDL'4M5Z-MO\3&T6<%9H3GMW1@FUYU-5>N?:[S[U0W]WFLC/J4.0N]MS#,
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MJK(+8&+'3BD%%EQE_5.RF3*DDLK&:%V.#$NQSB""@7=/D'F%<@JG+PSJ#CB
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MKWZ")&X_7(/.^L 5;P1Z(\^T2L;E*2M:/^7!:Y/[K4QC9M8S@[-A+EVV:^S
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M;H?)@TA=-M(A[8K97HIL->"(W4\:BAJP(:5*&R##SDN\V).0;<SAI00?9O_
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MY.][/XGZ<ZE/UD]>[E>ZRC_7^OSAY'YI#?#[&FRUWW*/?L5>O_&$?[(_JW.
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M9&2$\A5XI,UL\I^BC.[L9E8$*Q:'MNK&WDGY4ML0X?.BXLEK+XZJ(_8__.;
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M6)P,3>L>5+MID54)%^]9_0@O^/:<H55,OZ.CF\@W[8'TN(5(B0F:;MF1/=>
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M;5W]K]:V]H[.WUW=PR.C8^,3DU/PQ:7EE=6U]8W-+>3!X='QR2GJ[/POO[
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MN-B=R&NJYFAX>HIF]$=JH#\P$F, /R5+T<J9?Y\HO3<*M(6&&-NLQ=@! ]?
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M$!97H<)O^S@6A&2>W3D$W)G2*O'#WCN[$Q[E4WO=$28OQI;9W_^C<_ZSE5)
M*Z!M=X_"4K6G%:N;RP(Y8FS*QE[O20]'%X@,O&9)B/C5P:JYB_>F.(%5.%I4
M2OR"WW-;;U1*]"HWAX%%>6S?==K>66J#(ZV;9^J3IH9H0==:AA"'_1O_X(YG
MS"DM-ERF'4#()8G>6XW"FR21P#C$AIC*MYY.X![(%%SQM.-'VFL,P+K"?W%D
M3_\N6T3R2MEJ?'E].LZ'9HL>PCR([3S5]"0JY)A!^-BILD]X1,_?M<+>]W;O
M?4)]&IS"=^(LRZN"16UI@A*C1>R:8Z-65Y*.S>?$\*4D?6^!/\>& W(A>/EB
MQ(U.DJM1C-8[)<31Y5XZF-?]4!'OZW*M:WQQ U[DY0O-79PC7%I2="_\!+HP
M0 =^?]5K_'R.<7C'S1OL[?[YA$]E;LLV@O')8OQW\_AHA9UE>AU/J736LY?[
MCE6S4XYK N#0O0&3F_;S%7R>T@L6+ Q .@8Z7@AY)+V()+ZD,%_Z'+8()7#(
MS_)4T!]WS/VZ!";XSBPTHTR%=6'PX!/N88G'/V(-;?2X3I;EQ=PK3S,,8--U
M[.>X2/DWPHSIK!I(RE]$;Y-_/N9F1$\+!+&V *X/<VSKP;Y"S6\H0;H]H2?R
MPT=-WIUI],,^;UWR4%$MXX(.!HFG[YFG00-.VW1/0O7JHA/E$_STY;L6Z-\]
M&0@S+P=&2--[-F^KC#S  #X5OC!5)V*>URSW?!YKTD=;K\A6W[V/)5E[*(C7
MTD]M "64UM#*R^O8-345S8DJ;BC=6MOSS"NL'E"_:;A;^8&V&$"P/CPB\.M0
M<?:%8]/LC,$;A_%W4T5B,.3!@4E6!^<GN\_\VP$R6S*%)'X]& "YW80H'PN:
M-/WV7-K)D/J$<6 1R?W:SNB8WH/@57MQ0$%X6URX;?5YHA:,5_IX;O9B<TNQ
MNMW#KNJ&85N X*'O;IM3HED@OYAC6[^KO>Z\4%G6D]:8U%2)$5MY29-UR*K4
M9K7&O_68AN4;*G!1 R5SZ;MD3GA5N#L_"4_M3STI%>@Y;/QJ_/3BG?NZT]NX
M\&/1C)[R+MT3E>2U*O3S"Q_9*/%'94?_!TO_QE,5C2^ 5&P;1S^,J8S"FTX5
M4(W3-#$T%?^BKS1ACP&H4/]V&:ARF?^'Z$#DHJ4:K^71R[%.=&3 =9&E4;_=
MKSQL##K@6@(;25M=K\8?Y5NS3$8U^O=/R$"6QK]2 W;35>Z0HD% 6NMS?RD@
M3T,:C7R_;\XCHDN#/HG1"L\+-X#.YESBWE*1 'X&$GI2XTJ]QPV#69I3;KB+
M;V8Y)+Y'5SDNT8@\/AI$P'W3;Y?/L)8UCO"?T5#;4A*V$CZSR)K 04S)/WFG
M?O=IE3K<N:2C.X=;9;,B]Z:V_>1%WT)M7?RJ0(4^)350#QA>NAH&3WN6^/5A
M[R1;OAZ^^Y74_W8 "=ZV@2C35,62>E+.YND(RM@]\GP)/O[8HO8S.'BU5@;!
M^B/SZT/^+!)6O2VLE=#IK2<J[JM1\Q@ 3I1CR-Z RTVM69L/9L)OU$(T+_4+
MD&YVO1+ :7Y^<JHY^XQ%_F&D+MFOO92AT4+VW>YKSDZSZZ.*X%#\N"B=OUQ*
MX-G5J&&9.0^R/UU38]M)MV>+,$SQ\!#@5+ (\GD+7>H0BED0KLRX2JZL5#,M
MF2X6)W8,GIA[S]AP\YYOH'&B@(WV99:N IU]_3=URY2XC1C%6=/.=-NS57N(
M7 D1 3<6SOM:Q!]?K07*A4>=EID33_@BE]$J$\&0[2S(.1?/_00+/</.*1XC
M=""OFI/^&:Q8XSOD9JW^5NCT?Y1IH''Q9>\Y!O#G[I?FAW<IC $$=B$U9!#.
M)TDGBB=%L8HG\RP#!]5M^ZDI2>[N5OOWJK89[US%B@R$C'BZ.Q.BX&N. MKC
MSJYT^6X,)* 9X]EG-FSPW1 G4VM%PR].AQ0EBKC1CPLMA8LDW^:K\?#LG$Q<
M?BWB7K(MI8&8CTCL__F>"+/SU'SGH$/U"7$6B+C2OKA(\;THZ-'+UV,!(O-@
MLC,L.4I<@;&DBU9Q5PQ@RF7)/;=T"\XK3:LW*M(0S.>D[:LP3G&8$]4;^GC%
M2U:E]Y.@80\]B7=H34"W=D.X]#'ZY<EDR<Y)Z9^3^YK^!=Y='D-$=(:8M\;)
M9;=0'-;WB2B[K<HQ=TIE3'UY,=2Q@UTK6]B_!'@\A6) V,FB&D_%DM(>23..
MD?Q>(M[)K?T\!W]LK"S OT?024]RB^KIE/O,,O>=NVS^W>FX.E,YB2<--;-O
M],KX\@Z?:MC=N"-S4;"&I[=](,,N>3.W_!B8*E8/*Q=D.MRDN7*H.63Z=]U0
M=# *Q0EK)T=<HN(N6'Y)=N2)8  55P';U ?A*:>^A8@.GL7S_:#+Z.O>4Q8/
MV>0J<K QI#Z Q\Y2TJO903S/<?\,IFB>83_LRX=!R\ P43[F92/?>W.M*G5C
MUG6AO::2O ^593XK=2@]577/U>'MR6L9366-/<9;XNDZR'?PKODS-3+WNA":
M Z/)$-#@1JP\4U3&B'GLB9!COI%\CL9KOKI8 _8EI4\R;M&_ 6S/5@-=JJ$5
M=FV@62O-$2O$.>^)D'&?R(@#51E(V.0;B'K=_KGV6>ZG@ZD:$IFN.S\BB3EC
MG1.Y9X^V'=,:-D"%H:9&>^9_4,M>.-=B<#_2<3>VKU)R#?G(,PA-.K^ST5?X
MD_V">V9YX#[.'MYTI-7!KP.;W]PBC:(7S)X]^I5(ROY\Z:3TUNQ7YM,_E-ES
M[44\AH0L:4+U4GH.)@MMM:<-P@]DLA!U$@9O@[F_Y.RZOW?^<V0$"OUZH*1'
M!(5AOAK*(Y6;?!:JA7$>I9M(ODKU[K+&HA%_:G<W/7Z%Y>BZ!_Y#F^9EZ^%T
M"A>VY2?G-ENH9&(BZ0C*L:RD.:O,1\*%,PKA\ULGBC#^$NONCH9)3Y,T[I.@
M^3=Z0AJJ%4,W*T2(:\S9,3',56>RIZ2KN8 =W7P=;YEH.!+-KD_=XQ $G;6O
M<UV:*7[!^CWS5M/<KW^>Q'7^NJK^TI(.@$Y>)W3TMN02K#K6N4Q%1C7JH;7P
M3M?*SMD;#RM<6E]%KNG$:W)/ZOU:P]W['W?M3(E;]_]5;ND\>U0&YZ_+;8:9
MBE8.B""'^U;<SPO-H]*@[684$0; YM%J?HR8/^<KV+X&^7!\ IOK5\&V\7?*
MOV\$<\[B_Y%MY,<%\[T#-Y9BMYI_C,(LPK:!=)? H0=(R_J11@V[MVYN!1$"
M!#E>FJSMIC[+#<S/ 7LFZ[F47>:W$RR+"D943KVE0_<1(H$F:AJ?-=#TL)MV
MIWC4Q(D&LB9(2FX)])1]$)QL&R4*9UONNUUT6@:Z_:B'J+!G[7=^[2VK>UC=
MZP_\/5KGRW'#]^\T)V\$R37^0,S,/:SX\7D-?K)WR16N2!W U=AF)![-RJVP
M.AV@SBU=''>0_Z[S^**&!_ZR%%PQ?#-D(,&0*><EQ_[B//O\Q<GVU4](8_6H
M?#CGQ?-@4[ZQ\'0SQTQV5K:?+-S"CXHA%VRH828"%(_V#Y"IAA:25=R *$?1
M#<?9DN*IL:W7G4& Q>H'PR_<DK@651IWX]GCPMT.#V!^O\TF*,XK1F^X)LAB
MW!,SE'\A*M)4>%E)37IN:J=Y+$_-^S7?N&3.+=S/<IRJ$9>[AE_#2"M=3& =
MP" ((K^9'?7Q%Q.<"0Z;$F=4G):"<O2=R=G9KDU/Y*B9"-+H*5\\EN6#GX-S
MH&LA;F5")GT-3 HWY-D'MRE'KF(^8 !0I:AB?;2MWX1?[SR%J'GX/(Z/^#*#
MTUS_A,YH\\BZO$5D=&F2"Z]JI:00$Z_%M[)UH I/U%4 ;&6D\1K>SO/GYF_E
M_=0B/MDO%?S"[U)1]MTY=^#K_@;:B>K;AR^CU766F*X"K=&RC:'-&ZC3"WP?
M.508,JJ]F6UXOQ+OZ$K]K.2A:DJ=ODP6<2/.<^S._!)<- ,,J8H.D*:^SH(I
M&*K/+S>P]TU,ZTAX 4\6C&7-03OE6^669^=/#"!D'$KHHY6O7#"IFK=!NY?@
MDNXP."W=XV__!N#Q"9K4JUWP4YPHH,YDCZ&FE2D$2H@FV0[A_Y+&,Y$^YKH]
MRP)J;JBIJGBUFZOV'3Y=%+LF_U!]/047QY'F]PYD<1H#H(!ML"Q&71*E8 #A
MU\"_-X_*Q@">,1%"%E[/7]KFE' (%*RL&O@>S_^0UXLHJF8..DE%V 8A0#HH
M<+;A=HVQCQ\]5/7'Z#[?0J317FZ=.+E465$1<SAY(/XPO5M)C>Q5P27-$C"L
M?F:)0?%%)9*_=!'K]GC&CW;*@LW3MZ*M,^+)LOQCK*1I4#'XZC7*_FA1'6MY
MG?EI?9/'%MSC8MBVP&VL$GVMNQYE *LT IK)40,&(T=TIAIM]3880(0; ]B@
M(<9Q4)'PA_)K_:ZQ&35TM3*5PL$!Y7UJ6\LN3Y>3:(1!8"-'#HH,3O1^O57(
MTPXT9#>>75:C.B*=L8%^.>W5[JY@^:QFX'8-F1(<J^8?YD2AW#& =H%S/)05
M!H!]W>R7101V*JL*/;;'3#D.&J[DTFI>"M#[C9C='6O$73(G>C4N@0$D>2WL
MDK?J"\^WW((*=]@SS)F6?^/AX<</4.Z7H825^HW#B'W,E^D:9E75D7R)2>!E
M/O'V<Q>C:5#CB!25YG073O<(%C4?GD7W0'0;21/X_M_!Q(38Q0!"S8]($9WH
M.WT80,>U;/ME?GEYZ7T=WIAG ^8UQZ5GT*<^:DB^TG TJV=I&Y56'V5B<:'I
M? O#SUORD4:IHX(X'WX*]M^EV0,GEQ; _KPN34IKCSGEY?7T%1]E:S5,(I\2
MHY4TPF$[+X<@1RFZ)7>:AT<@%L 0JFLPRWUONF9A:JLGQ;EF;=M> HED>,Y:
M+=+Z[]1^647VC6!+P2XE(4M)5S@^0AB ?P4$F=R=9O-1.\6-JO1(7B5^IQ)=
M,I  +D,]6:83"()2-G(L.2IPK?T8=N,4X(@<T\NV5B24_?R W+]#Z7RB\;I4
MU*"Y((.*K4PH.G$,@";S[]&RE^K$UN8GRRLZ(LO5YA,).S?8=5G8%J!$L>@D
MO1B?FWX.;2>;R9C^932AG;KRX<'A&_?/= <*]][6EQ7#[($X XO@Z;#II^^9
M*$U\'F, GPB-IT&@JM#Z;VR=7]<*%P,Z5(([6FN)%@+X('^RQ"M_%:RG@SQT
M/K2]/+Z @/P"HT+-*VM:G<-/ZG."2N"H0I5!FW&1*UN"8HEQ."B?4%\5+,4?
M):B+P\6Y",59R:7F'<0 [.>#WA/_\E5L3=:/6WIZ!P0C<* EWSCY >^R>^LA
M_=QC0AQKV6MU,H:+_>$/D90[]PC-_PZ7OTBR\Z7V-4F.^@Q$B#FC'RE#;/*X
M'4I"^W@N8:4_?8Y+5AW5=N5.^A$1GVN6H&2OSFVKW(K PI[O%D4N+@Q?UH0<
MK??FV1JE!KM=E*X&$.LM%7@*G)0@B%MAE(:JV5.>4=I#:\B(_3#1N\Z\NQFU
M07U5R7C%B\\>\2SWLV7Q?YW^=2!O^\=P:?#K=2_OBKQW7K4Y94-;G23L>T-
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MR"K>=FNV$&36OV$R%FO/AP'HK!KS;)7^N2"4ZOP'P/MV<B>10(9K)?88=<U
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MQ#@2IM=]E<&I504VS%LDTO=(O;;FP#;ZB^Y<?X34VZS7W<@,8L&"Z-_*HFO
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MX0J;J[S&5(F]PPO\[O7NT#V-\JEM1L<VQN<]5$YQ78RRS3N%-A4)U.LLH)_
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M>1<HRO!@7*$2G(B4^;[N5^,N:4*S-JZOYN;Q'G1.? '='LG 7'E1^Z&/@!I
M6$7\=C_FP^>R?+;TVFK_YBW#5H1#=K>SRKL&?\JAH$);6L:JUH:1!97(VQ6C
M2L5 H"4-M"L\UVW ?UZ8$TNU_+9L__U&./,2 9*=0TUQ> ]4#AI-?3E]"N*E
M:/#S.9^7W B<!4,^P3]L5FL90;UGI\;9B55E3;FS0EEN'3&O2"(3Z&C /SS1
M@.M@F+8.NMO">QTYFL"GKH+*T(#CS)V(,BALX6M0%C)J70QT.6$,EQP,(%8U
MO$/^)R6.?U-S]KT!PZ^ ,W<D7'"&V5G4)R;&U$42[^][L5RYWV)\KRK<]<E@
M?3<F1\2IA%\YI=&3,7+GU Q^)YPO(T2@IH7XW8*<\]-Q]C73<C[ X?X/49R-
MP"Y'AP]U!5>XI51+=-_$Z98( J>4QSXJ>7!2'EY-$1E('JL.D=76,Z:OMSX>
MK*B&UT5Z.E3J&1<=@3,OSPC6XBN;'N;HN8'TG:-BKSR-[7:S0MDZ)9)8LD(!
M/[79,?!*GV3W>0K+7SML@QD=PXX9;70RK)<HB;6+<1+QOU1_V+Y'?8NB!-]G
MM17@*M@BFW08 *[6O5_2#70,^/ANEM!]R)W^,O2P'H6Y?9;B9V2 Z+*V,+C]
M< YQR_4[[^.OMY.B9,::/:](W,H_IOPX)/?%0R30O-AE#M_7:EOYQLM7QO!D
M2$IM$<!=)\RX5GF'Q'%E\=.13.Y*!Z^<D]5[VL5G,[DW=8V9-Y9:O3U.*,K4
MLM)^G*_:JR&Y$U2PI+);RL^<OG4F+%\PB&P0W?UHL8J"':5_J]!>=!ELCJFM
MA+-?V(3D)-_^!**,6'.(9CP/QL%4,;8Y\7QL&"0J5FGLW]"2D[L-!9Y685>G
MN&]4VU?V]4CS1,NT]DF8 NXJ S;XC887E28B(R>U4(_KJYW$:FE=OBCAZ_J]
MD]<59@"I[QC5RHJ6;\1T(^Y\H\P+X(28^.279@+M3000L=+J-M%H %L"E.<Y
M=_?[05=B5?F$@P)6-*"["@UH:>TM9(T'KTRC 0O&JQ,D+[8%*W\N+1I9PR67
MYQ;:022;I]E2S5/.11%4&A-<9"_E!P<>3NS"SA-TQOJQQ1J#V)6_9N=+).HT
M;'S@ Q,97N6I5ET^0P.FS_2,T #^J2O*U0[+*)RGY^'WG,:!B^&?MNZ0L/4:
MWOBJXSN6CC/>Y(NZ7UN7H/_U4#JVFQ'?//X!KYCMV\K4XEVM=O*;I(:9(>9X
MO;.^4Z249T'T$]Z/<R"KT=N8T/V^Y>5)-ZNA-!?G=(.$,Z)GQ7JSC_'/C9-X
MP@O*5"0QFQZ?]M=/3J)8]I=CJ5+)7;QZ=O.T@[^M[6FIXCZ1Z2?F^"3@!K"!
M9'R-N@UELU1I;K*(,>?9IFQ>FPU(H,@T:*JL>BWGP+,BU.Y\KDV#H^,R$J8>
M!E/9H_+(MXD +4OB&6V=JDEDX&R3;F$'3BJ&L6S,2%[(/.GGO?VD"("S3W^D
M3QFT1Y=CA2)1(;0QHIPZ;L0-K!&(M:$SJPG=?CPJ%ZDJEHB+8?:6(SY%?D[Q
M><XM!7*[/ 6$Y)(XZ2!'274O)5,Z=./JX:G'CUX,6V+&ZLB./5G--D9J1SSS
M[DL)=UI<]ZS ;K5:=UJ!VOH/!JV1R]-F"O<>!II_4B!FK7J!P=)//N^K1YTO
MZ"6YLTZ9)$@'D0PP&3'6-934B).+4JEL37QE 0G$0DU><F19)+BT\P:J+6R/
M65NZJ*34.I=%25!.^I)NTXI!],,BV%2L&>IK:]PY+>3D</I*[D81!\73?PG'
M8K@CIA61T0:^8WW!/QD/_-(DX,:M-U.GV-M>.".J8*>F=+GB/A?&EGD7"X,Z
MOUU,"9;>K8^P+$+P0%$H-B4I'/ZA/ ^'@A?UKY6-/'1[5L@7WJ>SZG\^5CA
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M/T[=;0E^E(?3YK@8K26,"W3$8L!1D='-7HEZM](TM5<FIOW%VM$JL?5UDT@
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MP^NI4<<-?IIQ5D:9P>8Z:4]%?&;\#=5RL#-N? KOTO6VGX#,*7=1A<T1;;9
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MHTYQ]EGZMTQ,SHU/W)^A]^6)-!4'2 [):L'>AU/X3Z0/MA4@E^]'ARE_'LM
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M2 HT<(AY7T"%\L&XR4M)U(!L05<EK$9RD1HNN<*7A@9\I;9AR-.UJ:-#+I2
M[(^D%__:%BE(#^Y.!V^;H8'1]-^YJH=@G3(Y8)+B%B_,0"#5[B@4!L,WI?]
M6J?Y+XTQ;QML3T@(4+AH *%&VRRQB8*C@6C[:320W E!41!@,H2]HSSPU# ,
M/@#Z@796]%^;@[:'@]# [00T4 M! Y9)PTL34U.@/7P/T/[[ <GU%S-JP;Q<
M K/MO]%W! 2#UR+X?J!O;XLPYFNF1 -U3#*?9,#%)WN0X[E[?^V#RPCB#/8
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M96.L:Q+4QH1>EI/8I![SHOOB>D5^K]FIE/O9"><ZJO.]16-C74+CYN2%UF\
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M>4?P"?8D&IB6^G(]Z';8*AK8)\% KD]^&'3=F5@A'B&YH&_7>N#_Y1?.S=%
MG0(F/>M6/T(#9T%(\[]V.^A([,X*_EPS?=+XY;?-^<$SC -H8)G-'3.;$: $
M^N%<L[BE]@&*ZL[QDU*[XW*-,7R;2LK(+)_$@BR?)"U\PC=]ONT\-[0RLYDV
M*RO35CW)LVFDKN,F&U_I[AV*]A#:,?FL*YU\+\3N'!K(-*'@\02/H-16#K;+
MLOGS2\0_U,BNE7N)Q!O<4O>-HUS_<LN"5"_'!+@Y+@H1A 828C+4-V%SG6VG
M39@!=*BF^TZ!%RT>@L.0WOXL67P_7G;-,>PYEG<R"X[.C+"IWYP #Q$A&U73
MM8OD/7@PK[/;_^5:[LFOYX=JDHZQ,]2_?&FD> !J4<6$<S0@);TMJ782@:E5
MQ/WC9TM9X+W?T  &*R X5+\KWZF@E,I+4/D98]A0C-.WR!#D[6=&V,JC@;>!
M(/T594F?F(?PN5751'_6]KH??XL)\T=P9QN"?,X!G@:?4"2&8+II.3N$POHB
M%;9Y#..D>GE[$G,$2'(WKI;9+Y^27<WJ.EFVDB@6^U:N28S:GEL."<I!RKOE
MYTD.>5V6S?2X&=ND!?87Z,)?XUO960E# V8X0D$SLF8@]L/=Z4V;C\'>U6?]
M1X1H L,+YD:5UO.F@P2LKY63G32FI$;8I=RR2O\<)DL>]SZ7F5Q:PL$G>*GK
MW)G;SP%8J@>0WVW4Q]@KICS+P:51V"<3RE2 6]JK,ZF591/$1'BSIR DL>SF
MM%W9_%"&LOJJXF9S!^?2>_EMIE'0Y16W34P63;3B5NT;YJ!?&A#-Q5CVO&VQ
M("(W(;HH"I@W @" ^F&)[0LG+_I^NEBM':4W K$D\8.;GDR[BZ3%9?%G=N5:
MKET4R\=MO1(L:!!6;=6[G++!."[\?EX!P0NW8=E,\-,8HBL1A ZZ>59I7&%=
MX9FH08040MB>LKNT17V:-JS0]P%AY]1<AGN)X]P;+.&0DGMQ5EM+7]H\"XNA
MX"(YO:DI,T.YH5R7SE)9HI^P@&EM:XDIL;+T+<9T-#!/9H<&=!,Q-FJ<66(I
M>7QA'#QD#MNG8,VYXPP>NF/!D;1R4A0)3YC5AEQR(5(=R)[WGG0Y;\EIH^&@
M/C.O:O'!V,1(G=.5^OJ\!@3>I[_#5=^692VDM/-^1R;#T37UV,VI *^8#(<:
MJO?0)O*2VAVN(_L%O@1UNM+;(:;QES8-PBB2- U#[XK9G%%7X;Z%E2[@D^0A
MNIWG9XV7&SX3![I7RI?2X]M9Q_*@_15QN&4Z5?\+WU6>1EL*AI([J9%+'R8\
MO/JS<VQ,8^L.YQ BGT_V5' R>:[$:I=;:QI(R&Z=D[]\%=)VYE&X=YD0,[Q^
M]L;!,%( Y,,_XO' 9G)DFG(L0.#LL,Y%HM-85T9\P6A??&&ZS3PY)=SEG:KV
M&#7_XA4&E<(Q.EZ&X%ZYG.:K<>^C:5/>B,7D),)!]?%4OJ,T]/4G>A$DQ2'L
M5T8T9;$;-BMUW[$&I?B=#TYZJ10#^BS:7+ P*MGL*:M;IMI3K.SIF<%1TI@2
MGY'!F%/%4Q-',A8B0&>*=?3<X.7\IFBHS,6N!G!0D0M;O1MM5MJRY!AX5)UW
M59'8F8O._])<T/!FB>]T_NEJ"-_9JT@5SOF)X4GDC>WXM%0:D;VZ$X[)^'OW
MK)G[9ES>!)VWB_.Q>W>3Q&5&YN(%I5F"<W#[QC?F,8LO4M;83!6T.1-,J&?/
MVH7%]F\LB[AA>W17='-1K;OFH('FV/)D+HL$5O,H/MU'M5Z.) J-,302VH6*
MY6_>$4QL8+D[CFN08V$IP$]GK6B852O*NS\.4J_:C0Y+T;1WL=;QPSEIDA7<
M9=]^:$DNO*/*GTQ$F1FY.0W'FGGM10<+N"O/T8J;8<) NGBI%HH0?C"I\<%H
MM^T,D9P15?#EQT8?^R5(X5P:G+955S].OJ<4LK=+E6):#!(K:_W\(4(I0LED
MVDZM0]&!9FYX]P;,G./!ZIQZ5:&+&,>UX8E;>.^6CZX).U3&-FM>21 -V?Q4
M)Y?&&GUCG"H51%ER$%]_-[QNU!;)X#PD6%!O2UK697JU#%H>(V316#K]:50N
MVYOON?)+P76-A#$7JGHGY\&A4A2H]V-5J=RL]ZPHRZ!<&+]QD)KWPNTLWN<B
M%^F>*LHF>DANPWP_^N/1U[O)1.!J@*R"1=G($U0A!DK\%Y3]AN]NKGG+V*DL
M8!W>WEE_&L\$[^",W5ZKF^30E3"/.9'7\I1@>X=3(<J6$4]/?Z<QW($<-X$<
MF?/I,\T6%E(!HEXZ-+^#'VO]D>8:>1ZCN_M@Q>LQ^2OOA(V(C;G/0#E[+]XP
MBEGE%&-+G%CI7ME;/B1Z=/-1HQ5C)K]RI+H,:_)C$V/'&ZLT?K<M^N!6LN70
M"F]KUJ9'G#W7RMYL]$0:WWJE<=[ ._CY?H8-:<F;BG47?=\: ;C?PY[-1)C5
MA.@CR*.>W)PD6"]#D7DVYP&5"V/)6?-W<H8:#A8:=,>94L8V.8H*F(Q&X!*'
M:=\^'M/HN3RME=*CR-'Z+NL,&T[&FUOF*?0J'RG4M-_>WJS-,Q@0$TI>"Q_K
MR+!PTGHUB 96C2N@\EI<<0S'"N="XEEB0V:#"-3(6WJ\2.!L]<ZT7J'3IU@*
M'WAAL2:IMW!L'D8(JV'1[8MG'L]4^R^&&'4^/ RNCGJ8G^]7&P5UOL8?KA+<
MH#L1ZS'1]<0CU7\@='NPL-3$_ QY+?/31WUSDSD6Q"O6,UL;#J6N#&7Q6P_E
MC+$=%0(85%6AV,,\URG&?#HUHTU.)1_";6<X+!7D!0APS*%;IEN,13HKVRV/
MS3PW6S3O]W;M$8K$NPTT;OMZ>]^L8/J0J%1S(=G(>>O>^$[7EB9F>G0-<!1.
MZ5 ZQNC:E2D-(6<IXE PS/R2N=]QF')O8U#+:&+R6H!K5?;-[5%A)P]OL0&?
M,S<X18:4T^!K#1+T(?H#ZPZUI+$?=?1NT4)P:TPZ"QCDIF74$O7I%X=E*-XP
M> /4!Y1#]2&_P<-(_#2V:P(R[Q2)MP0?*?F:$,*FPG'3%I_@0A\&6]U""B1+
MO'=-+8TP'G7<W+,WM^YNE$ #L&H>WXDINJ5J9A;M.VS-B3=T^>:HHT $CEV7
M]2Q^LTU?L0\PZR-5B$8#+G62+,+EI=YRM7L/(GD><SZR6=%QG&K>N@)W5ATH
M7H/A!6EK6:O/DO-O2&@'I%M/>W<VSJM%CO;*4Q='"5/-/A#B-E5,4"JTD,#=
M1KU,5$JRB"&-3;,@VB)<.8RT:[1EVO&;H'R>]G1Z_AF;B+X/[:58&<5K2ECF
MA!;7A4;5:XO+<'$XN^,?A]A,C-W4'>Z\*/)0)34^W:*YH#&M"7;9,F:ZL%>,
M J=6,+%"L2HF-7TP[#1Y.&>%Z Z=/>5KJ/<MT\F/UK7C?/L$H_?U"=<H'01I
MK_1S\H]L9"^45_J*9BA6CH_*/BLW+N4^MBR2H8@W-MBC>76F<G =R9-D,:DQ
MPA]+I<]J8 <*?_*F4)DLC/KQTTF-S;TAV[8^_TZP;_QE#-A0J@9CFP>YITG1
M5$>T672_YS"\]4INS$99E>AYV;D2ZGX$-L8 5"$T'AI9(R[.ZS4T?0Z5<5JZ
MI(<<HUGW\(+FPSRRO3H%%1 ?DX'/YU_YM1!OX:!Z-(2<)XGZ%KIS;38$!(I]
MYU0CG<+DTC[PJ!GAI3^_LDM(*Z?C][E)IA=5;C\=@J^G)6UE]]'"?DR:F+L9
M-U*YD.%I6/='E3+L5V%)B>%-K-E@W"H0?II5>MJK??Y^#C52G)*^!,*ZR]XO
M0#:JUX% 6IY&"4LGN*S+H8@62V(^GYAHL_ZN*-P/52<$.A'(PJ].:P#C.E2B
M@<NK42HZ>NSA$PKT%QP^,;;>./9<$T61"(:B 4DAV-$H>(?DD)A/A]_BEN"^
M0EKHL2^;7T%?GHH\F^#)<;R2M%LSDM6:'N5E"]XJ1@.S+&C 1S$9W-6Q=7H(
M04K;GN;X;J+F8D]UF@_U7>?W-;+!=:F]DDN+1RB$$NI:"%QU5!:)Q*0)4Q9H
MH$'Y:^UI-*#!<QHUZ2JNV><P%J2U*ZK]J+U(^-,Y:/D^R0H:V,XH#CD^QJ02
M-7UHX'7.%(&+>G.]LERI__HN*$93CE,V]2:UNH"]&RO!R&KG!TD\PQ0UU@V6
M@Z+*XRMPC;I2%'G1:%GD2O.6:;.^P3+;,W^V^4S5"$WACHFB_1A^BYD5S'^)
M&.B>W1'@K+^S9(*: R^;9JI5YL'W"M& '6R?3XWU*G3J.$9U:AY&]S-<C.,$
M<EI#E4$665.T\Q%0_8,O1T+56$G7>_5Q;_\<>G_]&- V'74[4ZWZRT:PI^PN
M"<&LOF1WCP?!@%?*W9]F!E/(.O &#-6F]F=)F=/W[=KRS\%ZSHKD[I67:Z<8
MIGK!\_180R>J2C.F[U W?I%!?+W.38P9#=#AZ,-!*%_SI#KP+E""2;DPJ9>I
M_S$K&FB,RD)VE=6C@8NT ;O"BL^TU08VZ\=:.JH67I5US?@G+8V@@:YLR!$"
M#11D>'R'^"/?:3!XDJE[^%C +#B@GE=LNXK0 $13<@N3_AG)0LS0@$0A>&H+
MU911>5[&* QH_<2 DLIQ@=;1R#9!2,28$UR.4$37^5M*1"/+,:DB&"$XJ4U<
MA-]R=:+$; \[W9:OXY/1$3:RI"(Y!F,GI*;)HS609VB ?L(#(7E\$(Y" ^!#
M?M=#\-X:\RGFGW6KQ:RNT4-1O(>Z)>'U3Y5((M^G6ZJ'C:S6N+5;/[VG(I<?
MK?8>7RF"?8S@\_"3%Z:VHX48Y#MX/VV&_Z4JM*B/BW^-S?-AAW:M!\)0UI[P
M^%YRT##^17P<NSB)'(FI$"3A*:IM4[8GWA."/&G%] U#4(I]8T1@M\2O68E4
MRV7N81_R%OW8-?C<_6ZCXOSX\49KXM)"N543=\/>!DTAA^#[LNW1K&9%ITE(
MZ5D0J8?X0%*?88\'1?:(%;3NG#M.*Q@OV_5-BL65"T5XE06+U@TO[9')6 <6
M8*5%6C00-1Z27O6+X<_K$WL-Z5WM]^#)3GV9L%+A5&!DGWJ] N$ )=VZT)\B
M=*?KR8L6$YPJ-ADI6YFG@'C-&X2ZQ2BD@<5#2-P7@JV0(S^S,7A2I^C"V</;
M2Z7/+C02^&).$VH<<3YQDUB,O[<:!H)?M<@-V)3M]OJ%$%3\ZT/!BN_W8%SE
ME*$=%J>QP@C^6(_A7;%-./C0JT3[>PN1_\MJ)[<&>!%!=KU2UKJ2<QWZO<TE
M?=](C25K7K_/V![3 2GRYW*P3"%^QK62O^2E_XSC^-MC\[WU+ROU2HA3-# \
M<)<%0\:@$UDSK_W]\Y[O.\Y\I]P"2ZV/._9L^3N&DC C]A/=183^TOXSE66O
MH6+QG1>.KDU]]SA$H@OE:8R9\:=.@U03@Z5/!:FWVC:E8=\]IOU.SAG2U $G
M3X2GHL8#?BU^8;+]X7^D<#(R.LP%V/('>_E<\\*8FNXK(03^8@UZC'.VERW?
MPKOT@L7O[M[H1<VHD3J?N1F:#W08_K"N9#69$G9?=8[3LW?3P]&+->5^]LQZ
M?%!N7%?"+P9MM13R]RM90PAL<-=Q-#BG&+;4AY1L.0']2I554Y_BQ1#@J#1+
M%7#RZ7":$:KH-!(-6$W!AO+<]9CH<=CYQYF/BU;S77W$'!G5 ]3W-92*_D;2
M;!",@.+&_\OT3AG%IX6C<&],3F;PTUZ%1_-I3,[WVDE<0XFMP\9M3W$'[KZN
MU=Y:1<3<MSD5U"4S_+5AYOWAT?\\FS(12-#^H"TG^<S^?5%H**I#_2^D#8YL
M8&MO4(:9JBQLL#W3L-@%[;\G_"6TF'K\HWUP(.>^U2U/%BL+\OEG3,T&J Z3
M;U #'^>]QPGL6O\4_9ACCZO?WRHT]!\?^K3V<B2+^ XM!(\GQ#81X(GL3"@:
MX(8@;-% 8?]='*4]T[>Q0]:5='\S!K5=KI4BB7]PV+4<?"^0 'O%4>QO7\MG
M!D641*CO0XXOU1Z@(HB\%\"+'=<[]G*@ZR]_+5T-C)K:C_^7S@G+* IC:_SA
M)A^BQ;K(5A#/EC3?7]&IUA0&G$KT$>3\QU>>A7HEL(;A;N9TO54*L^)\]?EZ
M)?MZU(55P53\SQ2(\0O>-$@/PR(6UUN;)F <;M(>]7-3OT$#8)8YA@-BC#-Y
M9"(NMR<B"8CN&OF>M3&AZB/=(QR? [C.(P<&%(4<W:^0N,?I2!:2^1@4^W<A
MW!N4#&Q3IRP$(X/$85%6U@Z/6C)>\\JQWRTB%3_# +!9J9[&B+%EY29R<A[H
M'L7H!D<RR,]I/-?B-F<*//:X2WY6_G-\[%,Y269X@+H@[)($I1Y<07F(8:?(
M7./$)H\Q&WNO-;&AE[%>J%.F)4[NQ<MG6-NA+S8FSVW#O*LT=^[:$NB,#%OI
M7>JMHC<0\EG/2R(<K2XJ\DQ<46[JXYRA+"X;Y_.6D<M]+V.G\0R5^Z0_K+KK
M9O%I+#^Y@'+&^)K;9E(ZZ+(6/$PA(.-C._3!G1V6JU<?7/9CR'S1*1AQCN0#
MQL_T7Z4&=PYZ:NA!Y/)+^Y^L\V=P&B+$/Y ]?V,4^!KZMK+F=GL[]\=([ O&
M+ISBV 2C5K<"ZLD*5BG/ZQ,P!7?.4BU6RP0YDC>=;V_7P;UR%,P3/-")?%"D
MCXW4'Q(#.Q*\1!J=777C#,''B&_T0!1O_*)L)\<"KYP.7K"NVGT-$K:X2GL'
M-/#\[F)UKC,!@AG^;'5,76'JBDLP:NF!=]U$[E+\L/REHJ>#B]SYY\]?P'Z6
M?"5,9E:K H*')"W<AKXV[E]'RLZ"BCH\F3(DH@[+YHKC=^_@L.]>FM.PGK?E
MV=R%%ES% CSZMOL0-R8\;L &-XWRPQLB)9AI^6JLBJP8=E(^7;(Q45?7S7;*
M(A1< EXTNC.O(U)6:B[#0W9$ZRGO7:=Y161QU!UWX]+^0K#V8_I'LQ1CG"W]
ME5M&U^N1U2PQ84J3J+S'81;BX)P0IT1_ML!/?]GBSY'%Y&65(2<;9*B7C&KI
MP5LGRT&,Q9Z2ZL3*TIK1?WZ__\8%?!C;XX@GVY1GYVCDFKK<+7Z0K'4O2WQ.
M6_JZMZV@^ A>M=J0S^=[+\][*Q7K:J<L%'?+&:M&8//XRP1]HL>RNHZ;UNU]
M:=WJ]<Y0[01!DQ=V0'TKX<J*F?$AI4<FQ> @4^ =#=-I!MWG>-ERT[0?KR13
M.X4J0Q^"&O2+)8)F.&C=J\VD!XK;*MU[C"0@SASOE(BBQ0Z83,M(X<;TYH21
M1F^)(QYSSY\F"(CFD8R,KNB15O47Q\;=[AV]^$IJ::)1XKV="Z[!TH- RAM[
MBX_/3\7;!8^@?H/?E;M".:;"F]TEJHL&K/5.,]4=5 T84,[OK[T+(K,JT&$-
M?,HZ&;$=53?*E)&V*JCED#_QZ))TN5!1X57_485'8P;/4E[Q5MC0A5UB"#M#
MUJ'(X5_E3A$CV[1!H!4N[X\C+L_I*&5VJ.UZ[19#P-.PFG7;%7(H!)SVKL&&
M2MY/ UX7PQS@2/,;?Y"2/DRAI+2TL'=C1K9K1&5FCV$(.V>W0/A8LN(<-2DL
M%7D]OQ=ID63%'4V?W\,_\H2_C=@'6F=BPBO:WJFP7:GZV)J F=F92NJ3&R$\
M&O[\$1IH&&\W$Y)P@(!;+YO9;,!6/^D8T9SL/71AXG)HKX)#3$!^50*9%B>F
M23GRLPSR_&LXC&_,0K6(!.4C[P3=O"D_/O?A3-C-7*)ZR1*07^Y4O9M-;MO%
MHDQI2]/=!>_SW@J^8X2NO.W,3\+*>9IFG$W\GP_ONT_Y45XX\G,(PLLQ\ZZ7
MD^O]-#+992N>+]=N5>@R80*ZRGI_\Q;=$E.&Q106DBM)9Z7/HA0ZJIDOE^0O
MBJ>^.2E,2A_=T).<8'KNQNGRDY!W\W:*(DX#9^V$ PA&A>["%#3]?*ND+D0T
M. V!K&)$E:F=]A3GLS?>M%D3FMQ]KA_HP]:A7G*:*48%ELC BYG0:S/EHW8J
M&E5@[#U-%7VF+O"A"BS6LR/2(,?PW.F#4^MV4EW!2L;C"CT.PD$JQI -PAU<
ME>."7&<S/^&NA]UA-]*3X%(SKX-Z<TJ.1FQTY ;QLG1C^0UXVW&=%O59Q>3\
MO:3UYI(NZZXX&56Y4TM4(VYW68"IN>'.RGT&"APRVB-<"= 8!>&-U)(0JVNZ
MP*KTIU99L592_/.Q;GF7D$^Z/<SFJA7JG.QTZC.&DW?S8^3P%WQ5_6\;R6L]
MJK$@.FL<F"^L\]S.70/#A+C3PB:7PPA#Q.C"AV9W,4,ER;:]EQ>>4CRJO3+Z
M[$R0'!#8/TD+UY[IPE[ST^C+R:.O'N&W6++4X&O$OK?&D$6L(M=*6)1(>.7F
ML4:WBDVLMB5;4[.F-+$ZP_>?*M#2S.4=TWSY72P#JI!3R@$_[7@1-! ZU2!Y
M>*4,#?3D/'(\D0'!N??U0^%Z?*>+>7#((B9".% _QL>7U3K8\M.[5CV8S>"_
MR0RFQX::)2% ZK0P".S"#,$EI5FKG([H;"/)JJBATX@CE-IZJ?H#B\&",6V9
M:[X\/FIY,1T[Q!\\@_*X6A U5+6&Q*@BKT=.*%LX#@Q)Z,:26//@E/B/E2JH
M(QJ@==+?%$+Y6J9H5Z"!$%&N(RHT("6@DDCEB0;>IRBB%'9_NOT-_1.*JU42
M5&+HZ"CMD:@DV'0P;C?\?./;+0_YBNDD9)XU17L /']5J!]\]0&*<>\4C^S3
MJ<8O-K)ST$ [,VH, UU*5+XK$RY;X-?X_'SQ;3(< R/()6"]F6K5S*C;W)[@
ME#LH4@NEN9",GV^O8_[$B?X"4KY?7,L+RT-JNL':$8&2VP;+,/J '2RD;Y[D
M6D+VR<B0(UMZB7NQ_(2J,'"N-QT-6$Z"N]HA1P.>',R<<BL]8&W054VI406-
MRA4T<#Y#9^@UBAPNVD2VYIGGHB0UN*7.<[F\WV'8AN'2;U>=1<*?R\^-#QF<
M9KFB 4E>\)1:%R9)'NJ&S3"A@5?V*,(-+A0AS1BX$%Q\#:'GM-4<4>GEA)P0
ML>\MO9\F#<>DO7QWQ:D0L.G0E7B<[<,W=DLKHZ3O#21'U-LZ2HJ"!1$BI\//
M/M*\+-RGC;B]-V/F?4!#VRQ?L>W[TC[E$:E@))_%VRK2A>!'33Y.J4K,@&FE
MY(9VU_%Q..HD":&^A_+Z\LEO^B)D'Y-O8U5.G$YMWQ?2ANM.=Q$)9%G17NDN
M>6B!/:8=NR%(417M)]?W+"Y3E&468KT]5$?JEA*<@N7C("= =2F22J%L?UG=
MRJ6?1#6H;H'X[$W@^9D<>0DF"^[)D@_Q+'V]&S:]M3FC)SQTY8[L;R,F(#SO
M"(DR@+>L!T.!UPK[UXO7@@S)!7!FKI841\ZH:S]_3H%K?E_;G.[#N<#  7O5
ML0,,MJ#=<CX"U_)8(W%F*D5/[Y\0$%@\T%OU;P7;T[Q38!R%3A+FZ[00/!W)
M0 K/*!+5#N(9?30_\?(S[J70&E,L47!I>WO&,!UH!7 1V",U._0KD84ZDY;7
M>D<E]"P6+@5T"C._:,U  R6VDDN+2HC5M!APWY^=LBJK?WL3\H< 4UR=D.!I
M[.Y-U!;\VE\ 0H[<@6A1:N>4>?C32&Y\=P.,%M5L_VB6'A Q"1F("GWVH-C1
MW6G/R^0NZ]1ASA(2B4D)/)6_V8ESE&TSZ@RIWZ\92-S=^&(@.%*5&/N(8,D"
MCT(A>WO,IP>RW^A]Y?%"PA?-WGVG!ON)\JLJO22WSWX=!>//65'5TX6!X&?,
MG<'.2,(4$MMO;5$#59A\X;WD5B87YU0($B@6A56B?E/QAWYK"_[#>\B^C ?0
MHIF:^.(UTMK?VDK^,;* -N@<&@ X\+<VT8"W:F+.-]\#_3$VZ86Q'8QB_FER
M(8(,(7]+T+.J"-Q[M!6I_9YFK/.M20"A$IXJ>$87[H["A*!C2B44:X6G49-3
M:47).D>.=D-/Y[*15<0%.4-N&9=&54P\6.U#O2R=@A-#YG0=5N=423[DV*SO
ML<X40E7N*_MLHMKO2<(UO&C1P$<P2B;\RY%H%,F4'VP9A)F$DM' ;%92\8[A
M5(M1R8!1^5,A$E]'0ZS<,]^&+]4P.[N^.-3QZBG%DX&Y^QQ@7R;KB'>4CME.
MASWLW$W<Z=69;C_3W+-RQ4I8%^K,<A/_[#NC1#W]7X@LXZL\+OS7JACGNXT@
M-I6EAY7:"KR<#.>SC)?RVBVA?VI%]=;G,6?D*1Y3@N=D6UI4QL]M4/??*)O]
M TT9Y]MT6\)>(EJJ_6%<SNXW^GB_:UE_]GO[667?"2*((>%SR=_P7_EO77?^
M$UWZ3[C \JUN4<:JLX4G:T[#\[,WL$83RNTY)'/$ NY2AVA4K*PMFO3\S,6S
MOGKGI7]BO/ES=_!;M%&#;(C"UCLP\X%S7.!2Z>@;88NT@R/*6U*Z>A.PZ?<.
M/W.FS*TOXC\G^H\+[G]L;'ZOP51+9ULP=DG#*Z)NB.6;\F?5DGEEO3%^(@-;
M8ZC?HGXJ^]Q_$QK?/U&%_ZZT[R_]!5F"?1E=]T7-0@/*)R+%O782:]2A.R:K
M7<5?MFI)UV'TK[^AR^YOQ1-__?J01 E!Z [C:L/31O*KV,/3H6\)>FMLX"2S
MX OF8%RD\#0:(#_U0=KA9S"/\;-5*A6O@D;U[%LX<<]H=IV78V[J3J;YA"\1
MEB>Q@]7$4@P&Z;A(U->=;+TN"? 4%I"7>7\H'735S)BZRXZ"HUP)H$VL^+AO
MV2!;L$L\18Z4<G7,UE]!L?7G:*ML#U;;"48QY8DW3D+$&-[Q(MN(B2ZJL[Z5
M)FT8Q4=NBM.6S(%(X.Z*.VH1(:\/5MB3N\5$,R8GVM*[Q ZM^#_J*>'PF :P
MRHMR9_+>I)(17T)19GW:7AF527$Y.G$*SS+OLR(5"1IG>=LUO]19HO\A_&F9
M)!/W_]/>=P=%_6SY#HBB1$'2D"4($B5G$!&0'"4' 8G#@.0!AB"2<QY$"4I4
MLL  DG,8\A!D@"&#9(:<>=Q;^][]_7;KWMVM][;VUJO]HZOZ5'VJOGU.G]AU
MNK\0U$!"AF] ;&IZQ.AVU1#^:9CNA+-[YP3+R'SL%(]CB<FB\.=><87BJQPB
M\P\I5*(;;@$]X/X;0/)9I2P&:_2:T8%PP=1G?TVU\?13#BJJ]@AH?0&N-.B'
MUJ15V.>PZJ=RU[*SU!AU(Z$N4O"2O0OSAO&C1K>N8Q_]R(*)PR6?49-?L[F.
MDK5+R>+3SZ8#WPN'Q-!8V:Z>WP">G];D0<*ZJ+U"<Y!'(&[UDY?B^_E?;,#]
MFA&ICVC#E\5[@#_!7??DZ/F3+G5CFACG((KJ>SL5Q>AUS+1*@)<-6 \]PL:]
M N,?C(4H6)(8S+\C5C8;/XH[*J^[C NOGB,U/<UJE^:LK,?(#]9]F1()JWYI
MYU&$*"SN3]I.%MQ7[NP+Q9I>EF5:9G',)C;:PXV&JGV'6AF[8U3MWV6R9\X*
M7L2X[J^75FD!]CT-N0BIHCM7E&M*&-']TVFIG;YE'ZXE[.B%,*RE2;;VA=-/
MLFO >1LB6@IP5!H\7E$LL"CU3.E:2#560=X.*G+:F W5;<!P4>-K"/H09:/<
M3WB*5M08::M4B[W8+A2!VPD#I(5;R-NEB]4[>HYIR;_[O/(?;&\M_UOQQ_GY
M-.3[!DHQV'EY&&QT8/I1OCKH_M2(;7QPS#**Z-=PN8WE,W(UP=(MF@PZ\@//
M#(_%K.!S0MB'W<Z3,,> :HN'#N)X397/JE+17I!Y?J-5PZ81+!LM?/YN89<0
M'@'!YFAZGC&PNU(^AN(K++$W-_>9T6^,5"-J9H.0('3],I^B7P<+"U(9BQ/M
M8NQ+<6SS.?H\,?*LJ,.?^;0FWPXE/R/RLT*DZVS-*O\MJB\)IR:\\UZ&&UOR
M2*A;G6[%.@?T.RH]+$::D9@"-"+O]AU?OSQYNKHIPAW,94V!J KVDX 6#/3<
M94O.F-I_AO?]6*/65> W-><J@I@4*E<'IUQM-P"E"5[4JA=))_Z8+;;9U4#O
MA5; 71&/3))#LLWYYAFX CGI#*O-P\\[0V<E]#'D>2F-H95>]H4#7^7(5R[:
MP'>_FLAQPYEM['D"Y6.%$Y@)<#%:6UGN/')SA66TIRE^2W?'#GT'\ 87T?NF
M9,4PSY^6&JP-97YOZ.Z(\YG/ G]]$7V,_] 36XCTI"O=N3V+O(N']TC*J>T8
MPN5<RO654L#82?N)P0BI&)U6EIUN.YE6*,L'R70V%]?,+'EH92$H@,3=KEHE
MB[AW$;=BS*,^PGJ"M\KP32/,.B3:<V4;J5YK >0493'N>A .Q215UQL_D&:%
MQ)F$JL3XZHYPE59[E$,<W=->ZAW/346Y3I)4=]:Y?(JW(&1GQ.70%<71R9VH
MX4SJ/[D5V"QQMSE%:8/&PMPV)PA! XHBE%8"YR)M^93?5BK4\7M[DMY?-41I
MWIEIHT28CLRO?/)EZ)"896AGF!:OB2BU2CX-,&BR<P]O0-BC#-7&L)C@*\Q,
ME.Q]@R&ZE5:"5TD;PZ[>6<I:YOP0C<XL4D>A(2S[)8VQK<.J:B1C,Q(I!P)9
M$V4U6Y(.)'C"S& /'=D5$Y]SW0#4)MP^O.<1_LLOG.+_=Z=.>\-MLL;<'!ZP
MQ7QK!SE&Y9MN?^[W:G[U+WTZ,OA= 0WC-X!'E[U;S@5(IZ4Z>'RGH"T'PFQ@
M@8%2=M%7E5;>E^IJ2^P&T V;/@N0(2W1($!MB!@-U"+Q64<SVF1'<%W1<T-Y
M+DM[R1BRF=RM2?.#?2G)'+Z2H.(O."M *:MKLX"/NX(Z5D3,6H\)3FDBH[%]
MYW6*YH=^_>4E5X+_.17Z?W$JM.X10+!!Z9/1/_*RA*:.P^M]I\YMO29W6[1E
MXM\  B@O0;^_3>9^(5N&[T!+3(1LM=5D=\ZIQ@]VXZYI-R;G&'@O%5T6S$E
M:+JZO2UQU^8PH0[D\D'PJ #7AVW/K=[J,%QFMH("9,!>N$/606O [N)?FQ_^
M0#@3O!:5^,;;$+ZPV6TG4Y?UR/QZ:(Y4TG=OK=7L_CBXV)V&E_#70&$W5'M"
M^Z3ULR$*K!I3D<.><KPPZ']V%I<+,6KO]J?#=*[%'A'?-4'/G";)5]>,N8/%
MSY%#R%UP%'MKJD?,EP23<FM71 MGK]!AW"43=<'EGOG%:?.2XA_F1I)@,4XQ
MI@SJ70V;ZU7HBA LIOA:V.Y:O'Z/>WR9'Z)T6%0D1:E=E8::J4;U/:S:EVW
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MEQ;&&\#"PW&9M: ;P%SG#8 Z?#+/:Y>WN:?.HLC0-V[GP$:(O/(&<#_TVPU
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MN 7B&@6M+6B$./.P98)9S>P7:M\O'^02PNT'.M(>UTJ#!$*I.)10NB[/:6\
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M1@8N[8MTYYTSZ'@95!73'=>@M.A\JNC<H%8P9R_R!)]00*6J.DZC1C[&0"/
MS;7>0(S+\W'/<]'> 0]I[$FH.49FD:\^J>N1H9V19T2>@XX]BD7KC+*&WSNO
MK9?+ND/5ZHTB3E M,U ZI^R2?$\_4@BG<:SJ/@\/A6!(FA+3@X1[Y-:OW[
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MJ1%(>1AG5M>!OZXZ#?6MNV^>L$Y<D6F9:6V&_.L?<OU_.AANIOX74$L#!!0
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MW]@8B$O&:R"^M#GZ\D2.H]A#N.T$?BC?9^%$QOC3TI_I->^3*/ G'S:\O1I
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MR<D@[8=;IF*#O9%4GY%$JTHT3#D_]A@">E8.2)TOHM^21N>J3*",ZDASN6-
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M9L>I3XKK[;)T]^IT!$<V+X5LFI!U_-A(9#3B0S5UUN&_P_\&'.?1"<6I]<W
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M'+IJK?I>ZKT=ME'7VOS BZO6<BCDJK4<[C0P[EMW-',QX&;@X#-,ZW1E)W5
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M:M"\LY 4=^3[I%3#)I9W, &6KHR<*6",V'I+NQ# UWT$1:Z?H2(G W@FOM(
MY,75:1,%(F,>D.E 9\<<@"Q%@X%:GK!A%X%AAS'G@E*YB7 '(PUEG=(H54K>
M".7-1?0=M=<H%T;+)WYR07\C*:]VODI-7!+P;(@BTL5&7K?PYA$ISM%LQMOE
M^PF\)(4O+P#V +7$"U"I@W70,W1.;[C$1Z.8U5$PSP )614H?BOUO@/8%H$W
M)B2C)\PJH+_'F%6@4&8< ),"=!KY;%]Z"5X9K9N4%D8[PB<]@]96Q@0\&H[]
M!2BB(2$7_* .BO:W_ %V9'A.3^?>)&\!ZM^8.Z[ESR*-!'ZB?%[>9(Z$1NB3
MQAX*DQ8IPE,DO?4/:@"OVY$%\W]F$7X?04 'U]84MA?:@1] <&>H#6@U#+0K
M W#0K<[\\#NHU5("-SH^[N">$A\0&.!FN[EWM:_+QB&-/X9H++4-D2G*$"70
M#8UA L0H%-A@LV7(-F,X3<J>2?Y$G9]X95%'!'7> ANQ)W@6?H2S>G PL&UB
M]MW@R1$BM.F$5X\9O-X(0$+WY%UX<$"\0/1.$!XP@XK!*/%C92^2==Q2#K3\
MT/@LQ[E6AJXL>,@Y+SZ2*_3APMN*IR[JP05YLD8K%JLE%9E-@4]!FVQ!:":B
M!9CV+%'0-AL3MB 63OUXCI]J- RN4)!$YR$9]4D*MX"/Q1)=U+F>K@'"D(6+
M Y,+5 E)MP9:6Q*A($$7SE@N4BU3+.&SQ61"H@DO?A[%"#O<:J@?:M&M_X-+
M+N%4/B*X3$C$J7 $DDJ0T19Q.^KEA"/P4GA;>SH%1<-VH?+.MQ'5T> [TKC!
M!R# ZOO0,JR &*7@0 $E%+\9*A(_1*%(WDCF#"&20U$\1F-  Z8<OAMY07VG
MP3[F_=%9[!=6H-T8]D"O\.'?"9X604]4R#XWYI#)> ;B,X#O:(Y*SGD\4,Z3
M[/VK<Q?X8N6Y =:&V;7H7M4;X ^X%I)S2J?S8C"J8Q4-($*P/R+T06M[[=EE
M2*\C]P$PEVO.ISGR;;>TI;F'=Q'Y$T_=U"3*1JD*O!"BR1_>?!'(EL+J(L[X
MB>(.%J5[AH:)P5?B#!  RFD.IQ!F&*UMS146)#HJ9K#\F_=[>V*Q.]\U+RB_
MF# Q0:"\-<\2/L G1C(73G499<&D=*K155$6$#SSQ?6N288]?0#Q1GJ5=4-+
M:A7 ' &]$:4HH4875::TV.#/JF^CA%S]AA8[Q);TGDIU)[8_GM^ UFD-WL23
M7^'NS5Q@17!5W",%$-5E6+":BB$ Y,1+)MX_%2#4G2EU"N&E.YNK![KJVT\.
MHQM!Z(]O[;,*LP&Y( (''?,MC5WC,NVS31BSC"ZZX,>!ER44[D*^B]JU3-[G
M<NX:M">4RQ5JI0ZOH@#8)4!77(#E"-R1SX<L5]D5BVL%.9Y6V22@.FRI^PVE
M1_I'SI_QS]MW$9O5YRII[Q^#*$*M[YS&48BMD9>4#X]B@T+&O[Y_O2<\Y+5;
M!AT[E)8">+6-+#GGQE5/;+<L ;P)+[(/4,G2]*&FG+%B*QJGPX[XF 6!!%U4
MJ;(HGF!9MNZ,YEZY X]41AGFL%)&D4)SR^C1R+S(1K#7&8'5.9;OQ;%\X!S+
MSK'L',O7.):1TS%'3,0GH(B%Z(7C79(L7J4KAMQ&-/H)!=%8LKP!]NW#&Z99
M.&;7!SE^D?L9K1HS 2D"'Y&K#FG9<AL5'!$K.6L2Y3P5]@$"P4@$8/%@@D7&
MQY:L"0%ZUWA0ED* 7ECP=50[)?R\Z\;("[^3:6UY-&"_N1>9W!N)Q(2N5<X5
M.Z=D \^%.JY$9R!\0_Z S2JW 4M[8Y\O/+_L+ZF/)KAY6LK!$Z>EF 1D@+ *
M_'\00T :3E(Y>MS,(_7 .6Z#C'KC<H(5$![XF4X]SI/X]->OR2 N9-=C!O$T
M0^0G3,)]AX"<"6!;PGYIDUIO+6$B*Q<1D<.8"2XA@IMY%^Q56'BQ(M-_W]O=
MV]NW^,)-\[,+)%U(#R:3*5F?_X_9?708\E3*5;DJ^F[\D-U:!8]OLG&6YE*.
M">&05@Z']HJ&C-6>:)/D,;K*7545&:X5"3$M.V*F?-#*96?IPE;&$W.64&O*
MA6S?7S>_H.Z/A:^2[LO)^TUD1*^?F!$M)V QAANDK9"P*XU+9CG2@_^4D9(3
MF*7A(L5\IK022?_]]>[>.TSI3C(*J!)=3/ Z2$[>--5+O*-HZ0TP;45N6B,1
M[4U-$(U0K)[P6SV'B-^/QM U<XE67\>=#FF)U3"*YUY0J!I3'_WT^Y:W;2P"
M^J? _!4%YAF%2HU3PEYS:5( 2!UFWQCIX1QEPZ>7I$V+I9R=$E%.U2@5!A1+
M@(CV(U S? P8&]F(,9,?VR!JKN96UKMF/6HSJQ))2;^_V@99E:1QQM1?>@-6
M6<#R(-5 "[$R-BO/R!Z9#<6Z2E(%0T=OCI62+<LL4.)QY"6^T76T(V]%Q':M
MUTB]CX(NE+YBN="2W/''"A,'KNVP&C!Y?'M43A(P4#TD!RF9-IPM/9)!=+F=
M9\+2ZU=>QRWK3VR>H7AO2R--7D,"H#;+<=(L-H:Z"8-?4B1(!);/@ X\U%EM
MN</^7^:PB*X4J-^VS:4K B20FB&0(MF118G54ARVPI124N,!K&@(BO%,PI7I
M]Z@K(D].V=A% >RC]U 5T.'?"['3/'4 F#:3N0F;P_82ZGZQ% [?7:%"YI%:
M2DT?2: 0,+%S]I+' M=@5#%[*]=/L>HPX->3C:.2WRORJ0M$26AHUL"W8_8"
M6,#:5XOO-U%QI63/S$V@0<Z9!]6+\9&,#WU7?%THREN5D%XTM.A\+9/M=AF)
MK8-M\3%+?*KB.519;^M@MKG^LJ2"'6H,7*YZA5L;8V(:0DPA:BFWH<SE0-:@
M*P0+YXA!@W&*?@EM$:01#IU>EPB?*XSE]/=2YCMCR=9HF_+K_95W0SD75"2,
M65I,46.$&*PT;^541I_!XM:ON4]^;>K^:E1K*8_2QOO+0FOYB=FBEIP*FFSG
MR NP^MFL(J$11=]W .0Q.I#.S0QZ@YF5-0<568I84_Q!Y/TF'U#Y6\01GF&"
MO295(DN1=TV!-26<L&B03_,$/-.ZJ]M2Q^/DN%475XT65'%<"?2;O+7B,K<U
M%UU/A2V;Q"Y]8$ZFSL<X7F MN/M)$>%V13N\XC]15\&25%DRKFY0+$):)!A*
MS(PQ'.9Q%1,)&53<7)#I7H),KUV0R0697)#IFB!3C&HFI2D;_;6HF63<J"#7
MEP+ODO)<_IFI(JW;%07N<U5@;A=[R&^S(%WEG$8AAHG\RFT:7.72K$HC4(45
M:]RS*A?93FRGXE5**243?:5-OJ1UFKV L0L7I9<<8ZZUUBSN5+>8BXO<'K!T
M./Z&O31_H1![4RLD5,6 +A;L4UMV$+)UI@^'!P@I;D%IBUC@H=)Q_)0E*MA.
M7$X[R:3003%<DY17=GE+#*L$+-)%ZOV0B=JP=ELJ^ZL(!4ICMB(Y!7@HA=+^
M.RZ^#-F"-\&YQA[(-38JN<9ZK-ZI-%&^&^T0HA#%U(KR+%_:+>N,0;="OQ3R
M%<[IOZ1<\2+Q/9P+JE"XO-);HY*@/!7SX8VU-MHD05 &2RGUAK.12@-\C9N#
MV/EGO!C!//<+%+\_][Y+M..\9%9V#.H,?-O1LIEK!3X>7=W(<[(M3*X:47@X
MCLD&AO=.8\^T6EJ&#ANV2;023'ZX297YCVVV!>ZR,'D$,4<?'H6CE$K#K[@R
MO*+,8_G=37=KUC6:TWR6.UZ*1I0)&MD,)B7 E<)UJ689J1U^7'*G57H,C=91
M,)S-2\I==GB%E'L->?A2BK^?^Y1(H+>AG-K2N'AL/E.,8="#9S).D-$K;= 4
MZ0"_T$4%H63^ X>-+D,J[/LQ5OU[?MW]]=>_;.[=^^+]\.?9'%=%HQ,HK- Q
M;VU!3Y::&JCEXIKU4.#<%+NNB!.B09)$Q&/0  ['"EJY_,D%QS6Y$V4@,4>R
M ,S)M*D-8*-*8ME469K>3ZY&60_/DZ U^RLZX30<<G_FW)L 5$:95GRYR.O:
M7!)>R%2E%+>+#M'BEC$E:.Y1E5<++".K?8@=QK,.=BMXZXHF:_$8W6? ZA,K
M5FBO'Z&AQH^DQ>T8MY)=N5'"WUOM<HL1@D"A:SH#?^ZG*H&*S0?:D8\@!2XB
MD_PD_*&^'JS%)8@EVX5\!.N-**YL(,0Y>+S0"Z+S*$LT^[&^!5]1=8B<#+2+
M-19R0>6N2XV&\BS]G-*F2Q3I4P,X,(:\Q:QE 8] %R<S?Y%K9+HV7Y6DCC$"
M0@8+H7S1(GZ]-3&L11>"B/8XK>(*-M/VPZ7RPYQ ;7:TGAC00[XB'(%V6HQ,
M3*D,MWD]5RA,\[S*<L8I*E_[VY6V/YQ_+O;W=O[:,C_^K]4?!C/TQP(Q$W9A
M(I@#JP8;T-= %#?%;MV6CE&1&YJ-T18%C3RN+E4[4PMX81BA,YKS2(NZ)08H
M7F];U*:B\\N/(1D951C3=5/$0ZZL)5R\$8.UX&_%R[3/'4&$EC>6+ZLJ6*^0
ME%H=.C,M&@JQLY9VX1NQ924R5FT83UJY:3*V"CL_PL9Z@,$1FB=9^1C6]@NI
M#EY13[&V5U#[4V7><=EL6DVQ91%4A895A[E/_?8EN^O?.'>]<]<[=_W#I2B^
M?>(4Q9,(YXN-5>L2*Y=:P%^F^5^4_%"N814&5DTIKE:;$%'>U#5!<6$YA>^0
MU<J@>\<=_LBSC>%TM=FDRO$&>NPDJ?:^E64DA2@J3A;;.UY*:R\XHW2Y#(=.
M2I$)XY\O>O&4PC.SBFY"I>V7KZ%EZZ]5[J>:=3>\!5G\_,1D86FIQ]YEXA)X
M'S&!5W<URTMW5'!K=8X1>QNBZ90<NU08%%5[FDNF7I\ZCG!EA0JJEHR4]EBW
MZEBY Z+H?+:H=F4ACP'ZHTY9YGUF+D">5@K;ZF? B/;?O%FY!6#'JAU6@>V$
MT8HXJQ6/Y'PI LRJM[=TWC-'!RV71 #(O]GT@X_(M0;?KPR]V(FEUI9G7L+[
M\L:J>9/VAI<;REWFB9I3JL$QU8)Y,B.54NG8CS$E+GQ 4DRLPD0Q?Y3I,DP
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MUDE;84M(=5TS!7,T1D@)MT;P @$"W[OV@C#T?$)&B8LU/CAI%4&?AB$-_7
M_C#J^]$@@,<Y7#RGX\N]]>1AG'Y_G'9I'Y]O9Y_'T".4?NV/*9VDDTXQ\/P
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M,O?^+ E;N&Z(V%H+'G=T&0Z]<' 69]IP- <*^7L.=T3?OQRC'U!+ P04
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ML"74-9#.0LLY2Q&0Q'9BOI1+>.?<-'>J1CZ$;D[;H!29Q 1(;(58==499T_
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M>%X?AF<AL:L'&,<@8OW7'+J<F4';IJQ,IR/=S>.O'@0:C-5]C]6;C=6X4\\
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ME*=U.%9$>OA6T*CRA<,#LW-X7Q97-Z:*L[CR&=+BH=3COP!02P,$%     @
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MP:%3G45!TTT1K%DTM;ZUQ0XE^0>LTG)]:,?BL4K8V216V4(AM\YCKFT,&I:
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M)1K\H?#Z4['TRNCT?5!ZR%\CI^^E/_D_4$L#!!0    ( !&%=E@DORRS^#D
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MP# $<G1R<HAKRB- 8(";:_MM:O./BT,:?\RM<6@I(E,Z1Y1 VRS:SA&C4#0
M%6..=#.#W11LK.-/9/]$+'W"#=*G S:B3_ L_ I[#6!C((IG;,O G2-$:-$Y
MSYXQ>(,A@(3.*;@.8(-X@*BL$QXPA<I AHXR46](F6N(3<EN&I]EQ])"7Y$#
M#]"[:'+XHU@FRNXV]^@:US(R;T8?,CX#\YB.EHF_BJN10A!'Y/28SP@C53H#
MI96Y#VH=(T(L1-A)E$WQ4XVQ\2TRG?0R(74U+^# \+$L1 .OY;,:=GP(<,:@
M3(!T$](!@RB9I\ATT/@Q"F>%YC\.H]KB&T5L#'%DFF;(U'"IB7ZH00CR6\IX
ME,#_ 5IA3NQ0S/EXJ^(Y+1&7(X,3.L&@,%IK,@$1SC5 \LJW\5:@*G.LT8@W
M0(#5QZ+YG8=#)=.ZASU"FOI"#8Z0@9(ACXE(@C?'9Z7I"+"!+QF?#6CP2=%
MS8_71WMQ!ZS!T!&L@8:(X.<8=XN@IPO+UBHFIOGH"EAM#.]HXDNF;=R0)5_N
M^F7?'@FMW3? VM#%!IVKC !?X%QX\PO:79"!NIB)+9WN@_L1H0_JD4OW'B8T
M'"G&0(=6[$\3[Z]=TI8F-,%U&HT#.:EQ.A\6XK8@1 N_!--9'#8$JWV<B7(A
M),Z%#\P=)EY0BS-P 9"ELS.",,-(>$N.T&/^*,3!]$\/=G?5K#EMF@'* Q,F
MY@B49^99P@?XQ#!Q;U<WZ3P>EW8UO/79!L'33JY73>SN;AUP7Z, .8=4$<(
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M4988P::N(ZS_N%@$:K@Q6QD5!F?*%@OYM-E\U25K':YDHTZSA93/:. W5ZR
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M!$X;+_%C1:9F,$)U1U/7WE?[=]E.-4I$N<%=%MR R].+#.+3F@W]/M:@TY?
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MAGNDU4.D''&8?$BJZZ<_FHPT>V@/7J;JV6"B;8-]R&NS_8*T@VSW^_$$A6,
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MC2$OB\G5#=Q.W8>IDH6 .U$P=I'-U(%]3XEC=!=Z1>^22,J2DE(4E04./ -
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M_=VZ?J"3]O&-%CQ$TEBL30L"]H<4?LSLV3W28]0HD<UBF$1"CK=9CM7,=(3
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M).@>N'<-*B_ />'H+MIU<-F*1R2RN4(,A9_/U:>@O[#PD,2=\BBR>A^VATT
MBTS[B%O\CNFWRH4U"TVD@$_1[^2YH7V!G"G,*9;Z@)KANF]*.Z'7-)P5@F@G
MUJQYN)DL+K!H[SSNV FS\6/'4O"J7I/ON.H/W6 %/R0_E3>@DNN0"]HP-9&[
MZ& *P\C#:S>%750B Z:-@>#0ARFFK7K<J"]TK^DS\PM,3HRF]"V5B,)_FT.T
M]4TM*J7G9Z5T&OZ.<RCUXOGDP6O01G-<Q\:HY]XQN$1)5OR2X3/,+I^S!V(2
M\/($4[[++;T[ZD5&G>!='HO734PD[R4EUKV&:V7"09X@2A)<GG[@^B-<8W<$
M*P7_L$'_"=^0C\:&\\_(YX!>@CD];I!!B*F,4S_,W#JJK03( ?ME;"DJ3GFJ
MJKL)M%:7SU95I#5FV+ZAL"/Q"F<P0&>38\(D&KJQZ1:V"/T-0SV1JLAT8^4:
M53R ^7*<-T,UQ9@=4Y[713:K=XT/+I#SE?,"<-.#BA9I\Z_S]-/RKA^%I EE
MS&#X3^)IR\?3WD@\[0G&TTAI@(YR<PU4J[64R>K*.GID\F\^,PF=.DUS:UG%
MG'CFJ\)35 ]6GF$VT^S#67SH<JLDPX/0:5I#;^ IT'$FMJ"<]:^HM)B*%71=
M/ 79)L%U1C0ON)4%6:AZY?*ZK+]]=CZQ(E3_-LM:N->6@192_5^A-J*0W3/K
ME(4E'_4F<<)9[*"[$1UPT+"]JB4GM[E_VEY1:@/(S2[A254'K*)TV0&5Z^O*
M;U-;-BJCR@]OT6MY30L%IQ\<)@8I.?'2--#!)W-8JJ-2GY3903DUQV1V2I;8
M BMD#5<[O7$.&8 RS97S_W)9MEF2U<,)H=,^L8Y[,/BMT[[JI#<23E!IBQS?
M<[)C&\7^ W/.](I.7K0?J@N1FKA&<D57-383)K[84DNG61-P@29/],:']7C*
M,=,BJ06&X?Q$WPIA<JZ)"%(*?X\W30'8:35CV&B69]&^S:+J%,?3*155"W+H
M.%>,VJHGH14+X?G#_V<PBRA6X3Z5F\%P<8&&22>=9D1=\V/)[EAHO66*25V9
M"&DIOM6=JPT.S_R,-,IMU\,?2KK ^KRT[07.*U]#OKD6QE%59+" @-9P,H_"
MJIC#!?C@LI:W\["#YZO($@AAY0-2M]6 ;0,\-^@B2_?O-;B'<O%':I1HJBZX
MO8?V5\RX)![N32KS**SDW^&=F-$]2Z=BK>IDN-^CT,A<"JY32< V' I4)PE6
MY*T;>-1N)3Q0':%GC%NC^I=S0SRV\V%.3LU2S@7GH7>I["VKV$"-7+'-KES+
M]M0"TR*I<SC796&%0KW]PJ6O0?VG];9@75> A>2)8IL!K4Z#ZPU*+&C\>ZZM
M.Y?)K.?N7 5)O#ZK--<Q8*.]1AL,!UF ^2-GMCIO1Z"ST=',0#9]3R5W83T&
MK7=C@3MBE6JS+XFUO0INV[;-M0G+$,UNS%EMX@JY8[H0,;!.[?F6\#SDA'SD
MUJH-REE7AC,*Z4TZ2K'TY!7K2-7$RE[>7\7+^P2]O!M6J8WE=*HN<<5:6U-W
MO:H_S?)NC!!(KR3M=,L9XJ_I>CM9Z-ZA%*5O5?AY/W%E.&';2_5*);AZ$SK.
M3>ITH3^ ,K'N06PV]X[%;Z'<6"Y9\KAK+'W>Y?STFSWNT+6S&'2R^'W66&-]
M:2!=J$S3ZN'I5KM8"4:C^LY,R2.4YKRT1Z'*DV"\! S?H5 E..F]D/R6B]=8
M*!-[69V$ZUPC5G"(OZ'N(99,["O4E5GRT'/+&1VL:<O2%7R=R<X-3I0GP]*6
MPRFE\-" 5L7(MA4E]RNT )U*IE>VP \,Q11.C-SU.+KG]0;K!B]XWJU7]1SY
MC3+7.2_J-M<SH9/'Y=JD:$OOS@Z[Z@YR?@H*NP@J@N92!L^F8U0J!%FRO*;M
MM/9?\*7TGR!)?>LD5'V&#[%DGMTU^LS0ES@8AH $TYR#;T;,&JJZ434.5I#B
M#V//QER>0ER3,/73@._VF;O:\M;@!;W$@0'30L<@+.1-0WN!BTT,2EZKXMB!
M[H;L\>AN0A525+6%!E[B&3WB5BD- Z^H+$L&(3 0SI:9R2B0;I\@&K6#HT1I
MH]?8A$0;9 2-TPR3IX!D4+)?O1D$Z=EI[S]$8SP@S%9^$!7@+U@C5^VY,M[T
M#FC)8!5OG!"%=495C]E\=\#M-Q%( GO&*M@N%W%6.?$:ATC?TRNV1[MJAF1A
M]:-$653F8I%,>@E&/X@5"U>+DO%*[AILV2GRE3+94T[."H5 X<Q<$UE:5*T+
M*N9JY;14C(M:A!>F1#8J=J:ZKTK>M,E9#N5;3/DL&%TE(R'A#K<+,4?5V03T
MD$7 5G*9F+I]E#<[$Z74[L+UQ=+;Q98DOQR8F7,=@?)-5"DZ4GK+&Z%04/3$
M@)F3K*R]A"+B685973%;!DG2S_#\U/"JB2=Z9T'L4P9FQWJ_A&X^>VI2LV/>
MY%M4<(W\P,N M,AA39A5=OV$N8VCMYT762U=4NR-@9SZPMS;,W5>0A\'CV),
M4!Y2#D;*1@BN?]:3CG:3X+KL%Y4O:R743,D.9$DK0Y7"C?*65PJPKGF .[T!
M>X76.V-$!HOQSN; '<8-](/[.2@7K8064B>T=/#*S A/&(O=(Q6)^@HQ]]F2
MT!E>E+3%:+!VH,H"&J2F37:#<QW#,E^:U'",(.BN* 48'5CH\ZA213\ T:?T
M(%U;4V ;L >=/;G;C=62/KV!<6%V9MGL.XD!J:O8.EZ=#,".K#Q7K8=*NE?N
MAN)3"1MR63Z=-@-G7Z,.%$:HRFC! R8/H6H6PT7]B%6XF7XK.1<I6HQM+8SE
MKY*I.!"JS ,%\:=C+0IW*F_]4HB,RVW)E]YC7GFX+=4P(3!G$*FV8;J0VA6/
M^<H>\]_$8_X$/>99A)>[R=%9 P>IB0D/P8R:!' UZ4^"L1%V=$6I2R?9B_VT
M*BEM-C-./(AK )II#W,6BJI&=+($RBA^M#@ ^45\S&S(C"^:3C)!O[6O,)[S
MB5C =67'US-S)]%=1B5X5%YEJ6H-NP8;FU:%@,:N3Z8,W 6Y_T"E75" 9J<4
MB/)4)AS/3F;:L[*99EVP^YP8;7!,GM/>+13WT@V#"!,XUHF5("SV98"N><,@
M:^W YP%K8KU?94ZYF'TK7J(!7 A>FQ,5!U776_6D<I_-W"@*B4]6(I R\YB-
MK&9(:^(DJS@UNQ"B;7J+"%C9G1)M?A]+5&@H!4Q9OF9Z=:S^?@I*NY#4C^EF
M(%1HY]-K">DG:1C( RN7ZH&I>>K6N%C^VFS>6L!=8:)<+A4ER_FS'9.+3$#'
M=E;A6A5ITACZ[$KFBWTCQR=9V8Q:4>48S98='0M8^6"W@Z >A,6YT[S&* L3
MNNQ8S08H@J3NY'2!*<M&4_MM:T#*5U^KTBLH-;KV4T=*O&QZH8Z'X5F[12B"
MXI%;[%II(4DMD6]6<7+<ER[!5VF=@Y:/![*CC'WY2>YJ:)9OB^O&I7.HOP<+
MZV_%;5J/D"?6!"<R%/D>.DL2+I[/%!7CF?/135J/,CWS*DCSSWWN>@<H<Q=U
MUZ.&B92%N(<"Q7%4)?^8SIF2)X/:C:"V4-GI0XTQ.I[$B&"_GR\0'($N5%U>
ML_%I,<P%G#H>J5:/!@NZ0G/GI(Q .LE?- NHR&_/8!4?4?:6X2&,_.;S!0OP
M;Y9]Q_G1M'J8]_NS;_7W5I_WIA9V8BYSIBIAQL =ZI09.T-\.31J3MY)['D1
MW")KTZR 3\T '<IVIP4OS"T QC)ZNL3$^(L6.6_+LYFML^(\4@@>SO7$#SB0
M.8S="<+)A91L;1SL2E[*(3VLOLK#BK[*%NR/'?VR58 NNYCJ26$X$.4192>;
M(,=UYLQ2DG/6"/1(YH2N&$QV(*_..MSM)*[U26^6)+9$3IN&_==G/'IO@ZSC
M30&251T@BQ<U;MY_5.8 58P]#^VQV>FV3\Y:3KO=1KS'+<UJ1O:JI[A!YNSJ
M_,&.[JP+Y_<F5N$Y**!7AT>/@&-6L84+F\$M&U>K;ZYY.ODT]O2Y3Y<E@Y;'
M[9>SD]$?C6.?08U5 "GK?HKZH!=%/PY@UV)3PC?5IRD;'NCNI-Y#C@5K49T#
M7,PILNO:*(,0]67?FUL$@G$M;@/'G>7XOIE5PI5KV;<;.J-94>!UPQ].2X6$
MI =V_',+VP!^[;2[[=:5TVE==EI7K?-NZ]3YW.JT/GQW/C?_:CGG%UWG0ZMU
M#@]\:E]UX9M3Y^OY::OC% 9HGG2=BX_.T1^O7C6<)OS]I06/G3I[^-S2.:@P
MZ@Q,V46G? 9GS6]7, 6)ZBT?U?M=HGJUC>H]3/R;Y]^=JVZSVSIT^-8*PG25
M%^@._/GUPW^W0+"[%R#_5]U.^Z3;OC@'*3MWNIWF^=7'5J?YH7W6[GYWFN>G
M^$P3;"#\YY?F=Z4[S).H.D!VX:&+LU.G]8^3UF47-<5EJ_.EW>WF% MJ$QRF
M>7EYUCYI?H!1:;9%>6\XEU\[5U^;YVJ.J*,Z39PDOJKUC]:72_JCBSKM8^?B
MBR:W??X7$'31N7*N/E]\A?G 1)O?D.;NYV87G_].-,#'G=;_?&WCY.$-'UI-
MGN#']GGS_*3=/',Z[:N_H]Z!C]M7#H\+NJ_K?(09-,_AD],6/-V&R0.E[8M3
M>K;]Q5YYIWUU]15(IU$*^X"S4%/ X2XN82PD[Z-S<O'U_*IU!F_ =WVA!8,=
M@X4Z/X$A8!FN/L)"7G2^X]2MUZB_6A\_TN8BP<@/EYV+RXLK)%3MF-HNW%,B
M#=[X!?:#AO_6[G[.;Q6,<-]V/5*TE]K(%&T-N-Q$M[-><G,'7][TF&-S4%VT
MZD([U:]6T/,ZW[A0XTQ1@R**?LK];4UWN&'1="&+I?BK/5<CA.5!13*72579
M/L6D=.4XOB)KOESL $*.=%IKA-972\7E^KW]\F_QFDC=SY45&GNJ=ZK5$Y)=
MS:.Q*C"GM^H^-ZJ*NU!\#Z]K\()SV(S70!6E\T=6D[RD'^?:XJGE-SG>IDB*
M2JD:]L;=4R6L^@RP+:SVGF,/.==2X*7<I,VU&EKW09.#-,33PM.)NGIK=L.9
M< ,&\IN-3+67#E'1!-5\_<2J"W)UH9@&L44WK_+PTJU>+_(A^;HSP!<U'?4:
M-X;U28U1?9GU59[!3_+9H46Q!<J4=D$H/8ID\P-[;H)! ^UEH0F\?ODFAQ]7
MQ:@"GKW<I?/X,3HMZ#95)T:N'W#E_,;YR[<^+ ;#<M"UKYC@J[ONS*D%O4&G
M<P@,E^88WD#ZJ%CS+*"A=O2V3IC+,3AJY^HR^% 66\%(+C*ZA2HS"\5/<=1)
M#RY$)@,VIZPG<.@$JE" SJ;0\OAK:D-N+HK.=<RKL1%EBPU-[=?3X;BIJ^ES
M$*09''-"BT%&^N%Y8[VON8BW9E@59Z>&I, W[%@@48(C(!JHTR.O%8%+W\DV
MK0%Z#4LO+'.@1PAB0VQF3T<:')%>EO^"\L[F"<PEF.J>@NPQ']-O*(^!U(9&
M^TPJ84HK;2Z=56'#61%NHFSY&JJN+= ["RZQ\IAH9#TBR:94]F3#,LXS,[IP
MI^!D6I_"1WD+ELU0ROTJ6F_%DZ@<H[>,1]9I CT[%]@?X@)["BZPY0-X?SV[
M^-T7N/QBD#;TH@DB>TC@;ID#YO6C!.XZF-L'A\$[YTJ!W6&Z%IF7#[M.M=DG
MP@F6Y'-"K8+(@I@F:A6WJ8\5#+"I1"U&]E51MFDZEI0V96U8@_CA/R<Q5]]Q
ME;C^0"<LJ3>7YM%HJ#^\<VGJ]21(;Y6_7[T,WQ1RN(X0+ACOTL:$[GEX0-MO
M]'YZ<1\3ELCNXU>8@HN97I]T4%^CC\2&HDW5N*J&6YD-.I_0>$[0)!C0U5(A
MV&KPE%$4>BEZAPS2*'IO],8-,^"'+#TNP[QV!V!NX T2C1(O3/@^8O ((XUC
MH6O[3:$S6$F4IZFKF[.L3DH1+-V)>':-Z6F-_IHC4>5.(DRNGB.L);I',;W-
MQ2PVR7%:15,]AK?G/'*^N>3[?(!6@A_IPC)=E)O7/)0'28*H@_XDBF"M1W><
MUSZ._5L?7<Y6B2RKD&CL42DT98(36V5.^##23Y$,P>#L_2'9=(-,^O4/$!S4
M)%?SU0\>5\CULX^KQ'_SN1)6Y6JJ(D&X?A6N?XQNLA\5 S239!)3V?M#LVKL
M6J\!=QE7FK7!&7:31,.J#*C6/WL L6TX3Q S1M5,J/49*W:N8LGR_52DP@Y4
M9+]78 PF%;)A1\BX)U<:3[+(@W%\-/(U.V.#Z3T+&N\0WK)RE?;=&$ZVR$"Y
MI/H8Q0QRO$8G-\I9F@4K2@[=5 'G3$:CG-?6BBUQ6B?B@E!L@0\:D;559.TQ
MFG&>$Z3,0P2LR; 0^"O+98<P5I-0%=$F^2I:!4J59:QEL#NN'5U6XL-&G2ZW
M(J [PO[N1Y/8QX/(BV\)L6C$:#L]$W=F0]AJPHY/,(('.YB&;I\0.^A8\@[H
M:X3MH>2ZY'&=^.UB%/OM1EQ2QG>CDEH^^-$_X":+@4K88F\"&PO:IQWV-^,1
M*[[^S9LWSAE6"7Z[<>.A<PJG]F9Z[Q5?C&-\=N'FUG P7VY3;\SE#Z5I^-8Y
MN4$[_B/<)<(^6D47C$3Z9R]^WT*&?.MTKE*0%UB/]+]Z?O03=B>U-N<01.UQ
M./2;1C\:&[28#"4&CPNXZ.%1R-IA']AY.RQ\$D6!-W7.SBZW\KI73FO4<^,^
MW+/BR#DA_]167GS\$M;_8Q!%VWG=E1LZ']'^\I-^!%+2=/YX?71T=/#ZY<O7
M6YE $R,$Y/9TT-UVXP/S?<&%WXZX*FF\'KDC?.E_]8G-'D_\^(!PLSR1MTY7
M@1<,!C&!%'DI'KC )5@/G/BIRL(VOS"9.2$"3H%=-]>]>]6_\;!>RFDZZ."T
MFHAH""%EWZK7*P0R?:[F/]4X"WI/30:0LG"Y>DN53<.]T!\3RD6&K:=\)'S@
MZ_"10L2[]K$D$QU,60MCA0.5(F(H6,E#ZLCL3A.%BZ4SV77.>:@*<ACOC>)"
MCY06LRMJ]GD$KXY?2O"JML&K.8?7)(#+!*;LN:/Q.^<DCD8$A;$M(^'H^(WS
M(8[<@7.5PLTZW9I-^SV*?S2<\^\.WEPW>$[G3LH#/BI[@3M)W?]*8.W[L.!T
M5()9RW9O,_:=#_C XVA5==%ES,#<755?#A>X<2(NYT*7SD89E$2&/\CGU=T-
MY1ESB7G#7*JK9YA=7Q<=G7ZYIS"1,2I! /!4&TT/#8! N'RQ$\+I31*?SL$;
M(#PQ^)SF-%;0\AJ&MC#/^9.BF6@<];&GJ\#-*U7*<0@[ZGS0'YZZT]E9<*>N
M^U=+V2'%69F:?I/FG&!F=68;68"[".265>:-#%*J<:X->$!EK.PQ*F.B@U(J
M71C,IDD<FG&5W\X;F.QABO$@D*.;V+EMZG>*#@,[HFV?PLSV%]AG6N'2O58.
MOEW;:LE,7LJ3^.81/(F?N<7>0UR)ND+_1OU4>PHQB]/7",E#8KX0N-C7.$$9
MRA1UZLN<B 4+F<%@'14^TE%:=3U@#SB5J>@+!(=^%;[OK;X<B%-[%5;\]1%8
M\03A4[P8-_\A[-C-!T(4'K<*\*BVC-G SA[R'6CZ#$5;)R%D+<>S[^R?[C=,
M TK[?F=S+L9T?& )-V!D?HJ]ZL?I:$=@(+SS*CSLV2%T!);@4ES@8\<YU554
M?+89TJS)<1Y+ G<G-\40,MXW2J)$16<ZQI01;B^.X(QP]OQ#[["AS[_Q8*B/
M.GA2?0BF4]8ZES*[K2054PA.52W6G#%OF'M95<T]/T^1W55D][='D-U/;'Z#
MR7#FWKUS3F'5L! ,Q5B,@7545VQ_%Q^@@HLZ6)<3:71!TF4X=C)M8 $B\D86
MT4<-T5>84ZJ&C\'V2/^QXS).<PVI]ZWFT0V#V9^UEV:?!3<(J0B4WQ<4S_0:
M=^VBVR.G$)"ZCB>J=+,/BSDP>>Y<982973J+G0 MX0]]S1?EML9JEJV(Q7];
M_1\.%T:\S26U*-M"L98?Q]YMU.=.+.$@WX8 /[-@9!!?T3=&,G>=LA(1L>&F
MP9/*MYY3B58__%#U>4CZ,=QDZ4>6H!&OJEXET]PW<T6P81IJV?$ G:F&+[ZC
MQ)=*052WQIP<FL?5>D4J30T#&&I4L#HF(X-.ZZI":+@-ITFER(%AE*:JJX?Y
MC,Q-)='JAU]#'Q4 _3[!0XP @O#)V* X7H&6@7>'V=?6BQI&];GC,:&!J;EE
MQ?:I;A9FNB(7,'JU&7H/C\"-9^1G9<CY'B4Z(,++4D0F(I.3^U7D&W<4NJ?-
MX2UE9<,5,-;U>@;-4\,AFY7F_>!UP"Z>:LJ(M$;59PQ+Q"6D*FG816#?/A4F
MG7$BL&[R-*!N*S38(4M8^?KE"':&:)/#(@VNB??\\ &TFH. ^_\D9.&& W/3
M" DMCNAFMK3W0K7.!BE6_A,S!S:_+511KJTS.3B<.KV!T^+9Q8J.)%94VUC1
M\S%MBE6;6S%M.$\=5>A?7CCQ5K-N[".+DLR3150]VA^D!4VEA=WT,HS(.L$W
M<&,]<EAK\!5WJ@P=_.L6*<B.,3]ME+?D??!U05EM.JUX-3(M+'!S!,V9K.Y>
M:I]8?)*:%JFY1] #J]VN*1M+ATZS>/[ME37L(B"'(<,'D_WB!@F]!59G#+>M
M_=PDYLSY 0<FK0B14V''6+W+QU8#,364@E%OF$.6HD.:3+EIK;'QSI;5$=RY
MIDX7.T"02IH#"S_'+;$H3GRK>?+9N6QVNM\)$;)[H8$AVYU.ZZ\+A/GZ[GQK
MMO]J734TI-C'KV=GK:NNT_I'%R'0,FBW#SEPL+/FMP8!AG7:GSYWG7:74,X(
M<!(&:CK=#B*KP6_^^VOG.P*/X;-GK4_PX67GXJ35.FV??W).VYW621<F<=%!
ME#7]5[/3OL*O+[X2(B5AF)TUN_@1S;)]Y30_=5HM FF[8#@W0CQK*G2[DXOS
M;NO+)?PF \/<^_:YA2!RSH<F(J1=G--3'?@)TMZA@7"2%_00_,]%Y_L^EG#,
M+.)><]\Y:76Z[8^(BD;@:^<7&?XF3/2O%BS.)S6[9A>&/V]]1U*R%\#"7L$<
M/C=SR)T-6'?\XXK7A![]UKZ"X>@U5U]A+KG??R/HN_,+(*)]SIAP?]%[/SIG
M[6[[$R'I-9RK5NOON':M\X\7G9,6[_1%I_7I A>56*!#&'!['Q3 6//D[^<7
MW\Y:IY\TC6U&B<.?JBE@Q35\JWD+-Y^01F$KOYXPW!Y2A7L[NV\?OL,:?;G
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MBI/&/;]ZF7_//4\?\]-G9R?/P\<I0KPM<NJ&*M .;[TD17@-AT1-L)Q$%':
MG!V7&HF@B4C5TT2L72JTX N(/-62'$F&7CL)@B\@:J!NY$@ZM*1#BSP_'7*D
MD'BWZ1&UL .$B5JH.3FB%D0M/!>U\ R=:H(O(-)40W+$I;:!2[C@"X@2J!,Y
MXE 3AYK(<WW(D52.>M C(E4;<D2DZD&/X L\67R!5X(O(/@"@B\@^ +;<=Z.
M!5_@":VWX ML=[T%7V#;"R[X FM<\%K=S.E!P1<HQQ<@"('JYV8+57^CH9U[
M?O?+^^;_^^"A?U]PZ*MNI]EM?6J?//@-O[Y9\!5GK?/3]ODG@EK07;Y[S\0U
M)5@+3TH)B/>U%M[7RIR?5POPU2-$(!<#6RB (,"A,/_YX]SC5W!(I]ZUWW_8
M6\Z\$(E_. Z$\^ER+JK#@T$=Z&$^/42Z! 1A\?E^\D(O=@/GTHW34! 01 YV
M@)P=%QF)\8E(B>&V+L,M;X@]&"3KTZ73;C<;SO*H5\+%8B")@21R4"-R=EQD
MQ$ 2D=HI VDWQ61+]M'#7%KM]CV.J?SPR_NE1-9K0MANRGK=S$A=H/(@:5](
MTK]XHQ[:I2)?(E^[0<Z.BZ*8IR)2]31/:P>V( BF(D^U)$?@%C9@ 0N"J:B!
M>I$C@ L"N"#R_'3($:C"W:9'U,(.$"9JH>;DB%H0M?!<U,(S=*H)@JE(4PW)
M$9?:!B[A@F J2J!.Y(A#31QJ(L_U(4=2.>I!CXA4;<@1D:H'/8)@^F013%\+
M@JD@F J"J2"8;L=Y.Q8$TR>TWH)@NMWU%@33;2^X()BN<<%K=3.G!P7!=+$E
M,!6\SMG5F4.P;I_A!S#1Q&E][71.G*O#?_^WX^/7[YSX,!!<SYW9[.-?FPVG
M%TT"[]:-!S#"U V<LX/CUZ__D W:A0TZF_ST1K!!\77#^022-W!.)_V;J1,-
MG>PKV:I=V*K.X<GAE;4KSOD$RY'?.A^.?_WC^/4;V:5=V"6)*TA<0>(*NT&/
MB)0DB"Y/CDH!3?W0:?5_>('(B<C)SI,CJ9\;2!<3'2 ZH$;D2.;GW,Q/0985
M*:X!.5(IN=OTB%K8 <)$+=2<'%$+HA:>BUIX@OZQCT$4N\Y?7AQ[_?Z-[XJL
MB*SL/#GB(UL[":('1 _4CASQDXF?3*1XU\F19(MZT",B51MR1*3J08_413_9
MNN@W4A<M==%2%RUUT1MD ^O!L=1%/Z'UEKKH[:ZWU$5O>\&E+GJ-"UZKFSD]
M*'71N27XY?U%\^_=3JO%Y<]?ST^=T]99\UNSTW(^7YR=ML\_77$==,/A#L"]
M9^*86>NFRFH]M@B([[$6OL?*1)97"_#5(T3=#'B$/_2<J[[OA7T8[,P+\;T,
M)_'I4JM.X2GI,K[ ?#]YH1>[@7/IQFDHH5*1@QT@9\=%1N(Z(E)BKJS)7''.
MTH%8*V*MB+4BJE6LE1TC342J#H3MIDBM7B7T*,;*B3OV4SAA.'5XY(5IT:$B
M<E$3PG93+NIF<DES,1& G2%GQV5%;"T1J7K:6CM7D?W%3=,;^/E5ZMW!95]$
M141EY\F1@NRUDR!J0-1 W<B1>NRY]=B^=*P6>:X3.0)5MMOTB%K8 <)$+=2<
M'%$+HA:>BUIXDOZR>.I\<H/ O0ZF(B@B*#M/CGC+-G"_%B4@2J!.Y(BO3'QE
M(L_U(4<2,.I!CXA4;<@1D:H'/8)B^&11#'\5%$-!,1040T$QW" ;6 ^.!<7P
M":VWH!AN=[V/YUK LMJRVCNZVK6ZD].#@E^XV!+\\OY_G ]1E*3.9W@.G;9G
M9R>"7BCHA;44 /$YBL_1)NV);=5\BV:7B!&!JDU6F!*2G4L+:]Z,O(%S[B;P
MO-,,#IJ]P22XOG%#7V1&9&:WR7D""6)O=FG^H@M$%]25G)KDB=4#G$<$^+$)
M$P&N.3GUD:$G18SDX-1C&O5-!?I-4H%JFPI4N>6ED1W^'6[-3*#GE_=7_1L/
M;D>>TS1AG-7G6/JN>9,F%L6?*3Z]G,3]&Q<&3G9E1L]+.?PNRJ&6RF%E-C<\
M\&<O?O\QBD=.-'2NO"# 6.]5&O5_W,"07NS\S\1+D(#0A9L9/ORA??&/D]:9
MT_W<ZC0O6U^[[9.KAM,^/SE<HPC/DD*?^"'(("?XB02S!/\A$EQ;"5Z)R^=U
MI6R&H??3::_YI-_8="\#-T3]<^HG:>SW)KC<6;))747S^.5617-5.;R-_,%]
M8OBB%PVF\)^;=!2\_[]02P,$%     @ $85V6*B##E<]%P  G*$  !@   !B
M=&%I+3(P,C,Q,C,Q>&5X.3=D,2YH=&WM77USVS;2_RIXW.E=/*-7VVE3.\V,
M8RM7SR66QU:NS9\0"4EH*)('@E;43__L+@ 2I&193AQ+[JDSC26*!/&R^]M7
M+%[_7[/9BR<\#D3(?AM\>,_"),BG(M8L4()KN#J3>L(&29KRF'T02LDH8F^5
M#,>"L6ZG];+5/3AH=9K--Z^AK3/[4!(?L\/VP4'[H'-PQ#JOC@^[QYTC=O6!
MO?@X.-NGN\_[9X-/5SWSVJN/;]]?G+&]9KO]^^%9NWT^.#<_'+4Z7390/,ZD
MEDG,HW:[=[G']B9:I\?M]FPV:\T.6XD:MP?7[8F>1D?M*$DRT0IUN/?F-5Z!
M?P4/W[R>"LU9,.$J$_K7O8^#=\U7<(>6.A)O7K?=7W/O, GG;UZ'\I9E>AZ)
M7_>F7(UEW-1)>GS82?4)/-F&GVOW?&G.9*@GQ]U.Y\>3E(>AC,?-2(ST\<O6
MJU?E)27'D^):8H9VK$3$M;P5V+;7:A )KHZ'B9Z<U%^P[,G4/3=*8MT<\:F,
MYL?_',BIR-BEF+'K9,KC?S;,%?B;"25'_SRANS/YEX"F87A:?-%-'LDQ-(Y]
M/3'C/X;?&/[?/3 ?\(W#RAM-&_"S:7(F:*C#) KAWMZ7B1Q*S7[YN=5]W1["
M'*;?H<<!T*]0C]3EMQ?]/\YZ[]G@M][UZ57OX^#B[*;!+B[/6L]D %=]X*Q/
M[%W_FEWWSOK_Z5U_8OUWK'=]W;_L]3_>O/_$3G\_O3[OG;.S_H>KWN7-Z>"B
M?_G]1O=GGFDYFIM+,@YAL,>'/Z4K:0Q;NV/(L$0R^2,0$1M,A.*IR+4,,EBB
M.&BQ%WHBV.LV/K*DD<I@8"PTE*N;#X-*]\U+_O'#JX.#SLF=;=76@'XZEAJ&
M'"Q;E;-D"H@Z?[RN==?IVMZ;?3;A&>-ADB).ZXG,V%4"?9RS4:+8M0B26Z'F
M+!FQGE))+)(\B^;L=,95"/=CKT6<<42=[9U;,Z"GG]H&$Z.1"!")&4PRS&$_
MT,E0*';08" )#[=WRGI%Q\]!@#_]U+78/W[H_M0Y.>,I=?(O)$ZAIAG+,_@H
MXPJI#G/-XD0SD(E"S60F6"A&,H8;X;N F[DJ+\'7&QP;4&RWVW+=0633?!@)
M-DR M-6O>YT]!B 261%=?,]2'MCO\(2"_T,W#. 4@!H>65PC/ ,%X60VD5HT
M\4%Q'"<SP*03([4)Y>P+CBVR/0Z\6O4$M 2=3,VL>AK+PX5&MY1N;1WZ@WX&
MW:>%" '*% %5,TBB1!W_T*'_%GZ-@$J.<Q!#"C\M_&PX)P/"(V@1*DOBC-WD
MPS^!J)A.F$,;?[K:2"AMHJ_G($ ''F]E$PX:/D]3@'T879 KA>8 CT.4$%,
ML_YH) .8!P0XQ#,KRAP+]W@P<??8UH:"*?'?7"KDZH1E, AHD/'@,[!'),(Q
M61Q\K(2@3VFNLIS'-+W 3-!>EGN-SM &H;OQAB&R,*P?&\ZI.P8VDE&#^AQ
MYV D:,4T? PY89-D)H"#\;:Y:_JAP-=\"_1V)_IU?UX/_3(VXC+*E? F9VZ&
M?.<4F8E%$(S%&"";AHZK!H!$6$>+4RXKM(QWV'%68/ Q6?A>V@MEED9\?BQC
MY+;F,$J"SQ5"QF<\M%S@^Z_I7TT,QD#'/%H&>P<6]LSD; /@5#2NNU'G66,,
M:.K0/"@?S;<\JVN92@0"?D*? @,-E8^ OXF4JRI+B[V#7P$XP"@668WZ&_1
MB&P"K1A$6?E2>/*)M;2]-VZ@3ZY\E2 ="@1/TIJ(/FG:3@VHH*JT5G/7>23
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M,2YX<V102P$"% ,4    "  1A798R.FU0*D/   .YP  %0
M@ &U$P  8G1A:2TR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ $85V6.H#
MC+!?.   .[@# !4              ( !D2,  &)T86DM,C R,S$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( !&%=ECD3M1W#7\  /"7"  5              "
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M,2YJ<&=02P$"% ,4    "  1A798__EPYL#S   /2 $ &
M@ %J:@< 8G1A:2TR,#(S,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ $85V
M6#R9N+!?ZP  SAT! !@              ( !8%X( &)T86DM,C R,S$R,S%X
M,3!K,# S+FIP9U!+ 0(4 Q0    ( !&%=EBKUPHDU-@  #?T   8
M      "  ?5)"0!B=&%I+3(P,C,Q,C,Q>#$P:S P-"YJ<&=02P$"% ,4
M"  1A798X9GN4+,! 0!T)0$ &               @ '_(@H 8G1A:2TR,#(S
M,3(S,7@Q,&LP,#4N:G!G4$L! A0#%     @ $85V6*+*H6,32P$ #H4! !@
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M,"YJ<&=02P$"% ,4    "  1A798#4]&\!!E   ]EP4 &@
M@ $2(A$ 8G1A:2TR,#(S,3(S,7AE>#$P9#(R-"YH=&U02P$"% ,4    "  1
MA798C_#)9#8"   .!0  &               @ %:AQ$ 8G1A:2TR,#(S,3(S
M,7AE>#(Q9#$N:'1M4$L! A0#%     @ $85V6-(_#;;<!   ]Q,  !@
M         ( !QHD1 &)T86DM,C R,S$R,S%X97@R,V0Q+FAT;5!+ 0(4 Q0
M   ( !&%=EBW?EB&L D  #1E   8              "  =B.$0!B=&%I+3(P
M,C,Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    "  1A798*Z'K3A8*  !U>P
M&               @ &^F!$ 8G1A:2TR,#(S,3(S,7AE>#,Q9#(N:'1M4$L!
M A0#%     @ $85V6&:\K;3[!0  :2L  !@              ( !"J,1 &)T
M86DM,C R,S$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    ( !&%=E@D\6)YXP4
M +TG   8              "  3NI$0!B=&%I+3(P,C,Q,C,Q>&5X,S)D,BYH
M=&U02P$"% ,4    "  1A798S=W4FML0  !L/P  %P              @ %4
MKQ$ 8G1A:2TR,#(S,3(S,7AE>#1D,2YH=&U02P$"% ,4    "  1A798)+\L
ML_@Y  "!-P$ %P              @ %DP!$ 8G1A:2TR,#(S,3(S,7AE>#1D
M-2YH=&U02P$"% ,4    "  1A798!C5KY_5C  !I=08 %P
M@ &1^A$ 8G1A:2TR,#(S,3(S,7AE>#1D-BYH=&U02P$"% ,4    "  1A798
MJ(,.5ST7  "<H0  &               @ &[7A( 8G1A:2TR,#(S,3(S,7AE
?>#DW9#$N:'1M4$L%!@     ; !L 2P<  "YV$@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>btai-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:btai="http://www.bioxceltherapeutics.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="btai-20231231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_xk0Q89gawUCTwiTOaOpAWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_PntQCMUJZkeGnizT8u1Fug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xHeZV4Ol5U-qHZKumtzK4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_x7P2HSC51kqvtDIeyiG1VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e3G2VXdksEeqw2aI3K5qYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eqYihjzZTUmciy86aDfMcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAiZHn3hQE6KSYUOLwW1Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yGTb9URg5keSwgCiIyKD1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_spu6vwv6wkeAKS8ZgaBZyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PRtGyQfymEacLjG_UJArXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2022_GlNf8HOiWUu7zXkTvkFBsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ZWLEjeNqVUifL0AxwuMoJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_kttjLkP_lUGbpgLUyc0SDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_EzEfX9_flUy4assVwEUnZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:StockPlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_u28NxTusVku5UX5Tspxcdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_QZPms-_JDE62jRgrcbtUIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-20</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_SZqxVW5oU0abbZ9IElW9dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Y1r3H-NssUGDKP2nkYl0gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_Y3C2KLUibEGjwn_Zo1eoew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v-MW3gW6_0OhWwhL83cZBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OTZS4zpsIUmXN4c6tbKJVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bVD8ivCGrESTiF07tgD9xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pKAAtUPo1Ey3Co1MIzsM-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WnuQlcoII0qSBZBbrHkrEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_h6CnSCl4dECh1YLUxQk6ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_p2sWFHswF0-DPdbaZVQ8aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p3_hhWFiREeo8nnIsabskA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5JKcWlgs30ac0qBkTIeQIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_UWn9MaHj40m9ggi57C5_7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IX6hI-H8FE6Sxk8kEK1KPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_VRCkfH11u0yQPf850NGkwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_us-gaap_GranteeStatusAxis_srt_ExecutiveOfficerMember_7KyW7kaoLEujFskhyoTCJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0uPjNo82rUCxuxmCApfRtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_LFEwrHLb3k630YwocgejDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENmMDZVWL0Sj71YGtPStYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_8_2023_To_8_8_2023_3YScg74_R0ConxpN-Oxzqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DPrRJZyMuUC3HpIpzHgSwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_qZV9TJRkVkSO1q1Z2RQAKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_dxjhG7eFUUSaXMpZC0s-aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lfv86wIfO0uGyrJUEO6W4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Q0FkyLMLpE6C08_6RQv7GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-GBUxd3EAE6_mzgWpsJOzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_hB0HP0jhXkSZURCC-uucwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ALKhxrCkjkOwdbr4SCwncA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_Vc2MKw-dukuwAowcKM-VEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GDQlj4QAs0O-w3hPNOGBnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_j_3iRADS3U-7NdeM4T4eaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_W29nsD5d7kyN70aN7TzDxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1XLHPADP90S8ZwGclsNpbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aNHYV9yCoUm00_-U0XfV2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_C6w_xNcT_EqUj9i8wEs-yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_CBA1W1BLL0GwUTYi-6y_ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vn8IA3nckU24niIfjblXlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Pe0_O6hXxUaHjPzlWLuThQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_7EMAZ25l10i2MUh_SEohkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_yu4AYaDZ_Ue7i6ZZWzIm3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_W2i9WK1SZUeMOgcqPDEO-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AXJr0CJxhEq-UxVe_rzlPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_owHhLehS_EmtWcsJidsnPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FwZJLNhx_0moyuSOcfdYXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V-ADkks9QE-9-kuUtA7EMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_huSrkOX7SUmY8-_tuWQFpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_RWFw3r1oWUC3XL39vHaqqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_7_8_2022_To_7_8_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_V64yF2oxIU6GdMLQcz2BkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-08</startDate>
            <endDate>2022-07-08</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2023Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SiWlKh8skUWL3uCUhIDNLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">btai:ShareBasedPaymentArrangementGrantDate2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2022Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9upi1ce5e0qUxLvJvKR5mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">btai:ShareBasedPaymentArrangementGrantDate2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_a1Cs0RhSBUWu9ebIk9a4Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uLG7LMwfw0CKpBUSpaBN1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CZOqcLp0PUKVcyA1bGHQyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_n9fLqTrqZkCK8GBCnlZSGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_NC_OkAZruUWuB05QvPr4mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_A6wlGoCQXEKa2GVlvoBZ6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mA8YOGT8Mk-UH8QN9ncEhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_zrIRZIK4QUyE2BqXAHd39w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGhzkv0Pn0-_E2xmVYozig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_EiQqzjUCAki7PrEDtNqD5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_nhdn74qyc0WhUslR4qua3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_UWym6eYkO0i2Db4epU9hOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember__t5_rrWTAkSvW4vx2R3MKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputProbabilityOfExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_l5-tles4rk6AJ38rbZ5qDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btai:MeasurementInputEstimatedPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2iBcLPYPak63zB2SGjujoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZjevHEcIPEOgTS172gTu_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wGIdAt1pk0uCvgXve4GiLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tz8ZkPV9rEagiQzVm1c8XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_7PDK9HAQOUe7s0Ry8BL5WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7hC-g0hRVUyUylsJ4F6ZoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnJ5CJh_wUO7oAOB1qWnWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VGlEMLwpK0G_B3i2obOKVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Wce1URlIPE-m9fYpV9zeJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BBwsCn9q10ez32Xp3IZYGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_If0SwRWVoEKPCeiBpygDpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_S6sTUJ5nc0O-S3nh1hH-8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__Ry2HIqDsUKb1qJ9uR4b3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:EquityInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z8wGFoFQHkGh9pMeSDi2Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_PfOMnn2r6Em4dZ9LbC_GWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_73tBnm99SkWJuAHEaVzHcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_lqY8_zjpaE6CKAXuo279Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_wzC_0CZ3tUyxRyd-2zvgHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_N1udVxFwqUa9M9O90JMIFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:TrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_v1M2BA7xuUyhRRqLClhhMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_h7P1Xd1OZUajABk9uxWk4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_gIbrrmF-LU2BVh3G5muq_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jfJvbh6zN0ezSU9wjtHC3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cC-JtWvLskOqp8xXQ1r_1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_LxCPLzm9okOLdFn3Z8l8lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_GpdoISruzku_097J5reooA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Z17gbjnh30i21j6FjyTHjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_r3W4hkyAb0-K4kHx7gA8ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jlMfMWAUtUG3OTUw8vN1rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LO90L5PoDEivpd5VLIVaEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_o3kSuLNg7k-AKoYTLeldyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YNOnCMIhzk-zL6WUrMzXvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_9h1xuVneFkulBXYqApNPsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:RestrictedStockUnitsOnkosxcelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember_uCqLAxkpTUCf_97fB1ROog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_Hr72ObP9Ykyp9_0xmJWLlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_T5Zf7K9_uEKO9VCroUlqcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:MatthewWileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_8dg2ROr62EmFMKrYPCbbVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_YXURVutUlkePgjsTcxszAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:VimalMehtaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:RichardSteinhartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:MatthewWileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:JavierRodriguezMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">btai:FrankYoccaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_8OBjMItu10CBEHoI7-kTZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2024_SyzKieY9dk2q39Ecc0mTCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2024-03-18</instant>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_bpv_lNdtNUaJOmv6QXYrHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:IncentiveAwardPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btai:TimeBasedProfitSharingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_qQIgqhjIAU-25A9Enh5x8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_CyJ8S634XkOrnMXvZQo-Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">btai:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_os9ZcTj60EKmwN-8QTANZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:Warrants2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_fZkIV0wemUSj8D-mDkwN0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:WarrantOaktreeAndQiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_qDjBignJyUitVErr7JersQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btai:OnkosxcelWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cSh0m3wu4kefKlStrPWJ1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_UZzwa5c1w0eu9CL07OEeQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_V8-C-RxYK0aXAjUC8xvmzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:FromAndAfterFundingOfTrancheBLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cxmDc-hxWEiaxO1wwjZa8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eky2EVddxU2Zk8lYvRBFDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QEq2Y_AI2EClDFuZWnDU8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KN9Fx05BHkKau-z8hNvRxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1kRdDymbCUqa9XieGI09Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="As_Of_12_4_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qN1X0eAfCkKStJDFYn04Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-04</instant>
        </period>
    </context>
    <context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fDwcE2NcAkalD934EMLcKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ORjQlGmsX0GTKU-h12WP4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-12</instant>
        </period>
    </context>
    <context id="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_Ku-HMoUhaECwUSnCUZw31A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_NXCCj7glw0uPyaR6Y2-w9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-13</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btai:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_anIgAQjD802S5HzYHrjq2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_wzQDKTToGUu0fupDsFLSUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i38r8XQuQEOi9Le4Y7r8lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">btai:PeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5UeYbgXGDEaW_6Z1qh8tGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:OfaAdministrativeAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember__S0J6TAmqEaBUKJsiY7Iag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_mAbI1B8ghUiyZZyzM0aMpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btai:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_dIkd-uFGvk-VmaG81kxPvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_oxNFZAw51EWZ3rfLAxMbLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btai:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-19</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_TCiII9VhN0SRNqnqQ9rjQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3yVQCurUjku_rn_lePc8vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">btai:BioxcelCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_LbKlmh1ElU2MfLJqOKFfxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_KcpdD2ZAMkKgL8-kiMrvzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg">
        <measure>btai:Y</measure>
    </unit>
    <unit id="Unit_Standard_segment_laXuDs1PtUqwsUSCfciCQA">
        <measure>btai:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      id="Hidden_eEl5TI-KZ0u2kjJRlD2BZw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      id="Hidden_xLbLaHMg2E6Pe0qsTwBCpw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      id="Hidden_XzcQek6kG0WjzoawbI-6aQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      id="Hidden_3ul1BO7V2EW5KZOaIYDk9A"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_BOF4tdKyO0uDQDNLs_0REg_2_1">0001720893</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_HMREsrWRUEih8oPX7ygMhw_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_4Tn2MUuckEuCacWAje5ueQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_PhAM4NFw1EKSkpK3apW7lA_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Hidden_5tpEl_7wWkyfmmgg0VxDAA"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">28147000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Hidden_PcWL0v_iXEK7OCLk66t6LA"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">29930000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Hidden_UzDBOVFgC0-CcCS6Fm3vVA"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Hidden_eRKTMJzlkkWDdufIKYHGfw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z8wGFoFQHkGh9pMeSDi2Ig"
      id="Hidden_lFagk5bTnEemlWdu4CgnkQ">http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      id="Hidden_YDje09iS6UufW2YFrYa5Ng">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENmMDZVWL0Sj71YGtPStYQ"
      id="Hidden_ENbZ6Viv9kSPsLzsnlVWSQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_9AF_nI_kpEmTFIV3GDpKmg">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_XzYZCzNrVECtMEFKpSJM1w_2_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_9OukaXrcu0u0Ps_2SPbKNA">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_8y4GVhwqwUqLmUcOZuPJ4w">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_eF03MWIreEWAyjIi2guLAw_5_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_VvertoLWQUyDJRtP43_iYA">001-38410</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_WPHkWBYVU0ebAuUNRGcwqQ">BioXcel Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_hKfX9qhyr0qvcrhiBfcpbg">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_Z8owcyIXSEyFVugQyJeZTw">82-1386754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_S8apThuCr0COIWpHBl8fpg">555 Long Wharf Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_8H5nHoSTO0WEfIduOAEoRw">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_OV6hfyUWvUmzyG5kIZhi2g">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_1NxXmi-I2UWlqQUmQmk_kg">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_y4Hv24AVPk6qfFhu32Zb8Q">475</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_CwU2jlhVjUWva0qPb541Ng">238-6837</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_MvInt1AU7ESBEjPEAfTJaA">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tc_69bD9rcA8UaaqgZaA3qzXA_2_1">BTAI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_7ya4PzZ5gEu5BOMgseq77g">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_NrAO8lkudEyJU2pFNFBiFA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_WnIM-cjaI0egUynFRbgfYA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_fWjLgQao-UCfEmLC5NCc6A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_fFV1iEc_xEKOad_ZacOf1Q">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_l3wJMGfwtECT5zAnSA2x3w">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_jxsg_BGdREeJu6d2cayLBg">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_uEUQQda_b0uGk1yw4XLsgg">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_60MFf6XUhU2g2EU42pu_KQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_PoE8soLhIkGejdIr_uQI9A">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_IFB5_FMcE0uLcn_fe3Hc4Q">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_8OBjMItu10CBEHoI7-kTZQ"
      decimals="0"
      id="Narr_RAiKlHS22kyLMA6a-t1_kw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">134938946</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_18_2024_SyzKieY9dk2q39Ecc0mTCg"
      decimals="INF"
      id="Narr_ydwpwXlsLUCZop-aQKNLcw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">30576671</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_ilUlPJ4wHkyKT7HW5pli-w">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_ktC_J4tAaEmr6CnAq-Ah8g">42</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_Xqki8CskQEWjGqWN2NkT1Q">Stamford, Connecticut</dei:AuditorLocation>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw"
      id="Tb_VfXAGLu4fUqQYeyeGuXIig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(b)&lt;/span&gt;&lt;/span&gt;On December 14, 2023, Vimal Mehta, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 34,938 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw"
      id="Narr_YHrK3BKvE06-QuOA9uXysA">December 14, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw"
      id="Narr_8qvmH6yYNECXr7zTax0ROw">Vimal Mehta</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw"
      id="Narr_U35vWvwAQUGpBXHv5ycM7g">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember__ZmkFluzUUWd28K5uqLjSw"
      id="Narr_f01ikmy5IkirkTGoiPbppg">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_VimalMehtaMember_uCqLAxkpTUCf_97fB1ROog"
      decimals="-3"
      id="Narr_Ft2kftlgr0-wl29niVLm3g"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">34938000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg"
      id="Tb_T9C6dk96bkuwZda1PrS6Dg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 14, 2023, Richard Steinhart, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg"
      id="Narr_ZX7JBV7vYUygloNSJX4mZQ">December 14, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg"
      id="Narr_6201VV_hLE6-BvEI2-AZjQ">Richard Steinhart</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg"
      id="Narr_jDbXazBPU0GCmAHHg7QbEg">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_itlbV4OkuEioyXu3RG82qg"
      id="Narr_nlKlIO2sakyTYefX-ojTtw">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_RichardSteinhartMember_Hr72ObP9Ykyp9_0xmJWLlQ"
      decimals="-3"
      id="Narr_TKpsvkjIdkm91P8kvV86sw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">25000000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA"
      id="Tb_mu3dFPpFNkqdVq-o59ZOzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 14, 2023, Javier Rodriguez, Senior Vice President, Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA"
      id="Narr_0M8yeF5X-Eaf-_oNGyG_1w">December 14, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA"
      id="Narr_men-ZErc10ea9-Upt7MrfQ">Javier Rodriguez</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA"
      id="Narr_SmlDUse_BEmJvakDXKe-1Q">Senior Vice President, Chief Legal Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_Ow8Zuz4wRkOuj6DcigOUFA"
      id="Narr_mL7z2qYhckO-yK8XCtgTXg">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_JavierRodriguezMember_8dg2ROr62EmFMKrYPCbbVA"
      decimals="-3"
      id="Narr_nOo901_WdUKEy33vSulg4g"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">25000000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA"
      id="Tb_FgWliStOX06G9Qb_7Gd1xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 14, 2023, Matthew Wiley, Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA"
      id="Narr_UcB2-RHmkU2p3gWJK2esQQ">December 14, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA"
      id="Narr_1_-kR_cqk0eSBQcR7tde3g">Matthew Wiley</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA"
      id="Narr_r8-oygCvek2eA5azu8I13Q">Chief Commercial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_pA8I39tdLUinP8SmPPV6RA"
      id="Narr_-iTaaN23C0et7x6CLp8Ypg">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_MatthewWileyMember_T5Zf7K9_uEKO9VCroUlqcA"
      decimals="-3"
      id="Narr_TZAQ28iChU6rKCSiFLlORQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">25000000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw"
      id="Tb_l5xTBQA5W0yeideFlK2PKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 14, 2023, Frank Yocca, Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#x2019;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw"
      id="Narr_1MC3K9NXwk6iz4YklCFnHA">December 14, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw"
      id="Narr_Js7E5LJcwU-YkIqUTaCR2g">Frank Yocca</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw"
      id="Narr_3hVNNx1upkKtAqVssCW77w">Chief Scientific Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_nkkVkTbgSk-lwWVif4MCDw"
      id="Narr_sVCEegUkkUOluhsOXXhUCg">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2023_ecd_IndividualAxis_btai_FrankYoccaMember_YXURVutUlkePgjsTcxszAg"
      decimals="-3"
      id="Narr_ExcRMVZ3sk-NMDuhn91qyQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">25000000</ecd:TrdArrSecuritiesAggAvailAmt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_BWRZZSWKiUSodaymszfN7A_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">65221000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_9-4ztyealEGYxAN6ECyftQ_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">193725000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_BSEqc0KIokWFUBfAQfZiwA_8_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">71000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_toAFGZF9B0WWI1IoGRsCiw_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">248000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_USKiHEOw60Ke6JIwDSAZ2A_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1991000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_4aVzCLM1ckSq3hV9GuaI8w_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1985000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_sDSUIATHn02SxkHWz9VEUQ_10_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2782000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_8MyJa5zFzki1ypXVCvfexw_10_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3067000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_oTrTvvjoYkue4w7nSo66DA_11_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2078000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_Z58MBupPqEChzb8f_ggpRw_11_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3843000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_qWsZsiIop0qplBAjVP8T5g_12_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">72143000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_pzgq8Sr8i0qg7JYmkDPOWw_12_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">202868000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_R8S2z5a7kkKEkaP6h-APkQ_13_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">784000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_kDsn7xx_q02oFVyVAOzfwQ_13_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1084000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_KSoxuDYmXU-vQpW2Wdi4Eg_14_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">688000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_oKQMKhlNHUKBWjTMT837ZA_14_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">976000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_mNqVsKIvo0-CCezeNEK96A_15_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">87000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_Aj4APlFLMkKJmTi_oW-zkQ_15_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">925000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_7bf_Fu7m1kmaCOmTPF3rEw_16_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">73702000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_IUu7iYkHoEqXJXn8nqe3rw_16_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">205853000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_LEHIBspiZUiriEbV56kZFQ_20_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">13654000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_0e7DBqYjWkqE6S3VDmKdkg_20_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">10228000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_AXLEqQ08xk-4w7tPNoDX2g_21_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">12424000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_LEdyF7D6TEOtDnW1Z1bOSg_21_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18669000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_C6w_xNcT_EqUj9i8wEs-yw"
      decimals="-3"
      id="Tc_4BfkSwOS1UKCdXd0Uu8e6w_22_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">107000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Pe0_O6hXxUaHjPzlWLuThQ"
      decimals="-3"
      id="Tc_DKNDgyvb5EuZWE2R7HUeSA_22_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">422000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_lJdbgksAgEOKAdDX_9_lnw_23_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">736000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_q1Hw8sn_XkKvItBN6V2K7Q_23_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3175000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_CBA1W1BLL0GwUTYi-6y_ZQ"
      decimals="-3"
      id="Tc_TclyUhmkbEeZyhqEt8xVsg_24_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">346000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_NonrelatedPartyMember_7EMAZ25l10i2MUh_SEohkQ"
      decimals="-3"
      id="Tc_8R0yjgi_DUWqVeNEgrmxXg_24_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">404000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_UN0aovcI_k2vysuvf8OeGw_25_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">27267000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_XTF4oh1MmUmWRNbj4s_9bg_25_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">32898000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_MVSzAd3gp0yOb2MFz7McUg_26_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">440000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_-MnQ0qdqxUmJMGtAhZB-dg_26_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">786000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_ugLEkdhASke76Lci9zVkfA_27_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1905000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_vHDEcrnxeU2fZDSLPr5lbA_27_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2343000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_ab-XteufdUa8E9pPKNcJHw_28_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">100598000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_HGCqGt0sz0GOthtJecydvw_28_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">93051000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_MGjf_cIdmU2TtIjT-JBNMw_29_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">130210000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_xr0rpPCYzkirEfnV-j5nJg_29_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">129078000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="INF"
      id="Narr_9wbbroIKd0CkXLx0jZmnoQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="INF"
      id="Narr_FTWH6w-eKkW0iuUTB-4nAQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_YS90i04BYkqGvsAyfROFEg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_TKiWECNySkm9jCZsl5BmmQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_3JAuSjMDVkqYEEVZhWEG6w"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_AQcR-ScKTEG-XznGjPYJHg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="INF"
      id="Narr_iVA5A_CXbEKYkrg-5XpIcQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="INF"
      id="Narr_C-8GCiBrjUqFKoHpp8NkDQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_iritMafr6k64OvPvDDp2pQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_n8cDIHR9w0Opl8azfGjkqQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_T8U_SKX90EKtdO3SWnd2Og"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">29930000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_JU0knSwYAUWohhAs4NDUQg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">28147000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_Xn-0_zITWkuYPYIn0UVNHg_34_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_uGkKO9mS6EqHMyRkMl3cAQ_34_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_Fls-goDxLUekNu_gd2_Sig_35_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">534060000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_9UipIyQMWEuA57xrBqnTHg_35_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">488292000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_CQZNugyA1kWIgdGsHAPSig_36_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-590598000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_jfWhj9fEsUi80yIOK5oh-g_36_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-411545000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc__dkoaZ3A1U2X8JlSoS_1lw_37_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-56508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_fT8giltOuUGT-wWF6eqChA_37_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">76775000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_7cV0BNllpkajEp75s-uzjw_38_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">73702000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_E1V_8opXDUKbw-DqNcLgnA_38_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">205853000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_KEg05O2E-EW_VmHlGrcPFQ_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc__rYiyt-BAUOtUntV31trlg_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_6kK3VKWBE0uvzrtoN5Jv-w_8_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1260000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_uYDksjD5pEOTFqCd0eStug_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_LNdVDfPITUK1T0kwe_lARA_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">84326000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_2atI2YnDR0G5wDWwpHTDtg_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">91239000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_R9FCX9vrQU6SP-K-Zu9CCw_10_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">83413000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_6CyaYeg4xkmDlE2wp1JGOA_10_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">68761000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_EPYUHURmO0KAkRV8xQ9l7w_11_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">4163000</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_nUkMDuIApEuUt5jKsYX48Q_12_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">173162000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_PbUfZFw8I0iuAY5vW3zwAw_12_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">160020000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_IcDP2pFH-kSy18WiDkF3Nw_13_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-171782000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_VbAgf_1dp02RFA02N_2Jqg_13_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-159645000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_-0lqJXKDn0mH5K1WdFem8g_15_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">13314000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_dQtVAU06fEq7UZOq-XWEwA_15_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">8213000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_3sn8jG-kWEG-2IvOwwzSoA_16_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">5649000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_Ytt_XHcej0eZvn8oXpcGNA_16_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2528000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_R4XuOWfWEkuH89JITIhOJg_17_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">394000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_QgOQwsh4DEy1zORXlRiDMA_17_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-427000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_ncNFrmsnMUqwC0SN-DMWFw_18_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_uHE_pEjmHkSCdK1H6PZvPg_18_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-165757000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="2"
      id="Tc_0KkHPx86O0a2v5bmBcxgJg_19_3"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">-6.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="2"
      id="Tc_WpN0nRgEEEmPmbuu-YIjPw_19_6"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">-5.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_x72pgrQvj0W9umNboJie5w_20_3"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">29129000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_m9JXwXesPE2GcUrF7Zc_Ow_20_6"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">28015000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A"
      decimals="-3"
      id="Tc_Rr1KiZZB10G0VGZqnI--tw_4_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">27980000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dvNH-5hXL06f_dj9csC73A"
      decimals="-3"
      id="Tc_tRuZX6gMx0-1NLonU-djOQ_4_5"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PRtGyQfymEacLjG_UJArXA"
      decimals="-3"
      id="Tc_Q4aB0H5MpUafRf3qFVn2gA_4_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">467427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_spu6vwv6wkeAKS8ZgaBZyw"
      decimals="-3"
      id="Tc_buc0tJiJpkiL85MQ8VDT7g_4_11"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-245788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA"
      decimals="-3"
      id="Tc_CQTBE1Z7m0Ci3wZsN3ibXQ_4_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">221667000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg"
      decimals="-3"
      id="Tc_U39kaL-MCEawWm0fyoIohA_5_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3245000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_-jO94JcmBUqaZ_fKd7Nacw_5_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3245000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg"
      decimals="-3"
      id="Tc_89R80t4SEkavA56gt5nCCg_6_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">17337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_clZm2OUdu0SLYghBVaGWNQ_6_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">17337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xHeZV4Ol5U-qHZKumtzK4g"
      decimals="-3"
      id="Tc_XXNs-VVhcUqJUiBV4d8JOQ_7_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">167000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PxmGkj-hdEWBZz0RKrKPAg"
      decimals="-3"
      id="Tc_IwbtiSEubUq0Wi_gQLOyzg_7_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">283000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_3RK091sZ9E--qw2PA-nk6g_7_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">283000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_owHhLehS_EmtWcsJidsnPw"
      decimals="-3"
      id="Tc_e7CkU6UcHE2n6yrrT9w02w_8_11"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-165757000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_6wD_IVna-Euboph0fagwtA_8_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-165757000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cC-JtWvLskOqp8xXQ1r_1g"
      decimals="-3"
      id="Tc_P2a29rXiS0iZUzeeGbVLcw_9_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">28147000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cC-JtWvLskOqp8xXQ1r_1g"
      decimals="-3"
      id="Tc_VlKp70YIZk-EOH8sLaAlSg_9_5"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yGTb9URg5keSwgCiIyKD1g"
      decimals="-3"
      id="Tc_VXN7QOeSVE2gFU7q-VXg0g_9_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">488292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAiZHn3hQE6KSYUOLwW1Cg"
      decimals="-3"
      id="Tc_zyfwKfwOW06zsy9Uax4O6Q_9_11"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-411545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_xigK2I-_YUSO1UzwmYgfEg_9_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">76775000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ"
      decimals="-3"
      id="Tc_Cwr2BVq4GEKFrDfdkeVdMw_10_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1408000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ"
      decimals="-3"
      id="Tc_kdiJvqkeLUWJqcfi9FUmlQ_10_5"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"
      decimals="-3"
      id="Tc_Nau4QcAQL0y5M1HcYm8CYw_10_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">26219000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_k3XxPJNmk0-KCTaRsovLig_10_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">26221000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"
      decimals="-3"
      id="Tc_rFAmHJwXAk2oin-B6Ydynw_11_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18614000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_x6icEqzX6kKZYV3KxkN64A_11_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18614000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ"
      decimals="-3"
      id="Tc_G22iAp9NtEKUYVpPs-dgYA_12_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">310000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"
      decimals="-3"
      id="Tc_yzAE5CZ3GUi0h2u-Q9vpjA_12_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">508000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_miUft1IZv0adbACxcgJRlA_12_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">508000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"
      decimals="-3"
      id="Tc_oBIwLqshGUOOxxVQwFue0Q_13_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_Nis9jd-orEalM-2fsBsQmQ_13_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"
      decimals="-3"
      id="Tc_onKqFmI6H0yKjaNQpptiKw_14_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_PYFABgDBuUKnU1UaYo5VPQ_14_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_R0zX5i6B_UyhROJ95QLRdQ"
      decimals="-3"
      id="Tc_FxY3F_W7IE6SY8hfblYxcQ_15_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">65000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_u36aOL2mx0mffmieXOZhsQ"
      decimals="-3"
      id="Tc_i3r0Uhg0U0mmOZpTkMthzA_15_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-27000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_9jSczZuYr021VM2slz4q2Q_15_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-27000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AXJr0CJxhEq-UxVe_rzlPQ"
      decimals="-3"
      id="Tc_aq_pv4kmJEuyujJkjInk_Q_16_11"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_Y0qojS7eSU2-aqnFoHLpgw_16_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jfJvbh6zN0ezSU9wjtHC3g"
      decimals="-3"
      id="Tc_XkrXVri52kGSMdyu1Z7xaA_17_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">29930000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jfJvbh6zN0ezSU9wjtHC3g"
      decimals="-3"
      id="Tc_-mCKqzSye0We8DsUsThFXA_17_5"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eqYihjzZTUmciy86aDfMcg"
      decimals="-3"
      id="Tc_2bYrAFY53Uqh32qqusleSw_17_8"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">534060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e3G2VXdksEeqw2aI3K5qYA"
      decimals="-3"
      id="Tc_irWr3LpIY0yzhAS5p33sSQ_17_11"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-590598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_CGzATqg7GkOZyGDz-zXgXA_17_14"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-56508000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_sNgSpYUFRUmZo8BLPJ0BEA_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-179053000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_SxZxaOMFNkCP6-VEWfrYFA_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-165757000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_KaThfFBI-UWMOmaVqWU7wQ_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">318000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_zWbNIma2hUuwrWsZ9yRwOg_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">327000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_t2w6b0YTZEGODpWjpFhyDQ_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1373000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_ppJtMtdOPUSHVXiALnukgg_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">860000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_JAriI6SaT0q9Yi63ieUFwA_8_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">438000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_TGZ3JkMypUK6zx-M-J0tFw_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-389000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_q44nHzQE8E2glZdCBCCXWA_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18614000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_ue91O4fkbUe16u1LA45yrw_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">17337000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_-E-AVMr54UeS8H8MzsPrhw_10_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1872000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_2FWIwnJ8PkmH7ZnuiZom7Q_10_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">807000</us-gaap:PaidInKindInterest>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_5rYcvkCcb0qT47sqLS0sdw_11_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_-AvDGR4YG0am4vt-2hEvTg_11_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-22000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_m7eBQaR3t0q1iFBLox6W7Q_12_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">288000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_NHg31Maa-0C1VzHrgdB_ww_12_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">271000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_1gfot_2Uk0SzG4guPS6jlg_14_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-177000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_2Bje9d97zkWnuBKXdh3nyw_14_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">248000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_xiS5n6-b_ESiBpiu5ivBTw_15_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">6000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_6DkKJesCnUGQWj1NsRxRdg_15_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1985000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_8mAz7NAoTUio42OE_LtwDw_16_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-2888000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_nwdwoPVlYEa2NwHkbCubhg_16_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3905000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_h-vxGdFfykO54ydcqOeiEA_17_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-3219000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_8bJcCzzpKkidj1PWqTgFoA_17_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">13030000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_0bdXNvsU_U-uEq7wmSswwA_18_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2497000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_5JshPmRCSUy0-WxSZwqGLQ_18_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3804000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_H4WMlOe0n06AtL4ljP_wpw_19_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-319000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_gOCEFqDllEy4s2Hq5y_n_A_19_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-293000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_wmdaTns4f0yqaqTG1wzHww_20_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-155006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_Msj0Gm2od0u6Ch9UkWeHvw_20_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-135341000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_uaqUaC7SmEGFro-FaZYguw_23_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_VkkCI07LkUylK6cat2Hp4w_23_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">139000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_GUpieyjcA0inLnwVY3mVPg_24_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-20000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_t3GTVA1hhkGjI0K-fI6W7A_24_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-139000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_xOa3C17n0Uyg-LBsWjYN1w_27_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">98600000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_0JNJwNGpQkOt03yUl-njiA_28_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">180000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_aMSrC3KjpEGAFJWN2TdH2g_28_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2646000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_Jr5XqDyFv0GZLI8RWkVvLw_29_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">27032000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_GBZkGfXsikKBKgwJH0IL3Q_30_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">811000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_sM-W5eOljE23WC8EwqJ_bA_31_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">27000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_Ci0USBsH4EqKEbj24mNb3Q_32_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">508000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_p2QyrZ2DOkynP1uFz49e4A_32_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">283000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_xSj-aHnSFUKOy9NHmM78mw_33_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">26522000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_Pa17OazklUSeugw7OLW38A_33_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">96237000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_RqzqjhyaA0q7bVJZ59Ay_g_35_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-128504000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_hd-sMYFwIUOPD5BiXzCw9Q_35_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-39243000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_haHglmmfn0aVs4_eHp-g6w_36_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">193725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA"
      decimals="-3"
      id="Tc_u61etzBwwkSIr2xmgRobUw_36_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">232968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_DjpsF3DgcEi_L4rihfE_XQ_37_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">65221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_qK024r6wxUCs1saxHx4ozw_37_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">193725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_5o8oCIalMkW122bXl5Kaag_40_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_MRAQc4kvn0ea9qUUFU1Mrg_40_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3245000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_AByLwnyBCkyNwXt9WeJ2fg_41_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">254000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_xrmsrv8nx06ZK3zJWi-Vqg_42_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">7551000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_eKF4R2Aas0Wa6lYasNhybQ_42_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2697000</us-gaap:InterestPaidNet>
    <btai:ConversionOfAccruedInterestToLongTermDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_Er5KVB9jJ0eluRGGZPHHNA_43_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-767000</btai:ConversionOfAccruedInterestToLongTermDebt>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_b36l4uXTFEaHOHMAL2Aeog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;1. Nature of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BioXcel Therapeutics, Inc. (&#x201c;BTI&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company utilizing artificial intelligence (&#x201c;AI&#x201d;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#x2019; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#x2019;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As used in these consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#x201c;BioXcel LLC&#x201d; refers to the Company&#x2019;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#x201c;OnkosXcel&#x201d; refers to BTI&#x2019;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On April 6, 2022, BTI announced that the United States (&#x201c;U.S.&#x201d;) Food and Drug Administration (&#x201c;FDA&#x201d;) approved IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; (dexmedetomidine or &#x201c;Dex&#x201d;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;, was commercially available in doses of 120 and 180 micrograms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#xef;ve to checkpoint inhibitors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#x2019;s principal office is in New Haven, Connecticut.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_lXmPQqYeJU-ascS7WVO3Zw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2. Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#x201c;U.S.&#x201d;) Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2023, the Company had cash and cash equivalents of $65,221 and an accumulated deficit of $590,598. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $179,053 and $165,757 for the years ended December 31, 2023 and 2022, respectively, and had net cash used in operating activities of $155,006 and $135,341 for the years ended December 31, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#x2019;s assessment that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;This going concern evaluation takes into consideration the potential mitigating effect of management&#x2019;s Reprioritization (as defined in Note 4, Restructuring). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#x2019;s Board of Directors. The Company&#x2019;s Reprioritization was approved by the Board of Directors on August 8, 2023; however, such plans will not mitigate the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, Debt and Credit Facilities) or other potential sources of debt or equity capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#x2019;s cost structure and operating plan. Management&#x2019;s plans to improve the Company&#x2019;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#x2019;s control:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;raise funding through the sale of the Company&#x2019;s equity securities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;raise funding through third-party investments in or other strategic options for OnkosXcel;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;raise funding through debt financing and/or restructuring of its existing OFA Facilities; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;establish collaborations with potential partners to advance the Company&#x2019;s product pipeline;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;establish collaborations with potential marketing partners;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;reduce overhead and headcount to focus on core priorities; and/or&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;any combination of the foregoing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_e6HnBbkJeEiWQcRBteNOHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#x201c;U.S.&#x201d;) Generally Accepted Accounting Principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_M5bKhZStek6xy96RRQKtpA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">65221000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_yu4KA6OkmEO5vETAAZRJ1w"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-590598000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr__zlU52Ct5UijVgoYQCbAKA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Narr_ohMqUMEzr0aMTOCNj0vNJQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-165757000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_ZQt30byNx0mevvuIn9KeGA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-155006000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Narr_KzaY8_oKIE6DTPwzG-Lj1A"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-135341000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_Jay4NB1yfEenoTGT-T1KKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;3. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;Accounts receivable arise from sales of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;IGALMI&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; and represent amounts due from distributors. Payment terms generally range from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;75 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2023, the Company determined that an allowance for credit losses was not required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company sells &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;IGALMI&lt;/span&gt;&lt;sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;span style="font-weight:normal;"&gt; through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#x201c;GPOs&#x201d;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;BTI capitalizes inventory costs associated with the Company&#x2019;s products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Initial Public Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#x2019;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:2.15pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.1pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;Lesser of life of improvement or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Selling, general and administrative expenses in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;ROU assets represent BTI&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#x2019;s leases do not provide an implicit rate, it used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and excludes lease incentives. The Company&#x2019;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Debt and Detachable Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#x201c;&lt;i style="font-style:italic;"&gt;Derivative Assets and Liabilities&lt;/i&gt;&#x201d; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions of the debt.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative Assets and Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s revenues consist of product sales of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI distributes IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#x2019;s behalf. The Company believes the hospitals are its customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; is to deliver the quantity of product ordered to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#x2019;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI sells IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Trade Discounts and Allowances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Government Rebates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost of Goods Sold&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#x201c;BTI RSUs&#x201d;), OnkosXcel profit sharing units (&#x201c;PSUs&#x201d;), OnkosXcel restricted stock units (&#x201c;OnkosXcel RSUs&#x201d;) and BTI performance stock units (&#x201c;Performance Units&#x201d;). The Company&#x2019;s 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) became effective in August 2017. The Company&#x2019;s 2020 Incentive Award Plan (the &#x201c;2020 Plan&#x201d;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#x2019;s closing stock price on the grant date. The estimated fair value of stock-options, OnkosXcel RSUs and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Black-Scholes pricing model is affected by the Company&#x2019;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards, and expected term of the award. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#x2019;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Most of the Company&#x2019;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#x2019;s estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Although management does not expect its estimates to be materially different from amounts actually incurred, management&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#x201c;more likely than not&#x201d; that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#x2019;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#x2019; full knowledge of the position and all relevant facts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not have any unrecognized tax benefits as of December 31, 2023 and 2022. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Earnings (Loss) per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Earnings (loss) per share (&#x201c;EPS&#x201d;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#x2019;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance (collectively, &#x201c;Topic 326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) - Effective Dates, which deferred the effective dates of Topic 326 for the Company, until fiscal year 2023. The Company adopted Topic 326 in 2023 and it did not have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements effective in future periods&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_GNrYA0rcHEmRZscaMTotqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_V0_8QrFcrkqX9LhCU9TjVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_VTKYEu1h20a4LnKY_9jz-Q">&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;Accounts receivable arise from sales of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;IGALMI&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; and represent amounts due from distributors. Payment terms generally range from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt;75 days&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"&gt; from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2023, the Company determined that an allowance for credit losses was not required.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <btai:AccountsReceivablePaymentTerm
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_LbKlmh1ElU2MfLJqOKFfxQ"
      id="Narr_kqFvR4KcpkC6i5vJCeIXjA">P30D</btai:AccountsReceivablePaymentTerm>
    <btai:AccountsReceivablePaymentTerm
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_KcpdD2ZAMkKgL8-kiMrvzw"
      id="Narr_1PPQDkeIWEuRfKdj2gllnQ">P75D</btai:AccountsReceivablePaymentTerm>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_2pV7PjiEgUK48NXPMsbAGw">&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company sells &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;IGALMI&lt;/span&gt;&lt;sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;span style="font-weight:normal;"&gt; through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#x201c;GPOs&#x201d;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_J0hn7f3M70GAK_dP9Sf7VA">&lt;p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;BTI capitalizes inventory costs associated with the Company&#x2019;s products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <btai:DeferredOfferingCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_ru65vK1H0kCVJD1VCxYI9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred Initial Public Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#x2019;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. &lt;/p&gt;</btai:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_MsbwejWR_EKu1adaMWD1rg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2570000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_ht0Oq7QrjUmx8B6IB6j9uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:2.15pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.1pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;Lesser of life of improvement or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Selling, general and administrative expenses in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_LxlWHhHzskeJoZQvrYJkZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:2.15pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;7 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.1pt;"&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"&gt;Lesser of life of improvement or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btai:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DPrRJZyMuUC3HpIpzHgSwA"
      id="Narr_c8TMIEzUSkeg19Gvwq-OGA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_qZV9TJRkVkSO1q1Z2RQAKQ"
      id="Narr_b2AY4BY9rUSNHrYuhjoM1Q">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lfv86wIfO0uGyrJUEO6W4g"
      id="Tc_YLyFczBaYUywqG1xKcxw2Q_2_1">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_h0r6LEToy0CZmXBYUR8xtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;ROU assets represent BTI&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#x2019;s leases do not provide an implicit rate, it used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and excludes lease incentives. The Company&#x2019;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_d57HbJUd8kWt1XZPq36Vgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Debt and Detachable Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#x201c;&lt;i style="font-style:italic;"&gt;Derivative Assets and Liabilities&lt;/i&gt;&#x201d; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions of the debt.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_QrH1IYMAg0SwjqBjVuD6QA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative Assets and Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_8aljX-WYMkuBcq_XgKXh7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s revenues consist of product sales of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI distributes IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#x2019;s behalf. The Company believes the hospitals are its customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#x2019;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#x2019;s only performance obligation identified for IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; is to deliver the quantity of product ordered to the location specified by the customer&#x2019;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#x2019;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI sells IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Trade Discounts and Allowances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Government Rebates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;</us-gaap:RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_Ef4cBfL1zEmdy3hnC0KycA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost of Goods Sold&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_rhFoKI21QU2jFAPot9xN3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#x201c;BTI RSUs&#x201d;), OnkosXcel profit sharing units (&#x201c;PSUs&#x201d;), OnkosXcel restricted stock units (&#x201c;OnkosXcel RSUs&#x201d;) and BTI performance stock units (&#x201c;Performance Units&#x201d;). The Company&#x2019;s 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) became effective in August 2017. The Company&#x2019;s 2020 Incentive Award Plan (the &#x201c;2020 Plan&#x201d;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#x2019;s closing stock price on the grant date. The estimated fair value of stock-options, OnkosXcel RSUs and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Black-Scholes pricing model is affected by the Company&#x2019;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards, and expected term of the award. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_YT5EIL9cV0i9ZfyaBOMiFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#x2019;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Most of the Company&#x2019;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#x2019;s estimates with the service providers and makes adjustments if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Although management does not expect its estimates to be materially different from amounts actually incurred, management&#x2019;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <btai:PatentCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_BFpZ3vXp7EK6EHcpUIMjdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;</btai:PatentCostsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_TQQ3wVnFUUqk_zagWNHR7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#x2019;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Level 3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#x2019;s estimates of market participant assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_MlgLYJPiRkS6PoEnlvM8HA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#x201c;more likely than not&#x201d; that all or a portion of deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#x2019;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#x2019; full knowledge of the position and all relevant facts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company does not have any unrecognized tax benefits as of December 31, 2023 and 2022. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_LBnX0ugemkeUxEjJhJ1gYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Earnings (Loss) per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Earnings (loss) per share (&#x201c;EPS&#x201d;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_5rWg85NMkEmFbHYXUTfIVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#x2019;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="INF"
      id="Narr_hJYHgsA0v0CTAt5haaOnxg"
      unitRef="Unit_Standard_segment_laXuDs1PtUqwsUSCfciCQA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_ERl-_RilREe9rv9asTG2bQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance (collectively, &#x201c;Topic 326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) - Effective Dates, which deferred the effective dates of Topic 326 for the Company, until fiscal year 2023. The Company adopted Topic 326 in 2023 and it did not have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accounting Pronouncements effective in future periods&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_G1gw2rqa9EKtbCecS9hvpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;4. Restructuring&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On August 8, 2023, the Company&#x2019;s Board of Directors approved a broad-based strategic reprioritization (the &#x201c;Reprioritization&#x201d;). The Company took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend its cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for &lt;/span&gt;IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;span style="background:#ffffff;"&gt; in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;As part of this strategy, the Company&#x2019;s Board of Directors approved a reduction of approximately &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;60%&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; of the Company&#x2019;s workforce. The Company notified impacted employees on August 14, 2023 and recorded total restructuring costs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$4,163&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; for the year ended December 31, 2023. These costs consisted of severance and benefit costs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$4,063&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; and contract termination costs of &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$100&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;. The Company paid $&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;3,998&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; of severance and benefit costs and &lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;$100&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; of contract termination costs in the year ended December 31, 2023. The Reprioritization is substantially complete as of December 31, 2023, and any remaining costs are expected to be paid during the first quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_8_8_2023_To_8_8_2023_3YScg74_R0ConxpN-Oxzqg"
      decimals="2"
      id="Narr_AOKpDy8BY0OJtwAThtnxGA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_mLAZyGcQJEqoMEFLFyn8yw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">4163000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GDQlj4QAs0O-w3hPNOGBnQ"
      decimals="-3"
      id="Narr_bCJRB0ZXSEOdzjagGDUOxg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">4063000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_j_3iRADS3U-7NdeM4T4eaw"
      decimals="-3"
      id="Narr_0-PWvBqhDkO5thZPToJN_Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">100000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_GDQlj4QAs0O-w3hPNOGBnQ"
      decimals="-3"
      id="Narr_ZcFhwtKZLky7n1Oa82tsIw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3998000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_j_3iRADS3U-7NdeM4T4eaw"
      decimals="-3"
      id="Narr_JLpB1YZXYkCCFsjpRBMpIQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">100000</us-gaap:PaymentsForRestructuring>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_9aimq17fbkqIyBG0qsWnCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;5. Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Inventory consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company recorded inventory write-downs of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1,191&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for the year ended December 31, 2023. &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; write-downs of inventory were recorded for the year ended December 31, 2022&lt;/span&gt;.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_dsBmmFXh2EmQHr3fkOocVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,991&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_yKEpIg2pyU2sWRxbJA378Q_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">935000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_WB6urcufvUq2q9Xjmdamig_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">682000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_xAfWKUk6skWIeyckzLBuSQ_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">651000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_dOG_b6VdrkeLwNUoRyBpJA_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">708000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_NUNOf6OFOkakYc5WCHL7YQ_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">405000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_aWtVXo7P5UqwyxfiEQcvHQ_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">595000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_BIAXUTf9OEuiWXbD6UiJbA_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1991000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_ADkkPV-NDUWb1DrKDgDykg_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1985000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_MmDEbZ3AfEmlflbezAqMAg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1191000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_gKIcbdSfU0eUKBFpzv0USQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_T_eXlG2qgEWvHlDdmCEvVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;6. Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Property and equipment, net consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,969&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,193)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (885)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$318&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$327&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; for the years ended December 31, 2023 and 2022, respectively&lt;/span&gt;.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_mIcf7XVPbU6sfkBkpIteVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,977&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,969&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,193)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (885)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Q0FkyLMLpE6C08_6RQv7GA"
      decimals="-3"
      id="Tc_pg8EVHNOgECFdEnWFBbLbg_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">202000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ALKhxrCkjkOwdbr4SCwncA"
      decimals="-3"
      id="Tc_DPbirmTZoE2hj6KIW-K3-A_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_lfv86wIfO0uGyrJUEO6W4g"
      decimals="-3"
      id="Tc_-SYQ3VWUcUeP1m7x0ND9Gw_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_hB0HP0jhXkSZURCC-uucwQ"
      decimals="-3"
      id="Tc_jr5oycoZdkWwyeQCdp71BA_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_dxjhG7eFUUSaXMpZC0s-aQ"
      decimals="-3"
      id="Tc_nxKyt8SvQ0ehngOSOb7NGQ_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-GBUxd3EAE6_mzgWpsJOzg"
      decimals="-3"
      id="Tc_8xEyuQhfm0uS-TSy7Mgnfw_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1181000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_3ZQ2j2j4CkyIc5HAkF2u9A_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_6qju0MkLdUuylKkIaBbFGQ_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1969000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_M7cFQA3i7EOdluNnBCczlQ_8_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1193000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc__t719AI0dEWbbVrD2_B4fw_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">885000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_dbF6p_vM4U-9RB6ny-5Cmw_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">784000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_02Ov6ERGw0e5x_On3QcaSA_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1084000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_-EC1dJ3DJ0COJDNSIcJYCA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">318000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Narr_Fxg3lLieK0WHpzzU43Y2fQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">327000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_ht_J-hw7aEmXFOi4-SRanw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;7. Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,406&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 820&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_RStWZ-_b40y4I63DXdNW1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,406&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,370&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,738&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 820&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <btai:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_Zy_ny3IZLUmRgEWcrgIjEQ_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">6406000</btai:AccruedResearchAndDevelopmentExpenses>
    <btai:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_gvry4W7upUebtE2JOa9w1w_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">8659000</btai:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_9dfgx6hcqUe77-RFFcI3Uw_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">163000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_JhsXTZPkDEi3hDd_rBlYQw_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">6370000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_KdwtDKtKBE-QWHEychFFSw_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">5562000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_tCs9SbmJpUi7j2IH4rOkfg_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2738000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_T1R2wB0M6kGusdT7PtCfWw_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">116000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_BdKZLeGjxE209aFH9fjuWw_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">82000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_scf5LvU2KE2285vZcC0jQQ_8_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">177000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_Ec6h63fjpkyW5baBvj2Zew_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">820000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_wyiSGyk0F0i6UHavyVBe5w_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">12424000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_D-MvTW0Znky9nlOfOoQtHg_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18669000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_rGcFaxfBRUKRNLv7VO7KVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;8. Transactions with BioXcel LLC&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#x201c;Services Agreement&#x201d;), pursuant to which BioXcel LLC has agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Under the Services Agreement, we have an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. We agreed to pay BioXcel LLC $18 per month from March 13, 2023, to December 31, 2024 in exchange for this option. We agreed to negotiate any such collaborative services agreement in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10,000 in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30,000 in the aggregate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Service charges recorded under the Services Agreement for the years December 31, 2023 and 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2023 and 2022, $0 and $310, respectively, of these service charges are included in Due to related parties in the Company&#x2019;s Consolidated Balance Sheets.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement
      contextRef="Duration_6_30_2017_To_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3yVQCurUjku_rn_lePc8vw"
      decimals="-3"
      id="Narr_3X5z5CvkRkmyLGTKKPPqew"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18000</btai:AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement>
    <btai:CollaborativeArrangementMilestonePaymentsPotential
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_DevelopmentMilestonesMember_mAbI1B8ghUiyZZyzM0aMpA"
      decimals="-3"
      id="Narr_Pts-AyVcwEyRqE-PBnmmXw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">10000000</btai:CollaborativeArrangementMilestonePaymentsPotential>
    <btai:CollaborativeArrangementMilestonePotentialPercent
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember__S0J6TAmqEaBUKJsiY7Iag"
      decimals="0"
      id="Narr_vA74-qr_vkyS9xVmXP8JTA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">3</btai:CollaborativeArrangementMilestonePotentialPercent>
    <btai:CollaborativeArrangementMilestonePaymentsPotential
      contextRef="As_Of_6_30_2017_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_TypeOfArrangementAxis_btai_SalesMilestonesMember__S0J6TAmqEaBUKJsiY7Iag"
      decimals="-3"
      id="Narr_-UGCosIHiku3lOZBH6lIXw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</btai:CollaborativeArrangementMilestonePaymentsPotential>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_7EzeZIFam0yP_o2CZPEVHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg"
      decimals="-3"
      id="Tc_idIS74rsW0iLgmnVSYQ-hA_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1075000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA"
      decimals="-3"
      id="Tc_T9op7jta4EOUSOjB6QCl_A_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1151000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg"
      decimals="-3"
      id="Tc_RZvch9VBG06h-4ALt2yWkg_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">211000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA"
      decimals="-3"
      id="Tc_O5eZu35xQ0OY8I4tHIVjVQ_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">250000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_oPnLrs-exE-V9JaLf5WMOg"
      decimals="-3"
      id="Tc_oacgvWYcfEO2DCYHG-liXw_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1286000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_3IzaryeeOU-jNkN8AS6XJA"
      decimals="-3"
      id="Tc_X8ogqfKUa0ioIYYlaReeIQ_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1401000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_aNHYV9yCoUm00_-U0XfV2g"
      decimals="-3"
      id="Narr_lYYt4QUhMkafIxumF8eb4Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_btai_BioxcelCorporationMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_Vn8IA3nckU24niIfjblXlQ"
      decimals="-3"
      id="Narr_Gfl_ayPde0eOF3XOFA1g4A"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">310000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_l6zc4q-qiUKtzbi-UdQFNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;9. Debt and Credit Facilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Debt, net of unamortized discounts and financing costs, consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenue Interest Financing Agreement ("RIFA")&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RIFA accrued interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,041&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RIFA payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     RIFA debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated Portion of RIFA debt liability to be paid within one-year &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,401)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     RIFA long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,630&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit Agreement and Guaranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payable-in-kind ("PIK") interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt premiums, discounts and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,386)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#x201c;Credit Agreement&#x201d;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#x201c;Lenders&#x201d;), and Oaktree Fund Administration LLC (&#x201c;OFA&#x201d;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#x201c;RIFA&#x201d;; and together with the Credit Agreement, the &#x201c;OFA Facilities&#x201d;) by and among the Company, the purchasers party thereto (the &#x201c;Purchasers&#x201d;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $260,000 in gross funding to support the Company&#x2019;s commercial activities of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#x2019;s disease, and for general corporate purposes. The Lenders and Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Waiver and First Amendment to Credit Agreement and Guaranty&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#x201c;First Amendment&#x201d;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from $25,000 at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#x2019;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"&gt;&lt;b style="font-weight:bold;"&gt;Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On December 5, 2023, (the &#x201c;Second Amendment Effective Date&#x201d;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#x201c;Second Amendment&#x201d;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $202,319 in senior secured term loans, including the initial Tranche A of $70,000, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $72,319. In addition, the $30,000 in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#x201c;Tranche A-2 Term Loan&#x201d;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865 at any time outstanding in OnkosXcel, increased from $30,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the First Amendment). As of December 31, 2023, $100,000 in commitments under the Credit Agreement remains unfunded, and Oaktree has an Equity Investment Right (as defined below) to purchase up to $5,000 of Common Stock from the Company. The blended effective interest rate on the Tranches A-1 and A-2 as of December 31, 2023 was approximately 13.5%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 0.1pt -0.75pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The remaining tranches may be borrowed at the Company&#x2019;s option prior to December 31, 2024, subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $20,000 and is available upon satisfaction of certain conditions and financial milestones. Tranche C of the Credit Agreement is $30,000 and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $50,000 and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a 200-basis point original issue discount and bear interest at a variable annual rate of TERM SOFR (but not less than 2.5% or more than 5.5%) plus 7.5%, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above 8% per annum is, at the Company&#x2019;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to 0.75% per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s obligations under the Credit Agreement are guaranteed by BTI&#x2019;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#x2019;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;a pledge of all of the equity interests of all of the Company&#x2019;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#x2019; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $15,000, (b) from and after the funding of the Tranche B loans, $20,000, and (c) from and after the Company&#x2019;s satisfaction of the funding conditions for the Tranche C loans, $15,000, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $37,500), provided that the minimum liquidity amount will in no event exceed 50% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#x2019;s fiscal quarter ending on December 31, 2024 (such six-month period the &#x201c;Revenue Covenant Measurement Period&#x201d;), that requires it and its subsidiaries&#x2019; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#x201c;Revenue Covenant Measurement Testing Date&#x201d; and the covenant described in this clause (ii) the &#x201c;Revenue Covenant&#x201d;). The Company&#x2019;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#x2019;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such minimum required revenue amount and the Company&#x2019;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#x201c;Employee Holdings&#x201d;), a subsidiary of BTI, and their respective subsidiaries, the &#x201c;BXCL701 Subsidiaries&#x201d;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#x2019;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#x2019;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events (&#x201c;Permitted BXCL701 Release Events&#x201d;), including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least 20% of the equity interests in the BXCL701 Subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#x2019;s secured creditors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue Interest Financing Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As noted, the RIFA was terminated when the Company entered into the Second Amendment, which amended the Credit Agreement (as amended by the First Amendment). The $30,000 Tranche A previously provided to the Company under the RIFA was converted to the Tranche A-2 Term Loan. Prior to termination, the RIFA provided up to $120,000 in potential financing in exchange for a capped revenue interest on net sales of IGALMI&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;, and other future BXCL501 products, if any, that received regulatory approval for sale. The initial Tranche A of $30,000 was funded on July 8, 2022. The effective interest rate on the RIFA as of December 31, 2022, was approximately 14%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Under the terms of the RIFA, the Purchasers were to receive tiered revenue interest payments on U.S. net sales of IGALMI&#x2122;, and other future BXCL501 products, if any, that receive regulatory approval for sale, equal to a royalty ranging from 0.375% to 7.750% of net sales of IGALMI&#x2122;, and other future BXCL501 products, if any, approved for sale in the U.S., subject to a hard cap equal to 1.75x the total amount funded. The Company would also have been required to make certain additional payments to the Purchasers from time to time to ensure that the aggregate amount of payments received by the Purchasers under the RIFA were at least equal to certain agreed upon minimum levels as of certain specified dates, subject to terms and conditions set forth in the RIFA. Revenue interest payments due under the RIFA were payable quarterly based on net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants and Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to 278 shares of the Company&#x2019;s common stock at an exercise price of $20.04 per share (the &#x201c;Original Warrants&#x201d;). Pursuant to the amendment and restatement of the Original Warrants, dated December 5, 2023 (the &#x201c;Amended and Restated Original Warrants&#x201d;), the exercise price of the Original Warrants has been reduced to $3.6452 per share. In addition, the Company granted new warrants to the Lenders to purchase up to 70 shares of the Company&#x2019;s common stock (the &#x201c;2023 Warrant Shares&#x201d;) at an exercise price of $3.6452 per share (the &#x201c;2023 Warrants&#x201d;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;and together with the Amended and Restated Original Warrants, the &#x201c;Warrants&#x201d;). The Amended and Restated Original Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#x2019;s election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#x2019;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#x2019; election to proceed with such equity investment (the &#x201c;Equity Investment Right&#x201d;). BTI entered into a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of BTI common stock issuable under the Warrants (including the Original Warrants and the 2023 Warrants) and Lenders&#x2019; Equity Investment Right was 5,852 as of December 31, 2023.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#x201c;Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase 175 individual limited liability company units (which number of units is not in thousands; referred to herein as the &#x201c;OnkosXcel Warrants&#x201d;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#x201c;Next Equity Financing&#x201d;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#x2019;s election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Maturities of long-term debt are expected to be as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Interest expense was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of debt discount and amortization of financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_grVppPvl60u0uKzkDeXTkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Revenue Interest Financing Agreement ("RIFA")&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RIFA accrued interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,041&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RIFA payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     RIFA debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated Portion of RIFA debt liability to be paid within one-year &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,401)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     RIFA long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,630&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit Agreement and Guaranty&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payable-in-kind ("PIK") interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unamortized debt premiums, discounts and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,082)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,386)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q"
      decimals="-3"
      id="Tc_sXbmQk2qF02AdMbUe67xqw_3_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_PfOMnn2r6Em4dZ9LbC_GWA"
      decimals="-3"
      id="Tc_AJbDUkXNv0uXFx5EzBaO-Q_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2041000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_PfOMnn2r6Em4dZ9LbC_GWA"
      decimals="-3"
      id="Tc_8Fo-ewt4eESfMLNfSyceOg_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">10000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q"
      decimals="-3"
      id="Tc_sLmPPKU0RUqB-EZ84dL-jQ_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">32031000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q"
      decimals="-3"
      id="Tc_C2BE3XBvvUW06t-gVpS8Yw_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1401000</us-gaap:DebtCurrent>
    <btai:LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q"
      decimals="-3"
      id="Tc_jvCMCoQV5U-F1TJ_j2p4IA_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30630000</btai:LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg"
      decimals="-3"
      id="Tc_68Fuy5qz-Ee8C82obZkBOA_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">102319000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_v1M2BA7xuUyhRRqLClhhMA"
      decimals="-3"
      id="Tc_dWlLE0v_jEGWl_T5e6FqhQ_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">70000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_W29nsD5d7kyN70aN7TzDxQ"
      decimals="-3"
      id="Tc_zf2HCUQ6hUSk2tAJjLXvLQ_10_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">361000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1XLHPADP90S8ZwGclsNpbQ"
      decimals="-3"
      id="Tc_FrRgUqoOL0eHIxKCOZkHRQ_10_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">807000</us-gaap:PaidInKindInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_AoERJqcMpkO4k_Ya4o6bEA_11_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">102680000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_Am589OBhj02aqp51oP9FCQ_11_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">101437000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_XLB8E3fj_0KZhkGf-IPaCw_12_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2082000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_Qh-KJRzscUqNbRZ0RQnuVw_12_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">8386000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_BcT1-68uGEih3vHeBz7AXw_13_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">100598000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_t6XSANplB02uF_5Os6J8gg_13_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">93051000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A"
      decimals="-3"
      id="Narr_vfYLl0s_aUWnm54pgYQgKg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">260000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fDwcE2NcAkalD934EMLcKg"
      decimals="-3"
      id="Narr_OV_RXp2ku0uR2AepwzpyqQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_11_12_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_ORjQlGmsX0GTKU-h12WP4g"
      decimals="-3"
      id="Narr_poE5-9WMiUq9l91IfqPjTw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">25000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_fDwcE2NcAkalD934EMLcKg"
      decimals="-3"
      id="Narr_AOt-gnuUFUS-_ikaKTK7OA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">180000</us-gaap:DebtInstrumentFeeAmount>
    <btai:LineOfCreditFacilityAmendmentFeePercentage
      contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_NXCCj7glw0uPyaR6Y2-w9w"
      decimals="4"
      id="Narr_I3l_VuTETU2itLAeYgytog"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0025</btai:LineOfCreditFacilityAmendmentFeePercentage>
    <btai:LineOfCreditFacilityExitFeePercentage
      contextRef="Duration_11_13_2023_To_11_13_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_NXCCj7glw0uPyaR6Y2-w9w"
      decimals="4"
      id="Narr_gZAGRMvsNUWlQ1y5KP0ggQ"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0025</btai:LineOfCreditFacilityExitFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1kRdDymbCUqa9XieGI09Zg"
      decimals="-3"
      id="Narr_NvtkvD7jEUe-Lv526_XjyA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">202319000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_28_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_N1udVxFwqUa9M9O90JMIFg"
      decimals="-3"
      id="Narr_F_a_cnu3Ek2O1E2shnNSew"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">70000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_lqY8_zjpaE6CKAXuo279Ww"
      decimals="-3"
      id="Narr_WjPmiPkQikCZcj37ztBU0Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">72319000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_5_2023_srt_StatementScenarioAxis_btai_TrancheTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_73tBnm99SkWJuAHEaVzHcw"
      decimals="-3"
      id="Narr_PYMwCB5Ts0KQeeBnY3CogA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_1kRdDymbCUqa9XieGI09Zg"
      decimals="-3"
      id="Narr_Cod_Q230gEGNr6Cryn3s2Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30865000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityInvestmentAllowed
      contextRef="As_Of_12_4_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_qN1X0eAfCkKStJDFYn04Lg"
      decimals="-3"
      id="Narr_KhPepcFZdU-GSF0RblZqiw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</btai:LineOfCreditFacilityInvestmentAllowed>
    <btai:LineOfCreditFacilityExitFeePercentage
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_Ku-HMoUhaECwUSnCUZw31A"
      decimals="4"
      id="Narr_1u9P2vaBYEuT6Recpq6EdA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0025</btai:LineOfCreditFacilityExitFeePercentage>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg"
      decimals="-3"
      id="Narr_vl3yE3YG3US0pRmigjJLnQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">100000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <btai:EquityInvestmentRightAmountUnfunded
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg"
      decimals="-3"
      id="Narr_5fArKjUXZEi38YBOAjMKsg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">5000000</btai:EquityInvestmentRightAmountUnfunded>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg"
      decimals="3"
      id="Narr_yR8vJ6DdUk-wCmSUqP9RmA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.135</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheBMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_huSrkOX7SUmY8-_tuWQFpg"
      decimals="-3"
      id="Narr_BlKRzxf6Ok2APyS1NapN_Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheCMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_V-ADkks9QE-9-kuUtA7EMg"
      decimals="-3"
      id="Narr_uJKEG_V200K2jG27Z0zPeA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_TrancheDMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_FwZJLNhx_0moyuSOcfdYXA"
      decimals="-3"
      id="Narr_UJL4NWosBES-760Ux0SACg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <btai:DebtInstrumentInterestRateDiscountRatePercentage
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_anIgAQjD802S5HzYHrjq2A"
      decimals="4"
      id="Narr_xUkvY3J0zEuPJMk2gh83iw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0200</btai:DebtInstrumentInterestRateDiscountRatePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_h7P1Xd1OZUajABk9uxWk4w"
      decimals="3"
      id="Narr_3F-uV4rOSEO4l3zNEWeuVw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_gIbrrmF-LU2BVh3G5muq_w"
      decimals="3"
      id="Narr_G0fnUYl7pEGd_rJth5XxnA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.055</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <btai:DebtInstrumentIncrementalOnVariableRatePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_VariableRateAxis_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_wzQDKTToGUu0fupDsFLSUw"
      decimals="3"
      id="Narr_U-_0oilp1UmlZDsGlpONTQ"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.075</btai:DebtInstrumentIncrementalOnVariableRatePercent>
    <btai:PaidInKindInterestPercentage
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_cSh0m3wu4kefKlStrPWJ1w"
      decimals="2"
      id="Narr_L7JGEcNHxUKexFt6FwFMBg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.08</btai:PaidInKindInterestPercentage>
    <btai:TickingFeesPercentage
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_anIgAQjD802S5HzYHrjq2A"
      decimals="4"
      id="Narr_wb6DOkSr00WV0af61LBb3w"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0075</btai:TickingFeesPercentage>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A"
      decimals="-3"
      id="Narr_7G8MxNHU7kCrfymguUmaQA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">15000000</btai:NetCashRequiredMinimum>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterFundingOfTrancheBLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_V8-C-RxYK0aXAjUC8xvmzw"
      decimals="-3"
      id="Narr_0XbnkPJCfkydIejzA1dKFQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20000000</btai:NetCashRequiredMinimum>
    <btai:NetCashRequiredMinimum
      contextRef="As_Of_4_19_2022_srt_StatementScenarioAxis_btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_UZzwa5c1w0eu9CL07OEeQA"
      decimals="-3"
      id="Narr_XtSZ4FyyOE6RwFCPvUWE4Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">15000000</btai:NetCashRequiredMinimum>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A"
      decimals="-3"
      id="Narr_xdpqseZIqUaTV2qK7aW8DQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">37500000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:PercentageOfOutstandingLoan
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_qDjBignJyUitVErr7JersQ"
      decimals="2"
      id="Narr_OhLMkr69qUqkLutMfP9crg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.50</btai:PercentageOfOutstandingLoan>
    <btai:SubsidiaryOwnershipPercentage
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_OfaAdministrativeAgentMember_kGJ9xD24Q0GfRC8XO_Kh_A"
      decimals="2"
      id="Narr_sSQGFILJhUq0OPoKv23IcA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.20</btai:SubsidiaryOwnershipPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="Duration_7_8_2022_To_7_8_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_V64yF2oxIU6GdMLQcz2BkA"
      decimals="-3"
      id="Narr_dOPWwxTRekKlOJg3boEm5A"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_RWFw3r1oWUC3XL39vHaqqg"
      decimals="-3"
      id="Narr_ay4SO4_18kKHXqHOOag8sA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">120000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_8_2022_srt_StatementScenarioAxis_btai_TrancheMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_wzC_0CZ3tUyxRyd-2zvgHQ"
      decimals="-3"
      id="Narr_M7W0GqQrWUKTcaAy19Ucmw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_d7gdT3RHyk20-zD9s_g88Q"
      decimals="2"
      id="Narr_ZZFS75tw0Ei4s785m1rH-w"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.14</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <btai:BorrowingsBasedOnNetSalesPercent
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_dIkd-uFGvk-VmaG81kxPvQ"
      decimals="5"
      id="Narr_NgD34CTYaU-8cDhMn7V8WA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.00375</btai:BorrowingsBasedOnNetSalesPercent>
    <btai:BorrowingsBasedOnNetSalesPercent
      contextRef="Duration_4_19_2022_To_4_19_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_oxNFZAw51EWZ3rfLAxMbLg"
      decimals="5"
      id="Narr_hcGF5dHneEOkYc5y7YmDlg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.07750</btai:BorrowingsBasedOnNetSalesPercent>
    <btai:ThresholdRatioOfDebtToRevenueRatio
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_DebtInstrumentAxis_btai_RevenueInterestFinancingAgreementMember_bpv_lNdtNUaJOmv6QXYrHA"
      decimals="2"
      id="Narr_pvgGtc9owEudmTbqR8iu_A"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">1.75</btai:ThresholdRatioOfDebtToRevenueRatio>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA"
      decimals="-3"
      id="Narr_Pu0kdhhF7UKG-_yJkqwL_g"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">278000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA"
      decimals="2"
      id="Narr_Tw5vLrfd2U6WGfe6OC_03A"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">20.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w"
      decimals="4"
      id="Narr_-bm2mPRg-EeiZn13fUr0jQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.6452</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_LxCPLzm9okOLdFn3Z8l8lw"
      decimals="-3"
      id="Narr_bCWOdbYeJESfgkoRKumgYQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">70000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_LxCPLzm9okOLdFn3Z8l8lw"
      decimals="4"
      id="Narr_bhMA1my51kSgs9bZTj_3Fg"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.6452</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:RightToPurchaseStockLenders
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA"
      decimals="-3"
      id="Narr__peyA2OnGkuVkLGcLvee3w"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">5000000</btai:RightToPurchaseStockLenders>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_fZkIV0wemUSj8D-mDkwN0g"
      decimals="2"
      id="Narr_ZUCtKAxWi0iRKkH1tsz3_Q"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.10</btai:PremiumSharePricePercent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA"
      decimals="-3"
      id="Narr_7cO2nGyvrEmFBO_4mhSwRQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">5852000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g"
      decimals="-3"
      id="Narr_kEK6kUEIbEOQ1EQ3shGZ-Q"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">175000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g"
      decimals="-3"
      id="Narr_UOFdiIw2s0yabPm3C6Zwrg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:ThresholdLiquidityEventAmountForExerciseOfWarrants
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_A9bTY3r_b0640HprtMKo5g"
      decimals="-3"
      id="Narr_SJGegqBoN062CxBb7TkP2A"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20000000</btai:ThresholdLiquidityEventAmountForExerciseOfWarrants>
    <btai:PremiumSharePricePercent
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ"
      decimals="2"
      id="Narr_lVXfIn70gkC0WIj9KFf8eg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.10</btai:PremiumSharePricePercent>
    <btai:PercentageOfFairValueConsiderationToBePaid
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ"
      decimals="2"
      id="Narr_-VIqjHCWVkmdVKSbOndluA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.75</btai:PercentageOfFairValueConsiderationToBePaid>
    <btai:PercentageOfValuationApplicableToInitialProfits
      contextRef="Duration_4_19_2022_To_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_eE6MgPzSe0ix5sSjAFSFKQ"
      decimals="2"
      id="Narr_XWuaE9OfB0-7Se6KxDIPBw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">1.50</btai:PercentageOfValuationApplicableToInitialProfits>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_pinmGz_jr0GJg5eY9MdxjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_hLFP91Lj-UqFsOAoIlZJ3Q_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">102680000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_V4yxO7bD00KBXWx8n_awKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion of debt discount and amortization of financing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</btai:ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_TPCSWpbarUqSTCknp2eLQQ_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">11941000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_27fQjTB8S0qwjF0qKtP-lg_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">7353000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_NhF3FtaxYEyg0psjgwbDkw_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1373000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_qa7kVVridUOV0ZH8Tq6OOA_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">860000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_9rmOQSepwUakCV8aWgkUmQ_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">13314000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_Lw5F8kHyvEeBX0MzO1CCYQ_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">8213000</us-gaap:InterestExpense>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_HWnbiOATUUmpcT-VZQ-biQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;10. Derivative Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options. The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#x2019;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheets. The respective derivative liabilities are recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#x2019;s Consolidated Statements of Operations.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <btai:FinancingActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_7M3rYJTu2EKGjrmvrE_SFg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;11. Common Stock Financing Activities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In May 2021, the Company entered into&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; an &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$100,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, from time to time, through an &#x201c;at the market offering&#x201d; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#x201c;at the market offering" program to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$150,000&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. The Company sold &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;1,408&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares under the Sale Agreement in the year ended December 31, 2023 for net proceeds of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$26,221&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. For the year ended December 2023, the Company sold shares for the gross amount of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$27,032&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, and incurred issuance costs of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$811&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. The Company did not sell any shares, and thus did &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;t receive any proceeds under this program, for the year ended December 31, 2022&lt;/span&gt;.&lt;/p&gt;</btai:FinancingActivitiesDisclosureTextBlock>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_5_1_2021_To_5_31_2021_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_CyJ8S634XkOrnMXvZQo-Gw"
      decimals="-3"
      id="Narr_MpvopprF1Uy9gO17cjhotw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">100000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_qQIgqhjIAU-25A9Enh5x8Q"
      decimals="-3"
      id="Narr_Z0t-eyayLkq6ZPcPw9d9YQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">150000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg"
      decimals="-3"
      id="Narr_P2WAahEr9ku9jvMIwlxm7A"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1408000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg"
      decimals="-3"
      id="Narr_6o0YoULu4kCvEc_9CM5-Jg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">26221000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg"
      decimals="-3"
      id="Narr_O13gEwksdEyEGGJ5M3MMAQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">27032000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_2ylKUm6nwE-xU4Tb65bKxg"
      decimals="-3"
      id="Narr_Bz9WxKSogU-giAidGUpB2w"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">811000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_Vc2MKw-dukuwAowcKM-VEQ"
      decimals="-3"
      id="Narr_tTTtcEcwK0ansq31yLe-SA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_mSAckiN4hky3V5UhNTcblA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;12. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;2017 Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020 Incentive Award Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s 2020 Plan was approved and became effective at the Company&#x2019;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) 911 shares of the Company&#x2019;s common stock and (ii) 233 shares of the Company&#x2019;s common stock, which represents the number of shares that remained available for issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#x2019;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#x2019;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) 4% of the aggregate number of shares of the Company&#x2019;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by 1,126 shares and 1,119 shares on January 1, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Stock-based awards granted under the 2020 Plan have a term of ten years. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally four years. Stock-based awards granted under the 2020 Plan include stock options, BTI RSUs, and Performance Units.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2023, there were 664 shares available to be granted under the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Restricted stock units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to BTI RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In 2023, the Company granted 133 time-based BTI RSUs to certain employees. All of the BTI RSUs vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. The weighted average grant date fair value per share for the BTI RSUs was $19.62. Unrecognized stock-based compensation expense related to these awards was $1,417 as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In 2022, the Company granted 122 (119, net of forfeitures) time-based BTI RSUs to certain employees and consultants. The majority of BTI RSUs granted to employees vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. There were 25 BTI RSUs granted to the employees in May 2022 which fully vested at the &lt;span style="-sec-ix-hidden:Hidden_ENbZ6Viv9kSPsLzsnlVWSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-year&lt;/span&gt;&lt;/span&gt; anniversary of the grant date. BTI RSUs granted to a third-party consultant vest 50% each on the first and second anniversaries of the grant date. The weighted average grant date fair value per share for the BTI RSUs granted in 2022 was $14.38. Unrecognized stock-based compensation expense related to these awards was $298 as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Performance stock units &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The table below summarizes activity relating to Performance Units related to BTI common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In October 2023, the Company granted 543 Performance Units to employees. 209 Performance Units vest on the one-year anniversary of the grant date, and the remaining 334 Performance Units are performance based and vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value of Performance Units granted and cancelled during 2023 was $2.43. None of the Performance Units had vested as of December 31, 2023. Unrecognized stock-based compensation expense related to the awards expected to vest was $515 as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OnkosXcel Profit sharing units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in whole dollars)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;During 2023, Employee Holdings, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted 30 individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. In 2022, Employee Holdings granted 1,310 (not in thousands) PSUs to employees and a consultant of the Company for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. All PSUs, other than those granted to certain &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;executive employees of the Company, vest ratably over 48 months. PSUs granted to certain executive employees of the Company, vested ratably over 24 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair values of the PSUs granted in 2023 and 2022 were $8 per unit and $4 per unit, respectively, and were estimated at the date of grant using a Black-Scholes option pricing model. The total fair value of the PSUs vested during the year ended December 31, 2023 was $1,942.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023 grant profit share unit valuation inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Unrecognized stock-based compensation expense related to the PSUs was $971 and $4,588 as of December 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;OnkosXcel restricted stock units&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The table below summarizes activity relating to the OnkosXcel RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;During the year ended December 31, 2023, the Company granted 225 individual (not in thousands) OnkosXcel RSUs to certain employees. 125 of the OnkosXcel RSUs vest upon the earlier to occur of (a) 180 days after an initial public offering of OnkosXcel, or (b) a change in control of OnkosXcel. The remaining OnkosXcel RSUs vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. The weighted average grant date fair value per unit for the OnkosXcel RSUs was approximately $10. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $552 as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BTI Stock options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity for the year ended December 31, 2023, is presented below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (651)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (309)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2023, the intrinsic value of options outstanding was $3,149. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#x2019;s common stock as of the reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The total intrinsic value of stock options exercised for the years ended December 31, 2023 and 2022 was $5,928 and $2,437, respectively. The total intrinsic value of stock options exercisable as of December 31, 2023 and 2022 was $3,148 and $40,255, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $15.53 and $11.62, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average grant date fair value of options vested as of December 31, 2023 was $12.86.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average remaining contractual life is 5.5 years for options exercisable as of December 31, 2023. The weighted average remaining contractual life was 6.4 years for options outstanding as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Unrecognized compensation expense related to unvested stock option awards as of December 31, 2023, was $9,478 and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 1.1 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The fair value of options granted during the years ended December 31, 2023 and 2022 was estimated using the Black-Scholes pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;96.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;109.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;92.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;99.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In 2023, the Company began using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#x2019;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the term of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is zero percent as the Company has no history of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#x2019;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel PSUs and OnkosXcel RSU&#x2019;s, of $18,614 and $17,337 for the years ended December 31, 2023 and 2022, respectively, which were comprised as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020 Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was also approved and became effective at the Company&#x2019;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#x2019;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that may be issued pursuant to rights granted under the ESPP is 100 shares of common stock. In addition, the number of shares available for issuance under the ESPP will increase on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#x201c;Section 423 Component&#x201d;) shall not exceed 500 shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by 281 shares and 280 shares on January 1, 2023 and 2022, respectively. To date, no shares have been sold under the ESPP. There were 905 shares available for issuance as of December 31, 2023.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_u28NxTusVku5UX5Tspxcdg"
      decimals="-3"
      id="Narr_lRosr2ZdgU21dRyvzJoIVg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">911000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_StockPlan2017Member_EzEfX9_flUy4assVwEUnZw"
      decimals="-3"
      id="Narr_VQ3Ck2z0Qki8fV8rCcgmWA"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg"
      decimals="2"
      id="Narr_L-xOEwJtpUqPm8U10KmTyw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.04</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_SZqxVW5oU0abbZ9IElW9dw"
      decimals="-3"
      id="Narr_m7ymKrejtkCtzxH1doj4Aw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_Y3C2KLUibEGjwn_Zo1eoew"
      decimals="-3"
      id="Narr_eH6zoW9_q02TwZhT5vUuRQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg"
      id="Narr_nR8Ol0H6r02jIwJYBPGN4g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ayDH9zm68k2h_vvr5zVAqg"
      id="Narr_Qzk6fFBbSkymUv0WpZv4TA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_IncentiveAwardPlan2020Member_ZWLEjeNqVUifL0AxwuMoJg"
      decimals="-3"
      id="Narr_d-0RaiPjaU69XbJKXTlp2A"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">664000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_Q5AKhFSDbEOxbYSKGi4aqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_p2sWFHswF0-DPdbaZVQ8aA"
      decimals="-3"
      id="Tc_2Q4QIHNZg0-19n-aXsHLfA_5_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"
      decimals="-3"
      id="Tc_r_siLFE8QkS5SlyeZQ3lBg_6_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"
      decimals="-3"
      id="Tc_j6sVDuXlVkGyv_bvBLYRyA_7_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">67000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_h6CnSCl4dECh1YLUxQk6ag"
      decimals="-3"
      id="Tc_9R8rciSuq0uDYmpT35JVZg_8_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"
      decimals="-3"
      id="Narr_5q9HVIUgyUeUlZWGNrFN8A"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"
      id="Narr_ODa3EU-15EqPg6LSYs-8sw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"
      decimals="2"
      id="Narr_7kdciTq9P0ChwZep8WboaA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_ZLWYbHXJ0E2qe4KlwKeNaQ"
      decimals="2"
      id="Narr_3qbtS_0rhE-DYbESZY9ehw"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">19.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2023Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_SiWlKh8skUWL3uCUhIDNLw"
      decimals="-3"
      id="Narr_zUeutilYMU-ogFV15mDFBQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1417000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A"
      decimals="-3"
      id="Narr_HIcuh8LU9UatecNs4rJlgw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_p2sWFHswF0-DPdbaZVQ8aA"
      decimals="-3"
      id="Narr_vW9iNuloskayMX6QfSlqRg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A"
      id="Narr_hQq_EHMacU-nn51XSEQRPA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A"
      decimals="2"
      id="Narr_8ppD3PRQ0kuJJFcJpRniMw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IX6hI-H8FE6Sxk8kEK1KPA"
      decimals="-3"
      id="Narr_uyPiX1BFHUiSgl8iDvplrQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ENmMDZVWL0Sj71YGtPStYQ"
      decimals="2"
      id="Narr_hVMO5qsCFkuEhOAVWcM1eg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_MR5qR4kyN0-hdzMJttdn5A"
      decimals="2"
      id="Narr_ta-CtRtqhk27TCmgBdefwg"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardDateAxis_btai_ShareBasedPaymentArrangementGrantDate2022Member_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9upi1ce5e0qUxLvJvKR5mg"
      decimals="-3"
      id="Narr_P32ujpSzwkempbq7G4csXA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">298000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw"
      id="Tb_KN0gzo-L5EqipSDhxCWlsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw"
      decimals="-3"
      id="Tc_pyZliU9SFUCAiJWY1fvo0g_5_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">543000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw"
      decimals="-3"
      id="Tc_c3VtU_gtok6YFAEmguGQpA_6_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_a1Cs0RhSBUWu9ebIk9a4Uw"
      decimals="-3"
      id="Tc_S4Xm8sKxtkS1tE7TPDmyjA_7_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">527000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_UWn9MaHj40m9ggi57C5_7A"
      decimals="-3"
      id="Narr_y-whzeCLAkufai43IpoueQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">543000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_10_1_2023_To_10_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5JKcWlgs30ac0qBkTIeQIw"
      decimals="-3"
      id="Narr_AyGbgDJcnkKo_S7WX91NLw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_p3_hhWFiREeo8nnIsabskA"
      decimals="-3"
      id="Narr_D5jqdzi_Xka0zpYIG5eJ9g"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw"
      decimals="2"
      id="Narr_JFYdWGKeD0a5yWVXKQ9oCg"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">2.43</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_Wkmv7D-DCUaqmZjIi60unw"
      decimals="-3"
      id="Narr_USSs7RZKlE6C7TICBuZUPg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_a1Cs0RhSBUWu9ebIk9a4Uw"
      decimals="-3"
      id="Narr_l1rUaSukEEmUskfXNXNMyQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">515000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      id="Tb_Ebf61CA_LUerYTJd0WDlSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per unit&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in whole dollars)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested units as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ"
      decimals="0"
      id="Tc_owEIm-zEdUysPQOKMlfGRQ_6_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ"
      decimals="0"
      id="Tc_6OcyRfO6sE68aBGJgItvqQ_6_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">5506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="0"
      id="Tc_h30eqbPawk-Hc0WLL3qsmQ_7_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="0"
      id="Tc_RP42BkKUmE22qj8rWEBCfg_7_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">10176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="0"
      id="Tc_v6rbPuIzIEaKeittyXoa4Q_8_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">100</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="0"
      id="Tc_wLlaVoF1YEWzlLP2dAsIxA_8_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">5506</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw"
      decimals="0"
      id="Tc_bX-Jb4qjY02sCaMxOt3ahQ_10_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw"
      decimals="0"
      id="Tc_qd1KTC2ltUGSCOtqJTAQEQ_12_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw"
      decimals="0"
      id="Tc__2hgc7BOr0uECqOudYbUZw_12_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">5533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="0"
      id="Narr_5QIi6CwIw0m7EWTNIksmJg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_VRCkfH11u0yQPf850NGkwQ"
      decimals="0"
      id="Narr_vPWbVG0qDEqpkW23L-kK3g"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      id="Narr_xiXAEv6gykWPYQxj3vMLYg">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_us-gaap_GranteeStatusAxis_srt_ExecutiveOfficerMember_7KyW7kaoLEujFskhyoTCJQ"
      id="Narr_dzsQEmMrpUy1L1VjHoXV6w">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="0"
      id="Narr_H_y6MGc5ukelIxWGb4E8OA"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_VRCkfH11u0yQPf850NGkwQ"
      decimals="0"
      id="Narr_HNzAOUWQG0-MDOIawMGsZw"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="-3"
      id="Narr_CQzZViI1iUaQ3KndtCXPpw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1942000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      id="Tb_NCeaFdPS7USzgBRgNL92Yw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023 grant profit share unit valuation inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="3"
      id="Tc_1WPT-eemIk-5oW-Lk83GOg_4_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="3"
      id="Tc__Tda7uRFGUOFfr1-G828Qg_5_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="3"
      id="Tc_wfC7LzRkYkG34Rx9wbSIUQ_6_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      id="Tc_XPopO7EUR0CwS4S_nHcbRQ_7_2">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_Brod3oi6106-eBbbCHVUPw"
      decimals="-3"
      id="Narr_hjtD8fThK02S4vdaBd7zRA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">971000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember_vvk8dyuBMEa40AOgq18BBQ"
      decimals="-3"
      id="Narr_ACQrzGigL0K71bKRJTfhBA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">4588000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA"
      id="Tb_rR2fEzb6W0GzwTim7c9a2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA"
      decimals="INF"
      id="Tc_-xEp0YxPJ02tt-tZwkKsog_6_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uLG7LMwfw0CKpBUSpaBN1w"
      decimals="INF"
      id="Tc_nP_3eZ5mDU68HIRXDGRCTQ_7_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA"
      decimals="0"
      id="Narr_9Tp5oHvd3UqTqQRNf9GNmQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_LFEwrHLb3k630YwocgejDw"
      decimals="-3"
      id="Narr_sq_NRDN5TECX7XzvMKDHlg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_LFEwrHLb3k630YwocgejDw"
      id="Narr_OxilrCKCHkGmd0FLiJp8Og">P180D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0uPjNo82rUCxuxmCApfRtg"
      id="Narr_ju017TyH9k6SzMcIpf7OYQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0uPjNo82rUCxuxmCApfRtg"
      decimals="2"
      id="Narr_NendxdHg9kWtcxStRzLPrw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_7hVcvz6PCkG5C8in_yDAdA"
      decimals="0"
      id="Narr_aYgvWVQDPEW3hWFzAi5Q9A"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_uLG7LMwfw0CKpBUSpaBN1w"
      decimals="-3"
      id="Narr_87_xhLiUqUO8u6RNTETqLQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">552000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_rlZHxGp9jEGKn5OLvqNwjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (651)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (309)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options vested and exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,479&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw"
      decimals="-3"
      id="Tc_q_r7tB2vG0SC-IxMc_pE1w_5_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">4882000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw"
      decimals="2"
      id="Tc_0laVdB89eESOrmnVenvTnA_5_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">17.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="-3"
      id="Tc_q0dAuxCmUk6gDThhs6OnOA_6_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">1090000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Tc_Zdy4Vb6xuUGLAnlUdUMdVg_6_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">19.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="-3"
      id="Tc_2oQfGpTyF0KcQnr0bYrkIA_7_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">651000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Tc_HI34gZSdM0Caru7hoVkMiw_7_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">17.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="-3"
      id="Tc_C8RjaylxzEqe5-S6PG8IuQ_8_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">36000</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Tc_7HY5l0VA0ESPo2eW5COA9g_8_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">24.67</btai:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="-3"
      id="Tc_4krTelo520arTRCGIKZWew_9_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">309000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Tc_sWo-QhwXLEqzMWR78J6utA_9_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="-3"
      id="Tc_kgxRP7z1m06UsiKaiocF_A_10_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">4976000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="2"
      id="Tc_9aMxu812qUqZiDg9_dNmQg_10_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">18.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="-3"
      id="Tc_UMtNOdoUAECOR9G5qwJjmQ_12_2"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">3479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="2"
      id="Tc_3EgQY3QsTki2UzDavGKAQQ_12_5"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">17.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="-3"
      id="Narr_CSM2LRV82EewpIj9XZ248w"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3149000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="-3"
      id="Narr_DnAuPrcRjEylW-3R328tQA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">5928000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"
      decimals="-3"
      id="Narr_8vGg6XL-Uka6Jg3pQo4xrQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2437000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="-3"
      id="Narr_GKF-bIbFA0-pSxcULfHk6w"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3148000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oEezeG7p30GsmWPq6fSCpw"
      decimals="-3"
      id="Narr_kKhtcip1AEqs0AGXnHTF1Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">40255000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Narr_YpsLWUdtjUi2kKabzqc6Iw"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"
      decimals="2"
      id="Narr_rmzYshSQF0e4zped8l2EWQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Narr_3jbd_C0b5Ei2jigfRpskQA"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">12.86</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      id="Narr__S1E3LohL0WPVuLBwwbqWw">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      id="Narr_d0poiiyit0WC3bSaELlL_Q">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_tobrkXDnjkSWBhWzowTy2A"
      decimals="-3"
      id="Narr_avYhochPdkCIgK1gg1ugLA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">9478000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      id="Narr_YIkmg_L0jkOYTw-cEox3Tg">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      id="Tb_88qxIVFcgE2I8SmNBdTXIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;96.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;109.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;92.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;99.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OTZS4zpsIUmXN4c6tbKJVw"
      id="Tc_4mDqRI6h60CMUh9mz-ZhCA_5_3">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bVD8ivCGrESTiF07tgD9xQ"
      id="Tc_zWlLo40z8kSw4hZHKxxWQw_5_6">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pKAAtUPo1Ey3Co1MIzsM-Q"
      id="Tc_wfh33KOlTEiL59Fn8A3njw_5_9">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WnuQlcoII0qSBZBbrHkrEg"
      id="Tc_tXErJON81US1nXT_VeoMcg_5_12">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="3"
      id="Tc_lcsKYo5p3US4B6kX0IeXJw_6_3"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="3"
      id="Tc_f1lhHW4ofUeJUh1MAuT21A_6_6"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">1.099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"
      decimals="3"
      id="Tc_Hfwyz4zTXECJhgefG1nARw_6_9"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"
      decimals="3"
      id="Tc_kaavVxHZe0uKsdGaTJ8axg_6_12"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="3"
      id="Tc_Jr41-ZstYk6rHuqzzDSKXQ_7_3"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="3"
      id="Tc_444eHLHcrUGE7jj5sXYoBw_7_6"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"
      decimals="3"
      id="Tc_JxTa1VZLikG28Uu8r0mbBw_7_9"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CL9JTvqy5UmWZOrM46w-Bg"
      decimals="3"
      id="Tc_2kE3Jpemek-q1uwvGgyheg_7_12"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OTZS4zpsIUmXN4c6tbKJVw"
      decimals="3"
      id="Tc_yiQ4J9VYuk-YKiWah1Yw8A_8_3"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_bVD8ivCGrESTiF07tgD9xQ"
      decimals="3"
      id="Tc_3Mf9OoIf-UuiSSjMfMHcKQ_8_6"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pKAAtUPo1Ey3Co1MIzsM-Q"
      decimals="3"
      id="Tc_RWTaPLsrz0Gn7VsR-yQUwA_8_9"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_WnuQlcoII0qSBZBbrHkrEg"
      decimals="3"
      id="Tc_jrCYY1ZqeE2qzYDocrT9Uw_8_12"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zn032FwMWUSmk75ILHSVrQ"
      decimals="2"
      id="Narr_nlVkDI2VI029a9Cd6txknQ"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_btai_TimeBasedProfitSharingUnitsMember__VV477dsRUqEDy0S9GVZKA"
      decimals="-3"
      id="Narr_7Nsm2jSr80iXG67T10cIQg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_btai_RestrictedStockUnitsOnkosxcelMember_9h1xuVneFkulBXYqApNPsA"
      decimals="-3"
      id="Narr_rWJo4J5bV02zjvnNUlNRhw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">17337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_KpqfUl0JsUuJkHH7wfqqKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,290&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LO90L5PoDEivpd5VLIVaEg"
      decimals="-3"
      id="Tc_L_JAjxn4wU2MPhZ4wl9HQw_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">6324000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_YNOnCMIhzk-zL6WUrMzXvQ"
      decimals="-3"
      id="Tc_X9wNPBA6QkO5j5vDGy6LiQ_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">4558000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jlMfMWAUtUG3OTUw8vN1rg"
      decimals="-3"
      id="Tc_r7V2RhISsE2DivEeAynOjQ_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">12290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_o3kSuLNg7k-AKoYTLeldyA"
      decimals="-3"
      id="Tc_fvDFKNRj0Ey4skoMa1iLaw_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">12779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_an4boZm7Q0KyDpSjidC6QA_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">18614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_vccsPtlmEUqJuff-JPZXQQ_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">17337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_QZPms-_JDE62jRgrcbtUIg"
      decimals="-3"
      id="Narr_HMfxwv7J4UmZqiNolnVXyw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg"
      decimals="2"
      id="Narr_wSvQMzt2ckqSOr92TKlJWQ"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.01</btai:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant>
    <btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg"
      decimals="-3"
      id="Narr_Fv8b46VO-UKJJvTjW_eUDw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">500000</btai:EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_5_20_2020_To_5_20_2020_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_AHywNuIj80KiyarRvxHvZg"
      decimals="2"
      id="Narr_8YJ3pkxw6UiwCNtdf5bFlg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_Y1r3H-NssUGDKP2nkYl0gg"
      decimals="-3"
      id="Narr_0qyYPCUUT0WEmJibevKalA"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">281000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_v-MW3gW6_0OhWwhL83cZBQ"
      decimals="-3"
      id="Narr_xcpHmIyVr0KUPy1msZahgQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_x7P2HSC51kqvtDIeyiG1VQ"
      decimals="-3"
      id="Narr_6YWyyetGw0mmhveZWJ8zCA"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_btai_EmployeeStockPurchasePlan2020Member_kttjLkP_lUGbpgLUyc0SDA"
      decimals="-3"
      id="Narr_6rWhvjEGv0SYyl9VBSk9MQ"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">905000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb__RCR3SL9eE2jiL4OqP3LTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;13. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#x201c;HQ Lease&#x201d;) under an operating lease that expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company also leases equipment such as copiers and information technology equipment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The future minimum annual lease payments under operating leases, as of December 31, 2023, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (51)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (346)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The current portion of the Company&#x2019;s operating lease liability of $346, as of December 31, 2023, is included in &lt;span style="-sec-ix-hidden:Hidden_YDje09iS6UufW2YFrYa5Ng;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt; on the Consolidated Balance Sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Lease expense was $392 and $410 for the years ended December 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Lease renewal options are not included in the ROU asset or lease liability.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Narr_Dd3zCmKItEmXat2oge76gw">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      id="Narr_1tBvtStaKUufSo9gYdjZbA">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_5Fb7vqCESEWtdVT9I_WZ6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; Imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (51)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 786&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (346)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     Long-term portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 440&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_oujHAnTL2kSApiJqoByfQw_3_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">381000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_3t7Y5PQZtkS85YoEL31FNA_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">391000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_Nswn9keCAU6TDRJxkb5Lww_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">65000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_xsQuQShtKkKaHb59j4G33w_9_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">837000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_S-3mLuc76EmUAq27ZgpE2w_10_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">51000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_WM9TXVkJ-Ua-vHHIswPoIg_11_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">786000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_d-iWJJ4_HUe5MkJHzVU7wg_12_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">346000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_lgdDx5ZDFkuQawSlFYsOeg_13_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">440000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_E2UcdRq4pEa1Wg2tCMegng"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">346000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_ecX48SUZ8E2UWZ9eKGgCog"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">392000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Narr_PxR2EfwZQE2V3n1CuwWKew"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">410000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DefinedBenefitPlanTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_idxdCA1nYkSU-Mdyh9nYDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 14. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company maintains a defined contribution retirement plan for its employees that complies with Section 401(k) of the Internal Revenue Code (the &#x201c;401(K) Plan&#x201d;). Employees are eligible to participate in the 401(K) Plan and can contribute a portion of their pay into the 401(K) Plan, subject to annual limits established by the U.S. Internal Revenue Service. Participating employees receive an employer matching contribution equal to 50% of eligible employee contributions on the first 5% of eligible compensation contributed. Employer contributions to the 401(K) Plan were $788 and $568&lt;span style="background:#ffffff;"&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="2"
      id="Narr_z7CoYZsPUk6ioJ-82dje3Q"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="2"
      id="Narr_8iEZKLABsUOCxgsZhOH2eg"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_IjVDJhEBJEGqUW0xPZAUdQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">788000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Narr_tefBzOlRNE6lzN_lpYskyg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">568000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_uOaOp-TM1EKXArrMRD6JVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;15. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, Summary of Significant Accounting Policies, for additional information on the accounting policies related to fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The carrying amounts of Cash and cash equivalents, Accounts receivable, net and Accounts payable approximate fair value due to the short-term nature of these instruments. As of December 31, 2023 and 2022, the Company had $64,860 and $191,022, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in Cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative liabilities measured at fair value on a recurring basis are summarized below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - Equity Investment Right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lFagk5bTnEemlWdu4CgnkQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Derivative liabilities are comprised of the OnkosXcel Warrants and Equity Investment Right held by the Lenders. The fair value of the derivative liabilities was determined using Monte Carlo simulation models for the Equity Investment Right, and Binomial Option Pricing and Distribution models for the OnkosXcel Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2023. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (438)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The derivative liabilities were reported at their fair values in the Consolidated Balance Sheets. The changes in the fair value of the derivative liabilities were reported in the Consolidated Statements of Operations as Other (income) expense, net, for the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;Inputs used to calculate the estimated fair value of the Equity Investment Right were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Strike price relative to volume weighted 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility (annual)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probability of exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Time period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated premium to 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at 100% based on the historical volatility of the Company&#x2019;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The estimated fair value of the Credit Agreement as of December 31, 2023, was $88,210. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $200 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 3. The inputs used were a strike price of $3.6452, the Company&#x2019;s stock price of $3.71, volatility of 99%, term of 5.4 years and risk-free rate of 4.14%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The fair value of the Original Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $3,245 was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 3. The inputs used were a strike price of $20.04, the Company&#x2019;s stock price of $14.93, volatility of 95%, term of 7 years and risk-free rate of 2.95%. As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment&lt;span style="font-size:12pt;"&gt; of the &lt;/span&gt;Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Original Warrants granted to the Lenders to have an exercise price of $3.6452 per share.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Using a Black-Scholes pricing model, the Company determined that the Amended and Restated Original Warrants&#x2019; fair values at the original strike price of $20.04 and the amended strike price of $3.6452 were $548 and $802, respectively, as of the Second Amendment Effective Date. The Amended and Restated Original Warrants&#x2019; incremental increase in fair value for the repricing of $254, was recorded as a component of stockholders&#x2019; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_Z17gbjnh30i21j6FjyTHjA"
      decimals="-3"
      id="Narr_b-8qfp22ckW3mio3LrpedA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">64860000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_r3W4hkyAb0-K4kHx7gA8ng"
      decimals="-3"
      id="Narr_t7csAPozNEKT9CQKcH0SPg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">191022000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_EJyycNpVrUiI3NE3kOk-zg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - Equity Investment Right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liability - OnkosXcel Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 712&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_lFagk5bTnEemlWdu4CgnkQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;     Total derivative liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_Wce1URlIPE-m9fYpV9zeJQ"
      decimals="-3"
      id="Tc_SvNv9jx6z0qfW9mdXY0k2g_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1193000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_VGlEMLwpK0G_B3i2obOKVQ"
      decimals="-3"
      id="Tc_vp02gghESk-dzyRILGK20w_5_12"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1193000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember__Ry2HIqDsUKb1qJ9uR4b3Q"
      decimals="-3"
      id="Tc_Lyi46rPtLUyriWrwAJj32g_5_15"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1193000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_LnJ5CJh_wUO7oAOB1qWnWQ"
      decimals="-3"
      id="Tc_c8MWGq9Ay0uRHycaFEO_3Q_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">712000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7hC-g0hRVUyUylsJ4F6ZoA"
      decimals="-3"
      id="Tc_9zheJjuY3UuCusNDACsUKA_6_12"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">712000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_S6sTUJ5nc0O-S3nh1hH-8g"
      decimals="-3"
      id="Tc_Ea_1diUXdEOWzxtGM29vEA_6_15"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">712000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_If0SwRWVoEKPCeiBpygDpA"
      decimals="-3"
      id="Tc_TF69AxboXEy9ljk0AJQ9eg_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1905000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BBwsCn9q10ez32Xp3IZYGw"
      decimals="-3"
      id="Tc_SWLCiWIe7kWyu66Se_4U7w_7_12"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1905000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_z8wGFoFQHkGh9pMeSDi2Ig"
      decimals="-3"
      id="Tc_ExxI2hNtoE6iDMAF1jlVmw_7_15"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1905000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_uwZ0jWHmLk6krSRZtFTIog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (438)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative liabilities, Balance - December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,905&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_8lEUU38T2Um4yVWzcVCGeA_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2343000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_Dblb8aBGC0S_PNnG90epNA"
      decimals="-3"
      id="Tc_4j4Tsidu-ECCbyVYDCgUlQ_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1954000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_IAHDWMrEHk2VXqkwg67NYA_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-438000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_bRGAyO6gLEyvViJmtnKsvg_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">389000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_K17OfBjfJEWEcedQhN3j3Q_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1905000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_ehyMRMpNoEWBiV6Vy7m_Aw_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2343000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_HT7qBQK3BkGVDH_zXjxyHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Equity Investment Right&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Strike price relative to volume weighted 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility (annual)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Probability of exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Time period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated premium to 30-day average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_nhdn74qyc0WhUslR4qua3g"
      decimals="3"
      id="Tc_HaC7igu9ZUWEAYpJZqVq3g_3_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">1.100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_JGhzkv0Pn0-_E2xmVYozig"
      decimals="3"
      id="Tc_j0jyl7sPgEqXzjNOMtPU2g_4_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.991</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputProbabilityOfExerciseMember__t5_rrWTAkSvW4vx2R3MKg"
      decimals="3"
      id="Tc_dsdFwnqo2k2SEeQdWCVuBA_5_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.900</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_EiQqzjUCAki7PrEDtNqD5g"
      decimals="1"
      id="Tc_HFf440RA90SSqCFOyNJFnw_6_2"
      unitRef="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg">3.3</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_btai_MeasurementInputEstimatedPremiumMember_l5-tles4rk6AJ38rbZ5qDQ"
      decimals="3"
      id="Tc_HoMZpmpfw0qS29VeDPoXIg_7_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.240</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_EquityInvestmentMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_UWym6eYkO0i2Db4epU9hOg"
      decimals="3"
      id="Tc_SdxOtaFVekemPOrWimLZmg_8_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.044</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_OnkosxcelWarrantMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_CZOqcLp0PUKVcyA1bGHQyQ"
      decimals="2"
      id="Narr_w5lH-Yt4K0mp24ZjcH_oLA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentFairValue
      contextRef="As_Of_12_31_2023_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_QqK6CXmt7USNlx7Fnq2UXg"
      decimals="-3"
      id="Narr_pjURN-RQpkuyFNs2A18mDg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">88210000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_xk0Q89gawUCTwiTOaOpAWQ"
      decimals="-3"
      id="Narr_OJVNgWcP4UO9C8Qm9yHEXg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">200000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_zrIRZIK4QUyE2BqXAHd39w"
      decimals="4"
      id="Narr_1tqEQKcbzk6S3pgaVaQwFA"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.6452</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_n9fLqTrqZkCK8GBCnlZSGQ"
      decimals="2"
      id="Narr_mDk1vGKhRkG3qZxOBos7fw"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.71</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_A6wlGoCQXEKa2GVlvoBZ6A"
      decimals="2"
      id="Narr_La9foYiGMU-I6RC46q55xQ"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.99</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mA8YOGT8Mk-UH8QN9ncEhQ"
      decimals="1"
      id="Narr_I-oHWsxW9UmCuUi-WZZHoA"
      unitRef="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg">5.4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_NewWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_NC_OkAZruUWuB05QvPr4mA"
      decimals="4"
      id="Narr_pV3lioHCJEugQDvAhf8CAw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0414</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_4_19_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_l0eKFbmYak-MM_PaI1sfPA"
      decimals="-3"
      id="Narr_JQIv3PvyeE2jLl13TCtVDw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">3245000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_7PDK9HAQOUe7s0Ry8BL5WA"
      decimals="2"
      id="Narr_CLU9czgWh06vDUOrlbskVw"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">20.04</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_2iBcLPYPak63zB2SGjujoQ"
      decimals="2"
      id="Narr_vFLvU335XESCZ8mRT5FpBA"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">14.93</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wGIdAt1pk0uCvgXve4GiLw"
      decimals="2"
      id="Narr_-4pA-ytFUUGhNfhV0cKvpw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.95</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tz8ZkPV9rEagiQzVm1c8XA"
      decimals="0"
      id="Narr_heKBBB8mK0evLfPFBmFuIg"
      unitRef="Unit_Standard_Y_cWD-oILnzUCRbA7a5cawdg">7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZjevHEcIPEOgTS172gTu_w"
      decimals="4"
      id="Narr_1MLGrTz11ke1pR5DzvPYQw"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.0295</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w"
      decimals="4"
      id="Narr_5jfXnpGwr0Ov5YYjFNBdBQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.6452</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_GpdoISruzku_097J5reooA"
      decimals="2"
      id="Narr_GzLy33kGwEG01njDoNOA_Q"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">20.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w"
      decimals="4"
      id="Narr_U3FPRNp3MEuqZZWeSvsSlQ"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.6452</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_GpdoISruzku_097J5reooA"
      decimals="-3"
      id="Narr_XujKl_OTekGFl_8mMf96Kg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">548000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_rgUj12lSNk-32G5bFeqe8w"
      decimals="-3"
      id="Narr_21H0KQb4f0WeBd7kaIVBMw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">802000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="Duration_12_5_2023_To_12_5_2023_us-gaap_ClassOfWarrantOrRightAxis_btai_WarrantOaktreeAndQiaMember_PntQCMUJZkeGnizT8u1Fug"
      decimals="-3"
      id="Narr_c04CF5aBJkuIO1RC6GIZEg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">254000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_Ug6q8k-x-0qcoEyHNkGErw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;16. Income Taxes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;There is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the years differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses primarily because of changes in valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;For tax years beginning on or after January 1, 2022, the 2017 Tax Cuts and Jobs Act amended Section 174&#160;of the U.S. Tax Code to eliminate current-year deductibility of research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the U.S. and fifteen years for research activities performed outside of the U.S. For the 2023 tax year, the Company capitalized $78,002 of research and development expenses. This resulted in an increase in the deferred tax asset associated with capitalized research and development of $20,985. In determining the realizability of the Company&#x2019;s net deferred tax asset, the Company considered numerous factors, including historical profitability, estimated future taxable income, and the industry in which it operates. Based on this information the Company has provided a valuation allowance for the full amount of its net deferred tax asset because the Company has determined that it is more likely than not that it will not be realized. The significant components of the Company&#x2019;s net deferred tax assets are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,048&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173,679)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (118,373)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized gain&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (256)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (197)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (256)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;The income tax benefit for the year ended December 31, 2023 differed from the amounts computed by applying the U.S. federal income tax rate of 21% to loss before tax benefit as a result of nondeductible expenses, tax credits generated and increases in the amount of the Company&#x2019;s valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;A reconciliation between the Company&#x2019;s effective tax rate and the federal statutory rate are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December&#160;31, 2023, the Company had approximately $351,284 of gross federal and $360,081 of gross state net operating loss (&#x201c;NOL&#x201d;) carryforwards. If not utilized, the federal and state NOL carryforwards will begin to expire in 2037. The federal NOL of $348,638 incurred after December 31, 2017, will be carried forward indefinitely. The utilization of such NOL carryforwards and realization of tax benefits in future&#160;years depends predominantly upon having taxable income. The Company has approximately $14,345 of federal orphan drug and research development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $1,206 of state drug research development credits which will begin to expire in 2040 if not utilized. &#160;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Utilization of the NOL and research tax credit carryforwards may be subject to a substantial annual limitation due to ownership limitations that have occurred or that could occur in the future, as required by section 382 of the U.S. Tax Code, as well as similar state and foreign provisions. These ownership changes may limit the amount of the NOL and research credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change," as defined by Section 382 of the U.S. Tax Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock by certain stockholders or public groups.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December&#160;31, 2023, there were no uncertain positions. The Company's U.S. federal and state NOLs have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of NOLs from prior years opens the relevant year to audit by the U.S. Internal Revenue Service and/or state taxing authorities. BTI did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2023 and 2022. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:AccruedIncomeTaxes
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_Ah7jMeqp30alwKKV5rl0dQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:AccruedIncomeTaxes>
    <btai:CapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_E_EYA6GrNEubMQPGYlb8Cg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">78002000</btai:CapitalizedResearchAndDevelopment>
    <btai:CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_190h41raN02j4Q9ORoH2mQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">20985000</btai:CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_-CEelx_t3Eagxd_OEcrr7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;State net operating losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,915&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,705&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,048&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,689&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,603&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,663&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (173,679)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (118,373)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Unrealized gain&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (256)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (197)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (256)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_1UKC_Rattk6NN7saRnPQUw_4_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">73770000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_nlAPatuptkm_g7Wwd_RjGg_4_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">46695000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_5sObLXNtkEaO3WuU_emp6A_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">21255000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_8O5T-VU-s0mr82kyBY6dMw_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">11271000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_U8Z9_5jTPECuO2_JpZlNmA_6_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">13915000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_yCRQCj6rn0q2kTh5CytkLQ_6_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">10705000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_ktkqgXFvrU-7o9lFBZQ0dA_7_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">15048000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_C-cBITydLUiICKbr0z6XmA_7_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">10689000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_he4tx3mrgkuCNf7-sBS5Wg_8_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">49603000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_l_EiM2F7BUubH5AlmdLqhA_8_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">36663000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_nhKNmcczaEaH3wM0Qii4yA_9_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">2171000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_k7c2dX_RlkuxEl87LCP7QQ_10_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">73000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_e06DajOXo0qw3EF1S_fx2g_10_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">42000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <btai:DeferredTaxAssetsLeaseAccountingLiability
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_0eDsaBTqlEGC08hTCkuYig_11_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">212000</btai:DeferredTaxAssetsLeaseAccountingLiability>
    <btai:DeferredTaxAssetsLeaseAccountingLiability
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_nsY3K0qp4U6ik-r34dX2iA_11_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">290000</btai:DeferredTaxAssetsLeaseAccountingLiability>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_ajBhG4GO2k6x4b19pJR9Yg_12_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">103000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_MLGIxIqfsEmLjeNtnvFLxg_13_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">173679000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_2M3LYXJifEOOMp6DsMGhJg_13_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">118373000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_Ff4Y39QqJEeaYCTQqxvGWQ_14_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">197000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_Hma7c0kwk0uhrUY397GM3g_14_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">256000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesDerivatives
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_T2raM4U900-YAegYDaz8OA_16_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">12000</us-gaap:DeferredTaxLiabilitiesDerivatives>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_yB3g1BEUSEW_0iIs0zPkNg_17_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">185000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_cf3Tb9HzLEqr5TU2a_8VlQ_17_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">256000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Tc_glJvVmzy8EWc6Z4ZdQhU8g_18_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">197000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Tc_T4Y-aGut3Um0RuSrU2IxrQ_18_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">256000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="2"
      id="Narr_GDdiXJekiE-hlCWC0UXDmA"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_3zW6X2RetEeRdgSq55vEPQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="3"
      id="Tc_GZDVRvICCEuTYVZ0au4cjw_3_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="3"
      id="Tc_gqtLJUPkh0CdxkdfE-MSqQ_3_5"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="3"
      id="Tc_4hbtG-Jt7k-9CV1AtyWpzw_4_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="3"
      id="Tc_V3upSTn0i0m0OYcPoHcvpw_4_5"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="3"
      id="Tc_jnoJfXx3QUOFEIO3VNKMLQ_5_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="3"
      id="Tc_m5q9_0luNE6mRapodF8ALQ_5_5"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="3"
      id="Tc_5nXWUd8fZkqRc4MVbJ9LRA_6_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="3"
      id="Tc_wjM2UhFfFU6Y5k9ZjYZC_A_6_5"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="3"
      id="Tc_aixN2BPN6Ei-rRCiJVjyyw_7_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="3"
      id="Tc_6yYJL38IBEGP4-2fGlbgNA_7_5"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="3"
      id="Tc_Xf2b--WTs0SHR49eOUlWaQ_8_2"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">-0.309</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="3"
      id="Tc_SAjA-9n1_kCs7vU2YImUNQ_8_5"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">-0.280</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_W2i9WK1SZUeMOgcqPDEO-A"
      decimals="-3"
      id="Narr_LcNf9Ly87EWia-AeSxjvvg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">351284000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_yu4AYaDZ_Ue7i6ZZWzIm3A"
      decimals="-3"
      id="Narr_0RQJJkT3qkiWqyADR99oYQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">360081000</us-gaap:OperatingLossCarryforwards>
    <btai:OperatingLossCarryforwardsNoExpiration
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_PAvNB56MBEKJ0Z-J0S2bhQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">348638000</btai:OperatingLossCarryforwardsNoExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_W2i9WK1SZUeMOgcqPDEO-A"
      decimals="-3"
      id="Narr_TJKhzoyoz0eDF5mbg1_ivw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">14345000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_yu4AYaDZ_Ue7i6ZZWzIm3A"
      decimals="-3"
      id="Narr_9r85Fsy8OkqjldcMvN1u5g"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1206000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_YOF5gbkWAk2sZ8f7Skl2ww"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_FtL5qDTu2Eys3VrD_0WYWg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_fVgu62CClkewAaWim32Wxg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_BhX-gLXZwkqpvcAe-5g7ZQ"
      decimals="-3"
      id="Narr_vjPPEcIvdkGRYKMm0wUCCA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2023_PJbdxmrynUyJxbXgOnhc5A"
      decimals="-3"
      id="Narr_bmYIy4WhfkyVUJbfKRVc0Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_lFkZ8RsLEkyeUxxBM1sgog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 17. Net Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Basic and diluted net loss per share are as follows&lt;/span&gt;:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss (numerator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (165,757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares (denominator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.92)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding as of December 31, 2023 and 2022 of 6,036 and 5,280 shares, respectively.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_rgn3W3IFsE6VZBluTq3Qvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss (numerator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (179,053)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (165,757)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares (denominator)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,015&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.92)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_DzTJhKBsFEyYDZFOQuOyrg_5_3"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-179053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_sDY0q0dKM0q6OwJl0NRoaw_5_6"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">-165757000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Tc_QemXQII2KkysM7FxeU2Pqw_6_3"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">29129000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Tc_r8qKtqDZA0--dSRB3VOmTQ_6_6"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">28015000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="2"
      id="Tc_J4L0h73f-E-zrNVQZHRFMQ_7_3"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">-6.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="2"
      id="Tc__9QNt-3U2EeWuVWLmQoZAw_7_6"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">-5.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      decimals="-3"
      id="Narr_XtKCtWRBk0CtDJ2VBuDr4w"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">6036000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2022_To_12_31_2022_W40fp1gjsE26w5h6JOifVw"
      decimals="-3"
      id="Narr_0Giq832W60-r9iqYIfBOgg"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">5280000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_FaWCWFW4P06L0Kn-882lCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 18. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned Martin v. BioXcel Therapeutics, et al., 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#x201c;Exchange Act&#x201d;) and SEC Rule 10b-5 promulgated thereunder. The amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#x2019;s-related agitation. Defendants filed a motion to dismiss on February 6, 2024, which has not been decided.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Panancherry et al v. Mehta et al, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation, 3:23-cv-1554 (D. Conn.). The above-captioned consolidated action is currently stayed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Smith v. Mehta et al, 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Derivative Litigation, 1:24-cv-00041 (D. Del.). The Company expects to seek a stay in the above-captioned consolidated action.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total $10,000 for the three-year period&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted
      contextRef="As_Of_4_30_2022_GlNf8HOiWUu7zXkTvkFBsQ"
      decimals="-3"
      id="Narr_GqHV3VzUu0Kzi9zxi_yXkg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">10000000</us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted>
    <btai:AgreementCommitmentPeriod
      contextRef="Duration_4_1_2022_To_4_30_2022_TCiII9VhN0SRNqnqQ9rjQw"
      id="Narr_OoEu7gQYNEqUFFRK8lWR9g">P3Y</btai:AgreementCommitmentPeriod>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_6pV4Izn3JU2iEP5ycJpW1w"
      id="Tb_2oy11pNaOEuj-BthIpRoTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 19. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#x201c;Third Amendment&#x201d;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#x2019;s independent auditors that contains a &#x201c;going concern&#x201d; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#x2019;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$40,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in gross proceeds from a registered public sale of the Company&#x2019;s common stock, warrants and/or pre-funded warrants&lt;/span&gt; on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 20, 2024 (the &#x201c;Effective Date&#x201d;), the Company entered into a Fourth Amendment (the &#x201c;Fourth Amendment&#x201d;) to the Credit Agreement and Guaranty (as amended from time to time, the &#x201c;Credit Agreement&#x201d;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the Lenders, and OFA as administrative agent, pursuant to which the Lenders waived the covenant that the Company not receive a report and opinion from the Company&#x2019;s independent registered public accounting firm that contains a &#x201c;going concern&#x201d; or similar qualification with respect to the Company&#x2019;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#x2019;s independent registered public accounting firm&#x2019;s report contained in this Annual Report on Form 10-K contains a &#x201c;going concern&#x201d; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#x201c;Minimum Liquidity Amount&#x201d; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $25,000 from $15,000, unless and until we have received, after the Effective Date and on or before November 30, 2024, at least $50,000 in gross proceeds from the issuance of the Company&#x2019;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In connection with the Fourth Amendment, on the Effective Date, the Company granted new warrants to the Lenders to purchase up to 100 shares of its common stock (the &#x201c;2024 Warrant Shares&#x201d;) at an exercise price of $3.0723 per share (the &#x201c;2024 Warrants&#x201d;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of the Company&#x2019;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#x2019;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#x201c;Second Amended and Restated Registration Rights Agreement&#x201d;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As discussed in Note 11, Common Stock Financings Activities, the Company has previously entered into an Open Market Sale Agreement (the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), as amended, pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to $150,000, from time to time, through an &#x201c;at the market offering&#x201d; program under which Jefferies will act as sale agent. From January 1, 2024 through March 19, 2024, the Company sold 647 shares under the Sale Agreement for gross proceeds of $1,743 and received proceeds of $1,691, net of issuance costs of $52.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_2_12_2024_To_2_12_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_KN9Fx05BHkKau-z8hNvRxg"
      decimals="-3"
      id="Narr_khtmQw8FNkKdEVEV0IEQoA"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodOneMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_QEq2Y_AI2EClDFuZWnDU8A"
      decimals="-3"
      id="Narr_fnR7PvC7w0SS13pOQhF7mQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">25000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eky2EVddxU2Zk8lYvRBFDw"
      decimals="-3"
      id="Narr_ZM0sP8wa7kyvA0nIOliCRQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodTwoMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cxmDc-hxWEiaxO1wwjZa8g"
      decimals="-3"
      id="Narr_oOv1S4GnQEu1RWTkuyxIqw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">40000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_i38r8XQuQEOi9Le4Y7r8lA"
      decimals="-3"
      id="Narr_9d9oAqrOYUezILR0tfIF3Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">25000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement
      contextRef="As_Of_3_20_2024_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5UeYbgXGDEaW_6Z1qh8tGw"
      decimals="-3"
      id="Narr_sNGwNrBLLkGcTfX90IuHJQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">15000000</btai:DebtInstrumentFinancialCovenantMinimumLiquidityRequirement>
    <btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt
      contextRef="Duration_3_20_2024_To_3_20_2024_srt_StatementScenarioAxis_btai_PeriodThreeMember_us-gaap_DebtInstrumentAxis_btai_CreditFacilityMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_eky2EVddxU2Zk8lYvRBFDw"
      decimals="-3"
      id="Narr_elJTal3_o0aQpzCgUDlc0Q"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">50000000</btai:MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw"
      decimals="INF"
      id="Narr_MibmYLJhpEiokQkpjq1Arw"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">100</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fK5PKvSO1EKKq-t3SYEzkw"
      decimals="INF"
      id="Narr_n-mB1hKa-UqOoW9qnFBNBw"
      unitRef="Unit_Divide_USD_shares_HRBNiHE26EW8SFXu7W1A1A">3.0723</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btai:PremiumSharePricePercent
      contextRef="Duration_3_20_2024_To_3_20_2024_us-gaap_ClassOfWarrantOrRightAxis_btai_Warrants2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_os9ZcTj60EKmwN-8QTANZA"
      decimals="2"
      id="Narr_HZpgkPXfKEWMSaWDE7go7Q"
      unitRef="Unit_Standard_pure_28kRd1o7zUStC3z3wMErvA">0.10</btai:PremiumSharePricePercent>
    <btai:SaleOfStockMaximumValueSharesToBeIssued
      contextRef="Duration_11_1_2023_To_11_30_2023_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_qQIgqhjIAU-25A9Enh5x8Q"
      decimals="-3"
      id="Narr_cShbXD1dvkqzQ3VZL1YTAw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">150000000</btai:SaleOfStockMaximumValueSharesToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA"
      decimals="-3"
      id="Narr_dGy5B-vzWUmHuLuLPYYK1g"
      unitRef="Unit_Standard_shares_T551OJDnQ0Snfc_cg1RhrQ">647000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA"
      decimals="-3"
      id="Narr_uFCJKBHwN0WnGwN358DILQ"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1743000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA"
      decimals="-3"
      id="Narr_5rBBO6cmrUGCaJ5-hdc3iw"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">1691000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_2_16_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_btai_JefferiesMember_y2callLQR0CCBGtl3wyRlA"
      decimals="-3"
      id="Narr_0zClK0avoEqMFjSDpWYRvg"
      unitRef="Unit_Standard_USD_UFC5ptHm8kaJOjiOmpP2RA">52000</us-gaap:PaymentsOfStockIssuanceCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024787216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioXcel Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1386754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Long Wharf Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-6837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTAI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Stamford, Connecticut<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,938,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,576,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025032800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,221<span></span>
</td>
<td class="nump">$ 193,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">2,782<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">72,143<span></span>
</td>
<td class="nump">202,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,702<span></span>
</td>
<td class="nump">205,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,654<span></span>
</td>
<td class="nump">10,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,424<span></span>
</td>
<td class="nump">18,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,267<span></span>
</td>
<td class="nump">32,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">100,598<span></span>
</td>
<td class="nump">93,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">130,210<span></span>
</td>
<td class="nump">129,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000 shares authorized as of December 31, 2023 and December 31, 2022; 29,930 and 28,147 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">534,060<span></span>
</td>
<td class="nump">488,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(590,598)<span></span>
</td>
<td class="num">(411,545)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="num">(56,508)<span></span>
</td>
<td class="nump">76,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' (deficit) equity</a></td>
<td class="nump">73,702<span></span>
</td>
<td class="nump">205,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023214240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">29,930<span></span>
</td>
<td class="nump">28,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">29,930<span></span>
</td>
<td class="nump">28,147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024629088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 1,380<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">84,326<span></span>
</td>
<td class="nump">91,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">83,413<span></span>
</td>
<td class="nump">68,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">4,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">173,162<span></span>
</td>
<td class="nump">160,020<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(171,782)<span></span>
</td>
<td class="num">(159,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">13,314<span></span>
</td>
<td class="nump">8,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(5,649)<span></span>
</td>
<td class="num">(2,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(394)<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (179,053)<span></span>
</td>
<td class="num">$ (165,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (6.15)<span></span>
</td>
<td class="num">$ (5.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (6.15)<span></span>
</td>
<td class="num">$ (5.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">29,129<span></span>
</td>
<td class="nump">28,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">29,129<span></span>
</td>
<td class="nump">28,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024505824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 467,427<span></span>
</td>
<td class="num">$ (245,788)<span></span>
</td>
<td class="nump">$ 221,667<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">27,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165,757)<span></span>
</td>
<td class="num">(165,757)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">488,292<span></span>
</td>
<td class="num">(411,545)<span></span>
</td>
<td class="nump">$ 76,775<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">28,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">26,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Vesting of restricted stock units, net of employee tax obligations (in shares)</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,053)<span></span>
</td>
<td class="num">(179,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 534,060<span></span>
</td>
<td class="num">$ (590,598)<span></span>
</td>
<td class="num">$ (56,508)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">29,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027436144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (179,053)<span></span>
</td>
<td class="num">$ (165,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of financing costs</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(438)<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">18,614<span></span>
</td>
<td class="nump">17,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payable-in-kind interest on Credit Agreement</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use assets</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts receivable</a></td>
<td class="nump">177<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets and other assets</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="num">(3,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, due to related parties, and other current liabilities</a></td>
<td class="num">(3,219)<span></span>
</td>
<td class="nump">13,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">3,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(155,006)<span></span>
</td>
<td class="num">(135,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment and leasehold improvements</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING CASH FLOW ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(2,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs for common stock issuance</a></td>
<td class="num">(811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee tax obligations related to vesting restricted stock units</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">26,522<span></span>
</td>
<td class="nump">96,237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(128,504)<span></span>
</td>
<td class="num">(39,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">193,725<span></span>
</td>
<td class="nump">232,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">65,221<span></span>
</td>
<td class="nump">193,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of stock purchase warrants</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">3,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Repricing of stock purchase warrants</a></td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">7,551<span></span>
</td>
<td class="nump">$ 2,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ConversionOfAccruedInterestToLongTermDebt', window );">Conversion of accrued interest to long-term debt</a></td>
<td class="nump">$ 767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ConversionOfAccruedInterestToLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of accrued interest that is converted into long erm debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ConversionOfAccruedInterestToLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025937584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_OrganizationAndPrincipalActivitiesAbstract', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (&#8220;BTI&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company utilizing artificial intelligence (&#8220;AI&#8221;) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients&#8217; lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company&#8217;s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms &#8220;BioXcel LLC&#8221; refers to the Company&#8217;s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. &#8220;OnkosXcel&#8221; refers to BTI&#8217;s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (dexmedetomidine or &#8220;Dex&#8221;) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment na&#239;ve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company&#8217;s principal office is in New Haven, Connecticut.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_OrganizationAndPrincipalActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_OrganizationAndPrincipalActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026026240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2. Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#8220;U.S.&#8221;) Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, the Company had cash and cash equivalents of $65,221 and an accumulated deficit of $590,598. BTI has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $179,053 and $165,757 for the years ended December 31, 2023 and 2022, respectively, and had net cash used in operating activities of $155,006 and $135,341 for the years ended December 31, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s history of significant losses, its negative cash flows from operations, potential near-term increased covenant-driven amortization payments under its Credit Agreement, its limited liquidity resources currently on hand, and its dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in management&#8217;s assessment that there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the issuance date of the financial statements included in this Annual Report on Form 10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This going concern evaluation takes into consideration the potential mitigating effect of management&#8217;s Reprioritization (as defined in Note 4, Restructuring). When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans need to be approved by the Company&#8217;s Board of Directors. The Company&#8217;s Reprioritization was approved by the Board of Directors on August 8, 2023; however, such plans will not mitigate the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and does not include any adjustments that may result from the outcome of this uncertainty. The going concern analysis does not consider possible future amendments to or restructuring of the Credit Agreement (as defined in Note 9, Debt and Credit Facilities) or other potential sources of debt or equity capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to support the Company&#8217;s cost structure and operating plan. Management&#8217;s plans to improve the Company&#8217;s liquidity and reduce its operating expenses and capital requirements include, among other things, pursuing one or more of the following steps to raise additional capital, none of which can be guaranteed or are entirely within the Company&#8217;s control:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through the sale of the Company&#8217;s equity securities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through third-party investments in or other strategic options for OnkosXcel;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>raise funding through debt financing and/or restructuring of its existing OFA Facilities; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential partners to advance the Company&#8217;s product pipeline;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>establish collaborations with potential marketing partners;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>reduce overhead and headcount to focus on core priorities; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>any combination of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the Company is unable to raise capital when needed or on acceptable terms, or if it is unable to procure collaboration arrangements to advance its programs, the Company would be forced to discontinue some of its operations or develop and implement a plan, beyond its Reprioritization initiatives, to further extend payables, reduce overhead, scale back or cease some or all of its revised operating plan until sufficient additional capital is raised to support further operations. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026401888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.</p><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounts Receivable, Net</b></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Accounts receivable arise from sales of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> and represent amounts due from distributors. Payment terms generally range from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">75 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2023, the Company determined that an allowance for credit losses was not required.</span></p><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company sells </span><span style="font-weight:normal;">IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-weight:normal;"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#8220;GPOs&#8221;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span></p><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BTI capitalizes inventory costs associated with the Company&#8217;s products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Deferred Initial Public Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#8217;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7 years</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Selling, general and administrative expenses in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ROU assets represent BTI&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#8217;s leases do not provide an implicit rate, it used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and excludes lease incentives. The Company&#8217;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Debt and Detachable Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#8220;<i style="font-style:italic;">Derivative Assets and Liabilities</i>&#8221; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions of the debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Derivative Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#8217;s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is to deliver the quantity of product ordered to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#8217;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#8217;s Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cost of Goods Sold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#8220;BTI RSUs&#8221;), OnkosXcel profit sharing units (&#8220;PSUs&#8221;), OnkosXcel restricted stock units (&#8220;OnkosXcel RSUs&#8221;) and BTI performance stock units (&#8220;Performance Units&#8221;). The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) became effective in August 2017. The Company&#8217;s 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#8217;s closing stock price on the grant date. The estimated fair value of stock-options, OnkosXcel RSUs and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Black-Scholes pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards, and expected term of the award. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#8217;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Most of the Company&#8217;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#8217;s estimates with the service providers and makes adjustments if necessary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although management does not expect its estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#8220;more likely than not&#8221; that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#8217;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#8217; full knowledge of the position and all relevant facts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not have any unrecognized tax benefits as of December 31, 2023 and 2022. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Earnings (Loss) per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Earnings (loss) per share (&#8220;EPS&#8221;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#8217;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance (collectively, &#8220;Topic 326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) - Effective Dates, which deferred the effective dates of Topic 326 for the Company, until fiscal year 2023. The Company adopted Topic 326 in 2023 and it did not have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026334480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4. Restructuring</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">On August 8, 2023, the Company&#8217;s Board of Directors approved a broad-based strategic reprioritization (the &#8220;Reprioritization&#8221;). The Company took actions to reduce certain operational and workforce expenses that were no longer deemed core to ongoing operations in order to extend its cash runway and drive innovation and growth in high potential clinical development and value creating opportunities. These actions included a shift in commercial strategy for </span>IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="background:#ffffff;"> in the institutional setting, a reduction of in-hospital commercialization expenses, a suspension of programs no longer determined to be core to ongoing operations, and a prioritization of at-home treatment setting opportunities for BXCL501.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;background:#ffffff;">As part of this strategy, the Company&#8217;s Board of Directors approved a reduction of approximately </span><span style="font-weight:normal;background:#ffffff;">60%</span><span style="font-weight:normal;background:#ffffff;"> of the Company&#8217;s workforce. The Company notified impacted employees on August 14, 2023 and recorded total restructuring costs of </span><span style="font-weight:normal;background:#ffffff;">$4,163</span><span style="font-weight:normal;background:#ffffff;"> for the year ended December 31, 2023. These costs consisted of severance and benefit costs of </span><span style="font-weight:normal;background:#ffffff;">$4,063</span><span style="font-weight:normal;background:#ffffff;"> and contract termination costs of </span><span style="font-weight:normal;background:#ffffff;">$100</span><span style="font-weight:normal;background:#ffffff;">. The Company paid $</span><span style="font-weight:normal;background:#ffffff;">3,998</span><span style="font-weight:normal;background:#ffffff;"> of severance and benefit costs and </span><span style="font-weight:normal;background:#ffffff;">$100</span><span style="font-weight:normal;background:#ffffff;"> of contract termination costs in the year ended December 31, 2023. The Reprioritization is substantially complete as of December 31, 2023, and any remaining costs are expected to be paid during the first quarter of 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026292240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inventory consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 935</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 682</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 595</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,991</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,985</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">The Company recorded inventory write-downs of </span><span style="font-weight:normal;">$1,191</span><span style="font-weight:normal;"> for the year ended December 31, 2023. </span><span style="font-weight:normal;">No</span><span style="font-weight:normal;"> write-downs of inventory were recorded for the year ended December 31, 2022</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026138096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment, net consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,181</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,969</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (885)</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">Depreciation expense was </span><span style="font-weight:normal;">$318</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$327</span><span style="font-weight:normal;"> for the years ended December 31, 2023 and 2022, respectively</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025958384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7. Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,659</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,370</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,738</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 820</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,669</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026401888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with BioXcel LLC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Transactions with BioXcel LLC</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8. Transactions with BioXcel LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into a Separation and Shared Services Agreement with BioXcel LLC that took effect on June 30, 2017, as amended and restated thereafter (the &#8220;Services Agreement&#8221;), pursuant to which BioXcel LLC has agreed to provide the Company with certain intellectual property prosecution and management and research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the Services Agreement, we have an option, exercisable until December 31, 2024, to enter into a separate collaborative services agreement with BioXcel LLC pursuant to which BioXcel LLC shall perform product identification and related services for us utilizing its EvolverAI. We agreed to pay BioXcel LLC $18 per month from March 13, 2023, to December 31, 2024 in exchange for this option. We agreed to negotiate any such collaborative services agreement in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">good faith and to incorporate reasonable market-based terms, including consideration for BioXcel LLC reflecting a low, single-digit royalty on net sales and reasonable development and commercialization milestone payments, provided that (i) development milestone payments shall not exceed $10,000 in the aggregate and not be payable prior to proof of concept in humans and (ii) commercialization milestone payments shall be based on reaching annual net sales levels, be limited to 3% of the applicable net sales level, and not exceed $30,000 in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Service charges recorded under the Services Agreement for the years December 31, 2023 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,151</p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,401</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2023 and 2022, $0 and $310, respectively, of these service charges are included in Due to related parties in the Company&#8217;s Consolidated Balance Sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026327696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Credit Facilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9. Debt and Credit Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Debt, net of unamortized discounts and financing costs, consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Interest Financing Agreement ("RIFA")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIFA accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,041</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIFA payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     RIFA debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated Portion of RIFA debt liability to be paid within one-year </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,401)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     RIFA long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,630</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,437</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,386)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,051</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 19, 2022, the Company entered into two strategic financing agreements: (i) a Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the lenders party thereto (the &#8220;Lenders&#8221;), and Oaktree Fund Administration LLC (&#8220;OFA&#8221;) as administrative agent, and (ii) a Revenue Interest Financing Agreement (the &#8220;RIFA&#8221;; and together with the Credit Agreement, the &#8220;OFA Facilities&#8221;) by and among the Company, the purchasers party thereto (the &#8220;Purchasers&#8221;) and OFA as administrative agent. Under the OFA Facilities, the Lenders and the Purchasers agreed to, in the aggregate between the two OFA Facilities, provide up to $260,000 in gross funding to support the Company&#8217;s commercial activities of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> sublingual film. In addition, the OFA Facilities are intended to support the expansion of clinical development efforts of BXCL501, which includes a Phase 3 program for the acute treatment of agitation in patients with Alzheimer&#8217;s disease, and for general corporate purposes. The Lenders and Purchasers are comprised of affiliates of Oaktree Capital Management, L.P. and Qatar Investment Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Waiver and First Amendment to Credit Agreement and Guaranty</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 13, 2023, the Company, the lenders party to the Credit Agreement and OFA entered into a Waiver and First Amendment to Credit Agreement and Guaranty (the &#8220;First Amendment&#8221;) that provided for (i) a waiver and a modification to the covenant in the Credit Agreement regarding investments in OnkosXcel and (ii) an agreement among </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the parties to further revise key financial terms in the Credit Agreement and terminate the RIFA. Pursuant to the First Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,000 at any time outstanding in OnkosXcel, increased from $25,000 at any time outstanding. The First Amendment also waived any defaults or events of default arising under the Credit Agreement due to a breach prior to the date of the First Amendment of the OnkosXcel investment covenant, or a breach of the Company&#8217;s obligation to notify OFA of such default. In connection with the First Amendment, the Company paid the Lenders a fee of $180 (representing 0.25% of the loans outstanding under the Credit Agreement on the date of the First Amendment) and agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:18.25pt;margin:0pt 0pt 0.1pt -0.25pt;"><b style="font-weight:bold;">Second Amendment to Credit Agreement and Guaranty and Termination of the RIFA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 5, 2023, (the &#8220;Second Amendment Effective Date&#8221;), the Company entered into the Second Amendment to Credit Agreement and Guaranty and Termination of Revenue Interest Financing Agreement (the &#8220;Second Amendment&#8221;), which further amended the Credit Agreement. On the Second Amendment Effective Date, the Credit Agreement was amended to provide up to $202,319 in senior secured term loans, including the initial Tranche A of $70,000, which was funded on April 28, 2022, and related capitalized interest on Tranche A through the Second Amendment Effective Date in the amount of $72,319. In addition, the $30,000 in financing previously provided to the Company under the RIFA on July 8, 2022 was converted to a term loan under the Credit Agreement (the &#8220;Tranche A-2 Term Loan&#8221;). The RIFA and all commitments for potential future funding thereunder were terminated. In addition, pursuant to the Second Amendment, the Lenders agreed to permit the Company to invest up to a maximum of $30,865 at any time outstanding in OnkosXcel, increased from $30,000. In connection with the Second Amendment, the Company agreed to pay to the Lenders an exit fee equal to 0.25% of the loans under the Credit Agreement repaid upon maturity or prepayment of the loans (which exit fee is in addition to, and not in lieu of, the exit fee provided for by the First Amendment). As of December 31, 2023, $100,000 in commitments under the Credit Agreement remains unfunded, and Oaktree has an Equity Investment Right (as defined below) to purchase up to $5,000 of Common Stock from the Company. The blended effective interest rate on the Tranches A-1 and A-2 as of December 31, 2023 was approximately 13.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt;margin:0pt 0pt 0.1pt -0.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The remaining tranches may be borrowed at the Company&#8217;s option prior to December 31, 2024, subject to satisfaction of certain conditions, including regulatory and financial milestones. Tranche B of the Credit Agreement is $20,000 and is available upon satisfaction of certain conditions and financial milestones. Tranche C of the Credit Agreement is $30,000 and is available upon satisfaction of certain conditions, including receipt of certain regulatory and financial milestones. Tranche D of the Credit Agreement is $50,000 and is available upon satisfaction of the Tranche C Term Loans conditions precedent to, and the funding of Tranche C Loans, including specified minimum net sales of the Company attributable to sales of BXCL501 for a trailing twelve consecutive month period, on or before December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The loans under the Credit Agreement do not amortize and mature on April 19, 2027. The Company may, at its option, no earlier than September 21, 2026 and no later than October 21, 2026, request an extension of the maturity date to April, 19, 2028, provided that the Company satisfies certain conditions including receipt of certain regulatory and financial milestones. Borrowings under the Credit Agreement are issued at a 200-basis point original issue discount and bear interest at a variable annual rate of TERM SOFR (but not less than 2.5% or more than 5.5%) plus 7.5%, payable quarterly. The rate resets every three months based on the current Term SOFR rate. Of such interest, above 8% per annum is, at the Company&#8217;s option, payable in kind by capitalizing and adding such interest to the outstanding principal amount of loans from the first payment date on which such interest is owed through<span style="font-size:12pt;"> </span>March 31, 2025, unless, with respect to any payment date, the Company elects to pay all or a portion of such interest in cash. The Company is required to pay a ticking fee equal to 0.75% per annum on the undrawn amount of the commitments, payable quarterly commencing 120 days after April 22, 2022 through the termination of the commitments, which is expensed as incurred and recognized as interest expense in the Consolidated Statements of Operations. The Company may voluntarily prepay the Credit Agreement at any time subject to a prepayment fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s obligations under the Credit Agreement are guaranteed by BTI&#8217;s existing and subsequently acquired or organized subsidiaries, subject to certain exceptions. BTI&#8217;s obligations under the Credit Agreement and the related guarantees thereunder are secured, subject to customary permitted liens and other agreed upon exceptions, by (i) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">a pledge of all of the equity interests of all of the Company&#8217;s existing and any future direct subsidiaries, and (ii) a perfected security interest in all of its and the guarantors&#8217; tangible and intangible assets (except that the guarantees provided by the BXCL701 Subsidiaries (as defined below) are unsecured).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, and dividends and other distributions, subject to certain exceptions, including specific exceptions with respect to product commercialization and development activities. The Company must also comply with certain financial covenants, including (i) maintenance of cash or permitted cash equivalent investments in accounts controlled by OFA for the Lenders, of at least (a) initially, $15,000, (b) from and after the funding of the Tranche B loans, $20,000, and (c) from and after the Company&#8217;s satisfaction of the funding conditions for the Tranche C loans, $15,000, provided, that the liquidity covenant applicable at any time will be increased upon certain events related to a sale of OnkosXcel (up to a maximum amount equal to $37,500), provided that the minimum liquidity amount will in no event exceed 50% of the aggregate amount of loans outstanding under the Credit Agreement at any time; and (ii) a minimum revenue test, measured quarterly beginning with the Company&#8217;s fiscal quarter ending on December 31, 2024 (such six-month period the &#8220;Revenue Covenant Measurement Period&#8221;), that requires it and its subsidiaries&#8217; consolidated net revenue for the six consecutive month period ending on the last day of each such fiscal quarter to not be less than a minimum revenue amount specified in the Credit Agreement (such testing date, the &#8220;Revenue Covenant Measurement Testing Date&#8221; and the covenant described in this clause (ii) the &#8220;Revenue Covenant&#8221;). The Company&#8217;s failure to comply with the financial covenants will result in an event of default, subject to certain cure rights with respect to the Revenue Covenant. If, as of a Revenue Covenant Measurement Testing Date, the Company&#8217;s revenue for the applicable Revenue Covenant Measurement Period is less than the minimum revenue amount specified for the applicable period then required under the Revenue Covenant, the Company would have a right to cure such shortfall for a total of three fiscal periods by making a revenue cure payment (which would be treated as prepayments of the loans subject to a prepayment fee) to the Lenders in an amount equal to the difference between such minimum required revenue amount and the Company&#8217;s actual revenues for such Revenue Covenant Measurement Period, such payment to not be less than $1,000. If paid, the Company will be deemed to have complied with the Revenue Covenant as of such Revenue Covenant Measurement Testing Date. Any such payment will be applied to the prepayment of the loans under the Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding the foregoing, the Credit Agreement permits OnkosXcel (together with OnkosXcel Employee Holdings, LLC (&#8220;Employee Holdings&#8221;), a subsidiary of BTI, and their respective subsidiaries, the &#8220;BXCL701 Subsidiaries&#8221;) to receive third-party investment or transfer all or substantially all of their assets to an unaffiliated third party, in each case subject to terms and conditions set forth in the Credit Agreement, including the escrow of certain proceeds received by BTI and its subsidiaries (other than the BXCL701 Subsidiaries) in respect of these disposition events and, under circumstances set forth in the Credit Agreement, the mandatory prepayment of such escrowed amounts. The Company&#8217;s equity interests in the BXCL701 Subsidiaries have been pledged in support of its obligations under the Credit Agreement, and the BXCL701 Subsidiaries have provided direct guarantees of BTI&#8217;s obligations under the Credit Agreement on an unsecured basis. However, the pledge, guarantee and other obligations of the BXCL701 Subsidiaries under the Credit Agreement will be released upon certain agreed upon events (&#8220;Permitted BXCL701 Release Events&#8221;), including an initial public offering by the BXCL701 Subsidiaries or the ownership by unaffiliated third parties of at least 20% of the equity interests in the BXCL701 Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Credit Agreement contains events of default that are customary for financings of this type relating to, among other things, payment defaults, breach of covenants, breach of representations and warranties, cross default to material indebtedness, bankruptcy-related defaults, judgment defaults, breach of the financial covenants described above, and the occurrence of certain change of control events. In certain circumstances, events of default are subject to customary cure periods. The Credit Agreement also contains certain regulatory-related events of default, which do not have cure periods. Following an event of default and any applicable cure period, the Lenders will have the right upon notice to terminate any undrawn commitments and may accelerate all amounts outstanding under the Credit Agreement, in addition to other remedies available to them as the Company&#8217;s secured creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Revenue Interest Financing Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As noted, the RIFA was terminated when the Company entered into the Second Amendment, which amended the Credit Agreement (as amended by the First Amendment). The $30,000 Tranche A previously provided to the Company under the RIFA was converted to the Tranche A-2 Term Loan. Prior to termination, the RIFA provided up to $120,000 in potential financing in exchange for a capped revenue interest on net sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, and other future BXCL501 products, if any, that received regulatory approval for sale. The initial Tranche A of $30,000 was funded on July 8, 2022. The effective interest rate on the RIFA as of December 31, 2022, was approximately 14%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the terms of the RIFA, the Purchasers were to receive tiered revenue interest payments on U.S. net sales of IGALMI&#8482;, and other future BXCL501 products, if any, that receive regulatory approval for sale, equal to a royalty ranging from 0.375% to 7.750% of net sales of IGALMI&#8482;, and other future BXCL501 products, if any, approved for sale in the U.S., subject to a hard cap equal to 1.75x the total amount funded. The Company would also have been required to make certain additional payments to the Purchasers from time to time to ensure that the aggregate amount of payments received by the Purchasers under the RIFA were at least equal to certain agreed upon minimum levels as of certain specified dates, subject to terms and conditions set forth in the RIFA. Revenue interest payments due under the RIFA were payable quarterly based on net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants and Equity Investment Right</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In connection with the closing of the Second Amendment, on the Second Amendment Effective Date, the Company amended and restated the warrants granted to the Lenders on April 19, 2022 to purchase up to 278 shares of the Company&#8217;s common stock at an exercise price of $20.04 per share (the &#8220;Original Warrants&#8221;). Pursuant to the amendment and restatement of the Original Warrants, dated December 5, 2023 (the &#8220;Amended and Restated Original Warrants&#8221;), the exercise price of the Original Warrants has been reduced to $3.6452 per share. In addition, the Company granted new warrants to the Lenders to purchase up to 70 shares of the Company&#8217;s common stock (the &#8220;2023 Warrant Shares&#8221;) at an exercise price of $3.6452 per share (the &#8220;2023 Warrants&#8221;<span style="font-size:12pt;"> </span>and together with the Amended and Restated Original Warrants, the &#8220;Warrants&#8221;). The Amended and Restated Original Warrants and the 2023 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. In addition, pursuant to the Credit Agreement, the Lenders have the right to purchase shares of the Company&#8217;s common stock after the Second Amendment Effective Date, so long as borrowings under the Credit Agreement are outstanding, for a purchase price of $5,000 at a price per share equal to a 10% premium to the volume-weighted average price of the common stock over the 30 trading days prior to the Lenders&#8217; election to proceed with such equity investment (the &#8220;Equity Investment Right&#8221;). BTI entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Lenders and filed a registration statement on Form S-3 to register the shares issuable upon exercise of the Warrants and, if issued, the shares related to the Equity Investment Right, for resale. The maximum shares of BTI common stock issuable under the Warrants (including the Original Warrants and the 2023 Warrants) and Lenders&#8217; Equity Investment Right was 5,852 as of December 31, 2023.<span style="font-size:12pt;"> </span>On the Second Amendment Effective Date, Company amended and restated its Registration Rights Agreement (the &#8220;Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, dated April 19, 2022, pursuant to which the Company agreed to register the 2023 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As part of the Credit Agreement, OnkosXcel, a wholly owned subsidiary of BTI, granted warrants to the Lenders to purchase 175 individual limited liability company units (which number of units is not in thousands; referred to herein as the &#8220;OnkosXcel Warrants&#8221;). The strike price of the OnkosXcel Warrants is formulaic based on the value of OnkosXcel at the time of exercise and can only be exercised upon occurrence of an equity related liquidity event for OnkosXcel of at least $20,000. The exercise price per unit of the OnkosXcel Warrants will be set upon the earlier of the closing of the next sale (or series of related sales) by OnkosXcel of equity securities of OnkosXcel with aggregate proceeds of not less than $20,000 to unrelated third parties (the &#8220;Next Equity Financing&#8221;) at an exercise price per unit equal to a 10% premium over the price per unit of the equity securities sold by OnkosXcel in such Next Equity Financing or, in the event of a sale of OnkosXcel prior to the Next Equity Financing or an initial public offering constituting the Next Equity Financing, the lesser of (x) 75% of the fair value of the consideration to be paid for a unit upon the consummation of such transaction and (y) 150% of the valuation applicable to the initial profits units issued by OnkosXcel after the closing of the Credit Agreement. The OnkosXcel Warrants are transferable with approval from BTI, which cannot be unreasonably withheld, expire on April 19, 2029, and may be net exercised at the holder&#8217;s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Maturities of long-term debt are expected to be as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,353</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 860</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,213</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026176656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10. Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">BTI identified certain freestanding financial instruments and/or embedded features that require separate accounting from the borrowings under the OFA Facilities. This includes the OnkosXcel Warrants and Equity Investment Right held by the Lenders, along with certain put/call options. The OnkosXcel Warrants and Equity Investment Right do not meet certain scope exceptions under U.S. GAAP, primarily because the exercise prices and number of shares of the Company&#8217;s common stock issuable under the instruments are variable, and the instruments meet the definition of a derivative instrument. Therefore, these instruments are recorded as Derivative liabilities in the Consolidated Balance Sheets. The respective derivative liabilities are recorded at fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded within Other (income) expense, net in the Company&#8217;s Consolidated Statements of Operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026227344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Financing Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_FinancingActivitiesAbstract', window );"><strong>Common Stock Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_FinancingActivitiesDisclosureTextBlock', window );">Common Stock Financing Activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;11. Common Stock Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt;"><span style="font-weight:normal;">In May 2021, the Company entered into</span><span style="font-weight:normal;"> an </span><span style="font-weight:normal;">Open Market Sale Agreement (as amended, supplemented and/or restated from time to time, the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to </span><span style="font-weight:normal;">$100,000</span><span style="font-weight:normal;">, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. In November 2023, the Company amended the Sale Agreement to increase the size of the &#8220;at the market offering" program to </span><span style="font-weight:normal;">$150,000</span><span style="font-weight:normal;">. The Company sold </span><span style="font-weight:normal;">1,408</span><span style="font-weight:normal;"> shares under the Sale Agreement in the year ended December 31, 2023 for net proceeds of </span><span style="font-weight:normal;">$26,221</span><span style="font-weight:normal;">. For the year ended December 2023, the Company sold shares for the gross amount of </span><span style="font-weight:normal;">$27,032</span><span style="font-weight:normal;">, and incurred issuance costs of </span><span style="font-weight:normal;">$811</span><span style="font-weight:normal;">. The Company did not sell any shares, and thus did </span><span style="font-weight:normal;">no</span><span style="font-weight:normal;">t receive any proceeds under this program, for the year ended December 31, 2022</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_FinancingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Financing Activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_FinancingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026286848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">2017 Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2017 Plan became effective in August 2017. Following the effective date of the Company's 2020 Plan, the Company ceased granting awards under the 2017 Plan, however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Incentive Award Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s 2020 Plan was approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020, and unless earlier terminated by the Board of Directors, will remain in effect until March 26, 2030. The 2020 Plan originally authorized for issuance the sum of (i) 911 shares of the Company&#8217;s common stock and (ii) 233 shares of the Company&#8217;s common stock, which represents the number of shares that remained available for issuance under the 2017 Plan immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders. Any shares of common stock which, immediately prior to the approval of the 2020 Plan by the Company&#8217;s stockholders, were subject to awards granted under the 2017 Plan that are forfeited or lapse unexercised and are not issued under the 2017 Plan will increase the number of shares of common stock available for grant under the 2020 Plan. In addition, the number of shares available for issuance under the 2020 Plan will increase on the first day of each calendar year, beginning January 1, 2021 and ending on and including January 1, 2030, by a number of shares equal to the lesser of (A) 4% of the aggregate number of shares of the Company&#8217;s common stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of shares of common stock as determined by the Board of Directors. The shares available for issuance under the 2020 Plan increased by 1,126 shares and 1,119 shares on January 1, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-based awards granted under the 2020 Plan have a term of ten years. The vesting schedule of all awards granted under the 2020 Plan is determined by the Board of Directors, which is generally four years. Stock-based awards granted under the 2020 Plan include stock options, BTI RSUs, and Performance Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, there were 664 shares available to be granted under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to BTI RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 133</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2023, the Company granted 133 time-based BTI RSUs to certain employees. All of the BTI RSUs vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. The weighted average grant date fair value per share for the BTI RSUs was $19.62. Unrecognized stock-based compensation expense related to these awards was $1,417 as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In 2022, the Company granted 122 (119, net of forfeitures) time-based BTI RSUs to certain employees and consultants. The majority of BTI RSUs granted to employees vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. There were 25 BTI RSUs granted to the employees in May 2022 which fully vested at the <span style="-sec-ix-hidden:Hidden_ENbZ6Viv9kSPsLzsnlVWSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span></span> anniversary of the grant date. BTI RSUs granted to a third-party consultant vest 50% each on the first and second anniversaries of the grant date. The weighted average grant date fair value per share for the BTI RSUs granted in 2022 was $14.38. Unrecognized stock-based compensation expense related to these awards was $298 as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Performance stock units </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below summarizes activity relating to Performance Units related to BTI common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In October 2023, the Company granted 543 Performance Units to employees. 209 Performance Units vest on the one-year anniversary of the grant date, and the remaining 334 Performance Units are performance based and vest on the one-year anniversary of the grant date, provided certain performance criteria are met. The weighted average value of Performance Units granted and cancelled during 2023 was $2.43. None of the Performance Units had vested as of December 31, 2023. Unrecognized stock-based compensation expense related to the awards expected to vest was $515 as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OnkosXcel Profit sharing units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the PSUs associated with OnkosXcel as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,176</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,533</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During 2023, Employee Holdings, a management holding company used to facilitate the grant of equity interests to service providers of OnkosXcel granted 30 individual (not in thousands) time-based PSUs related to OnkosXcel to certain employees of the Company in consideration for services provided to OnkosXcel. In 2022, Employee Holdings granted 1,310 (not in thousands) PSUs to employees and a consultant of the Company for services provided to OnkosXcel. The PSUs represent indirect equity interests in OnkosXcel. All PSUs, other than those granted to certain </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">executive employees of the Company, vest ratably over 48 months. PSUs granted to certain executive employees of the Company, vested ratably over 24 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair values of the PSUs granted in 2023 and 2022 were $8 per unit and $4 per unit, respectively, and were estimated at the date of grant using a Black-Scholes option pricing model. The total fair value of the PSUs vested during the year ended December 31, 2023 was $1,942.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized stock-based compensation expense related to the PSUs was $971 and $4,588 as of December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">OnkosXcel restricted stock units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The table below summarizes activity relating to the OnkosXcel RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 225</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2023, the Company granted 225 individual (not in thousands) OnkosXcel RSUs to certain employees. 125 of the OnkosXcel RSUs vest upon the earlier to occur of (a) 180 days after an initial public offering of OnkosXcel, or (b) a change in control of OnkosXcel. The remaining OnkosXcel RSUs vest over four years, with 25% vesting at the one-year anniversary of the grant date and the balance vesting ratably over the remaining 12 quarters of the vesting period. The weighted average grant date fair value per unit for the OnkosXcel RSUs was approximately $10. Unrecognized stock-based compensation expense related to the awards expected to vest was approximately $552 as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">BTI Stock options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A summary of the Company&#8217;s stock option activity for the year ended December 31, 2023, is presented below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (651)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of December 31, 2023, the intrinsic value of options outstanding was $3,149. The intrinsic value for stock options is calculated based on the difference between the exercise prices of the underlying awards and the quoted stock price of the Company&#8217;s common stock as of the reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The total intrinsic value of stock options exercised for the years ended December 31, 2023 and 2022 was $5,928 and $2,437, respectively. The total intrinsic value of stock options exercisable as of December 31, 2023 and 2022 was $3,148 and $40,255, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $15.53 and $11.62, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of options vested as of December 31, 2023 was $12.86.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The weighted average remaining contractual life is 5.5 years for options exercisable as of December 31, 2023. The weighted average remaining contractual life was 6.4 years for options outstanding as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unrecognized compensation expense related to unvested stock option awards as of December 31, 2023, was $9,478 and will be recognized over the remaining vesting periods of the underlying awards. The weighted-average period over which such compensation is expected to be recognized is 1.1 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The fair value of options granted during the years ended December 31, 2023 and 2022 was estimated using the Black-Scholes pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">109.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">92.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">99.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In 2023, the Company began using the historical volatility of its common stock to estimate volatility. Prior to 2023, volatility was estimated using a combination of the historical volatility of publicly traded peer companies and that of the Company&#8217;s common stock. The expected term of the awards is estimated based on the simplified method, which calculates the expected term based upon the midpoint of the term of the award and the vesting period. The Company uses the simplified method because it does not have sufficient option exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is zero percent as the Company has no history of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">paying dividends nor does management expect to pay dividends over the contractual terms of these options. The risk-free interest rates are determined by reference to the U.S. Treasury yield curve in effect at the time of grant, with maturities approximating the expected term of the stock options. The fair value of the underlying common stock is generally determined as the closing price of the Company&#8217;s common stock on The Nasdaq Capital Market on the grant date, with consideration of whether there is material nonpublic information that could impact that estimated fair value when it is released.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognized stock-based compensation expense related to awards issued under the 2017 Plan and the 2020 Plan, as well as the OnkosXcel PSUs and OnkosXcel RSU&#8217;s, of $18,614 and $17,337 for the years ended December 31, 2023 and 2022, respectively, which were comprised as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,558</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,779</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,337</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2020 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was also approved and became effective at the Company&#8217;s 2020 annual meeting of stockholders on May 20, 2020. The ESPP is designed to assist eligible employees of the Company with the opportunity to purchase the Company&#8217;s common stock at a discount through accumulated payroll deductions during successive offering periods. The aggregate number of shares that may be issued pursuant to rights granted under the ESPP is 100 shares of common stock. In addition, the number of shares available for issuance under the ESPP will increase on the first day of each calendar year, beginning on January 1, 2021 and ending on and including January 1, 2030, by a number of shares of common stock equal to the lesser of (a) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the Board of Directors. The number of shares that may be issued or transferred pursuant to rights granted under the component of the ESPP that is intended to qualify for favorable U.S. federal tax treatment under Section 423 of the Internal Revenue Code (the &#8220;Section 423 Component&#8221;) shall not exceed 500 shares. The purchase price will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85% of the fair value of a share on the first trading day or on the last trading day of the applicable offering period, whichever is lower. The shares available for issuance under the ESPP increased by 281 shares and 280 shares on January 1, 2023 and 2022, respectively. To date, no shares have been sold under the ESPP. There were 905 shares available for issuance as of December 31, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026015392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;13. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI leases office space for its corporate headquarters at 555 Long Wharf Drive, New Haven, Connecticut (the &#8220;HQ Lease&#8221;) under an operating lease that expires in February 2026. The Company has an option to renew the HQ Lease for one additional five-year term. Payments under the HQ Lease are fixed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company also leases equipment such as copiers and information technology equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The future minimum annual lease payments under operating leases, as of December 31, 2023, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 786</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (346)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The current portion of the Company&#8217;s operating lease liability of $346, as of December 31, 2023, is included in <span style="-sec-ix-hidden:Hidden_YDje09iS6UufW2YFrYa5Ng;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other current liabilities</span></span> on the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lease expense was $392 and $410 for the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lease renewal options are not included in the ROU asset or lease liability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025948144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 14. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company maintains a defined contribution retirement plan for its employees that complies with Section 401(k) of the Internal Revenue Code (the &#8220;401(K) Plan&#8221;). Employees are eligible to participate in the 401(K) Plan and can contribute a portion of their pay into the 401(K) Plan, subject to annual limits established by the U.S. Internal Revenue Service. Participating employees receive an employer matching contribution equal to 50% of eligible employee contributions on the first 5% of eligible compensation contributed. Employer contributions to the 401(K) Plan were $788 and $568<span style="background:#ffffff;"> for the years ended December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482236/912-715-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026179776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;15. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company groups its assets and liabilities measured at fair value in three levels based on the nature of the inputs and assumptions used to determine fair value. Refer to Note 3, Summary of Significant Accounting Policies, for additional information on the accounting policies related to fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The carrying amounts of Cash and cash equivalents, Accounts receivable, net and Accounts payable approximate fair value due to the short-term nature of these instruments. As of December 31, 2023 and 2022, the Company had $64,860 and $191,022, respectively, primarily in money market funds that hold U.S. government cash equivalent instruments (included in Cash and cash equivalents) which were valued based on Level 1 inputs. There were no transfers between levels within the hierarchy during the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities measured at fair value on a recurring basis are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - Equity Investment Right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lFagk5bTnEemlWdu4CgnkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">     Total derivative liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative liabilities are comprised of the OnkosXcel Warrants and Equity Investment Right held by the Lenders. The fair value of the derivative liabilities was determined using Monte Carlo simulation models for the Equity Investment Right, and Binomial Option Pricing and Distribution models for the OnkosXcel Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table presents changes in Level 3 liabilities measured at fair value for the year ended December 31, 2023. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Change in fair value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (438)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 389</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,343</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The derivative liabilities were reported at their fair values in the Consolidated Balance Sheets. The changes in the fair value of the derivative liabilities were reported in the Consolidated Statements of Operations as Other (income) expense, net, for the years ended December 31, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Inputs used to calculate the estimated fair value of the Equity Investment Right were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Investment Right</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Strike price relative to volume weighted 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility (annual)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probability of exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Time period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated premium to 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In estimating the fair value of the derivative liability related to the OnkosXcel Warrants, inputs included third-party fair value estimates of OnkosXcel limited liability company units along with the volatility of those units (which was set at 100% based on the historical volatility of the Company&#8217;s stock, along with a peer group of comparable publicly traded companies), and the timing and probability of the relevant capital transactions occurring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated fair value of the Credit Agreement as of December 31, 2023, was $88,210. Both observable and unobservable inputs were used to determine the fair value of long-term debt, which was classified within the Level 3 category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the 2023 Warrants, which is a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $200 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the Credit Agreement. This non-recurring measurement is classified as Level 3. The inputs used were a strike price of $3.6452, the Company&#8217;s stock price of $3.71, volatility of 99%, term of 5.4 years and risk-free rate of 4.14%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the Original Warrants, which was a non-recurring fair value, was determined as of the date of issuance using a Black-Scholes pricing model and the fair value of $3,245 was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts funded under the OFA Facilities. This non-recurring measurement is classified as Level 3. The inputs used were a strike price of $20.04, the Company&#8217;s stock price of $14.93, volatility of 95%, term of 7 years and risk-free rate of 2.95%. As discussed in Note 9, Debt and Credit Facilities, in connection with the closing of the Second Amendment<span style="font-size:12pt;"> of the </span>Credit Agreement, on the Second Amendment Effective Date, the Company amended and restated the Original Warrants granted to the Lenders to have an exercise price of $3.6452 per share.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Using a Black-Scholes pricing model, the Company determined that the Amended and Restated Original Warrants&#8217; fair values at the original strike price of $20.04 and the amended strike price of $3.6452 were $548 and $802, respectively, as of the Second Amendment Effective Date. The Amended and Restated Original Warrants&#8217; incremental increase in fair value for the repricing of $254, was recorded as a component of stockholders&#8217; equity in Additional-paid-in-capital in the Consolidated Balance Sheets, with the offset recorded as a discount on the amounts refinanced under the Credit Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025943888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;16. Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">There is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the years differs from the amount that would result from applying domestic federal statutory tax rates to pretax losses primarily because of changes in valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For tax years beginning on or after January 1, 2022, the 2017 Tax Cuts and Jobs Act amended Section 174&#160;of the U.S. Tax Code to eliminate current-year deductibility of research and development expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the U.S. and fifteen years for research activities performed outside of the U.S. For the 2023 tax year, the Company capitalized $78,002 of research and development expenses. This resulted in an increase in the deferred tax asset associated with capitalized research and development of $20,985. In determining the realizability of the Company&#8217;s net deferred tax asset, the Company considered numerous factors, including historical profitability, estimated future taxable income, and the industry in which it operates. Based on this information the Company has provided a valuation allowance for the full amount of its net deferred tax asset because the Company has determined that it is more likely than not that it will not be realized. The significant components of the Company&#8217;s net deferred tax assets are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,695</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,271</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,705</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,689</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,663</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,171</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173,679)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (118,373)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (197)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset (liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The income tax benefit for the year ended December 31, 2023 differed from the amounts computed by applying the U.S. federal income tax rate of 21% to loss before tax benefit as a result of nondeductible expenses, tax credits generated and increases in the amount of the Company&#8217;s valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A reconciliation between the Company&#8217;s effective tax rate and the federal statutory rate are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December&#160;31, 2023, the Company had approximately $351,284 of gross federal and $360,081 of gross state net operating loss (&#8220;NOL&#8221;) carryforwards. If not utilized, the federal and state NOL carryforwards will begin to expire in 2037. The federal NOL of $348,638 incurred after December 31, 2017, will be carried forward indefinitely. The utilization of such NOL carryforwards and realization of tax benefits in future&#160;years depends predominantly upon having taxable income. The Company has approximately $14,345 of federal orphan drug and research development credits which will begin to expire in 2037 if not utilized. The Company also has approximately $1,206 of state drug research development credits which will begin to expire in 2040 if not utilized. &#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Utilization of the NOL and research tax credit carryforwards may be subject to a substantial annual limitation due to ownership limitations that have occurred or that could occur in the future, as required by section 382 of the U.S. Tax Code, as well as similar state and foreign provisions. These ownership changes may limit the amount of the NOL and research credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change," as defined by Section 382 of the U.S. Tax Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock by certain stockholders or public groups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December&#160;31, 2023, there were no uncertain positions. The Company's U.S. federal and state NOLs have occurred since its inception in 2017 and as such, tax years subject to potential tax examination could apply from that date because the utilization of NOLs from prior years opens the relevant year to audit by the U.S. Internal Revenue Service and/or state taxing authorities. BTI did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2023 and 2022. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025956320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 17. Net Loss Per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Basic and diluted net loss per share are as follows</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (165,757)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,015</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.92)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Potentially dilutive securities outstanding consists of stock options, RSUs and performance units, and BTI warrants. The Company had common stock equivalents outstanding as of December 31, 2023 and 2022 of 6,036 and 5,280 shares, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026207728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note 18. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">From time to time, in the ordinary course of business, the Company may be subject to litigation and regulatory examinations as well as information gathering requests, inquiries and/or investigations. Other than the below, the Company is not currently subject to any matters where it believes there is a reasonable possibility that a material loss may be incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On July 7, 2023, plaintiff Katelyn Martin filed a class action complaint against the Company and certain executives in the United States District Court for the District of Connecticut, captioned Martin v. BioXcel Therapeutics, et al., 3:23-cv-00915 (D. Conn). On October 4, 2023, pursuant to the Private Securities Litigation Reform Act, the court appointed two co-Lead Plaintiffs. The co-Lead Plaintiffs filed an amended complaint on December 5, 2023, alleging violations of Sections 10(b) and 20A of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and SEC Rule 10b-5 promulgated thereunder. The amended complaint alleges that defendants made false or misleading statements regarding the TRANQUILITY II trial and the development of BXCL501 for an expanded indication related to the treatment of certain Alzheimer&#8217;s-related agitation. Defendants filed a motion to dismiss on February 6, 2024, which has not been decided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 28, 2023, Plaintiffs Pratheesan Panancherry and Jeffrey Bastress filed a stockholder derivative complaint in the United States District Court for the District of Connecticut purportedly on behalf of the Company and against Vimal Mehta, Richard I. Steinhart, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Panancherry et al v. Mehta et al, 3:23-cv-1554. Following the initial action, Plaintiffs Maria Vomvolakis (3:24-cv-3) and Kelly Fowler (3:24-cv-203) each filed separate stockholder derivative complaints in the District of Connecticut raising similar claims as Panancherry and Bastress, including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Stockholder Derivative Litigation, 3:23-cv-1554 (D. Conn.). The above-captioned consolidated action is currently stayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 11, 2024, Plaintiff Jeremy Smith filed a stockholder derivative complaint in the United States District Court for the District of Delaware purportedly on behalf of the Company and against Vimal Mehta, Peter Mueller, June Bray, Sandeep Laumas, Michael Miller, Michal Votruba, Richard I. Steinhart, Robert Risinger, and Krishnan Nandabalan as Defendants, and the Company as Nominal Defendant under the caption Smith v. Mehta et al, 1:24-cv-00041. Following the initial action, Plaintiff Janice Korff filed a stockholder derivative complaint in the District of Delaware raising similar claims as Smith (1:24-cv-130), including business torts and violations of the Securities Exchange Act of 1934. The cases have been consolidated under the caption In re BioXcel Therapeutics, Inc. Derivative Litigation, 1:24-cv-00041 (D. Del.). The Company expects to seek a stay in the above-captioned consolidated action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At this time, the Company does not believe the claims in the above-captioned matters have merit, and intends to vigorously defend against them; however, the potential costs and liabilities associated with this litigation are uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In April 2022, the Company signed a commercial supply agreement that requires minimum annual payments for the first three years of the agreement that in aggregate total $10,000 for the three-year period<span style="background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024736544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 19. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="background:#ffffff;">On February 12, 2024, the Company entered into the Third Amendment to Credit Agreement and Guaranty (the &#8220;Third Amendment&#8221;), which amended the Credit Agreement. Pursuant to the Third Amendment, the Lenders agreed to waive the covenant that the Company shall not receive a report and opinion from the Company&#8217;s independent auditors that contains a &#8220;going concern&#8221; or like qualification or exception or emphasis of matter of going concern footnote with respect to the Company&#8217;s financial statements for the fiscal year ended December 31, 2023 and, as a result, such event shall not be an event of default. As a condition to the effectiveness of the Third Amendment, among other things, the Company shall have received at least </span><span style="background:#ffffff;">$40,000</span><span style="background:#ffffff;"> in gross proceeds from a registered public sale of the Company&#8217;s common stock, warrants and/or pre-funded warrants</span> on or before February 20, 2024. The Company did not meet this condition and therefore the Third Amendment did not become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 20, 2024 (the &#8220;Effective Date&#8221;), the Company entered into a Fourth Amendment (the &#8220;Fourth Amendment&#8221;) to the Credit Agreement and Guaranty (as amended from time to time, the &#8220;Credit Agreement&#8221;) by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as subsidiary guarantors, the Lenders, and OFA as administrative agent, pursuant to which the Lenders waived the covenant that the Company not receive a report and opinion from the Company&#8217;s independent registered public accounting firm that contains a &#8220;going concern&#8221; or similar qualification with respect to the Company&#8217;s financial statements for the year ended December 31, 2023. Accordingly, while the Company&#8217;s independent registered public accounting firm&#8217;s report contained in this Annual Report on Form 10-K contains a &#8220;going concern&#8221; explanatory paragraph, it does not constitute an event of default under the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Fourth Amendment includes a covenant that the Company will receive, (i) after the Effective Date and on or before April 15, 2024, at least $25,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in non-refundable cash consideration from partnering transactions entered into after the Effective Date (so long as such partnering transactions would not require the Company or any of its subsidiaries to make any cash investments in connection with the partnering transactions and no such cash investments are made) and (ii) after the Effective Date and on or before November 30, 2024, at least $50,000 (for the avoidance of doubt, inclusive of amounts previously counted toward the preceding clause (i)) in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent (as defined in the Credit Agreement) in its sole discretion ) from partnering transactions entered into after the Effective Date. Failure to perform this covenant would constitute (A) a default under the Credit Agreement and (B) an event of default under the Credit Agreement, subject to a cure period, solely in the case of clause (i) of the preceding sentence, until May 15, 2024. For the avoidance of doubt, failure to perform clause (ii) of the preceding sentence would constitute an immediate event of default under the Credit Agreement without any cure or grace period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, the Fourth Amendment provides that if the Company has not, after the Effective Date and on or before September 30, 2024, received at least $40,000 in gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants, and/or cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date, the &#8220;Minimum Liquidity Amount&#8221; (as defined in the Credit Agreement) that the Company is required to maintain at all times will increase to $25,000 from $15,000, unless and until we have received, after the Effective Date and on or before November 30, 2024, at least $50,000 in gross proceeds from the issuance of the Company&#8217;s common stock, warrants and/or pre-funded warrants, and/or in cash and/or non-cash consideration (measured at fair market value, as determined by the Administrative Agent in its sole discretion) from partnering transactions entered into after the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Fourth Amendment, on the Effective Date, the Company granted new warrants to the Lenders to purchase up to 100 shares of its common stock (the &#8220;2024 Warrant Shares&#8221;) at an exercise price of $3.0723 per share (the &#8220;2024 Warrants&#8221;), which represents a 10% premium over the arithmetic average of the volume-weighted average price of the Company&#8217;s common stock on the Nasdaq Capital Market during the 30 trading days preceding the Effective Date. The 2024 Warrants will expire on April 19, 2029 and may be net exercised at the holder&#8217;s election. On the Effective Date, the Company amended and restated its Amended and Restated Registration Rights Agreement (the &#8220;Second Amended and Restated Registration Rights Agreement&#8221;) with the Lenders, originally dated April 19, 2022. Pursuant to the Second Amended and Restated Registration Rights Agreement, the Company agreed to register the 2024 Warrant Shares for resale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed in Note 11, Common Stock Financings Activities, the Company has previously entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), as amended, pursuant to which the Company could offer and sell shares of its common stock, having an aggregate offering price of up to $150,000, from time to time, through an &#8220;at the market offering&#8221; program under which Jefferies will act as sale agent. From January 1, 2024 through March 19, 2024, the Company sold 647 shares under the Sale Agreement for gross proceeds of $1,743 and received proceeds of $1,691, net of issuance costs of $52.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024508032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include those of the Company and its subsidiaries after elimination of all intercompany accounts and transactions and have been prepared in conformity with United States (&#8220;U.S.&#8221;) Generally Accepted Accounting Principles (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements include the accounts for the Company and all entities where BTI has a controlling financial interest after elimination of all intercompany accounts and transactions and have been prepared in conformity with U.S. GAAP.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and notes thereto. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022, cash equivalents were comprised primarily of money market funds. Cash and cash equivalents held at financial institutions may at times exceed federally insured amounts. BTI management believes it mitigates such risk by investing in or through major financial institutions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounts Receivable, Net</b></p><p style="font-family:'Liberation Serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Accounts receivable arise from sales of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">IGALMI</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> and represent amounts due from distributors. Payment terms generally range from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;">75 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;"> from the date of the sale transaction, and accordingly, do not involve a significant financing component. Receivables from product sales are recorded net of allowances which generally include distribution fees, prompt payment discounts, chargebacks, and credit losses. Allowances for distribution fees, prompt payment discounts and chargebacks are based on contractual terms. The Company estimated the current expected credit losses of its accounts receivable by assessing the risk of loss and available relevant information about collectability, existing contractual payment terms, actual payment patterns of its customers, individual customer circumstances, and reasonable and supportable forecast of economic conditions expected to exist throughout the contractual life of the receivable. Based on its assessment, as of December 31, 2023, the Company determined that an allowance for credit losses was not required.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company sells </span><span style="font-weight:normal;">IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-weight:normal;"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with intermediaries such as group purchasing organizations (&#8220;GPOs&#8221;). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Liberation Serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value. Cost of inventory is determined on a first-in, first-out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">BTI capitalizes inventory costs associated with the Company&#8217;s products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development expense in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, will be recorded within Cost of goods sold in the Consolidated Statements of Operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected, write-downs of inventory may be required.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Initial Public Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Deferred Initial Public Offering Costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Deferred initial public offering costs of $2,570, consisted of legal, accounting, and other costs that were directly related to the Company&#8217;s proposed initial public offering of OnkosXcel. These costs were charged to the Consolidated Statements of Operations during the year ended December 31, 2023 as the initial public offering was delayed for an extended period of time. The costs were recorded as Selling, general and administrative expenses. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Property and equipment are recorded at cost and depreciated over the shorter of their remaining lease term or their estimated useful life on a straight-line basis as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7 years</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Expenditures for maintenance and repairs which do not improve or extend the useful lives of the respective assets are expensed as incurred. When assets are sold or retired, the related cost and accumulated depreciation are removed from their respective accounts and any resulting gain or loss is included within Selling, general and administrative expenses in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated from its use and disposition. Impairment charges are recognized at the amount by which the carrying amount of an asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, other current liabilities, and the long-term portion of operating lease liabilities in the Consolidated Balance Sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ROU assets represent BTI&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses the implicit rate when readily determinable. As BTI&#8217;s leases do not provide an implicit rate, it used an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments made and excludes lease incentives. The Company&#8217;s leases may include options to extend the lease; such options are included in determining the lease term when it is reasonably certain that BTI will exercise that option. Lease expense is recognized on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt and Detachable Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Debt and Detachable Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Detachable warrants are evaluated for classification as either equity instruments, derivative liabilities, or liabilities depending on the specific terms of the warrant agreement. In circumstances in which debt is issued with equity-classified warrants, the proceeds from the issuance of debt are first allocated to the debt and then the warrants at their estimated fair values. The portion of the proceeds allocated to the warrants are accounted for as paid-in capital and a debt discount. The remaining proceeds, as further reduced by discounts created by the bifurcation of any embedded derivatives, are allocated to the debt. Detachable warrants classified as derivative liabilities are accounted for as indicated under &#8220;<i style="font-style:italic;">Derivative Assets and Liabilities</i>&#8221; section of this Note and as a debt discount. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. The Company considers </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">whether there are any embedded features in debt instruments that require bifurcation and separately accounts for them as derivative financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company entered into financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, amortization period of the debt discount, as well as the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments during each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions of the debt.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Derivative Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Derivative assets and liabilities are recorded on the Company`s Consolidated Balance Sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are settled or expire, with changes in the fair value between reporting periods recorded as other income or expense within Other (income) expense, net in the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not use derivative instruments for speculative purposes or to hedge exposures to cash-flow or market risks. Certain financing facilities entered into by the Company include freestanding financial instruments and/or embedded features that require separate accounting as derivative assets and/or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company&#8217;s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer&#8217;s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company&#8217;s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is to deliver the quantity of product ordered to the location specified by the customer&#8217;s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Consolidated Statements of Operations. Under the Company&#8217;s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> at wholesale acquisition cost and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI&#8217;s Consolidated Statements of Operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cost of Goods Sold</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenues during the respective period. Cost of goods sold also includes costs related to excess or obsolete inventory adjustment charges, as well as costs related to warehouse operations paid to distributors.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures and recognizes stock-based compensation expense based on estimated fair value for all share-based awards made to employees, non-employee service providers, and directors, including stock options, BTI restricted stock units (&#8220;BTI RSUs&#8221;), OnkosXcel profit sharing units (&#8220;PSUs&#8221;), OnkosXcel restricted stock units (&#8220;OnkosXcel RSUs&#8221;) and BTI performance stock units (&#8220;Performance Units&#8221;). The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) became effective in August 2017. The Company&#8217;s 2020 Incentive Award Plan (the &#8220;2020 Plan&#8221;) became effective in May 2020. Following the effective date of the 2020 Plan, the Company ceased granting awards under the 2017 Plan; however, the terms and conditions of the 2017 Plan continue to govern any outstanding awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s stock-based awards are valued at fair value on the date of grant and that fair value is recognized as an expense in the Consolidated Statements of Operations over the requisite service period using the accelerated attribution method. The estimated value of the BTI RSUs and Performance Units is based on the Company&#8217;s closing stock price on the grant date. The estimated fair value of stock-options, OnkosXcel RSUs and PSUs was determined using the Black-Scholes pricing model on the date of grant. For awards subject to performance-based vesting conditions, the Company recognizes stock-based compensation expense when the achievement of the performance condition becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Black-Scholes pricing model is affected by the Company&#8217;s stock price, as well as assumptions regarding variables including, but not limited to, the strike price of the instrument, the risk-free rate, the expected stock price volatility over the term of the awards, and expected term of the award. The Company has elected to account for forfeitures as they occur, by reversing compensation cost when the award is forfeited.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Research and development expenses include wages, benefits, non-cash stock-based compensation, facilities, supplies, external services, clinical study, manufacturing costs related to clinical trials and other expenses that are directly related to the Company&#8217;s research and development activities. At the end of the reporting period, the Company estimates the progress toward completion of the research or development objectives and, depending on the amount and timing of payments to the service providers may record net prepaid or accrued expense for associated research and development costs. Such estimates are subject to change as additional information becomes available. The Company expenses research and development costs as incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Most of the Company&#8217;s service providers invoice BTI monthly in arrears for services performed. The Company estimates its accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to management at that time. BTI management periodically confirms the accuracy of the Company&#8217;s estimates with the service providers and makes adjustments if necessary.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Although management does not expect its estimates to be materially different from amounts actually incurred, management&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in BTI reporting amounts that are too high or too low in any particular period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Costs related to filing and pursuing patent applications are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and are expensed as incurred since recoverability of such expenditures is uncertain.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company measures certain financial assets and liabilities at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company applies a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources, or observable inputs, and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances, or unobservable inputs. The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Fair value measurements must be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Level 3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management&#8217;s estimates of market participant assumptions.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considering counterparty credit risk in its assessment of fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI uses an asset and liability approach for financial accounting and reporting of income taxes. Deferred tax assets and liabilities are determined based on temporary differences between financial reporting and tax basis assets and liabilities and are measured by applying enacted rates and laws to taxable years in which differences are expected to be recovered or settled. Further, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that the rate changes. A valuation allowance is required when it is &#8220;more likely than not&#8221; that all or a portion of deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">U.S. GAAP prescribes a comprehensive model for how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the Company has taken or expects to take on a tax return, including a decision whether to file or not file a return in a particular jurisdiction. The Company&#8217;s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities&#8217; full knowledge of the position and all relevant facts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company does not have any unrecognized tax benefits as of December 31, 2023 and 2022. BTI reviews all tax positions to ensure the tax treatment selected is sustainable based on its technical merits and that the position would be sustained if challenged.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Earnings (Loss) per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Earnings (loss) per share (&#8220;EPS&#8221;) is calculated by dividing net income or loss attributable to common stockholders by the weighted average number of shares of common stock that were outstanding. Diluted EPS is calculated by adjusting the weighted average number of shares of common stock that were outstanding for the dilutive effect of common stock equivalents. In periods in which a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be antidilutive.&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the Company&#8217;s chief operating decision maker has made such decisions and assessed performance at the Company level as one segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently adopted accounting pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance (collectively, &#8220;Topic 326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) - Effective Dates, which deferred the effective dates of Topic 326 for the Company, until fiscal year 2023. The Company adopted Topic 326 in 2023 and it did not have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Pronouncements effective in future periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the FASB issued ASU 2023-07, Segment reporting, which requires disclosure of incremental segment information on an annual and interim basis. The standard is effective for years beginning after December 15, 2023, and interim periods beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, Improvements to income tax disclosures, which requires disclosure of disaggregated income taxes paid by jurisdiction, enhances disclosures in the effective tax rate reconciliation and modifies other income tax-related disclosures. The amendments are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the effect of adopting this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing revenue from a transaction on a gross or net basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027414480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Schedule of Property Plant and Equipment useful lives</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:2.15pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Equipment</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">3-5 years</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Furniture</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">7 years</p></td></tr><tr style="height:13.1pt;"><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:50%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">Lesser of life of improvement or lease term</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Property Plant And Equipment Useful Lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025997360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 935</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 682</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 405</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 595</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total inventory</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,991</p></td><td style="vertical-align:bottom;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,985</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026347424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 213</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 575</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,181</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,969</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,193)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (885)</p></td></tr><tr><td style="vertical-align:bottom;width:72.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,084</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026114992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,659</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,370</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,738</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 820</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total accrued expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,669</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025971120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Transactions with BioXcel LLC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of service charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#0563c1;font-size:14pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,151</p></td></tr><tr><td style="vertical-align:bottom;width:63.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,401</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026350048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue Interest Financing Agreement ("RIFA")</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIFA accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,041</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RIFA payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     RIFA debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated Portion of RIFA debt liability to be paid within one-year </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,401)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     RIFA long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,630</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit Agreement and Guaranty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payable-in-kind ("PIK") interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 807</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,437</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unamortized debt premiums, discounts and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,386)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total long-term debt</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,051</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities on long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock', window );">Schedule of long-term debt interest expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,353</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion of debt discount and amortization of financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 860</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total interest expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,213</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense associated with long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ScheduleOfInterestExpenseAssociatedWithLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023718608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of activity relating to RSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 133</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67)</p></td></tr><tr><td style="vertical-align:bottom;width:79.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (651)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,558</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,779</p></td></tr><tr><td style="vertical-align:bottom;width:57.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,337</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of activity relating to PSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of activity relating to RSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">     Granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 225</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of activity relating to PSUs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price per unit</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">units</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in whole dollars)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,176</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506</p></td></tr><tr><td style="vertical-align:bottom;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested units as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,533</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 grant profit share unit valuation inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.15969849%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:26.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">109.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">92.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">99.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding performance-based awards that are fully vested and expected to vest. Includes, but is not limited to, unvested awards for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026186736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Year ending December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 391</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease payments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Total lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 786</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less current portion of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (346)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">     Long-term portion of operating lease liability</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026287376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:53.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - Equity Investment Right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liability - OnkosXcel Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 712</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_lFagk5bTnEemlWdu4CgnkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">     Total derivative liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of changes in Level 3 liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Change in fair value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (438)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 389</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative liabilities, Balance - December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,343</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of fair value unobservable inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity Investment Right</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Strike price relative to volume weighted 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility (annual)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Probability of exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Time period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated premium to 30-day average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026326160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,695</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">State net operating losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,271</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,705</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,689</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,663</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,171</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (173,679)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (118,373)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (197)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (256)</p></td></tr><tr><td style="vertical-align:bottom;width:75.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net deferred tax asset (liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate and statutory rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:75.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026179776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss (numerator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179,053)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (165,757)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares (denominator)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,015</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.92)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027482400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,221<span></span>
</td>
<td class="nump">$ 193,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(590,598)<span></span>
</td>
<td class="num">(411,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(179,053)<span></span>
</td>
<td class="num">(165,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (155,006)<span></span>
</td>
<td class="num">$ (135,341)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024033888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="nump">$ 2,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AccountsReceivablePaymentTerm', window );">Accounts receivable payment term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AccountsReceivablePaymentTerm', window );">Accounts receivable payment term</a></td>
<td class="text">75 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AccountsReceivablePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The credit period offered to customers or receivables by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AccountsReceivablePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686022817408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Employees eliminated (as a percent)</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance and benefit costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract termination costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027322944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory write-downs</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027085296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="nump">$ 1,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,193)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027125872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 6,406<span></span>
</td>
<td class="nump">$ 8,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">6,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 12,424<span></span>
</td>
<td class="nump">$ 18,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023439872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with BioXcel LLC (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,326<span></span>
</td>
<td class="nump">$ 91,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,413<span></span>
</td>
<td class="nump">68,761<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,162<span></span>
</td>
<td class="nump">160,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement', window );">Monthly agreement option fees</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC | Development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BioXcel LLC | Sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Transactions with BioXcel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePaymentsPotential', window );">Potential milestone payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CollaborativeArrangementMilestonePotentialPercent', window );">Maximum milestone (as as percent)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fees per month to be paid to enter into collaborative service agreement option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AdditionalFeesPerMonthToEnterIntoCollaborativeServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CollaborativeArrangementMilestonePaymentsPotential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential maximum payments that could be paid under the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CollaborativeArrangementMilestonePaymentsPotential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CollaborativeArrangementMilestonePotentialPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of net sales payable under a collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CollaborativeArrangementMilestonePotentialPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=btai_BioxcelCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=btai_BioxcelCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btai_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btai_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btai_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btai_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024994528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Debt summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payable-in-kind ("PIK") interest</a></td>
<td class="nump">$ 1,872<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">102,680<span></span>
</td>
<td class="nump">101,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt premiums, discounts and issuance costs</a></td>
<td class="num">(2,082)<span></span>
</td>
<td class="num">(8,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">100,598<span></span>
</td>
<td class="nump">93,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payable-in-kind ("PIK") interest</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 102,319<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent', window );">Long-term debt liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt classified as current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LongTermDebtBeforeUnamortizedDiscountPremiumAndDebtIssuanceCostsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686022260320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Nov. 12, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 08, 2022</div></th>
<th class="th"><div>Apr. 28, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SubsidiaryOwnershipPercentage', window );">Subsidiary ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PercentageOfOutstandingLoan', window );">Outstanding loan (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA | From and after the funding of Tranche B loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember', window );">OFA | From and after satisfaction of funding conditions for tranche C loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_NetCashRequiredMinimum', window );">Cash maintenance in controlled accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LineOfCreditFacilityInvestmentAllowed', window );">Maximum investment allowed</a></td>
<td class="nump">$ 30,865<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LineOfCreditFacilityAmendmentFeePercentage', window );">Amendment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_LineOfCreditFacilityExitFeePercentage', window );">Exit fee (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt instrument fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 202,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_EquityInvestmentRightAmountUnfunded', window );">Equity Investment Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentInterestRateDiscountRatePercentage', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PaidInKindInterestPercentage', window );">Debt paid-in-kind interest (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_TickingFeesPercentage', window );">Ticking fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentIncrementalOnVariableRatePercent', window );">Incremental interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Minimum | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Maximum | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="nump">72,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Tranche A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Tranche C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty | Tranche D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity required per the financial covenant of debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentIncrementalOnVariableRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage points added to the reference rate and variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentIncrementalOnVariableRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentInterestRateDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of  basis point original issue discount at which the borrowings under the credit agreement are issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentInterestRateDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EquityInvestmentRightAmountUnfunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of equity investment right in the OFA that is currently unfunded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EquityInvestmentRightAmountUnfunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityAmendmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The line of credit facility fee for credit agreement amendment based on a loans outstanding, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityAmendmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The line of credit facility exit fee, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_LineOfCreditFacilityInvestmentAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the Lenders agree to permit the entity to invest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_LineOfCreditFacilityInvestmentAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_NetCashRequiredMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum maintenance of cash or permitted cash equivalent investments in accounts controlled by lenders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_NetCashRequiredMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PaidInKindInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid-in-kind interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PaidInKindInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfOutstandingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding Loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfOutstandingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SubsidiaryOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SubsidiaryOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_TickingFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents ticking fees percentage relating to debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_TickingFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_OfaAdministrativeAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_FromAndAfterFundingOfTrancheBLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_FromAndAfterFundingOfTrancheBLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_FromAndAfterSatisfactionOfFundingConditionsForTrancheCLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_TrancheDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_TrancheDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027088640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Revenue Interest Financing (Details) - Revenue interest financing - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 08, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt extinguishment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ThresholdRatioOfDebtToRevenueRatio', window );">Debt to revenue multiplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_BorrowingsBasedOnNetSalesPercent', window );">Borrowing allowed per net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_BorrowingsBasedOnNetSalesPercent', window );">Borrowing allowed per net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_BorrowingsBasedOnNetSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum borrowings allowed based on a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_BorrowingsBasedOnNetSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ThresholdRatioOfDebtToRevenueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents threshold ratio for debt to revenue ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ThresholdRatioOfDebtToRevenueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024817344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Warrants (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 20.04<span></span>
</td>
<td class="nump">$ 3.6452<span></span>
</td>
<td class="nump">$ 20.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_RightToPurchaseStockLenders', window );">Maximum equity investment allowed for lenders</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Common stock issuable (in shares)</a></td>
<td class="nump">5,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember', window );">OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ThresholdLiquidityEventAmountForExerciseOfWarrants', window );">Threshold amount of liquidity event for exercise of warrants</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PercentageOfFairValueConsiderationToBePaid', window );">Percentage of fair value of consideration to be paid</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PercentageOfValuationApplicableToInitialProfits', window );">Percentage of valuation applicable to initial profits</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfFairValueConsiderationToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of consideration to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfFairValueConsiderationToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PercentageOfValuationApplicableToInitialProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation applicable to initial profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PercentageOfValuationApplicableToInitialProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PremiumSharePricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents premium percentage for share price determined over a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PremiumSharePricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_RightToPurchaseStockLenders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum equity investment allowed for lenders in entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_RightToPurchaseStockLenders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ThresholdLiquidityEventAmountForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of  liquidity event for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ThresholdLiquidityEventAmountForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026185200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">$ 102,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027234928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt and Credit Facilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 11,941<span></span>
</td>
<td class="nump">$ 7,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Accretion of debt discount and amortization of financing costs</a></td>
<td class="nump">1,373<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 13,314<span></span>
</td>
<td class="nump">$ 8,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023714512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Financing Activities (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember', window );">Jefferies Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Shares issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SaleOfStockMaximumValueSharesToBeIssued', window );">Maximum value shares to be issued</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SaleOfStockMaximumValueSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate net offering price of shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SaleOfStockMaximumValueSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027469184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Description (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member', window );">2020 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant', window );">Annual increase in shares available for grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance (in shares)</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btai_StockPlan2017Member', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_IncentiveAwardPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_StockPlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_StockPlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024416432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Non-options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,614<span></span>
</td>
<td class="nump">$ 17,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.62<span></span>
</td>
<td class="nump">$ 14.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | Nonemployee consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | Grant Date 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">BTI RSU | Grant Date 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">BTI PSU | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested aggregate (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average price beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue', window );">Cancelled, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, Weighted average price ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 971<span></span>
</td>
<td class="nump">$ 4,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of non-options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested', window );">Total fair value of PSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU | Executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">$ 552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember', window );">OnkosXcel RSUs | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a cancelled event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFairValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=btai_ShareBasedPaymentArrangementGrantDate2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=btai_ShareBasedPaymentArrangementGrantDate2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=btai_ShareBasedPaymentArrangementGrantDate2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=btai_ShareBasedPaymentArrangementGrantDate2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_RestrictedStockUnitsOnkosxcelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025015872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options (Details) - Employee Stock Option - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">4,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Options cancelled (in shares)</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">4,976<span></span>
</td>
<td class="nump">4,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable (in shares)</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per shares)</a></td>
<td class="nump">$ 17.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">19.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per shares)</a></td>
<td class="nump">17.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice', window );">Options cancelled (in dollars per shares)</a></td>
<td class="nump">24.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per shares)</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end balance (in dollars per shares)</a></td>
<td class="nump">18.52<span></span>
</td>
<td class="nump">$ 17.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per shares)</a></td>
<td class="nump">$ 17.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, outstanding</a></td>
<td class="nump">$ 3,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="nump">5,928<span></span>
</td>
<td class="nump">$ 2,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, exercisable</a></td>
<td class="nump">$ 3,148<span></span>
</td>
<td class="nump">$ 40,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 15.53<span></span>
</td>
<td class="nump">$ 11.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options vested (in dollars per share)</a></td>
<td class="nump">$ 12.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, outstanding</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 9,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining unamortized expense period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686024414096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember', window );">OnkosXcel PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility (as a percent)</a></td>
<td class="nump">97.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest (as a percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum (as a percent)</a></td>
<td class="nump">96.90%<span></span>
</td>
<td class="nump">92.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum (as a percent)</a></td>
<td class="nump">109.90%<span></span>
</td>
<td class="nump">99.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate of interest, minimum (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate of interest, maximum (as a percent)</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btai_TimeBasedProfitSharingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027171040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs recognized</a></td>
<td class="nump">$ 18,614<span></span>
</td>
<td class="nump">$ 17,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs recognized</a></td>
<td class="nump">6,324<span></span>
</td>
<td class="nump">4,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation costs recognized</a></td>
<td class="nump">$ 12,290<span></span>
</td>
<td class="nump">$ 12,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027249584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - ESPP (Details) - 2020 Employee Stock Purchase Plan - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant', window );">Annual increase in shares available for grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred', window );">Maximum number of shares issued or transferred under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percent of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance (in shares)</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of shares issued or transferred under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_EmployeeStockPurchasePlanMaximumNumberOfSharesIssuedOrTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of aggregate number of shares of common stock outstanding of the immediately preceding calendar year as a increase to common stock available for grant under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInCommonStockAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btai_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btai_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027470048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of the operating lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">$ (346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion operating lease liability</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026218960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to renew the lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686027418912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer contribution percent on eligible contribution</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution amount</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023686384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value money market accounts</a></td>
<td class="nump">$ 64,860<span></span>
</td>
<td class="nump">$ 191,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Derivative Liability, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686025692064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Level 3 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Level 3 liabilities reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 2,343<span></span>
</td>
<td class="nump">$ 1,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Change in fair value</a></td>
<td class="num">(438)<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 2,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023247856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Inputs (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 05, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 19, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember', window );">Credit Agreement and Guaranty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value debt | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember', window );">Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.6452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.04<span></span>
</td>
<td class="nump">$ 20.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 3,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Repricing of stock purchase warrants | $</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember', window );">2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.6452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value warrant classified as equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Strike price | Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Strike price | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Strike price | 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility (annual) | Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility (annual) | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility (annual) | OnkosXcel Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility (annual) | 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputProbabilityOfExerciseMember', window );">Probability of exercise | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Time period | Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Time period | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Time period | 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputEstimatedPremiumMember', window );">Estimated premium to 30-day average | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Equity Investment Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Share price input | Original Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Share price input | 2023 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair value inputs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_WarrantOaktreeAndQiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_EquityInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_OnkosxcelWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputProbabilityOfExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputProbabilityOfExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputEstimatedPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btai_MeasurementInputEstimatedPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026993440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">$ 78,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease', window );">Capitalized R&amp;D deferred tax increase</a></td>
<td class="nump">20,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Income tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating losses</a></td>
<td class="nump">73,770<span></span>
</td>
<td class="nump">$ 46,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating losses</a></td>
<td class="nump">21,255<span></span>
</td>
<td class="nump">11,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">13,915<span></span>
</td>
<td class="nump">10,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credits</a></td>
<td class="nump">15,048<span></span>
</td>
<td class="nump">10,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research &amp; development</a></td>
<td class="nump">49,603<span></span>
</td>
<td class="nump">36,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DeferredTaxAssetsLeaseAccountingLiability', window );">Lease liability</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(173,679)<span></span>
</td>
<td class="num">(118,373)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDerivatives', window );">Unrealized gain</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (197)<span></span>
</td>
<td class="num">$ (256)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized research and development costs deferred tax increase (decrease).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_CapitalizedResearchAndDevelopmentDeferredTaxIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DeferredTaxAssetsLeaseAccountingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease accounting, liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DeferredTaxAssetsLeaseAccountingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686022096448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between effective tax rate and federal statutory rate, percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal tax credits (as a percent)</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance (as a percent)</a></td>
<td class="num">(30.90%)<span></span>
</td>
<td class="num">(28.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_OperatingLossCarryforwardsNoExpiration', window );">Operating loss carryforward with no expiration</a></td>
<td class="nump">$ 348,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax related interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between effective tax rate and federal statutory rate, percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">351,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">14,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between effective tax rate and federal statutory rate, percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">360,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_OperatingLossCarryforwardsNoExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward with no expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_OperatingLossCarryforwardsNoExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023487168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss (numerator)</a></td>
<td class="num">$ (179,053)<span></span>
</td>
<td class="num">$ (165,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares (denominator) - basic (in shares)</a></td>
<td class="nump">29,129<span></span>
</td>
<td class="nump">28,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares (denominator) - diluted (in shares)</a></td>
<td class="nump">29,129<span></span>
</td>
<td class="nump">28,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (6.15)<span></span>
</td>
<td class="num">$ (5.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (6.15)<span></span>
</td>
<td class="num">$ (5.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common stock equivalents outstanding</a></td>
<td class="nump">6,036<span></span>
</td>
<td class="nump">5,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026264784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted', window );">Minimum annual payments</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_AgreementCommitmentPeriod', window );">Commitment agreement period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_AgreementCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the agreement commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_AgreementCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686023374448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember', window );">Jefferies Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_SaleOfStockMaximumValueSharesToBeIssued', window );">Maximum value shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2024 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock (in shares)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.0723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_PremiumSharePricePercent', window );">Premium share price (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Facility | April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Facility | September 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Credit Facility | November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt', window );">Minimum revenue required</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement', window );">Minimum Liquidity Amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Jefferies Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity required per the financial covenant of debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_DebtInstrumentFinancialCovenantMinimumLiquidityRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of gross proceeds from the issuance of its common stock, warrants and/or pre-funded warrants for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_MinimumGrossProceedsFromIssuanceOfCommonStockWarrantsAndOrPreFundedWarrantsForDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_PremiumSharePricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents premium percentage for share price determined over a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_PremiumSharePricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btai_SaleOfStockMaximumValueSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate net offering price of shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btai_SaleOfStockMaximumValueSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btai_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=btai_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btai_Warrants2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btai_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=btai_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=btai_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026171360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (179,053)<span></span>
</td>
<td class="num">$ (165,757)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139686026938912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_VimalMehtaMember', window );">Vimal Mehta</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</span></span>On December 14, 2023, Vimal Mehta, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 34,938 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Vimal Mehta<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">34,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_RichardSteinhartMember', window );">Richard Steinhart</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 14, 2023, Richard Steinhart, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Richard Steinhart<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_JavierRodriguezMember', window );">Javier Rodriguez</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 14, 2023, Javier Rodriguez, Senior Vice President, Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Javier Rodriguez<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President, Chief Legal Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_MatthewWileyMember', window );">Matthew Wiley</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 14, 2023, Matthew Wiley, Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Matthew Wiley<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Commercial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_IndividualAxis=btai_FrankYoccaMember', window );">Frank Yocca</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 14, 2023, Frank Yocca, Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 25,000 shares of the Company&#8217;s common stock to cover taxes due in connection with the vesting of restricted stock units until December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Frank Yocca<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Scientific Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 14, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_VimalMehtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_VimalMehtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_RichardSteinhartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_RichardSteinhartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_JavierRodriguezMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_JavierRodriguezMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_MatthewWileyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_MatthewWileyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=btai_FrankYoccaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=btai_FrankYoccaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
